1	Interferon	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	alpha	_	O	O	_	_	_	_	_
4	induction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	STATs	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	DNA	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	growth	_	O	O	_	_	_	_	_
15	arrest	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	independent	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	Lck	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	active	_	O	O	_	_	_	_	_
22	mitogen	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	activated	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Type	_	O	O	_	_	_	_	_
2	I	_	O	O	_	_	_	_	_
3	interferons	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	IFNs	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	family	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cytokines	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	have	_	O	O	_	_	_	_	_
14	antiviral	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	antiproliferative	_	O	O	_	_	_	_	_
17	effects	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Data	_	O	O	_	_	_	_	_
2	regarding	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	processes	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	these	_	O	O	_	_	_	_	_
8	cytokines	_	O	O	_	_	_	_	_
9	transduce	_	O	O	_	_	_	_	_
10	signals	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	membrane	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	nucleus	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	becoming	_	O	O	_	_	_	_	_
20	increasingly	_	O	O	_	_	_	_	_
21	complex	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	most	_	O	O	_	_	_	_	_
3	characterized	_	O	O	_	_	_	_	_
4	pathway	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	via	_	O	O	_	_	_	_	_
7	JAK	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	STAT	_	O	O	_	_	_	_	_
10	signaling	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Previous	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	established	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	potential	_	O	O	_	_	_	_	_
6	role	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	Src	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	Lck	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	JAK	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	signaling	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	designed	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	analyze	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	Lck	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	IFN	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	signaling	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	using	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	Jurkat	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	JCam	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	an	_	O	O	_	_	_	_	_
26	Lck	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	defective	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	line	_	O	O	_	_	_	_	_
31	derived	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	Jurkat	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	JCam	_	O	O	_	_	_	_	_
38	/	_	O	O	_	_	_	_	_
39	Lck	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	JCam	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	with	_	O	O	_	_	_	_	_
44	Lck	_	O	O	_	_	_	_	_
45	restored	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	alpha	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	induce	_	O	O	_	_	_	_	_
10	MAPK	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	only	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	containing	_	O	O	_	_	_	_	_
18	Lck	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	STATs	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	effectively	_	O	O	_	_	_	_	_
10	phosphorylated	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	bind	_	O	O	_	_	_	_	_
15	DNA	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	absence	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	Lck	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	IFN	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	treated	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	demonstrate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	exerts	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	antiproliferative	_	O	O	_	_	_	_	_
13	effect	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	all	_	O	O	_	_	_	_	_
16	three	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	lines	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Lck	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	active	_	O	O	_	_	_	_	_
8	MAPK	_	O	O	_	_	_	_	_
9	do	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	affect	_	O	O	_	_	_	_	_
12	IFN	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	growth	_	O	O	_	_	_	_	_
18	arrest	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	induction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	STAT	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	s	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	DNA	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	ability	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Copyright	_	O	O	_	_	_	_	_
2	1999	_	O	O	_	_	_	_	_
3	Academic	_	O	O	_	_	_	_	_
4	Press	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_


1	Retinoic	_	O	O	_	_	_	_	_
2	acid	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	38	_	O	O	_	_	_	_	_
9	antigen	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	myeloid	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	through	_	O	O	_	_	_	_	_
16	retinoic	_	O	O	_	_	_	_	_
17	acid	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	alpha	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	38	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	leukocyte	_	O	O	_	_	_	_	_
6	differentiation	_	O	O	_	_	_	_	_
7	antigen	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	been	_	O	O	_	_	_	_	_
11	thought	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	phenotypic	_	O	O	_	_	_	_	_
16	marker	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	different	_	O	O	_	_	_	_	_
19	subpopulations	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	B	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	lymphocytes	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	myeloid	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	expressed	_	O	O	_	_	_	_	_
9	during	_	O	O	_	_	_	_	_
10	early	_	O	O	_	_	_	_	_
11	stages	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	differentiation	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Virtually	_	O	O	_	_	_	_	_
2	no	_	O	O	_	_	_	_	_
3	information	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	available	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	regulation	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	functions	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	38	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	reported	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	all	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	trans	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	retinoic	_	O	O	_	_	_	_	_
10	acid	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	ATRA	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	potent	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	highly	_	O	O	_	_	_	_	_
19	specific	_	O	O	_	_	_	_	_
20	inducer	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	38	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	promyelocytic	_	O	O	_	_	_	_	_
28	leukemia	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	ATRA	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	38	_	O	O	_	_	_	_	_
12	antigen	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	myeloid	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	through	_	O	O	_	_	_	_	_
19	retinoic	_	O	O	_	_	_	_	_
20	acid	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	alpha	_	O	O	_	_	_	_	_
23	receptor	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	RAR	_	O	O	_	_	_	_	_
26	alpha	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	ATRA	_	O	O	_	_	_	_	_
2	failed	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	induce	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	mutant	_	O	O	_	_	_	_	_
11	subclone	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	HL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	60	_	O	O	_	_	_	_	_
17	myeloid	_	O	O	_	_	_	_	_
18	leukemia	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	line	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	designated	_	O	O	_	_	_	_	_
23	HL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	60	_	O	O	_	_	_	_	_
26	R	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	is	_	O	O	_	_	_	_	_
30	relatively	_	O	O	_	_	_	_	_
31	resistant	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	ATRA	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	granulocytic	_	O	O	_	_	_	_	_
37	differentiation	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Retroviral	_	O	O	_	_	_	_	_
2	vector	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	transduction	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	RAR	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	into	_	O	O	_	_	_	_	_
14	this	_	O	O	_	_	_	_	_
15	HL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	60	_	O	O	_	_	_	_	_
18	R	_	O	O	_	_	_	_	_
19	subclone	_	O	O	_	_	_	_	_
20	completely	_	O	O	_	_	_	_	_
21	restored	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	sensitivity	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	these	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	ATRA	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	terms	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	their	_	O	O	_	_	_	_	_
33	ability	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	express	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	38	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	38	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	inducible	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	ATRA	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	HL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	60	_	O	O	_	_	_	_	_
16	R	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	transfected	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	functional	_	O	O	_	_	_	_	_
23	RAR	_	O	O	_	_	_	_	_
24	beta	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	RAR	_	O	O	_	_	_	_	_
27	gamma	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	or	_	O	O	_	_	_	_	_
30	RXR	_	O	O	_	_	_	_	_
31	alpha	_	O	O	_	_	_	_	_
32	receptor	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	38	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	acute	_	O	O	_	_	_	_	_
7	promyelocytic	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	acute	_	O	O	_	_	_	_	_
10	myeloblastic	_	O	O	_	_	_	_	_
11	leukemia	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	independent	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	ATRA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	cytodifferentiation	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	culture	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	ATRA	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	increased	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	38	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	levels	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	also	_	O	O	_	_	_	_	_
13	observed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	normal	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	34	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	bone	_	O	O	_	_	_	_	_
20	marrow	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	normal	_	O	O	_	_	_	_	_
27	circulating	_	O	O	_	_	_	_	_
28	granulocytes	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	From	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	conclude	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	38	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	ATRA	_	O	O	_	_	_	_	_
12	inducible	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	myeloid	_	O	O	_	_	_	_	_
15	leukemia	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	normal	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	34	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	bone	_	O	O	_	_	_	_	_
23	marrow	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	independent	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	differentiation	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	RAR	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	HL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	60	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	suggesting	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	similar	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	RAR	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	CD	_	O	O	_	_	_	_	_
28	38	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	other	_	O	O	_	_	_	_	_
32	hematopoietic	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	Stimulation	_	O	O	_	_	_	_	_
2	conditions	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	factors	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	cytokines	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	PBMC	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	cultured	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	volume	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	4	_	O	O	_	_	_	_	_
17	ml	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	sterile	_	O	O	_	_	_	_	_
20	pyrogen	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	free	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	well	_	O	O	_	_	_	_	_
26	culture	_	O	O	_	_	_	_	_
27	plates	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	Falcon	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	Heidelberg	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	Germany	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Cultures	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	stimulated	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	h	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	EMSA	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	or	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	0	_	O	O	_	_	_	_	_
13	h	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	48	_	O	O	_	_	_	_	_
16	h	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	ELISA	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	100	_	O	O	_	_	_	_	_
24	mug	_	O	O	_	_	_	_	_
25	per	_	O	O	_	_	_	_	_
26	106	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	GP	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	250	_	O	O	_	_	_	_	_
33	ng	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	106	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	TSST	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	Toxin	_	O	O	_	_	_	_	_
42	Technologies	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	Sarasota	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	FL	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	USA	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	or	_	O	O	_	_	_	_	_
51	with	_	O	O	_	_	_	_	_
52	250	_	O	O	_	_	_	_	_
53	ng	_	O	O	_	_	_	_	_
54	/	_	O	O	_	_	_	_	_
55	106	_	O	O	_	_	_	_	_
56	cells	_	O	O	_	_	_	_	_
57	wild	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	type	_	O	O	_	_	_	_	_
60	LPS	_	O	O	_	_	_	_	_
61	from	_	O	O	_	_	_	_	_
62	Escherichia	_	O	O	_	_	_	_	_
63	coli	_	O	O	_	_	_	_	_
64	serotype	_	O	O	_	_	_	_	_
65	0111	_	O	O	_	_	_	_	_
66	:	_	O	O	_	_	_	_	_
67	B	_	O	O	_	_	_	_	_
68	4	_	O	O	_	_	_	_	_
69	(	_	O	O	_	_	_	_	_
70	Sigma	_	O	O	_	_	_	_	_
71	,	_	O	O	_	_	_	_	_
72	Munich	_	O	O	_	_	_	_	_
73	,	_	O	O	_	_	_	_	_
74	Germany	_	O	O	_	_	_	_	_
75	)	_	O	O	_	_	_	_	_
76	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	costimulatory	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	PBMC	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	supplemented	_	O	O	_	_	_	_	_
8	simultaneously	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	combination	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	GP	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	TSST	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	combination	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	GP	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_



1	Progesterone	_	O	O	_	_	_	_	_
2	suppression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	pregnancy	_	O	O	_	_	_	_	_
5	lymphocytes	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	glucocorticoid	_	O	O	_	_	_	_	_
11	effect	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	investigated	_	O	O	_	_	_	_	_
4	whether	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	suppressive	_	O	O	_	_	_	_	_
7	effect	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	progesterone	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	pregnancy	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	progesterone	_	O	O	_	_	_	_	_
18	receptors	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	competitive	_	O	O	_	_	_	_	_
6	progesterone	_	O	O	_	_	_	_	_
7	antagonist	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	RU	_	O	O	_	_	_	_	_
10	486	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	glucocorticoid	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	blocker	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	RU	_	O	O	_	_	_	_	_
20	43044	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	were	_	O	O	_	_	_	_	_
23	tested	_	O	O	_	_	_	_	_
24	on	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	release	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	blocking	_	O	O	_	_	_	_	_
30	factor	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	progesterone	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	treated	_	O	O	_	_	_	_	_
35	pregnancy	_	O	O	_	_	_	_	_
36	lymphocytes	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	RU	_	O	O	_	_	_	_	_
2	486	_	O	O	_	_	_	_	_
3	tested	_	O	O	_	_	_	_	_
4	at	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	equal	_	O	O	_	_	_	_	_
7	concentration	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	progesterone	_	O	O	_	_	_	_	_
10	significantly	_	O	O	_	_	_	_	_
11	inhibited	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	production	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	blocking	_	O	O	_	_	_	_	_
17	factor	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	while	_	O	O	_	_	_	_	_
20	RU	_	O	O	_	_	_	_	_
21	43044	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	without	_	O	O	_	_	_	_	_
24	effect	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	pregnancy	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	lymphocyte	_	O	O	_	_	_	_	_
9	progesterone	_	O	O	_	_	_	_	_
10	acts	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	progesterone	_	O	O	_	_	_	_	_
14	receptors	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	glucocorticoid	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	sites	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	not	_	O	O	_	_	_	_	_
21	involved	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Introduction	_	O	O	_	_	_	_	_

1	Rheumatoid	_	O	O	_	_	_	_	_
2	arthritis	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	characterized	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	infiltrations	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	macrophages	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	into	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	joint	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	synovial	_	O	O	_	_	_	_	_
21	hyperplasia	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Proinflammatory	_	O	O	_	_	_	_	_
2	cytokines	_	O	O	_	_	_	_	_
3	released	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	these	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	known	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	important	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	destruction	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	joints	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	favorable	_	O	O	_	_	_	_	_
3	clinical	_	O	O	_	_	_	_	_
4	benefits	_	O	O	_	_	_	_	_
5	obtained	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	inhibitors	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	tumor	_	O	O	_	_	_	_	_
10	necrosis	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	TNF	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	interleukin	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	suggest	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	blockade	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	key	_	O	O	_	_	_	_	_
31	inflammatory	_	O	O	_	_	_	_	_
32	cytokines	_	O	O	_	_	_	_	_
33	has	_	O	O	_	_	_	_	_
34	been	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	important	_	O	O	_	_	_	_	_
37	issue	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	development	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	new	_	O	O	_	_	_	_	_
43	therapeutic	_	O	O	_	_	_	_	_
44	applications	_	O	O	_	_	_	_	_
45	[	_	O	O	_	_	_	_	_
46	2	_	O	O	_	_	_	_	_
47	]	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	little	_	O	O	_	_	_	_	_
3	over	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	decade	_	O	O	_	_	_	_	_
6	ago	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	primacy	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	pathogenesis	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	autoimmune	_	O	O	_	_	_	_	_
18	disease	_	O	O	_	_	_	_	_
19	such	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	undisputed	_	O	O	_	_	_	_	_
24	because	_	O	O	_	_	_	_	_
25	they	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	largest	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	population	_	O	O	_	_	_	_	_
31	infiltrating	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	synovium	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	series	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	studies	_	O	O	_	_	_	_	_
7	demonstrated	_	O	O	_	_	_	_	_
8	paucity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	derived	_	O	O	_	_	_	_	_
14	cytokines	_	O	O	_	_	_	_	_
15	such	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	interferon	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	gamma	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	joints	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	RA	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	whereas	_	O	O	_	_	_	_	_
31	macrophage	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	fibroblast	_	O	O	_	_	_	_	_
34	cytokines	_	O	O	_	_	_	_	_
35	including	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	15	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	18	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	TNF	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	alpha	_	O	O	_	_	_	_	_
55	were	_	O	O	_	_	_	_	_
56	abundant	_	O	O	_	_	_	_	_
57	in	_	O	O	_	_	_	_	_
58	rheumatoid	_	O	O	_	_	_	_	_
59	synovium	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	paradox	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	questioned	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	role	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	pathogenesis	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	]	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	already	_	O	O	_	_	_	_	_
5	demonstrated	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	enhanced	_	O	O	_	_	_	_	_
8	proliferation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	antigen	_	O	O	_	_	_	_	_
11	specific	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	especially	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	type	_	O	O	_	_	_	_	_
18	II	_	O	O	_	_	_	_	_
19	collagen	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	skewing	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	helper	_	O	O	_	_	_	_	_
27	type	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	Th	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	cytokines	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	RA	_	O	O	_	_	_	_	_
36	[	_	O	O	_	_	_	_	_
37	4	_	O	O	_	_	_	_	_
38	]	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	role	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	T	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	needs	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	be	_	O	O	_	_	_	_	_
48	elucidated	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	different	_	O	O	_	_	_	_	_
51	aspects	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	one	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	inflammatory	_	O	O	_	_	_	_	_
9	cytokines	_	O	O	_	_	_	_	_
10	secreted	_	O	O	_	_	_	_	_
11	mainly	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	activated	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	which	_	O	O	_	_	_	_	_
18	can	_	O	O	_	_	_	_	_
19	induce	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	8	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	fibroblasts	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	5	_	O	O	_	_	_	_	_
31	]	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	cytokine	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	interest	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	major	_	O	O	_	_	_	_	_
9	reasons	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	first	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	similarly	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	TNF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	17	_	O	O	_	_	_	_	_
26	has	_	O	O	_	_	_	_	_
27	proinflammatory	_	O	O	_	_	_	_	_
28	properties	_	O	O	_	_	_	_	_
29	;	_	O	O	_	_	_	_	_
30	second	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	it	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	produced	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	6	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Recent	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	17	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	activate	_	O	O	_	_	_	_	_
11	osteoclastic	_	O	O	_	_	_	_	_
12	bone	_	O	O	_	_	_	_	_
13	resorption	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	induction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	RANKL	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	receptor	_	O	O	_	_	_	_	_
21	activator	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	nuclear	_	O	O	_	_	_	_	_
24	factor	_	O	O	_	_	_	_	_
25	kappaB	_	O	O	_	_	_	_	_
26	[	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kappaB	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_
31	ligand	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	which	_	O	O	_	_	_	_	_
35	is	_	O	O	_	_	_	_	_
36	involved	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	bony	_	O	O	_	_	_	_	_
39	erosion	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	RA	_	O	O	_	_	_	_	_
42	[	_	O	O	_	_	_	_	_
43	7	_	O	O	_	_	_	_	_
44	]	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	stimulates	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	production	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	leukemia	_	O	O	_	_	_	_	_
12	inhibitory	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	synoviocytes	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	prostaglandin	_	O	O	_	_	_	_	_
20	E	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	nitric	_	O	O	_	_	_	_	_
24	oxide	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	chondrocytes	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	has	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	ability	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	differentiate	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	activate	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	dendritic	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	8	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	10	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Levels	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	synovial	_	O	O	_	_	_	_	_
8	fluids	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	significantly	_	O	O	_	_	_	_	_
11	higher	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	RA	_	O	O	_	_	_	_	_
16	than	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	patients	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	osteoarthritis	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	OA	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	it	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	produced	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	4	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	synovium	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	11	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	12	_	O	O	_	_	_	_	_
42	]	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	15	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	secreted	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	activated	_	O	O	_	_	_	_	_
8	macrophages	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	has	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	reported	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	important	_	O	O	_	_	_	_	_
17	trigger	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	17	_	O	O	_	_	_	_	_
22	production	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	RA	_	O	O	_	_	_	_	_
25	peripheral	_	O	O	_	_	_	_	_
26	blood	_	O	O	_	_	_	_	_
27	mononuclear	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	PBMC	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	cyclosporine	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	steroid	_	O	O	_	_	_	_	_
36	sensitive	_	O	O	_	_	_	_	_
37	pathways	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	13	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Happel	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	colleagues	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	showed	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	23	_	O	O	_	_	_	_	_
12	could	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	efficient	_	O	O	_	_	_	_	_
16	trigger	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	17	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	both	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	4	_	O	O	_	_	_	_	_
26	+	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	8	_	O	O	_	_	_	_	_
30	+	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	14	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Although	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contribution	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	17	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	joint	_	O	O	_	_	_	_	_
10	inflammation	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	documented	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	earlier	_	O	O	_	_	_	_	_
18	studies	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	12	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	15	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	16	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	intracellular	_	O	O	_	_	_	_	_
29	signal	_	O	O	_	_	_	_	_
30	transduction	_	O	O	_	_	_	_	_
31	pathway	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	17	_	O	O	_	_	_	_	_
36	production	_	O	O	_	_	_	_	_
37	remains	_	O	O	_	_	_	_	_
38	uncertain	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	used	_	O	O	_	_	_	_	_
7	various	_	O	O	_	_	_	_	_
8	stimuli	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	investigate	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	17	_	O	O	_	_	_	_	_
14	production	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	PBMC	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	patients	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	its	_	O	O	_	_	_	_	_
23	signaling	_	O	O	_	_	_	_	_
24	transduction	_	O	O	_	_	_	_	_
25	pathway	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	intracellular	_	O	O	_	_	_	_	_
6	signaling	_	O	O	_	_	_	_	_
7	pathway	_	O	O	_	_	_	_	_
8	involving	_	O	O	_	_	_	_	_
9	phosphoinositide	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	PI	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	K	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	Akt	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	kappaB	_	O	O	_	_	_	_	_
24	might	_	O	O	_	_	_	_	_
25	be	_	O	O	_	_	_	_	_
26	involved	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	overproduction	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	key	_	O	O	_	_	_	_	_
33	inflammatory	_	O	O	_	_	_	_	_
34	cytokine	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	17	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	RA	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	might	_	O	O	_	_	_	_	_
4	provide	_	O	O	_	_	_	_	_
5	new	_	O	O	_	_	_	_	_
6	insights	_	O	O	_	_	_	_	_
7	into	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	pathogenesis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	future	_	O	O	_	_	_	_	_
14	directions	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	new	_	O	O	_	_	_	_	_
17	therapeutic	_	O	O	_	_	_	_	_
18	strategies	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_



1	Reagents	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	17	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	18	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	15	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	monocyte	_	O	O	_	_	_	_	_
15	chemoattractant	_	O	O	_	_	_	_	_
16	protein	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	MCP	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	macrophage	_	O	O	_	_	_	_	_
26	inflammatory	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	MIP	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	alpha	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	MIP	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	beta	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	8	_	O	O	_	_	_	_	_
47	were	_	O	O	_	_	_	_	_
48	purchased	_	O	O	_	_	_	_	_
49	from	_	O	O	_	_	_	_	_
50	R	_	O	O	_	_	_	_	_
51	&	_	O	O	_	_	_	_	_
52	D	_	O	O	_	_	_	_	_
53	systems	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	Minneapolis	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	MN	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	USA	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	transforming	_	O	O	_	_	_	_	_
3	growth	_	O	O	_	_	_	_	_
4	factor	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	TGF	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	purchased	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	Peprotech	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	London	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	UK	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	TNF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	alpha	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	purchased	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	Endogen	_	O	O	_	_	_	_	_
13	Inc	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	Cambridge	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	MA	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	USA	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Cyclosporin	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	provided	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	Sandos	_	O	O	_	_	_	_	_
7	Ltd	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	Basel	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	Switzerland	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	Phytohemagglutinin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	PHA	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	pyrrolidine	_	O	O	_	_	_	_	_
7	dithiocarbamate	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	PDTC	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	rapamycin	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	dexamethasone	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	curcumin	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	all	_	O	O	_	_	_	_	_
19	obtained	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Sigma	_	O	O	_	_	_	_	_
23	Chemical	_	O	O	_	_	_	_	_
24	Co	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	St	_	O	O	_	_	_	_	_
3	Louis	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	MA	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	USA	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Anti	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	monoclonal	_	O	O	_	_	_	_	_
6	antibody	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	anti	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	28	_	O	O	_	_	_	_	_
12	monoclonal	_	O	O	_	_	_	_	_
13	antibody	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	obtained	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	BD	_	O	O	_	_	_	_	_
18	Biosciences	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	San	_	O	O	_	_	_	_	_
21	Diego	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	CA	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	USA	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	LY	_	O	O	_	_	_	_	_
2	294002	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	SB	_	O	O	_	_	_	_	_
5	203580	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	FK	_	O	O	_	_	_	_	_
8	506	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	wortmannin	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	PD	_	O	O	_	_	_	_	_
13	98059	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	obtained	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	Calbiochem	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	Schwalbach	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	Germany	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_



1	Aiolos	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	controls	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	death	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	regulating	_	O	O	_	_	_	_	_
12	Bcl	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	its	_	O	O	_	_	_	_	_
18	cellular	_	O	O	_	_	_	_	_
19	localization	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	searched	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	interact	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	Ras	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	interleukin	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	stimulated	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	deprived	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	found	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	factor	_	O	O	_	_	_	_	_
32	Aiolos	_	O	O	_	_	_	_	_
33	interacts	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	Ras	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Ras	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Aiolos	_	O	O	_	_	_	_	_
5	interaction	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	confirmed	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	vitro	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	vivo	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	co	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	immunoprecipitation	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Indirect	_	O	O	_	_	_	_	_
2	immunofluorescence	_	O	O	_	_	_	_	_
3	shows	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	controls	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cellular	_	O	O	_	_	_	_	_
11	distribution	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Aiolos	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	induces	_	O	O	_	_	_	_	_
16	its	_	O	O	_	_	_	_	_
17	tyrosine	_	O	O	_	_	_	_	_
18	phosphorylation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	required	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	dissociation	_	O	O	_	_	_	_	_
23	from	_	O	O	_	_	_	_	_
24	Ras	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	identified	_	O	O	_	_	_	_	_
4	functional	_	O	O	_	_	_	_	_
5	Aiolos	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	sites	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	Bcl	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	able	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	activate	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	luciferase	_	O	O	_	_	_	_	_
23	reporter	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Mutation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Aiolos	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	sites	_	O	O	_	_	_	_	_
7	within	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	Bcl	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	inhibits	_	O	O	_	_	_	_	_
14	transactivation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	reporter	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	luciferase	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	suggesting	_	O	O	_	_	_	_	_
22	direct	_	O	O	_	_	_	_	_
23	control	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	Bcl	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	Aiolos	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Co	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	transfection	_	O	O	_	_	_	_	_
4	experiments	_	O	O	_	_	_	_	_
5	confirm	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	Aiolos	_	O	O	_	_	_	_	_
8	induces	_	O	O	_	_	_	_	_
9	Bcl	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	prevents	_	O	O	_	_	_	_	_
15	apoptosis	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	deprived	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	propose	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	model	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	regulation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	Bcl	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	via	_	O	O	_	_	_	_	_
14	Aiolos	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Introduction	_	O	O	_	_	_	_	_

1	Sry	_	O	O	_	_	_	_	_
2	type	_	O	O	_	_	_	_	_
3	HMG	_	O	O	_	_	_	_	_
4	box	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	member	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	Sox	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	family	_	O	O	_	_	_	_	_
18	characterized	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	conserved	_	O	O	_	_	_	_	_
22	high	_	O	O	_	_	_	_	_
23	mobility	_	O	O	_	_	_	_	_
24	group	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	HMG	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	domain	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	consisting	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	79	_	O	O	_	_	_	_	_
33	amino	_	O	O	_	_	_	_	_
34	acids	_	O	O	_	_	_	_	_
35	involved	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	DNA	_	O	O	_	_	_	_	_
38	recognition	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	binding	_	O	O	_	_	_	_	_
41	[	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factors	_	O	O	_	_	_	_	_
4	bind	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	minor	_	O	O	_	_	_	_	_
8	groove	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	DNA	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	cause	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	70	_	O	O	_	_	_	_	_
15	degrees	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	85	_	O	O	_	_	_	_	_
18	degrees	_	O	O	_	_	_	_	_
19	bend	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	leads	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	local	_	O	O	_	_	_	_	_
27	conformational	_	O	O	_	_	_	_	_
28	changes	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	while	_	O	O	_	_	_	_	_
36	most	_	O	O	_	_	_	_	_
37	other	_	O	O	_	_	_	_	_
38	transcription	_	O	O	_	_	_	_	_
39	factors	_	O	O	_	_	_	_	_
40	target	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	major	_	O	O	_	_	_	_	_
43	groove	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	DNA	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	4	_	O	O	_	_	_	_	_
48	]	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	may	_	O	O	_	_	_	_	_
6	perform	_	O	O	_	_	_	_	_
7	part	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	their	_	O	O	_	_	_	_	_
10	function	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	architectural	_	O	O	_	_	_	_	_
13	proteins	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	organizing	_	O	O	_	_	_	_	_
16	local	_	O	O	_	_	_	_	_
17	chromatin	_	O	O	_	_	_	_	_
18	structure	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	assembling	_	O	O	_	_	_	_	_
21	other	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	bound	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	factors	_	O	O	_	_	_	_	_
27	into	_	O	O	_	_	_	_	_
28	biologically	_	O	O	_	_	_	_	_
29	active	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	sterically	_	O	O	_	_	_	_	_
32	defined	_	O	O	_	_	_	_	_
33	multiprotein	_	O	O	_	_	_	_	_
34	complexes	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	reported	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	able	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	act	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	either	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	activator	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	repressor	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	depending	_	O	O	_	_	_	_	_
20	on	_	O	O	_	_	_	_	_
21	its	_	O	O	_	_	_	_	_
22	interactors	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	its	_	O	O	_	_	_	_	_
25	target	_	O	O	_	_	_	_	_
26	promoter	_	O	O	_	_	_	_	_
27	context	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	5	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	6	_	O	O	_	_	_	_	_
32	]	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Intriguingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	has	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	shown	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	act	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	general	_	O	O	_	_	_	_	_
14	splicing	_	O	O	_	_	_	_	_
15	factor	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	participates	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	pre	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	mRNA	_	O	O	_	_	_	_	_
22	splicing	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	7	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Depletion	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	HeLa	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	extracts	_	O	O	_	_	_	_	_
9	blocked	_	O	O	_	_	_	_	_
10	splicing	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	multiple	_	O	O	_	_	_	_	_
13	substrates	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	HMG	_	O	O	_	_	_	_	_
20	domain	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	either	_	O	O	_	_	_	_	_
23	Sox	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	Sox	_	O	O	_	_	_	_	_
27	9	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	or	_	O	O	_	_	_	_	_
30	Sry	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	extracts	_	O	O	_	_	_	_	_
34	restored	_	O	O	_	_	_	_	_
35	splicing	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	indicating	_	O	O	_	_	_	_	_
38	functional	_	O	O	_	_	_	_	_
39	overlap	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	these	_	O	O	_	_	_	_	_
42	proteins	_	O	O	_	_	_	_	_
43	[	_	O	O	_	_	_	_	_
44	7	_	O	O	_	_	_	_	_
45	]	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Regardless	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	how	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	functions	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	regulating	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	previous	_	O	O	_	_	_	_	_
13	studies	_	O	O	_	_	_	_	_
14	have	_	O	O	_	_	_	_	_
15	demonstrated	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	Sox	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	important	_	O	O	_	_	_	_	_
22	regulatory	_	O	O	_	_	_	_	_
23	molecule	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	plays	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	role	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	development	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	central	_	O	O	_	_	_	_	_
34	nervous	_	O	O	_	_	_	_	_
35	system	_	O	O	_	_	_	_	_
36	[	_	O	O	_	_	_	_	_
37	8	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	11	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	cartilage	_	O	O	_	_	_	_	_
43	[	_	O	O	_	_	_	_	_
44	6	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	12	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	13	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	muscle	_	O	O	_	_	_	_	_
53	[	_	O	O	_	_	_	_	_
54	14	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	15	_	O	O	_	_	_	_	_
57	]	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	Sox	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	null	_	O	O	_	_	_	_	_
6	mutant	_	O	O	_	_	_	_	_
7	mouse	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	100	_	O	O	_	_	_	_	_
11	H	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	previously	_	O	O	_	_	_	_	_
15	been	_	O	O	_	_	_	_	_
16	identified	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	our	_	O	O	_	_	_	_	_
19	laboratory	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	14	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Mice	_	O	O	_	_	_	_	_
2	homozygous	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	100	_	O	O	_	_	_	_	_
6	H	_	O	O	_	_	_	_	_
7	show	_	O	O	_	_	_	_	_
8	delayed	_	O	O	_	_	_	_	_
9	growth	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	develop	_	O	O	_	_	_	_	_
12	myopathy	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	arterioventricular	_	O	O	_	_	_	_	_
15	heart	_	O	O	_	_	_	_	_
16	block	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	die	_	O	O	_	_	_	_	_
20	within	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	wk	_	O	O	_	_	_	_	_
23	after	_	O	O	_	_	_	_	_
24	birth	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	14	_	O	O	_	_	_	_	_
27	]	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	100	_	O	O	_	_	_	_	_
4	H	_	O	O	_	_	_	_	_
5	mutant	_	O	O	_	_	_	_	_
6	allele	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	associated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	Chromosome	_	O	O	_	_	_	_	_
12	7	_	O	O	_	_	_	_	_
13	inversion	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	disrupts	_	O	O	_	_	_	_	_
16	both	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	gene	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Sox	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	no	_	O	O	_	_	_	_	_
28	other	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	within	_	O	O	_	_	_	_	_
31	50	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	000	_	O	O	_	_	_	_	_
34	nucleotides	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	chromosomal	_	O	O	_	_	_	_	_
38	breakpoints	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	[	_	O	O	_	_	_	_	_
41	14	_	O	O	_	_	_	_	_
42	]	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	functions	_	O	O	_	_	_	_	_
6	solely	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	pigmentation	_	O	O	_	_	_	_	_
9	[	_	O	O	_	_	_	_	_
10	16	_	O	O	_	_	_	_	_
11	]	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	Sox	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	factor	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	implicated	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	all	_	O	O	_	_	_	_	_
22	other	_	O	O	_	_	_	_	_
23	phenotypes	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Among	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	HMG	_	O	O	_	_	_	_	_
4	box	_	O	O	_	_	_	_	_
5	proteins	_	O	O	_	_	_	_	_
6	distantly	_	O	O	_	_	_	_	_
7	related	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	Sry	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	first	_	O	O	_	_	_	_	_
13	member	_	O	O	_	_	_	_	_
14	identified	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	Sox	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	family	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	similarly	_	O	O	_	_	_	_	_
24	bind	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	minor	_	O	O	_	_	_	_	_
28	groove	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	bend	_	O	O	_	_	_	_	_
31	DNA	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	but	_	O	O	_	_	_	_	_
34	without	_	O	O	_	_	_	_	_
35	sequence	_	O	O	_	_	_	_	_
36	specificity	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	are	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	ubiquitously	_	O	O	_	_	_	_	_
41	expressed	_	O	O	_	_	_	_	_
42	HMG	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	HMG	_	O	O	_	_	_	_	_
46	2	_	O	O	_	_	_	_	_
47	proteins	_	O	O	_	_	_	_	_
48	[	_	O	O	_	_	_	_	_
49	17	_	O	O	_	_	_	_	_
50	]	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	Modulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	DNA	_	O	O	_	_	_	_	_
4	structure	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	other	_	O	O	_	_	_	_	_
9	HMG	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	can	_	O	O	_	_	_	_	_
12	mediate	_	O	O	_	_	_	_	_
13	long	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	range	_	O	O	_	_	_	_	_
16	enhancer	_	O	O	_	_	_	_	_
17	function	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	both	_	O	O	_	_	_	_	_
20	DNA	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	chromatin	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	assembled	_	O	O	_	_	_	_	_
25	genes	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	bringing	_	O	O	_	_	_	_	_
28	together	_	O	O	_	_	_	_	_
29	distant	_	O	O	_	_	_	_	_
30	regions	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	DNA	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	associated	_	O	O	_	_	_	_	_
35	factors	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Specifically	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	HMG	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	have	_	O	O	_	_	_	_	_
6	been	_	O	O	_	_	_	_	_
7	shown	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	modulate	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	globin	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	[	_	O	O	_	_	_	_	_
15	18	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	21	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	mouse	_	O	O	_	_	_	_	_
3	beta	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	globin	_	O	O	_	_	_	_	_
6	genes	_	O	O	_	_	_	_	_
7	{	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	betah	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	beta	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	major	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	beta	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	minor	_	O	O	_	_	_	_	_
21	}	_	O	O	_	_	_	_	_
22	are	_	O	O	_	_	_	_	_
23	clustered	_	O	O	_	_	_	_	_
24	on	_	O	O	_	_	_	_	_
25	Chromosome	_	O	O	_	_	_	_	_
26	7	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	they	_	O	O	_	_	_	_	_
29	are	_	O	O	_	_	_	_	_
30	highly	_	O	O	_	_	_	_	_
31	homologous	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	their	_	O	O	_	_	_	_	_
34	human	_	O	O	_	_	_	_	_
35	counterparts	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	organizational	_	O	O	_	_	_	_	_
38	structure	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	function	_	O	O	_	_	_	_	_
41	[	_	O	O	_	_	_	_	_
42	22	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	High	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	level	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	genes	_	O	O	_	_	_	_	_
8	requires	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	regulatory	_	O	O	_	_	_	_	_
11	element	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	locus	_	O	O	_	_	_	_	_
15	control	_	O	O	_	_	_	_	_
16	region	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	characterized	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	set	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	nuclease	_	O	O	_	_	_	_	_
25	hypersensitive	_	O	O	_	_	_	_	_
26	sites	_	O	O	_	_	_	_	_
27	spread	_	O	O	_	_	_	_	_
28	over	_	O	O	_	_	_	_	_
29	25	_	O	O	_	_	_	_	_
30	kb	_	O	O	_	_	_	_	_
31	located	_	O	O	_	_	_	_	_
32	5	_	O	O	_	_	_	_	_
33	'	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	epsilony	_	O	O	_	_	_	_	_
37	gene	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	23	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	beta	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	globin	_	O	O	_	_	_	_	_
5	genes	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	expressed	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	tissue	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	development	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	specific	_	O	O	_	_	_	_	_
16	fashion	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	mice	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	erythropoiesis	_	O	O	_	_	_	_	_
5	originates	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	embryonic	_	O	O	_	_	_	_	_
9	yolk	_	O	O	_	_	_	_	_
10	sac	_	O	O	_	_	_	_	_
11	where	_	O	O	_	_	_	_	_
12	primitive	_	O	O	_	_	_	_	_
13	erythroid	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	express	_	O	O	_	_	_	_	_
16	epsilony	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	betah	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	globins	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	22	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	11	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	d	_	O	O	_	_	_	_	_
6	post	_	O	O	_	_	_	_	_
7	coitus	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	dpc	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	erythropoiesis	_	O	O	_	_	_	_	_
13	shifts	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	fetal	_	O	O	_	_	_	_	_
17	liver	_	O	O	_	_	_	_	_
18	where	_	O	O	_	_	_	_	_
19	definitive	_	O	O	_	_	_	_	_
20	erythroid	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	express	_	O	O	_	_	_	_	_
23	adult	_	O	O	_	_	_	_	_
24	beta	_	O	O	_	_	_	_	_
25	globins	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	beta	_	O	O	_	_	_	_	_
28	major	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	minor	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	[	_	O	O	_	_	_	_	_
33	22	_	O	O	_	_	_	_	_
34	]	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	epsilony	_	O	O	_	_	_	_	_
3	gene	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	silenced	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	definitive	_	O	O	_	_	_	_	_
8	erythroid	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	silencing	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	its	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	counterpart	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	epsilon	_	O	O	_	_	_	_	_
11	globin	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	studied	_	O	O	_	_	_	_	_
16	extensively	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	definitive	_	O	O	_	_	_	_	_
3	erythropoiesis	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	epsilon	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	activated	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	silenced	_	O	O	_	_	_	_	_
10	autonomously	_	O	O	_	_	_	_	_
11	[	_	O	O	_	_	_	_	_
12	24	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	25	_	O	O	_	_	_	_	_
15	]	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	although	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	primitive	_	O	O	_	_	_	_	_
20	erythropoiesis	_	O	O	_	_	_	_	_
21	epsilon	_	O	O	_	_	_	_	_
22	also	_	O	O	_	_	_	_	_
23	appears	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	be	_	O	O	_	_	_	_	_
26	regulated	_	O	O	_	_	_	_	_
27	competitively	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	26	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	gamma	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	globin	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	adult	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	switch	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	controlled	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	competition	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	LCR	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	24	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	25	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	All	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	elements	_	O	O	_	_	_	_	_
4	responsible	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	silencing	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	epsilon	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	within	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	epsilon	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	adjacent	_	O	O	_	_	_	_	_
19	sequences	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	27	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	suggesting	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	silencing	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	primarily	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	autonomous	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	promoter	_	O	O	_	_	_	_	_
3	deletion	_	O	O	_	_	_	_	_
4	analyses	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	transgenic	_	O	O	_	_	_	_	_
7	mouse	_	O	O	_	_	_	_	_
8	models	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	transfection	_	O	O	_	_	_	_	_
12	assays	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	multiple	_	O	O	_	_	_	_	_
15	DNA	_	O	O	_	_	_	_	_
16	elements	_	O	O	_	_	_	_	_
17	important	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	silencing	_	O	O	_	_	_	_	_
21	process	_	O	O	_	_	_	_	_
22	have	_	O	O	_	_	_	_	_
23	been	_	O	O	_	_	_	_	_
24	previously	_	O	O	_	_	_	_	_
25	identified	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	both	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	proximal	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	distal	_	O	O	_	_	_	_	_
33	epsilon	_	O	O	_	_	_	_	_
34	gene	_	O	O	_	_	_	_	_
35	promoter	_	O	O	_	_	_	_	_
36	[	_	O	O	_	_	_	_	_
37	27	_	O	O	_	_	_	_	_
38	]	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Their	_	O	O	_	_	_	_	_
2	corresponding	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factors	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	such	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	GATA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	YY	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	COUP	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	TF	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	DRED	_	O	O	_	_	_	_	_
22	have	_	O	O	_	_	_	_	_
23	been	_	O	O	_	_	_	_	_
24	identified	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	shown	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	directly	_	O	O	_	_	_	_	_
29	bind	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	these	_	O	O	_	_	_	_	_
32	DNA	_	O	O	_	_	_	_	_
33	elements	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	part	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	protein	_	O	O	_	_	_	_	_
39	complexes	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	regulate	_	O	O	_	_	_	_	_
43	epsilon	_	O	O	_	_	_	_	_
44	silencing	_	O	O	_	_	_	_	_
45	[	_	O	O	_	_	_	_	_
46	27	_	O	O	_	_	_	_	_
47	]	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	appears	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	silencing	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	epsilon	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	involves	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	complicated	_	O	O	_	_	_	_	_
15	network	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	multiple	_	O	O	_	_	_	_	_
18	cis	_	O	O	_	_	_	_	_
19	elements	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	transacting	_	O	O	_	_	_	_	_
22	proteins	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	playing	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	important	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	development	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	central	_	O	O	_	_	_	_	_
14	nervous	_	O	O	_	_	_	_	_
15	system	_	O	O	_	_	_	_	_
16	[	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	11	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	cartilage	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	12	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	13	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	muscle	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	14	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	15	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	it	_	O	O	_	_	_	_	_
40	was	_	O	O	_	_	_	_	_
41	shown	_	O	O	_	_	_	_	_
42	that	_	O	O	_	_	_	_	_
43	Sox	_	O	O	_	_	_	_	_
44	6	_	O	O	_	_	_	_	_
45	is	_	O	O	_	_	_	_	_
46	upregulated	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	long	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	term	_	O	O	_	_	_	_	_
51	hematopoiesis	_	O	O	_	_	_	_	_
52	stem	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	LT	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	HSC	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	compared	_	O	O	_	_	_	_	_
60	with	_	O	O	_	_	_	_	_
61	multipotent	_	O	O	_	_	_	_	_
62	progenitors	_	O	O	_	_	_	_	_
63	of	_	O	O	_	_	_	_	_
64	adult	_	O	O	_	_	_	_	_
65	mouse	_	O	O	_	_	_	_	_
66	bone	_	O	O	_	_	_	_	_
67	marrow	_	O	O	_	_	_	_	_
68	lineage	_	O	O	_	_	_	_	_
69	[	_	O	O	_	_	_	_	_
70	28	_	O	O	_	_	_	_	_
71	]	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	describe	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	also	_	O	O	_	_	_	_	_
11	exerts	_	O	O	_	_	_	_	_
12	pleiotropic	_	O	O	_	_	_	_	_
13	effects	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	erythropoiesis	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	include	_	O	O	_	_	_	_	_
4	delayed	_	O	O	_	_	_	_	_
5	maturation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	erythrocytes	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	normally	_	O	O	_	_	_	_	_
11	enucleate	_	O	O	_	_	_	_	_
12	prior	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	entering	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	bloodstream	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	27	_	O	O	_	_	_	_	_
19	])	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	higher	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	embryonic	_	O	O	_	_	_	_	_
25	globin	_	O	O	_	_	_	_	_
26	genes	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	most	_	O	O	_	_	_	_	_
3	extreme	_	O	O	_	_	_	_	_
4	effect	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	persistence	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	high	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	embryonic	_	O	O	_	_	_	_	_
14	epsilony	_	O	O	_	_	_	_	_
15	globin	_	O	O	_	_	_	_	_
16	gene	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	describe	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	characterize	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	effects	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	globin	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	binds	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	proximal	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	epsilony	_	O	O	_	_	_	_	_
13	globin	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	represses	_	O	O	_	_	_	_	_
16	its	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	wild	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	type	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	WT	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	Sox	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	expressed	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	yolk	_	O	O	_	_	_	_	_
17	sac	_	O	O	_	_	_	_	_
18	blood	_	O	O	_	_	_	_	_
19	islands	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	but	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	expressed	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	fetal	_	O	O	_	_	_	_	_
26	liver	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	opposite	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	pattern	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	epsilony	_	O	O	_	_	_	_	_
34	globin	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	absence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	ectopically	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	fetal	_	O	O	_	_	_	_	_
16	liver	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	demonstrating	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	Sox	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	functions	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	definitive	_	O	O	_	_	_	_	_
25	erythropoiesis	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_



1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	production	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	PBMC	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	patients	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	OA	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	normal	_	O	O	_	_	_	_	_
17	individuals	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	separated	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	cultured	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	PHA	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	mug	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	ml	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	from	_	O	O	_	_	_	_	_
15	patients	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	OA	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	age	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	matched	_	O	O	_	_	_	_	_
27	normal	_	O	O	_	_	_	_	_
28	controls	_	O	O	_	_	_	_	_
29	;	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	17	_	O	O	_	_	_	_	_
33	levels	_	O	O	_	_	_	_	_
34	were	_	O	O	_	_	_	_	_
35	then	_	O	O	_	_	_	_	_
36	determined	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	culture	_	O	O	_	_	_	_	_
40	supernatants	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	Fig	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	amounts	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	basal	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	17	_	O	O	_	_	_	_	_
9	secretion	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	different	_	O	O	_	_	_	_	_
13	between	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	OA	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	normal	_	O	O	_	_	_	_	_
19	controls	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	62	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	31	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	43	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	19	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	43	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	10	_	O	O	_	_	_	_	_
38	pg	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	ml	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	respectively	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	IL	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	17	_	O	O	_	_	_	_	_
49	production	_	O	O	_	_	_	_	_
50	stimulated	_	O	O	_	_	_	_	_
51	by	_	O	O	_	_	_	_	_
52	PHA	_	O	O	_	_	_	_	_
53	was	_	O	O	_	_	_	_	_
54	significantly	_	O	O	_	_	_	_	_
55	higher	_	O	O	_	_	_	_	_
56	in	_	O	O	_	_	_	_	_
57	RA	_	O	O	_	_	_	_	_
58	PBMC	_	O	O	_	_	_	_	_
59	than	_	O	O	_	_	_	_	_
60	in	_	O	O	_	_	_	_	_
61	those	_	O	O	_	_	_	_	_
62	from	_	O	O	_	_	_	_	_
63	OA	_	O	O	_	_	_	_	_
64	and	_	O	O	_	_	_	_	_
65	controls	_	O	O	_	_	_	_	_
66	(	_	O	O	_	_	_	_	_
67	768	_	O	O	_	_	_	_	_
68	+	_	O	O	_	_	_	_	_
69	/	_	O	O	_	_	_	_	_
70	-	_	O	O	_	_	_	_	_
71	295	_	O	O	_	_	_	_	_
72	versus	_	O	O	_	_	_	_	_
73	463	_	O	O	_	_	_	_	_
74	+	_	O	O	_	_	_	_	_
75	/	_	O	O	_	_	_	_	_
76	-	_	O	O	_	_	_	_	_
77	211	_	O	O	_	_	_	_	_
78	pg	_	O	O	_	_	_	_	_
79	/	_	O	O	_	_	_	_	_
80	ml	_	O	O	_	_	_	_	_
81	[	_	O	O	_	_	_	_	_
82	P	_	O	O	_	_	_	_	_
83	<	_	O	O	_	_	_	_	_
84	0	_	O	O	_	_	_	_	_
85	.	_	O	O	_	_	_	_	_
86	05	_	O	O	_	_	_	_	_
87	]	_	O	O	_	_	_	_	_
88	and	_	O	O	_	_	_	_	_
89	241	_	O	O	_	_	_	_	_
90	+	_	O	O	_	_	_	_	_
91	/	_	O	O	_	_	_	_	_
92	-	_	O	O	_	_	_	_	_
93	29	_	O	O	_	_	_	_	_
94	pg	_	O	O	_	_	_	_	_
95	/	_	O	O	_	_	_	_	_
96	ml	_	O	O	_	_	_	_	_
97	[	_	O	O	_	_	_	_	_
98	P	_	O	O	_	_	_	_	_
99	<	_	O	O	_	_	_	_	_
100	0	_	O	O	_	_	_	_	_
101	.	_	O	O	_	_	_	_	_
102	001	_	O	O	_	_	_	_	_
103	])	_	O	O	_	_	_	_	_
104	.	_	O	O	_	_	_	_	_



1	Statistical	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_

1	Data	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	expressed	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	mean	_	O	O	_	_	_	_	_
7	value	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	standard	_	O	O	_	_	_	_	_
12	error	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	mean	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	box	_	O	O	_	_	_	_	_
18	plots	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	statistical	_	O	O	_	_	_	_	_
3	significance	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	differences	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	groups	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	determined	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Mann	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Whitney	_	O	O	_	_	_	_	_
16	U	_	O	O	_	_	_	_	_
17	test	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	Wilcoxon	_	O	O	_	_	_	_	_
21	signed	_	O	O	_	_	_	_	_
22	rank	_	O	O	_	_	_	_	_
23	test	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	P	_	O	O	_	_	_	_	_
2	<	_	O	O	_	_	_	_	_
3	0	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_
5	05	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	considered	_	O	O	_	_	_	_	_
8	significant	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_



1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	production	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	signal	_	O	O	_	_	_	_	_
9	transduction	_	O	O	_	_	_	_	_
10	inhibitors	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	anti	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	rheumatic	_	O	O	_	_	_	_	_
15	drugs	_	O	O	_	_	_	_	_

1	Having	_	O	O	_	_	_	_	_
2	observed	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	increased	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	17	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	PBMC	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	it	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	important	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	know	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	signal	_	O	O	_	_	_	_	_
20	transduction	_	O	O	_	_	_	_	_
21	pathways	_	O	O	_	_	_	_	_
22	were	_	O	O	_	_	_	_	_
23	involved	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	illustrated	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Fig	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	decrease	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	anti	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	observed	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	co	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	incubated	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kappaB	_	O	O	_	_	_	_	_
27	inhibitor	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	PDTC	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	dexamethasone	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	comparison	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	anti	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	alone	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	38	_	O	O	_	_	_	_	_
42	+	_	O	O	_	_	_	_	_
43	/	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	5	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	54	_	O	O	_	_	_	_	_
48	+	_	O	O	_	_	_	_	_
49	/	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	11	_	O	O	_	_	_	_	_
52	versus	_	O	O	_	_	_	_	_
53	98	_	O	O	_	_	_	_	_
54	+	_	O	O	_	_	_	_	_
55	/	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	19	_	O	O	_	_	_	_	_
58	pg	_	O	O	_	_	_	_	_
59	/	_	O	O	_	_	_	_	_
60	ml	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	respectively	_	O	O	_	_	_	_	_
63	;	_	O	O	_	_	_	_	_
64	P	_	O	O	_	_	_	_	_
65	<	_	O	O	_	_	_	_	_
66	0	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_
68	05	_	O	O	_	_	_	_	_
69	)	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_


1	LY	_	O	O	_	_	_	_	_
2	294002	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	wortmannin	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	inhibitor	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	PI	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	K	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	markedly	_	O	O	_	_	_	_	_
16	inhibited	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	anti	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	induced	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	17	_	O	O	_	_	_	_	_
27	production	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	PBMC	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	98	_	O	O	_	_	_	_	_
33	+	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	19	_	O	O	_	_	_	_	_
37	versus	_	O	O	_	_	_	_	_
38	38	_	O	O	_	_	_	_	_
39	+	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	10	_	O	O	_	_	_	_	_
43	pg	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	ml	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	P	_	O	O	_	_	_	_	_
48	<	_	O	O	_	_	_	_	_
49	0	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	005	_	O	O	_	_	_	_	_
52	]	_	O	O	_	_	_	_	_
53	and	_	O	O	_	_	_	_	_
54	48	_	O	O	_	_	_	_	_
55	+	_	O	O	_	_	_	_	_
56	/	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	4	_	O	O	_	_	_	_	_
59	pg	_	O	O	_	_	_	_	_
60	/	_	O	O	_	_	_	_	_
61	ml	_	O	O	_	_	_	_	_
62	[	_	O	O	_	_	_	_	_
63	P	_	O	O	_	_	_	_	_
64	<	_	O	O	_	_	_	_	_
65	0	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_
67	05	_	O	O	_	_	_	_	_
68	]	_	O	O	_	_	_	_	_
69	,	_	O	O	_	_	_	_	_
70	respectively	_	O	O	_	_	_	_	_
71	)	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	calcineurin	_	O	O	_	_	_	_	_
3	inhibitors	_	O	O	_	_	_	_	_
4	cyclosporin	_	O	O	_	_	_	_	_
5	A	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	FK	_	O	O	_	_	_	_	_
8	506	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	downregulated	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	17	_	O	O	_	_	_	_	_
15	secretion	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	well	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	mitogen	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	activated	_	O	O	_	_	_	_	_
23	protein	_	O	O	_	_	_	_	_
24	kinase	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	MAPK	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	38	_	O	O	_	_	_	_	_
30	inhibitor	_	O	O	_	_	_	_	_
31	SB	_	O	O	_	_	_	_	_
32	203580	_	O	O	_	_	_	_	_
33	did	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	whereas	_	O	O	_	_	_	_	_
36	rapamycin	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	PD	_	O	O	_	_	_	_	_
39	98059	_	O	O	_	_	_	_	_
40	had	_	O	O	_	_	_	_	_
41	no	_	O	O	_	_	_	_	_
42	effect	_	O	O	_	_	_	_	_
43	on	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	17	_	O	O	_	_	_	_	_
47	levels	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	Fig	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	evaluate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	possibility	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	non	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	specific	_	O	O	_	_	_	_	_
9	inhibition	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	drug	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	high	_	O	O	_	_	_	_	_
15	concentrations	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	we	_	O	O	_	_	_	_	_
18	observed	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	dose	_	O	O	_	_	_	_	_
21	response	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	PDTC	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	LY	_	O	O	_	_	_	_	_
26	294002	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	inhibition	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	17	_	O	O	_	_	_	_	_
34	production	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	PBMC	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	dose	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	dependent	_	O	O	_	_	_	_	_
6	inhibitions	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	17	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	chemical	_	O	O	_	_	_	_	_
14	inhibitors	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	Fig	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	other	_	O	O	_	_	_	_	_
3	inhibitors	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	addition	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	PDTC	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	LY	_	O	O	_	_	_	_	_
10	294002	_	O	O	_	_	_	_	_
11	showed	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	same	_	O	O	_	_	_	_	_
14	pattern	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	inhibition	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Cytotoxic	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	PBMC	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	chemical	_	O	O	_	_	_	_	_
8	inhibitors	_	O	O	_	_	_	_	_
9	at	_	O	O	_	_	_	_	_
10	experimental	_	O	O	_	_	_	_	_
11	concentrations	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	observed	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	Fig	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	b	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_



1	Sp	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	functions	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	chromatin	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	dependent	_	O	O	_	_	_	_	_
9	manner	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	augment	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	globin	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	5	_	O	O	_	_	_	_	_
3	'	_	O	O	_	_	_	_	_
4	flanking	_	O	O	_	_	_	_	_
5	region	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	globin	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	highly	_	O	O	_	_	_	_	_
15	G	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	C	_	O	O	_	_	_	_	_
18	rich	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	contains	_	O	O	_	_	_	_	_
21	multiple	_	O	O	_	_	_	_	_
22	copies	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	consensus	_	O	O	_	_	_	_	_
26	sequence	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	Sp	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	binding	_	O	O	_	_	_	_	_
32	site	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	role	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	G	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	rich	_	O	O	_	_	_	_	_
12	region	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	augmenting	_	O	O	_	_	_	_	_
15	alpha	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	globin	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	activity	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	presence	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	far	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	upstream	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	globin	_	O	O	_	_	_	_	_
31	enhancer	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	HS	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	40	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	transiently	_	O	O	_	_	_	_	_
6	transfected	_	O	O	_	_	_	_	_
7	erythroid	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	deletion	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	globin	_	O	O	_	_	_	_	_
16	G	_	O	O	_	_	_	_	_
17	+	_	O	O	_	_	_	_	_
18	C	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	rich	_	O	O	_	_	_	_	_
21	5	_	O	O	_	_	_	_	_
22	'	_	O	O	_	_	_	_	_
23	flanking	_	O	O	_	_	_	_	_
24	region	_	O	O	_	_	_	_	_
25	has	_	O	O	_	_	_	_	_
26	no	_	O	O	_	_	_	_	_
27	effect	_	O	O	_	_	_	_	_
28	on	_	O	O	_	_	_	_	_
29	alpha	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	globin	_	O	O	_	_	_	_	_
32	promoter	_	O	O	_	_	_	_	_
33	activity	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	upon	_	O	O	_	_	_	_	_
4	stable	_	O	O	_	_	_	_	_
5	integration	_	O	O	_	_	_	_	_
6	into	_	O	O	_	_	_	_	_
7	chromatin	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	deletion	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	this	_	O	O	_	_	_	_	_
12	region	_	O	O	_	_	_	_	_
13	causes	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	nearly	_	O	O	_	_	_	_	_
16	90	_	O	O	_	_	_	_	_
17	%	_	O	O	_	_	_	_	_
18	decrease	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	compared	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	from	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	globin	_	O	O	_	_	_	_	_
30	promoter	_	O	O	_	_	_	_	_
31	retaining	_	O	O	_	_	_	_	_
32	this	_	O	O	_	_	_	_	_
33	region	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	globin	_	O	O	_	_	_	_	_
9	G	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	C	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	rich	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	'	_	O	O	_	_	_	_	_
16	flanking	_	O	O	_	_	_	_	_
17	region	_	O	O	_	_	_	_	_
18	augments	_	O	O	_	_	_	_	_
19	alpha	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	globin	_	O	O	_	_	_	_	_
22	promoter	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	chromatin	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	dependent	_	O	O	_	_	_	_	_
29	manner	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	further	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	G	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	C	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	rich	_	O	O	_	_	_	_	_
11	region	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	required	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	globin	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	during	_	O	O	_	_	_	_	_
24	erythroid	_	O	O	_	_	_	_	_
25	differentiation	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	footprint	_	O	O	_	_	_	_	_
8	analysis	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	functional	_	O	O	_	_	_	_	_
11	assays	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	ability	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	G	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	C	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	rich	_	O	O	_	_	_	_	_
22	region	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	increase	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	globin	_	O	O	_	_	_	_	_
28	promoter	_	O	O	_	_	_	_	_
29	activity	_	O	O	_	_	_	_	_
30	from	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	stably	_	O	O	_	_	_	_	_
33	integrated	_	O	O	_	_	_	_	_
34	alpha	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	globin	_	O	O	_	_	_	_	_
37	gene	_	O	O	_	_	_	_	_
38	is	_	O	O	_	_	_	_	_
39	mediated	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	its	_	O	O	_	_	_	_	_
42	multiple	_	O	O	_	_	_	_	_
43	binding	_	O	O	_	_	_	_	_
44	sites	_	O	O	_	_	_	_	_
45	for	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	transcription	_	O	O	_	_	_	_	_
48	factor	_	O	O	_	_	_	_	_
49	Sp	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	situ	_	O	O	_	_	_	_	_
3	hybridization	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	Antisense	_	O	O	_	_	_	_	_
2	probes	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	designed	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	murine	_	O	O	_	_	_	_	_
7	epsilony	_	O	O	_	_	_	_	_
8	globin	_	O	O	_	_	_	_	_
9	nucleotides	_	O	O	_	_	_	_	_
10	509	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	584	_	O	O	_	_	_	_	_
13	;	_	O	O	_	_	_	_	_
14	betamaj	_	O	O	_	_	_	_	_
15	globin	_	O	O	_	_	_	_	_
16	nucleotides	_	O	O	_	_	_	_	_
17	458	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	549	_	O	O	_	_	_	_	_
20	;	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	mouse	_	O	O	_	_	_	_	_
23	Sox	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	nucleotides	_	O	O	_	_	_	_	_
26	1353	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1927	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Embryos	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	fixed	_	O	O	_	_	_	_	_
4	overnight	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	immersion	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	%	_	O	O	_	_	_	_	_
10	paraformaldehyde	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	embedded	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	paraffin	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	sectioned	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	mum	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	adhered	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	charge	_	O	O	_	_	_	_	_
25	modified	_	O	O	_	_	_	_	_
26	slides	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	VWR	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	West	_	O	O	_	_	_	_	_
31	Chester	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	Pennsylvania	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	United	_	O	O	_	_	_	_	_
36	States	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Slides	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	processed	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	situ	_	O	O	_	_	_	_	_
7	hybridization	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	described	_	O	O	_	_	_	_	_
10	[	_	O	O	_	_	_	_	_
11	52	_	O	O	_	_	_	_	_
12	]	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	vitro	_	O	O	_	_	_	_	_
16	transcribed	_	O	O	_	_	_	_	_
17	RNA	_	O	O	_	_	_	_	_
18	probes	_	O	O	_	_	_	_	_
19	labeled	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	33	_	O	O	_	_	_	_	_
22	P	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Darkfield	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	brightfield	_	O	O	_	_	_	_	_
4	images	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	obtained	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	Nikon	_	O	O	_	_	_	_	_
10	Optiphot	_	O	O	_	_	_	_	_
11	microscope	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	Nikon	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	Melville	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	New	_	O	O	_	_	_	_	_
18	York	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	United	_	O	O	_	_	_	_	_
21	States	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	SPOT	_	O	O	_	_	_	_	_
25	RT	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	Slider	_	O	O	_	_	_	_	_
28	digital	_	O	O	_	_	_	_	_
29	camera	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	Diagnostic	_	O	O	_	_	_	_	_
32	Instruments	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	Sterling	_	O	O	_	_	_	_	_
35	Heights	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	Michigan	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	United	_	O	O	_	_	_	_	_
40	States	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Objectives	_	O	O	_	_	_	_	_
2	used	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	x	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	NA	_	O	O	_	_	_	_	_
8	=	_	O	O	_	_	_	_	_
9	0	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	04	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	x	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	NA	_	O	O	_	_	_	_	_
18	=	_	O	O	_	_	_	_	_
19	0	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	5	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Images	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	processed	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	pseudocolored	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	combined	_	O	O	_	_	_	_	_
9	using	_	O	O	_	_	_	_	_
10	Photoshop	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	Adobe	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	San	_	O	O	_	_	_	_	_
15	Jose	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	California	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	United	_	O	O	_	_	_	_	_
20	States	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	software	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	Fovea	_	O	O	_	_	_	_	_
25	Pro	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	Reindeer	_	O	O	_	_	_	_	_
28	Graphics	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	Asheville	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	North	_	O	O	_	_	_	_	_
33	Carolina	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	United	_	O	O	_	_	_	_	_
36	States	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	plugins	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Original	_	O	O	_	_	_	_	_
2	images	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	available	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_



1	Transcription	_	O	O	_	_	_	_	_
2	factors	_	O	O	_	_	_	_	_
3	Sp	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	AP	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	mediate	_	O	O	_	_	_	_	_
10	induction	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	acid	_	O	O	_	_	_	_	_
13	sphingomyelinase	_	O	O	_	_	_	_	_
14	during	_	O	O	_	_	_	_	_
15	monocytic	_	O	O	_	_	_	_	_
16	differentiation	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Cells	_	O	O	_	_	_	_	_
2	from	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	monocytic	_	O	O	_	_	_	_	_
6	leukemia	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	line	_	O	O	_	_	_	_	_
9	THP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	differentiate	_	O	O	_	_	_	_	_
13	towards	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	macrophage	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	like	_	O	O	_	_	_	_	_
18	phenotype	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	stimulated	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	phorbol	_	O	O	_	_	_	_	_
23	12	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	myristate	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	13	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	acetate	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	PMA	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	25	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	dihydroxy	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	vitamin	_	O	O	_	_	_	_	_
41	D	_	O	O	_	_	_	_	_
42	3	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	various	_	O	O	_	_	_	_	_
46	other	_	O	O	_	_	_	_	_
47	agents	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	demonstrate	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	lysosomal	_	O	O	_	_	_	_	_
10	enzyme	_	O	O	_	_	_	_	_
11	acid	_	O	O	_	_	_	_	_
12	sphingomyelinase	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	ASM	_	O	O	_	_	_	_	_
15	;	_	O	O	_	_	_	_	_
16	E	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	C	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	4	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	12	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	induced	_	O	O	_	_	_	_	_
30	during	_	O	O	_	_	_	_	_
31	this	_	O	O	_	_	_	_	_
32	process	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	is	_	O	O	_	_	_	_	_
35	strongly	_	O	O	_	_	_	_	_
36	elevated	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	differentiated	_	O	O	_	_	_	_	_
39	THP	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	as	_	O	O	_	_	_	_	_
45	well	_	O	O	_	_	_	_	_
46	as	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	differentiated	_	O	O	_	_	_	_	_
49	human	_	O	O	_	_	_	_	_
50	mononuclear	_	O	O	_	_	_	_	_
51	phagocytes	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	Northern	_	O	O	_	_	_	_	_
3	blotting	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	RNase	_	O	O	_	_	_	_	_
6	protection	_	O	O	_	_	_	_	_
7	assay	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	nuclear	_	O	O	_	_	_	_	_
11	run	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	analyses	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	we	_	O	O	_	_	_	_	_
17	show	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	up	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	regulation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	ASM	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	regulated	_	O	O	_	_	_	_	_
28	mainly	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	level	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	transcription	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	new	_	O	O	_	_	_	_	_
37	protein	_	O	O	_	_	_	_	_
38	synthesis	_	O	O	_	_	_	_	_
39	is	_	O	O	_	_	_	_	_
40	required	_	O	O	_	_	_	_	_
41	for	_	O	O	_	_	_	_	_
42	enhanced	_	O	O	_	_	_	_	_
43	ASM	_	O	O	_	_	_	_	_
44	activity	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	type	_	O	O	_	_	_	_	_
5	specific	_	O	O	_	_	_	_	_
6	induction	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	PMA	_	O	O	_	_	_	_	_
9	treatment	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	further	_	O	O	_	_	_	_	_
12	investigated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	respect	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	transcriptional	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	series	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	'	_	O	O	_	_	_	_	_
6	deletion	_	O	O	_	_	_	_	_
7	derivatives	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	upstream	_	O	O	_	_	_	_	_
11	regulatory	_	O	O	_	_	_	_	_
12	region	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	used	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	transient	_	O	O	_	_	_	_	_
17	transfection	_	O	O	_	_	_	_	_
18	assays	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	identify	_	O	O	_	_	_	_	_
21	promoter	_	O	O	_	_	_	_	_
22	elements	_	O	O	_	_	_	_	_
23	required	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	basal	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	inducible	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	PMA	_	O	O	_	_	_	_	_
3	responsive	_	O	O	_	_	_	_	_
4	element	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	localized	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	region	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	319	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	219	_	O	O	_	_	_	_	_
16	bp	_	O	O	_	_	_	_	_
17	upstream	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	initiation	_	O	O	_	_	_	_	_
21	codon	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	co	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	transfections	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	transcription	_	O	O	_	_	_	_	_
28	factor	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	plasmids	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	AP	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	Sp	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	resulted	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	augmented	_	O	O	_	_	_	_	_
41	ASM	_	O	O	_	_	_	_	_
42	promoter	_	O	O	_	_	_	_	_
43	activity	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	which	_	O	O	_	_	_	_	_
46	was	_	O	O	_	_	_	_	_
47	abolished	_	O	O	_	_	_	_	_
48	when	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	binding	_	O	O	_	_	_	_	_
51	sites	_	O	O	_	_	_	_	_
52	for	_	O	O	_	_	_	_	_
53	these	_	O	O	_	_	_	_	_
54	two	_	O	O	_	_	_	_	_
55	factors	_	O	O	_	_	_	_	_
56	were	_	O	O	_	_	_	_	_
57	deleted	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	electrophoretic	_	O	O	_	_	_	_	_
3	mobility	_	O	O	_	_	_	_	_
4	shift	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	supershift	_	O	O	_	_	_	_	_
8	assays	_	O	O	_	_	_	_	_
9	we	_	O	O	_	_	_	_	_
10	demonstrate	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	this	_	O	O	_	_	_	_	_
13	region	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	specifically	_	O	O	_	_	_	_	_
16	bound	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	Sp	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	AP	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	factors	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	present	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	extracts	_	O	O	_	_	_	_	_
8	prepared	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	both	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	uninduced	_	O	O	_	_	_	_	_
14	THP	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	intensity	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	complex	_	O	O	_	_	_	_	_
8	formed	_	O	O	_	_	_	_	_
9	appeared	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	increase	_	O	O	_	_	_	_	_
12	when	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	extracts	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	PMA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	treated	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	used	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	From	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	conclude	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	concerted	_	O	O	_	_	_	_	_
10	action	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factors	_	O	O	_	_	_	_	_
15	AP	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	Sp	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	essential	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	up	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	regulation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	ASM	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	during	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	process	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	macrophage	_	O	O	_	_	_	_	_
36	differentiation	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Histology	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	18	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_
3	5	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	dpc	_	O	O	_	_	_	_	_
6	embryos	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	exsanguinated	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	peripheral	_	O	O	_	_	_	_	_
11	blood	_	O	O	_	_	_	_	_
12	smears	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	prepared	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	both	_	O	O	_	_	_	_	_
17	mutant	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	WT	_	O	O	_	_	_	_	_
20	mice	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	slides	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	Wright	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	stained	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	read	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	DAF	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	whole	_	O	O	_	_	_	_	_
3	mount	_	O	O	_	_	_	_	_
4	analysis	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	14	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	dpc	_	O	O	_	_	_	_	_
11	WT	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	mutant	_	O	O	_	_	_	_	_
14	embryos	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	postnatal	_	O	O	_	_	_	_	_
18	day	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	5	_	O	O	_	_	_	_	_
23	mice	_	O	O	_	_	_	_	_
24	were	_	O	O	_	_	_	_	_
25	fixed	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	10	_	O	O	_	_	_	_	_
28	%	_	O	O	_	_	_	_	_
29	formalin	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	paraffin	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	embedded	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	sectioned	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	mum	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	stained	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	hematoxylin	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	eosin	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Liver	_	O	O	_	_	_	_	_
2	samples	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	at	_	O	O	_	_	_	_	_
5	14	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_
7	5	_	O	O	_	_	_	_	_
8	dpc	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	18	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	dpc	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	prepared	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	similar	_	O	O	_	_	_	_	_
20	manner	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Images	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	obtained	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	Nikon	_	O	O	_	_	_	_	_
6	Labophot	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	microscope	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Objectives	_	O	O	_	_	_	_	_
2	used	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	Plan	_	O	O	_	_	_	_	_
6	40	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	0	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_
10	65	_	O	O	_	_	_	_	_
11	160	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	0	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	Nikon	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	40	_	O	O	_	_	_	_	_
19	x	_	O	O	_	_	_	_	_
20	objective	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	E	_	O	O	_	_	_	_	_
24	Plan	_	O	O	_	_	_	_	_
25	100	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	25	_	O	O	_	_	_	_	_
30	oil	_	O	O	_	_	_	_	_
31	160	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	0	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_
35	17	_	O	O	_	_	_	_	_
36	Nikon	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	100	_	O	O	_	_	_	_	_
39	x	_	O	O	_	_	_	_	_
40	objective	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	camera	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	Nikon	_	O	O	_	_	_	_	_
6	Coolpix	_	O	O	_	_	_	_	_
7	4300	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Original	_	O	O	_	_	_	_	_
2	images	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	available	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_



1	Extracellular	_	O	O	_	_	_	_	_
2	signal	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	regulated	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	kinase	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	ERK	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	ERK	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	independent	_	O	O	_	_	_	_	_
16	pathways	_	O	O	_	_	_	_	_
17	target	_	O	O	_	_	_	_	_
18	STAT	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	on	_	O	O	_	_	_	_	_
21	serine	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	727	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	human	_	O	O	_	_	_	_	_
26	neutrophils	_	O	O	_	_	_	_	_
27	stimulated	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	chemotactic	_	O	O	_	_	_	_	_
30	factors	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	cytokines	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	STAT	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	signal	_	O	O	_	_	_	_	_
5	transducer	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	activator	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	latent	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	activated	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	phosphorylation	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	Tyr	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	705	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	stimulated	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	cytokines	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	growth	_	O	O	_	_	_	_	_
35	factors	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Recent	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	one	_	O	O	_	_	_	_	_
6	or	_	O	O	_	_	_	_	_
7	more	_	O	O	_	_	_	_	_
8	cytoplasmic	_	O	O	_	_	_	_	_
9	serine	_	O	O	_	_	_	_	_
10	kinases	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	phosphorylate	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	necessary	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	maximal	_	O	O	_	_	_	_	_
20	gene	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	site	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	specific	_	O	O	_	_	_	_	_
10	antibody	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	phosphorylated	_	O	O	_	_	_	_	_
17	on	_	O	O	_	_	_	_	_
18	Ser	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	727	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	neutrophils	_	O	O	_	_	_	_	_
24	stimulated	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	chemotactic	_	O	O	_	_	_	_	_
27	factors	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	N	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	formyl	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	methionyl	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	leucyl	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	phenylalanine	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	complement	_	O	O	_	_	_	_	_
40	C	_	O	O	_	_	_	_	_
41	5	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	cytokines	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	granulocyte	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	macrophage	_	O	O	_	_	_	_	_
50	colony	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	stimulating	_	O	O	_	_	_	_	_
53	factor	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	GM	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	CSF	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	and	_	O	O	_	_	_	_	_
60	granulocyte	_	O	O	_	_	_	_	_
61	colony	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	stimulating	_	O	O	_	_	_	_	_
64	factor	_	O	O	_	_	_	_	_
65	(	_	O	O	_	_	_	_	_
66	G	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	CSF	_	O	O	_	_	_	_	_
69	)]	_	O	O	_	_	_	_	_
70	,	_	O	O	_	_	_	_	_
71	or	_	O	O	_	_	_	_	_
72	a	_	O	O	_	_	_	_	_
73	protein	_	O	O	_	_	_	_	_
74	kinase	_	O	O	_	_	_	_	_
75	C	_	O	O	_	_	_	_	_
76	activator	_	O	O	_	_	_	_	_
77	(	_	O	O	_	_	_	_	_
78	PMA	_	O	O	_	_	_	_	_
79	)	_	O	O	_	_	_	_	_
80	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Amino	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	'	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	methoxyphenyl	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	oxanaphthalen	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	one	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	PD	_	O	O	_	_	_	_	_
18	98059	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	inhibitor	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	extracellular	_	O	O	_	_	_	_	_
25	signal	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	regulated	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	kinase	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	ERK	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	activation	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	blocked	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	serine	_	O	O	_	_	_	_	_
38	phosphorylation	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	STAT	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	induced	_	O	O	_	_	_	_	_
43	by	_	O	O	_	_	_	_	_
44	chemotactic	_	O	O	_	_	_	_	_
45	factors	_	O	O	_	_	_	_	_
46	or	_	O	O	_	_	_	_	_
47	PMA	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	drug	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	less	_	O	O	_	_	_	_	_
5	effective	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	cytokines	_	O	O	_	_	_	_	_
8	:	_	O	O	_	_	_	_	_
9	it	_	O	O	_	_	_	_	_
10	virtually	_	O	O	_	_	_	_	_
11	abolished	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	GM	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	CSF	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	occurred	_	O	O	_	_	_	_	_
20	5	_	O	O	_	_	_	_	_
21	min	_	O	O	_	_	_	_	_
22	after	_	O	O	_	_	_	_	_
23	stimulation	_	O	O	_	_	_	_	_
24	but	_	O	O	_	_	_	_	_
25	only	_	O	O	_	_	_	_	_
26	partly	_	O	O	_	_	_	_	_
27	decreased	_	O	O	_	_	_	_	_
28	those	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	15	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	30	_	O	O	_	_	_	_	_
33	min	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	did	_	O	O	_	_	_	_	_
36	not	_	O	O	_	_	_	_	_
37	appreciably	_	O	O	_	_	_	_	_
38	alter	_	O	O	_	_	_	_	_
39	responses	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	G	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	CSF	_	O	O	_	_	_	_	_
44	regardless	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	incubation	_	O	O	_	_	_	_	_
47	time	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	Isoquinolinylsulphonyl	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	methylpiperazine	_	O	O	_	_	_	_	_
12	dihydrochloride	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	H	_	O	O	_	_	_	_	_
15	7	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	inhibitor	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	putative	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	serine	_	O	O	_	_	_	_	_
26	kinase	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	4	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	fluorophenyl	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	4	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	methylsulphinylphenyl	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	5	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	4	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	pyridyl	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	H	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	imidazole	_	O	O	_	_	_	_	_
56	(	_	O	O	_	_	_	_	_
57	SB	_	O	O	_	_	_	_	_
58	203580	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	an	_	O	O	_	_	_	_	_
62	inhibitor	_	O	O	_	_	_	_	_
63	of	_	O	O	_	_	_	_	_
64	p	_	O	O	_	_	_	_	_
65	38	_	O	O	_	_	_	_	_
66	mitogen	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	activated	_	O	O	_	_	_	_	_
69	protein	_	O	O	_	_	_	_	_
70	(	_	O	O	_	_	_	_	_
71	MAP	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	kinase	_	O	O	_	_	_	_	_
74	,	_	O	O	_	_	_	_	_
75	did	_	O	O	_	_	_	_	_
76	not	_	O	O	_	_	_	_	_
77	dampen	_	O	O	_	_	_	_	_
78	any	_	O	O	_	_	_	_	_
79	of	_	O	O	_	_	_	_	_
80	these	_	O	O	_	_	_	_	_
81	serine	_	O	O	_	_	_	_	_
82	phosphorylation	_	O	O	_	_	_	_	_
83	responses	_	O	O	_	_	_	_	_
84	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	propose	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	neutrophils	_	O	O	_	_	_	_	_
5	use	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	ERK	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	ERK	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	independent	_	O	O	_	_	_	_	_
14	pathways	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	phosphorylate	_	O	O	_	_	_	_	_
17	Ser	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	727	_	O	O	_	_	_	_	_
20	on	_	O	O	_	_	_	_	_
21	STAT	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	former	_	O	O	_	_	_	_	_
3	pathway	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	recruited	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	all	_	O	O	_	_	_	_	_
8	ERK	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	activating	_	O	O	_	_	_	_	_
11	stimuli	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	whereas	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	latter	_	O	O	_	_	_	_	_
16	pathway	_	O	O	_	_	_	_	_
17	uses	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	undefined	_	O	O	_	_	_	_	_
20	serine	_	O	O	_	_	_	_	_
21	kinase	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	recruited	_	O	O	_	_	_	_	_
25	selectively	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	cytokines	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Dimerization	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	KB	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	RelA	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	65	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	regulates	_	O	O	_	_	_	_	_
14	DNA	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	transcriptional	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	inhibition	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	an	_	O	O	_	_	_	_	_
24	I	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	MAD	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	Inducible	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	immunodeficiency	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	HIV	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	regulated	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	cellular	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	kappa	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	NF	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	NF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	kappa	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	composed	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	distinct	_	O	O	_	_	_	_	_
9	subunits	_	O	O	_	_	_	_	_
10	;	_	O	O	_	_	_	_	_
11	five	_	O	O	_	_	_	_	_
12	independent	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	NFKB	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	105	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	NFKB	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	100	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	RelA	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	p	_	O	O	_	_	_	_	_
32	65	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	c	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	rel	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	relB	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	that	_	O	O	_	_	_	_	_
42	encode	_	O	O	_	_	_	_	_
43	related	_	O	O	_	_	_	_	_
44	proteins	_	O	O	_	_	_	_	_
45	that	_	O	O	_	_	_	_	_
46	bind	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	kappa	_	O	O	_	_	_	_	_
49	B	_	O	O	_	_	_	_	_
50	DNA	_	O	O	_	_	_	_	_
51	elements	_	O	O	_	_	_	_	_
52	have	_	O	O	_	_	_	_	_
53	been	_	O	O	_	_	_	_	_
54	isolated	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	found	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	NFKB	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	49	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	52	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	acts	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	concert	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	RelA	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	65	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	stimulate	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	HIV	_	O	O	_	_	_	_	_
28	enhancer	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	Jurkat	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	leukemia	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	examine	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	biochemical	_	O	O	_	_	_	_	_
6	basis	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	transcriptional	_	O	O	_	_	_	_	_
10	regulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	HIV	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	NFKB	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	Scatchard	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	determined	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	dissociation	_	O	O	_	_	_	_	_
10	constants	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	homodimeric	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	49	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	heterodimeric	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	49	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	65	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	HIV	_	O	O	_	_	_	_	_
27	kappa	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	site	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	p	_	O	O	_	_	_	_	_
2	49	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	approximately	_	O	O	_	_	_	_	_
6	18	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	fold	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	lower	_	O	O	_	_	_	_	_
11	affinity	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	HIV	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	site	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	KD	_	O	O	_	_	_	_	_
20	=	_	O	O	_	_	_	_	_
21	69	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	pM	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	than	_	O	O	_	_	_	_	_
27	does	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	approximately	_	O	O	_	_	_	_	_
30	50	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	kDa	_	O	O	_	_	_	_	_
33	protein	_	O	O	_	_	_	_	_
34	NFKB	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	p	_	O	O	_	_	_	_	_
38	50	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	derived	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	p	_	O	O	_	_	_	_	_
43	105	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	KD	_	O	O	_	_	_	_	_
46	=	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_
49	9	_	O	O	_	_	_	_	_
50	pM	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	affinity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	heterodimeric	_	O	O	_	_	_	_	_
8	NFKB	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	49	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	RelA	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	65	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	this	_	O	O	_	_	_	_	_
22	site	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	approximately	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	fold	_	O	O	_	_	_	_	_
28	higher	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	KD	_	O	O	_	_	_	_	_
31	=	_	O	O	_	_	_	_	_
32	11	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	8	_	O	O	_	_	_	_	_
35	pM	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	than	_	O	O	_	_	_	_	_
38	that	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	p	_	O	O	_	_	_	_	_
41	49	_	O	O	_	_	_	_	_
42	alone	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	findings	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	vitro	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	stimulated	_	O	O	_	_	_	_	_
11	18	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	fold	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	addition	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	preformed	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	heterodimeric	_	O	O	_	_	_	_	_
21	NFKB	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	49	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	RelA	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	p	_	O	O	_	_	_	_	_
31	65	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	protein	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Transcriptional	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	HIV	_	O	O	_	_	_	_	_
6	enhancer	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	subject	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	regulation	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	recently	_	O	O	_	_	_	_	_
14	cloned	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	kappa	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	alpha	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	MAD	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	I	_	O	O	_	_	_	_	_
3	kappa	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	MAD	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	inhibited	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	DNA	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	65	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	49	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	65	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	50	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	p	_	O	O	_	_	_	_	_
32	65	_	O	O	_	_	_	_	_
33	but	_	O	O	_	_	_	_	_
34	stimulated	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	binding	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	NFKB	_	O	O	_	_	_	_	_
39	2	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	p	_	O	O	_	_	_	_	_
42	49	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	or	_	O	O	_	_	_	_	_
45	NFKB	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	p	_	O	O	_	_	_	_	_
49	50	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	Functional	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	HIV	_	O	O	_	_	_	_	_
6	reporter	_	O	O	_	_	_	_	_
7	plasmid	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	49	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	65	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	transiently	_	O	O	_	_	_	_	_
16	transfected	_	O	O	_	_	_	_	_
17	Jurkat	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	leukemia	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	also	_	O	O	_	_	_	_	_
24	inhibited	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	coexpression	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	MAD	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	ABSTRACT	_	O	O	_	_	_	_	_
3	TRUNCATED	_	O	O	_	_	_	_	_
4	AT	_	O	O	_	_	_	_	_
5	250	_	O	O	_	_	_	_	_
6	WORDS	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_

1	Interleukin	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	signaling	_	O	O	_	_	_	_	_
4	involves	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	phosphorylation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Stat	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_


1	One	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	most	_	O	O	_	_	_	_	_
5	important	_	O	O	_	_	_	_	_
6	cytokines	_	O	O	_	_	_	_	_
7	involved	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	immune	_	O	O	_	_	_	_	_
10	response	_	O	O	_	_	_	_	_
11	regulation	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	interleukin	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	potent	_	O	O	_	_	_	_	_
23	activator	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	proliferation	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	function	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	lymphocytes	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	natural	_	O	O	_	_	_	_	_
34	killer	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanisms	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	which	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	effects	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	propagated	_	O	O	_	_	_	_	_
13	within	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	understood	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	While	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	binding	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	its	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	recently	_	O	O	_	_	_	_	_
13	shown	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	lead	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	two	_	O	O	_	_	_	_	_
21	kinases	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	Jak	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	Jak	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	subsequent	_	O	O	_	_	_	_	_
32	steps	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	signaling	_	O	O	_	_	_	_	_
36	pathway	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	nucleus	_	O	O	_	_	_	_	_
40	that	_	O	O	_	_	_	_	_
41	lead	_	O	O	_	_	_	_	_
42	to	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	activation	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	specific	_	O	O	_	_	_	_	_
47	genes	_	O	O	_	_	_	_	_
48	had	_	O	O	_	_	_	_	_
49	not	_	O	O	_	_	_	_	_
50	been	_	O	O	_	_	_	_	_
51	characterized	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	many	_	O	O	_	_	_	_	_
3	cytokines	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	activate	_	O	O	_	_	_	_	_
6	Jak	_	O	O	_	_	_	_	_
7	kinases	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	lead	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	tyrosine	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	members	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	Stat	_	O	O	_	_	_	_	_
21	family	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	transcription	_	O	O	_	_	_	_	_
24	factors	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	ability	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	trigger	_	O	O	_	_	_	_	_
34	Stat	_	O	O	_	_	_	_	_
35	phosphorylation	_	O	O	_	_	_	_	_
36	was	_	O	O	_	_	_	_	_
37	examined	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Exposure	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	activated	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	natural	_	O	O	_	_	_	_	_
11	killer	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	line	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	NKL	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	leads	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	phosphorylation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	Stat	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	Stat	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	Stat	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	as	_	O	O	_	_	_	_	_
39	well	_	O	O	_	_	_	_	_
40	as	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	two	_	O	O	_	_	_	_	_
43	Stat	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	related	_	O	O	_	_	_	_	_
46	proteins	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	p	_	O	O	_	_	_	_	_
49	94	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	p	_	O	O	_	_	_	_	_
52	95	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	p	_	O	O	_	_	_	_	_
2	94	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	95	_	O	O	_	_	_	_	_
6	share	_	O	O	_	_	_	_	_
7	homology	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	Stat	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	at	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	Src	_	O	O	_	_	_	_	_
19	homology	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	SH	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	domain	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	but	_	O	O	_	_	_	_	_
28	otherwise	_	O	O	_	_	_	_	_
29	are	_	O	O	_	_	_	_	_
30	immunologically	_	O	O	_	_	_	_	_
31	distinct	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	Stat	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	Stat	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	found	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	translocate	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	nucleus	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	bind	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	DNA	_	O	O	_	_	_	_	_
18	sequence	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	mechanism	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	its	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	activate	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	genes	_	O	O	_	_	_	_	_
19	involved	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	immune	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	function	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Two	_	O	O	_	_	_	_	_
2	distinct	_	O	O	_	_	_	_	_
3	forms	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	active	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	factor	_	O	O	_	_	_	_	_
8	CREB	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	cAMP	_	O	O	_	_	_	_	_
11	response	_	O	O	_	_	_	_	_
12	element	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	Mammalian	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	express	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	distinct	_	O	O	_	_	_	_	_
6	forms	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	CREB	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	cAMP	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	element	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	protein	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	apparently	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	products	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	alternative	_	O	O	_	_	_	_	_
25	splicing	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	CREB	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	transcript	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	two	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	differ	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	14	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	amino	_	O	O	_	_	_	_	_
10	acid	_	O	O	_	_	_	_	_
11	serine	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	rich	_	O	O	_	_	_	_	_
14	insertion	_	O	O	_	_	_	_	_
15	present	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	one	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	CREB	_	O	O	_	_	_	_	_
21	isoforms	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	CREB	_	O	O	_	_	_	_	_
6	isoforms	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	expressed	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	many	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	types	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	mammalian	_	O	O	_	_	_	_	_
15	species	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	encode	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	bind	_	O	O	_	_	_	_	_
6	specifically	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	cAMP	_	O	O	_	_	_	_	_
10	response	_	O	O	_	_	_	_	_
11	element	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	vitro	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	expected	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	class	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	CREB	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	bind	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	dimers	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	proteins	_	O	O	_	_	_	_	_
3	impart	_	O	O	_	_	_	_	_
4	cAMP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	regulated	_	O	O	_	_	_	_	_
7	transcriptional	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	heterologous	_	O	O	_	_	_	_	_
12	DNA	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	domain	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	showing	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	cAMP	_	O	O	_	_	_	_	_
20	directly	_	O	O	_	_	_	_	_
21	modulates	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	transcriptional	_	O	O	_	_	_	_	_
24	stimulatory	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	CREB	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	presence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	multiple	_	O	O	_	_	_	_	_
5	CREB	_	O	O	_	_	_	_	_
6	isoforms	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	identical	_	O	O	_	_	_	_	_
9	DNA	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	specificities	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	differences	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	presumed	_	O	O	_	_	_	_	_
18	regulatory	_	O	O	_	_	_	_	_
19	domain	_	O	O	_	_	_	_	_
20	raises	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	possibility	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	CREB	_	O	O	_	_	_	_	_
25	proteins	_	O	O	_	_	_	_	_
26	may	_	O	O	_	_	_	_	_
27	be	_	O	O	_	_	_	_	_
28	able	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	integrate	_	O	O	_	_	_	_	_
31	distinct	_	O	O	_	_	_	_	_
32	regulatory	_	O	O	_	_	_	_	_
33	signals	_	O	O	_	_	_	_	_
34	at	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	level	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	gene	_	O	O	_	_	_	_	_
39	transcription	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	interleukin	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	interaction	_	O	O	_	_	_	_	_
8	activates	_	O	O	_	_	_	_	_
9	Lyn	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	Jak	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	tyrosine	_	O	O	_	_	_	_	_
14	kinases	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	propagates	_	O	O	_	_	_	_	_
17	signals	_	O	O	_	_	_	_	_
18	via	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	Ras	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	Raf	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	MAP	_	O	O	_	_	_	_	_
27	kinase	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	Jak	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	STAT	_	O	O	_	_	_	_	_
33	pathways	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	eosinophils	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	shown	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	interaction	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	interleukin	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	activates	_	O	O	_	_	_	_	_
18	Lyn	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	kinase	_	O	O	_	_	_	_	_
21	within	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	min	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	Jak	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	tyrosine	_	O	O	_	_	_	_	_
28	kinase	_	O	O	_	_	_	_	_
29	within	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	min	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	5	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	stimulates	_	O	O	_	_	_	_	_
6	GTP	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	21	_	O	O	_	_	_	_	_
11	ras	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	signal	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	subsequently	_	O	O	_	_	_	_	_
5	propagated	_	O	O	_	_	_	_	_
6	through	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Raf	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	MEK	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	MAP	_	O	O	_	_	_	_	_
18	kinases	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	shown	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	their	_	O	O	_	_	_	_	_
23	increased	_	O	O	_	_	_	_	_
24	autophosphorylation	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	vitro	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	phosphorylation	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	situ	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Jak	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	kinase	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	phosphorylate	_	O	O	_	_	_	_	_
9	STAT	_	O	O	_	_	_	_	_
10	nuclear	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	factors	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	studied	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	electrophoretic	_	O	O	_	_	_	_	_
11	mobility	_	O	O	_	_	_	_	_
12	shift	_	O	O	_	_	_	_	_
13	assay	_	O	O	_	_	_	_	_
14	using	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	gamma	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	site	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	GAS	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	probe	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	5	_	O	O	_	_	_	_	_
7	induces	_	O	O	_	_	_	_	_
8	two	_	O	O	_	_	_	_	_
9	GAS	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	proteins	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	eosinophils	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	one	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	STAT	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	5	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	signals	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	propagated	_	O	O	_	_	_	_	_
11	through	_	O	O	_	_	_	_	_
12	two	_	O	O	_	_	_	_	_
13	distinct	_	O	O	_	_	_	_	_
14	pathways	_	O	O	_	_	_	_	_
15	:	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	Lyn	_	O	O	_	_	_	_	_
20	--	_	O	O	_	_	_	_	_
21	>	_	O	O	_	_	_	_	_
22	Ras	_	O	O	_	_	_	_	_
23	--	_	O	O	_	_	_	_	_
24	>	_	O	O	_	_	_	_	_
25	Raf	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	--	_	O	O	_	_	_	_	_
29	>	_	O	O	_	_	_	_	_
30	MEK	_	O	O	_	_	_	_	_
31	--	_	O	O	_	_	_	_	_
32	>	_	O	O	_	_	_	_	_
33	MAP	_	O	O	_	_	_	_	_
34	kinase	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	Jak	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	--	_	O	O	_	_	_	_	_
42	>	_	O	O	_	_	_	_	_
43	STAT	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_


1	Mutations	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	Pit	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	children	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	combined	_	O	O	_	_	_	_	_
12	pituitary	_	O	O	_	_	_	_	_
13	hormone	_	O	O	_	_	_	_	_
14	deficiency	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Pit	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	pituitary	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	specific	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	binds	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	transactivates	_	O	O	_	_	_	_	_
16	promoters	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	growth	_	O	O	_	_	_	_	_
19	hormone	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	prolactin	_	O	O	_	_	_	_	_
22	genes	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	three	_	O	O	_	_	_	_	_
3	unrelated	_	O	O	_	_	_	_	_
4	Japanese	_	O	O	_	_	_	_	_
5	children	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	combined	_	O	O	_	_	_	_	_
8	pituitary	_	O	O	_	_	_	_	_
9	hormone	_	O	O	_	_	_	_	_
10	deficiency	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	identified	_	O	O	_	_	_	_	_
14	three	_	O	O	_	_	_	_	_
15	point	_	O	O	_	_	_	_	_
16	mutations	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	Pit	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	Pro	_	O	O	_	_	_	_	_
25	24	_	O	O	_	_	_	_	_
26	Leu	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	Arg	_	O	O	_	_	_	_	_
29	143	_	O	O	_	_	_	_	_
30	Gln	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	Arg	_	O	O	_	_	_	_	_
34	271	_	O	O	_	_	_	_	_
35	Trp	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	located	_	O	O	_	_	_	_	_
38	on	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	major	_	O	O	_	_	_	_	_
41	transactivation	_	O	O	_	_	_	_	_
42	region	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	POU	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	specific	_	O	O	_	_	_	_	_
47	domain	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	POU	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	homeodomain	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	respectively	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_


1	Latent	_	O	O	_	_	_	_	_
2	membrane	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	induces	_	O	O	_	_	_	_	_
7	cyclin	_	O	O	_	_	_	_	_
8	D	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	pRb	_	O	O	_	_	_	_	_
13	hyperphosphorylation	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	loss	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	TGF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	growth	_	O	O	_	_	_	_	_
25	inhibition	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	EBV	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	positive	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	normal	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	cycle	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	regulated	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	several	_	O	O	_	_	_	_	_
9	molecules	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	such	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	tumor	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	suppressor	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	pRb	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	G	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	cyclins	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	cyclin	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	dependent	_	O	O	_	_	_	_	_
29	kinases	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	their	_	O	O	_	_	_	_	_
33	inhibitors	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	regulators	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	targeted	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	negative	_	O	O	_	_	_	_	_
7	growth	_	O	O	_	_	_	_	_
8	regulatory	_	O	O	_	_	_	_	_
9	signals	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	such	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	provided	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	TGF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	beta	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	presence	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	either	_	O	O	_	_	_	_	_
10	wild	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	type	_	O	O	_	_	_	_	_
13	EBV	_	O	O	_	_	_	_	_
14	or	_	O	O	_	_	_	_	_
15	its	_	O	O	_	_	_	_	_
16	transforming	_	O	O	_	_	_	_	_
17	latent	_	O	O	_	_	_	_	_
18	membrane	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	LMP	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	results	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	loss	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	TGF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	beta	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	mediated	_	O	O	_	_	_	_	_
38	growth	_	O	O	_	_	_	_	_
39	inhibition	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	human	_	O	O	_	_	_	_	_
42	B	_	O	O	_	_	_	_	_
43	cells	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Chemical	_	O	O	_	_	_	_	_
2	cross	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	linking	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	125	_	O	O	_	_	_	_	_
7	I	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	labeled	_	O	O	_	_	_	_	_
10	TGF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	beta	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	showed	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	essentially	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	TGF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	profile	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	EBV	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	positive	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	EBV	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	negative	_	O	O	_	_	_	_	_
31	Burkitt	_	O	O	_	_	_	_	_
32	'	_	O	O	_	_	_	_	_
33	s	_	O	O	_	_	_	_	_
34	lymphoma	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	lines	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	these	_	O	O	_	_	_	_	_
40	receptors	_	O	O	_	_	_	_	_
41	were	_	O	O	_	_	_	_	_
42	shown	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	be	_	O	O	_	_	_	_	_
45	functional	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	transducing	_	O	O	_	_	_	_	_
48	signals	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	as	_	O	O	_	_	_	_	_
51	evidenced	_	O	O	_	_	_	_	_
52	by	_	O	O	_	_	_	_	_
53	the	_	O	O	_	_	_	_	_
54	TGF	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	beta	_	O	O	_	_	_	_	_
57	1	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	mediated	_	O	O	_	_	_	_	_
60	modulation	_	O	O	_	_	_	_	_
61	of	_	O	O	_	_	_	_	_
62	junB	_	O	O	_	_	_	_	_
63	gene	_	O	O	_	_	_	_	_
64	expression	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	TGF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	did	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	induce	_	O	O	_	_	_	_	_
10	dephosphorylation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	pRb	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	EBV	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	LMP	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	positive	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	opposed	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	EBV	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	negative	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	suggesting	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	dichotomy	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	TGF	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	beta	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	signaling	_	O	O	_	_	_	_	_
42	pathway	_	O	O	_	_	_	_	_
43	leading	_	O	O	_	_	_	_	_
44	to	_	O	O	_	_	_	_	_
45	separable	_	O	O	_	_	_	_	_
46	gene	_	O	O	_	_	_	_	_
47	regulatory	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	growth	_	O	O	_	_	_	_	_
50	inhibitory	_	O	O	_	_	_	_	_
51	responses	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	LMP	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	induce	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	cyclin	_	O	O	_	_	_	_	_
14	D	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	;	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	EBV	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	negative	_	O	O	_	_	_	_	_
24	Burkitt	_	O	O	_	_	_	_	_
25	'	_	O	O	_	_	_	_	_
26	s	_	O	O	_	_	_	_	_
27	lymphoma	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	do	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	express	_	O	O	_	_	_	_	_
32	D	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	type	_	O	O	_	_	_	_	_
35	cyclins	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	data	_	O	O	_	_	_	_	_
6	point	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	potential	_	O	O	_	_	_	_	_
10	mechanism	_	O	O	_	_	_	_	_
11	underlying	_	O	O	_	_	_	_	_
12	EBV	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	transformation	_	O	O	_	_	_	_	_
18	whereby	_	O	O	_	_	_	_	_
19	constitutive	_	O	O	_	_	_	_	_
20	induction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	key	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	cycle	_	O	O	_	_	_	_	_
25	regulators	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	LMP	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	can	_	O	O	_	_	_	_	_
31	lead	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	pRb	_	O	O	_	_	_	_	_
34	hyperphosphorylation	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	uncontrolled	_	O	O	_	_	_	_	_
37	cell	_	O	O	_	_	_	_	_
38	proliferation	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factors	_	O	O	_	_	_	_	_
5	led	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	reduced	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_

1	Pharmacological	_	O	O	_	_	_	_	_
2	inhibitors	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	used	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	demonstrate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	sites	_	O	O	_	_	_	_	_
12	within	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	relevant	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	induction	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	RA	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	GP	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	expected	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	inhibition	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	NFkappaB	_	O	O	_	_	_	_	_
8	via	_	O	O	_	_	_	_	_
9	CAPE	_	O	O	_	_	_	_	_
10	[	_	O	O	_	_	_	_	_
11	35	_	O	O	_	_	_	_	_
12	]	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	CyA	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	NFAT	_	O	O	_	_	_	_	_
17	via	_	O	O	_	_	_	_	_
18	CyA	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	NFIL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	via	_	O	O	_	_	_	_	_
24	CHX	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	36	_	O	O	_	_	_	_	_
27	]	_	O	O	_	_	_	_	_
28	could	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	be	_	O	O	_	_	_	_	_
31	overruled	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	GP	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	leading	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	down	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	regulated	_	O	O	_	_	_	_	_
41	binding	_	O	O	_	_	_	_	_
42	activity	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	transcription	_	O	O	_	_	_	_	_
46	factors	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	IL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	RA	_	O	O	_	_	_	_	_
53	sites	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	and	_	O	O	_	_	_	_	_
56	a	_	O	O	_	_	_	_	_
57	reduction	_	O	O	_	_	_	_	_
58	of	_	O	O	_	_	_	_	_
59	IL	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	1	_	O	O	_	_	_	_	_
62	RA	_	O	O	_	_	_	_	_
63	mRNA	_	O	O	_	_	_	_	_
64	and	_	O	O	_	_	_	_	_
65	IL	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	1	_	O	O	_	_	_	_	_
68	RA	_	O	O	_	_	_	_	_
69	protein	_	O	O	_	_	_	_	_
70	levels	_	O	O	_	_	_	_	_
71	(	_	O	O	_	_	_	_	_
72	Fig	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	extent	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	reduction	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	NFATP	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	exemplarily	_	O	O	_	_	_	_	_
13	shown	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	autoradiogram	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	Fig	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	left	_	O	O	_	_	_	_	_
5	side	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	graphically	_	O	O	_	_	_	_	_
9	summarized	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	n	_	O	O	_	_	_	_	_
12	=	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	Fig	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	right	_	O	O	_	_	_	_	_
5	side	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	NFkappaB	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	NFIL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	sites	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	similar	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	data	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	shown	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	highest	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	amount	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	found	_	O	O	_	_	_	_	_
11	at	_	O	O	_	_	_	_	_
12	24	_	O	O	_	_	_	_	_
13	h	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	mRNA	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	examined	_	O	O	_	_	_	_	_
18	following	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	h	_	O	O	_	_	_	_	_
21	inhibition	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	18	_	O	O	_	_	_	_	_
24	h	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	representative	_	O	O	_	_	_	_	_
3	gel	_	O	O	_	_	_	_	_
4	demonstrating	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	decrease	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	mRNA	_	O	O	_	_	_	_	_
13	after	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	CAPE	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	CyA	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	CHX	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	displayed	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	Fig	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	n	_	O	O	_	_	_	_	_
5	=	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	corresponding	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	levels	_	O	O	_	_	_	_	_
11	after	_	O	O	_	_	_	_	_
12	24	_	O	O	_	_	_	_	_
13	h	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	shown	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	Fig	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	C	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	n	_	O	O	_	_	_	_	_
5	=	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Altogether	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	NFkappaB	_	O	O	_	_	_	_	_
4	inhibition	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	CAPE	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	more	_	O	O	_	_	_	_	_
9	pronounced	_	O	O	_	_	_	_	_
10	at	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	whereas	_	O	O	_	_	_	_	_
19	CyA	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	CHX	_	O	O	_	_	_	_	_
22	mainly	_	O	O	_	_	_	_	_
23	led	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	decreased	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	RA	_	O	O	_	_	_	_	_
31	release	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_



1	Binding	_	O	O	_	_	_	_	_
2	activities	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NFkappaB	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	NFIL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	NFAT	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	PBMC	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	TNFalpha	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	IFNgamma	_	O	O	_	_	_	_	_
23	promoters	_	O	O	_	_	_	_	_
24	following	_	O	O	_	_	_	_	_
25	an	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vitro	_	O	O	_	_	_	_	_
28	stimulation	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	h	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	LPS	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	TSST	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	GP	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	GP	_	O	O	_	_	_	_	_
43	+	_	O	O	_	_	_	_	_
44	LPS	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	GP	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	TSST	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	induced	_	O	O	_	_	_	_	_
3	band	_	O	O	_	_	_	_	_
4	shifts	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	indicating	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NFkappaB	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	well	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NFIL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	corresponding	_	O	O	_	_	_	_	_
20	DNA	_	O	O	_	_	_	_	_
21	oligonucleotides	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	kappa	_	O	O	_	_	_	_	_
24	consensus	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	kappa	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	kappa	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	kappa	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	sites	_	O	O	_	_	_	_	_
35	from	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	TNFalpha	_	O	O	_	_	_	_	_
38	promoter	_	O	O	_	_	_	_	_
39	;	_	O	O	_	_	_	_	_
40	kappa	_	O	O	_	_	_	_	_
41	consensus	_	O	O	_	_	_	_	_
42	from	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	8	_	O	O	_	_	_	_	_
47	promoter	_	O	O	_	_	_	_	_
48	;	_	O	O	_	_	_	_	_
49	NFIL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	6	_	O	O	_	_	_	_	_
52	consensus	_	O	O	_	_	_	_	_
53	from	_	O	O	_	_	_	_	_
54	the	_	O	O	_	_	_	_	_
55	IL	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	6	_	O	O	_	_	_	_	_
58	promoter	_	O	O	_	_	_	_	_
59	;	_	O	O	_	_	_	_	_
60	Table	_	O	O	_	_	_	_	_
61	1	_	O	O	_	_	_	_	_
62	;	_	O	O	_	_	_	_	_
63	Fig	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	extent	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	band	_	O	O	_	_	_	_	_
6	shifts	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	statistically	_	O	O	_	_	_	_	_
13	different	_	O	O	_	_	_	_	_
14	when	_	O	O	_	_	_	_	_
15	compared	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	LPS	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	TSST	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	Fig	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	supershift	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	conducted	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	NFkappaB	_	O	O	_	_	_	_	_
8	consensus	_	O	O	_	_	_	_	_
9	site	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	8	_	O	O	_	_	_	_	_
15	promoter	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	demonstrated	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	GP	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	predominant	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	NFkappaB	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	65	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	lesser	_	O	O	_	_	_	_	_
32	degree	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	p	_	O	O	_	_	_	_	_
35	50	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	Fig	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	Accordingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	immunoblot	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	extracts	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	treated	_	O	O	_	_	_	_	_
12	PBMC	_	O	O	_	_	_	_	_
13	showed	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	strong	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	NFkappaB	_	O	O	_	_	_	_	_
19	p	_	O	O	_	_	_	_	_
20	65	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	weaker	_	O	O	_	_	_	_	_
24	reaction	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	50	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	whereas	_	O	O	_	_	_	_	_
30	p	_	O	O	_	_	_	_	_
31	52	_	O	O	_	_	_	_	_
32	was	_	O	O	_	_	_	_	_
33	negative	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	Fig	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	Simultaneous	_	O	O	_	_	_	_	_
2	co	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	PBMC	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	GP	_	O	O	_	_	_	_	_
9	did	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	change	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	LPS	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	NFkappaB	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	oligos	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	TNFalpha	_	O	O	_	_	_	_	_
23	promoter	_	O	O	_	_	_	_	_
24	significantly	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	Fig	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	but	_	O	O	_	_	_	_	_
6	substantially	_	O	O	_	_	_	_	_
7	decreased	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	TSST	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	NFkappaB	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	when	_	O	O	_	_	_	_	_
17	compared	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	TSST	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	GP	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	100	_	O	O	_	_	_	_	_
26	mug	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	thus	_	O	O	_	_	_	_	_
30	differed	_	O	O	_	_	_	_	_
31	completely	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	theoretical	_	O	O	_	_	_	_	_
35	value	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	GP	_	O	O	_	_	_	_	_
38	/	_	O	O	_	_	_	_	_
39	TSST	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	calc	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	n	_	O	O	_	_	_	_	_
3	=	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	;	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	<	_	O	O	_	_	_	_	_
8	0	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_
10	05	_	O	O	_	_	_	_	_
11	vs	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	TSST	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	calc	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	and	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	=	_	O	O	_	_	_	_	_
4	0	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_
6	07	_	O	O	_	_	_	_	_
7	vs	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	TSST	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	;	_	O	O	_	_	_	_	_
5	Fig	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	able	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	induce	_	O	O	_	_	_	_	_
7	band	_	O	O	_	_	_	_	_
8	shifts	_	O	O	_	_	_	_	_
9	indicative	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	particular	_	O	O	_	_	_	_	_
14	variants	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	NFAT	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	oligo	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	IFNgamma	_	O	O	_	_	_	_	_
23	promoter	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Fig	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	immunoblot	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	NFAT	_	O	O	_	_	_	_	_
6	subunits	_	O	O	_	_	_	_	_
7	demonstrated	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NFATc	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	lesser	_	O	O	_	_	_	_	_
20	degree	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	NFATc	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Fig	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_



1	Immuno	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Dot	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	blot	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	proteins	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	related	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	NFkappaB	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	NFAT	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	dot	_	O	O	_	_	_	_	_
16	blots	_	O	O	_	_	_	_	_
17	using	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	SRC	_	O	O	_	_	_	_	_
20	96	_	O	O	_	_	_	_	_
21	D	_	O	O	_	_	_	_	_
22	SNS	_	O	O	_	_	_	_	_
23	minifold	_	O	O	_	_	_	_	_
24	I	_	O	O	_	_	_	_	_
25	dot	_	O	O	_	_	_	_	_
26	blotter	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	Schleicher	_	O	O	_	_	_	_	_
29	&	_	O	O	_	_	_	_	_
30	Schull	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	Dassel	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	Germany	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	were	_	O	O	_	_	_	_	_
37	performed	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	following	_	O	O	_	_	_	_	_
41	positive	_	O	O	_	_	_	_	_
42	controls	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	antibodies	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	all	_	O	O	_	_	_	_	_
47	from	_	O	O	_	_	_	_	_
48	Santa	_	O	O	_	_	_	_	_
49	Cruz	_	O	O	_	_	_	_	_
50	Biotechnology	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	Heidelberg	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	Germany	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	:	_	O	O	_	_	_	_	_
57	positive	_	O	O	_	_	_	_	_
58	controls	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	10	_	O	O	_	_	_	_	_
61	ng	_	O	O	_	_	_	_	_
62	/	_	O	O	_	_	_	_	_
63	dot	_	O	O	_	_	_	_	_
64	)	_	O	O	_	_	_	_	_
65	:	_	O	O	_	_	_	_	_
66	NFkappaB	_	O	O	_	_	_	_	_
67	p	_	O	O	_	_	_	_	_
68	52	_	O	O	_	_	_	_	_
69	(	_	O	O	_	_	_	_	_
70	80	_	O	O	_	_	_	_	_
71	kD	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	sc	_	O	O	_	_	_	_	_
74	-	_	O	O	_	_	_	_	_
75	4095	_	O	O	_	_	_	_	_
76	WB	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	c	_	O	O	_	_	_	_	_
79	-	_	O	O	_	_	_	_	_
80	Rel	_	O	O	_	_	_	_	_
81	(	_	O	O	_	_	_	_	_
82	61	_	O	O	_	_	_	_	_
83	kD	_	O	O	_	_	_	_	_
84	)	_	O	O	_	_	_	_	_
85	sc	_	O	O	_	_	_	_	_
86	-	_	O	O	_	_	_	_	_
87	4030	_	O	O	_	_	_	_	_
88	WB	_	O	O	_	_	_	_	_
89	;	_	O	O	_	_	_	_	_
90	Jurkat	_	O	O	_	_	_	_	_
91	nuclear	_	O	O	_	_	_	_	_
92	extract	_	O	O	_	_	_	_	_
93	,	_	O	O	_	_	_	_	_
94	PMA	_	O	O	_	_	_	_	_
95	-	_	O	O	_	_	_	_	_
96	stimulated	_	O	O	_	_	_	_	_
97	;	_	O	O	_	_	_	_	_
98	primary	_	O	O	_	_	_	_	_
99	antibodies	_	O	O	_	_	_	_	_
100	(	_	O	O	_	_	_	_	_
101	1	_	O	O	_	_	_	_	_
102	mug	_	O	O	_	_	_	_	_
103	/	_	O	O	_	_	_	_	_
104	dot	_	O	O	_	_	_	_	_
105	)	_	O	O	_	_	_	_	_
106	:	_	O	O	_	_	_	_	_
107	anti	_	O	O	_	_	_	_	_
108	-	_	O	O	_	_	_	_	_
109	NFkappaB	_	O	O	_	_	_	_	_
110	p	_	O	O	_	_	_	_	_
111	50	_	O	O	_	_	_	_	_
112	(	_	O	O	_	_	_	_	_
113	NLS	_	O	O	_	_	_	_	_
114	)	_	O	O	_	_	_	_	_
115	sc	_	O	O	_	_	_	_	_
116	-	_	O	O	_	_	_	_	_
117	114	_	O	O	_	_	_	_	_
118	,	_	O	O	_	_	_	_	_
119	anti	_	O	O	_	_	_	_	_
120	-	_	O	O	_	_	_	_	_
121	NFkappaB	_	O	O	_	_	_	_	_
122	p	_	O	O	_	_	_	_	_
123	65	_	O	O	_	_	_	_	_
124	(	_	O	O	_	_	_	_	_
125	A	_	O	O	_	_	_	_	_
126	)	_	O	O	_	_	_	_	_
127	sc	_	O	O	_	_	_	_	_
128	-	_	O	O	_	_	_	_	_
129	109	_	O	O	_	_	_	_	_
130	,	_	O	O	_	_	_	_	_
131	anti	_	O	O	_	_	_	_	_
132	-	_	O	O	_	_	_	_	_
133	NFkappaB	_	O	O	_	_	_	_	_
134	p	_	O	O	_	_	_	_	_
135	52	_	O	O	_	_	_	_	_
136	(	_	O	O	_	_	_	_	_
137	447	_	O	O	_	_	_	_	_
138	)	_	O	O	_	_	_	_	_
139	sc	_	O	O	_	_	_	_	_
140	-	_	O	O	_	_	_	_	_
141	848	_	O	O	_	_	_	_	_
142	,	_	O	O	_	_	_	_	_
143	a	_	O	O	_	_	_	_	_
144	rabbit	_	O	O	_	_	_	_	_
145	polyclonal	_	O	O	_	_	_	_	_
146	IgG	_	O	O	_	_	_	_	_
147	1	_	O	O	_	_	_	_	_
148	antiserum	_	O	O	_	_	_	_	_
149	,	_	O	O	_	_	_	_	_
150	anti	_	O	O	_	_	_	_	_
151	-	_	O	O	_	_	_	_	_
152	c	_	O	O	_	_	_	_	_
153	-	_	O	O	_	_	_	_	_
154	rel	_	O	O	_	_	_	_	_
155	(	_	O	O	_	_	_	_	_
156	N	_	O	O	_	_	_	_	_
157	466	_	O	O	_	_	_	_	_
158	)	_	O	O	_	_	_	_	_
159	sc	_	O	O	_	_	_	_	_
160	-	_	O	O	_	_	_	_	_
161	272	_	O	O	_	_	_	_	_
162	,	_	O	O	_	_	_	_	_
163	anti	_	O	O	_	_	_	_	_
164	-	_	O	O	_	_	_	_	_
165	NFATc	_	O	O	_	_	_	_	_
166	2	_	O	O	_	_	_	_	_
167	(	_	O	O	_	_	_	_	_
168	M	_	O	O	_	_	_	_	_
169	-	_	O	O	_	_	_	_	_
170	20	_	O	O	_	_	_	_	_
171	)	_	O	O	_	_	_	_	_
172	sc	_	O	O	_	_	_	_	_
173	-	_	O	O	_	_	_	_	_
174	1151	_	O	O	_	_	_	_	_
175	,	_	O	O	_	_	_	_	_
176	anti	_	O	O	_	_	_	_	_
177	-	_	O	O	_	_	_	_	_
178	NFATc	_	O	O	_	_	_	_	_
179	1	_	O	O	_	_	_	_	_
180	(	_	O	O	_	_	_	_	_
181	K	_	O	O	_	_	_	_	_
182	-	_	O	O	_	_	_	_	_
183	18	_	O	O	_	_	_	_	_
184	)	_	O	O	_	_	_	_	_
185	sc	_	O	O	_	_	_	_	_
186	-	_	O	O	_	_	_	_	_
187	1149	_	O	O	_	_	_	_	_
188	,	_	O	O	_	_	_	_	_
189	two	_	O	O	_	_	_	_	_
190	goat	_	O	O	_	_	_	_	_
191	polyclonal	_	O	O	_	_	_	_	_
192	IgG	_	O	O	_	_	_	_	_
193	1	_	O	O	_	_	_	_	_
194	antisera	_	O	O	_	_	_	_	_
195	;	_	O	O	_	_	_	_	_
196	secondary	_	O	O	_	_	_	_	_
197	antibodies	_	O	O	_	_	_	_	_
198	(	_	O	O	_	_	_	_	_
199	0	_	O	O	_	_	_	_	_
200	.	_	O	O	_	_	_	_	_
201	8	_	O	O	_	_	_	_	_
202	mug	_	O	O	_	_	_	_	_
203	/	_	O	O	_	_	_	_	_
204	dot	_	O	O	_	_	_	_	_
205	)	_	O	O	_	_	_	_	_
206	:	_	O	O	_	_	_	_	_
207	goat	_	O	O	_	_	_	_	_
208	anti	_	O	O	_	_	_	_	_
209	-	_	O	O	_	_	_	_	_
210	rabbit	_	O	O	_	_	_	_	_
211	IgG	_	O	O	_	_	_	_	_
212	AP	_	O	O	_	_	_	_	_
213	-	_	O	O	_	_	_	_	_
214	conjugate	_	O	O	_	_	_	_	_
215	sc	_	O	O	_	_	_	_	_
216	-	_	O	O	_	_	_	_	_
217	2007	_	O	O	_	_	_	_	_
218	,	_	O	O	_	_	_	_	_
219	and	_	O	O	_	_	_	_	_
220	donkey	_	O	O	_	_	_	_	_
221	anti	_	O	O	_	_	_	_	_
222	-	_	O	O	_	_	_	_	_
223	goat	_	O	O	_	_	_	_	_
224	IgG	_	O	O	_	_	_	_	_
225	AP	_	O	O	_	_	_	_	_
226	-	_	O	O	_	_	_	_	_
227	conjugate	_	O	O	_	_	_	_	_
228	sc	_	O	O	_	_	_	_	_
229	-	_	O	O	_	_	_	_	_
230	2022	_	O	O	_	_	_	_	_
231	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	nuclear	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	blotted	_	O	O	_	_	_	_	_
6	onto	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	nitrocellulose	_	O	O	_	_	_	_	_
9	membrane	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Bio	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Rad	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	blocking	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	PBS	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	%	_	O	O	_	_	_	_	_
8	BSA	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Fluka	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	Deisenhofen	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	Germany	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	blot	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	incubated	_	O	O	_	_	_	_	_
21	overnight	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	primary	_	O	O	_	_	_	_	_
25	antibodies	_	O	O	_	_	_	_	_
26	diluted	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	:	_	O	O	_	_	_	_	_
29	2000	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	PBS	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	%	_	O	O	_	_	_	_	_
35	BSA	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	washed	_	O	O	_	_	_	_	_
38	again	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	incubated	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	alkaline	_	O	O	_	_	_	_	_
44	phosphatase	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	conjugated	_	O	O	_	_	_	_	_
47	secondary	_	O	O	_	_	_	_	_
48	antibody	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	:	_	O	O	_	_	_	_	_
52	500	_	O	O	_	_	_	_	_
53	in	_	O	O	_	_	_	_	_
54	PBS	_	O	O	_	_	_	_	_
55	/	_	O	O	_	_	_	_	_
56	1	_	O	O	_	_	_	_	_
57	%	_	O	O	_	_	_	_	_
58	BSA	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	developed	_	O	O	_	_	_	_	_
5	using	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	Vectastain	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	R	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	staining	_	O	O	_	_	_	_	_
12	kit	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	Vector	_	O	O	_	_	_	_	_
15	Laboratories	_	O	O	_	_	_	_	_
16	Inc	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Burlingame	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	CA	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	USA	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_



1	Visualization	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	endogenous	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	50	_	O	O	_	_	_	_	_
11	subunit	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	nucleus	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	follicular	_	O	O	_	_	_	_	_
17	dendritic	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	germinal	_	O	O	_	_	_	_	_
21	centers	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	NF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	kappa	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	50	_	O	O	_	_	_	_	_
8	kDa	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	65	_	O	O	_	_	_	_	_
11	kDa	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	50	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	65	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	heterodimer	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	ubiquitous	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	involved	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	positive	_	O	O	_	_	_	_	_
30	regulation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	various	_	O	O	_	_	_	_	_
33	immune	_	O	O	_	_	_	_	_
34	genes	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	aim	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	determine	_	O	O	_	_	_	_	_
9	whether	_	O	O	_	_	_	_	_
10	NF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	kappa	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	related	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	particular	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	type	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	differentiation	_	O	O	_	_	_	_	_
25	step	_	O	O	_	_	_	_	_
26	during	_	O	O	_	_	_	_	_
27	immunopoiesis	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	situ	_	O	O	_	_	_	_	_
4	hybridization	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	sections	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	non	_	O	O	_	_	_	_	_
9	HIV	_	O	O	_	_	_	_	_
10	hyperplastic	_	O	O	_	_	_	_	_
11	lymph	_	O	O	_	_	_	_	_
12	nodes	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	we	_	O	O	_	_	_	_	_
15	found	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	105	_	O	O	_	_	_	_	_
22	kDa	_	O	O	_	_	_	_	_
23	precursor	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	50	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	overexpressed	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	light	_	O	O	_	_	_	_	_
32	zone	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	germinal	_	O	O	_	_	_	_	_
35	centers	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	network	_	O	O	_	_	_	_	_
40	aspect	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	which	_	O	O	_	_	_	_	_
43	suggested	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	involvement	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	follicular	_	O	O	_	_	_	_	_
48	dendritic	_	O	O	_	_	_	_	_
49	cells	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	FDC	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	immunohistochemistry	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	50	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	detected	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cytoplasm	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	nucleus	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	FDC	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	confirming	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	involvement	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	FDC	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	50	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	detected	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cytoplasm	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	all	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	focused	_	O	O	_	_	_	_	_
5	our	_	O	O	_	_	_	_	_
6	study	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	isolated	_	O	O	_	_	_	_	_
9	FDC	_	O	O	_	_	_	_	_
10	clusters	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	normal	_	O	O	_	_	_	_	_
13	tonsils	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	showed	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	tissue	_	O	O	_	_	_	_	_
5	sections	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	detected	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	50	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	cytoplasm	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	nucleus	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	FDC	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Nuclei	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	lymphocytes	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	FDC	_	O	O	_	_	_	_	_
6	clusters	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	negative	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	next	_	O	O	_	_	_	_	_
3	studied	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	65	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	c	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	Rel	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	FDC	_	O	O	_	_	_	_	_
14	clusters	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	p	_	O	O	_	_	_	_	_
2	65	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	detected	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	cytoplasm	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	FDC	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	whereas	_	O	O	_	_	_	_	_
12	nuclei	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	negative	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	65	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	detected	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	nuclei	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	some	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	c	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Rel	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	detected	_	O	O	_	_	_	_	_
7	only	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cytoplasm	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	nucleus	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	cytoplasm	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	FDC	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	context	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dependent	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	immunopoiesis	_	O	O	_	_	_	_	_
17	occurring	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	FDC	_	O	O	_	_	_	_	_
20	clusters	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	p	_	O	O	_	_	_	_	_
23	50	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	mainly	_	O	O	_	_	_	_	_
26	related	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	FDC	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	massive	_	O	O	_	_	_	_	_
32	overexpression	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	nuclei	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	whereas	_	O	O	_	_	_	_	_
38	p	_	O	O	_	_	_	_	_
39	65	_	O	O	_	_	_	_	_
40	is	_	O	O	_	_	_	_	_
41	expressed	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	scattered	_	O	O	_	_	_	_	_
45	manner	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	nuclei	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	lymphocytes	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	c	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	Rel	_	O	O	_	_	_	_	_
55	protein	_	O	O	_	_	_	_	_
56	exclusively	_	O	O	_	_	_	_	_
57	in	_	O	O	_	_	_	_	_
58	the	_	O	O	_	_	_	_	_
59	cytoplasm	_	O	O	_	_	_	_	_
60	of	_	O	O	_	_	_	_	_
61	lymphocytes	_	O	O	_	_	_	_	_
62	from	_	O	O	_	_	_	_	_
63	FDC	_	O	O	_	_	_	_	_
64	clusters	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggested	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	two	_	O	O	_	_	_	_	_
7	subunits	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kappa	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Rel	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	have	_	O	O	_	_	_	_	_
20	different	_	O	O	_	_	_	_	_
21	roles	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	different	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	types	_	O	O	_	_	_	_	_
26	during	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	immunopoiesis	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Osteoclast	_	O	O	_	_	_	_	_
2	markers	_	O	O	_	_	_	_	_
3	accumulate	_	O	O	_	_	_	_	_
4	on	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	developing	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	peripheral	_	O	O	_	_	_	_	_
10	blood	_	O	O	_	_	_	_	_
11	mononuclear	_	O	O	_	_	_	_	_
12	precursors	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	Recent	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	osteoclasts	_	O	O	_	_	_	_	_
7	develop	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	vitro	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	hematopoietic	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	;	_	O	O	_	_	_	_	_
14	however	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	special	_	O	O	_	_	_	_	_
17	cultures	_	O	O	_	_	_	_	_
18	conditions	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	cytokine	_	O	O	_	_	_	_	_
23	mobilized	_	O	O	_	_	_	_	_
24	peripheral	_	O	O	_	_	_	_	_
25	blood	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	apparently	_	O	O	_	_	_	_	_
28	required	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	report	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	expressing	_	O	O	_	_	_	_	_
8	osteoclast	_	O	O	_	_	_	_	_
9	markers	_	O	O	_	_	_	_	_
10	differentiate	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	precursors	_	O	O	_	_	_	_	_
13	present	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	nonmobilized	_	O	O	_	_	_	_	_
16	peripheral	_	O	O	_	_	_	_	_
17	blood	_	O	O	_	_	_	_	_
18	mononuclear	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	PBMC	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	without	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	addition	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	stromal	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	growth	_	O	O	_	_	_	_	_
32	factors	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	cytokines	_	O	O	_	_	_	_	_
35	or	_	O	O	_	_	_	_	_
36	steroids	_	O	O	_	_	_	_	_
37	;	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	characterize	_	O	O	_	_	_	_	_
40	their	_	O	O	_	_	_	_	_
41	phenotype	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Three	_	O	O	_	_	_	_	_
2	days	_	O	O	_	_	_	_	_
3	after	_	O	O	_	_	_	_	_
4	establishing	_	O	O	_	_	_	_	_
5	high	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	density	_	O	O	_	_	_	_	_
8	PBMC	_	O	O	_	_	_	_	_
9	cultures	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	x	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	cm	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	serum	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	containing	_	O	O	_	_	_	_	_
29	medium	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	small	_	O	O	_	_	_	_	_
32	adherent	_	O	O	_	_	_	_	_
33	colonies	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	tartrate	_	O	O	_	_	_	_	_
36	resistant	_	O	O	_	_	_	_	_
37	acid	_	O	O	_	_	_	_	_
38	phosphatase	_	O	O	_	_	_	_	_
39	positive	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	TRAP	_	O	O	_	_	_	_	_
42	+	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	emerge	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	amidst	_	O	O	_	_	_	_	_
48	massive	_	O	O	_	_	_	_	_
49	monocyte	_	O	O	_	_	_	_	_
50	cell	_	O	O	_	_	_	_	_
51	death	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	adherent	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	eccentrically	_	O	O	_	_	_	_	_
7	placed	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	round	_	O	O	_	_	_	_	_
10	nucleus	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	express	_	O	O	_	_	_	_	_
14	low	_	O	O	_	_	_	_	_
15	levels	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	TRAP	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	sodium	_	O	O	_	_	_	_	_
20	fluoride	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	resistant	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	alpha	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	naphthyl	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	acetate	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	esterase	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	NaF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	R	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	NSE	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Over	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	next	_	O	O	_	_	_	_	_
4	week	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	population	_	O	O	_	_	_	_	_
9	accumulates	_	O	O	_	_	_	_	_
10	phenotypic	_	O	O	_	_	_	_	_
11	markers	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	osteoclasts	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	vitronectin	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	VR	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	calcitonin	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	TRAP	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	cathepsin	_	O	O	_	_	_	_	_
27	K	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	mRNA	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	increased	_	O	O	_	_	_	_	_
35	nuclearity	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	covering	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	entire	_	O	O	_	_	_	_	_
40	surface	_	O	O	_	_	_	_	_
41	by	_	O	O	_	_	_	_	_
42	15	_	O	O	_	_	_	_	_
43	days	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	cultured	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	bone	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	VR	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	TRAP	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	low	_	O	O	_	_	_	_	_
14	multinuclearity	_	O	O	_	_	_	_	_
15	appear	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	cover	_	O	O	_	_	_	_	_
18	up	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	50	_	O	O	_	_	_	_	_
21	%	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	surface	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Resorption	_	O	O	_	_	_	_	_
2	lacunae	_	O	O	_	_	_	_	_
3	can	_	O	O	_	_	_	_	_
4	be	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	day	_	O	O	_	_	_	_	_
8	22	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	pits	_	O	O	_	_	_	_	_
4	are	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	nearly	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	numerous	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	preosteoclast	_	O	O	_	_	_	_	_
14	phenotype	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	they	_	O	O	_	_	_	_	_
17	do	_	O	O	_	_	_	_	_
18	represent	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	activity	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	subset	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	osteoclast	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	like	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	has	_	O	O	_	_	_	_	_
31	achieved	_	O	O	_	_	_	_	_
32	osteoclastic	_	O	O	_	_	_	_	_
33	maturity	_	O	O	_	_	_	_	_
34	under	_	O	O	_	_	_	_	_
35	these	_	O	O	_	_	_	_	_
36	culture	_	O	O	_	_	_	_	_
37	conditions	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Transcripts	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	osteoprotegerin	_	O	O	_	_	_	_	_
4	ligand	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	OPGL	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	osteoclast	_	O	O	_	_	_	_	_
11	differentiation	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	known	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	RANKL	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	TRANCE	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	expressed	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	likely	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	adherent	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	adherent	_	O	O	_	_	_	_	_
5	population	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	preosteoclast	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	osteoclast	_	O	O	_	_	_	_	_
13	phenotypic	_	O	O	_	_	_	_	_
14	properties	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	arises	_	O	O	_	_	_	_	_
17	selectively	_	O	O	_	_	_	_	_
18	under	_	O	O	_	_	_	_	_
19	simple	_	O	O	_	_	_	_	_
20	culture	_	O	O	_	_	_	_	_
21	conditions	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	normal	_	O	O	_	_	_	_	_
24	PBMC	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	characterization	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	should	_	O	O	_	_	_	_	_
7	identify	_	O	O	_	_	_	_	_
8	factors	_	O	O	_	_	_	_	_
9	involved	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	growth	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	terminal	_	O	O	_	_	_	_	_
15	differentiation	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	osteoclasts	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Epstein	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Barr	_	O	O	_	_	_	_	_
4	virus	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	antigen	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	latent	_	O	O	_	_	_	_	_
10	membrane	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	independently	_	O	O	_	_	_	_	_
13	transactivate	_	O	O	_	_	_	_	_
14	p	_	O	O	_	_	_	_	_
15	53	_	O	O	_	_	_	_	_
16	through	_	O	O	_	_	_	_	_
17	induction	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	NF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	kappaB	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	B	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	immortalization	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	Epstein	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	Barr	_	O	O	_	_	_	_	_
9	virus	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	EBV	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	dependent	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	permanent	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	cellular	_	O	O	_	_	_	_	_
21	processes	_	O	O	_	_	_	_	_
22	which	_	O	O	_	_	_	_	_
23	normally	_	O	O	_	_	_	_	_
24	regulate	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	division	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	apoptosis	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	functions	_	O	O	_	_	_	_	_
31	possessed	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	p	_	O	O	_	_	_	_	_
34	53	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	number	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	normal	_	O	O	_	_	_	_	_
40	cell	_	O	O	_	_	_	_	_
41	types	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	initiated	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	evaluate	_	O	O	_	_	_	_	_
6	relationships	_	O	O	_	_	_	_	_
7	between	_	O	O	_	_	_	_	_
8	EBV	_	O	O	_	_	_	_	_
9	latent	_	O	O	_	_	_	_	_
10	genes	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	53	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	p	_	O	O	_	_	_	_	_
16	53	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	found	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	increase	_	O	O	_	_	_	_	_
22	approximately	_	O	O	_	_	_	_	_
23	10	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	fold	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	5	_	O	O	_	_	_	_	_
29	days	_	O	O	_	_	_	_	_
30	after	_	O	O	_	_	_	_	_
31	EBV	_	O	O	_	_	_	_	_
32	infection	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	purified	_	O	O	_	_	_	_	_
35	resting	_	O	O	_	_	_	_	_
36	human	_	O	O	_	_	_	_	_
37	B	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	;	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	induced	_	O	O	_	_	_	_	_
42	p	_	O	O	_	_	_	_	_
43	53	_	O	O	_	_	_	_	_
44	was	_	O	O	_	_	_	_	_
45	transcriptionally	_	O	O	_	_	_	_	_
46	active	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Latent	_	O	O	_	_	_	_	_
2	membrane	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	lesser	_	O	O	_	_	_	_	_
10	extent	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	EBV	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	antigen	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	mediated	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	increase	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	53	_	O	O	_	_	_	_	_
22	levels	_	O	O	_	_	_	_	_
23	via	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kappaB	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	factor	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Tyloxapol	_	O	O	_	_	_	_	_
2	inhibits	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	kappa	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	cytokine	_	O	O	_	_	_	_	_
9	release	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	scavenges	_	O	O	_	_	_	_	_
12	HOCI	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	reduces	_	O	O	_	_	_	_	_
16	viscosity	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	cystic	_	O	O	_	_	_	_	_
19	fibrosis	_	O	O	_	_	_	_	_
20	sputum	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Cystic	_	O	O	_	_	_	_	_
2	fibrosis	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	CF	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	develop	_	O	O	_	_	_	_	_
8	progressive	_	O	O	_	_	_	_	_
9	cytokine	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	mediated	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	lung	_	O	O	_	_	_	_	_
14	disease	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	abundant	_	O	O	_	_	_	_	_
18	production	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	thick	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	tenacious	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	protease	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	oxidant	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	rich	_	O	O	_	_	_	_	_
30	purulent	_	O	O	_	_	_	_	_
31	airway	_	O	O	_	_	_	_	_
32	secretions	_	O	O	_	_	_	_	_
33	that	_	O	O	_	_	_	_	_
34	are	_	O	O	_	_	_	_	_
35	difficult	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	clear	_	O	O	_	_	_	_	_
38	even	_	O	O	_	_	_	_	_
39	with	_	O	O	_	_	_	_	_
40	physiotherapy	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	search	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	potential	_	O	O	_	_	_	_	_
7	treatment	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	we	_	O	O	_	_	_	_	_
10	have	_	O	O	_	_	_	_	_
11	tested	_	O	O	_	_	_	_	_
12	tyloxapol	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	alkylaryl	_	O	O	_	_	_	_	_
16	polyether	_	O	O	_	_	_	_	_
17	alcohol	_	O	O	_	_	_	_	_
18	polymer	_	O	O	_	_	_	_	_
19	detergent	_	O	O	_	_	_	_	_
20	previously	_	O	O	_	_	_	_	_
21	used	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	mucolytic	_	O	O	_	_	_	_	_
25	agent	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	adult	_	O	O	_	_	_	_	_
28	chronic	_	O	O	_	_	_	_	_
29	bronchitis	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Tyloxapol	_	O	O	_	_	_	_	_
2	inhibits	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	factor	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kappa	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	NK	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	kappa	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	reduces	_	O	O	_	_	_	_	_
21	resting	_	O	O	_	_	_	_	_
22	secretion	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	cytokine	_	O	O	_	_	_	_	_
26	interleukin	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	8	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	8	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	cultured	_	O	O	_	_	_	_	_
36	human	_	O	O	_	_	_	_	_
37	monocytes	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	inhibits	_	O	O	_	_	_	_	_
41	lipopolysaccharide	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	LPS	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	stimulated	_	O	O	_	_	_	_	_
47	release	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	tumor	_	O	O	_	_	_	_	_
50	necrosis	_	O	O	_	_	_	_	_
51	factor	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	alpha	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	TNF	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	alpha	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	IL	_	O	O	_	_	_	_	_
61	-	_	O	O	_	_	_	_	_
62	1	_	O	O	_	_	_	_	_
63	beta	_	O	O	_	_	_	_	_
64	,	_	O	O	_	_	_	_	_
65	IL	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	6	_	O	O	_	_	_	_	_
68	,	_	O	O	_	_	_	_	_
69	IL	_	O	O	_	_	_	_	_
70	-	_	O	O	_	_	_	_	_
71	8	_	O	O	_	_	_	_	_
72	,	_	O	O	_	_	_	_	_
73	granulocyte	_	O	O	_	_	_	_	_
74	-	_	O	O	_	_	_	_	_
75	macrophage	_	O	O	_	_	_	_	_
76	colony	_	O	O	_	_	_	_	_
77	-	_	O	O	_	_	_	_	_
78	stimulating	_	O	O	_	_	_	_	_
79	factor	_	O	O	_	_	_	_	_
80	(	_	O	O	_	_	_	_	_
81	GM	_	O	O	_	_	_	_	_
82	-	_	O	O	_	_	_	_	_
83	CSF	_	O	O	_	_	_	_	_
84	)	_	O	O	_	_	_	_	_
85	,	_	O	O	_	_	_	_	_
86	and	_	O	O	_	_	_	_	_
87	the	_	O	O	_	_	_	_	_
88	eiconsanoids	_	O	O	_	_	_	_	_
89	thromboxane	_	O	O	_	_	_	_	_
90	A	_	O	O	_	_	_	_	_
91	2	_	O	O	_	_	_	_	_
92	and	_	O	O	_	_	_	_	_
93	leukotriene	_	O	O	_	_	_	_	_
94	B	_	O	O	_	_	_	_	_
95	4	_	O	O	_	_	_	_	_
96	(	_	O	O	_	_	_	_	_
97	LTB	_	O	O	_	_	_	_	_
98	4	_	O	O	_	_	_	_	_
99	)	_	O	O	_	_	_	_	_
100	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	tyloxapol	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	potent	_	O	O	_	_	_	_	_
10	antioxidant	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	hydroxyl	_	O	O	_	_	_	_	_
13	radicals	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	OH	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Tyloxapol	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	0	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_
5	05	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	0	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	%	_	O	O	_	_	_	_	_
11	wt	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	vol	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	effectively	_	O	O	_	_	_	_	_
16	scavenges	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	oxidant	_	O	O	_	_	_	_	_
19	hypochlorous	_	O	O	_	_	_	_	_
20	acid	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	HOCl	_	O	O	_	_	_	_	_
23	;	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	7	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	5	_	O	O	_	_	_	_	_
29	mM	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	vitro	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	protects	_	O	O	_	_	_	_	_
36	from	_	O	O	_	_	_	_	_
37	HOCl	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	mediated	_	O	O	_	_	_	_	_
40	lung	_	O	O	_	_	_	_	_
41	injury	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	rats	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Tyloxapol	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	reduces	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	viscosity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	CF	_	O	O	_	_	_	_	_
8	sputum	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	463	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	133	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	128	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	52	_	O	O	_	_	_	_	_
22	centipoise	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	tyloxapol	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	potentially	_	O	O	_	_	_	_	_
7	useful	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	new	_	O	O	_	_	_	_	_
11	antiinflammatory	_	O	O	_	_	_	_	_
12	therapy	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	CF	_	O	O	_	_	_	_	_
15	lung	_	O	O	_	_	_	_	_
16	disease	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	could	_	O	O	_	_	_	_	_
20	possibly	_	O	O	_	_	_	_	_
21	promote	_	O	O	_	_	_	_	_
22	clearance	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	secretions	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	CF	_	O	O	_	_	_	_	_
28	airway	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Materials	_	O	O	_	_	_	_	_

1	Water	_	O	O	_	_	_	_	_
2	soluble	_	O	O	_	_	_	_	_
3	phosphorylated	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	--	_	O	O	_	_	_	_	_
8	>	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	glucan	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	prepared	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	done	_	O	O	_	_	_	_	_
21	before	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	20	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	physicochemical	_	O	O	_	_	_	_	_
3	characteristics	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	determined	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	reported	_	O	O	_	_	_	_	_
10	previously	_	O	O	_	_	_	_	_
11	[	_	O	O	_	_	_	_	_
12	20	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	26	_	O	O	_	_	_	_	_
15	]	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	dissolved	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	aqueous	_	O	O	_	_	_	_	_
6	media	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	filter	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	sterilized	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	0	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	mum	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	screened	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	endotoxin	_	O	O	_	_	_	_	_
21	contamination	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	Endospecy	_	O	O	_	_	_	_	_
25	assay	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	Seigakaku	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	Tokyo	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	Japan	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	which	_	O	O	_	_	_	_	_
35	is	_	O	O	_	_	_	_	_
36	specific	_	O	O	_	_	_	_	_
37	for	_	O	O	_	_	_	_	_
38	endotoxin	_	O	O	_	_	_	_	_
39	but	_	O	O	_	_	_	_	_
40	does	_	O	O	_	_	_	_	_
41	not	_	O	O	_	_	_	_	_
42	respond	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	beta	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	--	_	O	O	_	_	_	_	_
48	>	_	O	O	_	_	_	_	_
49	3	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	D	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	glucans	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_



1	Binding	_	O	O	_	_	_	_	_
2	characteristics	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	glucocorticoid	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	peripheral	_	O	O	_	_	_	_	_
9	blood	_	O	O	_	_	_	_	_
10	lymphocytes	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	multiple	_	O	O	_	_	_	_	_
13	sclerosis	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Although	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	exact	_	O	O	_	_	_	_	_
4	etiology	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	multiple	_	O	O	_	_	_	_	_
7	sclerosis	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	MS	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	remains	_	O	O	_	_	_	_	_
12	unresolved	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	immune	_	O	O	_	_	_	_	_
15	reactions	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	believed	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	central	_	O	O	_	_	_	_	_
22	pathogenic	_	O	O	_	_	_	_	_
23	mechanisms	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Endogenous	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	therapeutic	_	O	O	_	_	_	_	_
4	steroid	_	O	O	_	_	_	_	_
5	hormones	_	O	O	_	_	_	_	_
6	affect	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	immune	_	O	O	_	_	_	_	_
9	system	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	diseases	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	associated	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	hypothalamic	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	pituitary	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	adrenal	_	O	O	_	_	_	_	_
25	axis	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	providing	_	O	O	_	_	_	_	_
28	evidence	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	an	_	O	O	_	_	_	_	_
31	immune	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	endocrine	_	O	O	_	_	_	_	_
34	interplay	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Function	_	O	O	_	_	_	_	_
2	tests	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	MS	_	O	O	_	_	_	_	_
5	have	_	O	O	_	_	_	_	_
6	revealed	_	O	O	_	_	_	_	_
7	dysregulation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	hypothalamic	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	pituitary	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	adrenal	_	O	O	_	_	_	_	_
15	system	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	substantial	_	O	O	_	_	_	_	_
19	proportion	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	characterized	_	O	O	_	_	_	_	_
3	glucocorticoid	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	GR	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	peripheral	_	O	O	_	_	_	_	_
11	blood	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	39	_	O	O	_	_	_	_	_
15	MS	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	14	_	O	O	_	_	_	_	_
19	age	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	sex	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	matched	_	O	O	_	_	_	_	_
25	controls	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	respect	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	dissociation	_	O	O	_	_	_	_	_
30	constant	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	binding	_	O	O	_	_	_	_	_
33	capacity	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	using	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	whole	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	binding	_	O	O	_	_	_	_	_
41	assay	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	[	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	H	_	O	O	_	_	_	_	_
46	]	_	O	O	_	_	_	_	_
47	dexamethasone	_	O	O	_	_	_	_	_
48	as	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	ligand	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	GR	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	parameters	_	O	O	_	_	_	_	_
4	did	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	differ	_	O	O	_	_	_	_	_
7	significantly	_	O	O	_	_	_	_	_
8	between	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Kd	_	O	O	_	_	_	_	_
12	8	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	98	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	07	_	O	O	_	_	_	_	_
21	nM	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	Bmax	_	O	O	_	_	_	_	_
24	183	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	29	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	8	_	O	O	_	_	_	_	_
31	fmol	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	mg	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	controls	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	Kd	_	O	O	_	_	_	_	_
39	9	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_
41	36	_	O	O	_	_	_	_	_
42	+	_	O	O	_	_	_	_	_
43	/	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_
47	17	_	O	O	_	_	_	_	_
48	nM	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	Bmax	_	O	O	_	_	_	_	_
51	158	_	O	O	_	_	_	_	_
52	+	_	O	O	_	_	_	_	_
53	/	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	16	_	O	O	_	_	_	_	_
56	fmol	_	O	O	_	_	_	_	_
57	/	_	O	O	_	_	_	_	_
58	mg	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	age	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	sex	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	course	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	duration	_	O	O	_	_	_	_	_
11	or	_	O	O	_	_	_	_	_
12	severity	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	disease	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	prior	_	O	O	_	_	_	_	_
18	steroid	_	O	O	_	_	_	_	_
19	treatments	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	detected	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	GR	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	parameters	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	analyzed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	relation	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	results	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	combined	_	O	O	_	_	_	_	_
14	dexamethasone	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CRH	_	O	O	_	_	_	_	_
17	test	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	which	_	O	O	_	_	_	_	_
20	reflects	_	O	O	_	_	_	_	_
21	corticosteroid	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	function	_	O	O	_	_	_	_	_
24	at	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	hypothalamus	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	30	_	O	O	_	_	_	_	_
30	patients	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	9	_	O	O	_	_	_	_	_
33	controls	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	While	_	O	O	_	_	_	_	_
2	controls	_	O	O	_	_	_	_	_
3	showed	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	moderate	_	O	O	_	_	_	_	_
6	correlation	_	O	O	_	_	_	_	_
7	between	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	affinity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	GR	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	lymphocytes	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	regulatory	_	O	O	_	_	_	_	_
17	function	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	hypothalamic	_	O	O	_	_	_	_	_
21	level	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	did	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	physiological	_	O	O	_	_	_	_	_
7	relationship	_	O	O	_	_	_	_	_
8	between	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	function	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	glucocorticoid	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	disturbed	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	MS	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	EMSA	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	Single	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	stranded	_	O	O	_	_	_	_	_
4	complementary	_	O	O	_	_	_	_	_
5	oligonucleotides	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	annealed	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	end	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	labeled	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	[	_	O	O	_	_	_	_	_
14	gamma	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	32	_	O	O	_	_	_	_	_
17	P	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	ATP	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	polynucleotide	_	O	O	_	_	_	_	_
24	kinase	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	EMSA	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	performed	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	5	_	O	O	_	_	_	_	_
6	mug	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	MEL	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	mul	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	vitro	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	translated	_	O	O	_	_	_	_	_
21	Sox	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	along	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	reticulocyte	_	O	O	_	_	_	_	_
27	lysate	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	buffer	_	O	O	_	_	_	_	_
31	:	_	O	O	_	_	_	_	_
32	100	_	O	O	_	_	_	_	_
33	mM	_	O	O	_	_	_	_	_
34	NaCl	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	10	_	O	O	_	_	_	_	_
37	%	_	O	O	_	_	_	_	_
38	glycerol	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	200	_	O	O	_	_	_	_	_
41	ng	_	O	O	_	_	_	_	_
42	/	_	O	O	_	_	_	_	_
43	mul	_	O	O	_	_	_	_	_
44	BSA	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	50	_	O	O	_	_	_	_	_
47	ng	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	mul	_	O	O	_	_	_	_	_
50	poly	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	dI	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	dC	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	or	_	O	O	_	_	_	_	_
57	poly	_	O	O	_	_	_	_	_
58	(	_	O	O	_	_	_	_	_
59	dG	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	dC	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	10	_	O	O	_	_	_	_	_
65	mM	_	O	O	_	_	_	_	_
66	HEPES	_	O	O	_	_	_	_	_
67	(	_	O	O	_	_	_	_	_
68	pH	_	O	O	_	_	_	_	_
69	7	_	O	O	_	_	_	_	_
70	)	_	O	O	_	_	_	_	_
71	,	_	O	O	_	_	_	_	_
72	0	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_
74	1	_	O	O	_	_	_	_	_
75	mM	_	O	O	_	_	_	_	_
76	EDTA	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	0	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_
80	25	_	O	O	_	_	_	_	_
81	mM	_	O	O	_	_	_	_	_
82	DTT	_	O	O	_	_	_	_	_
83	,	_	O	O	_	_	_	_	_
84	0	_	O	O	_	_	_	_	_
85	.	_	O	O	_	_	_	_	_
86	6	_	O	O	_	_	_	_	_
87	mM	_	O	O	_	_	_	_	_
88	MgCl	_	O	O	_	_	_	_	_
89	2	_	O	O	_	_	_	_	_
90	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	competition	_	O	O	_	_	_	_	_
3	or	_	O	O	_	_	_	_	_
4	supershift	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	indicated	_	O	O	_	_	_	_	_
9	unlabelled	_	O	O	_	_	_	_	_
10	oligonucleotide	_	O	O	_	_	_	_	_
11	competitor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	200	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	fold	_	O	O	_	_	_	_	_
16	molar	_	O	O	_	_	_	_	_
17	excess	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	antibody	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	mul	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	added	_	O	O	_	_	_	_	_
27	30	_	O	O	_	_	_	_	_
28	min	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	60	_	O	O	_	_	_	_	_
31	min	_	O	O	_	_	_	_	_
32	prior	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	addition	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	radiolabeled	_	O	O	_	_	_	_	_
37	probe	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	radiolabeled	_	O	O	_	_	_	_	_
6	probe	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	samples	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	incubated	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	30	_	O	O	_	_	_	_	_
14	min	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	60	_	O	O	_	_	_	_	_
17	min	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	room	_	O	O	_	_	_	_	_
20	temperature	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	loaded	_	O	O	_	_	_	_	_
23	on	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	4	_	O	O	_	_	_	_	_
26	%	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	6	_	O	O	_	_	_	_	_
29	%	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	w	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	v	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	polyacrylamide	_	O	O	_	_	_	_	_
36	gel	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Electrophoresis	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	performed	_	O	O	_	_	_	_	_
4	at	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	constant	_	O	O	_	_	_	_	_
7	19	_	O	O	_	_	_	_	_
8	mAmp	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	8	_	O	O	_	_	_	_	_
13	h	_	O	O	_	_	_	_	_
14	at	_	O	O	_	_	_	_	_
15	room	_	O	O	_	_	_	_	_
16	temperature	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	gels	_	O	O	_	_	_	_	_
21	were	_	O	O	_	_	_	_	_
22	dried	_	O	O	_	_	_	_	_
23	prior	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	autoradiography	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Antibodies	_	O	O	_	_	_	_	_
2	used	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	supershift	_	O	O	_	_	_	_	_
5	analyses	_	O	O	_	_	_	_	_
6	included	_	O	O	_	_	_	_	_
7	c	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	Myc	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	HA	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	Sox	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	antibodies	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	described	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	above	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	sequences	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	oligonucleotides	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	follows	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	only	_	O	O	_	_	_	_	_
12	forward	_	O	O	_	_	_	_	_
13	oligos	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	listed	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	:	_	O	O	_	_	_	_	_
18	For	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	36	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	bp	_	O	O	_	_	_	_	_
23	WT	_	O	O	_	_	_	_	_
24	probe	_	O	O	_	_	_	_	_
25	:	_	O	O	_	_	_	_	_
26	5	_	O	O	_	_	_	_	_
27	'	_	O	O	_	_	_	_	_
28	AATGCAGAACAAAGGGTCAGAACATTGTCTGCGAAG	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	'	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	MHB	_	O	O	_	_	_	_	_
33	1556	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	;	_	O	O	_	_	_	_	_
36	for	_	O	O	_	_	_	_	_
37	mutant	_	O	O	_	_	_	_	_
38	probe	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	M	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	:	_	O	O	_	_	_	_	_
45	5	_	O	O	_	_	_	_	_
46	'	_	O	O	_	_	_	_	_
47	AACAAAGGGTCAGAACATTGTCTGCGAAG	_	O	O	_	_	_	_	_
48	3	_	O	O	_	_	_	_	_
49	'	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	MHB	_	O	O	_	_	_	_	_
52	1644	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	;	_	O	O	_	_	_	_	_
55	for	_	O	O	_	_	_	_	_
56	mutant	_	O	O	_	_	_	_	_
57	probe	_	O	O	_	_	_	_	_
58	2	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	M	_	O	O	_	_	_	_	_
61	2	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	:	_	O	O	_	_	_	_	_
64	5	_	O	O	_	_	_	_	_
65	'	_	O	O	_	_	_	_	_
66	AATGCAGAACAAAGGGTCAGAtgagTGTCTGCGAAG	_	O	O	_	_	_	_	_
67	3	_	O	O	_	_	_	_	_
68	'	_	O	O	_	_	_	_	_
69	(	_	O	O	_	_	_	_	_
70	MHB	_	O	O	_	_	_	_	_
71	1648	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	;	_	O	O	_	_	_	_	_
74	for	_	O	O	_	_	_	_	_
75	mutant	_	O	O	_	_	_	_	_
76	probe	_	O	O	_	_	_	_	_
77	3	_	O	O	_	_	_	_	_
78	(	_	O	O	_	_	_	_	_
79	M	_	O	O	_	_	_	_	_
80	3	_	O	O	_	_	_	_	_
81	)	_	O	O	_	_	_	_	_
82	:	_	O	O	_	_	_	_	_
83	5	_	O	O	_	_	_	_	_
84	'	_	O	O	_	_	_	_	_
85	AATGCAGtgccAAGGGTCAGAACATTGTCTGCGAAG	_	O	O	_	_	_	_	_
86	3	_	O	O	_	_	_	_	_
87	'	_	O	O	_	_	_	_	_
88	(	_	O	O	_	_	_	_	_
89	MHB	_	O	O	_	_	_	_	_
90	1650	_	O	O	_	_	_	_	_
91	)	_	O	O	_	_	_	_	_
92	.	_	O	O	_	_	_	_	_



1	Background	_	O	O	_	_	_	_	_

1	beta	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	--	_	O	O	_	_	_	_	_
5	>	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	D	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	glucans	_	O	O	_	_	_	_	_
11	occur	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	principal	_	O	O	_	_	_	_	_
15	component	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	microbial	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	walls	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	can	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	secreted	_	O	O	_	_	_	_	_
24	from	_	O	O	_	_	_	_	_
25	both	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	non	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	pathogenic	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	pathogenic	_	O	O	_	_	_	_	_
32	fungi	_	O	O	_	_	_	_	_
33	such	_	O	O	_	_	_	_	_
34	as	_	O	O	_	_	_	_	_
35	S	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	cerevisae	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	albicans	_	O	O	_	_	_	_	_
2	[	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	]	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	beta	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	--	_	O	O	_	_	_	_	_
6	>	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	linked	_	O	O	_	_	_	_	_
12	glucose	_	O	O	_	_	_	_	_
13	polymers	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	characterized	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	fungal	_	O	O	_	_	_	_	_
19	pathogen	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	associated	_	O	O	_	_	_	_	_
22	molecular	_	O	O	_	_	_	_	_
23	pattern	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	PAMP	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	primary	_	O	O	_	_	_	_	_
3	cellular	_	O	O	_	_	_	_	_
4	recognition	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	--	_	O	O	_	_	_	_	_
10	>	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	D	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	glucans	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	several	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	--	_	O	O	_	_	_	_	_
24	>	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	D	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	glucan	_	O	O	_	_	_	_	_
30	receptors	_	O	O	_	_	_	_	_
31	on	_	O	O	_	_	_	_	_
32	phagocytes	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	3	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	4	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	other	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	[	_	O	O	_	_	_	_	_
42	5	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	6	_	O	O	_	_	_	_	_
45	]	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	as	_	O	O	_	_	_	_	_
3	well	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	murine	_	O	O	_	_	_	_	_
6	Dectin	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	been	_	O	O	_	_	_	_	_
11	demonstrated	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	major	_	O	O	_	_	_	_	_
16	pattern	_	O	O	_	_	_	_	_
17	recognition	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	PRR	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	intact	_	O	O	_	_	_	_	_
24	yeast	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	beta	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	--	_	O	O	_	_	_	_	_
30	>	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	D	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	glucan	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	containing	_	O	O	_	_	_	_	_
38	particles	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	i	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	e	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	zymosan	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	monocytes	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	macrophages	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	well	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	neutrophils	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	primary	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	7	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	11	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	murine	_	O	O	_	_	_	_	_
4	system	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	zymosan	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	Dectin	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	resulted	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	TNFalpha	_	O	O	_	_	_	_	_
18	through	_	O	O	_	_	_	_	_
19	Toll	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	like	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	adaptor	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	MyD	_	O	O	_	_	_	_	_
29	88	_	O	O	_	_	_	_	_
30	[	_	O	O	_	_	_	_	_
31	12	_	O	O	_	_	_	_	_
32	]	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Another	_	O	O	_	_	_	_	_
2	water	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	soluble	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	--	_	O	O	_	_	_	_	_
9	>	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	D	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	glucan	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	PGG	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	glucan	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	has	_	O	O	_	_	_	_	_
21	been	_	O	O	_	_	_	_	_
22	described	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	activate	_	O	O	_	_	_	_	_
25	NFkappaB	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	NFIL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	6	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	murine	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	lines	_	O	O	_	_	_	_	_
34	[	_	O	O	_	_	_	_	_
35	13	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	14	_	O	O	_	_	_	_	_
38	]	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Similarly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	beta	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	--	_	O	O	_	_	_	_	_
12	>	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	glucans	_	O	O	_	_	_	_	_
18	activate	_	O	O	_	_	_	_	_
19	NFkappaB	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	monocyte	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	like	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	line	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	15	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	human	_	O	O	_	_	_	_	_
34	polymorphonuclear	_	O	O	_	_	_	_	_
35	neutrophils	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	PMN	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	latter	_	O	O	_	_	_	_	_
43	case	_	O	O	_	_	_	_	_
44	without	_	O	O	_	_	_	_	_
45	secretion	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	pro	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	inflammatory	_	O	O	_	_	_	_	_
50	cytokines	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	IL	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	6	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	TNFalpha	_	O	O	_	_	_	_	_
61	)	_	O	O	_	_	_	_	_
62	[	_	O	O	_	_	_	_	_
63	16	_	O	O	_	_	_	_	_
64	]	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	proposed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	production	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	inflammatory	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	RA	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	human	_	O	O	_	_	_	_	_
24	monocytes	_	O	O	_	_	_	_	_
25	may	_	O	O	_	_	_	_	_
26	be	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	potentially	_	O	O	_	_	_	_	_
29	protective	_	O	O	_	_	_	_	_
30	mechanism	_	O	O	_	_	_	_	_
31	induced	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	beta	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	--	_	O	O	_	_	_	_	_
37	>	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	D	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	glucan	_	O	O	_	_	_	_	_
43	[	_	O	O	_	_	_	_	_
44	17	_	O	O	_	_	_	_	_
45	]	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Three	_	O	O	_	_	_	_	_
2	other	_	O	O	_	_	_	_	_
3	investigations	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	reported	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	leukocytes	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	vascular	_	O	O	_	_	_	_	_
12	endothelial	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	produce	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	response	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	zymosan	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	18	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	or	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	water	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	soluble	_	O	O	_	_	_	_	_
30	beta	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	--	_	O	O	_	_	_	_	_
34	>	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	D	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	glucan	_	O	O	_	_	_	_	_
40	[	_	O	O	_	_	_	_	_
41	6	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	19	_	O	O	_	_	_	_	_
44	]	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	--	_	O	O	_	_	_	_	_
8	>	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	glucans	_	O	O	_	_	_	_	_
14	seem	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	able	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	modify	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	response	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	pro	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	inflammatory	_	O	O	_	_	_	_	_
26	stimuli	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	even	_	O	O	_	_	_	_	_
29	sepsis	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	murine	_	O	O	_	_	_	_	_
4	polymicrobial	_	O	O	_	_	_	_	_
5	sepsis	_	O	O	_	_	_	_	_
6	model	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	beta	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	--	_	O	O	_	_	_	_	_
12	>	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	glucan	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	20	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	treatment	_	O	O	_	_	_	_	_
22	resulted	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	decreased	_	O	O	_	_	_	_	_
25	septic	_	O	O	_	_	_	_	_
26	morbidity	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	mortality	_	O	O	_	_	_	_	_
29	mediated	_	O	O	_	_	_	_	_
30	via	_	O	O	_	_	_	_	_
31	inhibition	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	NFkappaB	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	stimulation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	phosphoinositide	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	kinase	_	O	O	_	_	_	_	_
43	(	_	O	O	_	_	_	_	_
44	PI	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	K	_	O	O	_	_	_	_	_
47	)	_	O	O	_	_	_	_	_
48	pathway	_	O	O	_	_	_	_	_
49	[	_	O	O	_	_	_	_	_
50	21	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	22	_	O	O	_	_	_	_	_
53	]	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	animal	_	O	O	_	_	_	_	_
5	studies	_	O	O	_	_	_	_	_
6	[	_	O	O	_	_	_	_	_
7	23	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	24	_	O	O	_	_	_	_	_
10	]	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	well	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	clinical	_	O	O	_	_	_	_	_
16	trial	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	25	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_
20	support	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	protective	_	O	O	_	_	_	_	_
23	role	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	beta	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	--	_	O	O	_	_	_	_	_
29	>	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	D	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	glucan	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	certain	_	O	O	_	_	_	_	_
37	pro	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	inflammatory	_	O	O	_	_	_	_	_
40	conditions	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanisms	_	O	O	_	_	_	_	_
3	underlying	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	beneficial	_	O	O	_	_	_	_	_
6	effects	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	beta	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	--	_	O	O	_	_	_	_	_
12	>	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	glucan	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	only	_	O	O	_	_	_	_	_
20	partially	_	O	O	_	_	_	_	_
21	resolved	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	especially	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	humans	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	aim	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	study	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	elucidate	_	O	O	_	_	_	_	_
11	molecular	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	cellular	_	O	O	_	_	_	_	_
14	mechanisms	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	--	_	O	O	_	_	_	_	_
20	>	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	D	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	glucans	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	human	_	O	O	_	_	_	_	_
28	leukocytes	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	pro	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	inflammatory	_	O	O	_	_	_	_	_
33	conditions	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	special	_	O	O	_	_	_	_	_
36	emphasis	_	O	O	_	_	_	_	_
37	on	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	cytokine	_	O	O	_	_	_	_	_
40	profile	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	its	_	O	O	_	_	_	_	_
43	transcriptional	_	O	O	_	_	_	_	_
44	regulation	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	purpose	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	peripheral	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	mononuclear	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	PBMC	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	exposed	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	well	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	defined	_	O	O	_	_	_	_	_
19	beta	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	--	_	O	O	_	_	_	_	_
23	>	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	D	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	glucan	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	i	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	e	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	glucan	_	O	O	_	_	_	_	_
2	phosphate	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	[	_	O	O	_	_	_	_	_
7	20	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	26	_	O	O	_	_	_	_	_
10	]	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	alone	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	simultaneously	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	LPS	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	gram	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	negative	_	O	O	_	_	_	_	_
21	bacteria	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	superantigen	_	O	O	_	_	_	_	_
25	TSST	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	from	_	O	O	_	_	_	_	_
29	gram	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	positive	_	O	O	_	_	_	_	_
32	bacteria	_	O	O	_	_	_	_	_
33	over	_	O	O	_	_	_	_	_
34	48	_	O	O	_	_	_	_	_
35	h	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	potential	_	O	O	_	_	_	_	_
5	effect	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	--	_	O	O	_	_	_	_	_
11	>	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	D	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	glucan	_	O	O	_	_	_	_	_
17	on	_	O	O	_	_	_	_	_
18	cytokine	_	O	O	_	_	_	_	_
19	production	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	12	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	16	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	19	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	TNFalpha	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	beta	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	6	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	8	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	RA	_	O	O	_	_	_	_	_
47	were	_	O	O	_	_	_	_	_
48	measured	_	O	O	_	_	_	_	_
49	as	_	O	O	_	_	_	_	_
50	well	_	O	O	_	_	_	_	_
51	as	_	O	O	_	_	_	_	_
52	IFNgamma	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	IL	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	2	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	IL	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	4	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	IL	_	O	O	_	_	_	_	_
63	-	_	O	O	_	_	_	_	_
64	10	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	IL	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	12	_	O	O	_	_	_	_	_
69	and	_	O	O	_	_	_	_	_
70	TGFbeta	_	O	O	_	_	_	_	_
71	1	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_

1	Correspondingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	four	_	O	O	_	_	_	_	_
4	NFkappaB	_	O	O	_	_	_	_	_
5	sites	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	TNFalpha	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	kappa	_	O	O	_	_	_	_	_
12	consensus	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	kappa	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	kappa	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	27	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	consensus	_	O	O	_	_	_	_	_
30	site	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	8	_	O	O	_	_	_	_	_
36	promoter	_	O	O	_	_	_	_	_
37	[	_	O	O	_	_	_	_	_
38	28	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	an	_	O	O	_	_	_	_	_
42	NFAT	_	O	O	_	_	_	_	_
43	site	_	O	O	_	_	_	_	_
44	from	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	IFNgamma	_	O	O	_	_	_	_	_
47	promoter	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	ATP	_	O	O	_	_	_	_	_
50	2	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	[	_	O	O	_	_	_	_	_
53	29	_	O	O	_	_	_	_	_
54	]	_	O	O	_	_	_	_	_
55	and	_	O	O	_	_	_	_	_
56	a	_	O	O	_	_	_	_	_
57	consensus	_	O	O	_	_	_	_	_
58	NFIL	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	6	_	O	O	_	_	_	_	_
61	site	_	O	O	_	_	_	_	_
62	from	_	O	O	_	_	_	_	_
63	the	_	O	O	_	_	_	_	_
64	IL	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	6	_	O	O	_	_	_	_	_
67	promoter	_	O	O	_	_	_	_	_
68	[	_	O	O	_	_	_	_	_
69	13	_	O	O	_	_	_	_	_
70	]	_	O	O	_	_	_	_	_
71	were	_	O	O	_	_	_	_	_
72	examined	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	anti	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	inflammatory	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	we	_	O	O	_	_	_	_	_
15	focused	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	factors	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	promoter	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	element	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	three	_	O	O	_	_	_	_	_
6	positive	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	acting	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	response	_	O	O	_	_	_	_	_
12	elements	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	LRE	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	LRE	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	LRE	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	RA	_	O	O	_	_	_	_	_
32	promoter	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	including	_	O	O	_	_	_	_	_
35	NFkappaB	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	PU	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	NFIL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	6	_	O	O	_	_	_	_	_
44	sites	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	have	_	O	O	_	_	_	_	_
47	been	_	O	O	_	_	_	_	_
48	characterized	_	O	O	_	_	_	_	_
49	previously	_	O	O	_	_	_	_	_
50	[	_	O	O	_	_	_	_	_
51	30	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	33	_	O	O	_	_	_	_	_
54	]	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	computational	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	homology	_	O	O	_	_	_	_	_
6	search	_	O	O	_	_	_	_	_
7	[	_	O	O	_	_	_	_	_
8	34	_	O	O	_	_	_	_	_
9	]	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	we	_	O	O	_	_	_	_	_
12	looked	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	new	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	motifs	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	RA	_	O	O	_	_	_	_	_
23	promoter	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_



1	Molecular	_	O	O	_	_	_	_	_
2	mechanisms	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	steroid	_	O	O	_	_	_	_	_
5	action	_	O	O	_	_	_	_	_
6	:	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	novel	_	O	O	_	_	_	_	_
9	type	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cross	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	talk	_	O	O	_	_	_	_	_
14	between	_	O	O	_	_	_	_	_
15	glucocorticoids	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	factors	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Despite	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	widespread	_	O	O	_	_	_	_	_
4	use	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	glucocorticoids	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	treatment	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	diseases	_	O	O	_	_	_	_	_
12	characterized	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	inflammation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	molecular	_	O	O	_	_	_	_	_
18	mechanism	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	s	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	which	_	O	O	_	_	_	_	_
24	these	_	O	O	_	_	_	_	_
25	hormones	_	O	O	_	_	_	_	_
26	exert	_	O	O	_	_	_	_	_
27	this	_	O	O	_	_	_	_	_
28	beneficial	_	O	O	_	_	_	_	_
29	effect	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	patients	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	asthma	_	O	O	_	_	_	_	_
34	remains	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	be	_	O	O	_	_	_	_	_
37	elucidated	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	studied	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	transcriptional	_	O	O	_	_	_	_	_
8	regulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	intercellular	_	O	O	_	_	_	_	_
11	adhesion	_	O	O	_	_	_	_	_
12	molecule	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	ICAM	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	adhesion	_	O	O	_	_	_	_	_
22	molecules	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	likely	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	play	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	causal	_	O	O	_	_	_	_	_
29	role	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	inflammation	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	promoting	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	matrix	_	O	O	_	_	_	_	_
41	interactions	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	observed	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	monocytic	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	U	_	O	O	_	_	_	_	_
9	937	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	bronchial	_	O	O	_	_	_	_	_
14	epithelial	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	H	_	O	O	_	_	_	_	_
17	292	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	line	_	O	O	_	_	_	_	_
22	dexamethasone	_	O	O	_	_	_	_	_
23	strongly	_	O	O	_	_	_	_	_
24	suppressed	_	O	O	_	_	_	_	_
25	basal	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	induced	_	O	O	_	_	_	_	_
28	ICAM	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	expression	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Subsequent	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	ICAM	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	has	_	O	O	_	_	_	_	_
11	revealed	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	12	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	O	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	tetradecanoylphorbol	_	O	O	_	_	_	_	_
19	13	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	acetate	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	TPA	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	tumour	_	O	O	_	_	_	_	_
27	necrosis	_	O	O	_	_	_	_	_
28	factor	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	alpha	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	TNF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	alpha	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	upregulate	_	O	O	_	_	_	_	_
37	ICAM	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	expression	_	O	O	_	_	_	_	_
41	through	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	presence	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	a	_	O	O	_	_	_	_	_
46	nuclear	_	O	O	_	_	_	_	_
47	factor	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	NF	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	kappa	_	O	O	_	_	_	_	_
52	B	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	target	_	O	O	_	_	_	_	_
55	sequence	_	O	O	_	_	_	_	_
56	(	_	O	O	_	_	_	_	_
57	TGGAAATTCC	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	glucocorticoid	_	O	O	_	_	_	_	_
3	recognition	_	O	O	_	_	_	_	_
4	sequences	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	present	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	this	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	region	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	dexamethasone	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	still	_	O	O	_	_	_	_	_
15	able	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	repress	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	multimerized	_	O	O	_	_	_	_	_
22	NF	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	kappa	_	O	O	_	_	_	_	_
25	B	_	O	O	_	_	_	_	_
26	sequence	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	transactivated	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	TNF	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	alpha	_	O	O	_	_	_	_	_
33	upon	_	O	O	_	_	_	_	_
34	transfection	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	293	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	propose	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	direct	_	O	O	_	_	_	_	_
5	interaction	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kappa	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	factors	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	least	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	partial	_	O	O	_	_	_	_	_
22	explanation	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	effects	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	this	_	O	O	_	_	_	_	_
28	hormone	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	inflammatory	_	O	O	_	_	_	_	_
31	diseases	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Block	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	granulocytic	_	O	O	_	_	_	_	_
4	differentiation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	32	_	O	O	_	_	_	_	_
7	Dcl	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	AML	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ETO	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	MTG	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	not	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	highly	_	O	O	_	_	_	_	_
23	expressed	_	O	O	_	_	_	_	_
24	Bcl	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	chimeric	_	O	O	_	_	_	_	_
3	gene	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	AML	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	ETO	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	MTG	_	O	O	_	_	_	_	_
11	8	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	generated	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	t	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	21	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	acute	_	O	O	_	_	_	_	_
23	myeloid	_	O	O	_	_	_	_	_
24	leukemia	_	O	O	_	_	_	_	_
25	enhances	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	Bcl	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	evaluate	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	enhancement	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	primary	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	AML	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ETO	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	leukemogenesis	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	effects	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	over	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	Bcl	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	murine	_	O	O	_	_	_	_	_
30	myeloid	_	O	O	_	_	_	_	_
31	precursor	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	line	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	32	_	O	O	_	_	_	_	_
36	Dcl	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	were	_	O	O	_	_	_	_	_
40	examined	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	32	_	O	O	_	_	_	_	_
3	Dcl	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	expressing	_	O	O	_	_	_	_	_
7	exogenous	_	O	O	_	_	_	_	_
8	Bcl	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	differentiate	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	onset	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	morphological	_	O	O	_	_	_	_	_
20	differentiation	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	delayed	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	even	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	expressing	_	O	O	_	_	_	_	_
7	very	_	O	O	_	_	_	_	_
8	high	_	O	O	_	_	_	_	_
9	levels	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	exogenous	_	O	O	_	_	_	_	_
12	Bcl	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	eventually	_	O	O	_	_	_	_	_
16	underwent	_	O	O	_	_	_	_	_
17	differentiation	_	O	O	_	_	_	_	_
18	without	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	significant	_	O	O	_	_	_	_	_
21	decrease	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	synthesis	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	Bcl	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	32	_	O	O	_	_	_	_	_
6	Dcl	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	stably	_	O	O	_	_	_	_	_
10	expressing	_	O	O	_	_	_	_	_
11	AML	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ETO	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	completely	_	O	O	_	_	_	_	_
17	resistant	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	differentiation	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	continued	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	grow	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	presence	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	G	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	CSF	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	consistent	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	interpretation	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	stimulation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	Bcl	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	primary	_	O	O	_	_	_	_	_
19	target	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	AML	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	ETO	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Cleavage	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factor	_	O	O	_	_	_	_	_
5	SP	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	caspases	_	O	O	_	_	_	_	_
9	during	_	O	O	_	_	_	_	_
10	anti	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	IgM	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	apoptosis	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Apoptosis	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	instrumental	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	processes	_	O	O	_	_	_	_	_
7	generating	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	diversity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	repertoire	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Autoreactive	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	eliminated	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	anti	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	IgM	_	O	O	_	_	_	_	_
11	crosslinking	_	O	O	_	_	_	_	_
12	after	_	O	O	_	_	_	_	_
13	encountering	_	O	O	_	_	_	_	_
14	self	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	antigens	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	but	_	O	O	_	_	_	_	_
19	precise	_	O	O	_	_	_	_	_
20	mechanisms	_	O	O	_	_	_	_	_
21	leading	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	apoptosis	_	O	O	_	_	_	_	_
27	are	_	O	O	_	_	_	_	_
28	still	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	well	_	O	O	_	_	_	_	_
31	understood	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	report	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	cleavage	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	SP	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	Burkitt	_	O	O	_	_	_	_	_
16	lymphoma	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	line	_	O	O	_	_	_	_	_
19	BL	_	O	O	_	_	_	_	_
20	60	_	O	O	_	_	_	_	_
21	during	_	O	O	_	_	_	_	_
22	anti	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	IgM	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	induced	_	O	O	_	_	_	_	_
27	apoptosis	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Western	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	revealed	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	cleavage	_	O	O	_	_	_	_	_
7	products	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	approximately	_	O	O	_	_	_	_	_
10	68	_	O	O	_	_	_	_	_
11	kDa	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	45	_	O	O	_	_	_	_	_
14	kDa	_	O	O	_	_	_	_	_
15	after	_	O	O	_	_	_	_	_
16	induction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	apoptosis	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Cleavage	_	O	O	_	_	_	_	_
2	could	_	O	O	_	_	_	_	_
3	be	_	O	O	_	_	_	_	_
4	completely	_	O	O	_	_	_	_	_
5	inhibited	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	zDEVD	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	fmk	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	inhibitor	_	O	O	_	_	_	_	_
13	specific	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	caspase	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	like	_	O	O	_	_	_	_	_
19	proteases	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	vitro	_	O	O	_	_	_	_	_
4	cleavage	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	recombinant	_	O	O	_	_	_	_	_
7	SP	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	recombinant	_	O	O	_	_	_	_	_
11	caspase	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	CPP	_	O	O	_	_	_	_	_
15	32	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	caspase	_	O	O	_	_	_	_	_
19	7	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Mch	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	results	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	similar	_	O	O	_	_	_	_	_
27	cleavage	_	O	O	_	_	_	_	_
28	products	_	O	O	_	_	_	_	_
29	as	_	O	O	_	_	_	_	_
30	those	_	O	O	_	_	_	_	_
31	observed	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	vivo	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	caspase	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	Mch	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	primarily	_	O	O	_	_	_	_	_
9	generates	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	68	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	kDa	_	O	O	_	_	_	_	_
14	cleavage	_	O	O	_	_	_	_	_
15	product	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	observed	_	O	O	_	_	_	_	_
19	after	_	O	O	_	_	_	_	_
20	calcium	_	O	O	_	_	_	_	_
21	ionophore	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	CaI	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	induced	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	apoptosis	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	caspase	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	ICE	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	did	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	cleave	_	O	O	_	_	_	_	_
12	SP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	vitro	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	time	_	O	O	_	_	_	_	_
3	course	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	SP	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	cleavage	_	O	O	_	_	_	_	_
8	during	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	IgM	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	apoptosis	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	paralleled	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	increase	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	caspase	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	measured	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	DEVD	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	p	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	nitroanilide	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	DEVD	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	pNA	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	cleavage	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	DNA	_	O	O	_	_	_	_	_
2	band	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	shift	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	revealed	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	decrease	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	intensity	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	full	_	O	O	_	_	_	_	_
15	length	_	O	O	_	_	_	_	_
16	SP	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	DNA	_	O	O	_	_	_	_	_
20	complex	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	an	_	O	O	_	_	_	_	_
23	increase	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	intensity	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	smaller	_	O	O	_	_	_	_	_
30	complex	_	O	O	_	_	_	_	_
31	due	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	binding	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	one	_	O	O	_	_	_	_	_
37	SP	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	cleavage	_	O	O	_	_	_	_	_
40	product	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	Edman	_	O	O	_	_	_	_	_
3	sequencing	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	could	_	O	O	_	_	_	_	_
6	identify	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	caspase	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	cleavage	_	O	O	_	_	_	_	_
11	site	_	O	O	_	_	_	_	_
12	after	_	O	O	_	_	_	_	_
13	Asp	_	O	O	_	_	_	_	_
14	584	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	584	_	O	O	_	_	_	_	_
18	AQPQAGR	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	generating	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	22	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	kDa	_	O	O	_	_	_	_	_
26	C	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	terminal	_	O	O	_	_	_	_	_
29	SP	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	protein	_	O	O	_	_	_	_	_
32	fragment	_	O	O	_	_	_	_	_
33	which	_	O	O	_	_	_	_	_
34	still	_	O	O	_	_	_	_	_
35	contains	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	DNA	_	O	O	_	_	_	_	_
38	binding	_	O	O	_	_	_	_	_
39	site	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	cleavage	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	SP	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	vivo	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	vitro	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	underlining	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	central	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	caspase	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	like	_	O	O	_	_	_	_	_
28	proteases	_	O	O	_	_	_	_	_
29	during	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	process	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	anti	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	IgM	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	induced	_	O	O	_	_	_	_	_
38	apoptosis	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Quantification	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	semiquantitative	_	O	O	_	_	_	_	_
9	reverse	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	polymerase	_	O	O	_	_	_	_	_
13	chain	_	O	O	_	_	_	_	_
14	reaction	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	incubated	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	various	_	O	O	_	_	_	_	_
6	concentrations	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	anti	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	presence	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	absence	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	inhibitors	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	LY	_	O	O	_	_	_	_	_
21	294002	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	PDTC	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	16	_	O	O	_	_	_	_	_
3	hours	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	incubation	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	extracted	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	RNAzol	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	Biotex	_	O	O	_	_	_	_	_
15	Laboratories	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	Houston	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	TX	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	USA	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	accordance	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	manufacturer	_	O	O	_	_	_	_	_
28	'	_	O	O	_	_	_	_	_
29	s	_	O	O	_	_	_	_	_
30	instructions	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Reverse	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	mug	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	total	_	O	O	_	_	_	_	_
8	mRNA	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	performed	_	O	O	_	_	_	_	_
11	at	_	O	O	_	_	_	_	_
12	42	_	O	O	_	_	_	_	_
13	degreesC	_	O	O	_	_	_	_	_
14	using	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	Superscripttrade	_	O	O	_	_	_	_	_
17	reverse	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	system	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Takara	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	Shiga	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	Japan	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	PCR	_	O	O	_	_	_	_	_
2	amplification	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cDNA	_	O	O	_	_	_	_	_
5	aliquots	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	performed	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	adding	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	mM	_	O	O	_	_	_	_	_
14	dNTPs	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	U	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	Taq	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	polymerase	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Takara	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	0	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	25	_	O	O	_	_	_	_	_
31	muM	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	sense	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	antisense	_	O	O	_	_	_	_	_
36	primers	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	reaction	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	performed	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	PCR	_	O	O	_	_	_	_	_
7	buffer	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	mM	_	O	O	_	_	_	_	_
13	MgCl	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	50	_	O	O	_	_	_	_	_
17	mM	_	O	O	_	_	_	_	_
18	KCl	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	mM	_	O	O	_	_	_	_	_
22	Tris	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	HCl	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	pH	_	O	O	_	_	_	_	_
27	8	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	total	_	O	O	_	_	_	_	_
34	volume	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	25	_	O	O	_	_	_	_	_
37	mul	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	following	_	O	O	_	_	_	_	_
3	sense	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	antisense	_	O	O	_	_	_	_	_
6	primers	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	each	_	O	O	_	_	_	_	_
9	molecules	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	used	_	O	O	_	_	_	_	_
12	:	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	sense	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	'	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	ATG	_	O	O	_	_	_	_	_
22	ACT	_	O	O	_	_	_	_	_
23	CCT	_	O	O	_	_	_	_	_
24	GGG	_	O	O	_	_	_	_	_
25	AAG	_	O	O	_	_	_	_	_
26	ACC	_	O	O	_	_	_	_	_
27	TCA	_	O	O	_	_	_	_	_
28	TTG	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	';	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	17	_	O	O	_	_	_	_	_
35	antisense	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	'	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	TTA	_	O	O	_	_	_	_	_
41	GGC	_	O	O	_	_	_	_	_
42	CAC	_	O	O	_	_	_	_	_
43	ATG	_	O	O	_	_	_	_	_
44	GTG	_	O	O	_	_	_	_	_
45	GAC	_	O	O	_	_	_	_	_
46	AAT	_	O	O	_	_	_	_	_
47	CGG	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	3	_	O	O	_	_	_	_	_
50	';	_	O	O	_	_	_	_	_
51	glyceraldehyde	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	3	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	phosphate	_	O	O	_	_	_	_	_
56	dehydrogenase	_	O	O	_	_	_	_	_
57	(	_	O	O	_	_	_	_	_
58	GAPDH	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	sense	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	5	_	O	O	_	_	_	_	_
63	'	_	O	O	_	_	_	_	_
64	-	_	O	O	_	_	_	_	_
65	CGA	_	O	O	_	_	_	_	_
66	TGC	_	O	O	_	_	_	_	_
67	TGG	_	O	O	_	_	_	_	_
68	GCG	_	O	O	_	_	_	_	_
69	TGA	_	O	O	_	_	_	_	_
70	GTA	_	O	O	_	_	_	_	_
71	C	_	O	O	_	_	_	_	_
72	-	_	O	O	_	_	_	_	_
73	3	_	O	O	_	_	_	_	_
74	';	_	O	O	_	_	_	_	_
75	GAPDH	_	O	O	_	_	_	_	_
76	antisense	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	5	_	O	O	_	_	_	_	_
79	'	_	O	O	_	_	_	_	_
80	-	_	O	O	_	_	_	_	_
81	CGT	_	O	O	_	_	_	_	_
82	TCA	_	O	O	_	_	_	_	_
83	GCT	_	O	O	_	_	_	_	_
84	CAG	_	O	O	_	_	_	_	_
85	GGA	_	O	O	_	_	_	_	_
86	TGA	_	O	O	_	_	_	_	_
87	CC	_	O	O	_	_	_	_	_
88	-	_	O	O	_	_	_	_	_
89	3	_	O	O	_	_	_	_	_
90	'.	_	O	O	_	_	_	_	_

1	Reactions	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	processed	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	thermal	_	O	O	_	_	_	_	_
8	cycler	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Perkin	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Elmer	_	O	O	_	_	_	_	_
13	Cetus	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	Norwalk	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	CT	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	USA	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	through	_	O	O	_	_	_	_	_
22	cycles	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	30	_	O	O	_	_	_	_	_
25	s	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	denaturation	_	O	O	_	_	_	_	_
28	at	_	O	O	_	_	_	_	_
29	94	_	O	O	_	_	_	_	_
30	degreesC	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	min	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	annealing	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	56	_	O	O	_	_	_	_	_
38	degreesC	_	O	O	_	_	_	_	_
39	for	_	O	O	_	_	_	_	_
40	GAPDH	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	17	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	followed	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	min	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	elongation	_	O	O	_	_	_	_	_
52	at	_	O	O	_	_	_	_	_
53	72	_	O	O	_	_	_	_	_
54	degreesC	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	PCR	_	O	O	_	_	_	_	_
2	rounds	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	repeated	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	cycles	_	O	O	_	_	_	_	_
8	each	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	both	_	O	O	_	_	_	_	_
11	GAPDH	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	;	_	O	O	_	_	_	_	_
17	this	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	determined	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	falling	_	O	O	_	_	_	_	_
22	within	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	exponential	_	O	O	_	_	_	_	_
25	phase	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	amplification	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	each	_	O	O	_	_	_	_	_
30	molecule	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	level	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	presented	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	ratio	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	17	_	O	O	_	_	_	_	_
15	PCR	_	O	O	_	_	_	_	_
16	product	_	O	O	_	_	_	_	_
17	over	_	O	O	_	_	_	_	_
18	GAPDH	_	O	O	_	_	_	_	_
19	product	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_



1	Lymphocyte	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	lines	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	vitamin	_	O	O	_	_	_	_	_
6	D	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	dependent	_	O	O	_	_	_	_	_
9	rickets	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	II	_	O	O	_	_	_	_	_
12	show	_	O	O	_	_	_	_	_
13	functional	_	O	O	_	_	_	_	_
14	defects	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	25	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	dihydroxyvitamin	_	O	O	_	_	_	_	_
23	D	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Lymphocyte	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	lines	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	established	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	five	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	vitamin	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dependent	_	O	O	_	_	_	_	_
14	rickets	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	type	_	O	O	_	_	_	_	_
17	II	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	VDDR	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	II	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	lines	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	established	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	infection	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	lymphotrophic	_	O	O	_	_	_	_	_
12	virus	_	O	O	_	_	_	_	_
13	type	_	O	O	_	_	_	_	_
14	I	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	HTLV	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	I	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	[	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	H	_	O	O	_	_	_	_	_
6	]	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	dihydroxyvitamin	_	O	O	_	_	_	_	_
13	D	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	25	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	OH	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	D	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	receptor	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	these	_	O	O	_	_	_	_	_
31	cell	_	O	O	_	_	_	_	_
32	lines	_	O	O	_	_	_	_	_
33	was	_	O	O	_	_	_	_	_
34	compared	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	binding	_	O	O	_	_	_	_	_
37	studies	_	O	O	_	_	_	_	_
38	using	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	T	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	lymphocyte	_	O	O	_	_	_	_	_
43	cell	_	O	O	_	_	_	_	_
44	line	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	S	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	LB	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	from	_	O	O	_	_	_	_	_
52	a	_	O	O	_	_	_	_	_
53	normal	_	O	O	_	_	_	_	_
54	individual	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	25	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	OH	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	S	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	LB	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	comparable	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	well	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	characterized	_	O	O	_	_	_	_	_
24	chick	_	O	O	_	_	_	_	_
25	intestinal	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	25	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	OH	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	D	_	O	O	_	_	_	_	_
34	3	_	O	O	_	_	_	_	_
35	receptor	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	terms	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	its	_	O	O	_	_	_	_	_
40	ligand	_	O	O	_	_	_	_	_
41	binding	_	O	O	_	_	_	_	_
42	affinity	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	capacity	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	its	_	O	O	_	_	_	_	_
47	mobility	_	O	O	_	_	_	_	_
48	on	_	O	O	_	_	_	_	_
49	5	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	20	_	O	O	_	_	_	_	_
52	%	_	O	O	_	_	_	_	_
53	sucrose	_	O	O	_	_	_	_	_
54	gradients	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	and	_	O	O	_	_	_	_	_
57	its	_	O	O	_	_	_	_	_
58	adsorption	_	O	O	_	_	_	_	_
59	to	_	O	O	_	_	_	_	_
60	and	_	O	O	_	_	_	_	_
61	elution	_	O	O	_	_	_	_	_
62	properties	_	O	O	_	_	_	_	_
63	from	_	O	O	_	_	_	_	_
64	DNA	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	cellulose	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_

1	Three	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	lines	_	O	O	_	_	_	_	_
4	established	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	VDDR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	II	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	Rh	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	VDR	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	Sh	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	VDR	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	Ab	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	VDR	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	showed	_	O	O	_	_	_	_	_
26	no	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	25	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	OH	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	D	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	receptor	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	treatment	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	cultured	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	with	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	25	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	OH	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	2	_	O	O	_	_	_	_	_
56	D	_	O	O	_	_	_	_	_
57	3	_	O	O	_	_	_	_	_
58	did	_	O	O	_	_	_	_	_
59	not	_	O	O	_	_	_	_	_
60	stimulate	_	O	O	_	_	_	_	_
61	production	_	O	O	_	_	_	_	_
62	of	_	O	O	_	_	_	_	_
63	24	_	O	O	_	_	_	_	_
64	,	_	O	O	_	_	_	_	_
65	25	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	dihydroxy	_	O	O	_	_	_	_	_
68	-	_	O	O	_	_	_	_	_
69	vitamin	_	O	O	_	_	_	_	_
70	D	_	O	O	_	_	_	_	_
71	3	_	O	O	_	_	_	_	_
72	(	_	O	O	_	_	_	_	_
73	24	_	O	O	_	_	_	_	_
74	,	_	O	O	_	_	_	_	_
75	25	_	O	O	_	_	_	_	_
76	(	_	O	O	_	_	_	_	_
77	OH	_	O	O	_	_	_	_	_
78	)	_	O	O	_	_	_	_	_
79	2	_	O	O	_	_	_	_	_
80	D	_	O	O	_	_	_	_	_
81	3	_	O	O	_	_	_	_	_
82	)	_	O	O	_	_	_	_	_
83	,	_	O	O	_	_	_	_	_
84	a	_	O	O	_	_	_	_	_
85	response	_	O	O	_	_	_	_	_
86	which	_	O	O	_	_	_	_	_
87	is	_	O	O	_	_	_	_	_
88	diagnostic	_	O	O	_	_	_	_	_
89	of	_	O	O	_	_	_	_	_
90	the	_	O	O	_	_	_	_	_
91	presence	_	O	O	_	_	_	_	_
92	of	_	O	O	_	_	_	_	_
93	a	_	O	O	_	_	_	_	_
94	functional	_	O	O	_	_	_	_	_
95	1	_	O	O	_	_	_	_	_
96	,	_	O	O	_	_	_	_	_
97	25	_	O	O	_	_	_	_	_
98	(	_	O	O	_	_	_	_	_
99	OH	_	O	O	_	_	_	_	_
100	)	_	O	O	_	_	_	_	_
101	2	_	O	O	_	_	_	_	_
102	D	_	O	O	_	_	_	_	_
103	3	_	O	O	_	_	_	_	_
104	receptor	_	O	O	_	_	_	_	_
105	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	fourth	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	line	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	A	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	VDR	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	receptor	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	25	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	OH	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	D	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	had	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	low	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	capacity	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	25	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	OH	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	D	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	24	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	hydroxylase	_	O	O	_	_	_	_	_
40	activity	_	O	O	_	_	_	_	_
41	was	_	O	O	_	_	_	_	_
42	not	_	O	O	_	_	_	_	_
43	detectable	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	24	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	25	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	OH	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	synthesis	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	25	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	OH	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	D	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	observed	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	fifth	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	line	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	designated	_	O	O	_	_	_	_	_
33	Ro	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	VDR	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	although	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	sensitivity	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	hormone	_	O	O	_	_	_	_	_
42	treatment	_	O	O	_	_	_	_	_
43	was	_	O	O	_	_	_	_	_
44	lower	_	O	O	_	_	_	_	_
45	than	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	control	_	O	O	_	_	_	_	_
49	cell	_	O	O	_	_	_	_	_
50	line	_	O	O	_	_	_	_	_
51	from	_	O	O	_	_	_	_	_
52	a	_	O	O	_	_	_	_	_
53	normal	_	O	O	_	_	_	_	_
54	donor	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	capacity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	25	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	OH	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	D	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	low	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	Ro	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	VDR	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	all	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	lines	_	O	O	_	_	_	_	_
5	where	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	25	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	OH	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	D	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	detectable	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	receptor	_	O	O	_	_	_	_	_
24	had	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	typical	_	O	O	_	_	_	_	_
27	sedimentation	_	O	O	_	_	_	_	_
28	coefficient	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	7	_	O	O	_	_	_	_	_
33	S	_	O	O	_	_	_	_	_
34	on	_	O	O	_	_	_	_	_
35	sucrose	_	O	O	_	_	_	_	_
36	density	_	O	O	_	_	_	_	_
37	gradient	_	O	O	_	_	_	_	_
38	analysis	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	elution	_	O	O	_	_	_	_	_
4	properties	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	cellulose	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	however	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	differed	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	normal	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	both	_	O	O	_	_	_	_	_
17	Ro	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	VDR	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	VDR	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	where	_	O	O	_	_	_	_	_
27	elution	_	O	O	_	_	_	_	_
28	from	_	O	O	_	_	_	_	_
29	DNA	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	cellulose	_	O	O	_	_	_	_	_
32	occurred	_	O	O	_	_	_	_	_
33	at	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	lower	_	O	O	_	_	_	_	_
36	salt	_	O	O	_	_	_	_	_
37	concentration	_	O	O	_	_	_	_	_
38	than	_	O	O	_	_	_	_	_
39	is	_	O	O	_	_	_	_	_
40	typical	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	25	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	OH	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	2	_	O	O	_	_	_	_	_
50	D	_	O	O	_	_	_	_	_
51	3	_	O	O	_	_	_	_	_
52	receptor	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	While	_	O	O	_	_	_	_	_
2	Ro	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	VDR	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	showed	_	O	O	_	_	_	_	_
7	typical	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	localization	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	unoccupied	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	25	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	OH	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	D	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	neither	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	unoccupied	_	O	O	_	_	_	_	_
27	nor	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	occupied	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	A	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	VDR	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	was	_	O	O	_	_	_	_	_
38	completely	_	O	O	_	_	_	_	_
39	localized	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	nucleus	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	series	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	functional	_	O	O	_	_	_	_	_
6	studies	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	modulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	level	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	mRNAs	_	O	O	_	_	_	_	_
17	coding	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	both	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	c	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	myc	_	O	O	_	_	_	_	_
24	oncogene	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	growth	_	O	O	_	_	_	_	_
28	factor	_	O	O	_	_	_	_	_
29	known	_	O	O	_	_	_	_	_
30	as	_	O	O	_	_	_	_	_
31	granulocyte	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	monocyte	_	O	O	_	_	_	_	_
34	colony	_	O	O	_	_	_	_	_
35	stimulating	_	O	O	_	_	_	_	_
36	activity	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	25	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	OH	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	2	_	O	O	_	_	_	_	_
45	D	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	correlated	_	O	O	_	_	_	_	_
48	with	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	25	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	OH	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	2	_	O	O	_	_	_	_	_
57	D	_	O	O	_	_	_	_	_
58	3	_	O	O	_	_	_	_	_
59	receptor	_	O	O	_	_	_	_	_
60	status	_	O	O	_	_	_	_	_
61	of	_	O	O	_	_	_	_	_
62	these	_	O	O	_	_	_	_	_
63	cells	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	Use	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	lines	_	O	O	_	_	_	_	_
6	will	_	O	O	_	_	_	_	_
7	facilitate	_	O	O	_	_	_	_	_
8	further	_	O	O	_	_	_	_	_
9	study	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	molecular	_	O	O	_	_	_	_	_
13	defect	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	s	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	25	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	OH	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	D	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	vitamin	_	O	O	_	_	_	_	_
32	D	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	dependent	_	O	O	_	_	_	_	_
35	rickets	_	O	O	_	_	_	_	_
36	type	_	O	O	_	_	_	_	_
37	II	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	will	_	O	O	_	_	_	_	_
40	allow	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	correlation	_	O	O	_	_	_	_	_
43	with	_	O	O	_	_	_	_	_
44	impairment	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	cellular	_	O	O	_	_	_	_	_
47	functions	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_


1	Persistent	_	O	O	_	_	_	_	_
2	Expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Embryonic	_	O	O	_	_	_	_	_
6	Globin	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	Sox	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	Deficient	_	O	O	_	_	_	_	_
15	Mice	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	epsilony	_	O	O	_	_	_	_	_
3	globin	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	initially	_	O	O	_	_	_	_	_
7	identified	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	upregulated	_	O	O	_	_	_	_	_
11	transcript	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	p	_	O	O	_	_	_	_	_
15	100	_	O	O	_	_	_	_	_
16	H	_	O	O	_	_	_	_	_
17	mouse	_	O	O	_	_	_	_	_
18	using	_	O	O	_	_	_	_	_
19	subtractive	_	O	O	_	_	_	_	_
20	hybridization	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	identify	_	O	O	_	_	_	_	_
23	Sox	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	downstream	_	O	O	_	_	_	_	_
26	targets	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	initial	_	O	O	_	_	_	_	_
3	observation	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	confirmed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	independent	_	O	O	_	_	_	_	_
9	knock	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	out	_	O	O	_	_	_	_	_
12	allele	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	Sox	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	[	_	O	O	_	_	_	_	_
17	13	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	using	_	O	O	_	_	_	_	_
20	real	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	time	_	O	O	_	_	_	_	_
23	polymerase	_	O	O	_	_	_	_	_
24	chain	_	O	O	_	_	_	_	_
25	reaction	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	PCR	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	unpublished	_	O	O	_	_	_	_	_
31	data	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Real	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	time	_	O	O	_	_	_	_	_
4	PCR	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	used	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	quantitate	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	other	_	O	O	_	_	_	_	_
14	globin	_	O	O	_	_	_	_	_
15	genes	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	100	_	O	O	_	_	_	_	_
19	H	_	O	O	_	_	_	_	_
20	mutant	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	WT	_	O	O	_	_	_	_	_
23	mouse	_	O	O	_	_	_	_	_
24	livers	_	O	O	_	_	_	_	_
25	at	_	O	O	_	_	_	_	_
26	two	_	O	O	_	_	_	_	_
27	developmental	_	O	O	_	_	_	_	_
28	stages	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	15	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	5	_	O	O	_	_	_	_	_
33	dpc	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	18	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	dpc	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Figure	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	expressed	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	high	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	at	_	O	O	_	_	_	_	_
16	both	_	O	O	_	_	_	_	_
17	time	_	O	O	_	_	_	_	_
18	points	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	mutant	_	O	O	_	_	_	_	_
21	mice	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	contrast	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	decline	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	observed	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	WT	_	O	O	_	_	_	_	_
33	mice	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	difference	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	seen	_	O	O	_	_	_	_	_
5	between	_	O	O	_	_	_	_	_
6	WT	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	heterozygous	_	O	O	_	_	_	_	_
9	mice	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	unpublished	_	O	O	_	_	_	_	_
12	data	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	other	_	O	O	_	_	_	_	_
9	two	_	O	O	_	_	_	_	_
10	embryonic	_	O	O	_	_	_	_	_
11	globin	_	O	O	_	_	_	_	_
12	genes	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	zeta	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	betah	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	also	_	O	O	_	_	_	_	_
21	higher	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	100	_	O	O	_	_	_	_	_
25	H	_	O	O	_	_	_	_	_
26	homozygous	_	O	O	_	_	_	_	_
27	mice	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	compared	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	WT	_	O	O	_	_	_	_	_
32	mice	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	but	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	much	_	O	O	_	_	_	_	_
38	lesser	_	O	O	_	_	_	_	_
39	extent	_	O	O	_	_	_	_	_
40	than	_	O	O	_	_	_	_	_
41	seen	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	epsilony	_	O	O	_	_	_	_	_
44	globin	_	O	O	_	_	_	_	_
45	at	_	O	O	_	_	_	_	_
46	18	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_
48	5	_	O	O	_	_	_	_	_
49	dpc	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	Figure	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	level	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	adult	_	O	O	_	_	_	_	_
8	beta	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	somewhat	_	O	O	_	_	_	_	_
13	higher	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	p	_	O	O	_	_	_	_	_
16	100	_	O	O	_	_	_	_	_
17	H	_	O	O	_	_	_	_	_
18	homozygous	_	O	O	_	_	_	_	_
19	mice	_	O	O	_	_	_	_	_
20	than	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	WT	_	O	O	_	_	_	_	_
23	mice	_	O	O	_	_	_	_	_
24	at	_	O	O	_	_	_	_	_
25	18	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	5	_	O	O	_	_	_	_	_
28	dpc	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	Figure	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Perinatal	_	O	O	_	_	_	_	_
2	lethality	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	mutant	_	O	O	_	_	_	_	_
5	mice	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	presumably	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	heart	_	O	O	_	_	_	_	_
11	defect	_	O	O	_	_	_	_	_
12	[	_	O	O	_	_	_	_	_
13	14	_	O	O	_	_	_	_	_
14	])	_	O	O	_	_	_	_	_
15	precludes	_	O	O	_	_	_	_	_
16	us	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	evaluating	_	O	O	_	_	_	_	_
19	postnatal	_	O	O	_	_	_	_	_
20	globin	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	graphs	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Figure	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	illustrate	_	O	O	_	_	_	_	_
7	real	_	O	O	_	_	_	_	_
8	time	_	O	O	_	_	_	_	_
9	PCR	_	O	O	_	_	_	_	_
10	results	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	performed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	triplicate	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	standard	_	O	O	_	_	_	_	_
18	deviation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	data	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	shown	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	error	_	O	O	_	_	_	_	_
26	bars	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	all	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	performed	_	O	O	_	_	_	_	_
8	at	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	same	_	O	O	_	_	_	_	_
11	time	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	same	_	O	O	_	_	_	_	_
15	internal	_	O	O	_	_	_	_	_
16	control	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	levels	_	O	O	_	_	_	_	_
20	shown	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	relative	_	O	O	_	_	_	_	_
23	levels	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	thus	_	O	O	_	_	_	_	_
27	comparable	_	O	O	_	_	_	_	_
28	across	_	O	O	_	_	_	_	_
29	all	_	O	O	_	_	_	_	_
30	samples	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	are	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	agreement	_	O	O	_	_	_	_	_
35	with	_	O	O	_	_	_	_	_
36	previously	_	O	O	_	_	_	_	_
37	published	_	O	O	_	_	_	_	_
38	results	_	O	O	_	_	_	_	_
39	for	_	O	O	_	_	_	_	_
40	WT	_	O	O	_	_	_	_	_
41	fetal	_	O	O	_	_	_	_	_
42	mice	_	O	O	_	_	_	_	_
43	[	_	O	O	_	_	_	_	_
44	29	_	O	O	_	_	_	_	_
45	]	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	note	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	level	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	epsilony	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	livers	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	15	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	dpc	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	18	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	5	_	O	O	_	_	_	_	_
21	dpc	_	O	O	_	_	_	_	_
22	homozygous	_	O	O	_	_	_	_	_
23	mutant	_	O	O	_	_	_	_	_
24	mice	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	statistically	_	O	O	_	_	_	_	_
27	equivalent	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	level	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	betamaj	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	min	_	O	O	_	_	_	_	_
35	expression	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	livers	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	15	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	5	_	O	O	_	_	_	_	_
43	dpc	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	18	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_
47	5	_	O	O	_	_	_	_	_
48	dpc	_	O	O	_	_	_	_	_
49	homozygous	_	O	O	_	_	_	_	_
50	WT	_	O	O	_	_	_	_	_
51	mice	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_



1	Nuclear	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	extract	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	vitro	_	O	O	_	_	_	_	_
7	translation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	extracts	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	prepared	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	MEL	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	x	_	O	O	_	_	_	_	_
11	107	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	kit	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	Active	_	O	O	_	_	_	_	_
18	Motif	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	Carlsbad	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	California	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	United	_	O	O	_	_	_	_	_
25	States	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Sox	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	vitro	_	O	O	_	_	_	_	_
6	translation	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	vector	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	tagged	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	c	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	Myc	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	HA	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	described	_	O	O	_	_	_	_	_
20	before	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	15	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	translation	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	performed	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	reticulocyte	_	O	O	_	_	_	_	_
8	lysate	_	O	O	_	_	_	_	_
9	based	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	vitro	_	O	O	_	_	_	_	_
12	translational	_	O	O	_	_	_	_	_
13	system	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	TNT	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	R	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	Quick	_	O	O	_	_	_	_	_
20	Coupled	_	O	O	_	_	_	_	_
21	Transcription	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	Translation	_	O	O	_	_	_	_	_
24	Systems	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	Promega	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	vector	_	O	O	_	_	_	_	_
3	without	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	coding	_	O	O	_	_	_	_	_
8	sequence	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	also	_	O	O	_	_	_	_	_
11	translated	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	negative	_	O	O	_	_	_	_	_
15	control	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_



1	Glucocorticoid	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	mediated	_	O	O	_	_	_	_	_
4	inhibition	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	interleukin	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	beta	_	O	O	_	_	_	_	_
14	subunit	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	mechanism	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	GC	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	mediated	_	O	O	_	_	_	_	_
12	inhibition	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	functions	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	effect	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	dexamethasone	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	DM	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	proliferation	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	interleukin	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	R	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	generation	_	O	O	_	_	_	_	_
41	were	_	O	O	_	_	_	_	_
42	studied	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Dexamethasone	_	O	O	_	_	_	_	_
2	inhibited	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	proliferation	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	30	_	O	O	_	_	_	_	_
13	%	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	88	_	O	O	_	_	_	_	_
16	%,	_	O	O	_	_	_	_	_
17	relative	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	its	_	O	O	_	_	_	_	_
20	concentration	_	O	O	_	_	_	_	_
21	within	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	cultures	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	DM	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	R	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	Tac	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	55	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	25	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	beta	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	75	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	genes	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	activated	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	was	_	O	O	_	_	_	_	_
34	examined	_	O	O	_	_	_	_	_
35	next	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	stimulated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	purified	_	O	O	_	_	_	_	_
7	phytohemagglutinin	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	PHA	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	beta	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	phorbol	_	O	O	_	_	_	_	_
18	12	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	myristate	_	O	O	_	_	_	_	_
21	13	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	acetate	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	PMA	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	addition	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	DM	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	cultures	_	O	O	_	_	_	_	_
33	resulted	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	a	_	O	O	_	_	_	_	_
36	60	_	O	O	_	_	_	_	_
37	%	_	O	O	_	_	_	_	_
38	reduction	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	R	_	O	O	_	_	_	_	_
44	alpha	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	30	_	O	O	_	_	_	_	_
48	%	_	O	O	_	_	_	_	_
49	reduction	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	IL	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	2	_	O	O	_	_	_	_	_
54	R	_	O	O	_	_	_	_	_
55	beta	_	O	O	_	_	_	_	_
56	membrane	_	O	O	_	_	_	_	_
57	expression	_	O	O	_	_	_	_	_
58	compared	_	O	O	_	_	_	_	_
59	to	_	O	O	_	_	_	_	_
60	T	_	O	O	_	_	_	_	_
61	cells	_	O	O	_	_	_	_	_
62	cultured	_	O	O	_	_	_	_	_
63	in	_	O	O	_	_	_	_	_
64	the	_	O	O	_	_	_	_	_
65	absence	_	O	O	_	_	_	_	_
66	of	_	O	O	_	_	_	_	_
67	DM	_	O	O	_	_	_	_	_
68	(	_	O	O	_	_	_	_	_
69	p	_	O	O	_	_	_	_	_
70	<	_	O	O	_	_	_	_	_
71	0	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_
73	01	_	O	O	_	_	_	_	_
74	)	_	O	O	_	_	_	_	_
75	.	_	O	O	_	_	_	_	_

1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	membrane	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	R	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	R	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	M	_	O	O	_	_	_	_	_
23	DM	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	partially	_	O	O	_	_	_	_	_
26	reversible	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	recombinant	_	O	O	_	_	_	_	_
29	human	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	rhIL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	Northern	_	O	O	_	_	_	_	_
3	blot	_	O	O	_	_	_	_	_
4	analysis	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	DM	_	O	O	_	_	_	_	_
7	caused	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	comparable	_	O	O	_	_	_	_	_
10	decrease	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	R	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	R	_	O	O	_	_	_	_	_
23	beta	_	O	O	_	_	_	_	_
24	mRNA	_	O	O	_	_	_	_	_
25	levels	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	membrane	_	O	O	_	_	_	_	_
28	receptor	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	mitogen	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	stimulated	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	vitro	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	DM	_	O	O	_	_	_	_	_
8	regulated	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	R	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	gene	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	transcriptional	_	O	O	_	_	_	_	_
19	level	_	O	O	_	_	_	_	_
20	while	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	R	_	O	O	_	_	_	_	_
27	beta	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	unaffected	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	DM	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	action	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	DM	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	R	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	examined	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	determining	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	50	_	O	O	_	_	_	_	_
25	subunit	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	nuclear	_	O	O	_	_	_	_	_
28	factor	_	O	O	_	_	_	_	_
29	kappa	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	NF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	kappa	_	O	O	_	_	_	_	_
35	B	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	transcription	_	O	O	_	_	_	_	_
40	factor	_	O	O	_	_	_	_	_
41	that	_	O	O	_	_	_	_	_
42	stimulates	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	2	_	O	O	_	_	_	_	_
46	R	_	O	O	_	_	_	_	_
47	alpha	_	O	O	_	_	_	_	_
48	gene	_	O	O	_	_	_	_	_
49	expression	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	M	_	O	O	_	_	_	_	_
11	DM	_	O	O	_	_	_	_	_
12	increased	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	p	_	O	O	_	_	_	_	_
16	50	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	mRNA	_	O	O	_	_	_	_	_
22	levels	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	four	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	fold	_	O	O	_	_	_	_	_
27	compared	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	levels	_	O	O	_	_	_	_	_
31	obtained	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	absence	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	DM	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	level	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	proteins	_	O	O	_	_	_	_	_
8	capable	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	sites	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	activated	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	increased	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	response	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	DM	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	sum	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	DM	_	O	O	_	_	_	_	_
5	regulates	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	membrane	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	R	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	more	_	O	O	_	_	_	_	_
17	than	_	O	O	_	_	_	_	_
18	one	_	O	O	_	_	_	_	_
19	molecular	_	O	O	_	_	_	_	_
20	mechanism	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	suppression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	function	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	kappa	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	serine	_	O	O	_	_	_	_	_
16	protease	_	O	O	_	_	_	_	_
17	inhibitors	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	blocked	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	N	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	acetylcysteine	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Direct	_	O	O	_	_	_	_	_
2	evidence	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	N	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	acetylcysteine	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	NAC	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	enhances	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	immune	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	peripheral	_	O	O	_	_	_	_	_
16	blood	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	at	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	level	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	NF	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	presented	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	NAC	_	O	O	_	_	_	_	_
5	blocks	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	suppression	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	mitogenesis	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	cytokine	_	O	O	_	_	_	_	_
14	production	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	protease	_	O	O	_	_	_	_	_
17	inhibitors	_	O	O	_	_	_	_	_
18	such	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	N	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	tosylphenylalanine	_	O	O	_	_	_	_	_
23	chloromethyl	_	O	O	_	_	_	_	_
24	ketone	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	TPCK	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	proliferative	_	O	O	_	_	_	_	_
3	responses	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	purified	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	or	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	8	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	suppressed	_	O	O	_	_	_	_	_
17	more	_	O	O	_	_	_	_	_
18	strongly	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	TPCK	_	O	O	_	_	_	_	_
21	when	_	O	O	_	_	_	_	_
22	anti	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	28	_	O	O	_	_	_	_	_
26	rather	_	O	O	_	_	_	_	_
27	than	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	phorbol	_	O	O	_	_	_	_	_
30	ester	_	O	O	_	_	_	_	_
31	PMA	_	O	O	_	_	_	_	_
32	is	_	O	O	_	_	_	_	_
33	used	_	O	O	_	_	_	_	_
34	as	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	mitogenic	_	O	O	_	_	_	_	_
37	coactivator	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Cytokine	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	INF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	inhibited	_	O	O	_	_	_	_	_
18	95	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	100	_	O	O	_	_	_	_	_
21	%	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	concentrations	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	TPCK	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	totally	_	O	O	_	_	_	_	_
28	suppress	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	mitogenesis	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	or	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	8	_	O	O	_	_	_	_	_
38	+	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	electrophoretic	_	O	O	_	_	_	_	_
3	mobility	_	O	O	_	_	_	_	_
4	shift	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	find	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	TPCK	_	O	O	_	_	_	_	_
11	virtually	_	O	O	_	_	_	_	_
12	abolishes	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	less	_	O	O	_	_	_	_	_
16	than	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	%	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	levels	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	NF	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	but	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	Oct	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	found	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	nuclear	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	whole	_	O	O	_	_	_	_	_
40	cell	_	O	O	_	_	_	_	_
41	extracts	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	activated	_	O	O	_	_	_	_	_
44	T	_	O	O	_	_	_	_	_
45	cells	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Strikingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	immunosuppressive	_	O	O	_	_	_	_	_
5	effects	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	TPCK	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	blocked	_	O	O	_	_	_	_	_
10	when	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	pretreated	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	15	_	O	O	_	_	_	_	_
17	min	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	mM	_	O	O	_	_	_	_	_
21	NAC	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	NAC	_	O	O	_	_	_	_	_
2	not	_	O	O	_	_	_	_	_
3	only	_	O	O	_	_	_	_	_
4	blocks	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	effect	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	TPCK	_	O	O	_	_	_	_	_
9	but	_	O	O	_	_	_	_	_
10	enhances	_	O	O	_	_	_	_	_
11	mitogenesis	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	cytokine	_	O	O	_	_	_	_	_
14	production	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	>	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	fold	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	some	_	O	O	_	_	_	_	_
24	cases	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	upon	_	O	O	_	_	_	_	_
27	activation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	unsuppressed	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	support	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	notion	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	I	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	proteases	_	O	O	_	_	_	_	_
19	play	_	O	O	_	_	_	_	_
20	obligate	_	O	O	_	_	_	_	_
21	roles	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	activation	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	mitogenesis	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	roles	_	O	O	_	_	_	_	_
30	that	_	O	O	_	_	_	_	_
31	are	_	O	O	_	_	_	_	_
32	enhanced	_	O	O	_	_	_	_	_
33	significantly	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	NAC	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	HTLV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	Tax	_	O	O	_	_	_	_	_
5	induces	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	various	_	O	O	_	_	_	_	_
9	immediate	_	O	O	_	_	_	_	_
10	early	_	O	O	_	_	_	_	_
11	serum	_	O	O	_	_	_	_	_
12	responsive	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	leukemia	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	type	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	HTLV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	etiological	_	O	O	_	_	_	_	_
17	agent	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	adult	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	leukemia	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	ATL	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	showed	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	mobility	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	shift	_	O	O	_	_	_	_	_
8	assay	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	lines	_	O	O	_	_	_	_	_
14	transformed	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	virus	_	O	O	_	_	_	_	_
18	contained	_	O	O	_	_	_	_	_
19	high	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	AP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	activities	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	result	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	lines	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	mRNAs	_	O	O	_	_	_	_	_
14	encoding	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	AP	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	c	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	Fos	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	Fra	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	c	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	Jun	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	JunB	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	JunD	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Previously	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	c	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	fos	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	has	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	reported	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	transactivated	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	viral	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	Tax	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	line	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	JPX	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	9	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	expression	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	Tax	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	inducible	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	we	_	O	O	_	_	_	_	_
26	showed	_	O	O	_	_	_	_	_
27	that	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	mRNAs	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	Fra	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	c	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	Jun	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	JunD	_	O	O	_	_	_	_	_
42	was	_	O	O	_	_	_	_	_
43	also	_	O	O	_	_	_	_	_
44	transactivated	_	O	O	_	_	_	_	_
45	by	_	O	O	_	_	_	_	_
46	Tax	_	O	O	_	_	_	_	_
47	1	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Tax	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	activated	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	two	_	O	O	_	_	_	_	_
9	other	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	factors	_	O	O	_	_	_	_	_
12	having	_	O	O	_	_	_	_	_
13	zinc	_	O	O	_	_	_	_	_
14	finger	_	O	O	_	_	_	_	_
15	motifs	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	Egr	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	Egr	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	same	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Tax	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	inducible	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	factors	_	O	O	_	_	_	_	_
8	identified	_	O	O	_	_	_	_	_
9	here	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	encoded	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	members	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	immediate	_	O	O	_	_	_	_	_
17	early	_	O	O	_	_	_	_	_
18	genes	_	O	O	_	_	_	_	_
19	under	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	control	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	growth	_	O	O	_	_	_	_	_
24	signals	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Tax	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	suggested	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	replace	_	O	O	_	_	_	_	_
9	growth	_	O	O	_	_	_	_	_
10	signals	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	least	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	part	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	this	_	O	O	_	_	_	_	_
19	mechanism	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Naive	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	45	_	O	O	_	_	_	_	_
5	RA	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	lymphocytes	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	more	_	O	O	_	_	_	_	_
12	sensitive	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	oxidative	_	O	O	_	_	_	_	_
15	stress	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	signals	_	O	O	_	_	_	_	_
19	than	_	O	O	_	_	_	_	_
20	memory	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	45	_	O	O	_	_	_	_	_
24	RO	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Formation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	reactive	_	O	O	_	_	_	_	_
4	oxygen	_	O	O	_	_	_	_	_
5	intermediates	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	ROI	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	after	_	O	O	_	_	_	_	_
10	oxidative	_	O	O	_	_	_	_	_
11	stress	_	O	O	_	_	_	_	_
12	has	_	O	O	_	_	_	_	_
13	been	_	O	O	_	_	_	_	_
14	shown	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	signal	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	lymphocytes	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	e	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	g	_	O	O	_	_	_	_	_
27	.,	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	its	_	O	O	_	_	_	_	_
35	receptor	_	O	O	_	_	_	_	_
36	are	_	O	O	_	_	_	_	_
37	induced	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	ROI	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	effects	_	O	O	_	_	_	_	_
6	can	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	large	_	O	O	_	_	_	_	_
11	extent	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	attributed	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	transcription	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	NF	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	kappaB	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Now	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	examined	_	O	O	_	_	_	_	_
5	whether	_	O	O	_	_	_	_	_
6	naive	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	memory	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	lymphocytes	_	O	O	_	_	_	_	_
11	differ	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	their	_	O	O	_	_	_	_	_
14	sensitivity	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	ROI	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	mediated	_	O	O	_	_	_	_	_
19	signals	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	45	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	naive	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	45	_	O	O	_	_	_	_	_
12	RO	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	memory	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	lymphocytes	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	directly	_	O	O	_	_	_	_	_
21	stimulated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	H	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	O	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	kappaB	_	O	O	_	_	_	_	_
31	nuclear	_	O	O	_	_	_	_	_
32	translocation	_	O	O	_	_	_	_	_
33	was	_	O	O	_	_	_	_	_
34	stronger	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	naive	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	than	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	memory	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	it	_	O	O	_	_	_	_	_
44	could	_	O	O	_	_	_	_	_
45	be	_	O	O	_	_	_	_	_
46	induced	_	O	O	_	_	_	_	_
47	with	_	O	O	_	_	_	_	_
48	lower	_	O	O	_	_	_	_	_
49	doses	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	composition	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappaB	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	50	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	RelA	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	similar	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	these	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	types	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	magnitude	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	kinetics	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	intracellular	_	O	O	_	_	_	_	_
7	ROI	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	similar	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	suggesting	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	there	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	no	_	O	O	_	_	_	_	_
16	differences	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	ROI	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	forming	_	O	O	_	_	_	_	_
21	mechanisms	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	antioxidative	_	O	O	_	_	_	_	_
24	capacities	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	probable	_	O	O	_	_	_	_	_
3	regulatory	_	O	O	_	_	_	_	_
4	point	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	cytoplasmic	_	O	O	_	_	_	_	_
8	IkappaB	_	O	O	_	_	_	_	_
9	inhibitor	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	45	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	H	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	O	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	caused	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	more	_	O	O	_	_	_	_	_
25	profound	_	O	O	_	_	_	_	_
26	depression	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	levels	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	IkappaB	_	O	O	_	_	_	_	_
32	alpha	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	representing	_	O	O	_	_	_	_	_
8	different	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	differentiation	_	O	O	_	_	_	_	_
14	stages	_	O	O	_	_	_	_	_
15	can	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	differentially	_	O	O	_	_	_	_	_
18	responsive	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	ROI	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	mediated	_	O	O	_	_	_	_	_
23	signals	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Increased	_	O	O	_	_	_	_	_
2	glucocorticoid	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	airway	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	insensitive	_	O	O	_	_	_	_	_
12	asthma	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	Glucocorticoid	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	GC	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	insensitive	_	O	O	_	_	_	_	_
7	asthma	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	challenging	_	O	O	_	_	_	_	_
11	clinical	_	O	O	_	_	_	_	_
12	problem	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	can	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	associated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	life	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	threatening	_	O	O	_	_	_	_	_
21	disease	_	O	O	_	_	_	_	_
22	progression	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	molecular	_	O	O	_	_	_	_	_
3	basis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	GC	_	O	O	_	_	_	_	_
6	insensitivity	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	unknown	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Alternative	_	O	O	_	_	_	_	_
2	splicing	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	GC	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	GCR	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	pre	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	mRNA	_	O	O	_	_	_	_	_
13	generates	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	second	_	O	O	_	_	_	_	_
16	GCR	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	termed	_	O	O	_	_	_	_	_
19	GCRbeta	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	which	_	O	O	_	_	_	_	_
22	does	_	O	O	_	_	_	_	_
23	not	_	O	O	_	_	_	_	_
24	bind	_	O	O	_	_	_	_	_
25	GC	_	O	O	_	_	_	_	_
26	but	_	O	O	_	_	_	_	_
27	antagonizes	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	transactivating	_	O	O	_	_	_	_	_
30	activity	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	classic	_	O	O	_	_	_	_	_
34	GCR	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	increased	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	GCRbeta	_	O	O	_	_	_	_	_
6	could	_	O	O	_	_	_	_	_
7	account	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	insensitivity	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Bronchoalveolar	_	O	O	_	_	_	_	_
2	lavage	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	BAL	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	peripheral	_	O	O	_	_	_	_	_
9	blood	_	O	O	_	_	_	_	_
10	mononuclear	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	PBMC	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	examined	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	GCRbeta	_	O	O	_	_	_	_	_
19	immunoreactivity	_	O	O	_	_	_	_	_
20	using	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	GCRbeta	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	specific	_	O	O	_	_	_	_	_
25	antibody	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	immunohistochemical	_	O	O	_	_	_	_	_
28	staining	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Cell	_	O	O	_	_	_	_	_
2	localization	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	GCRbeta	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	performed	_	O	O	_	_	_	_	_
8	using	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	double	_	O	O	_	_	_	_	_
11	immunostaining	_	O	O	_	_	_	_	_
12	technique	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Patients	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	GC	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	insensitive	_	O	O	_	_	_	_	_
6	asthma	_	O	O	_	_	_	_	_
7	expressed	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	significantly	_	O	O	_	_	_	_	_
10	higher	_	O	O	_	_	_	_	_
11	number	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	GCRbeta	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	immunoreactive	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	their	_	O	O	_	_	_	_	_
19	BAL	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	peripheral	_	O	O	_	_	_	_	_
22	blood	_	O	O	_	_	_	_	_
23	than	_	O	O	_	_	_	_	_
24	GC	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	sensitive	_	O	O	_	_	_	_	_
27	asthmatics	_	O	O	_	_	_	_	_
28	or	_	O	O	_	_	_	_	_
29	normal	_	O	O	_	_	_	_	_
30	control	_	O	O	_	_	_	_	_
31	subjects	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	GCRbeta	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	GC	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	insensitive	_	O	O	_	_	_	_	_
9	asthma	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	particularly	_	O	O	_	_	_	_	_
12	high	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	airway	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	thought	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	play	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	major	_	O	O	_	_	_	_	_
25	role	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	pathogenesis	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	asthma	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	GCRbeta	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	specimens	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	airways	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	patients	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	chronic	_	O	O	_	_	_	_	_
17	bronchitis	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	chronic	_	O	O	_	_	_	_	_
3	bronchitis	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	few	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	GCRbeta	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	positive	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	their	_	O	O	_	_	_	_	_
13	numbers	_	O	O	_	_	_	_	_
14	did	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	differ	_	O	O	_	_	_	_	_
17	significantly	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	normal	_	O	O	_	_	_	_	_
20	control	_	O	O	_	_	_	_	_
21	subjects	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	GC	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	insensitive	_	O	O	_	_	_	_	_
7	asthma	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	associated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	increased	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	GCRbeta	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	airway	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Diminished	_	O	O	_	_	_	_	_
2	responses	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	13	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	monocytes	_	O	O	_	_	_	_	_
10	differentiated	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	vitro	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	role	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	13	_	O	O	_	_	_	_	_
20	Ralpha	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	chain	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	STAT	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	primary	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	13	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	complex	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	monocytes	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	believed	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	heterodimer	_	O	O	_	_	_	_	_
17	comprised	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	R	_	O	O	_	_	_	_	_
24	alpha	_	O	O	_	_	_	_	_
25	chain	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	R	_	O	O	_	_	_	_	_
32	gamma	_	O	O	_	_	_	_	_
33	chain	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	gamma	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	c	_	O	O	_	_	_	_	_
38	))	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	like	_	O	O	_	_	_	_	_
41	molecule	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	13	_	O	O	_	_	_	_	_
46	R	_	O	O	_	_	_	_	_
47	alpha	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	mRNA	_	O	O	_	_	_	_	_
2	levels	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	13	_	O	O	_	_	_	_	_
7	R	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	R	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	markedly	_	O	O	_	_	_	_	_
21	decreased	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	vitro	_	O	O	_	_	_	_	_
25	monocyte	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	derived	_	O	O	_	_	_	_	_
28	macrophages	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	MDMac	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	increasing	_	O	O	_	_	_	_	_
36	time	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	monocytes	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	culture	_	O	O	_	_	_	_	_
41	correlated	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	loss	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	IL	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	13	_	O	O	_	_	_	_	_
49	regulation	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	lipopolysaccharide	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	induced	_	O	O	_	_	_	_	_
54	TNF	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	alpha	_	O	O	_	_	_	_	_
57	production	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Analysis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	lines	_	O	O	_	_	_	_	_
5	Daudi	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	THP	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	differentially	_	O	O	_	_	_	_	_
12	express	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	13	_	O	O	_	_	_	_	_
21	R	_	O	O	_	_	_	_	_
22	alpha	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	showed	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	13	_	O	O	_	_	_	_	_
29	can	_	O	O	_	_	_	_	_
30	activate	_	O	O	_	_	_	_	_
31	STAT	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	13	_	O	O	_	_	_	_	_
37	R	_	O	O	_	_	_	_	_
38	alpha	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	positive	_	O	O	_	_	_	_	_
42	THP	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	cells	_	O	O	_	_	_	_	_
46	but	_	O	O	_	_	_	_	_
47	not	_	O	O	_	_	_	_	_
48	in	_	O	O	_	_	_	_	_
49	gamma	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	c	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	positive	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	13	_	O	O	_	_	_	_	_
59	R	_	O	O	_	_	_	_	_
60	alpha	_	O	O	_	_	_	_	_
61	1	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	negative	_	O	O	_	_	_	_	_
64	Daudi	_	O	O	_	_	_	_	_
65	cells	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	13	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	STAT	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	reduced	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	MDMac	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	associated	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	diminished	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	13	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	23	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	MHC	_	O	O	_	_	_	_	_
28	class	_	O	O	_	_	_	_	_
29	II	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	reduced	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	13	_	O	O	_	_	_	_	_
8	R	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	low	_	O	O	_	_	_	_	_
14	nuclear	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	some	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	13	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	responses	_	O	O	_	_	_	_	_
26	were	_	O	O	_	_	_	_	_
27	unaltered	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	magnitude	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	MDMac	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	absence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	functional	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	13	_	O	O	_	_	_	_	_
9	R	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	13	_	O	O	_	_	_	_	_
21	must	_	O	O	_	_	_	_	_
22	signal	_	O	O	_	_	_	_	_
23	through	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	alternative	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	complex	_	O	O	_	_	_	_	_
28	on	_	O	O	_	_	_	_	_
29	MDMac	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Experiments	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	blocking	_	O	O	_	_	_	_	_
5	antibody	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	R	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	showed	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	this	_	O	O	_	_	_	_	_
15	chain	_	O	O	_	_	_	_	_
16	remains	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	essential	_	O	O	_	_	_	_	_
19	component	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	13	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	complex	_	O	O	_	_	_	_	_
27	on	_	O	O	_	_	_	_	_
28	MDMac	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Apoptosis	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	growth	_	O	O	_	_	_	_	_
4	inhibition	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	malignant	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	after	_	O	O	_	_	_	_	_
9	treatment	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	arsenic	_	O	O	_	_	_	_	_
12	trioxide	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	clinically	_	O	O	_	_	_	_	_
15	achievable	_	O	O	_	_	_	_	_
16	concentrations	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	see	_	O	O	_	_	_	_	_
19	comments	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_

1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Arsenic	_	O	O	_	_	_	_	_
4	trioxide	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	As	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	O	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	can	_	O	O	_	_	_	_	_
12	induce	_	O	O	_	_	_	_	_
13	clinical	_	O	O	_	_	_	_	_
14	remission	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	acute	_	O	O	_	_	_	_	_
19	promyelocytic	_	O	O	_	_	_	_	_
20	leukemia	_	O	O	_	_	_	_	_
21	via	_	O	O	_	_	_	_	_
22	induction	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	differentiation	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	programmed	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	death	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	apoptosis	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	As	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	O	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	panel	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	malignant	_	O	O	_	_	_	_	_
15	lymphocytes	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	determine	_	O	O	_	_	_	_	_
18	whether	_	O	O	_	_	_	_	_
19	growth	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	inhibitory	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	apoptotic	_	O	O	_	_	_	_	_
24	effects	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	As	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	O	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	can	_	O	O	_	_	_	_	_
31	be	_	O	O	_	_	_	_	_
32	observed	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	these	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	clinically	_	O	O	_	_	_	_	_
38	achievable	_	O	O	_	_	_	_	_
39	concentrations	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Eight	_	O	O	_	_	_	_	_
4	malignant	_	O	O	_	_	_	_	_
5	lymphocytic	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	lines	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	primary	_	O	O	_	_	_	_	_
10	cultures	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	lymphocytic	_	O	O	_	_	_	_	_
13	leukemia	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	lymphoma	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	treated	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	As	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	O	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	or	_	O	O	_	_	_	_	_
27	without	_	O	O	_	_	_	_	_
28	dithiothreitol	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	DTT	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	or	_	O	O	_	_	_	_	_
33	buthionine	_	O	O	_	_	_	_	_
34	sulfoximine	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	BSO	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	an	_	O	O	_	_	_	_	_
40	inhibitor	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	glutathione	_	O	O	_	_	_	_	_
43	synthesis	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Apoptosis	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	assessed	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	morphology	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	flow	_	O	O	_	_	_	_	_
9	cytometry	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	annexin	_	O	O	_	_	_	_	_
12	V	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	level	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	terminal	_	O	O	_	_	_	_	_
18	deoxynucleotidyl	_	O	O	_	_	_	_	_
19	transferase	_	O	O	_	_	_	_	_
20	labeling	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	fragments	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Cellular	_	O	O	_	_	_	_	_
2	proliferation	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	determined	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	5	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	bromo	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	'	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	deoxyuridine	_	O	O	_	_	_	_	_
14	incorporation	_	O	O	_	_	_	_	_
15	into	_	O	O	_	_	_	_	_
16	DNA	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	flow	_	O	O	_	_	_	_	_
19	cytometry	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	use	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	mitotic	_	O	O	_	_	_	_	_
26	arrest	_	O	O	_	_	_	_	_
27	assay	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Mitochondrial	_	O	O	_	_	_	_	_
2	transmembrane	_	O	O	_	_	_	_	_
3	potential	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	delta	_	O	O	_	_	_	_	_
6	psi	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	m	_	O	O	_	_	_	_	_
9	))	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	measured	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	means	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	rhodamine	_	O	O	_	_	_	_	_
16	123	_	O	O	_	_	_	_	_
17	staining	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	flow	_	O	O	_	_	_	_	_
20	cytometry	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Protein	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	assessed	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	western	_	O	O	_	_	_	_	_
7	blot	_	O	O	_	_	_	_	_
8	analysis	_	O	O	_	_	_	_	_
9	or	_	O	O	_	_	_	_	_
10	immunofluorescence	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Therapeutic	_	O	O	_	_	_	_	_
4	concentrations	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	As	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	O	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	microM	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	had	_	O	O	_	_	_	_	_
17	dual	_	O	O	_	_	_	_	_
18	effects	_	O	O	_	_	_	_	_
19	on	_	O	O	_	_	_	_	_
20	malignant	_	O	O	_	_	_	_	_
21	lymphocytes	_	O	O	_	_	_	_	_
22	:	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	inhibition	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	growth	_	O	O	_	_	_	_	_
28	through	_	O	O	_	_	_	_	_
29	adenosine	_	O	O	_	_	_	_	_
30	triphosphate	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	ATP	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	depletion	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	prolongation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	cycle	_	O	O	_	_	_	_	_
40	time	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	induction	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	apoptosis	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	O	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	apoptosis	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	preceded	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	delta	_	O	O	_	_	_	_	_
12	psi	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	m	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	collapse	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	DTT	_	O	O	_	_	_	_	_
2	antagonized	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	BSO	_	O	O	_	_	_	_	_
5	enhanced	_	O	O	_	_	_	_	_
6	As	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	O	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	ATP	_	O	O	_	_	_	_	_
13	depletion	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	delta	_	O	O	_	_	_	_	_
16	psi	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	m	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	collapse	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	apoptosis	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Caspase	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	usually	_	O	O	_	_	_	_	_
7	resulting	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	delta	_	O	O	_	_	_	_	_
10	psi	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	m	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	collapse	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	always	_	O	O	_	_	_	_	_
19	associated	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	As	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	O	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	induced	_	O	O	_	_	_	_	_
27	apoptosis	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	O	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	PML	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	promyelocytic	_	O	O	_	_	_	_	_
9	leukemia	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	degradation	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	did	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	modulate	_	O	O	_	_	_	_	_
17	expression	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	cycle	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	related	_	O	O	_	_	_	_	_
23	proteins	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	including	_	O	O	_	_	_	_	_
26	c	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	myc	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	retinoblastoma	_	O	O	_	_	_	_	_
31	protein	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	cyclin	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	dependent	_	O	O	_	_	_	_	_
36	kinase	_	O	O	_	_	_	_	_
37	4	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	cyclin	_	O	O	_	_	_	_	_
40	D	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	p	_	O	O	_	_	_	_	_
45	53	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	or	_	O	O	_	_	_	_	_
48	expression	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	differentiation	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	related	_	O	O	_	_	_	_	_
53	antigens	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Substantial	_	O	O	_	_	_	_	_
4	growth	_	O	O	_	_	_	_	_
5	inhibition	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	apoptosis	_	O	O	_	_	_	_	_
8	without	_	O	O	_	_	_	_	_
9	evidence	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	differentiation	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	most	_	O	O	_	_	_	_	_
16	malignant	_	O	O	_	_	_	_	_
17	lymphocytic	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	treated	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	microM	_	O	O	_	_	_	_	_
25	As	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	O	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	O	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	may	_	O	O	_	_	_	_	_
6	prove	_	O	O	_	_	_	_	_
7	useful	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	treatment	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	malignant	_	O	O	_	_	_	_	_
13	lymphoproliferative	_	O	O	_	_	_	_	_
14	disorders	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	T	_	O	O	_	_	_	_	_
2	helper	_	O	O	_	_	_	_	_
3	differentiation	_	O	O	_	_	_	_	_
4	proceeds	_	O	O	_	_	_	_	_
5	through	_	O	O	_	_	_	_	_
6	Stat	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	Stat	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	dependent	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	Stat	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	independent	_	O	O	_	_	_	_	_
20	phases	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Much	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	our	_	O	O	_	_	_	_	_
4	focus	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	understanding	_	O	O	_	_	_	_	_
7	Th	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	Th	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	development	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	signals	_	O	O	_	_	_	_	_
18	delivered	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	12	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	as	_	O	O	_	_	_	_	_
28	final	_	O	O	_	_	_	_	_
29	determinants	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	terminal	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	cell	_	O	O	_	_	_	_	_
34	differentiation	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	extinction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	12	_	O	O	_	_	_	_	_
7	signaling	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	early	_	O	O	_	_	_	_	_
10	Th	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	development	_	O	O	_	_	_	_	_
13	could	_	O	O	_	_	_	_	_
14	potentially	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	important	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	imprinting	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	more	_	O	O	_	_	_	_	_
21	permanent	_	O	O	_	_	_	_	_
22	Th	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	phenotype	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	population	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	we	_	O	O	_	_	_	_	_
33	have	_	O	O	_	_	_	_	_
34	also	_	O	O	_	_	_	_	_
35	examined	_	O	O	_	_	_	_	_
36	various	_	O	O	_	_	_	_	_
37	parameters	_	O	O	_	_	_	_	_
38	regulating	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	12	_	O	O	_	_	_	_	_
43	signaling	_	O	O	_	_	_	_	_
44	pathway	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Whereas	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	appears	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	repress	_	O	O	_	_	_	_	_
8	functional	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	12	_	O	O	_	_	_	_	_
12	signaling	_	O	O	_	_	_	_	_
13	through	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	12	_	O	O	_	_	_	_	_
19	R	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	IFN	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	gamma	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	mouse	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	IFN	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	alpha	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	human	_	O	O	_	_	_	_	_
38	appear	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	induce	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	12	_	O	O	_	_	_	_	_
44	R	_	O	O	_	_	_	_	_
45	beta	_	O	O	_	_	_	_	_
46	2	_	O	O	_	_	_	_	_
47	expression	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	promote	_	O	O	_	_	_	_	_
50	IL	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	12	_	O	O	_	_	_	_	_
53	responsiveness	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	propose	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	Th	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	development	_	O	O	_	_	_	_	_
7	can	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	considered	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	two	_	O	O	_	_	_	_	_
12	stages	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	capacitance	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	development	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Capacitance	_	O	O	_	_	_	_	_
2	would	_	O	O	_	_	_	_	_
3	simply	_	O	O	_	_	_	_	_
4	involve	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	12	_	O	O	_	_	_	_	_
10	R	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	subunits	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	regulated	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	TCR	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	4	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	IFNs	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	second	_	O	O	_	_	_	_	_
3	stage	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	development	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	propose	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	true	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	12	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	developmental	_	O	O	_	_	_	_	_
17	stage	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	involving	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	Stat	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	inducible	_	O	O	_	_	_	_	_
25	proteins	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	human	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	occur	_	O	O	_	_	_	_	_
9	via	_	O	O	_	_	_	_	_
10	IFN	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	able	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	activate	_	O	O	_	_	_	_	_
19	Stat	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	perhaps	_	O	O	_	_	_	_	_
4	possible	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	all	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Stat	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	actions	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	Th	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	development	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	exert	_	O	O	_	_	_	_	_
18	directly	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	Stat	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	at	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	IFN	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	gamma	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	however	_	O	O	_	_	_	_	_
30	we	_	O	O	_	_	_	_	_
31	suggest	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	more	_	O	O	_	_	_	_	_
35	likely	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	Stat	_	O	O	_	_	_	_	_
38	4	_	O	O	_	_	_	_	_
39	may	_	O	O	_	_	_	_	_
40	act	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	induce	_	O	O	_	_	_	_	_
43	Th	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	development	_	O	O	_	_	_	_	_
46	through	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	induction	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	other	_	O	O	_	_	_	_	_
51	non	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	cytokine	_	O	O	_	_	_	_	_
54	genes	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	whose	_	O	O	_	_	_	_	_
57	stable	_	O	O	_	_	_	_	_
58	expression	_	O	O	_	_	_	_	_
59	maintains	_	O	O	_	_	_	_	_
60	the	_	O	O	_	_	_	_	_
61	transcriptional	_	O	O	_	_	_	_	_
62	state	_	O	O	_	_	_	_	_
63	of	_	O	O	_	_	_	_	_
64	a	_	O	O	_	_	_	_	_
65	Th	_	O	O	_	_	_	_	_
66	1	_	O	O	_	_	_	_	_
67	cell	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_


1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	ICAM	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	LFA	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	Tax	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	leukemia	_	O	O	_	_	_	_	_
19	virus	_	O	O	_	_	_	_	_
20	type	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	mechanism	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	down	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	regulation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	ICAM	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	or	_	O	O	_	_	_	_	_
33	LFA	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	adult	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	leukemia	_	O	O	_	_	_	_	_
44	cell	_	O	O	_	_	_	_	_
45	lines	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	undertaken	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	determine	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	HTLV	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	I	_	O	O	_	_	_	_	_
14	TaxI	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	up	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	regulation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	ICAM	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	I	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	LFA	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	human	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	transformed	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	HTLV	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	I	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	mechanism	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	down	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	regulation	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	ICAM	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	I	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	LFA	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	I	_	O	O	_	_	_	_	_
52	in	_	O	O	_	_	_	_	_
53	ATL	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	derived	_	O	O	_	_	_	_	_
56	cell	_	O	O	_	_	_	_	_
57	lines	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	TaxI	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	line	_	O	O	_	_	_	_	_
11	Jurkat	_	O	O	_	_	_	_	_
12	carrying	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	TaxI	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	under	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	metallothionein	_	O	O	_	_	_	_	_
19	promoter	_	O	O	_	_	_	_	_
20	led	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	increases	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	mRNA	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	surface	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	ICAM	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	I	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	response	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	LFA	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	TaxI	_	O	O	_	_	_	_	_
9	induction	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	other	_	O	O	_	_	_	_	_
15	hand	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	relatively	_	O	O	_	_	_	_	_
18	slow	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	weak	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	might	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	indirect	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Transactivation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	ICAM	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	promoter	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	TaxI	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	further	_	O	O	_	_	_	_	_
12	shown	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	co	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	transfection	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	CAT	_	O	O	_	_	_	_	_
20	reporter	_	O	O	_	_	_	_	_
21	construct	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	ICAM	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	I	_	O	O	_	_	_	_	_
27	promoter	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	plasmid	_	O	O	_	_	_	_	_
31	expressing	_	O	O	_	_	_	_	_
32	TaxI	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	down	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	regulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	ICAM	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	I	_	O	O	_	_	_	_	_
11	or	_	O	O	_	_	_	_	_
12	LFA	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	I	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	4	_	O	O	_	_	_	_	_
17	ATL	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lines	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	next	_	O	O	_	_	_	_	_
22	examined	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	ICAM	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	quite	_	O	O	_	_	_	_	_
7	low	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	MT	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	I	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	no	_	O	O	_	_	_	_	_
15	genomic	_	O	O	_	_	_	_	_
16	changes	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	found	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	CAT	_	O	O	_	_	_	_	_
3	reporter	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	ICAM	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	inactive	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	MT	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	combined	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	MT	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	azacytidine	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	IFN	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	gamma	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	re	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	ICAM	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	I	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Collectively	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	transcriptional	_	O	O	_	_	_	_	_
7	factor	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	s	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	necessary	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	ICAM	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	I	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	may	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	repressed	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	MT	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	I	_	O	O	_	_	_	_	_
26	through	_	O	O	_	_	_	_	_
27	DNA	_	O	O	_	_	_	_	_
28	methylation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Three	_	O	O	_	_	_	_	_
2	other	_	O	O	_	_	_	_	_
3	ATL	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	lines	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	TL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	OmI	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	H	_	O	O	_	_	_	_	_
12	582	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	HuT	_	O	O	_	_	_	_	_
15	102	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	found	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	have	_	O	O	_	_	_	_	_
21	little	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	LFA	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	I	_	O	O	_	_	_	_	_
28	beta	_	O	O	_	_	_	_	_
29	chain	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	18	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	H	_	O	O	_	_	_	_	_
2	582	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	HuT	_	O	O	_	_	_	_	_
5	102	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	negative	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	LFA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	I	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	chain	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	CDIIa	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	genomic	_	O	O	_	_	_	_	_
3	changes	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	found	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	CAT	_	O	O	_	_	_	_	_
10	reporter	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	18	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	inactive	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	them	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	again	_	O	O	_	_	_	_	_
26	suggesting	_	O	O	_	_	_	_	_
27	lack	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	transcriptional	_	O	O	_	_	_	_	_
33	factor	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	s	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	necessary	_	O	O	_	_	_	_	_
38	for	_	O	O	_	_	_	_	_
39	CD	_	O	O	_	_	_	_	_
40	18	_	O	O	_	_	_	_	_
41	expression	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_


1	Nuclear	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	ATp	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	hallmark	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	unstimulated	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	CLL	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	B	_	O	O	_	_	_	_	_
2	lymphocytes	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	peripheral	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	chronic	_	O	O	_	_	_	_	_
11	lymphocytic	_	O	O	_	_	_	_	_
12	leukaemia	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	CLL	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	analysed	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	nuclear	_	O	O	_	_	_	_	_
21	presence	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	DNA	_	O	O	_	_	_	_	_
24	binding	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	panel	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	factors	_	O	O	_	_	_	_	_
31	which	_	O	O	_	_	_	_	_
32	are	_	O	O	_	_	_	_	_
33	involved	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	gene	_	O	O	_	_	_	_	_
37	control	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	lymphoid	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	following	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factors	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	studied	_	O	O	_	_	_	_	_
7	:	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	Octamer	_	O	O	_	_	_	_	_
10	factors	_	O	O	_	_	_	_	_
11	Oct	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	Oct	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	members	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	AP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	family	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	AT	_	O	O	_	_	_	_	_
31	factors	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	particular	_	O	O	_	_	_	_	_
35	NF	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	ATp	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	members	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	Rel	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	NF	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	kB	_	O	O	_	_	_	_	_
48	family	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	constitutive	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	translocation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	ATp	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	member	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	growing	_	O	O	_	_	_	_	_
18	family	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	NF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	AT	_	O	O	_	_	_	_	_
23	factors	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	hallmark	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	nonstimulated	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	CLL	_	O	O	_	_	_	_	_
34	patients	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	distinguishes	_	O	O	_	_	_	_	_
37	B	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	CLL	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	'	_	O	O	_	_	_	_	_
43	normal	_	O	O	_	_	_	_	_
44	'	_	O	O	_	_	_	_	_
45	B	_	O	O	_	_	_	_	_
46	lymphocytes	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	nuclear	_	O	O	_	_	_	_	_
3	appearance	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	observed	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kB	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	52	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	further	_	O	O	_	_	_	_	_
5	factor	_	O	O	_	_	_	_	_
6	proteins	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	DNA	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	such	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	JunD	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	c	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	Fos	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	FosB	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	detected	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	several	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	whereas	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	localisation	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	DNA	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	other	_	O	O	_	_	_	_	_
33	factors	_	O	O	_	_	_	_	_
34	such	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	c	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	Jun	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	RelA	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	p	_	O	O	_	_	_	_	_
43	65	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	c	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	Rel	_	O	O	_	_	_	_	_
48	was	_	O	O	_	_	_	_	_
49	unaltered	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	remarkable	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	CLL	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	appearance	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	DNA	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factors	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	dramatically	_	O	O	_	_	_	_	_
22	affected	_	O	O	_	_	_	_	_
23	whereas	_	O	O	_	_	_	_	_
24	other	_	O	O	_	_	_	_	_
25	members	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	same	_	O	O	_	_	_	_	_
29	factor	_	O	O	_	_	_	_	_
30	family	_	O	O	_	_	_	_	_
31	remained	_	O	O	_	_	_	_	_
32	unaltered	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	these	_	O	O	_	_	_	_	_
35	leukemic	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	remains	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	be	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	molecular	_	O	O	_	_	_	_	_
8	events	_	O	O	_	_	_	_	_
9	lead	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	'	_	O	O	_	_	_	_	_
14	pre	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	',	_	O	O	_	_	_	_	_
18	i	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	e	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	constitutive	_	O	O	_	_	_	_	_
2	nuclear	_	O	O	_	_	_	_	_
3	translocation	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	these	_	O	O	_	_	_	_	_
10	members	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	NF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	AT	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	NF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	kB	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	AP	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	families	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Cartoon	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	sense	_	O	O	_	_	_	_	_
5	strand	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Relative	_	O	O	_	_	_	_	_
2	locations	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	previously	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	LRE	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	[	_	O	O	_	_	_	_	_
11	30	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	33	_	O	O	_	_	_	_	_
14	]	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	newly	_	O	O	_	_	_	_	_
17	described	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	boxed	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	positively	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	black	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	negatively	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	gray	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	regulatory	_	O	O	_	_	_	_	_
32	transcription	_	O	O	_	_	_	_	_
33	factor	_	O	O	_	_	_	_	_
34	binding	_	O	O	_	_	_	_	_
35	sites	_	O	O	_	_	_	_	_
36	are	_	O	O	_	_	_	_	_
37	depicted	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_



1	Role	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	NFkappaB	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	NFIL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	NFAT	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	LPS	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	TSST	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	GP	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	GP	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	GP	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	TSST	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	induced	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	RA	_	O	O	_	_	_	_	_
39	expression	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	human	_	O	O	_	_	_	_	_
42	PBMC	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	band	_	O	O	_	_	_	_	_
5	shifts	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	NFkappaB	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	NFIL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	NFAT	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	but	_	O	O	_	_	_	_	_
17	no	_	O	O	_	_	_	_	_
18	TNFalpha	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	IFNgamma	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	we	_	O	O	_	_	_	_	_
27	hypothesized	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	activated	_	O	O	_	_	_	_	_
31	transcription	_	O	O	_	_	_	_	_
32	factors	_	O	O	_	_	_	_	_
33	might	_	O	O	_	_	_	_	_
34	bind	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	sites	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	RA	_	O	O	_	_	_	_	_
43	promoter	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	previoulsy	_	O	O	_	_	_	_	_
4	described	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	newly	_	O	O	_	_	_	_	_
7	discovered	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	sites	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	Table	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	using	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	program	_	O	O	_	_	_	_	_
26	OMIGA	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	v	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	3	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	Oxford	_	O	O	_	_	_	_	_
37	Molecular	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	Oxford	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	UK	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	LPS	_	O	O	_	_	_	_	_
3	responsive	_	O	O	_	_	_	_	_
4	kappaB	_	O	O	_	_	_	_	_
5	consensus	_	O	O	_	_	_	_	_
6	site	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	LRE	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	between	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	84	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	93	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	30	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	displayed	_	O	O	_	_	_	_	_
23	band	_	O	O	_	_	_	_	_
24	shifts	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	but	_	O	O	_	_	_	_	_
27	no	_	O	O	_	_	_	_	_
28	significant	_	O	O	_	_	_	_	_
29	alterations	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	its	_	O	O	_	_	_	_	_
32	binding	_	O	O	_	_	_	_	_
33	activity	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	irrespective	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	treatment	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	data	_	O	O	_	_	_	_	_
41	not	_	O	O	_	_	_	_	_
42	shown	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	new	_	O	O	_	_	_	_	_
3	kappaB	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	site	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	100	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	130	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	within	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	LRE	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	30	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	showed	_	O	O	_	_	_	_	_
22	increased	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	TSST	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	+	_	O	O	_	_	_	_	_
31	30	_	O	O	_	_	_	_	_
32	%	_	O	O	_	_	_	_	_
33	vs	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	control	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	but	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	co	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	treatment	_	O	O	_	_	_	_	_
9	up	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	regulated	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	LPS	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	65	_	O	O	_	_	_	_	_
17	%	_	O	O	_	_	_	_	_
18	vs	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	control	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	TSST	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	110	_	O	O	_	_	_	_	_
12	%	_	O	O	_	_	_	_	_
13	vs	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	control	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	superadditive	_	O	O	_	_	_	_	_
9	synergistic	_	O	O	_	_	_	_	_
10	fashion	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	when	_	O	O	_	_	_	_	_
13	compared	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	medium	_	O	O	_	_	_	_	_
16	control	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	well	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	LPS	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	TSST	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	or	_	O	O	_	_	_	_	_
27	GP	_	O	O	_	_	_	_	_
28	or	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	theoretical	_	O	O	_	_	_	_	_
31	values	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	GP	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	LPS	_	O	O	_	_	_	_	_
36	calc	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	or	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	calc	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	all	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	<	_	O	O	_	_	_	_	_
5	0	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_
7	05	_	O	O	_	_	_	_	_
8	;	_	O	O	_	_	_	_	_
9	Fig	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	new	_	O	O	_	_	_	_	_
5	kappaB	_	O	O	_	_	_	_	_
6	consensus	_	O	O	_	_	_	_	_
7	site	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	between	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	266	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	280	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	significantly	_	O	O	_	_	_	_	_
18	elevated	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	GP	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	TSST	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	<	_	O	O	_	_	_	_	_
28	0	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	05	_	O	O	_	_	_	_	_
31	;	_	O	O	_	_	_	_	_
32	data	_	O	O	_	_	_	_	_
33	not	_	O	O	_	_	_	_	_
34	shown	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	LPS	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	TSST	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	LPS	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	new	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	site	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	288	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	302	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	was	_	O	O	_	_	_	_	_
32	down	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	regulated	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	about	_	O	O	_	_	_	_	_
37	20	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	35	_	O	O	_	_	_	_	_
40	%	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	comparison	_	O	O	_	_	_	_	_
43	with	_	O	O	_	_	_	_	_
44	medium	_	O	O	_	_	_	_	_
45	control	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	p	_	O	O	_	_	_	_	_
48	<	_	O	O	_	_	_	_	_
49	0	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	05	_	O	O	_	_	_	_	_
52	;	_	O	O	_	_	_	_	_
53	data	_	O	O	_	_	_	_	_
54	not	_	O	O	_	_	_	_	_
55	shown	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	NFIL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	site	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	147	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	170	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	close	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	LRE	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	31	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	32	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	showed	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	up	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	regulation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	all	_	O	O	_	_	_	_	_
32	compounds	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	combinations	_	O	O	_	_	_	_	_
35	vs	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	medium	_	O	O	_	_	_	_	_
2	control	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	ranging	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	110	_	O	O	_	_	_	_	_
9	%	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	<	_	O	O	_	_	_	_	_
13	0	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	05	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	GP	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	TSST	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	induced	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	NFIL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	site	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	comparison	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	TSST	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	fold	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	GP	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	fold	_	O	O	_	_	_	_	_
37	;	_	O	O	_	_	_	_	_
38	p	_	O	O	_	_	_	_	_
39	<	_	O	O	_	_	_	_	_
40	0	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	05	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	data	_	O	O	_	_	_	_	_
47	not	_	O	O	_	_	_	_	_
48	shown	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	new	_	O	O	_	_	_	_	_
3	binding	_	O	O	_	_	_	_	_
4	site	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	NFATP	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	found	_	O	O	_	_	_	_	_
12	more	_	O	O	_	_	_	_	_
13	distal	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	start	_	O	O	_	_	_	_	_
18	site	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	between	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	471	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	490	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	displaying	_	O	O	_	_	_	_	_
28	again	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	substantial	_	O	O	_	_	_	_	_
31	increase	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	binding	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	all	_	O	O	_	_	_	_	_
36	compounds	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	combinations	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	when	_	O	O	_	_	_	_	_
41	compared	_	O	O	_	_	_	_	_
42	to	_	O	O	_	_	_	_	_
43	medium	_	O	O	_	_	_	_	_
44	control	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	p	_	O	O	_	_	_	_	_
47	<	_	O	O	_	_	_	_	_
48	0	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_
50	05	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	NFATP	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	site	_	O	O	_	_	_	_	_
12	following	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	LPS	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	fold	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	GP	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	GP	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	TSST	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_
35	5	_	O	O	_	_	_	_	_
36	fold	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	GP	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	25	_	O	O	_	_	_	_	_
43	fold	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	TSST	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	1	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	was	_	O	O	_	_	_	_	_
50	elevated	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	p	_	O	O	_	_	_	_	_
53	<	_	O	O	_	_	_	_	_
54	0	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_
56	05	_	O	O	_	_	_	_	_
57	;	_	O	O	_	_	_	_	_
58	Fig	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	5	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	but	_	O	O	_	_	_	_	_
5	only	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	additive	_	O	O	_	_	_	_	_
9	synergistic	_	O	O	_	_	_	_	_
10	manner	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	i	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	e	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	the	_	O	O	_	_	_	_	_
2	experimental	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	different	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	theoretical	_	O	O	_	_	_	_	_
10	values	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	calc	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_



1	Gel	_	O	O	_	_	_	_	_
2	mobility	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	shift	_	O	O	_	_	_	_	_
5	assay	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappaB	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	site	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	proteins	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	extracted	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	about	_	O	O	_	_	_	_	_
7	5	_	O	O	_	_	_	_	_
8	x	_	O	O	_	_	_	_	_
9	106	_	O	O	_	_	_	_	_
10	PBMC	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Oligonucleotide	_	O	O	_	_	_	_	_
2	probes	_	O	O	_	_	_	_	_
3	encompassing	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	kappaB	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	site	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	'	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	ATG	_	O	O	_	_	_	_	_
22	ACC	_	O	O	_	_	_	_	_
23	TGG	_	O	O	_	_	_	_	_
24	AAA	_	O	O	_	_	_	_	_
25	TAC	_	O	O	_	_	_	_	_
26	CCA	_	O	O	_	_	_	_	_
27	AAA	_	O	O	_	_	_	_	_
28	TTC	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	'	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	were	_	O	O	_	_	_	_	_
34	generated	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	5	_	O	O	_	_	_	_	_
37	'	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	end	_	O	O	_	_	_	_	_
40	labeling	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	sense	_	O	O	_	_	_	_	_
44	strand	_	O	O	_	_	_	_	_
45	with	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	gamma	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	32	_	O	O	_	_	_	_	_
50	P	_	O	O	_	_	_	_	_
51	]	_	O	O	_	_	_	_	_
52	dATP	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	Amersham	_	O	O	_	_	_	_	_
55	Pharmacia	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	T	_	O	O	_	_	_	_	_
59	4	_	O	O	_	_	_	_	_
60	polynucleotide	_	O	O	_	_	_	_	_
61	kinase	_	O	O	_	_	_	_	_
62	(	_	O	O	_	_	_	_	_
63	TaKaRa	_	O	O	_	_	_	_	_
64	)	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	Unincorporated	_	O	O	_	_	_	_	_
2	nucleotides	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	removed	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	NucTrap	_	O	O	_	_	_	_	_
7	probe	_	O	O	_	_	_	_	_
8	purification	_	O	O	_	_	_	_	_
9	columns	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Stratagene	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	La	_	O	O	_	_	_	_	_
14	Jolla	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	CA	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	USA	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	extracts	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	mug	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	incubated	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	radiolabeled	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	probes	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	10	_	O	O	_	_	_	_	_
17	ng	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	100	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	000	_	O	O	_	_	_	_	_
22	c	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	m	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	30	_	O	O	_	_	_	_	_
31	min	_	O	O	_	_	_	_	_
32	at	_	O	O	_	_	_	_	_
33	room	_	O	O	_	_	_	_	_
34	temperature	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	20	_	O	O	_	_	_	_	_
37	mul	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	binding	_	O	O	_	_	_	_	_
40	buffer	_	O	O	_	_	_	_	_
41	consisting	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	20	_	O	O	_	_	_	_	_
44	mM	_	O	O	_	_	_	_	_
45	Tris	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	HCl	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	pH	_	O	O	_	_	_	_	_
50	7	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_
52	9	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	50	_	O	O	_	_	_	_	_
55	mM	_	O	O	_	_	_	_	_
56	KCl	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	1	_	O	O	_	_	_	_	_
59	mM	_	O	O	_	_	_	_	_
60	dithiothreitol	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	0	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_
64	5	_	O	O	_	_	_	_	_
65	mM	_	O	O	_	_	_	_	_
66	EDTA	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	5	_	O	O	_	_	_	_	_
69	%	_	O	O	_	_	_	_	_
70	glycerol	_	O	O	_	_	_	_	_
71	,	_	O	O	_	_	_	_	_
72	1	_	O	O	_	_	_	_	_
73	mg	_	O	O	_	_	_	_	_
74	/	_	O	O	_	_	_	_	_
75	ml	_	O	O	_	_	_	_	_
76	BSA	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	0	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_
80	2	_	O	O	_	_	_	_	_
81	%	_	O	O	_	_	_	_	_
82	Nonidet	_	O	O	_	_	_	_	_
83	P	_	O	O	_	_	_	_	_
84	40	_	O	O	_	_	_	_	_
85	and	_	O	O	_	_	_	_	_
86	50	_	O	O	_	_	_	_	_
87	ng	_	O	O	_	_	_	_	_
88	/	_	O	O	_	_	_	_	_
89	mul	_	O	O	_	_	_	_	_
90	poly	_	O	O	_	_	_	_	_
91	(	_	O	O	_	_	_	_	_
92	dI	_	O	O	_	_	_	_	_
93	-	_	O	O	_	_	_	_	_
94	dC	_	O	O	_	_	_	_	_
95	)	_	O	O	_	_	_	_	_
96	.	_	O	O	_	_	_	_	_

1	Samples	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	subjected	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	electrophoresis	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	nondenaturing	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	%	_	O	O	_	_	_	_	_
10	polyacrylamide	_	O	O	_	_	_	_	_
11	gels	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	0	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	x	_	O	O	_	_	_	_	_
17	Tris	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	borate	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	EDTA	_	O	O	_	_	_	_	_
22	buffer	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	pH	_	O	O	_	_	_	_	_
25	8	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	0	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	100	_	O	O	_	_	_	_	_
31	V	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Gels	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	dried	_	O	O	_	_	_	_	_
4	under	_	O	O	_	_	_	_	_
5	vacuum	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	exposed	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	Kodak	_	O	O	_	_	_	_	_
10	X	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	OMAT	_	O	O	_	_	_	_	_
13	film	_	O	O	_	_	_	_	_
14	at	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	70	_	O	O	_	_	_	_	_
17	degreesC	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	intensifying	_	O	O	_	_	_	_	_
20	screens	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Rabbit	_	O	O	_	_	_	_	_
2	polyclonal	_	O	O	_	_	_	_	_
3	antibodies	_	O	O	_	_	_	_	_
4	against	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	kappaB	_	O	O	_	_	_	_	_
8	subunits	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	50	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	65	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Rel	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	Santa	_	O	O	_	_	_	_	_
21	Cruz	_	O	O	_	_	_	_	_
22	Biotechnology	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	Santa	_	O	O	_	_	_	_	_
25	Cruz	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	CA	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	USA	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_



1	Mice	_	O	O	_	_	_	_	_
2	deficient	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	55	_	O	O	_	_	_	_	_
6	kd	_	O	O	_	_	_	_	_
7	tumor	_	O	O	_	_	_	_	_
8	necrosis	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	resistant	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	endotoxic	_	O	O	_	_	_	_	_
15	shock	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	yet	_	O	O	_	_	_	_	_
18	succumb	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	L	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	monocytogenes	_	O	O	_	_	_	_	_
2	infection	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	multiple	_	O	O	_	_	_	_	_
3	biological	_	O	O	_	_	_	_	_
4	activities	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	tumor	_	O	O	_	_	_	_	_
7	necrosis	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	TNF	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	mediated	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	distinct	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	surface	_	O	O	_	_	_	_	_
19	receptors	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	55	_	O	O	_	_	_	_	_
22	kd	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	TNFRp	_	O	O	_	_	_	_	_
25	55	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	75	_	O	O	_	_	_	_	_
29	kd	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	TNFRp	_	O	O	_	_	_	_	_
32	75	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	gene	_	O	O	_	_	_	_	_
3	targeting	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	generated	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	TNFRp	_	O	O	_	_	_	_	_
9	55	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	deficient	_	O	O	_	_	_	_	_
12	mouse	_	O	O	_	_	_	_	_
13	strain	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	from	_	O	O	_	_	_	_	_
3	TNFRp	_	O	O	_	_	_	_	_
4	55	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	mutant	_	O	O	_	_	_	_	_
9	mice	_	O	O	_	_	_	_	_
10	lack	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	TNFRp	_	O	O	_	_	_	_	_
14	55	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	display	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	numbers	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	high	_	O	O	_	_	_	_	_
21	affinity	_	O	O	_	_	_	_	_
22	TNFRp	_	O	O	_	_	_	_	_
23	75	_	O	O	_	_	_	_	_
24	molecules	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Thymocyte	_	O	O	_	_	_	_	_
2	development	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	lymphocyte	_	O	O	_	_	_	_	_
5	populations	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	unaltered	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	clonal	_	O	O	_	_	_	_	_
11	deletion	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	potentially	_	O	O	_	_	_	_	_
14	self	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	reactive	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	not	_	O	O	_	_	_	_	_
21	impaired	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	TNF	_	O	O	_	_	_	_	_
4	signaling	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	largely	_	O	O	_	_	_	_	_
7	abolished	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	judged	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	failure	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	TNF	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	induce	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kappa	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	lymphocytes	_	O	O	_	_	_	_	_
25	from	_	O	O	_	_	_	_	_
26	TNFRp	_	O	O	_	_	_	_	_
27	55	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	deficient	_	O	O	_	_	_	_	_
30	mice	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	loss	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	TNFRp	_	O	O	_	_	_	_	_
5	55	_	O	O	_	_	_	_	_
6	function	_	O	O	_	_	_	_	_
7	renders	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	resistant	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	lethal	_	O	O	_	_	_	_	_
12	dosages	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	either	_	O	O	_	_	_	_	_
15	lipopolysaccharides	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	S	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	aureus	_	O	O	_	_	_	_	_
2	enterotoxin	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	TNFRp	_	O	O	_	_	_	_	_
5	55	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	deficient	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	severely	_	O	O	_	_	_	_	_
11	impaired	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	clear	_	O	O	_	_	_	_	_
14	L	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	monocytogenes	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	readily	_	O	O	_	_	_	_	_
4	succumb	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	infection	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	55	_	O	O	_	_	_	_	_
5	kd	_	O	O	_	_	_	_	_
6	TNFR	_	O	O	_	_	_	_	_
7	plays	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	decisive	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	host	_	O	O	_	_	_	_	_
14	'	_	O	O	_	_	_	_	_
15	s	_	O	O	_	_	_	_	_
16	defense	_	O	O	_	_	_	_	_
17	against	_	O	O	_	_	_	_	_
18	microorganisms	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	their	_	O	O	_	_	_	_	_
21	pathogenic	_	O	O	_	_	_	_	_
22	factors	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Tumor	_	O	O	_	_	_	_	_
2	necrosis	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	alpha	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	accumulation	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	myelomonocytic	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	lines	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Role	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	transcriptional	_	O	O	_	_	_	_	_
4	regulation	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	sequence	_	O	O	_	_	_	_	_
8	motifs	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	stabilization	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	cytokine	_	O	O	_	_	_	_	_
3	TNF	_	O	O	_	_	_	_	_
4	mediates	_	O	O	_	_	_	_	_
5	many	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	pathologic	_	O	O	_	_	_	_	_
9	signs	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cachexia	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	inflammation	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	sepsis	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	current	_	O	O	_	_	_	_	_
3	work	_	O	O	_	_	_	_	_
4	describes	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	regulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	TNF	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	myelomonocytic	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	lines	_	O	O	_	_	_	_	_
14	after	_	O	O	_	_	_	_	_
15	PMA	_	O	O	_	_	_	_	_
16	stimulation	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	lines	_	O	O	_	_	_	_	_
4	exhibit	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	low	_	O	O	_	_	_	_	_
7	level	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	constitutive	_	O	O	_	_	_	_	_
10	TNF	_	O	O	_	_	_	_	_
11	mRNA	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Within	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	h	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	PMA	_	O	O	_	_	_	_	_
8	exposure	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	steady	_	O	O	_	_	_	_	_
11	state	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	TNF	_	O	O	_	_	_	_	_
15	mRNA	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	markedly	_	O	O	_	_	_	_	_
18	elevated	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	all	_	O	O	_	_	_	_	_
21	myelomonocytic	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	lines	_	O	O	_	_	_	_	_
24	studied	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	rise	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	due	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	increased	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	stability	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	which	_	O	O	_	_	_	_	_
11	increased	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	almost	_	O	O	_	_	_	_	_
14	twofold	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	overall	_	O	O	_	_	_	_	_
20	increase	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	transcription	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	rises	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	more	_	O	O	_	_	_	_	_
28	than	_	O	O	_	_	_	_	_
29	sixfold	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	level	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	genomic	_	O	O	_	_	_	_	_
7	TNF	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	DNase	_	O	O	_	_	_	_	_
12	I	_	O	O	_	_	_	_	_
13	hypersensitive	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	detected	_	O	O	_	_	_	_	_
17	within	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	TNF	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	between	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	200	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	100	_	O	O	_	_	_	_	_
27	bp	_	O	O	_	_	_	_	_
28	relative	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	transcription	_	O	O	_	_	_	_	_
32	initiation	_	O	O	_	_	_	_	_
33	site	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	absent	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	nonexpressing	_	O	O	_	_	_	_	_
5	erythroleukemia	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	lines	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	DNase	_	O	O	_	_	_	_	_
11	I	_	O	O	_	_	_	_	_
12	site	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	present	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	uninduced	_	O	O	_	_	_	_	_
17	myelomonocytic	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lines	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	not	_	O	O	_	_	_	_	_
23	changed	_	O	O	_	_	_	_	_
24	after	_	O	O	_	_	_	_	_
25	PMA	_	O	O	_	_	_	_	_
26	induction	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	PMA	_	O	O	_	_	_	_	_
3	induction	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	fos	_	O	O	_	_	_	_	_
8	mRNA	_	O	O	_	_	_	_	_
9	correlated	_	O	O	_	_	_	_	_
10	well	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	TNF	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	induction	_	O	O	_	_	_	_	_
15	;	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	genes	_	O	O	_	_	_	_	_
19	encoding	_	O	O	_	_	_	_	_
20	other	_	O	O	_	_	_	_	_
21	proteins	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	AP	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	complex	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	junB	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	junD	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	were	_	O	O	_	_	_	_	_
34	also	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	PMA	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	nuclear	_	O	O	_	_	_	_	_
3	extracts	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	resting	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	ML	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	contain	_	O	O	_	_	_	_	_
13	proteins	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	specifically	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	AP	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	AP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	sequence	_	O	O	_	_	_	_	_
31	located	_	O	O	_	_	_	_	_
32	within	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	TNF	_	O	O	_	_	_	_	_
35	promoter	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	PMA	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	increases	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	level	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	number	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	specific	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	complexes	_	O	O	_	_	_	_	_
13	relative	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	resting	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	regulatory	_	O	O	_	_	_	_	_
3	mechanisms	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	murine	_	O	O	_	_	_	_	_
9	TNF	_	O	O	_	_	_	_	_
10	genes	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	discussed	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	human	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Interaction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	fibronectin	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	VLA	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	5	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	4	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	induces	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	AP	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Fibronectin	_	O	O	_	_	_	_	_
2	synergized	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	anti	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	antibody	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	promote	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	proliferation	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	serum	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	free	_	O	O	_	_	_	_	_
20	culture	_	O	O	_	_	_	_	_
21	system	_	O	O	_	_	_	_	_
22	whereas	_	O	O	_	_	_	_	_
23	no	_	O	O	_	_	_	_	_
24	proliferation	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	observed	_	O	O	_	_	_	_	_
27	when	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	4	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	were	_	O	O	_	_	_	_	_
32	cultured	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	anti	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	alone	_	O	O	_	_	_	_	_
39	or	_	O	O	_	_	_	_	_
40	fibronectin	_	O	O	_	_	_	_	_
41	alone	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	anti	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	29	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	integrin	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	well	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	anti	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	VLA	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	5	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	fibronectin	_	O	O	_	_	_	_	_
24	receptor	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	antibodies	_	O	O	_	_	_	_	_
27	blocked	_	O	O	_	_	_	_	_
28	this	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	4	_	O	O	_	_	_	_	_
31	cell	_	O	O	_	_	_	_	_
32	activation	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	this	_	O	O	_	_	_	_	_
35	system	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	anti	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	alone	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	fibronectin	_	O	O	_	_	_	_	_
9	alone	_	O	O	_	_	_	_	_
10	cannot	_	O	O	_	_	_	_	_
11	induce	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	message	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	combination	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	anti	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	plus	_	O	O	_	_	_	_	_
29	fibronectin	_	O	O	_	_	_	_	_
30	induced	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	message	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	4	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	an	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	molecular	_	O	O	_	_	_	_	_
7	mechanism	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	which	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	message	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	generated	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	we	_	O	O	_	_	_	_	_
18	showed	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	fibronectin	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	VLA	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	5	_	O	O	_	_	_	_	_
26	fibronectin	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	interaction	_	O	O	_	_	_	_	_
29	may	_	O	O	_	_	_	_	_
30	contribute	_	O	O	_	_	_	_	_
31	an	_	O	O	_	_	_	_	_
32	independent	_	O	O	_	_	_	_	_
33	signal	_	O	O	_	_	_	_	_
34	distinct	_	O	O	_	_	_	_	_
35	from	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	pathway	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	activation	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	induction	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	an	_	O	O	_	_	_	_	_
47	AP	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	transcriptional	_	O	O	_	_	_	_	_
51	factor	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	VLA	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	5	_	O	O	_	_	_	_	_
6	fibronectin	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	can	_	O	O	_	_	_	_	_
13	play	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	complementary	_	O	O	_	_	_	_	_
16	role	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	TCR	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	signal	_	O	O	_	_	_	_	_
25	transduction	_	O	O	_	_	_	_	_
26	through	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	interaction	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	fibronectin	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Glucocorticoids	_	O	O	_	_	_	_	_
2	promote	_	O	O	_	_	_	_	_
3	nonphlogistic	_	O	O	_	_	_	_	_
4	phagocytosis	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	apoptotic	_	O	O	_	_	_	_	_
7	leukocytes	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_


1	Phagocyte	_	O	O	_	_	_	_	_
2	recognition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	uptake	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	nonphlogistic	_	O	O	_	_	_	_	_
8	degradation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	neutrophils	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	other	_	O	O	_	_	_	_	_
13	leukocytes	_	O	O	_	_	_	_	_
14	undergoing	_	O	O	_	_	_	_	_
15	apoptosis	_	O	O	_	_	_	_	_
16	promote	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	resolution	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	inflammation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	assessed	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	effects	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	anti	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	inflammatory	_	O	O	_	_	_	_	_
10	glucocorticoids	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	this	_	O	O	_	_	_	_	_
13	leukocyte	_	O	O	_	_	_	_	_
14	clearance	_	O	O	_	_	_	_	_
15	mechanism	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Pretreatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	""""	_	O	O	_	_	_	_	_
4	semimature	_	O	O	_	_	_	_	_
5	""""	_	O	O	_	_	_	_	_
6	5	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	day	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	monocyte	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	derived	_	O	O	_	_	_	_	_
13	macrophages	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	M	_	O	O	_	_	_	_	_
16	phi	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	24	_	O	O	_	_	_	_	_
20	h	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	methylprednisolone	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	dexamethasone	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	hydrocortisone	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	but	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	nonglucocorticoid	_	O	O	_	_	_	_	_
33	steroids	_	O	O	_	_	_	_	_
34	aldosterone	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	estradiol	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	progesterone	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	potentiated	_	O	O	_	_	_	_	_
42	phagocytosis	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	apoptotic	_	O	O	_	_	_	_	_
45	neutrophils	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	potentiated	_	O	O	_	_	_	_	_
9	phagocytosis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	apoptotic	_	O	O	_	_	_	_	_
12	neutrophils	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	completely	_	O	O	_	_	_	_	_
15	blocked	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	glucocorticoid	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	antagonist	_	O	O	_	_	_	_	_
21	RU	_	O	O	_	_	_	_	_
22	38486	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	glucocorticoids	_	O	O	_	_	_	_	_
26	did	_	O	O	_	_	_	_	_
27	not	_	O	O	_	_	_	_	_
28	promote	_	O	O	_	_	_	_	_
29	5	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	day	_	O	O	_	_	_	_	_
32	M	_	O	O	_	_	_	_	_
33	phi	_	O	O	_	_	_	_	_
34	ingestion	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	opsonized	_	O	O	_	_	_	_	_
37	erythrocytes	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Similar	_	O	O	_	_	_	_	_
2	glucocorticoid	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	potentiation	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	observed	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	day	_	O	O	_	_	_	_	_
12	M	_	O	O	_	_	_	_	_
13	phi	_	O	O	_	_	_	_	_
14	uptake	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	alternative	_	O	O	_	_	_	_	_
17	apoptotic	_	O	O	_	_	_	_	_
18	""""	_	O	O	_	_	_	_	_
19	targets	_	O	O	_	_	_	_	_
20	""""	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	eosinophils	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	Jurkat	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	uptake	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	apoptotic	_	O	O	_	_	_	_	_
33	neutrophils	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	alternative	_	O	O	_	_	_	_	_
36	phagocytes	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	human	_	O	O	_	_	_	_	_
39	glomerular	_	O	O	_	_	_	_	_
40	mesangial	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	murine	_	O	O	_	_	_	_	_
44	M	_	O	O	_	_	_	_	_
45	phi	_	O	O	_	_	_	_	_
46	elicited	_	O	O	_	_	_	_	_
47	into	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	peritoneum	_	O	O	_	_	_	_	_
50	or	_	O	O	_	_	_	_	_
51	derived	_	O	O	_	_	_	_	_
52	from	_	O	O	_	_	_	_	_
53	bone	_	O	O	_	_	_	_	_
54	marrow	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Importantly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	methylprednisolone	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	enhancement	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	uptake	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	apoptotic	_	O	O	_	_	_	_	_
12	neutrophils	_	O	O	_	_	_	_	_
13	did	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	trigger	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	release	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	chemokines	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	8	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	monocyte	_	O	O	_	_	_	_	_
26	chemoattractant	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	longer	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	term	_	O	O	_	_	_	_	_
6	potentiation	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	methylprednisolone	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	observed	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	maturing	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	monocyte	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	derived	_	O	O	_	_	_	_	_
17	M	_	O	O	_	_	_	_	_
18	phi	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	greater	_	O	O	_	_	_	_	_
22	increases	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	5	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	day	_	O	O	_	_	_	_	_
27	M	_	O	O	_	_	_	_	_
28	phi	_	O	O	_	_	_	_	_
29	uptake	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	apoptotic	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	being	_	O	O	_	_	_	_	_
34	observed	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	earlier	_	O	O	_	_	_	_	_
37	glucocorticoids	_	O	O	_	_	_	_	_
38	were	_	O	O	_	_	_	_	_
39	added	_	O	O	_	_	_	_	_
40	during	_	O	O	_	_	_	_	_
41	monocyte	_	O	O	_	_	_	_	_
42	maturation	_	O	O	_	_	_	_	_
43	into	_	O	O	_	_	_	_	_
44	M	_	O	O	_	_	_	_	_
45	phi	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	potentiation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	nonphlogistic	_	O	O	_	_	_	_	_
7	clearance	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	apoptotic	_	O	O	_	_	_	_	_
10	leukocytes	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	phagocytes	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	hitherto	_	O	O	_	_	_	_	_
16	unrecognized	_	O	O	_	_	_	_	_
17	property	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	glucocorticoids	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	has	_	O	O	_	_	_	_	_
22	potential	_	O	O	_	_	_	_	_
23	implications	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	therapies	_	O	O	_	_	_	_	_
26	aimed	_	O	O	_	_	_	_	_
27	at	_	O	O	_	_	_	_	_
28	promoting	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	resolution	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	inflammatory	_	O	O	_	_	_	_	_
33	diseases	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	Elevated	_	O	O	_	_	_	_	_
2	cyclic	_	O	O	_	_	_	_	_
3	AMP	_	O	O	_	_	_	_	_
4	inhibits	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	kappaB	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	monocytic	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	endothelial	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	kappaB	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	Rel	_	O	O	_	_	_	_	_
7	family	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factors	_	O	O	_	_	_	_	_
11	regulates	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	inducible	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	many	_	O	O	_	_	_	_	_
17	genes	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	activated	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	monocytes	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	endothelial	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	examined	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	molecular	_	O	O	_	_	_	_	_
9	mechanism	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	which	_	O	O	_	_	_	_	_
12	agents	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	elevate	_	O	O	_	_	_	_	_
15	intracellular	_	O	O	_	_	_	_	_
16	cAMP	_	O	O	_	_	_	_	_
17	inhibit	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	tumor	_	O	O	_	_	_	_	_
23	necrosis	_	O	O	_	_	_	_	_
24	factor	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	TNFalpha	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	tissue	_	O	O	_	_	_	_	_
31	factor	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	endothelial	_	O	O	_	_	_	_	_
34	leukocyte	_	O	O	_	_	_	_	_
35	adhesion	_	O	O	_	_	_	_	_
36	molecule	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	vascular	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	adhesion	_	O	O	_	_	_	_	_
44	molecule	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	genes	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	forskolin	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	dibutyryl	_	O	O	_	_	_	_	_
5	cAMP	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	elevate	_	O	O	_	_	_	_	_
9	intracellular	_	O	O	_	_	_	_	_
10	cAMP	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	independent	_	O	O	_	_	_	_	_
13	mechanisms	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	inhibited	_	O	O	_	_	_	_	_
16	TNFalpha	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	tissue	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	at	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	level	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	kappaB	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependent	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	transiently	_	O	O	_	_	_	_	_
12	transfected	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	monocytic	_	O	O	_	_	_	_	_
15	THP	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	umbilical	_	O	O	_	_	_	_	_
22	vein	_	O	O	_	_	_	_	_
23	endothelial	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	inhibited	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	elevated	_	O	O	_	_	_	_	_
29	cAMP	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	overexpression	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	catalytic	_	O	O	_	_	_	_	_
36	subunit	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	protein	_	O	O	_	_	_	_	_
39	kinase	_	O	O	_	_	_	_	_
40	A	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	PKA	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Elevated	_	O	O	_	_	_	_	_
2	cAMP	_	O	O	_	_	_	_	_
3	did	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	prevent	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	translocation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	50	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	65	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Rel	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	p	_	O	O	_	_	_	_	_
20	65	_	O	O	_	_	_	_	_
21	heterodimers	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	decrease	_	O	O	_	_	_	_	_
24	nuclear	_	O	O	_	_	_	_	_
25	translocation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	p	_	O	O	_	_	_	_	_
28	65	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	significantly	_	O	O	_	_	_	_	_
32	modify	_	O	O	_	_	_	_	_
33	TNFalpha	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	phosphorylation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	p	_	O	O	_	_	_	_	_
39	65	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Functional	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	transcriptional	_	O	O	_	_	_	_	_
6	activation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	plasmid	_	O	O	_	_	_	_	_
10	containing	_	O	O	_	_	_	_	_
11	multimerized	_	O	O	_	_	_	_	_
12	kappaB	_	O	O	_	_	_	_	_
13	sites	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	p	_	O	O	_	_	_	_	_
16	65	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	inhibited	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	agents	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	elevate	_	O	O	_	_	_	_	_
23	cAMP	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	overexpression	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	catalytic	_	O	O	_	_	_	_	_
30	subunit	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	PKA	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	indicates	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	PKA	_	O	O	_	_	_	_	_
8	reduces	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	induction	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	distinct	_	O	O	_	_	_	_	_
14	set	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	genes	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	monocytes	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	endothelial	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	inhibiting	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kappaB	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	mediated	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Mononuclear	_	O	O	_	_	_	_	_
2	leukocyte	_	O	O	_	_	_	_	_
3	glucocorticoid	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	characteristics	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	down	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	regulation	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	major	_	O	O	_	_	_	_	_
13	depression	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Some	_	O	O	_	_	_	_	_
2	patients	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	major	_	O	O	_	_	_	_	_
5	depressive	_	O	O	_	_	_	_	_
6	disorder	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	MDD	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	have	_	O	O	_	_	_	_	_
11	elevated	_	O	O	_	_	_	_	_
12	plasma	_	O	O	_	_	_	_	_
13	cortisol	_	O	O	_	_	_	_	_
14	concentrations	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	show	_	O	O	_	_	_	_	_
17	failure	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	suppress	_	O	O	_	_	_	_	_
20	cortisol	_	O	O	_	_	_	_	_
21	secretion	_	O	O	_	_	_	_	_
22	upon	_	O	O	_	_	_	_	_
23	administration	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	dexamethasone	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	DEX	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	yet	_	O	O	_	_	_	_	_
31	they	_	O	O	_	_	_	_	_
32	do	_	O	O	_	_	_	_	_
33	not	_	O	O	_	_	_	_	_
34	have	_	O	O	_	_	_	_	_
35	Cushingoid	_	O	O	_	_	_	_	_
36	features	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	represents	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	GC	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	resistance	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	[	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	H	_	O	O	_	_	_	_	_
15	]	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	DEX	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	assays	_	O	O	_	_	_	_	_
21	were	_	O	O	_	_	_	_	_
22	used	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	measure	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vitro	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	GC	_	O	O	_	_	_	_	_
31	receptor	_	O	O	_	_	_	_	_
32	affinity	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	Kd	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	number	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	Bmax	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	mononuclear	_	O	O	_	_	_	_	_
45	leukocytes	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	11	_	O	O	_	_	_	_	_
48	MDD	_	O	O	_	_	_	_	_
49	patients	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	15	_	O	O	_	_	_	_	_
52	control	_	O	O	_	_	_	_	_
53	subjects	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	abnormalities	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	detected	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	MDD	_	O	O	_	_	_	_	_
9	group	_	O	O	_	_	_	_	_
10	;	_	O	O	_	_	_	_	_
11	thus	_	O	O	_	_	_	_	_
12	any	_	O	O	_	_	_	_	_
13	cellular	_	O	O	_	_	_	_	_
14	defect	_	O	O	_	_	_	_	_
15	leading	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	lack	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	responsiveness	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	GC	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	MDD	_	O	O	_	_	_	_	_
26	patients	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	if	_	O	O	_	_	_	_	_
29	present	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	probably	_	O	O	_	_	_	_	_
32	lies	_	O	O	_	_	_	_	_
33	beyond	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	initial	_	O	O	_	_	_	_	_
36	receptor	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	DEX	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_
5	0	_	O	O	_	_	_	_	_
6	mg	_	O	O	_	_	_	_	_
7	orally	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	administered	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	study	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	vivo	_	O	O	_	_	_	_	_
15	GC	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	down	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	regulation	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Compared	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	control	_	O	O	_	_	_	_	_
5	group	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	fewer	_	O	O	_	_	_	_	_
8	depressed	_	O	O	_	_	_	_	_
9	subjects	_	O	O	_	_	_	_	_
10	down	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	regulated	_	O	O	_	_	_	_	_
13	Bmax	_	O	O	_	_	_	_	_
14	after	_	O	O	_	_	_	_	_
15	DEX	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	paired	_	O	O	_	_	_	_	_
3	t	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	test	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	Bmax	_	O	O	_	_	_	_	_
8	decreased	_	O	O	_	_	_	_	_
9	significantly	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	control	_	O	O	_	_	_	_	_
13	group	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	depressed	_	O	O	_	_	_	_	_
19	group	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Receptor	_	O	O	_	_	_	_	_
2	number	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	control	_	O	O	_	_	_	_	_
6	day	_	O	O	_	_	_	_	_
7	did	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	correlate	_	O	O	_	_	_	_	_
10	significantly	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	degree	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	down	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	regulation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	severity	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	depression	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	cortisol	_	O	O	_	_	_	_	_
25	concentrations	_	O	O	_	_	_	_	_
26	across	_	O	O	_	_	_	_	_
27	all	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	subjects	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	do	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	lend	_	O	O	_	_	_	_	_
6	support	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	previous	_	O	O	_	_	_	_	_
9	reports	_	O	O	_	_	_	_	_
10	suggesting	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	GC	_	O	O	_	_	_	_	_
13	resistance	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	MDD	_	O	O	_	_	_	_	_
16	results	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	GC	_	O	O	_	_	_	_	_
20	receptor	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	abnormality	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	they	_	O	O	_	_	_	_	_
27	emphasize	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	importance	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	considering	_	O	O	_	_	_	_	_
32	receptor	_	O	O	_	_	_	_	_
33	studies	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	context	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	GC	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	mediated	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	processes	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	order	_	O	O	_	_	_	_	_
45	to	_	O	O	_	_	_	_	_
46	identify	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	exact	_	O	O	_	_	_	_	_
49	cellular	_	O	O	_	_	_	_	_
50	defect	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	s	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	leading	_	O	O	_	_	_	_	_
55	to	_	O	O	_	_	_	_	_
56	GC	_	O	O	_	_	_	_	_
57	resistance	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_


1	Protein	_	O	O	_	_	_	_	_
2	kinase	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Akt	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	phosphatidylinositol	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	kinase	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	STAT	_	O	O	_	_	_	_	_
17	5	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	activated	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	erythropoietin	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	EPO	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	HCD	_	O	O	_	_	_	_	_
27	57	_	O	O	_	_	_	_	_
28	erythroid	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	but	_	O	O	_	_	_	_	_
31	are	_	O	O	_	_	_	_	_
32	constitutively	_	O	O	_	_	_	_	_
33	active	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	an	_	O	O	_	_	_	_	_
36	EPO	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	independent	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	apoptosis	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	resistant	_	O	O	_	_	_	_	_
43	subclone	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	HCD	_	O	O	_	_	_	_	_
46	57	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	SREI	_	O	O	_	_	_	_	_
49	cells	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	erythropoietin	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	EPO	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	stem	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	SCF	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	activated	_	O	O	_	_	_	_	_
16	protein	_	O	O	_	_	_	_	_
17	kinase	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	PKB	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	Akt	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	EPO	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	dependent	_	O	O	_	_	_	_	_
28	HCD	_	O	O	_	_	_	_	_
29	57	_	O	O	_	_	_	_	_
30	erythroid	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	better	_	O	O	_	_	_	_	_
3	understand	_	O	O	_	_	_	_	_
4	signals	_	O	O	_	_	_	_	_
5	controlling	_	O	O	_	_	_	_	_
6	proliferation	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	viability	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	erythroid	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	resist	_	O	O	_	_	_	_	_
14	apoptosis	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	absence	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	EPO	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	subcloned	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	characterized	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	HCD	_	O	O	_	_	_	_	_
26	57	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	SREI	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	activations	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	PKB	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	Akt	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	b	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	noted	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	these	_	O	O	_	_	_	_	_
20	EPO	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	independent	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	PI	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	kinase	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	upstream	_	O	O	_	_	_	_	_
9	activator	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	PKB	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	Akt	_	O	O	_	_	_	_	_
14	because	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	PI	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kinase	_	O	O	_	_	_	_	_
20	inhibitor	_	O	O	_	_	_	_	_
21	LY	_	O	O	_	_	_	_	_
22	294002	_	O	O	_	_	_	_	_
23	blocked	_	O	O	_	_	_	_	_
24	both	_	O	O	_	_	_	_	_
25	constitutive	_	O	O	_	_	_	_	_
26	PKB	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	Akt	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	factor	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	dependent	_	O	O	_	_	_	_	_
33	PKB	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	Akt	_	O	O	_	_	_	_	_
36	activity	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	LY	_	O	O	_	_	_	_	_
3	294002	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	showed	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	proliferation	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	viability	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	both	_	O	O	_	_	_	_	_
12	HCD	_	O	O	_	_	_	_	_
13	57	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	SREI	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	HCD	_	O	O	_	_	_	_	_
18	57	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	correlated	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	PKB	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	Akt	_	O	O	_	_	_	_	_
28	;	_	O	O	_	_	_	_	_
29	however	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	PKB	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	Akt	_	O	O	_	_	_	_	_
34	activity	_	O	O	_	_	_	_	_
35	alone	_	O	O	_	_	_	_	_
36	did	_	O	O	_	_	_	_	_
37	not	_	O	O	_	_	_	_	_
38	protect	_	O	O	_	_	_	_	_
39	these	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	apoptosis	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	HCD	_	O	O	_	_	_	_	_
4	57	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	SCF	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	PKB	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	Akt	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	did	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	protect	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	apoptosis	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	result	_	O	O	_	_	_	_	_
3	suggested	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	PKB	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	PI	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kinase	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	necessary	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	sufficient	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	promote	_	O	O	_	_	_	_	_
19	viability	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	proliferation	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	STAT	_	O	O	_	_	_	_	_
3	5	_	O	O	_	_	_	_	_
4	activity	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	through	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	unknown	_	O	O	_	_	_	_	_
10	pathway	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	including	_	O	O	_	_	_	_	_
13	JAK	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	EPOR	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	may	_	O	O	_	_	_	_	_
19	act	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	concert	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	constitutive	_	O	O	_	_	_	_	_
25	PI	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	kinase	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	PKB	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	Akt	_	O	O	_	_	_	_	_
33	pathway	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	protect	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	EPO	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	independent	_	O	O	_	_	_	_	_
40	HCD	_	O	O	_	_	_	_	_
41	57	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	SREI	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	from	_	O	O	_	_	_	_	_
46	apoptosis	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	promote	_	O	O	_	_	_	_	_
49	limited	_	O	O	_	_	_	_	_
50	proliferation	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Glucocorticoid	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	death	_	O	O	_	_	_	_	_
6	requires	_	O	O	_	_	_	_	_
7	autoinduction	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	leukemic	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	negative	_	O	O	_	_	_	_	_
6	autoregulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	GR	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	seen	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	most	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	tissues	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	GR	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	positively	_	O	O	_	_	_	_	_
25	autoregulated	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	human	_	O	O	_	_	_	_	_
28	leukemic	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	other	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	sensitive	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	glucocorticoid	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	induced	_	O	O	_	_	_	_	_
40	cell	_	O	O	_	_	_	_	_
41	death	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	positive	_	O	O	_	_	_	_	_
5	autoregulation	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	necessary	_	O	O	_	_	_	_	_
9	component	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	glucocorticoid	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	death	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	wild	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	type	_	O	O	_	_	_	_	_
21	GR	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	under	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	control	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	tetracycline	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	regulated	_	O	O	_	_	_	_	_
31	promoter	_	O	O	_	_	_	_	_
32	was	_	O	O	_	_	_	_	_
33	stably	_	O	O	_	_	_	_	_
34	transfected	_	O	O	_	_	_	_	_
35	into	_	O	O	_	_	_	_	_
36	glucocorticoid	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	resistant	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	lacking	_	O	O	_	_	_	_	_
41	endogenous	_	O	O	_	_	_	_	_
42	functional	_	O	O	_	_	_	_	_
43	receptor	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Transfectants	_	O	O	_	_	_	_	_
2	grown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	presence	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	tetracycline	_	O	O	_	_	_	_	_
8	contained	_	O	O	_	_	_	_	_
9	about	_	O	O	_	_	_	_	_
10	15	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	000	_	O	O	_	_	_	_	_
13	receptors	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	value	_	O	O	_	_	_	_	_
19	approximately	_	O	O	_	_	_	_	_
20	equal	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	basal	_	O	O	_	_	_	_	_
23	level	_	O	O	_	_	_	_	_
24	GR	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	glucocorticoid	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	sensitive	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	TG	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	before	_	O	O	_	_	_	_	_
37	steroid	_	O	O	_	_	_	_	_
38	treatment	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Under	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	conditions	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	dexamethasone	_	O	O	_	_	_	_	_
6	had	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	minimal	_	O	O	_	_	_	_	_
9	effect	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	growth	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	elicited	_	O	O	_	_	_	_	_
15	little	_	O	O	_	_	_	_	_
16	internucleosomal	_	O	O	_	_	_	_	_
17	DNA	_	O	O	_	_	_	_	_
18	fragmentation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	no	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	cycle	_	O	O	_	_	_	_	_
25	perturbation	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	absence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	tetracycline	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	GR	_	O	O	_	_	_	_	_
8	mRNA	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	increased	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	fold	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	expressed	_	O	O	_	_	_	_	_
22	48	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	000	_	O	O	_	_	_	_	_
25	receptors	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	level	_	O	O	_	_	_	_	_
29	nearly	_	O	O	_	_	_	_	_
30	equivalent	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	present	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	TG	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	after	_	O	O	_	_	_	_	_
42	18	_	O	O	_	_	_	_	_
43	h	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	autoinduction	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Under	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	conditions	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	dexamethasone	_	O	O	_	_	_	_	_
6	markedly	_	O	O	_	_	_	_	_
7	inhibited	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	growth	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	caused	_	O	O	_	_	_	_	_
12	G	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	arrest	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	significant	_	O	O	_	_	_	_	_
19	internucleosomal	_	O	O	_	_	_	_	_
20	DNA	_	O	O	_	_	_	_	_
21	fragmentation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	therefore	_	O	O	_	_	_	_	_
4	suggest	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	basal	_	O	O	_	_	_	_	_
7	level	_	O	O	_	_	_	_	_
8	GR	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	inadequate	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	mediate	_	O	O	_	_	_	_	_
14	glucocorticoid	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	apoptosis	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	glucocorticoid	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	sensitive	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	positive	_	O	O	_	_	_	_	_
27	autoregulation	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	necessary	_	O	O	_	_	_	_	_
31	component	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	this	_	O	O	_	_	_	_	_
34	process	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Comparative	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	identifies	_	O	O	_	_	_	_	_
4	conserved	_	O	O	_	_	_	_	_
5	tumor	_	O	O	_	_	_	_	_
6	necrosis	_	O	O	_	_	_	_	_
7	factor	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	associated	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	simian	_	O	O	_	_	_	_	_
20	Epstein	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	Barr	_	O	O	_	_	_	_	_
23	virus	_	O	O	_	_	_	_	_
24	oncogene	_	O	O	_	_	_	_	_
25	LMP	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Nonhuman	_	O	O	_	_	_	_	_
2	primates	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	naturally	_	O	O	_	_	_	_	_
5	infected	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	lymphotropic	_	O	O	_	_	_	_	_
11	herpesvirus	_	O	O	_	_	_	_	_
12	closely	_	O	O	_	_	_	_	_
13	related	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	Epstein	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Barr	_	O	O	_	_	_	_	_
18	virus	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	EBV	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	simian	_	O	O	_	_	_	_	_
3	EBV	_	O	O	_	_	_	_	_
4	share	_	O	O	_	_	_	_	_
5	considerable	_	O	O	_	_	_	_	_
6	genetic	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	biologic	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	epidemiologic	_	O	O	_	_	_	_	_
12	features	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	EBV	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	including	_	O	O	_	_	_	_	_
18	virus	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	tumorigenesis	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	latent	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	transformation	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	associated	_	O	O	_	_	_	_	_
8	viral	_	O	O	_	_	_	_	_
9	genes	_	O	O	_	_	_	_	_
10	demonstrate	_	O	O	_	_	_	_	_
11	marked	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	divergence	_	O	O	_	_	_	_	_
14	among	_	O	O	_	_	_	_	_
15	species	_	O	O	_	_	_	_	_
16	despite	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	conserved	_	O	O	_	_	_	_	_
19	functions	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	cloned	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	latent	_	O	O	_	_	_	_	_
6	membrane	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	LMP	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	homologs	_	O	O	_	_	_	_	_
14	from	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	simian	_	O	O	_	_	_	_	_
17	EBV	_	O	O	_	_	_	_	_
18	naturally	_	O	O	_	_	_	_	_
19	infecting	_	O	O	_	_	_	_	_
20	baboons	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	cercopithicine	_	O	O	_	_	_	_	_
23	herpesvirus	_	O	O	_	_	_	_	_
24	12	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	herpesvirus	_	O	O	_	_	_	_	_
27	papio	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	rhesus	_	O	O	_	_	_	_	_
31	monkeys	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	cercopithicine	_	O	O	_	_	_	_	_
34	herpesvirus	_	O	O	_	_	_	_	_
35	15	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	for	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	comparative	_	O	O	_	_	_	_	_
40	study	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	human	_	O	O	_	_	_	_	_
44	EBV	_	O	O	_	_	_	_	_
45	oncogene	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	transmembrane	_	O	O	_	_	_	_	_
3	domains	_	O	O	_	_	_	_	_
4	are	_	O	O	_	_	_	_	_
5	well	_	O	O	_	_	_	_	_
6	conserved	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	but	_	O	O	_	_	_	_	_
9	there	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	striking	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	divergence	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	carboxy	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	terminal	_	O	O	_	_	_	_	_
19	cytoplasmic	_	O	O	_	_	_	_	_
20	domain	_	O	O	_	_	_	_	_
21	essential	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	immortalization	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	interaction	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	tumor	_	O	O	_	_	_	_	_
32	necrosis	_	O	O	_	_	_	_	_
33	factor	_	O	O	_	_	_	_	_
34	receptor	_	O	O	_	_	_	_	_
35	signaling	_	O	O	_	_	_	_	_
36	pathway	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Nevertheless	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	simian	_	O	O	_	_	_	_	_
5	EBV	_	O	O	_	_	_	_	_
6	LMP	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	s	_	O	O	_	_	_	_	_
9	retain	_	O	O	_	_	_	_	_
10	most	_	O	O	_	_	_	_	_
11	functions	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	common	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	EBV	_	O	O	_	_	_	_	_
16	LMP	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	including	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	ability	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	induce	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	kappa	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	activity	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	human	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	bind	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	tumor	_	O	O	_	_	_	_	_
39	necrosis	_	O	O	_	_	_	_	_
40	factor	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	associated	_	O	O	_	_	_	_	_
43	factor	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	TRAF	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	vitro	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	to	_	O	O	_	_	_	_	_
54	induce	_	O	O	_	_	_	_	_
55	expression	_	O	O	_	_	_	_	_
56	of	_	O	O	_	_	_	_	_
57	tumor	_	O	O	_	_	_	_	_
58	necrosis	_	O	O	_	_	_	_	_
59	factor	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	responsive	_	O	O	_	_	_	_	_
62	genes	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	such	_	O	O	_	_	_	_	_
65	as	_	O	O	_	_	_	_	_
66	ICAM	_	O	O	_	_	_	_	_
67	1	_	O	O	_	_	_	_	_
68	,	_	O	O	_	_	_	_	_
69	in	_	O	O	_	_	_	_	_
70	human	_	O	O	_	_	_	_	_
71	B	_	O	O	_	_	_	_	_
72	lymphocytes	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_

1	Multiple	_	O	O	_	_	_	_	_
2	TRAF	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	sites	_	O	O	_	_	_	_	_
6	containing	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	PXQXT	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	S	_	O	O	_	_	_	_	_
11	core	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	can	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	identified	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	simian	_	O	O	_	_	_	_	_
19	EBV	_	O	O	_	_	_	_	_
20	LMP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	s	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	vitro	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	assay	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	PXQXT	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	S	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	containing	_	O	O	_	_	_	_	_
7	sequence	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	present	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	cytoplasmic	_	O	O	_	_	_	_	_
14	domain	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	Hodgkin	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	s	_	O	O	_	_	_	_	_
20	disease	_	O	O	_	_	_	_	_
21	marker	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	30	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	binds	_	O	O	_	_	_	_	_
28	TRAF	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	vitro	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	last	_	O	O	_	_	_	_	_
3	13	_	O	O	_	_	_	_	_
4	amino	_	O	O	_	_	_	_	_
5	acids	_	O	O	_	_	_	_	_
6	containing	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	PXQXT	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	S	_	O	O	_	_	_	_	_
11	sequence	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	highly	_	O	O	_	_	_	_	_
14	conserved	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	simian	_	O	O	_	_	_	_	_
19	EBV	_	O	O	_	_	_	_	_
20	LMP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	but	_	O	O	_	_	_	_	_
23	do	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	bind	_	O	O	_	_	_	_	_
26	TRAF	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	suggesting	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	distinct	_	O	O	_	_	_	_	_
32	role	_	O	O	_	_	_	_	_
33	for	_	O	O	_	_	_	_	_
34	this	_	O	O	_	_	_	_	_
35	conserved	_	O	O	_	_	_	_	_
36	region	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	LMP	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	conserved	_	O	O	_	_	_	_	_
3	TRAF	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	sites	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	LMP	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	30	_	O	O	_	_	_	_	_
14	Hodgkin	_	O	O	_	_	_	_	_
15	'	_	O	O	_	_	_	_	_
16	s	_	O	O	_	_	_	_	_
17	disease	_	O	O	_	_	_	_	_
18	marker	_	O	O	_	_	_	_	_
19	provides	_	O	O	_	_	_	_	_
20	further	_	O	O	_	_	_	_	_
21	evidence	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	TRAF	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	mediated	_	O	O	_	_	_	_	_
28	signal	_	O	O	_	_	_	_	_
29	transduction	_	O	O	_	_	_	_	_
30	pathway	_	O	O	_	_	_	_	_
31	may	_	O	O	_	_	_	_	_
32	be	_	O	O	_	_	_	_	_
33	important	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	malignant	_	O	O	_	_	_	_	_
36	transformation	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Cellular	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	molecular	_	O	O	_	_	_	_	_
4	mechanisms	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	IFN	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	gamma	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	12	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	NK	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	line	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Interferon	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	gamma	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	an	_	O	O	_	_	_	_	_
11	important	_	O	O	_	_	_	_	_
12	immunoregulatory	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	produced	_	O	O	_	_	_	_	_
15	predominantly	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	large	_	O	O	_	_	_	_	_
21	granular	_	O	O	_	_	_	_	_
22	lymphocytes	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	LGL	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	response	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	different	_	O	O	_	_	_	_	_
30	extracellular	_	O	O	_	_	_	_	_
31	signals	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	particular	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	interleukins	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	ILs	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	12	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	have	_	O	O	_	_	_	_	_
19	been	_	O	O	_	_	_	_	_
20	shown	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	potent	_	O	O	_	_	_	_	_
24	inducers	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	IFN	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	gamma	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	both	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	LGL	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	it	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	reported	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	there	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	some	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	lines	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	produce	_	O	O	_	_	_	_	_
15	IFN	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	gamma	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	response	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	12	_	O	O	_	_	_	_	_
28	stimulation	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	there	_	O	O	_	_	_	_	_
31	has	_	O	O	_	_	_	_	_
32	as	_	O	O	_	_	_	_	_
33	yet	_	O	O	_	_	_	_	_
34	been	_	O	O	_	_	_	_	_
35	no	_	O	O	_	_	_	_	_
36	report	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	natural	_	O	O	_	_	_	_	_
40	killer	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	NK	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	cell	_	O	O	_	_	_	_	_
45	line	_	O	O	_	_	_	_	_
46	that	_	O	O	_	_	_	_	_
47	responds	_	O	O	_	_	_	_	_
48	in	_	O	O	_	_	_	_	_
49	a	_	O	O	_	_	_	_	_
50	similar	_	O	O	_	_	_	_	_
51	manner	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	present	_	O	O	_	_	_	_	_
6	evidence	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	line	_	O	O	_	_	_	_	_
11	NK	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	derived	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	NK	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	responds	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	both	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	12	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	as	_	O	O	_	_	_	_	_
33	measured	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	increases	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	IFN	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	gamma	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	granulocyte	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	macrophage	_	O	O	_	_	_	_	_
44	colony	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	stimulating	_	O	O	_	_	_	_	_
47	factor	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	GM	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	CSF	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	cytoplasmic	_	O	O	_	_	_	_	_
54	mRNA	_	O	O	_	_	_	_	_
55	and	_	O	O	_	_	_	_	_
56	protein	_	O	O	_	_	_	_	_
57	expression	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	when	_	O	O	_	_	_	_	_
5	used	_	O	O	_	_	_	_	_
6	together	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	12	_	O	O	_	_	_	_	_
14	synergized	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	induction	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IFN	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	gamma	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	GM	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	CSF	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	this	_	O	O	_	_	_	_	_
28	synergy	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	attributed	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	increased	_	O	O	_	_	_	_	_
34	accumulation	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	stability	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	IFN	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	gamma	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	GM	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	CSF	_	O	O	_	_	_	_	_
46	mRNAs	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	signaling	_	O	O	_	_	_	_	_
5	pathways	_	O	O	_	_	_	_	_
6	involved	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	induction	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	five	_	O	O	_	_	_	_	_
13	inhibitors	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	cyclosporin	_	O	O	_	_	_	_	_
16	A	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	CsA	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	transforming	_	O	O	_	_	_	_	_
22	growth	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	beta	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	cycloheximide	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	genistein	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	staurosporine	_	O	O	_	_	_	_	_
33	A	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	were	_	O	O	_	_	_	_	_
36	used	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	analyzing	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	effects	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	2	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	IL	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	12	_	O	O	_	_	_	_	_
49	on	_	O	O	_	_	_	_	_
50	NK	_	O	O	_	_	_	_	_
51	3	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_
53	3	_	O	O	_	_	_	_	_
54	cells	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	new	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	synthesis	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	required	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	induction	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IFN	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	gamma	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	GM	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	CSF	_	O	O	_	_	_	_	_
32	cytoplasmic	_	O	O	_	_	_	_	_
33	mRNA	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	12	_	O	O	_	_	_	_	_
7	induction	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IFN	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	cytoplasmic	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	appears	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	only	_	O	O	_	_	_	_	_
17	partially	_	O	O	_	_	_	_	_
18	depend	_	O	O	_	_	_	_	_
19	on	_	O	O	_	_	_	_	_
20	activation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	protein	_	O	O	_	_	_	_	_
23	kinase	_	O	O	_	_	_	_	_
24	C	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	both	_	O	O	_	_	_	_	_
4	transforming	_	O	O	_	_	_	_	_
5	growth	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	beta	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	genistein	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	tyrosine	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	inhibitor	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	could	_	O	O	_	_	_	_	_
18	suppress	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	12	_	O	O	_	_	_	_	_
26	signaling	_	O	O	_	_	_	_	_
27	but	_	O	O	_	_	_	_	_
28	CsA	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	generally	_	O	O	_	_	_	_	_
31	inactive	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	observed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	suppression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	cytokine	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	these	_	O	O	_	_	_	_	_
13	agents	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	independent	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	inhibition	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	proliferation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	but	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	12	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	factors	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	AP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	regulation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	nuclear	_	O	O	_	_	_	_	_
28	levels	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	these	_	O	O	_	_	_	_	_
31	two	_	O	O	_	_	_	_	_
32	DNA	_	O	O	_	_	_	_	_
33	binding	_	O	O	_	_	_	_	_
34	protein	_	O	O	_	_	_	_	_
35	complexes	_	O	O	_	_	_	_	_
36	is	_	O	O	_	_	_	_	_
37	correlated	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	IFN	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	gamma	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	GM	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	CSF	_	O	O	_	_	_	_	_
46	gene	_	O	O	_	_	_	_	_
47	expression	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	12	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	have	_	O	O	_	_	_	_	_
14	distinct	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	pathways	_	O	O	_	_	_	_	_
17	leading	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	induction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	IFN	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	gamma	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	GM	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	CSF	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	that	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	NK	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	line	_	O	O	_	_	_	_	_
41	may	_	O	O	_	_	_	_	_
42	serve	_	O	O	_	_	_	_	_
43	as	_	O	O	_	_	_	_	_
44	a	_	O	O	_	_	_	_	_
45	novel	_	O	O	_	_	_	_	_
46	model	_	O	O	_	_	_	_	_
47	for	_	O	O	_	_	_	_	_
48	dissecting	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	biochemical	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	molecular	_	O	O	_	_	_	_	_
53	events	_	O	O	_	_	_	_	_
54	involved	_	O	O	_	_	_	_	_
55	in	_	O	O	_	_	_	_	_
56	these	_	O	O	_	_	_	_	_
57	pathways	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_


1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	T	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	extracellular	_	O	O	_	_	_	_	_
9	matrix	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	tenascin	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	Tenascin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	TN	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	extracellular	_	O	O	_	_	_	_	_
8	matrix	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	widely	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	fetus	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	sparingly	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	adult	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	reappears	_	O	O	_	_	_	_	_
25	at	_	O	O	_	_	_	_	_
26	high	_	O	O	_	_	_	_	_
27	levels	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	certain	_	O	O	_	_	_	_	_
30	areas	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	tissue	_	O	O	_	_	_	_	_
33	insult	_	O	O	_	_	_	_	_
34	such	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	tumor	_	O	O	_	_	_	_	_
37	matrices	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	sites	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	wound	_	O	O	_	_	_	_	_
42	healing	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	soluble	_	O	O	_	_	_	_	_
6	TN	_	O	O	_	_	_	_	_
7	inhibits	_	O	O	_	_	_	_	_
8	proliferation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	response	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	Ab	_	O	O	_	_	_	_	_
20	co	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	immobilized	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	extracellular	_	O	O	_	_	_	_	_
26	matrix	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	fibronectin	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	FN	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	TN	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	inhibits	_	O	O	_	_	_	_	_
4	proliferation	_	O	O	_	_	_	_	_
5	driven	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	alpha	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	or	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	phorbol	_	O	O	_	_	_	_	_
17	ester	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	prevents	_	O	O	_	_	_	_	_
26	high	_	O	O	_	_	_	_	_
27	level	_	O	O	_	_	_	_	_
28	induction	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	R	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	presence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	TN	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	culture	_	O	O	_	_	_	_	_
7	medium	_	O	O	_	_	_	_	_
8	does	_	O	O	_	_	_	_	_
9	not	_	O	O	_	_	_	_	_
10	detectably	_	O	O	_	_	_	_	_
11	alter	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	pattern	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	tyrosine	_	O	O	_	_	_	_	_
16	phosphorylation	_	O	O	_	_	_	_	_
17	resulting	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	triggering	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	alpha	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	but	_	O	O	_	_	_	_	_
28	at	_	O	O	_	_	_	_	_
29	later	_	O	O	_	_	_	_	_
30	time	_	O	O	_	_	_	_	_
31	points	_	O	O	_	_	_	_	_
32	prevents	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	appearance	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	functional	_	O	O	_	_	_	_	_
37	NF	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	AT	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	transcription	_	O	O	_	_	_	_	_
42	factor	_	O	O	_	_	_	_	_
43	complexes	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	T	_	O	O	_	_	_	_	_
46	cell	_	O	O	_	_	_	_	_
47	nuclear	_	O	O	_	_	_	_	_
48	extracts	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	consistent	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	postulated	_	O	O	_	_	_	_	_
8	role	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	TN	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	natural	_	O	O	_	_	_	_	_
14	antagonist	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	FN	_	O	O	_	_	_	_	_
17	action	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	suggest	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	responses	_	O	O	_	_	_	_	_
25	occurring	_	O	O	_	_	_	_	_
26	at	_	O	O	_	_	_	_	_
27	tissue	_	O	O	_	_	_	_	_
28	sites	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	TN	_	O	O	_	_	_	_	_
32	is	_	O	O	_	_	_	_	_
33	expressed	_	O	O	_	_	_	_	_
34	could	_	O	O	_	_	_	_	_
35	be	_	O	O	_	_	_	_	_
36	influenced	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	its	_	O	O	_	_	_	_	_
39	presence	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	Cloning	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	murine	_	O	O	_	_	_	_	_
4	TCF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	interacting	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	functional	_	O	O	_	_	_	_	_
18	motifs	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	epsilon	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	receptor	_	O	O	_	_	_	_	_
29	alpha	_	O	O	_	_	_	_	_
30	enhancers	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	epsilon	_	O	O	_	_	_	_	_
5	gene	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	confined	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	lineage	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	recently	_	O	O	_	_	_	_	_
4	identified	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	cloned	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	TCF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	binds	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	functional	_	O	O	_	_	_	_	_
21	element	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	lymphocyte	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	enhancer	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	epsilon	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	panel	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	lines	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	TCF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	restricted	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	lineage	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	TCF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	belonged	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	novel	_	O	O	_	_	_	_	_
8	family	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	genes	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	contain	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	so	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	called	_	O	O	_	_	_	_	_
17	high	_	O	O	_	_	_	_	_
18	mobility	_	O	O	_	_	_	_	_
19	group	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	HMG	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	box	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	cloning	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	murine	_	O	O	_	_	_	_	_
8	TCF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	splice	_	O	O	_	_	_	_	_
3	alternatives	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	identified	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	previously	_	O	O	_	_	_	_	_
10	observed	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	TCF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Murine	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	human	_	O	O	_	_	_	_	_
4	TCF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	displayed	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	95	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	%	_	O	O	_	_	_	_	_
13	overall	_	O	O	_	_	_	_	_
14	amino	_	O	O	_	_	_	_	_
15	acid	_	O	O	_	_	_	_	_
16	homology	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	murine	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	TCF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	recognized	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	same	_	O	O	_	_	_	_	_
11	sequence	_	O	O	_	_	_	_	_
12	motif	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	epsilon	_	O	O	_	_	_	_	_
19	enhancer	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	judged	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	gel	_	O	O	_	_	_	_	_
24	retardation	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	methylation	_	O	O	_	_	_	_	_
27	interference	_	O	O	_	_	_	_	_
28	assays	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	With	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	murine	_	O	O	_	_	_	_	_
4	cDNA	_	O	O	_	_	_	_	_
5	clones	_	O	O	_	_	_	_	_
6	several	_	O	O	_	_	_	_	_
7	aspects	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	TCF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	analyzed	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	First	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	deletion	_	O	O	_	_	_	_	_
4	analysis	_	O	O	_	_	_	_	_
5	revealed	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	region	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	TCF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	containing	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	HMG	_	O	O	_	_	_	_	_
16	box	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	sufficient	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	sequence	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	specific	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Second	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	high	_	O	O	_	_	_	_	_
5	stringency	_	O	O	_	_	_	_	_
6	Northern	_	O	O	_	_	_	_	_
7	blotting	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	situ	_	O	O	_	_	_	_	_
11	hybridization	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	TCF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	shown	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	confined	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	thymus	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	areas	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	spleen	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Third	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	TCF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	bound	_	O	O	_	_	_	_	_
7	specifically	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	functional	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	element	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	receptor	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	TCR	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	enhancer	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	lineage	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	specific	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	affinity	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	functional	_	O	O	_	_	_	_	_
12	motifs	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	TCR	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	epsilon	_	O	O	_	_	_	_	_
23	enhancers	_	O	O	_	_	_	_	_
24	imply	_	O	O	_	_	_	_	_
25	an	_	O	O	_	_	_	_	_
26	important	_	O	O	_	_	_	_	_
27	role	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	TCF	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	establishment	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	mature	_	O	O	_	_	_	_	_
38	T	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	phenotype	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	p	_	O	O	_	_	_	_	_
2	70	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	s	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	k	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	integrates	_	O	O	_	_	_	_	_
9	phosphatidylinositol	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	rapamycin	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	regulated	_	O	O	_	_	_	_	_
17	signals	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	E	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	F	_	O	O	_	_	_	_	_
22	regulation	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	lymphocytes	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	lymphocytes	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	hematopoietic	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	interleukin	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	uses	_	O	O	_	_	_	_	_
17	phosphatidylinositol	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kinase	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	PI	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	induced	_	O	O	_	_	_	_	_
29	signaling	_	O	O	_	_	_	_	_
30	pathways	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	regulate	_	O	O	_	_	_	_	_
33	E	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	F	_	O	O	_	_	_	_	_
36	transcriptional	_	O	O	_	_	_	_	_
37	activity	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	critical	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	cycle	_	O	O	_	_	_	_	_
43	checkpoint	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	PI	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	kinase	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	regulates	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	70	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	s	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	k	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	40	_	O	O	_	_	_	_	_
20	S	_	O	O	_	_	_	_	_
21	ribosomal	_	O	O	_	_	_	_	_
22	protein	_	O	O	_	_	_	_	_
23	S	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	response	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	is	_	O	O	_	_	_	_	_
31	abrogated	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	macrolide	_	O	O	_	_	_	_	_
35	rapamycin	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	immunosuppressive	_	O	O	_	_	_	_	_
3	drug	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	known	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	prevent	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	proliferation	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	precise	_	O	O	_	_	_	_	_
16	point	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	rapamycin	_	O	O	_	_	_	_	_
20	regulates	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	cycle	_	O	O	_	_	_	_	_
25	progression	_	O	O	_	_	_	_	_
26	has	_	O	O	_	_	_	_	_
27	yet	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	be	_	O	O	_	_	_	_	_
30	elucidated	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	rapamycin	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	role	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	70	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	s	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	k	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	PI	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kinase	_	O	O	_	_	_	_	_
30	activation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	E	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	Fs	_	O	O	_	_	_	_	_
35	have	_	O	O	_	_	_	_	_
36	not	_	O	O	_	_	_	_	_
37	been	_	O	O	_	_	_	_	_
38	characterized	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	PI	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	pathways	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	regulation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	E	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	F	_	O	O	_	_	_	_	_
25	transcriptional	_	O	O	_	_	_	_	_
26	activity	_	O	O	_	_	_	_	_
27	include	_	O	O	_	_	_	_	_
28	both	_	O	O	_	_	_	_	_
29	rapamycin	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	resistant	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	rapamycin	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	sensitive	_	O	O	_	_	_	_	_
36	components	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	rapamycin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	resistant	_	O	O	_	_	_	_	_
7	mutant	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	70	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	s	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	k	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	could	_	O	O	_	_	_	_	_
20	restore	_	O	O	_	_	_	_	_
21	rapamycin	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	suppressed	_	O	O	_	_	_	_	_
24	E	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	F	_	O	O	_	_	_	_	_
27	responses	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	rapamycin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	controlled	_	O	O	_	_	_	_	_
7	processes	_	O	O	_	_	_	_	_
8	involved	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	E	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	F	_	O	O	_	_	_	_	_
13	regulation	_	O	O	_	_	_	_	_
14	appear	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	p	_	O	O	_	_	_	_	_
20	70	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	s	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	k	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	rapamycin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	resistant	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	70	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	s	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	k	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	could	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	rescue	_	O	O	_	_	_	_	_
17	rapamycin	_	O	O	_	_	_	_	_
18	inhibition	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	cycle	_	O	O	_	_	_	_	_
24	entry	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	consistent	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	involvement	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	additional	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	rapamycin	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	sensitive	_	O	O	_	_	_	_	_
36	pathways	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	control	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	T	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	cell	_	O	O	_	_	_	_	_
44	cycle	_	O	O	_	_	_	_	_
45	progression	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	thus	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	70	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	s	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	k	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	able	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	regulate	_	O	O	_	_	_	_	_
18	E	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	F	_	O	O	_	_	_	_	_
21	transcriptional	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	provide	_	O	O	_	_	_	_	_
25	direct	_	O	O	_	_	_	_	_
26	evidence	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	first	_	O	O	_	_	_	_	_
30	time	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	link	_	O	O	_	_	_	_	_
34	between	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	receptors	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	PI	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	kinase	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	p	_	O	O	_	_	_	_	_
47	70	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	s	_	O	O	_	_	_	_	_
50	6	_	O	O	_	_	_	_	_
51	k	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	that	_	O	O	_	_	_	_	_
54	regulates	_	O	O	_	_	_	_	_
55	a	_	O	O	_	_	_	_	_
56	crucial	_	O	O	_	_	_	_	_
57	G	_	O	O	_	_	_	_	_
58	1	_	O	O	_	_	_	_	_
59	checkpoint	_	O	O	_	_	_	_	_
60	in	_	O	O	_	_	_	_	_
61	T	_	O	O	_	_	_	_	_
62	lymphocytes	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_


1	Analysis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	modulation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	transcriptional	_	O	O	_	_	_	_	_
7	activity	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	myelopoiesis	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	leukemogenesis	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	Acute	_	O	O	_	_	_	_	_
2	myeloid	_	O	O	_	_	_	_	_
3	leukemia	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	AML	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	still	_	O	O	_	_	_	_	_
9	associated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	mortality	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	60	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	80	_	O	O	_	_	_	_	_
17	%.	_	O	O	_	_	_	_	_

1	AML	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	characterized	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	block	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	myeloid	_	O	O	_	_	_	_	_
9	differentiation	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factors	_	O	O	_	_	_	_	_
4	PU	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	C	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	EBPalpha	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	responsible	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	normal	_	O	O	_	_	_	_	_
15	myeloid	_	O	O	_	_	_	_	_
16	differentiation	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	stem	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	monocytes	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	granulocytes	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	particular	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	PU	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	induces	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	macrophage	_	O	O	_	_	_	_	_
12	colony	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	stimulating	_	O	O	_	_	_	_	_
15	factor	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	M	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	CSF	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	development	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	monocytes	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	whereas	_	O	O	_	_	_	_	_
29	C	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	EBPalpha	_	O	O	_	_	_	_	_
32	increases	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	expression	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	granulocyte	_	O	O	_	_	_	_	_
38	colony	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	stimulating	_	O	O	_	_	_	_	_
41	factor	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	G	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	CSF	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	receptor	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	leads	_	O	O	_	_	_	_	_
50	to	_	O	O	_	_	_	_	_
51	mature	_	O	O	_	_	_	_	_
52	granulocytes	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	AML	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	chromosomal	_	O	O	_	_	_	_	_
5	aberrations	_	O	O	_	_	_	_	_
6	result	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	oncoproteins	_	O	O	_	_	_	_	_
9	such	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	AML	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ETO	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	PML	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	RARalpha	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	activated	_	O	O	_	_	_	_	_
22	Ras	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	can	_	O	O	_	_	_	_	_
26	deregulate	_	O	O	_	_	_	_	_
27	genes	_	O	O	_	_	_	_	_
28	important	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	normal	_	O	O	_	_	_	_	_
31	myelopoiesis	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	AML	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	ETO	_	O	O	_	_	_	_	_
7	can	_	O	O	_	_	_	_	_
8	bind	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	C	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	EBPalpha	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	inhibit	_	O	O	_	_	_	_	_
18	C	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	EBPalpha	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	dependent	_	O	O	_	_	_	_	_
23	transcription	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	block	_	O	O	_	_	_	_	_
27	granulocytic	_	O	O	_	_	_	_	_
28	differentiation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	AML	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	ETO	_	O	O	_	_	_	_	_
7	can	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	synergize	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	AML	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	enhance	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	activity	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	M	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	CSF	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	promoter	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	hand	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	PML	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	RARalpha	_	O	O	_	_	_	_	_
10	fusion	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	causes	_	O	O	_	_	_	_	_
13	transcriptional	_	O	O	_	_	_	_	_
14	repression	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	recruiting	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	corepressor	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	N	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	CoR	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	histone	_	O	O	_	_	_	_	_
26	deacetylase	_	O	O	_	_	_	_	_
27	complex	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	DNA	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	which	_	O	O	_	_	_	_	_
33	results	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	decreased	_	O	O	_	_	_	_	_
36	histone	_	O	O	_	_	_	_	_
37	acetylation	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	repressive	_	O	O	_	_	_	_	_
41	chromatin	_	O	O	_	_	_	_	_
42	organization	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	describe	_	O	O	_	_	_	_	_
4	methods	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	investigate	_	O	O	_	_	_	_	_
7	whether	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	how	_	O	O	_	_	_	_	_
10	signaling	_	O	O	_	_	_	_	_
11	agonists	_	O	O	_	_	_	_	_
12	induce	_	O	O	_	_	_	_	_
13	myeloid	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	how	_	O	O	_	_	_	_	_
17	oncoproteins	_	O	O	_	_	_	_	_
18	might	_	O	O	_	_	_	_	_
19	cause	_	O	O	_	_	_	_	_
20	AML	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	modulating	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	transcription	_	O	O	_	_	_	_	_
27	factors	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	are	_	O	O	_	_	_	_	_
30	pivotal	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	normal	_	O	O	_	_	_	_	_
33	myeloid	_	O	O	_	_	_	_	_
34	development	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Copyright	_	O	O	_	_	_	_	_
2	1999	_	O	O	_	_	_	_	_
3	Academic	_	O	O	_	_	_	_	_
4	Press	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_


1	Microtubules	_	O	O	_	_	_	_	_
2	mediate	_	O	O	_	_	_	_	_
3	cellular	_	O	O	_	_	_	_	_
4	25	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	hydroxyvitamin	_	O	O	_	_	_	_	_
7	D	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	trafficking	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	genomic	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	25	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	dihydroxyvitamin	_	O	O	_	_	_	_	_
20	D	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	normal	_	O	O	_	_	_	_	_
24	human	_	O	O	_	_	_	_	_
25	monocytes	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	genomic	_	O	O	_	_	_	_	_
3	actions	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dihydroxyvitamin	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	25	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	OH	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	D	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	mediated	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	intracellular	_	O	O	_	_	_	_	_
28	vitamin	_	O	O	_	_	_	_	_
29	D	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	VDR	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	immunocytochemistry	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	disruption	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	microtubular	_	O	O	_	_	_	_	_
9	assembly	_	O	O	_	_	_	_	_
10	prevents	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	access	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	sterol	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	VDR	_	O	O	_	_	_	_	_
18	complex	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	role	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	microtubules	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	response	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	25	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	OH	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	D	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	has	_	O	O	_	_	_	_	_
38	not	_	O	O	_	_	_	_	_
39	been	_	O	O	_	_	_	_	_
40	studied	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	viable	_	O	O	_	_	_	_	_
43	cells	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	interaction	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	normal	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	monocytes	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Monocytes	_	O	O	_	_	_	_	_
2	convert	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	OH	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	D	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	25	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	OH	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	D	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	24	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	hydroxylated	_	O	O	_	_	_	_	_
24	metabolites	_	O	O	_	_	_	_	_
25	more	_	O	O	_	_	_	_	_
26	polar	_	O	O	_	_	_	_	_
27	than	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	25	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	OH	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	D	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Microtubule	_	O	O	_	_	_	_	_
2	disruption	_	O	O	_	_	_	_	_
3	totally	_	O	O	_	_	_	_	_
4	abolished	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	ability	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	exogenous	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	25	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	OH	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	suppress	_	O	O	_	_	_	_	_
20	its	_	O	O	_	_	_	_	_
21	own	_	O	O	_	_	_	_	_
22	synthesis	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	induce	_	O	O	_	_	_	_	_
26	24	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	hydroxylase	_	O	O	_	_	_	_	_
29	mRNA	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	activity	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	without	_	O	O	_	_	_	_	_
34	affecting	_	O	O	_	_	_	_	_
35	either	_	O	O	_	_	_	_	_
36	total	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	25	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	OH	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	D	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	uptake	_	O	O	_	_	_	_	_
47	or	_	O	O	_	_	_	_	_
48	maximal	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	25	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	OH	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	2	_	O	O	_	_	_	_	_
56	D	_	O	O	_	_	_	_	_
57	3	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	VDR	_	O	O	_	_	_	_	_
60	binding	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	intact	_	O	O	_	_	_	_	_
4	microtubules	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	essential	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	OH	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	dependent	_	O	O	_	_	_	_	_
19	modulation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	transcription	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	microtubule	_	O	O	_	_	_	_	_
4	disruption	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	decreased	_	O	O	_	_	_	_	_
7	monocyte	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	OH	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	synthesis	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	decreasing	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	Vmax	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	monocyte	_	O	O	_	_	_	_	_
26	mitochondrial	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	hydroxylase	_	O	O	_	_	_	_	_
31	but	_	O	O	_	_	_	_	_
32	through	_	O	O	_	_	_	_	_
33	an	_	O	O	_	_	_	_	_
34	increase	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	Km	_	O	O	_	_	_	_	_
38	for	_	O	O	_	_	_	_	_
39	25	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	OH	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	D	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	examined	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	OH	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	D	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	transport	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Microtubule	_	O	O	_	_	_	_	_
2	disruption	_	O	O	_	_	_	_	_
3	did	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	affect	_	O	O	_	_	_	_	_
6	total	_	O	O	_	_	_	_	_
7	cellular	_	O	O	_	_	_	_	_
8	25	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	OH	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	D	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	uptake	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	reduced	_	O	O	_	_	_	_	_
17	its	_	O	O	_	_	_	_	_
18	intracellular	_	O	O	_	_	_	_	_
19	trafficking	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	mitochondria	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	microtubules	_	O	O	_	_	_	_	_
4	participate	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	intracellular	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	OH	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	transport	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	their	_	O	O	_	_	_	_	_
17	integrity	_	O	O	_	_	_	_	_
18	determines	_	O	O	_	_	_	_	_
19	normal	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	25	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	OH	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	D	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	synthesis	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	HIV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	envelope	_	O	O	_	_	_	_	_
5	glycoproteins	_	O	O	_	_	_	_	_
6	induce	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	published	_	O	O	_	_	_	_	_
21	erratum	_	O	O	_	_	_	_	_
22	appears	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	J	_	O	O	_	_	_	_	_
25	Biol	_	O	O	_	_	_	_	_
26	Chem	_	O	O	_	_	_	_	_
27	1995	_	O	O	_	_	_	_	_
28	Dec	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	;	_	O	O	_	_	_	_	_
31	270	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	48	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	:	_	O	O	_	_	_	_	_
36	29038	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_

1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	positive	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	primary	_	O	O	_	_	_	_	_
11	requirement	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	immunodeficiency	_	O	O	_	_	_	_	_
15	virus	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	HIV	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	entry	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	efficient	_	O	O	_	_	_	_	_
22	HIV	_	O	O	_	_	_	_	_
23	replication	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	progression	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	AIDS	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	Utilizing	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	positive	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	lines	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	purified	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	normal	_	O	O	_	_	_	_	_
43	individuals	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	we	_	O	O	_	_	_	_	_
46	have	_	O	O	_	_	_	_	_
47	demonstrated	_	O	O	_	_	_	_	_
48	that	_	O	O	_	_	_	_	_
49	native	_	O	O	_	_	_	_	_
50	envelope	_	O	O	_	_	_	_	_
51	glycoproteins	_	O	O	_	_	_	_	_
52	of	_	O	O	_	_	_	_	_
53	HIV	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	gp	_	O	O	_	_	_	_	_
56	160	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	can	_	O	O	_	_	_	_	_
59	induce	_	O	O	_	_	_	_	_
60	activation	_	O	O	_	_	_	_	_
61	of	_	O	O	_	_	_	_	_
62	transcription	_	O	O	_	_	_	_	_
63	factor	_	O	O	_	_	_	_	_
64	,	_	O	O	_	_	_	_	_
65	activated	_	O	O	_	_	_	_	_
66	protein	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	1	_	O	O	_	_	_	_	_
69	(	_	O	O	_	_	_	_	_
70	AP	_	O	O	_	_	_	_	_
71	-	_	O	O	_	_	_	_	_
72	1	_	O	O	_	_	_	_	_
73	)	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	stimulatory	_	O	O	_	_	_	_	_
3	effects	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	gp	_	O	O	_	_	_	_	_
6	160	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	through	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	molecule	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	since	_	O	O	_	_	_	_	_
16	treatment	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	gp	_	O	O	_	_	_	_	_
19	160	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	soluble	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	IgG	_	O	O	_	_	_	_	_
26	abrogates	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	negative	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	lines	_	O	O	_	_	_	_	_
37	fail	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	be	_	O	O	_	_	_	_	_
40	stimulated	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	gp	_	O	O	_	_	_	_	_
43	160	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Immunoprecipitation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	gp	_	O	O	_	_	_	_	_
5	160	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	extracts	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	polyclonal	_	O	O	_	_	_	_	_
12	antibodies	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	Fos	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	Jun	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	indicates	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	AP	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	complex	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	comprised	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	members	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	these	_	O	O	_	_	_	_	_
30	family	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	proteins	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	gp	_	O	O	_	_	_	_	_
3	160	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	AP	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	complex	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	upon	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	tyrosine	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	synthesis	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	independent	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	stimulation	_	O	O	_	_	_	_	_
3	can	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	be	_	O	O	_	_	_	_	_
6	abolished	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	inhibitors	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	kinase	_	O	O	_	_	_	_	_
12	C	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	it	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	unaffected	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	calcium	_	O	O	_	_	_	_	_
20	channel	_	O	O	_	_	_	_	_
21	blocker	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	cyclosporine	_	O	O	_	_	_	_	_
24	A	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	gp	_	O	O	_	_	_	_	_
3	160	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	adversely	_	O	O	_	_	_	_	_
6	affects	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	functional	_	O	O	_	_	_	_	_
9	capabilities	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	pre	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	treatment	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	gp	_	O	O	_	_	_	_	_
25	160	_	O	O	_	_	_	_	_
26	for	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	h	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	37	_	O	O	_	_	_	_	_
31	degrees	_	O	O	_	_	_	_	_
32	C	_	O	O	_	_	_	_	_
33	inhibited	_	O	O	_	_	_	_	_
34	anti	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	induced	_	O	O	_	_	_	_	_
40	interleukin	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	secretion	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Effects	_	O	O	_	_	_	_	_
2	similar	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	gp	_	O	O	_	_	_	_	_
5	160	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	seen	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	mAb	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	aberrant	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	AP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	gp	_	O	O	_	_	_	_	_
10	160	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	positive	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	could	_	O	O	_	_	_	_	_
18	result	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	up	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	regulation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	cytokines	_	O	O	_	_	_	_	_
25	containing	_	O	O	_	_	_	_	_
26	AP	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	sites	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	e	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	g	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	granulocyte	_	O	O	_	_	_	_	_
6	macrophage	_	O	O	_	_	_	_	_
7	colony	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	stimulating	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	concurrently	_	O	O	_	_	_	_	_
14	lead	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	unresponsiveness	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	inhibiting	_	O	O	_	_	_	_	_
21	interleukin	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	secretion	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Resistance	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	inhibition	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	interferon	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	production	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	suppressor	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	signaling	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	from	_	O	O	_	_	_	_	_
26	patients	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	rheumatoid	_	O	O	_	_	_	_	_
29	arthritis	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	block	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	antigen	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	inhibiting	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	28	_	O	O	_	_	_	_	_
23	signaling	_	O	O	_	_	_	_	_
24	pathway	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	peripheral	_	O	O	_	_	_	_	_
5	blood	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	patients	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	active	_	O	O	_	_	_	_	_
15	rheumatoid	_	O	O	_	_	_	_	_
16	arthritis	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	able	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	produce	_	O	O	_	_	_	_	_
24	greater	_	O	O	_	_	_	_	_
25	amounts	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	interferon	_	O	O	_	_	_	_	_
28	gamma	_	O	O	_	_	_	_	_
29	after	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	CD	_	O	O	_	_	_	_	_
34	28	_	O	O	_	_	_	_	_
35	costimulation	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	presence	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	ng	_	O	O	_	_	_	_	_
42	/	_	O	O	_	_	_	_	_
43	ml	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	10	_	O	O	_	_	_	_	_
47	than	_	O	O	_	_	_	_	_
48	were	_	O	O	_	_	_	_	_
49	normal	_	O	O	_	_	_	_	_
50	control	_	O	O	_	_	_	_	_
51	CD	_	O	O	_	_	_	_	_
52	4	_	O	O	_	_	_	_	_
53	+	_	O	O	_	_	_	_	_
54	T	_	O	O	_	_	_	_	_
55	cells	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	although	_	O	O	_	_	_	_	_
58	their	_	O	O	_	_	_	_	_
59	surface	_	O	O	_	_	_	_	_
60	expression	_	O	O	_	_	_	_	_
61	of	_	O	O	_	_	_	_	_
62	the	_	O	O	_	_	_	_	_
63	type	_	O	O	_	_	_	_	_
64	1	_	O	O	_	_	_	_	_
65	IL	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	10	_	O	O	_	_	_	_	_
68	receptor	_	O	O	_	_	_	_	_
69	was	_	O	O	_	_	_	_	_
70	increased	_	O	O	_	_	_	_	_
71	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	phosphorylation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	signal	_	O	O	_	_	_	_	_
5	transducer	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	activator	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	sustained	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	blood	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	synovial	_	O	O	_	_	_	_	_
18	tissue	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	RA	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	but	_	O	O	_	_	_	_	_
28	it	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	augmented	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	presence	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	ng	_	O	O	_	_	_	_	_
38	/	_	O	O	_	_	_	_	_
39	ml	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	10	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Sera	_	O	O	_	_	_	_	_
2	from	_	O	O	_	_	_	_	_
3	RA	_	O	O	_	_	_	_	_
4	patients	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	signal	_	O	O	_	_	_	_	_
7	transducer	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	activator	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	normal	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	which	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	mostly	_	O	O	_	_	_	_	_
25	abolished	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	neutralizing	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	antibody	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Preincubation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	normal	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	reduced	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	10	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	mediated	_	O	O	_	_	_	_	_
19	inhibition	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	interferon	_	O	O	_	_	_	_	_
22	gamma	_	O	O	_	_	_	_	_
23	production	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Blood	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	contained	_	O	O	_	_	_	_	_
11	higher	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	suppressor	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	signaling	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	lower	_	O	O	_	_	_	_	_
21	levels	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	suppressor	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	cytokine	_	O	O	_	_	_	_	_
26	signaling	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	mRNA	_	O	O	_	_	_	_	_
29	compared	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	control	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	T	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	as	_	O	O	_	_	_	_	_
39	determined	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	real	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	time	_	O	O	_	_	_	_	_
44	PCR	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	RA	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	become	_	O	O	_	_	_	_	_
12	resistant	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	immunosuppressive	_	O	O	_	_	_	_	_
16	effect	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	before	_	O	O	_	_	_	_	_
22	migration	_	O	O	_	_	_	_	_
23	into	_	O	O	_	_	_	_	_
24	synovial	_	O	O	_	_	_	_	_
25	tissue	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	this	_	O	O	_	_	_	_	_
29	impaired	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	signaling	_	O	O	_	_	_	_	_
34	may	_	O	O	_	_	_	_	_
35	be	_	O	O	_	_	_	_	_
36	associated	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	sustained	_	O	O	_	_	_	_	_
39	signal	_	O	O	_	_	_	_	_
40	transducer	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	activator	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	transcription	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	activation	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	suppressor	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	cytokine	_	O	O	_	_	_	_	_
51	signaling	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	induction	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_



1	Transient	_	O	O	_	_	_	_	_
2	pseudo	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	hypoaldosteronism	_	O	O	_	_	_	_	_
5	following	_	O	O	_	_	_	_	_
6	resection	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	ileum	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	normal	_	O	O	_	_	_	_	_
12	level	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	lymphocytic	_	O	O	_	_	_	_	_
15	aldosterone	_	O	O	_	_	_	_	_
16	receptors	_	O	O	_	_	_	_	_
17	outside	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	acute	_	O	O	_	_	_	_	_
20	phase	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Pseudo	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	hypoaldosteronism	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	PHA	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	due	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	mineralocorticoid	_	O	O	_	_	_	_	_
11	resistance	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	manifests	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	hyponatremia	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	hyperkalemia	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	increased	_	O	O	_	_	_	_	_
20	plasma	_	O	O	_	_	_	_	_
21	aldosterone	_	O	O	_	_	_	_	_
22	levels	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	may	_	O	O	_	_	_	_	_
3	be	_	O	O	_	_	_	_	_
4	familial	_	O	O	_	_	_	_	_
5	or	_	O	O	_	_	_	_	_
6	secondary	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	abnormal	_	O	O	_	_	_	_	_
9	renal	_	O	O	_	_	_	_	_
10	sodium	_	O	O	_	_	_	_	_
11	handling	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	report	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	case	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	54	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	year	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	old	_	O	O	_	_	_	_	_
12	woman	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	multifocal	_	O	O	_	_	_	_	_
15	cancer	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	colon	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	who	_	O	O	_	_	_	_	_
21	developed	_	O	O	_	_	_	_	_
22	PHA	_	O	O	_	_	_	_	_
23	after	_	O	O	_	_	_	_	_
24	subtotal	_	O	O	_	_	_	_	_
25	colectomy	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	ileal	_	O	O	_	_	_	_	_
28	resection	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	jejunostomy	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	She	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	treated	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	g	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	salt	_	O	O	_	_	_	_	_
9	daily	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	prevent	_	O	O	_	_	_	_	_
12	dehydration	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	she	_	O	O	_	_	_	_	_
16	stopped	_	O	O	_	_	_	_	_
17	herself	_	O	O	_	_	_	_	_
18	because	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	reduced	_	O	O	_	_	_	_	_
21	fecal	_	O	O	_	_	_	_	_
22	losses	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	month	_	O	O	_	_	_	_	_
3	later	_	O	O	_	_	_	_	_
4	she	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	admitted	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	signs	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	acute	_	O	O	_	_	_	_	_
11	adrenal	_	O	O	_	_	_	_	_
12	failure	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	i	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	e	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	fatigue	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	severe	_	O	O	_	_	_	_	_
4	nausea	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	pressure	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	80	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	60	_	O	O	_	_	_	_	_
12	mmHg	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	extracellular	_	O	O	_	_	_	_	_
15	dehydration	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	hyponatremia	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	118	_	O	O	_	_	_	_	_
20	mmol	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	l	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	;	_	O	O	_	_	_	_	_
25	hyperkalemia	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	7	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	6	_	O	O	_	_	_	_	_
30	mmol	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	l	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	increased	_	O	O	_	_	_	_	_
36	blood	_	O	O	_	_	_	_	_
37	urea	_	O	O	_	_	_	_	_
38	nitrogen	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	BUN	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	200	_	O	O	_	_	_	_	_
44	mg	_	O	O	_	_	_	_	_
45	/	_	O	O	_	_	_	_	_
46	dl	_	O	O	_	_	_	_	_
47	)	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	creatininemia	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	2	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_
53	5	_	O	O	_	_	_	_	_
54	mg	_	O	O	_	_	_	_	_
55	/	_	O	O	_	_	_	_	_
56	dl	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	and	_	O	O	_	_	_	_	_
60	decreased	_	O	O	_	_	_	_	_
61	plasma	_	O	O	_	_	_	_	_
62	bicarbonates	_	O	O	_	_	_	_	_
63	level	_	O	O	_	_	_	_	_
64	(	_	O	O	_	_	_	_	_
65	HCO	_	O	O	_	_	_	_	_
66	3	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	:	_	O	O	_	_	_	_	_
69	16	_	O	O	_	_	_	_	_
70	mmol	_	O	O	_	_	_	_	_
71	/	_	O	O	_	_	_	_	_
72	l	_	O	O	_	_	_	_	_
73	;	_	O	O	_	_	_	_	_
74	N	_	O	O	_	_	_	_	_
75	:	_	O	O	_	_	_	_	_
76	27	_	O	O	_	_	_	_	_
77	-	_	O	O	_	_	_	_	_
78	30	_	O	O	_	_	_	_	_
79	)	_	O	O	_	_	_	_	_
80	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	plasma	_	O	O	_	_	_	_	_
5	cortisol	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	high	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	66	_	O	O	_	_	_	_	_
10	microg	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	100	_	O	O	_	_	_	_	_
13	ml	_	O	O	_	_	_	_	_
14	at	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	:	_	O	O	_	_	_	_	_
17	00	_	O	O	_	_	_	_	_
18	h	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	N	_	O	O	_	_	_	_	_
21	:	_	O	O	_	_	_	_	_
22	8	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	15	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	ACTH	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	normal	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	13	_	O	O	_	_	_	_	_
33	pg	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	ml	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	N	_	O	O	_	_	_	_	_
38	:	_	O	O	_	_	_	_	_
39	10	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	60	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	;	_	O	O	_	_	_	_	_
44	there	_	O	O	_	_	_	_	_
45	was	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	marked	_	O	O	_	_	_	_	_
48	increase	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	plasma	_	O	O	_	_	_	_	_
51	renin	_	O	O	_	_	_	_	_
52	activity	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	>	_	O	O	_	_	_	_	_
55	37	_	O	O	_	_	_	_	_
56	ng	_	O	O	_	_	_	_	_
57	/	_	O	O	_	_	_	_	_
58	ml	_	O	O	_	_	_	_	_
59	/	_	O	O	_	_	_	_	_
60	h	_	O	O	_	_	_	_	_
61	;	_	O	O	_	_	_	_	_
62	N	_	O	O	_	_	_	_	_
63	supine	_	O	O	_	_	_	_	_
64	<	_	O	O	_	_	_	_	_
65	3	_	O	O	_	_	_	_	_
66	)	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	active	_	O	O	_	_	_	_	_
69	renin	_	O	O	_	_	_	_	_
70	(	_	O	O	_	_	_	_	_
71	869	_	O	O	_	_	_	_	_
72	pg	_	O	O	_	_	_	_	_
73	/	_	O	O	_	_	_	_	_
74	ml	_	O	O	_	_	_	_	_
75	;	_	O	O	_	_	_	_	_
76	N	_	O	O	_	_	_	_	_
77	supine	_	O	O	_	_	_	_	_
78	:	_	O	O	_	_	_	_	_
79	1	_	O	O	_	_	_	_	_
80	.	_	O	O	_	_	_	_	_
81	120	_	O	O	_	_	_	_	_
82	)	_	O	O	_	_	_	_	_
83	,	_	O	O	_	_	_	_	_
84	aldosterone	_	O	O	_	_	_	_	_
85	(	_	O	O	_	_	_	_	_
86	>	_	O	O	_	_	_	_	_
87	2000	_	O	O	_	_	_	_	_
88	pg	_	O	O	_	_	_	_	_
89	/	_	O	O	_	_	_	_	_
90	ml	_	O	O	_	_	_	_	_
91	;	_	O	O	_	_	_	_	_
92	N	_	O	O	_	_	_	_	_
93	supine	_	O	O	_	_	_	_	_
94	<	_	O	O	_	_	_	_	_
95	150	_	O	O	_	_	_	_	_
96	)	_	O	O	_	_	_	_	_
97	and	_	O	O	_	_	_	_	_
98	plasma	_	O	O	_	_	_	_	_
99	AVP	_	O	O	_	_	_	_	_
100	(	_	O	O	_	_	_	_	_
101	20	_	O	O	_	_	_	_	_
102	pmol	_	O	O	_	_	_	_	_
103	/	_	O	O	_	_	_	_	_
104	l	_	O	O	_	_	_	_	_
105	;	_	O	O	_	_	_	_	_
106	N	_	O	O	_	_	_	_	_
107	:	_	O	O	_	_	_	_	_
108	0	_	O	O	_	_	_	_	_
109	.	_	O	O	_	_	_	_	_
110	5	_	O	O	_	_	_	_	_
111	-	_	O	O	_	_	_	_	_
112	2	_	O	O	_	_	_	_	_
113	.	_	O	O	_	_	_	_	_
114	5	_	O	O	_	_	_	_	_
115	)	_	O	O	_	_	_	_	_
116	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	plasma	_	O	O	_	_	_	_	_
3	ANH	_	O	O	_	_	_	_	_
4	level	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	pmol	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	l	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	N	_	O	O	_	_	_	_	_
12	supine	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	25	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	urinary	_	O	O	_	_	_	_	_
3	steroidogram	_	O	O	_	_	_	_	_
4	resulted	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	highly	_	O	O	_	_	_	_	_
7	elevated	_	O	O	_	_	_	_	_
8	tetrahydrocortisol	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	THF	_	O	O	_	_	_	_	_
11	:	_	O	O	_	_	_	_	_
12	13	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	mg	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	24	_	O	O	_	_	_	_	_
18	h	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	N	_	O	O	_	_	_	_	_
21	:	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	4	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	0	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	8	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	no	_	O	O	_	_	_	_	_
34	increase	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	tetrahydrocortisone	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	THE	_	O	O	_	_	_	_	_
39	:	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	16	_	O	O	_	_	_	_	_
43	mg	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	24	_	O	O	_	_	_	_	_
46	h	_	O	O	_	_	_	_	_
47	;	_	O	O	_	_	_	_	_
48	N	_	O	O	_	_	_	_	_
49	:	_	O	O	_	_	_	_	_
50	2	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_
52	7	_	O	O	_	_	_	_	_
53	+	_	O	O	_	_	_	_	_
54	/	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	2	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_
58	0	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	excretion	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	and	_	O	O	_	_	_	_	_
63	with	_	O	O	_	_	_	_	_
64	low	_	O	O	_	_	_	_	_
65	THE	_	O	O	_	_	_	_	_
66	/	_	O	O	_	_	_	_	_
67	THF	_	O	O	_	_	_	_	_
68	(	_	O	O	_	_	_	_	_
69	0	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_
71	24	_	O	O	_	_	_	_	_
72	;	_	O	O	_	_	_	_	_
73	N	_	O	O	_	_	_	_	_
74	:	_	O	O	_	_	_	_	_
75	1	_	O	O	_	_	_	_	_
76	.	_	O	O	_	_	_	_	_
77	87	_	O	O	_	_	_	_	_
78	+	_	O	O	_	_	_	_	_
79	/	_	O	O	_	_	_	_	_
80	-	_	O	O	_	_	_	_	_
81	0	_	O	O	_	_	_	_	_
82	.	_	O	O	_	_	_	_	_
83	36	_	O	O	_	_	_	_	_
84	)	_	O	O	_	_	_	_	_
85	and	_	O	O	_	_	_	_	_
86	alpha	_	O	O	_	_	_	_	_
87	THF	_	O	O	_	_	_	_	_
88	/	_	O	O	_	_	_	_	_
89	THF	_	O	O	_	_	_	_	_
90	(	_	O	O	_	_	_	_	_
91	0	_	O	O	_	_	_	_	_
92	.	_	O	O	_	_	_	_	_
93	35	_	O	O	_	_	_	_	_
94	;	_	O	O	_	_	_	_	_
95	N	_	O	O	_	_	_	_	_
96	:	_	O	O	_	_	_	_	_
97	0	_	O	O	_	_	_	_	_
98	.	_	O	O	_	_	_	_	_
99	92	_	O	O	_	_	_	_	_
100	+	_	O	O	_	_	_	_	_
101	/	_	O	O	_	_	_	_	_
102	-	_	O	O	_	_	_	_	_
103	0	_	O	O	_	_	_	_	_
104	.	_	O	O	_	_	_	_	_
105	42	_	O	O	_	_	_	_	_
106	)	_	O	O	_	_	_	_	_
107	ratios	_	O	O	_	_	_	_	_
108	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	number	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	mineralocorticoid	_	O	O	_	_	_	_	_
5	receptors	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	mononuclear	_	O	O	_	_	_	_	_
8	leukocytes	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	lower	_	O	O	_	_	_	_	_
13	normal	_	O	O	_	_	_	_	_
14	range	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	age	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	while	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	number	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	glucocorticoid	_	O	O	_	_	_	_	_
23	receptors	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	reduced	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Small	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	bowel	_	O	O	_	_	_	_	_
4	resection	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	ileostomized	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	causes	_	O	O	_	_	_	_	_
9	excessive	_	O	O	_	_	_	_	_
10	fecal	_	O	O	_	_	_	_	_
11	sodium	_	O	O	_	_	_	_	_
12	losses	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	results	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	chronic	_	O	O	_	_	_	_	_
17	sodium	_	O	O	_	_	_	_	_
18	depletion	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	contraction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	plasma	_	O	O	_	_	_	_	_
24	volume	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	severe	_	O	O	_	_	_	_	_
27	secondary	_	O	O	_	_	_	_	_
28	hyperaldosteronism	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Nevertheless	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	hyperaldosteronism	_	O	O	_	_	_	_	_
5	may	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	associated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	hyponatremia	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	hyperkalemia	_	O	O	_	_	_	_	_
12	suggesting	_	O	O	_	_	_	_	_
13	PHA	_	O	O	_	_	_	_	_
14	related	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	major	_	O	O	_	_	_	_	_
18	importance	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	colon	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	absorption	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	sodium	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	case	_	O	O	_	_	_	_	_
6	report	_	O	O	_	_	_	_	_
7	emphasizes	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	possibility	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	syndrome	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	acquired	_	O	O	_	_	_	_	_
17	PHA	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	severe	_	O	O	_	_	_	_	_
20	hyperkalemia	_	O	O	_	_	_	_	_
21	after	_	O	O	_	_	_	_	_
22	resection	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	ileum	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	colon	_	O	O	_	_	_	_	_
28	responding	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	oral	_	O	O	_	_	_	_	_
31	salt	_	O	O	_	_	_	_	_
32	supplementation	_	O	O	_	_	_	_	_
33	;	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	major	_	O	O	_	_	_	_	_
38	increase	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	AVP	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	small	_	O	O	_	_	_	_	_
44	increase	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	ANH	_	O	O	_	_	_	_	_
47	;	_	O	O	_	_	_	_	_
48	3	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	strong	_	O	O	_	_	_	_	_
52	increase	_	O	O	_	_	_	_	_
53	in	_	O	O	_	_	_	_	_
54	urinary	_	O	O	_	_	_	_	_
55	THF	_	O	O	_	_	_	_	_
56	with	_	O	O	_	_	_	_	_
57	low	_	O	O	_	_	_	_	_
58	THE	_	O	O	_	_	_	_	_
59	/	_	O	O	_	_	_	_	_
60	THF	_	O	O	_	_	_	_	_
61	and	_	O	O	_	_	_	_	_
62	alpha	_	O	O	_	_	_	_	_
63	THF	_	O	O	_	_	_	_	_
64	/	_	O	O	_	_	_	_	_
65	THF	_	O	O	_	_	_	_	_
66	ratios	_	O	O	_	_	_	_	_
67	;	_	O	O	_	_	_	_	_
68	4	_	O	O	_	_	_	_	_
69	)	_	O	O	_	_	_	_	_
70	the	_	O	O	_	_	_	_	_
71	normal	_	O	O	_	_	_	_	_
72	number	_	O	O	_	_	_	_	_
73	of	_	O	O	_	_	_	_	_
74	lymphocytic	_	O	O	_	_	_	_	_
75	mineralocorticoid	_	O	O	_	_	_	_	_
76	receptors	_	O	O	_	_	_	_	_
77	outside	_	O	O	_	_	_	_	_
78	the	_	O	O	_	_	_	_	_
79	acute	_	O	O	_	_	_	_	_
80	episode	_	O	O	_	_	_	_	_
81	.	_	O	O	_	_	_	_	_


1	PU	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	Spi	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	C	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	EBP	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	regulate	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	granulocyte	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	macrophage	_	O	O	_	_	_	_	_
21	colony	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	stimulating	_	O	O	_	_	_	_	_
24	factor	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	alpha	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Growth	_	O	O	_	_	_	_	_
2	factor	_	O	O	_	_	_	_	_
3	receptors	_	O	O	_	_	_	_	_
4	play	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	important	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	hematopoiesis	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	order	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	further	_	O	O	_	_	_	_	_
5	understand	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	mechanisms	_	O	O	_	_	_	_	_
8	directing	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	these	_	O	O	_	_	_	_	_
13	key	_	O	O	_	_	_	_	_
14	regulators	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	hematopoiesis	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	we	_	O	O	_	_	_	_	_
19	initiated	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	study	_	O	O	_	_	_	_	_
22	investigating	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	factors	_	O	O	_	_	_	_	_
26	activating	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	granulocyte	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	macrophage	_	O	O	_	_	_	_	_
34	colony	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	stimulating	_	O	O	_	_	_	_	_
37	factor	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	GM	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	CSF	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	receptor	_	O	O	_	_	_	_	_
44	alpha	_	O	O	_	_	_	_	_
45	gene	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	GM	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CSF	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	promoter	_	O	O	_	_	_	_	_
14	directs	_	O	O	_	_	_	_	_
15	reporter	_	O	O	_	_	_	_	_
16	gene	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	tissue	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	specific	_	O	O	_	_	_	_	_
23	fashion	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	myelomonocytic	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	which	_	O	O	_	_	_	_	_
29	correlates	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	its	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	pattern	_	O	O	_	_	_	_	_
34	as	_	O	O	_	_	_	_	_
35	analyzed	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	reverse	_	O	O	_	_	_	_	_
38	transcription	_	O	O	_	_	_	_	_
39	PCR	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	GM	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	CSF	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	promoter	_	O	O	_	_	_	_	_
8	contains	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	important	_	O	O	_	_	_	_	_
11	functional	_	O	O	_	_	_	_	_
12	site	_	O	O	_	_	_	_	_
13	between	_	O	O	_	_	_	_	_
14	positions	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	53	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	41	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	identified	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	deletion	_	O	O	_	_	_	_	_
24	analysis	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	reporter	_	O	O	_	_	_	_	_
27	constructs	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	myeloid	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	PU	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	binds	_	O	O	_	_	_	_	_
15	specifically	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	this	_	O	O	_	_	_	_	_
18	site	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	CCAAT	_	O	O	_	_	_	_	_
8	site	_	O	O	_	_	_	_	_
9	located	_	O	O	_	_	_	_	_
10	upstream	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	PU	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	site	_	O	O	_	_	_	_	_
17	between	_	O	O	_	_	_	_	_
18	positions	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	70	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	54	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	involved	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	positive	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	negative	_	O	O	_	_	_	_	_
30	regulation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	GM	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	CSF	_	O	O	_	_	_	_	_
36	receptor	_	O	O	_	_	_	_	_
37	alpha	_	O	O	_	_	_	_	_
38	promoter	_	O	O	_	_	_	_	_
39	activity	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	C	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	EBP	_	O	O	_	_	_	_	_
4	alpha	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	major	_	O	O	_	_	_	_	_
8	CCAAT	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	enhancer	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	C	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	EBP	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	form	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	this	_	O	O	_	_	_	_	_
23	site	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	nuclear	_	O	O	_	_	_	_	_
26	extracts	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	U	_	O	O	_	_	_	_	_
29	937	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Point	_	O	O	_	_	_	_	_
2	mutations	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	either	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	PU	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	site	_	O	O	_	_	_	_	_
10	or	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	C	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	EBP	_	O	O	_	_	_	_	_
15	site	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	abolish	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	respective	_	O	O	_	_	_	_	_
23	factors	_	O	O	_	_	_	_	_
24	result	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	significant	_	O	O	_	_	_	_	_
28	decrease	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	GM	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	CSF	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	alpha	_	O	O	_	_	_	_	_
35	promoter	_	O	O	_	_	_	_	_
36	activity	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	myelomonocytic	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	only	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	myeloid	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	extracts	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	PU	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	forms	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	novel	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	specific	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	more	_	O	O	_	_	_	_	_
23	slowly	_	O	O	_	_	_	_	_
24	migrating	_	O	O	_	_	_	_	_
25	complex	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	PU	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	SF	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	when	_	O	O	_	_	_	_	_
32	binding	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	GM	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	CSF	_	O	O	_	_	_	_	_
37	receptor	_	O	O	_	_	_	_	_
38	alpha	_	O	O	_	_	_	_	_
39	promoter	_	O	O	_	_	_	_	_
40	PU	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	site	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	first	_	O	O	_	_	_	_	_
5	demonstration	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	specific	_	O	O	_	_	_	_	_
9	interaction	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	PU	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	myeloid	_	O	O	_	_	_	_	_
17	PU	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	site	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	novel	_	O	O	_	_	_	_	_
3	complex	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	distinct	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	described	_	O	O	_	_	_	_	_
9	previously	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	enhancer	_	O	O	_	_	_	_	_
16	sites	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	can	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	formed	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	addition	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	PU	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	extracts	_	O	O	_	_	_	_	_
29	from	_	O	O	_	_	_	_	_
30	certain	_	O	O	_	_	_	_	_
31	nonmyeloid	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	types	_	O	O	_	_	_	_	_
34	which	_	O	O	_	_	_	_	_
35	do	_	O	O	_	_	_	_	_
36	not	_	O	O	_	_	_	_	_
37	express	_	O	O	_	_	_	_	_
38	PU	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	including	_	O	O	_	_	_	_	_
43	T	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	epithelial	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	but	_	O	O	_	_	_	_	_
50	not	_	O	O	_	_	_	_	_
51	from	_	O	O	_	_	_	_	_
52	erythroid	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	PU	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	SF	_	O	O	_	_	_	_	_
10	complex	_	O	O	_	_	_	_	_
11	binds	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	PU	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	sites	_	O	O	_	_	_	_	_
17	found	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	number	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	myeloid	_	O	O	_	_	_	_	_
23	promoters	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	its	_	O	O	_	_	_	_	_
27	formation	_	O	O	_	_	_	_	_
28	requires	_	O	O	_	_	_	_	_
29	an	_	O	O	_	_	_	_	_
30	intact	_	O	O	_	_	_	_	_
31	PU	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	site	_	O	O	_	_	_	_	_
35	adjacent	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	single	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	stranded	_	O	O	_	_	_	_	_
41	region	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	PU	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	nonmyeloid	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	can	_	O	O	_	_	_	_	_
10	activate	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	GM	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	CSF	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	promoter	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Deletion	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	amino	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	terminal	_	O	O	_	_	_	_	_
7	region	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	PU	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	results	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	failure	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	form	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	PU	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	SF	_	O	O	_	_	_	_	_
22	complex	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	concomitant	_	O	O	_	_	_	_	_
27	loss	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	transactivation	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	suggesting	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	formation	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	PU	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	SF	_	O	O	_	_	_	_	_
39	complex	_	O	O	_	_	_	_	_
40	is	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	functional	_	O	O	_	_	_	_	_
43	importance	_	O	O	_	_	_	_	_
44	for	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	activity	_	O	O	_	_	_	_	_
47	of	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	GM	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	CSF	_	O	O	_	_	_	_	_
52	receptor	_	O	O	_	_	_	_	_
53	alpha	_	O	O	_	_	_	_	_
54	promoter	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	C	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	EBP	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	can	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	active	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	GM	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CSF	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	promoter	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	nonmyeloid	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	ABSTRACT	_	O	O	_	_	_	_	_
3	TRUNCATED	_	O	O	_	_	_	_	_
4	AT	_	O	O	_	_	_	_	_
5	400	_	O	O	_	_	_	_	_
6	WORDS	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_

1	Discussion	_	O	O	_	_	_	_	_

1	Animal	_	O	O	_	_	_	_	_
2	models	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	sepsis	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	myocardial	_	O	O	_	_	_	_	_
7	injury	_	O	O	_	_	_	_	_
8	suggest	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	--	_	O	O	_	_	_	_	_
15	>	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	D	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	glucan	_	O	O	_	_	_	_	_
21	like	_	O	O	_	_	_	_	_
22	GP	_	O	O	_	_	_	_	_
23	mediates	_	O	O	_	_	_	_	_
24	its	_	O	O	_	_	_	_	_
25	protective	_	O	O	_	_	_	_	_
26	mechanisms	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	part	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	via	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	rapid	_	O	O	_	_	_	_	_
34	shift	_	O	O	_	_	_	_	_
35	from	_	O	O	_	_	_	_	_
36	NFkappaB	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	PI	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	K	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	signaling	_	O	O	_	_	_	_	_
44	[	_	O	O	_	_	_	_	_
45	22	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	37	_	O	O	_	_	_	_	_
48	]	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	provides	_	O	O	_	_	_	_	_
4	novel	_	O	O	_	_	_	_	_
5	evidence	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	downstream	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	recognition	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	signaling	_	O	O	_	_	_	_	_
12	pro	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	inflammatory	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	cytokine	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	leukocytes	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	switched	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	inflammatory	_	O	O	_	_	_	_	_
31	phenotype	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	GP	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	confirmed	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	extended	_	O	O	_	_	_	_	_
5	previous	_	O	O	_	_	_	_	_
6	results	_	O	O	_	_	_	_	_
7	[	_	O	O	_	_	_	_	_
8	13	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	16	_	O	O	_	_	_	_	_
11	]	_	O	O	_	_	_	_	_
12	indicating	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	absence	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	other	_	O	O	_	_	_	_	_
20	stimuli	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	beta	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	--	_	O	O	_	_	_	_	_
26	>	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	D	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	glucans	_	O	O	_	_	_	_	_
32	induced	_	O	O	_	_	_	_	_
33	binding	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	NFkappaB	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	NFIL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	6	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	NFAT	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	mers	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	cytokine	_	O	O	_	_	_	_	_
48	promoters	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	multiple	_	O	O	_	_	_	_	_
5	band	_	O	O	_	_	_	_	_
6	shifts	_	O	O	_	_	_	_	_
7	observed	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	NFAT	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	Fig	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	one	_	O	O	_	_	_	_	_
6	could	_	O	O	_	_	_	_	_
7	speculate	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	there	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	several	_	O	O	_	_	_	_	_
14	different	_	O	O	_	_	_	_	_
15	NFAT	_	O	O	_	_	_	_	_
16	isoforms	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	probably	_	O	O	_	_	_	_	_
19	derived	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	alternative	_	O	O	_	_	_	_	_
22	splicing	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	38	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	transformed	_	O	O	_	_	_	_	_
11	only	_	O	O	_	_	_	_	_
12	into	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	very	_	O	O	_	_	_	_	_
15	limited	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	namely	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	8	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	RA	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	Fig	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	Hence	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	our	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	aggreement	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	few	_	O	O	_	_	_	_	_
11	reports	_	O	O	_	_	_	_	_
12	describing	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	--	_	O	O	_	_	_	_	_
18	>	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	D	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	glucan	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	mediated	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	8	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	16	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	19	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	RA	_	O	O	_	_	_	_	_
41	production	_	O	O	_	_	_	_	_
42	[	_	O	O	_	_	_	_	_
43	17	_	O	O	_	_	_	_	_
44	]	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	EMSA	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	supershift	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	immunoblotting	_	O	O	_	_	_	_	_
10	results	_	O	O	_	_	_	_	_
11	demonstrated	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	GP	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	mediated	_	O	O	_	_	_	_	_
16	predominant	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	NFkappaB	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	65	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	lesser	_	O	O	_	_	_	_	_
26	extent	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	50	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	kappaB	_	O	O	_	_	_	_	_
33	consensus	_	O	O	_	_	_	_	_
34	site	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	8	_	O	O	_	_	_	_	_
40	promoter	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	Figs	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	Results	_	O	O	_	_	_	_	_
2	by	_	O	O	_	_	_	_	_
3	Schulte	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	colleagues	_	O	O	_	_	_	_	_
6	[	_	O	O	_	_	_	_	_
7	28	_	O	O	_	_	_	_	_
8	]	_	O	O	_	_	_	_	_
9	pointed	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	induction	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	8	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	depending	_	O	O	_	_	_	_	_
19	on	_	O	O	_	_	_	_	_
20	activation	_	O	O	_	_	_	_	_
21	via	_	O	O	_	_	_	_	_
22	an	_	O	O	_	_	_	_	_
23	NFkappaB	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	65	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	65	_	O	O	_	_	_	_	_
28	homodimer	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	rather	_	O	O	_	_	_	_	_
31	than	_	O	O	_	_	_	_	_
32	via	_	O	O	_	_	_	_	_
33	p	_	O	O	_	_	_	_	_
34	65	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	50	_	O	O	_	_	_	_	_
37	heterodimers	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	which	_	O	O	_	_	_	_	_
40	might	_	O	O	_	_	_	_	_
41	be	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	case	_	O	O	_	_	_	_	_
44	for	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	GP	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	mediated	_	O	O	_	_	_	_	_
49	IL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	8	_	O	O	_	_	_	_	_
52	transcription	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	8	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	based	_	O	O	_	_	_	_	_
10	upon	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	cooperation	_	O	O	_	_	_	_	_
13	between	_	O	O	_	_	_	_	_
14	transactivated	_	O	O	_	_	_	_	_
15	NFkappaB	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	65	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	NFIL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	13	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	39	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	NFATc	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	dimer	_	O	O	_	_	_	_	_
31	binding	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	8	_	O	O	_	_	_	_	_
37	kappaB	_	O	O	_	_	_	_	_
38	site	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	38	_	O	O	_	_	_	_	_
41	]	_	O	O	_	_	_	_	_
42	seems	_	O	O	_	_	_	_	_
43	also	_	O	O	_	_	_	_	_
44	possible	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	8	_	O	O	_	_	_	_	_
5	kappaB	_	O	O	_	_	_	_	_
6	consensus	_	O	O	_	_	_	_	_
7	site	_	O	O	_	_	_	_	_
8	exhibits	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	preferentially	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	65	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	half	_	O	O	_	_	_	_	_
15	site	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	thus	_	O	O	_	_	_	_	_
18	differs	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	kappaB	_	O	O	_	_	_	_	_
22	half	_	O	O	_	_	_	_	_
23	site	_	O	O	_	_	_	_	_
24	described	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	TNFalpha	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	beta	_	O	O	_	_	_	_	_
32	[	_	O	O	_	_	_	_	_
33	27	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	40	_	O	O	_	_	_	_	_
36	]	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	supporting	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	idea	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	regulating	_	O	O	_	_	_	_	_
43	NFkappaB	_	O	O	_	_	_	_	_
44	binding	_	O	O	_	_	_	_	_
45	through	_	O	O	_	_	_	_	_
46	combinatorial	_	O	O	_	_	_	_	_
47	associations	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	subunits	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	the	_	O	O	_	_	_	_	_
53	specific	_	O	O	_	_	_	_	_
54	sequence	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	decameric	_	O	O	_	_	_	_	_
58	kappaB	_	O	O	_	_	_	_	_
59	motif	_	O	O	_	_	_	_	_
60	[	_	O	O	_	_	_	_	_
61	41	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	42	_	O	O	_	_	_	_	_
64	]	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	Unlike	_	O	O	_	_	_	_	_
2	LPS	_	O	O	_	_	_	_	_
3	or	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	found	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	GP	_	O	O	_	_	_	_	_
12	did	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	induce	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	beta	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	it	_	O	O	_	_	_	_	_
22	strongly	_	O	O	_	_	_	_	_
23	induced	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	RA	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	suggesting	_	O	O	_	_	_	_	_
30	an	_	O	O	_	_	_	_	_
31	immediate	_	O	O	_	_	_	_	_
32	anti	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	inflammatory	_	O	O	_	_	_	_	_
35	potential	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	GP	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Analysing	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	promoter	_	O	O	_	_	_	_	_
8	[	_	O	O	_	_	_	_	_
9	34	_	O	O	_	_	_	_	_
10	]	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	discovered	_	O	O	_	_	_	_	_
14	four	_	O	O	_	_	_	_	_
15	new	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	sites	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	Fig	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	8	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	:	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	NFkappaB	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	site	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	between	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	100	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	130	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	NFkappaB	_	O	O	_	_	_	_	_
19	consensus	_	O	O	_	_	_	_	_
20	site	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	266	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	280	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	another	_	O	O	_	_	_	_	_
30	NFkappaB	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	site	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	288	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	302	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	more	_	O	O	_	_	_	_	_
45	distal	_	O	O	_	_	_	_	_
46	NFATP	_	O	O	_	_	_	_	_
47	2	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	3	_	O	O	_	_	_	_	_
50	site	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	471	_	O	O	_	_	_	_	_
54	and	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	490	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	leads	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	primarily	_	O	O	_	_	_	_	_
15	via	_	O	O	_	_	_	_	_
16	induction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	NFATP	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	NFIL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	DNA	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	which	_	O	O	_	_	_	_	_
30	might	_	O	O	_	_	_	_	_
31	be	_	O	O	_	_	_	_	_
32	due	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	differences	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	motif	_	O	O	_	_	_	_	_
39	or	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	composition	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	activated	_	O	O	_	_	_	_	_
45	transcription	_	O	O	_	_	_	_	_
46	factors	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	NFAT	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	between	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	IFNgamma	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	IL	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	6	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	IL	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	1	_	O	O	_	_	_	_	_
61	RA	_	O	O	_	_	_	_	_
62	promoter	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	differential	_	O	O	_	_	_	_	_
3	decrease	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	NFkappaB	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	NFAT	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	NFIL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	promoter	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	well	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	mRNA	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	protein	_	O	O	_	_	_	_	_
33	induced	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	selective	_	O	O	_	_	_	_	_
36	inhibitors	_	O	O	_	_	_	_	_
37	prior	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	GP	_	O	O	_	_	_	_	_
40	treatment	_	O	O	_	_	_	_	_
41	might	_	O	O	_	_	_	_	_
42	suggest	_	O	O	_	_	_	_	_
43	that	_	O	O	_	_	_	_	_
44	these	_	O	O	_	_	_	_	_
45	steps	_	O	O	_	_	_	_	_
46	are	_	O	O	_	_	_	_	_
47	linked	_	O	O	_	_	_	_	_
48	to	_	O	O	_	_	_	_	_
49	each	_	O	O	_	_	_	_	_
50	other	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	necessary	_	O	O	_	_	_	_	_
53	for	_	O	O	_	_	_	_	_
54	induction	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	1	_	O	O	_	_	_	_	_
59	RA	_	O	O	_	_	_	_	_
60	(	_	O	O	_	_	_	_	_
61	Fig	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	Regarding	_	O	O	_	_	_	_	_
2	cellular	_	O	O	_	_	_	_	_
3	sources	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	both	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	monocytes	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	well	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	neutrophils	_	O	O	_	_	_	_	_
12	have	_	O	O	_	_	_	_	_
13	been	_	O	O	_	_	_	_	_
14	reported	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	produce	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	32	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Flow	_	O	O	_	_	_	_	_
2	cytometric	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	seemed	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	confirm	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	monocytes	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	neutrophils	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	able	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	produce	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	just	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	response	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	GP	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	data	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	shown	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	cytokine	_	O	O	_	_	_	_	_
6	profile	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	substantially	_	O	O	_	_	_	_	_
9	more	_	O	O	_	_	_	_	_
10	restricted	_	O	O	_	_	_	_	_
11	than	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	TSST	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	which	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	likely	_	O	O	_	_	_	_	_
23	due	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	differences	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	recognition	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	signaling	_	O	O	_	_	_	_	_
30	between	_	O	O	_	_	_	_	_
31	LPS	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	TSST	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	GP	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Recognition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	mainly	_	O	O	_	_	_	_	_
6	mediated	_	O	O	_	_	_	_	_
7	through	_	O	O	_	_	_	_	_
8	Toll	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	like	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	subsequent	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	via	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	NFkappaB	_	O	O	_	_	_	_	_
19	pathway	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	leading	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	pro	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	inflammatory	_	O	O	_	_	_	_	_
28	mediators	_	O	O	_	_	_	_	_
29	like	_	O	O	_	_	_	_	_
30	TNFalpha	_	O	O	_	_	_	_	_
31	[	_	O	O	_	_	_	_	_
32	43	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	bacterial	_	O	O	_	_	_	_	_
3	superantigen	_	O	O	_	_	_	_	_
4	like	_	O	O	_	_	_	_	_
5	TSST	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	acts	_	O	O	_	_	_	_	_
9	through	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	MHC	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	II	_	O	O	_	_	_	_	_
15	molecules	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	subsequently	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	leading	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	release	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	mainly	_	O	O	_	_	_	_	_
28	IFNgamma	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	TNFalpha	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	latter	_	O	O	_	_	_	_	_
34	via	_	O	O	_	_	_	_	_
35	both	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	PI	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	K	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	p	_	O	O	_	_	_	_	_
42	38	_	O	O	_	_	_	_	_
43	mitogen	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	activated	_	O	O	_	_	_	_	_
46	kinase	_	O	O	_	_	_	_	_
47	signaling	_	O	O	_	_	_	_	_
48	[	_	O	O	_	_	_	_	_
49	44	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	45	_	O	O	_	_	_	_	_
52	]	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Altogether	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	induction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	neutrophil	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	attracting	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	8	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	anti	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	inflammatory	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	fungal	_	O	O	_	_	_	_	_
24	carbohydrates	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	may	_	O	O	_	_	_	_	_
29	well	_	O	O	_	_	_	_	_
30	fit	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	benign	_	O	O	_	_	_	_	_
34	PAMP	_	O	O	_	_	_	_	_
35	response	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	mounting	_	O	O	_	_	_	_	_
38	defensive	_	O	O	_	_	_	_	_
39	mechanisms	_	O	O	_	_	_	_	_
40	against	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	possible	_	O	O	_	_	_	_	_
43	microbial	_	O	O	_	_	_	_	_
44	attack	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_


1	Potentially	_	O	O	_	_	_	_	_
2	even	_	O	O	_	_	_	_	_
3	more	_	O	O	_	_	_	_	_
4	relevant	_	O	O	_	_	_	_	_
5	than	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	specific	_	O	O	_	_	_	_	_
8	cytokine	_	O	O	_	_	_	_	_
9	panel	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	GP	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	we	_	O	O	_	_	_	_	_
15	found	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	presence	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	other	_	O	O	_	_	_	_	_
23	stimuli	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	or	_	O	O	_	_	_	_	_
27	TSST	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	GP	_	O	O	_	_	_	_	_
33	ameliorated	_	O	O	_	_	_	_	_
34	their	_	O	O	_	_	_	_	_
35	pro	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	inflammatory	_	O	O	_	_	_	_	_
38	immune	_	O	O	_	_	_	_	_
39	reactions	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	similar	_	O	O	_	_	_	_	_
42	to	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	effects	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	murine	_	O	O	_	_	_	_	_
47	models	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	sepsis	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	inflammation	_	O	O	_	_	_	_	_
52	[	_	O	O	_	_	_	_	_
53	21	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	24	_	O	O	_	_	_	_	_
56	]	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	Mainly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	GP	_	O	O	_	_	_	_	_
4	altered	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	TSST	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	ratio	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	pro	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	anti	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	inflammatory	_	O	O	_	_	_	_	_
30	profile	_	O	O	_	_	_	_	_
31	via	_	O	O	_	_	_	_	_
32	down	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	regulation	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	beta	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	6	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	at	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	same	_	O	O	_	_	_	_	_
48	time	_	O	O	_	_	_	_	_
49	there	_	O	O	_	_	_	_	_
50	was	_	O	O	_	_	_	_	_
51	a	_	O	O	_	_	_	_	_
52	synergistic	_	O	O	_	_	_	_	_
53	up	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	regulation	_	O	O	_	_	_	_	_
56	of	_	O	O	_	_	_	_	_
57	IL	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	1	_	O	O	_	_	_	_	_
60	RA	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	part	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	change	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	caused	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	mediated	_	O	O	_	_	_	_	_
13	modulations	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	TSST	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	NFkappaB	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	NFIL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	NFAT	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	known	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	up	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	now	_	O	O	_	_	_	_	_
35	unknown	_	O	O	_	_	_	_	_
36	sites	_	O	O	_	_	_	_	_
37	within	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	8	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	RA	_	O	O	_	_	_	_	_
47	promoter	_	O	O	_	_	_	_	_
48	instead	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	TNFalpha	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	IL	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	beta	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	IL	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	6	_	O	O	_	_	_	_	_
61	or	_	O	O	_	_	_	_	_
62	IFNgamma	_	O	O	_	_	_	_	_
63	promoter	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	Accordingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	found	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	TSST	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NFkappaB	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	sites	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	TNFalpha	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	negatively	_	O	O	_	_	_	_	_
22	correlated	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	GP	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	mediated	_	O	O	_	_	_	_	_
28	enhancement	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	TSST	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	RA	_	O	O	_	_	_	_	_
40	production	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	r	_	O	O	_	_	_	_	_
43	=	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	0	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_
47	88	_	O	O	_	_	_	_	_
48	;	_	O	O	_	_	_	_	_
49	p	_	O	O	_	_	_	_	_
50	<	_	O	O	_	_	_	_	_
51	0	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_
53	01	_	O	O	_	_	_	_	_
54	;	_	O	O	_	_	_	_	_
55	data	_	O	O	_	_	_	_	_
56	not	_	O	O	_	_	_	_	_
57	shown	_	O	O	_	_	_	_	_
58	in	_	O	O	_	_	_	_	_
59	detail	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	Of	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	four	_	O	O	_	_	_	_	_
4	examined	_	O	O	_	_	_	_	_
5	NFkappaB	_	O	O	_	_	_	_	_
6	sites	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	promoter	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	mostly	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	TSST	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	LPS	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	NFkappaB	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	TSST	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	induced	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	new	_	O	O	_	_	_	_	_
41	NFkappaB	_	O	O	_	_	_	_	_
42	consensus	_	O	O	_	_	_	_	_
43	site	_	O	O	_	_	_	_	_
44	seemed	_	O	O	_	_	_	_	_
45	to	_	O	O	_	_	_	_	_
46	be	_	O	O	_	_	_	_	_
47	increased	_	O	O	_	_	_	_	_
48	by	_	O	O	_	_	_	_	_
49	GP	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	So	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	while	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	GP	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	down	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	regulation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	LPS	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	TSST	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	induced	_	O	O	_	_	_	_	_
24	NFkappaB	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	sites	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	TNFalpha	_	O	O	_	_	_	_	_
31	promoter	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	there	_	O	O	_	_	_	_	_
34	was	_	O	O	_	_	_	_	_
35	an	_	O	O	_	_	_	_	_
36	up	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	regulation	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	NFkappaB	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	NFkappaB	_	O	O	_	_	_	_	_
44	consensus	_	O	O	_	_	_	_	_
45	sites	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	RA	_	O	O	_	_	_	_	_
52	promoter	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	seemingly	_	O	O	_	_	_	_	_
3	contradictory	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	could	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	explained	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	differences	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	either	_	O	O	_	_	_	_	_
12	NFkappaB	_	O	O	_	_	_	_	_
13	subunits	_	O	O	_	_	_	_	_
14	or	_	O	O	_	_	_	_	_
15	conserved	_	O	O	_	_	_	_	_
16	nucleotides	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	#	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	within	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	decameric	_	O	O	_	_	_	_	_
30	NFkappaB	_	O	O	_	_	_	_	_
31	binding	_	O	O	_	_	_	_	_
32	motif	_	O	O	_	_	_	_	_
33	between	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	TNFalpha	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	RA	_	O	O	_	_	_	_	_
42	promoter	_	O	O	_	_	_	_	_
43	(	_	O	O	_	_	_	_	_
44	for	_	O	O	_	_	_	_	_
45	NFkappaB	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	RA	_	O	O	_	_	_	_	_
52	motif	_	O	O	_	_	_	_	_
53	contains	_	O	O	_	_	_	_	_
54	a	_	O	O	_	_	_	_	_
55	T	_	O	O	_	_	_	_	_
56	on	_	O	O	_	_	_	_	_
57	position	_	O	O	_	_	_	_	_
58	10	_	O	O	_	_	_	_	_
59	instead	_	O	O	_	_	_	_	_
60	of	_	O	O	_	_	_	_	_
61	the	_	O	O	_	_	_	_	_
62	conserved	_	O	O	_	_	_	_	_
63	C	_	O	O	_	_	_	_	_
64	in	_	O	O	_	_	_	_	_
65	the	_	O	O	_	_	_	_	_
66	TNFalpha	_	O	O	_	_	_	_	_
67	motif	_	O	O	_	_	_	_	_
68	,	_	O	O	_	_	_	_	_
69	see	_	O	O	_	_	_	_	_
70	Table	_	O	O	_	_	_	_	_
71	1	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	,	_	O	O	_	_	_	_	_
74	probably	_	O	O	_	_	_	_	_
75	leading	_	O	O	_	_	_	_	_
76	to	_	O	O	_	_	_	_	_
77	differences	_	O	O	_	_	_	_	_
78	in	_	O	O	_	_	_	_	_
79	binding	_	O	O	_	_	_	_	_
80	[	_	O	O	_	_	_	_	_
81	41	_	O	O	_	_	_	_	_
82	,	_	O	O	_	_	_	_	_
83	42	_	O	O	_	_	_	_	_
84	]	_	O	O	_	_	_	_	_
85	.	_	O	O	_	_	_	_	_

1	Despite	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	location	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	new	_	O	O	_	_	_	_	_
7	NFkappaB	_	O	O	_	_	_	_	_
8	consensus	_	O	O	_	_	_	_	_
9	site	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	266	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	280	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	inhibitory	_	O	O	_	_	_	_	_
20	element	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	250	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	294	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	RA	_	O	O	_	_	_	_	_
34	promoter	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	30	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	we	_	O	O	_	_	_	_	_
40	observed	_	O	O	_	_	_	_	_
41	no	_	O	O	_	_	_	_	_
42	inhibition	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	side	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	inhibitory	_	O	O	_	_	_	_	_
10	NFkappaB	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	288	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	302	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	towards	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	end	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	inhibitory	_	O	O	_	_	_	_	_
28	element	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	demonstrating	_	O	O	_	_	_	_	_
31	down	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	regulations	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	LPS	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	TSST	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	induced	_	O	O	_	_	_	_	_
44	binding	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	which	_	O	O	_	_	_	_	_
47	could	_	O	O	_	_	_	_	_
48	not	_	O	O	_	_	_	_	_
49	be	_	O	O	_	_	_	_	_
50	altered	_	O	O	_	_	_	_	_
51	by	_	O	O	_	_	_	_	_
52	GP	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	our	_	O	O	_	_	_	_	_
3	opinion	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	site	_	O	O	_	_	_	_	_
7	may	_	O	O	_	_	_	_	_
8	therefore	_	O	O	_	_	_	_	_
9	represent	_	O	O	_	_	_	_	_
10	at	_	O	O	_	_	_	_	_
11	least	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	part	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	previoulsy	_	O	O	_	_	_	_	_
17	described	_	O	O	_	_	_	_	_
18	inhibitory	_	O	O	_	_	_	_	_
19	element	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	30	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	modulated	_	O	O	_	_	_	_	_
5	increase	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	TSST	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	new	_	O	O	_	_	_	_	_
16	NFkappaB	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	NFkappaB	_	O	O	_	_	_	_	_
20	consensus	_	O	O	_	_	_	_	_
21	site	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	NFIL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	site	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	32	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	well	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	novel	_	O	O	_	_	_	_	_
37	NFATP	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	site	_	O	O	_	_	_	_	_
42	may	_	O	O	_	_	_	_	_
43	explain	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	synergistic	_	O	O	_	_	_	_	_
46	up	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	regulation	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	TSST	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	1	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	induced	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	1	_	O	O	_	_	_	_	_
59	RA	_	O	O	_	_	_	_	_
60	production	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	think	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	modulated	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	reflected	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	decrease	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	beta	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	ratio	_	O	O	_	_	_	_	_
28	following	_	O	O	_	_	_	_	_
29	GP	_	O	O	_	_	_	_	_
30	+	_	O	O	_	_	_	_	_
31	TSST	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	Fig	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	6	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	context	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	it	_	O	O	_	_	_	_	_
6	has	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	postulated	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	vitro	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	100	_	O	O	_	_	_	_	_
14	fold	_	O	O	_	_	_	_	_
15	excess	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	over	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	beta	_	O	O	_	_	_	_	_
26	might	_	O	O	_	_	_	_	_
27	control	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	biological	_	O	O	_	_	_	_	_
30	effects	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	46	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	47	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	fact	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	RA	_	O	O	_	_	_	_	_
16	ratio	_	O	O	_	_	_	_	_
17	following	_	O	O	_	_	_	_	_
18	GP	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	TSST	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	partially	_	O	O	_	_	_	_	_
25	less	_	O	O	_	_	_	_	_
26	than	_	O	O	_	_	_	_	_
27	0	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	01	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	it	_	O	O	_	_	_	_	_
32	is	_	O	O	_	_	_	_	_
33	not	_	O	O	_	_	_	_	_
34	unreasonable	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	assume	_	O	O	_	_	_	_	_
37	that	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	beta	_	O	O	_	_	_	_	_
42	bioactivity	_	O	O	_	_	_	_	_
43	is	_	O	O	_	_	_	_	_
44	inactivated	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	our	_	O	O	_	_	_	_	_
47	system	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Indeed	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	GP	_	O	O	_	_	_	_	_
4	reduced	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	TSST	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dependent	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	production	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	murine	_	O	O	_	_	_	_	_
23	EL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	4	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	data	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	shown	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	detail	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	weaker	_	O	O	_	_	_	_	_
3	modulating	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	GP	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	immune	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	observed	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	this	_	O	O	_	_	_	_	_
17	study	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	may	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	attributed	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	delicately	_	O	O	_	_	_	_	_
24	balanced	_	O	O	_	_	_	_	_
25	differences	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	signaling	_	O	O	_	_	_	_	_
28	pathways	_	O	O	_	_	_	_	_
29	between	_	O	O	_	_	_	_	_
30	LPS	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	TSST	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	43	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	45	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	TSST	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	use	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	PI	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	K	_	O	O	_	_	_	_	_
13	pathway	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	[	_	O	O	_	_	_	_	_
17	44	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	this	_	O	O	_	_	_	_	_
21	effect	_	O	O	_	_	_	_	_
22	may	_	O	O	_	_	_	_	_
23	be	_	O	O	_	_	_	_	_
24	sustained	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	treatment	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	22	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	37	_	O	O	_	_	_	_	_
32	]	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	has	_	O	O	_	_	_	_	_
3	been	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	septic	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	adapted	_	O	O	_	_	_	_	_
12	leukocytes	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	PI	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	K	_	O	O	_	_	_	_	_
17	pathway	_	O	O	_	_	_	_	_
18	selectively	_	O	O	_	_	_	_	_
19	controls	_	O	O	_	_	_	_	_
20	sIL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	but	_	O	O	_	_	_	_	_
25	not	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	beta	_	O	O	_	_	_	_	_
30	production	_	O	O	_	_	_	_	_
31	[	_	O	O	_	_	_	_	_
32	48	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Signaling	_	O	O	_	_	_	_	_
2	via	_	O	O	_	_	_	_	_
3	PI	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	K	_	O	O	_	_	_	_	_
6	has	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	reported	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	involved	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	NFAT	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	49	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	NFkappaB	_	O	O	_	_	_	_	_
4	can	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	take	_	O	O	_	_	_	_	_
7	place	_	O	O	_	_	_	_	_
8	via	_	O	O	_	_	_	_	_
9	PI	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	K	_	O	O	_	_	_	_	_
12	[	_	O	O	_	_	_	_	_
13	50	_	O	O	_	_	_	_	_
14	]	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	may	_	O	O	_	_	_	_	_
18	offer	_	O	O	_	_	_	_	_
19	an	_	O	O	_	_	_	_	_
20	explanation	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	difference	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	signaling	_	O	O	_	_	_	_	_
26	between	_	O	O	_	_	_	_	_
27	GP	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	PI	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	K	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	LPS	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	mitogen	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	activated	_	O	O	_	_	_	_	_
39	kinase	_	O	O	_	_	_	_	_
40	signaling	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	idea	_	O	O	_	_	_	_	_
3	may	_	O	O	_	_	_	_	_
4	be	_	O	O	_	_	_	_	_
5	supported	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	another	_	O	O	_	_	_	_	_
8	study	_	O	O	_	_	_	_	_
9	showing	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	despite	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	use	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	similar	_	O	O	_	_	_	_	_
16	PRR	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	LPS	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	peptidoglycan	_	O	O	_	_	_	_	_
21	activated	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	through	_	O	O	_	_	_	_	_
29	different	_	O	O	_	_	_	_	_
30	mechanisms	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	DNA	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	binding	_	O	O	_	_	_	_	_
35	proteins	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	acted	_	O	O	_	_	_	_	_
38	synergistically	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	combination	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	suggestive	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	signals	_	O	O	_	_	_	_	_
45	which	_	O	O	_	_	_	_	_
46	are	_	O	O	_	_	_	_	_
47	not	_	O	O	_	_	_	_	_
48	equivalent	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	all	_	O	O	_	_	_	_	_
51	parts	_	O	O	_	_	_	_	_
52	[	_	O	O	_	_	_	_	_
53	51	_	O	O	_	_	_	_	_
54	]	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_



1	Retinoic	_	O	O	_	_	_	_	_
2	acid	_	O	O	_	_	_	_	_
3	activates	_	O	O	_	_	_	_	_
4	interferon	_	O	O	_	_	_	_	_
5	regulatory	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	myeloid	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	All	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	trans	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	retinoic	_	O	O	_	_	_	_	_
6	acid	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	ATRA	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	drug	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	choice	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	treatment	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	acute	_	O	O	_	_	_	_	_
20	promyelocytic	_	O	O	_	_	_	_	_
21	leukemia	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	APL	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	ATRA	_	O	O	_	_	_	_	_
2	induces	_	O	O	_	_	_	_	_
3	both	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	vitro	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	vivo	_	O	O	_	_	_	_	_
9	differentiation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	APL	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	into	_	O	O	_	_	_	_	_
14	mature	_	O	O	_	_	_	_	_
15	granulocytes	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	molecular	_	O	O	_	_	_	_	_
5	mechanisms	_	O	O	_	_	_	_	_
6	involved	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	ATRA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	dependent	_	O	O	_	_	_	_	_
11	growth	_	O	O	_	_	_	_	_
12	inhibition	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	cellular	_	O	O	_	_	_	_	_
15	differentiation	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	presently	_	O	O	_	_	_	_	_
19	understood	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	NB	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	line	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	derived	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	bone	_	O	O	_	_	_	_	_
13	marrow	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	patient	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	APL	_	O	O	_	_	_	_	_
19	during	_	O	O	_	_	_	_	_
20	relapse	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	can	_	O	O	_	_	_	_	_
23	be	_	O	O	_	_	_	_	_
24	used	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	model	_	O	O	_	_	_	_	_
28	system	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	study	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	growth	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	differentiation	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	APL	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	interferon	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	IFN	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	regulatory	_	O	O	_	_	_	_	_
7	factors	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	IRF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	IRF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	other	_	O	O	_	_	_	_	_
19	IFN	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	inducible	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	products	_	O	O	_	_	_	_	_
24	regulate	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	growth	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	we	_	O	O	_	_	_	_	_
29	analyzed	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	effects	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	ATRA	_	O	O	_	_	_	_	_
34	on	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	these	_	O	O	_	_	_	_	_
39	genes	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	ATRA	_	O	O	_	_	_	_	_
5	directly	_	O	O	_	_	_	_	_
6	activates	_	O	O	_	_	_	_	_
7	IRF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	followed	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IRF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	'	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	5	_	O	O	_	_	_	_	_
25	'	_	O	O	_	_	_	_	_
26	oligoadenylate	_	O	O	_	_	_	_	_
27	synthetase	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	OAS	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	gene	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	slower	_	O	O	_	_	_	_	_
35	kinetics	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	NB	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	ATRA	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	activated	_	O	O	_	_	_	_	_
11	IRF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	gene	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	HL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	60	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	U	_	O	O	_	_	_	_	_
22	937	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	THP	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	all	_	O	O	_	_	_	_	_
32	respond	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	ATRA	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	growth	_	O	O	_	_	_	_	_
37	inhibition	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	more	_	O	O	_	_	_	_	_
3	than	_	O	O	_	_	_	_	_
4	additive	_	O	O	_	_	_	_	_
5	increase	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	IRF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	seen	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	ATRA	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	IFN	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	gamma	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	NB	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	ATRA	_	O	O	_	_	_	_	_
2	did	_	O	O	_	_	_	_	_
3	not	_	O	O	_	_	_	_	_
4	activate	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	or	_	O	O	_	_	_	_	_
10	signal	_	O	O	_	_	_	_	_
11	transducer	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	activator	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	pathways	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	suggesting	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	alternate	_	O	O	_	_	_	_	_
26	mechanism	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	involved	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	IRF	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	gene	_	O	O	_	_	_	_	_
34	activation	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	ATRA	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IRF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	activator	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	repressor	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	transformation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	may	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	one	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	molecular	_	O	O	_	_	_	_	_
26	mechanisms	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	ATRA	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	induced	_	O	O	_	_	_	_	_
31	growth	_	O	O	_	_	_	_	_
32	inhibition	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	basis	_	O	O	_	_	_	_	_
37	for	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	synergistic	_	O	O	_	_	_	_	_
40	actions	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	ATRA	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	IFNs	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	myeloid	_	O	O	_	_	_	_	_
47	leukemia	_	O	O	_	_	_	_	_
48	cells	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_


1	SCL	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	related	_	O	O	_	_	_	_	_
4	hemopoietic	_	O	O	_	_	_	_	_
5	helix	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	loop	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	helix	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	factors	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	helix	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	loop	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	helix	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	HLH	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	family	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	factors	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	include	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	critical	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	differentiation	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	development	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	species	_	O	O	_	_	_	_	_
27	ranging	_	O	O	_	_	_	_	_
28	from	_	O	O	_	_	_	_	_
29	plants	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	mammals	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Five	_	O	O	_	_	_	_	_
2	members	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	family	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	MYC	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	SCL	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	TAL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	LYL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	E	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	implicated	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	oncogenic	_	O	O	_	_	_	_	_
27	events	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	human	_	O	O	_	_	_	_	_
30	lymphoid	_	O	O	_	_	_	_	_
31	tumors	_	O	O	_	_	_	_	_
32	because	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	their	_	O	O	_	_	_	_	_
35	consistent	_	O	O	_	_	_	_	_
36	involvement	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	chromosomal	_	O	O	_	_	_	_	_
39	translocations	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	activated	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	leukemias	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	SCL	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	LYL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	low	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	undetectable	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	normal	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	populations	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	SCL	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	expressed	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	erythroid	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	megakaryocyte	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	mast	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	populations	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	same	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	lineages	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	GATA	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	zinc	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	finger	_	O	O	_	_	_	_	_
26	transcription	_	O	O	_	_	_	_	_
27	factor	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	SCL	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	GATA	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	undergo	_	O	O	_	_	_	_	_
11	coordinate	_	O	O	_	_	_	_	_
12	modulation	_	O	O	_	_	_	_	_
13	during	_	O	O	_	_	_	_	_
14	chemically	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	differentiation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	mouse	_	O	O	_	_	_	_	_
20	erythroleukemia	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	down	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	modulated	_	O	O	_	_	_	_	_
27	during	_	O	O	_	_	_	_	_
28	myeloid	_	O	O	_	_	_	_	_
29	differentiation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	human	_	O	O	_	_	_	_	_
32	K	_	O	O	_	_	_	_	_
33	562	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	thus	_	O	O	_	_	_	_	_
37	implying	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	role	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	SCL	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	erythroid	_	O	O	_	_	_	_	_
44	differentiation	_	O	O	_	_	_	_	_
45	events	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	contrast	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	GATA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	SCL	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	developing	_	O	O	_	_	_	_	_
16	brain	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Studies	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	function	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	SCL	_	O	O	_	_	_	_	_
7	suggest	_	O	O	_	_	_	_	_
8	it	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	also	_	O	O	_	_	_	_	_
11	important	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	proliferation	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	self	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	renewal	_	O	O	_	_	_	_	_
18	events	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	erythroid	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	CBP	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	300	_	O	O	_	_	_	_	_
5	integrates	_	O	O	_	_	_	_	_
6	Raf	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	Rac	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	signaling	_	O	O	_	_	_	_	_
11	pathways	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	transcriptional	_	O	O	_	_	_	_	_
15	induction	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	ATc	_	O	O	_	_	_	_	_
20	during	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	NF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	ATc	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	inducibly	_	O	O	_	_	_	_	_
7	expressed	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	controls	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	cardiomyocytes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	transcriptional	_	O	O	_	_	_	_	_
7	co	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	activators	_	O	O	_	_	_	_	_
10	CBP	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	300	_	O	O	_	_	_	_	_
14	bind	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	activity	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	inducible	_	O	O	_	_	_	_	_
23	N	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	terminal	_	O	O	_	_	_	_	_
26	transactivation	_	O	O	_	_	_	_	_
27	domain	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	NF	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	ATc	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	TAD	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	A	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Similar	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	N	_	O	O	_	_	_	_	_
5	terminal	_	O	O	_	_	_	_	_
6	transactivation	_	O	O	_	_	_	_	_
7	domain	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Jun	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	TAD	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	A	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	inducibly	_	O	O	_	_	_	_	_
18	phosphorylated	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	this	_	O	O	_	_	_	_	_
22	phosphorylation	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	dispensable	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	interaction	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	CBP	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	p	_	O	O	_	_	_	_	_
32	300	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	active	_	O	O	_	_	_	_	_
3	versions	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Raf	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	Rac	_	O	O	_	_	_	_	_
10	synergistically	_	O	O	_	_	_	_	_
11	enhance	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	CBP	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	p	_	O	O	_	_	_	_	_
16	300	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	mediated	_	O	O	_	_	_	_	_
19	increase	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	TAD	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	A	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	indicating	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	important	_	O	O	_	_	_	_	_
29	role	_	O	O	_	_	_	_	_
30	CBP	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	p	_	O	O	_	_	_	_	_
33	300	_	O	O	_	_	_	_	_
34	plays	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	integration	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	cell	_	O	O	_	_	_	_	_
41	activation	_	O	O	_	_	_	_	_
42	signals	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	mutation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	CBP	_	O	O	_	_	_	_	_
6	abolishing	_	O	O	_	_	_	_	_
7	HAT	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	almost	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	active	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	wild	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	type	_	O	O	_	_	_	_	_
17	CBP	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	functions	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	CBP	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	300	_	O	O	_	_	_	_	_
28	other	_	O	O	_	_	_	_	_
29	than	_	O	O	_	_	_	_	_
30	histone	_	O	O	_	_	_	_	_
31	acetylation	_	O	O	_	_	_	_	_
32	appear	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	control	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	NF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	AT	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	dependent	_	O	O	_	_	_	_	_
41	transcription	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	T	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	40	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	but	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	lipopolysaccharide	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	anti	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	IgM	_	O	O	_	_	_	_	_
11	stimulation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	primary	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	lymphocytes	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	leads	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	persistent	_	O	O	_	_	_	_	_
21	nuclear	_	O	O	_	_	_	_	_
22	accumulation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	RelB	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	analyzed	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	effect	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	40	_	O	O	_	_	_	_	_
11	stimulation	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	activity	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	nuclear	_	O	O	_	_	_	_	_
17	appearance	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	Rel	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	nuclear	_	O	O	_	_	_	_	_
22	factor	_	O	O	_	_	_	_	_
23	kappaB	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	kappaB	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	factors	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	primary	_	O	O	_	_	_	_	_
32	murine	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	lymphocytes	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	triggering	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	40	_	O	O	_	_	_	_	_
8	signaling	_	O	O	_	_	_	_	_
9	pathway	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	s	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	40	_	O	O	_	_	_	_	_
16	ligands	_	O	O	_	_	_	_	_
17	expressed	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	L	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	led	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	strong	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kappaB	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	controlled	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	globin	_	O	O	_	_	_	_	_
35	reporter	_	O	O	_	_	_	_	_
36	gene	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	primary	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	lymphocytes	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	transgenic	_	O	O	_	_	_	_	_
43	mice	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Analyses	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	translocation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	individual	_	O	O	_	_	_	_	_
7	members	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	Rel	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	after	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	40	_	O	O	_	_	_	_	_
14	induction	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	primary	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	showed	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	strong	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	long	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	lasting	_	O	O	_	_	_	_	_
26	accumulation	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	RelB	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	less	_	O	O	_	_	_	_	_
32	pronounced	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	c	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	Rel	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	LPS	_	O	O	_	_	_	_	_
2	stimulation	_	O	O	_	_	_	_	_
3	did	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	give	_	O	O	_	_	_	_	_
6	rise	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	persistent	_	O	O	_	_	_	_	_
10	nuclear	_	O	O	_	_	_	_	_
11	accumulation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	RelB	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Rel	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	whereas	_	O	O	_	_	_	_	_
20	nuclear	_	O	O	_	_	_	_	_
21	c	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	Rel	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	but	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	RelB	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	accumulated	_	O	O	_	_	_	_	_
30	after	_	O	O	_	_	_	_	_
31	B	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	stimulation	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	40	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	only	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	translocation	_	O	O	_	_	_	_	_
8	but	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	de	_	O	O	_	_	_	_	_
11	novo	_	O	O	_	_	_	_	_
12	synthesis	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	RelB	_	O	O	_	_	_	_	_
15	RNA	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	S	_	O	O	_	_	_	_	_
2	107	_	O	O	_	_	_	_	_
3	plasmacytoma	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	express	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	40	_	O	O	_	_	_	_	_
10	but	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	defective	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	appearance	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	50	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	65	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kappaB	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	do	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	express	_	O	O	_	_	_	_	_
31	RelB	_	O	O	_	_	_	_	_
32	after	_	O	O	_	_	_	_	_
33	CD	_	O	O	_	_	_	_	_
34	40	_	O	O	_	_	_	_	_
35	stimulation	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	S	_	O	O	_	_	_	_	_
3	107	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	stably	_	O	O	_	_	_	_	_
6	transfected	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	relB	_	O	O	_	_	_	_	_
9	genes	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	stimulation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	RelB	_	O	O	_	_	_	_	_
15	translocation	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	40	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	observed	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	stimulation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	40	_	O	O	_	_	_	_	_
9	signaling	_	O	O	_	_	_	_	_
10	pathways	_	O	O	_	_	_	_	_
11	exerts	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	long	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	lasting	_	O	O	_	_	_	_	_
16	stimulatory	_	O	O	_	_	_	_	_
17	effect	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	both	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	nuclear	_	O	O	_	_	_	_	_
24	translocation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	RelB	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	LPS	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	anti	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	IgM	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	unable	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	activate	_	O	O	_	_	_	_	_
11	RelB	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	40	_	O	O	_	_	_	_	_
15	appears	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	trigger	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	special	_	O	O	_	_	_	_	_
20	program	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	involved	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	proliferation	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	differentiation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	lymphocytes	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	12	_	O	O	_	_	_	_	_
3	induces	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	phosphorylation	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	STAT	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	12	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	12	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	important	_	O	O	_	_	_	_	_
11	immunoregulatory	_	O	O	_	_	_	_	_
12	cytokine	_	O	O	_	_	_	_	_
13	whose	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	member	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	hematopoietin	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	superfamily	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	recently	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	stimulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	natural	_	O	O	_	_	_	_	_
12	killer	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	12	_	O	O	_	_	_	_	_
18	induces	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	phosphorylation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	Janus	_	O	O	_	_	_	_	_
24	family	_	O	O	_	_	_	_	_
25	tyrosine	_	O	O	_	_	_	_	_
26	kinase	_	O	O	_	_	_	_	_
27	JAK	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	Tyk	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	implicating	_	O	O	_	_	_	_	_
34	these	_	O	O	_	_	_	_	_
35	kinases	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	immediate	_	O	O	_	_	_	_	_
39	biochemical	_	O	O	_	_	_	_	_
40	response	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	12	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factors	_	O	O	_	_	_	_	_
5	known	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	STATs	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	signal	_	O	O	_	_	_	_	_
10	transducers	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	activators	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	have	_	O	O	_	_	_	_	_
17	been	_	O	O	_	_	_	_	_
18	shown	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	phosphorylated	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	activated	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	response	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	number	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	cytokines	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	bind	_	O	O	_	_	_	_	_
34	hematopoietin	_	O	O	_	_	_	_	_
35	receptors	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	activate	_	O	O	_	_	_	_	_
38	JAK	_	O	O	_	_	_	_	_
39	kinases	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	demonstrate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	12	_	O	O	_	_	_	_	_
10	induces	_	O	O	_	_	_	_	_
11	tyrosine	_	O	O	_	_	_	_	_
12	phosphorylation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	recently	_	O	O	_	_	_	_	_
16	identified	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	family	_	O	O	_	_	_	_	_
19	member	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	STAT	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	show	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	STAT	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	is	_	O	O	_	_	_	_	_
31	regulated	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	activation	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	12	_	O	O	_	_	_	_	_
9	stimulates	_	O	O	_	_	_	_	_
10	formation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	complex	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	recognizes	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	DNA	_	O	O	_	_	_	_	_
21	sequence	_	O	O	_	_	_	_	_
22	previously	_	O	O	_	_	_	_	_
23	shown	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	bind	_	O	O	_	_	_	_	_
26	STAT	_	O	O	_	_	_	_	_
27	proteins	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	this	_	O	O	_	_	_	_	_
31	complex	_	O	O	_	_	_	_	_
32	contains	_	O	O	_	_	_	_	_
33	STAT	_	O	O	_	_	_	_	_
34	4	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	recent	_	O	O	_	_	_	_	_
7	demonstration	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	JAK	_	O	O	_	_	_	_	_
10	phosphorylation	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	12	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	identify	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	rapid	_	O	O	_	_	_	_	_
19	signal	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	transduction	_	O	O	_	_	_	_	_
22	pathway	_	O	O	_	_	_	_	_
23	likely	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	mediate	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	12	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	induced	_	O	O	_	_	_	_	_
31	gene	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	induces	_	O	O	_	_	_	_	_
5	tyrosine	_	O	O	_	_	_	_	_
6	phosphorylation	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	translocation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	stat	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	An	_	O	O	_	_	_	_	_
2	early	_	O	O	_	_	_	_	_
3	biochemical	_	O	O	_	_	_	_	_
4	event	_	O	O	_	_	_	_	_
5	associated	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	through	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	interleukin	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	R	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	tyrosine	_	O	O	_	_	_	_	_
24	phosphorylation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	several	_	O	O	_	_	_	_	_
27	intracellular	_	O	O	_	_	_	_	_
28	substrates	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	exact	_	O	O	_	_	_	_	_
3	mechanism	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	which	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	regulates	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	different	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	presently	_	O	O	_	_	_	_	_
16	unknown	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	report	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	stimulation	_	O	O	_	_	_	_	_
7	through	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	R	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	tyrosine	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	subsequent	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	translocation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	stat	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	newly	_	O	O	_	_	_	_	_
26	identified	_	O	O	_	_	_	_	_
27	member	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	signal	_	O	O	_	_	_	_	_
31	transducers	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	activators	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	transcription	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	STAT	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	family	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	proteins	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	stat	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	proteins	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	tyrosine	_	O	O	_	_	_	_	_
10	phosphorylated	_	O	O	_	_	_	_	_
11	after	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	ligation	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	whereas	_	O	O	_	_	_	_	_
18	tyrosine	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	phosphorylated	_	O	O	_	_	_	_	_
21	stat	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	proteins	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	91	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	84	_	O	O	_	_	_	_	_
28	kDa	_	O	O	_	_	_	_	_
29	proteins	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	were	_	O	O	_	_	_	_	_
32	translocated	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	nucleus	_	O	O	_	_	_	_	_
36	following	_	O	O	_	_	_	_	_
37	interferon	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	gamma	_	O	O	_	_	_	_	_
40	treatment	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	HeLa	_	O	O	_	_	_	_	_
43	cells	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Apart	_	O	O	_	_	_	_	_
2	from	_	O	O	_	_	_	_	_
3	stat	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	another	_	O	O	_	_	_	_	_
7	cytoplasmic	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	tyrosine	_	O	O	_	_	_	_	_
11	phosphorylated	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	subsequently	_	O	O	_	_	_	_	_
14	translocated	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	nucleus	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	response	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	had	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	apparent	_	O	O	_	_	_	_	_
6	molecular	_	O	O	_	_	_	_	_
7	mass	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	84	_	O	O	_	_	_	_	_
10	kDa	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	recognized	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	stat	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	stat	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	mAb	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	antisera	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	translocation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	84	_	O	O	_	_	_	_	_
11	kDa	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	stat	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	followed	_	O	O	_	_	_	_	_
17	identical	_	O	O	_	_	_	_	_
18	kinetics	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	84	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	candidate	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	new	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	yet	_	O	O	_	_	_	_	_
30	undefined	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	member	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	STAT	_	O	O	_	_	_	_	_
36	family	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	report	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	induces	_	O	O	_	_	_	_	_
11	tyrosine	_	O	O	_	_	_	_	_
12	phosphorylation	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	subsequent	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	translocation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	stat	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	yet	_	O	O	_	_	_	_	_
24	undefined	_	O	O	_	_	_	_	_
25	84	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	kDa	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	antigen	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	specific	_	O	O	_	_	_	_	_
33	human	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	lines	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	HLA	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	DR	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	33	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	56	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	16	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	myeloid	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	natural	_	O	O	_	_	_	_	_
20	killer	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	acute	_	O	O	_	_	_	_	_
23	leukemia	_	O	O	_	_	_	_	_
24	:	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	previously	_	O	O	_	_	_	_	_
27	unrecognized	_	O	O	_	_	_	_	_
28	form	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	acute	_	O	O	_	_	_	_	_
31	leukemia	_	O	O	_	_	_	_	_
32	potentially	_	O	O	_	_	_	_	_
33	misdiagnosed	_	O	O	_	_	_	_	_
34	as	_	O	O	_	_	_	_	_
35	French	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	American	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	British	_	O	O	_	_	_	_	_
40	acute	_	O	O	_	_	_	_	_
41	myeloid	_	O	O	_	_	_	_	_
42	leukemia	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	M	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	see	_	O	O	_	_	_	_	_
48	comments	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	identified	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	characterized	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	previously	_	O	O	_	_	_	_	_
8	unrecognized	_	O	O	_	_	_	_	_
9	form	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	acute	_	O	O	_	_	_	_	_
12	leukemia	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	shares	_	O	O	_	_	_	_	_
15	features	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	both	_	O	O	_	_	_	_	_
18	myeloid	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	natural	_	O	O	_	_	_	_	_
21	killer	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	NK	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	From	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	consecutive	_	O	O	_	_	_	_	_
4	series	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	350	_	O	O	_	_	_	_	_
7	cases	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	adult	_	O	O	_	_	_	_	_
10	de	_	O	O	_	_	_	_	_
11	novo	_	O	O	_	_	_	_	_
12	acute	_	O	O	_	_	_	_	_
13	myeloid	_	O	O	_	_	_	_	_
14	leukemia	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	AML	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	we	_	O	O	_	_	_	_	_
20	identified	_	O	O	_	_	_	_	_
21	20	_	O	O	_	_	_	_	_
22	cases	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	%	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	unique	_	O	O	_	_	_	_	_
30	immunophenotype	_	O	O	_	_	_	_	_
31	:	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	33	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	56	_	O	O	_	_	_	_	_
38	+	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	CD	_	O	O	_	_	_	_	_
41	11	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	+	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	CD	_	O	O	_	_	_	_	_
46	13	_	O	O	_	_	_	_	_
47	lo	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	CD	_	O	O	_	_	_	_	_
50	15	_	O	O	_	_	_	_	_
51	lo	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	CD	_	O	O	_	_	_	_	_
54	34	_	O	O	_	_	_	_	_
55	+	_	O	O	_	_	_	_	_
56	/	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	HLA	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	DR	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	CD	_	O	O	_	_	_	_	_
65	16	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_

1	Multicolor	_	O	O	_	_	_	_	_
2	flow	_	O	O	_	_	_	_	_
3	cytometric	_	O	O	_	_	_	_	_
4	assays	_	O	O	_	_	_	_	_
5	confirmed	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	coexpression	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	myeloid	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	33	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	13	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	15	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	NK	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	associated	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	56	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	antigens	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	each	_	O	O	_	_	_	_	_
32	case	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	whereas	_	O	O	_	_	_	_	_
35	reverse	_	O	O	_	_	_	_	_
36	transcription	_	O	O	_	_	_	_	_
37	polymerase	_	O	O	_	_	_	_	_
38	chain	_	O	O	_	_	_	_	_
39	reaction	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	RT	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	PCR	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	assays	_	O	O	_	_	_	_	_
46	confirmed	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	identity	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	CD	_	O	O	_	_	_	_	_
51	56	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	neural	_	O	O	_	_	_	_	_
54	cell	_	O	O	_	_	_	_	_
55	adhesion	_	O	O	_	_	_	_	_
56	molecule	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	in	_	O	O	_	_	_	_	_
59	leukemic	_	O	O	_	_	_	_	_
60	blasts	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	two	_	O	O	_	_	_	_	_
3	cases	_	O	O	_	_	_	_	_
4	expressed	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	no	_	O	O	_	_	_	_	_
9	case	_	O	O	_	_	_	_	_
10	expressed	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	8	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	no	_	O	O	_	_	_	_	_
22	case	_	O	O	_	_	_	_	_
23	showed	_	O	O	_	_	_	_	_
24	clonal	_	O	O	_	_	_	_	_
25	rearrangement	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	genes	_	O	O	_	_	_	_	_
28	encoding	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	TCR	_	O	O	_	_	_	_	_
36	beta	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	gamma	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	delta	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Leukemic	_	O	O	_	_	_	_	_
2	blasts	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	majority	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	cases	_	O	O	_	_	_	_	_
8	shared	_	O	O	_	_	_	_	_
9	unique	_	O	O	_	_	_	_	_
10	morphologic	_	O	O	_	_	_	_	_
11	features	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	deeply	_	O	O	_	_	_	_	_
14	invaginated	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	membranes	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	scant	_	O	O	_	_	_	_	_
19	cytoplasm	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	fine	_	O	O	_	_	_	_	_
22	azurophilic	_	O	O	_	_	_	_	_
23	granularity	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	finely	_	O	O	_	_	_	_	_
27	granular	_	O	O	_	_	_	_	_
28	Sudan	_	O	O	_	_	_	_	_
29	black	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	myeloperoxidase	_	O	O	_	_	_	_	_
33	cytochemical	_	O	O	_	_	_	_	_
34	reactivity	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	that	_	O	O	_	_	_	_	_
37	were	_	O	O	_	_	_	_	_
38	remarkably	_	O	O	_	_	_	_	_
39	similar	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	those	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	acute	_	O	O	_	_	_	_	_
44	promyelocytic	_	O	O	_	_	_	_	_
45	leukemia	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	APL	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	;	_	O	O	_	_	_	_	_
50	particularly	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	microgranular	_	O	O	_	_	_	_	_
53	variant	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	FAB	_	O	O	_	_	_	_	_
56	AML	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	M	_	O	O	_	_	_	_	_
59	3	_	O	O	_	_	_	_	_
60	v	_	O	O	_	_	_	_	_
61	)	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	all	_	O	O	_	_	_	_	_
4	20	_	O	O	_	_	_	_	_
5	cases	_	O	O	_	_	_	_	_
6	lacked	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	t	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	15	_	O	O	_	_	_	_	_
11	;	_	O	O	_	_	_	_	_
12	17	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	cases	_	O	O	_	_	_	_	_
17	tested	_	O	O	_	_	_	_	_
18	lacked	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	promyelocytic	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	retinoic	_	O	O	_	_	_	_	_
23	acid	_	O	O	_	_	_	_	_
24	receptor	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	RAR	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	fusion	_	O	O	_	_	_	_	_
31	transcript	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	RT	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	PCR	_	O	O	_	_	_	_	_
36	assays	_	O	O	_	_	_	_	_
37	;	_	O	O	_	_	_	_	_
38	12	_	O	O	_	_	_	_	_
39	cases	_	O	O	_	_	_	_	_
40	had	_	O	O	_	_	_	_	_
41	46	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	XX	_	O	O	_	_	_	_	_
44	or	_	O	O	_	_	_	_	_
45	46	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	XY	_	O	O	_	_	_	_	_
48	karyotypes	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	whereas	_	O	O	_	_	_	_	_
51	2	_	O	O	_	_	_	_	_
52	cases	_	O	O	_	_	_	_	_
53	had	_	O	O	_	_	_	_	_
54	abnormalities	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	chromosome	_	O	O	_	_	_	_	_
57	17	_	O	O	_	_	_	_	_
58	q	_	O	O	_	_	_	_	_
59	:	_	O	O	_	_	_	_	_
60	1	_	O	O	_	_	_	_	_
61	with	_	O	O	_	_	_	_	_
62	del	_	O	O	_	_	_	_	_
63	(	_	O	O	_	_	_	_	_
64	17	_	O	O	_	_	_	_	_
65	)	_	O	O	_	_	_	_	_
66	(	_	O	O	_	_	_	_	_
67	q	_	O	O	_	_	_	_	_
68	25	_	O	O	_	_	_	_	_
69	)	_	O	O	_	_	_	_	_
70	and	_	O	O	_	_	_	_	_
71	the	_	O	O	_	_	_	_	_
72	other	_	O	O	_	_	_	_	_
73	with	_	O	O	_	_	_	_	_
74	t	_	O	O	_	_	_	_	_
75	(	_	O	O	_	_	_	_	_
76	11	_	O	O	_	_	_	_	_
77	;	_	O	O	_	_	_	_	_
78	17	_	O	O	_	_	_	_	_
79	)	_	O	O	_	_	_	_	_
80	(	_	O	O	_	_	_	_	_
81	q	_	O	O	_	_	_	_	_
82	23	_	O	O	_	_	_	_	_
83	;	_	O	O	_	_	_	_	_
84	q	_	O	O	_	_	_	_	_
85	21	_	O	O	_	_	_	_	_
86	)	_	O	O	_	_	_	_	_
87	and	_	O	O	_	_	_	_	_
88	the	_	O	O	_	_	_	_	_
89	promyelocytic	_	O	O	_	_	_	_	_
90	leukemia	_	O	O	_	_	_	_	_
91	zinc	_	O	O	_	_	_	_	_
92	finger	_	O	O	_	_	_	_	_
93	/	_	O	O	_	_	_	_	_
94	RAR	_	O	O	_	_	_	_	_
95	alpha	_	O	O	_	_	_	_	_
96	fusion	_	O	O	_	_	_	_	_
97	transcript	_	O	O	_	_	_	_	_
98	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	cases	_	O	O	_	_	_	_	_
3	tested	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	20	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	including	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	case	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	t	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	11	_	O	O	_	_	_	_	_
17	;	_	O	O	_	_	_	_	_
18	17	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	failed	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	differentiate	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	vitro	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	response	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	all	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	trans	_	O	O	_	_	_	_	_
32	retinoic	_	O	O	_	_	_	_	_
33	acid	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	ATRA	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	suggesting	_	O	O	_	_	_	_	_
39	that	_	O	O	_	_	_	_	_
40	these	_	O	O	_	_	_	_	_
41	cases	_	O	O	_	_	_	_	_
42	may	_	O	O	_	_	_	_	_
43	account	_	O	O	_	_	_	_	_
44	for	_	O	O	_	_	_	_	_
45	some	_	O	O	_	_	_	_	_
46	APLs	_	O	O	_	_	_	_	_
47	that	_	O	O	_	_	_	_	_
48	have	_	O	O	_	_	_	_	_
49	not	_	O	O	_	_	_	_	_
50	shown	_	O	O	_	_	_	_	_
51	a	_	O	O	_	_	_	_	_
52	clinical	_	O	O	_	_	_	_	_
53	response	_	O	O	_	_	_	_	_
54	to	_	O	O	_	_	_	_	_
55	ATRA	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Four	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	cases	_	O	O	_	_	_	_	_
5	tested	_	O	O	_	_	_	_	_
6	showed	_	O	O	_	_	_	_	_
7	functional	_	O	O	_	_	_	_	_
8	NK	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	mediated	_	O	O	_	_	_	_	_
12	cytotoxicity	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	suggesting	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	relationship	_	O	O	_	_	_	_	_
17	between	_	O	O	_	_	_	_	_
18	these	_	O	O	_	_	_	_	_
19	unique	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	33	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	56	_	O	O	_	_	_	_	_
26	+	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	16	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	acute	_	O	O	_	_	_	_	_
32	leukemias	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	normal	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	56	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	CD	_	O	O	_	_	_	_	_
40	16	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	NK	_	O	O	_	_	_	_	_
43	precursor	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	combination	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	panning	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	multiparameter	_	O	O	_	_	_	_	_
8	flow	_	O	O	_	_	_	_	_
9	cytometric	_	O	O	_	_	_	_	_
10	sorting	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	identified	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	normal	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	56	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	33	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	16	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	counterpart	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	frequency	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	%	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	%	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	peripheral	_	O	O	_	_	_	_	_
41	blood	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	healthy	_	O	O	_	_	_	_	_
44	individuals	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	form	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	acute	_	O	O	_	_	_	_	_
9	leukemia	_	O	O	_	_	_	_	_
10	may	_	O	O	_	_	_	_	_
11	arise	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	transformation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	precursor	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	common	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	both	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	myeloid	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	NK	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	lineages	_	O	O	_	_	_	_	_
27	;	_	O	O	_	_	_	_	_
28	thus	_	O	O	_	_	_	_	_
29	we	_	O	O	_	_	_	_	_
30	propose	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	designation	_	O	O	_	_	_	_	_
33	myeloid	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	NK	_	O	O	_	_	_	_	_
36	acute	_	O	O	_	_	_	_	_
37	leukemia	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Recognition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	new	_	O	O	_	_	_	_	_
5	leukemic	_	O	O	_	_	_	_	_
6	entity	_	O	O	_	_	_	_	_
7	will	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	important	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	distinguishing	_	O	O	_	_	_	_	_
12	these	_	O	O	_	_	_	_	_
13	ATRA	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	nonresponsive	_	O	O	_	_	_	_	_
16	cases	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	ATRA	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	responsive	_	O	O	_	_	_	_	_
21	true	_	O	O	_	_	_	_	_
22	APL	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	role	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NFATp	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	cyclosporin	_	O	O	_	_	_	_	_
7	A	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	sensitive	_	O	O	_	_	_	_	_
10	tumor	_	O	O	_	_	_	_	_
11	necrosis	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	tumor	_	O	O	_	_	_	_	_
3	necrosis	_	O	O	_	_	_	_	_
4	factor	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	TNF	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	immediate	_	O	O	_	_	_	_	_
15	early	_	O	O	_	_	_	_	_
16	gene	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	activated	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	rapidly	_	O	O	_	_	_	_	_
27	induced	_	O	O	_	_	_	_	_
28	without	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	requirement	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	protein	_	O	O	_	_	_	_	_
33	synthesis	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Maximal	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	TNF	_	O	O	_	_	_	_	_
5	alpha	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	can	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	treatment	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	calcium	_	O	O	_	_	_	_	_
17	ionophores	_	O	O	_	_	_	_	_
18	alone	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	via	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	calcineurin	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	dependent	_	O	O	_	_	_	_	_
25	process	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	blocked	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	cyclosporin	_	O	O	_	_	_	_	_
31	A	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	identified	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	promoter	_	O	O	_	_	_	_	_
7	element	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	required	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	calcium	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	stimulated	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	cyclosporin	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	sensitive	_	O	O	_	_	_	_	_
24	induction	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	TNF	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	activated	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	contains	_	O	O	_	_	_	_	_
12	NFATp	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	cyclosporin	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	sensitive	_	O	O	_	_	_	_	_
18	DNA	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	required	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	interleukin	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	transcription	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	NFATp	_	O	O	_	_	_	_	_
2	binds	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	sites	_	O	O	_	_	_	_	_
6	within	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	kappa	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	element	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	occupancy	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	both	_	O	O	_	_	_	_	_
16	sites	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	required	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	TNF	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	induction	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	although	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	kappa	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	element	_	O	O	_	_	_	_	_
8	has	_	O	O	_	_	_	_	_
9	little	_	O	O	_	_	_	_	_
10	sequence	_	O	O	_	_	_	_	_
11	similarity	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	other	_	O	O	_	_	_	_	_
14	NFATp	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	sites	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	it	_	O	O	_	_	_	_	_
20	appears	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	function	_	O	O	_	_	_	_	_
23	as	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	cyclosporin	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	sensitive	_	O	O	_	_	_	_	_
28	promoter	_	O	O	_	_	_	_	_
29	element	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	by	_	O	O	_	_	_	_	_
34	virtue	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	its	_	O	O	_	_	_	_	_
37	ability	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	bind	_	O	O	_	_	_	_	_
40	NFATp	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	involvement	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NFATp	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	transcriptional	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	both	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	interleukin	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	TNF	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	genes	_	O	O	_	_	_	_	_
18	suggests	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	this	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	plays	_	O	O	_	_	_	_	_
23	an	_	O	O	_	_	_	_	_
24	important	_	O	O	_	_	_	_	_
25	role	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	coordinate	_	O	O	_	_	_	_	_
29	induction	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	multiple	_	O	O	_	_	_	_	_
32	cytokine	_	O	O	_	_	_	_	_
33	genes	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	starting	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	earliest	_	O	O	_	_	_	_	_
39	stages	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	T	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	activation	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	TCF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	encodes	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	nuclear	_	O	O	_	_	_	_	_
10	DNA	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	uniquely	_	O	O	_	_	_	_	_
15	expressed	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	neoplastic	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	lineage	_	O	O	_	_	_	_	_
23	lymphocytes	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	TCF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	gene	_	O	O	_	_	_	_	_
6	encodes	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	putative	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	affinity	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	sequence	_	O	O	_	_	_	_	_
16	motif	_	O	O	_	_	_	_	_
17	occurring	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	number	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	enhancers	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	TCF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	originally	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	expressed	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	fashion	_	O	O	_	_	_	_	_
18	within	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	set	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	mouse	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	lines	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	reportedly	_	O	O	_	_	_	_	_
6	occurs	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	multiple	_	O	O	_	_	_	_	_
9	nonlymphoid	_	O	O	_	_	_	_	_
10	tissues	_	O	O	_	_	_	_	_
11	during	_	O	O	_	_	_	_	_
12	murine	_	O	O	_	_	_	_	_
13	embryogenesis	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	now	_	O	O	_	_	_	_	_
4	raised	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	monoclonal	_	O	O	_	_	_	_	_
7	antibody	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	document	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	biochemistry	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	TCF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	expected	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	TCF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	detectable	_	O	O	_	_	_	_	_
11	only	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	lines	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	lineage	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Its	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	always	_	O	O	_	_	_	_	_
5	restricted	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	nucleus	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Immunohistochemistry	_	O	O	_	_	_	_	_
2	on	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	panel	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	tissues	_	O	O	_	_	_	_	_
8	revealed	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	TCF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	found	_	O	O	_	_	_	_	_
17	exclusively	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	thymocytes	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	peripheral	_	O	O	_	_	_	_	_
29	lymphoid	_	O	O	_	_	_	_	_
30	tissues	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Western	_	O	O	_	_	_	_	_
2	blotting	_	O	O	_	_	_	_	_
3	yielded	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	set	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	bands	_	O	O	_	_	_	_	_
8	ranging	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	kD	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	55	_	O	O	_	_	_	_	_
14	kD	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	resulting	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	extensive	_	O	O	_	_	_	_	_
19	alternative	_	O	O	_	_	_	_	_
20	splicing	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	TCF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	detectable	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	all	_	O	O	_	_	_	_	_
10	samples	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	set	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	22	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	malignancies	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	various	_	O	O	_	_	_	_	_
22	stages	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	maturation	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	but	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	absent	_	O	O	_	_	_	_	_
29	from	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	large	_	O	O	_	_	_	_	_
32	number	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	other	_	O	O	_	_	_	_	_
35	hematologic	_	O	O	_	_	_	_	_
36	neoplasms	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	imply	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	specific	_	O	O	_	_	_	_	_
9	function	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	TCF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	notion	_	O	O	_	_	_	_	_
17	corroborated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	recent	_	O	O	_	_	_	_	_
20	observations	_	O	O	_	_	_	_	_
21	on	_	O	O	_	_	_	_	_
22	Tcf	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	knock	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	out	_	O	O	_	_	_	_	_
28	mice	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	TCF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	can	_	O	O	_	_	_	_	_
14	serve	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	pan	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	lineage	_	O	O	_	_	_	_	_
22	marker	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	diagnosis	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	lymphoid	_	O	O	_	_	_	_	_
28	malignancies	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Tyrosine	_	O	O	_	_	_	_	_
2	kinase	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	cAMP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	dependent	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	activities	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	40	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	vitro	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	undergo	_	O	O	_	_	_	_	_
8	long	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	term	_	O	O	_	_	_	_	_
11	proliferation	_	O	O	_	_	_	_	_
12	when	_	O	O	_	_	_	_	_
13	activated	_	O	O	_	_	_	_	_
14	through	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	40	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	expressed	_	O	O	_	_	_	_	_
21	on	_	O	O	_	_	_	_	_
22	their	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	surface	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	nature	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	40	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependent	_	O	O	_	_	_	_	_
8	signals	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	proliferating	_	O	O	_	_	_	_	_
11	fresh	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	Epstein	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Barr	_	O	O	_	_	_	_	_
16	virus	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	negative	_	O	O	_	_	_	_	_
19	B	_	O	O	_	_	_	_	_
20	lymphocytes	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	currently	_	O	O	_	_	_	_	_
23	unknown	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	40	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	culture	_	O	O	_	_	_	_	_
13	system	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	used	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	examine	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	role	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	different	_	O	O	_	_	_	_	_
22	signal	_	O	O	_	_	_	_	_
23	transduction	_	O	O	_	_	_	_	_
24	elements	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Protein	_	O	O	_	_	_	_	_
2	kinase	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	PKC	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	depletion	_	O	O	_	_	_	_	_
8	generated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	long	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	term	_	O	O	_	_	_	_	_
14	phorbol	_	O	O	_	_	_	_	_
15	12	_	O	O	_	_	_	_	_
16	myristate	_	O	O	_	_	_	_	_
17	13	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	acetate	_	O	O	_	_	_	_	_
20	treatment	_	O	O	_	_	_	_	_
21	had	_	O	O	_	_	_	_	_
22	weak	_	O	O	_	_	_	_	_
23	effects	_	O	O	_	_	_	_	_
24	on	_	O	O	_	_	_	_	_
25	proliferation	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Rather	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	tyrosine	_	O	O	_	_	_	_	_
4	phosphorylation	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	directly	_	O	O	_	_	_	_	_
10	involved	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	mediating	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	40	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dependent	_	O	O	_	_	_	_	_
17	signals	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	use	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	PTK	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	inhibitor	_	O	O	_	_	_	_	_
14	herbimycin	_	O	O	_	_	_	_	_
15	A	_	O	O	_	_	_	_	_
16	dramatically	_	O	O	_	_	_	_	_
17	decreased	_	O	O	_	_	_	_	_
18	cellular	_	O	O	_	_	_	_	_
19	proliferation	_	O	O	_	_	_	_	_
20	without	_	O	O	_	_	_	_	_
21	altering	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	immunodeficiency	_	O	O	_	_	_	_	_
28	virus	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	long	_	O	O	_	_	_	_	_
32	terminal	_	O	O	_	_	_	_	_
33	repeat	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	HIV	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	LTR	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	promoter	_	O	O	_	_	_	_	_
43	largely	_	O	O	_	_	_	_	_
44	dependent	_	O	O	_	_	_	_	_
45	on	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	binding	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	nuclear	_	O	O	_	_	_	_	_
50	factor	_	O	O	_	_	_	_	_
51	kappa	_	O	O	_	_	_	_	_
52	B	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	NF	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	kappa	_	O	O	_	_	_	_	_
57	B	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	cAMP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependent	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	kinase	_	O	O	_	_	_	_	_
10	specific	_	O	O	_	_	_	_	_
11	inhibitor	_	O	O	_	_	_	_	_
12	H	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	89	_	O	O	_	_	_	_	_
15	totally	_	O	O	_	_	_	_	_
16	inhibited	_	O	O	_	_	_	_	_
17	HIV	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	LTR	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	at	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	concentration	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	low	_	O	O	_	_	_	_	_
27	as	_	O	O	_	_	_	_	_
28	100	_	O	O	_	_	_	_	_
29	nM	_	O	O	_	_	_	_	_
30	without	_	O	O	_	_	_	_	_
31	affecting	_	O	O	_	_	_	_	_
32	cellular	_	O	O	_	_	_	_	_
33	proliferation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Electrophoretic	_	O	O	_	_	_	_	_
2	mobility	_	O	O	_	_	_	_	_
3	shift	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	EMSA	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	supershift	_	O	O	_	_	_	_	_
10	assay	_	O	O	_	_	_	_	_
11	using	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	sequence	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	kappa	_	O	O	_	_	_	_	_
22	light	_	O	O	_	_	_	_	_
23	chain	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	probe	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	revealed	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	both	_	O	O	_	_	_	_	_
31	p	_	O	O	_	_	_	_	_
32	65	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	RelA	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	c	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	Rel	_	O	O	_	_	_	_	_
40	were	_	O	O	_	_	_	_	_
41	present	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	40	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	stimulated	_	O	O	_	_	_	_	_
47	B	_	O	O	_	_	_	_	_
48	cells	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	While	_	O	O	_	_	_	_	_
2	PKC	_	O	O	_	_	_	_	_
3	depletion	_	O	O	_	_	_	_	_
4	did	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	alter	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappa	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	level	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	treatment	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	H	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	89	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	herbimycin	_	O	O	_	_	_	_	_
24	A	_	O	O	_	_	_	_	_
25	provoked	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	decrease	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	NF	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	kappa	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	level	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	establish	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	importance	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	different	_	O	O	_	_	_	_	_
8	signal	_	O	O	_	_	_	_	_
9	transducing	_	O	O	_	_	_	_	_
10	pathways	_	O	O	_	_	_	_	_
11	leading	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	40	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	lymphocytes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	STAT	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	inhibition	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	effect	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_

1	STAT	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	activated	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	many	_	O	O	_	_	_	_	_
7	cytokines	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	growth	_	O	O	_	_	_	_	_
10	factors	_	O	O	_	_	_	_	_
11	such	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	family	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	cytokines	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	11	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	leukemia	_	O	O	_	_	_	_	_
30	inhibitory	_	O	O	_	_	_	_	_
31	factor	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	oncostatin	_	O	O	_	_	_	_	_
35	M	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	platelet	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	derived	_	O	O	_	_	_	_	_
41	growth	_	O	O	_	_	_	_	_
42	factor	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	epidermal	_	O	O	_	_	_	_	_
46	growth	_	O	O	_	_	_	_	_
47	factor	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	addition	_	O	O	_	_	_	_	_
51	to	_	O	O	_	_	_	_	_
52	IL	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	10	_	O	O	_	_	_	_	_
55	[	_	O	O	_	_	_	_	_
56	4	_	O	O	_	_	_	_	_
57	]	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	but	_	O	O	_	_	_	_	_
60	previous	_	O	O	_	_	_	_	_
61	studies	_	O	O	_	_	_	_	_
62	have	_	O	O	_	_	_	_	_
63	demonstrated	_	O	O	_	_	_	_	_
64	that	_	O	O	_	_	_	_	_
65	IL	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	6	_	O	O	_	_	_	_	_
68	is	_	O	O	_	_	_	_	_
69	the	_	O	O	_	_	_	_	_
70	major	_	O	O	_	_	_	_	_
71	factor	_	O	O	_	_	_	_	_
72	in	_	O	O	_	_	_	_	_
73	RA	_	O	O	_	_	_	_	_
74	synovial	_	O	O	_	_	_	_	_
75	fluid	_	O	O	_	_	_	_	_
76	that	_	O	O	_	_	_	_	_
77	induces	_	O	O	_	_	_	_	_
78	constitutive	_	O	O	_	_	_	_	_
79	activation	_	O	O	_	_	_	_	_
80	of	_	O	O	_	_	_	_	_
81	STAT	_	O	O	_	_	_	_	_
82	3	_	O	O	_	_	_	_	_
83	in	_	O	O	_	_	_	_	_
84	mononuclear	_	O	O	_	_	_	_	_
85	cells	_	O	O	_	_	_	_	_
86	[	_	O	O	_	_	_	_	_
87	31	_	O	O	_	_	_	_	_
88	]	_	O	O	_	_	_	_	_
89	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	abundant	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	sera	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	active	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	frequently	_	O	O	_	_	_	_	_
16	detected	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	>	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	ng	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	ml	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	27	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	we	_	O	O	_	_	_	_	_
28	examined	_	O	O	_	_	_	_	_
29	whether	_	O	O	_	_	_	_	_
30	persistent	_	O	O	_	_	_	_	_
31	exposure	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	CD	_	O	O	_	_	_	_	_
34	4	_	O	O	_	_	_	_	_
35	+	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	high	_	O	O	_	_	_	_	_
40	concentrations	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	6	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	blood	_	O	O	_	_	_	_	_
48	circulation	_	O	O	_	_	_	_	_
49	was	_	O	O	_	_	_	_	_
50	responsible	_	O	O	_	_	_	_	_
51	for	_	O	O	_	_	_	_	_
52	their	_	O	O	_	_	_	_	_
53	sustained	_	O	O	_	_	_	_	_
54	STAT	_	O	O	_	_	_	_	_
55	3	_	O	O	_	_	_	_	_
56	activation	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	resistance	_	O	O	_	_	_	_	_
59	to	_	O	O	_	_	_	_	_
60	IL	_	O	O	_	_	_	_	_
61	-	_	O	O	_	_	_	_	_
62	10	_	O	O	_	_	_	_	_
63	inhibition	_	O	O	_	_	_	_	_
64	in	_	O	O	_	_	_	_	_
65	active	_	O	O	_	_	_	_	_
66	RA	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	STAT	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	normal	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	data	_	O	O	_	_	_	_	_
23	not	_	O	O	_	_	_	_	_
24	shown	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	agreement	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	previous	_	O	O	_	_	_	_	_
31	observations	_	O	O	_	_	_	_	_
32	[	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	]	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Normal	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	thus	_	O	O	_	_	_	_	_
9	incubated	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	20	_	O	O	_	_	_	_	_
12	min	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	culture	_	O	O	_	_	_	_	_
15	medium	_	O	O	_	_	_	_	_
16	containing	_	O	O	_	_	_	_	_
17	30	_	O	O	_	_	_	_	_
18	%	_	O	O	_	_	_	_	_
19	serum	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	active	_	O	O	_	_	_	_	_
22	RA	_	O	O	_	_	_	_	_
23	patients	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	neutralizing	_	O	O	_	_	_	_	_
26	anti	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	antibody	_	O	O	_	_	_	_	_
32	or	_	O	O	_	_	_	_	_
33	control	_	O	O	_	_	_	_	_
34	antibody	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	STAT	_	O	O	_	_	_	_	_
38	phosphorylation	_	O	O	_	_	_	_	_
39	was	_	O	O	_	_	_	_	_
40	examined	_	O	O	_	_	_	_	_
41	by	_	O	O	_	_	_	_	_
42	western	_	O	O	_	_	_	_	_
43	blot	_	O	O	_	_	_	_	_
44	analysis	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	RA	_	O	O	_	_	_	_	_
2	serum	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	able	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	induce	_	O	O	_	_	_	_	_
7	tyrosine	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	this	_	O	O	_	_	_	_	_
19	STAT	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	mostly	_	O	O	_	_	_	_	_
24	abolished	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	neutralization	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	activity	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	Fig	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	5	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	dominant	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	activating	_	O	O	_	_	_	_	_
15	factor	_	O	O	_	_	_	_	_
16	contained	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	sera	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	active	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	patients	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	lack	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	activation	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	serum	_	O	O	_	_	_	_	_
10	suggests	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	much	_	O	O	_	_	_	_	_
13	higher	_	O	O	_	_	_	_	_
14	concentrations	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	may	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	required	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	activation	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	compared	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	STAT	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	that	_	O	O	_	_	_	_	_
35	inhibitors	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	STAT	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	signaling	_	O	O	_	_	_	_	_
40	may	_	O	O	_	_	_	_	_
41	be	_	O	O	_	_	_	_	_
42	present	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	RA	_	O	O	_	_	_	_	_
45	serum	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	next	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	whether	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	could	_	O	O	_	_	_	_	_
9	suppress	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	effect	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	inhibit	_	O	O	_	_	_	_	_
18	IFN	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	gamma	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	4	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	preincubation	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	or	_	O	O	_	_	_	_	_
5	without	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	ng	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	ml	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	36	_	O	O	_	_	_	_	_
15	hours	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	stimulated	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	28	_	O	O	_	_	_	_	_
31	costimulation	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	presence	_	O	O	_	_	_	_	_
35	or	_	O	O	_	_	_	_	_
36	absence	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	ng	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	ml	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	10	_	O	O	_	_	_	_	_
45	for	_	O	O	_	_	_	_	_
46	36	_	O	O	_	_	_	_	_
47	hours	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	IFN	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	gamma	_	O	O	_	_	_	_	_
54	production	_	O	O	_	_	_	_	_
55	was	_	O	O	_	_	_	_	_
56	measured	_	O	O	_	_	_	_	_
57	by	_	O	O	_	_	_	_	_
58	ELISA	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	pretreatment	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	normal	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	reduced	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	10	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	mediated	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IFN	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	production	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Fig	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	5	_	O	O	_	_	_	_	_
2	b	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	indicating	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	high	_	O	O	_	_	_	_	_
8	concentrations	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	could	_	O	O	_	_	_	_	_
14	modulate	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	responsiveness	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	findings	_	O	O	_	_	_	_	_
6	suggest	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	persistent	_	O	O	_	_	_	_	_
9	exposure	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	serum	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	have	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	role	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	both	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	induction	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	STAT	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	activation	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	resistance	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	inhibitory	_	O	O	_	_	_	_	_
33	effect	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	10	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	RA	_	O	O	_	_	_	_	_
40	CD	_	O	O	_	_	_	_	_
41	4	_	O	O	_	_	_	_	_
42	+	_	O	O	_	_	_	_	_
43	T	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_



1	Transcriptional	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	macrophage	_	O	O	_	_	_	_	_
6	colony	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	stimulating	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	associated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	secretion	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	bioactive	_	O	O	_	_	_	_	_
21	macrophage	_	O	O	_	_	_	_	_
22	colony	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	stimulating	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	protein	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	monocytes	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	involves	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	transcription	_	O	O	_	_	_	_	_
35	factor	_	O	O	_	_	_	_	_
36	NF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	kappa	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	peripheral	_	O	O	_	_	_	_	_
3	blood	_	O	O	_	_	_	_	_
4	monocytes	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	Mo	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	constitutively	_	O	O	_	_	_	_	_
9	display	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	chain	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	whereas	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	R	_	O	O	_	_	_	_	_
30	alpha	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	chain	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	not	_	O	O	_	_	_	_	_
35	constitutive	_	O	O	_	_	_	_	_
36	but	_	O	O	_	_	_	_	_
37	inducible	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	2	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	its	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	leads	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	transcriptional	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	macrophage	_	O	O	_	_	_	_	_
22	CSF	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	M	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	CSF	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	Mo	_	O	O	_	_	_	_	_
31	resulting	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	accumulation	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	M	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	CSF	_	O	O	_	_	_	_	_
38	mRNA	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	subsequent	_	O	O	_	_	_	_	_
41	release	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	bioactive	_	O	O	_	_	_	_	_
44	M	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	CSF	_	O	O	_	_	_	_	_
47	protein	_	O	O	_	_	_	_	_
48	as	_	O	O	_	_	_	_	_
49	demonstrated	_	O	O	_	_	_	_	_
50	by	_	O	O	_	_	_	_	_
51	ELISA	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	inhibition	_	O	O	_	_	_	_	_
54	of	_	O	O	_	_	_	_	_
55	IL	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	2	_	O	O	_	_	_	_	_
58	induced	_	O	O	_	_	_	_	_
59	release	_	O	O	_	_	_	_	_
60	of	_	O	O	_	_	_	_	_
61	an	_	O	O	_	_	_	_	_
62	activity	_	O	O	_	_	_	_	_
63	-	_	O	O	_	_	_	_	_
64	stimulating	_	O	O	_	_	_	_	_
65	growth	_	O	O	_	_	_	_	_
66	of	_	O	O	_	_	_	_	_
67	monocyte	_	O	O	_	_	_	_	_
68	-	_	O	O	_	_	_	_	_
69	type	_	O	O	_	_	_	_	_
70	colonies	_	O	O	_	_	_	_	_
71	by	_	O	O	_	_	_	_	_
72	a	_	O	O	_	_	_	_	_
73	neutralizing	_	O	O	_	_	_	_	_
74	anti	_	O	O	_	_	_	_	_
75	-	_	O	O	_	_	_	_	_
76	M	_	O	O	_	_	_	_	_
77	-	_	O	O	_	_	_	_	_
78	CSF	_	O	O	_	_	_	_	_
79	antibody	_	O	O	_	_	_	_	_
80	.	_	O	O	_	_	_	_	_

1	Transcriptional	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	M	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	CSF	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	preceded	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	enhanced	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	activity	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	factor	_	O	O	_	_	_	_	_
23	NF	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	its	_	O	O	_	_	_	_	_
29	recognition	_	O	O	_	_	_	_	_
30	sequence	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	5	_	O	O	_	_	_	_	_
34	'	_	O	O	_	_	_	_	_
35	regulatory	_	O	O	_	_	_	_	_
36	enhancer	_	O	O	_	_	_	_	_
37	region	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	M	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	CSF	_	O	O	_	_	_	_	_
43	gene	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	using	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	heterologous	_	O	O	_	_	_	_	_
6	promoter	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	herpes	_	O	O	_	_	_	_	_
9	thymidine	_	O	O	_	_	_	_	_
10	kinase	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	construct	_	O	O	_	_	_	_	_
13	containing	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	consensus	_	O	O	_	_	_	_	_
20	sequence	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	it	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	shown	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	NF	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	induced	_	O	O	_	_	_	_	_
38	monocyte	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	derived	_	O	O	_	_	_	_	_
41	nuclear	_	O	O	_	_	_	_	_
42	protein	_	O	O	_	_	_	_	_
43	confers	_	O	O	_	_	_	_	_
44	reporter	_	O	O	_	_	_	_	_
45	gene	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	human	_	O	O	_	_	_	_	_
48	growth	_	O	O	_	_	_	_	_
49	hormone	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	activity	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	findings	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	induces	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	M	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	CSF	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	human	_	O	O	_	_	_	_	_
20	blood	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	derived	_	O	O	_	_	_	_	_
23	Mo	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	provide	_	O	O	_	_	_	_	_
26	evidence	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	involvement	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	NF	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	kappa	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	transcriptional	_	O	O	_	_	_	_	_
36	regulation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	this	_	O	O	_	_	_	_	_
39	gene	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	Detection	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	non	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	erythroid	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	characteristics	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	EF	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	erythroid	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factor	_	O	O	_	_	_	_	_
5	erythroid	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	EF	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	plays	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	critical	_	O	O	_	_	_	_	_
16	role	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	erythroid	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	specific	_	O	O	_	_	_	_	_
24	genes	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	presence	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	mobility	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	sequence	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	specific	_	O	O	_	_	_	_	_
16	DNA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	characteristics	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	EF	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	at	_	O	O	_	_	_	_	_
24	low	_	O	O	_	_	_	_	_
25	abundance	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	wide	_	O	O	_	_	_	_	_
29	variety	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	non	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	erythroid	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	types	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	first	_	O	O	_	_	_	_	_
5	report	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	EF	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	like	_	O	O	_	_	_	_	_
12	activity	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	non	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	indicates	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	this	_	O	O	_	_	_	_	_
22	factor	_	O	O	_	_	_	_	_
23	may	_	O	O	_	_	_	_	_
24	play	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	role	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	regulation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	genes	_	O	O	_	_	_	_	_
32	expressed	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	such	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Ras	_	O	O	_	_	_	_	_
2	oncogene	_	O	O	_	_	_	_	_
3	transformation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	lymphoblasts	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	associated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	lymphocyte	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	block	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	differentiation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	21	_	O	O	_	_	_	_	_
4	ras	_	O	O	_	_	_	_	_
5	small	_	O	O	_	_	_	_	_
6	GTP	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	participate	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	signal	_	O	O	_	_	_	_	_
12	transduction	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	surface	_	O	O	_	_	_	_	_
16	receptors	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	affect	_	O	O	_	_	_	_	_
19	neoplastic	_	O	O	_	_	_	_	_
20	transformation	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	development	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	many	_	O	O	_	_	_	_	_
25	different	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	types	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	examined	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	relationship	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	ras	_	O	O	_	_	_	_	_
12	transformation	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	lymphocytes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	constitutive	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	24	_	O	O	_	_	_	_	_
11	Ha	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	ras	_	O	O	_	_	_	_	_
14	oncogene	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	EBV	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	immortalized	_	O	O	_	_	_	_	_
19	B	_	O	O	_	_	_	_	_
20	lymphoblasts	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	associated	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	induction	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	interleukin	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	alpha	_	O	O	_	_	_	_	_
32	subunit	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	an	_	O	O	_	_	_	_	_
36	impaired	_	O	O	_	_	_	_	_
37	immunoglobulin	_	O	O	_	_	_	_	_
38	gene	_	O	O	_	_	_	_	_
39	expression	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	altered	_	O	O	_	_	_	_	_
42	adhesion	_	O	O	_	_	_	_	_
43	properties	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	increased	_	O	O	_	_	_	_	_
46	survival	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	serum	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	free	_	O	O	_	_	_	_	_
51	medium	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	subunit	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	hallmark	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	lymphocyte	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	we	_	O	O	_	_	_	_	_
19	suggest	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	21	_	O	O	_	_	_	_	_
23	ras	_	O	O	_	_	_	_	_
24	naturally	_	O	O	_	_	_	_	_
25	triggers	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	activation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	ras	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	transformed	_	O	O	_	_	_	_	_
5	lymphocytes	_	O	O	_	_	_	_	_
6	displayed	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	fully	_	O	O	_	_	_	_	_
9	functional	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	r	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	assessed	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	c	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	fos	_	O	O	_	_	_	_	_
21	induction	_	O	O	_	_	_	_	_
22	following	_	O	O	_	_	_	_	_
23	treatment	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	;	_	O	O	_	_	_	_	_
29	nevertheless	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	they	_	O	O	_	_	_	_	_
32	were	_	O	O	_	_	_	_	_
33	not	_	O	O	_	_	_	_	_
34	growth	_	O	O	_	_	_	_	_
35	stimulated	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	this	_	O	O	_	_	_	_	_
38	lymphokine	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	decreased	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	immunoglobulin	_	O	O	_	_	_	_	_
6	genes	_	O	O	_	_	_	_	_
7	indicates	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	ras	_	O	O	_	_	_	_	_
11	oncogene	_	O	O	_	_	_	_	_
12	blocks	_	O	O	_	_	_	_	_
13	terminal	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	plasma	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	possibly	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	inhibiting	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	lymphocyte	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	transcription	_	O	O	_	_	_	_	_
29	factors	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Somewhat	_	O	O	_	_	_	_	_
2	unexpectedly	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	constitutive	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	21	_	O	O	_	_	_	_	_
8	ras	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	did	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	cause	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	increased	_	O	O	_	_	_	_	_
15	DNA	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factors	_	O	O	_	_	_	_	_
20	PEA	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	AP	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	PEA	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	Oct	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	NF	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	kB	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	isolation	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	MACS	_	O	O	_	_	_	_	_

1	Anti	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	microbeads	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	used	_	O	O	_	_	_	_	_
8	essentially	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	recommended	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	manufacturer	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	Miltenyi	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	19	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	resuspended	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	80	_	O	O	_	_	_	_	_
6	mul	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	FBS	_	O	O	_	_	_	_	_
9	staining	_	O	O	_	_	_	_	_
10	buffer	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Anti	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	microbeads	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	20	_	O	O	_	_	_	_	_
8	mul	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	added	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	incubated	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	15	_	O	O	_	_	_	_	_
16	min	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	12	_	O	O	_	_	_	_	_
21	degreesC	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Saturating	_	O	O	_	_	_	_	_
2	amounts	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	fluorochrome	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	conjugated	_	O	O	_	_	_	_	_
7	antibodies	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	added	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	further	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	min	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	diluted	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_
7	5	_	O	O	_	_	_	_	_
8	ml	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	FBS	_	O	O	_	_	_	_	_
11	staining	_	O	O	_	_	_	_	_
12	buffer	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	pelleted	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	resuspended	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	500	_	O	O	_	_	_	_	_
19	mul	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	magnetically	_	O	O	_	_	_	_	_
22	separated	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	usually	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	AutoMACS	_	O	O	_	_	_	_	_
28	magnet	_	O	O	_	_	_	_	_
29	fitted	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	MACS	_	O	O	_	_	_	_	_
33	MS	_	O	O	_	_	_	_	_
34	column	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Flow	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	through	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	ml	_	O	O	_	_	_	_	_
8	washes	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	collected	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	negative	_	O	O	_	_	_	_	_
14	fraction	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Enriched	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	collected	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	two	_	O	O	_	_	_	_	_
7	0	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	ml	_	O	O	_	_	_	_	_
11	aliquots	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	column	_	O	O	_	_	_	_	_
15	after	_	O	O	_	_	_	_	_
16	removal	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	magnet	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Alternatively	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	stained	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	anti	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	phycoerythrin	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	washed	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	magnetically	_	O	O	_	_	_	_	_
16	labeled	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	anti	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	phycoerythrin	_	O	O	_	_	_	_	_
21	microbeads	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	20	_	O	O	_	_	_	_	_
24	mul	_	O	O	_	_	_	_	_
25	added	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	80	_	O	O	_	_	_	_	_
28	mul	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	suspension	_	O	O	_	_	_	_	_
32	;	_	O	O	_	_	_	_	_
33	15	_	O	O	_	_	_	_	_
34	min	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	6	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	12	_	O	O	_	_	_	_	_
39	degreesC	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	magnetically	_	O	O	_	_	_	_	_
44	separated	_	O	O	_	_	_	_	_
45	as	_	O	O	_	_	_	_	_
46	described	_	O	O	_	_	_	_	_
47	above	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	purity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	assessed	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	flow	_	O	O	_	_	_	_	_
9	cytometric	_	O	O	_	_	_	_	_
10	analysis	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	stained	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	FACS	_	O	O	_	_	_	_	_
17	Vantage	_	O	O	_	_	_	_	_
18	sorter	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Most	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	more	_	O	O	_	_	_	_	_
4	than	_	O	O	_	_	_	_	_
5	97	_	O	O	_	_	_	_	_
6	%	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	isolated	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	had	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	marker	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_



1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kappaB	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	activator	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	AP	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	pathway	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	17	_	O	O	_	_	_	_	_
23	promoter	_	O	O	_	_	_	_	_
24	region	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	further	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	intracellular	_	O	O	_	_	_	_	_
6	signaling	_	O	O	_	_	_	_	_
7	pathway	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	anti	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	plus	_	O	O	_	_	_	_	_
15	anti	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	28	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	concanavalin	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	PHA	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	15	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	responsible	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	inducing	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	17	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	we	_	O	O	_	_	_	_	_
39	performed	_	O	O	_	_	_	_	_
40	an	_	O	O	_	_	_	_	_
41	electrophoretic	_	O	O	_	_	_	_	_
42	mobility	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	shift	_	O	O	_	_	_	_	_
45	assay	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	EMSA	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	NF	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	kappaB	_	O	O	_	_	_	_	_
53	recognition	_	O	O	_	_	_	_	_
54	sites	_	O	O	_	_	_	_	_
55	in	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	promoters	_	O	O	_	_	_	_	_
58	of	_	O	O	_	_	_	_	_
59	IL	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	17	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Fig	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	nuclear	_	O	O	_	_	_	_	_
5	extracts	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	PBMC	_	O	O	_	_	_	_	_
9	stimulated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	anti	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	plus	_	O	O	_	_	_	_	_
16	anti	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	28	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	lane	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	demonstrated	_	O	O	_	_	_	_	_
25	increased	_	O	O	_	_	_	_	_
26	binding	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	kappaB	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	17	_	O	O	_	_	_	_	_
35	promoters	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	comparison	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	that	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	controls	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	lane	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	supershift	_	O	O	_	_	_	_	_
3	assay	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	shifted	_	O	O	_	_	_	_	_
6	bands	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	65	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	50	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	lanes	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	c	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	Rel	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	lane	_	O	O	_	_	_	_	_
26	5	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	normal	_	O	O	_	_	_	_	_
3	PBMC	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	same	_	O	O	_	_	_	_	_
6	pattern	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	observed	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	but	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	degree	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	kappaB	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	anti	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	plus	_	O	O	_	_	_	_	_
24	anti	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	28	_	O	O	_	_	_	_	_
28	was	_	O	O	_	_	_	_	_
29	less	_	O	O	_	_	_	_	_
30	intense	_	O	O	_	_	_	_	_
31	than	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	RA	_	O	O	_	_	_	_	_
35	PBMC	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	Fig	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	b	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	confirm	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	link	_	O	O	_	_	_	_	_
5	between	_	O	O	_	_	_	_	_
6	PI	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	K	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	NF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	kappaB	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	we	_	O	O	_	_	_	_	_
16	performed	_	O	O	_	_	_	_	_
17	EMSA	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	determine	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	kappaB	_	O	O	_	_	_	_	_
24	binding	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	after	_	O	O	_	_	_	_	_
27	treatment	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	LY	_	O	O	_	_	_	_	_
31	294002	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	PDTC	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	agents	_	O	O	_	_	_	_	_
3	block	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kappaB	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	activity	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	Fig	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	c	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	Western	_	O	O	_	_	_	_	_
2	blotting	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	IkappaB	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	showed	_	O	O	_	_	_	_	_
8	inhibition	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	degradation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	IkappaB	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	LY	_	O	O	_	_	_	_	_
17	294002	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	PDTC	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	same	_	O	O	_	_	_	_	_
23	time	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Fig	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	7	_	O	O	_	_	_	_	_
2	c	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	AP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	pathway	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	activated	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	stimulation	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	anti	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	plus	_	O	O	_	_	_	_	_
20	anti	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	28	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	data	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	shown	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	demonstrating	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	NF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	kappaB	_	O	O	_	_	_	_	_
35	is	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	main	_	O	O	_	_	_	_	_
38	intracellular	_	O	O	_	_	_	_	_
39	signaling	_	O	O	_	_	_	_	_
40	pathway	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	17	_	O	O	_	_	_	_	_
45	production	_	O	O	_	_	_	_	_
46	by	_	O	O	_	_	_	_	_
47	activated	_	O	O	_	_	_	_	_
48	PBMC	_	O	O	_	_	_	_	_
49	from	_	O	O	_	_	_	_	_
50	patients	_	O	O	_	_	_	_	_
51	with	_	O	O	_	_	_	_	_
52	RA	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_



1	C	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	EBP	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	rheumatoid	_	O	O	_	_	_	_	_
7	arthritis	_	O	O	_	_	_	_	_
8	:	_	O	O	_	_	_	_	_
9	correlation	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	inflammation	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	disease	_	O	O	_	_	_	_	_
15	specificity	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	Rheumatoid	_	O	O	_	_	_	_	_
2	arthritis	_	O	O	_	_	_	_	_
3	synovial	_	O	O	_	_	_	_	_
4	tissue	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	examined	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	compared	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	osteoarthritis	_	O	O	_	_	_	_	_
11	tissue	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	presence	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	nuclear	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	C	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	EBP	_	O	O	_	_	_	_	_
23	beta	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	6	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	region	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	lining	_	O	O	_	_	_	_	_
5	or	_	O	O	_	_	_	_	_
6	sublining	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	subcellular	_	O	O	_	_	_	_	_
14	distribution	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	cytoplasmic	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	C	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	EBP	_	O	O	_	_	_	_	_
27	beta	_	O	O	_	_	_	_	_
28	was	_	O	O	_	_	_	_	_
29	characterized	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Rheumatoid	_	O	O	_	_	_	_	_
2	arthritis	_	O	O	_	_	_	_	_
3	synovial	_	O	O	_	_	_	_	_
4	fluid	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	normal	_	O	O	_	_	_	_	_
9	peripheral	_	O	O	_	_	_	_	_
10	blood	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	also	_	O	O	_	_	_	_	_
13	examined	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	C	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	EBP	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	detected	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	synovial	_	O	O	_	_	_	_	_
10	lining	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	sublining	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	synovial	_	O	O	_	_	_	_	_
17	tissue	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	rheumatoid	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	osteoarthritis	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	significant	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	P	_	O	O	_	_	_	_	_
5	<	_	O	O	_	_	_	_	_
6	0	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_
8	001	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	<	_	O	O	_	_	_	_	_
11	0	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	05	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	respectively	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	increase	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	percentage	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	nuclear	_	O	O	_	_	_	_	_
25	staining	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	seen	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	lining	_	O	O	_	_	_	_	_
31	layer	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	compared	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	sublining	_	O	O	_	_	_	_	_
39	region	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	rheumatoid	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	osteoarthritis	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	both	_	O	O	_	_	_	_	_
3	diseases	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	strong	_	O	O	_	_	_	_	_
6	correlation	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	r	_	O	O	_	_	_	_	_
9	=	_	O	O	_	_	_	_	_
10	0	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	79	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	P	_	O	O	_	_	_	_	_
15	<	_	O	O	_	_	_	_	_
16	0	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	001	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	observed	_	O	O	_	_	_	_	_
22	between	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	percentage	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	synovial	_	O	O	_	_	_	_	_
30	lining	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	were	_	O	O	_	_	_	_	_
33	positive	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	nuclear	_	O	O	_	_	_	_	_
36	C	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	EBP	_	O	O	_	_	_	_	_
39	beta	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	lining	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	depth	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	color	_	O	O	_	_	_	_	_
4	immunohistochemistry	_	O	O	_	_	_	_	_
5	demonstrated	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	both	_	O	O	_	_	_	_	_
8	macrophages	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	fibroblast	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	like	_	O	O	_	_	_	_	_
13	synoviocytes	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	positive	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	nuclear	_	O	O	_	_	_	_	_
18	C	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	EBP	_	O	O	_	_	_	_	_
21	beta	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	presence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	C	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	EBP	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	confirmed	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	immunohistochemistry	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	Western	_	O	O	_	_	_	_	_
14	blot	_	O	O	_	_	_	_	_
15	analysis	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	isolated	_	O	O	_	_	_	_	_
18	synovial	_	O	O	_	_	_	_	_
19	fibroblasts	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	C	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	EBP	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	detected	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	rheumatoid	_	O	O	_	_	_	_	_
11	synovial	_	O	O	_	_	_	_	_
12	fluid	_	O	O	_	_	_	_	_
13	monocytes	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	macrophages	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	lymphocytes	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	neutrophils	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Western	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	confirmed	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	presence	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	C	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	EBP	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	these	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	intensity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	C	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	EBP	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	staining	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	greater	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	P	_	O	O	_	_	_	_	_
13	<	_	O	O	_	_	_	_	_
14	0	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	001	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	synovial	_	O	O	_	_	_	_	_
20	fluid	_	O	O	_	_	_	_	_
21	monocytes	_	O	O	_	_	_	_	_
22	than	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	those	_	O	O	_	_	_	_	_
25	from	_	O	O	_	_	_	_	_
26	normal	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	rheumatoid	_	O	O	_	_	_	_	_
29	peripheral	_	O	O	_	_	_	_	_
30	blood	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	enhanced	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	staining	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	EBP	_	O	O	_	_	_	_	_
12	beta	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	synovial	_	O	O	_	_	_	_	_
16	lining	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	compared	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	sublining	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	suggesting	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	lining	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	positive	_	O	O	_	_	_	_	_
32	correlation	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	lining	_	O	O	_	_	_	_	_
35	layer	_	O	O	_	_	_	_	_
36	depth	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	percentage	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	lining	_	O	O	_	_	_	_	_
45	positive	_	O	O	_	_	_	_	_
46	for	_	O	O	_	_	_	_	_
47	nuclear	_	O	O	_	_	_	_	_
48	C	_	O	O	_	_	_	_	_
49	/	_	O	O	_	_	_	_	_
50	EBP	_	O	O	_	_	_	_	_
51	beta	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	suggest	_	O	O	_	_	_	_	_
54	a	_	O	O	_	_	_	_	_
55	potential	_	O	O	_	_	_	_	_
56	role	_	O	O	_	_	_	_	_
57	for	_	O	O	_	_	_	_	_
58	C	_	O	O	_	_	_	_	_
59	/	_	O	O	_	_	_	_	_
60	EBP	_	O	O	_	_	_	_	_
61	beta	_	O	O	_	_	_	_	_
62	in	_	O	O	_	_	_	_	_
63	chronic	_	O	O	_	_	_	_	_
64	inflammation	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	regulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	production	_	O	O	_	_	_	_	_
6	or	_	O	O	_	_	_	_	_
7	activity	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	EBP	_	O	O	_	_	_	_	_
12	beta	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	inhibit	_	O	O	_	_	_	_	_
16	inflammatory	_	O	O	_	_	_	_	_
17	mediator	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	synovial	_	O	O	_	_	_	_	_
21	macrophages	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	fibroblasts	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	offers	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	novel	_	O	O	_	_	_	_	_
28	approach	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	therapeutic	_	O	O	_	_	_	_	_
31	intervention	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	GP	_	O	O	_	_	_	_	_
4	led	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NFAT	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	NFkappaB	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	NFIL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	PBMC	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	medium	_	O	O	_	_	_	_	_
7	control	_	O	O	_	_	_	_	_
8	or	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	100	_	O	O	_	_	_	_	_
14	mug	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	h	_	O	O	_	_	_	_	_
19	at	_	O	O	_	_	_	_	_
20	37	_	O	O	_	_	_	_	_
21	degreesC	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	extracts	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	32	_	O	O	_	_	_	_	_
8	P	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	labeled	_	O	O	_	_	_	_	_
11	NFAT	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	NFkappaB	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	NFIL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	NFkappaB	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	8	_	O	O	_	_	_	_	_
24	oligonucleotide	_	O	O	_	_	_	_	_
25	probe	_	O	O	_	_	_	_	_
26	corresponding	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	IFNgamma	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	TNFalpha	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	8	_	O	O	_	_	_	_	_
40	gene	_	O	O	_	_	_	_	_
41	promoters	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	Table	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Arrows	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	black	_	O	O	_	_	_	_	_
5	head	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	migrational	_	O	O	_	_	_	_	_
8	location	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	NFAT	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	NFkappaB	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	DNA	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	NFIL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	DNA	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	NFkappaB	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	8	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	DNA	_	O	O	_	_	_	_	_
32	complex	_	O	O	_	_	_	_	_
33	compared	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	free	_	O	O	_	_	_	_	_
36	probe	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	no	_	O	O	_	_	_	_	_
39	shift	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Arrow	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	open	_	O	O	_	_	_	_	_
5	head	_	O	O	_	_	_	_	_
6	indicates	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	supershift	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	NFkappaB	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	8	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	DNA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	anti	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	65	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	50	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	respectively	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	autoradiogram	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	representative	_	O	O	_	_	_	_	_
6	experiment	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	shown	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	n	_	O	O	_	_	_	_	_
11	=	_	O	O	_	_	_	_	_
12	7	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	B	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Decreased	_	O	O	_	_	_	_	_
4	DNA	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	NFkappaB	_	O	O	_	_	_	_	_
8	following	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	TSST	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	compared	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	TSST	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	GP	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	TSST	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	GP	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	PBMC	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	medium	_	O	O	_	_	_	_	_
7	control	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	TSST	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	100	_	O	O	_	_	_	_	_
18	mug	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	GP	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	TSST	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	GP	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	LPS	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	h	_	O	O	_	_	_	_	_
33	at	_	O	O	_	_	_	_	_
34	37	_	O	O	_	_	_	_	_
35	degreesC	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	autoradiogram	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	representative	_	O	O	_	_	_	_	_
6	experiment	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	shown	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Schematic	_	O	O	_	_	_	_	_
2	representation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NFkappaB	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	following	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	100	_	O	O	_	_	_	_	_
15	mug	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	TSST	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	treatment	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	250	_	O	O	_	_	_	_	_
24	ng	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	well	_	O	O	_	_	_	_	_
28	as	_	O	O	_	_	_	_	_
29	simultaneous	_	O	O	_	_	_	_	_
30	administration	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	both	_	O	O	_	_	_	_	_
33	compounds	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	theoretical	_	O	O	_	_	_	_	_
37	value	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	GP	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	TSST	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	calc	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Medium	_	O	O	_	_	_	_	_
2	control	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	set	_	O	O	_	_	_	_	_
6	equal	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	SEM	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	significances	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	*	_	O	O	_	_	_	_	_
17	=	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	<	_	O	O	_	_	_	_	_
20	0	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	05	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	are	_	O	O	_	_	_	_	_
25	shown	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	respect	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	medium	_	O	O	_	_	_	_	_
30	control	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	n	_	O	O	_	_	_	_	_
33	=	_	O	O	_	_	_	_	_
34	4	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_



1	Human	_	O	O	_	_	_	_	_
2	immunodeficiency	_	O	O	_	_	_	_	_
3	viruses	_	O	O	_	_	_	_	_
4	containing	_	O	O	_	_	_	_	_
5	heterologous	_	O	O	_	_	_	_	_
6	enhancer	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	promoters	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	replication	_	O	O	_	_	_	_	_
11	competent	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	exhibit	_	O	O	_	_	_	_	_
14	different	_	O	O	_	_	_	_	_
15	lymphocyte	_	O	O	_	_	_	_	_
16	tropisms	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	immunodeficiency	_	O	O	_	_	_	_	_
4	virus	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	HIV	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	type	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	long	_	O	O	_	_	_	_	_
11	terminal	_	O	O	_	_	_	_	_
12	repeat	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	LTR	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	contains	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	sites	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	nuclear	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	kappa	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	kappa	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	constitutively	_	O	O	_	_	_	_	_
33	expressed	_	O	O	_	_	_	_	_
34	transcription	_	O	O	_	_	_	_	_
35	factor	_	O	O	_	_	_	_	_
36	Sp	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	both	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	which	_	O	O	_	_	_	_	_
42	are	_	O	O	_	_	_	_	_
43	highly	_	O	O	_	_	_	_	_
44	conserved	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	HIV	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	simian	_	O	O	_	_	_	_	_
49	immunodeficiency	_	O	O	_	_	_	_	_
50	virus	_	O	O	_	_	_	_	_
51	isolates	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	delineate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	motifs	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	replicative	_	O	O	_	_	_	_	_
11	capacity	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	HIV	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	explore	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	possibility	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	extending	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	virus	_	O	O	_	_	_	_	_
23	host	_	O	O	_	_	_	_	_
24	range	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	known	_	O	O	_	_	_	_	_
27	heterologous	_	O	O	_	_	_	_	_
28	enhancer	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	promoters	_	O	O	_	_	_	_	_
31	were	_	O	O	_	_	_	_	_
32	inserted	_	O	O	_	_	_	_	_
33	into	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	HIV	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	LTR	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	place	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	NF	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	kappa	_	O	O	_	_	_	_	_
46	B	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	Sp	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	binding	_	O	O	_	_	_	_	_
51	sites	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	substitutions	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	viral	_	O	O	_	_	_	_	_
8	replication	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	transfected	_	O	O	_	_	_	_	_
11	HeLa	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	HIV	_	O	O	_	_	_	_	_
16	infection	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	human	_	O	O	_	_	_	_	_
19	peripheral	_	O	O	_	_	_	_	_
20	blood	_	O	O	_	_	_	_	_
21	lymphocytes	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	continuous	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	leukemia	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	lines	_	O	O	_	_	_	_	_
29	were	_	O	O	_	_	_	_	_
30	evaluated	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	HIVs	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	which	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	Sp	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	enhancer	_	O	O	_	_	_	_	_
13	plus	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	downstream	_	O	O	_	_	_	_	_
16	TATA	_	O	O	_	_	_	_	_
17	element	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	replaced	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	heterologous	_	O	O	_	_	_	_	_
22	enhancer	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	promoters	_	O	O	_	_	_	_	_
25	were	_	O	O	_	_	_	_	_
26	also	_	O	O	_	_	_	_	_
27	constructed	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Viruses	_	O	O	_	_	_	_	_
2	containing	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	cytomegalovirus	_	O	O	_	_	_	_	_
6	immediate	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	enhancer	_	O	O	_	_	_	_	_
10	exhibited	_	O	O	_	_	_	_	_
11	infectious	_	O	O	_	_	_	_	_
12	kinetics	_	O	O	_	_	_	_	_
13	similar	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	wild	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	type	_	O	O	_	_	_	_	_
20	HIV	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	activated	_	O	O	_	_	_	_	_
23	human	_	O	O	_	_	_	_	_
24	peripheral	_	O	O	_	_	_	_	_
25	blood	_	O	O	_	_	_	_	_
26	lymphocytes	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	AA	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	but	_	O	O	_	_	_	_	_
32	replicated	_	O	O	_	_	_	_	_
33	less	_	O	O	_	_	_	_	_
34	efficiently	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	H	_	O	O	_	_	_	_	_
37	9	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	CEM	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	heterologous	_	O	O	_	_	_	_	_
6	enhancer	_	O	O	_	_	_	_	_
7	elements	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	capable	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	restoring	_	O	O	_	_	_	_	_
12	Tat	_	O	O	_	_	_	_	_
13	responsiveness	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	HIV	_	O	O	_	_	_	_	_
17	LTR	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	context	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	directing	_	O	O	_	_	_	_	_
23	reporter	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	well	_	O	O	_	_	_	_	_
28	as	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	production	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	infectious	_	O	O	_	_	_	_	_
34	progeny	_	O	O	_	_	_	_	_
35	virions	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	PI	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	K	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	Akt	_	O	O	_	_	_	_	_
8	signal	_	O	O	_	_	_	_	_
9	transduction	_	O	O	_	_	_	_	_
10	pathway	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	17	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	anti	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	downstream	_	O	O	_	_	_	_	_
4	effector	_	O	O	_	_	_	_	_
5	molecules	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	PI	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	K	_	O	O	_	_	_	_	_
11	pathway	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	we	_	O	O	_	_	_	_	_
14	evaluated	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	Akt	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	western	_	O	O	_	_	_	_	_
21	blotting	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Fig	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	6	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	at	_	O	O	_	_	_	_	_
4	10	_	O	O	_	_	_	_	_
5	min	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	incubation	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	mug	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	ml	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	LY	_	O	O	_	_	_	_	_
21	294002	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	20	_	O	O	_	_	_	_	_
24	muM	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	no	_	O	O	_	_	_	_	_
28	difference	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	amounts	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	phosphorylated	_	O	O	_	_	_	_	_
34	Akt	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	observed	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	after	_	O	O	_	_	_	_	_
4	30	_	O	O	_	_	_	_	_
5	min	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	incubation	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	phosphorylated	_	O	O	_	_	_	_	_
10	Akt	_	O	O	_	_	_	_	_
11	increased	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	lane	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	effect	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	inhibition	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	LY	_	O	O	_	_	_	_	_
24	294002	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	lane	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	reached	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	peak	_	O	O	_	_	_	_	_
32	at	_	O	O	_	_	_	_	_
33	60	_	O	O	_	_	_	_	_
34	min	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	lasting	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	120	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	240	_	O	O	_	_	_	_	_
41	min	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	non	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	phosphorylated	_	O	O	_	_	_	_	_
7	Akt	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	actin	_	O	O	_	_	_	_	_
12	remained	_	O	O	_	_	_	_	_
13	unchanged	_	O	O	_	_	_	_	_
14	regardless	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	incubation	_	O	O	_	_	_	_	_
17	time	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	PHA	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	concanavalin	_	O	O	_	_	_	_	_
4	A	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	15	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	demonstrated	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	same	_	O	O	_	_	_	_	_
13	effect	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	phosphorylated	_	O	O	_	_	_	_	_
16	Akt	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	shown	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	anti	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	which	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	inhibition	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	wortmannin	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	PDTC	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	well	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	LY	_	O	O	_	_	_	_	_
38	294002	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	data	_	O	O	_	_	_	_	_
41	not	_	O	O	_	_	_	_	_
42	shown	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_



1	Latent	_	O	O	_	_	_	_	_
2	membrane	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	Epstein	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	Barr	_	O	O	_	_	_	_	_
9	virus	_	O	O	_	_	_	_	_
10	interacts	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	JAK	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	activates	_	O	O	_	_	_	_	_
16	STAT	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Latent	_	O	O	_	_	_	_	_
2	membrane	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	LMP	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	acts	_	O	O	_	_	_	_	_
10	like	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	permanently	_	O	O	_	_	_	_	_
13	activated	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	tumor	_	O	O	_	_	_	_	_
18	necrosis	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	TNF	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	receptor	_	O	O	_	_	_	_	_
25	superfamily	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	absolutely	_	O	O	_	_	_	_	_
29	required	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	B	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	immortalization	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	Epstein	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	Barr	_	O	O	_	_	_	_	_
38	virus	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Molecular	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	biochemical	_	O	O	_	_	_	_	_
4	approaches	_	O	O	_	_	_	_	_
5	demonstrated	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	LMP	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	usurps	_	O	O	_	_	_	_	_
10	cellular	_	O	O	_	_	_	_	_
11	signaling	_	O	O	_	_	_	_	_
12	pathways	_	O	O	_	_	_	_	_
13	resulting	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	induction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kappaB	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	AP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	via	_	O	O	_	_	_	_	_
26	two	_	O	O	_	_	_	_	_
27	C	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	terminal	_	O	O	_	_	_	_	_
30	activating	_	O	O	_	_	_	_	_
31	regions	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	demonstrate	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	third	_	O	O	_	_	_	_	_
7	region	_	O	O	_	_	_	_	_
8	encompassing	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	proline	_	O	O	_	_	_	_	_
11	rich	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	within	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	33	_	O	O	_	_	_	_	_
16	bp	_	O	O	_	_	_	_	_
17	repetitive	_	O	O	_	_	_	_	_
18	stretch	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	LMP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	'	_	O	O	_	_	_	_	_
23	s	_	O	O	_	_	_	_	_
24	C	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	terminus	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	required	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	Janus	_	O	O	_	_	_	_	_
34	kinase	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	JAK	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	interaction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	LMP	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	JAK	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	leads	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	enhanced	_	O	O	_	_	_	_	_
13	tyrosine	_	O	O	_	_	_	_	_
14	auto	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	transphosphorylation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	JAK	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	within	_	O	O	_	_	_	_	_
21	minutes	_	O	O	_	_	_	_	_
22	after	_	O	O	_	_	_	_	_
23	crosslinking	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	conditional	_	O	O	_	_	_	_	_
27	NGF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	R	_	O	O	_	_	_	_	_
30	:	_	O	O	_	_	_	_	_
31	LMP	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	chimera	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	is	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	prerequisite	_	O	O	_	_	_	_	_
38	for	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	activation	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	STAT	_	O	O	_	_	_	_	_
43	transcription	_	O	O	_	_	_	_	_
44	factors	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	reveal	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	novel	_	O	O	_	_	_	_	_
6	activating	_	O	O	_	_	_	_	_
7	region	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	LMP	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	C	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	terminus	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	identify	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	JAK	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	STAT	_	O	O	_	_	_	_	_
21	pathway	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	target	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	this	_	O	O	_	_	_	_	_
27	viral	_	O	O	_	_	_	_	_
28	integral	_	O	O	_	_	_	_	_
29	membrane	_	O	O	_	_	_	_	_
30	protein	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	Daidzein	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	genistein	_	O	O	_	_	_	_	_
4	glucuronides	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	vitro	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	weakly	_	O	O	_	_	_	_	_
9	estrogenic	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	activate	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	natural	_	O	O	_	_	_	_	_
14	killer	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	nutritionally	_	O	O	_	_	_	_	_
18	relevant	_	O	O	_	_	_	_	_
19	concentrations	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Daidzein	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	genistein	_	O	O	_	_	_	_	_
4	glucuronides	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	DG	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	GG	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	major	_	O	O	_	_	_	_	_
12	isoflavone	_	O	O	_	_	_	_	_
13	metabolites	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	partly	_	O	O	_	_	_	_	_
18	responsible	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	biological	_	O	O	_	_	_	_	_
21	effects	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	isoflavones	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	such	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	estrogen	_	O	O	_	_	_	_	_
28	receptor	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	natural	_	O	O	_	_	_	_	_
32	killer	_	O	O	_	_	_	_	_
33	cell	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	NK	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	activation	_	O	O	_	_	_	_	_
38	or	_	O	O	_	_	_	_	_
39	inhibition	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	DG	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	GG	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	synthesized	_	O	O	_	_	_	_	_
6	using	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	methylcholanthrene	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	rat	_	O	O	_	_	_	_	_
13	liver	_	O	O	_	_	_	_	_
14	microsomes	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Km	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	Vmax	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	daidzein	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	genistein	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	9	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	0	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	7	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	7	_	O	O	_	_	_	_	_
17	micromol	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	L	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	0	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	7	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	6	_	O	O	_	_	_	_	_
29	micromol	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	mg	_	O	O	_	_	_	_	_
33	protein	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	min	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	respectively	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	absence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	ultraviolet	_	O	O	_	_	_	_	_
5	absorbance	_	O	O	_	_	_	_	_
6	maxima	_	O	O	_	_	_	_	_
7	shifts	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	presence	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	sodium	_	O	O	_	_	_	_	_
13	acetate	_	O	O	_	_	_	_	_
14	confirmed	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	synthesized	_	O	O	_	_	_	_	_
18	products	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	7	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	O	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	glucuronides	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	DG	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	GG	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	further	_	O	O	_	_	_	_	_
6	purified	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	Sephadex	_	O	O	_	_	_	_	_
10	LH	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	20	_	O	O	_	_	_	_	_
13	column	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	DG	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	GG	_	O	O	_	_	_	_	_
4	competed	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	17	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	H	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	estradiol	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	estrogen	_	O	O	_	_	_	_	_
19	receptors	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	D	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	F	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	mouse	_	O	O	_	_	_	_	_
28	uterine	_	O	O	_	_	_	_	_
29	cytosol	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	concentrations	_	O	O	_	_	_	_	_
3	required	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	50	_	O	O	_	_	_	_	_
6	%	_	O	O	_	_	_	_	_
7	displacement	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	17	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	H	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	estradiol	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	CB	_	O	O	_	_	_	_	_
19	50	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	were	_	O	O	_	_	_	_	_
22	:	_	O	O	_	_	_	_	_
23	17	_	O	O	_	_	_	_	_
24	beta	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	estradiol	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	34	_	O	O	_	_	_	_	_
31	nmol	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	L	_	O	O	_	_	_	_	_
34	;	_	O	O	_	_	_	_	_
35	diethylstilbestrol	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_
39	46	_	O	O	_	_	_	_	_
40	nmol	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	L	_	O	O	_	_	_	_	_
43	;	_	O	O	_	_	_	_	_
44	daidzein	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_
48	6	_	O	O	_	_	_	_	_
49	micromol	_	O	O	_	_	_	_	_
50	/	_	O	O	_	_	_	_	_
51	L	_	O	O	_	_	_	_	_
52	;	_	O	O	_	_	_	_	_
53	DG	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	14	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_
57	7	_	O	O	_	_	_	_	_
58	micromol	_	O	O	_	_	_	_	_
59	/	_	O	O	_	_	_	_	_
60	L	_	O	O	_	_	_	_	_
61	;	_	O	O	_	_	_	_	_
62	genistein	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	0	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_
66	154	_	O	O	_	_	_	_	_
67	micromol	_	O	O	_	_	_	_	_
68	/	_	O	O	_	_	_	_	_
69	L	_	O	O	_	_	_	_	_
70	;	_	O	O	_	_	_	_	_
71	GG	_	O	O	_	_	_	_	_
72	,	_	O	O	_	_	_	_	_
73	7	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_
75	27	_	O	O	_	_	_	_	_
76	micromol	_	O	O	_	_	_	_	_
77	/	_	O	O	_	_	_	_	_
78	L	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	peripheral	_	O	O	_	_	_	_	_
4	blood	_	O	O	_	_	_	_	_
5	NK	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	genistein	_	O	O	_	_	_	_	_
9	at	_	O	O	_	_	_	_	_
10	<	_	O	O	_	_	_	_	_
11	0	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	micromol	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	L	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	DG	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	GG	_	O	O	_	_	_	_	_
21	at	_	O	O	_	_	_	_	_
22	0	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	10	_	O	O	_	_	_	_	_
27	micromol	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	L	_	O	O	_	_	_	_	_
30	enhanced	_	O	O	_	_	_	_	_
31	NK	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	mediated	_	O	O	_	_	_	_	_
35	K	_	O	O	_	_	_	_	_
36	562	_	O	O	_	_	_	_	_
37	cancer	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	killing	_	O	O	_	_	_	_	_
40	significantly	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	P	_	O	O	_	_	_	_	_
43	<	_	O	O	_	_	_	_	_
44	0	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_
46	05	_	O	O	_	_	_	_	_
47	)	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	>	_	O	O	_	_	_	_	_
3	0	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_
5	5	_	O	O	_	_	_	_	_
6	micromol	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	L	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	genistein	_	O	O	_	_	_	_	_
11	inhibited	_	O	O	_	_	_	_	_
12	NK	_	O	O	_	_	_	_	_
13	cytotoxicity	_	O	O	_	_	_	_	_
14	significantly	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	P	_	O	O	_	_	_	_	_
17	<	_	O	O	_	_	_	_	_
18	0	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	05	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	glucuronides	_	O	O	_	_	_	_	_
3	only	_	O	O	_	_	_	_	_
4	inhibited	_	O	O	_	_	_	_	_
5	NK	_	O	O	_	_	_	_	_
6	cytotoxicity	_	O	O	_	_	_	_	_
7	at	_	O	O	_	_	_	_	_
8	50	_	O	O	_	_	_	_	_
9	micromol	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	L	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Isoflavones	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	especially	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	isoflavone	_	O	O	_	_	_	_	_
7	glucuronides	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	enhanced	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	NK	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	interleukin	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	additively	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	physiological	_	O	O	_	_	_	_	_
3	concentrations	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	DG	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	GG	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	weakly	_	O	O	_	_	_	_	_
10	estrogenic	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	they	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	NK	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	nutritionally	_	O	O	_	_	_	_	_
20	relevant	_	O	O	_	_	_	_	_
21	concentrations	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	vitro	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	probably	_	O	O	_	_	_	_	_
26	at	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	site	_	O	O	_	_	_	_	_
29	different	_	O	O	_	_	_	_	_
30	from	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	action	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	immunodeficiency	_	O	O	_	_	_	_	_
3	virus	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	associated	_	O	O	_	_	_	_	_
6	Hodgkin	_	O	O	_	_	_	_	_
7	'	_	O	O	_	_	_	_	_
8	s	_	O	O	_	_	_	_	_
9	disease	_	O	O	_	_	_	_	_
10	derives	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	post	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	germinal	_	O	O	_	_	_	_	_
15	center	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	immunodeficiency	_	O	O	_	_	_	_	_
3	virus	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	associated	_	O	O	_	_	_	_	_
6	Hodgkin	_	O	O	_	_	_	_	_
7	'	_	O	O	_	_	_	_	_
8	s	_	O	O	_	_	_	_	_
9	disease	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	HIV	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	HD	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	displays	_	O	O	_	_	_	_	_
16	several	_	O	O	_	_	_	_	_
17	peculiarities	_	O	O	_	_	_	_	_
18	when	_	O	O	_	_	_	_	_
19	compared	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	HD	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	general	_	O	O	_	_	_	_	_
25	population	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	include	_	O	O	_	_	_	_	_
3	overrepresentation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	clinically	_	O	O	_	_	_	_	_
6	aggressive	_	O	O	_	_	_	_	_
7	histologic	_	O	O	_	_	_	_	_
8	types	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	frequent	_	O	O	_	_	_	_	_
11	infection	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Reed	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Sternberg	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	RS	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	Epstein	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	Barr	_	O	O	_	_	_	_	_
24	virus	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	EBV	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	reported	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	histogenesis	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	HD	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	general	_	O	O	_	_	_	_	_
14	population	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	assessed	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	monitoring	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	pattern	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	BCL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	factor	_	O	O	_	_	_	_	_
31	expressed	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	germinal	_	O	O	_	_	_	_	_
34	center	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	GC	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	B	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	138	_	O	O	_	_	_	_	_
45	/	_	O	O	_	_	_	_	_
46	syndecan	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	syn	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	a	_	O	O	_	_	_	_	_
56	proteoglycan	_	O	O	_	_	_	_	_
57	associated	_	O	O	_	_	_	_	_
58	with	_	O	O	_	_	_	_	_
59	post	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	GC	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	terminal	_	O	O	_	_	_	_	_
64	B	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	cell	_	O	O	_	_	_	_	_
67	differentiation	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	applied	_	O	O	_	_	_	_	_
8	these	_	O	O	_	_	_	_	_
9	two	_	O	O	_	_	_	_	_
10	markers	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	study	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	HIV	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	HD	_	O	O	_	_	_	_	_
18	histogenesis	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	correlated	_	O	O	_	_	_	_	_
21	their	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	status	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	virologic	_	O	O	_	_	_	_	_
27	features	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	this	_	O	O	_	_	_	_	_
30	disease	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	found	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	RS	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	all	_	O	O	_	_	_	_	_
9	histologic	_	O	O	_	_	_	_	_
10	categories	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	HIV	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	HD	_	O	O	_	_	_	_	_
15	consistently	_	O	O	_	_	_	_	_
16	display	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	BCL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	syn	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	phenotype	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	thus	_	O	O	_	_	_	_	_
34	reflect	_	O	O	_	_	_	_	_
35	post	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	GC	_	O	O	_	_	_	_	_
38	B	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	BCL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	syn	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	RS	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	HIV	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	HD	_	O	O	_	_	_	_	_
21	express	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	40	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	they	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	not	_	O	O	_	_	_	_	_
28	surrounded	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	40	_	O	O	_	_	_	_	_
32	ligand	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	positive	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	40	_	O	O	_	_	_	_	_
38	L	_	O	O	_	_	_	_	_
39	+	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	reactive	_	O	O	_	_	_	_	_
42	T	_	O	O	_	_	_	_	_
43	lymphocytes	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	which	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	HD	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	general	_	O	O	_	_	_	_	_
52	population	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	are	_	O	O	_	_	_	_	_
55	thought	_	O	O	_	_	_	_	_
56	to	_	O	O	_	_	_	_	_
57	regulate	_	O	O	_	_	_	_	_
58	the	_	O	O	_	_	_	_	_
59	disease	_	O	O	_	_	_	_	_
60	phenotype	_	O	O	_	_	_	_	_
61	through	_	O	O	_	_	_	_	_
62	CD	_	O	O	_	_	_	_	_
63	40	_	O	O	_	_	_	_	_
64	/	_	O	O	_	_	_	_	_
65	CD	_	O	O	_	_	_	_	_
66	40	_	O	O	_	_	_	_	_
67	L	_	O	O	_	_	_	_	_
68	interactions	_	O	O	_	_	_	_	_
69	.	_	O	O	_	_	_	_	_

1	Conversely	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	RS	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	virtually	_	O	O	_	_	_	_	_
7	all	_	O	O	_	_	_	_	_
8	HIV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	HD	_	O	O	_	_	_	_	_
11	express	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	EBV	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	encoded	_	O	O	_	_	_	_	_
16	latent	_	O	O	_	_	_	_	_
17	membrane	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	LMP	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	which	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	being	_	O	O	_	_	_	_	_
28	functionally	_	O	O	_	_	_	_	_
29	homologous	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	40	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	may	_	O	O	_	_	_	_	_
35	contribute	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	at	_	O	O	_	_	_	_	_
38	least	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	part	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	to	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	modulation	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	HIV	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	HD	_	O	O	_	_	_	_	_
50	phenotype	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	down	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	regulated	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	12	_	O	O	_	_	_	_	_
13	h	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	24	_	O	O	_	_	_	_	_
16	h	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	following	_	O	O	_	_	_	_	_
19	GP	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	TSST	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	when	_	O	O	_	_	_	_	_
25	compared	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	TSST	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Time	_	O	O	_	_	_	_	_
2	course	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	48	_	O	O	_	_	_	_	_
5	h	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	production	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	pg	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	ml	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	human	_	O	O	_	_	_	_	_
20	PBMC	_	O	O	_	_	_	_	_
21	incubated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	medium	_	O	O	_	_	_	_	_
24	control	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	100	_	O	O	_	_	_	_	_
27	mug	_	O	O	_	_	_	_	_
28	GP	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	250	_	O	O	_	_	_	_	_
31	ng	_	O	O	_	_	_	_	_
32	TSST	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	GP	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	TSST	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	250	_	O	O	_	_	_	_	_
43	ng	_	O	O	_	_	_	_	_
44	LPS	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	GP	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	LPS	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	18	_	O	O	_	_	_	_	_
3	h	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	24	_	O	O	_	_	_	_	_
6	h	_	O	O	_	_	_	_	_
7	there	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	marked	_	O	O	_	_	_	_	_
11	reduction	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	following	_	O	O	_	_	_	_	_
19	GP	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	TSST	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	when	_	O	O	_	_	_	_	_
25	compared	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	TSST	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	*	_	O	O	_	_	_	_	_
32	=	_	O	O	_	_	_	_	_
33	p	_	O	O	_	_	_	_	_
34	<	_	O	O	_	_	_	_	_
35	0	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	05	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Graphs	_	O	O	_	_	_	_	_
2	depicting	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	theoretical	_	O	O	_	_	_	_	_
5	values	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	GP	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	calc	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	and	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	calc	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	are	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	shown	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	supernatnant	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	obtained	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	Elisa	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	shown	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	mean	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	SEM	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	n	_	O	O	_	_	_	_	_
24	=	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	B	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	exaggerated	_	O	O	_	_	_	_	_
9	following	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	TSST	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	12	_	O	O	_	_	_	_	_
17	h	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	48	_	O	O	_	_	_	_	_
20	h	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	when	_	O	O	_	_	_	_	_
23	compared	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	TSST	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Time	_	O	O	_	_	_	_	_
2	course	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	48	_	O	O	_	_	_	_	_
5	h	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	production	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	pg	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	ml	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	human	_	O	O	_	_	_	_	_
20	PBMC	_	O	O	_	_	_	_	_
21	incubated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	medium	_	O	O	_	_	_	_	_
24	control	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	100	_	O	O	_	_	_	_	_
27	mug	_	O	O	_	_	_	_	_
28	GP	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	250	_	O	O	_	_	_	_	_
31	ng	_	O	O	_	_	_	_	_
32	TSST	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	GP	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	TSST	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	250	_	O	O	_	_	_	_	_
43	ng	_	O	O	_	_	_	_	_
44	LPS	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	GP	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	LPS	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Between	_	O	O	_	_	_	_	_
2	18	_	O	O	_	_	_	_	_
3	h	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	48	_	O	O	_	_	_	_	_
6	h	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	simultaneous	_	O	O	_	_	_	_	_
9	treatment	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	PBMC	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	GP	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	TSST	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	led	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	synergistic	_	O	O	_	_	_	_	_
22	effect	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	i	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	e	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	a	_	O	O	_	_	_	_	_
2	higher	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	when	_	O	O	_	_	_	_	_
9	compared	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	addition	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	single	_	O	O	_	_	_	_	_
16	values	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	TSST	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	GP	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	*	_	O	O	_	_	_	_	_
25	=	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	<	_	O	O	_	_	_	_	_
28	0	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	05	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Graphs	_	O	O	_	_	_	_	_
2	depicting	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	theoretical	_	O	O	_	_	_	_	_
5	values	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	GP	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	calc	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	and	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	calc	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	are	_	O	O	_	_	_	_	_
2	included	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	supernatnant	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	obtained	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	Elisa	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	shown	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	mean	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	SEM	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	n	_	O	O	_	_	_	_	_
24	=	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_



1	Tyrphostin	_	O	O	_	_	_	_	_
2	AG	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	490	_	O	O	_	_	_	_	_
5	inhibits	_	O	O	_	_	_	_	_
6	cytokine	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	JAK	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	b	_	O	O	_	_	_	_	_
17	signal	_	O	O	_	_	_	_	_
18	transduction	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	cellular	_	O	O	_	_	_	_	_
21	proliferation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	antigen	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	activated	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Janus	_	O	O	_	_	_	_	_
2	kinase	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	JAK	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	cytoplasmic	_	O	O	_	_	_	_	_
11	tyrosine	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	required	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	development	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	activated	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	cytokines	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	utilize	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	interleukin	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	common	_	O	O	_	_	_	_	_
35	gamma	_	O	O	_	_	_	_	_
36	chain	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	gamma	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	c	_	O	O	_	_	_	_	_
41	))	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Genetic	_	O	O	_	_	_	_	_
2	inactivation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	JAK	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	manifested	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	severe	_	O	O	_	_	_	_	_
10	combined	_	O	O	_	_	_	_	_
11	immunodeficiency	_	O	O	_	_	_	_	_
12	disease	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	SCID	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	humans	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	mice	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	suggested	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	JAK	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	represents	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	pharmacological	_	O	O	_	_	_	_	_
11	target	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	control	_	O	O	_	_	_	_	_
14	certain	_	O	O	_	_	_	_	_
15	lymphoid	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	derived	_	O	O	_	_	_	_	_
18	diseases	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	provide	_	O	O	_	_	_	_	_
4	novel	_	O	O	_	_	_	_	_
5	evidence	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	AG	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	490	_	O	O	_	_	_	_	_
10	potently	_	O	O	_	_	_	_	_
11	inhibits	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	autokinase	_	O	O	_	_	_	_	_
14	activity	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	JAK	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	phosphorylation	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	signal	_	O	O	_	_	_	_	_
26	transducer	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	activator	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	5	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	5	_	O	O	_	_	_	_	_
35	b	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	STAT	_	O	O	_	_	_	_	_
38	5	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	b	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Similar	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	effects	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	other	_	O	O	_	_	_	_	_
8	cytokines	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	use	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	c	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	AG	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	490	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	inhibited	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	mediated	_	O	O	_	_	_	_	_
11	proliferative	_	O	O	_	_	_	_	_
12	growth	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	IC	_	O	O	_	_	_	_	_
20	50	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	=	_	O	O	_	_	_	_	_
23	25	_	O	O	_	_	_	_	_
24	microM	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	partially	_	O	O	_	_	_	_	_
28	recoverable	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrate	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	inhibitor	_	O	O	_	_	_	_	_
8	prevented	_	O	O	_	_	_	_	_
9	tetanus	_	O	O	_	_	_	_	_
10	toxoid	_	O	O	_	_	_	_	_
11	antigen	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	specific	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	proliferation	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	expansion	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	failed	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	block	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	Zap	_	O	O	_	_	_	_	_
26	70	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	56	_	O	O	_	_	_	_	_
30	Lck	_	O	O	_	_	_	_	_
31	after	_	O	O	_	_	_	_	_
32	anti	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	CD	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	stimulation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	human	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	findings	_	O	O	_	_	_	_	_
6	suggest	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	AG	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	490	_	O	O	_	_	_	_	_
11	inhibits	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	JAK	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	mediated	_	O	O	_	_	_	_	_
17	Type	_	O	O	_	_	_	_	_
18	II	_	O	O	_	_	_	_	_
19	signaling	_	O	O	_	_	_	_	_
20	pathway	_	O	O	_	_	_	_	_
21	but	_	O	O	_	_	_	_	_
22	not	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	derived	_	O	O	_	_	_	_	_
29	Type	_	O	O	_	_	_	_	_
30	I	_	O	O	_	_	_	_	_
31	pathway	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	possesses	_	O	O	_	_	_	_	_
34	therapeutic	_	O	O	_	_	_	_	_
35	potential	_	O	O	_	_	_	_	_
36	for	_	O	O	_	_	_	_	_
37	T	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	derived	_	O	O	_	_	_	_	_
41	pathologies	_	O	O	_	_	_	_	_
42	such	_	O	O	_	_	_	_	_
43	as	_	O	O	_	_	_	_	_
44	graft	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	versus	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	host	_	O	O	_	_	_	_	_
49	disease	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	allergy	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	and	_	O	O	_	_	_	_	_
54	autoimmune	_	O	O	_	_	_	_	_
55	disorders	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	rhombotin	_	O	O	_	_	_	_	_
3	family	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	cysteine	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	rich	_	O	O	_	_	_	_	_
8	LIM	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	domain	_	O	O	_	_	_	_	_
11	oncogenes	_	O	O	_	_	_	_	_
12	:	_	O	O	_	_	_	_	_
13	distinct	_	O	O	_	_	_	_	_
14	members	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	involved	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	translocations	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	human	_	O	O	_	_	_	_	_
24	chromosomes	_	O	O	_	_	_	_	_
25	11	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	15	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	11	_	O	O	_	_	_	_	_
30	p	_	O	O	_	_	_	_	_
31	13	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	chromosomal	_	O	O	_	_	_	_	_
3	translocation	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	leukemia	_	O	O	_	_	_	_	_
10	involving	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	short	_	O	O	_	_	_	_	_
13	arm	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	chromosome	_	O	O	_	_	_	_	_
17	11	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	band	_	O	O	_	_	_	_	_
20	11	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	15	_	O	O	_	_	_	_	_
23	disrupts	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	rhombotin	_	O	O	_	_	_	_	_
26	gene	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	gene	_	O	O	_	_	_	_	_
3	encodes	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	duplicated	_	O	O	_	_	_	_	_
8	cysteine	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	rich	_	O	O	_	_	_	_	_
11	regions	_	O	O	_	_	_	_	_
12	called	_	O	O	_	_	_	_	_
13	LIM	_	O	O	_	_	_	_	_
14	domains	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	show	_	O	O	_	_	_	_	_
18	homology	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	zinc	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	proteins	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	iron	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	sulfur	_	O	O	_	_	_	_	_
29	centers	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	ferredoxins	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	homologues	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	rhombotin	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	have	_	O	O	_	_	_	_	_
8	now	_	O	O	_	_	_	_	_
9	been	_	O	O	_	_	_	_	_
10	isolated	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	designated	_	O	O	_	_	_	_	_
6	Rhom	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	located	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	chromosome	_	O	O	_	_	_	_	_
15	11	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	band	_	O	O	_	_	_	_	_
18	11	_	O	O	_	_	_	_	_
19	p	_	O	O	_	_	_	_	_
20	13	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	where	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	cluster	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	leukemia	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	specific	_	O	O	_	_	_	_	_
32	translocations	_	O	O	_	_	_	_	_
33	occur	_	O	O	_	_	_	_	_
34	;	_	O	O	_	_	_	_	_
35	all	_	O	O	_	_	_	_	_
36	translocation	_	O	O	_	_	_	_	_
37	breakpoints	_	O	O	_	_	_	_	_
38	at	_	O	O	_	_	_	_	_
39	11	_	O	O	_	_	_	_	_
40	p	_	O	O	_	_	_	_	_
41	13	_	O	O	_	_	_	_	_
42	are	_	O	O	_	_	_	_	_
43	upstream	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	Rhom	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	2	_	O	O	_	_	_	_	_
49	gene	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	mouse	_	O	O	_	_	_	_	_
4	Rhom	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	highly	_	O	O	_	_	_	_	_
9	conserved	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	like	_	O	O	_	_	_	_	_
13	rhombotin	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	encode	_	O	O	_	_	_	_	_
16	two	_	O	O	_	_	_	_	_
17	tandem	_	O	O	_	_	_	_	_
18	cysteine	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	rich	_	O	O	_	_	_	_	_
21	LIM	_	O	O	_	_	_	_	_
22	domains	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Rhom	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	mouse	_	O	O	_	_	_	_	_
10	development	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	central	_	O	O	_	_	_	_	_
13	nervous	_	O	O	_	_	_	_	_
14	system	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	lung	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	kidney	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	liver	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	spleen	_	O	O	_	_	_	_	_
24	but	_	O	O	_	_	_	_	_
25	only	_	O	O	_	_	_	_	_
26	very	_	O	O	_	_	_	_	_
27	low	_	O	O	_	_	_	_	_
28	levels	_	O	O	_	_	_	_	_
29	occur	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	thymus	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	other	_	O	O	_	_	_	_	_
3	gene	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	designated	_	O	O	_	_	_	_	_
6	Rhom	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	chromosome	_	O	O	_	_	_	_	_
14	11	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	also	_	O	O	_	_	_	_	_
17	retains	_	O	O	_	_	_	_	_
18	homology	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	LIM	_	O	O	_	_	_	_	_
22	domain	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	rhombotin	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	Rhom	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	such	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	common	_	O	O	_	_	_	_	_
11	site	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	chromosomal	_	O	O	_	_	_	_	_
14	damage	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	tumors	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	consistency	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	translocations	_	O	O	_	_	_	_	_
25	near	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	rhombotin	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	further	_	O	O	_	_	_	_	_
31	examined	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	second	_	O	O	_	_	_	_	_
3	translocation	_	O	O	_	_	_	_	_
4	adjacent	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	rhombotin	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	at	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	same	_	O	O	_	_	_	_	_
13	position	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	previous	_	O	O	_	_	_	_	_
18	example	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	chromosome	_	O	O	_	_	_	_	_
4	bands	_	O	O	_	_	_	_	_
5	11	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	15	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	rhombotin	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	11	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	13	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	Rhom	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	consistent	_	O	O	_	_	_	_	_
22	sites	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	chromosome	_	O	O	_	_	_	_	_
25	translocation	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	leukemia	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	11	_	O	O	_	_	_	_	_
35	p	_	O	O	_	_	_	_	_
36	15	_	O	O	_	_	_	_	_
37	target	_	O	O	_	_	_	_	_
38	more	_	O	O	_	_	_	_	_
39	rarely	_	O	O	_	_	_	_	_
40	involved	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	define	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	rhombotin	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	family	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	class	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	oncogenes	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	duplicated	_	O	O	_	_	_	_	_
18	cysteine	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	rich	_	O	O	_	_	_	_	_
21	LIM	_	O	O	_	_	_	_	_
22	domains	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Cytomegalovirus	_	O	O	_	_	_	_	_
2	modulates	_	O	O	_	_	_	_	_
3	interleukin	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_


1	Complications	_	O	O	_	_	_	_	_
2	after	_	O	O	_	_	_	_	_
3	lung	_	O	O	_	_	_	_	_
4	transplantation	_	O	O	_	_	_	_	_
5	include	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	development	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	rejection	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	increased	_	O	O	_	_	_	_	_
13	incidence	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	infection	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	particularly	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	cytomegalovirus	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	CMV	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Several	_	O	O	_	_	_	_	_
2	recent	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	suggested	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	interleukin	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	may	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	used	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	detect	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	infection	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	rejection	_	O	O	_	_	_	_	_
22	after	_	O	O	_	_	_	_	_
23	lung	_	O	O	_	_	_	_	_
24	transplantation	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	may	_	O	O	_	_	_	_	_
8	play	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	development	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	bronchiolitis	_	O	O	_	_	_	_	_
16	obliterans	_	O	O	_	_	_	_	_
17	after	_	O	O	_	_	_	_	_
18	transplantation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	CMV	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	associated	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	development	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	bronchiolitis	_	O	O	_	_	_	_	_
11	obliterans	_	O	O	_	_	_	_	_
12	after	_	O	O	_	_	_	_	_
13	transplantation	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	we	_	O	O	_	_	_	_	_
16	determined	_	O	O	_	_	_	_	_
17	whether	_	O	O	_	_	_	_	_
18	CMV	_	O	O	_	_	_	_	_
19	induces	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	demonstrated	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	CMV	_	O	O	_	_	_	_	_
5	infection	_	O	O	_	_	_	_	_
6	increased	_	O	O	_	_	_	_	_
7	both	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	peripheral	_	O	O	_	_	_	_	_
16	blood	_	O	O	_	_	_	_	_
17	mononuclear	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	CMV	_	O	O	_	_	_	_	_
7	immediate	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	product	_	O	O	_	_	_	_	_
12	increased	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	promoter	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	CMV	_	O	O	_	_	_	_	_
6	immediate	_	O	O	_	_	_	_	_
7	early	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	product	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	dependent	_	O	O	_	_	_	_	_
13	upon	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	presence	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	sites	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	promoter	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	CMV	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	important	_	O	O	_	_	_	_	_
10	cofactor	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	development	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	rejection	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	infection	_	O	O	_	_	_	_	_
18	after	_	O	O	_	_	_	_	_
19	transplantation	_	O	O	_	_	_	_	_
20	through	_	O	O	_	_	_	_	_
21	its	_	O	O	_	_	_	_	_
22	effects	_	O	O	_	_	_	_	_
23	on	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	p	_	O	O	_	_	_	_	_
2	38	_	O	O	_	_	_	_	_
3	mitogen	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	activated	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	mediates	_	O	O	_	_	_	_	_
9	signal	_	O	O	_	_	_	_	_
10	integration	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	TCR	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	28	_	O	O	_	_	_	_	_
16	costimulation	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	primary	_	O	O	_	_	_	_	_
19	murine	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Optimal	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	requires	_	O	O	_	_	_	_	_
6	two	_	O	O	_	_	_	_	_
7	signals	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	one	_	O	O	_	_	_	_	_
10	generated	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	TCR	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	another	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	28	_	O	O	_	_	_	_	_
19	costimulatory	_	O	O	_	_	_	_	_
20	receptor	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	investigated	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	regulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	costimulation	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	mitogen	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	activated	_	O	O	_	_	_	_	_
16	protein	_	O	O	_	_	_	_	_
17	kinase	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	MAPK	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	primary	_	O	O	_	_	_	_	_
24	mouse	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	reported	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	Jurkat	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	found	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	p	_	O	O	_	_	_	_	_
16	38	_	O	O	_	_	_	_	_
17	MAPK	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	not	_	O	O	_	_	_	_	_
21	Jun	_	O	O	_	_	_	_	_
22	NH	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	terminal	_	O	O	_	_	_	_	_
26	kinase	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	JNK	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	weakly	_	O	O	_	_	_	_	_
33	activated	_	O	O	_	_	_	_	_
34	upon	_	O	O	_	_	_	_	_
35	stimulation	_	O	O	_	_	_	_	_
36	with	_	O	O	_	_	_	_	_
37	either	_	O	O	_	_	_	_	_
38	anti	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	CD	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	or	_	O	O	_	_	_	_	_
43	anti	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	CD	_	O	O	_	_	_	_	_
46	28	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	murine	_	O	O	_	_	_	_	_
49	thymocytes	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	splenic	_	O	O	_	_	_	_	_
52	T	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	38	_	O	O	_	_	_	_	_
5	MAPK	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	activated	_	O	O	_	_	_	_	_
8	strongly	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	synergistically	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	either	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	28	_	O	O	_	_	_	_	_
18	coligation	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	PMA	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	Ca	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	ionophore	_	O	O	_	_	_	_	_
26	stimulation	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	which	_	O	O	_	_	_	_	_
29	mimics	_	O	O	_	_	_	_	_
30	TCR	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	28	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	mediated	_	O	O	_	_	_	_	_
39	signaling	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	38	_	O	O	_	_	_	_	_
5	MAPK	_	O	O	_	_	_	_	_
6	correlates	_	O	O	_	_	_	_	_
7	closely	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	stimulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	proliferation	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	PMA	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	JNK	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	inhibited	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	Ca	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	ionophore	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	T	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	proliferation	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	production	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IFN	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	28	_	O	O	_	_	_	_	_
30	ligation	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	nuclear	_	O	O	_	_	_	_	_
34	expression	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	c	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	Jun	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	ATF	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	proteins	_	O	O	_	_	_	_	_
45	are	_	O	O	_	_	_	_	_
46	each	_	O	O	_	_	_	_	_
47	blocked	_	O	O	_	_	_	_	_
48	by	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	p	_	O	O	_	_	_	_	_
51	38	_	O	O	_	_	_	_	_
52	MAPK	_	O	O	_	_	_	_	_
53	inhibitor	_	O	O	_	_	_	_	_
54	SB	_	O	O	_	_	_	_	_
55	203580	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	MAPK	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	plays	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	important	_	O	O	_	_	_	_	_
13	role	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	signal	_	O	O	_	_	_	_	_
16	integration	_	O	O	_	_	_	_	_
17	during	_	O	O	_	_	_	_	_
18	costimulation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	primary	_	O	O	_	_	_	_	_
21	mouse	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	may	_	O	O	_	_	_	_	_
28	be	_	O	O	_	_	_	_	_
29	involved	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	induction	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	c	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	Jun	_	O	O	_	_	_	_	_
37	activation	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	augmentation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	AP	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	transcriptional	_	O	O	_	_	_	_	_
45	activity	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	3	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	regulates	_	O	O	_	_	_	_	_
51	whether	_	O	O	_	_	_	_	_
52	T	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	enter	_	O	O	_	_	_	_	_
55	a	_	O	O	_	_	_	_	_
56	state	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	functional	_	O	O	_	_	_	_	_
59	unresponsiveness	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_


1	Cell	_	O	O	_	_	_	_	_
2	cycle	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	dependent	_	O	O	_	_	_	_	_
5	initiation	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	lineage	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	abrogation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	GATA	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	pure	_	O	O	_	_	_	_	_
18	differentiating	_	O	O	_	_	_	_	_
19	hematopoietic	_	O	O	_	_	_	_	_
20	progenitors	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	programmed	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	/	_	O	O	_	_	_	_	_
5	repression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factors	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	early	_	O	O	_	_	_	_	_
11	hematopoietic	_	O	O	_	_	_	_	_
12	differentiation	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	yet	_	O	O	_	_	_	_	_
16	been	_	O	O	_	_	_	_	_
17	explored	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	GATA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	required	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	normal	_	O	O	_	_	_	_	_
13	erythroid	_	O	O	_	_	_	_	_
14	development	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	regulates	_	O	O	_	_	_	_	_
17	erythroid	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	expressed	_	O	O	_	_	_	_	_
20	genes	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	maturing	_	O	O	_	_	_	_	_
23	erythroblasts	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	analyzed	_	O	O	_	_	_	_	_
3	GATA	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	adult	_	O	O	_	_	_	_	_
11	hematopoiesis	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	vitro	_	O	O	_	_	_	_	_
17	system	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	which	_	O	O	_	_	_	_	_
20	""""	_	O	O	_	_	_	_	_
21	pure	_	O	O	_	_	_	_	_
22	""""	_	O	O	_	_	_	_	_
23	early	_	O	O	_	_	_	_	_
24	hematopoietic	_	O	O	_	_	_	_	_
25	progenitors	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	induced	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	gradual	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	synchronized	_	O	O	_	_	_	_	_
32	differentiation	_	O	O	_	_	_	_	_
33	selectively	_	O	O	_	_	_	_	_
34	along	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	erythroid	_	O	O	_	_	_	_	_
37	or	_	O	O	_	_	_	_	_
38	granulocyte	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	macrophage	_	O	O	_	_	_	_	_
41	pathway	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	differential	_	O	O	_	_	_	_	_
44	treatment	_	O	O	_	_	_	_	_
45	with	_	O	O	_	_	_	_	_
46	hematopoietic	_	O	O	_	_	_	_	_
47	growth	_	O	O	_	_	_	_	_
48	factors	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	GATA	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	gene	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	though	_	O	O	_	_	_	_	_
8	virtually	_	O	O	_	_	_	_	_
9	silent	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	quiescent	_	O	O	_	_	_	_	_
12	progenitors	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	activated	_	O	O	_	_	_	_	_
16	after	_	O	O	_	_	_	_	_
17	entrance	_	O	O	_	_	_	_	_
18	into	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	cycle	_	O	O	_	_	_	_	_
22	upon	_	O	O	_	_	_	_	_
23	stimulation	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	hematopoietic	_	O	O	_	_	_	_	_
26	growth	_	O	O	_	_	_	_	_
27	factors	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Subsequently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	increasing	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	along	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	erythroid	_	O	O	_	_	_	_	_
8	pathway	_	O	O	_	_	_	_	_
9	contrasts	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	abrupt	_	O	O	_	_	_	_	_
13	downregulation	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	granulocyte	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	macrophage	_	O	O	_	_	_	_	_
19	lineage	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	microenvironment	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	directed	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	two	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	step	_	O	O	_	_	_	_	_
12	model	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	GATA	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	expression	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	differentiating	_	O	O	_	_	_	_	_
20	hematopoietic	_	O	O	_	_	_	_	_
21	progenitors	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	involves	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	i	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	cycle	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	dependent	_	O	O	_	_	_	_	_
30	initiation	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	ii	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	lineage	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	dependent	_	O	O	_	_	_	_	_
38	maintenance	_	O	O	_	_	_	_	_
39	or	_	O	O	_	_	_	_	_
40	suppression	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Hypothetically	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	/	_	O	O	_	_	_	_	_
5	off	_	O	O	_	_	_	_	_
6	switches	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	lineage	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	restricted	_	O	O	_	_	_	_	_
11	transactivators	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	underlie	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	binary	_	O	O	_	_	_	_	_
16	fate	_	O	O	_	_	_	_	_
17	decisions	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	hematopoietic	_	O	O	_	_	_	_	_
20	progenitors	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Erythropoietin	_	O	O	_	_	_	_	_
2	stimulates	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	TAL	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	SCL	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	phosphorylation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	its	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	products	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	TAL	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	SCL	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	originally	_	O	O	_	_	_	_	_
13	identified	_	O	O	_	_	_	_	_
14	through	_	O	O	_	_	_	_	_
15	its	_	O	O	_	_	_	_	_
16	involvement	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	recurrent	_	O	O	_	_	_	_	_
20	chromosomal	_	O	O	_	_	_	_	_
21	translocation	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	most	_	O	O	_	_	_	_	_
26	frequent	_	O	O	_	_	_	_	_
27	molecular	_	O	O	_	_	_	_	_
28	lesion	_	O	O	_	_	_	_	_
29	recognized	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	cell	_	O	O	_	_	_	_	_
34	acute	_	O	O	_	_	_	_	_
35	lymphoblastic	_	O	O	_	_	_	_	_
36	leukemia	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	products	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	contain	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	basic	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	helix	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	loop	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	helix	_	O	O	_	_	_	_	_
16	motif	_	O	O	_	_	_	_	_
17	characteristic	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	large	_	O	O	_	_	_	_	_
21	family	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	transcription	_	O	O	_	_	_	_	_
24	factors	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	bind	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	canonical	_	O	O	_	_	_	_	_
30	DNA	_	O	O	_	_	_	_	_
31	sequence	_	O	O	_	_	_	_	_
32	CANNTG	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	protein	_	O	O	_	_	_	_	_
35	heterodimers	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	TAL	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	erythroid	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	vivo	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	chemical	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	erythroleukemia	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	lines	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	vivo	_	O	O	_	_	_	_	_
19	suggested	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	might	_	O	O	_	_	_	_	_
23	regulate	_	O	O	_	_	_	_	_
24	aspects	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	erythroid	_	O	O	_	_	_	_	_
27	differentiation	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	terminal	_	O	O	_	_	_	_	_
4	events	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	erythropoiesis	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	controlled	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	glycoprotein	_	O	O	_	_	_	_	_
12	hormone	_	O	O	_	_	_	_	_
13	erythropoietin	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	Epo	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	we	_	O	O	_	_	_	_	_
19	investigated	_	O	O	_	_	_	_	_
20	whether	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	TAL	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	its	_	O	O	_	_	_	_	_
32	protein	_	O	O	_	_	_	_	_
33	products	_	O	O	_	_	_	_	_
34	were	_	O	O	_	_	_	_	_
35	affected	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	Epo	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	splenic	_	O	O	_	_	_	_	_
40	erythroblasts	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	mice	_	O	O	_	_	_	_	_
43	infected	_	O	O	_	_	_	_	_
44	with	_	O	O	_	_	_	_	_
45	an	_	O	O	_	_	_	_	_
46	anemia	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	inducing	_	O	O	_	_	_	_	_
49	strain	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	Friend	_	O	O	_	_	_	_	_
52	virus	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	FVA	_	O	O	_	_	_	_	_
55	cells	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	Epo	_	O	O	_	_	_	_	_
2	elicited	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	rapid	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	dose	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	related	_	O	O	_	_	_	_	_
9	increase	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	TAL	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	increasing	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	gene	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	stabilizing	_	O	O	_	_	_	_	_
22	one	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	its	_	O	O	_	_	_	_	_
25	mRNAs	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	Epo	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	inducible	_	O	O	_	_	_	_	_
5	TAL	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	identified	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	FVA	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	extracts	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	subsequently	_	O	O	_	_	_	_	_
19	decayed	_	O	O	_	_	_	_	_
20	despite	_	O	O	_	_	_	_	_
21	accumulating	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	DNA	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	associated	_	O	O	_	_	_	_	_
8	temporally	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	Epo	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	TAL	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Epo	_	O	O	_	_	_	_	_
6	acts	_	O	O	_	_	_	_	_
7	at	_	O	O	_	_	_	_	_
8	both	_	O	O	_	_	_	_	_
9	transcriptional	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	posttranscriptional	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	TAL	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	locus	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	Friend	_	O	O	_	_	_	_	_
20	virus	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	induced	_	O	O	_	_	_	_	_
23	erythroblasts	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	establish	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	link	_	O	O	_	_	_	_	_
28	between	_	O	O	_	_	_	_	_
29	Epo	_	O	O	_	_	_	_	_
30	signaling	_	O	O	_	_	_	_	_
31	mechanisms	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	member	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	family	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	transcription	_	O	O	_	_	_	_	_
40	factors	_	O	O	_	_	_	_	_
41	involved	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	differentiation	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	diverse	_	O	O	_	_	_	_	_
47	cell	_	O	O	_	_	_	_	_
48	lineages	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_


1	Evidence	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	polyclonal	_	O	O	_	_	_	_	_
5	etiology	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	palmar	_	O	O	_	_	_	_	_
8	fibromatosis	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_


1	X	_	O	O	_	_	_	_	_
2	chromosome	_	O	O	_	_	_	_	_
3	inactivation	_	O	O	_	_	_	_	_
4	patterns	_	O	O	_	_	_	_	_
5	at	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	androgen	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	locus	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	evaluated	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	determine	_	O	O	_	_	_	_	_
14	clonality	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	microdissected	_	O	O	_	_	_	_	_
17	lesional	_	O	O	_	_	_	_	_
18	tissue	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	leukocytes	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	women	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	Dupuytren	_	O	O	_	_	_	_	_
27	'	_	O	O	_	_	_	_	_
28	s	_	O	O	_	_	_	_	_
29	disease	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	tissue	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	patients	_	O	O	_	_	_	_	_
6	generated	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	polyclonal	_	O	O	_	_	_	_	_
9	pattern	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	X	_	O	O	_	_	_	_	_
12	chromosome	_	O	O	_	_	_	_	_
13	inactivation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	androgen	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	gene	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	finding	_	O	O	_	_	_	_	_
3	supports	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	polyclonal	_	O	O	_	_	_	_	_
6	reactive	_	O	O	_	_	_	_	_
7	process	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	underlying	_	O	O	_	_	_	_	_
11	etiology	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	palmar	_	O	O	_	_	_	_	_
14	fibromatosis	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Impaired	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	DQ	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	DQ	_	O	O	_	_	_	_	_
9	8	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	HSV	_	O	O	_	_	_	_	_
13	VP	_	O	O	_	_	_	_	_
14	16	_	O	O	_	_	_	_	_
15	peptide	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	DQA	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	*	_	O	O	_	_	_	_	_
21	0501	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	DQB	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	*	_	O	O	_	_	_	_	_
26	0302	_	O	O	_	_	_	_	_
27	trans	_	O	O	_	_	_	_	_
28	class	_	O	O	_	_	_	_	_
29	II	_	O	O	_	_	_	_	_
30	heterodimer	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	DQalpha	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	DQbeta	_	O	O	_	_	_	_	_
4	trans	_	O	O	_	_	_	_	_
5	heterodimeric	_	O	O	_	_	_	_	_
6	HLA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	DQ	_	O	O	_	_	_	_	_
9	molecules	_	O	O	_	_	_	_	_
10	form	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	individuals	_	O	O	_	_	_	_	_
13	heterozygous	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	DQ	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	DQ	_	O	O	_	_	_	_	_
20	8	_	O	O	_	_	_	_	_
21	specificities	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Unique	_	O	O	_	_	_	_	_
2	functions	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	disease	_	O	O	_	_	_	_	_
5	associations	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	postulated	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	such	_	O	O	_	_	_	_	_
11	trans	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dimers	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	which	_	O	O	_	_	_	_	_
16	may	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	different	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	cis	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	encoded	_	O	O	_	_	_	_	_
23	DQ	_	O	O	_	_	_	_	_
24	molecules	_	O	O	_	_	_	_	_
25	encoded	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	corresponding	_	O	O	_	_	_	_	_
29	haplotypes	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	analyzed	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	ability	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	trans	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dimer	_	O	O	_	_	_	_	_
10	encoded	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	HLA	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	DQA	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	*	_	O	O	_	_	_	_	_
17	0501	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	DQB	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	*	_	O	O	_	_	_	_	_
22	0302	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	bind	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	peptide	_	O	O	_	_	_	_	_
27	antigen	_	O	O	_	_	_	_	_
28	which	_	O	O	_	_	_	_	_
29	interacts	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	DQ	_	O	O	_	_	_	_	_
32	molecules	_	O	O	_	_	_	_	_
33	encoded	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	both	_	O	O	_	_	_	_	_
36	parental	_	O	O	_	_	_	_	_
37	haplotypes	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Markedly	_	O	O	_	_	_	_	_
2	impaired	_	O	O	_	_	_	_	_
3	binding	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	consistent	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	both	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	use	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	different	_	O	O	_	_	_	_	_
14	anchor	_	O	O	_	_	_	_	_
15	residues	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	changes	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	DQ	_	O	O	_	_	_	_	_
23	cis	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	dimer	_	O	O	_	_	_	_	_
26	availability	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	peptide	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	interactions	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Megakaryocytic	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	erythrocytic	_	O	O	_	_	_	_	_
4	lineages	_	O	O	_	_	_	_	_
5	share	_	O	O	_	_	_	_	_
6	specific	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factors	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_


1	Erythroid	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	specific	_	O	O	_	_	_	_	_
4	genes	_	O	O	_	_	_	_	_
5	contain	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	sites	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	E	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	called	_	O	O	_	_	_	_	_
16	GF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	Eryf	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	;	_	O	O	_	_	_	_	_
24	refs	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	respectively	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	principal	_	O	O	_	_	_	_	_
33	DNA	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	binding	_	O	O	_	_	_	_	_
36	protein	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	erythrocytic	_	O	O	_	_	_	_	_
40	lineage	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	NF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	E	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	seems	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	restricted	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	erythrocytic	_	O	O	_	_	_	_	_
13	lineage	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	closely	_	O	O	_	_	_	_	_
3	related	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	if	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	identical	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	found	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	megakaryocytic	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	line	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	purified	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	megakaryocytes	_	O	O	_	_	_	_	_
23	;	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	binds	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	promoter	_	O	O	_	_	_	_	_
28	regions	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	two	_	O	O	_	_	_	_	_
31	megakaryocytic	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	specific	_	O	O	_	_	_	_	_
34	genes	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	sites	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	partial	_	O	O	_	_	_	_	_
6	proteolysis	_	O	O	_	_	_	_	_
7	profile	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	this	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	indistinguishable	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	those	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	erythroid	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	also	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	NF	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	E	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	messenger	_	O	O	_	_	_	_	_
27	RNA	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	same	_	O	O	_	_	_	_	_
31	size	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	both	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	megakaryocytic	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	erythroid	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	lines	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	point	_	O	O	_	_	_	_	_
4	mutations	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	abolish	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	E	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	result	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	70	_	O	O	_	_	_	_	_
17	%	_	O	O	_	_	_	_	_
18	decrease	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	transcriptional	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	megakaryocytic	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	promoter	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	find	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	E	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	another	_	O	O	_	_	_	_	_
11	trans	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	acting	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	erythrocytic	_	O	O	_	_	_	_	_
18	lineage	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	present	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	megakaryocytes	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Transcriptional	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	lineages	_	O	O	_	_	_	_	_
6	might	_	O	O	_	_	_	_	_
7	then	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	part	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	same	_	O	O	_	_	_	_	_
15	specific	_	O	O	_	_	_	_	_
16	trans	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	acting	_	O	O	_	_	_	_	_
19	factors	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	strengthen	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	idea	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	close	_	O	O	_	_	_	_	_
9	association	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	erythrocytic	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	megakaryocytic	_	O	O	_	_	_	_	_
16	lineages	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	could	_	O	O	_	_	_	_	_
19	also	_	O	O	_	_	_	_	_
20	explain	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	markers	_	O	O	_	_	_	_	_
25	specific	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	erythrocytic	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	megakaryocytic	_	O	O	_	_	_	_	_
31	lineages	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	most	_	O	O	_	_	_	_	_
34	erythroblastic	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	megakaryoblastic	_	O	O	_	_	_	_	_
37	permanent	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	lines	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	UV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	CYP	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	A	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	human	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	tryptophan	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cytochrome	_	O	O	_	_	_	_	_
4	P	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	4501	_	O	O	_	_	_	_	_
7	A	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	CYP	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	A	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	UV	_	O	O	_	_	_	_	_
18	has	_	O	O	_	_	_	_	_
19	been	_	O	O	_	_	_	_	_
20	observed	_	O	O	_	_	_	_	_
21	earlier	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	animal	_	O	O	_	_	_	_	_
24	studies	_	O	O	_	_	_	_	_
25	via	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	mechanism	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	has	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	yet	_	O	O	_	_	_	_	_
32	been	_	O	O	_	_	_	_	_
33	resolved	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	previous	_	O	O	_	_	_	_	_
3	data	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	indicated	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	formylated	_	O	O	_	_	_	_	_
8	indolocarbazoles	_	O	O	_	_	_	_	_
9	which	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	formed	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	UV	_	O	O	_	_	_	_	_
14	irradiation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	tryptophan	_	O	O	_	_	_	_	_
17	solutions	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	very	_	O	O	_	_	_	_	_
20	potent	_	O	O	_	_	_	_	_
21	Ah	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	receptor	_	O	O	_	_	_	_	_
24	agonists	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	evaluate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effect	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	UV	_	O	O	_	_	_	_	_
7	light	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	cytochrome	_	O	O	_	_	_	_	_
10	P	_	O	O	_	_	_	_	_
11	4501	_	O	O	_	_	_	_	_
12	A	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	gene	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	we	_	O	O	_	_	_	_	_
18	studied	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	induction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	CYP	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	A	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	mRNA	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	UV	_	O	O	_	_	_	_	_
29	irradiation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	cultured	_	O	O	_	_	_	_	_
32	human	_	O	O	_	_	_	_	_
33	keratinocytes	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	HaCaT	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	line	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	primary	_	O	O	_	_	_	_	_
41	human	_	O	O	_	_	_	_	_
42	blood	_	O	O	_	_	_	_	_
43	lymphocytes	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	mouse	_	O	O	_	_	_	_	_
46	Hepa	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	cells	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	exposed	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	UV	_	O	O	_	_	_	_	_
7	light	_	O	O	_	_	_	_	_
8	delivered	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	bank	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	Philips	_	O	O	_	_	_	_	_
15	TL	_	O	O	_	_	_	_	_
16	20	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	12	_	O	O	_	_	_	_	_
19	RS	_	O	O	_	_	_	_	_
20	sun	_	O	O	_	_	_	_	_
21	lamps	_	O	O	_	_	_	_	_
22	emitting	_	O	O	_	_	_	_	_
23	primarily	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	UVB	_	O	O	_	_	_	_	_
27	range	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	absence	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	presence	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	tryptophan	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	semiquantitative	_	O	O	_	_	_	_	_
3	reverse	_	O	O	_	_	_	_	_
4	transcriptase	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	linked	_	O	O	_	_	_	_	_
7	polymerase	_	O	O	_	_	_	_	_
8	chain	_	O	O	_	_	_	_	_
9	reaction	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	RT	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	PCR	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	used	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	analysis	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	gene	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	treated	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	CYP	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	A	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	level	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	UV	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	presence	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	tryptophan	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	higher	_	O	O	_	_	_	_	_
22	than	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	UV	_	O	O	_	_	_	_	_
27	alone	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	HaCaT	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	lymphocytes	_	O	O	_	_	_	_	_
34	after	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	h	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	incubation	_	O	O	_	_	_	_	_
39	post	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	UV	_	O	O	_	_	_	_	_
42	irradiation	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	find	_	O	O	_	_	_	_	_
3	out	_	O	O	_	_	_	_	_
4	if	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	induction	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	UV	_	O	O	_	_	_	_	_
9	light	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	caused	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	formation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	an	_	O	O	_	_	_	_	_
17	Ah	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	ligand	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	Hepa	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	wild	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	type	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	Ah	_	O	O	_	_	_	_	_
29	receptor	_	O	O	_	_	_	_	_
30	deficient	_	O	O	_	_	_	_	_
31	c	_	O	O	_	_	_	_	_
32	12	_	O	O	_	_	_	_	_
33	cell	_	O	O	_	_	_	_	_
34	lines	_	O	O	_	_	_	_	_
35	were	_	O	O	_	_	_	_	_
36	applied	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Wild	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	type	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	wt	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	inducible	_	O	O	_	_	_	_	_
10	either	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	tryptophan	_	O	O	_	_	_	_	_
14	photoproduct	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	formylindolo	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	b	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	carbazole	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	FICZ	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	or	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	UV	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	irradiation	_	O	O	_	_	_	_	_
34	but	_	O	O	_	_	_	_	_
35	very	_	O	O	_	_	_	_	_
36	low	_	O	O	_	_	_	_	_
37	or	_	O	O	_	_	_	_	_
38	undetectable	_	O	O	_	_	_	_	_
39	levels	_	O	O	_	_	_	_	_
40	were	_	O	O	_	_	_	_	_
41	observed	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	c	_	O	O	_	_	_	_	_
45	12	_	O	O	_	_	_	_	_
46	cells	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	shows	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	induction	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	FICZ	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	UV	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	Ah	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	dependent	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Together	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	indicate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	UV	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	CYP	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	A	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	gene	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	mammalian	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	mediated	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	an	_	O	O	_	_	_	_	_
23	Ah	_	O	O	_	_	_	_	_
24	receptor	_	O	O	_	_	_	_	_
25	ligand	_	O	O	_	_	_	_	_
26	formed	_	O	O	_	_	_	_	_
27	from	_	O	O	_	_	_	_	_
28	tryptophan	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	photoproducts	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	tryptophan	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	suggested	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	mediators	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	light	_	O	O	_	_	_	_	_
14	via	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	Ah	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	such	_	O	O	_	_	_	_	_
23	also	_	O	O	_	_	_	_	_
24	could	_	O	O	_	_	_	_	_
25	have	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	role	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	light	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	regulated	_	O	O	_	_	_	_	_
32	biological	_	O	O	_	_	_	_	_
33	rhythms	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Legionella	_	O	O	_	_	_	_	_
3	pneumophila	_	O	O	_	_	_	_	_
4	rpoS	_	O	O	_	_	_	_	_
5	gene	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	required	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	growth	_	O	O	_	_	_	_	_
10	within	_	O	O	_	_	_	_	_
11	Acanthamoeba	_	O	O	_	_	_	_	_
12	castellanii	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	regulatory	_	O	O	_	_	_	_	_
4	networks	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	Legionella	_	O	O	_	_	_	_	_
7	pneumophila	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	encoding	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	homolog	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	Escherichia	_	O	O	_	_	_	_	_
17	coli	_	O	O	_	_	_	_	_
18	stress	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	stationary	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	phase	_	O	O	_	_	_	_	_
23	sigma	_	O	O	_	_	_	_	_
24	factor	_	O	O	_	_	_	_	_
25	RpoS	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	identified	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	complementation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	an	_	O	O	_	_	_	_	_
32	E	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	coli	_	O	O	_	_	_	_	_
2	rpoS	_	O	O	_	_	_	_	_
3	mutation	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	open	_	O	O	_	_	_	_	_
3	reading	_	O	O	_	_	_	_	_
4	frame	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	approximately	_	O	O	_	_	_	_	_
8	60	_	O	O	_	_	_	_	_
9	%	_	O	O	_	_	_	_	_
10	identical	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	E	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	coli	_	O	O	_	_	_	_	_
2	rpoS	_	O	O	_	_	_	_	_
3	gene	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	identified	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	Western	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	level	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	L	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	pneumophila	_	O	O	_	_	_	_	_
2	RpoS	_	O	O	_	_	_	_	_
3	increased	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	stationary	_	O	O	_	_	_	_	_
6	phase	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	insertion	_	O	O	_	_	_	_	_
3	mutation	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	constructed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	rpoS	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	chromosome	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	L	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	pneumophila	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	ability	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	this	_	O	O	_	_	_	_	_
8	mutant	_	O	O	_	_	_	_	_
9	strain	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	survive	_	O	O	_	_	_	_	_
12	various	_	O	O	_	_	_	_	_
13	stress	_	O	O	_	_	_	_	_
14	conditions	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	assayed	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	compared	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	results	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	wild	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	type	_	O	O	_	_	_	_	_
26	strain	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	mutant	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	wild	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	type	_	O	O	_	_	_	_	_
8	strains	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	more	_	O	O	_	_	_	_	_
11	resistant	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	stress	_	O	O	_	_	_	_	_
14	when	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	stationary	_	O	O	_	_	_	_	_
17	phase	_	O	O	_	_	_	_	_
18	than	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	logarithmic	_	O	O	_	_	_	_	_
23	phase	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	growth	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	finding	_	O	O	_	_	_	_	_
3	indicates	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	L	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	pneumophila	_	O	O	_	_	_	_	_
2	RpoS	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	required	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	stationary	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	phase	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	dependent	_	O	O	_	_	_	_	_
13	resistance	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	stress	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	mutant	_	O	O	_	_	_	_	_
4	strain	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	able	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	kill	_	O	O	_	_	_	_	_
9	HL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	60	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	THP	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	derived	_	O	O	_	_	_	_	_
19	macrophages	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	it	_	O	O	_	_	_	_	_
22	could	_	O	O	_	_	_	_	_
23	not	_	O	O	_	_	_	_	_
24	replicate	_	O	O	_	_	_	_	_
25	within	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	protozoan	_	O	O	_	_	_	_	_
28	host	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	Acanthamoeba	_	O	O	_	_	_	_	_
31	castellanii	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	L	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	pneumophila	_	O	O	_	_	_	_	_
2	possesses	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	growth	_	O	O	_	_	_	_	_
5	phase	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependent	_	O	O	_	_	_	_	_
8	resistance	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	stress	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	independent	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	RpoS	_	O	O	_	_	_	_	_
16	control	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	RpoS	_	O	O	_	_	_	_	_
20	likely	_	O	O	_	_	_	_	_
21	regulates	_	O	O	_	_	_	_	_
22	genes	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	enable	_	O	O	_	_	_	_	_
25	it	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	survive	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	environment	_	O	O	_	_	_	_	_
31	within	_	O	O	_	_	_	_	_
32	protozoa	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	role	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	rpoS	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	L	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	pneumophila	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	very	_	O	O	_	_	_	_	_
4	different	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	what	_	O	O	_	_	_	_	_
7	has	_	O	O	_	_	_	_	_
8	previously	_	O	O	_	_	_	_	_
9	been	_	O	O	_	_	_	_	_
10	reported	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	E	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	coli	_	O	O	_	_	_	_	_
2	rpoS	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_


1	Infection	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	Theileria	_	O	O	_	_	_	_	_
4	annulata	_	O	O	_	_	_	_	_
5	induces	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	matrix	_	O	O	_	_	_	_	_
9	metalloproteinase	_	O	O	_	_	_	_	_
10	9	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	AP	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	bovine	_	O	O	_	_	_	_	_
19	leucocytes	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Theileria	_	O	O	_	_	_	_	_
2	annulata	_	O	O	_	_	_	_	_
3	infects	_	O	O	_	_	_	_	_
4	bovine	_	O	O	_	_	_	_	_
5	leucocytes	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	results	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	their	_	O	O	_	_	_	_	_
10	reversible	_	O	O	_	_	_	_	_
11	transformation	_	O	O	_	_	_	_	_
12	such	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	they	_	O	O	_	_	_	_	_
15	become	_	O	O	_	_	_	_	_
16	immortalised	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	metastatic	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	describes	_	O	O	_	_	_	_	_
5	parasite	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	changes	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	host	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	have	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	direct	_	O	O	_	_	_	_	_
18	bearing	_	O	O	_	_	_	_	_
19	on	_	O	O	_	_	_	_	_
20	this	_	O	O	_	_	_	_	_
21	transformation	_	O	O	_	_	_	_	_
22	process	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	T	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	annulata	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	infected	_	O	O	_	_	_	_	_
4	leucocytes	_	O	O	_	_	_	_	_
5	produce	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	number	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	novel	_	O	O	_	_	_	_	_
10	metalloproteinase	_	O	O	_	_	_	_	_
11	activities	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	previously	_	O	O	_	_	_	_	_
6	called	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	97	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kDa	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	secreted	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	large	_	O	O	_	_	_	_	_
21	amounts	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	has	_	O	O	_	_	_	_	_
24	been	_	O	O	_	_	_	_	_
25	purified	_	O	O	_	_	_	_	_
26	from	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	free	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	conditioned	_	O	O	_	_	_	_	_
32	medium	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	antiserum	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	enzyme	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	used	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	isolate	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	cDNA	_	O	O	_	_	_	_	_
12	clone	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	predicted	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	sequence	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	81	_	O	O	_	_	_	_	_
10	%	_	O	O	_	_	_	_	_
11	identical	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	matrix	_	O	O	_	_	_	_	_
15	metalloproteinase	_	O	O	_	_	_	_	_
16	9	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	MMP	_	O	O	_	_	_	_	_
19	9	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	demonstrating	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	bovine	_	O	O	_	_	_	_	_
28	homologue	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	this	_	O	O	_	_	_	_	_
31	enzyme	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	RNAase	_	O	O	_	_	_	_	_
2	protection	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	MMP	_	O	O	_	_	_	_	_
8	9	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	unique	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	infected	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	due	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	increased	_	O	O	_	_	_	_	_
20	MMP	_	O	O	_	_	_	_	_
21	9	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	levels	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	assayed	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	AP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	demonstrated	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	it	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	constitutively	_	O	O	_	_	_	_	_
18	present	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	increased	_	O	O	_	_	_	_	_
21	amounts	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	Theileria	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	infected	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	assayed	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	level	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	mRNA	_	O	O	_	_	_	_	_
9	encoding	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Fos	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	common	_	O	O	_	_	_	_	_
16	component	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	AP	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	observed	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	indeed	_	O	O	_	_	_	_	_
27	up	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	regulated	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	infected	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	AP	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	implicated	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	control	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	cycle	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	MMP	_	O	O	_	_	_	_	_
17	9	_	O	O	_	_	_	_	_
18	can	_	O	O	_	_	_	_	_
19	confer	_	O	O	_	_	_	_	_
20	metastatic	_	O	O	_	_	_	_	_
21	properties	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	these	_	O	O	_	_	_	_	_
24	results	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	considerable	_	O	O	_	_	_	_	_
28	significance	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	respect	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	transformed	_	O	O	_	_	_	_	_
34	phenotype	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	Theileria	_	O	O	_	_	_	_	_
38	infection	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Flow	_	O	O	_	_	_	_	_
2	cytometric	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	R	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	sample	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	x	_	O	O	_	_	_	_	_
6	105	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	PBMC	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	resuspended	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	PBS	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	%	_	O	O	_	_	_	_	_
17	FCS	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	incubated	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	saturating	_	O	O	_	_	_	_	_
6	concentrations	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	anti	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	R	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	mAb	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	IgG	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	R	_	O	O	_	_	_	_	_
21	&	_	O	O	_	_	_	_	_
22	D	_	O	O	_	_	_	_	_
23	systems	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	Minneapolis	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	MN	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	USA	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	or	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	isotype	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	matched	_	O	O	_	_	_	_	_
36	control	_	O	O	_	_	_	_	_
37	mAb	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	Immunotech	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	followed	_	O	O	_	_	_	_	_
43	by	_	O	O	_	_	_	_	_
44	incubation	_	O	O	_	_	_	_	_
45	with	_	O	O	_	_	_	_	_
46	FITC	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	conjugated	_	O	O	_	_	_	_	_
49	goat	_	O	O	_	_	_	_	_
50	anti	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	mouse	_	O	O	_	_	_	_	_
53	IgG	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	polyclonal	_	O	O	_	_	_	_	_
56	antibody	_	O	O	_	_	_	_	_
57	(	_	O	O	_	_	_	_	_
58	Santa	_	O	O	_	_	_	_	_
59	Cruz	_	O	O	_	_	_	_	_
60	Biotechnologies	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	Santa	_	O	O	_	_	_	_	_
63	Cruz	_	O	O	_	_	_	_	_
64	,	_	O	O	_	_	_	_	_
65	CA	_	O	O	_	_	_	_	_
66	,	_	O	O	_	_	_	_	_
67	USA	_	O	O	_	_	_	_	_
68	)	_	O	O	_	_	_	_	_
69	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	then	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	phycoerythrin	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	conjugated	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	mAb	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	Becton	_	O	O	_	_	_	_	_
16	Dickinson	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	washed	_	O	O	_	_	_	_	_
4	well	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	%	_	O	O	_	_	_	_	_
8	FCS	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	PBS	_	O	O	_	_	_	_	_
11	between	_	O	O	_	_	_	_	_
12	incubations	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Analysis	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	performed	_	O	O	_	_	_	_	_
4	on	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	FACScan	_	O	O	_	_	_	_	_
7	flow	_	O	O	_	_	_	_	_
8	cytometer	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Becton	_	O	O	_	_	_	_	_
11	Dickinson	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_



1	CD	_	O	O	_	_	_	_	_
2	14	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	signal	_	O	O	_	_	_	_	_
6	pathway	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Porphyromonas	_	O	O	_	_	_	_	_
9	gingivalis	_	O	O	_	_	_	_	_
10	lipopolysaccharide	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	gingival	_	O	O	_	_	_	_	_
14	fibroblasts	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Lipopolysaccharide	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	induces	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	inflammatory	_	O	O	_	_	_	_	_
9	cytokines	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	monocytes	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	macrophages	_	O	O	_	_	_	_	_
14	via	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	14	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	one	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	LPS	_	O	O	_	_	_	_	_
22	receptors	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	expressed	_	O	O	_	_	_	_	_
27	predominantly	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	these	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	has	_	O	O	_	_	_	_	_
3	been	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	Porphyromonas	_	O	O	_	_	_	_	_
7	gingivalis	_	O	O	_	_	_	_	_
8	LPS	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	P	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	LPS	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	able	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	induce	_	O	O	_	_	_	_	_
19	inflammatory	_	O	O	_	_	_	_	_
20	cytokines	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	gingival	_	O	O	_	_	_	_	_
24	fibroblasts	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	important	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	determine	_	O	O	_	_	_	_	_
8	whether	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	14	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	gingival	_	O	O	_	_	_	_	_
15	fibroblasts	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	define	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	P	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	LPS	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	mediated	_	O	O	_	_	_	_	_
25	signal	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	transducing	_	O	O	_	_	_	_	_
28	mechanism	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	observed	_	O	O	_	_	_	_	_
7	unexpectedly	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	immunohistochemical	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	Western	_	O	O	_	_	_	_	_
12	blotting	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	immunoblotting	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	Northern	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	RNA	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	blotting	_	O	O	_	_	_	_	_
23	assays	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	14	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	expressed	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	high	_	O	O	_	_	_	_	_
31	density	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	human	_	O	O	_	_	_	_	_
34	gingival	_	O	O	_	_	_	_	_
35	fibroblasts	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	P	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	monocyte	_	O	O	_	_	_	_	_
10	chemoattractant	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	MCP	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	inhibited	_	O	O	_	_	_	_	_
24	markedly	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	treatment	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	14	_	O	O	_	_	_	_	_
33	antibody	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	completely	_	O	O	_	_	_	_	_
37	inhibited	_	O	O	_	_	_	_	_
38	by	_	O	O	_	_	_	_	_
39	herbimycin	_	O	O	_	_	_	_	_
40	A	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	potent	_	O	O	_	_	_	_	_
44	inhibitor	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	tyrosine	_	O	O	_	_	_	_	_
47	kinase	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	inhibitor	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	dramatically	_	O	O	_	_	_	_	_
5	inhibited	_	O	O	_	_	_	_	_
6	monocyte	_	O	O	_	_	_	_	_
7	chemotactic	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	MCP	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	production	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	P	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	LPS	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	MCP	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	gene	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	also	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	blocked	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	inhibitors	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	two	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	factors	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	i	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	e	_	O	O	_	_	_	_	_
31	.,	_	O	O	_	_	_	_	_
32	curcumin	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	an	_	O	O	_	_	_	_	_
35	inhibitor	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	AP	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	pyrolidine	_	O	O	_	_	_	_	_
43	dithiocarbamate	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	an	_	O	O	_	_	_	_	_
46	inhibitor	_	O	O	_	_	_	_	_
47	of	_	O	O	_	_	_	_	_
48	NF	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	kappaB	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	inhibitors	_	O	O	_	_	_	_	_
3	inhibited	_	O	O	_	_	_	_	_
4	monocyte	_	O	O	_	_	_	_	_
5	chemotactic	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	culture	_	O	O	_	_	_	_	_
10	supernatant	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	P	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	treated	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Gel	_	O	O	_	_	_	_	_
2	shift	_	O	O	_	_	_	_	_
3	mobility	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	showed	_	O	O	_	_	_	_	_
6	stimulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	AP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappaB	_	O	O	_	_	_	_	_
16	contents	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	P	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	LPS	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	treated	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	first	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	demonstrate	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	14	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	gingival	_	O	O	_	_	_	_	_
16	fibroblasts	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	show	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	signal	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	transducing	_	O	O	_	_	_	_	_
25	pathway	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	P	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	LPS	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	mediated	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	14	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_


1	Conclusion	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	active	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	characterized	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	their	_	O	O	_	_	_	_	_
14	resistance	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	inhibition	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	IFN	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	gamma	_	O	O	_	_	_	_	_
24	production	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	due	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	constitutive	_	O	O	_	_	_	_	_
29	STAT	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	phosphorylation	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	impaired	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	10	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	mediated	_	O	O	_	_	_	_	_
39	STAT	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	activation	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	defective	_	O	O	_	_	_	_	_
3	STAT	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	signaling	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	possibly	_	O	O	_	_	_	_	_
8	associated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	SOCS	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	predominance	_	O	O	_	_	_	_	_
13	over	_	O	O	_	_	_	_	_
14	SOCS	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	abnormalities	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	active	_	O	O	_	_	_	_	_
5	RA	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	thought	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	mainly	_	O	O	_	_	_	_	_
12	after	_	O	O	_	_	_	_	_
13	chronic	_	O	O	_	_	_	_	_
14	exposure	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	high	_	O	O	_	_	_	_	_
17	concentrations	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	limited	_	O	O	_	_	_	_	_
3	efficacy	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	treatment	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	patients	_	O	O	_	_	_	_	_
12	[	_	O	O	_	_	_	_	_
13	50	_	O	O	_	_	_	_	_
14	]	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	explained	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	part	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	unresponsiveness	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	10	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	inflammatory	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	including	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	therapeutic	_	O	O	_	_	_	_	_
7	efficacy	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	antibody	_	O	O	_	_	_	_	_
16	has	_	O	O	_	_	_	_	_
17	been	_	O	O	_	_	_	_	_
18	reported	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	51	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	one	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	effects	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	this	_	O	O	_	_	_	_	_
33	therapy	_	O	O	_	_	_	_	_
34	may	_	O	O	_	_	_	_	_
35	be	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	normalize	_	O	O	_	_	_	_	_
38	T	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	through	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	inhibition	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	6	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	dependent	_	O	O	_	_	_	_	_
49	STAT	_	O	O	_	_	_	_	_
50	3	_	O	O	_	_	_	_	_
51	activation	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	More	_	O	O	_	_	_	_	_
2	specific	_	O	O	_	_	_	_	_
3	therapy	_	O	O	_	_	_	_	_
4	targeting	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	will	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	awaited	_	O	O	_	_	_	_	_
11	;	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	example	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	induction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	SOCS	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	efficacy	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	which	_	O	O	_	_	_	_	_
27	has	_	O	O	_	_	_	_	_
28	been	_	O	O	_	_	_	_	_
29	demonstrated	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	animal	_	O	O	_	_	_	_	_
32	models	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	37	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_



1	[	_	O	O	_	_	_	_	_
2	Glucocorticoid	_	O	O	_	_	_	_	_
3	receptors	_	O	O	_	_	_	_	_
4	on	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	peripheral	_	O	O	_	_	_	_	_
7	mononuclear	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	polymorphonuclear	_	O	O	_	_	_	_	_
10	leucocytes	_	O	O	_	_	_	_	_
11	:	_	O	O	_	_	_	_	_
12	changes	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	patients	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	yang	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	deficiency	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	found	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	former	_	O	O	_	_	_	_	_
8	works	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	glucocorticoid	_	O	O	_	_	_	_	_
12	receptors	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	GCR	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	peripheral	_	O	O	_	_	_	_	_
18	mixed	_	O	O	_	_	_	_	_
19	leucocytes	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	Yang	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	deficiency	_	O	O	_	_	_	_	_
26	were	_	O	O	_	_	_	_	_
27	decreased	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	work	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	mixed	_	O	O	_	_	_	_	_
7	leucocytes	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	further	_	O	O	_	_	_	_	_
10	separated	_	O	O	_	_	_	_	_
11	into	_	O	O	_	_	_	_	_
12	mononuclear	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	MNL	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	polymorphonuclear	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	PML	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	leucocytes	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	GCR	_	O	O	_	_	_	_	_
25	were	_	O	O	_	_	_	_	_
26	determined	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	each	_	O	O	_	_	_	_	_
29	part	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	leucocytes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	GCR	_	O	O	_	_	_	_	_
2	on	_	O	O	_	_	_	_	_
3	MNL	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	PML	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	Yang	_	O	O	_	_	_	_	_
9	deficient	_	O	O	_	_	_	_	_
10	patients	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	3473	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	413	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	4433	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	651	_	O	O	_	_	_	_	_
23	sites	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	respectively	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	statistically	_	O	O	_	_	_	_	_
29	significant	_	O	O	_	_	_	_	_
30	from	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	normal	_	O	O	_	_	_	_	_
33	control	_	O	O	_	_	_	_	_
34	group	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	4462	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	/	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	962	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	5622	_	O	O	_	_	_	_	_
43	+	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	782	_	O	O	_	_	_	_	_
47	sites	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	cell	_	O	O	_	_	_	_	_
50	respectively	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	P	_	O	O	_	_	_	_	_
53	less	_	O	O	_	_	_	_	_
54	than	_	O	O	_	_	_	_	_
55	0	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_
57	05	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	GCR	_	O	O	_	_	_	_	_
2	on	_	O	O	_	_	_	_	_
3	MNL	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	PML	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	mixed	_	O	O	_	_	_	_	_
8	leucocytes	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	patients	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	determined	_	O	O	_	_	_	_	_
14	simultaneously	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	all	_	O	O	_	_	_	_	_
18	lowered	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	control	_	O	O	_	_	_	_	_
22	group	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	3369	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	370	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	4986	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	419	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	4524	_	O	O	_	_	_	_	_
17	+	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	852	_	O	O	_	_	_	_	_
21	sites	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	respectively	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	lowest	_	O	O	_	_	_	_	_
29	GCR	_	O	O	_	_	_	_	_
30	on	_	O	O	_	_	_	_	_
31	MNL	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	highest	_	O	O	_	_	_	_	_
34	on	_	O	O	_	_	_	_	_
35	PML	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Isolation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_

1	Peripheral	_	O	O	_	_	_	_	_
2	blood	_	O	O	_	_	_	_	_
3	mononuclear	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	PBMC	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	prepared	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	heparinized	_	O	O	_	_	_	_	_
12	blood	_	O	O	_	_	_	_	_
13	samples	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	centrifugation	_	O	O	_	_	_	_	_
16	over	_	O	O	_	_	_	_	_
17	Ficoll	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	Hypaque	_	O	O	_	_	_	_	_
20	density	_	O	O	_	_	_	_	_
21	gradients	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	Pharmacia	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	Uppsala	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	Sweden	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	purified	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	PBMC	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	positive	_	O	O	_	_	_	_	_
12	selection	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	mAb	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	coated	_	O	O	_	_	_	_	_
21	magnetic	_	O	O	_	_	_	_	_
22	beads	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	Miltenyi	_	O	O	_	_	_	_	_
25	Biotec	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	Gladbach	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	Germany	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	according	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	manufacturer	_	O	O	_	_	_	_	_
36	'	_	O	O	_	_	_	_	_
37	s	_	O	O	_	_	_	_	_
38	instructions	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	isolated	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	ST	_	O	O	_	_	_	_	_
10	samples	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	previously	_	O	O	_	_	_	_	_
14	described	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	27	_	O	O	_	_	_	_	_
17	]	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Briefly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	fresh	_	O	O	_	_	_	_	_
4	ST	_	O	O	_	_	_	_	_
5	samples	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	fragmented	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	digested	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	collagenase	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	DNase	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	hour	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	37	_	O	O	_	_	_	_	_
19	degreesC	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	removing	_	O	O	_	_	_	_	_
3	tissue	_	O	O	_	_	_	_	_
4	debris	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	ST	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	suspensions	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	culture	_	O	O	_	_	_	_	_
11	medium	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	RPMI	_	O	O	_	_	_	_	_
14	1640	_	O	O	_	_	_	_	_
15	medium	_	O	O	_	_	_	_	_
16	;	_	O	O	_	_	_	_	_
17	Life	_	O	O	_	_	_	_	_
18	Technologies	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	Gaithersburg	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	MD	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	USA	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	supplemented	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	25	_	O	O	_	_	_	_	_
29	mM	_	O	O	_	_	_	_	_
30	HEPES	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	mM	_	O	O	_	_	_	_	_
34	L	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	glutamine	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	%	_	O	O	_	_	_	_	_
40	nonessential	_	O	O	_	_	_	_	_
41	amino	_	O	O	_	_	_	_	_
42	acids	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	100	_	O	O	_	_	_	_	_
45	IU	_	O	O	_	_	_	_	_
46	/	_	O	O	_	_	_	_	_
47	ml	_	O	O	_	_	_	_	_
48	penicillin	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	100	_	O	O	_	_	_	_	_
52	mg	_	O	O	_	_	_	_	_
53	/	_	O	O	_	_	_	_	_
54	ml	_	O	O	_	_	_	_	_
55	streptomycin	_	O	O	_	_	_	_	_
56	;	_	O	O	_	_	_	_	_
57	Life	_	O	O	_	_	_	_	_
58	Technologies	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	with	_	O	O	_	_	_	_	_
61	10	_	O	O	_	_	_	_	_
62	%	_	O	O	_	_	_	_	_
63	heat	_	O	O	_	_	_	_	_
64	-	_	O	O	_	_	_	_	_
65	inactivated	_	O	O	_	_	_	_	_
66	FCS	_	O	O	_	_	_	_	_
67	(	_	O	O	_	_	_	_	_
68	Life	_	O	O	_	_	_	_	_
69	Technologies	_	O	O	_	_	_	_	_
70	)	_	O	O	_	_	_	_	_
71	were	_	O	O	_	_	_	_	_
72	incubated	_	O	O	_	_	_	_	_
73	at	_	O	O	_	_	_	_	_
74	37	_	O	O	_	_	_	_	_
75	degreesC	_	O	O	_	_	_	_	_
76	in	_	O	O	_	_	_	_	_
77	six	_	O	O	_	_	_	_	_
78	-	_	O	O	_	_	_	_	_
79	well	_	O	O	_	_	_	_	_
80	plates	_	O	O	_	_	_	_	_
81	(	_	O	O	_	_	_	_	_
82	Coster	_	O	O	_	_	_	_	_
83	,	_	O	O	_	_	_	_	_
84	Cambridge	_	O	O	_	_	_	_	_
85	,	_	O	O	_	_	_	_	_
86	MA	_	O	O	_	_	_	_	_
87	,	_	O	O	_	_	_	_	_
88	USA	_	O	O	_	_	_	_	_
89	)	_	O	O	_	_	_	_	_
90	for	_	O	O	_	_	_	_	_
91	45	_	O	O	_	_	_	_	_
92	min	_	O	O	_	_	_	_	_
93	.	_	O	O	_	_	_	_	_

1	Non	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	adherent	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	harvested	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	purified	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	positive	_	O	O	_	_	_	_	_
17	selection	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	already	_	O	O	_	_	_	_	_
20	described	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_



1	Interferon	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	beta	_	O	O	_	_	_	_	_
4	mediates	_	O	O	_	_	_	_	_
5	stromal	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	rescue	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	apoptosis	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	resolution	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	immune	_	O	O	_	_	_	_	_
5	responses	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	characterized	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	extensive	_	O	O	_	_	_	_	_
10	apoptosis	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	generate	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	maintain	_	O	O	_	_	_	_	_
7	immunological	_	O	O	_	_	_	_	_
8	memory	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	some	_	O	O	_	_	_	_	_
11	antigen	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	specific	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	must	_	O	O	_	_	_	_	_
17	survive	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	revert	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	resting	_	O	O	_	_	_	_	_
23	G	_	O	O	_	_	_	_	_
24	0	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	G	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	state	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Cytokines	_	O	O	_	_	_	_	_
2	that	_	O	O	_	_	_	_	_
3	bind	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	common	_	O	O	_	_	_	_	_
7	gamma	_	O	O	_	_	_	_	_
8	chain	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	promote	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	survival	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	blasts	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	also	_	O	O	_	_	_	_	_
25	induce	_	O	O	_	_	_	_	_
26	proliferation	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	soluble	_	O	O	_	_	_	_	_
5	factors	_	O	O	_	_	_	_	_
6	secreted	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	stromal	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	induce	_	O	O	_	_	_	_	_
11	Tcell	_	O	O	_	_	_	_	_
12	survival	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	resting	_	O	O	_	_	_	_	_
16	G	_	O	O	_	_	_	_	_
17	0	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	G	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	state	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	now	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	interferon	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	principal	_	O	O	_	_	_	_	_
11	mediator	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	stromal	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	mediated	_	O	O	_	_	_	_	_
17	Tcell	_	O	O	_	_	_	_	_
18	rescue	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	apoptosis	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Interferon	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	alpha	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	promote	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	reversion	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	blast	_	O	O	_	_	_	_	_
12	Tcells	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	resting	_	O	O	_	_	_	_	_
16	G	_	O	O	_	_	_	_	_
17	0	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	G	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	configuration	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	all	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	characteristic	_	O	O	_	_	_	_	_
26	features	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	stromal	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	rescue	_	O	O	_	_	_	_	_
31	;	_	O	O	_	_	_	_	_
32	such	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	high	_	O	O	_	_	_	_	_
35	Bcl	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	XL	_	O	O	_	_	_	_	_
38	expression	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	low	_	O	O	_	_	_	_	_
41	Bcl	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Type	_	O	O	_	_	_	_	_
2	I	_	O	O	_	_	_	_	_
3	interferons	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	stromal	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	stimulate	_	O	O	_	_	_	_	_
8	apparently	_	O	O	_	_	_	_	_
9	identical	_	O	O	_	_	_	_	_
10	signaling	_	O	O	_	_	_	_	_
11	pathways	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	leading	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	mechanism	_	O	O	_	_	_	_	_
7	may	_	O	O	_	_	_	_	_
8	play	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	fundamental	_	O	O	_	_	_	_	_
11	role	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	persistence	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	sites	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	chronic	_	O	O	_	_	_	_	_
22	inflammation	_	O	O	_	_	_	_	_
23	;	_	O	O	_	_	_	_	_
24	suggesting	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	chronic	_	O	O	_	_	_	_	_
27	inflammation	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	an	_	O	O	_	_	_	_	_
30	aberrant	_	O	O	_	_	_	_	_
31	consequence	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	immunological	_	O	O	_	_	_	_	_
34	memory	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Detection	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	intracellular	_	O	O	_	_	_	_	_
4	phosphorylated	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	flow	_	O	O	_	_	_	_	_
10	cytometry	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	applied	_	O	O	_	_	_	_	_
4	flow	_	O	O	_	_	_	_	_
5	cytometry	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	investigation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	interferon	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	gamma	_	O	O	_	_	_	_	_
13	activation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	monocytes	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	approach	_	O	O	_	_	_	_	_
3	uses	_	O	O	_	_	_	_	_
4	monoclonal	_	O	O	_	_	_	_	_
5	antibodies	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	distinguish	_	O	O	_	_	_	_	_
8	between	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	native	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	phosphorylated	_	O	O	_	_	_	_	_
13	forms	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	enables	_	O	O	_	_	_	_	_
3	rapid	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	quantitative	_	O	O	_	_	_	_	_
6	assessment	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	phosphorylation	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	discrete	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	basis	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	both	_	O	O	_	_	_	_	_
20	more	_	O	O	_	_	_	_	_
21	sensitive	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	less	_	O	O	_	_	_	_	_
24	time	_	O	O	_	_	_	_	_
25	consuming	_	O	O	_	_	_	_	_
26	than	_	O	O	_	_	_	_	_
27	immunoblotting	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	allows	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	discrimination	_	O	O	_	_	_	_	_
7	between	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	mixture	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	differ	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	their	_	O	O	_	_	_	_	_
16	response	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	interferon	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	gamma	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	approach	_	O	O	_	_	_	_	_
3	should	_	O	O	_	_	_	_	_
4	allow	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	evaluation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	different	_	O	O	_	_	_	_	_
10	intracellular	_	O	O	_	_	_	_	_
11	signaling	_	O	O	_	_	_	_	_
12	pathways	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	combination	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	monoclonal	_	O	O	_	_	_	_	_
18	reagents	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	specific	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	native	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	activation	_	O	O	_	_	_	_	_
26	modified	_	O	O	_	_	_	_	_
27	proteins	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Application	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	form	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	testing	_	O	O	_	_	_	_	_
7	should	_	O	O	_	_	_	_	_
8	prove	_	O	O	_	_	_	_	_
9	valuable	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	screening	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	signaling	_	O	O	_	_	_	_	_
14	defects	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	selected	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	recurrent	_	O	O	_	_	_	_	_
20	infections	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	technique	_	O	O	_	_	_	_	_
6	should	_	O	O	_	_	_	_	_
7	permit	_	O	O	_	_	_	_	_
8	dissection	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	full	_	O	O	_	_	_	_	_
12	range	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	cellular	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	pathways	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	level	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Direct	_	O	O	_	_	_	_	_
2	demonstration	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NFATp	_	O	O	_	_	_	_	_
5	dephosphorylation	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	nuclear	_	O	O	_	_	_	_	_
8	localization	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	activated	_	O	O	_	_	_	_	_
11	HT	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	using	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	NFATp	_	O	O	_	_	_	_	_
19	polyclonal	_	O	O	_	_	_	_	_
20	antibody	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Nuclear	_	O	O	_	_	_	_	_
2	factor	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	activated	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	NFAT	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	regulates	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	number	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	genes	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	NFAT	_	O	O	_	_	_	_	_
21	DNA	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	stimulated	_	O	O	_	_	_	_	_
26	following	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	activation	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Several	_	O	O	_	_	_	_	_
2	lines	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	evidence	_	O	O	_	_	_	_	_
5	have	_	O	O	_	_	_	_	_
6	suggested	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	NFAT	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	substrate	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	calcineurin	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	serine	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	threonine	_	O	O	_	_	_	_	_
19	phosphatase	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	polyclonal	_	O	O	_	_	_	_	_
4	antibody	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	murine	_	O	O	_	_	_	_	_
7	NFATp	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	Western	_	O	O	_	_	_	_	_
10	blot	_	O	O	_	_	_	_	_
11	analysis	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	various	_	O	O	_	_	_	_	_
14	mouse	_	O	O	_	_	_	_	_
15	tissues	_	O	O	_	_	_	_	_
16	demonstrated	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	110	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	130	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	kDa	_	O	O	_	_	_	_	_
24	NFATp	_	O	O	_	_	_	_	_
25	protein	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	highly	_	O	O	_	_	_	_	_
28	expressed	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	thymus	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	spleen	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	immunoprecipitated	_	O	O	_	_	_	_	_
4	NFATp	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	untreated	_	O	O	_	_	_	_	_
7	HT	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	calcineurin	_	O	O	_	_	_	_	_
13	resulted	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	dephosphorylation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	NFATp	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	demonstrating	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	NFATp	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	vitro	_	O	O	_	_	_	_	_
27	substrate	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	calcineurin	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	NFATp	_	O	O	_	_	_	_	_
2	immunoprecipitated	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	32	_	O	O	_	_	_	_	_
5	P	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	labeled	_	O	O	_	_	_	_	_
8	HT	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	migrated	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	approximately	_	O	O	_	_	_	_	_
16	120	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	kDa	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	localized	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	cytosol	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	ionomycin	_	O	O	_	_	_	_	_
7	resulted	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	decrease	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	molecular	_	O	O	_	_	_	_	_
14	weight	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	NFATp	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	loss	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	32	_	O	O	_	_	_	_	_
22	P	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	consistent	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	NFATp	_	O	O	_	_	_	_	_
27	dephosphorylation	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	dephosphorylation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NFATp	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	accompanied	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	localization	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	nuclear	_	O	O	_	_	_	_	_
15	fraction	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	events	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	blocked	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	preincubation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	FK	_	O	O	_	_	_	_	_
14	506	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	calcineurin	_	O	O	_	_	_	_	_
18	inhibitor	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	consistent	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	hypothesis	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	NFATp	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	calcineurin	_	O	O	_	_	_	_	_
29	substrate	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Monoallelic	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Pax	_	O	O	_	_	_	_	_
5	5	_	O	O	_	_	_	_	_
6	:	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	paradigm	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	haploinsufficiency	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	mammalian	_	O	O	_	_	_	_	_
14	Pax	_	O	O	_	_	_	_	_
15	genes	_	O	O	_	_	_	_	_
16	?	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	generally	_	O	O	_	_	_	_	_
4	assumed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	most	_	O	O	_	_	_	_	_
7	mammalian	_	O	O	_	_	_	_	_
8	genes	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	transcribed	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	both	_	O	O	_	_	_	_	_
13	alleles	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Hence	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	diploid	_	O	O	_	_	_	_	_
5	state	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	genome	_	O	O	_	_	_	_	_
9	offers	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	advantage	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	loss	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	function	_	O	O	_	_	_	_	_
19	mutation	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	one	_	O	O	_	_	_	_	_
22	allele	_	O	O	_	_	_	_	_
23	can	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	compensated	_	O	O	_	_	_	_	_
26	for	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	remaining	_	O	O	_	_	_	_	_
30	wild	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	type	_	O	O	_	_	_	_	_
33	allele	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	same	_	O	O	_	_	_	_	_
37	gene	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Indeed	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	vast	_	O	O	_	_	_	_	_
5	majority	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	disease	_	O	O	_	_	_	_	_
9	syndromes	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	engineered	_	O	O	_	_	_	_	_
12	mutations	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	mouse	_	O	O	_	_	_	_	_
16	genome	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	recessive	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	indicating	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	recessiveness	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	'	_	O	O	_	_	_	_	_
26	default	_	O	O	_	_	_	_	_
27	'	_	O	O	_	_	_	_	_
28	state	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	minority	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	genes	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	semi	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	dominant	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	heterozygous	_	O	O	_	_	_	_	_
14	loss	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	function	_	O	O	_	_	_	_	_
19	mutation	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	these	_	O	O	_	_	_	_	_
22	genes	_	O	O	_	_	_	_	_
23	leads	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	phenotypic	_	O	O	_	_	_	_	_
26	abnormalities	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	condition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	known	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	haploinsufficiency	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	has	_	O	O	_	_	_	_	_
9	been	_	O	O	_	_	_	_	_
10	described	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	five	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	nine	_	O	O	_	_	_	_	_
16	mammalian	_	O	O	_	_	_	_	_
17	Pax	_	O	O	_	_	_	_	_
18	genes	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	which	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	associated	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	mouse	_	O	O	_	_	_	_	_
25	developmental	_	O	O	_	_	_	_	_
26	mutants	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	human	_	O	O	_	_	_	_	_
29	disease	_	O	O	_	_	_	_	_
30	syndromes	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	reported	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	Pax	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	subject	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	allele	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	specific	_	O	O	_	_	_	_	_
16	regulation	_	O	O	_	_	_	_	_
17	during	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	development	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Pax	_	O	O	_	_	_	_	_
2	5	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	predominantly	_	O	O	_	_	_	_	_
5	transcribed	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	only	_	O	O	_	_	_	_	_
8	one	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	its	_	O	O	_	_	_	_	_
11	two	_	O	O	_	_	_	_	_
12	alleles	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	early	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	lymphoid	_	O	O	_	_	_	_	_
18	progenitors	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	mature	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	while	_	O	O	_	_	_	_	_
25	it	_	O	O	_	_	_	_	_
26	transiently	_	O	O	_	_	_	_	_
27	switches	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	biallelic	_	O	O	_	_	_	_	_
31	mode	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	transcription	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	pre	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	B	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	immature	_	O	O	_	_	_	_	_
40	B	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	consequence	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	lymphoid	_	O	O	_	_	_	_	_
8	tissues	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	mosaic	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	regard	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	transcribed	_	O	O	_	_	_	_	_
16	allele	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	heterozygous	_	O	O	_	_	_	_	_
20	mutation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	Pax	_	O	O	_	_	_	_	_
23	5	_	O	O	_	_	_	_	_
24	therefore	_	O	O	_	_	_	_	_
25	results	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	deletion	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	lymphocytes	_	O	O	_	_	_	_	_
31	expressing	_	O	O	_	_	_	_	_
32	only	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	mutant	_	O	O	_	_	_	_	_
35	allele	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	allele	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	regulation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Pax	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	raises	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	intriguing	_	O	O	_	_	_	_	_
12	possibility	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	monoallelic	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	may	_	O	O	_	_	_	_	_
17	also	_	O	O	_	_	_	_	_
18	be	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	mechanism	_	O	O	_	_	_	_	_
21	causing	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	haploinsufficiency	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	other	_	O	O	_	_	_	_	_
26	Pax	_	O	O	_	_	_	_	_
27	genes	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	review	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	discuss	_	O	O	_	_	_	_	_
7	different	_	O	O	_	_	_	_	_
8	models	_	O	O	_	_	_	_	_
9	accounting	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	haploinsufficiency	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	mammalian	_	O	O	_	_	_	_	_
15	Pax	_	O	O	_	_	_	_	_
16	genes	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	provide	_	O	O	_	_	_	_	_
19	further	_	O	O	_	_	_	_	_
20	evidence	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	support	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	allele	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	regulation	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	Pax	_	O	O	_	_	_	_	_
31	5	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	discuss	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	implication	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	these	_	O	O	_	_	_	_	_
38	findings	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	context	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	recent	_	O	O	_	_	_	_	_
45	literature	_	O	O	_	_	_	_	_
46	describing	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	stochastic	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	monoallelic	_	O	O	_	_	_	_	_
51	activation	_	O	O	_	_	_	_	_
52	of	_	O	O	_	_	_	_	_
53	other	_	O	O	_	_	_	_	_
54	hematopoietic	_	O	O	_	_	_	_	_
55	genes	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_


1	Epstein	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Barr	_	O	O	_	_	_	_	_
4	virus	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	antigen	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	transactivates	_	O	O	_	_	_	_	_
9	latent	_	O	O	_	_	_	_	_
10	membrane	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	LMP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Several	_	O	O	_	_	_	_	_
2	lines	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	evidence	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	compatible	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	hypothesis	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	Epstein	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Barr	_	O	O	_	_	_	_	_
14	virus	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	EBV	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	antigen	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	EBNA	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	or	_	O	O	_	_	_	_	_
27	leader	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	EBNA	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	LP	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	affects	_	O	O	_	_	_	_	_
35	expression	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	EBV	_	O	O	_	_	_	_	_
39	latent	_	O	O	_	_	_	_	_
40	infection	_	O	O	_	_	_	_	_
41	membrane	_	O	O	_	_	_	_	_
42	protein	_	O	O	_	_	_	_	_
43	LMP	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	now	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	following	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	i	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Acute	_	O	O	_	_	_	_	_
5	transfection	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	EBNA	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	under	_	O	O	_	_	_	_	_
13	control	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	simian	_	O	O	_	_	_	_	_
16	virus	_	O	O	_	_	_	_	_
17	40	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	Moloney	_	O	O	_	_	_	_	_
20	murine	_	O	O	_	_	_	_	_
21	leukemia	_	O	O	_	_	_	_	_
22	virus	_	O	O	_	_	_	_	_
23	promoters	_	O	O	_	_	_	_	_
24	resulted	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	increased	_	O	O	_	_	_	_	_
27	LMP	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	P	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	HR	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	infected	_	O	O	_	_	_	_	_
38	Burkitt	_	O	O	_	_	_	_	_
39	'	_	O	O	_	_	_	_	_
40	s	_	O	O	_	_	_	_	_
41	lymphoma	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	P	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	HR	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	or	_	O	O	_	_	_	_	_
51	Daudi	_	O	O	_	_	_	_	_
52	cell	_	O	O	_	_	_	_	_
53	line	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	ii	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Transfection	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	EBNA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	LP	_	O	O	_	_	_	_	_
11	alone	_	O	O	_	_	_	_	_
12	had	_	O	O	_	_	_	_	_
13	no	_	O	O	_	_	_	_	_
14	effect	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	LMP	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	did	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	act	_	O	O	_	_	_	_	_
23	synergistically	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	EBNA	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	affect	_	O	O	_	_	_	_	_
30	LMP	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	iii	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	LMP	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	Daudi	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	P	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	HR	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	infected	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	controlled	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	level	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	EBNA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	Daudi	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	increased	_	O	O	_	_	_	_	_
34	LMP	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	mRNA	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	iv	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	No	_	O	O	_	_	_	_	_
5	other	_	O	O	_	_	_	_	_
6	EBV	_	O	O	_	_	_	_	_
7	genes	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	required	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	EBNA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	transactivation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	LMP	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	since	_	O	O	_	_	_	_	_
19	cotransfection	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	recombinant	_	O	O	_	_	_	_	_
22	EBNA	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	vectors	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	genomic	_	O	O	_	_	_	_	_
29	LMP	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	DNA	_	O	O	_	_	_	_	_
32	fragments	_	O	O	_	_	_	_	_
33	enhanced	_	O	O	_	_	_	_	_
34	LMP	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	EBV	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	negative	_	O	O	_	_	_	_	_
42	B	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	lymphoma	_	O	O	_	_	_	_	_
45	cell	_	O	O	_	_	_	_	_
46	lines	_	O	O	_	_	_	_	_
47	BJAB	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	Louckes	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	BL	_	O	O	_	_	_	_	_
53	30	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	v	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	An	_	O	O	_	_	_	_	_
5	EBNA	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	responsive	_	O	O	_	_	_	_	_
10	element	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	found	_	O	O	_	_	_	_	_
13	within	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	512	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	40	_	O	O	_	_	_	_	_
20	LMP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	since	_	O	O	_	_	_	_	_
24	this	_	O	O	_	_	_	_	_
25	DNA	_	O	O	_	_	_	_	_
26	linked	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	chloramphenicol	_	O	O	_	_	_	_	_
30	acetyltransferase	_	O	O	_	_	_	_	_
31	reporter	_	O	O	_	_	_	_	_
32	gene	_	O	O	_	_	_	_	_
33	was	_	O	O	_	_	_	_	_
34	transactivated	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	cotransfection	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	an	_	O	O	_	_	_	_	_
39	EBNA	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	2	_	O	O	_	_	_	_	_
42	expression	_	O	O	_	_	_	_	_
43	vector	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	vi	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	The	_	O	O	_	_	_	_	_
5	EBV	_	O	O	_	_	_	_	_
6	type	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	EBNA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	transactivated	_	O	O	_	_	_	_	_
12	LMP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	well	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	EBV	_	O	O	_	_	_	_	_
19	type	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	EBNA	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	vii	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Two	_	O	O	_	_	_	_	_
5	deletions	_	O	O	_	_	_	_	_
6	within	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	EBNA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	rendered	_	O	O	_	_	_	_	_
14	EBV	_	O	O	_	_	_	_	_
15	transformation	_	O	O	_	_	_	_	_
16	incompetent	_	O	O	_	_	_	_	_
17	did	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	transactivate	_	O	O	_	_	_	_	_
20	LMP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	whereas	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	transformation	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	competent	_	O	O	_	_	_	_	_
28	EBNA	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	deletion	_	O	O	_	_	_	_	_
32	mutant	_	O	O	_	_	_	_	_
33	did	_	O	O	_	_	_	_	_
34	transactivate	_	O	O	_	_	_	_	_
35	LMP	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	LMP	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	potent	_	O	O	_	_	_	_	_
6	effector	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	lymphocyte	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	can	_	O	O	_	_	_	_	_
14	act	_	O	O	_	_	_	_	_
15	synergistically	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	EBNA	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	induce	_	O	O	_	_	_	_	_
22	cellular	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	23	_	O	O	_	_	_	_	_
25	gene	_	O	O	_	_	_	_	_
26	expression	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	EBNA	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	transactivation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	LMP	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	amplifies	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	biological	_	O	O	_	_	_	_	_
13	impact	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	EBNA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	underscores	_	O	O	_	_	_	_	_
20	its	_	O	O	_	_	_	_	_
21	central	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	EBV	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	induced	_	O	O	_	_	_	_	_
27	growth	_	O	O	_	_	_	_	_
28	transformation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Bcl	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	reactive	_	O	O	_	_	_	_	_
7	follicular	_	O	O	_	_	_	_	_
8	hyperplasia	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	follicular	_	O	O	_	_	_	_	_
11	lymphoma	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	angioimmunoblastic	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	lymphoma	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	hyperplastic	_	O	O	_	_	_	_	_
21	germinal	_	O	O	_	_	_	_	_
22	centers	_	O	O	_	_	_	_	_
23	:	_	O	O	_	_	_	_	_
24	heterogeneity	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	intrafollicular	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	their	_	O	O	_	_	_	_	_
32	altered	_	O	O	_	_	_	_	_
33	distribution	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	pathogenesis	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	angioimmunoblastic	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	lymphoma	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_


1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	Bcl	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	product	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	phosphoprotein	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	expressed	_	O	O	_	_	_	_	_
16	independently	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	Bcl	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	rearrangement	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	lymph	_	O	O	_	_	_	_	_
3	nodes	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Bcl	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	restricted	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	germinal	_	O	O	_	_	_	_	_
15	center	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	GC	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	B	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	10	_	O	O	_	_	_	_	_
24	%	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	15	_	O	O	_	_	_	_	_
27	%	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	intrafollicular	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Interfollicular	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	negative	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	Bcl	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	except	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	rare	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	reported	_	O	O	_	_	_	_	_
5	cases	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	angioimmunoblastic	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	lymphoma	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	AITL	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	hyperplastic	_	O	O	_	_	_	_	_
17	GCs	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	AITL	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	GC	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	observed	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	borders	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	enlarged	_	O	O	_	_	_	_	_
30	GCs	_	O	O	_	_	_	_	_
31	were	_	O	O	_	_	_	_	_
32	ill	_	O	O	_	_	_	_	_
33	defined	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	with	_	O	O	_	_	_	_	_
36	features	_	O	O	_	_	_	_	_
37	suggestive	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	an	_	O	O	_	_	_	_	_
40	outward	_	O	O	_	_	_	_	_
41	migration	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	GC	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	to	_	O	O	_	_	_	_	_
46	surrounding	_	O	O	_	_	_	_	_
47	interfollicular	_	O	O	_	_	_	_	_
48	zones	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	prompted	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	follicular	_	O	O	_	_	_	_	_
7	borders	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	Bcl	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	staining	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	reactive	_	O	O	_	_	_	_	_
15	follicular	_	O	O	_	_	_	_	_
16	hyperplasias	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	follicular	_	O	O	_	_	_	_	_
19	lymphomas	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	compare	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	AITL	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	GC	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	MATERIALS	_	O	O	_	_	_	_	_
2	AND	_	O	O	_	_	_	_	_
3	METHODS	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	Formalin	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	fixed	_	O	O	_	_	_	_	_
8	paraffin	_	O	O	_	_	_	_	_
9	sections	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	used	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	immunostaining	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	Bcl	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Six	_	O	O	_	_	_	_	_
2	cases	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	AITL	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	GC	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	12	_	O	O	_	_	_	_	_
9	nonspecific	_	O	O	_	_	_	_	_
10	reactive	_	O	O	_	_	_	_	_
11	follicular	_	O	O	_	_	_	_	_
12	hyperplasia	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	FH	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	7	_	O	O	_	_	_	_	_
18	HIV	_	O	O	_	_	_	_	_
19	adenopathy	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	10	_	O	O	_	_	_	_	_
22	follicular	_	O	O	_	_	_	_	_
23	lymphoma	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	FL	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	8	_	O	O	_	_	_	_	_
30	typical	_	O	O	_	_	_	_	_
31	AITL	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	ie	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	AITL	_	O	O	_	_	_	_	_
36	without	_	O	O	_	_	_	_	_
37	GC	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	were	_	O	O	_	_	_	_	_
40	studied	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Double	_	O	O	_	_	_	_	_
2	staining	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	Bcl	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	20	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	Bcl	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	Bcl	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	57	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	performed	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	selected	_	O	O	_	_	_	_	_
29	cases	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	FH	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	HIV	_	O	O	_	_	_	_	_
7	adenopathy	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	staining	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	Bcl	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	revealed	_	O	O	_	_	_	_	_
15	densely	_	O	O	_	_	_	_	_
16	populated	_	O	O	_	_	_	_	_
17	GCs	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	well	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	defined	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	regular	_	O	O	_	_	_	_	_
24	GC	_	O	O	_	_	_	_	_
25	borders	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	whereas	_	O	O	_	_	_	_	_
28	Bcl	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	+	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	were	_	O	O	_	_	_	_	_
34	rare	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	interfollicular	_	O	O	_	_	_	_	_
38	areas	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	occasional	_	O	O	_	_	_	_	_
3	GC	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	ill	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	defined	_	O	O	_	_	_	_	_
9	border	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	invariably	_	O	O	_	_	_	_	_
12	surrounded	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	broad	_	O	O	_	_	_	_	_
16	mantle	_	O	O	_	_	_	_	_
17	zone	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	those	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	indistinct	_	O	O	_	_	_	_	_
22	mantle	_	O	O	_	_	_	_	_
23	zones	_	O	O	_	_	_	_	_
24	had	_	O	O	_	_	_	_	_
25	well	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	defined	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	regular	_	O	O	_	_	_	_	_
30	borders	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	FL	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	follicles	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	densely	_	O	O	_	_	_	_	_
7	populated	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	their	_	O	O	_	_	_	_	_
11	borders	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	irregular	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	some	_	O	O	_	_	_	_	_
17	Bcl	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	6	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	interfollicular	_	O	O	_	_	_	_	_
25	zones	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	AITL	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	GC	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	GCs	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	less	_	O	O	_	_	_	_	_
9	dense	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	GC	_	O	O	_	_	_	_	_
12	borders	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	ill	_	O	O	_	_	_	_	_
15	defined	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	irregular	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	number	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	interfollicular	_	O	O	_	_	_	_	_
24	Bcl	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	+	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	markedly	_	O	O	_	_	_	_	_
31	increased	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Double	_	O	O	_	_	_	_	_
2	staining	_	O	O	_	_	_	_	_
3	revealed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	these	_	O	O	_	_	_	_	_
6	interfollicular	_	O	O	_	_	_	_	_
7	Bcl	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	AITL	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	GC	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	Bcl	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	20	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	57	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	intrafollicular	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	depleted	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	AITL	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	GC	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	whereas	_	O	O	_	_	_	_	_
17	they	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	abundant	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	FH	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Intrafollicular	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	57	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	did	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	stain	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	Bcl	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	also	_	O	O	_	_	_	_	_
17	depleted	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	AITL	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	GC	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	typical	_	O	O	_	_	_	_	_
3	AITL	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	some	_	O	O	_	_	_	_	_
6	neoplastic	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	positive	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	Bcl	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	showing	_	O	O	_	_	_	_	_
16	variable	_	O	O	_	_	_	_	_
17	degrees	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	staining	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	GCs	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	AITL	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	GC	_	O	O	_	_	_	_	_
11	differed	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	those	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	other	_	O	O	_	_	_	_	_
16	reactive	_	O	O	_	_	_	_	_
17	follicular	_	O	O	_	_	_	_	_
18	hyperplasias	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	follicular	_	O	O	_	_	_	_	_
21	lymphomas	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	staining	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	Bcl	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	6	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	useful	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	discern	_	O	O	_	_	_	_	_
33	them	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Intrafollicular	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	many	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	which	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	also	_	O	O	_	_	_	_	_
16	positive	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	Bcl	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	were	_	O	O	_	_	_	_	_
23	markedly	_	O	O	_	_	_	_	_
24	depleted	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	AITL	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	GC	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	increased	_	O	O	_	_	_	_	_
32	interfollicular	_	O	O	_	_	_	_	_
33	Bcl	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	+	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	CD	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	+	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	suggesting	_	O	O	_	_	_	_	_
44	an	_	O	O	_	_	_	_	_
45	outward	_	O	O	_	_	_	_	_
46	migration	_	O	O	_	_	_	_	_
47	of	_	O	O	_	_	_	_	_
48	intrafollicular	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	cells	_	O	O	_	_	_	_	_
51	in	_	O	O	_	_	_	_	_
52	this	_	O	O	_	_	_	_	_
53	condition	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Interfollicular	_	O	O	_	_	_	_	_
5	Bcl	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	AITL	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	GC	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	too	_	O	O	_	_	_	_	_
20	numerous	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	accounted	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	migration	_	O	O	_	_	_	_	_
27	alone	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	suggesting	_	O	O	_	_	_	_	_
30	local	_	O	O	_	_	_	_	_
31	proliferation	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Intrafollicular	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	57	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	negative	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	Bcl	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	indicating	_	O	O	_	_	_	_	_
17	heterogeneity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	intrafollicular	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	population	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	5	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	Some	_	O	O	_	_	_	_	_
5	neoplastic	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	AITL	_	O	O	_	_	_	_	_
9	stained	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	Bcl	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	suggesting	_	O	O	_	_	_	_	_
16	up	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	regulation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	Bcl	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	this	_	O	O	_	_	_	_	_
26	tumor	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Introduction	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	key	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	regulating	_	O	O	_	_	_	_	_
10	inflammatory	_	O	O	_	_	_	_	_
11	responses	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	mainly	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	inhibiting	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	function	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	proinflammatory	_	O	O	_	_	_	_	_
22	cytokines	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	binds	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	R	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	complex	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	composed	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	two	_	O	O	_	_	_	_	_
23	subunits	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	primary	_	O	O	_	_	_	_	_
27	ligand	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	component	_	O	O	_	_	_	_	_
31	type	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	10	_	O	O	_	_	_	_	_
36	R	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	10	_	O	O	_	_	_	_	_
41	R	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	accessory	_	O	O	_	_	_	_	_
47	component	_	O	O	_	_	_	_	_
48	type	_	O	O	_	_	_	_	_
49	2	_	O	O	_	_	_	_	_
50	IL	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	10	_	O	O	_	_	_	_	_
53	R	_	O	O	_	_	_	_	_
54	[	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	]	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	interaction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	R	_	O	O	_	_	_	_	_
12	engages	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	Janus	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	JAK	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	family	_	O	O	_	_	_	_	_
20	tyrosine	_	O	O	_	_	_	_	_
21	kinases	_	O	O	_	_	_	_	_
22	Jak	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	Tyk	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	which	_	O	O	_	_	_	_	_
29	are	_	O	O	_	_	_	_	_
30	constitutively	_	O	O	_	_	_	_	_
31	associated	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	10	_	O	O	_	_	_	_	_
36	R	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	type	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	10	_	O	O	_	_	_	_	_
44	R	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	respectively	_	O	O	_	_	_	_	_
47	[	_	O	O	_	_	_	_	_
48	2	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	induces	_	O	O	_	_	_	_	_
5	tyrosine	_	O	O	_	_	_	_	_
6	phosphorylation	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	latent	_	O	O	_	_	_	_	_
12	transcriptional	_	O	O	_	_	_	_	_
13	factors	_	O	O	_	_	_	_	_
14	signal	_	O	O	_	_	_	_	_
15	transducer	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	activator	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	STAT	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	STAT	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Upon	_	O	O	_	_	_	_	_
2	phosphorylation	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	form	_	O	O	_	_	_	_	_
11	homodimers	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	heterodimers	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	rapidly	_	O	O	_	_	_	_	_
16	translocate	_	O	O	_	_	_	_	_
17	into	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	nucleus	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	modulate	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Intriguingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	STAT	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	indispensable	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	both	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	10	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	derived	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	inflammatory	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	derived	_	O	O	_	_	_	_	_
23	proinflammatory	_	O	O	_	_	_	_	_
24	responses	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	]	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Studies	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	specific	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	deficient	_	O	O	_	_	_	_	_
12	mice	_	O	O	_	_	_	_	_
13	have	_	O	O	_	_	_	_	_
14	shown	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	STAT	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	essential	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	10	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	mediated	_	O	O	_	_	_	_	_
27	anti	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	inflammatory	_	O	O	_	_	_	_	_
30	reactions	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	macrophages	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	neutrophils	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	5	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	but	_	O	O	_	_	_	_	_
40	is	_	O	O	_	_	_	_	_
41	responsible	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	6	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	mediated	_	O	O	_	_	_	_	_
48	prevention	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	apoptosis	_	O	O	_	_	_	_	_
51	in	_	O	O	_	_	_	_	_
52	T	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	[	_	O	O	_	_	_	_	_
55	6	_	O	O	_	_	_	_	_
56	]	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	suppressor	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cytokine	_	O	O	_	_	_	_	_
5	signaling	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	SOCS	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	have	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	identified	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	family	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	endogenous	_	O	O	_	_	_	_	_
18	JAK	_	O	O	_	_	_	_	_
19	kinase	_	O	O	_	_	_	_	_
20	inhibitors	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	can	_	O	O	_	_	_	_	_
23	act	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	classic	_	O	O	_	_	_	_	_
26	feedback	_	O	O	_	_	_	_	_
27	inhibition	_	O	O	_	_	_	_	_
28	loops	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	but	_	O	O	_	_	_	_	_
31	their	_	O	O	_	_	_	_	_
32	roles	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	mediators	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	crosstalk	_	O	O	_	_	_	_	_
38	inhibition	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	opposing	_	O	O	_	_	_	_	_
41	cytokine	_	O	O	_	_	_	_	_
42	signaling	_	O	O	_	_	_	_	_
43	pathways	_	O	O	_	_	_	_	_
44	have	_	O	O	_	_	_	_	_
45	been	_	O	O	_	_	_	_	_
46	clarified	_	O	O	_	_	_	_	_
47	[	_	O	O	_	_	_	_	_
48	7	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	Recent	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	SOCS	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	plays	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	key	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	regulating	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	divergent	_	O	O	_	_	_	_	_
15	action	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	specifically	_	O	O	_	_	_	_	_
27	blocking	_	O	O	_	_	_	_	_
28	STAT	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	activation	_	O	O	_	_	_	_	_
31	induced	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	but	_	O	O	_	_	_	_	_
37	not	_	O	O	_	_	_	_	_
38	that	_	O	O	_	_	_	_	_
39	induced	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	10	_	O	O	_	_	_	_	_
44	[	_	O	O	_	_	_	_	_
45	8	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	9	_	O	O	_	_	_	_	_
48	]	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	synovial	_	O	O	_	_	_	_	_
3	membrane	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	rheumatoid	_	O	O	_	_	_	_	_
6	arthritis	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	characterized	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	infiltrate	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	variety	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	inflammatory	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	such	_	O	O	_	_	_	_	_
23	as	_	O	O	_	_	_	_	_
24	lymphocytes	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	macrophages	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	dendritic	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	together	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	proliferation	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	synovial	_	O	O	_	_	_	_	_
37	fibroblast	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	like	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Numerous	_	O	O	_	_	_	_	_
2	cytokines	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	overproduced	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	inflamed	_	O	O	_	_	_	_	_
8	joint	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	macrophages	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	synovial	_	O	O	_	_	_	_	_
14	fibroblasts	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	an	_	O	O	_	_	_	_	_
17	important	_	O	O	_	_	_	_	_
18	source	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	proinflammatory	_	O	O	_	_	_	_	_
21	cytokines	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Tumor	_	O	O	_	_	_	_	_
2	necrosis	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	alpha	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	TNF	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	major	_	O	O	_	_	_	_	_
17	macrophage	_	O	O	_	_	_	_	_
18	products	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	crucial	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	process	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	chronic	_	O	O	_	_	_	_	_
27	inflammation	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	joint	_	O	O	_	_	_	_	_
30	destruction	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	they	_	O	O	_	_	_	_	_
34	give	_	O	O	_	_	_	_	_
35	rise	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	effector	_	O	O	_	_	_	_	_
38	components	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	including	_	O	O	_	_	_	_	_
41	other	_	O	O	_	_	_	_	_
42	inflammatory	_	O	O	_	_	_	_	_
43	cytokines	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	chemokines	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	growth	_	O	O	_	_	_	_	_
48	factors	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	matrix	_	O	O	_	_	_	_	_
51	proteases	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	nitric	_	O	O	_	_	_	_	_
54	oxide	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	and	_	O	O	_	_	_	_	_
57	reactive	_	O	O	_	_	_	_	_
58	oxygen	_	O	O	_	_	_	_	_
59	species	_	O	O	_	_	_	_	_
60	[	_	O	O	_	_	_	_	_
61	10	_	O	O	_	_	_	_	_
62	]	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	pleiotropic	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	produced	_	O	O	_	_	_	_	_
9	substantially	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	activated	_	O	O	_	_	_	_	_
12	fibroblasts	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	its	_	O	O	_	_	_	_	_
16	proinflammatory	_	O	O	_	_	_	_	_
17	actions	_	O	O	_	_	_	_	_
18	include	_	O	O	_	_	_	_	_
19	simulating	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	acute	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	phase	_	O	O	_	_	_	_	_
24	response	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	maturation	_	O	O	_	_	_	_	_
30	into	_	O	O	_	_	_	_	_
31	plasma	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	functions	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	hematopoietic	_	O	O	_	_	_	_	_
41	precursor	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	differentiation	_	O	O	_	_	_	_	_
44	[	_	O	O	_	_	_	_	_
45	11	_	O	O	_	_	_	_	_
46	]	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_


1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	anti	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	inflammatory	_	O	O	_	_	_	_	_
6	cytokines	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	cytokine	_	O	O	_	_	_	_	_
9	inhibitors	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	present	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	large	_	O	O	_	_	_	_	_
15	quantities	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	joints	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	produced	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	macrophages	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	partly	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	synovial	_	O	O	_	_	_	_	_
16	tissue	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	ST	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	best	_	O	O	_	_	_	_	_
23	known	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	negative	_	O	O	_	_	_	_	_
27	regulator	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	macrophage	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	Th	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	but	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	expression	_	O	O	_	_	_	_	_
38	level	_	O	O	_	_	_	_	_
39	is	_	O	O	_	_	_	_	_
40	insufficient	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	counterbalance	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	cascade	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	proinflammatory	_	O	O	_	_	_	_	_
47	events	_	O	O	_	_	_	_	_
48	[	_	O	O	_	_	_	_	_
49	12	_	O	O	_	_	_	_	_
50	]	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	anti	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	inflammatory	_	O	O	_	_	_	_	_
8	action	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	appears	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	modulated	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	level	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	signal	_	O	O	_	_	_	_	_
22	transduction	_	O	O	_	_	_	_	_
23	during	_	O	O	_	_	_	_	_
24	chronic	_	O	O	_	_	_	_	_
25	inflammation	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	signaling	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	impaired	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	macrophages	_	O	O	_	_	_	_	_
9	upon	_	O	O	_	_	_	_	_
10	chronic	_	O	O	_	_	_	_	_
11	exposure	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	proinflammatory	_	O	O	_	_	_	_	_
14	cytokines	_	O	O	_	_	_	_	_
15	such	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	TNF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	alpha	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	immune	_	O	O	_	_	_	_	_
26	complexes	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	13	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	14	_	O	O	_	_	_	_	_
31	]	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Cell	_	O	O	_	_	_	_	_
2	surface	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	R	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	decreased	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	synovial	_	O	O	_	_	_	_	_
14	fluid	_	O	O	_	_	_	_	_
15	dendritic	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	due	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	presence	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	TNF	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	alpha	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	granulocyte	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	macrophage	_	O	O	_	_	_	_	_
34	colony	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	stimulating	_	O	O	_	_	_	_	_
37	factor	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	15	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	arthritogenic	_	O	O	_	_	_	_	_
11	antigens	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	conjunction	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	28	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	mediated	_	O	O	_	_	_	_	_
20	costimulatory	_	O	O	_	_	_	_	_
21	signaling	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	RA	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	significance	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	autoimmune	_	O	O	_	_	_	_	_
6	process	_	O	O	_	_	_	_	_
7	has	_	O	O	_	_	_	_	_
8	been	_	O	O	_	_	_	_	_
9	supported	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	linkage	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	MHC	_	O	O	_	_	_	_	_
16	class	_	O	O	_	_	_	_	_
17	II	_	O	O	_	_	_	_	_
18	antigens	_	O	O	_	_	_	_	_
19	HLA	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	DRB	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	*	_	O	O	_	_	_	_	_
24	0404	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	HLA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	DRB	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	*	_	O	O	_	_	_	_	_
31	0401	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	disease	_	O	O	_	_	_	_	_
34	susceptibility	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	severity	_	O	O	_	_	_	_	_
37	[	_	O	O	_	_	_	_	_
38	16	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	17	_	O	O	_	_	_	_	_
41	]	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	by	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	high	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	level	_	O	O	_	_	_	_	_
49	expression	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	MHC	_	O	O	_	_	_	_	_
52	class	_	O	O	_	_	_	_	_
53	II	_	O	O	_	_	_	_	_
54	molecules	_	O	O	_	_	_	_	_
55	and	_	O	O	_	_	_	_	_
56	both	_	O	O	_	_	_	_	_
57	CD	_	O	O	_	_	_	_	_
58	28	_	O	O	_	_	_	_	_
59	ligands	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	CD	_	O	O	_	_	_	_	_
62	80	_	O	O	_	_	_	_	_
63	and	_	O	O	_	_	_	_	_
64	CD	_	O	O	_	_	_	_	_
65	86	_	O	O	_	_	_	_	_
66	,	_	O	O	_	_	_	_	_
67	in	_	O	O	_	_	_	_	_
68	the	_	O	O	_	_	_	_	_
69	inflamed	_	O	O	_	_	_	_	_
70	ST	_	O	O	_	_	_	_	_
71	[	_	O	O	_	_	_	_	_
72	18	_	O	O	_	_	_	_	_
73	-	_	O	O	_	_	_	_	_
74	20	_	O	O	_	_	_	_	_
75	]	_	O	O	_	_	_	_	_
76	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	continuing	_	O	O	_	_	_	_	_
3	emergence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	activated	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	even	_	O	O	_	_	_	_	_
13	though	_	O	O	_	_	_	_	_
14	few	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	number	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	may	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	crucial	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	sustaining	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	macrophages	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	synovial	_	O	O	_	_	_	_	_
29	fibroblasts	_	O	O	_	_	_	_	_
30	through	_	O	O	_	_	_	_	_
31	cell	_	O	O	_	_	_	_	_
32	surface	_	O	O	_	_	_	_	_
33	signaling	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	means	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	cell	_	O	O	_	_	_	_	_
38	surface	_	O	O	_	_	_	_	_
39	CD	_	O	O	_	_	_	_	_
40	69	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	CD	_	O	O	_	_	_	_	_
43	11	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	as	_	O	O	_	_	_	_	_
46	well	_	O	O	_	_	_	_	_
47	as	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	release	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	proinflammatory	_	O	O	_	_	_	_	_
52	Th	_	O	O	_	_	_	_	_
53	1	_	O	O	_	_	_	_	_
54	cytokines	_	O	O	_	_	_	_	_
55	such	_	O	O	_	_	_	_	_
56	as	_	O	O	_	_	_	_	_
57	interferon	_	O	O	_	_	_	_	_
58	gamma	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	IFN	_	O	O	_	_	_	_	_
61	)	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	gamma	_	O	O	_	_	_	_	_
64	and	_	O	O	_	_	_	_	_
65	IL	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	17	_	O	O	_	_	_	_	_
68	[	_	O	O	_	_	_	_	_
69	21	_	O	O	_	_	_	_	_
70	,	_	O	O	_	_	_	_	_
71	22	_	O	O	_	_	_	_	_
72	]	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	could	_	O	O	_	_	_	_	_
10	stimulate	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	production	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	autoantibodies	_	O	O	_	_	_	_	_
17	such	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	rheumatoid	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	osteoclast	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	mediated	_	O	O	_	_	_	_	_
25	bone	_	O	O	_	_	_	_	_
26	destruction	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Their	_	O	O	_	_	_	_	_
2	obligatory	_	O	O	_	_	_	_	_
3	role	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	RA	_	O	O	_	_	_	_	_
6	synovitis	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	recently	_	O	O	_	_	_	_	_
9	proved	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	successful	_	O	O	_	_	_	_	_
12	treatment	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	active	_	O	O	_	_	_	_	_
15	disease	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	selective	_	O	O	_	_	_	_	_
18	inhibition	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	fusion	_	O	O	_	_	_	_	_
26	protein	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	cytotoxic	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	cell	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	associated	_	O	O	_	_	_	_	_
34	antigen	_	O	O	_	_	_	_	_
35	4	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	152	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	IgG	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	which	_	O	O	_	_	_	_	_
44	can	_	O	O	_	_	_	_	_
45	block	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	engagement	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	CD	_	O	O	_	_	_	_	_
50	28	_	O	O	_	_	_	_	_
51	on	_	O	O	_	_	_	_	_
52	T	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	by	_	O	O	_	_	_	_	_
55	binding	_	O	O	_	_	_	_	_
56	to	_	O	O	_	_	_	_	_
57	CD	_	O	O	_	_	_	_	_
58	80	_	O	O	_	_	_	_	_
59	and	_	O	O	_	_	_	_	_
60	CD	_	O	O	_	_	_	_	_
61	86	_	O	O	_	_	_	_	_
62	with	_	O	O	_	_	_	_	_
63	high	_	O	O	_	_	_	_	_
64	avidity	_	O	O	_	_	_	_	_
65	[	_	O	O	_	_	_	_	_
66	23	_	O	O	_	_	_	_	_
67	]	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	efficiently	_	O	O	_	_	_	_	_
5	blocks	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	antigen	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	specific	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	cytokine	_	O	O	_	_	_	_	_
14	response	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	inhibiting	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	28	_	O	O	_	_	_	_	_
20	signaling	_	O	O	_	_	_	_	_
21	pathway	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	24	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	well	_	O	O	_	_	_	_	_
28	as	_	O	O	_	_	_	_	_
29	indirectly	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	downregulating	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	function	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	antigen	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	presenting	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	elucidate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	resistance	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	this	_	O	O	_	_	_	_	_
13	direct	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	we	_	O	O	_	_	_	_	_
19	investigated	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	IFN	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	gamma	_	O	O	_	_	_	_	_
26	after	_	O	O	_	_	_	_	_
27	CD	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	28	_	O	O	_	_	_	_	_
32	costimulation	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	presence	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	10	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	induction	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	STAT	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	STAT	_	O	O	_	_	_	_	_
48	3	_	O	O	_	_	_	_	_
49	phosphorylation	_	O	O	_	_	_	_	_
50	by	_	O	O	_	_	_	_	_
51	IL	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	10	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	and	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	expression	_	O	O	_	_	_	_	_
58	of	_	O	O	_	_	_	_	_
59	SOCS	_	O	O	_	_	_	_	_
60	1	_	O	O	_	_	_	_	_
61	and	_	O	O	_	_	_	_	_
62	SOCS	_	O	O	_	_	_	_	_
63	3	_	O	O	_	_	_	_	_
64	mRNA	_	O	O	_	_	_	_	_
65	in	_	O	O	_	_	_	_	_
66	peripheral	_	O	O	_	_	_	_	_
67	blood	_	O	O	_	_	_	_	_
68	(	_	O	O	_	_	_	_	_
69	PB	_	O	O	_	_	_	_	_
70	)	_	O	O	_	_	_	_	_
71	CD	_	O	O	_	_	_	_	_
72	4	_	O	O	_	_	_	_	_
73	+	_	O	O	_	_	_	_	_
74	T	_	O	O	_	_	_	_	_
75	cells	_	O	O	_	_	_	_	_
76	from	_	O	O	_	_	_	_	_
77	RA	_	O	O	_	_	_	_	_
78	patients	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_



1	p	_	O	O	_	_	_	_	_
2	105	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	98	_	O	O	_	_	_	_	_
6	precursor	_	O	O	_	_	_	_	_
7	proteins	_	O	O	_	_	_	_	_
8	play	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	active	_	O	O	_	_	_	_	_
11	role	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	mediated	_	O	O	_	_	_	_	_
19	signal	_	O	O	_	_	_	_	_
20	transduction	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Rel	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kappa	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	family	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	factors	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	composed	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	distinct	_	O	O	_	_	_	_	_
17	subgroups	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	undergo	_	O	O	_	_	_	_	_
22	proteolytic	_	O	O	_	_	_	_	_
23	processing	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	contain	_	O	O	_	_	_	_	_
26	SWI	_	O	O	_	_	_	_	_
27	6	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	ankyrin	_	O	O	_	_	_	_	_
30	repeats	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	their	_	O	O	_	_	_	_	_
33	carboxyl	_	O	O	_	_	_	_	_
34	termini	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	p	_	O	O	_	_	_	_	_
37	105	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	p	_	O	O	_	_	_	_	_
40	98	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	those	_	O	O	_	_	_	_	_
45	without	_	O	O	_	_	_	_	_
46	such	_	O	O	_	_	_	_	_
47	repeats	_	O	O	_	_	_	_	_
48	that	_	O	O	_	_	_	_	_
49	do	_	O	O	_	_	_	_	_
50	not	_	O	O	_	_	_	_	_
51	require	_	O	O	_	_	_	_	_
52	processing	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	p	_	O	O	_	_	_	_	_
55	65	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	c	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	Rel	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	RelB	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	and	_	O	O	_	_	_	_	_
64	Dorsal	_	O	O	_	_	_	_	_
65	)	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	demonstrate	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	105	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	98	_	O	O	_	_	_	_	_
10	precursors	_	O	O	_	_	_	_	_
11	share	_	O	O	_	_	_	_	_
12	functional	_	O	O	_	_	_	_	_
13	properties	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	I	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	which	_	O	O	_	_	_	_	_
22	also	_	O	O	_	_	_	_	_
23	contain	_	O	O	_	_	_	_	_
24	SWI	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	ankyrin	_	O	O	_	_	_	_	_
28	repeats	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	105	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	98	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	form	_	O	O	_	_	_	_	_
11	stable	_	O	O	_	_	_	_	_
12	complexes	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	other	_	O	O	_	_	_	_	_
15	Rel	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	family	_	O	O	_	_	_	_	_
22	members	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	including	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	65	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	c	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	Rel	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Association	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	precursors	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	sufficient	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	cytoplasmic	_	O	O	_	_	_	_	_
9	retention	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	either	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	65	_	O	O	_	_	_	_	_
14	or	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Rel	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	both	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	which	_	O	O	_	_	_	_	_
22	are	_	O	O	_	_	_	_	_
23	otherwise	_	O	O	_	_	_	_	_
24	nuclear	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	complexes	_	O	O	_	_	_	_	_
3	undergo	_	O	O	_	_	_	_	_
4	stimulus	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	responsive	_	O	O	_	_	_	_	_
7	processing	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	produce	_	O	O	_	_	_	_	_
10	active	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	50	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	c	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	Rel	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	55	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	c	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	Rel	_	O	O	_	_	_	_	_
24	complexes	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	second	_	O	O	_	_	_	_	_
6	pathway	_	O	O	_	_	_	_	_
7	leading	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kappa	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	induction	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	processing	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	precursors	_	O	O	_	_	_	_	_
21	rather	_	O	O	_	_	_	_	_
22	than	_	O	O	_	_	_	_	_
23	phosphorylation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	I	_	O	O	_	_	_	_	_
26	kappa	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	plays	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	major	_	O	O	_	_	_	_	_
31	role	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	internal	_	O	O	_	_	_	_	_
3	methionine	_	O	O	_	_	_	_	_
4	codons	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	leukemia	_	O	O	_	_	_	_	_
11	virus	_	O	O	_	_	_	_	_
12	type	_	O	O	_	_	_	_	_
13	II	_	O	O	_	_	_	_	_
14	rex	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	required	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	24	_	O	O	_	_	_	_	_
22	rex	_	O	O	_	_	_	_	_
23	production	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	virus	_	O	O	_	_	_	_	_
26	replication	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	transformation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	leukemia	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	types	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	HTLV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	I	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	II	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	HTLV	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	II	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	have	_	O	O	_	_	_	_	_
22	two	_	O	O	_	_	_	_	_
23	nonstructural	_	O	O	_	_	_	_	_
24	trans	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	acting	_	O	O	_	_	_	_	_
27	regulatory	_	O	O	_	_	_	_	_
28	genes	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	tax	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	rex	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	located	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	'	_	O	O	_	_	_	_	_
39	region	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	viral	_	O	O	_	_	_	_	_
43	genome	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	tax	_	O	O	_	_	_	_	_
3	gene	_	O	O	_	_	_	_	_
4	product	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	HTLV	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	40	_	O	O	_	_	_	_	_
11	tax	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	HTLV	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	II	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	37	_	O	O	_	_	_	_	_
18	tax	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	transcriptional	_	O	O	_	_	_	_	_
23	activator	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	viral	_	O	O	_	_	_	_	_
27	long	_	O	O	_	_	_	_	_
28	terminal	_	O	O	_	_	_	_	_
29	repeat	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	rex	_	O	O	_	_	_	_	_
3	gene	_	O	O	_	_	_	_	_
4	encodes	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	products	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	27	_	O	O	_	_	_	_	_
11	rex	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	21	_	O	O	_	_	_	_	_
15	rex	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	26	_	O	O	_	_	_	_	_
19	rex	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	24	_	O	O	_	_	_	_	_
23	rex	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	HTLV	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	I	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	HTLV	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	II	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	respectively	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Rex	_	O	O	_	_	_	_	_
2	acts	_	O	O	_	_	_	_	_
3	posttranscriptionally	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	facilitate	_	O	O	_	_	_	_	_
6	accumulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	full	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	length	_	O	O	_	_	_	_	_
11	gag	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	pol	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	singly	_	O	O	_	_	_	_	_
16	spliced	_	O	O	_	_	_	_	_
17	env	_	O	O	_	_	_	_	_
18	mRNA	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	cytoplasm	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	HTLV	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	infected	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Previous	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	showed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	first	_	O	O	_	_	_	_	_
7	ATG	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	rex	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	critical	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	Rex	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	function	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	importance	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	internal	_	O	O	_	_	_	_	_
6	ATGs	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	Rex	_	O	O	_	_	_	_	_
9	function	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	known	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	vitro	_	O	O	_	_	_	_	_
5	mutagenesis	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	HTLV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	I	_	O	O	_	_	_	_	_
11	rex	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	provided	_	O	O	_	_	_	_	_
15	indirect	_	O	O	_	_	_	_	_
16	evidence	_	O	O	_	_	_	_	_
17	which	_	O	O	_	_	_	_	_
18	suggests	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	21	_	O	O	_	_	_	_	_
22	rex	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	analogy	_	O	O	_	_	_	_	_
27	HTLV	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	II	_	O	O	_	_	_	_	_
30	p	_	O	O	_	_	_	_	_
31	24	_	O	O	_	_	_	_	_
32	rex	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	results	_	O	O	_	_	_	_	_
35	from	_	O	O	_	_	_	_	_
36	initiation	_	O	O	_	_	_	_	_
37	at	_	O	O	_	_	_	_	_
38	an	_	O	O	_	_	_	_	_
39	internal	_	O	O	_	_	_	_	_
40	AUG	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	tax	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	rex	_	O	O	_	_	_	_	_
46	mRNA	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	infectious	_	O	O	_	_	_	_	_
5	molecular	_	O	O	_	_	_	_	_
6	clone	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	HTLV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	II	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	investigated	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	importance	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	internal	_	O	O	_	_	_	_	_
19	ATGs	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	rex	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	on	_	O	O	_	_	_	_	_
25	Rex	_	O	O	_	_	_	_	_
26	protein	_	O	O	_	_	_	_	_
27	production	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	function	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	24	_	O	O	_	_	_	_	_
7	rex	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	HTLV	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	II	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	initiated	_	O	O	_	_	_	_	_
15	at	_	O	O	_	_	_	_	_
16	an	_	O	O	_	_	_	_	_
17	internal	_	O	O	_	_	_	_	_
18	AUG	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	internal	_	O	O	_	_	_	_	_
23	methionine	_	O	O	_	_	_	_	_
24	codons	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	crucial	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	function	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	rex	_	O	O	_	_	_	_	_
34	gene	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	ultimately	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	transforming	_	O	O	_	_	_	_	_
41	properties	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	virus	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_


1	Increased	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	surface	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	R	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	functional	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	complex	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	consists	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	two	_	O	O	_	_	_	_	_
12	subunits	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	primary	_	O	O	_	_	_	_	_
16	ligand	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	component	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	R	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	accessory	_	O	O	_	_	_	_	_
28	component	_	O	O	_	_	_	_	_
29	type	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	10	_	O	O	_	_	_	_	_
34	R	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	R	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	plays	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	critical	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	cellular	_	O	O	_	_	_	_	_
13	responses	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	29	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	resistance	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	inhibition	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	due	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	limited	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	surface	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	R	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	on	_	O	O	_	_	_	_	_
36	PB	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	4	_	O	O	_	_	_	_	_
39	+	_	O	O	_	_	_	_	_
40	T	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	from	_	O	O	_	_	_	_	_
43	active	_	O	O	_	_	_	_	_
44	RA	_	O	O	_	_	_	_	_
45	patients	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	from	_	O	O	_	_	_	_	_
48	healthy	_	O	O	_	_	_	_	_
49	controls	_	O	O	_	_	_	_	_
50	was	_	O	O	_	_	_	_	_
51	determined	_	O	O	_	_	_	_	_
52	by	_	O	O	_	_	_	_	_
53	flow	_	O	O	_	_	_	_	_
54	cytometric	_	O	O	_	_	_	_	_
55	analysis	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Fig	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	b	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	intensity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	R	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	significantly	_	O	O	_	_	_	_	_
24	increased	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	patients	_	O	O	_	_	_	_	_
28	compared	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	healthy	_	O	O	_	_	_	_	_
32	controls	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	intracellular	_	O	O	_	_	_	_	_
7	signal	_	O	O	_	_	_	_	_
8	transduction	_	O	O	_	_	_	_	_
9	pathway	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	may	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	impaired	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	active	_	O	O	_	_	_	_	_
25	RA	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_



1	Jeg	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	choriocarcinoma	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	immunosuppression	_	O	O	_	_	_	_	_
9	:	_	O	O	_	_	_	_	_
10	downregulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	interleukin	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	interleukin	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	alpha	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	chain	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	its	_	O	O	_	_	_	_	_
26	Jak	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	Stat	_	O	O	_	_	_	_	_
29	signaling	_	O	O	_	_	_	_	_
30	pathway	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	PROBLEM	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	mechanisms	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	immunosuppressive	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	immunosuppression	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	inducing	_	O	O	_	_	_	_	_
12	capacities	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	Jeg	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	choriocarcinoma	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	line	_	O	O	_	_	_	_	_
21	supernatants	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	HCSs	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	yet	_	O	O	_	_	_	_	_
28	completely	_	O	O	_	_	_	_	_
29	understood	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	influence	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	interleukin	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	interferon	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	IFN	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	gamma	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	R	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	alpha	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	beta	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	gamma	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	chain	_	O	O	_	_	_	_	_
43	;	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	signaling	_	O	O	_	_	_	_	_
47	pathway	_	O	O	_	_	_	_	_
48	molecules	_	O	O	_	_	_	_	_
49	Janus	_	O	O	_	_	_	_	_
50	kinase	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	Jak	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	Jak	_	O	O	_	_	_	_	_
57	3	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	signal	_	O	O	_	_	_	_	_
60	transducers	_	O	O	_	_	_	_	_
61	and	_	O	O	_	_	_	_	_
62	activators	_	O	O	_	_	_	_	_
63	of	_	O	O	_	_	_	_	_
64	transcription	_	O	O	_	_	_	_	_
65	(	_	O	O	_	_	_	_	_
66	Stat	_	O	O	_	_	_	_	_
67	)	_	O	O	_	_	_	_	_
68	1	_	O	O	_	_	_	_	_
69	,	_	O	O	_	_	_	_	_
70	Stat	_	O	O	_	_	_	_	_
71	3	_	O	O	_	_	_	_	_
72	,	_	O	O	_	_	_	_	_
73	and	_	O	O	_	_	_	_	_
74	Stat	_	O	O	_	_	_	_	_
75	5	_	O	O	_	_	_	_	_
76	should	_	O	O	_	_	_	_	_
77	be	_	O	O	_	_	_	_	_
78	investigated	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_

1	METHOD	_	O	O	_	_	_	_	_
2	OF	_	O	O	_	_	_	_	_
3	STUDY	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	For	_	O	O	_	_	_	_	_
6	assessment	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	whole	_	O	O	_	_	_	_	_
12	peripheral	_	O	O	_	_	_	_	_
13	venous	_	O	O	_	_	_	_	_
14	blood	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	healthy	_	O	O	_	_	_	_	_
17	donors	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	stimulated	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	phorbol	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	myristate	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	acetate	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	ionomycine	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Secretion	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	ILs	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	blocked	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	monensine	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Intracellular	_	O	O	_	_	_	_	_
2	ILs	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	analyzed	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	flow	_	O	O	_	_	_	_	_
7	cytometry	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	R	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	signaling	_	O	O	_	_	_	_	_
8	pathway	_	O	O	_	_	_	_	_
9	molecule	_	O	O	_	_	_	_	_
10	analysis	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	peripheral	_	O	O	_	_	_	_	_
13	blood	_	O	O	_	_	_	_	_
14	lymphocytes	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	stimulated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	phytohemagglutinin	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	PHA	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	R	_	O	O	_	_	_	_	_
5	chains	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	measured	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	flow	_	O	O	_	_	_	_	_
10	cytometry	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	Jaks	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	Stats	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	sodium	_	O	O	_	_	_	_	_
18	dodecyl	_	O	O	_	_	_	_	_
19	sulfate	_	O	O	_	_	_	_	_
20	polyacrylamide	_	O	O	_	_	_	_	_
21	gel	_	O	O	_	_	_	_	_
22	electrophoresis	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	SDS	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	PAGE	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	Western	_	O	O	_	_	_	_	_
30	blot	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Phorbol	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	myristate	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	acetate	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	ionomycine	_	O	O	_	_	_	_	_
10	strongly	_	O	O	_	_	_	_	_
11	increase	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	percent	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	age	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	an	_	O	O	_	_	_	_	_
24	additional	_	O	O	_	_	_	_	_
25	50	_	O	O	_	_	_	_	_
26	%	_	O	O	_	_	_	_	_
27	HCSs	_	O	O	_	_	_	_	_
28	significantly	_	O	O	_	_	_	_	_
29	suppresses	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	percentage	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	below	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	level	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	unstimulated	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	IFN	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	production	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	strongly	_	O	O	_	_	_	_	_
7	decreased	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	HCSs	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	some	_	O	O	_	_	_	_	_
12	cases	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	others	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	PHA	_	O	O	_	_	_	_	_
2	stimulates	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	R	_	O	O	_	_	_	_	_
7	alpha	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	gamma	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	chain	_	O	O	_	_	_	_	_
17	expression	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	their	_	O	O	_	_	_	_	_
20	signaling	_	O	O	_	_	_	_	_
21	pathway	_	O	O	_	_	_	_	_
22	molecules	_	O	O	_	_	_	_	_
23	Jak	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	Jak	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	Stat	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	Stat	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	Stat	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	50	_	O	O	_	_	_	_	_
2	%	_	O	O	_	_	_	_	_
3	HCS	_	O	O	_	_	_	_	_
4	downregulates	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	chain	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	slightly	_	O	O	_	_	_	_	_
11	upregulates	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	beta	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	chain	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Jak	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	Jak	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	Stat	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	Stat	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	Stat	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	suppressed	_	O	O	_	_	_	_	_
19	approximately	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	below	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	level	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	unstimulated	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	HCS	_	O	O	_	_	_	_	_
4	forcefully	_	O	O	_	_	_	_	_
5	blocks	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	;	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	R	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	chain	_	O	O	_	_	_	_	_
21	;	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	Jak	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	Jak	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	Stat	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	Stat	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	Stat	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	expression	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	observed	_	O	O	_	_	_	_	_
3	phenomena	_	O	O	_	_	_	_	_
4	might	_	O	O	_	_	_	_	_
5	be	_	O	O	_	_	_	_	_
6	caused	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	downregulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	an	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	R	_	O	O	_	_	_	_	_
15	regulation	_	O	O	_	_	_	_	_
16	gene	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	might	_	O	O	_	_	_	_	_
20	play	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	key	_	O	O	_	_	_	_	_
23	role	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	expansion	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	choriocarcinoma	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	possibly	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	survival	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	fetal	_	O	O	_	_	_	_	_
38	allograft	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Sense	_	O	O	_	_	_	_	_
2	strand	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	oligonucleotides	_	O	O	_	_	_	_	_
5	used	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	EMSAs	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_



1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	HIV	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	enhancer	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	LEF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	HMG	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	nucleosome	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	assembled	_	O	O	_	_	_	_	_
19	DNA	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	vitro	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Lymphoid	_	O	O	_	_	_	_	_
2	enhancer	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	factor	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	LEF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	regulatory	_	O	O	_	_	_	_	_
15	high	_	O	O	_	_	_	_	_
16	mobility	_	O	O	_	_	_	_	_
17	group	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	HMG	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	activates	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	TCR	_	O	O	_	_	_	_	_
31	alpha	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	enhancer	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	a	_	O	O	_	_	_	_	_
36	context	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	restricted	_	O	O	_	_	_	_	_
39	manner	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	T	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	paper	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	demonstrate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	distal	_	O	O	_	_	_	_	_
9	region	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	immunodeficiency	_	O	O	_	_	_	_	_
14	virus	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	HIV	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	enhancer	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	contains	_	O	O	_	_	_	_	_
26	DNA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	sites	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	LEF	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	Ets	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	also	_	O	O	_	_	_	_	_
40	provides	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	functional	_	O	O	_	_	_	_	_
43	context	_	O	O	_	_	_	_	_
44	for	_	O	O	_	_	_	_	_
45	activation	_	O	O	_	_	_	_	_
46	by	_	O	O	_	_	_	_	_
47	LEF	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	First	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	mutations	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	LEF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	inhibit	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	multimerized	_	O	O	_	_	_	_	_
20	copies	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	HIV	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	enhancer	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	Jurkat	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	that	_	O	O	_	_	_	_	_
34	LEF	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	GAL	_	O	O	_	_	_	_	_
39	4	_	O	O	_	_	_	_	_
40	can	_	O	O	_	_	_	_	_
41	activate	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	GAL	_	O	O	_	_	_	_	_
44	4	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	substituted	_	O	O	_	_	_	_	_
47	HIV	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	enhancer	_	O	O	_	_	_	_	_
51	80	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	to	_	O	O	_	_	_	_	_
54	100	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	fold	_	O	O	_	_	_	_	_
57	in	_	O	O	_	_	_	_	_
58	vivo	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	Second	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	recombinant	_	O	O	_	_	_	_	_
4	LEF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	shown	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	activate	_	O	O	_	_	_	_	_
11	HIV	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	chromatin	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	assembled	_	O	O	_	_	_	_	_
19	DNA	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	vitro	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	nucleosome	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	assembly	_	O	O	_	_	_	_	_
7	system	_	O	O	_	_	_	_	_
8	derived	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	Drosophila	_	O	O	_	_	_	_	_
11	embryos	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	we	_	O	O	_	_	_	_	_
14	find	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	packaging	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	DNA	_	O	O	_	_	_	_	_
20	into	_	O	O	_	_	_	_	_
21	chromatin	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	vitro	_	O	O	_	_	_	_	_
24	strongly	_	O	O	_	_	_	_	_
25	represses	_	O	O	_	_	_	_	_
26	HIV	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	repression	_	O	O	_	_	_	_	_
33	can	_	O	O	_	_	_	_	_
34	be	_	O	O	_	_	_	_	_
35	counteracted	_	O	O	_	_	_	_	_
36	efficiently	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	preincubation	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	DNA	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	LEF	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	or	_	O	O	_	_	_	_	_
48	LEF	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	Ets	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	supplemented	_	O	O	_	_	_	_	_
57	with	_	O	O	_	_	_	_	_
58	fractions	_	O	O	_	_	_	_	_
59	containing	_	O	O	_	_	_	_	_
60	the	_	O	O	_	_	_	_	_
61	promoter	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	binding	_	O	O	_	_	_	_	_
64	protein	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	Sp	_	O	O	_	_	_	_	_
67	1	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_

1	Addition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	TFE	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	binds	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	an	_	O	O	_	_	_	_	_
11	E	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	box	_	O	O	_	_	_	_	_
14	motif	_	O	O	_	_	_	_	_
15	upstream	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	LEF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	Ets	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	sites	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	further	_	O	O	_	_	_	_	_
28	augments	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	this	_	O	O	_	_	_	_	_
32	system	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Individually	_	O	O	_	_	_	_	_
2	or	_	O	O	_	_	_	_	_
3	collectively	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	none	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	three	_	O	O	_	_	_	_	_
9	enhancer	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	proteins	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	LEF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	Ets	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	TFE	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	could	_	O	O	_	_	_	_	_
28	activate	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	absence	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	Sp	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	truncation	_	O	O	_	_	_	_	_
3	mutant	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	LEF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	HMG	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	88	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	contains	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	HMG	_	O	O	_	_	_	_	_
18	box	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	lacks	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	trans	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	domain	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	did	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	activate	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	nucleosomal	_	O	O	_	_	_	_	_
33	DNA	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	indicating	_	O	O	_	_	_	_	_
36	that	_	O	O	_	_	_	_	_
37	bending	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	DNA	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	HMG	_	O	O	_	_	_	_	_
43	domain	_	O	O	_	_	_	_	_
44	is	_	O	O	_	_	_	_	_
45	not	_	O	O	_	_	_	_	_
46	sufficient	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	activate	_	O	O	_	_	_	_	_
49	transcription	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	vitro	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	LEF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	vitro	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	chromatin	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dependent	_	O	O	_	_	_	_	_
17	process	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	requires	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	functional	_	O	O	_	_	_	_	_
22	trans	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	domain	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	addition	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	HMG	_	O	O	_	_	_	_	_
31	domain	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	High	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	induces	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	potent	_	O	O	_	_	_	_	_
7	inhibitors	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	JAKs	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	SOCS	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	SOCS	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	proteins	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	only	_	O	O	_	_	_	_	_
21	act	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	mediators	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	negative	_	O	O	_	_	_	_	_
26	feedback	_	O	O	_	_	_	_	_
27	inhibition	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	but	_	O	O	_	_	_	_	_
30	also	_	O	O	_	_	_	_	_
31	play	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	major	_	O	O	_	_	_	_	_
34	role	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	crosstalk	_	O	O	_	_	_	_	_
37	inhibition	_	O	O	_	_	_	_	_
38	by	_	O	O	_	_	_	_	_
39	opposing	_	O	O	_	_	_	_	_
40	other	_	O	O	_	_	_	_	_
41	cytokine	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	signaling	_	O	O	_	_	_	_	_
44	pathways	_	O	O	_	_	_	_	_
45	[	_	O	O	_	_	_	_	_
46	7	_	O	O	_	_	_	_	_
47	]	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	SOCS	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	recently	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	specifically	_	O	O	_	_	_	_	_
9	inhibit	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	but	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	10	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	thereby	_	O	O	_	_	_	_	_
26	regulating	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	divergent	_	O	O	_	_	_	_	_
29	action	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	6	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	10	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	8	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	9	_	O	O	_	_	_	_	_
42	]	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	SOCS	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	able	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	partially	_	O	O	_	_	_	_	_
11	inhibit	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	mediated	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	cellular	_	O	O	_	_	_	_	_
22	responses	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	well	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	IFN	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	gamma	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	mediated	_	O	O	_	_	_	_	_
32	STAT	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	activation	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	32	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	SOCSs	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	involved	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	defective	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	levels	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	SOCS	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	SOCS	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	mRNA	_	O	O	_	_	_	_	_
35	expression	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	PB	_	O	O	_	_	_	_	_
38	CD	_	O	O	_	_	_	_	_
39	4	_	O	O	_	_	_	_	_
40	+	_	O	O	_	_	_	_	_
41	T	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	from	_	O	O	_	_	_	_	_
44	active	_	O	O	_	_	_	_	_
45	RA	_	O	O	_	_	_	_	_
46	patients	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	from	_	O	O	_	_	_	_	_
49	healthy	_	O	O	_	_	_	_	_
50	controls	_	O	O	_	_	_	_	_
51	were	_	O	O	_	_	_	_	_
52	compared	_	O	O	_	_	_	_	_
53	by	_	O	O	_	_	_	_	_
54	semiquantitative	_	O	O	_	_	_	_	_
55	real	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	time	_	O	O	_	_	_	_	_
58	PCR	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	RA	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	contained	_	O	O	_	_	_	_	_
9	higher	_	O	O	_	_	_	_	_
10	levels	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	SOCS	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	lower	_	O	O	_	_	_	_	_
16	levels	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	SOCS	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	transcripts	_	O	O	_	_	_	_	_
21	than	_	O	O	_	_	_	_	_
22	did	_	O	O	_	_	_	_	_
23	control	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	4	_	O	O	_	_	_	_	_
26	+	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	Fig	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	6	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	comparable	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	normal	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	stimulated	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	10	_	O	O	_	_	_	_	_
29	ng	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	ml	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	6	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	Fig	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	6	_	O	O	_	_	_	_	_
2	b	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	supporting	_	O	O	_	_	_	_	_
6	its	_	O	O	_	_	_	_	_
7	functional	_	O	O	_	_	_	_	_
8	significance	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Defective	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	10	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	therefore	_	O	O	_	_	_	_	_
11	appears	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	due	_	O	O	_	_	_	_	_
15	at	_	O	O	_	_	_	_	_
16	least	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	part	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	abundance	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	SOCS	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	CD	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_



1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	STAT	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	relies	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	Janus	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	function	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	tyrosine	_	O	O	_	_	_	_	_
19	phosphorylation	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	can	_	O	O	_	_	_	_	_
23	contribute	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	both	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	proliferation	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	regulation	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	investigated	_	O	O	_	_	_	_	_
4	mechanisms	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	consequences	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	through	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	4	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	R	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	functionally	_	O	O	_	_	_	_	_
3	expressing	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	mutants	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	murine	_	O	O	_	_	_	_	_
9	pro	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	line	_	O	O	_	_	_	_	_
14	Ba	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	F	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	we	_	O	O	_	_	_	_	_
20	could	_	O	O	_	_	_	_	_
21	show	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	phosphorylated	_	O	O	_	_	_	_	_
24	tyrosine	_	O	O	_	_	_	_	_
25	residues	_	O	O	_	_	_	_	_
26	within	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	4	_	O	O	_	_	_	_	_
31	R	_	O	O	_	_	_	_	_
32	alpha	_	O	O	_	_	_	_	_
33	chain	_	O	O	_	_	_	_	_
34	are	_	O	O	_	_	_	_	_
35	dispensable	_	O	O	_	_	_	_	_
36	for	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	4	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	induced	_	O	O	_	_	_	_	_
42	STAT	_	O	O	_	_	_	_	_
43	5	_	O	O	_	_	_	_	_
44	activity	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	disruption	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	membrane	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	proximal	_	O	O	_	_	_	_	_
9	proline	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	rich	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	motif	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	'	_	O	O	_	_	_	_	_
16	box	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	either	_	O	O	_	_	_	_	_
22	subunit	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	bipartite	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	R	_	O	O	_	_	_	_	_
30	abolished	_	O	O	_	_	_	_	_
31	not	_	O	O	_	_	_	_	_
32	only	_	O	O	_	_	_	_	_
33	ligand	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	tyrosine	_	O	O	_	_	_	_	_
37	phosphorylation	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	Janus	_	O	O	_	_	_	_	_
40	kinases	_	O	O	_	_	_	_	_
41	JAK	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	JAK	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	but	_	O	O	_	_	_	_	_
48	also	_	O	O	_	_	_	_	_
49	IL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	4	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	triggered	_	O	O	_	_	_	_	_
54	activation	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	STAT	_	O	O	_	_	_	_	_
57	5	_	O	O	_	_	_	_	_
58	and	_	O	O	_	_	_	_	_
59	concomitant	_	O	O	_	_	_	_	_
60	cell	_	O	O	_	_	_	_	_
61	proliferation	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	dominant	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	negative	_	O	O	_	_	_	_	_
5	version	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	b	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	interfered	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	DNA	_	O	O	_	_	_	_	_
26	synthesis	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	Ba	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	F	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	suggesting	_	O	O	_	_	_	_	_
35	an	_	O	O	_	_	_	_	_
36	involvement	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	STAT	_	O	O	_	_	_	_	_
39	5	_	O	O	_	_	_	_	_
40	b	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	control	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	cell	_	O	O	_	_	_	_	_
46	proliferation	_	O	O	_	_	_	_	_
47	through	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	4	_	O	O	_	_	_	_	_
51	R	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Reporter	_	O	O	_	_	_	_	_
2	gene	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	finally	_	O	O	_	_	_	_	_
5	showed	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	promoters	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	target	_	O	O	_	_	_	_	_
14	genes	_	O	O	_	_	_	_	_
15	can	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	specifically	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	challenging	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	4	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	STAT	_	O	O	_	_	_	_	_
31	5	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	STAT	_	O	O	_	_	_	_	_
35	5	_	O	O	_	_	_	_	_
36	b	_	O	O	_	_	_	_	_
37	can	_	O	O	_	_	_	_	_
38	contribute	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	4	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	triggered	_	O	O	_	_	_	_	_
45	transcriptional	_	O	O	_	_	_	_	_
46	control	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_


1	Antibodies	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	antibodies	_	O	O	_	_	_	_	_
4	used	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	study	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	either	_	O	O	_	_	_	_	_
10	kindly	_	O	O	_	_	_	_	_
11	provided	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	Dr	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Enzo	_	O	O	_	_	_	_	_
2	Lalli	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	Universite	_	O	O	_	_	_	_	_
5	Louis	_	O	O	_	_	_	_	_
6	Pasteur	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	France	_	O	O	_	_	_	_	_
9	[	_	O	O	_	_	_	_	_
10	7	_	O	O	_	_	_	_	_
11	])	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	commercially	_	O	O	_	_	_	_	_
14	obtained	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	Catalog	_	O	O	_	_	_	_	_
17	No	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	sc	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17332	_	O	O	_	_	_	_	_
4	X	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	Santa	_	O	O	_	_	_	_	_
7	Cruz	_	O	O	_	_	_	_	_
8	Biotechnology	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	Santa	_	O	O	_	_	_	_	_
11	Cruz	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	California	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	United	_	O	O	_	_	_	_	_
16	States	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	Sox	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	antibodies	_	O	O	_	_	_	_	_
5	generated	_	O	O	_	_	_	_	_
6	similar	_	O	O	_	_	_	_	_
7	results	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	c	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Myc	_	O	O	_	_	_	_	_
4	antibody	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	purchased	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	Invitrogen	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Normal	_	O	O	_	_	_	_	_
2	rabbit	_	O	O	_	_	_	_	_
3	IgG	_	O	O	_	_	_	_	_
4	antibody	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	obtained	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	Upstate	_	O	O	_	_	_	_	_
9	Biotechnology	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Lake	_	O	O	_	_	_	_	_
12	Placid	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	New	_	O	O	_	_	_	_	_
15	York	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	United	_	O	O	_	_	_	_	_
18	States	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_



1	Statistical	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_

1	Data	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	expressed	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	means	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	SEM	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Statistical	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	performed	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	Student	_	O	O	_	_	_	_	_
7	'	_	O	O	_	_	_	_	_
8	s	_	O	O	_	_	_	_	_
9	t	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	test	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	matched	_	O	O	_	_	_	_	_
14	pairs	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	P	_	O	O	_	_	_	_	_
2	values	_	O	O	_	_	_	_	_
3	less	_	O	O	_	_	_	_	_
4	than	_	O	O	_	_	_	_	_
5	0	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_
7	05	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	considered	_	O	O	_	_	_	_	_
10	significant	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_



1	Association	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	interleukin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	chain	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	47	_	O	O	_	_	_	_	_
13	phox	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	activator	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	phagocyte	_	O	O	_	_	_	_	_
20	NADPH	_	O	O	_	_	_	_	_
21	oxidase	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	plays	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	important	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	IgE	_	O	O	_	_	_	_	_
13	synthesis	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	Th	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	differentiation	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	conducts	_	O	O	_	_	_	_	_
5	its	_	O	O	_	_	_	_	_
6	biological	_	O	O	_	_	_	_	_
7	activities	_	O	O	_	_	_	_	_
8	through	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	R	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	on	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	surface	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	target	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	R	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	thought	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	composed	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	R	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	chain	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	R	_	O	O	_	_	_	_	_
23	alpha	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	either	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	R	_	O	O	_	_	_	_	_
32	gamma	_	O	O	_	_	_	_	_
33	chain	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	13	_	O	O	_	_	_	_	_
39	R	_	O	O	_	_	_	_	_
40	alpha	_	O	O	_	_	_	_	_
41	chain	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	membrane	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	proximal	_	O	O	_	_	_	_	_
10	portion	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	cytoplasmic	_	O	O	_	_	_	_	_
14	domain	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	R	_	O	O	_	_	_	_	_
22	alpha	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	hIL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	R	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	is	_	O	O	_	_	_	_	_
31	critical	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	proliferation	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	generation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	germline	_	O	O	_	_	_	_	_
38	epsilon	_	O	O	_	_	_	_	_
39	transcript	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	activation	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	STAT	_	O	O	_	_	_	_	_
45	6	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	based	_	O	O	_	_	_	_	_
48	on	_	O	O	_	_	_	_	_
49	analyses	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	truncated	_	O	O	_	_	_	_	_
52	hIL	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	4	_	O	O	_	_	_	_	_
55	R	_	O	O	_	_	_	_	_
56	alphas	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	found	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	47	_	O	O	_	_	_	_	_
10	phox	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	activator	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	phagocyte	_	O	O	_	_	_	_	_
17	NADPH	_	O	O	_	_	_	_	_
18	oxidase	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	binds	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	this	_	O	O	_	_	_	_	_
23	portion	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	two	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	hybrid	_	O	O	_	_	_	_	_
29	system	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	observed	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	association	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	47	_	O	O	_	_	_	_	_
10	phox	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	hIL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	R	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	B	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	derived	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	normal	_	O	O	_	_	_	_	_
25	donor	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	47	_	O	O	_	_	_	_	_
7	phox	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	involved	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	signal	_	O	O	_	_	_	_	_
13	transduction	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	B	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	23	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	IgE	_	O	O	_	_	_	_	_
14	synthesis	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	affected	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	47	_	O	O	_	_	_	_	_
26	phox	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	deficient	_	O	O	_	_	_	_	_
29	patients	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	which	_	O	O	_	_	_	_	_
32	raises	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	possibility	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	p	_	O	O	_	_	_	_	_
37	47	_	O	O	_	_	_	_	_
38	phox	_	O	O	_	_	_	_	_
39	may	_	O	O	_	_	_	_	_
40	be	_	O	O	_	_	_	_	_
41	important	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	other	_	O	O	_	_	_	_	_
44	signaling	_	O	O	_	_	_	_	_
45	activities	_	O	O	_	_	_	_	_
46	as	_	O	O	_	_	_	_	_
47	well	_	O	O	_	_	_	_	_
48	in	_	O	O	_	_	_	_	_
49	B	_	O	O	_	_	_	_	_
50	cells	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Cell	_	O	O	_	_	_	_	_
2	viability	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	Trypan	_	O	O	_	_	_	_	_
5	blue	_	O	O	_	_	_	_	_
6	dye	_	O	O	_	_	_	_	_
7	exclusion	_	O	O	_	_	_	_	_
8	assay	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	viability	_	O	O	_	_	_	_	_
4	assays	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	trypan	_	O	O	_	_	_	_	_
8	blue	_	O	O	_	_	_	_	_
9	dye	_	O	O	_	_	_	_	_
10	exclusion	_	O	O	_	_	_	_	_
11	method	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	used	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	evaluate	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	potential	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	direct	_	O	O	_	_	_	_	_
20	cytotoxic	_	O	O	_	_	_	_	_
21	effect	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	inhibitors	_	O	O	_	_	_	_	_
24	on	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	incubation	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	24	_	O	O	_	_	_	_	_
5	hours	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	harvested	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	percentage	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	viability	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	calculated	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	formula	_	O	O	_	_	_	_	_
21	100	_	O	O	_	_	_	_	_
22	x	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	number	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	viable	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	number	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	both	_	O	O	_	_	_	_	_
32	viable	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	dead	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	[	_	O	O	_	_	_	_	_
38	21	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_



1	Circadian	_	O	O	_	_	_	_	_
2	rhythm	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	glucocorticoid	_	O	O	_	_	_	_	_
5	receptors	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	peripheral	_	O	O	_	_	_	_	_
9	leukocytes	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	their	_	O	O	_	_	_	_	_
12	reactivity	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	glucocorticoids	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	1	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	There	_	O	O	_	_	_	_	_
4	exists	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	CR	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	GR	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	leukocytes	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	PMN	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	monocytes	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	peak	_	O	O	_	_	_	_	_
20	values	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	0400	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	0800	_	O	O	_	_	_	_	_
25	hr	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	trough	_	O	O	_	_	_	_	_
29	values	_	O	O	_	_	_	_	_
30	between	_	O	O	_	_	_	_	_
31	2300	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	0000	_	O	O	_	_	_	_	_
34	hr	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	difference	_	O	O	_	_	_	_	_
3	between	_	O	O	_	_	_	_	_
4	them	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	significant	_	O	O	_	_	_	_	_
7	statistically	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	FI	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	chemotactic	_	O	O	_	_	_	_	_
8	migration	_	O	O	_	_	_	_	_
9	rate	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	PMN	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	cortisol	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	showed	_	O	O	_	_	_	_	_
16	diurnal	_	O	O	_	_	_	_	_
17	changes	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	synchronous	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	GR	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	indicates	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	CR	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	GR	_	O	O	_	_	_	_	_
8	may	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	functional	_	O	O	_	_	_	_	_
12	significance	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	Cushing	_	O	O	_	_	_	_	_
5	'	_	O	O	_	_	_	_	_
6	s	_	O	O	_	_	_	_	_
7	syndrome	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	CR	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	GR	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	normal	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	spite	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	fact	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	CR	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	plasma	_	O	O	_	_	_	_	_
25	cortisol	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	disturbed	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	indicates	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	independency	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	CR	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	GR	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	cortisol	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	apoplexy	_	O	O	_	_	_	_	_
5	caused	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	brain	_	O	O	_	_	_	_	_
8	ischemia	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	CR	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	GR	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	abolished	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	basal	_	O	O	_	_	_	_	_
20	lesions	_	O	O	_	_	_	_	_
21	but	_	O	O	_	_	_	_	_
22	preserved	_	O	O	_	_	_	_	_
23	when	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	lesions	_	O	O	_	_	_	_	_
26	were	_	O	O	_	_	_	_	_
27	located	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	cerebral	_	O	O	_	_	_	_	_
31	cortex	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	strongly	_	O	O	_	_	_	_	_
4	suggest	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	main	_	O	O	_	_	_	_	_
8	""""	_	O	O	_	_	_	_	_
9	circadian	_	O	O	_	_	_	_	_
10	pacemaker	_	O	O	_	_	_	_	_
11	""""	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	GR	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	located	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	basal	_	O	O	_	_	_	_	_
19	brain	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	most	_	O	O	_	_	_	_	_
22	probably	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	suprachiasmatic	_	O	O	_	_	_	_	_
26	nuclei	_	O	O	_	_	_	_	_
27	as	_	O	O	_	_	_	_	_
28	has	_	O	O	_	_	_	_	_
29	been	_	O	O	_	_	_	_	_
30	suggested	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	rodents	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Effects	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	diesel	_	O	O	_	_	_	_	_
4	organic	_	O	O	_	_	_	_	_
5	extracts	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	chemokine	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	peripheral	_	O	O	_	_	_	_	_
11	blood	_	O	O	_	_	_	_	_
12	mononuclear	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Polyaromatic	_	O	O	_	_	_	_	_
4	hydrocarbons	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	PAHs	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	associated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	diesel	_	O	O	_	_	_	_	_
11	exhaust	_	O	O	_	_	_	_	_
12	particles	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	DEPs	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	found	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	atmospheric	_	O	O	_	_	_	_	_
21	urban	_	O	O	_	_	_	_	_
22	pollution	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Such	_	O	O	_	_	_	_	_
2	compounds	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	favor	_	O	O	_	_	_	_	_
8	IgE	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	bronchial	_	O	O	_	_	_	_	_
12	hyperresponsiveness	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	airway	_	O	O	_	_	_	_	_
16	inflammation	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Chemokines	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	group	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	chemotactic	_	O	O	_	_	_	_	_
7	cytokines	_	O	O	_	_	_	_	_
8	involved	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	recruitment	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	inflammatory	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	OBJECTIVE	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	We	_	O	O	_	_	_	_	_
4	investigated	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	effect	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	DEP	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	PAHs	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	release	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	mRNA	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	8	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	MCP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	RANTES	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	PBMCs	_	O	O	_	_	_	_	_
30	obtained	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	healthy	_	O	O	_	_	_	_	_
33	subjects	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Protein	_	O	O	_	_	_	_	_
4	production	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	supernatants	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	assessed	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	ELISA	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	evaluated	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	semiquantitative	_	O	O	_	_	_	_	_
19	RT	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	PCR	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Secretion	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	8	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	RANTES	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	dose	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	dependent	_	O	O	_	_	_	_	_
16	manner	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	increasing	_	O	O	_	_	_	_	_
19	concentrations	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	DEP	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	PAHs	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	range	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	0	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	5	_	O	O	_	_	_	_	_
30	ng	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	50	_	O	O	_	_	_	_	_
33	ng	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	mL	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	release	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	MCP	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	significantly	_	O	O	_	_	_	_	_
13	inhibited	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	also	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	dose	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	dependent	_	O	O	_	_	_	_	_
21	manner	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Messenger	_	O	O	_	_	_	_	_
2	RNA	_	O	O	_	_	_	_	_
3	production	_	O	O	_	_	_	_	_
4	coding	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	8	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	RANTES	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	MCP	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	showed	_	O	O	_	_	_	_	_
17	parallel	_	O	O	_	_	_	_	_
18	variations	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	correspondent	_	O	O	_	_	_	_	_
25	proteins	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Effects	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	DEP	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	PAHs	_	O	O	_	_	_	_	_
6	became	_	O	O	_	_	_	_	_
7	significant	_	O	O	_	_	_	_	_
8	at	_	O	O	_	_	_	_	_
9	7	_	O	O	_	_	_	_	_
10	hours	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	up	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	48	_	O	O	_	_	_	_	_
15	hours	_	O	O	_	_	_	_	_
16	time	_	O	O	_	_	_	_	_
17	culture	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	MCP	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	up	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	24	_	O	O	_	_	_	_	_
27	hours	_	O	O	_	_	_	_	_
28	time	_	O	O	_	_	_	_	_
29	culture	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	8	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	RANTES	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	supernatants	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	DEP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	PAH	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	compared	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	those	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	controls	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	exhibited	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	significantly	_	O	O	_	_	_	_	_
21	enhanced	_	O	O	_	_	_	_	_
22	chemotactic	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	neutrophils	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	eosinophils	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	which	_	O	O	_	_	_	_	_
30	was	_	O	O	_	_	_	_	_
31	significantly	_	O	O	_	_	_	_	_
32	inhibited	_	O	O	_	_	_	_	_
33	by	_	O	O	_	_	_	_	_
34	pretreatment	_	O	O	_	_	_	_	_
35	with	_	O	O	_	_	_	_	_
36	anti	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	8	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	anti	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	RANTES	_	O	O	_	_	_	_	_
45	neutralizing	_	O	O	_	_	_	_	_
46	antibodies	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	respectively	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	CONCLUSION	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	These	_	O	O	_	_	_	_	_
4	findings	_	O	O	_	_	_	_	_
5	suggest	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	chemokine	_	O	O	_	_	_	_	_
9	pathways	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	modulated	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	DEP	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	PAHs	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	transcriptional	_	O	O	_	_	_	_	_
19	level	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	reinforcing	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	idea	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	development	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	inflammatory	_	O	O	_	_	_	_	_
29	reactions	_	O	O	_	_	_	_	_
30	might	_	O	O	_	_	_	_	_
31	be	_	O	O	_	_	_	_	_
32	affected	_	O	O	_	_	_	_	_
33	by	_	O	O	_	_	_	_	_
34	diesel	_	O	O	_	_	_	_	_
35	exhaust	_	O	O	_	_	_	_	_
36	emission	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Phorbol	_	O	O	_	_	_	_	_
2	ester	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	mononuclear	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	differentiation	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	blocked	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	mitogen	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	kinase	_	O	O	_	_	_	_	_
17	kinase	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	MEK	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	inhibitor	_	O	O	_	_	_	_	_
22	PD	_	O	O	_	_	_	_	_
23	98059	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	purpose	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	evaluate	_	O	O	_	_	_	_	_
9	whether	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	mitogen	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	activated	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	MAPK	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	signaling	_	O	O	_	_	_	_	_
20	pathway	_	O	O	_	_	_	_	_
21	contributes	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	12	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	O	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	tetradecanoylphorbol	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	13	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	acetate	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	TPA	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	induced	_	O	O	_	_	_	_	_
37	mononuclear	_	O	O	_	_	_	_	_
38	differentiation	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	human	_	O	O	_	_	_	_	_
42	myeloblastic	_	O	O	_	_	_	_	_
43	leukemia	_	O	O	_	_	_	_	_
44	ML	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Upon	_	O	O	_	_	_	_	_
2	TPA	_	O	O	_	_	_	_	_
3	treatment	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	ERK	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	ERK	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	rapidly	_	O	O	_	_	_	_	_
14	increased	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	maximal	_	O	O	_	_	_	_	_
18	induction	_	O	O	_	_	_	_	_
19	between	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	h	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	while	_	O	O	_	_	_	_	_
26	ERK	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	levels	_	O	O	_	_	_	_	_
30	remained	_	O	O	_	_	_	_	_
31	constant	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	activity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	JNK	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	significantly	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	JNK	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	levels	_	O	O	_	_	_	_	_
16	increasing	_	O	O	_	_	_	_	_
17	moderately	_	O	O	_	_	_	_	_
18	during	_	O	O	_	_	_	_	_
19	exposure	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	TPA	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	PD	_	O	O	_	_	_	_	_
6	98059	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	specific	_	O	O	_	_	_	_	_
10	inhibitor	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	mitogen	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	kinase	_	O	O	_	_	_	_	_
17	kinase	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	MEK	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	inhibited	_	O	O	_	_	_	_	_
23	TPA	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	induced	_	O	O	_	_	_	_	_
26	ERK	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	PD	_	O	O	_	_	_	_	_
4	98059	_	O	O	_	_	_	_	_
5	completely	_	O	O	_	_	_	_	_
6	blocked	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	TPA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	differentiation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	ML	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	assessed	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	number	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	features	_	O	O	_	_	_	_	_
25	associated	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	mononuclear	_	O	O	_	_	_	_	_
28	differentiation	_	O	O	_	_	_	_	_
29	including	_	O	O	_	_	_	_	_
30	changes	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	morphology	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	nonspecific	_	O	O	_	_	_	_	_
35	esterase	_	O	O	_	_	_	_	_
36	activity	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	phagocytic	_	O	O	_	_	_	_	_
39	ability	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	NADPH	_	O	O	_	_	_	_	_
42	oxidase	_	O	O	_	_	_	_	_
43	activity	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	mitochondrial	_	O	O	_	_	_	_	_
46	respiration	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	c	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	jun	_	O	O	_	_	_	_	_
52	mRNA	_	O	O	_	_	_	_	_
53	inducibility	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	MEK	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	ERK	_	O	O	_	_	_	_	_
10	signaling	_	O	O	_	_	_	_	_
11	pathway	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	necessary	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	TPA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	mononuclear	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	differentiation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Jak	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	signaling	_	O	O	_	_	_	_	_
10	pathway	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	eosinophils	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	intracellular	_	O	O	_	_	_	_	_
3	signal	_	O	O	_	_	_	_	_
4	transduction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	eosinophils	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	unknown	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	objective	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	investigate	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	involvement	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	newly	_	O	O	_	_	_	_	_
14	discovered	_	O	O	_	_	_	_	_
15	Jak	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	pathway	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	5	_	O	O	_	_	_	_	_
24	signal	_	O	O	_	_	_	_	_
25	transduction	_	O	O	_	_	_	_	_
26	mechanism	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Eosinophils	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	purified	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	peripheral	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	discontinuous	_	O	O	_	_	_	_	_
9	Percoll	_	O	O	_	_	_	_	_
10	gradients	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	stimulated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	involvement	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Jak	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	investigated	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	immunoprecipitation	_	O	O	_	_	_	_	_
10	followed	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	immunoblotting	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	tyrosine	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Jak	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	studied	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	autophosphorylation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	immunoprecipitated	_	O	O	_	_	_	_	_
13	kinase	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Jak	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	phosphorylated	_	O	O	_	_	_	_	_
6	within	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	min	_	O	O	_	_	_	_	_
11	after	_	O	O	_	_	_	_	_
12	stimulation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	eosinophils	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	immunoprecipitated	_	O	O	_	_	_	_	_
5	Jak	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	obtained	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	stimulated	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	underwent	_	O	O	_	_	_	_	_
16	autophosphorylation	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Jak	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	coprecipitated	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	subunit	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	suggesting	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	physical	_	O	O	_	_	_	_	_
19	association	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	kinase	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	nuclear	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	91	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	investigated	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	immunoprecipitation	_	O	O	_	_	_	_	_
15	followed	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	immunoblotting	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	phosphorylation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	STAT	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	tyrosine	_	O	O	_	_	_	_	_
6	phosphorylated	_	O	O	_	_	_	_	_
7	within	_	O	O	_	_	_	_	_
8	15	_	O	O	_	_	_	_	_
9	min	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	stimulation	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	presence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	nuclear	_	O	O	_	_	_	_	_
10	extract	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	studied	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	electrophoretic	_	O	O	_	_	_	_	_
15	mobility	_	O	O	_	_	_	_	_
16	shift	_	O	O	_	_	_	_	_
17	assay	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	5	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	proteins	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	bound	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	activating	_	O	O	_	_	_	_	_
14	sequence	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	presence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	anti	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	Ab	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	band	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	supershifted	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	Jak	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	signaling	_	O	O	_	_	_	_	_
17	pathway	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	eosinophils	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	speculate	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Jak	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	pathway	_	O	O	_	_	_	_	_
11	may	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	involved	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	5	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	inducible	_	O	O	_	_	_	_	_
23	genes	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	eosinophils	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	human	_	O	O	_	_	_	_	_
4	monocytic	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	Treponema	_	O	O	_	_	_	_	_
8	pallidum	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	Borrelia	_	O	O	_	_	_	_	_
11	burgdorferi	_	O	O	_	_	_	_	_
12	lipoproteins	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	synthetic	_	O	O	_	_	_	_	_
15	lipopeptides	_	O	O	_	_	_	_	_
16	proceeds	_	O	O	_	_	_	_	_
17	via	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	pathway	_	O	O	_	_	_	_	_
20	distinct	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	lipopolysaccharide	_	O	O	_	_	_	_	_
25	but	_	O	O	_	_	_	_	_
26	involves	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	transcriptional	_	O	O	_	_	_	_	_
29	activator	_	O	O	_	_	_	_	_
30	NF	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	kappa	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	There	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	increasing	_	O	O	_	_	_	_	_
4	evidence	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	lipoproteins	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Treponema	_	O	O	_	_	_	_	_
9	pallidum	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	Borrelia	_	O	O	_	_	_	_	_
12	burgdorferi	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	key	_	O	O	_	_	_	_	_
15	inflammatory	_	O	O	_	_	_	_	_
16	mediators	_	O	O	_	_	_	_	_
17	during	_	O	O	_	_	_	_	_
18	syphilis	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	Lyme	_	O	O	_	_	_	_	_
21	disease	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	principal	_	O	O	_	_	_	_	_
3	objective	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	present	_	O	O	_	_	_	_	_
7	study	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	identify	_	O	O	_	_	_	_	_
11	more	_	O	O	_	_	_	_	_
12	precisely	_	O	O	_	_	_	_	_
13	similarities	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	divergences	_	O	O	_	_	_	_	_
16	among	_	O	O	_	_	_	_	_
17	lipopolysaccharide	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	LPS	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	lipoprotein	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	lipopeptide	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	induced	_	O	O	_	_	_	_	_
28	immune	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	signaling	_	O	O	_	_	_	_	_
31	events	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Like	_	O	O	_	_	_	_	_
2	LPS	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	purified	_	O	O	_	_	_	_	_
5	native	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	burgdorferi	_	O	O	_	_	_	_	_
2	OspA	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	synthetic	_	O	O	_	_	_	_	_
5	analogs	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	OspA	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	OspB	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	two	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	pallidum	_	O	O	_	_	_	_	_
2	lipoproteins	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	Tpp	_	O	O	_	_	_	_	_
5	47	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	Tpp	_	O	O	_	_	_	_	_
8	17	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	all	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	NF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kappa	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	translocation	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	THP	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	monocytoid	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Acylation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	OspA	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	synthetic	_	O	O	_	_	_	_	_
7	peptides	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	requisite	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Polymyxin	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	abrogated	_	O	O	_	_	_	_	_
4	only	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	response	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	LPS	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	70	_	O	O	_	_	_	_	_
4	Z	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	derived	_	O	O	_	_	_	_	_
9	pre	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	lines	_	O	O	_	_	_	_	_
15	either	_	O	O	_	_	_	_	_
16	lacking	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	expressing	_	O	O	_	_	_	_	_
19	human	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	14	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	LPS	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	it	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	observed	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	human	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	14	_	O	O	_	_	_	_	_
37	imparted	_	O	O	_	_	_	_	_
38	responsiveness	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	LPS	_	O	O	_	_	_	_	_
41	but	_	O	O	_	_	_	_	_
42	not	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	OspA	_	O	O	_	_	_	_	_
45	or	_	O	O	_	_	_	_	_
46	spirochetal	_	O	O	_	_	_	_	_
47	lipopeptides	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	assessed	_	O	O	_	_	_	_	_
50	by	_	O	O	_	_	_	_	_
51	induction	_	O	O	_	_	_	_	_
52	of	_	O	O	_	_	_	_	_
53	NF	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	kappa	_	O	O	_	_	_	_	_
56	B	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	expression	_	O	O	_	_	_	_	_
59	of	_	O	O	_	_	_	_	_
60	surface	_	O	O	_	_	_	_	_
61	immunoglobulin	_	O	O	_	_	_	_	_
62	M	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	biological	_	O	O	_	_	_	_	_
5	relevance	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	observation	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	pallidum	_	O	O	_	_	_	_	_
2	lipoproteins	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	lipopeptides	_	O	O	_	_	_	_	_
5	induce	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	cytokine	_	O	O	_	_	_	_	_
13	production	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	monocytes	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	supported	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	ability	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	synthetic	_	O	O	_	_	_	_	_
24	analogs	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	promote	_	O	O	_	_	_	_	_
27	human	_	O	O	_	_	_	_	_
28	immunodeficiency	_	O	O	_	_	_	_	_
29	virus	_	O	O	_	_	_	_	_
30	replication	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	chronically	_	O	O	_	_	_	_	_
33	infected	_	O	O	_	_	_	_	_
34	U	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	monocytoid	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	;	_	O	O	_	_	_	_	_
39	these	_	O	O	_	_	_	_	_
40	observations	_	O	O	_	_	_	_	_
41	also	_	O	O	_	_	_	_	_
42	suggest	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	potential	_	O	O	_	_	_	_	_
45	mechanism	_	O	O	_	_	_	_	_
46	whereby	_	O	O	_	_	_	_	_
47	a	_	O	O	_	_	_	_	_
48	syphilitic	_	O	O	_	_	_	_	_
49	chancre	_	O	O	_	_	_	_	_
50	can	_	O	O	_	_	_	_	_
51	serve	_	O	O	_	_	_	_	_
52	as	_	O	O	_	_	_	_	_
53	a	_	O	O	_	_	_	_	_
54	cofactor	_	O	O	_	_	_	_	_
55	for	_	O	O	_	_	_	_	_
56	human	_	O	O	_	_	_	_	_
57	immunodeficiency	_	O	O	_	_	_	_	_
58	virus	_	O	O	_	_	_	_	_
59	transmission	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	combined	_	O	O	_	_	_	_	_
3	data	_	O	O	_	_	_	_	_
4	lend	_	O	O	_	_	_	_	_
5	additional	_	O	O	_	_	_	_	_
6	support	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	proposal	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	spirochetal	_	O	O	_	_	_	_	_
12	lipoproteins	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	initiate	_	O	O	_	_	_	_	_
16	monocyte	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	via	_	O	O	_	_	_	_	_
19	different	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	surface	_	O	O	_	_	_	_	_
22	events	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	signaling	_	O	O	_	_	_	_	_
27	pathways	_	O	O	_	_	_	_	_
28	ultimately	_	O	O	_	_	_	_	_
29	converge	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	produce	_	O	O	_	_	_	_	_
32	qualitatively	_	O	O	_	_	_	_	_
33	similar	_	O	O	_	_	_	_	_
34	cellular	_	O	O	_	_	_	_	_
35	responses	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Heterogeneous	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Epstein	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	Barr	_	O	O	_	_	_	_	_
7	virus	_	O	O	_	_	_	_	_
8	latent	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	endemic	_	O	O	_	_	_	_	_
12	Burkitt	_	O	O	_	_	_	_	_
13	'	_	O	O	_	_	_	_	_
14	s	_	O	O	_	_	_	_	_
15	lymphoma	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	Epstein	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Barr	_	O	O	_	_	_	_	_
4	virus	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	EBV	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	infected	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	may	_	O	O	_	_	_	_	_
12	sustain	_	O	O	_	_	_	_	_
13	three	_	O	O	_	_	_	_	_
14	distinct	_	O	O	_	_	_	_	_
15	forms	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	virus	_	O	O	_	_	_	_	_
18	latency	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	lymphoblastoid	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	lines	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	six	_	O	O	_	_	_	_	_
7	EBV	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	encoded	_	O	O	_	_	_	_	_
10	nuclear	_	O	O	_	_	_	_	_
11	antigens	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	EBNA	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	A	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	B	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	C	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	LP	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	three	_	O	O	_	_	_	_	_
32	latent	_	O	O	_	_	_	_	_
33	membrane	_	O	O	_	_	_	_	_
34	proteins	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	LMP	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	2	_	O	O	_	_	_	_	_
40	A	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	B	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	two	_	O	O	_	_	_	_	_
48	nuclear	_	O	O	_	_	_	_	_
49	RNAs	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	EBERs	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	are	_	O	O	_	_	_	_	_
54	expressed	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	form	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	latency	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	termed	_	O	O	_	_	_	_	_
7	latency	_	O	O	_	_	_	_	_
8	III	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	encountered	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	some	_	O	O	_	_	_	_	_
15	posttransplant	_	O	O	_	_	_	_	_
16	lymphoproliferative	_	O	O	_	_	_	_	_
17	disorders	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	EBV	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	positive	_	O	O	_	_	_	_	_
5	cases	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Hodgkin	_	O	O	_	_	_	_	_
8	'	_	O	O	_	_	_	_	_
9	s	_	O	O	_	_	_	_	_
10	disease	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	EBERs	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	EBNA	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	LMPs	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	expressed	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	latency	_	O	O	_	_	_	_	_
25	II	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	whereas	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	Burkitt	_	O	O	_	_	_	_	_
31	'	_	O	O	_	_	_	_	_
32	s	_	O	O	_	_	_	_	_
33	lymphoma	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	BL	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	only	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	EBERs	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	EBNA	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	have	_	O	O	_	_	_	_	_
44	been	_	O	O	_	_	_	_	_
45	detected	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	latency	_	O	O	_	_	_	_	_
48	I	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	studied	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	EBV	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	17	_	O	O	_	_	_	_	_
11	cases	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	EBV	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	positive	_	O	O	_	_	_	_	_
16	endemic	_	O	O	_	_	_	_	_
17	BL	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	immunohistology	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	LMP	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	seen	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	variable	_	O	O	_	_	_	_	_
9	proportions	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	tumor	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	two	_	O	O	_	_	_	_	_
15	cases	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	EBNA	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	detected	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	some	_	O	O	_	_	_	_	_
23	tumor	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	three	_	O	O	_	_	_	_	_
27	other	_	O	O	_	_	_	_	_
28	cases	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Also	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	BZLF	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	trans	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	activator	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	expressed	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	few	_	O	O	_	_	_	_	_
15	tumor	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	cases	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	indicating	_	O	O	_	_	_	_	_
22	entry	_	O	O	_	_	_	_	_
23	into	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	lytic	_	O	O	_	_	_	_	_
26	cycle	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	phenotypic	_	O	O	_	_	_	_	_
3	drift	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	latency	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	latency	_	O	O	_	_	_	_	_
9	III	_	O	O	_	_	_	_	_
10	has	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	observed	_	O	O	_	_	_	_	_
13	previously	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	some	_	O	O	_	_	_	_	_
16	BL	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	lines	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	similar	_	O	O	_	_	_	_	_
7	phenomenon	_	O	O	_	_	_	_	_
8	may	_	O	O	_	_	_	_	_
9	occur	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	BL	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	vivo	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	indicate	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	operational	_	O	O	_	_	_	_	_
19	definition	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	EBV	_	O	O	_	_	_	_	_
22	latencies	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	easily	_	O	O	_	_	_	_	_
26	applied	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	human	_	O	O	_	_	_	_	_
29	tumors	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Grf	_	O	O	_	_	_	_	_
2	40	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	A	_	O	O	_	_	_	_	_
5	novel	_	O	O	_	_	_	_	_
6	Grb	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	family	_	O	O	_	_	_	_	_
9	member	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	involved	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	signaling	_	O	O	_	_	_	_	_
17	through	_	O	O	_	_	_	_	_
18	interaction	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	SLP	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	76	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	LAT	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	molecularly	_	O	O	_	_	_	_	_
3	cloned	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	new	_	O	O	_	_	_	_	_
6	Grb	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	family	_	O	O	_	_	_	_	_
9	member	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	named	_	O	O	_	_	_	_	_
12	Grf	_	O	O	_	_	_	_	_
13	40	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	containing	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	common	_	O	O	_	_	_	_	_
18	SH	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	SH	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	SH	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	motif	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Grf	_	O	O	_	_	_	_	_
4	40	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	predominant	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	hematopoietic	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	particularly	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Grf	_	O	O	_	_	_	_	_
2	40	_	O	O	_	_	_	_	_
3	binds	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	SH	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	domain	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	containing	_	O	O	_	_	_	_	_
11	leukocyte	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	76	_	O	O	_	_	_	_	_
15	kD	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	SLP	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	76	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	via	_	O	O	_	_	_	_	_
22	its	_	O	O	_	_	_	_	_
23	SH	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	domain	_	O	O	_	_	_	_	_
26	more	_	O	O	_	_	_	_	_
27	tightly	_	O	O	_	_	_	_	_
28	than	_	O	O	_	_	_	_	_
29	Grb	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Incidentally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Grf	_	O	O	_	_	_	_	_
4	40	_	O	O	_	_	_	_	_
5	binds	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	linker	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	LAT	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	possibly	_	O	O	_	_	_	_	_
17	via	_	O	O	_	_	_	_	_
18	its	_	O	O	_	_	_	_	_
19	SH	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	domain	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Overexpression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	wild	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	Grf	_	O	O	_	_	_	_	_
7	40	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	Jurkat	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	significant	_	O	O	_	_	_	_	_
14	increase	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	SLP	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	76	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	dependent	_	O	O	_	_	_	_	_
21	interleukin	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	promoter	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	nuclear	_	O	O	_	_	_	_	_
30	factor	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	activated	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	NF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	AT	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	activation	_	O	O	_	_	_	_	_
41	upon	_	O	O	_	_	_	_	_
42	T	_	O	O	_	_	_	_	_
43	cell	_	O	O	_	_	_	_	_
44	receptor	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	TCR	_	O	O	_	_	_	_	_
47	)	_	O	O	_	_	_	_	_
48	stimulation	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	whereas	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	COOH	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	terminal	_	O	O	_	_	_	_	_
55	SH	_	O	O	_	_	_	_	_
56	3	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	deleted	_	O	O	_	_	_	_	_
59	Grf	_	O	O	_	_	_	_	_
60	40	_	O	O	_	_	_	_	_
61	mutant	_	O	O	_	_	_	_	_
62	lacked	_	O	O	_	_	_	_	_
63	any	_	O	O	_	_	_	_	_
64	recognizable	_	O	O	_	_	_	_	_
65	increase	_	O	O	_	_	_	_	_
66	in	_	O	O	_	_	_	_	_
67	IL	_	O	O	_	_	_	_	_
68	-	_	O	O	_	_	_	_	_
69	2	_	O	O	_	_	_	_	_
70	promoter	_	O	O	_	_	_	_	_
71	activity	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	SH	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	deleted	_	O	O	_	_	_	_	_
8	Grf	_	O	O	_	_	_	_	_
9	40	_	O	O	_	_	_	_	_
10	mutant	_	O	O	_	_	_	_	_
11	led	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	marked	_	O	O	_	_	_	_	_
15	inhibition	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	these	_	O	O	_	_	_	_	_
18	regulatory	_	O	O	_	_	_	_	_
19	activities	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	effect	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	apparently	_	O	O	_	_	_	_	_
27	stronger	_	O	O	_	_	_	_	_
28	than	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	SH	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	deleted	_	O	O	_	_	_	_	_
36	Grb	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	mutant	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Grf	_	O	O	_	_	_	_	_
6	40	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	adaptor	_	O	O	_	_	_	_	_
10	molecule	_	O	O	_	_	_	_	_
11	involved	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	TCR	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	mediated	_	O	O	_	_	_	_	_
16	signaling	_	O	O	_	_	_	_	_
17	through	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	more	_	O	O	_	_	_	_	_
20	efficient	_	O	O	_	_	_	_	_
21	interaction	_	O	O	_	_	_	_	_
22	than	_	O	O	_	_	_	_	_
23	Grb	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	SLP	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	76	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	LAT	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	nucleoside	_	O	O	_	_	_	_	_
5	diphosphate	_	O	O	_	_	_	_	_
6	kinase	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	skin	_	O	O	_	_	_	_	_
10	cancers	_	O	O	_	_	_	_	_
11	:	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	immunohistochemical	_	O	O	_	_	_	_	_
14	study	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	nucleoside	_	O	O	_	_	_	_	_
4	diphosphate	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	NDP	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	which	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	homologous	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	nm	_	O	O	_	_	_	_	_
16	23	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	product	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	variety	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	species	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	has	_	O	O	_	_	_	_	_
26	been	_	O	O	_	_	_	_	_
27	found	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	be	_	O	O	_	_	_	_	_
30	inversely	_	O	O	_	_	_	_	_
31	associated	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	metastatic	_	O	O	_	_	_	_	_
34	potential	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	relationship	_	O	O	_	_	_	_	_
5	remains	_	O	O	_	_	_	_	_
6	controversial	_	O	O	_	_	_	_	_
7	according	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	tumor	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	types	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	experimental	_	O	O	_	_	_	_	_
15	system	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	conflicting	_	O	O	_	_	_	_	_
19	results	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	different	_	O	O	_	_	_	_	_
22	research	_	O	O	_	_	_	_	_
23	groups	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	order	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	determine	_	O	O	_	_	_	_	_
5	whether	_	O	O	_	_	_	_	_
6	NDP	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	serves	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	marker	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	metastatic	_	O	O	_	_	_	_	_
15	potential	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	skin	_	O	O	_	_	_	_	_
19	cancer	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	we	_	O	O	_	_	_	_	_
22	assessed	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	levels	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	NDP	_	O	O	_	_	_	_	_
27	kinase	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	9	_	O	O	_	_	_	_	_
31	keratoacanthomas	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	KAs	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	26	_	O	O	_	_	_	_	_
37	squamous	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	carcinomas	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	SCCs	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	25	_	O	O	_	_	_	_	_
46	basal	_	O	O	_	_	_	_	_
47	cell	_	O	O	_	_	_	_	_
48	carcinomas	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	BCCs	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	using	_	O	O	_	_	_	_	_
53	immunohistochemistry	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NDP	_	O	O	_	_	_	_	_
5	kinase	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	intense	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	KA	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	SCC	_	O	O	_	_	_	_	_
12	compared	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	BCC	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	difference	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	NDP	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	between	_	O	O	_	_	_	_	_
10	KA	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	SCC	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	statistically	_	O	O	_	_	_	_	_
16	significant	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	And	_	O	O	_	_	_	_	_
2	there	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	no	_	O	O	_	_	_	_	_
5	statistically	_	O	O	_	_	_	_	_
6	significant	_	O	O	_	_	_	_	_
7	difference	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	NDP	_	O	O	_	_	_	_	_
10	kinase	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	between	_	O	O	_	_	_	_	_
13	SCC	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	metastasis	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	SCC	_	O	O	_	_	_	_	_
18	without	_	O	O	_	_	_	_	_
19	metastasis	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	contradict	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	hypothesis	_	O	O	_	_	_	_	_
6	concerning	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	possible	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	nm	_	O	O	_	_	_	_	_
12	23	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	metastatic	_	O	O	_	_	_	_	_
17	suppressor	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	skin	_	O	O	_	_	_	_	_
22	cancer	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	overexpression	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	various	_	O	O	_	_	_	_	_
7	tumor	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	types	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	its	_	O	O	_	_	_	_	_
12	biological	_	O	O	_	_	_	_	_
13	significance	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	cutaneous	_	O	O	_	_	_	_	_
16	carcinogenesis	_	O	O	_	_	_	_	_
17	remain	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	determined	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Oxidative	_	O	O	_	_	_	_	_
2	stress	_	O	O	_	_	_	_	_
3	triggers	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	nuclear	_	O	O	_	_	_	_	_
10	translocation	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Oxidizing	_	O	O	_	_	_	_	_
2	agents	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	powerful	_	O	O	_	_	_	_	_
5	activators	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	factors	_	O	O	_	_	_	_	_
8	responsible	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	transcriptional	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	cytokine	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	encoding	_	O	O	_	_	_	_	_
17	genes	_	O	O	_	_	_	_	_
18	involved	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	tissue	_	O	O	_	_	_	_	_
21	injury	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	evidence	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	whose	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	modulated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	H	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	O	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	human	_	O	O	_	_	_	_	_
25	lymphocytes	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	which	_	O	O	_	_	_	_	_
29	endogenous	_	O	O	_	_	_	_	_
30	catalase	_	O	O	_	_	_	_	_
31	had	_	O	O	_	_	_	_	_
32	previously	_	O	O	_	_	_	_	_
33	been	_	O	O	_	_	_	_	_
34	inhibited	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	H	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	O	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	nuclear	_	O	O	_	_	_	_	_
8	translocation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	form	_	O	O	_	_	_	_	_
14	sequence	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	DNA	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	bound	_	O	O	_	_	_	_	_
20	complexes	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	evidenced	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	immunoblotting	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	nuclear	_	O	O	_	_	_	_	_
27	fractions	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	electrophoretic	_	O	O	_	_	_	_	_
30	mobility	_	O	O	_	_	_	_	_
31	shift	_	O	O	_	_	_	_	_
32	assays	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	vanadate	_	O	O	_	_	_	_	_
36	was	_	O	O	_	_	_	_	_
37	found	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	strongly	_	O	O	_	_	_	_	_
40	synergize	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	H	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	O	_	O	O	_	_	_	_	_
45	2	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	anti	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	antibodies	_	O	O	_	_	_	_	_
8	specifically	_	O	O	_	_	_	_	_
9	precipitated	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	92	_	O	O	_	_	_	_	_
14	kDa	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	becomes	_	O	O	_	_	_	_	_
17	phosphorylated	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	upon	_	O	O	_	_	_	_	_
21	lymphocyte	_	O	O	_	_	_	_	_
22	treatment	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	H	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	O	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Phenylarsine	_	O	O	_	_	_	_	_
2	oxide	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	tyrosine	_	O	O	_	_	_	_	_
6	phosphatase	_	O	O	_	_	_	_	_
7	inhibitor	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	genistein	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	tyrosine	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	inhibitor	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	cooperated	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	cancelled	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	respectively	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	H	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	O	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	promoted	_	O	O	_	_	_	_	_
30	STAT	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	nuclear	_	O	O	_	_	_	_	_
33	translocation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Evidence	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	presented	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	using	_	O	O	_	_	_	_	_
7	Fe	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	Cu	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	ions	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	OH	_	O	O	_	_	_	_	_
19	generated	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	H	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	O	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	through	_	O	O	_	_	_	_	_
26	Fenton	_	O	O	_	_	_	_	_
27	reactions	_	O	O	_	_	_	_	_
28	could	_	O	O	_	_	_	_	_
29	be	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	candidate	_	O	O	_	_	_	_	_
32	oxygen	_	O	O	_	_	_	_	_
33	reactive	_	O	O	_	_	_	_	_
34	species	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	directly	_	O	O	_	_	_	_	_
37	activate	_	O	O	_	_	_	_	_
38	STAT	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Present	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	H	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	O	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	vanadate	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	likely	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	inhibit	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	intracellular	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	phosphatase	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	s	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	leading	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	enhanced	_	O	O	_	_	_	_	_
28	STAT	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	tyrosine	_	O	O	_	_	_	_	_
31	phosphorylation	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	hence	_	O	O	_	_	_	_	_
34	its	_	O	O	_	_	_	_	_
35	translocation	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	nucleus	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	can	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	modulated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	oxidizing	_	O	O	_	_	_	_	_
17	agents	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	provide	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	framework	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	understand	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	effects	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	oxidative	_	O	O	_	_	_	_	_
28	stress	_	O	O	_	_	_	_	_
29	on	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	JAK	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	STAT	_	O	O	_	_	_	_	_
34	signaling	_	O	O	_	_	_	_	_
35	pathway	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Differential	_	O	O	_	_	_	_	_
2	regulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	monocytic	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	lines	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	inhibit	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cytokine	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	monocytes	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	macrophages	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	molecular	_	O	O	_	_	_	_	_
5	mechanism	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	inhibitory	_	O	O	_	_	_	_	_
9	effect	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	transcriptional	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	post	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	transcriptional	_	O	O	_	_	_	_	_
16	regulation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	10	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	we	_	O	O	_	_	_	_	_
33	studied	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	6	_	O	O	_	_	_	_	_
37	production	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	expression	_	O	O	_	_	_	_	_
40	level	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	6	_	O	O	_	_	_	_	_
45	mRNA	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	IL	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	6	_	O	O	_	_	_	_	_
50	promoter	_	O	O	_	_	_	_	_
51	activity	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	transcriptional	_	O	O	_	_	_	_	_
54	activity	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	NF	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	kappaB	_	O	O	_	_	_	_	_
59	and	_	O	O	_	_	_	_	_
60	NF	_	O	O	_	_	_	_	_
61	-	_	O	O	_	_	_	_	_
62	IL	_	O	O	_	_	_	_	_
63	-	_	O	O	_	_	_	_	_
64	6	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	and	_	O	O	_	_	_	_	_
67	IL	_	O	O	_	_	_	_	_
68	-	_	O	O	_	_	_	_	_
69	6	_	O	O	_	_	_	_	_
70	mRNA	_	O	O	_	_	_	_	_
71	stability	_	O	O	_	_	_	_	_
72	in	_	O	O	_	_	_	_	_
73	human	_	O	O	_	_	_	_	_
74	monocytic	_	O	O	_	_	_	_	_
75	cell	_	O	O	_	_	_	_	_
76	lines	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	THP	_	O	O	_	_	_	_	_
79	-	_	O	O	_	_	_	_	_
80	1	_	O	O	_	_	_	_	_
81	and	_	O	O	_	_	_	_	_
82	U	_	O	O	_	_	_	_	_
83	937	_	O	O	_	_	_	_	_
84	,	_	O	O	_	_	_	_	_
85	stimulated	_	O	O	_	_	_	_	_
86	by	_	O	O	_	_	_	_	_
87	PMA	_	O	O	_	_	_	_	_
88	and	_	O	O	_	_	_	_	_
89	LPS	_	O	O	_	_	_	_	_
90	in	_	O	O	_	_	_	_	_
91	the	_	O	O	_	_	_	_	_
92	absence	_	O	O	_	_	_	_	_
93	or	_	O	O	_	_	_	_	_
94	the	_	O	O	_	_	_	_	_
95	presence	_	O	O	_	_	_	_	_
96	of	_	O	O	_	_	_	_	_
97	IL	_	O	O	_	_	_	_	_
98	-	_	O	O	_	_	_	_	_
99	4	_	O	O	_	_	_	_	_
100	or	_	O	O	_	_	_	_	_
101	IL	_	O	O	_	_	_	_	_
102	-	_	O	O	_	_	_	_	_
103	10	_	O	O	_	_	_	_	_
104	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	seen	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	inhibit	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	mRNA	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	both	_	O	O	_	_	_	_	_
27	monocytic	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	lines	_	O	O	_	_	_	_	_
30	studied	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	chloramphenicol	_	O	O	_	_	_	_	_
3	acetyltransferase	_	O	O	_	_	_	_	_
4	assays	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	utilizing	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	transient	_	O	O	_	_	_	_	_
9	transfection	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	chloramphenicol	_	O	O	_	_	_	_	_
13	acetyltransferase	_	O	O	_	_	_	_	_
14	reporter	_	O	O	_	_	_	_	_
15	plasmid	_	O	O	_	_	_	_	_
16	containing	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	promoter	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	but	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	suppressed	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	transcriptional	_	O	O	_	_	_	_	_
37	activity	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	gene	_	O	O	_	_	_	_	_
44	promoter	_	O	O	_	_	_	_	_
45	stimulated	_	O	O	_	_	_	_	_
46	by	_	O	O	_	_	_	_	_
47	PMA	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	LPS	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	Electrophoretic	_	O	O	_	_	_	_	_
2	mobility	_	O	O	_	_	_	_	_
3	shift	_	O	O	_	_	_	_	_
4	assays	_	O	O	_	_	_	_	_
5	showed	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	inhibited	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	NF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	kappaB	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	did	_	O	O	_	_	_	_	_
34	not	_	O	O	_	_	_	_	_
35	affect	_	O	O	_	_	_	_	_
36	NF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	6	_	O	O	_	_	_	_	_
41	activity	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	hand	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	enhanced	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	degradation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	mRNA	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	stability	_	O	O	_	_	_	_	_
21	assay	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	may	_	O	O	_	_	_	_	_
9	inhibit	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	affecting	_	O	O	_	_	_	_	_
20	NF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	kappaB	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	while	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	may	_	O	O	_	_	_	_	_
31	inhibit	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	mRNA	_	O	O	_	_	_	_	_
37	levels	_	O	O	_	_	_	_	_
38	post	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	transcriptionally	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	without	_	O	O	_	_	_	_	_
43	suppressing	_	O	O	_	_	_	_	_
44	promoter	_	O	O	_	_	_	_	_
45	activity	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	conclude	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	inhibit	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	different	_	O	O	_	_	_	_	_
20	mechanisms	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	monocytic	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	lines	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Numerous	_	O	O	_	_	_	_	_
2	cytokines	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	proinflammatory	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	anti	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	inflammatory	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	have	_	O	O	_	_	_	_	_
12	been	_	O	O	_	_	_	_	_
13	detected	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	ST	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	balance	_	O	O	_	_	_	_	_
23	between	_	O	O	_	_	_	_	_
24	these	_	O	O	_	_	_	_	_
25	opposing	_	O	O	_	_	_	_	_
26	cytokine	_	O	O	_	_	_	_	_
27	activities	_	O	O	_	_	_	_	_
28	regulates	_	O	O	_	_	_	_	_
29	disease	_	O	O	_	_	_	_	_
30	severity	_	O	O	_	_	_	_	_
31	[	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Endogenous	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	10	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	produced	_	O	O	_	_	_	_	_
7	mainly	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	macrophages	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	inhibits	_	O	O	_	_	_	_	_
15	proinflammatory	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	ST	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	12	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	regulatory	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	seems	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	restricted	_	O	O	_	_	_	_	_
10	during	_	O	O	_	_	_	_	_
11	chronic	_	O	O	_	_	_	_	_
12	inflammation	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	extracellular	_	O	O	_	_	_	_	_
7	stimulus	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	regulated	_	O	O	_	_	_	_	_
10	kinase	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	38	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	pathways	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	TNF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	inhibits	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	Jak	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	STAT	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	signaling	_	O	O	_	_	_	_	_
35	pathway	_	O	O	_	_	_	_	_
36	shared	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	10	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	6	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	adhered	_	O	O	_	_	_	_	_
47	macrophages	_	O	O	_	_	_	_	_
48	[	_	O	O	_	_	_	_	_
49	13	_	O	O	_	_	_	_	_
50	]	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	More	_	O	O	_	_	_	_	_
2	importantly	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	STAT	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	mostly	_	O	O	_	_	_	_	_
14	undetectable	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	synovial	_	O	O	_	_	_	_	_
18	macrophages	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	impaired	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	signaling	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	probably	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	chronic	_	O	O	_	_	_	_	_
12	exposure	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	immune	_	O	O	_	_	_	_	_
15	complexes	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	vivo	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	because	_	O	O	_	_	_	_	_
20	both	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	surface	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	R	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	induced	_	O	O	_	_	_	_	_
35	Jak	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	activation	_	O	O	_	_	_	_	_
38	are	_	O	O	_	_	_	_	_
39	suppressed	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	IFN	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	gamma	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	primed	_	O	O	_	_	_	_	_
46	macrophages	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	a	_	O	O	_	_	_	_	_
49	protein	_	O	O	_	_	_	_	_
50	kinase	_	O	O	_	_	_	_	_
51	C	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	dependent	_	O	O	_	_	_	_	_
54	pathway	_	O	O	_	_	_	_	_
55	following	_	O	O	_	_	_	_	_
56	ligation	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	the	_	O	O	_	_	_	_	_
59	IgG	_	O	O	_	_	_	_	_
60	Fc	_	O	O	_	_	_	_	_
61	gamma	_	O	O	_	_	_	_	_
62	receptor	_	O	O	_	_	_	_	_
63	[	_	O	O	_	_	_	_	_
64	14	_	O	O	_	_	_	_	_
65	]	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	dendritic	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	synovial	_	O	O	_	_	_	_	_
8	fluids	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	resistant	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	immunoregulatory	_	O	O	_	_	_	_	_
14	effect	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	due	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	decreased	_	O	O	_	_	_	_	_
22	transport	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	intracellular	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	10	_	O	O	_	_	_	_	_
28	R	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	presence	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	proinflammatory	_	O	O	_	_	_	_	_
35	cytokine	_	O	O	_	_	_	_	_
36	stimuli	_	O	O	_	_	_	_	_
37	such	_	O	O	_	_	_	_	_
38	as	_	O	O	_	_	_	_	_
39	TNF	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	alpha	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	granulocyte	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	macrophage	_	O	O	_	_	_	_	_
51	colony	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	stimulating	_	O	O	_	_	_	_	_
54	factor	_	O	O	_	_	_	_	_
55	[	_	O	O	_	_	_	_	_
56	15	_	O	O	_	_	_	_	_
57	]	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	resistance	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	may	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	associated	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	defective	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	dependent	_	O	O	_	_	_	_	_
28	STAT	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	activation	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	but	_	O	O	_	_	_	_	_
33	not	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	10	_	O	O	_	_	_	_	_
38	R	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	expression	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Inhibitory	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	these	_	O	O	_	_	_	_	_
9	inflammatory	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	types	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	therefore	_	O	O	_	_	_	_	_
14	differentially	_	O	O	_	_	_	_	_
15	modulated	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	signal	_	O	O	_	_	_	_	_
19	transduction	_	O	O	_	_	_	_	_
20	level	_	O	O	_	_	_	_	_
21	under	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	inflammatory	_	O	O	_	_	_	_	_
24	environment	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	association	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	impaired	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	found	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	tyrosine	_	O	O	_	_	_	_	_
21	phosphorylated	_	O	O	_	_	_	_	_
22	persistently	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	up	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	hours	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	freshly	_	O	O	_	_	_	_	_
31	isolated	_	O	O	_	_	_	_	_
32	PB	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	ST	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	4	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	T	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	from	_	O	O	_	_	_	_	_
41	RA	_	O	O	_	_	_	_	_
42	patients	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	STAT	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	activated	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	variety	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	cytokines	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	notably	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	family	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	cytokines	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	e	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	g	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	11	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	leukemia	_	O	O	_	_	_	_	_
10	inhibitory	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	oncostatin	_	O	O	_	_	_	_	_
15	M	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	growth	_	O	O	_	_	_	_	_
19	factors	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	addition	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	10	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Of	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	cytokines	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	plays	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	predominant	_	O	O	_	_	_	_	_
11	role	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	eliciting	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	systemic	_	O	O	_	_	_	_	_
16	reaction	_	O	O	_	_	_	_	_
17	such	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	acute	_	O	O	_	_	_	_	_
21	phase	_	O	O	_	_	_	_	_
22	response	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	active	_	O	O	_	_	_	_	_
25	RA	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	due	_	O	O	_	_	_	_	_
28	mainly	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	its	_	O	O	_	_	_	_	_
31	abundance	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	blood	_	O	O	_	_	_	_	_
35	circulation	_	O	O	_	_	_	_	_
36	[	_	O	O	_	_	_	_	_
37	27	_	O	O	_	_	_	_	_
38	]	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	notion	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	major	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	activating	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	contained	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	serum	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	active	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	responsiveness	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	was	_	O	O	_	_	_	_	_
34	suppressed	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	normal	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	4	_	O	O	_	_	_	_	_
39	+	_	O	O	_	_	_	_	_
40	T	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	after	_	O	O	_	_	_	_	_
43	36	_	O	O	_	_	_	_	_
44	hours	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	incubation	_	O	O	_	_	_	_	_
47	with	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	6	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	both	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	sustained	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	resistance	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	inhibition	_	O	O	_	_	_	_	_
19	found	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	may	_	O	O	_	_	_	_	_
28	be	_	O	O	_	_	_	_	_
29	induced	_	O	O	_	_	_	_	_
30	after	_	O	O	_	_	_	_	_
31	chronic	_	O	O	_	_	_	_	_
32	exposure	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	vivo	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	high	_	O	O	_	_	_	_	_
37	concentrations	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	serum	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	possible	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	activity	_	O	O	_	_	_	_	_
11	could	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	constitutively	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	their	_	O	O	_	_	_	_	_
23	own	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	10	_	O	O	_	_	_	_	_
27	secretion	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	leading	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	loss	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	sensitivity	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	exogenous	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	10	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	because	_	O	O	_	_	_	_	_
42	RA	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	4	_	O	O	_	_	_	_	_
45	+	_	O	O	_	_	_	_	_
46	T	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	in	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	ST	_	O	O	_	_	_	_	_
51	are	_	O	O	_	_	_	_	_
52	capable	_	O	O	_	_	_	_	_
53	of	_	O	O	_	_	_	_	_
54	producing	_	O	O	_	_	_	_	_
55	significant	_	O	O	_	_	_	_	_
56	levels	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	IL	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	10	_	O	O	_	_	_	_	_
61	[	_	O	O	_	_	_	_	_
62	34	_	O	O	_	_	_	_	_
63	]	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	isolated	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	ST	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	also	_	O	O	_	_	_	_	_
13	showed	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	defect	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	induced	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	signaling	_	O	O	_	_	_	_	_
26	pathway	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	most	_	O	O	_	_	_	_	_
4	probable	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	resistance	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	can	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	even	_	O	O	_	_	_	_	_
21	augmented	_	O	O	_	_	_	_	_
22	after	_	O	O	_	_	_	_	_
23	migration	_	O	O	_	_	_	_	_
24	into	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	inflamed	_	O	O	_	_	_	_	_
27	ST	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	because	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	highly	_	O	O	_	_	_	_	_
35	concentrated	_	O	O	_	_	_	_	_
36	compared	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	blood	_	O	O	_	_	_	_	_
40	level	_	O	O	_	_	_	_	_
41	[	_	O	O	_	_	_	_	_
42	27	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	involvement	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	other	_	O	O	_	_	_	_	_
8	essential	_	O	O	_	_	_	_	_
9	proinflammatory	_	O	O	_	_	_	_	_
10	cytokines	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	this	_	O	O	_	_	_	_	_
13	process	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	suggested	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	our	_	O	O	_	_	_	_	_
18	preliminary	_	O	O	_	_	_	_	_
19	experiments	_	O	O	_	_	_	_	_
20	demonstrating	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	10	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	mediated	_	O	O	_	_	_	_	_
27	IFN	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	gamma	_	O	O	_	_	_	_	_
30	inhibition	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	T	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	was	_	O	O	_	_	_	_	_
38	reduced	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	pretreatment	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	beta	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	TNF	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	alpha	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	although	_	O	O	_	_	_	_	_
52	less	_	O	O	_	_	_	_	_
53	effectively	_	O	O	_	_	_	_	_
54	than	_	O	O	_	_	_	_	_
55	by	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	6	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	data	_	O	O	_	_	_	_	_
61	not	_	O	O	_	_	_	_	_
62	shown	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IFN	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	produced	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	themselves	_	O	O	_	_	_	_	_
18	could	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	responsible	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	impaired	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	signaling	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	ST	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	because	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	infiltrates	_	O	O	_	_	_	_	_
36	produce	_	O	O	_	_	_	_	_
37	both	_	O	O	_	_	_	_	_
38	cytokines	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	34	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	35	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	an	_	O	O	_	_	_	_	_
3	autocrine	_	O	O	_	_	_	_	_
4	fashion	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	may	_	O	O	_	_	_	_	_
10	persistently	_	O	O	_	_	_	_	_
11	stimulate	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IFN	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	can	_	O	O	_	_	_	_	_
20	induce	_	O	O	_	_	_	_	_
21	SOCS	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	protein	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	crosstalk	_	O	O	_	_	_	_	_
27	inhibitor	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	10	_	O	O	_	_	_	_	_
32	signaling	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	32	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	inhibitory	_	O	O	_	_	_	_	_
7	effect	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	10	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	therefore	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	modulated	_	O	O	_	_	_	_	_
16	complicatedly	_	O	O	_	_	_	_	_
17	upon	_	O	O	_	_	_	_	_
18	exposure	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	inflammatory	_	O	O	_	_	_	_	_
22	environment	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	RA	_	O	O	_	_	_	_	_
25	joints	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	where	_	O	O	_	_	_	_	_
28	many	_	O	O	_	_	_	_	_
29	cytokines	_	O	O	_	_	_	_	_
30	are	_	O	O	_	_	_	_	_
31	present	_	O	O	_	_	_	_	_
32	substantially	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	10	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_



1	Culture	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_

1	PB	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	populations	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	resuspended	_	O	O	_	_	_	_	_
11	at	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	density	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	x	_	O	O	_	_	_	_	_
17	106	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	ml	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	culture	_	O	O	_	_	_	_	_
23	medium	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	%	_	O	O	_	_	_	_	_
27	FCS	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	0	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	5	_	O	O	_	_	_	_	_
33	ml	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	suspensions	_	O	O	_	_	_	_	_
36	were	_	O	O	_	_	_	_	_
37	dispensed	_	O	O	_	_	_	_	_
38	into	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	wells	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	24	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	well	_	O	O	_	_	_	_	_
45	microtiter	_	O	O	_	_	_	_	_
46	plates	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	Coster	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	coated	_	O	O	_	_	_	_	_
51	with	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	mug	_	O	O	_	_	_	_	_
54	/	_	O	O	_	_	_	_	_
55	ml	_	O	O	_	_	_	_	_
56	anti	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	CD	_	O	O	_	_	_	_	_
59	3	_	O	O	_	_	_	_	_
60	mAb	_	O	O	_	_	_	_	_
61	(	_	O	O	_	_	_	_	_
62	Immunotech	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	Marseille	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	France	_	O	O	_	_	_	_	_
67	)	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	mug	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	ml	_	O	O	_	_	_	_	_
10	anti	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	28	_	O	O	_	_	_	_	_
14	mAb	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	Immunotech	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	presence	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	absence	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	indicated	_	O	O	_	_	_	_	_
26	concentrations	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	10	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	Becton	_	O	O	_	_	_	_	_
33	Dickinson	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	San	_	O	O	_	_	_	_	_
36	Jose	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	CA	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	USA	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	at	_	O	O	_	_	_	_	_
43	37	_	O	O	_	_	_	_	_
44	degreesC	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	humidified	_	O	O	_	_	_	_	_
48	atmosphere	_	O	O	_	_	_	_	_
49	containing	_	O	O	_	_	_	_	_
50	5	_	O	O	_	_	_	_	_
51	%	_	O	O	_	_	_	_	_
52	CO	_	O	O	_	_	_	_	_
53	2	_	O	O	_	_	_	_	_
54	[	_	O	O	_	_	_	_	_
55	28	_	O	O	_	_	_	_	_
56	]	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	Culture	_	O	O	_	_	_	_	_
2	supernatants	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	collected	_	O	O	_	_	_	_	_
5	36	_	O	O	_	_	_	_	_
6	hours	_	O	O	_	_	_	_	_
7	later	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	free	_	O	O	_	_	_	_	_
12	samples	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	stored	_	O	O	_	_	_	_	_
15	at	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	30	_	O	O	_	_	_	_	_
18	degreesC	_	O	O	_	_	_	_	_
19	until	_	O	O	_	_	_	_	_
20	cytokine	_	O	O	_	_	_	_	_
21	assay	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effect	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	responsiveness	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	from	_	O	O	_	_	_	_	_
25	healthy	_	O	O	_	_	_	_	_
26	controls	_	O	O	_	_	_	_	_
27	were	_	O	O	_	_	_	_	_
28	incubated	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	culture	_	O	O	_	_	_	_	_
31	medium	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	10	_	O	O	_	_	_	_	_
34	%	_	O	O	_	_	_	_	_
35	FCS	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	presence	_	O	O	_	_	_	_	_
39	or	_	O	O	_	_	_	_	_
40	absence	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	10	_	O	O	_	_	_	_	_
43	ng	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	ml	_	O	O	_	_	_	_	_
46	IL	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	6	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	Becton	_	O	O	_	_	_	_	_
51	Dickinson	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	for	_	O	O	_	_	_	_	_
54	36	_	O	O	_	_	_	_	_
55	hours	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	then	_	O	O	_	_	_	_	_
4	stimulated	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	36	_	O	O	_	_	_	_	_
7	hours	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	mAb	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	anti	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	28	_	O	O	_	_	_	_	_
19	mAb	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	presence	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	absence	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	ng	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	ml	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Culture	_	O	O	_	_	_	_	_
2	supernatants	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	measured	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	IFN	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	gamma	_	O	O	_	_	_	_	_
9	concentrations	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_



1	Regulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	interferon	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_


1	Interferon	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	gamma	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	also	_	O	O	_	_	_	_	_
11	known	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	type	_	O	O	_	_	_	_	_
14	II	_	O	O	_	_	_	_	_
15	interferon	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	important	_	O	O	_	_	_	_	_
20	immunoregulatory	_	O	O	_	_	_	_	_
21	gene	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	has	_	O	O	_	_	_	_	_
24	multiple	_	O	O	_	_	_	_	_
25	effects	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	development	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	maturation	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	function	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	immune	_	O	O	_	_	_	_	_
37	system	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	IFN	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	expressed	_	O	O	_	_	_	_	_
9	predominantly	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	large	_	O	O	_	_	_	_	_
15	granular	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	IFN	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	gamma	_	O	O	_	_	_	_	_
5	mRNA	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	inhibited	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	these	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	types	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	wide	_	O	O	_	_	_	_	_
17	variety	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	extracellular	_	O	O	_	_	_	_	_
20	signals	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	thus	_	O	O	_	_	_	_	_
23	implicating	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	number	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	diverse	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	yet	_	O	O	_	_	_	_	_
30	convergent	_	O	O	_	_	_	_	_
31	signal	_	O	O	_	_	_	_	_
32	transduction	_	O	O	_	_	_	_	_
33	pathways	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	its	_	O	O	_	_	_	_	_
36	transcriptional	_	O	O	_	_	_	_	_
37	control	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	review	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	I	_	O	O	_	_	_	_	_
6	describe	_	O	O	_	_	_	_	_
7	how	_	O	O	_	_	_	_	_
8	DNA	_	O	O	_	_	_	_	_
9	methylation	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	specific	_	O	O	_	_	_	_	_
12	DNA	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	proteins	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	regulate	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IFN	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	gamma	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	response	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	extracellular	_	O	O	_	_	_	_	_
28	signals	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Characterization	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	43	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	leukosialin	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	pathway	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	inducing	_	O	O	_	_	_	_	_
13	apoptosis	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	lymphoblastoid	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	monoclonal	_	O	O	_	_	_	_	_
3	antibody	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	mAb	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	J	_	O	O	_	_	_	_	_
8	393	_	O	O	_	_	_	_	_
9	induces	_	O	O	_	_	_	_	_
10	apoptosis	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	Jurkat	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	NH	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	terminal	_	O	O	_	_	_	_	_
5	amino	_	O	O	_	_	_	_	_
6	acid	_	O	O	_	_	_	_	_
7	sequence	_	O	O	_	_	_	_	_
8	analysis	_	O	O	_	_	_	_	_
9	identified	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	140	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	kDa	_	O	O	_	_	_	_	_
14	surface	_	O	O	_	_	_	_	_
15	antigen	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	mAb	_	O	O	_	_	_	_	_
18	J	_	O	O	_	_	_	_	_
19	393	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	43	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	leukosialin	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	major	_	O	O	_	_	_	_	_
28	sialoglycoprotein	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	leukocytes	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	While	_	O	O	_	_	_	_	_
2	Jurkat	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	co	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	discrete	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	surface	_	O	O	_	_	_	_	_
12	isoforms	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	43	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	recognized	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	mAb	_	O	O	_	_	_	_	_
20	J	_	O	O	_	_	_	_	_
21	393	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	mAb	_	O	O	_	_	_	_	_
24	G	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	respectively	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	only	_	O	O	_	_	_	_	_
32	J	_	O	O	_	_	_	_	_
33	393	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	43	_	O	O	_	_	_	_	_
37	signaled	_	O	O	_	_	_	_	_
38	apoptosis	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	J	_	O	O	_	_	_	_	_
2	393	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	43	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	hyposialylated	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	bearing	_	O	O	_	_	_	_	_
13	predominantly	_	O	O	_	_	_	_	_
14	O	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	linked	_	O	O	_	_	_	_	_
17	monosaccharide	_	O	O	_	_	_	_	_
18	glycans	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	whereas	_	O	O	_	_	_	_	_
21	G	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	43	_	O	O	_	_	_	_	_
28	bore	_	O	O	_	_	_	_	_
29	complex	_	O	O	_	_	_	_	_
30	sialylated	_	O	O	_	_	_	_	_
31	tetra	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	hexasaccharide	_	O	O	_	_	_	_	_
35	chains	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	soluble	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	bivalent	_	O	O	_	_	_	_	_
6	mAb	_	O	O	_	_	_	_	_
7	J	_	O	O	_	_	_	_	_
8	393	_	O	O	_	_	_	_	_
9	killed	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	50	_	O	O	_	_	_	_	_
13	%	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	population	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	while	_	O	O	_	_	_	_	_
20	concomitant	_	O	O	_	_	_	_	_
21	engagement	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	either	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	TcR	_	O	O	_	_	_	_	_
29	complex	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	integrins	_	O	O	_	_	_	_	_
33	CD	_	O	O	_	_	_	_	_
34	18	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	29	_	O	O	_	_	_	_	_
38	significantly	_	O	O	_	_	_	_	_
39	potentiated	_	O	O	_	_	_	_	_
40	this	_	O	O	_	_	_	_	_
41	effect	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Jurkat	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	mAb	_	O	O	_	_	_	_	_
7	J	_	O	O	_	_	_	_	_
8	393	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	tyrosine	_	O	O	_	_	_	_	_
11	phosphorylation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	specific	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	substrates	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	underwent	_	O	O	_	_	_	_	_
18	hyperphosphorylation	_	O	O	_	_	_	_	_
19	upon	_	O	O	_	_	_	_	_
20	antigen	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	costimulation	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Tyrosine	_	O	O	_	_	_	_	_
2	kinase	_	O	O	_	_	_	_	_
3	inhibition	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	herbimycin	_	O	O	_	_	_	_	_
6	A	_	O	O	_	_	_	_	_
7	diminished	_	O	O	_	_	_	_	_
8	J	_	O	O	_	_	_	_	_
9	393	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	43	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	apoptosis	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	whereas	_	O	O	_	_	_	_	_
18	inhibition	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	phosphotyrosine	_	O	O	_	_	_	_	_
21	phosphatase	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	bis	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	maltolato	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	oxovanadium	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	IV	_	O	O	_	_	_	_	_
31	enhanced	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	death	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Signal	_	O	O	_	_	_	_	_
2	transduction	_	O	O	_	_	_	_	_
3	through	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	kinase	_	O	O	_	_	_	_	_
6	activation	_	O	O	_	_	_	_	_
7	may	_	O	O	_	_	_	_	_
8	lead	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	altered	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	J	_	O	O	_	_	_	_	_
16	393	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	43	_	O	O	_	_	_	_	_
20	ligation	_	O	O	_	_	_	_	_
21	prompted	_	O	O	_	_	_	_	_
22	decreases	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	nuclear	_	O	O	_	_	_	_	_
26	localization	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	transcriptional	_	O	O	_	_	_	_	_
30	regulatory	_	O	O	_	_	_	_	_
31	protein	_	O	O	_	_	_	_	_
32	NF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	kappaB	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	proteins	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	interferon	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	inducible	_	O	O	_	_	_	_	_
42	regulatory	_	O	O	_	_	_	_	_
43	element	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	peripheral	_	O	O	_	_	_	_	_
3	blood	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	express	_	O	O	_	_	_	_	_
8	cryptic	_	O	O	_	_	_	_	_
9	epitopes	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	mAb	_	O	O	_	_	_	_	_
12	J	_	O	O	_	_	_	_	_
13	393	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	these	_	O	O	_	_	_	_	_
16	findings	_	O	O	_	_	_	_	_
17	demonstrate	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	existence	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	tightly	_	O	O	_	_	_	_	_
23	regulated	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	43	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	mediated	_	O	O	_	_	_	_	_
28	pathway	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	inducing	_	O	O	_	_	_	_	_
31	apoptosis	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	human	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	lineages	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_


1	Immune	_	O	O	_	_	_	_	_
2	functions	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	clinical	_	O	O	_	_	_	_	_
5	parameters	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	hormone	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	status	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	breast	_	O	O	_	_	_	_	_
12	cancer	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	carried	_	O	O	_	_	_	_	_
4	out	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	detailed	_	O	O	_	_	_	_	_
7	analysis	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cellular	_	O	O	_	_	_	_	_
11	immune	_	O	O	_	_	_	_	_
12	functions	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	breast	_	O	O	_	_	_	_	_
15	cancer	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	comparison	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	healthy	_	O	O	_	_	_	_	_
21	controls	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	possible	_	O	O	_	_	_	_	_
3	correlation	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	immune	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	clinical	_	O	O	_	_	_	_	_
8	parameters	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	analysed	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	50	_	O	O	_	_	_	_	_
13	breast	_	O	O	_	_	_	_	_
14	cancer	_	O	O	_	_	_	_	_
15	patients	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Immune	_	O	O	_	_	_	_	_
2	parameters	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	natural	_	O	O	_	_	_	_	_
5	killer	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	lymphocyte	_	O	O	_	_	_	_	_
10	functions	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	numbers	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	circulating	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	analysed	_	O	O	_	_	_	_	_
20	against	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	clinical	_	O	O	_	_	_	_	_
23	parameters	_	O	O	_	_	_	_	_
24	comprising	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	tumour	_	O	O	_	_	_	_	_
27	burden	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	stage	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	disease	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	hormone	_	O	O	_	_	_	_	_
39	receptors	_	O	O	_	_	_	_	_
40	on	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	tumour	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	order	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	analyse	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	immune	_	O	O	_	_	_	_	_
7	function	_	O	O	_	_	_	_	_
8	data	_	O	O	_	_	_	_	_
9	effectively	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	low	_	O	O	_	_	_	_	_
12	responders	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	identified	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	stringent	_	O	O	_	_	_	_	_
17	cut	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	off	_	O	O	_	_	_	_	_
20	values	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Considerably	_	O	O	_	_	_	_	_
2	higher	_	O	O	_	_	_	_	_
3	proportions	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	low	_	O	O	_	_	_	_	_
6	responders	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	among	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	patient	_	O	O	_	_	_	_	_
12	population	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Elevated	_	O	O	_	_	_	_	_
2	numbers	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	circulating	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	directed	_	O	O	_	_	_	_	_
12	cytolysis	_	O	O	_	_	_	_	_
13	correlated	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	oestrogen	_	O	O	_	_	_	_	_
19	receptors	_	O	O	_	_	_	_	_
20	independently	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	clinical	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	histological	_	O	O	_	_	_	_	_
26	parameters	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	HIV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	LTR	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	40	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	activated	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	dependent	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	40	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	stimulated	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	highly	_	O	O	_	_	_	_	_
10	permissive	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	productive	_	O	O	_	_	_	_	_
14	infection	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	immunodeficiency	_	O	O	_	_	_	_	_
19	virus	_	O	O	_	_	_	_	_
20	type	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	factors	_	O	O	_	_	_	_	_
7	involved	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	HIV	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	LTR	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	which	_	O	O	_	_	_	_	_
18	contains	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	transcriptional	_	O	O	_	_	_	_	_
21	control	_	O	O	_	_	_	_	_
22	elements	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	virus	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	are	_	O	O	_	_	_	_	_
28	unknown	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Transient	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	plasmids	_	O	O	_	_	_	_	_
6	containing	_	O	O	_	_	_	_	_
7	deleted	_	O	O	_	_	_	_	_
8	parts	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	LTR	_	O	O	_	_	_	_	_
12	region	_	O	O	_	_	_	_	_
13	linked	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	reporter	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	showed	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	kappaB	_	O	O	_	_	_	_	_
24	binding	_	O	O	_	_	_	_	_
25	site	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	essential	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	HIV	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	LTR	_	O	O	_	_	_	_	_
33	activity	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	40	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	stimulated	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	lymphocytes	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	electrophoretic	_	O	O	_	_	_	_	_
5	mobility	_	O	O	_	_	_	_	_
6	shift	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	supershift	_	O	O	_	_	_	_	_
9	assays	_	O	O	_	_	_	_	_
10	revealed	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	important	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappaB	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	composed	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	least	_	O	O	_	_	_	_	_
22	p	_	O	O	_	_	_	_	_
23	50	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	65	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	c	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	Rel	_	O	O	_	_	_	_	_
32	NF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	kappaB	_	O	O	_	_	_	_	_
35	subunits	_	O	O	_	_	_	_	_
36	was	_	O	O	_	_	_	_	_
37	present	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	nuclei	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	CD	_	O	O	_	_	_	_	_
42	40	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	stimulated	_	O	O	_	_	_	_	_
45	B	_	O	O	_	_	_	_	_
46	cells	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	confirm	_	O	O	_	_	_	_	_
4	at	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	molecular	_	O	O	_	_	_	_	_
7	level	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	ability	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	HIV	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	replicate	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	this	_	O	O	_	_	_	_	_
22	activity	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	strongly	_	O	O	_	_	_	_	_
25	associated	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kappaB	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	GP	_	O	O	_	_	_	_	_
2	modulated	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	TSST	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	new	_	O	O	_	_	_	_	_
15	NFkappaB	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	site	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	promoter	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	enhanced	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	LPS	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	TSST	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	when	_	O	O	_	_	_	_	_
16	compared	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	LPS	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	TSST	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	GP	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	LPS	_	O	O	_	_	_	_	_
29	calc	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	or	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	calc	_	O	O	_	_	_	_	_
8	.,	_	O	O	_	_	_	_	_
9	respectively	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	*	_	O	O	_	_	_	_	_
12	=	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	<	_	O	O	_	_	_	_	_
15	0	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_
17	05	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	**	_	O	O	_	_	_	_	_
20	=	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	<	_	O	O	_	_	_	_	_
23	0	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	01	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Medium	_	O	O	_	_	_	_	_
2	control	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	set	_	O	O	_	_	_	_	_
6	equal	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	SEM	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	n	_	O	O	_	_	_	_	_
15	=	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	DNA	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	assessed	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	EMSA	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	see	_	O	O	_	_	_	_	_
9	methods	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_



1	In	_	O	O	_	_	_	_	_
2	vivo	_	O	O	_	_	_	_	_
3	modulation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	glucocorticoid	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	inhaled	_	O	O	_	_	_	_	_
10	fluticasone	_	O	O	_	_	_	_	_
11	propionate	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	bronchial	_	O	O	_	_	_	_	_
14	mucosa	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	blood	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	subjects	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	mild	_	O	O	_	_	_	_	_
22	asthma	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	vivo	_	O	O	_	_	_	_	_
5	regulation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	GR	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	glucocorticoids	_	O	O	_	_	_	_	_
15	provides	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	means	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	modulating	_	O	O	_	_	_	_	_
20	sensitivity	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	targeted	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	OBJECTIVE	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	We	_	O	O	_	_	_	_	_
4	sought	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	determine	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	vivo	_	O	O	_	_	_	_	_
10	modulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	GR	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	fluticasone	_	O	O	_	_	_	_	_
17	propionate	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	FP	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	subjects	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	mild	_	O	O	_	_	_	_	_
25	asthma	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Ten	_	O	O	_	_	_	_	_
4	atopic	_	O	O	_	_	_	_	_
5	asthmatic	_	O	O	_	_	_	_	_
6	subjects	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	treated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	FP	_	O	O	_	_	_	_	_
11	250	_	O	O	_	_	_	_	_
12	microg	_	O	O	_	_	_	_	_
13	twice	_	O	O	_	_	_	_	_
14	daily	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	4	_	O	O	_	_	_	_	_
17	weeks	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Before	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	after	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	underwent	_	O	O	_	_	_	_	_
9	fiberoptic	_	O	O	_	_	_	_	_
10	bronchoscopy	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	endobronchial	_	O	O	_	_	_	_	_
13	biopsy	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	sampling	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	venous	_	O	O	_	_	_	_	_
18	blood	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	measurements	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	GR	_	O	O	_	_	_	_	_
23	mRNA	_	O	O	_	_	_	_	_
24	levels	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	solution	_	O	O	_	_	_	_	_
3	hybridization	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	used	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	quantitative	_	O	O	_	_	_	_	_
9	analysis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	GR	_	O	O	_	_	_	_	_
12	mRNA	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	24	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	hour	_	O	O	_	_	_	_	_
8	urinary	_	O	O	_	_	_	_	_
9	cortisol	_	O	O	_	_	_	_	_
10	excretion	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	adrenocorticotropic	_	O	O	_	_	_	_	_
14	hormone	_	O	O	_	_	_	_	_
15	test	_	O	O	_	_	_	_	_
16	before	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	after	_	O	O	_	_	_	_	_
19	treatment	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	FP	_	O	O	_	_	_	_	_
22	were	_	O	O	_	_	_	_	_
23	performed	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	A	_	O	O	_	_	_	_	_
4	high	_	O	O	_	_	_	_	_
5	interindividual	_	O	O	_	_	_	_	_
6	variation	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	GR	_	O	O	_	_	_	_	_
9	mRNA	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	seen	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	detected	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	significant	_	O	O	_	_	_	_	_
7	reduction	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	GR	_	O	O	_	_	_	_	_
11	mRNA	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	endobronchial	_	O	O	_	_	_	_	_
16	biopsy	_	O	O	_	_	_	_	_
17	specimens	_	O	O	_	_	_	_	_
18	after	_	O	O	_	_	_	_	_
19	FP	_	O	O	_	_	_	_	_
20	treatment	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	36	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	23	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	25	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	0	_	O	O	_	_	_	_	_
35	+	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	10	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	9	_	O	O	_	_	_	_	_
41	amol	_	O	O	_	_	_	_	_
42	GR	_	O	O	_	_	_	_	_
43	mRNA	_	O	O	_	_	_	_	_
44	/	_	O	O	_	_	_	_	_
45	microg	_	O	O	_	_	_	_	_
46	RNA	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	respectively	_	O	O	_	_	_	_	_
49	;	_	O	O	_	_	_	_	_
50	P	_	O	O	_	_	_	_	_
51	<	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_
53	01	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	peripheral	_	O	O	_	_	_	_	_
4	blood	_	O	O	_	_	_	_	_
5	lymphocytes	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	even	_	O	O	_	_	_	_	_
8	more	_	O	O	_	_	_	_	_
9	striking	_	O	O	_	_	_	_	_
10	downregulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	GR	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	its	_	O	O	_	_	_	_	_
16	cognate	_	O	O	_	_	_	_	_
17	ligand	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	documented	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	30	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	26	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	5	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	8	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	8	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	amol	_	O	O	_	_	_	_	_
39	GR	_	O	O	_	_	_	_	_
40	mRNA	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	microg	_	O	O	_	_	_	_	_
43	RNA	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	respectively	_	O	O	_	_	_	_	_
46	;	_	O	O	_	_	_	_	_
47	P	_	O	O	_	_	_	_	_
48	<	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_
50	001	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	possibly	_	O	O	_	_	_	_	_
54	reflecting	_	O	O	_	_	_	_	_
55	differences	_	O	O	_	_	_	_	_
56	in	_	O	O	_	_	_	_	_
57	glucocorticoid	_	O	O	_	_	_	_	_
58	sensitivity	_	O	O	_	_	_	_	_
59	between	_	O	O	_	_	_	_	_
60	tissues	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	small	_	O	O	_	_	_	_	_
3	but	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	reduction	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	24	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	hour	_	O	O	_	_	_	_	_
11	urinary	_	O	O	_	_	_	_	_
12	cortisol	_	O	O	_	_	_	_	_
13	excretion	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	observed	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	233	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	109	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	157	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	66	_	O	O	_	_	_	_	_
28	nmol	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	L	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	respectively	_	O	O	_	_	_	_	_
33	;	_	O	O	_	_	_	_	_
34	P	_	O	O	_	_	_	_	_
35	<	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	01	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	whereas	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	feedback	_	O	O	_	_	_	_	_
43	regulation	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	glucocorticoid	_	O	O	_	_	_	_	_
46	synthesis	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	means	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	hypothalamic	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	pituitary	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	adrenal	_	O	O	_	_	_	_	_
56	axis	_	O	O	_	_	_	_	_
57	as	_	O	O	_	_	_	_	_
58	assessed	_	O	O	_	_	_	_	_
59	by	_	O	O	_	_	_	_	_
60	the	_	O	O	_	_	_	_	_
61	adrenocorticotropic	_	O	O	_	_	_	_	_
62	hormone	_	O	O	_	_	_	_	_
63	test	_	O	O	_	_	_	_	_
64	remained	_	O	O	_	_	_	_	_
65	normal	_	O	O	_	_	_	_	_
66	after	_	O	O	_	_	_	_	_
67	treatment	_	O	O	_	_	_	_	_
68	with	_	O	O	_	_	_	_	_
69	FP	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	CONCLUSION	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	study	_	O	O	_	_	_	_	_
8	confirm	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	potency	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	inhaled	_	O	O	_	_	_	_	_
14	corticosteroid	_	O	O	_	_	_	_	_
15	FP	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	provide	_	O	O	_	_	_	_	_
18	evidence	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	considerable	_	O	O	_	_	_	_	_
22	tissue	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	specific	_	O	O	_	_	_	_	_
25	interindividual	_	O	O	_	_	_	_	_
26	variation	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	GR	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Functional	_	O	O	_	_	_	_	_
2	roles	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	vivo	_	O	O	_	_	_	_	_
6	footprinted	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	motifs	_	O	O	_	_	_	_	_
9	within	_	O	O	_	_	_	_	_
10	an	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	globin	_	O	O	_	_	_	_	_
14	enhancer	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Erythroid	_	O	O	_	_	_	_	_
2	lineage	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	developmental	_	O	O	_	_	_	_	_
5	stage	_	O	O	_	_	_	_	_
6	specificities	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_


1	Transcriptional	_	O	O	_	_	_	_	_
2	regulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	like	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	genes	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	embryonic	_	O	O	_	_	_	_	_
13	zeta	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	adult	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	during	_	O	O	_	_	_	_	_
20	erythroid	_	O	O	_	_	_	_	_
21	development	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	distal	_	O	O	_	_	_	_	_
27	enhancer	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	HS	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	40	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Previous	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	DNA	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	studies	_	O	O	_	_	_	_	_
7	have	_	O	O	_	_	_	_	_
8	shown	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	HS	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	40	_	O	O	_	_	_	_	_
13	consists	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	multiple	_	O	O	_	_	_	_	_
16	nuclear	_	O	O	_	_	_	_	_
17	factor	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	motifs	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	occupied	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	vivo	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	erythroid	_	O	O	_	_	_	_	_
28	lineage	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	developmental	_	O	O	_	_	_	_	_
32	stage	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	specific	_	O	O	_	_	_	_	_
35	manner	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	systematically	_	O	O	_	_	_	_	_
4	analyzed	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	functional	_	O	O	_	_	_	_	_
7	roles	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	these	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	motifs	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	HS	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	40	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	site	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	directed	_	O	O	_	_	_	_	_
21	mutagenesis	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	transient	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	assay	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	erythroid	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	cultures	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Three	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	HS	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	40	_	O	O	_	_	_	_	_
7	enhancer	_	O	O	_	_	_	_	_
8	motifs	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	'	_	O	O	_	_	_	_	_
12	NF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	E	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	AP	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	GT	_	O	O	_	_	_	_	_
21	II	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	GATA	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	c	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	positively	_	O	O	_	_	_	_	_
32	regulate	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	zeta	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	globin	_	O	O	_	_	_	_	_
38	promoter	_	O	O	_	_	_	_	_
39	activity	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	embryonic	_	O	O	_	_	_	_	_
42	/	_	O	O	_	_	_	_	_
43	fetal	_	O	O	_	_	_	_	_
44	erythroid	_	O	O	_	_	_	_	_
45	K	_	O	O	_	_	_	_	_
46	562	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	adult	_	O	O	_	_	_	_	_
51	alpha	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	globin	_	O	O	_	_	_	_	_
54	promoter	_	O	O	_	_	_	_	_
55	activity	_	O	O	_	_	_	_	_
56	in	_	O	O	_	_	_	_	_
57	adult	_	O	O	_	_	_	_	_
58	erythroid	_	O	O	_	_	_	_	_
59	MEL	_	O	O	_	_	_	_	_
60	cells	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	hand	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	'	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	E	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	AP	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	motif	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	able	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	exert	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	positive	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	negative	_	O	O	_	_	_	_	_
25	regulatory	_	O	O	_	_	_	_	_
26	effects	_	O	O	_	_	_	_	_
27	on	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	zeta	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	globin	_	O	O	_	_	_	_	_
33	promoter	_	O	O	_	_	_	_	_
34	activity	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	K	_	O	O	_	_	_	_	_
37	562	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	this	_	O	O	_	_	_	_	_
42	dual	_	O	O	_	_	_	_	_
43	function	_	O	O	_	_	_	_	_
44	appears	_	O	O	_	_	_	_	_
45	to	_	O	O	_	_	_	_	_
46	be	_	O	O	_	_	_	_	_
47	modulated	_	O	O	_	_	_	_	_
48	through	_	O	O	_	_	_	_	_
49	differential	_	O	O	_	_	_	_	_
50	binding	_	O	O	_	_	_	_	_
51	of	_	O	O	_	_	_	_	_
52	the	_	O	O	_	_	_	_	_
53	ubiquitous	_	O	O	_	_	_	_	_
54	AP	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	factors	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	the	_	O	O	_	_	_	_	_
59	erythroid	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	enriched	_	O	O	_	_	_	_	_
62	NF	_	O	O	_	_	_	_	_
63	-	_	O	O	_	_	_	_	_
64	E	_	O	O	_	_	_	_	_
65	2	_	O	O	_	_	_	_	_
66	factor	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_

1	Mutation	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	GATA	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	d	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	motif	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	exhibits	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	adult	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	specific	_	O	O	_	_	_	_	_
19	genomic	_	O	O	_	_	_	_	_
20	footprint	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	decreases	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	HS	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	40	_	O	O	_	_	_	_	_
27	enhancer	_	O	O	_	_	_	_	_
28	function	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	dimethyl	_	O	O	_	_	_	_	_
31	sulfoxide	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	induced	_	O	O	_	_	_	_	_
34	MEL	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	but	_	O	O	_	_	_	_	_
37	not	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	K	_	O	O	_	_	_	_	_
40	562	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	defined	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	regulatory	_	O	O	_	_	_	_	_
7	roles	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	different	_	O	O	_	_	_	_	_
11	HS	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	40	_	O	O	_	_	_	_	_
14	motifs	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	remarkable	_	O	O	_	_	_	_	_
3	correlation	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	genomic	_	O	O	_	_	_	_	_
6	footprinting	_	O	O	_	_	_	_	_
7	data	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	mutagenesis	_	O	O	_	_	_	_	_
11	results	_	O	O	_	_	_	_	_
12	also	_	O	O	_	_	_	_	_
13	suggests	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	lineage	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	developmental	_	O	O	_	_	_	_	_
21	stage	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	specific	_	O	O	_	_	_	_	_
24	regulation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	like	_	O	O	_	_	_	_	_
30	globin	_	O	O	_	_	_	_	_
31	promoters	_	O	O	_	_	_	_	_
32	is	_	O	O	_	_	_	_	_
33	indeed	_	O	O	_	_	_	_	_
34	modulated	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	stable	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	specific	_	O	O	_	_	_	_	_
40	nuclear	_	O	O	_	_	_	_	_
41	factors	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	vivo	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	GP	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	NFkappaB	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	NFAT	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	NFIL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	promoter	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	A	_	O	O	_	_	_	_	_
4	representative	_	O	O	_	_	_	_	_
5	autoradiogram	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	lane	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	:	_	O	O	_	_	_	_	_
10	control	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	lane	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	:	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	lane	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	:	_	O	O	_	_	_	_	_
20	GP	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	unlabeled	_	O	O	_	_	_	_	_
23	mutated	_	O	O	_	_	_	_	_
24	NFATP	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	oligo	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	lane	_	O	O	_	_	_	_	_
31	4	_	O	O	_	_	_	_	_
32	:	_	O	O	_	_	_	_	_
33	GP	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	CAPE	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	lane	_	O	O	_	_	_	_	_
38	5	_	O	O	_	_	_	_	_
39	:	_	O	O	_	_	_	_	_
40	GP	_	O	O	_	_	_	_	_
41	+	_	O	O	_	_	_	_	_
42	CyA	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	lane	_	O	O	_	_	_	_	_
45	6	_	O	O	_	_	_	_	_
46	:	_	O	O	_	_	_	_	_
47	GP	_	O	O	_	_	_	_	_
48	+	_	O	O	_	_	_	_	_
49	CHX	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	lane	_	O	O	_	_	_	_	_
52	7	_	O	O	_	_	_	_	_
53	:	_	O	O	_	_	_	_	_
54	GP	_	O	O	_	_	_	_	_
55	+	_	O	O	_	_	_	_	_
56	unlabeled	_	O	O	_	_	_	_	_
57	NFATP	_	O	O	_	_	_	_	_
58	2	_	O	O	_	_	_	_	_
59	/	_	O	O	_	_	_	_	_
60	3	_	O	O	_	_	_	_	_
61	oligo	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	lane	_	O	O	_	_	_	_	_
64	8	_	O	O	_	_	_	_	_
65	:	_	O	O	_	_	_	_	_
66	water	_	O	O	_	_	_	_	_
67	)	_	O	O	_	_	_	_	_
68	as	_	O	O	_	_	_	_	_
69	well	_	O	O	_	_	_	_	_
70	as	_	O	O	_	_	_	_	_
71	a	_	O	O	_	_	_	_	_
72	graphical	_	O	O	_	_	_	_	_
73	summary	_	O	O	_	_	_	_	_
74	for	_	O	O	_	_	_	_	_
75	the	_	O	O	_	_	_	_	_
76	NFATP	_	O	O	_	_	_	_	_
77	2	_	O	O	_	_	_	_	_
78	/	_	O	O	_	_	_	_	_
79	3	_	O	O	_	_	_	_	_
80	site	_	O	O	_	_	_	_	_
81	,	_	O	O	_	_	_	_	_
82	depicting	_	O	O	_	_	_	_	_
83	a	_	O	O	_	_	_	_	_
84	decrease	_	O	O	_	_	_	_	_
85	in	_	O	O	_	_	_	_	_
86	binding	_	O	O	_	_	_	_	_
87	following	_	O	O	_	_	_	_	_
88	inhibition	_	O	O	_	_	_	_	_
89	when	_	O	O	_	_	_	_	_
90	compared	_	O	O	_	_	_	_	_
91	to	_	O	O	_	_	_	_	_
92	GP	_	O	O	_	_	_	_	_
93	is	_	O	O	_	_	_	_	_
94	displayed	_	O	O	_	_	_	_	_
95	(	_	O	O	_	_	_	_	_
96	*	_	O	O	_	_	_	_	_
97	=	_	O	O	_	_	_	_	_
98	p	_	O	O	_	_	_	_	_
99	<	_	O	O	_	_	_	_	_
100	0	_	O	O	_	_	_	_	_
101	.	_	O	O	_	_	_	_	_
102	05	_	O	O	_	_	_	_	_
103	)	_	O	O	_	_	_	_	_
104	.	_	O	O	_	_	_	_	_

1	Data	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	shown	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	mean	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	SEM	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	n	_	O	O	_	_	_	_	_
12	=	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	B	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Inhibition	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	NFkappaB	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	NFAT	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	NFIL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	resulted	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	decreased	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	following	_	O	O	_	_	_	_	_
21	CHX	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	CAPE	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	CyA	_	O	O	_	_	_	_	_
26	compared	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	GP	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	GAPDH	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	used	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	housekeeping	_	O	O	_	_	_	_	_
6	control	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	representative	_	O	O	_	_	_	_	_
9	gel	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	n	_	O	O	_	_	_	_	_
12	=	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	C	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Inhibition	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	NFkappaB	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	NFAT	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	NFIL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	significantly	_	O	O	_	_	_	_	_
13	reduced	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	PBMC	_	O	O	_	_	_	_	_
24	following	_	O	O	_	_	_	_	_
25	treatment	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	CHX	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	CAPE	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	CyA	_	O	O	_	_	_	_	_
32	when	_	O	O	_	_	_	_	_
33	compared	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	GP	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	*	_	O	O	_	_	_	_	_
38	=	_	O	O	_	_	_	_	_
39	p	_	O	O	_	_	_	_	_
40	<	_	O	O	_	_	_	_	_
41	0	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_
43	05	_	O	O	_	_	_	_	_
44	;	_	O	O	_	_	_	_	_
45	**	_	O	O	_	_	_	_	_
46	=	_	O	O	_	_	_	_	_
47	p	_	O	O	_	_	_	_	_
48	<	_	O	O	_	_	_	_	_
49	0	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	01	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Data	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	shown	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	mean	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	SEM	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	n	_	O	O	_	_	_	_	_
12	=	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_



1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	differentiation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	myeloid	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	lines	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	redox	_	O	O	_	_	_	_	_
12	changes	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	through	_	O	O	_	_	_	_	_
15	glutathione	_	O	O	_	_	_	_	_
16	depletion	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	investigated	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	effect	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	redox	_	O	O	_	_	_	_	_
8	changes	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	vivo	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	differentiation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	myeloid	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lines	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	HL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	60	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	KG	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	glutathione	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	depleting	_	O	O	_	_	_	_	_
5	agent	_	O	O	_	_	_	_	_
6	diethyl	_	O	O	_	_	_	_	_
7	maleate	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	DEM	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	prevented	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	development	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	differentiated	_	O	O	_	_	_	_	_
16	features	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	response	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	phorbol	_	O	O	_	_	_	_	_
21	esters	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	including	_	O	O	_	_	_	_	_
24	adherence	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	plastic	_	O	O	_	_	_	_	_
30	surfaces	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	repression	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	myeloperoxidase	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	34	_	O	O	_	_	_	_	_
39	genes	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	DEM	_	O	O	_	_	_	_	_
4	abolished	_	O	O	_	_	_	_	_
5	phorbol	_	O	O	_	_	_	_	_
6	12	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	myristate	_	O	O	_	_	_	_	_
9	13	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	acetate	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	factors	_	O	O	_	_	_	_	_
19	AP	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	Egr	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	suggesting	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	inhibition	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	differentiation	_	O	O	_	_	_	_	_
32	may	_	O	O	_	_	_	_	_
33	be	_	O	O	_	_	_	_	_
34	due	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	least	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	part	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	redox	_	O	O	_	_	_	_	_
43	modifications	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	these	_	O	O	_	_	_	_	_
46	proteins	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_


1	c	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Myc	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	E	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	A	_	O	O	_	_	_	_	_
8	induced	_	O	O	_	_	_	_	_
9	cellular	_	O	O	_	_	_	_	_
10	sensitivity	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	NK	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	involves	_	O	O	_	_	_	_	_
16	cytotoxic	_	O	O	_	_	_	_	_
17	granules	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	death	_	O	O	_	_	_	_	_
20	effectors	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	contact	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	natural	_	O	O	_	_	_	_	_
5	killer	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	NK	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	foreign	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	certain	_	O	O	_	_	_	_	_
16	virus	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	infected	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	tumor	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	triggers	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	cytolytic	_	O	O	_	_	_	_	_
25	machinery	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	NK	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	triggering	_	O	O	_	_	_	_	_
3	leads	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	exocytosis	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	cytotoxic	_	O	O	_	_	_	_	_
9	NK	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	granules	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	oncoproteins	_	O	O	_	_	_	_	_
3	c	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Myc	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	E	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	A	_	O	O	_	_	_	_	_
10	render	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	vulnerable	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	NK	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	mediated	_	O	O	_	_	_	_	_
17	cytolysis	_	O	O	_	_	_	_	_
18	yet	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	mechanisms	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	sensitization	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	well	_	O	O	_	_	_	_	_
26	understood	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	model	_	O	O	_	_	_	_	_
4	where	_	O	O	_	_	_	_	_
5	foreign	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	rat	_	O	O	_	_	_	_	_
9	fibroblasts	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	cocultured	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	activated	_	O	O	_	_	_	_	_
19	NK	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	we	_	O	O	_	_	_	_	_
23	observed	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	NK	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	were	_	O	O	_	_	_	_	_
28	capable	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	efficiently	_	O	O	_	_	_	_	_
31	killing	_	O	O	_	_	_	_	_
32	their	_	O	O	_	_	_	_	_
33	targets	_	O	O	_	_	_	_	_
34	only	_	O	O	_	_	_	_	_
35	if	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	overexpressed	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	oncogene	_	O	O	_	_	_	_	_
41	c	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	Myc	_	O	O	_	_	_	_	_
44	or	_	O	O	_	_	_	_	_
45	E	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	A	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	parental	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	oncogene	_	O	O	_	_	_	_	_
7	expressing	_	O	O	_	_	_	_	_
8	fibroblasts	_	O	O	_	_	_	_	_
9	similarly	_	O	O	_	_	_	_	_
10	triggered	_	O	O	_	_	_	_	_
11	phosphoinositide	_	O	O	_	_	_	_	_
12	hydrolysis	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	bound	_	O	O	_	_	_	_	_
16	NK	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	demonstrating	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	NK	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	cytolytically	_	O	O	_	_	_	_	_
25	activated	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	contact	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	resistant	_	O	O	_	_	_	_	_
31	parental	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	oncogene	_	O	O	_	_	_	_	_
34	expressing	_	O	O	_	_	_	_	_
35	sensitive	_	O	O	_	_	_	_	_
36	target	_	O	O	_	_	_	_	_
37	fibroblasts	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	death	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	independent	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	wild	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	type	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	53	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	inhibited	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	anti	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	apoptotic	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	EIB	_	O	O	_	_	_	_	_
23	19	_	O	O	_	_	_	_	_
24	K	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	provided	_	O	O	_	_	_	_	_
4	evidence	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	c	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	Myc	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	E	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	A	_	O	O	_	_	_	_	_
13	activated	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	NK	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	cytolysis	_	O	O	_	_	_	_	_
19	at	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	post	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	triggering	_	O	O	_	_	_	_	_
24	stage	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	NK	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	target	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	interaction	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	consistence	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Myc	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	E	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	A	_	O	O	_	_	_	_	_
12	overexpressing	_	O	O	_	_	_	_	_
13	fibroblasts	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	more	_	O	O	_	_	_	_	_
16	sensitive	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	cytolytic	_	O	O	_	_	_	_	_
20	effects	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	isolated	_	O	O	_	_	_	_	_
23	NK	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	derived	_	O	O	_	_	_	_	_
27	granules	_	O	O	_	_	_	_	_
28	than	_	O	O	_	_	_	_	_
29	parental	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	oncogenes	_	O	O	_	_	_	_	_
6	activate	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	cytotoxicity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	NK	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	granules	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	can	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	role	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	directing	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cytolytic	_	O	O	_	_	_	_	_
11	action	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	NK	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	towards	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	virus	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	infected	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	cancer	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Statistical	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Kolmogorow	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Smirnov	_	O	O	_	_	_	_	_
5	test	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	used	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	evaluate	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	whether	_	O	O	_	_	_	_	_
12	cytokine	_	O	O	_	_	_	_	_
13	amounts	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	activities	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factors	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	normally	_	O	O	_	_	_	_	_
22	distributed	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Correlation	_	O	O	_	_	_	_	_
2	coefficients	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	corresponding	_	O	O	_	_	_	_	_
5	significances	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	analyzed	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	Pearson	_	O	O	_	_	_	_	_
11	test	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	normal	_	O	O	_	_	_	_	_
14	distribution	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	Spearman	_	O	O	_	_	_	_	_
19	test	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	non	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	normal	_	O	O	_	_	_	_	_
24	distribution	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	compare	_	O	O	_	_	_	_	_
3	experimental	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	theoretical	_	O	O	_	_	_	_	_
8	value	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	example	_	O	O	_	_	_	_	_
12	GP	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	TSST	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	vs	_	O	O	_	_	_	_	_
18	GP	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	TSST	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	calc	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	we	_	O	O	_	_	_	_	_
27	calculated	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	sum	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	individual	_	O	O	_	_	_	_	_
33	effects	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	added	_	O	O	_	_	_	_	_
36	these	_	O	O	_	_	_	_	_
37	values	_	O	O	_	_	_	_	_
38	into	_	O	O	_	_	_	_	_
39	Fig	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Significances	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	differences	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	experimental	_	O	O	_	_	_	_	_
6	data	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	example	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	vs	_	O	O	_	_	_	_	_
12	LPS	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	well	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	between	_	O	O	_	_	_	_	_
18	experimental	_	O	O	_	_	_	_	_
19	data	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	theoretical	_	O	O	_	_	_	_	_
22	values	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	example	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	+	_	O	O	_	_	_	_	_
28	TSST	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	vs	_	O	O	_	_	_	_	_
32	GP	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	TSST	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	calc	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	were	_	O	O	_	_	_	_	_
41	analysed	_	O	O	_	_	_	_	_
42	using	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	Student	_	O	O	_	_	_	_	_
45	'	_	O	O	_	_	_	_	_
46	s	_	O	O	_	_	_	_	_
47	t	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	test	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	normal	_	O	O	_	_	_	_	_
52	distribution	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	or	_	O	O	_	_	_	_	_
55	the	_	O	O	_	_	_	_	_
56	Wilcoxon	_	O	O	_	_	_	_	_
57	Signed	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	Rank	_	O	O	_	_	_	_	_
60	test	_	O	O	_	_	_	_	_
61	(	_	O	O	_	_	_	_	_
62	non	_	O	O	_	_	_	_	_
63	-	_	O	O	_	_	_	_	_
64	normal	_	O	O	_	_	_	_	_
65	distribution	_	O	O	_	_	_	_	_
66	)	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	(	_	O	O	_	_	_	_	_
69	SPSS	_	O	O	_	_	_	_	_
70	for	_	O	O	_	_	_	_	_
71	Windows	_	O	O	_	_	_	_	_
72	;	_	O	O	_	_	_	_	_
73	SPSS	_	O	O	_	_	_	_	_
74	Science	_	O	O	_	_	_	_	_
75	Software	_	O	O	_	_	_	_	_
76	,	_	O	O	_	_	_	_	_
77	Erkrath	_	O	O	_	_	_	_	_
78	,	_	O	O	_	_	_	_	_
79	Germany	_	O	O	_	_	_	_	_
80	)	_	O	O	_	_	_	_	_
81	.	_	O	O	_	_	_	_	_



1	Conclusion	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	summary	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	data	_	O	O	_	_	_	_	_
6	demonstrated	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	vitro	_	O	O	_	_	_	_	_
10	glucan	_	O	O	_	_	_	_	_
11	phosphate	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	factor	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	subsequent	_	O	O	_	_	_	_	_
20	cytokine	_	O	O	_	_	_	_	_
21	profile	_	O	O	_	_	_	_	_
22	different	_	O	O	_	_	_	_	_
23	from	_	O	O	_	_	_	_	_
24	LPS	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	also	_	O	O	_	_	_	_	_
27	from	_	O	O	_	_	_	_	_
28	TSST	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	moreover	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	switched	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	pro	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	inflammatory	_	O	O	_	_	_	_	_
40	TSST	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	induced	_	O	O	_	_	_	_	_
45	response	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	an	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	RA	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	mediated	_	O	O	_	_	_	_	_
54	anti	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	inflammatory	_	O	O	_	_	_	_	_
57	reaction	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	generated	_	O	O	_	_	_	_	_
5	new	_	O	O	_	_	_	_	_
6	insights	_	O	O	_	_	_	_	_
7	into	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	very	_	O	O	_	_	_	_	_
10	complex	_	O	O	_	_	_	_	_
11	interplay	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	various	_	O	O	_	_	_	_	_
18	known	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	newly	_	O	O	_	_	_	_	_
21	identified	_	O	O	_	_	_	_	_
22	sites	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	RA	_	O	O	_	_	_	_	_
29	promoter	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	Fig	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	8	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	which	_	O	O	_	_	_	_	_
5	can	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	regulated	_	O	O	_	_	_	_	_
8	differentially	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	fungal	_	O	O	_	_	_	_	_
12	carbohydrate	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Together	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	vivo	_	O	O	_	_	_	_	_
6	studies	_	O	O	_	_	_	_	_
7	[	_	O	O	_	_	_	_	_
8	22	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	37	_	O	O	_	_	_	_	_
11	]	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	our	_	O	O	_	_	_	_	_
14	findings	_	O	O	_	_	_	_	_
15	might	_	O	O	_	_	_	_	_
16	support	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	concept	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	protective	_	O	O	_	_	_	_	_
21	effects	_	O	O	_	_	_	_	_
22	mediated	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	glucan	_	O	O	_	_	_	_	_
25	phosphate	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	pro	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	inflammatory	_	O	O	_	_	_	_	_
30	conditions	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	especially	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	dysregulated	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	beta	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	RA	_	O	O	_	_	_	_	_
45	ratio	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	52	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	53	_	O	O	_	_	_	_	_
50	]	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_



1	Regulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	balance	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	cytokine	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	signal	_	O	O	_	_	_	_	_
11	transducer	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	activator	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	cytokines	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	inflammatory	_	O	O	_	_	_	_	_
26	synovial	_	O	O	_	_	_	_	_
27	fluids	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	balance	_	O	O	_	_	_	_	_
3	between	_	O	O	_	_	_	_	_
4	type	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	helper	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	cytokine	_	O	O	_	_	_	_	_
12	production	_	O	O	_	_	_	_	_
13	plays	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	important	_	O	O	_	_	_	_	_
16	role	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	several	_	O	O	_	_	_	_	_
19	animal	_	O	O	_	_	_	_	_
20	models	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	autoimmunity	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	skewed	_	O	O	_	_	_	_	_
26	patterns	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	cytokine	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	have	_	O	O	_	_	_	_	_
31	been	_	O	O	_	_	_	_	_
32	described	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	human	_	O	O	_	_	_	_	_
35	inflammatory	_	O	O	_	_	_	_	_
36	diseases	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Many	_	O	O	_	_	_	_	_
2	cytokines	_	O	O	_	_	_	_	_
3	activate	_	O	O	_	_	_	_	_
4	signal	_	O	O	_	_	_	_	_
5	transducer	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factors	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	turn	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	activate	_	O	O	_	_	_	_	_
22	transcription	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	inflammatory	_	O	O	_	_	_	_	_
25	effector	_	O	O	_	_	_	_	_
26	genes	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	used	_	O	O	_	_	_	_	_
3	mononuclear	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	priming	_	O	O	_	_	_	_	_
6	cultures	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	inflammatory	_	O	O	_	_	_	_	_
9	synovial	_	O	O	_	_	_	_	_
10	fluids	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	SFs	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	derived	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	arthritis	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	examine	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	regulation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	cytokine	_	O	O	_	_	_	_	_
24	production	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	STAT	_	O	O	_	_	_	_	_
27	activity	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	an	_	O	O	_	_	_	_	_
30	inflammatory	_	O	O	_	_	_	_	_
31	synovial	_	O	O	_	_	_	_	_
32	microenvironment	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Exposure	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	SFs	_	O	O	_	_	_	_	_
4	during	_	O	O	_	_	_	_	_
5	priming	_	O	O	_	_	_	_	_
6	resulted	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	81	_	O	O	_	_	_	_	_
10	%	_	O	O	_	_	_	_	_
11	inhibition	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	interferon	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	IFN	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	interleukin	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	production	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	effector	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	generated	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	priming	_	O	O	_	_	_	_	_
35	cultures	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	SF	_	O	O	_	_	_	_	_
2	suppression	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	12	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	it	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	reversed	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	dominant	_	O	O	_	_	_	_	_
28	fashion	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	exogenous	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	12	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	SFs	_	O	O	_	_	_	_	_
2	blocked	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	sustained	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	Stat	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	Stat	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	during	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	priming	_	O	O	_	_	_	_	_
20	period	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	Stat	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	differentially	_	O	O	_	_	_	_	_
28	regulated	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	cytokines	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	parallel	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	their	_	O	O	_	_	_	_	_
35	positive	_	O	O	_	_	_	_	_
36	or	_	O	O	_	_	_	_	_
37	negative	_	O	O	_	_	_	_	_
38	regulation	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	IFN	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	gamma	_	O	O	_	_	_	_	_
43	production	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Active	_	O	O	_	_	_	_	_
2	Stat	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	but	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	Stat	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	detected	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	from	_	O	O	_	_	_	_	_
15	inflamed	_	O	O	_	_	_	_	_
16	joints	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	role	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	altered	_	O	O	_	_	_	_	_
8	balance	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Stat	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	transcriptional	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	regulation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	differentiation	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	pathogenesis	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	inflammatory	_	O	O	_	_	_	_	_
30	synovitis	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Vitamin	_	O	O	_	_	_	_	_
2	D	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	'	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	untranslated	_	O	O	_	_	_	_	_
8	region	_	O	O	_	_	_	_	_
9	polymorphisms	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	lack	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	effect	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	mRNA	_	O	O	_	_	_	_	_
16	stability	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Allelic	_	O	O	_	_	_	_	_
2	variation	_	O	O	_	_	_	_	_
3	at	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	'	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	end	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	vitamin	_	O	O	_	_	_	_	_
12	D	_	O	O	_	_	_	_	_
13	receptor	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	VDR	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	has	_	O	O	_	_	_	_	_
19	been	_	O	O	_	_	_	_	_
20	associated	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	5	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	fold	_	O	O	_	_	_	_	_
28	increased	_	O	O	_	_	_	_	_
29	risk	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	developing	_	O	O	_	_	_	_	_
32	prostate	_	O	O	_	_	_	_	_
33	cancer	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	with	_	O	O	_	_	_	_	_
36	differences	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	bone	_	O	O	_	_	_	_	_
39	mineralization	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	genetic	_	O	O	_	_	_	_	_
3	diversity	_	O	O	_	_	_	_	_
4	does	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	alter	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	VDR	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	structurally	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	instead	_	O	O	_	_	_	_	_
14	may	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	marker	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	s	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	other	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	nearby	_	O	O	_	_	_	_	_
25	polymorphisms	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	influence	_	O	O	_	_	_	_	_
28	message	_	O	O	_	_	_	_	_
29	stability	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	translation	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	work	_	O	O	_	_	_	_	_
3	reported	_	O	O	_	_	_	_	_
4	here	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	instigated	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	identify	_	O	O	_	_	_	_	_
9	additional	_	O	O	_	_	_	_	_
10	VDR	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	'	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	UTR	_	O	O	_	_	_	_	_
15	polymorphisms	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	may	_	O	O	_	_	_	_	_
18	have	_	O	O	_	_	_	_	_
19	functional	_	O	O	_	_	_	_	_
20	significance	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	then	_	O	O	_	_	_	_	_
24	test	_	O	O	_	_	_	_	_
25	whether	_	O	O	_	_	_	_	_
26	these	_	O	O	_	_	_	_	_
27	genetic	_	O	O	_	_	_	_	_
28	variants	_	O	O	_	_	_	_	_
29	alter	_	O	O	_	_	_	_	_
30	message	_	O	O	_	_	_	_	_
31	stability	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Initially	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	four	_	O	O	_	_	_	_	_
4	novel	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	frequently	_	O	O	_	_	_	_	_
7	occurring	_	O	O	_	_	_	_	_
8	sequence	_	O	O	_	_	_	_	_
9	variants	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	identified	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	associated	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	common	_	O	O	_	_	_	_	_
17	haplotypes	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	described	_	O	O	_	_	_	_	_
21	previously	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	common	_	O	O	_	_	_	_	_
3	sequence	_	O	O	_	_	_	_	_
4	variants	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	within	_	O	O	_	_	_	_	_
9	three	_	O	O	_	_	_	_	_
10	message	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	destabilizing	_	O	O	_	_	_	_	_
13	elements	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	we	_	O	O	_	_	_	_	_
16	mapped	_	O	O	_	_	_	_	_
17	within	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	'	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	UTR	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	vitamin	_	O	O	_	_	_	_	_
26	D	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	mRNA	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	VDR	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	'	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	UTR	_	O	O	_	_	_	_	_
10	haplotypes	_	O	O	_	_	_	_	_
11	conferred	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	identical	_	O	O	_	_	_	_	_
14	half	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	life	_	O	O	_	_	_	_	_
17	on	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	heterologous	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	globin	_	O	O	_	_	_	_	_
23	reporter	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	vitro	_	O	O	_	_	_	_	_
30	assay	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	therefore	_	O	O	_	_	_	_	_
3	conclude	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	common	_	O	O	_	_	_	_	_
6	polymorphisms	_	O	O	_	_	_	_	_
7	within	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	VDR	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	'	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	UTR	_	O	O	_	_	_	_	_
14	do	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	influence	_	O	O	_	_	_	_	_
17	message	_	O	O	_	_	_	_	_
18	stability	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Increased	_	O	O	_	_	_	_	_
2	interleukin	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	17	_	O	O	_	_	_	_	_
5	production	_	O	O	_	_	_	_	_
6	via	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	phosphoinositide	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kinase	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	Akt	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	kappaB	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	dependent	_	O	O	_	_	_	_	_
20	pathway	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	patients	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	rheumatoid	_	O	O	_	_	_	_	_
25	arthritis	_	O	O	_	_	_	_	_

1	Inflammatory	_	O	O	_	_	_	_	_
2	mediators	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	recognized	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	being	_	O	O	_	_	_	_	_
8	important	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	pathogenesis	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	rheumatoid	_	O	O	_	_	_	_	_
14	arthritis	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Interleukin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	17	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	important	_	O	O	_	_	_	_	_
10	regulator	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	immune	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	inflammatory	_	O	O	_	_	_	_	_
15	responses	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	including	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	induction	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	proinflammatory	_	O	O	_	_	_	_	_
22	cytokines	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	osteoclastic	_	O	O	_	_	_	_	_
25	bone	_	O	O	_	_	_	_	_
26	resorption	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Evidence	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	proinflammatory	_	O	O	_	_	_	_	_
7	activity	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	17	_	O	O	_	_	_	_	_
12	has	_	O	O	_	_	_	_	_
13	been	_	O	O	_	_	_	_	_
14	demonstrated	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	synovium	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	animal	_	O	O	_	_	_	_	_
21	models	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	some	_	O	O	_	_	_	_	_
3	cytokines	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	15	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	23	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	have	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	reported	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	regulate	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	17	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	intracellular	_	O	O	_	_	_	_	_
25	signaling	_	O	O	_	_	_	_	_
26	pathways	_	O	O	_	_	_	_	_
27	that	_	O	O	_	_	_	_	_
28	regulate	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	17	_	O	O	_	_	_	_	_
32	production	_	O	O	_	_	_	_	_
33	remain	_	O	O	_	_	_	_	_
34	unknown	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	investigated	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	phosphoinositide	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	PI	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	K	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	Akt	_	O	O	_	_	_	_	_
23	pathway	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	regulation	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	17	_	O	O	_	_	_	_	_
31	production	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	RA	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Peripheral	_	O	O	_	_	_	_	_
2	blood	_	O	O	_	_	_	_	_
3	mononuclear	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	PBMC	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	n	_	O	O	_	_	_	_	_
14	=	_	O	O	_	_	_	_	_
15	24	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	separated	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	then	_	O	O	_	_	_	_	_
21	stimulated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	various	_	O	O	_	_	_	_	_
24	agents	_	O	O	_	_	_	_	_
25	including	_	O	O	_	_	_	_	_
26	anti	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	anti	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	CD	_	O	O	_	_	_	_	_
34	28	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	phytohemagglutinin	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	PHA	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	several	_	O	O	_	_	_	_	_
42	inflammatory	_	O	O	_	_	_	_	_
43	cytokines	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	chemokines	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	levels	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	determined	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	sandwich	_	O	O	_	_	_	_	_
9	enzyme	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	linked	_	O	O	_	_	_	_	_
12	immunosorbent	_	O	O	_	_	_	_	_
13	assay	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	reverse	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	polymerase	_	O	O	_	_	_	_	_
19	chain	_	O	O	_	_	_	_	_
20	reaction	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	production	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	17	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	significantly	_	O	O	_	_	_	_	_
9	increased	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	treated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	antibody	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	without	_	O	O	_	_	_	_	_
22	anti	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	28	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	PHA	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	P	_	O	O	_	_	_	_	_
30	<	_	O	O	_	_	_	_	_
31	0	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	05	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Among	_	O	O	_	_	_	_	_
2	tested	_	O	O	_	_	_	_	_
3	cytokines	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	chemokines	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	15	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	monocyte	_	O	O	_	_	_	_	_
12	chemoattractant	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	6	_	O	O	_	_	_	_	_
20	upregulated	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	17	_	O	O	_	_	_	_	_
24	production	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	P	_	O	O	_	_	_	_	_
27	<	_	O	O	_	_	_	_	_
28	0	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	05	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	whereas	_	O	O	_	_	_	_	_
34	tumor	_	O	O	_	_	_	_	_
35	necrosis	_	O	O	_	_	_	_	_
36	factor	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	alpha	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	beta	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	IL	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	18	_	O	O	_	_	_	_	_
48	or	_	O	O	_	_	_	_	_
49	transforming	_	O	O	_	_	_	_	_
50	growth	_	O	O	_	_	_	_	_
51	factor	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	beta	_	O	O	_	_	_	_	_
54	did	_	O	O	_	_	_	_	_
55	not	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	detected	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	PBMC	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	patients	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	osteoarthritis	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	their	_	O	O	_	_	_	_	_
17	expression	_	O	O	_	_	_	_	_
18	levels	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	much	_	O	O	_	_	_	_	_
21	lower	_	O	O	_	_	_	_	_
22	than	_	O	O	_	_	_	_	_
23	those	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	RA	_	O	O	_	_	_	_	_
26	PBMC	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Anti	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	antibody	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	PI	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	K	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	Akt	_	O	O	_	_	_	_	_
13	pathway	_	O	O	_	_	_	_	_
14	;	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	this	_	O	O	_	_	_	_	_
18	pathway	_	O	O	_	_	_	_	_
19	resulted	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	pronounced	_	O	O	_	_	_	_	_
23	augmentation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	nuclear	_	O	O	_	_	_	_	_
26	factor	_	O	O	_	_	_	_	_
27	kappaB	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	NF	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	kappaB	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	DNA	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	binding	_	O	O	_	_	_	_	_
36	activity	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	production	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	PBMC	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	completely	_	O	O	_	_	_	_	_
11	or	_	O	O	_	_	_	_	_
12	partly	_	O	O	_	_	_	_	_
13	blocked	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	presence	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	NF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	kappaB	_	O	O	_	_	_	_	_
22	inhibitor	_	O	O	_	_	_	_	_
23	pyrrolidine	_	O	O	_	_	_	_	_
24	dithiocarbamate	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	PI	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	K	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	Akt	_	O	O	_	_	_	_	_
32	inhibitor	_	O	O	_	_	_	_	_
33	wortmannin	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	LY	_	O	O	_	_	_	_	_
36	294002	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	respectively	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	inhibition	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	activator	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	extracellular	_	O	O	_	_	_	_	_
11	signal	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	regulated	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	did	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	affect	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	17	_	O	O	_	_	_	_	_
24	production	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	signal	_	O	O	_	_	_	_	_
6	transduction	_	O	O	_	_	_	_	_
7	pathways	_	O	O	_	_	_	_	_
8	dependent	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	PI	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	K	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	Akt	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	NF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	kappaB	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	involved	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	overproduction	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	key	_	O	O	_	_	_	_	_
27	inflammatory	_	O	O	_	_	_	_	_
28	cytokine	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	17	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	RA	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_



1	Isolation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	mRNA	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	real	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	time	_	O	O	_	_	_	_	_
8	PCR	_	O	O	_	_	_	_	_

1	Total	_	O	O	_	_	_	_	_
2	cellular	_	O	O	_	_	_	_	_
3	RNA	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	extracted	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	PB	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	RNA	_	O	O	_	_	_	_	_
16	isolation	_	O	O	_	_	_	_	_
17	kit	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	RNeasy	_	O	O	_	_	_	_	_
20	Mini	_	O	O	_	_	_	_	_
21	kit	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	Qiagen	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	Valencia	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	CA	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	USA	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	according	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	manufacturer	_	O	O	_	_	_	_	_
36	'	_	O	O	_	_	_	_	_
37	s	_	O	O	_	_	_	_	_
38	instructions	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	cDNA	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	synthesized	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	total	_	O	O	_	_	_	_	_
6	RNA	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	Molony	_	O	O	_	_	_	_	_
9	murine	_	O	O	_	_	_	_	_
10	leukemia	_	O	O	_	_	_	_	_
11	virus	_	O	O	_	_	_	_	_
12	reverse	_	O	O	_	_	_	_	_
13	transcriptase	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	US	_	O	O	_	_	_	_	_
16	Biochemical	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	Cleveland	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	OH	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	USA	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	oligo	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	dT	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	15	_	O	O	_	_	_	_	_
31	primers	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	Promega	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	Madison	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	WI	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	USA	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Real	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	time	_	O	O	_	_	_	_	_
4	PCR	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	performed	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	LightCycler	_	O	O	_	_	_	_	_
10	Instrument	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	Roche	_	O	O	_	_	_	_	_
13	Diagnostics	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	Penzberg	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	Germany	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	glass	_	O	O	_	_	_	_	_
21	capillaries	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	reaction	_	O	O	_	_	_	_	_
3	mix	_	O	O	_	_	_	_	_
4	containing	_	O	O	_	_	_	_	_
5	Taq	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	polymerase	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	DNA	_	O	O	_	_	_	_	_
10	double	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	strand	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	SYBR	_	O	O	_	_	_	_	_
16	Green	_	O	O	_	_	_	_	_
17	I	_	O	O	_	_	_	_	_
18	dye	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	Lightcycler	_	O	O	_	_	_	_	_
21	FastStart	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	Master	_	O	O	_	_	_	_	_
24	SYBR	_	O	O	_	_	_	_	_
25	Green	_	O	O	_	_	_	_	_
26	I	_	O	O	_	_	_	_	_
27	;	_	O	O	_	_	_	_	_
28	Roche	_	O	O	_	_	_	_	_
29	Diagnostics	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	specific	_	O	O	_	_	_	_	_
33	primers	_	O	O	_	_	_	_	_
34	were	_	O	O	_	_	_	_	_
35	added	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	cDNA	_	O	O	_	_	_	_	_
38	dilutions	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	cDNA	_	O	O	_	_	_	_	_
3	samples	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	denatured	_	O	O	_	_	_	_	_
6	at	_	O	O	_	_	_	_	_
7	95	_	O	O	_	_	_	_	_
8	degrees	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	10	_	O	O	_	_	_	_	_
12	min	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	then	_	O	O	_	_	_	_	_
17	amplified	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	40	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	50	_	O	O	_	_	_	_	_
22	cycles	_	O	O	_	_	_	_	_
23	:	_	O	O	_	_	_	_	_
24	at	_	O	O	_	_	_	_	_
25	95	_	O	O	_	_	_	_	_
26	degrees	_	O	O	_	_	_	_	_
27	C	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	s	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	at	_	O	O	_	_	_	_	_
34	65	_	O	O	_	_	_	_	_
35	degrees	_	O	O	_	_	_	_	_
36	C	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	15	_	O	O	_	_	_	_	_
39	s	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	72	_	O	O	_	_	_	_	_
44	degrees	_	O	O	_	_	_	_	_
45	C	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	22	_	O	O	_	_	_	_	_
48	s	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	for	_	O	O	_	_	_	_	_
51	beta	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	actin	_	O	O	_	_	_	_	_
54	;	_	O	O	_	_	_	_	_
55	at	_	O	O	_	_	_	_	_
56	95	_	O	O	_	_	_	_	_
57	degrees	_	O	O	_	_	_	_	_
58	C	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	10	_	O	O	_	_	_	_	_
61	s	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	at	_	O	O	_	_	_	_	_
65	62	_	O	O	_	_	_	_	_
66	degrees	_	O	O	_	_	_	_	_
67	C	_	O	O	_	_	_	_	_
68	(	_	O	O	_	_	_	_	_
69	15	_	O	O	_	_	_	_	_
70	s	_	O	O	_	_	_	_	_
71	)	_	O	O	_	_	_	_	_
72	,	_	O	O	_	_	_	_	_
73	and	_	O	O	_	_	_	_	_
74	at	_	O	O	_	_	_	_	_
75	72	_	O	O	_	_	_	_	_
76	degrees	_	O	O	_	_	_	_	_
77	C	_	O	O	_	_	_	_	_
78	(	_	O	O	_	_	_	_	_
79	10	_	O	O	_	_	_	_	_
80	s	_	O	O	_	_	_	_	_
81	)	_	O	O	_	_	_	_	_
82	for	_	O	O	_	_	_	_	_
83	SOCS	_	O	O	_	_	_	_	_
84	1	_	O	O	_	_	_	_	_
85	;	_	O	O	_	_	_	_	_
86	and	_	O	O	_	_	_	_	_
87	at	_	O	O	_	_	_	_	_
88	96	_	O	O	_	_	_	_	_
89	degrees	_	O	O	_	_	_	_	_
90	C	_	O	O	_	_	_	_	_
91	(	_	O	O	_	_	_	_	_
92	10	_	O	O	_	_	_	_	_
93	s	_	O	O	_	_	_	_	_
94	)	_	O	O	_	_	_	_	_
95	,	_	O	O	_	_	_	_	_
96	at	_	O	O	_	_	_	_	_
97	68	_	O	O	_	_	_	_	_
98	degrees	_	O	O	_	_	_	_	_
99	C	_	O	O	_	_	_	_	_
100	(	_	O	O	_	_	_	_	_
101	15	_	O	O	_	_	_	_	_
102	s	_	O	O	_	_	_	_	_
103	)	_	O	O	_	_	_	_	_
104	,	_	O	O	_	_	_	_	_
105	and	_	O	O	_	_	_	_	_
106	at	_	O	O	_	_	_	_	_
107	72	_	O	O	_	_	_	_	_
108	degrees	_	O	O	_	_	_	_	_
109	C	_	O	O	_	_	_	_	_
110	(	_	O	O	_	_	_	_	_
111	15	_	O	O	_	_	_	_	_
112	s	_	O	O	_	_	_	_	_
113	)	_	O	O	_	_	_	_	_
114	for	_	O	O	_	_	_	_	_
115	SOCS	_	O	O	_	_	_	_	_
116	3	_	O	O	_	_	_	_	_
117	.	_	O	O	_	_	_	_	_

1	Amplification	_	O	O	_	_	_	_	_
2	curves	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	fluorescence	_	O	O	_	_	_	_	_
6	values	_	O	O	_	_	_	_	_
7	versus	_	O	O	_	_	_	_	_
8	cycle	_	O	O	_	_	_	_	_
9	number	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	obtained	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	melting	_	O	O	_	_	_	_	_
16	curve	_	O	O	_	_	_	_	_
17	analysis	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	then	_	O	O	_	_	_	_	_
20	performed	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	levels	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	SOCS	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	determined	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	normalizing	_	O	O	_	_	_	_	_
14	relative	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	actin	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	forward	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	reverse	_	O	O	_	_	_	_	_
5	primers	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	follows	_	O	O	_	_	_	_	_
9	:	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	actin	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	'	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	GTGGGGCGCCCCAGGCACCA	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	'	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	5	_	O	O	_	_	_	_	_
24	'	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	CTCCTTAATGTCACGCACGATTTC	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	'	_	O	O	_	_	_	_	_
30	;	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	SOCS	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	5	_	O	O	_	_	_	_	_
36	'	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	AGACCCCTTCTCACCTCTTG	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	'	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	5	_	O	O	_	_	_	_	_
44	'	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	GCACAGCAGAAAAATAAAGC	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	3	_	O	O	_	_	_	_	_
49	'	_	O	O	_	_	_	_	_
50	;	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	for	_	O	O	_	_	_	_	_
53	SOCS	_	O	O	_	_	_	_	_
54	3	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	5	_	O	O	_	_	_	_	_
57	'	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	CCCGCCGGCACCTTTCTG	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	3	_	O	O	_	_	_	_	_
62	'	_	O	O	_	_	_	_	_
63	and	_	O	O	_	_	_	_	_
64	5	_	O	O	_	_	_	_	_
65	'	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	AGGGGCCGGCTCAACACC	_	O	O	_	_	_	_	_
68	-	_	O	O	_	_	_	_	_
69	3	_	O	O	_	_	_	_	_
70	'.	_	O	O	_	_	_	_	_



1	Protein	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	tyrosine	_	O	O	_	_	_	_	_
4	kinase	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	required	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	lipopolysaccharide	_	O	O	_	_	_	_	_
10	induction	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	interleukin	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	NFkappaB	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	not	_	O	O	_	_	_	_	_
21	NFkappaB	_	O	O	_	_	_	_	_
22	nuclear	_	O	O	_	_	_	_	_
23	translocation	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	monocytes	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	interleukin	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	steady	_	O	O	_	_	_	_	_
12	state	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	increased	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	response	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	lipopolysaccharide	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	predominantly	_	O	O	_	_	_	_	_
23	as	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	result	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	increased	_	O	O	_	_	_	_	_
28	transcription	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	interleukin	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	beta	_	O	O	_	_	_	_	_
34	gene	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	interleukin	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	other	_	O	O	_	_	_	_	_
8	cytokines	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	such	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	interleukin	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	tumor	_	O	O	_	_	_	_	_
16	necrosis	_	O	O	_	_	_	_	_
17	factor	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	has	_	O	O	_	_	_	_	_
21	been	_	O	O	_	_	_	_	_
22	shown	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	dependent	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	activation	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	transcription	_	O	O	_	_	_	_	_
32	factor	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	NFkappaB	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	recent	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	lipopolysaccharide	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	tyrosine	_	O	O	_	_	_	_	_
11	kinase	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	required	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	NFkappaB	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	translocation	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	we	_	O	O	_	_	_	_	_
22	sought	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	determine	_	O	O	_	_	_	_	_
25	whether	_	O	O	_	_	_	_	_
26	NFkappaB	_	O	O	_	_	_	_	_
27	translocated	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	absence	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	tyrosine	_	O	O	_	_	_	_	_
33	kinase	_	O	O	_	_	_	_	_
34	activity	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	active	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	stimulating	_	O	O	_	_	_	_	_
39	transcription	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	found	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	pro	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	monocytic	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	line	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	THP	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	lipopolysaccharide	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	induced	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	interleukin	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	beta	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	dependent	_	O	O	_	_	_	_	_
30	on	_	O	O	_	_	_	_	_
31	tyrosine	_	O	O	_	_	_	_	_
32	kinase	_	O	O	_	_	_	_	_
33	activation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Tyrosine	_	O	O	_	_	_	_	_
2	kinases	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	required	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	lipopolysaccharide	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	mediated	_	O	O	_	_	_	_	_
10	nuclear	_	O	O	_	_	_	_	_
11	translocation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	NFkappaB	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	absence	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	tyrosine	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	ability	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NFkappaB	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	stimulate	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	impaired	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	inhibition	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	specific	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	NFkappaB	_	O	O	_	_	_	_	_
9	;	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	absence	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	tyrosine	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	AP	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	dependent	_	O	O	_	_	_	_	_
23	transcription	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	enhanced	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	while	_	O	O	_	_	_	_	_
7	lipopolysaccharide	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	mediators	_	O	O	_	_	_	_	_
14	requires	_	O	O	_	_	_	_	_
15	tyrosine	_	O	O	_	_	_	_	_
16	kinase	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	kinase	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	not	_	O	O	_	_	_	_	_
24	obligatory	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	lipopolysaccharide	_	O	O	_	_	_	_	_
27	signal	_	O	O	_	_	_	_	_
28	transduction	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	role	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	gamma	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	delta	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	positive	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	pregnancy	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	PROBLEM	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Due	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	lack	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	classical	_	O	O	_	_	_	_	_
9	HLA	_	O	O	_	_	_	_	_
10	antigens	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	trophoblast	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	fetal	_	O	O	_	_	_	_	_
16	antigens	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	possibly	_	O	O	_	_	_	_	_
19	presented	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	non	_	O	O	_	_	_	_	_
23	major	_	O	O	_	_	_	_	_
24	histocompatibility	_	O	O	_	_	_	_	_
25	complex	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	MHC	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	restricted	_	O	O	_	_	_	_	_
30	way	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Decidual	_	O	O	_	_	_	_	_
2	gammadelta	_	O	O	_	_	_	_	_
3	T	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	significantly	_	O	O	_	_	_	_	_
8	increase	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	number	_	O	O	_	_	_	_	_
11	during	_	O	O	_	_	_	_	_
12	pregnancy	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	might	_	O	O	_	_	_	_	_
15	play	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	role	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	recognition	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	fetal	_	O	O	_	_	_	_	_
22	antigens	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	also	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	determining	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	quality	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	response	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	these	_	O	O	_	_	_	_	_
34	antigens	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	aimed	_	O	O	_	_	_	_	_
5	at	_	O	O	_	_	_	_	_
6	investigating	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	role	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	this	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	population	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	progesterone	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dependent	_	O	O	_	_	_	_	_
17	immunomodulation	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	METHOD	_	O	O	_	_	_	_	_
2	OF	_	O	O	_	_	_	_	_
3	STUDY	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	Peripheral	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	healthy	_	O	O	_	_	_	_	_
9	pregnant	_	O	O	_	_	_	_	_
10	women	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	habitual	_	O	O	_	_	_	_	_
14	aborters	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	tested	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	immunocytochemistry	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	presence	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	gamma	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	delta	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	receptor	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	TCR	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	progesterone	_	O	O	_	_	_	_	_
34	receptor	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effect	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	treatment	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	pan	_	O	O	_	_	_	_	_
10	anti	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	delta	_	O	O	_	_	_	_	_
14	antibody	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	incubated	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	hr	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	antibody	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	then	_	O	O	_	_	_	_	_
28	interleukin	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	10	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	12	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	progesterone	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	induced	_	O	O	_	_	_	_	_
42	blocking	_	O	O	_	_	_	_	_
43	factor	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	PIBF	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	expression	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	by	_	O	O	_	_	_	_	_
50	immuno	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	cytochemistry	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	as	_	O	O	_	_	_	_	_
55	well	_	O	O	_	_	_	_	_
56	as	_	O	O	_	_	_	_	_
57	natural	_	O	O	_	_	_	_	_
58	killer	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	NK	_	O	O	_	_	_	_	_
61	)	_	O	O	_	_	_	_	_
62	cell	_	O	O	_	_	_	_	_
63	activity	_	O	O	_	_	_	_	_
64	were	_	O	O	_	_	_	_	_
65	determined	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	peripheral	_	O	O	_	_	_	_	_
5	blood	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	healthy	_	O	O	_	_	_	_	_
8	pregnant	_	O	O	_	_	_	_	_
9	women	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	percentage	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	delta	_	O	O	_	_	_	_	_
16	TCR	_	O	O	_	_	_	_	_
17	+	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	significantly	_	O	O	_	_	_	_	_
21	higher	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	P	_	O	O	_	_	_	_	_
24	<	_	O	O	_	_	_	_	_
25	0	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	001	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	than	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	recurrent	_	O	O	_	_	_	_	_
34	aborters	_	O	O	_	_	_	_	_
35	or	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	non	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	pregnant	_	O	O	_	_	_	_	_
40	individuals	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Ninety	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	seven	_	O	O	_	_	_	_	_
4	percent	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	gamma	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	delta	_	O	O	_	_	_	_	_
9	TCR	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	pregnancy	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	expressed	_	O	O	_	_	_	_	_
14	progesterone	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	antibody	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	gamma	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	delta	_	O	O	_	_	_	_	_
11	TCR	_	O	O	_	_	_	_	_
12	inhibited	_	O	O	_	_	_	_	_
13	PIBF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	well	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	production	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	whereas	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	increased	_	O	O	_	_	_	_	_
26	NK	_	O	O	_	_	_	_	_
27	activity	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	12	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	These	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	suggest	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	delta	_	O	O	_	_	_	_	_
12	TCR	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	bearing	_	O	O	_	_	_	_	_
15	lymphocytes	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	progesterone	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	dependent	_	O	O	_	_	_	_	_
20	immunomodulation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Prolactin	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	interleukin	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	receptors	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	lymphocytes	_	O	O	_	_	_	_	_
10	signal	_	O	O	_	_	_	_	_
11	through	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	MGF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	like	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	surface	_	O	O	_	_	_	_	_
4	receptors	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	PRL	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	interleukin	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	structurally	_	O	O	_	_	_	_	_
18	distinct	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	share	_	O	O	_	_	_	_	_
22	regulatory	_	O	O	_	_	_	_	_
23	tasks	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	lymphocytes	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	They	_	O	O	_	_	_	_	_
2	can	_	O	O	_	_	_	_	_
3	stimulate	_	O	O	_	_	_	_	_
4	proliferation	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	activate	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	over	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	lapping	_	O	O	_	_	_	_	_
12	sets	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	genes	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	PRL	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	both	_	O	O	_	_	_	_	_
10	linked	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Jak	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	Stat	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	signal	_	O	O	_	_	_	_	_
18	transducer	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	activator	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	transcription	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	pathway	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	ability	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	PRL	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	activate	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	proteins	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	different	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lines	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	binding	_	O	O	_	_	_	_	_
4	specificities	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	reactivities	_	O	O	_	_	_	_	_
8	toward	_	O	O	_	_	_	_	_
9	Stat	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	specific	_	O	O	_	_	_	_	_
12	antisera	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	mol	_	O	O	_	_	_	_	_
17	wt	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	PRL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	induced	_	O	O	_	_	_	_	_
27	DNA	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	proteins	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	Nb	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	C	_	O	O	_	_	_	_	_
36	196	_	O	O	_	_	_	_	_
37	T	_	O	O	_	_	_	_	_
38	cell	_	O	O	_	_	_	_	_
39	lines	_	O	O	_	_	_	_	_
40	were	_	O	O	_	_	_	_	_
41	investigated	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	comparison	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Stat	_	O	O	_	_	_	_	_
6	proteins	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	interferon	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	PRL	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	47	_	O	O	_	_	_	_	_
22	D	_	O	O	_	_	_	_	_
23	mammary	_	O	O	_	_	_	_	_
24	tumor	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	made	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	parameters	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	indistinguishable	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	one	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	PRL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	factors	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	closely	_	O	O	_	_	_	_	_
5	related	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	mammary	_	O	O	_	_	_	_	_
8	gland	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Stat	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	rapidly	_	O	O	_	_	_	_	_
15	activated	_	O	O	_	_	_	_	_
16	upon	_	O	O	_	_	_	_	_
17	interaction	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	PRL	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	their	_	O	O	_	_	_	_	_
26	respective	_	O	O	_	_	_	_	_
27	receptors	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	second	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	related	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	Stat	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	observed	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	emphasize	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	role	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	PRL	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	regulator	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	immune	_	O	O	_	_	_	_	_
14	response	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	indicate	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	Stat	_	O	O	_	_	_	_	_
20	factors	_	O	O	_	_	_	_	_
21	mammary	_	O	O	_	_	_	_	_
22	gland	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	Stat	_	O	O	_	_	_	_	_
26	5	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	Stat	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	play	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	role	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	regulation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	gene	_	O	O	_	_	_	_	_
38	expression	_	O	O	_	_	_	_	_
39	during	_	O	O	_	_	_	_	_
40	T	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	development	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_


1	Western	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Akt	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	phosphorylated	_	O	O	_	_	_	_	_
8	Akt	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	IkappaB	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	incubated	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	anti	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	mug	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	ml	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	presence	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	absence	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	LY	_	O	O	_	_	_	_	_
22	294002	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	20	_	O	O	_	_	_	_	_
25	muM	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	incubation	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	hour	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	whole	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	lysates	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	prepared	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	about	_	O	O	_	_	_	_	_
14	107	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	homogenization	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	lysis	_	O	O	_	_	_	_	_
21	buffer	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	centrifuged	_	O	O	_	_	_	_	_
25	at	_	O	O	_	_	_	_	_
26	14	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	000	_	O	O	_	_	_	_	_
29	r	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_
31	p	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	m	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	19	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	000	_	O	O	_	_	_	_	_
5	g	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	15	_	O	O	_	_	_	_	_
9	min	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Protein	_	O	O	_	_	_	_	_
2	concentrations	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	supernatants	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	determined	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	Bradford	_	O	O	_	_	_	_	_
11	method	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	Bio	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Rad	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	Hercules	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	CA	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	USA	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Protein	_	O	O	_	_	_	_	_
2	samples	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	separated	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	%	_	O	O	_	_	_	_	_
8	SDS	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	PAGE	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	transferred	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	nitrocellulose	_	O	O	_	_	_	_	_
16	membrane	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	Amersham	_	O	O	_	_	_	_	_
19	Pharmacia	_	O	O	_	_	_	_	_
20	Biotech	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	Uppsala	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	Sweden	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	western	_	O	O	_	_	_	_	_
3	hybridization	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	membrane	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	preincubated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	0	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	%	_	O	O	_	_	_	_	_
13	skimmed	_	O	O	_	_	_	_	_
14	milk	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	TBS	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	buffer	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	0	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	%	_	O	O	_	_	_	_	_
25	Tween	_	O	O	_	_	_	_	_
26	20	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	Tris	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	buffered	_	O	O	_	_	_	_	_
31	saline	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	at	_	O	O	_	_	_	_	_
34	room	_	O	O	_	_	_	_	_
35	temperature	_	O	O	_	_	_	_	_
36	for	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	hours	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	then	_	O	O	_	_	_	_	_
41	primary	_	O	O	_	_	_	_	_
42	antibodies	_	O	O	_	_	_	_	_
43	against	_	O	O	_	_	_	_	_
44	Akt	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	phosphorylated	_	O	O	_	_	_	_	_
47	Akt	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	IkappaB	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	alpha	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	Cell	_	O	O	_	_	_	_	_
54	Signaling	_	O	O	_	_	_	_	_
55	Technology	_	O	O	_	_	_	_	_
56	Inc	_	O	O	_	_	_	_	_
57	.,	_	O	O	_	_	_	_	_
58	Beverly	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	MA	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	USA	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	,	_	O	O	_	_	_	_	_
65	diluted	_	O	O	_	_	_	_	_
66	1	_	O	O	_	_	_	_	_
67	:	_	O	O	_	_	_	_	_
68	1000	_	O	O	_	_	_	_	_
69	in	_	O	O	_	_	_	_	_
70	5	_	O	O	_	_	_	_	_
71	%	_	O	O	_	_	_	_	_
72	BSA	_	O	O	_	_	_	_	_
73	/	_	O	O	_	_	_	_	_
74	TBS	_	O	O	_	_	_	_	_
75	-	_	O	O	_	_	_	_	_
76	T	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	were	_	O	O	_	_	_	_	_
79	added	_	O	O	_	_	_	_	_
80	and	_	O	O	_	_	_	_	_
81	incubated	_	O	O	_	_	_	_	_
82	overnight	_	O	O	_	_	_	_	_
83	at	_	O	O	_	_	_	_	_
84	4	_	O	O	_	_	_	_	_
85	degreesC	_	O	O	_	_	_	_	_
86	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	washing	_	O	O	_	_	_	_	_
3	four	_	O	O	_	_	_	_	_
4	times	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	TBS	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	horseradish	_	O	O	_	_	_	_	_
11	peroxidase	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	conjugated	_	O	O	_	_	_	_	_
14	secondary	_	O	O	_	_	_	_	_
15	antibodies	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	added	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	allowed	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	incubate	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	hour	_	O	O	_	_	_	_	_
25	at	_	O	O	_	_	_	_	_
26	room	_	O	O	_	_	_	_	_
27	temperature	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	TBS	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	washing	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	hybridized	_	O	O	_	_	_	_	_
8	bands	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	detected	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	enhanced	_	O	O	_	_	_	_	_
14	chemiluminescence	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	ECL	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	detection	_	O	O	_	_	_	_	_
19	kit	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	Hyperfilm	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	ECL	_	O	O	_	_	_	_	_
24	reagents	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	Amersham	_	O	O	_	_	_	_	_
27	Pharmacia	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_



1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	dexamethasone	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	glucocorticoid	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	New	_	O	O	_	_	_	_	_
11	World	_	O	O	_	_	_	_	_
12	primate	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	extracts	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	if	_	O	O	_	_	_	_	_
4	New	_	O	O	_	_	_	_	_
5	World	_	O	O	_	_	_	_	_
6	primates	_	O	O	_	_	_	_	_
7	express	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	inhibitor	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	influences	_	O	O	_	_	_	_	_
12	glucocorticoid	_	O	O	_	_	_	_	_
13	receptor	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	GR	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	characteristics	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	we	_	O	O	_	_	_	_	_
21	examined	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	H	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	dexamethasone	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	cytosol	_	O	O	_	_	_	_	_
30	prepared	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	95	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	8	_	O	O	_	_	_	_	_
36	lymphoid	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	derived	_	O	O	_	_	_	_	_
40	from	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	cotton	_	O	O	_	_	_	_	_
43	top	_	O	O	_	_	_	_	_
44	tamarin	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	Saguinus	_	O	O	_	_	_	_	_
47	oedipus	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	combination	_	O	O	_	_	_	_	_
52	with	_	O	O	_	_	_	_	_
53	cytosol	_	O	O	_	_	_	_	_
54	prepared	_	O	O	_	_	_	_	_
55	from	_	O	O	_	_	_	_	_
56	human	_	O	O	_	_	_	_	_
57	or	_	O	O	_	_	_	_	_
58	rat	_	O	O	_	_	_	_	_
59	tissues	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	B	_	O	O	_	_	_	_	_
2	95	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	8	_	O	O	_	_	_	_	_
5	cytosol	_	O	O	_	_	_	_	_
6	inhibited	_	O	O	_	_	_	_	_
7	specific	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	[	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	H	_	O	O	_	_	_	_	_
13	]	_	O	O	_	_	_	_	_
14	dexamethasone	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	P	_	O	O	_	_	_	_	_
17	<	_	O	O	_	_	_	_	_
18	0	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	01	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	when	_	O	O	_	_	_	_	_
23	mixed	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	cytosol	_	O	O	_	_	_	_	_
26	prepared	_	O	O	_	_	_	_	_
27	from	_	O	O	_	_	_	_	_
28	either	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	lymphoid	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	line	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	HL	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	or	_	O	O	_	_	_	_	_
38	rat	_	O	O	_	_	_	_	_
39	thymus	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	activity	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	heat	_	O	O	_	_	_	_	_
6	labile	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	trypsin	_	O	O	_	_	_	_	_
9	sensitive	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Peak	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	activity	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	found	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	150	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	200	_	O	O	_	_	_	_	_
11	kd	_	O	O	_	_	_	_	_
12	fractions	_	O	O	_	_	_	_	_
13	after	_	O	O	_	_	_	_	_
14	Sephacryl	_	O	O	_	_	_	_	_
15	G	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	200	_	O	O	_	_	_	_	_
18	ultrafiltration	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Scatchard	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	[	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	H	_	O	O	_	_	_	_	_
7	]	_	O	O	_	_	_	_	_
8	dexamethasone	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	using	_	O	O	_	_	_	_	_
11	mixed	_	O	O	_	_	_	_	_
12	cytosol	_	O	O	_	_	_	_	_
13	showed	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	diminished	_	O	O	_	_	_	_	_
16	GR	_	O	O	_	_	_	_	_
17	apparent	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	affinity	_	O	O	_	_	_	_	_
20	when	_	O	O	_	_	_	_	_
21	compared	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	HL	_	O	O	_	_	_	_	_
24	cytosol	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Kinetic	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	using	_	O	O	_	_	_	_	_
4	mixed	_	O	O	_	_	_	_	_
5	cytosol	_	O	O	_	_	_	_	_
6	indicated	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	95	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	8	_	O	O	_	_	_	_	_
12	cytosol	_	O	O	_	_	_	_	_
13	did	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	affect	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	apparent	_	O	O	_	_	_	_	_
18	dissociation	_	O	O	_	_	_	_	_
19	rate	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	H	_	O	O	_	_	_	_	_
24	]	_	O	O	_	_	_	_	_
25	dexamethasone	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	95	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	8	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	contain	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	competitive	_	O	O	_	_	_	_	_
13	inhibitor	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	prevents	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	dexamethasone	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	its	_	O	O	_	_	_	_	_
21	cognate	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	[	_	O	O	_	_	_	_	_
2	Induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	apoptosis	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	glucocorticoids	_	O	O	_	_	_	_	_
9	:	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	physiology	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	pharmacology	_	O	O	_	_	_	_	_
14	]	_	O	O	_	_	_	_	_

1	Glucocorticoids	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	physiological	_	O	O	_	_	_	_	_
4	molecules	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	extensively	_	O	O	_	_	_	_	_
9	used	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	clinics	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	anti	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	inflammatory	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	immunosuppressive	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	anti	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	tumoral	_	O	O	_	_	_	_	_
22	agents	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Glucocorticoids	_	O	O	_	_	_	_	_
2	can	_	O	O	_	_	_	_	_
3	induce	_	O	O	_	_	_	_	_
4	apoptosis	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	normal	_	O	O	_	_	_	_	_
7	lymphoid	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	play	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	key	_	O	O	_	_	_	_	_
13	role	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	physiology	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	thymic	_	O	O	_	_	_	_	_
19	selection	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	clinics	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	molecules	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	used	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	their	_	O	O	_	_	_	_	_
10	potencies	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	inducing	_	O	O	_	_	_	_	_
13	apoptosis	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	malignant	_	O	O	_	_	_	_	_
16	lymphoid	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Glucocorticoids	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	mediating	_	O	O	_	_	_	_	_
4	their	_	O	O	_	_	_	_	_
5	effects	_	O	O	_	_	_	_	_
6	after	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	intracellular	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	belonging	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	steroid	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	superfamily	_	O	O	_	_	_	_	_
18	:	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	glucocorticoid	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	GR	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Once	_	O	O	_	_	_	_	_
2	activated	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	GR	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	can	_	O	O	_	_	_	_	_
8	mediate	_	O	O	_	_	_	_	_
9	his	_	O	O	_	_	_	_	_
10	effects	_	O	O	_	_	_	_	_
11	through	_	O	O	_	_	_	_	_
12	direct	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	DNA	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	via	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	interactions	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	factors	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Depending	_	O	O	_	_	_	_	_
2	on	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	type	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	lymphocytes	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	mechanism	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	apoptosis	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	glucocorticoids	_	O	O	_	_	_	_	_
15	fall	_	O	O	_	_	_	_	_
16	roughly	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	two	_	O	O	_	_	_	_	_
19	categories	_	O	O	_	_	_	_	_
20	:	_	O	O	_	_	_	_	_
21	induction	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	""""	_	O	O	_	_	_	_	_
24	death	_	O	O	_	_	_	_	_
25	genes	_	O	O	_	_	_	_	_
26	""""	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	activated	_	O	O	_	_	_	_	_
30	GR	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	I	_	O	O	_	_	_	_	_
33	kappa	_	O	O	_	_	_	_	_
34	B	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	c	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	jun	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	or	_	O	O	_	_	_	_	_
41	repression	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	survival	_	O	O	_	_	_	_	_
44	factors	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	AP	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	c	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	Myc	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	case	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	thymic	_	O	O	_	_	_	_	_
6	selection	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	mechanism	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	more	_	O	O	_	_	_	_	_
11	subtle	_	O	O	_	_	_	_	_
12	depending	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	mutual	_	O	O	_	_	_	_	_
16	repression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	Nur	_	O	O	_	_	_	_	_
19	77	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	GR	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Constitutively	_	O	O	_	_	_	_	_
2	activated	_	O	O	_	_	_	_	_
3	Jak	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	pathway	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	transformed	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	HTLV	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	I	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	lymphotropic	_	O	O	_	_	_	_	_
5	virus	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	HTLV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	I	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	etiological	_	O	O	_	_	_	_	_
15	agent	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	adult	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	leukemia	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	tropical	_	O	O	_	_	_	_	_
23	spastic	_	O	O	_	_	_	_	_
24	paraparesis	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	also	_	O	O	_	_	_	_	_
27	termed	_	O	O	_	_	_	_	_
28	HTLV	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	I	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	associated	_	O	O	_	_	_	_	_
33	myelopathy	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	HTLV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	infected	_	O	O	_	_	_	_	_
6	peripheral	_	O	O	_	_	_	_	_
7	blood	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	exhibit	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	initial	_	O	O	_	_	_	_	_
13	phase	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	interleukin	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	dependent	_	O	O	_	_	_	_	_
25	growth	_	O	O	_	_	_	_	_
26	;	_	O	O	_	_	_	_	_
27	over	_	O	O	_	_	_	_	_
28	time	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	an	_	O	O	_	_	_	_	_
32	unknown	_	O	O	_	_	_	_	_
33	mechanism	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	become	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	independent	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Whereas	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	Jak	_	O	O	_	_	_	_	_
4	kinases	_	O	O	_	_	_	_	_
5	Jak	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	Jak	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	signal	_	O	O	_	_	_	_	_
13	transducer	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	activator	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	proteins	_	O	O	_	_	_	_	_
19	Stat	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	Stat	_	O	O	_	_	_	_	_
23	5	_	O	O	_	_	_	_	_
24	are	_	O	O	_	_	_	_	_
25	activated	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	normal	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	response	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	this	_	O	O	_	_	_	_	_
38	signaling	_	O	O	_	_	_	_	_
39	pathway	_	O	O	_	_	_	_	_
40	was	_	O	O	_	_	_	_	_
41	constitutively	_	O	O	_	_	_	_	_
42	activated	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	HTLV	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	I	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	transformed	_	O	O	_	_	_	_	_
49	cells	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	HTLV	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	I	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	infected	_	O	O	_	_	_	_	_
7	cord	_	O	O	_	_	_	_	_
8	blood	_	O	O	_	_	_	_	_
9	lymphocytes	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	transition	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	dependent	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	independent	_	O	O	_	_	_	_	_
25	growth	_	O	O	_	_	_	_	_
26	correlated	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	acquisition	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	constitutively	_	O	O	_	_	_	_	_
33	activated	_	O	O	_	_	_	_	_
34	Jak	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	STAT	_	O	O	_	_	_	_	_
37	pathway	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	which	_	O	O	_	_	_	_	_
40	suggests	_	O	O	_	_	_	_	_
41	that	_	O	O	_	_	_	_	_
42	this	_	O	O	_	_	_	_	_
43	pathway	_	O	O	_	_	_	_	_
44	participates	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	HTLV	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	I	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	mediated	_	O	O	_	_	_	_	_
51	T	_	O	O	_	_	_	_	_
52	cell	_	O	O	_	_	_	_	_
53	transformation	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_


1	Staphylococcal	_	O	O	_	_	_	_	_
2	enterotoxins	_	O	O	_	_	_	_	_
3	modulate	_	O	O	_	_	_	_	_
4	interleukin	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	ligand	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	tyrosine	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	Janus	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	kinase	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	Jak	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	signal	_	O	O	_	_	_	_	_
28	transducers	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	activators	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	transcription	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	Stat	_	O	O	_	_	_	_	_
35	proteins	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Staphylococcal	_	O	O	_	_	_	_	_
2	enterotoxins	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	SE	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	stimulate	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	expressing	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	appropriate	_	O	O	_	_	_	_	_
12	variable	_	O	O	_	_	_	_	_
13	region	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	chain	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	V	_	O	O	_	_	_	_	_
19	beta	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	receptors	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	have	_	O	O	_	_	_	_	_
27	been	_	O	O	_	_	_	_	_
28	implicated	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	pathogenesis	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	several	_	O	O	_	_	_	_	_
34	autoimmune	_	O	O	_	_	_	_	_
35	diseases	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Depending	_	O	O	_	_	_	_	_
2	on	_	O	O	_	_	_	_	_
3	costimulatory	_	O	O	_	_	_	_	_
4	signals	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	SE	_	O	O	_	_	_	_	_
7	induce	_	O	O	_	_	_	_	_
8	either	_	O	O	_	_	_	_	_
9	proliferation	_	O	O	_	_	_	_	_
10	or	_	O	O	_	_	_	_	_
11	anergy	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	SE	_	O	O	_	_	_	_	_
5	can	_	O	O	_	_	_	_	_
6	induce	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	interleukin	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	nonresponsive	_	O	O	_	_	_	_	_
17	state	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	apoptosis	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	SE	_	O	O	_	_	_	_	_
7	induce	_	O	O	_	_	_	_	_
8	dynamic	_	O	O	_	_	_	_	_
9	changes	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	signal	_	O	O	_	_	_	_	_
16	transduction	_	O	O	_	_	_	_	_
17	through	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	R	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	beta	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	gamma	_	O	O	_	_	_	_	_
32	chains	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	R	_	O	O	_	_	_	_	_
38	beta	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	R	_	O	O	_	_	_	_	_
44	gamma	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	human	_	O	O	_	_	_	_	_
48	antigen	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	specific	_	O	O	_	_	_	_	_
51	CD	_	O	O	_	_	_	_	_
52	4	_	O	O	_	_	_	_	_
53	+	_	O	O	_	_	_	_	_
54	T	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	cell	_	O	O	_	_	_	_	_
57	lines	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	after	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	hr	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	exposure	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	SEA	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	SEB	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	R	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	down	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	regulated	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	R	_	O	O	_	_	_	_	_
30	gamma	_	O	O	_	_	_	_	_
31	was	_	O	O	_	_	_	_	_
32	slightly	_	O	O	_	_	_	_	_
33	up	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	regulated	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	while	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	R	_	O	O	_	_	_	_	_
42	alpha	_	O	O	_	_	_	_	_
43	remained	_	O	O	_	_	_	_	_
44	largely	_	O	O	_	_	_	_	_
45	unaffected	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	changes	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	composition	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	Rs	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	accompanied	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	phosphorylation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	Janus	_	O	O	_	_	_	_	_
26	protein	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	tyrosine	_	O	O	_	_	_	_	_
29	kinase	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	Jak	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	signal	_	O	O	_	_	_	_	_
37	transducers	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	activators	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	transcription	_	O	O	_	_	_	_	_
42	called	_	O	O	_	_	_	_	_
43	Stat	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	Stat	_	O	O	_	_	_	_	_
47	5	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	parallel	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	driven	_	O	O	_	_	_	_	_
10	proliferation	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	inhibited	_	O	O	_	_	_	_	_
13	significantly	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	16	_	O	O	_	_	_	_	_
3	hr	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	exposure	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	SE	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	R	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	remained	_	O	O	_	_	_	_	_
18	low	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	while	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	R	_	O	O	_	_	_	_	_
26	alpha	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	R	_	O	O	_	_	_	_	_
31	gamma	_	O	O	_	_	_	_	_
32	was	_	O	O	_	_	_	_	_
33	further	_	O	O	_	_	_	_	_
34	up	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	regulated	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	ligand	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	induced	_	O	O	_	_	_	_	_
42	tyrosine	_	O	O	_	_	_	_	_
43	phosphorylation	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	Jak	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	Stat	_	O	O	_	_	_	_	_
49	proteins	_	O	O	_	_	_	_	_
50	was	_	O	O	_	_	_	_	_
51	partly	_	O	O	_	_	_	_	_
52	normalized	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Yet	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	driven	_	O	O	_	_	_	_	_
8	proliferation	_	O	O	_	_	_	_	_
9	remained	_	O	O	_	_	_	_	_
10	profoundly	_	O	O	_	_	_	_	_
11	inhibited	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	suggesting	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	events	_	O	O	_	_	_	_	_
17	other	_	O	O	_	_	_	_	_
18	than	_	O	O	_	_	_	_	_
19	Jak	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	Stat	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	had	_	O	O	_	_	_	_	_
25	also	_	O	O	_	_	_	_	_
26	been	_	O	O	_	_	_	_	_
27	changed	_	O	O	_	_	_	_	_
28	following	_	O	O	_	_	_	_	_
29	SE	_	O	O	_	_	_	_	_
30	stimulation	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	data	_	O	O	_	_	_	_	_
6	suggest	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	SE	_	O	O	_	_	_	_	_
9	can	_	O	O	_	_	_	_	_
10	modulate	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	R	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	signal	_	O	O	_	_	_	_	_
18	transduction	_	O	O	_	_	_	_	_
19	involving	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	Jak	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	Stat	_	O	O	_	_	_	_	_
24	pathway	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	cell	_	O	O	_	_	_	_	_
32	lines	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Glucocorticoid	_	O	O	_	_	_	_	_
2	receptors	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	anorexia	_	O	O	_	_	_	_	_
5	nervosa	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	Cushing	_	O	O	_	_	_	_	_
8	'	_	O	O	_	_	_	_	_
9	s	_	O	O	_	_	_	_	_
10	disease	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_


1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Patients	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	anorexia	_	O	O	_	_	_	_	_
6	nervosa	_	O	O	_	_	_	_	_
7	do	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	display	_	O	O	_	_	_	_	_
10	cushingoid	_	O	O	_	_	_	_	_
11	features	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	spite	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	elevated	_	O	O	_	_	_	_	_
16	cortisol	_	O	O	_	_	_	_	_
17	plasma	_	O	O	_	_	_	_	_
18	levels	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Whether	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	cortisol	_	O	O	_	_	_	_	_
4	resistance	_	O	O	_	_	_	_	_
5	or	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	reduced	_	O	O	_	_	_	_	_
8	availability	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	metabolic	_	O	O	_	_	_	_	_
12	substrates	_	O	O	_	_	_	_	_
13	necessary	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	develop	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	effect	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	glucocorticoids	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	responsible	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	this	_	O	O	_	_	_	_	_
24	has	_	O	O	_	_	_	_	_
25	not	_	O	O	_	_	_	_	_
26	been	_	O	O	_	_	_	_	_
27	established	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Twenty	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	severe	_	O	O	_	_	_	_	_
9	restrictive	_	O	O	_	_	_	_	_
10	anorexia	_	O	O	_	_	_	_	_
11	nervosa	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	patients	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	active	_	O	O	_	_	_	_	_
17	Cushing	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	s	_	O	O	_	_	_	_	_
20	disease	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	24	_	O	O	_	_	_	_	_
24	healthy	_	O	O	_	_	_	_	_
25	volunteers	_	O	O	_	_	_	_	_
26	without	_	O	O	_	_	_	_	_
27	psychiatric	_	O	O	_	_	_	_	_
28	disorders	_	O	O	_	_	_	_	_
29	or	_	O	O	_	_	_	_	_
30	mood	_	O	O	_	_	_	_	_
31	alterations	_	O	O	_	_	_	_	_
32	were	_	O	O	_	_	_	_	_
33	investigated	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Glucocorticoid	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	characteristics	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	examined	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	mononuclear	_	O	O	_	_	_	_	_
8	leukocytes	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	measuring	_	O	O	_	_	_	_	_
11	[	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	H	_	O	O	_	_	_	_	_
14	]	_	O	O	_	_	_	_	_
15	dexamethasone	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	effect	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	dexamethasone	_	O	O	_	_	_	_	_
22	on	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	H	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	thymidine	_	O	O	_	_	_	_	_
28	incorporation	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	represents	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	index	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	DNA	_	O	O	_	_	_	_	_
36	synthesis	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	number	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	receptors	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	mononuclear	_	O	O	_	_	_	_	_
10	leukocytes	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	MNL	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	comparable	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	anorexia	_	O	O	_	_	_	_	_
20	nervosa	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	patients	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	active	_	O	O	_	_	_	_	_
25	Cushing	_	O	O	_	_	_	_	_
26	'	_	O	O	_	_	_	_	_
27	s	_	O	O	_	_	_	_	_
28	disease	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	normal	_	O	O	_	_	_	_	_
32	subjects	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	binding	_	O	O	_	_	_	_	_
35	capacity	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	+	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	0	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_
44	23	_	O	O	_	_	_	_	_
45	vs	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_
3	7	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	0	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	30	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	0	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	20	_	O	O	_	_	_	_	_
20	fmol	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Conversely	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	glucocorticoid	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	affinity	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	significantly	_	O	O	_	_	_	_	_
8	decreased	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	anorexia	_	O	O	_	_	_	_	_
11	nervosa	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	well	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	Cushing	_	O	O	_	_	_	_	_
17	'	_	O	O	_	_	_	_	_
18	s	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	compared	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	control	_	O	O	_	_	_	_	_
23	subjects	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	dissociation	_	O	O	_	_	_	_	_
26	constant	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	0	_	O	O	_	_	_	_	_
30	+	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	0	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_
35	31	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	4	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	+	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	0	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_
45	34	_	O	O	_	_	_	_	_
46	vs	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_
3	9	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	0	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	29	_	O	O	_	_	_	_	_
10	nmol	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	L	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	p	_	O	O	_	_	_	_	_
15	<	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_
17	001	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	inversely	_	O	O	_	_	_	_	_
21	correlated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	levels	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	urinary	_	O	O	_	_	_	_	_
27	free	_	O	O	_	_	_	_	_
28	cortisol	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	both	_	O	O	_	_	_	_	_
31	groups	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	patients	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Basal	_	O	O	_	_	_	_	_
2	[	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	H	_	O	O	_	_	_	_	_
5	]	_	O	O	_	_	_	_	_
6	thymidine	_	O	O	_	_	_	_	_
7	incorporation	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	MNL	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	significantly	_	O	O	_	_	_	_	_
12	reduced	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	anorexia	_	O	O	_	_	_	_	_
15	nervosa	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	well	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	Cushing	_	O	O	_	_	_	_	_
21	'	_	O	O	_	_	_	_	_
22	s	_	O	O	_	_	_	_	_
23	patients	_	O	O	_	_	_	_	_
24	compared	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	control	_	O	O	_	_	_	_	_
27	subjects	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	p	_	O	O	_	_	_	_	_
30	<	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	001	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	diminished	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	dexamethasone	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	an	_	O	O	_	_	_	_	_
41	extent	_	O	O	_	_	_	_	_
42	similar	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	control	_	O	O	_	_	_	_	_
45	subjects	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	patients	_	O	O	_	_	_	_	_
48	with	_	O	O	_	_	_	_	_
49	anorexia	_	O	O	_	_	_	_	_
50	nervosa	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	but	_	O	O	_	_	_	_	_
53	significantly	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	p	_	O	O	_	_	_	_	_
56	<	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_
58	001	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	less	_	O	O	_	_	_	_	_
61	in	_	O	O	_	_	_	_	_
62	those	_	O	O	_	_	_	_	_
63	with	_	O	O	_	_	_	_	_
64	Cushing	_	O	O	_	_	_	_	_
65	'	_	O	O	_	_	_	_	_
66	s	_	O	O	_	_	_	_	_
67	disease	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	patients	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	anorexia	_	O	O	_	_	_	_	_
5	nervosa	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	incorporation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	[	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	H	_	O	O	_	_	_	_	_
13	]	_	O	O	_	_	_	_	_
14	thymidine	_	O	O	_	_	_	_	_
15	into	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	MNL	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	inversely	_	O	O	_	_	_	_	_
20	correlated	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	urinary	_	O	O	_	_	_	_	_
23	free	_	O	O	_	_	_	_	_
24	cortisol	_	O	O	_	_	_	_	_
25	levels	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	These	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	indicate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	lack	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	cushingoid	_	O	O	_	_	_	_	_
11	features	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	anorexia	_	O	O	_	_	_	_	_
16	nervosa	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	ascribable	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	reduced	_	O	O	_	_	_	_	_
23	sensitivity	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	glucocorticoids	_	O	O	_	_	_	_	_
26	but	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	more	_	O	O	_	_	_	_	_
29	likely	_	O	O	_	_	_	_	_
30	due	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	paucity	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	metabolic	_	O	O	_	_	_	_	_
36	substrates	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Estrogen	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	progesterone	_	O	O	_	_	_	_	_
4	induction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	survival	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	monoblastoid	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	undergoing	_	O	O	_	_	_	_	_
11	TNF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	apoptosis	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	apoptosis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	mononucleated	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	physiological	_	O	O	_	_	_	_	_
10	process	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	regulating	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	intensity	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	immune	_	O	O	_	_	_	_	_
18	response	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	female	_	O	O	_	_	_	_	_
3	steroid	_	O	O	_	_	_	_	_
4	hormones	_	O	O	_	_	_	_	_
5	estrogen	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	E	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	progesterone	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	Prog	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	known	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	modulate	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	reactivity	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	immune	_	O	O	_	_	_	_	_
24	system	_	O	O	_	_	_	_	_
25	;	_	O	O	_	_	_	_	_
26	recently	_	O	O	_	_	_	_	_
27	it	_	O	O	_	_	_	_	_
28	has	_	O	O	_	_	_	_	_
29	been	_	O	O	_	_	_	_	_
30	demonstrated	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	they	_	O	O	_	_	_	_	_
33	can	_	O	O	_	_	_	_	_
34	regulate	_	O	O	_	_	_	_	_
35	induction	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	apoptosis	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	endothelial	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	osteoblasts	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	TNF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	alpha	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	induction	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	apoptosis	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	been	_	O	O	_	_	_	_	_
11	well	_	O	O	_	_	_	_	_
12	characterized	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	myeloid	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	Prog	_	O	O	_	_	_	_	_
8	could	_	O	O	_	_	_	_	_
9	interfere	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	TNF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	apoptosis	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	monoblastoid	_	O	O	_	_	_	_	_
20	U	_	O	O	_	_	_	_	_
21	937	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	line	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	E	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	or	_	O	O	_	_	_	_	_
6	Prog	_	O	O	_	_	_	_	_
7	increased	_	O	O	_	_	_	_	_
8	survival	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	prevented	_	O	O	_	_	_	_	_
11	apoptosis	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	TNF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	undifferentiated	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	macrophage	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	like	_	O	O	_	_	_	_	_
24	PMA	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	differentiated	_	O	O	_	_	_	_	_
27	U	_	O	O	_	_	_	_	_
28	937	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	assessed	_	O	O	_	_	_	_	_
33	by	_	O	O	_	_	_	_	_
34	trypan	_	O	O	_	_	_	_	_
35	blue	_	O	O	_	_	_	_	_
36	exclusion	_	O	O	_	_	_	_	_
37	cell	_	O	O	_	_	_	_	_
38	counting	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	thymidine	_	O	O	_	_	_	_	_
41	incorporation	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	AnnexinV	_	O	O	_	_	_	_	_
44	labeling	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	followed	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	flow	_	O	O	_	_	_	_	_
49	cytometry	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	DNA	_	O	O	_	_	_	_	_
52	fragmentation	_	O	O	_	_	_	_	_
53	studies	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	can	_	O	O	_	_	_	_	_
4	be	_	O	O	_	_	_	_	_
5	associated	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	specific	_	O	O	_	_	_	_	_
11	hormone	_	O	O	_	_	_	_	_
12	receptors	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	since	_	O	O	_	_	_	_	_
15	we	_	O	O	_	_	_	_	_
16	observed	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	estrogen	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	alpha	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	ER	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	ER	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	progesterone	_	O	O	_	_	_	_	_
36	receptor	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	PR	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	mRNAs	_	O	O	_	_	_	_	_
41	;	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	ER	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	alpha	_	O	O	_	_	_	_	_
46	protein	_	O	O	_	_	_	_	_
47	expression	_	O	O	_	_	_	_	_
48	was	_	O	O	_	_	_	_	_
49	confirmed	_	O	O	_	_	_	_	_
50	by	_	O	O	_	_	_	_	_
51	immunocytochemical	_	O	O	_	_	_	_	_
52	analysis	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	hormone	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	mediated	_	O	O	_	_	_	_	_
7	survival	_	O	O	_	_	_	_	_
8	against	_	O	O	_	_	_	_	_
9	apoptosis	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	concentration	_	O	O	_	_	_	_	_
12	dependent	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	reaching	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	half	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	maximal	_	O	O	_	_	_	_	_
19	effect	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	10	_	O	O	_	_	_	_	_
22	nM	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	blocked	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	ER	_	O	O	_	_	_	_	_
28	antagonist	_	O	O	_	_	_	_	_
29	ICI	_	O	O	_	_	_	_	_
30	182	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	780	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	undifferentiated	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	further	_	O	O	_	_	_	_	_
38	supporting	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	receptor	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	mediated	_	O	O	_	_	_	_	_
43	mechanism	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	cell	_	O	O	_	_	_	_	_
46	survival	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Other	_	O	O	_	_	_	_	_
2	steroid	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	drugs	_	O	O	_	_	_	_	_
5	such	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	Raloxifene	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	RU	_	O	O	_	_	_	_	_
10	486	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	ICI	_	O	O	_	_	_	_	_
15	182	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	780	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	PMA	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	differentiated	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	displayed	_	O	O	_	_	_	_	_
24	agonist	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	preventing	_	O	O	_	_	_	_	_
28	TNF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	alpha	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	induced	_	O	O	_	_	_	_	_
33	apoptosis	_	O	O	_	_	_	_	_
34	as	_	O	O	_	_	_	_	_
35	efficiently	_	O	O	_	_	_	_	_
36	as	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	hormones	_	O	O	_	_	_	_	_
39	alone	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	providing	_	O	O	_	_	_	_	_
42	further	_	O	O	_	_	_	_	_
43	evidence	_	O	O	_	_	_	_	_
44	to	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	notion	_	O	O	_	_	_	_	_
47	that	_	O	O	_	_	_	_	_
48	steroid	_	O	O	_	_	_	_	_
49	receptor	_	O	O	_	_	_	_	_
50	drugs	_	O	O	_	_	_	_	_
51	may	_	O	O	_	_	_	_	_
52	manifest	_	O	O	_	_	_	_	_
53	agonist	_	O	O	_	_	_	_	_
54	or	_	O	O	_	_	_	_	_
55	antagonist	_	O	O	_	_	_	_	_
56	activities	_	O	O	_	_	_	_	_
57	depending	_	O	O	_	_	_	_	_
58	on	_	O	O	_	_	_	_	_
59	the	_	O	O	_	_	_	_	_
60	cellular	_	O	O	_	_	_	_	_
61	context	_	O	O	_	_	_	_	_
62	in	_	O	O	_	_	_	_	_
63	which	_	O	O	_	_	_	_	_
64	they	_	O	O	_	_	_	_	_
65	are	_	O	O	_	_	_	_	_
66	studied	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	E	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	associated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	time	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	dependent	_	O	O	_	_	_	_	_
13	decrease	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	mRNA	_	O	O	_	_	_	_	_
17	level	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	proapoptotic	_	O	O	_	_	_	_	_
21	Nip	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	supporting	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	hypothesis	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	hormone	_	O	O	_	_	_	_	_
31	responsiveness	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	U	_	O	O	_	_	_	_	_
34	937	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	is	_	O	O	_	_	_	_	_
37	mediated	_	O	O	_	_	_	_	_
38	by	_	O	O	_	_	_	_	_
39	target	_	O	O	_	_	_	_	_
40	gene	_	O	O	_	_	_	_	_
41	transcription	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Together	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	demonstrate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	ER	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	PR	_	O	O	_	_	_	_	_
10	can	_	O	O	_	_	_	_	_
11	be	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	endogenous	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	exogenous	_	O	O	_	_	_	_	_
17	ligands	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	induce	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	genetic	_	O	O	_	_	_	_	_
22	response	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	impairs	_	O	O	_	_	_	_	_
25	TNF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	induced	_	O	O	_	_	_	_	_
30	apoptosis	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	U	_	O	O	_	_	_	_	_
33	937	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	presented	_	O	O	_	_	_	_	_
4	here	_	O	O	_	_	_	_	_
5	suggest	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	female	_	O	O	_	_	_	_	_
9	steroid	_	O	O	_	_	_	_	_
10	receptors	_	O	O	_	_	_	_	_
11	play	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	role	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	regulation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	immune	_	O	O	_	_	_	_	_
19	response	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	preventing	_	O	O	_	_	_	_	_
22	apoptosis	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	monoblastoid	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	;	_	O	O	_	_	_	_	_
27	this	_	O	O	_	_	_	_	_
28	effect	_	O	O	_	_	_	_	_
29	might	_	O	O	_	_	_	_	_
30	have	_	O	O	_	_	_	_	_
31	important	_	O	O	_	_	_	_	_
32	consequences	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	clinical	_	O	O	_	_	_	_	_
36	use	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	steroid	_	O	O	_	_	_	_	_
39	receptor	_	O	O	_	_	_	_	_
40	drugs	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	--	_	O	O	_	_	_	_	_
2	Vegeto	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	.,	_	O	O	_	_	_	_	_
6	Pollio	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	G	_	O	O	_	_	_	_	_
9	.,	_	O	O	_	_	_	_	_
10	Pellicciari	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	C	_	O	O	_	_	_	_	_
13	.,	_	O	O	_	_	_	_	_
14	Maggi	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	A	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Estrogen	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	progesterone	_	O	O	_	_	_	_	_
4	induction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	survival	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	monoblastoid	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	undergoing	_	O	O	_	_	_	_	_
11	TNF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	inuced	_	O	O	_	_	_	_	_
16	apoptosis	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Cell	_	O	O	_	_	_	_	_
2	type	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	stage	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	specific	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	20	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	antigen	_	O	O	_	_	_	_	_
17	correlates	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	activity	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	diverged	_	O	O	_	_	_	_	_
24	octamer	_	O	O	_	_	_	_	_
25	DNA	_	O	O	_	_	_	_	_
26	motif	_	O	O	_	_	_	_	_
27	present	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	its	_	O	O	_	_	_	_	_
30	promoter	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	20	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	encodes	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	involved	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	regulation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	B	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	proliferation	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	differentiation	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Studies	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	5	_	O	O	_	_	_	_	_
4	'	_	O	O	_	_	_	_	_
5	deletion	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	20	_	O	O	_	_	_	_	_
8	promoter	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CAT	_	O	O	_	_	_	_	_
11	constructs	_	O	O	_	_	_	_	_
12	have	_	O	O	_	_	_	_	_
13	previously	_	O	O	_	_	_	_	_
14	revealed	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	regions	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	promoter	_	O	O	_	_	_	_	_
20	between	_	O	O	_	_	_	_	_
21	bases	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	186	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	280	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	between	_	O	O	_	_	_	_	_
29	bases	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	280	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	454	_	O	O	_	_	_	_	_
35	which	_	O	O	_	_	_	_	_
36	contained	_	O	O	_	_	_	_	_
37	positive	_	O	O	_	_	_	_	_
38	regulatory	_	O	O	_	_	_	_	_
39	elements	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	identified	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	sequence	_	O	O	_	_	_	_	_
8	element	_	O	O	_	_	_	_	_
9	present	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	most	_	O	O	_	_	_	_	_
13	proximal	_	O	O	_	_	_	_	_
14	region	_	O	O	_	_	_	_	_
15	located	_	O	O	_	_	_	_	_
16	between	_	O	O	_	_	_	_	_
17	bases	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	214	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	201	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	TTCTTCTAATTAA	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	which	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	important	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	high	_	O	O	_	_	_	_	_
32	constitutive	_	O	O	_	_	_	_	_
33	expression	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	20	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	mature	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	induction	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	CD	_	O	O	_	_	_	_	_
46	20	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	pre	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	B	_	O	O	_	_	_	_	_
51	cells	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	sequence	_	O	O	_	_	_	_	_
3	element	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	referred	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	BAT	_	O	O	_	_	_	_	_
10	box	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	its	_	O	O	_	_	_	_	_
13	deletion	_	O	O	_	_	_	_	_
14	significantly	_	O	O	_	_	_	_	_
15	reduced	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	20	_	O	O	_	_	_	_	_
22	promoter	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	CAT	_	O	O	_	_	_	_	_
25	construct	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Mobility	_	O	O	_	_	_	_	_
2	shift	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	various	_	O	O	_	_	_	_	_
6	mutant	_	O	O	_	_	_	_	_
7	probes	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	extracts	_	O	O	_	_	_	_	_
13	demonstrated	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	core	_	O	O	_	_	_	_	_
17	sequence	_	O	O	_	_	_	_	_
18	TAAT	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	essential	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	this	_	O	O	_	_	_	_	_
25	site	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Cross	_	O	O	_	_	_	_	_
2	competition	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	octamer	_	O	O	_	_	_	_	_
7	sequence	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	Ig	_	O	O	_	_	_	_	_
11	heavy	_	O	O	_	_	_	_	_
12	chain	_	O	O	_	_	_	_	_
13	promoter	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	BAT	_	O	O	_	_	_	_	_
17	box	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	TA	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	rich	_	O	O	_	_	_	_	_
24	sequence	_	O	O	_	_	_	_	_
25	present	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	21	_	O	O	_	_	_	_	_
30	promoter	_	O	O	_	_	_	_	_
31	revealed	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	all	_	O	O	_	_	_	_	_
34	three	_	O	O	_	_	_	_	_
35	sequences	_	O	O	_	_	_	_	_
36	bound	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	same	_	O	O	_	_	_	_	_
39	nuclear	_	O	O	_	_	_	_	_
40	proteins	_	O	O	_	_	_	_	_
41	suggesting	_	O	O	_	_	_	_	_
42	that	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	BAT	_	O	O	_	_	_	_	_
45	box	_	O	O	_	_	_	_	_
46	binding	_	O	O	_	_	_	_	_
47	proteins	_	O	O	_	_	_	_	_
48	were	_	O	O	_	_	_	_	_
49	Oct	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	Oct	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	2	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Southwestern	_	O	O	_	_	_	_	_
2	blotting	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	UV	_	O	O	_	_	_	_	_
5	cross	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	linking	_	O	O	_	_	_	_	_
8	studies	_	O	O	_	_	_	_	_
9	confirmed	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	BAT	_	O	O	_	_	_	_	_
13	box	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	proteins	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	Oct	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	Oct	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	affinity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	BAT	_	O	O	_	_	_	_	_
6	box	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	BAT	_	O	O	_	_	_	_	_
12	box	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	approximately	_	O	O	_	_	_	_	_
15	25	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	fold	_	O	O	_	_	_	_	_
18	less	_	O	O	_	_	_	_	_
19	than	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	octamer	_	O	O	_	_	_	_	_
23	sequence	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	BAT	_	O	O	_	_	_	_	_
27	box	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	proteins	_	O	O	_	_	_	_	_
30	dissociated	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	BAT	_	O	O	_	_	_	_	_
34	box	_	O	O	_	_	_	_	_
35	10	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	fold	_	O	O	_	_	_	_	_
38	more	_	O	O	_	_	_	_	_
39	rapidly	_	O	O	_	_	_	_	_
40	than	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	octamer	_	O	O	_	_	_	_	_
44	sequence	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Despite	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	lower	_	O	O	_	_	_	_	_
4	affinity	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	trimer	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	BAT	_	O	O	_	_	_	_	_
11	box	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	efficiently	_	O	O	_	_	_	_	_
16	transactivated	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	Oct	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	vector	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	trimer	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	octamer	_	O	O	_	_	_	_	_
31	sequence	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	HeLa	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	BAT	_	O	O	_	_	_	_	_
3	box	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	Oct	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	implicated	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	induction	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	20	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	pre	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	line	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	PB	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	697	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	via	_	O	O	_	_	_	_	_
30	phorbol	_	O	O	_	_	_	_	_
31	esters	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	20	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	temporally	_	O	O	_	_	_	_	_
9	associated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	induction	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Oct	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	mRNA	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	BAT	_	O	O	_	_	_	_	_
20	box	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	deleted	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	20	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	CAT	_	O	O	_	_	_	_	_
27	construct	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	contrast	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	wild	_	O	O	_	_	_	_	_
34	type	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	was	_	O	O	_	_	_	_	_
37	poorly	_	O	O	_	_	_	_	_
38	induced	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	phorbol	_	O	O	_	_	_	_	_
41	esters	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Together	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	suggest	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	BAT	_	O	O	_	_	_	_	_
8	box	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	important	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	20	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	perhaps	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	21	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	transcriptionally	_	O	O	_	_	_	_	_
3	active	_	O	O	_	_	_	_	_
4	factors	_	O	O	_	_	_	_	_
5	mediating	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	effect	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	HTLV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	I	_	O	O	_	_	_	_	_
13	Tax	_	O	O	_	_	_	_	_
14	transactivator	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	R	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	kappa	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	enhancer	_	O	O	_	_	_	_	_
25	include	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	product	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	c	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	rel	_	O	O	_	_	_	_	_
33	proto	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	oncogene	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	transactivator	_	O	O	_	_	_	_	_
3	HTLV	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	I	_	O	O	_	_	_	_	_
6	Tax	_	O	O	_	_	_	_	_
7	activates	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	coding	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	interleukin	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	chain	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	R	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	via	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	kappa	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	site	_	O	O	_	_	_	_	_
34	that	_	O	O	_	_	_	_	_
35	can	_	O	O	_	_	_	_	_
36	bind	_	O	O	_	_	_	_	_
37	several	_	O	O	_	_	_	_	_
38	protein	_	O	O	_	_	_	_	_
39	species	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	rel	_	O	O	_	_	_	_	_
43	family	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Tax	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	strongly	_	O	O	_	_	_	_	_
4	activates	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	enhancer	_	O	O	_	_	_	_	_
7	activity	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	this	_	O	O	_	_	_	_	_
10	motif	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	epithelial	_	O	O	_	_	_	_	_
15	HeLa	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	lymphoid	_	O	O	_	_	_	_	_
18	Jurkat	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	undifferentiated	_	O	O	_	_	_	_	_
8	embryocarcinoma	_	O	O	_	_	_	_	_
9	F	_	O	O	_	_	_	_	_
10	9	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Overexpression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	50	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	65	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	Rel	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	these	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	showed	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	significant	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	R	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	kappa	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	site	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	observed	_	O	O	_	_	_	_	_
31	only	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	Rel	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	Rel	_	O	O	_	_	_	_	_
36	plus	_	O	O	_	_	_	_	_
37	p	_	O	O	_	_	_	_	_
38	65	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	whereas	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	Tax	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	phorbol	_	O	O	_	_	_	_	_
8	12	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	myristate	_	O	O	_	_	_	_	_
11	13	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	acetate	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	PMA	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	able	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	efficiently	_	O	O	_	_	_	_	_
21	induce	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	kappa	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	R	_	O	O	_	_	_	_	_
35	alpha	_	O	O	_	_	_	_	_
36	kappa	_	O	O	_	_	_	_	_
37	B	_	O	O	_	_	_	_	_
38	site	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	PMA	_	O	O	_	_	_	_	_
41	is	_	O	O	_	_	_	_	_
42	functionally	_	O	O	_	_	_	_	_
43	inactive	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	DNA	_	O	O	_	_	_	_	_
4	affinity	_	O	O	_	_	_	_	_
5	precipitation	_	O	O	_	_	_	_	_
6	assay	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	observed	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	Tax	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	able	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	efficiently	_	O	O	_	_	_	_	_
17	induce	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	Rel	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	whereas	_	O	O	_	_	_	_	_
24	PMA	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	established	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	clear	_	O	O	_	_	_	_	_
5	difference	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	both	_	O	O	_	_	_	_	_
8	stimuli	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	indicating	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	Rel	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	functionally	_	O	O	_	_	_	_	_
16	active	_	O	O	_	_	_	_	_
17	factor	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	functional	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	members	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	rel	_	O	O	_	_	_	_	_
15	family	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	regulated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	their	_	O	O	_	_	_	_	_
20	interaction	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	Rel	_	O	O	_	_	_	_	_
26	can	_	O	O	_	_	_	_	_
27	be	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	potent	_	O	O	_	_	_	_	_
30	transcriptional	_	O	O	_	_	_	_	_
31	activator	_	O	O	_	_	_	_	_
32	on	_	O	O	_	_	_	_	_
33	specific	_	O	O	_	_	_	_	_
34	kappa	_	O	O	_	_	_	_	_
35	B	_	O	O	_	_	_	_	_
36	sites	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Activation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	factor	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kappaB	_	O	O	_	_	_	_	_
7	via	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	requires	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	Raf	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	Ca	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	influx	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Functional	_	O	O	_	_	_	_	_
2	synergy	_	O	O	_	_	_	_	_
3	between	_	O	O	_	_	_	_	_
4	Raf	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	calcineurin	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_


1	Signals	_	O	O	_	_	_	_	_
2	transduced	_	O	O	_	_	_	_	_
3	via	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	TCR	_	O	O	_	_	_	_	_
6	activate	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	nuclear	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	kappaB	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappaB	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	which	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	turn	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	critical	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	transcriptional	_	O	O	_	_	_	_	_
30	induction	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	many	_	O	O	_	_	_	_	_
33	genes	_	O	O	_	_	_	_	_
34	important	_	O	O	_	_	_	_	_
35	for	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	proliferation	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	expression	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	differentiated	_	O	O	_	_	_	_	_
43	phenotype	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	T	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	activator	_	O	O	_	_	_	_	_
11	PMA	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	combination	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	Ca	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	+	_	O	O	_	_	_	_	_
18	ionophores	_	O	O	_	_	_	_	_
19	mimics	_	O	O	_	_	_	_	_
20	this	_	O	O	_	_	_	_	_
21	process	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	two	_	O	O	_	_	_	_	_
26	agents	_	O	O	_	_	_	_	_
27	are	_	O	O	_	_	_	_	_
28	often	_	O	O	_	_	_	_	_
29	substituted	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	TCR	_	O	O	_	_	_	_	_
32	stimulation	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	bypassing	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	TCR	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	identify	_	O	O	_	_	_	_	_
4	intracellular	_	O	O	_	_	_	_	_
5	signaling	_	O	O	_	_	_	_	_
6	components	_	O	O	_	_	_	_	_
7	involved	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	NF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	kappaB	_	O	O	_	_	_	_	_
14	following	_	O	O	_	_	_	_	_
15	TCR	_	O	O	_	_	_	_	_
16	stimulation	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	TCR	_	O	O	_	_	_	_	_
2	signaling	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	triggered	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	treating	_	O	O	_	_	_	_	_
7	Jurkat	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	PHA	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	anti	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	Abs	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	NF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	kappaB	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	monitored	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	electrophoretic	_	O	O	_	_	_	_	_
28	mobility	_	O	O	_	_	_	_	_
29	shift	_	O	O	_	_	_	_	_
30	assays	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	kappaB	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	dependent	_	O	O	_	_	_	_	_
38	reporter	_	O	O	_	_	_	_	_
39	assays	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Contrary	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	idea	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	C	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	involved	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	TCR	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	high	_	O	O	_	_	_	_	_
22	doses	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	staurosporine	_	O	O	_	_	_	_	_
25	did	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	interfere	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	activation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	NF	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	kappaB	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	PHA	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	while	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	same	_	O	O	_	_	_	_	_
40	dose	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	staurosporine	_	O	O	_	_	_	_	_
43	completely	_	O	O	_	_	_	_	_
44	blocked	_	O	O	_	_	_	_	_
45	activation	_	O	O	_	_	_	_	_
46	by	_	O	O	_	_	_	_	_
47	PMA	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	PHA	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	kappaB	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	dependent	_	O	O	_	_	_	_	_
7	reporter	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	however	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	effectively	_	O	O	_	_	_	_	_
14	blocked	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	dominant	_	O	O	_	_	_	_	_
18	negative	_	O	O	_	_	_	_	_
19	form	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	Raf	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	suggesting	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	critical	_	O	O	_	_	_	_	_
28	role	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	Raf	_	O	O	_	_	_	_	_
32	kinase	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	TCR	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappaB	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	dependent	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	Ca	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	+	_	O	O	_	_	_	_	_
18	influx	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	because	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Ca	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	channel	_	O	O	_	_	_	_	_
26	blocker	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	SK	_	O	O	_	_	_	_	_
29	&	_	O	O	_	_	_	_	_
30	F	_	O	O	_	_	_	_	_
31	96365	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	well	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	other	_	O	O	_	_	_	_	_
37	agents	_	O	O	_	_	_	_	_
38	that	_	O	O	_	_	_	_	_
39	prevented	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	Ca	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	+	_	O	O	_	_	_	_	_
44	influx	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	inhibited	_	O	O	_	_	_	_	_
47	NF	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	kappaB	_	O	O	_	_	_	_	_
50	activation	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	Cotransfection	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	constitutively	_	O	O	_	_	_	_	_
5	active	_	O	O	_	_	_	_	_
6	form	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	calcineurin	_	O	O	_	_	_	_	_
9	largely	_	O	O	_	_	_	_	_
10	substituted	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Ca	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	requirement	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	reversed	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	blockade	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	SK	_	O	O	_	_	_	_	_
23	&	_	O	O	_	_	_	_	_
24	F	_	O	O	_	_	_	_	_
25	96365	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	observations	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	coexpression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	constitutively	_	O	O	_	_	_	_	_
9	active	_	O	O	_	_	_	_	_
10	forms	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	Raf	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	calcineurin	_	O	O	_	_	_	_	_
17	synergistically	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	dependent	_	O	O	_	_	_	_	_
22	reporter	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	suggesting	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	physiologically	_	O	O	_	_	_	_	_
28	relevant	_	O	O	_	_	_	_	_
29	functional	_	O	O	_	_	_	_	_
30	interaction	_	O	O	_	_	_	_	_
31	between	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	kinase	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	phosphatase	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	chemokine	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	BLR	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	EBI	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	specifically	_	O	O	_	_	_	_	_
13	transactivated	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	Epstein	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Barr	_	O	O	_	_	_	_	_
18	virus	_	O	O	_	_	_	_	_
19	nuclear	_	O	O	_	_	_	_	_
20	antigen	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	our	_	O	O	_	_	_	_	_
3	attempt	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	identify	_	O	O	_	_	_	_	_
6	chemokine	_	O	O	_	_	_	_	_
7	receptors	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	related	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	Burkitt	_	O	O	_	_	_	_	_
13	'	_	O	O	_	_	_	_	_
14	s	_	O	O	_	_	_	_	_
15	lymphoma	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	BLR	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	expressed	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	activated	_	O	O	_	_	_	_	_
27	lymphocytes	_	O	O	_	_	_	_	_
28	we	_	O	O	_	_	_	_	_
29	used	_	O	O	_	_	_	_	_
30	RT	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	PCR	_	O	O	_	_	_	_	_
33	resulting	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	isolation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	cDNA	_	O	O	_	_	_	_	_
40	encoding	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	seven	_	O	O	_	_	_	_	_
43	transmembrane	_	O	O	_	_	_	_	_
44	receptor	_	O	O	_	_	_	_	_
45	termed	_	O	O	_	_	_	_	_
46	BLR	_	O	O	_	_	_	_	_
47	2	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	shows	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	sequence	_	O	O	_	_	_	_	_
6	similarities	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	family	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	G	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	coupled	_	O	O	_	_	_	_	_
15	chemokine	_	O	O	_	_	_	_	_
16	receptors	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	turned	_	O	O	_	_	_	_	_
19	out	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	identical	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	recently	_	O	O	_	_	_	_	_
26	described	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	EBI	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	revealed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	BLR	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	mRNA	_	O	O	_	_	_	_	_
9	could	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	highly	_	O	O	_	_	_	_	_
12	stimulated	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	mitogen	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	anti	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	treated	_	O	O	_	_	_	_	_
23	peripheral	_	O	O	_	_	_	_	_
24	blood	_	O	O	_	_	_	_	_
25	lymphocytes	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	BLR	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	mRNA	_	O	O	_	_	_	_	_
6	could	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	detected	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	all	_	O	O	_	_	_	_	_
11	Epstein	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Barr	_	O	O	_	_	_	_	_
14	virus	_	O	O	_	_	_	_	_
15	positive	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	lines	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	BLR	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	could	_	O	O	_	_	_	_	_
11	be	_	O	O	_	_	_	_	_
12	specifically	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	Epstein	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Barr	_	O	O	_	_	_	_	_
18	virus	_	O	O	_	_	_	_	_
19	negative	_	O	O	_	_	_	_	_
20	BL	_	O	O	_	_	_	_	_
21	41	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	via	_	O	O	_	_	_	_	_
24	estrogen	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	mediated	_	O	O	_	_	_	_	_
27	activation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	Epstein	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	Barr	_	O	O	_	_	_	_	_
32	virus	_	O	O	_	_	_	_	_
33	nuclear	_	O	O	_	_	_	_	_
34	antigen	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	key	_	O	O	_	_	_	_	_
39	regulator	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	viral	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	cellular	_	O	O	_	_	_	_	_
44	genes	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	immortalized	_	O	O	_	_	_	_	_
47	B	_	O	O	_	_	_	_	_
48	cells	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	involvement	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	BLR	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	regulation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	migration	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	activated	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	viral	_	O	O	_	_	_	_	_
20	pathogenesis	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	[	_	O	O	_	_	_	_	_
2	The	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	24	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dihydroxyvitamin	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	dioxyvit	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	Ca	_	O	O	_	_	_	_	_
17	metabolism	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	immune	_	O	O	_	_	_	_	_
20	status	_	O	O	_	_	_	_	_
21	during	_	O	O	_	_	_	_	_
22	chronic	_	O	O	_	_	_	_	_
23	kidney	_	O	O	_	_	_	_	_
24	failure	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_

1	Active	_	O	O	_	_	_	_	_
2	metabolite	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	vitamin	_	O	O	_	_	_	_	_
5	D	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	24	_	O	O	_	_	_	_	_
9	R	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	25	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	OH	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	dioxyvit	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	used	_	O	O	_	_	_	_	_
23	at	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	daily	_	O	O	_	_	_	_	_
26	dose	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	100	_	O	O	_	_	_	_	_
29	micrograms	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	treatment	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	children	_	O	O	_	_	_	_	_
34	affected	_	O	O	_	_	_	_	_
35	with	_	O	O	_	_	_	_	_
36	tubulointerstitial	_	O	O	_	_	_	_	_
37	disease	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	kidney	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	chronic	_	O	O	_	_	_	_	_
43	glomerulonephritis	_	O	O	_	_	_	_	_
44	under	_	O	O	_	_	_	_	_
45	conditions	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	kidney	_	O	O	_	_	_	_	_
48	insufficiency	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	drug	_	O	O	_	_	_	_	_
3	exhibited	_	O	O	_	_	_	_	_
4	distinct	_	O	O	_	_	_	_	_
5	normalizing	_	O	O	_	_	_	_	_
6	effect	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	patterns	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	calcium	_	O	O	_	_	_	_	_
11	metabolism	_	O	O	_	_	_	_	_
12	:	_	O	O	_	_	_	_	_
13	increase	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	total	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	ionized	_	O	O	_	_	_	_	_
18	Ca	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	25	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	OHD	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	decrease	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	concentration	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	parath	_	O	O	_	_	_	_	_
32	hormone	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	osteocalcine	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	blood	_	O	O	_	_	_	_	_
37	serum	_	O	O	_	_	_	_	_
38	as	_	O	O	_	_	_	_	_
39	well	_	O	O	_	_	_	_	_
40	as	_	O	O	_	_	_	_	_
41	on	_	O	O	_	_	_	_	_
42	immunological	_	O	O	_	_	_	_	_
43	parameters	_	O	O	_	_	_	_	_
44	:	_	O	O	_	_	_	_	_
45	restoration	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	decreased	_	O	O	_	_	_	_	_
48	content	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	T	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	0	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	lymphocytes	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Concentration	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	receptors	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	hormonal	_	O	O	_	_	_	_	_
6	form	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	OH	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	found	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	minimal	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	lymphocytes	_	O	O	_	_	_	_	_
24	under	_	O	O	_	_	_	_	_
25	conditions	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	chronic	_	O	O	_	_	_	_	_
28	kidney	_	O	O	_	_	_	_	_
29	insufficiency	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	while	_	O	O	_	_	_	_	_
32	their	_	O	O	_	_	_	_	_
33	expression	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	after	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	dioxyvit	_	O	O	_	_	_	_	_
38	action	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	was	_	O	O	_	_	_	_	_
41	detected	_	O	O	_	_	_	_	_
42	only	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	patients	_	O	O	_	_	_	_	_
45	with	_	O	O	_	_	_	_	_
46	glomerulonephritis	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Specific	_	O	O	_	_	_	_	_
2	calcitropic	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	dioxyvit	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	simultaneous	_	O	O	_	_	_	_	_
8	correction	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	vitamin	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	deficiency	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	apparently	_	O	O	_	_	_	_	_
15	responsible	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	high	_	O	O	_	_	_	_	_
18	efficacy	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	drug	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	treatment	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	calcium	_	O	O	_	_	_	_	_
26	metabolism	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	immunity	_	O	O	_	_	_	_	_
29	impairments	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	children	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	renal	_	O	O	_	_	_	_	_
34	deteriorations	_	O	O	_	_	_	_	_
35	at	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	step	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	chronic	_	O	O	_	_	_	_	_
40	kidney	_	O	O	_	_	_	_	_
41	insufficiency	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_


1	Phenotypic	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	functional	_	O	O	_	_	_	_	_
4	studies	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	leukocytes	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	endometrium	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	endometriosis	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	aetiology	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	endometriosis	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	common	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	disabling	_	O	O	_	_	_	_	_
10	disorder	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	presently	_	O	O	_	_	_	_	_
14	unknown	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	although	_	O	O	_	_	_	_	_
17	immune	_	O	O	_	_	_	_	_
18	dysfunction	_	O	O	_	_	_	_	_
19	could	_	O	O	_	_	_	_	_
20	allow	_	O	O	_	_	_	_	_
21	ectopic	_	O	O	_	_	_	_	_
22	endometrial	_	O	O	_	_	_	_	_
23	fragments	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	survive	_	O	O	_	_	_	_	_
26	outside	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	uterine	_	O	O	_	_	_	_	_
29	cavity	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	investigate	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	relationship	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	leukocyte	_	O	O	_	_	_	_	_
8	populations	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	steroid	_	O	O	_	_	_	_	_
11	hormone	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	proliferative	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	bcl	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	apoptosis	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	eutopic	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	ectopic	_	O	O	_	_	_	_	_
28	endometrium	_	O	O	_	_	_	_	_
29	from	_	O	O	_	_	_	_	_
30	women	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	endometriosis	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	adenomyosis	_	O	O	_	_	_	_	_
35	at	_	O	O	_	_	_	_	_
36	different	_	O	O	_	_	_	_	_
37	phases	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	menstrual	_	O	O	_	_	_	_	_
41	cycle	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Significantly	_	O	O	_	_	_	_	_
2	increased	_	O	O	_	_	_	_	_
3	oestrogen	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	bcl	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	numbers	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	8	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	leukocytes	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	found	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	ectopic	_	O	O	_	_	_	_	_
22	compared	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	eutopic	_	O	O	_	_	_	_	_
25	endometrium	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	endometriosis	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	56	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	endometrial	_	O	O	_	_	_	_	_
34	granulated	_	O	O	_	_	_	_	_
35	lymphocytes	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	eGLs	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	were	_	O	O	_	_	_	_	_
40	significantly	_	O	O	_	_	_	_	_
41	reduced	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	ectopic	_	O	O	_	_	_	_	_
44	endometrium	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Apoptotic	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	rarely	_	O	O	_	_	_	_	_
5	found	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	control	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	subject	_	O	O	_	_	_	_	_
10	endometria	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	endometriosis	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	adenomyotic	_	O	O	_	_	_	_	_
7	lesions	_	O	O	_	_	_	_	_
8	showed	_	O	O	_	_	_	_	_
9	identical	_	O	O	_	_	_	_	_
10	steroid	_	O	O	_	_	_	_	_
11	hormone	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	proliferative	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	bcl	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	leukocyte	_	O	O	_	_	_	_	_
24	subpopulations	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	eutopic	_	O	O	_	_	_	_	_
27	endometrium	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	indicating	_	O	O	_	_	_	_	_
30	different	_	O	O	_	_	_	_	_
31	aetiologies	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	these	_	O	O	_	_	_	_	_
34	disorders	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	unusual	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	56	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	16	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	eGLs	_	O	O	_	_	_	_	_
10	present	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	large	_	O	O	_	_	_	_	_
13	numbers	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	late	_	O	O	_	_	_	_	_
16	secretory	_	O	O	_	_	_	_	_
17	phase	_	O	O	_	_	_	_	_
18	eutopic	_	O	O	_	_	_	_	_
19	endometrium	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	highly	_	O	O	_	_	_	_	_
22	purified	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	>	_	O	O	_	_	_	_	_
25	98	_	O	O	_	_	_	_	_
26	%	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	immunomagnetic	_	O	O	_	_	_	_	_
30	separation	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Except	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	negligible	_	O	O	_	_	_	_	_
5	cytotoxic	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	eGLs	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	early	_	O	O	_	_	_	_	_
11	proliferative	_	O	O	_	_	_	_	_
12	samples	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	cytotoxic	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	eGLs	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	non	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	pregnant	_	O	O	_	_	_	_	_
22	endometrium	_	O	O	_	_	_	_	_
23	during	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	menstrual	_	O	O	_	_	_	_	_
26	cycle	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	comparable	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	those	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	peripheral	_	O	O	_	_	_	_	_
33	blood	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	predominantly	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	56	_	O	O	_	_	_	_	_
38	+	_	O	O	_	_	_	_	_
39	CD	_	O	O	_	_	_	_	_
40	16	_	O	O	_	_	_	_	_
41	+	_	O	O	_	_	_	_	_
42	natural	_	O	O	_	_	_	_	_
43	killer	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	eGLs	_	O	O	_	_	_	_	_
2	from	_	O	O	_	_	_	_	_
3	non	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	pregnant	_	O	O	_	_	_	_	_
6	endometrium	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	pregnancy	_	O	O	_	_	_	_	_
10	showed	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	variable	_	O	O	_	_	_	_	_
13	proliferative	_	O	O	_	_	_	_	_
14	response	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	100	_	O	O	_	_	_	_	_
19	U	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	ml	_	O	O	_	_	_	_	_
22	interleukin	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	over	_	O	O	_	_	_	_	_
26	48	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	h	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	120	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	h	_	O	O	_	_	_	_	_
33	time	_	O	O	_	_	_	_	_
34	courses	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	eGLs	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	evidently	_	O	O	_	_	_	_	_
4	functionally	_	O	O	_	_	_	_	_
5	important	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	eutopic	_	O	O	_	_	_	_	_
9	endometrium	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Their	_	O	O	_	_	_	_	_
2	absence	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	endometriotic	_	O	O	_	_	_	_	_
5	lesions	_	O	O	_	_	_	_	_
6	together	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	increased	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	8	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	numbers	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	increased	_	O	O	_	_	_	_	_
18	oestrogen	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	bcl	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	may	_	O	O	_	_	_	_	_
26	have	_	O	O	_	_	_	_	_
27	significant	_	O	O	_	_	_	_	_
28	effects	_	O	O	_	_	_	_	_
29	on	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	development	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	progression	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	endometriosis	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Transcriptional	_	O	O	_	_	_	_	_
2	activity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	core	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	AML	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	subunits	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	murine	_	O	O	_	_	_	_	_
18	leukemia	_	O	O	_	_	_	_	_
19	virus	_	O	O	_	_	_	_	_
20	enhancer	_	O	O	_	_	_	_	_
21	cores	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Core	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	CBF	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	known	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	polyomavirus	_	O	O	_	_	_	_	_
12	enhancer	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	SL	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	enhancer	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	mammalian	_	O	O	_	_	_	_	_
27	transcription	_	O	O	_	_	_	_	_
28	factor	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	binds	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	element	_	O	O	_	_	_	_	_
34	termed	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	core	_	O	O	_	_	_	_	_
37	within	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	enhancers	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	murine	_	O	O	_	_	_	_	_
43	leukemia	_	O	O	_	_	_	_	_
44	virus	_	O	O	_	_	_	_	_
45	family	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	retroviruses	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	core	_	O	O	_	_	_	_	_
3	elements	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	SL	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	virus	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	important	_	O	O	_	_	_	_	_
11	genetic	_	O	O	_	_	_	_	_
12	determinants	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	ability	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	this	_	O	O	_	_	_	_	_
18	virus	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	induce	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	lymphomas	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	transcriptional	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	viral	_	O	O	_	_	_	_	_
32	long	_	O	O	_	_	_	_	_
33	terminal	_	O	O	_	_	_	_	_
34	repeat	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	lymphocytes	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	CBF	_	O	O	_	_	_	_	_
2	consists	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	subunits	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	DNA	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	subunit	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	CBF	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	second	_	O	O	_	_	_	_	_
18	subunit	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	CBF	_	O	O	_	_	_	_	_
21	beta	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	stimulates	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	DNA	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	CBF	_	O	O	_	_	_	_	_
31	alpha	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	genes	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	encodes	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	CBF	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	subunit	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	AML	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	also	_	O	O	_	_	_	_	_
16	called	_	O	O	_	_	_	_	_
17	Cbf	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	locus	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	rearranged	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	chromosomal	_	O	O	_	_	_	_	_
7	translocations	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	myeloproliferative	_	O	O	_	_	_	_	_
11	disorders	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	leukemias	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	exogenously	_	O	O	_	_	_	_	_
3	expressed	_	O	O	_	_	_	_	_
4	Cbf	_	O	O	_	_	_	_	_
5	alpha	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	encoded	_	O	O	_	_	_	_	_
9	subunit	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	CBF	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	451	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	stimulated	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	SL	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	enhancer	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	P	_	O	O	_	_	_	_	_
26	19	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	HeLa	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Activity	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	mediated	_	O	O	_	_	_	_	_
4	through	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	core	_	O	O	_	_	_	_	_
7	elements	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Three	_	O	O	_	_	_	_	_
2	different	_	O	O	_	_	_	_	_
3	isoforms	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	CBF	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	tested	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	transcriptional	_	O	O	_	_	_	_	_
12	activity	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	SL	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	enhancer	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	longest	_	O	O	_	_	_	_	_
3	form	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	CBF	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	187	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	transcriptional	_	O	O	_	_	_	_	_
13	stimulation	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	CBF	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	451	_	O	O	_	_	_	_	_
20	twofold	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	HeLa	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	although	_	O	O	_	_	_	_	_
26	it	_	O	O	_	_	_	_	_
27	had	_	O	O	_	_	_	_	_
28	no	_	O	O	_	_	_	_	_
29	effect	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	P	_	O	O	_	_	_	_	_
32	19	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Transcriptional	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	CBF	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	required	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	CBF	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	subunit	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	form	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	CBF	_	O	O	_	_	_	_	_
19	beta	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	lacked	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	ability	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	CBF	_	O	O	_	_	_	_	_
26	beta	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	148	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	failed	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	increase	_	O	O	_	_	_	_	_
33	activity	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	at	_	O	O	_	_	_	_	_
6	least	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	certain	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	types	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	maximum	_	O	O	_	_	_	_	_
14	activity	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	CBF	_	O	O	_	_	_	_	_
17	required	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	subunits	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	They	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	provided	_	O	O	_	_	_	_	_
4	support	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	hypothesis	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	CBF	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	lymphocytes	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	responsible	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	recognition	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	SL	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	cores	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	whether	_	O	O	_	_	_	_	_
5	CBF	_	O	O	_	_	_	_	_
6	could	_	O	O	_	_	_	_	_
7	distinguish	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	bp	_	O	O	_	_	_	_	_
12	difference	_	O	O	_	_	_	_	_
13	between	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	enhancer	_	O	O	_	_	_	_	_
16	core	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	SL	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	core	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	nonleukemogenic	_	O	O	_	_	_	_	_
26	virus	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	Akv	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	difference	_	O	O	_	_	_	_	_
3	strongly	_	O	O	_	_	_	_	_
4	affects	_	O	O	_	_	_	_	_
5	transcription	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	leukemogenicity	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	SL	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	combination	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	CBF	_	O	O	_	_	_	_	_
7	alpha	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	CBF	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	subunits	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	we	_	O	O	_	_	_	_	_
14	tested	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	able	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	distinguish	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	bp	_	O	O	_	_	_	_	_
23	difference	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	assays	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	complete	_	O	O	_	_	_	_	_
5	understanding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	how	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	recognize	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	SL	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	core	_	O	O	_	_	_	_	_
15	remains	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	elucidated	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	C	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	EBP	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	activate	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	immunodeficiency	_	O	O	_	_	_	_	_
11	virus	_	O	O	_	_	_	_	_
12	type	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	long	_	O	O	_	_	_	_	_
15	terminal	_	O	O	_	_	_	_	_
16	repeat	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	macrophages	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	monocytes	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Three	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	sites	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	C	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	EBP	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	found	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	immunodeficiency	_	O	O	_	_	_	_	_
15	virus	_	O	O	_	_	_	_	_
16	type	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	HIV	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	long	_	O	O	_	_	_	_	_
24	terminal	_	O	O	_	_	_	_	_
25	repeat	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	LTR	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	V	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	M	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Tesmer	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	A	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_
5	Rajadhyaksha	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	J	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	Babin	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	M	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	Bina	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	Proc	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	Natl	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	Acad	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	Sci	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	USA	_	O	O	_	_	_	_	_
2	90	_	O	O	_	_	_	_	_
3	:	_	O	O	_	_	_	_	_
4	7298	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	7302	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	1993	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	determined	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	functional	_	O	O	_	_	_	_	_
6	role	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	C	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	EBP	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	C	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	EBP	_	O	O	_	_	_	_	_
16	sites	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	regulating	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	HIV	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	LTR	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	monocytes	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	macrophages	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	endogenous	_	O	O	_	_	_	_	_
4	C	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	EBP	_	O	O	_	_	_	_	_
7	proteins	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	using	_	O	O	_	_	_	_	_
10	either	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	excess	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	C	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	EBP	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	sites	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	trans	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	dominant	_	O	O	_	_	_	_	_
24	negative	_	O	O	_	_	_	_	_
25	inhibitor	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	demonstrated	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	C	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	EBP	_	O	O	_	_	_	_	_
32	proteins	_	O	O	_	_	_	_	_
33	are	_	O	O	_	_	_	_	_
34	required	_	O	O	_	_	_	_	_
35	for	_	O	O	_	_	_	_	_
36	basal	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	activated	_	O	O	_	_	_	_	_
39	levels	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	HIV	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	LTR	_	O	O	_	_	_	_	_
45	transcription	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	promonocytic	_	O	O	_	_	_	_	_
49	cell	_	O	O	_	_	_	_	_
50	line	_	O	O	_	_	_	_	_
51	U	_	O	O	_	_	_	_	_
52	937	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	RNA	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	blots	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	assays	_	O	O	_	_	_	_	_
9	showed	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	NF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	only	_	O	O	_	_	_	_	_
18	known	_	O	O	_	_	_	_	_
19	C	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	EBP	_	O	O	_	_	_	_	_
22	family	_	O	O	_	_	_	_	_
23	member	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	increased	_	O	O	_	_	_	_	_
27	when	_	O	O	_	_	_	_	_
28	U	_	O	O	_	_	_	_	_
29	937	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	are	_	O	O	_	_	_	_	_
32	activated	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Mutational	_	O	O	_	_	_	_	_
2	analyses	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	HIV	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	LTR	_	O	O	_	_	_	_	_
9	showed	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	one	_	O	O	_	_	_	_	_
12	C	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	EBP	_	O	O	_	_	_	_	_
15	site	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	required	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	normal	_	O	O	_	_	_	_	_
20	LTR	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	both	_	O	O	_	_	_	_	_
23	before	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	after	_	O	O	_	_	_	_	_
26	cellular	_	O	O	_	_	_	_	_
27	activation	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	two	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	'	_	O	O	_	_	_	_	_
34	C	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	EBP	_	O	O	_	_	_	_	_
37	sites	_	O	O	_	_	_	_	_
38	are	_	O	O	_	_	_	_	_
39	functionally	_	O	O	_	_	_	_	_
40	equivalent	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	crippled	_	O	O	_	_	_	_	_
6	HIV	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	LTRs	_	O	O	_	_	_	_	_
10	lacking	_	O	O	_	_	_	_	_
11	C	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	EBP	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	can	_	O	O	_	_	_	_	_
16	still	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	following	_	O	O	_	_	_	_	_
20	activation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	U	_	O	O	_	_	_	_	_
23	937	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Several	_	O	O	_	_	_	_	_
2	models	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	suggested	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	how	_	O	O	_	_	_	_	_
7	elevated	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	participate	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	autostimulatory	_	O	O	_	_	_	_	_
17	loop	_	O	O	_	_	_	_	_
18	involving	_	O	O	_	_	_	_	_
19	HIV	_	O	O	_	_	_	_	_
20	infection	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	macrophage	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	cytokine	_	O	O	_	_	_	_	_
26	expression	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	HIV	_	O	O	_	_	_	_	_
30	replication	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Glucocorticoid	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	patients	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	lupus	_	O	O	_	_	_	_	_
7	nephritis	_	O	O	_	_	_	_	_
8	:	_	O	O	_	_	_	_	_
9	relationship	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	mononuclear	_	O	O	_	_	_	_	_
15	leukocytes	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	effect	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	glucocorticoid	_	O	O	_	_	_	_	_
20	therapy	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	clinical	_	O	O	_	_	_	_	_
5	significance	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	glucocorticoid	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	determination	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	20	_	O	O	_	_	_	_	_
12	patients	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	systemic	_	O	O	_	_	_	_	_
15	lupus	_	O	O	_	_	_	_	_
16	erythematosus	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	SLE	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	who	_	O	O	_	_	_	_	_
21	afterwards	_	O	O	_	_	_	_	_
22	developed	_	O	O	_	_	_	_	_
23	nephrotic	_	O	O	_	_	_	_	_
24	syndrome	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Glucocorticoid	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	concentrations	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	mononuclear	_	O	O	_	_	_	_	_
6	leukocytes	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	MNL	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	these	_	O	O	_	_	_	_	_
12	patients	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	comparable	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	those	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	other	_	O	O	_	_	_	_	_
20	patients	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	SLE	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	healthy	_	O	O	_	_	_	_	_
25	persons	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Improvement	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	urinary	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	excretion	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	disease	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	which	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	scored	_	O	O	_	_	_	_	_
14	according	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	SLE	_	O	O	_	_	_	_	_
18	Disease	_	O	O	_	_	_	_	_
19	Activity	_	O	O	_	_	_	_	_
20	Index	_	O	O	_	_	_	_	_
21	system	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	University	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	Toronto	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	closely	_	O	O	_	_	_	_	_
29	related	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	glucocorticoid	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	concentrations	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	MNL	_	O	O	_	_	_	_	_
37	isolated	_	O	O	_	_	_	_	_
38	from	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	corresponding	_	O	O	_	_	_	_	_
41	patients	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	summary	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	glucocorticoid	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	determination	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	lupus	_	O	O	_	_	_	_	_
11	nephritis	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	predictive	_	O	O	_	_	_	_	_
16	clue	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	assessing	_	O	O	_	_	_	_	_
19	responsiveness	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	glucocorticoid	_	O	O	_	_	_	_	_
22	therapy	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	1	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Dihydroxyvitamin	_	O	O	_	_	_	_	_
6	D	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	induces	_	O	O	_	_	_	_	_
9	differentiation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	retinoic	_	O	O	_	_	_	_	_
13	acid	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	resistant	_	O	O	_	_	_	_	_
16	acute	_	O	O	_	_	_	_	_
17	promyelocytic	_	O	O	_	_	_	_	_
18	leukemia	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	line	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	UF	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	associated	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	p	_	O	O	_	_	_	_	_
31	21	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	WAF	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	CIP	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	p	_	O	O	_	_	_	_	_
41	27	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	KIP	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_


1	Retinoic	_	O	O	_	_	_	_	_
2	acid	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	resistance	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	serious	_	O	O	_	_	_	_	_
10	problem	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	patients	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	acute	_	O	O	_	_	_	_	_
15	promyelocytic	_	O	O	_	_	_	_	_
16	leukemia	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	APL	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	who	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	receiving	_	O	O	_	_	_	_	_
23	all	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	trans	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	mechanisms	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	strategies	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	overcome	_	O	O	_	_	_	_	_
9	RA	_	O	O	_	_	_	_	_
10	resistance	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	APL	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	still	_	O	O	_	_	_	_	_
16	unclear	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	biologic	_	O	O	_	_	_	_	_
3	effects	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	RA	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	mediated	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	two	_	O	O	_	_	_	_	_
10	distinct	_	O	O	_	_	_	_	_
11	families	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	transcriptional	_	O	O	_	_	_	_	_
14	factors	_	O	O	_	_	_	_	_
15	:	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	receptors	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	RARs	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	retinoid	_	O	O	_	_	_	_	_
23	X	_	O	O	_	_	_	_	_
24	receptors	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	RXRs	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	RXRs	_	O	O	_	_	_	_	_
2	heterodimerize	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	dihydroxyvitamin	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	[	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	25	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	OH	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	D	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	VDR	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	enabling	_	O	O	_	_	_	_	_
28	their	_	O	O	_	_	_	_	_
29	efficient	_	O	O	_	_	_	_	_
30	transcriptional	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	cyclin	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	dependent	_	O	O	_	_	_	_	_
5	kinase	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	cdk	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	inhibitor	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	21	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	WAF	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	CIP	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	has	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	vitamin	_	O	O	_	_	_	_	_
22	D	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	responsive	_	O	O	_	_	_	_	_
26	element	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	VDRE	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	its	_	O	O	_	_	_	_	_
32	promoter	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	25	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	OH	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	2	_	O	O	_	_	_	_	_
42	D	_	O	O	_	_	_	_	_
43	3	_	O	O	_	_	_	_	_
44	enhances	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	expression	_	O	O	_	_	_	_	_
47	of	_	O	O	_	_	_	_	_
48	p	_	O	O	_	_	_	_	_
49	21	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	WAF	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	/	_	O	O	_	_	_	_	_
54	CIP	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	induces	_	O	O	_	_	_	_	_
59	differentiation	_	O	O	_	_	_	_	_
60	of	_	O	O	_	_	_	_	_
61	selected	_	O	O	_	_	_	_	_
62	myeloid	_	O	O	_	_	_	_	_
63	leukemic	_	O	O	_	_	_	_	_
64	cell	_	O	O	_	_	_	_	_
65	lines	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	recently	_	O	O	_	_	_	_	_
4	established	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	novel	_	O	O	_	_	_	_	_
7	APL	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	line	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	UF	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	features	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	resistance	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	OH	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	D	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	can	_	O	O	_	_	_	_	_
11	induce	_	O	O	_	_	_	_	_
12	growth	_	O	O	_	_	_	_	_
13	inhibition	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	G	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	arrest	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	UF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	resulting	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	differentiation	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	these	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	toward	_	O	O	_	_	_	_	_
31	granulocytes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	25	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	OH	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	G	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	arrest	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	enhanced	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	all	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	trans	_	O	O	_	_	_	_	_
22	RA	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Also	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	25	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	OH	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	10	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	7	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	mol	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	L	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	combination	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	RA	_	O	O	_	_	_	_	_
32	markedly	_	O	O	_	_	_	_	_
33	inhibits	_	O	O	_	_	_	_	_
34	cellular	_	O	O	_	_	_	_	_
35	proliferation	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	dose	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	time	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	dependent	_	O	O	_	_	_	_	_
44	manner	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Associated	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	findings	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	levels	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	21	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	WAF	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	CIP	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	p	_	O	O	_	_	_	_	_
20	27	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	KIP	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	mRNA	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	increased	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	these	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	21	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	WAF	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	CIP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	27	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	KIP	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	increased	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	these	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	21	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	WAF	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	CIP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	27	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	KIP	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	transcripts	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	after	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	hours	_	O	O	_	_	_	_	_
28	'	_	O	O	_	_	_	_	_
29	exposure	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	25	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	OH	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	D	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	then	_	O	O	_	_	_	_	_
42	decreased	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	basal	_	O	O	_	_	_	_	_
45	levels	_	O	O	_	_	_	_	_
46	over	_	O	O	_	_	_	_	_
47	48	_	O	O	_	_	_	_	_
48	hours	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Western	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	21	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	WAF	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	CIP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	levels	_	O	O	_	_	_	_	_
17	increased	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	became	_	O	O	_	_	_	_	_
20	detectable	_	O	O	_	_	_	_	_
21	after	_	O	O	_	_	_	_	_
22	12	_	O	O	_	_	_	_	_
23	hours	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	25	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	OH	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	D	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	treatment	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	induction	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	p	_	O	O	_	_	_	_	_
39	27	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	KIP	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	protein	_	O	O	_	_	_	_	_
45	was	_	O	O	_	_	_	_	_
46	much	_	O	O	_	_	_	_	_
47	more	_	O	O	_	_	_	_	_
48	gradual	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	sustained	_	O	O	_	_	_	_	_
51	in	_	O	O	_	_	_	_	_
52	UF	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	cells	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	combination	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	25	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	OH	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	D	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	markedly	_	O	O	_	_	_	_	_
18	enhanced	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	p	_	O	O	_	_	_	_	_
23	27	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	KIP	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	transcript	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	protein	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	compared	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	levels	_	O	O	_	_	_	_	_
35	induced	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	25	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	OH	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	D	_	O	O	_	_	_	_	_
45	3	_	O	O	_	_	_	_	_
46	alone	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	exogenous	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	27	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	KIP	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	can	_	O	O	_	_	_	_	_
13	enhance	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	level	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	11	_	O	O	_	_	_	_	_
19	b	_	O	O	_	_	_	_	_
20	antigen	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	myeloid	_	O	O	_	_	_	_	_
23	leukemic	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	alone	_	O	O	_	_	_	_	_
6	can	_	O	O	_	_	_	_	_
7	induce	_	O	O	_	_	_	_	_
8	G	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	arrest	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	UF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	;	_	O	O	_	_	_	_	_
17	however	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	it	_	O	O	_	_	_	_	_
20	did	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	result	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	increase	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	p	_	O	O	_	_	_	_	_
28	21	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	WAF	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	CIP	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	p	_	O	O	_	_	_	_	_
38	27	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	KIP	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	transcript	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	protein	_	O	O	_	_	_	_	_
46	expression	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	RA	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	resistant	_	O	O	_	_	_	_	_
51	cells	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	conclude	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	25	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	OH	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	D	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	induces	_	O	O	_	_	_	_	_
17	increased	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	cdk	_	O	O	_	_	_	_	_
21	inhibitors	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	which	_	O	O	_	_	_	_	_
24	mediates	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	G	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	arrest	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	this	_	O	O	_	_	_	_	_
32	may	_	O	O	_	_	_	_	_
33	be	_	O	O	_	_	_	_	_
34	associated	_	O	O	_	_	_	_	_
35	with	_	O	O	_	_	_	_	_
36	differentiation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	RA	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	resistant	_	O	O	_	_	_	_	_
41	UF	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	toward	_	O	O	_	_	_	_	_
46	mature	_	O	O	_	_	_	_	_
47	granulocytes	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_


1	Anti	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	immunoglobulin	_	O	O	_	_	_	_	_
4	M	_	O	O	_	_	_	_	_
5	activates	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	calcium	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	calmodulin	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	kinase	_	O	O	_	_	_	_	_
14	II	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	lymphocytes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	others	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	previously	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	nuclear	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	Ets	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	phosphorylated	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	calcium	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	dependent	_	O	O	_	_	_	_	_
23	manner	_	O	O	_	_	_	_	_
24	after	_	O	O	_	_	_	_	_
25	ligation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	immunoglobulin	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	Ig	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	M	_	O	O	_	_	_	_	_
32	on	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	lymphocytes	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	phosphorylation	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	independent	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	C	_	O	O	_	_	_	_	_
10	activity	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	tested	_	O	O	_	_	_	_	_
14	whether	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	calcium	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	calmodulin	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	dependent	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	kinase	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	CaM	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	might	_	O	O	_	_	_	_	_
28	phosphorylate	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	Ets	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	protein	_	O	O	_	_	_	_	_
34	after	_	O	O	_	_	_	_	_
35	elevation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	intracellular	_	O	O	_	_	_	_	_
38	free	_	O	O	_	_	_	_	_
39	calcium	_	O	O	_	_	_	_	_
40	concentrations	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	dephosphorylated	_	O	O	_	_	_	_	_
3	form	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Ets	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	has	_	O	O	_	_	_	_	_
9	been	_	O	O	_	_	_	_	_
10	shown	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	bind	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	chromatin	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	suggesting	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	operative	_	O	O	_	_	_	_	_
20	kinase	_	O	O	_	_	_	_	_
21	should	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	detectable	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	nucleus	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	prepared	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	extracts	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	two	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	lines	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	increased	_	O	O	_	_	_	_	_
14	intracellular	_	O	O	_	_	_	_	_
15	free	_	O	O	_	_	_	_	_
16	calcium	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	correlated	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	increased	_	O	O	_	_	_	_	_
21	phosphorylation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	Ets	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Activity	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	CaM	_	O	O	_	_	_	_	_
5	kinases	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	determined	_	O	O	_	_	_	_	_
8	using	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	synthetic	_	O	O	_	_	_	_	_
11	peptide	_	O	O	_	_	_	_	_
12	substrate	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	absence	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	presence	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	inhibitor	_	O	O	_	_	_	_	_
22	specific	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	CaM	_	O	O	_	_	_	_	_
26	kinase	_	O	O	_	_	_	_	_
27	family	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	KN	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	62	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Stimulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	anti	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	IgM	_	O	O	_	_	_	_	_
8	led	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	nuclear	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	could	_	O	O	_	_	_	_	_
18	phosphorylate	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	peptide	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	this	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	reduced	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	10	_	O	O	_	_	_	_	_
29	microM	_	O	O	_	_	_	_	_
30	KN	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	62	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Kinase	_	O	O	_	_	_	_	_
2	activity	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	reduced	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	lysates	_	O	O	_	_	_	_	_
7	preadsorbed	_	O	O	_	_	_	_	_
8	using	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	antibody	_	O	O	_	_	_	_	_
11	specific	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	CaM	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	II	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	dimensional	_	O	O	_	_	_	_	_
4	phosphopeptide	_	O	O	_	_	_	_	_
5	maps	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	Ets	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	incubated	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	ionomycin	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	anti	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	IgM	_	O	O	_	_	_	_	_
21	contained	_	O	O	_	_	_	_	_
22	two	_	O	O	_	_	_	_	_
23	unique	_	O	O	_	_	_	_	_
24	phosphopeptides	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	were	_	O	O	_	_	_	_	_
27	absent	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	untreated	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Incubation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	isolated	_	O	O	_	_	_	_	_
4	Ets	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	purified	_	O	O	_	_	_	_	_
10	CaM	_	O	O	_	_	_	_	_
11	kinase	_	O	O	_	_	_	_	_
12	II	_	O	O	_	_	_	_	_
13	produced	_	O	O	_	_	_	_	_
14	phosphorylation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	peptides	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	migrated	_	O	O	_	_	_	_	_
19	identically	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	those	_	O	O	_	_	_	_	_
22	found	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	incubated	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	either	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	IgM	_	O	O	_	_	_	_	_
31	or	_	O	O	_	_	_	_	_
32	ionomycin	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	model	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	signal	_	O	O	_	_	_	_	_
8	transduction	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	antigen	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	lymphocytes	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	which	_	O	O	_	_	_	_	_
18	increased	_	O	O	_	_	_	_	_
19	intracellular	_	O	O	_	_	_	_	_
20	free	_	O	O	_	_	_	_	_
21	calcium	_	O	O	_	_	_	_	_
22	can	_	O	O	_	_	_	_	_
23	rapidly	_	O	O	_	_	_	_	_
24	activate	_	O	O	_	_	_	_	_
25	nuclear	_	O	O	_	_	_	_	_
26	CaM	_	O	O	_	_	_	_	_
27	kinase	_	O	O	_	_	_	_	_
28	II	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	potentially	_	O	O	_	_	_	_	_
31	resulting	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	phosphorylation	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	regulation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	DNA	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	binding	_	O	O	_	_	_	_	_
40	proteins	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	G	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Anh	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	MTetra	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	natural	_	O	O	_	_	_	_	_
9	bacterial	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	wall	_	O	O	_	_	_	_	_
12	breakdown	_	O	O	_	_	_	_	_
13	product	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	induces	_	O	O	_	_	_	_	_
16	interleukin	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	beta	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	interleukin	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	monocytes	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	molecular	_	O	O	_	_	_	_	_
6	mechanisms	_	O	O	_	_	_	_	_
7	involved	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	inflammatory	_	O	O	_	_	_	_	_
10	cytokine	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	[	_	O	O	_	_	_	_	_
13	published	_	O	O	_	_	_	_	_
14	erratum	_	O	O	_	_	_	_	_
15	appears	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	J	_	O	O	_	_	_	_	_
18	Biol	_	O	O	_	_	_	_	_
19	Chem	_	O	O	_	_	_	_	_
20	1994	_	O	O	_	_	_	_	_
21	Jun	_	O	O	_	_	_	_	_
22	17	_	O	O	_	_	_	_	_
23	;	_	O	O	_	_	_	_	_
24	269	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	24	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	:	_	O	O	_	_	_	_	_
29	16983	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	believed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	induction	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	bacterial	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	wall	_	O	O	_	_	_	_	_
13	components	_	O	O	_	_	_	_	_
14	plays	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	role	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	development	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	course	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	sepsis	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	most	_	O	O	_	_	_	_	_
4	attention	_	O	O	_	_	_	_	_
5	has	_	O	O	_	_	_	_	_
6	been	_	O	O	_	_	_	_	_
7	focused	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	lipopolysaccharide	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	LPS	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	studied	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	ability	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	N	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	acetylglucosaminyl	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	anhydro	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	N	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	acetylmuramyl	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	L	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	alanyl	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	D	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	isoglutamyl	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	m	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	diaminopimelyl	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	D	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	alanine	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	G	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	Anh	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	MTetra	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	naturally	_	O	O	_	_	_	_	_
45	occurring	_	O	O	_	_	_	_	_
46	breakdown	_	O	O	_	_	_	_	_
47	product	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	peptidoglycan	_	O	O	_	_	_	_	_
50	that	_	O	O	_	_	_	_	_
51	is	_	O	O	_	_	_	_	_
52	produced	_	O	O	_	_	_	_	_
53	by	_	O	O	_	_	_	_	_
54	soluble	_	O	O	_	_	_	_	_
55	lytic	_	O	O	_	_	_	_	_
56	transglycosylase	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	Escherichia	_	O	O	_	_	_	_	_
59	coli	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	to	_	O	O	_	_	_	_	_
62	induce	_	O	O	_	_	_	_	_
63	cytokine	_	O	O	_	_	_	_	_
64	expression	_	O	O	_	_	_	_	_
65	in	_	O	O	_	_	_	_	_
66	human	_	O	O	_	_	_	_	_
67	monocytes	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_

1	G	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Anh	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	MTetra	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	strongly	_	O	O	_	_	_	_	_
10	induce	_	O	O	_	_	_	_	_
11	interleukin	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	beta	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	after	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	h	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	beta	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	protein	_	O	O	_	_	_	_	_
37	secretion	_	O	O	_	_	_	_	_
38	after	_	O	O	_	_	_	_	_
39	48	_	O	O	_	_	_	_	_
40	h	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	activation	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	increase	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	accumulation	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	at	_	O	O	_	_	_	_	_
8	least	_	O	O	_	_	_	_	_
9	partly	_	O	O	_	_	_	_	_
10	due	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	increase	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	rates	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	respective	_	O	O	_	_	_	_	_
21	genes	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	accompanied	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	strong	_	O	O	_	_	_	_	_
28	induction	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	nuclear	_	O	O	_	_	_	_	_
31	factor	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	kappa	_	O	O	_	_	_	_	_
34	B	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	activator	_	O	O	_	_	_	_	_
37	protein	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	transcription	_	O	O	_	_	_	_	_
41	factor	_	O	O	_	_	_	_	_
42	expression	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Experiments	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	inhibitors	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	kinase	_	O	O	_	_	_	_	_
7	C	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	kinase	_	O	O	_	_	_	_	_
11	A	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	tyrosine	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	dependent	_	O	O	_	_	_	_	_
18	pathways	_	O	O	_	_	_	_	_
19	revealed	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	G	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	Anh	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	MTetra	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	induced	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	beta	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	mRNA	_	O	O	_	_	_	_	_
37	expression	_	O	O	_	_	_	_	_
38	involves	_	O	O	_	_	_	_	_
39	activation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	an	_	O	O	_	_	_	_	_
42	H	_	O	O	_	_	_	_	_
43	7	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	inhibitable	_	O	O	_	_	_	_	_
46	pathway	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	synthesis	_	O	O	_	_	_	_	_
6	inhibitor	_	O	O	_	_	_	_	_
7	cycloheximide	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	it	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	shown	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	G	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	Anh	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	MTetra	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	mRNA	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	depends	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	synthesis	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	new	_	O	O	_	_	_	_	_
31	protein	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	whereas	_	O	O	_	_	_	_	_
34	G	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	Anh	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	MTetra	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	induced	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	beta	_	O	O	_	_	_	_	_
45	mRNA	_	O	O	_	_	_	_	_
46	accumulation	_	O	O	_	_	_	_	_
47	does	_	O	O	_	_	_	_	_
48	not	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	responses	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	G	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	Anh	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	MTetra	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	compared	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	those	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	muramyldipeptide	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	MDP	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	it	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	found	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	optimal	_	O	O	_	_	_	_	_
27	response	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	G	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	Anh	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	MTetra	_	O	O	_	_	_	_	_
34	induction	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	similar	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	that	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	LPS	_	O	O	_	_	_	_	_
41	but	_	O	O	_	_	_	_	_
42	significantly	_	O	O	_	_	_	_	_
43	higher	_	O	O	_	_	_	_	_
44	than	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	response	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	MDP	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	maximal	_	O	O	_	_	_	_	_
4	G	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	Anh	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	MTetra	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	could	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	enhanced	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	co	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	stimulation	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	LPS	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	MDP	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	suggesting	_	O	O	_	_	_	_	_
34	that	_	O	O	_	_	_	_	_
35	different	_	O	O	_	_	_	_	_
36	receptors	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	/	_	O	O	_	_	_	_	_
39	or	_	O	O	_	_	_	_	_
40	transduction	_	O	O	_	_	_	_	_
41	pathways	_	O	O	_	_	_	_	_
42	were	_	O	O	_	_	_	_	_
43	involved	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	G	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	Anh	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	MTetra	_	O	O	_	_	_	_	_
10	induces	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	monocytes	_	O	O	_	_	_	_	_
23	suggesting	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	possible	_	O	O	_	_	_	_	_
26	role	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	G	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	Anh	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	MTetra	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	release	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	cytokines	_	O	O	_	_	_	_	_
38	during	_	O	O	_	_	_	_	_
39	sepsis	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	central	_	O	O	_	_	_	_	_
3	role	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	single	_	O	O	_	_	_	_	_
7	c	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	Myb	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	site	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	thymic	_	O	O	_	_	_	_	_
15	locus	_	O	O	_	_	_	_	_
16	control	_	O	O	_	_	_	_	_
17	region	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Locus	_	O	O	_	_	_	_	_
2	control	_	O	O	_	_	_	_	_
3	regions	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	LCRs	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	powerful	_	O	O	_	_	_	_	_
9	assemblies	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cis	_	O	O	_	_	_	_	_
12	elements	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	organize	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	actions	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	type	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	specific	_	O	O	_	_	_	_	_
23	trans	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	acting	_	O	O	_	_	_	_	_
26	factors	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kb	_	O	O	_	_	_	_	_
7	LCR	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	adenosine	_	O	O	_	_	_	_	_
12	deaminase	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	ADA	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	gene	_	O	O	_	_	_	_	_
17	first	_	O	O	_	_	_	_	_
18	intron	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	which	_	O	O	_	_	_	_	_
21	controls	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	thymocytes	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	composed	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	200	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	bp	_	O	O	_	_	_	_	_
33	enhancer	_	O	O	_	_	_	_	_
34	domain	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	extended	_	O	O	_	_	_	_	_
37	flanking	_	O	O	_	_	_	_	_
38	sequences	_	O	O	_	_	_	_	_
39	that	_	O	O	_	_	_	_	_
40	facilitate	_	O	O	_	_	_	_	_
41	activation	_	O	O	_	_	_	_	_
42	from	_	O	O	_	_	_	_	_
43	within	_	O	O	_	_	_	_	_
44	chromatin	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Prior	_	O	O	_	_	_	_	_
2	analyses	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	enhancer	_	O	O	_	_	_	_	_
8	contains	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	28	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	bp	_	O	O	_	_	_	_	_
13	core	_	O	O	_	_	_	_	_
14	region	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	local	_	O	O	_	_	_	_	_
17	adjacent	_	O	O	_	_	_	_	_
18	augmentative	_	O	O	_	_	_	_	_
19	cis	_	O	O	_	_	_	_	_
20	elements	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	now	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	core	_	O	O	_	_	_	_	_
7	contains	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	single	_	O	O	_	_	_	_	_
10	critical	_	O	O	_	_	_	_	_
11	c	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Myb	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	site	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	both	_	O	O	_	_	_	_	_
3	transiently	_	O	O	_	_	_	_	_
4	cotransfected	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	stable	_	O	O	_	_	_	_	_
9	chromatin	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	integrated	_	O	O	_	_	_	_	_
12	yeast	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Myb	_	O	O	_	_	_	_	_
18	strongly	_	O	O	_	_	_	_	_
19	transactivated	_	O	O	_	_	_	_	_
20	reporter	_	O	O	_	_	_	_	_
21	constructs	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	contained	_	O	O	_	_	_	_	_
24	polymerized	_	O	O	_	_	_	_	_
25	core	_	O	O	_	_	_	_	_
26	sequences	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	c	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Myb	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	strongly	_	O	O	_	_	_	_	_
7	evident	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	lymphoblasts	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	enhancer	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	active	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	localized	_	O	O	_	_	_	_	_
20	within	_	O	O	_	_	_	_	_
21	discrete	_	O	O	_	_	_	_	_
22	nuclear	_	O	O	_	_	_	_	_
23	structures	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Fetal	_	O	O	_	_	_	_	_
2	murine	_	O	O	_	_	_	_	_
3	thymus	_	O	O	_	_	_	_	_
4	exhibited	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	striking	_	O	O	_	_	_	_	_
7	concordance	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	endogenous	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	myb	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	mouse	_	O	O	_	_	_	_	_
18	ADA	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	ADA	_	O	O	_	_	_	_	_
22	LCR	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	directed	_	O	O	_	_	_	_	_
25	transgene	_	O	O	_	_	_	_	_
26	expression	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Point	_	O	O	_	_	_	_	_
2	mutation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Myb	_	O	O	_	_	_	_	_
8	site	_	O	O	_	_	_	_	_
9	within	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	intact	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	kb	_	O	O	_	_	_	_	_
17	LCR	_	O	O	_	_	_	_	_
18	severely	_	O	O	_	_	_	_	_
19	attenuated	_	O	O	_	_	_	_	_
20	enhancer	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	transfections	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	LCR	_	O	O	_	_	_	_	_
26	activity	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	transgenic	_	O	O	_	_	_	_	_
29	thymocytes	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Within	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	context	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	complex	_	O	O	_	_	_	_	_
7	enhancer	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	LCR	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	c	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Myb	_	O	O	_	_	_	_	_
14	can	_	O	O	_	_	_	_	_
15	act	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	organizer	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	thymocyte	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	specific	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	via	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	single	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	site	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Abnormalities	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cyclic	_	O	O	_	_	_	_	_
4	adenosine	_	O	O	_	_	_	_	_
5	monophosphate	_	O	O	_	_	_	_	_
6	signaling	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	platelets	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	untreated	_	O	O	_	_	_	_	_
11	patients	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	bipolar	_	O	O	_	_	_	_	_
14	disorder	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Abnormalities	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	cyclic	_	O	O	_	_	_	_	_
7	adenosine	_	O	O	_	_	_	_	_
8	monophosphate	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	cAMP	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dependent	_	O	O	_	_	_	_	_
14	phosphorylation	_	O	O	_	_	_	_	_
15	system	_	O	O	_	_	_	_	_
16	have	_	O	O	_	_	_	_	_
17	been	_	O	O	_	_	_	_	_
18	recently	_	O	O	_	_	_	_	_
19	reported	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	bipolar	_	O	O	_	_	_	_	_
24	disorder	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	evaluated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	immunoreactivity	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	regulatory	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	catalytic	_	O	O	_	_	_	_	_
10	subunits	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	cAMP	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	dependent	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	kinase	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	kinase	_	O	O	_	_	_	_	_
20	A	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	its	_	O	O	_	_	_	_	_
26	substrates	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	Rap	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	platelets	_	O	O	_	_	_	_	_
33	from	_	O	O	_	_	_	_	_
34	untreated	_	O	O	_	_	_	_	_
35	euthymic	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	manic	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	depressed	_	O	O	_	_	_	_	_
41	patients	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	bipolar	_	O	O	_	_	_	_	_
44	disorder	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	healthy	_	O	O	_	_	_	_	_
47	subjects	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Platelets	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	collected	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	112	_	O	O	_	_	_	_	_
8	drug	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	free	_	O	O	_	_	_	_	_
11	patients	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	bipolar	_	O	O	_	_	_	_	_
14	disorder	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	52	_	O	O	_	_	_	_	_
17	euthymic	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	29	_	O	O	_	_	_	_	_
20	depressed	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	31	_	O	O	_	_	_	_	_
24	manic	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	62	_	O	O	_	_	_	_	_
28	healthy	_	O	O	_	_	_	_	_
29	subjects	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	levels	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cAMP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	dependent	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	Rap	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	assessed	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	Western	_	O	O	_	_	_	_	_
16	blot	_	O	O	_	_	_	_	_
17	analysis	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	immunostaining	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	computer	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	assisted	_	O	O	_	_	_	_	_
25	imaging	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	immunolabeling	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	catalytic	_	O	O	_	_	_	_	_
8	subunit	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	cAMP	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	dependent	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	kinase	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	significantly	_	O	O	_	_	_	_	_
17	different	_	O	O	_	_	_	_	_
18	among	_	O	O	_	_	_	_	_
19	groups	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	P	_	O	O	_	_	_	_	_
22	<	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_
24	001	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	higher	_	O	O	_	_	_	_	_
29	values	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	untreated	_	O	O	_	_	_	_	_
32	depressed	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	manic	_	O	O	_	_	_	_	_
35	patients	_	O	O	_	_	_	_	_
36	with	_	O	O	_	_	_	_	_
37	bipolar	_	O	O	_	_	_	_	_
38	disorder	_	O	O	_	_	_	_	_
39	compared	_	O	O	_	_	_	_	_
40	with	_	O	O	_	_	_	_	_
41	untreated	_	O	O	_	_	_	_	_
42	euthymic	_	O	O	_	_	_	_	_
43	patients	_	O	O	_	_	_	_	_
44	with	_	O	O	_	_	_	_	_
45	bipolar	_	O	O	_	_	_	_	_
46	disorder	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	healthy	_	O	O	_	_	_	_	_
49	subjects	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	significant	_	O	O	_	_	_	_	_
3	differences	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	found	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	immunolabeling	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	regulatory	_	O	O	_	_	_	_	_
12	subunits	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	type	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	type	_	O	O	_	_	_	_	_
18	II	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	cAMP	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	dependent	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	immunolabeling	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Rap	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	significantly	_	O	O	_	_	_	_	_
8	higher	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	P	_	O	O	_	_	_	_	_
11	<	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	001	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	untreated	_	O	O	_	_	_	_	_
17	euthymic	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	depressed	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	manic	_	O	O	_	_	_	_	_
23	patients	_	O	O	_	_	_	_	_
24	than	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	healthy	_	O	O	_	_	_	_	_
27	persons	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Levels	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Rap	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	catalytic	_	O	O	_	_	_	_	_
10	subunit	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	cAMP	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	dependent	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	kinase	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	altered	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	platelets	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	bipolar	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	may	_	O	O	_	_	_	_	_
4	provide	_	O	O	_	_	_	_	_
5	clues	_	O	O	_	_	_	_	_
6	toward	_	O	O	_	_	_	_	_
7	understanding	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	involvement	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cAMP	_	O	O	_	_	_	_	_
12	signaling	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	pathogenesis	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	bipolar	_	O	O	_	_	_	_	_
18	disorder	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	new	_	O	O	_	_	_	_	_
3	member	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	leucine	_	O	O	_	_	_	_	_
7	zipper	_	O	O	_	_	_	_	_
8	class	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	binds	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	HLA	_	O	O	_	_	_	_	_
16	DR	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Several	_	O	O	_	_	_	_	_
2	mutants	_	O	O	_	_	_	_	_
3	derived	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	transformed	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	lines	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	defective	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	expressing	_	O	O	_	_	_	_	_
14	major	_	O	O	_	_	_	_	_
15	histocompatibility	_	O	O	_	_	_	_	_
16	complex	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	MHC	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	class	_	O	O	_	_	_	_	_
21	II	_	O	O	_	_	_	_	_
22	genes	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	failure	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	express	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	class	_	O	O	_	_	_	_	_
7	II	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	at	_	O	O	_	_	_	_	_
11	least	_	O	O	_	_	_	_	_
12	one	_	O	O	_	_	_	_	_
13	such	_	O	O	_	_	_	_	_
14	mutant	_	O	O	_	_	_	_	_
15	line	_	O	O	_	_	_	_	_
16	has	_	O	O	_	_	_	_	_
17	been	_	O	O	_	_	_	_	_
18	mapped	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	MHC	_	O	O	_	_	_	_	_
22	class	_	O	O	_	_	_	_	_
23	II	_	O	O	_	_	_	_	_
24	X	_	O	O	_	_	_	_	_
25	box	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	conserved	_	O	O	_	_	_	_	_
29	transcriptional	_	O	O	_	_	_	_	_
30	element	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	promoter	_	O	O	_	_	_	_	_
34	region	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	complementary	_	O	O	_	_	_	_	_
3	DNA	_	O	O	_	_	_	_	_
4	encoding	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	human	_	O	O	_	_	_	_	_
12	X	_	O	O	_	_	_	_	_
13	box	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	hXBP	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	whose	_	O	O	_	_	_	_	_
22	target	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	human	_	O	O	_	_	_	_	_
26	DR	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	X	_	O	O	_	_	_	_	_
29	box	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	'	_	O	O	_	_	_	_	_
34	flanking	_	O	O	_	_	_	_	_
35	region	_	O	O	_	_	_	_	_
36	has	_	O	O	_	_	_	_	_
37	now	_	O	O	_	_	_	_	_
38	been	_	O	O	_	_	_	_	_
39	cloned	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	complementary	_	O	O	_	_	_	_	_
3	DNA	_	O	O	_	_	_	_	_
4	encoded	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	structural	_	O	O	_	_	_	_	_
9	similarities	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	c	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	jun	_	O	O	_	_	_	_	_
15	proto	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	oncogene	_	O	O	_	_	_	_	_
18	product	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	its	_	O	O	_	_	_	_	_
22	target	_	O	O	_	_	_	_	_
23	sequence	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	closely	_	O	O	_	_	_	_	_
26	related	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	palindromic	_	O	O	_	_	_	_	_
30	target	_	O	O	_	_	_	_	_
31	sequence	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	c	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	jun	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Mutation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	hXBP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	target	_	O	O	_	_	_	_	_
9	sequence	_	O	O	_	_	_	_	_
10	decreased	_	O	O	_	_	_	_	_
11	DR	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	promoter	_	O	O	_	_	_	_	_
14	activity	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	vivo	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	hXBP	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	acts	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	ChIP	_	O	O	_	_	_	_	_
2	assay	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	described	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	Nouzova	_	O	O	_	_	_	_	_
5	[	_	O	O	_	_	_	_	_
6	53	_	O	O	_	_	_	_	_
7	]	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	brief	_	O	O	_	_	_	_	_
11	:	_	O	O	_	_	_	_	_
12	Cells	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	MEL	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	x	_	O	O	_	_	_	_	_
19	107	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	fetal	_	O	O	_	_	_	_	_
23	liver	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	from	_	O	O	_	_	_	_	_
26	three	_	O	O	_	_	_	_	_
27	15	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	5	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	dpc	_	O	O	_	_	_	_	_
32	WT	_	O	O	_	_	_	_	_
33	mice	_	O	O	_	_	_	_	_
34	were	_	O	O	_	_	_	_	_
35	treated	_	O	O	_	_	_	_	_
36	with	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	%	_	O	O	_	_	_	_	_
39	formaldehyde	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	10	_	O	O	_	_	_	_	_
42	min	_	O	O	_	_	_	_	_
43	at	_	O	O	_	_	_	_	_
44	37	_	O	O	_	_	_	_	_
45	degreesC	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	rinsed	_	O	O	_	_	_	_	_
48	in	_	O	O	_	_	_	_	_
49	ice	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	cold	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	x	_	O	O	_	_	_	_	_
54	Hanks	_	O	O	_	_	_	_	_
55	'	_	O	O	_	_	_	_	_
56	balanced	_	O	O	_	_	_	_	_
57	salt	_	O	O	_	_	_	_	_
58	solution	_	O	O	_	_	_	_	_
59	with	_	O	O	_	_	_	_	_
60	0	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_
62	1	_	O	O	_	_	_	_	_
63	%	_	O	O	_	_	_	_	_
64	EDTA	_	O	O	_	_	_	_	_
65	containing	_	O	O	_	_	_	_	_
66	protease	_	O	O	_	_	_	_	_
67	inhibitors	_	O	O	_	_	_	_	_
68	,	_	O	O	_	_	_	_	_
69	collected	_	O	O	_	_	_	_	_
70	by	_	O	O	_	_	_	_	_
71	centrifugation	_	O	O	_	_	_	_	_
72	at	_	O	O	_	_	_	_	_
73	4	_	O	O	_	_	_	_	_
74	degreesC	_	O	O	_	_	_	_	_
75	,	_	O	O	_	_	_	_	_
76	resuspended	_	O	O	_	_	_	_	_
77	in	_	O	O	_	_	_	_	_
78	a	_	O	O	_	_	_	_	_
79	SDS	_	O	O	_	_	_	_	_
80	lysis	_	O	O	_	_	_	_	_
81	buffer	_	O	O	_	_	_	_	_
82	containing	_	O	O	_	_	_	_	_
83	protease	_	O	O	_	_	_	_	_
84	inhibitors	_	O	O	_	_	_	_	_
85	,	_	O	O	_	_	_	_	_
86	and	_	O	O	_	_	_	_	_
87	incubated	_	O	O	_	_	_	_	_
88	on	_	O	O	_	_	_	_	_
89	ice	_	O	O	_	_	_	_	_
90	for	_	O	O	_	_	_	_	_
91	10	_	O	O	_	_	_	_	_
92	min	_	O	O	_	_	_	_	_
93	.	_	O	O	_	_	_	_	_

1	DNA	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	complexes	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	sonicated	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	200	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	600	_	O	O	_	_	_	_	_
11	bp	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	tenth	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	sample	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	set	_	O	O	_	_	_	_	_
9	aside	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	input	_	O	O	_	_	_	_	_
12	control	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	remaining	_	O	O	_	_	_	_	_
17	sample	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	precleared	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	A	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	Sepharose	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	Amersham	_	O	O	_	_	_	_	_
27	Biosciences	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	Piscataway	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	New	_	O	O	_	_	_	_	_
32	Jersey	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	United	_	O	O	_	_	_	_	_
35	States	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	preclearing	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	samples	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	split	_	O	O	_	_	_	_	_
8	into	_	O	O	_	_	_	_	_
9	thirds	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	one	_	O	O	_	_	_	_	_
12	sample	_	O	O	_	_	_	_	_
13	treated	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	anti	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Sox	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	second	_	O	O	_	_	_	_	_
22	treated	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	normal	_	O	O	_	_	_	_	_
25	rabbit	_	O	O	_	_	_	_	_
26	IgG	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	third	_	O	O	_	_	_	_	_
31	sample	_	O	O	_	_	_	_	_
32	without	_	O	O	_	_	_	_	_
33	Ab	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	last	_	O	O	_	_	_	_	_
3	two	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	used	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	negative	_	O	O	_	_	_	_	_
8	controls	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	chromatin	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	antibody	_	O	O	_	_	_	_	_
5	complexes	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	eluted	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	DNA	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	cross	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	links	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	reversed	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	M	_	O	O	_	_	_	_	_
21	NaCl	_	O	O	_	_	_	_	_
22	at	_	O	O	_	_	_	_	_
23	65	_	O	O	_	_	_	_	_
24	degreesC	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	h	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Input	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	or	_	O	O	_	_	_	_	_
4	immunoprecipitated	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	used	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	template	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	PCR	_	O	O	_	_	_	_	_
14	reaction	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	PCR	_	O	O	_	_	_	_	_
2	amplification	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	epsilony	_	O	O	_	_	_	_	_
6	promoter	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	performed	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	yielded	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	172	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	bp	_	O	O	_	_	_	_	_
15	amplicon	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	corresponding	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	nucleotides	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	31	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	140	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	epsilony	_	O	O	_	_	_	_	_
28	promoter	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	primers	_	O	O	_	_	_	_	_
31	MHB	_	O	O	_	_	_	_	_
32	1688	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	5	_	O	O	_	_	_	_	_
35	'	_	O	O	_	_	_	_	_
36	CGAAGAATAAAAGGCCACCA	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	';	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	MHB	_	O	O	_	_	_	_	_
41	1689	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	5	_	O	O	_	_	_	_	_
44	'	_	O	O	_	_	_	_	_
45	GCTTCACCACCAACCTCTTC	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	'	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	PCR	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	performed	_	O	O	_	_	_	_	_
4	under	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	following	_	O	O	_	_	_	_	_
7	conditions	_	O	O	_	_	_	_	_
8	:	_	O	O	_	_	_	_	_
9	95	_	O	O	_	_	_	_	_
10	degreesC	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	15	_	O	O	_	_	_	_	_
13	min	_	O	O	_	_	_	_	_
14	followed	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	30	_	O	O	_	_	_	_	_
17	cycles	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	95	_	O	O	_	_	_	_	_
20	degreesC	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	30	_	O	O	_	_	_	_	_
23	s	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	60	_	O	O	_	_	_	_	_
26	degreesC	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	30	_	O	O	_	_	_	_	_
29	s	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	72	_	O	O	_	_	_	_	_
33	degreesC	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	45	_	O	O	_	_	_	_	_
36	s	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	ending	_	O	O	_	_	_	_	_
39	with	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	final	_	O	O	_	_	_	_	_
42	extension	_	O	O	_	_	_	_	_
43	at	_	O	O	_	_	_	_	_
44	72	_	O	O	_	_	_	_	_
45	degreesC	_	O	O	_	_	_	_	_
46	for	_	O	O	_	_	_	_	_
47	5	_	O	O	_	_	_	_	_
48	min	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_



1	HLA	_	O	O	_	_	_	_	_
2	class	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	induction	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	proliferation	_	O	O	_	_	_	_	_
10	involves	_	O	O	_	_	_	_	_
11	cyclin	_	O	O	_	_	_	_	_
12	E	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	inactivation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	Rb	_	O	O	_	_	_	_	_
18	function	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	induction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	E	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	F	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Chronic	_	O	O	_	_	_	_	_
2	rejection	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	transplanted	_	O	O	_	_	_	_	_
5	organs	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	manifested	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	atherosclerosis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	blood	_	O	O	_	_	_	_	_
13	vessels	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	allograft	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	HLA	_	O	O	_	_	_	_	_
2	class	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	Ags	_	O	O	_	_	_	_	_
5	have	_	O	O	_	_	_	_	_
6	been	_	O	O	_	_	_	_	_
7	implicated	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	play	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	major	_	O	O	_	_	_	_	_
12	role	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	this	_	O	O	_	_	_	_	_
15	process	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	since	_	O	O	_	_	_	_	_
18	signaling	_	O	O	_	_	_	_	_
19	via	_	O	O	_	_	_	_	_
20	HLA	_	O	O	_	_	_	_	_
21	class	_	O	O	_	_	_	_	_
22	I	_	O	O	_	_	_	_	_
23	molecules	_	O	O	_	_	_	_	_
24	can	_	O	O	_	_	_	_	_
25	induce	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	proliferation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	aortic	_	O	O	_	_	_	_	_
30	endothelial	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	well	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	smooth	_	O	O	_	_	_	_	_
35	muscle	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	show	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	HLA	_	O	O	_	_	_	_	_
9	class	_	O	O	_	_	_	_	_
10	I	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	mediated	_	O	O	_	_	_	_	_
13	induction	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	proliferation	_	O	O	_	_	_	_	_
17	correlates	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	inactivation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Rb	_	O	O	_	_	_	_	_
23	protein	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	line	_	O	O	_	_	_	_	_
29	Jurkat	_	O	O	_	_	_	_	_
30	as	_	O	O	_	_	_	_	_
31	well	_	O	O	_	_	_	_	_
32	as	_	O	O	_	_	_	_	_
33	human	_	O	O	_	_	_	_	_
34	aortic	_	O	O	_	_	_	_	_
35	endothelial	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	HLA	_	O	O	_	_	_	_	_
2	class	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	inactivation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Rb	_	O	O	_	_	_	_	_
9	can	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	inhibited	_	O	O	_	_	_	_	_
12	specifically	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	neutralizing	_	O	O	_	_	_	_	_
15	Abs	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	basic	_	O	O	_	_	_	_	_
18	fibroblast	_	O	O	_	_	_	_	_
19	growth	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	bFGF	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	suggesting	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	role	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	FGF	_	O	O	_	_	_	_	_
30	receptors	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	signaling	_	O	O	_	_	_	_	_
34	process	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Signaling	_	O	O	_	_	_	_	_
2	through	_	O	O	_	_	_	_	_
3	HLA	_	O	O	_	_	_	_	_
4	class	_	O	O	_	_	_	_	_
5	I	_	O	O	_	_	_	_	_
6	molecules	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	cyclin	_	O	O	_	_	_	_	_
9	E	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	associated	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	within	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	h	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	quiescent	_	O	O	_	_	_	_	_
19	endothelial	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	appeared	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	mediate	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	inactivation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	Rb	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	cdk	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	inhibitor	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	Olomoucine	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	well	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	dominant	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	negative	_	O	O	_	_	_	_	_
15	cdk	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	construct	_	O	O	_	_	_	_	_
18	prevented	_	O	O	_	_	_	_	_
19	HLA	_	O	O	_	_	_	_	_
20	class	_	O	O	_	_	_	_	_
21	I	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	inactivation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	Rb	_	O	O	_	_	_	_	_
27	;	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	contrast	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	dominant	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	negative	_	O	O	_	_	_	_	_
34	cdk	_	O	O	_	_	_	_	_
35	4	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	cdk	_	O	O	_	_	_	_	_
38	6	_	O	O	_	_	_	_	_
39	constructs	_	O	O	_	_	_	_	_
40	had	_	O	O	_	_	_	_	_
41	no	_	O	O	_	_	_	_	_
42	effect	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	there	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	no	_	O	O	_	_	_	_	_
6	increase	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	cyclin	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	associated	_	O	O	_	_	_	_	_
12	kinase	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	upon	_	O	O	_	_	_	_	_
15	HLA	_	O	O	_	_	_	_	_
16	class	_	O	O	_	_	_	_	_
17	I	_	O	O	_	_	_	_	_
18	ligation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	suggesting	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	cyclin	_	O	O	_	_	_	_	_
23	E	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	dependent	_	O	O	_	_	_	_	_
26	kinase	_	O	O	_	_	_	_	_
27	activity	_	O	O	_	_	_	_	_
28	mediates	_	O	O	_	_	_	_	_
29	Rb	_	O	O	_	_	_	_	_
30	inactivation	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	leading	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	E	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	F	_	O	O	_	_	_	_	_
37	activation	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	proliferation	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	c	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	fos	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	c	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	jun	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	jun	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	peripheral	_	O	O	_	_	_	_	_
15	blood	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	young	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	elderly	_	O	O	_	_	_	_	_
21	adults	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	c	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	fos	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	c	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	jun	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	jun	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	proto	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	oncogenes	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	studied	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	phytohemagglutinin	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	PHA	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	activated	_	O	O	_	_	_	_	_
25	peripheral	_	O	O	_	_	_	_	_
26	blood	_	O	O	_	_	_	_	_
27	lymphocytes	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	PBL	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	young	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	aged	_	O	O	_	_	_	_	_
35	humans	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Specific	_	O	O	_	_	_	_	_
2	mRNAs	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	c	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	fos	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	c	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	jun	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	detectable	_	O	O	_	_	_	_	_
13	within	_	O	O	_	_	_	_	_
14	30	_	O	O	_	_	_	_	_
15	min	_	O	O	_	_	_	_	_
16	after	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	reached	_	O	O	_	_	_	_	_
21	maximal	_	O	O	_	_	_	_	_
22	levels	_	O	O	_	_	_	_	_
23	within	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	h	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	c	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	fos	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	jun	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	mRNAs	_	O	O	_	_	_	_	_
9	decreased	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	pre	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	activation	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	within	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	h	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	while	_	O	O	_	_	_	_	_
20	c	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	jun	_	O	O	_	_	_	_	_
23	mRNA	_	O	O	_	_	_	_	_
24	remained	_	O	O	_	_	_	_	_
25	elevated	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	PHA	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	activated	_	O	O	_	_	_	_	_
5	PBL	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	no	_	O	O	_	_	_	_	_
8	age	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	related	_	O	O	_	_	_	_	_
11	differences	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	observed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	fos	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	jun	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	mRNA	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	c	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	jun	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	levels	_	O	O	_	_	_	_	_
8	decreased	_	O	O	_	_	_	_	_
9	significantly	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_
13	73	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	0	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	08	_	O	O	_	_	_	_	_
20	vs	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_
3	16	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	0	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	09	_	O	O	_	_	_	_	_
10	arbitrary	_	O	O	_	_	_	_	_
11	units	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	P	_	O	O	_	_	_	_	_
14	<	_	O	O	_	_	_	_	_
15	0	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_
17	01	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	young	_	O	O	_	_	_	_	_
20	vs	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	old	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	PBL	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	elderly	_	O	O	_	_	_	_	_
7	individuals	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	PHA	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	previous	_	O	O	_	_	_	_	_
3	work	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	demonstrated	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	elderly	_	O	O	_	_	_	_	_
11	individuals	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	display	_	O	O	_	_	_	_	_
14	normal	_	O	O	_	_	_	_	_
15	proliferative	_	O	O	_	_	_	_	_
16	responses	_	O	O	_	_	_	_	_
17	when	_	O	O	_	_	_	_	_
18	activated	_	O	O	_	_	_	_	_
19	via	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	anti	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	pathway	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	c	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	jun	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	jun	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	mRNA	_	O	O	_	_	_	_	_
34	expression	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	also	_	O	O	_	_	_	_	_
37	studied	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	anti	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	CD	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	activated	_	O	O	_	_	_	_	_
45	purified	_	O	O	_	_	_	_	_
46	T	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	age	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	related	_	O	O	_	_	_	_	_
5	differences	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	either	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	these	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	proto	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	oncogenes	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	anti	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	activated	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	decreased	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	production	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	proliferative	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	displayed	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	PHA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	activated	_	O	O	_	_	_	_	_
19	PBL	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	elderly	_	O	O	_	_	_	_	_
22	adults	_	O	O	_	_	_	_	_
23	may	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	related	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	age	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	related	_	O	O	_	_	_	_	_
30	changes	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	c	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	jun	_	O	O	_	_	_	_	_
35	mRNA	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	ratio	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	c	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	fos	_	O	O	_	_	_	_	_
45	to	_	O	O	_	_	_	_	_
46	c	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	jun	_	O	O	_	_	_	_	_
49	mRNA	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	novel	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	derived	_	O	O	_	_	_	_	_
7	coactivator	_	O	O	_	_	_	_	_
8	potentiates	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	immunoglobulin	_	O	O	_	_	_	_	_
13	promoters	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	octamer	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	factors	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	novel	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	restricted	_	O	O	_	_	_	_	_
7	activity	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	required	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	high	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	octamer	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	Oct	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	dependent	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	immunoglobulin	_	O	O	_	_	_	_	_
23	heavy	_	O	O	_	_	_	_	_
24	chain	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	IgH	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	promoter	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	was	_	O	O	_	_	_	_	_
31	detected	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	an	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	vitro	_	O	O	_	_	_	_	_
36	system	_	O	O	_	_	_	_	_
37	consisting	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	HeLa	_	O	O	_	_	_	_	_
40	cell	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	derived	_	O	O	_	_	_	_	_
43	extracts	_	O	O	_	_	_	_	_
44	complemented	_	O	O	_	_	_	_	_
45	with	_	O	O	_	_	_	_	_
46	fractionated	_	O	O	_	_	_	_	_
47	B	_	O	O	_	_	_	_	_
48	cell	_	O	O	_	_	_	_	_
49	nuclear	_	O	O	_	_	_	_	_
50	proteins	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	factor	_	O	O	_	_	_	_	_
3	responsible	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	designated	_	O	O	_	_	_	_	_
9	Oct	_	O	O	_	_	_	_	_
10	coactivator	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	OCA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	OCA	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	stimulates	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	IgH	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	conjunction	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	either	_	O	O	_	_	_	_	_
15	Oct	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	Oct	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	but	_	O	O	_	_	_	_	_
23	shows	_	O	O	_	_	_	_	_
24	no	_	O	O	_	_	_	_	_
25	significant	_	O	O	_	_	_	_	_
26	effect	_	O	O	_	_	_	_	_
27	on	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	octamer	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	Oct	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	dependent	_	O	O	_	_	_	_	_
34	transcription	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	ubiquitously	_	O	O	_	_	_	_	_
38	expressed	_	O	O	_	_	_	_	_
39	histone	_	O	O	_	_	_	_	_
40	H	_	O	O	_	_	_	_	_
41	2	_	O	O	_	_	_	_	_
42	B	_	O	O	_	_	_	_	_
43	promoter	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	transcription	_	O	O	_	_	_	_	_
47	of	_	O	O	_	_	_	_	_
48	USF	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	Sp	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	regulated	_	O	O	_	_	_	_	_
55	promoters	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	suggest	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	OCA	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	tissue	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	specific	_	O	O	_	_	_	_	_
23	coactivator	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	OCA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	may	_	O	O	_	_	_	_	_
30	be	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	major	_	O	O	_	_	_	_	_
33	determinant	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	B	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	specific	_	O	O	_	_	_	_	_
39	activation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	immunoglobulin	_	O	O	_	_	_	_	_
42	promoters	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	light	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	evidence	_	O	O	_	_	_	_	_
6	showing	_	O	O	_	_	_	_	_
7	physical	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	functional	_	O	O	_	_	_	_	_
10	interactions	_	O	O	_	_	_	_	_
11	between	_	O	O	_	_	_	_	_
12	Oct	_	O	O	_	_	_	_	_
13	factors	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	OCA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	we	_	O	O	_	_	_	_	_
20	propose	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	mechanism	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	action	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	OCA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	discuss	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	implications	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	OCA	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	B	_	O	O	_	_	_	_	_
37	for	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	transcriptional	_	O	O	_	_	_	_	_
40	regulation	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	other	_	O	O	_	_	_	_	_
43	tissue	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	specific	_	O	O	_	_	_	_	_
46	promoters	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_


1	Signal	_	O	O	_	_	_	_	_
2	transduction	_	O	O	_	_	_	_	_
3	through	_	O	O	_	_	_	_	_
4	interferon	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	gamma	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	eosinophils	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_


1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	We	_	O	O	_	_	_	_	_
4	reported	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	constitutive	_	O	O	_	_	_	_	_
8	interferon	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	gamma	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	IFN	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	gammaR	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	expression	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	eosinophils	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	But	_	O	O	_	_	_	_	_
2	signal	_	O	O	_	_	_	_	_
3	transduction	_	O	O	_	_	_	_	_
4	through	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	gammaR	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	eosinophils	_	O	O	_	_	_	_	_
10	remains	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	elucidated	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	examined	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	involvement	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	Jak	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	pathway	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	signaling	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	eosinophils	_	O	O	_	_	_	_	_
20	after	_	O	O	_	_	_	_	_
21	IFN	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	gammaR	_	O	O	_	_	_	_	_
24	conjugation	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	ligand	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Purified	_	O	O	_	_	_	_	_
4	peripheral	_	O	O	_	_	_	_	_
5	eosinophils	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	stimulated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	IFN	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	37	_	O	O	_	_	_	_	_
14	degrees	_	O	O	_	_	_	_	_
15	C	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	60	_	O	O	_	_	_	_	_
20	min	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Tyrosine	_	O	O	_	_	_	_	_
2	phosphorylation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IFN	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	gammaR	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	Jak	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	Jak	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	Stat	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	examined	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	immunoblotting	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Gel	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	shift	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	examined	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	show	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	formation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	alpha	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	DNA	_	O	O	_	_	_	_	_
18	complexes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	We	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IFN	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	gamma	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	eosinophils	_	O	O	_	_	_	_	_
14	initiated	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	series	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	events	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	resulted	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	rapid	_	O	O	_	_	_	_	_
24	tyrosine	_	O	O	_	_	_	_	_
25	phosphorylation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	not	_	O	O	_	_	_	_	_
28	only	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	IFN	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	gammaRalpha	_	O	O	_	_	_	_	_
33	chain	_	O	O	_	_	_	_	_
34	but	_	O	O	_	_	_	_	_
35	also	_	O	O	_	_	_	_	_
36	Jak	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	Jak	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	Stat	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	alpha	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IFN	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	gamma	_	O	O	_	_	_	_	_
7	enhanced	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	DNA	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	activity	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	Stat	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	CONCLUSION	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	These	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	indicate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	affects	_	O	O	_	_	_	_	_
11	eosinophils	_	O	O	_	_	_	_	_
12	through	_	O	O	_	_	_	_	_
13	its	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	utilizes	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	Jak	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	Stat	_	O	O	_	_	_	_	_
22	pathway	_	O	O	_	_	_	_	_
23	as	_	O	O	_	_	_	_	_
24	its	_	O	O	_	_	_	_	_
25	mode	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	signaling	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	production	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	hemorrhagic	_	O	O	_	_	_	_	_
7	shock	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	accompanied	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	neutrophil	_	O	O	_	_	_	_	_
12	recruitment	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	lung	_	O	O	_	_	_	_	_
15	injury	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	Hemorrhagic	_	O	O	_	_	_	_	_
2	shock	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	HS	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	initiates	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	inflammatory	_	O	O	_	_	_	_	_
9	cascade	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	includes	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	production	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	cytokines	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	recruitment	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	neutrophils	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	PMN	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	may	_	O	O	_	_	_	_	_
25	progress	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	organ	_	O	O	_	_	_	_	_
28	failure	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	inducing	_	O	O	_	_	_	_	_
31	acute	_	O	O	_	_	_	_	_
32	respiratory	_	O	O	_	_	_	_	_
33	distress	_	O	O	_	_	_	_	_
34	syndrome	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	ARDS	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	hypothesis	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	interleukin	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	contributes	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	PMN	_	O	O	_	_	_	_	_
17	infiltration	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	lung	_	O	O	_	_	_	_	_
20	damage	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	HS	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	we	_	O	O	_	_	_	_	_
25	examined	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	lungs	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	rats	_	O	O	_	_	_	_	_
30	subjected	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	unresuscitated	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	resuscitated	_	O	O	_	_	_	_	_
35	HS	_	O	O	_	_	_	_	_
36	for	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	production	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	activation	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	Stat	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	semiquantitative	_	O	O	_	_	_	_	_
3	RT	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	PCR	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	striking	_	O	O	_	_	_	_	_
11	increase	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	mRNA	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	only	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	resuscitated	_	O	O	_	_	_	_	_
21	HS	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	peak	_	O	O	_	_	_	_	_
25	levels	_	O	O	_	_	_	_	_
26	observed	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	h	_	O	O	_	_	_	_	_
29	after	_	O	O	_	_	_	_	_
30	initiation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	resuscitation	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Increased	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	localized	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	bronchial	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	alveolar	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Electrophoretic	_	O	O	_	_	_	_	_
2	mobility	_	O	O	_	_	_	_	_
3	shift	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	extracts	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	shock	_	O	O	_	_	_	_	_
10	lungs	_	O	O	_	_	_	_	_
11	exhibited	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	increase	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	Stat	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	kinetics	_	O	O	_	_	_	_	_
20	similar	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	mRNA	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	situ	_	O	O	_	_	_	_	_
3	DNA	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	assay	_	O	O	_	_	_	_	_
6	determined	_	O	O	_	_	_	_	_
7	Stat	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	predominantly	_	O	O	_	_	_	_	_
11	within	_	O	O	_	_	_	_	_
12	alveoli	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Intratracheal	_	O	O	_	_	_	_	_
2	instillation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	alone	_	O	O	_	_	_	_	_
8	into	_	O	O	_	_	_	_	_
9	normal	_	O	O	_	_	_	_	_
10	rats	_	O	O	_	_	_	_	_
11	resulted	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	PMN	_	O	O	_	_	_	_	_
14	infiltration	_	O	O	_	_	_	_	_
15	into	_	O	O	_	_	_	_	_
16	lung	_	O	O	_	_	_	_	_
17	interstitium	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	alveoli	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	marked	_	O	O	_	_	_	_	_
22	elevation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	bronchoalveolar	_	O	O	_	_	_	_	_
25	lavage	_	O	O	_	_	_	_	_
26	cellularity	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	increased	_	O	O	_	_	_	_	_
30	wet	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	dry	_	O	O	_	_	_	_	_
35	ratio	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	Stat	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	occur	_	O	O	_	_	_	_	_
14	early	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	HS	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	may	_	O	O	_	_	_	_	_
19	contribute	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	PMN	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	lung	_	O	O	_	_	_	_	_
25	injury	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	including	_	O	O	_	_	_	_	_
28	ARDS	_	O	O	_	_	_	_	_
29	after	_	O	O	_	_	_	_	_
30	HS	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Cell	_	O	O	_	_	_	_	_
2	culture	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	transfection	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	GM	_	O	O	_	_	_	_	_
2	979	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	Coriell	_	O	O	_	_	_	_	_
6	Cell	_	O	O	_	_	_	_	_
7	Repositories	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	Camden	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	New	_	O	O	_	_	_	_	_
12	Jersey	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	United	_	O	O	_	_	_	_	_
15	States	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	cultured	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	Ham	_	O	O	_	_	_	_	_
21	'	_	O	O	_	_	_	_	_
22	s	_	O	O	_	_	_	_	_
23	F	_	O	O	_	_	_	_	_
24	12	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	mM	_	O	O	_	_	_	_	_
28	L	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	glutamine	_	O	O	_	_	_	_	_
31	supplemented	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	heat	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	inactivated	_	O	O	_	_	_	_	_
36	10	_	O	O	_	_	_	_	_
37	%	_	O	O	_	_	_	_	_
38	fetal	_	O	O	_	_	_	_	_
39	calf	_	O	O	_	_	_	_	_
40	serum	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	Ivitrogen	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	Carlsbad	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	California	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	United	_	O	O	_	_	_	_	_
49	States	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	penicillin	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	100	_	O	O	_	_	_	_	_
55	units	_	O	O	_	_	_	_	_
56	/	_	O	O	_	_	_	_	_
57	ml	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	streptomycin	_	O	O	_	_	_	_	_
61	100	_	O	O	_	_	_	_	_
62	mug	_	O	O	_	_	_	_	_
63	/	_	O	O	_	_	_	_	_
64	ml	_	O	O	_	_	_	_	_
65	)	_	O	O	_	_	_	_	_
66	,	_	O	O	_	_	_	_	_
67	and	_	O	O	_	_	_	_	_
68	L	_	O	O	_	_	_	_	_
69	-	_	O	O	_	_	_	_	_
70	glutamine	_	O	O	_	_	_	_	_
71	(	_	O	O	_	_	_	_	_
72	2	_	O	O	_	_	_	_	_
73	mM	_	O	O	_	_	_	_	_
74	)	_	O	O	_	_	_	_	_
75	.	_	O	O	_	_	_	_	_

1	MEL	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	cultured	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	DMEM	_	O	O	_	_	_	_	_
7	supplemented	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	above	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	without	_	O	O	_	_	_	_	_
12	heat	_	O	O	_	_	_	_	_
13	inactivating	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	serum	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	GM	_	O	O	_	_	_	_	_
2	979	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	x	_	O	O	_	_	_	_	_
7	105	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	log	_	O	O	_	_	_	_	_
11	phase	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	growth	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	transfected	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	plasmids	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	FuGENE	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	Roche	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	Indianapolis	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	Indiana	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	United	_	O	O	_	_	_	_	_
29	States	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	transfected	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	epsilony	_	O	O	_	_	_	_	_
6	promoter	_	O	O	_	_	_	_	_
7	reporter	_	O	O	_	_	_	_	_
8	constructs	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	500	_	O	O	_	_	_	_	_
11	ng	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	along	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	either	_	O	O	_	_	_	_	_
16	empty	_	O	O	_	_	_	_	_
17	vector	_	O	O	_	_	_	_	_
18	or	_	O	O	_	_	_	_	_
19	Sox	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	overexpression	_	O	O	_	_	_	_	_
22	vector	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	1000	_	O	O	_	_	_	_	_
25	ng	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	assays	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	dosage	_	O	O	_	_	_	_	_
5	effect	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	used	_	O	O	_	_	_	_	_
9	200	_	O	O	_	_	_	_	_
10	ng	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	500	_	O	O	_	_	_	_	_
13	ng	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	1000	_	O	O	_	_	_	_	_
17	ng	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	pRL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	CMV	_	O	O	_	_	_	_	_
4	15	_	O	O	_	_	_	_	_
5	ng	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	Promega	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	used	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	control	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	transfection	_	O	O	_	_	_	_	_
16	efficiency	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_



1	A	_	O	O	_	_	_	_	_
2	mutation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	glucocorticoid	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	primary	_	O	O	_	_	_	_	_
9	cortisol	_	O	O	_	_	_	_	_
10	resistance	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	precise	_	O	O	_	_	_	_	_
3	molecular	_	O	O	_	_	_	_	_
4	abnormalities	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	cause	_	O	O	_	_	_	_	_
7	primary	_	O	O	_	_	_	_	_
8	cortisol	_	O	O	_	_	_	_	_
9	resistance	_	O	O	_	_	_	_	_
10	have	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	been	_	O	O	_	_	_	_	_
13	completely	_	O	O	_	_	_	_	_
14	described	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	subject	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	primary	_	O	O	_	_	_	_	_
6	cortisol	_	O	O	_	_	_	_	_
7	resistance	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	have	_	O	O	_	_	_	_	_
10	observed	_	O	O	_	_	_	_	_
11	glucocorticoid	_	O	O	_	_	_	_	_
12	receptors	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	hGR	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	decreased	_	O	O	_	_	_	_	_
19	affinity	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	dexamethasone	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	hypothesize	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	mutation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	hGR	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	domain	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	cause	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	cortisol	_	O	O	_	_	_	_	_
18	resistance	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Total	_	O	O	_	_	_	_	_
2	RNA	_	O	O	_	_	_	_	_
3	isolated	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	index	_	O	O	_	_	_	_	_
7	subject	_	O	O	_	_	_	_	_
8	'	_	O	O	_	_	_	_	_
9	s	_	O	O	_	_	_	_	_
10	mononuclear	_	O	O	_	_	_	_	_
11	leukocytes	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	used	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	produce	_	O	O	_	_	_	_	_
16	first	_	O	O	_	_	_	_	_
17	strand	_	O	O	_	_	_	_	_
18	hGR	_	O	O	_	_	_	_	_
19	cDNAs	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	entire	_	O	O	_	_	_	_	_
24	hGR	_	O	O	_	_	_	_	_
25	cDNA	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	amplified	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	segments	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	sequenced	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	nucleotide	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	317	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	identified	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	homozygous	_	O	O	_	_	_	_	_
10	A	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	G	_	O	O	_	_	_	_	_
13	point	_	O	O	_	_	_	_	_
14	mutation	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	predicts	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	isoleucine	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	ATT	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	valine	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	GTT	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	substitution	_	O	O	_	_	_	_	_
28	at	_	O	O	_	_	_	_	_
29	amino	_	O	O	_	_	_	_	_
30	acid	_	O	O	_	_	_	_	_
31	729	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	wild	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	hGR	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	hGR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	Ile	_	O	O	_	_	_	_	_
11	729	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	expressed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	COS	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	assayed	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	H	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	Dexamethasone	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	dissociation	_	O	O	_	_	_	_	_
32	constants	_	O	O	_	_	_	_	_
33	were	_	O	O	_	_	_	_	_
34	0	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_
36	799	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	/	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	0	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	068	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_
46	54	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	0	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_
52	06	_	O	O	_	_	_	_	_
53	nM	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	mean	_	O	O	_	_	_	_	_
56	+	_	O	O	_	_	_	_	_
57	/	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	SEM	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	(	_	O	O	_	_	_	_	_
62	P	_	O	O	_	_	_	_	_
63	<	_	O	O	_	_	_	_	_
64	0	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_
66	01	_	O	O	_	_	_	_	_
67	)	_	O	O	_	_	_	_	_
68	,	_	O	O	_	_	_	_	_
69	respectively	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	wild	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	hGR	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	hGR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	Ile	_	O	O	_	_	_	_	_
11	729	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	expressed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	CV	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	cotransfected	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	mouse	_	O	O	_	_	_	_	_
25	mammary	_	O	O	_	_	_	_	_
26	tumor	_	O	O	_	_	_	_	_
27	virus	_	O	O	_	_	_	_	_
28	long	_	O	O	_	_	_	_	_
29	terminal	_	O	O	_	_	_	_	_
30	repeat	_	O	O	_	_	_	_	_
31	fused	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	chloramphenicol	_	O	O	_	_	_	_	_
35	acetyl	_	O	O	_	_	_	_	_
36	transferase	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	CAT	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	gene	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	hGR	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	Ile	_	O	O	_	_	_	_	_
46	729	_	O	O	_	_	_	_	_
47	conferred	_	O	O	_	_	_	_	_
48	a	_	O	O	_	_	_	_	_
49	fourfold	_	O	O	_	_	_	_	_
50	decrease	_	O	O	_	_	_	_	_
51	in	_	O	O	_	_	_	_	_
52	apparent	_	O	O	_	_	_	_	_
53	potency	_	O	O	_	_	_	_	_
54	on	_	O	O	_	_	_	_	_
55	dexamethasone	_	O	O	_	_	_	_	_
56	stimulation	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	CAT	_	O	O	_	_	_	_	_
59	activity	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	isoleucine	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	valine	_	O	O	_	_	_	_	_
5	substitution	_	O	O	_	_	_	_	_
6	at	_	O	O	_	_	_	_	_
7	amino	_	O	O	_	_	_	_	_
8	acid	_	O	O	_	_	_	_	_
9	729	_	O	O	_	_	_	_	_
10	impairs	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	function	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	hGR	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	likely	_	O	O	_	_	_	_	_
20	cause	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	primary	_	O	O	_	_	_	_	_
23	cortisol	_	O	O	_	_	_	_	_
24	resistance	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	this	_	O	O	_	_	_	_	_
27	subject	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	USF	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	c	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Myc	_	O	O	_	_	_	_	_
6	enhances	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	while	_	O	O	_	_	_	_	_
9	Yin	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Yang	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	suppresses	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	CXCR	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	coreceptor	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	HIV	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	entry	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Transcription	_	O	O	_	_	_	_	_
2	factors	_	O	O	_	_	_	_	_
3	USF	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	USF	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	up	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	regulate	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	i	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	e	_	O	O	_	_	_	_	_
17	.,	_	O	O	_	_	_	_	_
18	HIV	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	long	_	O	O	_	_	_	_	_
22	terminal	_	O	O	_	_	_	_	_
23	repeats	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	via	_	O	O	_	_	_	_	_
26	interaction	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	an	_	O	O	_	_	_	_	_
29	E	_	O	O	_	_	_	_	_
30	box	_	O	O	_	_	_	_	_
31	on	_	O	O	_	_	_	_	_
32	their	_	O	O	_	_	_	_	_
33	target	_	O	O	_	_	_	_	_
34	promoters	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	which	_	O	O	_	_	_	_	_
37	is	_	O	O	_	_	_	_	_
38	also	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	binding	_	O	O	_	_	_	_	_
41	site	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	c	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	Myc	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	c	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Myc	_	O	O	_	_	_	_	_
5	oncoprotein	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	important	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	control	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cellular	_	O	O	_	_	_	_	_
12	proliferation	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	while	_	O	O	_	_	_	_	_
17	Yin	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	Yang	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	YY	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	has	_	O	O	_	_	_	_	_
26	been	_	O	O	_	_	_	_	_
27	shown	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	control	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	expression	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	number	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	cellular	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	viral	_	O	O	_	_	_	_	_
39	genes	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	two	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	physically	_	O	O	_	_	_	_	_
5	interact	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	each	_	O	O	_	_	_	_	_
8	other	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	mutually	_	O	O	_	_	_	_	_
11	inhibit	_	O	O	_	_	_	_	_
12	their	_	O	O	_	_	_	_	_
13	respective	_	O	O	_	_	_	_	_
14	biological	_	O	O	_	_	_	_	_
15	functions	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	show	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	USF	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Myc	_	O	O	_	_	_	_	_
13	up	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	regulates	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	while	_	O	O	_	_	_	_	_
18	YY	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	down	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	regulates	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	promoter	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	CXCR	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	coreceptor	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	tropic	_	O	O	_	_	_	_	_
37	HIV	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	entry	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	identified	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	E	_	O	O	_	_	_	_	_
6	box	_	O	O	_	_	_	_	_
7	around	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	260	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	YY	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	site	_	O	O	_	_	_	_	_
16	around	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	300	_	O	O	_	_	_	_	_
19	relative	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	transcription	_	O	O	_	_	_	_	_
23	start	_	O	O	_	_	_	_	_
24	site	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Mutation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	box	_	O	O	_	_	_	_	_
6	abolished	_	O	O	_	_	_	_	_
7	USF	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Myc	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	mediated	_	O	O	_	_	_	_	_
14	up	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	regulation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	CXCR	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	mutation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	YY	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	site	_	O	O	_	_	_	_	_
31	was	_	O	O	_	_	_	_	_
32	associated	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	unresponsiveness	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	YY	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	mediated	_	O	O	_	_	_	_	_
40	inhibition	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	USF	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	c	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	Myc	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	YY	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	may	_	O	O	_	_	_	_	_
14	play	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	important	_	O	O	_	_	_	_	_
17	role	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	HIV	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	replicative	_	O	O	_	_	_	_	_
25	cycle	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	modulating	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	viral	_	O	O	_	_	_	_	_
32	fusion	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	entry	_	O	O	_	_	_	_	_
35	process	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	viral	_	O	O	_	_	_	_	_
38	expression	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Age	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	related	_	O	O	_	_	_	_	_
4	decreases	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	human	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	associated	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	impaired	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	nuclear	_	O	O	_	_	_	_	_
21	transcriptional	_	O	O	_	_	_	_	_
22	factors	_	O	O	_	_	_	_	_
23	AP	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	AT	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Although	_	O	O	_	_	_	_	_
2	transcriptional	_	O	O	_	_	_	_	_
3	factors	_	O	O	_	_	_	_	_
4	AP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	activated	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	AT	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	important	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	normal	_	O	O	_	_	_	_	_
24	induction	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	it	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	unknown	_	O	O	_	_	_	_	_
33	if	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	age	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	related	_	O	O	_	_	_	_	_
38	decline	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	production	_	O	O	_	_	_	_	_
44	by	_	O	O	_	_	_	_	_
45	activated	_	O	O	_	_	_	_	_
46	human	_	O	O	_	_	_	_	_
47	T	_	O	O	_	_	_	_	_
48	cells	_	O	O	_	_	_	_	_
49	may	_	O	O	_	_	_	_	_
50	be	_	O	O	_	_	_	_	_
51	associated	_	O	O	_	_	_	_	_
52	with	_	O	O	_	_	_	_	_
53	aberrancies	_	O	O	_	_	_	_	_
54	in	_	O	O	_	_	_	_	_
55	transcriptional	_	O	O	_	_	_	_	_
56	regulatory	_	O	O	_	_	_	_	_
57	proteins	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	current	_	O	O	_	_	_	_	_
4	studies	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	elderly	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	mean	_	O	O	_	_	_	_	_
17	78	_	O	O	_	_	_	_	_
18	years	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	young	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	mean	_	O	O	_	_	_	_	_
24	37	_	O	O	_	_	_	_	_
25	years	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	humans	_	O	O	_	_	_	_	_
28	was	_	O	O	_	_	_	_	_
29	measured	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	cultures	_	O	O	_	_	_	_	_
32	stimulated	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	PHA	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	PHA	_	O	O	_	_	_	_	_
37	plus	_	O	O	_	_	_	_	_
38	PMA	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	crosslinked	_	O	O	_	_	_	_	_
41	anti	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	mAB	_	O	O	_	_	_	_	_
46	OKT	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	plus	_	O	O	_	_	_	_	_
49	PMA	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	or	_	O	O	_	_	_	_	_
52	PMA	_	O	O	_	_	_	_	_
53	plus	_	O	O	_	_	_	_	_
54	ionomycin	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Substantial	_	O	O	_	_	_	_	_
2	decreases	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	observed	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	cultures	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	7	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	12	_	O	O	_	_	_	_	_
17	elderly	_	O	O	_	_	_	_	_
18	individuals	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	response	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	different	_	O	O	_	_	_	_	_
24	stimuli	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	whereas	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	levels	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	produced	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	stimulated	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	from	_	O	O	_	_	_	_	_
39	other	_	O	O	_	_	_	_	_
40	elderly	_	O	O	_	_	_	_	_
41	individuals	_	O	O	_	_	_	_	_
42	were	_	O	O	_	_	_	_	_
43	equivalent	_	O	O	_	_	_	_	_
44	to	_	O	O	_	_	_	_	_
45	those	_	O	O	_	_	_	_	_
46	observed	_	O	O	_	_	_	_	_
47	for	_	O	O	_	_	_	_	_
48	stimulated	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	cells	_	O	O	_	_	_	_	_
51	of	_	O	O	_	_	_	_	_
52	young	_	O	O	_	_	_	_	_
53	subjects	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	Analyses	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	extracts	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	electrophoretic	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	mobility	_	O	O	_	_	_	_	_
9	shift	_	O	O	_	_	_	_	_
10	assays	_	O	O	_	_	_	_	_
11	showed	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	decreased	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	stimulated	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	elderly	_	O	O	_	_	_	_	_
24	individuals	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	closely	_	O	O	_	_	_	_	_
27	associated	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	impairments	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	activation	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	both	_	O	O	_	_	_	_	_
35	AP	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	NF	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	AT	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	elderly	_	O	O	_	_	_	_	_
8	subjects	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	normal	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	exhibited	_	O	O	_	_	_	_	_
18	normal	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	AP	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	AT	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	competition	_	O	O	_	_	_	_	_
8	experiments	_	O	O	_	_	_	_	_
9	analyzing	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	normal	_	O	O	_	_	_	_	_
12	components	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	AT	_	O	O	_	_	_	_	_
17	showed	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	age	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	related	_	O	O	_	_	_	_	_
23	reductions	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	stimulus	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	dependent	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	AT	_	O	O	_	_	_	_	_
31	complexes	_	O	O	_	_	_	_	_
32	corresponded	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	slow	_	O	O	_	_	_	_	_
36	migrating	_	O	O	_	_	_	_	_
37	complexes	_	O	O	_	_	_	_	_
38	that	_	O	O	_	_	_	_	_
39	were	_	O	O	_	_	_	_	_
40	composed	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	c	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	Fos	_	O	O	_	_	_	_	_
45	/	_	O	O	_	_	_	_	_
46	c	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	Jun	_	O	O	_	_	_	_	_
49	AP	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	resting	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	stimulated	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	kappa	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	reduced	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	certain	_	O	O	_	_	_	_	_
17	elderly	_	O	O	_	_	_	_	_
18	individuals	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	however	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	alterations	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	did	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	correlate	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	changes	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	age	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	related	_	O	O	_	_	_	_	_
10	impairments	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	activation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	AP	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	NF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	AT	_	O	O	_	_	_	_	_
22	are	_	O	O	_	_	_	_	_
23	closely	_	O	O	_	_	_	_	_
24	associated	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	decreased	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	further	_	O	O	_	_	_	_	_
34	suggest	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	aberrancies	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	signaling	_	O	O	_	_	_	_	_
40	pathways	_	O	O	_	_	_	_	_
41	important	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	induction	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	transcriptionally	_	O	O	_	_	_	_	_
47	active	_	O	O	_	_	_	_	_
48	c	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	Fos	_	O	O	_	_	_	_	_
51	/	_	O	O	_	_	_	_	_
52	c	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	Jun	_	O	O	_	_	_	_	_
55	AP	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	1	_	O	O	_	_	_	_	_
58	may	_	O	O	_	_	_	_	_
59	contribute	_	O	O	_	_	_	_	_
60	to	_	O	O	_	_	_	_	_
61	the	_	O	O	_	_	_	_	_
62	impaired	_	O	O	_	_	_	_	_
63	activation	_	O	O	_	_	_	_	_
64	of	_	O	O	_	_	_	_	_
65	NF	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	AT	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_


1	Glucocorticoid	_	O	O	_	_	_	_	_
2	hormone	_	O	O	_	_	_	_	_
3	suppression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	neutrophil	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	tumor	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	cytostasis	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	have	_	O	O	_	_	_	_	_
8	investigated	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	effect	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	glucocorticoid	_	O	O	_	_	_	_	_
13	hormones	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	neutrophil	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	tumor	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	cytostasis	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	found	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	hydrocortisone	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	synthetic	_	O	O	_	_	_	_	_
28	hormone	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	dexamethasone	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	Dex	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	inhibited	_	O	O	_	_	_	_	_
36	cytostasis	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	presence	_	O	O	_	_	_	_	_
40	or	_	O	O	_	_	_	_	_
41	absence	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	tumor	_	O	O	_	_	_	_	_
44	necrosis	_	O	O	_	_	_	_	_
45	factor	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	alpha	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Dex	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	completely	_	O	O	_	_	_	_	_
7	reversed	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	glucocorticoid	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	antagonist	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	RU	_	O	O	_	_	_	_	_
15	38486	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	clarify	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	underlying	_	O	O	_	_	_	_	_
5	mechanisms	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	examined	_	O	O	_	_	_	_	_
9	effects	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	Dex	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	avidity	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	beta	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	integrin	_	O	O	_	_	_	_	_
20	on	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	neutrophil	_	O	O	_	_	_	_	_
23	surface	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	how	_	O	O	_	_	_	_	_
26	these	_	O	O	_	_	_	_	_
27	might	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	turn	_	O	O	_	_	_	_	_
30	affect	_	O	O	_	_	_	_	_
31	neutrophil	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	tumor	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Dex	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	found	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	inhibit	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	neutrophil	_	O	O	_	_	_	_	_
8	properties	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	RU	_	O	O	_	_	_	_	_
12	38486	_	O	O	_	_	_	_	_
13	completely	_	O	O	_	_	_	_	_
14	suppressed	_	O	O	_	_	_	_	_
15	both	_	O	O	_	_	_	_	_
16	forms	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	Dex	_	O	O	_	_	_	_	_
19	inhibition	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	findings	_	O	O	_	_	_	_	_
6	suggest	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	hormone	_	O	O	_	_	_	_	_
10	inhibition	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	neutrophil	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	tumor	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	cytostasis	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	at	_	O	O	_	_	_	_	_
20	least	_	O	O	_	_	_	_	_
21	partially	_	O	O	_	_	_	_	_
22	due	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	lowering	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	ligand	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	avidity	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	integrin	_	O	O	_	_	_	_	_
35	on	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	neutrophil	_	O	O	_	_	_	_	_
38	surface	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Patients	_	O	O	_	_	_	_	_

1	Informed	_	O	O	_	_	_	_	_
2	consent	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	obtained	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	24	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	men	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	19	_	O	O	_	_	_	_	_
13	women	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	who	_	O	O	_	_	_	_	_
18	fulfilled	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	1987	_	O	O	_	_	_	_	_
21	revised	_	O	O	_	_	_	_	_
22	criteria	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	American	_	O	O	_	_	_	_	_
26	College	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	Rheumatology	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	formerly	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	American	_	O	O	_	_	_	_	_
33	Rheumatism	_	O	O	_	_	_	_	_
34	Association	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	[	_	O	O	_	_	_	_	_
37	17	_	O	O	_	_	_	_	_
38	]	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	age	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	patients	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	50	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	8	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	mean	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	SEM	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	years	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	range	_	O	O	_	_	_	_	_
24	23	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	71	_	O	O	_	_	_	_	_
27	years	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	medications	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	stopped	_	O	O	_	_	_	_	_
5	48	_	O	O	_	_	_	_	_
6	hours	_	O	O	_	_	_	_	_
7	before	_	O	O	_	_	_	_	_
8	entry	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	study	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Comparisons	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	made	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	14	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	OA	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	men	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	11	_	O	O	_	_	_	_	_
14	women	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	14	_	O	O	_	_	_	_	_
19	healthy	_	O	O	_	_	_	_	_
20	controls	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	men	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	11	_	O	O	_	_	_	_	_
26	women	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	who	_	O	O	_	_	_	_	_
29	had	_	O	O	_	_	_	_	_
30	no	_	O	O	_	_	_	_	_
31	rheumatic	_	O	O	_	_	_	_	_
32	diseases	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mean	_	O	O	_	_	_	_	_
3	ages	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	OA	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	healthy	_	O	O	_	_	_	_	_
12	controls	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	50	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	years	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	range	_	O	O	_	_	_	_	_
22	34	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	68	_	O	O	_	_	_	_	_
25	years	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	30	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	years	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	range	_	O	O	_	_	_	_	_
36	24	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	57	_	O	O	_	_	_	_	_
39	years	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Informed	_	O	O	_	_	_	_	_
2	consent	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	obtained	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	protocol	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	approved	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Catholic	_	O	O	_	_	_	_	_
14	University	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	Korea	_	O	O	_	_	_	_	_
17	Human	_	O	O	_	_	_	_	_
18	Research	_	O	O	_	_	_	_	_
19	Ethics	_	O	O	_	_	_	_	_
20	Committee	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_



1	Effects	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	intranasal	_	O	O	_	_	_	_	_
4	glucocorticoids	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	endogenous	_	O	O	_	_	_	_	_
7	glucocorticoid	_	O	O	_	_	_	_	_
8	peripheral	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	central	_	O	O	_	_	_	_	_
11	function	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	Glucocorticoids	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	among	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	most	_	O	O	_	_	_	_	_
6	potent	_	O	O	_	_	_	_	_
7	antiinflammatory	_	O	O	_	_	_	_	_
8	agents	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	can	_	O	O	_	_	_	_	_
11	be	_	O	O	_	_	_	_	_
12	used	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	treatment	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	rhinitis	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Their	_	O	O	_	_	_	_	_
2	mechanisms	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	action	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	multiple	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	complex	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	number	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	reports	_	O	O	_	_	_	_	_
14	describe	_	O	O	_	_	_	_	_
15	significant	_	O	O	_	_	_	_	_
16	systemic	_	O	O	_	_	_	_	_
17	effects	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	locally	_	O	O	_	_	_	_	_
20	administered	_	O	O	_	_	_	_	_
21	glucocorticoids	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	order	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	evaluate	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	short	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	term	_	O	O	_	_	_	_	_
9	systemic	_	O	O	_	_	_	_	_
10	effects	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	intranasally	_	O	O	_	_	_	_	_
13	administered	_	O	O	_	_	_	_	_
14	glucocorticoids	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	14	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	healthy	_	O	O	_	_	_	_	_
19	subjects	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	treated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	two	_	O	O	_	_	_	_	_
24	doses	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	either	_	O	O	_	_	_	_	_
27	budesonide	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	BUD	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	or	_	O	O	_	_	_	_	_
32	fluticasone	_	O	O	_	_	_	_	_
33	propionate	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	FP	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	for	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	weeks	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Before	_	O	O	_	_	_	_	_
2	treatment	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	at	_	O	O	_	_	_	_	_
5	regular	_	O	O	_	_	_	_	_
6	intervals	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	treatment	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	week	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	finally	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	weeks	_	O	O	_	_	_	_	_
17	after	_	O	O	_	_	_	_	_
18	termination	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	treatment	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	effects	_	O	O	_	_	_	_	_
24	on	_	O	O	_	_	_	_	_
25	glucocorticoid	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	GR	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	methallothionein	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	MTIIa	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	mRNA	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	levels	_	O	O	_	_	_	_	_
38	were	_	O	O	_	_	_	_	_
39	examined	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	peripheral	_	O	O	_	_	_	_	_
42	lymphocytes	_	O	O	_	_	_	_	_
43	using	_	O	O	_	_	_	_	_
44	a	_	O	O	_	_	_	_	_
45	solution	_	O	O	_	_	_	_	_
46	hybridization	_	O	O	_	_	_	_	_
47	assay	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Serum	_	O	O	_	_	_	_	_
2	cortisol	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	osteocalcin	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	urinary	_	O	O	_	_	_	_	_
7	cortisol	_	O	O	_	_	_	_	_
8	levels	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	also	_	O	O	_	_	_	_	_
11	determined	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	insulin	_	O	O	_	_	_	_	_
3	tolerance	_	O	O	_	_	_	_	_
4	test	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	ITT	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	performed	_	O	O	_	_	_	_	_
10	at	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	end	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	second	_	O	O	_	_	_	_	_
16	week	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	treatment	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	end	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	week	_	O	O	_	_	_	_	_
28	washout	_	O	O	_	_	_	_	_
29	period	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	no	_	O	O	_	_	_	_	_
32	statistically	_	O	O	_	_	_	_	_
33	significant	_	O	O	_	_	_	_	_
34	change	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	cortisol	_	O	O	_	_	_	_	_
37	response	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	peripheral	_	O	O	_	_	_	_	_
3	lymphocytes	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	GR	_	O	O	_	_	_	_	_
6	mRNA	_	O	O	_	_	_	_	_
7	levels	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	significantly	_	O	O	_	_	_	_	_
10	down	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	regulated	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	MTIIa	_	O	O	_	_	_	_	_
2	mRNA	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	increased	_	O	O	_	_	_	_	_
5	significantly	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_

1	Serum	_	O	O	_	_	_	_	_
2	osteocalcin	_	O	O	_	_	_	_	_
3	decreased	_	O	O	_	_	_	_	_
4	significantly	_	O	O	_	_	_	_	_
5	during	_	O	O	_	_	_	_	_
6	treatment	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	both	_	O	O	_	_	_	_	_
9	BUD	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	FP	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Serum	_	O	O	_	_	_	_	_
2	cortisol	_	O	O	_	_	_	_	_
3	decreased	_	O	O	_	_	_	_	_
4	after	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	week	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	treatment	_	O	O	_	_	_	_	_
9	whereas	_	O	O	_	_	_	_	_
10	urinary	_	O	O	_	_	_	_	_
11	cortisol	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	affected	_	O	O	_	_	_	_	_
15	until	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	second	_	O	O	_	_	_	_	_
18	week	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	treatment	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	intranasal	_	O	O	_	_	_	_	_
5	glucocorticoids	_	O	O	_	_	_	_	_
6	at	_	O	O	_	_	_	_	_
7	clinically	_	O	O	_	_	_	_	_
8	recommended	_	O	O	_	_	_	_	_
9	doses	_	O	O	_	_	_	_	_
10	have	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	only	_	O	O	_	_	_	_	_
13	significant	_	O	O	_	_	_	_	_
14	systemic	_	O	O	_	_	_	_	_
15	effects	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	adrenal	_	O	O	_	_	_	_	_
18	function	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	also	_	O	O	_	_	_	_	_
22	have	_	O	O	_	_	_	_	_
23	an	_	O	O	_	_	_	_	_
24	effect	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	specific	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	peripheral	_	O	O	_	_	_	_	_
31	lymphocytes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	dependent	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	reversible	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	according	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	serum	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	urinary	_	O	O	_	_	_	_	_
16	cortisol	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	ITT	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	leave	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	hypothalamic	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	pituitary	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	adrenal	_	O	O	_	_	_	_	_
28	function	_	O	O	_	_	_	_	_
29	intact	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	short	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	term	_	O	O	_	_	_	_	_
7	systemic	_	O	O	_	_	_	_	_
8	effects	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	associated	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	any	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	noticeable	_	O	O	_	_	_	_	_
17	side	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	effects	_	O	O	_	_	_	_	_
20	usually	_	O	O	_	_	_	_	_
21	observed	_	O	O	_	_	_	_	_
22	during	_	O	O	_	_	_	_	_
23	long	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	term	_	O	O	_	_	_	_	_
26	treatment	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	glucocorticoids	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	PBMC	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	see	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	enhanced	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	17	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	could	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	regulated	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	transcriptional	_	O	O	_	_	_	_	_
15	level	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	semi	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	quantatitive	_	O	O	_	_	_	_	_
20	reverse	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	polymerase	_	O	O	_	_	_	_	_
24	chain	_	O	O	_	_	_	_	_
25	reaction	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	performed	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	observed	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	dose	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	dependent	_	O	O	_	_	_	_	_
7	increase	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	17	_	O	O	_	_	_	_	_
12	mRNA	_	O	O	_	_	_	_	_
13	transcripts	_	O	O	_	_	_	_	_
14	after	_	O	O	_	_	_	_	_
15	stimulation	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	anti	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	;	_	O	O	_	_	_	_	_
22	this	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	inhibited	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	PI	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	K	_	O	O	_	_	_	_	_
30	inhibitor	_	O	O	_	_	_	_	_
31	LY	_	O	O	_	_	_	_	_
32	294002	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	NF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	kappaB	_	O	O	_	_	_	_	_
39	inhibitor	_	O	O	_	_	_	_	_
40	PDTC	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	Fig	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	5	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_



1	Chronic	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	immunodeficiency	_	O	O	_	_	_	_	_
4	virus	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	infection	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	myeloid	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	disrupts	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	autoregulatory	_	O	O	_	_	_	_	_
14	control	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	Rel	_	O	O	_	_	_	_	_
22	pathway	_	O	O	_	_	_	_	_
23	via	_	O	O	_	_	_	_	_
24	enhanced	_	O	O	_	_	_	_	_
25	IkappaBalpha	_	O	O	_	_	_	_	_
26	degradation	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Productive	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	immunodeficiency	_	O	O	_	_	_	_	_
4	virus	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	HIV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	infection	_	O	O	_	_	_	_	_
13	causes	_	O	O	_	_	_	_	_
14	sustained	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappaB	_	O	O	_	_	_	_	_
18	DNA	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	chronically	_	O	O	_	_	_	_	_
24	infected	_	O	O	_	_	_	_	_
25	monocytic	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	direct	_	O	O	_	_	_	_	_
3	temporal	_	O	O	_	_	_	_	_
4	correlation	_	O	O	_	_	_	_	_
5	exists	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	HIV	_	O	O	_	_	_	_	_
8	infection	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	appearance	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappaB	_	O	O	_	_	_	_	_
16	DNA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	activity	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	myelomonoblastic	_	O	O	_	_	_	_	_
22	PLB	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	985	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	molecular	_	O	O	_	_	_	_	_
5	basis	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	constitutive	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappaB	_	O	O	_	_	_	_	_
11	DNA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	activity	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	HIV	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	infected	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	we	_	O	O	_	_	_	_	_
23	analyzed	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	phosphorylation	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	turnover	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	IkappaBalpha	_	O	O	_	_	_	_	_
30	protein	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	activity	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	double	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	stranded	_	O	O	_	_	_	_	_
39	RNA	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	dependent	_	O	O	_	_	_	_	_
42	protein	_	O	O	_	_	_	_	_
43	kinase	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	PKR	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	intracellular	_	O	O	_	_	_	_	_
50	levels	_	O	O	_	_	_	_	_
51	of	_	O	O	_	_	_	_	_
52	NF	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	kappaB	_	O	O	_	_	_	_	_
55	subunits	_	O	O	_	_	_	_	_
56	in	_	O	O	_	_	_	_	_
57	the	_	O	O	_	_	_	_	_
58	PLB	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	985	_	O	O	_	_	_	_	_
61	and	_	O	O	_	_	_	_	_
62	U	_	O	O	_	_	_	_	_
63	937	_	O	O	_	_	_	_	_
64	myeloid	_	O	O	_	_	_	_	_
65	cell	_	O	O	_	_	_	_	_
66	models	_	O	O	_	_	_	_	_
67	.	_	O	O	_	_	_	_	_

1	HIV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	infection	_	O	O	_	_	_	_	_
5	resulted	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	constitutive	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	low	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	level	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	type	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	interferon	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	IFN	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	level	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	PKR	_	O	O	_	_	_	_	_
3	activity	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	detected	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	HIV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	infected	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	result	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	low	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	level	_	O	O	_	_	_	_	_
21	IFN	_	O	O	_	_	_	_	_
22	production	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	since	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	addition	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	IFN	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	alpha	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	beta	_	O	O	_	_	_	_	_
35	antibody	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	decreased	_	O	O	_	_	_	_	_
40	PKR	_	O	O	_	_	_	_	_
41	expression	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	analysis	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	IkappaBalpha	_	O	O	_	_	_	_	_
7	turnover	_	O	O	_	_	_	_	_
8	demonstrated	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	degradation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	IkappaBalpha	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	HIV	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	infected	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	may	_	O	O	_	_	_	_	_
23	account	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	constitutive	_	O	O	_	_	_	_	_
27	DNA	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	activity	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	dramatic	_	O	O	_	_	_	_	_
3	increase	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	intracellular	_	O	O	_	_	_	_	_
7	levels	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kappaB	_	O	O	_	_	_	_	_
12	subunits	_	O	O	_	_	_	_	_
13	c	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Rel	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	100	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	moderate	_	O	O	_	_	_	_	_
26	increase	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	kappaB	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	p	_	O	O	_	_	_	_	_
33	52	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	RelA	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	p	_	O	O	_	_	_	_	_
38	65	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	were	_	O	O	_	_	_	_	_
41	detected	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	HIV	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	infected	_	O	O	_	_	_	_	_
48	cells	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	whereas	_	O	O	_	_	_	_	_
51	NF	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	kappaB	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	p	_	O	O	_	_	_	_	_
56	105	_	O	O	_	_	_	_	_
57	/	_	O	O	_	_	_	_	_
58	p	_	O	O	_	_	_	_	_
59	50	_	O	O	_	_	_	_	_
60	levels	_	O	O	_	_	_	_	_
61	were	_	O	O	_	_	_	_	_
62	not	_	O	O	_	_	_	_	_
63	altered	_	O	O	_	_	_	_	_
64	relative	_	O	O	_	_	_	_	_
65	to	_	O	O	_	_	_	_	_
66	the	_	O	O	_	_	_	_	_
67	levels	_	O	O	_	_	_	_	_
68	in	_	O	O	_	_	_	_	_
69	uninfected	_	O	O	_	_	_	_	_
70	cells	_	O	O	_	_	_	_	_
71	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	suggest	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	HIV	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	infection	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	myeloid	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	induces	_	O	O	_	_	_	_	_
12	IFN	_	O	O	_	_	_	_	_
13	production	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	PKR	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	turn	_	O	O	_	_	_	_	_
21	contribute	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	enhanced	_	O	O	_	_	_	_	_
24	IkappaBalpha	_	O	O	_	_	_	_	_
25	phosphorylation	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	subsequent	_	O	O	_	_	_	_	_
28	degradation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	translocation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kappaB	_	O	O	_	_	_	_	_
7	subunits	_	O	O	_	_	_	_	_
8	may	_	O	O	_	_	_	_	_
9	ultimately	_	O	O	_	_	_	_	_
10	increase	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	intracellular	_	O	O	_	_	_	_	_
13	pool	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappaB	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	IkappaBalpha	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	autoregulatory	_	O	O	_	_	_	_	_
23	mechanism	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Enhanced	_	O	O	_	_	_	_	_
2	turnover	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IkappaBalpha	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	accumulation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kappaB	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	Rel	_	O	O	_	_	_	_	_
14	proteins	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	contribute	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	chronically	_	O	O	_	_	_	_	_
20	activated	_	O	O	_	_	_	_	_
21	state	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	HIV	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	infected	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Epstein	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Barr	_	O	O	_	_	_	_	_
5	virus	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	EBV	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	BMRF	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	promoter	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	early	_	O	O	_	_	_	_	_
14	antigen	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	EA	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	D	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	regulated	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	EBV	_	O	O	_	_	_	_	_
25	transactivators	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	BRLF	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	BZLF	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	specific	_	O	O	_	_	_	_	_
38	manner	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Epstein	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Barr	_	O	O	_	_	_	_	_
5	virus	_	O	O	_	_	_	_	_
6	early	_	O	O	_	_	_	_	_
7	antigen	_	O	O	_	_	_	_	_
8	diffuse	_	O	O	_	_	_	_	_
9	component	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	EA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	D	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	essential	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	Epstein	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	Barr	_	O	O	_	_	_	_	_
21	virus	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	polymerase	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	is	_	O	O	_	_	_	_	_
30	suppressed	_	O	O	_	_	_	_	_
31	during	_	O	O	_	_	_	_	_
32	latent	_	O	O	_	_	_	_	_
33	infection	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	regulation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	promoter	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	BMRF	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	this	_	O	O	_	_	_	_	_
14	early	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	studying	_	O	O	_	_	_	_	_
18	its	_	O	O	_	_	_	_	_
19	responsiveness	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	vitro	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	two	_	O	O	_	_	_	_	_
24	immediate	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	early	_	O	O	_	_	_	_	_
27	viral	_	O	O	_	_	_	_	_
28	transactivators	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	BZLF	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	Z	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	BRLF	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	R	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	focusing	_	O	O	_	_	_	_	_
43	on	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	differences	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	response	_	O	O	_	_	_	_	_
48	in	_	O	O	_	_	_	_	_
49	lymphoid	_	O	O	_	_	_	_	_
50	cells	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	epithelial	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	lymphoid	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	Z	_	O	O	_	_	_	_	_
6	or	_	O	O	_	_	_	_	_
7	R	_	O	O	_	_	_	_	_
8	alone	_	O	O	_	_	_	_	_
9	produced	_	O	O	_	_	_	_	_
10	only	_	O	O	_	_	_	_	_
11	small	_	O	O	_	_	_	_	_
12	increases	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	EA	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	promoter	_	O	O	_	_	_	_	_
18	activity	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	whereas	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	transactivators	_	O	O	_	_	_	_	_
23	together	_	O	O	_	_	_	_	_
24	produced	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	large	_	O	O	_	_	_	_	_
27	stimulatory	_	O	O	_	_	_	_	_
28	effect	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	epithelial	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	Z	_	O	O	_	_	_	_	_
7	transactivator	_	O	O	_	_	_	_	_
8	alone	_	O	O	_	_	_	_	_
9	produced	_	O	O	_	_	_	_	_
10	maximal	_	O	O	_	_	_	_	_
11	stimulation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	EA	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	promoter	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	effect	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	R	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	Z	_	O	O	_	_	_	_	_
25	together	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	no	_	O	O	_	_	_	_	_
28	greater	_	O	O	_	_	_	_	_
29	than	_	O	O	_	_	_	_	_
30	that	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	Z	_	O	O	_	_	_	_	_
33	alone	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Deletional	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	site	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	directed	_	O	O	_	_	_	_	_
7	mutagenesis	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	EA	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	D	_	O	O	_	_	_	_	_
13	promoter	_	O	O	_	_	_	_	_
14	demonstrated	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	epithelial	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	potential	_	O	O	_	_	_	_	_
21	AP	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	binding	_	O	O	_	_	_	_	_
25	site	_	O	O	_	_	_	_	_
26	plays	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	essential	_	O	O	_	_	_	_	_
29	role	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	Z	_	O	O	_	_	_	_	_
32	responsiveness	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	although	_	O	O	_	_	_	_	_
35	sequences	_	O	O	_	_	_	_	_
36	further	_	O	O	_	_	_	_	_
37	upstream	_	O	O	_	_	_	_	_
38	are	_	O	O	_	_	_	_	_
39	also	_	O	O	_	_	_	_	_
40	important	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	lymphoid	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	only	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	upstream	_	O	O	_	_	_	_	_
8	sequences	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	required	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	transactivation	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	Z	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	R	_	O	O	_	_	_	_	_
18	combination	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	AP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	site	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	dispensable	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	EA	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	D	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	BMRF	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	regulation	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	Z	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	R	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	type	_	O	O	_	_	_	_	_
21	specific	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	appears	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	involve	_	O	O	_	_	_	_	_
26	different	_	O	O	_	_	_	_	_
27	mechanisms	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	each	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	type	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Immunoassay	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	IFN	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_

1	Concentrations	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IFN	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	culture	_	O	O	_	_	_	_	_
12	supernatants	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	measured	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	duplicate	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	quantitative	_	O	O	_	_	_	_	_
26	sandwich	_	O	O	_	_	_	_	_
27	ELISA	_	O	O	_	_	_	_	_
28	using	_	O	O	_	_	_	_	_
29	cytokine	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	specific	_	O	O	_	_	_	_	_
32	capture	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	biotinylated	_	O	O	_	_	_	_	_
35	detection	_	O	O	_	_	_	_	_
36	mAb	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	recombinant	_	O	O	_	_	_	_	_
39	cytokine	_	O	O	_	_	_	_	_
40	proteins	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	all	_	O	O	_	_	_	_	_
43	from	_	O	O	_	_	_	_	_
44	Becton	_	O	O	_	_	_	_	_
45	Dickinson	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	according	_	O	O	_	_	_	_	_
49	to	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	manufacturer	_	O	O	_	_	_	_	_
52	'	_	O	O	_	_	_	_	_
53	s	_	O	O	_	_	_	_	_
54	protocol	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	detection	_	O	O	_	_	_	_	_
3	limits	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	gamma	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	15	_	O	O	_	_	_	_	_
14	pg	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	ml	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_



1	Constitutive	_	O	O	_	_	_	_	_
2	overexpression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	L	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	selectin	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	fresh	_	O	O	_	_	_	_	_
11	leukemic	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	adult	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	leukemia	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	can	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	transactivated	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	human	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	lymphotropic	_	O	O	_	_	_	_	_
29	virus	_	O	O	_	_	_	_	_
30	type	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	Tax	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	L	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	selectin	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	adhesion	_	O	O	_	_	_	_	_
7	molecule	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	selectin	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	mediates	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	initial	_	O	O	_	_	_	_	_
16	step	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	leukocyte	_	O	O	_	_	_	_	_
19	adhesion	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	vascular	_	O	O	_	_	_	_	_
22	endothelium	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Upon	_	O	O	_	_	_	_	_
2	cellular	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	L	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	selectin	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	downregulated	_	O	O	_	_	_	_	_
14	at	_	O	O	_	_	_	_	_
15	both	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	understand	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	mechanism	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	leukemic	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	infiltration	_	O	O	_	_	_	_	_
9	into	_	O	O	_	_	_	_	_
10	organs	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	studied	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	regulation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	L	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	selectin	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	fresh	_	O	O	_	_	_	_	_
25	leukemic	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	adult	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	cell	_	O	O	_	_	_	_	_
32	leukemia	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	ATL	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	patients	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	investigated	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	response	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	L	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	selectin	_	O	O	_	_	_	_	_
46	promoter	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	human	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	cell	_	O	O	_	_	_	_	_
52	lymphotropic	_	O	O	_	_	_	_	_
53	virus	_	O	O	_	_	_	_	_
54	type	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	(	_	O	O	_	_	_	_	_
57	HTLV	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	1	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	Tax	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	which	_	O	O	_	_	_	_	_
64	is	_	O	O	_	_	_	_	_
65	a	_	O	O	_	_	_	_	_
66	viral	_	O	O	_	_	_	_	_
67	transcriptional	_	O	O	_	_	_	_	_
68	transactivator	_	O	O	_	_	_	_	_
69	.	_	O	O	_	_	_	_	_

1	Flow	_	O	O	_	_	_	_	_
2	cytometry	_	O	O	_	_	_	_	_
3	showed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	L	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	selectin	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	fresh	_	O	O	_	_	_	_	_
12	ATL	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	along	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	other	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	antigens	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	ATL	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	overexpressed	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	L	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	selectin	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	level	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	aberrantly	_	O	O	_	_	_	_	_
20	upregulated	_	O	O	_	_	_	_	_
21	after	_	O	O	_	_	_	_	_
22	PMA	_	O	O	_	_	_	_	_
23	stimulation	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Studies	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	situ	_	O	O	_	_	_	_	_
5	hybridization	_	O	O	_	_	_	_	_
6	showed	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	L	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	selectin	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	infiltrating	_	O	O	_	_	_	_	_
17	leukemic	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	liver	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	two	_	O	O	_	_	_	_	_
24	ATL	_	O	O	_	_	_	_	_
25	patients	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Intravenous	_	O	O	_	_	_	_	_
2	injection	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	rat	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	line	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	overexpresses	_	O	O	_	_	_	_	_
12	L	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	selectin	_	O	O	_	_	_	_	_
15	showed	_	O	O	_	_	_	_	_
16	increased	_	O	O	_	_	_	_	_
17	organ	_	O	O	_	_	_	_	_
18	infiltration	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Tax	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	JPX	_	O	O	_	_	_	_	_
8	9	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	resulted	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	about	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	twofold	_	O	O	_	_	_	_	_
15	increase	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	mRNA	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	compared	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	basal	_	O	O	_	_	_	_	_
25	level	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Chloramphenicol	_	O	O	_	_	_	_	_
2	acetyltransferase	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	CAT	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	assay	_	O	O	_	_	_	_	_
7	after	_	O	O	_	_	_	_	_
8	transient	_	O	O	_	_	_	_	_
9	cotransfection	_	O	O	_	_	_	_	_
10	showed	_	O	O	_	_	_	_	_
11	about	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	fivefold	_	O	O	_	_	_	_	_
14	transactivation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	L	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	selectin	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	Tax	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	serum	_	O	O	_	_	_	_	_
3	level	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	shed	_	O	O	_	_	_	_	_
7	form	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	L	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	selectin	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	significantly	_	O	O	_	_	_	_	_
14	increased	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	ATL	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	mean	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	SD	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	4	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	215	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	4	_	O	O	_	_	_	_	_
30	+	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	111	_	O	O	_	_	_	_	_
36	ng	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	mL	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	compared	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	those	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	asymptomatic	_	O	O	_	_	_	_	_
45	carriers	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	healthy	_	O	O	_	_	_	_	_
48	blood	_	O	O	_	_	_	_	_
49	donors	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	mean	_	O	O	_	_	_	_	_
52	+	_	O	O	_	_	_	_	_
53	/	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	SD	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	1	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	148	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_
61	0	_	O	O	_	_	_	_	_
62	+	_	O	O	_	_	_	_	_
63	/	_	O	O	_	_	_	_	_
64	-	_	O	O	_	_	_	_	_
65	269	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_
67	0	_	O	O	_	_	_	_	_
68	ng	_	O	O	_	_	_	_	_
69	/	_	O	O	_	_	_	_	_
70	mL	_	O	O	_	_	_	_	_
71	and	_	O	O	_	_	_	_	_
72	991	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_
74	9	_	O	O	_	_	_	_	_
75	+	_	O	O	_	_	_	_	_
76	/	_	O	O	_	_	_	_	_
77	-	_	O	O	_	_	_	_	_
78	224	_	O	O	_	_	_	_	_
79	ng	_	O	O	_	_	_	_	_
80	/	_	O	O	_	_	_	_	_
81	mL	_	O	O	_	_	_	_	_
82	,	_	O	O	_	_	_	_	_
83	respectively	_	O	O	_	_	_	_	_
84	)	_	O	O	_	_	_	_	_
85	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	ATL	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	constitutively	_	O	O	_	_	_	_	_
8	overexpress	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	L	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	selectin	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	can	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	transactivated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	HTLV	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	Tax	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	overexpression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	L	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	selectin	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	well	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	cytokines	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	ATL	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	may	_	O	O	_	_	_	_	_
19	provide	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	basis	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	ATL	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	attach	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	vascular	_	O	O	_	_	_	_	_
29	endothelium	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	leading	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	transmigration	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	organ	_	O	O	_	_	_	_	_
36	infitration	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Bacterial	_	O	O	_	_	_	_	_
2	peptidoglycan	_	O	O	_	_	_	_	_
3	induces	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	14	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependent	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	factors	_	O	O	_	_	_	_	_
12	CREB	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ATF	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	AP	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Peptidoglycan	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	PGN	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	major	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	wall	_	O	O	_	_	_	_	_
10	component	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	Gram	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	positive	_	O	O	_	_	_	_	_
15	bacteria	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	induces	_	O	O	_	_	_	_	_
18	secretion	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	cytokines	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	macrophages	_	O	O	_	_	_	_	_
23	through	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	14	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	pattern	_	O	O	_	_	_	_	_
29	recognition	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	binds	_	O	O	_	_	_	_	_
33	lipopolysaccharide	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	other	_	O	O	_	_	_	_	_
36	microbial	_	O	O	_	_	_	_	_
37	products	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	begin	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	elucidate	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	mechanisms	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	regulate	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	cytokine	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	we	_	O	O	_	_	_	_	_
16	wanted	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	determine	_	O	O	_	_	_	_	_
19	which	_	O	O	_	_	_	_	_
20	transcription	_	O	O	_	_	_	_	_
21	factors	_	O	O	_	_	_	_	_
22	are	_	O	O	_	_	_	_	_
23	activated	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	PGN	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	mouse	_	O	O	_	_	_	_	_
28	RAW	_	O	O	_	_	_	_	_
29	264	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_
31	7	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	human	_	O	O	_	_	_	_	_
34	THP	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	macrophage	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	:	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	i	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	PGN	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	phosphorylation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	factors	_	O	O	_	_	_	_	_
16	ATF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	CREB	_	O	O	_	_	_	_	_
21	;	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	ii	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	ATF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	CREB	_	O	O	_	_	_	_	_
30	bound	_	O	O	_	_	_	_	_
31	DNA	_	O	O	_	_	_	_	_
32	as	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	dimer	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	induced	_	O	O	_	_	_	_	_
37	transcriptional	_	O	O	_	_	_	_	_
38	activation	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	CRE	_	O	O	_	_	_	_	_
42	reporter	_	O	O	_	_	_	_	_
43	plasmid	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	which	_	O	O	_	_	_	_	_
46	was	_	O	O	_	_	_	_	_
47	inhibited	_	O	O	_	_	_	_	_
48	by	_	O	O	_	_	_	_	_
49	dominant	_	O	O	_	_	_	_	_
50	negative	_	O	O	_	_	_	_	_
51	CREB	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	ATF	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	;	_	O	O	_	_	_	_	_
57	(	_	O	O	_	_	_	_	_
58	iii	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	PGN	_	O	O	_	_	_	_	_
61	induced	_	O	O	_	_	_	_	_
62	phosphorylation	_	O	O	_	_	_	_	_
63	of	_	O	O	_	_	_	_	_
64	c	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	Jun	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	protein	_	O	O	_	_	_	_	_
69	synthesis	_	O	O	_	_	_	_	_
70	of	_	O	O	_	_	_	_	_
71	JunB	_	O	O	_	_	_	_	_
72	and	_	O	O	_	_	_	_	_
73	c	_	O	O	_	_	_	_	_
74	-	_	O	O	_	_	_	_	_
75	Fos	_	O	O	_	_	_	_	_
76	,	_	O	O	_	_	_	_	_
77	and	_	O	O	_	_	_	_	_
78	transcriptional	_	O	O	_	_	_	_	_
79	activation	_	O	O	_	_	_	_	_
80	of	_	O	O	_	_	_	_	_
81	the	_	O	O	_	_	_	_	_
82	AP	_	O	O	_	_	_	_	_
83	-	_	O	O	_	_	_	_	_
84	1	_	O	O	_	_	_	_	_
85	reporter	_	O	O	_	_	_	_	_
86	plasmid	_	O	O	_	_	_	_	_
87	,	_	O	O	_	_	_	_	_
88	which	_	O	O	_	_	_	_	_
89	was	_	O	O	_	_	_	_	_
90	inhibited	_	O	O	_	_	_	_	_
91	by	_	O	O	_	_	_	_	_
92	dominant	_	O	O	_	_	_	_	_
93	negative	_	O	O	_	_	_	_	_
94	c	_	O	O	_	_	_	_	_
95	-	_	O	O	_	_	_	_	_
96	Fos	_	O	O	_	_	_	_	_
97	;	_	O	O	_	_	_	_	_
98	and	_	O	O	_	_	_	_	_
99	(	_	O	O	_	_	_	_	_
100	iv	_	O	O	_	_	_	_	_
101	)	_	O	O	_	_	_	_	_
102	PGN	_	O	O	_	_	_	_	_
103	-	_	O	O	_	_	_	_	_
104	induced	_	O	O	_	_	_	_	_
105	activation	_	O	O	_	_	_	_	_
106	of	_	O	O	_	_	_	_	_
107	CREB	_	O	O	_	_	_	_	_
108	/	_	O	O	_	_	_	_	_
109	ATF	_	O	O	_	_	_	_	_
110	and	_	O	O	_	_	_	_	_
111	AP	_	O	O	_	_	_	_	_
112	-	_	O	O	_	_	_	_	_
113	1	_	O	O	_	_	_	_	_
114	was	_	O	O	_	_	_	_	_
115	mediated	_	O	O	_	_	_	_	_
116	through	_	O	O	_	_	_	_	_
117	CD	_	O	O	_	_	_	_	_
118	14	_	O	O	_	_	_	_	_
119	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	first	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	demonstrate	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	CREB	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	ATF	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	AP	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	factors	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	PGN	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	any	_	O	O	_	_	_	_	_
24	other	_	O	O	_	_	_	_	_
25	component	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	Gram	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	positive	_	O	O	_	_	_	_	_
30	bacteria	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	E	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	A	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	induces	_	O	O	_	_	_	_	_
7	susceptibility	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	killing	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	NK	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	following	_	O	O	_	_	_	_	_
14	immortalization	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	adenovirus	_	O	O	_	_	_	_	_
18	infection	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Adenovirus	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Ad	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	infection	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	E	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	A	_	O	O	_	_	_	_	_
10	transfection	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	used	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	model	_	O	O	_	_	_	_	_
15	changes	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	susceptibility	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	NK	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	killing	_	O	O	_	_	_	_	_
22	caused	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	transient	_	O	O	_	_	_	_	_
25	vs	_	O	O	_	_	_	_	_
26	stable	_	O	O	_	_	_	_	_
27	E	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	A	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	human	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Only	_	O	O	_	_	_	_	_
2	stably	_	O	O	_	_	_	_	_
3	transfected	_	O	O	_	_	_	_	_
4	target	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	exhibited	_	O	O	_	_	_	_	_
7	cytolytic	_	O	O	_	_	_	_	_
8	susceptibility	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	despite	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	equivalent	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	E	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	A	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	Ad	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	infected	_	O	O	_	_	_	_	_
24	targets	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	inability	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	A	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	products	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	induce	_	O	O	_	_	_	_	_
11	cytolytic	_	O	O	_	_	_	_	_
12	susceptibility	_	O	O	_	_	_	_	_
13	during	_	O	O	_	_	_	_	_
14	infection	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	explained	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	an	_	O	O	_	_	_	_	_
20	inhibitory	_	O	O	_	_	_	_	_
21	effect	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	viral	_	O	O	_	_	_	_	_
24	infection	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	otherwise	_	O	O	_	_	_	_	_
27	susceptible	_	O	O	_	_	_	_	_
28	target	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	viral	_	O	O	_	_	_	_	_
33	gene	_	O	O	_	_	_	_	_
34	effects	_	O	O	_	_	_	_	_
35	on	_	O	O	_	_	_	_	_
36	class	_	O	O	_	_	_	_	_
37	I	_	O	O	_	_	_	_	_
38	MHC	_	O	O	_	_	_	_	_
39	antigen	_	O	O	_	_	_	_	_
40	expression	_	O	O	_	_	_	_	_
41	on	_	O	O	_	_	_	_	_
42	target	_	O	O	_	_	_	_	_
43	cells	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	differential	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	E	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	A	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cytolytic	_	O	O	_	_	_	_	_
12	phenotypes	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	infected	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	stably	_	O	O	_	_	_	_	_
17	transfected	_	O	O	_	_	_	_	_
18	human	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	suggests	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	NK	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	provide	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	effective	_	O	O	_	_	_	_	_
28	immunologic	_	O	O	_	_	_	_	_
29	barrier	_	O	O	_	_	_	_	_
30	against	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	vivo	_	O	O	_	_	_	_	_
34	survival	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	neoplastic	_	O	O	_	_	_	_	_
37	progression	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	E	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	A	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	immortalized	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	that	_	O	O	_	_	_	_	_
46	may	_	O	O	_	_	_	_	_
47	emerge	_	O	O	_	_	_	_	_
48	from	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	reservoir	_	O	O	_	_	_	_	_
51	of	_	O	O	_	_	_	_	_
52	persistently	_	O	O	_	_	_	_	_
53	infected	_	O	O	_	_	_	_	_
54	cells	_	O	O	_	_	_	_	_
55	in	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	human	_	O	O	_	_	_	_	_
58	host	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	Directly	_	O	O	_	_	_	_	_
4	Silences	_	O	O	_	_	_	_	_
5	Epsilon	_	O	O	_	_	_	_	_
6	Globin	_	O	O	_	_	_	_	_
7	Expression	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	Definitive	_	O	O	_	_	_	_	_
10	Erythropoiesis	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	member	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factor	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	defined	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	conserved	_	O	O	_	_	_	_	_
18	high	_	O	O	_	_	_	_	_
19	mobility	_	O	O	_	_	_	_	_
20	group	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	HMG	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	DNA	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	domain	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	first	_	O	O	_	_	_	_	_
29	described	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	testis	_	O	O	_	_	_	_	_
33	determining	_	O	O	_	_	_	_	_
34	gene	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	Sry	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Previous	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	suggested	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	plays	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	development	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	central	_	O	O	_	_	_	_	_
17	nervous	_	O	O	_	_	_	_	_
18	system	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	cartilage	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	muscle	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	deficient	_	O	O	_	_	_	_	_
7	mouse	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	100	_	O	O	_	_	_	_	_
11	H	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	globin	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	persistently	_	O	O	_	_	_	_	_
17	expressed	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	increased	_	O	O	_	_	_	_	_
21	numbers	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	nucleated	_	O	O	_	_	_	_	_
24	red	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	present	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	fetal	_	O	O	_	_	_	_	_
31	circulation	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Transfection	_	O	O	_	_	_	_	_
2	assays	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	GM	_	O	O	_	_	_	_	_
5	979	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	erythroleukemic	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	define	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	36	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	base	_	O	O	_	_	_	_	_
15	pair	_	O	O	_	_	_	_	_
16	region	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	epsilony	_	O	O	_	_	_	_	_
20	proximal	_	O	O	_	_	_	_	_
21	promoter	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	critical	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	Sox	_	O	O	_	_	_	_	_
27	6	_	O	O	_	_	_	_	_
28	mediated	_	O	O	_	_	_	_	_
29	repression	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Electrophoretic	_	O	O	_	_	_	_	_
2	mobility	_	O	O	_	_	_	_	_
3	shift	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	EMSA	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	chromatin	_	O	O	_	_	_	_	_
10	immunoprecipitation	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	ChIP	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	assays	_	O	O	_	_	_	_	_
15	demonstrate	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	Sox	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	acts	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	repressor	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	directly	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	epsilony	_	O	O	_	_	_	_	_
29	promoter	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	normal	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	wild	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	fetal	_	O	O	_	_	_	_	_
12	liver	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	ectopic	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	epsilony	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	100	_	O	O	_	_	_	_	_
22	H	_	O	O	_	_	_	_	_
23	homozygous	_	O	O	_	_	_	_	_
24	fetal	_	O	O	_	_	_	_	_
25	liver	_	O	O	_	_	_	_	_
26	demonstrate	_	O	O	_	_	_	_	_
27	that	_	O	O	_	_	_	_	_
28	Sox	_	O	O	_	_	_	_	_
29	6	_	O	O	_	_	_	_	_
30	functions	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	definitive	_	O	O	_	_	_	_	_
33	erythropoiesis	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	shows	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	required	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	silencing	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	globin	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	definitive	_	O	O	_	_	_	_	_
17	erythropoiesis	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	suggests	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	role	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	Sox	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	erythroid	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	maturation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	regulation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	epsilony	_	O	O	_	_	_	_	_
8	globin	_	O	O	_	_	_	_	_
9	might	_	O	O	_	_	_	_	_
10	provide	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	novel	_	O	O	_	_	_	_	_
13	therapeutical	_	O	O	_	_	_	_	_
14	target	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	treatment	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	hemoglobinopathies	_	O	O	_	_	_	_	_
20	such	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	sickle	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	anemia	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	thalassemia	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Synopsis	_	O	O	_	_	_	_	_

1	Beta	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	globin	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	switching	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	transition	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	embryonic	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	fetal	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	adult	_	O	O	_	_	_	_	_
15	synthesis	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	globin	_	O	O	_	_	_	_	_
19	chains	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	results	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	hemoglobins	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	different	_	O	O	_	_	_	_	_
26	affinity	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	oxygen	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	system	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	longstanding	_	O	O	_	_	_	_	_
6	paradigm	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	developmental	_	O	O	_	_	_	_	_
9	biology	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	directly	_	O	O	_	_	_	_	_
13	relevant	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	disease	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	since	_	O	O	_	_	_	_	_
19	small	_	O	O	_	_	_	_	_
20	amounts	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	normal	_	O	O	_	_	_	_	_
23	embryonic	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	fetal	_	O	O	_	_	_	_	_
26	beta	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	globins	_	O	O	_	_	_	_	_
29	can	_	O	O	_	_	_	_	_
30	""""	_	O	O	_	_	_	_	_
31	balance	_	O	O	_	_	_	_	_
32	""""	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	detrimental	_	O	O	_	_	_	_	_
35	effect	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	abnormal	_	O	O	_	_	_	_	_
38	or	_	O	O	_	_	_	_	_
39	missing	_	O	O	_	_	_	_	_
40	adult	_	O	O	_	_	_	_	_
41	globins	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	diseases	_	O	O	_	_	_	_	_
44	such	_	O	O	_	_	_	_	_
45	as	_	O	O	_	_	_	_	_
46	sickle	_	O	O	_	_	_	_	_
47	cell	_	O	O	_	_	_	_	_
48	anemia	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	beta	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	thalassemia	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	current	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	identified	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	novel	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	crucial	_	O	O	_	_	_	_	_
18	silencing	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	epsilon	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	embryonic	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	globin	_	O	O	_	_	_	_	_
26	through	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	somewhat	_	O	O	_	_	_	_	_
29	serendipitous	_	O	O	_	_	_	_	_
30	pathway	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	authors	_	O	O	_	_	_	_	_
3	had	_	O	O	_	_	_	_	_
4	previously	_	O	O	_	_	_	_	_
5	identified	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	chromosomal	_	O	O	_	_	_	_	_
8	inversion	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	100	_	O	O	_	_	_	_	_
12	H	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	virtue	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	its	_	O	O	_	_	_	_	_
18	effect	_	O	O	_	_	_	_	_
19	on	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	pink	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	eyed	_	O	O	_	_	_	_	_
24	dilution	_	O	O	_	_	_	_	_
25	gene	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	found	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	same	_	O	O	_	_	_	_	_
31	inversion	_	O	O	_	_	_	_	_
32	also	_	O	O	_	_	_	_	_
33	disrupts	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	Sox	_	O	O	_	_	_	_	_
36	6	_	O	O	_	_	_	_	_
37	gene	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	100	_	O	O	_	_	_	_	_
4	H	_	O	O	_	_	_	_	_
5	mutant	_	O	O	_	_	_	_	_
6	mice	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	tool	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	identifying	_	O	O	_	_	_	_	_
12	downstream	_	O	O	_	_	_	_	_
13	targets	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	Sox	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	authors	_	O	O	_	_	_	_	_
20	discovered	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	epsilon	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	globin	_	O	O	_	_	_	_	_
25	levels	_	O	O	_	_	_	_	_
26	were	_	O	O	_	_	_	_	_
27	dramatically	_	O	O	_	_	_	_	_
28	elevated	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	paving	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	way	_	O	O	_	_	_	_	_
33	for	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	series	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	molecular	_	O	O	_	_	_	_	_
38	genetic	_	O	O	_	_	_	_	_
39	experiments	_	O	O	_	_	_	_	_
40	demonstrating	_	O	O	_	_	_	_	_
41	that	_	O	O	_	_	_	_	_
42	Sox	_	O	O	_	_	_	_	_
43	6	_	O	O	_	_	_	_	_
44	directly	_	O	O	_	_	_	_	_
45	binds	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	normally	_	O	O	_	_	_	_	_
49	inhibits	_	O	O	_	_	_	_	_
50	transcription	_	O	O	_	_	_	_	_
51	from	_	O	O	_	_	_	_	_
52	the	_	O	O	_	_	_	_	_
53	epsilon	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	globin	_	O	O	_	_	_	_	_
56	gene	_	O	O	_	_	_	_	_
57	promoter	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	work	_	O	O	_	_	_	_	_
3	provides	_	O	O	_	_	_	_	_
4	fundamental	_	O	O	_	_	_	_	_
5	new	_	O	O	_	_	_	_	_
6	insights	_	O	O	_	_	_	_	_
7	into	_	O	O	_	_	_	_	_
8	regulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	globin	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	during	_	O	O	_	_	_	_	_
14	development	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	provides	_	O	O	_	_	_	_	_
18	new	_	O	O	_	_	_	_	_
19	clues	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	manipulating	_	O	O	_	_	_	_	_
22	globin	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	approach	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	treat	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	blood	_	O	O	_	_	_	_	_
32	diseases	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_



1	20	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Epi	_	O	O	_	_	_	_	_
4	analogues	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	25	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	dihydroxyvitamin	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	highly	_	O	O	_	_	_	_	_
15	potent	_	O	O	_	_	_	_	_
16	inducers	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	DRIP	_	O	O	_	_	_	_	_
19	coactivator	_	O	O	_	_	_	_	_
20	complex	_	O	O	_	_	_	_	_
21	binding	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	vitamin	_	O	O	_	_	_	_	_
25	D	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	1	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Dihydroxyvitamin	_	O	O	_	_	_	_	_
6	D	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	25	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	OH	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	plays	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	major	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	stimulation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	bone	_	O	O	_	_	_	_	_
28	growth	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	mineralization	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	intestinal	_	O	O	_	_	_	_	_
34	calcium	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	phosphate	_	O	O	_	_	_	_	_
37	absorption	_	O	O	_	_	_	_	_
38	;	_	O	O	_	_	_	_	_
39	it	_	O	O	_	_	_	_	_
40	also	_	O	O	_	_	_	_	_
41	acts	_	O	O	_	_	_	_	_
42	as	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	general	_	O	O	_	_	_	_	_
45	inhibitor	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	cellular	_	O	O	_	_	_	_	_
48	proliferation	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Several	_	O	O	_	_	_	_	_
2	new	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	clinically	_	O	O	_	_	_	_	_
5	relevant	_	O	O	_	_	_	_	_
6	compounds	_	O	O	_	_	_	_	_
7	dissociate	_	O	O	_	_	_	_	_
8	antiproliferative	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	calcemic	_	O	O	_	_	_	_	_
11	activities	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	25	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	OH	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	D	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	molecular	_	O	O	_	_	_	_	_
26	basis	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	this	_	O	O	_	_	_	_	_
29	has	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	been	_	O	O	_	_	_	_	_
32	clearly	_	O	O	_	_	_	_	_
33	elucidated	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	tested	_	O	O	_	_	_	_	_
5	whether	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	potency	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	one	_	O	O	_	_	_	_	_
10	class	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	compounds	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	20	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	epi	_	O	O	_	_	_	_	_
17	analogues	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	induce	_	O	O	_	_	_	_	_
21	myeloid	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	differentiation	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	because	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	direct	_	O	O	_	_	_	_	_
29	molecular	_	O	O	_	_	_	_	_
30	effects	_	O	O	_	_	_	_	_
31	on	_	O	O	_	_	_	_	_
32	vitamin	_	O	O	_	_	_	_	_
33	D	_	O	O	_	_	_	_	_
34	receptor	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	VDR	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	report	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	20	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	epi	_	O	O	_	_	_	_	_
8	analogues	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	MC	_	O	O	_	_	_	_	_
11	1627	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	MC	_	O	O	_	_	_	_	_
14	1288	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	differentiation	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	21	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	Waf	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	Cip	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	key	_	O	O	_	_	_	_	_
33	VDR	_	O	O	_	_	_	_	_
34	target	_	O	O	_	_	_	_	_
35	gene	_	O	O	_	_	_	_	_
36	involved	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	growth	_	O	O	_	_	_	_	_
39	inhibition	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	at	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	concentration	_	O	O	_	_	_	_	_
44	100	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	fold	_	O	O	_	_	_	_	_
47	lower	_	O	O	_	_	_	_	_
48	than	_	O	O	_	_	_	_	_
49	that	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	25	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	OH	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	2	_	O	O	_	_	_	_	_
58	D	_	O	O	_	_	_	_	_
59	3	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	compared	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	sensitivity	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	analogue	_	O	O	_	_	_	_	_
7	effects	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	VDR	_	O	O	_	_	_	_	_
10	interacting	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	:	_	O	O	_	_	_	_	_
13	RXR	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	GRIP	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	DRIP	_	O	O	_	_	_	_	_
21	205	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	subunit	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	DRIP	_	O	O	_	_	_	_	_
28	coactivator	_	O	O	_	_	_	_	_
29	complex	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Compared	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	interaction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	VDR	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	RXR	_	O	O	_	_	_	_	_
9	or	_	O	O	_	_	_	_	_
10	GRIP	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	differentiation	_	O	O	_	_	_	_	_
16	dose	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	response	_	O	O	_	_	_	_	_
19	most	_	O	O	_	_	_	_	_
20	closely	_	O	O	_	_	_	_	_
21	correlated	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	ligand	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	dependent	_	O	O	_	_	_	_	_
27	recruitment	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	DRIP	_	O	O	_	_	_	_	_
31	coactivator	_	O	O	_	_	_	_	_
32	complex	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	VDR	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	ability	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	receptor	_	O	O	_	_	_	_	_
42	to	_	O	O	_	_	_	_	_
43	activate	_	O	O	_	_	_	_	_
44	transcription	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	cell	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	free	_	O	O	_	_	_	_	_
50	system	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	provide	_	O	O	_	_	_	_	_
4	compelling	_	O	O	_	_	_	_	_
5	links	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	efficiency	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	20	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	epi	_	O	O	_	_	_	_	_
14	analogue	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	inducing	_	O	O	_	_	_	_	_
17	VDR	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	DRIP	_	O	O	_	_	_	_	_
20	interactions	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	transactivation	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	vitro	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	enhanced	_	O	O	_	_	_	_	_
29	ability	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	induce	_	O	O	_	_	_	_	_
32	cellular	_	O	O	_	_	_	_	_
33	differentiation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	EMSA	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	ChIP	_	O	O	_	_	_	_	_
4	Assays	_	O	O	_	_	_	_	_
5	Show	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	Sox	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	Directly	_	O	O	_	_	_	_	_
10	Binds	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	Promoter	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	might	_	O	O	_	_	_	_	_
4	repress	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	epsilony	_	O	O	_	_	_	_	_
7	promoter	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	either	_	O	O	_	_	_	_	_
10	through	_	O	O	_	_	_	_	_
11	direct	_	O	O	_	_	_	_	_
12	physical	_	O	O	_	_	_	_	_
13	contact	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	regulating	_	O	O	_	_	_	_	_
20	intermediates	_	O	O	_	_	_	_	_
21	affecting	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	epsilony	_	O	O	_	_	_	_	_
24	promoter	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	directly	_	O	O	_	_	_	_	_
8	associated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	epsilony	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	we	_	O	O	_	_	_	_	_
15	first	_	O	O	_	_	_	_	_
16	performed	_	O	O	_	_	_	_	_
17	electrophoretic	_	O	O	_	_	_	_	_
18	mobility	_	O	O	_	_	_	_	_
19	shift	_	O	O	_	_	_	_	_
20	assays	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	EMSA	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	using	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	c	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	Myc	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	tagged	_	O	O	_	_	_	_	_
31	Sox	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	reticulocyte	_	O	O	_	_	_	_	_
36	lysate	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	based	_	O	O	_	_	_	_	_
39	transcription	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	translation	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	vitro	_	O	O	_	_	_	_	_
44	system	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	probes	_	O	O	_	_	_	_	_
3	used	_	O	O	_	_	_	_	_
4	are	_	O	O	_	_	_	_	_
5	listed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	Figure	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	A	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	36	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	base	_	O	O	_	_	_	_	_
5	pair	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	bp	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	WT	_	O	O	_	_	_	_	_
10	probe	_	O	O	_	_	_	_	_
11	corresponds	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	critical	_	O	O	_	_	_	_	_
15	region	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	epsilony	_	O	O	_	_	_	_	_
19	promoter	_	O	O	_	_	_	_	_
20	defined	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	our	_	O	O	_	_	_	_	_
23	promoter	_	O	O	_	_	_	_	_
24	deletion	_	O	O	_	_	_	_	_
25	analyses	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	probe	_	O	O	_	_	_	_	_
3	contains	_	O	O	_	_	_	_	_
4	two	_	O	O	_	_	_	_	_
5	consensus	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	sites	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Also	_	O	O	_	_	_	_	_
2	included	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	EMSA	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	three	_	O	O	_	_	_	_	_
8	mutated	_	O	O	_	_	_	_	_
9	probes	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	either	_	O	O	_	_	_	_	_
14	truncated	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	M	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	mutated	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	M	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	M	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	Sox	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	Sox	_	O	O	_	_	_	_	_
33	6	_	O	O	_	_	_	_	_
34	binding	_	O	O	_	_	_	_	_
35	sites	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	Figure	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	A	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	able	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	physically	_	O	O	_	_	_	_	_
7	associate	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	36	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	bp	_	O	O	_	_	_	_	_
13	region	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	Figure	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	within	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	epsilony	_	O	O	_	_	_	_	_
22	promoter	_	O	O	_	_	_	_	_
23	defined	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	deletion	_	O	O	_	_	_	_	_
27	analysis	_	O	O	_	_	_	_	_
28	experiments	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	Figure	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	C	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	36	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	bp	_	O	O	_	_	_	_	_
5	probe	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	shifted	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	tagged	_	O	O	_	_	_	_	_
11	Sox	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	both	_	O	O	_	_	_	_	_
4	c	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	Myc	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	antibodies	_	O	O	_	_	_	_	_
11	supershift	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	band	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	indicating	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	Sox	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	specific	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	rule	_	O	O	_	_	_	_	_
3	out	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	possibility	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	c	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	Myc	_	O	O	_	_	_	_	_
11	tag	_	O	O	_	_	_	_	_
12	itself	_	O	O	_	_	_	_	_
13	binds	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	probe	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	HA	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	tagged	_	O	O	_	_	_	_	_
22	Sox	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	used	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	another	_	O	O	_	_	_	_	_
28	EMSA	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	confirmed	_	O	O	_	_	_	_	_
31	these	_	O	O	_	_	_	_	_
32	results	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	Figure	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	C	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_


1	Next	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	extracts	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	MEL	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	used	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	EMSA	_	O	O	_	_	_	_	_
12	employing	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	same	_	O	O	_	_	_	_	_
15	36	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	bp	_	O	O	_	_	_	_	_
18	probe	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	MEL	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	murine	_	O	O	_	_	_	_	_
6	erythroleukemic	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	line	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	express	_	O	O	_	_	_	_	_
11	adult	_	O	O	_	_	_	_	_
12	beta	_	O	O	_	_	_	_	_
13	globins	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	epsilony	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	33	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	directly	_	O	O	_	_	_	_	_
4	binds	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	sequence	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	MEL	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	Figure	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	intact	_	O	O	_	_	_	_	_
3	consensus	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	sites	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	DNA	_	O	O	_	_	_	_	_
13	probe	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	required	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	binding	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	shown	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	competition	_	O	O	_	_	_	_	_
25	assay	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	Figure	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	E	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Ablation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	putative	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	sites	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	M	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	M	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	abolish	_	O	O	_	_	_	_	_
18	their	_	O	O	_	_	_	_	_
19	ability	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	compete	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	EMSA	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Figure	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	E	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	M	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	mutant	_	O	O	_	_	_	_	_
5	probe	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	compete	_	O	O	_	_	_	_	_
8	partially	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	WT	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	functional	_	O	O	_	_	_	_	_
5	significance	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	intact	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	Sox	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	epsilony	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	reporter	_	O	O	_	_	_	_	_
20	constructs	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	mutagenized	_	O	O	_	_	_	_	_
23	Sox	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	Sox	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	sites	_	O	O	_	_	_	_	_
29	were	_	O	O	_	_	_	_	_
30	co	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	transfected	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	Sox	_	O	O	_	_	_	_	_
36	6	_	O	O	_	_	_	_	_
37	overexpression	_	O	O	_	_	_	_	_
38	vector	_	O	O	_	_	_	_	_
39	into	_	O	O	_	_	_	_	_
40	GM	_	O	O	_	_	_	_	_
41	979	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	EMSA	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	mutant	_	O	O	_	_	_	_	_
9	epsilony	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	reporter	_	O	O	_	_	_	_	_
12	constructs	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	either	_	O	O	_	_	_	_	_
16	one	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	Sox	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	Sox	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	sites	_	O	O	_	_	_	_	_
25	mutagenized	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	do	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	result	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	significant	_	O	O	_	_	_	_	_
32	promoter	_	O	O	_	_	_	_	_
33	repression	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	transfection	_	O	O	_	_	_	_	_
36	studies	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	Figure	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	F	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	both	_	O	O	_	_	_	_	_
4	sites	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	required	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	maximal	_	O	O	_	_	_	_	_
9	repression	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	epsilony	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	Sox	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	but	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	same	_	O	O	_	_	_	_	_
21	degree	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	tested	_	O	O	_	_	_	_	_
4	whether	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	binds	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	epsilony	_	O	O	_	_	_	_	_
11	promoter	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	vivo	_	O	O	_	_	_	_	_
14	using	_	O	O	_	_	_	_	_
15	chromatin	_	O	O	_	_	_	_	_
16	immunoprecipitation	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	ChIP	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Figure	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Sox	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	containing	_	O	O	_	_	_	_	_
6	complex	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	immunoprecipitated	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	MEL	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	liver	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	15	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	dpc	_	O	O	_	_	_	_	_
21	WT	_	O	O	_	_	_	_	_
22	mice	_	O	O	_	_	_	_	_
23	using	_	O	O	_	_	_	_	_
24	Sox	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	antibody	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Figure	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	shows	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	epsilony	_	O	O	_	_	_	_	_
7	proximal	_	O	O	_	_	_	_	_
8	promoter	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	readily	_	O	O	_	_	_	_	_
11	immunoprecipitated	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	Sox	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	antibody	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	both	_	O	O	_	_	_	_	_
18	MEL	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	liver	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Normal	_	O	O	_	_	_	_	_
2	IgG	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	used	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	negative	_	O	O	_	_	_	_	_
8	control	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Figure	_	O	O	_	_	_	_	_
11	4	_	O	O	_	_	_	_	_
12	A	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	above	_	O	O	_	_	_	_	_
3	data	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	Figures	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	clearly	_	O	O	_	_	_	_	_
11	indicate	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	Sox	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	acts	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	repressor	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	epsilony	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	directly	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	epsilony	_	O	O	_	_	_	_	_
29	promoter	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	probably	_	O	O	_	_	_	_	_
32	as	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	dimer	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_



1	STAT	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	implicated	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	pathogenesis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Active	_	O	O	_	_	_	_	_
2	STAT	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	constitutively	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	synovial	_	O	O	_	_	_	_	_
9	fluid	_	O	O	_	_	_	_	_
10	mononuclear	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	patients	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	36	_	O	O	_	_	_	_	_
17	]	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	major	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	activating	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	present	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	synovial	_	O	O	_	_	_	_	_
15	fluid	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	which	_	O	O	_	_	_	_	_
18	has	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	crucial	_	O	O	_	_	_	_	_
21	role	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	monocyte	_	O	O	_	_	_	_	_
27	functions	_	O	O	_	_	_	_	_
28	such	_	O	O	_	_	_	_	_
29	as	_	O	O	_	_	_	_	_
30	gene	_	O	O	_	_	_	_	_
31	expression	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	Fc	_	O	O	_	_	_	_	_
35	gamma	_	O	O	_	_	_	_	_
36	receptor	_	O	O	_	_	_	_	_
37	type	_	O	O	_	_	_	_	_
38	I	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	type	_	O	O	_	_	_	_	_
41	III	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	HLA	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	DR	_	O	O	_	_	_	_	_
47	[	_	O	O	_	_	_	_	_
48	31	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	More	_	O	O	_	_	_	_	_
2	recently	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	high	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	activated	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	thought	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	mainly	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	6	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	have	_	O	O	_	_	_	_	_
22	been	_	O	O	_	_	_	_	_
23	detected	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	ST	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	STAT	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	has	_	O	O	_	_	_	_	_
33	been	_	O	O	_	_	_	_	_
34	shown	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	be	_	O	O	_	_	_	_	_
37	involved	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	synovial	_	O	O	_	_	_	_	_
40	fibroblast	_	O	O	_	_	_	_	_
41	proliferation	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	6	_	O	O	_	_	_	_	_
46	production	_	O	O	_	_	_	_	_
47	[	_	O	O	_	_	_	_	_
48	37	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	regard	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	critical	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	survival	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	expansion	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	growth	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	dependent	_	O	O	_	_	_	_	_
19	synovial	_	O	O	_	_	_	_	_
20	fibroblasts	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	38	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	significance	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	persistent	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	signaling	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	Th	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dominated	_	O	O	_	_	_	_	_
17	autoimmune	_	O	O	_	_	_	_	_
18	arthritis	_	O	O	_	_	_	_	_
19	has	_	O	O	_	_	_	_	_
20	been	_	O	O	_	_	_	_	_
21	suggested	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	studies	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	gp	_	O	O	_	_	_	_	_
27	130	_	O	O	_	_	_	_	_
28	F	_	O	O	_	_	_	_	_
29	759	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	F	_	O	O	_	_	_	_	_
32	759	_	O	O	_	_	_	_	_
33	mice	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	which	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	Src	_	O	O	_	_	_	_	_
39	homology	_	O	O	_	_	_	_	_
40	phosphatase	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	binding	_	O	O	_	_	_	_	_
44	site	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	gp	_	O	O	_	_	_	_	_
47	130	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	transmembrane	_	O	O	_	_	_	_	_
51	glycoprotein	_	O	O	_	_	_	_	_
52	beta	_	O	O	_	_	_	_	_
53	subunit	_	O	O	_	_	_	_	_
54	of	_	O	O	_	_	_	_	_
55	the	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	6	_	O	O	_	_	_	_	_
59	family	_	O	O	_	_	_	_	_
60	cytokine	_	O	O	_	_	_	_	_
61	receptor	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	tyrosine	_	O	O	_	_	_	_	_
65	759	_	O	O	_	_	_	_	_
66	,	_	O	O	_	_	_	_	_
67	was	_	O	O	_	_	_	_	_
68	mutated	_	O	O	_	_	_	_	_
69	to	_	O	O	_	_	_	_	_
70	phenylalanine	_	O	O	_	_	_	_	_
71	[	_	O	O	_	_	_	_	_
72	39	_	O	O	_	_	_	_	_
73	]	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	gp	_	O	O	_	_	_	_	_
4	130	_	O	O	_	_	_	_	_
5	F	_	O	O	_	_	_	_	_
6	759	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	F	_	O	O	_	_	_	_	_
9	759	_	O	O	_	_	_	_	_
10	mice	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	particularly	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	subset	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	chronically	_	O	O	_	_	_	_	_
27	activated	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	resistant	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	induced	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	death	_	O	O	_	_	_	_	_
36	through	_	O	O	_	_	_	_	_
37	gp	_	O	O	_	_	_	_	_
38	130	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	mediated	_	O	O	_	_	_	_	_
41	STAT	_	O	O	_	_	_	_	_
42	3	_	O	O	_	_	_	_	_
43	activation	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	longevity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cytokine	_	O	O	_	_	_	_	_
5	signals	_	O	O	_	_	_	_	_
6	transduced	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	JAK	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	pathway	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	regulated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	SOCS	_	O	O	_	_	_	_	_
18	family	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	7	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	patients	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	active	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	expressed	_	O	O	_	_	_	_	_
15	higher	_	O	O	_	_	_	_	_
16	levels	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	SOCS	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	but	_	O	O	_	_	_	_	_
22	lower	_	O	O	_	_	_	_	_
23	levels	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	SOCS	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	compared	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	normal	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	+	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	SOCS	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	prevents	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	JAK	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	directly	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	JAK	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	SOCS	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	inhibits	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	action	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	JAK	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	Src	_	O	O	_	_	_	_	_
26	homology	_	O	O	_	_	_	_	_
27	phosphatase	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	binding	_	O	O	_	_	_	_	_
32	domain	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	receptors	_	O	O	_	_	_	_	_
35	such	_	O	O	_	_	_	_	_
36	as	_	O	O	_	_	_	_	_
37	gp	_	O	O	_	_	_	_	_
38	130	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	40	_	O	O	_	_	_	_	_
41	]	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	SOCS	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	various	_	O	O	_	_	_	_	_
10	cytokines	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	including	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	6	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	mediators	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	negative	_	O	O	_	_	_	_	_
25	feedback	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	crosstalk	_	O	O	_	_	_	_	_
28	inhibition	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	7	_	O	O	_	_	_	_	_
31	]	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Recent	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	mice	_	O	O	_	_	_	_	_
5	lacking	_	O	O	_	_	_	_	_
6	SOCS	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	or	_	O	O	_	_	_	_	_
9	SOCS	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	revealed	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	SOCS	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	negative	_	O	O	_	_	_	_	_
18	regulator	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	signaling	_	O	O	_	_	_	_	_
24	but	_	O	O	_	_	_	_	_
25	not	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	signaling	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Studies	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	conditional	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	deficient	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	have	_	O	O	_	_	_	_	_
10	shown	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	SOCS	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	deficiency	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	but	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	SOCS	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	deficiency	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	results	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	sustained	_	O	O	_	_	_	_	_
25	activation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	STAT	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	response	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	6	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	8	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	41	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	deficient	_	O	O	_	_	_	_	_
8	macrophages	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	indicated	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	SOCS	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	crucial	_	O	O	_	_	_	_	_
17	inhibitor	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	transcriptional	_	O	O	_	_	_	_	_
26	response	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	42	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	SOCS	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	dispensable	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	both	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	negative	_	O	O	_	_	_	_	_
11	feedback	_	O	O	_	_	_	_	_
12	inhibition	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	immunoregulatory	_	O	O	_	_	_	_	_
16	action	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	macrophages	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	41	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	SOCS	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	directly	_	O	O	_	_	_	_	_
11	inhibit	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	mediated	_	O	O	_	_	_	_	_
17	signaling	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	43	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Increased	_	O	O	_	_	_	_	_
2	SOCS	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	therefore	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	associated	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	both	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	impaired	_	O	O	_	_	_	_	_
20	responsiveness	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	10	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	mediated	_	O	O	_	_	_	_	_
32	STAT	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	activation	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	defective	_	O	O	_	_	_	_	_
38	SOCS	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	expression	_	O	O	_	_	_	_	_
41	may	_	O	O	_	_	_	_	_
42	be	_	O	O	_	_	_	_	_
43	responsible	_	O	O	_	_	_	_	_
44	for	_	O	O	_	_	_	_	_
45	persistent	_	O	O	_	_	_	_	_
46	STAT	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	activation	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	response	_	O	O	_	_	_	_	_
51	to	_	O	O	_	_	_	_	_
52	serum	_	O	O	_	_	_	_	_
53	IL	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	6	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_


1	There	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	possibility	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	SOCS	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	induction	_	O	O	_	_	_	_	_
9	may	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	associated	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	ability	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	produce	_	O	O	_	_	_	_	_
23	IFN	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	gamma	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	because	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	4	_	O	O	_	_	_	_	_
30	+	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	from	_	O	O	_	_	_	_	_
34	active	_	O	O	_	_	_	_	_
35	RA	_	O	O	_	_	_	_	_
36	could	_	O	O	_	_	_	_	_
37	produce	_	O	O	_	_	_	_	_
38	high	_	O	O	_	_	_	_	_
39	levels	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	IFN	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	gamma	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	presence	_	O	O	_	_	_	_	_
47	of	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	10	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	because	_	O	O	_	_	_	_	_
54	IFN	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	gamma	_	O	O	_	_	_	_	_
57	has	_	O	O	_	_	_	_	_
58	been	_	O	O	_	_	_	_	_
59	known	_	O	O	_	_	_	_	_
60	as	_	O	O	_	_	_	_	_
61	a	_	O	O	_	_	_	_	_
62	potent	_	O	O	_	_	_	_	_
63	inducer	_	O	O	_	_	_	_	_
64	of	_	O	O	_	_	_	_	_
65	SOCS	_	O	O	_	_	_	_	_
66	1	_	O	O	_	_	_	_	_
67	[	_	O	O	_	_	_	_	_
68	32	_	O	O	_	_	_	_	_
69	]	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	interest	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	regard	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	indicate	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	polarized	_	O	O	_	_	_	_	_
12	Th	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	Th	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	express	_	O	O	_	_	_	_	_
19	high	_	O	O	_	_	_	_	_
20	levels	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	SOCS	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	SOCS	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	mRNA	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	respectively	_	O	O	_	_	_	_	_
30	[	_	O	O	_	_	_	_	_
31	44	_	O	O	_	_	_	_	_
32	]	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	12	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	STAT	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	inhibited	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	SOCS	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	induction	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	Th	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	whereas	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	induced	_	O	O	_	_	_	_	_
26	STAT	_	O	O	_	_	_	_	_
27	6	_	O	O	_	_	_	_	_
28	signaling	_	O	O	_	_	_	_	_
29	is	_	O	O	_	_	_	_	_
30	diminished	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	SOCS	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	induction	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	Th	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	SOCS	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	thus	_	O	O	_	_	_	_	_
8	have	_	O	O	_	_	_	_	_
9	important	_	O	O	_	_	_	_	_
10	roles	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	Th	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	specific	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	Th	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	specific	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	mutually	_	O	O	_	_	_	_	_
23	exclusive	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	cross	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	talk	_	O	O	_	_	_	_	_
28	repressors	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	4	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	STAT	_	O	O	_	_	_	_	_
36	6	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	12	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	STAT	_	O	O	_	_	_	_	_
44	4	_	O	O	_	_	_	_	_
45	signaling	_	O	O	_	_	_	_	_
46	pathways	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	respectively	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	notion	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	PB	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	patients	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	allergic	_	O	O	_	_	_	_	_
13	diseases	_	O	O	_	_	_	_	_
14	significantly	_	O	O	_	_	_	_	_
15	express	_	O	O	_	_	_	_	_
16	high	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	SOCS	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	transcripts	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	SOCS	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	correlates	_	O	O	_	_	_	_	_
29	well	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	serum	_	O	O	_	_	_	_	_
32	IgE	_	O	O	_	_	_	_	_
33	levels	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	disease	_	O	O	_	_	_	_	_
36	pathology	_	O	O	_	_	_	_	_
37	[	_	O	O	_	_	_	_	_
38	45	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Higher	_	O	O	_	_	_	_	_
2	SOCS	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	lower	_	O	O	_	_	_	_	_
7	SOCS	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	PB	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	compared	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	healthy	_	O	O	_	_	_	_	_
24	controls	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	therefore	_	O	O	_	_	_	_	_
28	probably	_	O	O	_	_	_	_	_
29	consistent	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	their	_	O	O	_	_	_	_	_
32	systemic	_	O	O	_	_	_	_	_
33	bias	_	O	O	_	_	_	_	_
34	towards	_	O	O	_	_	_	_	_
35	a	_	O	O	_	_	_	_	_
36	Th	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	phenotype	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	as	_	O	O	_	_	_	_	_
41	has	_	O	O	_	_	_	_	_
42	previously	_	O	O	_	_	_	_	_
43	been	_	O	O	_	_	_	_	_
44	demonstrated	_	O	O	_	_	_	_	_
45	[	_	O	O	_	_	_	_	_
46	46	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	49	_	O	O	_	_	_	_	_
49	]	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_



1	Genes	_	O	O	_	_	_	_	_
2	that	_	O	O	_	_	_	_	_
3	regulate	_	O	O	_	_	_	_	_
4	interleukin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	immunomodulatory	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	which	_	O	O	_	_	_	_	_
9	plays	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	central	_	O	O	_	_	_	_	_
12	role	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	regulation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	allergic	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	atopic	_	O	O	_	_	_	_	_
20	immune	_	O	O	_	_	_	_	_
21	responses	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Significant	_	O	O	_	_	_	_	_
2	progress	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	made	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	gaining	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	detailed	_	O	O	_	_	_	_	_
10	understanding	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	transcriptional	_	O	O	_	_	_	_	_
14	regulation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	interleukin	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	gene	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	recent	_	O	O	_	_	_	_	_
3	identification	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	characterization	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	several	_	O	O	_	_	_	_	_
8	key	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factors	_	O	O	_	_	_	_	_
11	has	_	O	O	_	_	_	_	_
12	helped	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	elucidate	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	molecular	_	O	O	_	_	_	_	_
17	mechanisms	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	helper	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	cytokine	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	MDS	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	EVI	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	enhances	_	O	O	_	_	_	_	_
7	TGF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	signaling	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	strengthens	_	O	O	_	_	_	_	_
14	its	_	O	O	_	_	_	_	_
15	growth	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	inhibitory	_	O	O	_	_	_	_	_
18	effect	_	O	O	_	_	_	_	_
19	but	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	leukemia	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	associated	_	O	O	_	_	_	_	_
24	fusion	_	O	O	_	_	_	_	_
25	protein	_	O	O	_	_	_	_	_
26	AML	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	MDS	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	EVI	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	product	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	t	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	;	_	O	O	_	_	_	_	_
42	21	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	abrogates	_	O	O	_	_	_	_	_
46	growth	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	inhibition	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	response	_	O	O	_	_	_	_	_
51	to	_	O	O	_	_	_	_	_
52	TGF	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	beta	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_


1	MDS	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	EVI	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	located	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	chromosome	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	band	_	O	O	_	_	_	_	_
12	q	_	O	O	_	_	_	_	_
13	26	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	encodes	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	zinc	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	finger	_	O	O	_	_	_	_	_
20	DNA	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	transcription	_	O	O	_	_	_	_	_
24	activator	_	O	O	_	_	_	_	_
25	not	_	O	O	_	_	_	_	_
26	detected	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	normal	_	O	O	_	_	_	_	_
29	hematopoietic	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	but	_	O	O	_	_	_	_	_
32	expressed	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	several	_	O	O	_	_	_	_	_
35	normal	_	O	O	_	_	_	_	_
36	tissues	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	MDS	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	EVI	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	inappropriately	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	myeloid	_	O	O	_	_	_	_	_
11	leukemias	_	O	O	_	_	_	_	_
12	following	_	O	O	_	_	_	_	_
13	chromosomal	_	O	O	_	_	_	_	_
14	rearrangements	_	O	O	_	_	_	_	_
15	involving	_	O	O	_	_	_	_	_
16	band	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	q	_	O	O	_	_	_	_	_
19	26	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	rearrangements	_	O	O	_	_	_	_	_
3	lead	_	O	O	_	_	_	_	_
4	either	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	truncation	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	repressor	_	O	O	_	_	_	_	_
16	EVI	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	seen	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	t	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	;	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	q	_	O	O	_	_	_	_	_
31	21	_	O	O	_	_	_	_	_
32	;	_	O	O	_	_	_	_	_
33	q	_	O	O	_	_	_	_	_
34	26	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	inv	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	q	_	O	O	_	_	_	_	_
43	21	_	O	O	_	_	_	_	_
44	q	_	O	O	_	_	_	_	_
45	26	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	or	_	O	O	_	_	_	_	_
49	to	_	O	O	_	_	_	_	_
50	gene	_	O	O	_	_	_	_	_
51	fusion	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	as	_	O	O	_	_	_	_	_
54	seen	_	O	O	_	_	_	_	_
55	in	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	t	_	O	O	_	_	_	_	_
58	(	_	O	O	_	_	_	_	_
59	3	_	O	O	_	_	_	_	_
60	;	_	O	O	_	_	_	_	_
61	21	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	(	_	O	O	_	_	_	_	_
64	q	_	O	O	_	_	_	_	_
65	26	_	O	O	_	_	_	_	_
66	;	_	O	O	_	_	_	_	_
67	q	_	O	O	_	_	_	_	_
68	22	_	O	O	_	_	_	_	_
69	)	_	O	O	_	_	_	_	_
70	which	_	O	O	_	_	_	_	_
71	results	_	O	O	_	_	_	_	_
72	in	_	O	O	_	_	_	_	_
73	the	_	O	O	_	_	_	_	_
74	fusion	_	O	O	_	_	_	_	_
75	protein	_	O	O	_	_	_	_	_
76	AML	_	O	O	_	_	_	_	_
77	1	_	O	O	_	_	_	_	_
78	/	_	O	O	_	_	_	_	_
79	MDS	_	O	O	_	_	_	_	_
80	1	_	O	O	_	_	_	_	_
81	/	_	O	O	_	_	_	_	_
82	EVI	_	O	O	_	_	_	_	_
83	1	_	O	O	_	_	_	_	_
84	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	fusion	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	contains	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	domain	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	AML	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	fused	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	frame	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	entire	_	O	O	_	_	_	_	_
23	MDS	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	EVI	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	exclusion	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	its	_	O	O	_	_	_	_	_
33	first	_	O	O	_	_	_	_	_
34	12	_	O	O	_	_	_	_	_
35	amino	_	O	O	_	_	_	_	_
36	acids	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	analyzed	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	response	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	hematopoietic	_	O	O	_	_	_	_	_
13	precursor	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	line	_	O	O	_	_	_	_	_
16	32	_	O	O	_	_	_	_	_
17	Dcl	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	expressing	_	O	O	_	_	_	_	_
21	either	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	normal	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	MDS	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	EVI	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	fusion	_	O	O	_	_	_	_	_
33	protein	_	O	O	_	_	_	_	_
34	AML	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	MDS	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	EVI	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	factors	_	O	O	_	_	_	_	_
45	that	_	O	O	_	_	_	_	_
46	control	_	O	O	_	_	_	_	_
47	cell	_	O	O	_	_	_	_	_
48	differentiation	_	O	O	_	_	_	_	_
49	or	_	O	O	_	_	_	_	_
50	cell	_	O	O	_	_	_	_	_
51	replication	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	32	_	O	O	_	_	_	_	_
3	Dcl	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	growth	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	they	_	O	O	_	_	_	_	_
16	differentiate	_	O	O	_	_	_	_	_
17	into	_	O	O	_	_	_	_	_
18	granulocytes	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	exposed	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	G	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	CSF	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	They	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	growth	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	inhibited	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	TGF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	whereas	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	MDS	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	EVI	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	no	_	O	O	_	_	_	_	_
15	effect	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	granulocytic	_	O	O	_	_	_	_	_
18	differentiation	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	G	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	CSF	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	AML	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	MDS	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	EVI	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	blocks	_	O	O	_	_	_	_	_
36	differentiation	_	O	O	_	_	_	_	_
37	resulting	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	death	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	similar	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	previously	_	O	O	_	_	_	_	_
8	described	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	others	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	32	_	O	O	_	_	_	_	_
13	Dcl	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	express	_	O	O	_	_	_	_	_
18	transgenic	_	O	O	_	_	_	_	_
19	Evil	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	whereas	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	fusion	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	AML	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	MDS	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	EVI	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	completely	_	O	O	_	_	_	_	_
22	abrogates	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	growth	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	inhibitory	_	O	O	_	_	_	_	_
27	effect	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	TGF	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	beta	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	allows	_	O	O	_	_	_	_	_
35	32	_	O	O	_	_	_	_	_
36	Dcl	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	proliferate	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	expression	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	normal	_	O	O	_	_	_	_	_
46	protein	_	O	O	_	_	_	_	_
47	MDS	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	/	_	O	O	_	_	_	_	_
50	EVI	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	has	_	O	O	_	_	_	_	_
53	the	_	O	O	_	_	_	_	_
54	opposite	_	O	O	_	_	_	_	_
55	effect	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	and	_	O	O	_	_	_	_	_
58	it	_	O	O	_	_	_	_	_
59	strengthens	_	O	O	_	_	_	_	_
60	the	_	O	O	_	_	_	_	_
61	response	_	O	O	_	_	_	_	_
62	of	_	O	O	_	_	_	_	_
63	cells	_	O	O	_	_	_	_	_
64	to	_	O	O	_	_	_	_	_
65	the	_	O	O	_	_	_	_	_
66	growth	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	inhibitory	_	O	O	_	_	_	_	_
69	effect	_	O	O	_	_	_	_	_
70	of	_	O	O	_	_	_	_	_
71	TGF	_	O	O	_	_	_	_	_
72	-	_	O	O	_	_	_	_	_
73	beta	_	O	O	_	_	_	_	_
74	1	_	O	O	_	_	_	_	_
75	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	yeast	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	hybrid	_	O	O	_	_	_	_	_
8	system	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	we	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	show	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	EVI	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	contained	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	its	_	O	O	_	_	_	_	_
20	entirety	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	MDS	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	EVI	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	AML	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	MDS	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	EVI	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	physically	_	O	O	_	_	_	_	_
38	interacts	_	O	O	_	_	_	_	_
39	with	_	O	O	_	_	_	_	_
40	SMAD	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	which	_	O	O	_	_	_	_	_
44	is	_	O	O	_	_	_	_	_
45	an	_	O	O	_	_	_	_	_
46	intracellular	_	O	O	_	_	_	_	_
47	mediator	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	TGF	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	beta	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	signaling	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	correlated	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	response	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	G	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	CSF	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	TGF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	beta	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	ability	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	normal	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	fusion	_	O	O	_	_	_	_	_
28	proteins	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	activate	_	O	O	_	_	_	_	_
31	or	_	O	O	_	_	_	_	_
32	repress	_	O	O	_	_	_	_	_
33	promoters	_	O	O	_	_	_	_	_
34	which	_	O	O	_	_	_	_	_
35	they	_	O	O	_	_	_	_	_
36	can	_	O	O	_	_	_	_	_
37	directly	_	O	O	_	_	_	_	_
38	regulate	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	binding	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	promoter	_	O	O	_	_	_	_	_
44	site	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	propose	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	mutations	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	MDS	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	EVI	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	either	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	truncation	_	O	O	_	_	_	_	_
15	resulting	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	repressor	_	O	O	_	_	_	_	_
20	EVI	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	fusion	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	AML	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	lead	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	an	_	O	O	_	_	_	_	_
32	altered	_	O	O	_	_	_	_	_
33	cellular	_	O	O	_	_	_	_	_
34	response	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	growth	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	differentiation	_	O	O	_	_	_	_	_
39	factors	_	O	O	_	_	_	_	_
40	that	_	O	O	_	_	_	_	_
41	could	_	O	O	_	_	_	_	_
42	result	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	leukemic	_	O	O	_	_	_	_	_
45	transformation	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	different	_	O	O	_	_	_	_	_
3	response	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	myeloid	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	ectopically	_	O	O	_	_	_	_	_
8	expressing	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	normal	_	O	O	_	_	_	_	_
11	or	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	fusion	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	G	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	CSF	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	TGF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	beta	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	could	_	O	O	_	_	_	_	_
25	depend	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	different	_	O	O	_	_	_	_	_
29	transactivation	_	O	O	_	_	_	_	_
30	properties	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	these	_	O	O	_	_	_	_	_
33	proteins	_	O	O	_	_	_	_	_
34	resulting	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	divergent	_	O	O	_	_	_	_	_
37	expression	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	downstream	_	O	O	_	_	_	_	_
40	genes	_	O	O	_	_	_	_	_
41	regulated	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	two	_	O	O	_	_	_	_	_
45	proteins	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_


1	Selective	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	interleukin	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	stimulated	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	molecules	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	monocytes	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	It	_	O	O	_	_	_	_	_
2	has	_	O	O	_	_	_	_	_
3	been	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	interferon	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	gamma	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	IFN	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	gamma	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	interleukin	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	10	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	have	_	O	O	_	_	_	_	_
24	various	_	O	O	_	_	_	_	_
25	reverse	_	O	O	_	_	_	_	_
26	effects	_	O	O	_	_	_	_	_
27	on	_	O	O	_	_	_	_	_
28	macrophages	_	O	O	_	_	_	_	_
29	;	_	O	O	_	_	_	_	_
30	however	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	molecular	_	O	O	_	_	_	_	_
34	mechanism	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	this	_	O	O	_	_	_	_	_
37	difference	_	O	O	_	_	_	_	_
38	has	_	O	O	_	_	_	_	_
39	not	_	O	O	_	_	_	_	_
40	been	_	O	O	_	_	_	_	_
41	fully	_	O	O	_	_	_	_	_
42	understood	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	analyzed	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IFN	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	activated	_	O	O	_	_	_	_	_
21	STAT	_	O	O	_	_	_	_	_
22	molecules	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	two	_	O	O	_	_	_	_	_
25	kinds	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	GAS	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	motif	_	O	O	_	_	_	_	_
30	sequences	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	activated	_	O	O	_	_	_	_	_
6	STAT	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	could	_	O	O	_	_	_	_	_
9	bind	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	GAS	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	motif	_	O	O	_	_	_	_	_
15	sequence	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	region	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Fcgamma	_	O	O	_	_	_	_	_
23	receptor	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	but	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	promoter	_	O	O	_	_	_	_	_
32	region	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	COX	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	gene	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	whereas	_	O	O	_	_	_	_	_
41	IFN	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	gamma	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	activated	_	O	O	_	_	_	_	_
46	STAT	_	O	O	_	_	_	_	_
47	1	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	STAT	_	O	O	_	_	_	_	_
50	5	_	O	O	_	_	_	_	_
51	could	_	O	O	_	_	_	_	_
52	bind	_	O	O	_	_	_	_	_
53	to	_	O	O	_	_	_	_	_
54	both	_	O	O	_	_	_	_	_
55	sequences	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	inhibited	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	gamma	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	without	_	O	O	_	_	_	_	_
13	newly	_	O	O	_	_	_	_	_
14	synthesized	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	further	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	aspirin	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	but	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	dexamethasone	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	suppressed	_	O	O	_	_	_	_	_
12	IFN	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	gamma	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	suggest	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	has	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	specificity	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	GAS	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	motif	_	O	O	_	_	_	_	_
25	sequences	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	whereas	_	O	O	_	_	_	_	_
28	IFN	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	gamma	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	activated	_	O	O	_	_	_	_	_
33	STAT	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	STAT	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	have	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	broader	_	O	O	_	_	_	_	_
41	spectrum	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	binding	_	O	O	_	_	_	_	_
44	to	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	GAS	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	motif	_	O	O	_	_	_	_	_
49	sequences	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	may	_	O	O	_	_	_	_	_
3	explain	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	difference	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	IFN	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	biological	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	inhibitory	_	O	O	_	_	_	_	_
21	effect	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	10	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	IFN	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	gamma	_	O	O	_	_	_	_	_
30	activities	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Plasmid	_	O	O	_	_	_	_	_
2	construction	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	epsilony	_	O	O	_	_	_	_	_
3	promoter	_	O	O	_	_	_	_	_
4	deletion	_	O	O	_	_	_	_	_
5	reporter	_	O	O	_	_	_	_	_
6	plasmid	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	E	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	luc	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	generated	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	PCR	_	O	O	_	_	_	_	_
16	amplification	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	epsilony	_	O	O	_	_	_	_	_
20	proximal	_	O	O	_	_	_	_	_
21	promoter	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kb	_	O	O	_	_	_	_	_
7	fragment	_	O	O	_	_	_	_	_
8	upstream	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	epsilony	_	O	O	_	_	_	_	_
12	globin	_	O	O	_	_	_	_	_
13	initiation	_	O	O	_	_	_	_	_
14	codon	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	ATG	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	used	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	because	_	O	O	_	_	_	_	_
22	it	_	O	O	_	_	_	_	_
23	has	_	O	O	_	_	_	_	_
24	been	_	O	O	_	_	_	_	_
25	shown	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	all	_	O	O	_	_	_	_	_
28	sequences	_	O	O	_	_	_	_	_
29	required	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	epsilon	_	O	O	_	_	_	_	_
32	gene	_	O	O	_	_	_	_	_
33	silencing	_	O	O	_	_	_	_	_
34	are	_	O	O	_	_	_	_	_
35	located	_	O	O	_	_	_	_	_
36	within	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	7	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	kb	_	O	O	_	_	_	_	_
43	EcoRI	_	O	O	_	_	_	_	_
44	fragment	_	O	O	_	_	_	_	_
45	containing	_	O	O	_	_	_	_	_
46	about	_	O	O	_	_	_	_	_
47	2	_	O	O	_	_	_	_	_
48	kb	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	sequence	_	O	O	_	_	_	_	_
51	upstream	_	O	O	_	_	_	_	_
52	of	_	O	O	_	_	_	_	_
53	the	_	O	O	_	_	_	_	_
54	epsilon	_	O	O	_	_	_	_	_
55	globin	_	O	O	_	_	_	_	_
56	gene	_	O	O	_	_	_	_	_
57	cap	_	O	O	_	_	_	_	_
58	site	_	O	O	_	_	_	_	_
59	[	_	O	O	_	_	_	_	_
60	50	_	O	O	_	_	_	_	_
61	]	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	Nucleotide	_	O	O	_	_	_	_	_
2	numbering	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	relative	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	start	_	O	O	_	_	_	_	_
9	site	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	transcriptional	_	O	O	_	_	_	_	_
3	start	_	O	O	_	_	_	_	_
4	site	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	based	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	longest	_	O	O	_	_	_	_	_
10	cDNA	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Fantom	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	Functional	_	O	O	_	_	_	_	_
16	Annotation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	Mouse	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	database	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	PCR	_	O	O	_	_	_	_	_
3	primers	_	O	O	_	_	_	_	_
4	contained	_	O	O	_	_	_	_	_
5	XhoI	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	HindIII	_	O	O	_	_	_	_	_
8	sites	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	used	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	clone	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	epsilony	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	fragment	_	O	O	_	_	_	_	_
18	upstream	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	firefly	_	O	O	_	_	_	_	_
22	luciferase	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	pGL	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	Basic	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	Promega	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	Madison	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	Wisconsin	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	United	_	O	O	_	_	_	_	_
36	States	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_
4	5	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kb	_	O	O	_	_	_	_	_
7	SstI	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	XhoI	_	O	O	_	_	_	_	_
10	fragment	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	muLCRbeta	_	O	O	_	_	_	_	_
13	9	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	micro	_	O	O	_	_	_	_	_
18	LCR	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	31	_	O	O	_	_	_	_	_
22	])	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	then	_	O	O	_	_	_	_	_
25	inserted	_	O	O	_	_	_	_	_
26	upstream	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	epsilony	_	O	O	_	_	_	_	_
30	promoter	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	above	_	O	O	_	_	_	_	_
34	pGL	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	Basic	_	O	O	_	_	_	_	_
37	plasmid	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	resulting	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	reporter	_	O	O	_	_	_	_	_
43	construct	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	which	_	O	O	_	_	_	_	_
46	luciferase	_	O	O	_	_	_	_	_
47	expression	_	O	O	_	_	_	_	_
48	is	_	O	O	_	_	_	_	_
49	driven	_	O	O	_	_	_	_	_
50	by	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	epsilony	_	O	O	_	_	_	_	_
53	promoter	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	series	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	deletion	_	O	O	_	_	_	_	_
5	constructs	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	generated	_	O	O	_	_	_	_	_
12	similarly	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Forward	_	O	O	_	_	_	_	_
2	primers	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	XhoI	_	O	O	_	_	_	_	_
6	site	_	O	O	_	_	_	_	_
7	include	_	O	O	_	_	_	_	_
8	:	_	O	O	_	_	_	_	_
9	MHB	_	O	O	_	_	_	_	_
10	1457	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	'	_	O	O	_	_	_	_	_
14	CCGCTCGAGTGCTAGGCAAACACTCA	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	'	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2077	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2052	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	;	_	O	O	_	_	_	_	_
25	MHB	_	O	O	_	_	_	_	_
26	1503	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	5	_	O	O	_	_	_	_	_
29	'	_	O	O	_	_	_	_	_
30	CCGCTCGAGTCTCTACACTGTCACTCCCTG	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	'	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	634	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	605	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	;	_	O	O	_	_	_	_	_
41	MHB	_	O	O	_	_	_	_	_
42	1505	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	5	_	O	O	_	_	_	_	_
45	'	_	O	O	_	_	_	_	_
46	CCGCTCGAGGGAGCCAAAAAAAGAATGC	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	'	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	197	_	O	O	_	_	_	_	_
52	to	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	169	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	;	_	O	O	_	_	_	_	_
57	MHB	_	O	O	_	_	_	_	_
58	1506	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	5	_	O	O	_	_	_	_	_
61	'	_	O	O	_	_	_	_	_
62	CCGCTCGAGCTGACCAATGGCTTCAAAG	_	O	O	_	_	_	_	_
63	3	_	O	O	_	_	_	_	_
64	'	_	O	O	_	_	_	_	_
65	(	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	85	_	O	O	_	_	_	_	_
68	to	_	O	O	_	_	_	_	_
69	-	_	O	O	_	_	_	_	_
70	58	_	O	O	_	_	_	_	_
71	)	_	O	O	_	_	_	_	_
72	;	_	O	O	_	_	_	_	_
73	MHB	_	O	O	_	_	_	_	_
74	1532	_	O	O	_	_	_	_	_
75	,	_	O	O	_	_	_	_	_
76	5	_	O	O	_	_	_	_	_
77	'	_	O	O	_	_	_	_	_
78	CCGCTCGAGAATGCAGAACAAAGGGTCAGA	_	O	O	_	_	_	_	_
79	3	_	O	O	_	_	_	_	_
80	'	_	O	O	_	_	_	_	_
81	(	_	O	O	_	_	_	_	_
82	-	_	O	O	_	_	_	_	_
83	63	_	O	O	_	_	_	_	_
84	to	_	O	O	_	_	_	_	_
85	-	_	O	O	_	_	_	_	_
86	34	_	O	O	_	_	_	_	_
87	)	_	O	O	_	_	_	_	_
88	;	_	O	O	_	_	_	_	_
89	and	_	O	O	_	_	_	_	_
90	MHB	_	O	O	_	_	_	_	_
91	1507	_	O	O	_	_	_	_	_
92	,	_	O	O	_	_	_	_	_
93	5	_	O	O	_	_	_	_	_
94	'	_	O	O	_	_	_	_	_
95	CCGCTCGAGGTCTGCGAAGAATAAAAGGC	_	O	O	_	_	_	_	_
96	3	_	O	O	_	_	_	_	_
97	'	_	O	O	_	_	_	_	_
98	(	_	O	O	_	_	_	_	_
99	-	_	O	O	_	_	_	_	_
100	37	_	O	O	_	_	_	_	_
101	to	_	O	O	_	_	_	_	_
102	-	_	O	O	_	_	_	_	_
103	9	_	O	O	_	_	_	_	_
104	)	_	O	O	_	_	_	_	_
105	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	forward	_	O	O	_	_	_	_	_
3	primers	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	used	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	combination	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	reverse	_	O	O	_	_	_	_	_
11	primer	_	O	O	_	_	_	_	_
12	HindIII	_	O	O	_	_	_	_	_
13	site	_	O	O	_	_	_	_	_
14	:	_	O	O	_	_	_	_	_
15	MHB	_	O	O	_	_	_	_	_
16	1477	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	'	_	O	O	_	_	_	_	_
20	CGGAAGCTTGGGAGGTTGCTGGTGA	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	'	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	45	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	+	_	O	O	_	_	_	_	_
28	20	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	pcDNA	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	[	_	O	O	_	_	_	_	_
9	15	_	O	O	_	_	_	_	_
10	]	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	used	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	overexpress	_	O	O	_	_	_	_	_
15	Sox	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	truncated	_	O	O	_	_	_	_	_
3	version	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	overexpression	_	O	O	_	_	_	_	_
9	construct	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Sox	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	DeltaHMG	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	pcDNA	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	lacks	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	HMG	_	O	O	_	_	_	_	_
25	domain	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	generated	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	as	_	O	O	_	_	_	_	_
30	described	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	others	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	32	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Mutagenesis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	/	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	consensus	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	sites	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	epsilony	_	O	O	_	_	_	_	_
13	promoter	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	done	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	PCR	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Forward	_	O	O	_	_	_	_	_
2	primers	_	O	O	_	_	_	_	_
3	used	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	generate	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	mutagenized	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	promoter	_	O	O	_	_	_	_	_
10	reporter	_	O	O	_	_	_	_	_
11	constructs	_	O	O	_	_	_	_	_
12	include	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	MHB	_	O	O	_	_	_	_	_
15	1661	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	5	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	CCGCTCGAGAATGCAGTGCCAAGGGTCAGAACATTGTCTGCGAAG	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	'	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	63	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	19	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	;	_	O	O	_	_	_	_	_
30	MHB	_	O	O	_	_	_	_	_
31	1662	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	5	_	O	O	_	_	_	_	_
34	'	_	O	O	_	_	_	_	_
35	CCGCTCGAGAATGCAGAACAAAGGGTCAGATGAGTGTCTGCGAAGAA	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	'	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	63	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	16	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	;	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	MHB	_	O	O	_	_	_	_	_
48	1663	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	5	_	O	O	_	_	_	_	_
51	'	_	O	O	_	_	_	_	_
52	CCGCTCGAGAATGCATGCCAAGGGTCAGATGAGTGTCTGCGAAGAA	_	O	O	_	_	_	_	_
53	3	_	O	O	_	_	_	_	_
54	'	_	O	O	_	_	_	_	_
55	(	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	63	_	O	O	_	_	_	_	_
58	to	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	18	_	O	O	_	_	_	_	_
61	)	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_



1	Decreased	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	ratio	_	O	O	_	_	_	_	_
12	following	_	O	O	_	_	_	_	_
13	GP	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	TSST	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	when	_	O	O	_	_	_	_	_
19	compared	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	TSST	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Time	_	O	O	_	_	_	_	_
2	course	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	48	_	O	O	_	_	_	_	_
5	h	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	beta	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	ratio	_	O	O	_	_	_	_	_
19	following	_	O	O	_	_	_	_	_
20	incubation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	PBMC	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	TSST	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	GP	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	LPS	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	GP	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	LPS	_	O	O	_	_	_	_	_
38	calc	_	O	O	_	_	_	_	_
39	.,	_	O	O	_	_	_	_	_
40	GP	_	O	O	_	_	_	_	_
41	+	_	O	O	_	_	_	_	_
42	TSST	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	or	_	O	O	_	_	_	_	_
46	GP	_	O	O	_	_	_	_	_
47	/	_	O	O	_	_	_	_	_
48	TSST	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	calc	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	LPS	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	GP	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	LPS	_	O	O	_	_	_	_	_
6	treatments	_	O	O	_	_	_	_	_
7	resulted	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	generating	_	O	O	_	_	_	_	_
10	more	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	than	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	up	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	24	_	O	O	_	_	_	_	_
23	h	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	comparing	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	or	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	LPS	_	O	O	_	_	_	_	_
8	calc	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	vs	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	LPS	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	did	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	find	_	O	O	_	_	_	_	_
9	significant	_	O	O	_	_	_	_	_
10	alterations	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	ratio	_	O	O	_	_	_	_	_
23	over	_	O	O	_	_	_	_	_
24	48	_	O	O	_	_	_	_	_
25	h	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	With	_	O	O	_	_	_	_	_
2	respect	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	GP	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	TSST	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	calc	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	vs	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	observed	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	pronounced	_	O	O	_	_	_	_	_
11	anti	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	inflammatory	_	O	O	_	_	_	_	_
14	action	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	GP	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	demonstrated	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	about	_	O	O	_	_	_	_	_
23	10	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	100	_	O	O	_	_	_	_	_
26	fold	_	O	O	_	_	_	_	_
27	reduced	_	O	O	_	_	_	_	_
28	ratio	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	18	_	O	O	_	_	_	_	_
31	h	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	24	_	O	O	_	_	_	_	_
34	h	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	i	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_
38	e	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	a	_	O	O	_	_	_	_	_
2	higher	_	O	O	_	_	_	_	_
3	production	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	than	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	*	_	O	O	_	_	_	_	_
17	=	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	<	_	O	O	_	_	_	_	_
20	0	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	05	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Data	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	shown	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	mean	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	SEM	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	n	_	O	O	_	_	_	_	_
12	=	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_



1	Temperature	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	down	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	regulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	peripheral	_	O	O	_	_	_	_	_
13	blood	_	O	O	_	_	_	_	_
14	mononuclear	_	O	O	_	_	_	_	_
15	leucocyte	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	sepsis	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	septic	_	O	O	_	_	_	_	_
22	shock	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	OBJECTIVE	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Activation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	hypothalamic	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	pituitary	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	adrenal	_	O	O	_	_	_	_	_
11	axis	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	vital	_	O	O	_	_	_	_	_
15	importance	_	O	O	_	_	_	_	_
16	during	_	O	O	_	_	_	_	_
17	critical	_	O	O	_	_	_	_	_
18	illness	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	studied	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	adaptive	_	O	O	_	_	_	_	_
6	mechanisms	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	occur	_	O	O	_	_	_	_	_
9	at	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	level	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	glucocorticoid	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	glucocorticoid	_	O	O	_	_	_	_	_
18	target	_	O	O	_	_	_	_	_
19	tissues	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	sepsis	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	septic	_	O	O	_	_	_	_	_
26	shock	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	DESIGN	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	hypercortisolaemia	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	hyperthermia	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	cellular	_	O	O	_	_	_	_	_
11	composition	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	number	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	glucocorticoid	_	O	O	_	_	_	_	_
16	receptors	_	O	O	_	_	_	_	_
17	per	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	their	_	O	O	_	_	_	_	_
21	affinity	_	O	O	_	_	_	_	_
22	were	_	O	O	_	_	_	_	_
23	evaluated	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	both	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vitro	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	vivo	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	peripheral	_	O	O	_	_	_	_	_
34	blood	_	O	O	_	_	_	_	_
35	mononuclear	_	O	O	_	_	_	_	_
36	leucocytes	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	control	_	O	O	_	_	_	_	_
39	subjects	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	patients	_	O	O	_	_	_	_	_
43	with	_	O	O	_	_	_	_	_
44	sepsis	_	O	O	_	_	_	_	_
45	or	_	O	O	_	_	_	_	_
46	septic	_	O	O	_	_	_	_	_
47	shock	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	SUBJECTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Fifteen	_	O	O	_	_	_	_	_
4	patients	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	age	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	79	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	sepsis	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	septic	_	O	O	_	_	_	_	_
15	shock	_	O	O	_	_	_	_	_
16	who	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	admitted	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	intensive	_	O	O	_	_	_	_	_
22	care	_	O	O	_	_	_	_	_
23	unit	_	O	O	_	_	_	_	_
24	were	_	O	O	_	_	_	_	_
25	studied	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	control	_	O	O	_	_	_	_	_
3	group	_	O	O	_	_	_	_	_
4	consisted	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	24	_	O	O	_	_	_	_	_
7	healthy	_	O	O	_	_	_	_	_
8	laboratory	_	O	O	_	_	_	_	_
9	employees	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	MEASUREMENTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	capacity	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	affinity	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	glucocorticoid	_	O	O	_	_	_	_	_
11	receptors	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	measured	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	compared	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	clinical	_	O	O	_	_	_	_	_
18	data	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	plasma	_	O	O	_	_	_	_	_
22	cortisol	_	O	O	_	_	_	_	_
23	concentrations	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Hypercortisolaemia	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	vitro	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	resulted	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	decreased	_	O	O	_	_	_	_	_
12	affinity	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	decreased	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	capacity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	glucocorticoid	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	vitro	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	hyperthermia	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	well	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	variations	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cellular	_	O	O	_	_	_	_	_
12	composition	_	O	O	_	_	_	_	_
13	did	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	influence	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	glucocorticoid	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	vivo	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	there	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	no	_	O	O	_	_	_	_	_
7	change	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	number	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	receptors	_	O	O	_	_	_	_	_
13	per	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	sepsis	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	septic	_	O	O	_	_	_	_	_
21	shock	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	compared	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	healthy	_	O	O	_	_	_	_	_
26	controls	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	decreased	_	O	O	_	_	_	_	_
5	affinity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	observed	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	weak	_	O	O	_	_	_	_	_
5	but	_	O	O	_	_	_	_	_
6	significant	_	O	O	_	_	_	_	_
7	negative	_	O	O	_	_	_	_	_
8	correlation	_	O	O	_	_	_	_	_
9	between	_	O	O	_	_	_	_	_
10	body	_	O	O	_	_	_	_	_
11	temperature	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	number	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	glucocorticoid	_	O	O	_	_	_	_	_
17	receptors	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	patient	_	O	O	_	_	_	_	_
21	group	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	relation	_	O	O	_	_	_	_	_
5	between	_	O	O	_	_	_	_	_
6	circulating	_	O	O	_	_	_	_	_
7	cortisol	_	O	O	_	_	_	_	_
8	concentrations	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	glucocorticoid	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	affinity	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	number	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	There	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	no	_	O	O	_	_	_	_	_
6	obvious	_	O	O	_	_	_	_	_
7	regulation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	number	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	glucocorticoid	_	O	O	_	_	_	_	_
13	receptors	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	plasma	_	O	O	_	_	_	_	_
16	cortisol	_	O	O	_	_	_	_	_
17	concentrations	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	vivo	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	decreased	_	O	O	_	_	_	_	_
3	affinity	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	together	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	negative	_	O	O	_	_	_	_	_
12	correlation	_	O	O	_	_	_	_	_
13	between	_	O	O	_	_	_	_	_
14	hyperthermia	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	number	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	glucocorticoid	_	O	O	_	_	_	_	_
20	receptors	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	patients	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	sepsis	_	O	O	_	_	_	_	_
25	or	_	O	O	_	_	_	_	_
26	septic	_	O	O	_	_	_	_	_
27	shock	_	O	O	_	_	_	_	_
28	suggest	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	hypothalamic	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	pituitary	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	adrenal	_	O	O	_	_	_	_	_
35	axis	_	O	O	_	_	_	_	_
36	activation	_	O	O	_	_	_	_	_
37	during	_	O	O	_	_	_	_	_
38	critical	_	O	O	_	_	_	_	_
39	illness	_	O	O	_	_	_	_	_
40	is	_	O	O	_	_	_	_	_
41	accompanied	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	peripheral	_	O	O	_	_	_	_	_
44	adaptation	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	glucocorticoid	_	O	O	_	_	_	_	_
47	receptor	_	O	O	_	_	_	_	_
48	number	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	affinity	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Nonradioactive	_	O	O	_	_	_	_	_
2	quantification	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	glucocorticoid	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	differentiation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	monocytic	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	U	_	O	O	_	_	_	_	_
15	937	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	describe	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	method	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	relative	_	O	O	_	_	_	_	_
7	quantification	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	specific	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	using	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	nonradioactive	_	O	O	_	_	_	_	_
14	assay	_	O	O	_	_	_	_	_
15	based	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	DNA	_	O	O	_	_	_	_	_
18	strand	_	O	O	_	_	_	_	_
19	competition	_	O	O	_	_	_	_	_
20	between	_	O	O	_	_	_	_	_
21	identical	_	O	O	_	_	_	_	_
22	sequences	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	biotin	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	fluorescein	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	labeled	_	O	O	_	_	_	_	_
30	amplicon	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	probe	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	unlabeled	_	O	O	_	_	_	_	_
36	amplicon	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	target	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	during	_	O	O	_	_	_	_	_
41	hybridization	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	target	_	O	O	_	_	_	_	_
4	quantity	_	O	O	_	_	_	_	_
5	increased	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	double	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	labeled	_	O	O	_	_	_	_	_
13	probe	_	O	O	_	_	_	_	_
14	decreased	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	accordance	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	mass	_	O	O	_	_	_	_	_
20	action	_	O	O	_	_	_	_	_
21	law	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	technique	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	successfully	_	O	O	_	_	_	_	_
5	applied	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	evaluate	_	O	O	_	_	_	_	_
8	differences	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	glucocorticoid	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	U	_	O	O	_	_	_	_	_
15	937	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	before	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	after	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	addition	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	potent	_	O	O	_	_	_	_	_
24	differentiation	_	O	O	_	_	_	_	_
25	inducers	_	O	O	_	_	_	_	_
26	:	_	O	O	_	_	_	_	_
27	12	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	O	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	tetradecanoylphorbol	_	O	O	_	_	_	_	_
32	13	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	acetate	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	TPA	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	combination	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	all	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	trans	_	O	O	_	_	_	_	_
45	retinoic	_	O	O	_	_	_	_	_
46	acid	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	RA	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	25	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	dihydroxyvitamin	_	O	O	_	_	_	_	_
56	D	_	O	O	_	_	_	_	_
57	2	_	O	O	_	_	_	_	_
58	(	_	O	O	_	_	_	_	_
59	VD	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	observed	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	TPA	_	O	O	_	_	_	_	_
5	treatment	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	associated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	increase	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	H	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	dexamethasone	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	up	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	regulation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	GR	_	O	O	_	_	_	_	_
26	mRNA	_	O	O	_	_	_	_	_
27	while	_	O	O	_	_	_	_	_
28	no	_	O	O	_	_	_	_	_
29	enhanced	_	O	O	_	_	_	_	_
30	GR	_	O	O	_	_	_	_	_
31	expression	_	O	O	_	_	_	_	_
32	was	_	O	O	_	_	_	_	_
33	perceived	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	RA	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	VD	_	O	O	_	_	_	_	_
38	treatment	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Accession	_	O	O	_	_	_	_	_
2	Numbers	_	O	O	_	_	_	_	_

1	Accession	_	O	O	_	_	_	_	_
2	numbers	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	genes	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	products	_	O	O	_	_	_	_	_
9	discussed	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	this	_	O	O	_	_	_	_	_
12	paper	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	betaH	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	globin	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	GenBank	_	O	O	_	_	_	_	_
19	NM	_	O	O	_	_	_	_	_
20	_	_	O	O	_	_	_	_	_
21	008219	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	betamaj	_	O	O	_	_	_	_	_
25	globin	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	J	_	O	O	_	_	_	_	_
28	00413	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	situ	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	betamaj	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	min	_	O	O	_	_	_	_	_
38	globin	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	NM	_	O	O	_	_	_	_	_
41	_	_	O	O	_	_	_	_	_
42	008220	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	real	_	O	O	_	_	_	_	_
46	time	_	O	O	_	_	_	_	_
47	PCR	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	epsilony	_	O	O	_	_	_	_	_
51	globin	_	O	O	_	_	_	_	_
52	cDNA	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	NM	_	O	O	_	_	_	_	_
55	_	_	O	O	_	_	_	_	_
56	008221	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	from	_	O	O	_	_	_	_	_
59	the	_	O	O	_	_	_	_	_
60	Fantom	_	O	O	_	_	_	_	_
61	(	_	O	O	_	_	_	_	_
62	Functional	_	O	O	_	_	_	_	_
63	Annotation	_	O	O	_	_	_	_	_
64	of	_	O	O	_	_	_	_	_
65	Mouse	_	O	O	_	_	_	_	_
66	)	_	O	O	_	_	_	_	_
67	database	_	O	O	_	_	_	_	_
68	(	_	O	O	_	_	_	_	_
69	http	_	O	O	_	_	_	_	_
70	://	_	O	O	_	_	_	_	_
71	fantom	_	O	O	_	_	_	_	_
72	2	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_
74	gsc	_	O	O	_	_	_	_	_
75	.	_	O	O	_	_	_	_	_
76	riken	_	O	O	_	_	_	_	_
77	.	_	O	O	_	_	_	_	_
78	jp	_	O	O	_	_	_	_	_
79	)	_	O	O	_	_	_	_	_
80	,	_	O	O	_	_	_	_	_
81	zeta	_	O	O	_	_	_	_	_
82	globin	_	O	O	_	_	_	_	_
83	(	_	O	O	_	_	_	_	_
84	GenBank	_	O	O	_	_	_	_	_
85	NM	_	O	O	_	_	_	_	_
86	_	_	O	O	_	_	_	_	_
87	010405	_	O	O	_	_	_	_	_
88	)	_	O	O	_	_	_	_	_
89	,	_	O	O	_	_	_	_	_
90	and	_	O	O	_	_	_	_	_
91	mouse	_	O	O	_	_	_	_	_
92	Sox	_	O	O	_	_	_	_	_
93	6	_	O	O	_	_	_	_	_
94	(	_	O	O	_	_	_	_	_
95	U	_	O	O	_	_	_	_	_
96	32614	_	O	O	_	_	_	_	_
97	)	_	O	O	_	_	_	_	_
98	.	_	O	O	_	_	_	_	_



1	A	_	O	O	_	_	_	_	_
2	newly	_	O	O	_	_	_	_	_
3	established	_	O	O	_	_	_	_	_
4	megakaryoblastic	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	erythroid	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	line	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	differentiates	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	red	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	presence	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	erythropoietin	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	produces	_	O	O	_	_	_	_	_
21	platelet	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	like	_	O	O	_	_	_	_	_
24	particles	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	August	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	1992	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	established	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	leukemic	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	line	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	NS	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Meg	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	patient	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	megakaryoblastic	_	O	O	_	_	_	_	_
22	transformation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	Philadelphia	_	O	O	_	_	_	_	_
25	chromosome	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	positive	_	O	O	_	_	_	_	_
28	chronic	_	O	O	_	_	_	_	_
29	myeloid	_	O	O	_	_	_	_	_
30	leukemia	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	NS	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Meg	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	positive	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	naphthyl	_	O	O	_	_	_	_	_
12	acetate	_	O	O	_	_	_	_	_
13	esterase	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	periodic	_	O	O	_	_	_	_	_
16	acid	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	Schiff	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	PAS	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	staining	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	surface	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	7	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	13	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	34	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	CD	_	O	O	_	_	_	_	_
39	41	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	glycophorin	_	O	O	_	_	_	_	_
44	A	_	O	O	_	_	_	_	_
45	antigens	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Ultrastructurally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	had	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	granules	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	demarcation	_	O	O	_	_	_	_	_
11	membranes	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	platelet	_	O	O	_	_	_	_	_
15	peroxidase	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	NS	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Meg	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	spontaneously	_	O	O	_	_	_	_	_
7	produced	_	O	O	_	_	_	_	_
8	platelet	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	like	_	O	O	_	_	_	_	_
11	particles	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	contained	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	granules	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	mitochondria	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	dense	_	O	O	_	_	_	_	_
21	bodies	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	strongly	_	O	O	_	_	_	_	_
24	suggesting	_	O	O	_	_	_	_	_
25	platelet	_	O	O	_	_	_	_	_
26	production	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Erythropoietin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Epo	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	granulocyte	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	macrophage	_	O	O	_	_	_	_	_
9	colony	_	O	O	_	_	_	_	_
10	stimulating	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	GM	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	CSF	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	interleukin	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	promoted	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	growth	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	NS	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	Meg	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Phorbol	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	12	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	myristate	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	13	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	acetate	_	O	O	_	_	_	_	_
10	increased	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	41	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	61	_	O	O	_	_	_	_	_
21	antigens	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Ten	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	day	_	O	O	_	_	_	_	_
4	exposure	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	Epo	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	mature	_	O	O	_	_	_	_	_
9	erythroblasts	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	red	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	benzidine	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	positive	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	positive	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	hemoglobin	_	O	O	_	_	_	_	_
10	F	_	O	O	_	_	_	_	_
11	staining	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Untreated	_	O	O	_	_	_	_	_
2	NS	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Meg	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	Epo	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	EpoR	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	GATA	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	alpha	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	alpha	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	gamma	_	O	O	_	_	_	_	_
30	globin	_	O	O	_	_	_	_	_
31	genes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	NS	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Meg	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	undergo	_	O	O	_	_	_	_	_
10	terminal	_	O	O	_	_	_	_	_
11	differentiation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	megakaryocytic	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	lineages	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	line	_	O	O	_	_	_	_	_
4	should	_	O	O	_	_	_	_	_
5	be	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	very	_	O	O	_	_	_	_	_
8	useful	_	O	O	_	_	_	_	_
9	tool	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	investigation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	megakaryocytic	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	erythroid	_	O	O	_	_	_	_	_
18	maturation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Evidence	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	normal	_	O	O	_	_	_	_	_
4	vitamin	_	O	O	_	_	_	_	_
5	D	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	messenger	_	O	O	_	_	_	_	_
8	ribonucleic	_	O	O	_	_	_	_	_
9	acid	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	genotype	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	absorptive	_	O	O	_	_	_	_	_
14	hypercalciuria	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Absorptive	_	O	O	_	_	_	_	_
2	hypercalciuria	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	stone	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	forming	_	O	O	_	_	_	_	_
8	condition	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	characterized	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	gut	_	O	O	_	_	_	_	_
14	hyperabsorption	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	calcium	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	hypercalciuria	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	reduced	_	O	O	_	_	_	_	_
22	bone	_	O	O	_	_	_	_	_
23	density	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Inasmuch	_	O	O	_	_	_	_	_
2	as	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	features	_	O	O	_	_	_	_	_
5	implicate	_	O	O	_	_	_	_	_
6	enhanced	_	O	O	_	_	_	_	_
7	calcitriol	_	O	O	_	_	_	_	_
8	action	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	gut	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	bone	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	we	_	O	O	_	_	_	_	_
15	analyzed	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	vitamin	_	O	O	_	_	_	_	_
18	D	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	VDR	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	ascertain	_	O	O	_	_	_	_	_
26	whether	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	abnormality	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	this	_	O	O	_	_	_	_	_
31	gene	_	O	O	_	_	_	_	_
32	marks	_	O	O	_	_	_	_	_
33	patients	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	intestinal	_	O	O	_	_	_	_	_
36	hyperabsorption	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	calcium	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	compared	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	frequency	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	restriction	_	O	O	_	_	_	_	_
9	fragment	_	O	O	_	_	_	_	_
10	length	_	O	O	_	_	_	_	_
11	polymorphism	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	Bsm	_	O	O	_	_	_	_	_
14	I	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	associated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	different	_	O	O	_	_	_	_	_
19	alleles	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	VDR	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	group	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	33	_	O	O	_	_	_	_	_
29	well	_	O	O	_	_	_	_	_
30	characterized	_	O	O	_	_	_	_	_
31	absorptive	_	O	O	_	_	_	_	_
32	hypercalciuric	_	O	O	_	_	_	_	_
33	patients	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	a	_	O	O	_	_	_	_	_
36	group	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	36	_	O	O	_	_	_	_	_
39	normal	_	O	O	_	_	_	_	_
40	race	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	age	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	matched	_	O	O	_	_	_	_	_
46	control	_	O	O	_	_	_	_	_
47	subjects	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	difference	_	O	O	_	_	_	_	_
5	between	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	distribution	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	VDR	_	O	O	_	_	_	_	_
11	alleles	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	patient	_	O	O	_	_	_	_	_
15	population	_	O	O	_	_	_	_	_
16	when	_	O	O	_	_	_	_	_
17	compared	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	normal	_	O	O	_	_	_	_	_
21	population	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	coding	_	O	O	_	_	_	_	_
3	region	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	VDR	_	O	O	_	_	_	_	_
6	messenger	_	O	O	_	_	_	_	_
7	RNA	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	normal	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	determined	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	both	_	O	O	_	_	_	_	_
16	DNA	_	O	O	_	_	_	_	_
17	sequence	_	O	O	_	_	_	_	_
18	analysis	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	chemical	_	O	O	_	_	_	_	_
21	mismatch	_	O	O	_	_	_	_	_
22	cleavage	_	O	O	_	_	_	_	_
23	analysis	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	copy	_	O	O	_	_	_	_	_
26	DNA	_	O	O	_	_	_	_	_
27	from	_	O	O	_	_	_	_	_
28	11	_	O	O	_	_	_	_	_
29	index	_	O	O	_	_	_	_	_
30	absorptive	_	O	O	_	_	_	_	_
31	hypercalciuric	_	O	O	_	_	_	_	_
32	patients	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	basis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	these	_	O	O	_	_	_	_	_
6	results	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	propose	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	enhanced	_	O	O	_	_	_	_	_
13	intestinal	_	O	O	_	_	_	_	_
14	calcium	_	O	O	_	_	_	_	_
15	absorption	_	O	O	_	_	_	_	_
16	invariably	_	O	O	_	_	_	_	_
17	seen	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	absorptive	_	O	O	_	_	_	_	_
20	hypercalciuria	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	attendant	_	O	O	_	_	_	_	_
23	symptoms	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	this	_	O	O	_	_	_	_	_
26	disorder	_	O	O	_	_	_	_	_
27	are	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	attributable	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	mutations	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	VDR	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	are	_	O	O	_	_	_	_	_
37	not	_	O	O	_	_	_	_	_
38	linked	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	common	_	O	O	_	_	_	_	_
42	VDR	_	O	O	_	_	_	_	_
43	genotype	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	Isolation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	human	_	O	O	_	_	_	_	_
4	PBMC	_	O	O	_	_	_	_	_

1	Buffy	_	O	O	_	_	_	_	_
2	coats	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	obtained	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	healthy	_	O	O	_	_	_	_	_
7	blood	_	O	O	_	_	_	_	_
8	donors	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	compliance	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Helsinki	_	O	O	_	_	_	_	_
14	declaration	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	approval	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	ethics	_	O	O	_	_	_	_	_
22	committee	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	University	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	Luebeck	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	buffy	_	O	O	_	_	_	_	_
3	coats	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	separated	_	O	O	_	_	_	_	_
6	over	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	Ficoll	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	Hypaque	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	Biochrom	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	Berlin	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	Germany	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	gradient	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	54	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	55	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	isolation	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	PBMC	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	cultured	_	O	O	_	_	_	_	_
7	at	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	final	_	O	O	_	_	_	_	_
10	concentration	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	x	_	O	O	_	_	_	_	_
14	106	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	ml	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	ELISA	_	O	O	_	_	_	_	_
21	measurements	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	5	_	O	O	_	_	_	_	_
25	x	_	O	O	_	_	_	_	_
26	106	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	ml	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	gel	_	O	O	_	_	_	_	_
32	shifts	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	x	_	O	O	_	_	_	_	_
37	106	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	ml	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	flow	_	O	O	_	_	_	_	_
44	cytometry	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	RPMI	_	O	O	_	_	_	_	_
48	1640	_	O	O	_	_	_	_	_
49	medium	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	BioWhittaker	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	Heidelberg	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	Germany	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	LPS	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	free	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	containing	_	O	O	_	_	_	_	_
63	10	_	O	O	_	_	_	_	_
64	%	_	O	O	_	_	_	_	_
65	heat	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	inactivated	_	O	O	_	_	_	_	_
68	fetal	_	O	O	_	_	_	_	_
69	calf	_	O	O	_	_	_	_	_
70	serum	_	O	O	_	_	_	_	_
71	(	_	O	O	_	_	_	_	_
72	FCS	_	O	O	_	_	_	_	_
73	,	_	O	O	_	_	_	_	_
74	low	_	O	O	_	_	_	_	_
75	-	_	O	O	_	_	_	_	_
76	LPS	_	O	O	_	_	_	_	_
77	,	_	O	O	_	_	_	_	_
78	Invitrogen	_	O	O	_	_	_	_	_
79	,	_	O	O	_	_	_	_	_
80	Karlsruhe	_	O	O	_	_	_	_	_
81	,	_	O	O	_	_	_	_	_
82	Germany	_	O	O	_	_	_	_	_
83	)	_	O	O	_	_	_	_	_
84	,	_	O	O	_	_	_	_	_
85	1	_	O	O	_	_	_	_	_
86	%	_	O	O	_	_	_	_	_
87	penicillin	_	O	O	_	_	_	_	_
88	(	_	O	O	_	_	_	_	_
89	10000	_	O	O	_	_	_	_	_
90	U	_	O	O	_	_	_	_	_
91	/	_	O	O	_	_	_	_	_
92	ml	_	O	O	_	_	_	_	_
93	)	_	O	O	_	_	_	_	_
94	,	_	O	O	_	_	_	_	_
95	1	_	O	O	_	_	_	_	_
96	%	_	O	O	_	_	_	_	_
97	streptomycin	_	O	O	_	_	_	_	_
98	(	_	O	O	_	_	_	_	_
99	10000	_	O	O	_	_	_	_	_
100	mug	_	O	O	_	_	_	_	_
101	/	_	O	O	_	_	_	_	_
102	ml	_	O	O	_	_	_	_	_
103	)	_	O	O	_	_	_	_	_
104	,	_	O	O	_	_	_	_	_
105	and	_	O	O	_	_	_	_	_
106	1	_	O	O	_	_	_	_	_
107	%	_	O	O	_	_	_	_	_
108	200	_	O	O	_	_	_	_	_
109	mM	_	O	O	_	_	_	_	_
110	L	_	O	O	_	_	_	_	_
111	-	_	O	O	_	_	_	_	_
112	glutamine	_	O	O	_	_	_	_	_
113	(	_	O	O	_	_	_	_	_
114	BioWhittaker	_	O	O	_	_	_	_	_
115	)	_	O	O	_	_	_	_	_
116	.	_	O	O	_	_	_	_	_



1	A	_	O	O	_	_	_	_	_
2	role	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	RanBP	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	release	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	CRM	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	nuclear	_	O	O	_	_	_	_	_
15	pore	_	O	O	_	_	_	_	_
16	complex	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	terminal	_	O	O	_	_	_	_	_
20	step	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	nuclear	_	O	O	_	_	_	_	_
23	export	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	recently	_	O	O	_	_	_	_	_
3	developed	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	assay	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	export	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	shuttling	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	NFAT	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	nuclear	_	O	O	_	_	_	_	_
18	factor	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	activated	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	can	_	O	O	_	_	_	_	_
25	be	_	O	O	_	_	_	_	_
26	reconstituted	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	permeabilized	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	GTPase	_	O	O	_	_	_	_	_
33	Ran	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	nuclear	_	O	O	_	_	_	_	_
37	export	_	O	O	_	_	_	_	_
38	receptor	_	O	O	_	_	_	_	_
39	CRM	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	now	_	O	O	_	_	_	_	_
4	used	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	assay	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	identify	_	O	O	_	_	_	_	_
9	another	_	O	O	_	_	_	_	_
10	export	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	preincubation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	permeabilized	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	Ran	_	O	O	_	_	_	_	_
9	mutant	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	cannot	_	O	O	_	_	_	_	_
12	hydrolyze	_	O	O	_	_	_	_	_
13	GTP	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	RanQ	_	O	O	_	_	_	_	_
16	69	_	O	O	_	_	_	_	_
17	L	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	cytosol	_	O	O	_	_	_	_	_
21	supports	_	O	O	_	_	_	_	_
22	NFAT	_	O	O	_	_	_	_	_
23	export	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	but	_	O	O	_	_	_	_	_
26	CRM	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	Ran	_	O	O	_	_	_	_	_
30	alone	_	O	O	_	_	_	_	_
31	do	_	O	O	_	_	_	_	_
32	not	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	RanQ	_	O	O	_	_	_	_	_
3	69	_	O	O	_	_	_	_	_
4	L	_	O	O	_	_	_	_	_
5	preincubation	_	O	O	_	_	_	_	_
6	leads	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	accumulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	CRM	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	cytoplasmic	_	O	O	_	_	_	_	_
15	periphery	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	pore	_	O	O	_	_	_	_	_
20	complex	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	NPC	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	association	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	62	_	O	O	_	_	_	_	_
30	complex	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	Can	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	Nup	_	O	O	_	_	_	_	_
35	214	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	RanGTP	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	dependent	_	O	O	_	_	_	_	_
4	association	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	CRM	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	these	_	O	O	_	_	_	_	_
10	nucleoporins	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	reconstituted	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	vitro	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	biochemical	_	O	O	_	_	_	_	_
3	fractionation	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	reconstitution	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	showed	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	RanBP	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	restores	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	export	_	O	O	_	_	_	_	_
15	after	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	RanQ	_	O	O	_	_	_	_	_
18	69	_	O	O	_	_	_	_	_
19	L	_	O	O	_	_	_	_	_
20	preincubation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	stimulates	_	O	O	_	_	_	_	_
4	nuclear	_	O	O	_	_	_	_	_
5	export	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	have	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	preincubated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	RanQ	_	O	O	_	_	_	_	_
15	69	_	O	O	_	_	_	_	_
16	L	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	RanBP	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	as	_	O	O	_	_	_	_	_
4	well	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	Ran	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	domains	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	cytoplasmic	_	O	O	_	_	_	_	_
13	nucleoporin	_	O	O	_	_	_	_	_
14	RanBP	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	promote	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	release	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	CRM	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	NPC	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	RanGTP	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	important	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	targeting	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	export	_	O	O	_	_	_	_	_
16	complexes	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	cytoplasmic	_	O	O	_	_	_	_	_
20	side	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	NPC	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	RanBP	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	probably	_	O	O	_	_	_	_	_
30	RanBP	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	are	_	O	O	_	_	_	_	_
33	involved	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	dissociation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	nuclear	_	O	O	_	_	_	_	_
39	export	_	O	O	_	_	_	_	_
40	complexes	_	O	O	_	_	_	_	_
41	from	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	NPC	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	a	_	O	O	_	_	_	_	_
46	terminal	_	O	O	_	_	_	_	_
47	step	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	transport	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Ah	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	recognizes	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	sites	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	BSAP	_	O	O	_	_	_	_	_
16	:	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	possible	_	O	O	_	_	_	_	_
19	mechanism	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	dioxin	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	alteration	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	19	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	human	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	lymphocytes	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	2	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	7	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	8	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	tetrachlorodibenzo	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dioxin	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	TCDD	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	inhibits	_	O	O	_	_	_	_	_
18	murine	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	lymphocyte	_	O	O	_	_	_	_	_
23	immunoglobulin	_	O	O	_	_	_	_	_
24	production	_	O	O	_	_	_	_	_
25	through	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	unknown	_	O	O	_	_	_	_	_
28	mechanism	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	investigated	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	effect	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	TCDD	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	19	_	O	O	_	_	_	_	_
14	gene	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	lymphocyte	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	line	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	TCDD	_	O	O	_	_	_	_	_
7	treatment	_	O	O	_	_	_	_	_
8	decreased	_	O	O	_	_	_	_	_
9	steady	_	O	O	_	_	_	_	_
10	state	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	19	_	O	O	_	_	_	_	_
15	mRNA	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	67	_	O	O	_	_	_	_	_
18	%	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	IM	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	9	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	line	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	gel	_	O	O	_	_	_	_	_
4	mobility	_	O	O	_	_	_	_	_
5	shift	_	O	O	_	_	_	_	_
6	assay	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	identified	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	DNA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	complex	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	IM	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	9	_	O	O	_	_	_	_	_
19	nuclear	_	O	O	_	_	_	_	_
20	extracts	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	several	_	O	O	_	_	_	_	_
24	criteria	_	O	O	_	_	_	_	_
25	appears	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	be	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	Ah	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Ah	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	complex	_	O	O	_	_	_	_	_
8	recognized	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	DNA	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	site	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	lineage	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	specific	_	O	O	_	_	_	_	_
19	activator	_	O	O	_	_	_	_	_
20	protein	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	BSAP	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	promoter	_	O	O	_	_	_	_	_
27	region	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	19	_	O	O	_	_	_	_	_
33	gene	_	O	O	_	_	_	_	_
34	which	_	O	O	_	_	_	_	_
35	is	_	O	O	_	_	_	_	_
36	similar	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	consensus	_	O	O	_	_	_	_	_
40	Ah	_	O	O	_	_	_	_	_
41	receptor	_	O	O	_	_	_	_	_
42	DNA	_	O	O	_	_	_	_	_
43	binding	_	O	O	_	_	_	_	_
44	site	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	AhR	_	O	O	_	_	_	_	_
7	could	_	O	O	_	_	_	_	_
8	interfere	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	BSAP	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	stimulated	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	19	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	competition	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	common	_	O	O	_	_	_	_	_
22	DNA	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	site	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Transcription	_	O	O	_	_	_	_	_
2	factors	_	O	O	_	_	_	_	_
3	as	_	O	O	_	_	_	_	_
4	targets	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	oxidative	_	O	O	_	_	_	_	_
7	signalling	_	O	O	_	_	_	_	_
8	during	_	O	O	_	_	_	_	_
9	lymphocyte	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	previously	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	requirement	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	oxidative	_	O	O	_	_	_	_	_
9	events	_	O	O	_	_	_	_	_
10	during	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	cycle	_	O	O	_	_	_	_	_
13	entry	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	have	_	O	O	_	_	_	_	_
19	hypothesised	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	reactive	_	O	O	_	_	_	_	_
22	oxygen	_	O	O	_	_	_	_	_
23	species	_	O	O	_	_	_	_	_
24	may	_	O	O	_	_	_	_	_
25	act	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	intracellular	_	O	O	_	_	_	_	_
28	signalling	_	O	O	_	_	_	_	_
29	agents	_	O	O	_	_	_	_	_
30	during	_	O	O	_	_	_	_	_
31	lymphocyte	_	O	O	_	_	_	_	_
32	activation	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	current	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	cysteamine	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	aminothiol	_	O	O	_	_	_	_	_
10	compound	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	antioxidant	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	has	_	O	O	_	_	_	_	_
16	been	_	O	O	_	_	_	_	_
17	used	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	further	_	O	O	_	_	_	_	_
20	investigate	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	oxidative	_	O	O	_	_	_	_	_
25	signalling	_	O	O	_	_	_	_	_
26	during	_	O	O	_	_	_	_	_
27	lymphocyte	_	O	O	_	_	_	_	_
28	activation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	normal	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	peripheral	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	cysteamine	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	vitro	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	found	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	inhibit	_	O	O	_	_	_	_	_
16	proliferation	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	dose	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	dependent	_	O	O	_	_	_	_	_
22	manner	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	essentially	_	O	O	_	_	_	_	_
26	complete	_	O	O	_	_	_	_	_
27	inhibition	_	O	O	_	_	_	_	_
28	occurring	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	dose	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	400	_	O	O	_	_	_	_	_
34	microM	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	limited	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	first	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	h	_	O	O	_	_	_	_	_
11	after	_	O	O	_	_	_	_	_
12	mitogenic	_	O	O	_	_	_	_	_
13	activation	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	localizing	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	time	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	frame	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	action	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	cysteamine	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	within	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	commitment	_	O	O	_	_	_	_	_
28	period	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	therefore	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	interest	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	establish	_	O	O	_	_	_	_	_
8	which	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	if	_	O	O	_	_	_	_	_
11	any	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	commitment	_	O	O	_	_	_	_	_
14	events	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	affected	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	oxidative	_	O	O	_	_	_	_	_
19	signalling	_	O	O	_	_	_	_	_
20	during	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	cycle	_	O	O	_	_	_	_	_
23	entry	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Taking	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	candidate	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	we	_	O	O	_	_	_	_	_
12	examined	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	effect	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	cysteamine	_	O	O	_	_	_	_	_
17	treatment	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	early	_	O	O	_	_	_	_	_
20	gene	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	during	_	O	O	_	_	_	_	_
23	lymphocyte	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	on	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	activity	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	transcription	_	O	O	_	_	_	_	_
32	factors	_	O	O	_	_	_	_	_
33	AP	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	NF	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	kappa	_	O	O	_	_	_	_	_
40	B	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	NF	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	AT	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	Oct	_	O	O	_	_	_	_	_
47	1	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	whose	_	O	O	_	_	_	_	_
50	functions	_	O	O	_	_	_	_	_
51	are	_	O	O	_	_	_	_	_
52	required	_	O	O	_	_	_	_	_
53	for	_	O	O	_	_	_	_	_
54	expression	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	IL	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	2	_	O	O	_	_	_	_	_
60	mRNA	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	Cysteamine	_	O	O	_	_	_	_	_
2	treatment	_	O	O	_	_	_	_	_
3	inhibited	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	mRNA	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	secretion	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	into	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	culture	_	O	O	_	_	_	_	_
21	medium	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	cysteamine	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	at	_	O	O	_	_	_	_	_
10	least	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	part	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	effect	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	factor	_	O	O	_	_	_	_	_
19	function	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	DNA	_	O	O	_	_	_	_	_
24	binding	_	O	O	_	_	_	_	_
25	activities	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	AP	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	NF	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	kappa	_	O	O	_	_	_	_	_
34	B	_	O	O	_	_	_	_	_
35	extracted	_	O	O	_	_	_	_	_
36	from	_	O	O	_	_	_	_	_
37	mitogen	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	stimulated	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	were	_	O	O	_	_	_	_	_
42	significantly	_	O	O	_	_	_	_	_
43	inhibited	_	O	O	_	_	_	_	_
44	by	_	O	O	_	_	_	_	_
45	cysteamine	_	O	O	_	_	_	_	_
46	treatment	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Oct	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	NF	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	AT	_	O	O	_	_	_	_	_
9	DNA	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	affected	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	cysteamine	_	O	O	_	_	_	_	_
17	treatment	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	suggesting	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	oxidative	_	O	O	_	_	_	_	_
22	signalling	_	O	O	_	_	_	_	_
23	processes	_	O	O	_	_	_	_	_
24	operate	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	selective	_	O	O	_	_	_	_	_
28	manner	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	identification	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	regulatory	_	O	O	_	_	_	_	_
5	proteins	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	such	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	factors	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	molecular	_	O	O	_	_	_	_	_
14	targets	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	oxidative	_	O	O	_	_	_	_	_
17	signalling	_	O	O	_	_	_	_	_
18	provides	_	O	O	_	_	_	_	_
19	further	_	O	O	_	_	_	_	_
20	evidence	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	implicate	_	O	O	_	_	_	_	_
23	oxidative	_	O	O	_	_	_	_	_
24	signalling	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	being	_	O	O	_	_	_	_	_
27	intimately	_	O	O	_	_	_	_	_
28	involved	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	G	_	O	O	_	_	_	_	_
32	0	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	G	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	phase	_	O	O	_	_	_	_	_
37	transition	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	lymphocytes	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	Multiple	_	O	O	_	_	_	_	_
2	proteins	_	O	O	_	_	_	_	_
3	interact	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	inhibitory	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	repressor	_	O	O	_	_	_	_	_
10	element	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	interleukin	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	promoter	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	T	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	interleukin	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	directed	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	positive	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	negative	_	O	O	_	_	_	_	_
18	cis	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	acting	_	O	O	_	_	_	_	_
21	DNA	_	O	O	_	_	_	_	_
22	elements	_	O	O	_	_	_	_	_
23	clustered	_	O	O	_	_	_	_	_
24	within	_	O	O	_	_	_	_	_
25	300	_	O	O	_	_	_	_	_
26	base	_	O	O	_	_	_	_	_
27	pairs	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	transcriptional	_	O	O	_	_	_	_	_
31	start	_	O	O	_	_	_	_	_
32	site	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	strong	_	O	O	_	_	_	_	_
3	repressor	_	O	O	_	_	_	_	_
4	element	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	termed	_	O	O	_	_	_	_	_
7	nuclear	_	O	O	_	_	_	_	_
8	inhibitory	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	NIP	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	previously	_	O	O	_	_	_	_	_
16	mapped	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	segment	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	promoter	_	O	O	_	_	_	_	_
26	between	_	O	O	_	_	_	_	_
27	nucleotides	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	271	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	250	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Functional	_	O	O	_	_	_	_	_
2	characterization	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	element	_	O	O	_	_	_	_	_
6	demonstrates	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	it	_	O	O	_	_	_	_	_
9	can	_	O	O	_	_	_	_	_
10	mediate	_	O	O	_	_	_	_	_
11	repression	_	O	O	_	_	_	_	_
12	when	_	O	O	_	_	_	_	_
13	linked	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	cis	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	heterologous	_	O	O	_	_	_	_	_
19	promoter	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	DNA	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	carried	_	O	O	_	_	_	_	_
6	out	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	characterize	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	repressor	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	varying	_	O	O	_	_	_	_	_
3	conditions	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	three	_	O	O	_	_	_	_	_
6	distinct	_	O	O	_	_	_	_	_
7	complexes	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	shown	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	interact	_	O	O	_	_	_	_	_
12	specifically	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	NIP	_	O	O	_	_	_	_	_
16	region	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	although	_	O	O	_	_	_	_	_
19	only	_	O	O	_	_	_	_	_
20	one	_	O	O	_	_	_	_	_
21	correlates	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	repressor	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Complex	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	ubiquitous	_	O	O	_	_	_	_	_
9	polypeptide	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	recognizes	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	'	_	O	O	_	_	_	_	_
15	portion	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	this	_	O	O	_	_	_	_	_
18	sequence	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	required	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	repression	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Complex	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	corresponds	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	upstream	_	O	O	_	_	_	_	_
11	stimulatory	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	E	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	box	_	O	O	_	_	_	_	_
19	motif	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	5	_	O	O	_	_	_	_	_
23	'	_	O	O	_	_	_	_	_
24	portion	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	NIP	_	O	O	_	_	_	_	_
28	region	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	DNA	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	specificity	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	complex	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	overlaps	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	upstream	_	O	O	_	_	_	_	_
12	stimulatory	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	clearly	_	O	O	_	_	_	_	_
17	distinct	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	which	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	latter	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	complexes	_	O	O	_	_	_	_	_
9	represents	_	O	O	_	_	_	_	_
10	NIP	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	we	_	O	O	_	_	_	_	_
14	incorporated	_	O	O	_	_	_	_	_
15	small	_	O	O	_	_	_	_	_
16	alterations	_	O	O	_	_	_	_	_
17	into	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	NIP	_	O	O	_	_	_	_	_
20	site	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	an	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	promoter	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	linked	_	O	O	_	_	_	_	_
29	reporter	_	O	O	_	_	_	_	_
30	construct	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	examined	_	O	O	_	_	_	_	_
33	their	_	O	O	_	_	_	_	_
34	effects	_	O	O	_	_	_	_	_
35	on	_	O	O	_	_	_	_	_
36	NIP	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	mediated	_	O	O	_	_	_	_	_
39	repression	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Functional	_	O	O	_	_	_	_	_
2	specificity	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	repression	_	O	O	_	_	_	_	_
5	matches	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	specificity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	complex	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	;	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	repressor	_	O	O	_	_	_	_	_
16	activity	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	complex	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	require	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	consensus	_	O	O	_	_	_	_	_
24	sequence	_	O	O	_	_	_	_	_
25	CTCACNTNC	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	[	_	O	O	_	_	_	_	_
2	Effect	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	regimen	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	kidney	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	tonifying	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	qi	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	invigorating	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	aging	_	O	O	_	_	_	_	_
16	changes	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	glucocorticoid	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	plasma	_	O	O	_	_	_	_	_
3	cortisol	_	O	O	_	_	_	_	_
4	concentration	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	sites	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	GCR	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	peripheral	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	measured	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	32	_	O	O	_	_	_	_	_
22	healthy	_	O	O	_	_	_	_	_
23	aged	_	O	O	_	_	_	_	_
24	persons	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	13	_	O	O	_	_	_	_	_
27	young	_	O	O	_	_	_	_	_
28	adults	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	animal	_	O	O	_	_	_	_	_
3	experiment	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	GCR	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	spleen	_	O	O	_	_	_	_	_
8	lymphocytic	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	measured	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	18	_	O	O	_	_	_	_	_
15	aged	_	O	O	_	_	_	_	_
16	rats	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	9	_	O	O	_	_	_	_	_
19	young	_	O	O	_	_	_	_	_
20	rats	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	showed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	GCR	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	significantly	_	O	O	_	_	_	_	_
8	lower	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	aged	_	O	O	_	_	_	_	_
12	persons	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	rats	_	O	O	_	_	_	_	_
15	than	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	young	_	O	O	_	_	_	_	_
20	while	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	plasma	_	O	O	_	_	_	_	_
23	cortisol	_	O	O	_	_	_	_	_
24	level	_	O	O	_	_	_	_	_
25	didn	_	O	O	_	_	_	_	_
26	'	_	O	O	_	_	_	_	_
27	t	_	O	O	_	_	_	_	_
28	change	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	aging	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	So	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	think	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	GCR	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	more	_	O	O	_	_	_	_	_
8	sensitive	_	O	O	_	_	_	_	_
9	than	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	plasma	_	O	O	_	_	_	_	_
12	cortisol	_	O	O	_	_	_	_	_
13	level	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	reflect	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	aging	_	O	O	_	_	_	_	_
18	change	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	adrenal	_	O	O	_	_	_	_	_
22	cortex	_	O	O	_	_	_	_	_
23	function	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	treatment	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	regimen	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Kidney	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	tonifying	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	Qi	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	invigorating	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	GCR	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	aged	_	O	O	_	_	_	_	_
21	persons	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	rats	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	enhanced	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	this	_	O	O	_	_	_	_	_
30	way	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	function	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	aged	_	O	O	_	_	_	_	_
37	adrenal	_	O	O	_	_	_	_	_
38	cortex	_	O	O	_	_	_	_	_
39	was	_	O	O	_	_	_	_	_
40	improved	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	Nonopsonic	_	O	O	_	_	_	_	_
2	phagocytosis	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Pseudomonas	_	O	O	_	_	_	_	_
5	aeruginosa	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	macrophages	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	polymorphonuclear	_	O	O	_	_	_	_	_
10	leukocytes	_	O	O	_	_	_	_	_
11	requires	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	presence	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	bacterial	_	O	O	_	_	_	_	_
17	flagellum	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Whereas	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	mechanism	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	nonopsonic	_	O	O	_	_	_	_	_
6	phagocytosis	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Pseudomonas	_	O	O	_	_	_	_	_
9	aeruginosa	_	O	O	_	_	_	_	_
10	has	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	described	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	bacterial	_	O	O	_	_	_	_	_
16	ligands	_	O	O	_	_	_	_	_
17	required	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	poorly	_	O	O	_	_	_	_	_
20	understood	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	identify	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	requisite	_	O	O	_	_	_	_	_
5	bacterial	_	O	O	_	_	_	_	_
6	ligands	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	studies	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	isogenic	_	O	O	_	_	_	_	_
11	mutants	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	P	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	aeruginosa	_	O	O	_	_	_	_	_
2	PAK	_	O	O	_	_	_	_	_
3	lacking	_	O	O	_	_	_	_	_
4	pili	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	flagella	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	RpoN	_	O	O	_	_	_	_	_
11	sigma	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	undertaken	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	RpoN	_	O	O	_	_	_	_	_
3	mutant	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	lacking	_	O	O	_	_	_	_	_
6	pili	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	flagella	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	nonpilus	_	O	O	_	_	_	_	_
12	adhesins	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	bound	_	O	O	_	_	_	_	_
15	poorly	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	resistant	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	ingestion	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	both	_	O	O	_	_	_	_	_
23	macrophages	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	neutrophils	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Pili	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	not	_	O	O	_	_	_	_	_
4	absolutely	_	O	O	_	_	_	_	_
5	required	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	or	_	O	O	_	_	_	_	_
9	phagocytosis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	P	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	aeruginosa	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	presence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	flagellum	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	required	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	P	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	aeruginosa	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	macrophages	_	O	O	_	_	_	_	_
4	but	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	critical	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	subsequent	_	O	O	_	_	_	_	_
10	internalization	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	bacterium	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	suggesting	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	this	_	O	O	_	_	_	_	_
18	factor	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	surface	_	O	O	_	_	_	_	_
22	ligand	_	O	O	_	_	_	_	_
23	associated	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	its	_	O	O	_	_	_	_	_
26	assembly	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	responsible	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	stimulation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	nonopsonic	_	O	O	_	_	_	_	_
33	phagocytosis	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	SOCS	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	tyrosine	_	O	O	_	_	_	_	_
6	phosphorylated	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	response	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	interleukin	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	suppresses	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	phosphorylation	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	lymphocyte	_	O	O	_	_	_	_	_
20	proliferation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Members	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	recently	_	O	O	_	_	_	_	_
5	discovered	_	O	O	_	_	_	_	_
6	SOCS	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	CIS	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	SSI	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	have	_	O	O	_	_	_	_	_
13	been	_	O	O	_	_	_	_	_
14	proposed	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	regulators	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	cytokine	_	O	O	_	_	_	_	_
19	signaling	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	while	_	O	O	_	_	_	_	_
23	targets	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	mechanisms	_	O	O	_	_	_	_	_
26	have	_	O	O	_	_	_	_	_
27	been	_	O	O	_	_	_	_	_
28	suggested	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	some	_	O	O	_	_	_	_	_
31	family	_	O	O	_	_	_	_	_
32	members	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	precise	_	O	O	_	_	_	_	_
36	role	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	these	_	O	O	_	_	_	_	_
39	proteins	_	O	O	_	_	_	_	_
40	remains	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	be	_	O	O	_	_	_	_	_
43	defined	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	date	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	proteins	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	specifically	_	O	O	_	_	_	_	_
9	implicated	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	interleukin	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	signaling	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	response	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	both	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lines	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	peripheral	_	O	O	_	_	_	_	_
23	blood	_	O	O	_	_	_	_	_
24	lymphocytes	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	SOCS	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	detectable	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	30	_	O	O	_	_	_	_	_
11	min	_	O	O	_	_	_	_	_
12	following	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	stimulation	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	while	_	O	O	_	_	_	_	_
19	CIS	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	seen	_	O	O	_	_	_	_	_
22	only	_	O	O	_	_	_	_	_
23	at	_	O	O	_	_	_	_	_
24	low	_	O	O	_	_	_	_	_
25	levels	_	O	O	_	_	_	_	_
26	after	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	h	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Unlike	_	O	O	_	_	_	_	_
2	CIS	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	rapidly	_	O	O	_	_	_	_	_
9	tyrosine	_	O	O	_	_	_	_	_
10	phosphorylated	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	response	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Tyrosine	_	O	O	_	_	_	_	_
2	phosphorylation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	SOCS	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	observed	_	O	O	_	_	_	_	_
9	upon	_	O	O	_	_	_	_	_
10	coexpression	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	Jak	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	Jak	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	only	_	O	O	_	_	_	_	_
19	weakly	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	Jak	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	SOCS	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	associated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	Jak	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	inhibited	_	O	O	_	_	_	_	_
14	Jak	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	phosphorylation	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	this	_	O	O	_	_	_	_	_
20	inhibition	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	markedly	_	O	O	_	_	_	_	_
23	enhanced	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	presence	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	receptor	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	chain	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	Rbeta	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	following	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	stimulation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	SOCS	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	able	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	interact	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	receptor	_	O	O	_	_	_	_	_
25	complex	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	particular	_	O	O	_	_	_	_	_
30	tyrosine	_	O	O	_	_	_	_	_
31	phosphorylated	_	O	O	_	_	_	_	_
32	Jak	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	Rbeta	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Additionally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	lymphocytes	_	O	O	_	_	_	_	_
5	expressing	_	O	O	_	_	_	_	_
6	SOCS	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	but	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	CIS	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	tyrosine	_	O	O	_	_	_	_	_
19	phosphorylation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	STAT	_	O	O	_	_	_	_	_
22	5	_	O	O	_	_	_	_	_
23	b	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	markedly	_	O	O	_	_	_	_	_
26	reduced	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	while	_	O	O	_	_	_	_	_
29	there	_	O	O	_	_	_	_	_
30	was	_	O	O	_	_	_	_	_
31	only	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	weak	_	O	O	_	_	_	_	_
34	effect	_	O	O	_	_	_	_	_
35	on	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	mediated	_	O	O	_	_	_	_	_
41	STAT	_	O	O	_	_	_	_	_
42	5	_	O	O	_	_	_	_	_
43	b	_	O	O	_	_	_	_	_
44	tyrosine	_	O	O	_	_	_	_	_
45	phosphorylation	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	proliferation	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	significantly	_	O	O	_	_	_	_	_
17	inhibited	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	presence	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	SOCS	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	when	_	O	O	_	_	_	_	_
6	SOCS	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	rapidly	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	it	_	O	O	_	_	_	_	_
21	acts	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	inhibit	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	responses	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	classical	_	O	O	_	_	_	_	_
31	negative	_	O	O	_	_	_	_	_
32	feedback	_	O	O	_	_	_	_	_
33	loop	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	[	_	O	O	_	_	_	_	_
2	Hormonal	_	O	O	_	_	_	_	_
3	metabolic	_	O	O	_	_	_	_	_
4	status	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	breast	_	O	O	_	_	_	_	_
7	cancer	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	after	_	O	O	_	_	_	_	_
10	conservative	_	O	O	_	_	_	_	_
11	surgery	_	O	O	_	_	_	_	_
12	:	_	O	O	_	_	_	_	_
13	comparison	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	known	_	O	O	_	_	_	_	_
16	prognostic	_	O	O	_	_	_	_	_
17	criteria	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_

1	Body	_	O	O	_	_	_	_	_
2	weight	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	body	_	O	O	_	_	_	_	_
5	mass	_	O	O	_	_	_	_	_
6	index	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	body	_	O	O	_	_	_	_	_
9	fat	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	lean	_	O	O	_	_	_	_	_
12	body	_	O	O	_	_	_	_	_
13	mass	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	blood	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	glucose	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	cholesterol	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	HDL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cholesterol	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	triglyceride	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	beta	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	lipoproteins	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	insulin	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	gonadotropin	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	estradiol	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	testosterone	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	SHBG	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	T	_	O	O	_	_	_	_	_
42	3	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	T	_	O	O	_	_	_	_	_
45	4	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	TSH	_	O	O	_	_	_	_	_
48	levels	_	O	O	_	_	_	_	_
49	as	_	O	O	_	_	_	_	_
50	well	_	O	O	_	_	_	_	_
51	as	_	O	O	_	_	_	_	_
52	estradiol	_	O	O	_	_	_	_	_
53	and	_	O	O	_	_	_	_	_
54	progesterone	_	O	O	_	_	_	_	_
55	receptor	_	O	O	_	_	_	_	_
56	levels	_	O	O	_	_	_	_	_
57	in	_	O	O	_	_	_	_	_
58	excised	_	O	O	_	_	_	_	_
59	tumor	_	O	O	_	_	_	_	_
60	were	_	O	O	_	_	_	_	_
61	studied	_	O	O	_	_	_	_	_
62	in	_	O	O	_	_	_	_	_
63	40	_	O	O	_	_	_	_	_
64	patients	_	O	O	_	_	_	_	_
65	with	_	O	O	_	_	_	_	_
66	breast	_	O	O	_	_	_	_	_
67	cancer	_	O	O	_	_	_	_	_
68	prior	_	O	O	_	_	_	_	_
69	to	_	O	O	_	_	_	_	_
70	conservative	_	O	O	_	_	_	_	_
71	treatment	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_

1	Said	_	O	O	_	_	_	_	_
2	anthropometric	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	metabolic	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	hormonal	_	O	O	_	_	_	_	_
7	parameters	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	compared	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	index	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	lymphocytic	_	O	O	_	_	_	_	_
15	infiltration	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	tumor	_	O	O	_	_	_	_	_
18	selected	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	prognostic	_	O	O	_	_	_	_	_
22	factor	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	significant	_	O	O	_	_	_	_	_
3	correlation	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	high	_	O	O	_	_	_	_	_
6	lymphocytic	_	O	O	_	_	_	_	_
7	infiltration	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	points	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	low	_	O	O	_	_	_	_	_
16	body	_	O	O	_	_	_	_	_
17	mass	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	fat	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	identified	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Also	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	smoking	_	O	O	_	_	_	_	_
4	contributed	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	loss	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	body	_	O	O	_	_	_	_	_
9	mass	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	fat	_	O	O	_	_	_	_	_
12	;	_	O	O	_	_	_	_	_
13	however	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	it	_	O	O	_	_	_	_	_
16	caused	_	O	O	_	_	_	_	_
17	lymphocytic	_	O	O	_	_	_	_	_
18	infiltration	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	rise	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Moderate	_	O	O	_	_	_	_	_
2	body	_	O	O	_	_	_	_	_
3	mass	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	relatively	_	O	O	_	_	_	_	_
6	low	_	O	O	_	_	_	_	_
7	fat	_	O	O	_	_	_	_	_
8	level	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	positive	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	status	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	among	_	O	O	_	_	_	_	_
15	factors	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	good	_	O	O	_	_	_	_	_
18	prognosis	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	breast	_	O	O	_	_	_	_	_
21	cancer	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	early	_	O	O	_	_	_	_	_
24	stages	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Modulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	CD	_	O	O	_	_	_	_	_
4	28	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	:	_	O	O	_	_	_	_	_
7	distinct	_	O	O	_	_	_	_	_
8	regulatory	_	O	O	_	_	_	_	_
9	pathways	_	O	O	_	_	_	_	_
10	during	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	replicative	_	O	O	_	_	_	_	_
14	senescence	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	costimulatory	_	O	O	_	_	_	_	_
3	molecule	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	28	_	O	O	_	_	_	_	_
6	has	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	restricted	_	O	O	_	_	_	_	_
9	tissue	_	O	O	_	_	_	_	_
10	distribution	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	expressed	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	some	_	O	O	_	_	_	_	_
19	plasmacytoma	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	28	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	constitutively	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	its	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	transiently	_	O	O	_	_	_	_	_
12	down	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	regulated	_	O	O	_	_	_	_	_
15	following	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	declines	_	O	O	_	_	_	_	_
21	progressively	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	vitro	_	O	O	_	_	_	_	_
25	senescence	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	vivo	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	8	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	less	_	O	O	_	_	_	_	_
12	frequently	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	may	_	O	O	_	_	_	_	_
20	completely	_	O	O	_	_	_	_	_
21	lose	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	28	_	O	O	_	_	_	_	_
24	surface	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	during	_	O	O	_	_	_	_	_
27	chronic	_	O	O	_	_	_	_	_
28	infections	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	aging	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	correlates	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	changes	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	activities	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	two	_	O	O	_	_	_	_	_
13	motifs	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	site	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	beta	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	within	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	28	_	O	O	_	_	_	_	_
24	minimal	_	O	O	_	_	_	_	_
25	promoter	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	alpha	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	bound	_	O	O	_	_	_	_	_
8	complexes	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	found	_	O	O	_	_	_	_	_
11	only	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	lymphoid	_	O	O	_	_	_	_	_
14	tissues	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	28	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	some	_	O	O	_	_	_	_	_
26	transformed	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	complexes	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	coordinately	_	O	O	_	_	_	_	_
5	expressed	_	O	O	_	_	_	_	_
6	except	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	replicative	_	O	O	_	_	_	_	_
9	senescence	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	which	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	characterized	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	down	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	modulation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	site	_	O	O	_	_	_	_	_
21	beta	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	site	_	O	O	_	_	_	_	_
26	alpha	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	activities	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	activation	_	O	O	_	_	_	_	_
7	induces	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	parallel	_	O	O	_	_	_	_	_
10	decline	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	both	_	O	O	_	_	_	_	_
13	site	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	beta	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	activities	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	8	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	differ	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	their	_	O	O	_	_	_	_	_
13	beta	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	profiles	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	may	_	O	O	_	_	_	_	_
20	explain	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	more	_	O	O	_	_	_	_	_
23	pronounced	_	O	O	_	_	_	_	_
24	down	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	regulation	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	CD	_	O	O	_	_	_	_	_
29	28	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	senescent	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	8	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	T	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	vivo	_	O	O	_	_	_	_	_
3	expanded	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	28	_	O	O	_	_	_	_	_
9	null	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	8	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	28	_	O	O	_	_	_	_	_
16	null	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	uniformly	_	O	O	_	_	_	_	_
20	lack	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	beta	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	bound	_	O	O	_	_	_	_	_
27	complexes	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	resembling	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	pattern	_	O	O	_	_	_	_	_
32	seen	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	chronically	_	O	O	_	_	_	_	_
35	activated	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	not	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	senescent	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_


1	Signal	_	O	O	_	_	_	_	_
2	transduction	_	O	O	_	_	_	_	_
3	pathways	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	normal	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	monocytes	_	O	O	_	_	_	_	_
8	stimulated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	cytokines	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	mediators	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	comparative	_	O	O	_	_	_	_	_
15	study	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	human	_	O	O	_	_	_	_	_
19	neutrophils	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	transformed	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	putative	_	O	O	_	_	_	_	_
26	roles	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	functionality	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	biology	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Granulocyte	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	macrophage	_	O	O	_	_	_	_	_
4	colony	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	stimulating	_	O	O	_	_	_	_	_
7	factor	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	GM	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	CSF	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	interleukin	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	phosphorylation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	92	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kDa	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	normal	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	monocytes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	identified	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	92	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kDa	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	STAT	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	STATs	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	nor	_	O	O	_	_	_	_	_
23	c	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	fes	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	vav	_	O	O	_	_	_	_	_
28	protooncogene	_	O	O	_	_	_	_	_
29	products	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	demonstrated	_	O	O	_	_	_	_	_
33	its	_	O	O	_	_	_	_	_
34	translocation	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	nucleus	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	enhancement	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	specific	_	O	O	_	_	_	_	_
42	DNA	_	O	O	_	_	_	_	_
43	binding	_	O	O	_	_	_	_	_
44	capacity	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	potentiation	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	trancriptional	_	O	O	_	_	_	_	_
50	activity	_	O	O	_	_	_	_	_
51	by	_	O	O	_	_	_	_	_
52	GM	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	CSF	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	N	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	formyl	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	methionyl	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	leucyl	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	phenylalanine	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	FMLP	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	phorbol	_	O	O	_	_	_	_	_
15	myristate	_	O	O	_	_	_	_	_
16	acetate	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	PMA	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	phosphorylation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	42	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	44	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kDa	_	O	O	_	_	_	_	_
30	proteins	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	which	_	O	O	_	_	_	_	_
33	were	_	O	O	_	_	_	_	_
34	identified	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	extracellular	_	O	O	_	_	_	_	_
37	signal	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	regulated	_	O	O	_	_	_	_	_
40	kinase	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	ERK	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	human	_	O	O	_	_	_	_	_
47	monocytes	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	marked	_	O	O	_	_	_	_	_
3	contrast	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	neutrophils	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	MO	_	O	O	_	_	_	_	_
8	7	_	O	O	_	_	_	_	_
9	e	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	GM	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	CSF	_	O	O	_	_	_	_	_
15	did	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	induce	_	O	O	_	_	_	_	_
18	tyrosine	_	O	O	_	_	_	_	_
19	phosphorylation	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	ERK	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	monocytes	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Among	_	O	O	_	_	_	_	_
2	upstream	_	O	O	_	_	_	_	_
3	signaling	_	O	O	_	_	_	_	_
4	molecules	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	ERK	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	Shc	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	constitutively	_	O	O	_	_	_	_	_
11	associated	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	Grb	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	tyrosine	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	phosphorylated	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	GM	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	CSF	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	FMLP	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	Sos	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	c	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	Raf	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	were	_	O	O	_	_	_	_	_
38	not	_	O	O	_	_	_	_	_
39	phosphorylated	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	GM	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	CSF	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	IL	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	TNF	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	FMLP	_	O	O	_	_	_	_	_
53	in	_	O	O	_	_	_	_	_
54	monocytes	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	whereas	_	O	O	_	_	_	_	_
57	all	_	O	O	_	_	_	_	_
58	these	_	O	O	_	_	_	_	_
59	signaling	_	O	O	_	_	_	_	_
60	molecules	_	O	O	_	_	_	_	_
61	were	_	O	O	_	_	_	_	_
62	affected	_	O	O	_	_	_	_	_
63	and	_	O	O	_	_	_	_	_
64	/	_	O	O	_	_	_	_	_
65	or	_	O	O	_	_	_	_	_
66	utilized	_	O	O	_	_	_	_	_
67	by	_	O	O	_	_	_	_	_
68	GM	_	O	O	_	_	_	_	_
69	-	_	O	O	_	_	_	_	_
70	CSF	_	O	O	_	_	_	_	_
71	in	_	O	O	_	_	_	_	_
72	MO	_	O	O	_	_	_	_	_
73	7	_	O	O	_	_	_	_	_
74	e	_	O	O	_	_	_	_	_
75	cells	_	O	O	_	_	_	_	_
76	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	neutrophils	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	38	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	constitutively	_	O	O	_	_	_	_	_
10	phosphorylated	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	agonist	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	dependent	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	detected	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	monocytes	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Superoxide	_	O	O	_	_	_	_	_
2	release	_	O	O	_	_	_	_	_
3	stimulated	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	FMLP	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	inhibited	_	O	O	_	_	_	_	_
8	partially	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	PD	_	O	O	_	_	_	_	_
11	98059	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	SB	_	O	O	_	_	_	_	_
14	203580	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	inhibitor	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	ERK	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	p	_	O	O	_	_	_	_	_
23	38	_	O	O	_	_	_	_	_
24	pathway	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	almost	_	O	O	_	_	_	_	_
29	completely	_	O	O	_	_	_	_	_
30	inhibited	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	combination	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	both	_	O	O	_	_	_	_	_
36	inhibitors	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	whereas	_	O	O	_	_	_	_	_
39	PMA	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	induced	_	O	O	_	_	_	_	_
42	superoxide	_	O	O	_	_	_	_	_
43	release	_	O	O	_	_	_	_	_
44	was	_	O	O	_	_	_	_	_
45	resistant	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	these	_	O	O	_	_	_	_	_
48	two	_	O	O	_	_	_	_	_
49	inhibitors	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	monocytes	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	PD	_	O	O	_	_	_	_	_
2	98059	_	O	O	_	_	_	_	_
3	inhibited	_	O	O	_	_	_	_	_
4	GM	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	CSF	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	dependent	_	O	O	_	_	_	_	_
9	proliferation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	MO	_	O	O	_	_	_	_	_
12	7	_	O	O	_	_	_	_	_
13	e	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Present	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	trancriptional	_	O	O	_	_	_	_	_
5	roles	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	functional	_	O	O	_	_	_	_	_
11	roles	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	ERK	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	38	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	normal	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	monocytes	_	O	O	_	_	_	_	_
23	stimulated	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	physiological	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	mediated	_	O	O	_	_	_	_	_
29	agonists	_	O	O	_	_	_	_	_
30	GM	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	CSF	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	FMLP	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Possible	_	O	O	_	_	_	_	_
2	roles	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	ERK	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	proliferation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	transformed	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	suggested	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	Cutting	_	O	O	_	_	_	_	_
2	edge	_	O	O	_	_	_	_	_
3	:	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	eosinophils	_	O	O	_	_	_	_	_
14	:	_	O	O	_	_	_	_	_
15	regulation	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	5	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	report	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	AT	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	AT	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	expressed	_	O	O	_	_	_	_	_
15	cytoplasmically	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	resting	_	O	O	_	_	_	_	_
18	eosinophils	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	whereas	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	AT	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	NF	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	AT	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	have	_	O	O	_	_	_	_	_
31	not	_	O	O	_	_	_	_	_
32	been	_	O	O	_	_	_	_	_
33	seen	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Likewise	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	AT	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	AT	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	have	_	O	O	_	_	_	_	_
15	been	_	O	O	_	_	_	_	_
16	detected	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	resting	_	O	O	_	_	_	_	_
19	eosinophils	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	their	_	O	O	_	_	_	_	_
23	levels	_	O	O	_	_	_	_	_
24	can	_	O	O	_	_	_	_	_
25	be	_	O	O	_	_	_	_	_
26	significantly	_	O	O	_	_	_	_	_
27	up	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	regulated	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	Th	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	associated	_	O	O	_	_	_	_	_
36	cytokines	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	4	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	5	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	detectable	_	O	O	_	_	_	_	_
5	NF	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	AT	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	nuclei	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	resting	_	O	O	_	_	_	_	_
15	eosinophils	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	ATs	_	O	O	_	_	_	_	_
5	appear	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	nuclei	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	5	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	ionomycin	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	stimulated	_	O	O	_	_	_	_	_
24	eosinophils	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Only	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	AT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	AT	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	NF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	AT	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	NF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	AT	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	have	_	O	O	_	_	_	_	_
25	translocated	_	O	O	_	_	_	_	_
26	into	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	nuclei	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	stimulated	_	O	O	_	_	_	_	_
40	eosinophils	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	delineate	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	novel	_	O	O	_	_	_	_	_
6	pathway	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	cytokine	_	O	O	_	_	_	_	_
10	network	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	Th	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	lymphocytes	_	O	O	_	_	_	_	_
16	""""	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	""""	_	O	O	_	_	_	_	_
19	eosinophils	_	O	O	_	_	_	_	_
20	via	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	release	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	5	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	activation	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	NF	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	AT	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	eosinophils	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	suggest	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	later	_	O	O	_	_	_	_	_
8	feedback	_	O	O	_	_	_	_	_
9	""""	_	O	O	_	_	_	_	_
10	talking	_	O	O	_	_	_	_	_
11	""""	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	exist	_	O	O	_	_	_	_	_
14	between	_	O	O	_	_	_	_	_
15	eosinophils	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	Th	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	lymphocytes	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	65	_	O	O	_	_	_	_	_
4	subunit	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	NF	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	kappa	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	regulates	_	O	O	_	_	_	_	_
11	I	_	O	O	_	_	_	_	_
12	kappa	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	two	_	O	O	_	_	_	_	_
16	distinct	_	O	O	_	_	_	_	_
17	mechanisms	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Transcription	_	O	O	_	_	_	_	_
2	factor	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	kappa	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	50	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	65	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	generally	_	O	O	_	_	_	_	_
16	localized	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	cytoplasm	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	its	_	O	O	_	_	_	_	_
22	inhibitor	_	O	O	_	_	_	_	_
23	I	_	O	O	_	_	_	_	_
24	kappa	_	O	O	_	_	_	_	_
25	B	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Overproduced	_	O	O	_	_	_	_	_
2	I	_	O	O	_	_	_	_	_
3	kappa	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	free	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappa	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	rapidly	_	O	O	_	_	_	_	_
15	degraded	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Overexpression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	65	_	O	O	_	_	_	_	_
5	increases	_	O	O	_	_	_	_	_
6	endogenous	_	O	O	_	_	_	_	_
7	I	_	O	O	_	_	_	_	_
8	kappa	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	both	_	O	O	_	_	_	_	_
13	carcinoma	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	lymphoid	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	two	_	O	O	_	_	_	_	_
19	mechanisms	_	O	O	_	_	_	_	_
20	:	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	stabilization	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	increased	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	I	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	mRNA	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	65	_	O	O	_	_	_	_	_
6	delta	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	naturally	_	O	O	_	_	_	_	_
10	occurring	_	O	O	_	_	_	_	_
11	splice	_	O	O	_	_	_	_	_
12	variant	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	fails	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	markedly	_	O	O	_	_	_	_	_
17	augment	_	O	O	_	_	_	_	_
18	I	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	levels	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	overexpressed	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	65	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	coexpressed	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	50	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	cytoplasmic	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	whereas	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	65	_	O	O	_	_	_	_	_
15	delta	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	partly	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	indicating	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	I	_	O	O	_	_	_	_	_
24	kappa	_	O	O	_	_	_	_	_
25	B	_	O	O	_	_	_	_	_
26	induced	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	65	_	O	O	_	_	_	_	_
30	can	_	O	O	_	_	_	_	_
31	maintain	_	O	O	_	_	_	_	_
32	NF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	kappa	_	O	O	_	_	_	_	_
35	B	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	cytoplasm	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	65	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	linked	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	autoregulatory	_	O	O	_	_	_	_	_
14	loop	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	ensuring	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kappa	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	held	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	cytoplasm	_	O	O	_	_	_	_	_
27	until	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	are	_	O	O	_	_	_	_	_
30	specifically	_	O	O	_	_	_	_	_
31	induced	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	translocate	_	O	O	_	_	_	_	_
34	it	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	nucleus	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_


1	Comparison	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	retinoic	_	O	O	_	_	_	_	_
4	acid	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	phorbol	_	O	O	_	_	_	_	_
7	myristate	_	O	O	_	_	_	_	_
8	acetate	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	inducers	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	monocytic	_	O	O	_	_	_	_	_
13	differentiation	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Several	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	myeloid	_	O	O	_	_	_	_	_
4	leukemia	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	lines	_	O	O	_	_	_	_	_
7	growing	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	vitro	_	O	O	_	_	_	_	_
10	can	_	O	O	_	_	_	_	_
11	be	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	differentiate	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	more	_	O	O	_	_	_	_	_
17	mature	_	O	O	_	_	_	_	_
18	monocyte	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	macrophage	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	like	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	treatment	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	protein	_	O	O	_	_	_	_	_
28	kinase	_	O	O	_	_	_	_	_
29	C	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	activating	_	O	O	_	_	_	_	_
32	phorbol	_	O	O	_	_	_	_	_
33	esters	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	such	_	O	O	_	_	_	_	_
36	as	_	O	O	_	_	_	_	_
37	PMA	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	PMA	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	THP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	myeloid	_	O	O	_	_	_	_	_
13	leukemia	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	line	_	O	O	_	_	_	_	_
16	acquire	_	O	O	_	_	_	_	_
17	macrophage	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	like	_	O	O	_	_	_	_	_
20	characteristics	_	O	O	_	_	_	_	_
21	after	_	O	O	_	_	_	_	_
22	treatment	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	all	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	trans	_	O	O	_	_	_	_	_
27	retinoic	_	O	O	_	_	_	_	_
28	acid	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	RA	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	analyze	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	signal	_	O	O	_	_	_	_	_
5	transduction	_	O	O	_	_	_	_	_
6	mechanisms	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	RA	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	we	_	O	O	_	_	_	_	_
12	first	_	O	O	_	_	_	_	_
13	compared	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	effects	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	PMA	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	on	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	genes	_	O	O	_	_	_	_	_
25	which	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	known	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	be	_	O	O	_	_	_	_	_
30	regulated	_	O	O	_	_	_	_	_
31	during	_	O	O	_	_	_	_	_
32	monocytic	_	O	O	_	_	_	_	_
33	differentiation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	RA	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	PMA	_	O	O	_	_	_	_	_
5	effectively	_	O	O	_	_	_	_	_
6	down	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	regulated	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	myc	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	while	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	myb	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	decreased	_	O	O	_	_	_	_	_
20	only	_	O	O	_	_	_	_	_
21	after	_	O	O	_	_	_	_	_
22	PMA	_	O	O	_	_	_	_	_
23	treatment	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	beta	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	integrin	_	O	O	_	_	_	_	_
8	genes	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	11	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	11	_	O	O	_	_	_	_	_
16	b	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	clearly	_	O	O	_	_	_	_	_
20	increased	_	O	O	_	_	_	_	_
21	after	_	O	O	_	_	_	_	_
22	both	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	these	_	O	O	_	_	_	_	_
25	treatments	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Their	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	src	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	family	_	O	O	_	_	_	_	_
8	tyrosine	_	O	O	_	_	_	_	_
9	kinase	_	O	O	_	_	_	_	_
10	genes	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	different	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	hck	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	similarly	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	these	_	O	O	_	_	_	_	_
21	agents	_	O	O	_	_	_	_	_
22	but	_	O	O	_	_	_	_	_
23	lyn	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	stronger	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	more	_	O	O	_	_	_	_	_
29	rapid	_	O	O	_	_	_	_	_
30	after	_	O	O	_	_	_	_	_
31	RA	_	O	O	_	_	_	_	_
32	treatment	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	RA	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	enhanced	_	O	O	_	_	_	_	_
4	lyn	_	O	O	_	_	_	_	_
5	mRNA	_	O	O	_	_	_	_	_
6	production	_	O	O	_	_	_	_	_
7	rapidly	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	HL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	60	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	indicating	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	lyn	_	O	O	_	_	_	_	_
19	gene	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	common	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	monocytic	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	granulocytic	_	O	O	_	_	_	_	_
27	maturation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	myeloid	_	O	O	_	_	_	_	_
30	leukemia	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	AP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	enhancer	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	involved	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	monocytic	_	O	O	_	_	_	_	_
17	differentiation	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	THP	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	transiently	_	O	O	_	_	_	_	_
25	transfected	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	chloramphenicol	_	O	O	_	_	_	_	_
29	acetyl	_	O	O	_	_	_	_	_
30	transferase	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	CAT	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	reporter	_	O	O	_	_	_	_	_
36	gene	_	O	O	_	_	_	_	_
37	containing	_	O	O	_	_	_	_	_
38	5	_	O	O	_	_	_	_	_
39	copies	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	AP	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	binding	_	O	O	_	_	_	_	_
46	sites	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	PMA	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	did	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	induce	_	O	O	_	_	_	_	_
10	any	_	O	O	_	_	_	_	_
11	CAT	_	O	O	_	_	_	_	_
12	activity	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	these	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	thus	_	O	O	_	_	_	_	_
18	suggesting	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	induced	_	O	O	_	_	_	_	_
24	changes	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	those	_	O	O	_	_	_	_	_
30	genes	_	O	O	_	_	_	_	_
31	described	_	O	O	_	_	_	_	_
32	above	_	O	O	_	_	_	_	_
33	were	_	O	O	_	_	_	_	_
34	not	_	O	O	_	_	_	_	_
35	dependent	_	O	O	_	_	_	_	_
36	on	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	AP	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	enhancer	_	O	O	_	_	_	_	_
42	activity	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_


1	Signal	_	O	O	_	_	_	_	_
2	transduction	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	DR	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	death	_	O	O	_	_	_	_	_
9	domain	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	containing	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	related	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	TNFR	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	95	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	Tumor	_	O	O	_	_	_	_	_
2	necrosis	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	TNFR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	95	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	also	_	O	O	_	_	_	_	_
17	called	_	O	O	_	_	_	_	_
18	Fas	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	APO	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	are	_	O	O	_	_	_	_	_
25	cytokine	_	O	O	_	_	_	_	_
26	receptors	_	O	O	_	_	_	_	_
27	that	_	O	O	_	_	_	_	_
28	engage	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	apoptosis	_	O	O	_	_	_	_	_
31	pathway	_	O	O	_	_	_	_	_
32	through	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	region	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	intracellular	_	O	O	_	_	_	_	_
37	homology	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	designated	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	""""	_	O	O	_	_	_	_	_
42	death	_	O	O	_	_	_	_	_
43	domain	_	O	O	_	_	_	_	_
44	"."""	_	O	O	_	_	_	_	_
45	Another	_	O	O	_	_	_	_	_
46	death	_	O	O	_	_	_	_	_
47	domain	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	containing	_	O	O	_	_	_	_	_
50	member	_	O	O	_	_	_	_	_
51	of	_	O	O	_	_	_	_	_
52	the	_	O	O	_	_	_	_	_
53	TNFR	_	O	O	_	_	_	_	_
54	family	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	death	_	O	O	_	_	_	_	_
57	receptor	_	O	O	_	_	_	_	_
58	3	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	DR	_	O	O	_	_	_	_	_
61	3	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	was	_	O	O	_	_	_	_	_
65	identified	_	O	O	_	_	_	_	_
66	and	_	O	O	_	_	_	_	_
67	was	_	O	O	_	_	_	_	_
68	shown	_	O	O	_	_	_	_	_
69	to	_	O	O	_	_	_	_	_
70	induce	_	O	O	_	_	_	_	_
71	both	_	O	O	_	_	_	_	_
72	apoptosis	_	O	O	_	_	_	_	_
73	and	_	O	O	_	_	_	_	_
74	activation	_	O	O	_	_	_	_	_
75	of	_	O	O	_	_	_	_	_
76	nuclear	_	O	O	_	_	_	_	_
77	factor	_	O	O	_	_	_	_	_
78	kappaB	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	DR	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	appears	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	restricted	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	tissues	_	O	O	_	_	_	_	_
11	enriched	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	DR	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	signal	_	O	O	_	_	_	_	_
4	transduction	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	mediated	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	complex	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	intracellular	_	O	O	_	_	_	_	_
12	signaling	_	O	O	_	_	_	_	_
13	molecules	_	O	O	_	_	_	_	_
14	including	_	O	O	_	_	_	_	_
15	TRADD	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	TRAF	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	FADD	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	FLICE	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	DR	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	likely	_	O	O	_	_	_	_	_
6	plays	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	role	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	regulating	_	O	O	_	_	_	_	_
11	lymphocyte	_	O	O	_	_	_	_	_
12	homeostasis	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	rel	_	O	O	_	_	_	_	_
2	Is	_	O	O	_	_	_	_	_
3	rapidly	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	phosphorylated	_	O	O	_	_	_	_	_
7	following	_	O	O	_	_	_	_	_
8	granulocyte	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	colony	_	O	O	_	_	_	_	_
11	stimulating	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	treatment	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	neutrophils	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Stimulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	neutrophils	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	granulocyte	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	colony	_	O	O	_	_	_	_	_
8	stimulating	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	G	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	CSF	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	results	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	enhanced	_	O	O	_	_	_	_	_
19	respiratory	_	O	O	_	_	_	_	_
20	burst	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	prolonged	_	O	O	_	_	_	_	_
23	survival	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	increased	_	O	O	_	_	_	_	_
27	tumor	_	O	O	_	_	_	_	_
28	cell	_	O	O	_	_	_	_	_
29	killing	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	G	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	CSF	_	O	O	_	_	_	_	_
7	are	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	high	_	O	O	_	_	_	_	_
15	affinity	_	O	O	_	_	_	_	_
16	receptors	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	G	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	CSF	_	O	O	_	_	_	_	_
4	receptors	_	O	O	_	_	_	_	_
5	lack	_	O	O	_	_	_	_	_
6	intrinsic	_	O	O	_	_	_	_	_
7	tyrosine	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	results	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	rapid	_	O	O	_	_	_	_	_
20	induction	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	tyrosine	_	O	O	_	_	_	_	_
23	kinase	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Antiphosphotyrosine	_	O	O	_	_	_	_	_
2	immunoblots	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	whole	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	lysates	_	O	O	_	_	_	_	_
7	prepared	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	neutrophils	_	O	O	_	_	_	_	_
10	show	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	G	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	CSF	_	O	O	_	_	_	_	_
16	rapidly	_	O	O	_	_	_	_	_
17	induces	_	O	O	_	_	_	_	_
18	prominent	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	phosphorylation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	protein	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	relative	_	O	O	_	_	_	_	_
27	molecular	_	O	O	_	_	_	_	_
28	mass	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	80	_	O	O	_	_	_	_	_
31	kDa	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	monospecific	_	O	O	_	_	_	_	_
3	antibodies	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	80	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	kDa	_	O	O	_	_	_	_	_
9	tyrosine	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	phosphorylated	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	shown	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	80	_	O	O	_	_	_	_	_
20	c	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	rel	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	proto	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	oncogene	_	O	O	_	_	_	_	_
28	belonging	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	family	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	transcriptional	_	O	O	_	_	_	_	_
34	regulators	_	O	O	_	_	_	_	_
35	which	_	O	O	_	_	_	_	_
36	include	_	O	O	_	_	_	_	_
37	NF	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	kB	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	phosphorylation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	80	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	rel	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	unique	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	G	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	CSF	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	granulocyte	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	macrophage	_	O	O	_	_	_	_	_
23	colony	_	O	O	_	_	_	_	_
24	stimulating	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	which	_	O	O	_	_	_	_	_
27	also	_	O	O	_	_	_	_	_
28	stimulates	_	O	O	_	_	_	_	_
29	neutrophils	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	induces	_	O	O	_	_	_	_	_
32	tyrosine	_	O	O	_	_	_	_	_
33	phosphorylation	_	O	O	_	_	_	_	_
34	does	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	result	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	tyrosine	_	O	O	_	_	_	_	_
39	phosphorylation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	p	_	O	O	_	_	_	_	_
42	80	_	O	O	_	_	_	_	_
43	c	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	rel	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	consequences	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	80	_	O	O	_	_	_	_	_
6	c	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	rel	_	O	O	_	_	_	_	_
9	tyrosine	_	O	O	_	_	_	_	_
10	phosphorylation	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	yet	_	O	O	_	_	_	_	_
14	known	_	O	O	_	_	_	_	_
15	;	_	O	O	_	_	_	_	_
16	however	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	tyrosine	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	phosphorylated	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	80	_	O	O	_	_	_	_	_
23	c	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	rel	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	capable	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	DNA	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	G	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	CSF	_	O	O	_	_	_	_	_
37	stimulation	_	O	O	_	_	_	_	_
38	results	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	an	_	O	O	_	_	_	_	_
41	increase	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	amount	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	p	_	O	O	_	_	_	_	_
47	80	_	O	O	_	_	_	_	_
48	c	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	rel	_	O	O	_	_	_	_	_
51	which	_	O	O	_	_	_	_	_
52	binds	_	O	O	_	_	_	_	_
53	to	_	O	O	_	_	_	_	_
54	DNA	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	one	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	first	_	O	O	_	_	_	_	_
9	biochemical	_	O	O	_	_	_	_	_
10	events	_	O	O	_	_	_	_	_
11	which	_	O	O	_	_	_	_	_
12	occurs	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	neutrophils	_	O	O	_	_	_	_	_
15	following	_	O	O	_	_	_	_	_
16	G	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	CSF	_	O	O	_	_	_	_	_
19	stimulation	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	tyrosine	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	leads	_	O	O	_	_	_	_	_
28	directly	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	tyrosine	_	O	O	_	_	_	_	_
32	phosphorylation	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	p	_	O	O	_	_	_	_	_
35	80	_	O	O	_	_	_	_	_
36	c	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	rel	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	kinase	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	G	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CSF	_	O	O	_	_	_	_	_
11	appears	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	directly	_	O	O	_	_	_	_	_
14	transduce	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	signal	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	which	_	O	O	_	_	_	_	_
21	functions	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	transcriptional	_	O	O	_	_	_	_	_
25	regulator	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	factor	_	O	O	_	_	_	_	_
5	kappa	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	subunit	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	65	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	accumulation	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	lipopolysaccharide	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	stimulated	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	monocytic	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	treated	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	sodium	_	O	O	_	_	_	_	_
22	salicylate	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Lipopolysaccharide	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	one	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	most	_	O	O	_	_	_	_	_
7	potent	_	O	O	_	_	_	_	_
8	trigger	_	O	O	_	_	_	_	_
9	substances	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	monocytes	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	macrophages	_	O	O	_	_	_	_	_
14	causing	_	O	O	_	_	_	_	_
15	secretion	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	inflammatory	_	O	O	_	_	_	_	_
18	mediators	_	O	O	_	_	_	_	_
19	such	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	tumor	_	O	O	_	_	_	_	_
22	necrosis	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	interleukin	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	nature	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	factors	_	O	O	_	_	_	_	_
7	involved	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	regulation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	these	_	O	O	_	_	_	_	_
12	cytokine	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	still	_	O	O	_	_	_	_	_
16	unknown	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	factor	_	O	O	_	_	_	_	_
3	kappa	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	NF	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	kappa	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	;	_	O	O	_	_	_	_	_
11	heterodimer	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	50	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	65	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	have	_	O	O	_	_	_	_	_
21	been	_	O	O	_	_	_	_	_
22	suggested	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	play	_	O	O	_	_	_	_	_
25	an	_	O	O	_	_	_	_	_
26	important	_	O	O	_	_	_	_	_
27	role	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	inflammatory	_	O	O	_	_	_	_	_
33	mediators	_	O	O	_	_	_	_	_
34	when	_	O	O	_	_	_	_	_
35	monocytes	_	O	O	_	_	_	_	_
36	are	_	O	O	_	_	_	_	_
37	stimulated	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	lipopolysaccharide	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Nonsteroidal	_	O	O	_	_	_	_	_
2	anti	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	inflammatory	_	O	O	_	_	_	_	_
5	drugs	_	O	O	_	_	_	_	_
6	such	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	salicylates	_	O	O	_	_	_	_	_
9	have	_	O	O	_	_	_	_	_
10	been	_	O	O	_	_	_	_	_
11	used	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	treat	_	O	O	_	_	_	_	_
14	symptoms	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	inflammation	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	new	_	O	O	_	_	_	_	_
21	mechanism	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	drug	_	O	O	_	_	_	_	_
24	action	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	suggested	_	O	O	_	_	_	_	_
27	recently	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Salicylates	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	been	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	inhibit	_	O	O	_	_	_	_	_
7	lipopolysaccharide	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	via	_	O	O	_	_	_	_	_
13	inhibition	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	preventing	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	degradation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	kappa	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	inhibitor	_	O	O	_	_	_	_	_
30	""""	_	O	O	_	_	_	_	_
31	I	_	O	O	_	_	_	_	_
32	kappa	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	""","	_	O	O	_	_	_	_	_
35	blocking	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	translocation	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	NF	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	kappa	_	O	O	_	_	_	_	_
42	B	_	O	O	_	_	_	_	_
43	into	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	nuclear	_	O	O	_	_	_	_	_
46	compartment	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	nature	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	subunit	_	O	O	_	_	_	_	_
8	involved	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	this	_	O	O	_	_	_	_	_
11	mechanism	_	O	O	_	_	_	_	_
12	has	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	defined	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	mechanisms	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	salicylates	_	O	O	_	_	_	_	_
8	affect	_	O	O	_	_	_	_	_
9	cytokine	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	amount	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	active	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	inactive	_	O	O	_	_	_	_	_
19	NF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	kappa	_	O	O	_	_	_	_	_
22	B	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kappa	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	mRNA	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	Porphyromonas	_	O	O	_	_	_	_	_
32	gingivalis	_	O	O	_	_	_	_	_
33	lipopolysaccharide	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	stimulated	_	O	O	_	_	_	_	_
36	human	_	O	O	_	_	_	_	_
37	monocytic	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	was	_	O	O	_	_	_	_	_
40	assessed	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	High	_	O	O	_	_	_	_	_
2	doses	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	sodium	_	O	O	_	_	_	_	_
5	salicylate	_	O	O	_	_	_	_	_
6	suppressed	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	65	_	O	O	_	_	_	_	_
13	mRNA	_	O	O	_	_	_	_	_
14	accumulation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	resulting	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	suppression	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	total	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	kappa	_	O	O	_	_	_	_	_
24	B	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	50	_	O	O	_	_	_	_	_
28	on	_	O	O	_	_	_	_	_
29	tissue	_	O	O	_	_	_	_	_
30	oligonucleotide	_	O	O	_	_	_	_	_
31	had	_	O	O	_	_	_	_	_
32	no	_	O	O	_	_	_	_	_
33	effects	_	O	O	_	_	_	_	_
34	on	_	O	O	_	_	_	_	_
35	lipopolysaccharide	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	induced	_	O	O	_	_	_	_	_
38	NF	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	kappa	_	O	O	_	_	_	_	_
41	B	_	O	O	_	_	_	_	_
42	activation	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	65	_	O	O	_	_	_	_	_
8	subunit	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	NF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	kappa	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	inhibited	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	salicylate	_	O	O	_	_	_	_	_
18	treatment	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	highlight	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	salicylate	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	control	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	inflammatory	_	O	O	_	_	_	_	_
33	mediators	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	BCL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	molecular	_	O	O	_	_	_	_	_
7	pathogenesis	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	lymphoma	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	presented	_	O	O	_	_	_	_	_
4	identify	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	first	_	O	O	_	_	_	_	_
7	genetic	_	O	O	_	_	_	_	_
8	lesion	_	O	O	_	_	_	_	_
9	associated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	DLCL	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	most	_	O	O	_	_	_	_	_
15	clinically	_	O	O	_	_	_	_	_
16	relevant	_	O	O	_	_	_	_	_
17	form	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	NHL	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	no	_	O	O	_	_	_	_	_
3	proof	_	O	O	_	_	_	_	_
4	yet	_	O	O	_	_	_	_	_
5	exists	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	role	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	these	_	O	O	_	_	_	_	_
11	lesions	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	DLCL	_	O	O	_	_	_	_	_
14	pathogenesis	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	feature	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	BCL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	product	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	its	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	pattern	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	clustering	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	lesions	_	O	O	_	_	_	_	_
40	disrupting	_	O	O	_	_	_	_	_
41	its	_	O	O	_	_	_	_	_
42	regulatory	_	O	O	_	_	_	_	_
43	domain	_	O	O	_	_	_	_	_
44	strongly	_	O	O	_	_	_	_	_
45	suggest	_	O	O	_	_	_	_	_
46	that	_	O	O	_	_	_	_	_
47	deregulation	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	BCL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	6	_	O	O	_	_	_	_	_
52	expression	_	O	O	_	_	_	_	_
53	may	_	O	O	_	_	_	_	_
54	contribute	_	O	O	_	_	_	_	_
55	to	_	O	O	_	_	_	_	_
56	DLCL	_	O	O	_	_	_	_	_
57	development	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	more	_	O	O	_	_	_	_	_
3	precise	_	O	O	_	_	_	_	_
4	definition	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	BCL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	normal	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	neoplastic	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	development	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	goal	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	ongoing	_	O	O	_	_	_	_	_
25	study	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	transgenic	_	O	O	_	_	_	_	_
28	mice	_	O	O	_	_	_	_	_
29	engineered	_	O	O	_	_	_	_	_
30	either	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	express	_	O	O	_	_	_	_	_
33	BCL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	under	_	O	O	_	_	_	_	_
37	heterologous	_	O	O	_	_	_	_	_
38	promoters	_	O	O	_	_	_	_	_
39	or	_	O	O	_	_	_	_	_
40	lacking	_	O	O	_	_	_	_	_
41	BCL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	6	_	O	O	_	_	_	_	_
44	function	_	O	O	_	_	_	_	_
45	due	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	targeted	_	O	O	_	_	_	_	_
48	deletions	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	contributing	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	understanding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	DLCL	_	O	O	_	_	_	_	_
10	pathogenesis	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	identification	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	BCL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	lesions	_	O	O	_	_	_	_	_
19	may	_	O	O	_	_	_	_	_
20	have	_	O	O	_	_	_	_	_
21	relevant	_	O	O	_	_	_	_	_
22	clinical	_	O	O	_	_	_	_	_
23	implications	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	DLCL	_	O	O	_	_	_	_	_
2	represent	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	heterogeneous	_	O	O	_	_	_	_	_
5	group	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	neoplasms	_	O	O	_	_	_	_	_
8	which	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	treated	_	O	O	_	_	_	_	_
11	homogeneously	_	O	O	_	_	_	_	_
12	despite	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	fact	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	only	_	O	O	_	_	_	_	_
17	50	_	O	O	_	_	_	_	_
18	%	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	patients	_	O	O	_	_	_	_	_
21	experience	_	O	O	_	_	_	_	_
22	long	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	term	_	O	O	_	_	_	_	_
25	disease	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	free	_	O	O	_	_	_	_	_
28	survival	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	Schneider	_	O	O	_	_	_	_	_
31	et	_	O	O	_	_	_	_	_
32	al	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	1990	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	fact	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	BCL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	rearrangements	_	O	O	_	_	_	_	_
8	identify	_	O	O	_	_	_	_	_
9	biologically	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	clinically	_	O	O	_	_	_	_	_
12	distinct	_	O	O	_	_	_	_	_
13	subsets	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	DLCL	_	O	O	_	_	_	_	_
16	suggests	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	these	_	O	O	_	_	_	_	_
19	lesions	_	O	O	_	_	_	_	_
20	may	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	useful	_	O	O	_	_	_	_	_
23	as	_	O	O	_	_	_	_	_
24	markers	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	selection	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	differential	_	O	O	_	_	_	_	_
29	therapeutic	_	O	O	_	_	_	_	_
30	strategies	_	O	O	_	_	_	_	_
31	based	_	O	O	_	_	_	_	_
32	on	_	O	O	_	_	_	_	_
33	different	_	O	O	_	_	_	_	_
34	risk	_	O	O	_	_	_	_	_
35	groups	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	BCL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	rearrangements	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	used	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	identify	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	monitor	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	malignant	_	O	O	_	_	_	_	_
17	clone	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	sensitive	_	O	O	_	_	_	_	_
20	PCR	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	based	_	O	O	_	_	_	_	_
23	techniques	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	clinical	_	O	O	_	_	_	_	_
3	remission	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	observed	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	significant	_	O	O	_	_	_	_	_
10	fraction	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	DLCL	_	O	O	_	_	_	_	_
13	cases	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	these	_	O	O	_	_	_	_	_
16	markers	_	O	O	_	_	_	_	_
17	may	_	O	O	_	_	_	_	_
18	serve	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	critical	_	O	O	_	_	_	_	_
21	tools	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	sensitive	_	O	O	_	_	_	_	_
24	monitoring	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	minimal	_	O	O	_	_	_	_	_
27	residual	_	O	O	_	_	_	_	_
28	disease	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	early	_	O	O	_	_	_	_	_
31	diagnosis	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	relapse	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	Gribben	_	O	O	_	_	_	_	_
36	et	_	O	O	_	_	_	_	_
37	al	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	1993	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	direct	_	O	O	_	_	_	_	_
3	interaction	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	adaptor	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	Cbl	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	b	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	kinase	_	O	O	_	_	_	_	_
14	zap	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	70	_	O	O	_	_	_	_	_
17	induces	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	positive	_	O	O	_	_	_	_	_
20	signal	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Engagement	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	TCR	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	complex	_	O	O	_	_	_	_	_
15	induces	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	rapid	_	O	O	_	_	_	_	_
18	increase	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	activities	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	Src	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	family	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	Syk	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	Zap	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	70	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	family	_	O	O	_	_	_	_	_
34	kinases	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	2	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	activated	_	O	O	_	_	_	_	_
3	kinases	_	O	O	_	_	_	_	_
4	then	_	O	O	_	_	_	_	_
5	induce	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	tyrosine	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	multiple	_	O	O	_	_	_	_	_
11	intracellular	_	O	O	_	_	_	_	_
12	proteins	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	eventually	_	O	O	_	_	_	_	_
15	leading	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	activation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	prominent	_	O	O	_	_	_	_	_
5	substrates	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	these	_	O	O	_	_	_	_	_
8	kinases	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	adaptor	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	Cbl	_	O	O	_	_	_	_	_
14	[	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	]	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	recent	_	O	O	_	_	_	_	_
19	studies	_	O	O	_	_	_	_	_
20	suggest	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	Cbl	_	O	O	_	_	_	_	_
23	negatively	_	O	O	_	_	_	_	_
24	regulates	_	O	O	_	_	_	_	_
25	upstream	_	O	O	_	_	_	_	_
26	kinases	_	O	O	_	_	_	_	_
27	such	_	O	O	_	_	_	_	_
28	as	_	O	O	_	_	_	_	_
29	Syk	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	Zap	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	70	_	O	O	_	_	_	_	_
34	[	_	O	O	_	_	_	_	_
35	4	_	O	O	_	_	_	_	_
36	]	_	O	O	_	_	_	_	_
37	[	_	O	O	_	_	_	_	_
38	5	_	O	O	_	_	_	_	_
39	]	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Cbl	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	b	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	homologue	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Cbl	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	widely	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	many	_	O	O	_	_	_	_	_
15	tissues	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	including	_	O	O	_	_	_	_	_
19	hematopoietic	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	[	_	O	O	_	_	_	_	_
25	7	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Cbl	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	b	_	O	O	_	_	_	_	_
4	undergoes	_	O	O	_	_	_	_	_
5	rapid	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	upon	_	O	O	_	_	_	_	_
9	stimulation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	TCR	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	cytokine	_	O	O	_	_	_	_	_
15	receptors	_	O	O	_	_	_	_	_
16	[	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	9	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	role	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Cbl	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	b	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	unclear	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	however	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	overexpression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Cbl	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	b	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	constitutive	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	transcription	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	nuclear	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	activated	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	NFAT	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	loss	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	function	_	O	O	_	_	_	_	_
7	mutation	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	Cbl	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	b	_	O	O	_	_	_	_	_
12	disrupted	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	interaction	_	O	O	_	_	_	_	_
15	between	_	O	O	_	_	_	_	_
16	Cbl	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	b	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	Zap	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	70	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	nearly	_	O	O	_	_	_	_	_
25	completely	_	O	O	_	_	_	_	_
26	abrogated	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	Cbl	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	b	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	mediated	_	O	O	_	_	_	_	_
33	activation	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	NFAT	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Unlike	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	proposed	_	O	O	_	_	_	_	_
4	role	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	Cbl	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	negative	_	O	O	_	_	_	_	_
10	regulator	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	our	_	O	O	_	_	_	_	_
13	results	_	O	O	_	_	_	_	_
14	suggest	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	Cbl	_	O	O	_	_	_	_	_
18	homologue	_	O	O	_	_	_	_	_
19	Cbl	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	b	_	O	O	_	_	_	_	_
22	has	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	positive	_	O	O	_	_	_	_	_
25	role	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	T	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	signaling	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	most	_	O	O	_	_	_	_	_
33	likely	_	O	O	_	_	_	_	_
34	via	_	O	O	_	_	_	_	_
35	a	_	O	O	_	_	_	_	_
36	direct	_	O	O	_	_	_	_	_
37	interaction	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	the	_	O	O	_	_	_	_	_
40	upstream	_	O	O	_	_	_	_	_
41	kinase	_	O	O	_	_	_	_	_
42	Zap	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	70	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_


1	Constitutive	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	HIV	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	tat	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	Jurkat	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	using	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	BK	_	O	O	_	_	_	_	_
17	virus	_	O	O	_	_	_	_	_
18	vector	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	production	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	characterization	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	Jurkat	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	lines	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	constitutively	_	O	O	_	_	_	_	_
11	express	_	O	O	_	_	_	_	_
12	functional	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	immune	_	O	O	_	_	_	_	_
15	deficiency	_	O	O	_	_	_	_	_
16	virus	_	O	O	_	_	_	_	_
17	type	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	HIV	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	tat	_	O	O	_	_	_	_	_
25	protein	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	using	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	BK	_	O	O	_	_	_	_	_
30	virus	_	O	O	_	_	_	_	_
31	plasmid	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	vector	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	HIV	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	tat	_	O	O	_	_	_	_	_
39	cDNA	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	is	_	O	O	_	_	_	_	_
42	described	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	increased	_	O	O	_	_	_	_	_
3	growth	_	O	O	_	_	_	_	_
4	rate	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	Jurkat	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	tat	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	lines	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	compared	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	control	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	lines	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	observed	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Growth	_	O	O	_	_	_	_	_
2	regulation	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	cellular	_	O	O	_	_	_	_	_
5	changes	_	O	O	_	_	_	_	_
6	during	_	O	O	_	_	_	_	_
7	differentiation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	prostatic	_	O	O	_	_	_	_	_
11	cancer	_	O	O	_	_	_	_	_
12	LNCaP	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	lymphocyte	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	conditioned	_	O	O	_	_	_	_	_
21	medium	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	prostatic	_	O	O	_	_	_	_	_
3	epithelial	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	androgen	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	LNCaP	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	line	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	examined	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	response	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	conditioned	_	O	O	_	_	_	_	_
19	medium	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	CM	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	derived	_	O	O	_	_	_	_	_
24	from	_	O	O	_	_	_	_	_
25	phytohemagglutinin	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	PHA	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	stimulated	_	O	O	_	_	_	_	_
31	lymphocytes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Addition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	CM	_	O	O	_	_	_	_	_
4	caused	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	greater	_	O	O	_	_	_	_	_
7	than	_	O	O	_	_	_	_	_
8	70	_	O	O	_	_	_	_	_
9	%	_	O	O	_	_	_	_	_
10	reduction	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	proliferation	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	counting	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	cycle	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	showed	_	O	O	_	_	_	_	_
4	G	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	phase	_	O	O	_	_	_	_	_
7	arrest	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	clonogenicity	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	reduced	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	growth	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	modulating	_	O	O	_	_	_	_	_
5	effect	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	dose	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	due	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	lysis	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	apoptosis	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	androgen	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	androgen	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	these	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	showed	_	O	O	_	_	_	_	_
12	approximately	_	O	O	_	_	_	_	_
13	50	_	O	O	_	_	_	_	_
14	%	_	O	O	_	_	_	_	_
15	reduction	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	underlining	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	proliferation	_	O	O	_	_	_	_	_
20	reduction	_	O	O	_	_	_	_	_
21	mechanism	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	prostate	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	antigen	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	PSA	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	downregulated	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	approximately	_	O	O	_	_	_	_	_
13	75	_	O	O	_	_	_	_	_
14	%	_	O	O	_	_	_	_	_
15	during	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	process	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Cell	_	O	O	_	_	_	_	_
2	morphology	_	O	O	_	_	_	_	_
3	showed	_	O	O	_	_	_	_	_
4	dendritic	_	O	O	_	_	_	_	_
5	processes	_	O	O	_	_	_	_	_
6	extending	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	cytoplasm	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	other	_	O	O	_	_	_	_	_
11	neuroendocrine	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	characteristics	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	several	_	O	O	_	_	_	_	_
5	cytoskeleton	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	intracellular	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	increased	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	determined	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	immunostaining	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	slides	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	ELISA	_	O	O	_	_	_	_	_
19	procedures	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	included	_	O	O	_	_	_	_	_
3	vimentin	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	correlating	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	shape	_	O	O	_	_	_	_	_
9	changes	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	cytokeratins	_	O	O	_	_	_	_	_
12	8	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	18	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	associated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	differentiated	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	types	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	prostate	_	O	O	_	_	_	_	_
23	epithelia	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	neuron	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	specific	_	O	O	_	_	_	_	_
29	enolase	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	serotonin	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	associated	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	neuroendocrine	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	From	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	cellular	_	O	O	_	_	_	_	_
4	changes	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	can	_	O	O	_	_	_	_	_
8	infer	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	growth	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	modulated	_	O	O	_	_	_	_	_
15	along	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	induction	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	terminal	_	O	O	_	_	_	_	_
20	differentiation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Activated	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	demonstrated	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	important	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	providing	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	modulating	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	growth	_	O	O	_	_	_	_	_
3	modulator	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	semipurified	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	had	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	estimated	_	O	O	_	_	_	_	_
10	molecular	_	O	O	_	_	_	_	_
11	weight	_	O	O	_	_	_	_	_
12	13	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	000	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	24	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	000	_	O	O	_	_	_	_	_
19	Da	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	activity	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	determined	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	distinct	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	TGF	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	TNF	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	some	_	O	O	_	_	_	_	_
15	commonly	_	O	O	_	_	_	_	_
16	known	_	O	O	_	_	_	_	_
17	lymphokines	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	interaction	_	O	O	_	_	_	_	_
3	between	_	O	O	_	_	_	_	_
4	lymphoid	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	prostatic	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	growth	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	development	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	described	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Lipopolysaccharide	_	O	O	_	_	_	_	_
2	induces	_	O	O	_	_	_	_	_
3	phosphorylation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	MAD	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Rel	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	related	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	monocytic	_	O	O	_	_	_	_	_
23	THP	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Many	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	lipopolysaccharide	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	LPS	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	including	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	immunodeficiency	_	O	O	_	_	_	_	_
17	virus	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	HIV	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	monocytic	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	mediated	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	activation	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	kappa	_	O	O	_	_	_	_	_
31	B	_	O	O	_	_	_	_	_
32	DNA	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	binding	_	O	O	_	_	_	_	_
35	proteins	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	members	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappa	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	Rel	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	factor	_	O	O	_	_	_	_	_
16	family	_	O	O	_	_	_	_	_
17	involved	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	LPS	_	O	O	_	_	_	_	_
21	response	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	mechanisms	_	O	O	_	_	_	_	_
26	through	_	O	O	_	_	_	_	_
27	which	_	O	O	_	_	_	_	_
28	LPS	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	generated	_	O	O	_	_	_	_	_
31	signals	_	O	O	_	_	_	_	_
32	are	_	O	O	_	_	_	_	_
33	transduced	_	O	O	_	_	_	_	_
34	remain	_	O	O	_	_	_	_	_
35	unclear	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	LPS	_	O	O	_	_	_	_	_
6	induces	_	O	O	_	_	_	_	_
7	nuclear	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Rel	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	p	_	O	O	_	_	_	_	_
15	50	_	O	O	_	_	_	_	_
16	heterodimers	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	well	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	50	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	65	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	NF	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	kappa	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	DNA	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	binding	_	O	O	_	_	_	_	_
36	complexes	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	human	_	O	O	_	_	_	_	_
39	monocytic	_	O	O	_	_	_	_	_
40	THP	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	cells	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	localization	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	proteins	_	O	O	_	_	_	_	_
6	occurred	_	O	O	_	_	_	_	_
7	concomitantly	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	rapid	_	O	O	_	_	_	_	_
11	decrease	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	their	_	O	O	_	_	_	_	_
14	cytosolic	_	O	O	_	_	_	_	_
15	levels	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	independent	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	phorbol	_	O	O	_	_	_	_	_
21	ester	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	sensitive	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	kinase	_	O	O	_	_	_	_	_
26	C	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Within	_	O	O	_	_	_	_	_
2	24	_	O	O	_	_	_	_	_
3	h	_	O	O	_	_	_	_	_
4	following	_	O	O	_	_	_	_	_
5	LPS	_	O	O	_	_	_	_	_
6	stimulation	_	O	O	_	_	_	_	_
7	there	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	striking	_	O	O	_	_	_	_	_
11	increase	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	c	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	Rel	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	105	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	50	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	cytosol	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	increased	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	these	_	O	O	_	_	_	_	_
6	proteins	_	O	O	_	_	_	_	_
7	correlated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	increases	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	amounts	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	their	_	O	O	_	_	_	_	_
15	mRNAs	_	O	O	_	_	_	_	_
16	during	_	O	O	_	_	_	_	_
17	LPS	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	THP	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	LPS	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	THP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	resulted	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	phosphorylation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	MAD	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	I	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	like	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	rapid	_	O	O	_	_	_	_	_
26	increase	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	MAD	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	mRNA	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	an	_	O	O	_	_	_	_	_
34	increase	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	MAD	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	protein	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	h	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	monocytic	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	results	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	c	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	Rel	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	50	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	50	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	65	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	kappa	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	induces	_	O	O	_	_	_	_	_
34	phosphorylation	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	MAD	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_


1	NFkappaB	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	65	_	O	O	_	_	_	_	_
4	/	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	50	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	NFATc	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	c	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	involved	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	GP	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	DNA	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	order	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	determine	_	O	O	_	_	_	_	_
5	whether	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	activated	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	GP	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	related	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	NFkappaB	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	NFAT	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	immuno	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	dot	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	blot	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	performed	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	representative	_	O	O	_	_	_	_	_
3	dot	_	O	O	_	_	_	_	_
4	blot	_	O	O	_	_	_	_	_
5	showing	_	O	O	_	_	_	_	_
6	staining	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	negative	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	positive	_	O	O	_	_	_	_	_
11	controls	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	recombinant	_	O	O	_	_	_	_	_
14	proteins	_	O	O	_	_	_	_	_
15	NFkappaB	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	52	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	c	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	rel	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	nuclear	_	O	O	_	_	_	_	_
24	extracts	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	PMA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	treated	_	O	O	_	_	_	_	_
29	Jurkat	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	positive	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	NFkappaB	_	O	O	_	_	_	_	_
34	p	_	O	O	_	_	_	_	_
35	50	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	p	_	O	O	_	_	_	_	_
38	65	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	NFATc	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	c	_	O	O	_	_	_	_	_
45	2	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	upper	_	O	O	_	_	_	_	_
50	panel	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	staining	_	O	O	_	_	_	_	_
53	of	_	O	O	_	_	_	_	_
54	nuclear	_	O	O	_	_	_	_	_
55	extracts	_	O	O	_	_	_	_	_
56	of	_	O	O	_	_	_	_	_
57	GP	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	treated	_	O	O	_	_	_	_	_
60	PBMC	_	O	O	_	_	_	_	_
61	(	_	O	O	_	_	_	_	_
62	positive	_	O	O	_	_	_	_	_
63	for	_	O	O	_	_	_	_	_
64	NFkappaB	_	O	O	_	_	_	_	_
65	p	_	O	O	_	_	_	_	_
66	65	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	p	_	O	O	_	_	_	_	_
69	50	_	O	O	_	_	_	_	_
70	and	_	O	O	_	_	_	_	_
71	NFAT	_	O	O	_	_	_	_	_
72	c	_	O	O	_	_	_	_	_
73	2	_	O	O	_	_	_	_	_
74	,	_	O	O	_	_	_	_	_
75	c	_	O	O	_	_	_	_	_
76	1	_	O	O	_	_	_	_	_
77	)	_	O	O	_	_	_	_	_
78	in	_	O	O	_	_	_	_	_
79	the	_	O	O	_	_	_	_	_
80	lower	_	O	O	_	_	_	_	_
81	panel	_	O	O	_	_	_	_	_
82	is	_	O	O	_	_	_	_	_
83	shown	_	O	O	_	_	_	_	_
84	(	_	O	O	_	_	_	_	_
85	n	_	O	O	_	_	_	_	_
86	=	_	O	O	_	_	_	_	_
87	3	_	O	O	_	_	_	_	_
88	)	_	O	O	_	_	_	_	_
89	.	_	O	O	_	_	_	_	_



1	Single	_	O	O	_	_	_	_	_
2	point	_	O	O	_	_	_	_	_
3	estimation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	glucocorticoid	_	O	O	_	_	_	_	_
6	receptors	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	lymphocytes	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	normal	_	O	O	_	_	_	_	_
11	subjects	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	children	_	O	O	_	_	_	_	_
15	under	_	O	O	_	_	_	_	_
16	long	_	O	O	_	_	_	_	_
17	term	_	O	O	_	_	_	_	_
18	glucocorticoid	_	O	O	_	_	_	_	_
19	treatment	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	single	_	O	O	_	_	_	_	_
3	point	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	receptors	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	GR	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	based	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	measurement	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	specific	_	O	O	_	_	_	_	_
20	dexamethasone	_	O	O	_	_	_	_	_
21	binding	_	O	O	_	_	_	_	_
22	has	_	O	O	_	_	_	_	_
23	been	_	O	O	_	_	_	_	_
24	developed	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	compared	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	common	_	O	O	_	_	_	_	_
30	multi	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	point	_	O	O	_	_	_	_	_
33	Scatchard	_	O	O	_	_	_	_	_
34	analysis	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	assay	_	O	O	_	_	_	_	_
3	conditions	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	concentration	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	ligand	_	O	O	_	_	_	_	_
9	20	_	O	O	_	_	_	_	_
10	nmol	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	l	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	incubation	_	O	O	_	_	_	_	_
15	time	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	h	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	count	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	mil	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	cells	_	O	O	_	_	_	_	_
2	/	_	O	O	_	_	_	_	_
3	tube	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	assay	_	O	O	_	_	_	_	_
7	volume	_	O	O	_	_	_	_	_
8	0	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	ml	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	found	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	optimal	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	attempt	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	undertaken	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	use	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	harvester	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	separation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	unbound	_	O	O	_	_	_	_	_
18	ligand	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Though	_	O	O	_	_	_	_	_
2	specifically	_	O	O	_	_	_	_	_
3	bound	_	O	O	_	_	_	_	_
4	dexamethasone	_	O	O	_	_	_	_	_
5	measured	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	whole	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	assay	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	using	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	harvester	_	O	O	_	_	_	_	_
16	correlated	_	O	O	_	_	_	_	_
17	well	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	almost	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	one	_	O	O	_	_	_	_	_
22	order	_	O	O	_	_	_	_	_
23	lower	_	O	O	_	_	_	_	_
24	values	_	O	O	_	_	_	_	_
25	obtained	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	latter	_	O	O	_	_	_	_	_
29	method	_	O	O	_	_	_	_	_
30	render	_	O	O	_	_	_	_	_
31	it	_	O	O	_	_	_	_	_
32	non	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	applicable	_	O	O	_	_	_	_	_
35	for	_	O	O	_	_	_	_	_
36	receptor	_	O	O	_	_	_	_	_
37	quantitation	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	9	_	O	O	_	_	_	_	_
5	healthy	_	O	O	_	_	_	_	_
6	volunteers	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	average	_	O	O	_	_	_	_	_
9	GR	_	O	O	_	_	_	_	_
10	concentration	_	O	O	_	_	_	_	_
11	7131	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1256	_	O	O	_	_	_	_	_
16	sites	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	correlated	_	O	O	_	_	_	_	_
21	excellently	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	those	_	O	O	_	_	_	_	_
24	obtained	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	Scatchard	_	O	O	_	_	_	_	_
28	analysis	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	single	_	O	O	_	_	_	_	_
3	point	_	O	O	_	_	_	_	_
4	assay	_	O	O	_	_	_	_	_
5	has	_	O	O	_	_	_	_	_
6	been	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	applied	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	determination	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	GH	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	children	_	O	O	_	_	_	_	_
16	treated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	large	_	O	O	_	_	_	_	_
19	doses	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	prednisone	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	average	_	O	O	_	_	_	_	_
3	values	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	healthy	_	O	O	_	_	_	_	_
6	volunteers	_	O	O	_	_	_	_	_
7	did	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	differ	_	O	O	_	_	_	_	_
10	significantly	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	those	_	O	O	_	_	_	_	_
13	found	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	these	_	O	O	_	_	_	_	_
16	children	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	though	_	O	O	_	_	_	_	_
19	much	_	O	O	_	_	_	_	_
20	broader	_	O	O	_	_	_	_	_
21	range	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	found	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	patients	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Preparation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	extracts	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	electrophoretic	_	O	O	_	_	_	_	_
7	mobility	_	O	O	_	_	_	_	_
8	shift	_	O	O	_	_	_	_	_
9	assays	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	EMSA	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	extracts	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	purified	_	O	O	_	_	_	_	_
5	PBMCs	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	prepared	_	O	O	_	_	_	_	_
8	according	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	technique	_	O	O	_	_	_	_	_
12	described	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	Trede	_	O	O	_	_	_	_	_
15	et	_	O	O	_	_	_	_	_
16	al	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	[	_	O	O	_	_	_	_	_
2	27	_	O	O	_	_	_	_	_
3	]	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	modified	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	our	_	O	O	_	_	_	_	_
8	experimental	_	O	O	_	_	_	_	_
9	setup	_	O	O	_	_	_	_	_
10	[	_	O	O	_	_	_	_	_
11	56	_	O	O	_	_	_	_	_
12	]	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	intensity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	shifted	_	O	O	_	_	_	_	_
5	bands	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	normalized	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	bands	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	unstimulated	_	O	O	_	_	_	_	_
12	controls	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Competition	_	O	O	_	_	_	_	_
2	experiments	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	labeled	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	unlabeled	_	O	O	_	_	_	_	_
7	mutated	_	O	O	_	_	_	_	_
8	oligos	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	cytokine	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	see	_	O	O	_	_	_	_	_
17	above	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	carried	_	O	O	_	_	_	_	_
21	out	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	order	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	prevent	_	O	O	_	_	_	_	_
26	non	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	specific	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	nuclear	_	O	O	_	_	_	_	_
32	proteins	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	such	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	excess	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	50	_	O	O	_	_	_	_	_
11	x	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	unlabeled	_	O	O	_	_	_	_	_
15	oligos	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	added	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	nuclear	_	O	O	_	_	_	_	_
21	extracts	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	specificity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	supershift	_	O	O	_	_	_	_	_
7	assays	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	NFkappaB	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	combined	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	65	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	50	_	O	O	_	_	_	_	_
17	antibody	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	performed	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	data	_	O	O	_	_	_	_	_
22	not	_	O	O	_	_	_	_	_
23	shown	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	exclude	_	O	O	_	_	_	_	_
3	non	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	specific	_	O	O	_	_	_	_	_
6	reactions	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	30	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	fold	_	O	O	_	_	_	_	_
12	molar	_	O	O	_	_	_	_	_
13	excess	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	Oct	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	DNA	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	unrelated	_	O	O	_	_	_	_	_
21	DNA	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	Table	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	used	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	which	_	O	O	_	_	_	_	_
30	did	_	O	O	_	_	_	_	_
31	not	_	O	O	_	_	_	_	_
32	compete	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	specific	_	O	O	_	_	_	_	_
35	binding	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_



1	Modulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	E	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	F	_	O	O	_	_	_	_	_
6	complexes	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	G	_	O	O	_	_	_	_	_
9	0	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	S	_	O	O	_	_	_	_	_
12	phase	_	O	O	_	_	_	_	_
13	transition	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	primary	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	lymphocytes	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	pocket	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	E	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	F	_	O	O	_	_	_	_	_
8	complexes	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	convergence	_	O	O	_	_	_	_	_
11	points	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	cycle	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	report	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	identified	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	monitored	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	pocket	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	E	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	F	_	O	O	_	_	_	_	_
17	complexes	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	human	_	O	O	_	_	_	_	_
20	primary	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	lymphocytes	_	O	O	_	_	_	_	_
24	after	_	O	O	_	_	_	_	_
25	activation	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	phorbol	_	O	O	_	_	_	_	_
28	12	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	myristate	_	O	O	_	_	_	_	_
31	13	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	acetate	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	previous	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	mouse	_	O	O	_	_	_	_	_
9	fibroblasts	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	E	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	F	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	DP	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	form	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	predominant	_	O	O	_	_	_	_	_
25	E	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	F	_	O	O	_	_	_	_	_
28	heterodimers	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	G	_	O	O	_	_	_	_	_
32	0	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	G	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	phases	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	human	_	O	O	_	_	_	_	_
40	B	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	lymphocyte	_	O	O	_	_	_	_	_
43	cell	_	O	O	_	_	_	_	_
44	cycle	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	whereas	_	O	O	_	_	_	_	_
47	E	_	O	O	_	_	_	_	_
48	2	_	O	O	_	_	_	_	_
49	F	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	3	_	O	O	_	_	_	_	_
54	are	_	O	O	_	_	_	_	_
55	first	_	O	O	_	_	_	_	_
56	detected	_	O	O	_	_	_	_	_
57	in	_	O	O	_	_	_	_	_
58	late	_	O	O	_	_	_	_	_
59	G	_	O	O	_	_	_	_	_
60	1	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	and	_	O	O	_	_	_	_	_
63	their	_	O	O	_	_	_	_	_
64	expression	_	O	O	_	_	_	_	_
65	levels	_	O	O	_	_	_	_	_
66	increase	_	O	O	_	_	_	_	_
67	towards	_	O	O	_	_	_	_	_
68	S	_	O	O	_	_	_	_	_
69	phase	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	Intriguingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	major	_	O	O	_	_	_	_	_
5	E	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	F	_	O	O	_	_	_	_	_
8	complex	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	we	_	O	O	_	_	_	_	_
11	detected	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	quiescent	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	consisted	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	pRB	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	E	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	F	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	DP	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Though	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	DP	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	increase	_	O	O	_	_	_	_	_
11	when	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	progress	_	O	O	_	_	_	_	_
14	from	_	O	O	_	_	_	_	_
15	G	_	O	O	_	_	_	_	_
16	0	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	S	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	proportion	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	DP	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	DP	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	remains	_	O	O	_	_	_	_	_
29	relatively	_	O	O	_	_	_	_	_
30	constant	_	O	O	_	_	_	_	_
31	during	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	cell	_	O	O	_	_	_	_	_
34	cycle	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	observed	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	increase	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	electrophoretic	_	O	O	_	_	_	_	_
8	mobility	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	predominant	_	O	O	_	_	_	_	_
12	E	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	F	_	O	O	_	_	_	_	_
15	components	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	DP	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	E	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	F	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	lymphocytes	_	O	O	_	_	_	_	_
29	progressed	_	O	O	_	_	_	_	_
30	from	_	O	O	_	_	_	_	_
31	G	_	O	O	_	_	_	_	_
32	0	_	O	O	_	_	_	_	_
33	into	_	O	O	_	_	_	_	_
34	early	_	O	O	_	_	_	_	_
35	G	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	increase	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	mobility	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	attributable	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	dephosphorylation	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	lambda	_	O	O	_	_	_	_	_
12	phosphatase	_	O	O	_	_	_	_	_
13	treatment	_	O	O	_	_	_	_	_
14	could	_	O	O	_	_	_	_	_
15	convert	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	slower	_	O	O	_	_	_	_	_
18	migrating	_	O	O	_	_	_	_	_
19	forms	_	O	O	_	_	_	_	_
20	into	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	corresponding	_	O	O	_	_	_	_	_
23	faster	_	O	O	_	_	_	_	_
24	mobility	_	O	O	_	_	_	_	_
25	forms	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	further	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	change	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	status	_	O	O	_	_	_	_	_
10	correlates	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	decrease	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	DNA	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	modulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	DNA	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	mediated	_	O	O	_	_	_	_	_
8	through	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	dephosphorylation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	DP	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	E	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	F	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	could	_	O	O	_	_	_	_	_
20	help	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	explain	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	lack	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vivo	_	O	O	_	_	_	_	_
28	DNA	_	O	O	_	_	_	_	_
29	footprinting	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	late	_	O	O	_	_	_	_	_
32	G	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	S	_	O	O	_	_	_	_	_
36	phases	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	gene	_	O	O	_	_	_	_	_
39	promoters	_	O	O	_	_	_	_	_
40	negatively	_	O	O	_	_	_	_	_
41	regulated	_	O	O	_	_	_	_	_
42	through	_	O	O	_	_	_	_	_
43	E	_	O	O	_	_	_	_	_
44	2	_	O	O	_	_	_	_	_
45	F	_	O	O	_	_	_	_	_
46	sites	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	suggests	_	O	O	_	_	_	_	_
49	a	_	O	O	_	_	_	_	_
50	novel	_	O	O	_	_	_	_	_
51	mechanism	_	O	O	_	_	_	_	_
52	for	_	O	O	_	_	_	_	_
53	controlling	_	O	O	_	_	_	_	_
54	E	_	O	O	_	_	_	_	_
55	2	_	O	O	_	_	_	_	_
56	F	_	O	O	_	_	_	_	_
57	transcriptional	_	O	O	_	_	_	_	_
58	activity	_	O	O	_	_	_	_	_
59	during	_	O	O	_	_	_	_	_
60	the	_	O	O	_	_	_	_	_
61	transition	_	O	O	_	_	_	_	_
62	from	_	O	O	_	_	_	_	_
63	quiescence	_	O	O	_	_	_	_	_
64	to	_	O	O	_	_	_	_	_
65	proliferation	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	zinc	_	O	O	_	_	_	_	_
3	finger	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	factor	_	O	O	_	_	_	_	_
6	Egr	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	essential	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	restricts	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	along	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	macrophage	_	O	O	_	_	_	_	_
18	lineage	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	isolated	_	O	O	_	_	_	_	_
4	cDNA	_	O	O	_	_	_	_	_
5	clones	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	myeloid	_	O	O	_	_	_	_	_
8	differentiation	_	O	O	_	_	_	_	_
9	primary	_	O	O	_	_	_	_	_
10	response	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	MyD	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	genes	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	activated	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	absence	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	de	_	O	O	_	_	_	_	_
22	novo	_	O	O	_	_	_	_	_
23	protein	_	O	O	_	_	_	_	_
24	synthesis	_	O	O	_	_	_	_	_
25	following	_	O	O	_	_	_	_	_
26	induction	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	differentiation	_	O	O	_	_	_	_	_
29	along	_	O	O	_	_	_	_	_
30	either	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	macrophage	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	granulocyte	_	O	O	_	_	_	_	_
35	lineage	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	human	_	O	O	_	_	_	_	_
38	myeloblastic	_	O	O	_	_	_	_	_
39	leukemia	_	O	O	_	_	_	_	_
40	HL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	60	_	O	O	_	_	_	_	_
43	cells	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	cDNA	_	O	O	_	_	_	_	_
3	clone	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	primary	_	O	O	_	_	_	_	_
7	response	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	expressed	_	O	O	_	_	_	_	_
11	upon	_	O	O	_	_	_	_	_
12	macrophage	_	O	O	_	_	_	_	_
13	differentiation	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	encoded	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	Egr	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	zinc	_	O	O	_	_	_	_	_
23	finger	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Egr	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	gene	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	observed	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	transcriptionally	_	O	O	_	_	_	_	_
11	silent	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	HL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	60	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	but	_	O	O	_	_	_	_	_
19	active	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	U	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	937	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	M	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	latter	_	O	O	_	_	_	_	_
31	two	_	O	O	_	_	_	_	_
32	being	_	O	O	_	_	_	_	_
33	predetermined	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	macrophage	_	O	O	_	_	_	_	_
36	differentiation	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Egr	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	antisense	_	O	O	_	_	_	_	_
5	oligomers	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	culture	_	O	O	_	_	_	_	_
9	media	_	O	O	_	_	_	_	_
10	blocked	_	O	O	_	_	_	_	_
11	macrophage	_	O	O	_	_	_	_	_
12	differentiation	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	myeloid	_	O	O	_	_	_	_	_
16	leukemia	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	lines	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	normal	_	O	O	_	_	_	_	_
21	myeloblasts	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	HL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	60	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	constitutively	_	O	O	_	_	_	_	_
6	expressing	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	Egr	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	transgene	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	HL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	60	_	O	O	_	_	_	_	_
16	Egr	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	could	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	induced	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	macrophage	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	but	_	O	O	_	_	_	_	_
27	not	_	O	O	_	_	_	_	_
28	granulocyte	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	differentiation	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Egr	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	essential	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	restricts	_	O	O	_	_	_	_	_
15	differentiation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	myeloblasts	_	O	O	_	_	_	_	_
18	along	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	macrophage	_	O	O	_	_	_	_	_
21	lineage	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	microtitre	_	O	O	_	_	_	_	_
3	assay	_	O	O	_	_	_	_	_
4	system	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	receptors	_	O	O	_	_	_	_	_
8	:	_	O	O	_	_	_	_	_
9	decreased	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	concentration	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	myocardial	_	O	O	_	_	_	_	_
14	infarction	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	major	_	O	O	_	_	_	_	_
3	difficulty	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	determination	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	glucocorticoid	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	sites	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	very	_	O	O	_	_	_	_	_
13	complicated	_	O	O	_	_	_	_	_
14	assay	_	O	O	_	_	_	_	_
15	procedure	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	describe	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	microtitre	_	O	O	_	_	_	_	_
7	assay	_	O	O	_	_	_	_	_
8	system	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	glucocorticoid	_	O	O	_	_	_	_	_
11	receptors	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	whole	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	competitive	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	radioassay	_	O	O	_	_	_	_	_
21	using	_	O	O	_	_	_	_	_
22	[	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	H	_	O	O	_	_	_	_	_
25	]	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	dexamethasone	_	O	O	_	_	_	_	_
28	as	_	O	O	_	_	_	_	_
29	radioligand	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	modification	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	previously	_	O	O	_	_	_	_	_
6	described	_	O	O	_	_	_	_	_
7	protocol	_	O	O	_	_	_	_	_
8	simplifies	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	reduces	_	O	O	_	_	_	_	_
11	laboratory	_	O	O	_	_	_	_	_
12	work	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	allows	_	O	O	_	_	_	_	_
15	assay	_	O	O	_	_	_	_	_
16	reproducibility	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	be	_	O	O	_	_	_	_	_
19	controlled	_	O	O	_	_	_	_	_
20	more	_	O	O	_	_	_	_	_
21	reliably	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	enabled	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	perform	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	test	_	O	O	_	_	_	_	_
7	on	_	O	O	_	_	_	_	_
8	multiple	_	O	O	_	_	_	_	_
9	blood	_	O	O	_	_	_	_	_
10	samples	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	parallel	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	we	_	O	O	_	_	_	_	_
15	investigated	_	O	O	_	_	_	_	_
16	cardiac	_	O	O	_	_	_	_	_
17	infarction	_	O	O	_	_	_	_	_
18	patients	_	O	O	_	_	_	_	_
19	over	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	12	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	day	_	O	O	_	_	_	_	_
24	period	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	test	_	O	O	_	_	_	_	_
27	if	_	O	O	_	_	_	_	_
28	glucocorticoid	_	O	O	_	_	_	_	_
29	receptor	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	altered	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	this	_	O	O	_	_	_	_	_
35	'	_	O	O	_	_	_	_	_
36	stressful	_	O	O	_	_	_	_	_
37	'	_	O	O	_	_	_	_	_
38	disease	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	first	_	O	O	_	_	_	_	_
4	day	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	disease	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	capacity	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	significantly	_	O	O	_	_	_	_	_
14	decreased	_	O	O	_	_	_	_	_
15	without	_	O	O	_	_	_	_	_
16	alteration	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	ligand	_	O	O	_	_	_	_	_
22	affinity	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	whereas	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	days	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	12	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	number	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	sites	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	normal	_	O	O	_	_	_	_	_
37	again	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	result	_	O	O	_	_	_	_	_
3	fits	_	O	O	_	_	_	_	_
4	well	_	O	O	_	_	_	_	_
5	into	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	general	_	O	O	_	_	_	_	_
8	observation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	stress	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	down	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	regulation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	immune	_	O	O	_	_	_	_	_
18	responses	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	1	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Dihydroxyvitamin	_	O	O	_	_	_	_	_
6	D	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	RNA	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	hematopoietic	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	1	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	25	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Dihydroxyvitamin	_	O	O	_	_	_	_	_
6	D	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	[	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	25	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	OH	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	induces	_	O	O	_	_	_	_	_
20	differentiation	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	inhibits	_	O	O	_	_	_	_	_
23	proliferation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	myeloid	_	O	O	_	_	_	_	_
26	leukemic	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	from	_	O	O	_	_	_	_	_
29	various	_	O	O	_	_	_	_	_
30	lines	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	patients	_	O	O	_	_	_	_	_
33	;	_	O	O	_	_	_	_	_
34	these	_	O	O	_	_	_	_	_
35	effects	_	O	O	_	_	_	_	_
36	are	_	O	O	_	_	_	_	_
37	probably	_	O	O	_	_	_	_	_
38	mediated	_	O	O	_	_	_	_	_
39	through	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	25	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	OH	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	2	_	O	O	_	_	_	_	_
48	D	_	O	O	_	_	_	_	_
49	3	_	O	O	_	_	_	_	_
50	receptor	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	Little	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	known	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	25	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	OH	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	D	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	RNA	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	hematopoietic	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	examined	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	modulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	25	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	OH	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	D	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	RNA	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	various	_	O	O	_	_	_	_	_
23	proliferating	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	nonproliferating	_	O	O	_	_	_	_	_
26	hematopoietic	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	OH	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	receptor	_	O	O	_	_	_	_	_
14	RNA	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	detected	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	various	_	O	O	_	_	_	_	_
19	kinds	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	hematopoietic	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	including	_	O	O	_	_	_	_	_
25	macrophages	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	activated	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	lymphocytes	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	well	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	lines	_	O	O	_	_	_	_	_
37	KG	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	myeloblasts	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	HL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	60	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	promyelocytes	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	ML	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	3	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	myelomonoblasts	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	U	_	O	O	_	_	_	_	_
59	937	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	THP	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	1	_	O	O	_	_	_	_	_
64	(	_	O	O	_	_	_	_	_
65	monoblasts	_	O	O	_	_	_	_	_
66	)	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	K	_	O	O	_	_	_	_	_
69	562	_	O	O	_	_	_	_	_
70	(	_	O	O	_	_	_	_	_
71	erythroblasts	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	,	_	O	O	_	_	_	_	_
74	and	_	O	O	_	_	_	_	_
75	S	_	O	O	_	_	_	_	_
76	-	_	O	O	_	_	_	_	_
77	LB	_	O	O	_	_	_	_	_
78	1	_	O	O	_	_	_	_	_
79	(	_	O	O	_	_	_	_	_
80	HTLV	_	O	O	_	_	_	_	_
81	-	_	O	O	_	_	_	_	_
82	1	_	O	O	_	_	_	_	_
83	-	_	O	O	_	_	_	_	_
84	transfected	_	O	O	_	_	_	_	_
85	T	_	O	O	_	_	_	_	_
86	lymphocytes	_	O	O	_	_	_	_	_
87	)	_	O	O	_	_	_	_	_
88	.	_	O	O	_	_	_	_	_

1	Receptor	_	O	O	_	_	_	_	_
2	transcripts	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	kilobases	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	kb	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	no	_	O	O	_	_	_	_	_
14	variant	_	O	O	_	_	_	_	_
15	sizes	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	observed	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	lines	_	O	O	_	_	_	_	_
4	examined	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	group	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	25	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	OH	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	D	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	receptors	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Most	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	lymphocyte	_	O	O	_	_	_	_	_
4	lines	_	O	O	_	_	_	_	_
5	expressed	_	O	O	_	_	_	_	_
6	negligible	_	O	O	_	_	_	_	_
7	levels	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	25	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	OH	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	D	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	RNA	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	however	_	O	O	_	_	_	_	_
24	;	_	O	O	_	_	_	_	_
25	analysis	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	lymphoid	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	myeloid	_	O	O	_	_	_	_	_
31	somatic	_	O	O	_	_	_	_	_
32	hybrid	_	O	O	_	_	_	_	_
33	suggested	_	O	O	_	_	_	_	_
34	that	_	O	O	_	_	_	_	_
35	suppression	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	expression	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	25	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	OH	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	2	_	O	O	_	_	_	_	_
46	D	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	receptor	_	O	O	_	_	_	_	_
49	RNA	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	B	_	O	O	_	_	_	_	_
52	lymphocytes	_	O	O	_	_	_	_	_
53	may	_	O	O	_	_	_	_	_
54	be	_	O	O	_	_	_	_	_
55	a	_	O	O	_	_	_	_	_
56	dominant	_	O	O	_	_	_	_	_
57	characteristic	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	HL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	60	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	cultured	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	7	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	mol	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	L	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	25	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	OH	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	D	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	24	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	72	_	O	O	_	_	_	_	_
29	hours	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	levels	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	expression	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	25	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	OH	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	D	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	receptor	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	its	_	O	O	_	_	_	_	_
48	RNA	_	O	O	_	_	_	_	_
49	were	_	O	O	_	_	_	_	_
50	examined	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	Levels	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	RNA	_	O	O	_	_	_	_	_
4	coding	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	not	_	O	O	_	_	_	_	_
10	modulated	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	exposure	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	high	_	O	O	_	_	_	_	_
15	levels	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	ligand	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Levels	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	occupied	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	OH	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	D	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	receptor	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	increased	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	these	_	O	O	_	_	_	_	_
18	HL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	60	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	total	_	O	O	_	_	_	_	_
26	number	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	25	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	OH	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	D	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	receptors	_	O	O	_	_	_	_	_
38	decreased	_	O	O	_	_	_	_	_
39	about	_	O	O	_	_	_	_	_
40	50	_	O	O	_	_	_	_	_
41	%	_	O	O	_	_	_	_	_
42	at	_	O	O	_	_	_	_	_
43	24	_	O	O	_	_	_	_	_
44	hours	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	returned	_	O	O	_	_	_	_	_
47	toward	_	O	O	_	_	_	_	_
48	normal	_	O	O	_	_	_	_	_
49	at	_	O	O	_	_	_	_	_
50	72	_	O	O	_	_	_	_	_
51	hours	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Steady	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	state	_	O	O	_	_	_	_	_
4	levels	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	25	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	OH	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	D	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	RNA	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	affected	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	terminal	_	O	O	_	_	_	_	_
22	differentiation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	HL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	60	_	O	O	_	_	_	_	_
27	toward	_	O	O	_	_	_	_	_
28	either	_	O	O	_	_	_	_	_
29	granulocytes	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	macrophages	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Nondividing	_	O	O	_	_	_	_	_
2	macrophages	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	normal	_	O	O	_	_	_	_	_
5	individuals	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	expressed	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	25	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	OH	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	D	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	RNA	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	nondividing	_	O	O	_	_	_	_	_
5	peripheral	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	normal	_	O	O	_	_	_	_	_
10	individuals	_	O	O	_	_	_	_	_
11	did	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	express	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	25	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	OH	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	D	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	receptor	_	O	O	_	_	_	_	_
24	RNA	_	O	O	_	_	_	_	_
25	;	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	stimulation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	proliferation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	these	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	accumulation	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	25	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	OH	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	D	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	receptor	_	O	O	_	_	_	_	_
46	RNA	_	O	O	_	_	_	_	_
47	increased	_	O	O	_	_	_	_	_
48	markedly	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Half	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	life	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	t	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	25	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	OH	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	D	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	receptor	_	O	O	_	_	_	_	_
21	RNA	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	lymphocytes	_	O	O	_	_	_	_	_
25	was	_	O	O	_	_	_	_	_
26	short	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	hour	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	determined	_	O	O	_	_	_	_	_
33	by	_	O	O	_	_	_	_	_
34	measuring	_	O	O	_	_	_	_	_
35	decay	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	message	_	O	O	_	_	_	_	_
39	after	_	O	O	_	_	_	_	_
40	addition	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	actinomycin	_	O	O	_	_	_	_	_
43	D	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	short	_	O	O	_	_	_	_	_
5	t	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	accumulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	25	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	OH	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	D	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	receptor	_	O	O	_	_	_	_	_
22	RNA	_	O	O	_	_	_	_	_
23	increased	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	their	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	synthesis	_	O	O	_	_	_	_	_
30	was	_	O	O	_	_	_	_	_
31	inhibited	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	required	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	understand	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	physiologic	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	25	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	OH	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	D	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	receptors	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	myeloid	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	proliferating	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	lymphocytes	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Phosphorylation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	transcription	_	O	O	_	_	_	_	_
5	factor	_	O	O	_	_	_	_	_
6	NFATp	_	O	O	_	_	_	_	_
7	inhibits	_	O	O	_	_	_	_	_
8	its	_	O	O	_	_	_	_	_
9	DNA	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	activity	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	cyclosporin	_	O	O	_	_	_	_	_
14	A	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	treated	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Cyclosporin	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	CsA	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	exerts	_	O	O	_	_	_	_	_
7	its	_	O	O	_	_	_	_	_
8	immunosuppressive	_	O	O	_	_	_	_	_
9	effect	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	inhibiting	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	nuclear	_	O	O	_	_	_	_	_
16	factor	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	activated	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	NFAT	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	thus	_	O	O	_	_	_	_	_
26	preventing	_	O	O	_	_	_	_	_
27	transcriptional	_	O	O	_	_	_	_	_
28	induction	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	several	_	O	O	_	_	_	_	_
31	cytokine	_	O	O	_	_	_	_	_
32	genes	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	thought	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	largely	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	through	_	O	O	_	_	_	_	_
10	inactivation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	phosphatase	_	O	O	_	_	_	_	_
14	calcineurin	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	turn	_	O	O	_	_	_	_	_
19	inhibits	_	O	O	_	_	_	_	_
20	translocation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	an	_	O	O	_	_	_	_	_
23	NFAT	_	O	O	_	_	_	_	_
24	component	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	nucleus	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	CsA	_	O	O	_	_	_	_	_
6	treatment	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	Raji	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	Jurkat	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	lines	_	O	O	_	_	_	_	_
15	yields	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	phosphorylated	_	O	O	_	_	_	_	_
18	form	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	NFATp	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	inhibited	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	DNA	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	its	_	O	O	_	_	_	_	_
31	ability	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	form	_	O	O	_	_	_	_	_
34	an	_	O	O	_	_	_	_	_
35	NFAT	_	O	O	_	_	_	_	_
36	complex	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	Fos	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	Jun	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	Immunoblot	_	O	O	_	_	_	_	_
2	analyses	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	metabolic	_	O	O	_	_	_	_	_
5	labeling	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	[	_	O	O	_	_	_	_	_
8	32	_	O	O	_	_	_	_	_
9	P	_	O	O	_	_	_	_	_
10	]	_	O	O	_	_	_	_	_
11	orthophosphate	_	O	O	_	_	_	_	_
12	show	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	CsA	_	O	O	_	_	_	_	_
15	alters	_	O	O	_	_	_	_	_
16	NFATp	_	O	O	_	_	_	_	_
17	migration	_	O	O	_	_	_	_	_
18	on	_	O	O	_	_	_	_	_
19	SDS	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	polyacrylamide	_	O	O	_	_	_	_	_
22	gel	_	O	O	_	_	_	_	_
23	electrophoresis	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	increasing	_	O	O	_	_	_	_	_
26	its	_	O	O	_	_	_	_	_
27	phosphorylation	_	O	O	_	_	_	_	_
28	level	_	O	O	_	_	_	_	_
29	without	_	O	O	_	_	_	_	_
30	affecting	_	O	O	_	_	_	_	_
31	subcellular	_	O	O	_	_	_	_	_
32	distribution	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Dephosphorylation	_	O	O	_	_	_	_	_
2	by	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	vitro	_	O	O	_	_	_	_	_
5	treatment	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	calcineurin	_	O	O	_	_	_	_	_
8	or	_	O	O	_	_	_	_	_
9	alkaline	_	O	O	_	_	_	_	_
10	phosphatase	_	O	O	_	_	_	_	_
11	restores	_	O	O	_	_	_	_	_
12	NFATp	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	its	_	O	O	_	_	_	_	_
18	ability	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	reconstitute	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	NFAT	_	O	O	_	_	_	_	_
23	complex	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	Fos	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	Jun	_	O	O	_	_	_	_	_
28	proteins	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	point	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	new	_	O	O	_	_	_	_	_
7	mechanism	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	CsA	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	sensitive	_	O	O	_	_	_	_	_
12	regulation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	NFATp	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	dephosphorylation	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	critical	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	DNA	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Increased	_	O	O	_	_	_	_	_
2	proliferation	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	cytotoxicity	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	after	_	O	O	_	_	_	_	_
10	stimulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	peripheral	_	O	O	_	_	_	_	_
14	blood	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	through	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	surface	_	O	O	_	_	_	_	_
20	ganglioside	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	GD	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	published	_	O	O	_	_	_	_	_
27	erratum	_	O	O	_	_	_	_	_
28	appears	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	J	_	O	O	_	_	_	_	_
31	Immunol	_	O	O	_	_	_	_	_
32	1994	_	O	O	_	_	_	_	_
33	Jul	_	O	O	_	_	_	_	_
34	15	_	O	O	_	_	_	_	_
35	;	_	O	O	_	_	_	_	_
36	153	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	:	_	O	O	_	_	_	_	_
41	910	_	O	O	_	_	_	_	_
42	]	_	O	O	_	_	_	_	_

1	Previous	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	have	_	O	O	_	_	_	_	_
4	suggested	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	gangliosides	_	O	O	_	_	_	_	_
7	have	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	important	_	O	O	_	_	_	_	_
10	role	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	signaling	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	recognition	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	their	_	O	O	_	_	_	_	_
4	specific	_	O	O	_	_	_	_	_
5	function	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	these	_	O	O	_	_	_	_	_
8	processes	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	clearly	_	O	O	_	_	_	_	_
13	defined	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	mAb	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	R	_	O	O	_	_	_	_	_
5	24	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	reacts	_	O	O	_	_	_	_	_
9	specifically	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	surface	_	O	O	_	_	_	_	_
14	ganglioside	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	GD	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	has	_	O	O	_	_	_	_	_
20	been	_	O	O	_	_	_	_	_
21	demonstrated	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	stimulate	_	O	O	_	_	_	_	_
24	proliferation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	derived	_	O	O	_	_	_	_	_
29	from	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	peripheral	_	O	O	_	_	_	_	_
32	blood	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	investigated	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	mechanisms	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	which	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	R	_	O	O	_	_	_	_	_
14	24	_	O	O	_	_	_	_	_
15	mAb	_	O	O	_	_	_	_	_
16	affects	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	functions	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	observed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	R	_	O	O	_	_	_	_	_
7	24	_	O	O	_	_	_	_	_
8	mAb	_	O	O	_	_	_	_	_
9	stimulates	_	O	O	_	_	_	_	_
10	GD	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	proliferation	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	cytotoxicity	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	surface	_	O	O	_	_	_	_	_
21	marker	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	R	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	chain	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	R	_	O	O	_	_	_	_	_
36	beta	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	chain	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	HLA	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	DR	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	CD	_	O	O	_	_	_	_	_
45	11	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	and	_	O	O	_	_	_	_	_
49	CD	_	O	O	_	_	_	_	_
50	11	_	O	O	_	_	_	_	_
51	c	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Additionally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IFN	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	but	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	present	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	culture	_	O	O	_	_	_	_	_
26	supernatants	_	O	O	_	_	_	_	_
27	72	_	O	O	_	_	_	_	_
28	h	_	O	O	_	_	_	_	_
29	after	_	O	O	_	_	_	_	_
30	R	_	O	O	_	_	_	_	_
31	24	_	O	O	_	_	_	_	_
32	stimulation	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	some	_	O	O	_	_	_	_	_
3	donors	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	increased	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	TNF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	alpha	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	detected	_	O	O	_	_	_	_	_
17	after	_	O	O	_	_	_	_	_
18	R	_	O	O	_	_	_	_	_
19	24	_	O	O	_	_	_	_	_
20	treatment	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	R	_	O	O	_	_	_	_	_
4	24	_	O	O	_	_	_	_	_
5	treatment	_	O	O	_	_	_	_	_
6	resulted	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	translocation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	rel	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	little	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	no	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	50	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	p	_	O	O	_	_	_	_	_
25	65	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	from	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	cytoplasm	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	nucleus	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	an	_	O	O	_	_	_	_	_
35	increase	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	NF	_	O	O	_	_	_	_	_
38	kappa	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	binding	_	O	O	_	_	_	_	_
41	complexes	_	O	O	_	_	_	_	_
42	containing	_	O	O	_	_	_	_	_
43	c	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	rel	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	p	_	O	O	_	_	_	_	_
48	50	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	treatment	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	caused	_	O	O	_	_	_	_	_
5	increased	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	specific	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	substrates	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	R	_	O	O	_	_	_	_	_
2	24	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	stimulated	_	O	O	_	_	_	_	_
5	increases	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	proliferation	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	cytotoxicity	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	surface	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	could	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	blocked	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	cyclosporin	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	staurosporin	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	indicating	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	cyclophilin	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	calcineurin	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	protein	_	O	O	_	_	_	_	_
31	kinase	_	O	O	_	_	_	_	_
32	C	_	O	O	_	_	_	_	_
33	may	_	O	O	_	_	_	_	_
34	be	_	O	O	_	_	_	_	_
35	involved	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	R	_	O	O	_	_	_	_	_
39	24	_	O	O	_	_	_	_	_
40	signaling	_	O	O	_	_	_	_	_
41	pathway	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Additionally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	herbimycin	_	O	O	_	_	_	_	_
4	A	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	tyrosine	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	inhibitor	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	blocked	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	R	_	O	O	_	_	_	_	_
14	24	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	stimulated	_	O	O	_	_	_	_	_
17	increase	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	proliferation	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	cytotoxicity	_	O	O	_	_	_	_	_
23	at	_	O	O	_	_	_	_	_
24	concentrations	_	O	O	_	_	_	_	_
25	consistent	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	specificity	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	tyrosine	_	O	O	_	_	_	_	_
30	kinases	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	multiple	_	O	O	_	_	_	_	_
6	biochemical	_	O	O	_	_	_	_	_
7	pathways	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	involved	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	R	_	O	O	_	_	_	_	_
19	24	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	c	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	rel	_	O	O	_	_	_	_	_
5	protooncogene	_	O	O	_	_	_	_	_
6	product	_	O	O	_	_	_	_	_
7	represses	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappa	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	65	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	mediated	_	O	O	_	_	_	_	_
16	transcriptional	_	O	O	_	_	_	_	_
17	activation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	long	_	O	O	_	_	_	_	_
21	terminal	_	O	O	_	_	_	_	_
22	repeat	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	type	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	immunodeficiency	_	O	O	_	_	_	_	_
28	virus	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	long	_	O	O	_	_	_	_	_
3	terminal	_	O	O	_	_	_	_	_
4	repeat	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	LTR	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	immunodeficiency	_	O	O	_	_	_	_	_
14	virus	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	HIV	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	5	_	O	O	_	_	_	_	_
23	'	_	O	O	_	_	_	_	_
24	regulatory	_	O	O	_	_	_	_	_
25	region	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	encoding	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	interleukin	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	receptor	_	O	O	_	_	_	_	_
34	alpha	_	O	O	_	_	_	_	_
35	subunit	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	2	_	O	O	_	_	_	_	_
40	R	_	O	O	_	_	_	_	_
41	alpha	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	share	_	O	O	_	_	_	_	_
44	functional	_	O	O	_	_	_	_	_
45	kappa	_	O	O	_	_	_	_	_
46	B	_	O	O	_	_	_	_	_
47	enhancer	_	O	O	_	_	_	_	_
48	elements	_	O	O	_	_	_	_	_
49	involved	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	regulation	_	O	O	_	_	_	_	_
53	of	_	O	O	_	_	_	_	_
54	these	_	O	O	_	_	_	_	_
55	inducible	_	O	O	_	_	_	_	_
56	transcription	_	O	O	_	_	_	_	_
57	units	_	O	O	_	_	_	_	_
58	during	_	O	O	_	_	_	_	_
59	T	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	cell	_	O	O	_	_	_	_	_
62	activation	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	kappa	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	enhancer	_	O	O	_	_	_	_	_
5	elements	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	recognized	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	structurally	_	O	O	_	_	_	_	_
11	related	_	O	O	_	_	_	_	_
12	family	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	interactive	_	O	O	_	_	_	_	_
15	proteins	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	includes	_	O	O	_	_	_	_	_
18	p	_	O	O	_	_	_	_	_
19	50	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	65	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	product	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	c	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	rel	_	O	O	_	_	_	_	_
32	protooncogene	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	c	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	Rel	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Recent	_	O	O	_	_	_	_	_
2	biochemical	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	65	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	50	_	O	O	_	_	_	_	_
12	form	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	prototypical	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	complex	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	which	_	O	O	_	_	_	_	_
22	is	_	O	O	_	_	_	_	_
23	rapidly	_	O	O	_	_	_	_	_
24	translocated	_	O	O	_	_	_	_	_
25	from	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	cytoplasm	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	nucleus	_	O	O	_	_	_	_	_
31	during	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	activation	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	intracellular	_	O	O	_	_	_	_	_
3	signaling	_	O	O	_	_	_	_	_
4	complex	_	O	O	_	_	_	_	_
5	potently	_	O	O	_	_	_	_	_
6	stimulates	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	directed	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	either	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	HIV	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	LTR	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	R	_	O	O	_	_	_	_	_
25	alpha	_	O	O	_	_	_	_	_
26	promoter	_	O	O	_	_	_	_	_
27	via	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	strong	_	O	O	_	_	_	_	_
30	transactivation	_	O	O	_	_	_	_	_
31	domain	_	O	O	_	_	_	_	_
32	present	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	p	_	O	O	_	_	_	_	_
35	65	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	now	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Rel	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	which	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	either	_	O	O	_	_	_	_	_
18	phorbol	_	O	O	_	_	_	_	_
19	ester	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	tumor	_	O	O	_	_	_	_	_
22	necrosis	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	alpha	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	delayed	_	O	O	_	_	_	_	_
27	kinetics	_	O	O	_	_	_	_	_
28	relative	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	p	_	O	O	_	_	_	_	_
31	65	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	markedly	_	O	O	_	_	_	_	_
34	represses	_	O	O	_	_	_	_	_
35	p	_	O	O	_	_	_	_	_
36	65	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	mediated	_	O	O	_	_	_	_	_
39	activation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	these	_	O	O	_	_	_	_	_
42	transcription	_	O	O	_	_	_	_	_
43	units	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	inhibitory	_	O	O	_	_	_	_	_
3	effects	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Rel	_	O	O	_	_	_	_	_
8	correlate	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	its	_	O	O	_	_	_	_	_
11	DNA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	activity	_	O	O	_	_	_	_	_
15	but	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	its	_	O	O	_	_	_	_	_
19	ability	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	heterodimerize	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	50	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	suggesting	_	O	O	_	_	_	_	_
27	that	_	O	O	_	_	_	_	_
28	c	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	Rel	_	O	O	_	_	_	_	_
31	inhibition	_	O	O	_	_	_	_	_
32	involves	_	O	O	_	_	_	_	_
33	competition	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	p	_	O	O	_	_	_	_	_
36	50	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	p	_	O	O	_	_	_	_	_
39	65	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	occupancy	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	kappa	_	O	O	_	_	_	_	_
45	B	_	O	O	_	_	_	_	_
46	enhancer	_	O	O	_	_	_	_	_
47	element	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Together	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	findings	_	O	O	_	_	_	_	_
5	suggest	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	one	_	O	O	_	_	_	_	_
8	function	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	c	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Rel	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	physiologic	_	O	O	_	_	_	_	_
17	repressor	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	HIV	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	LTR	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	R	_	O	O	_	_	_	_	_
29	alpha	_	O	O	_	_	_	_	_
30	promoters	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	serving	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	efficiently	_	O	O	_	_	_	_	_
35	counter	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	strong	_	O	O	_	_	_	_	_
38	transcriptional	_	O	O	_	_	_	_	_
39	activating	_	O	O	_	_	_	_	_
40	effects	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	p	_	O	O	_	_	_	_	_
43	65	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	Synergistic	_	O	O	_	_	_	_	_
2	interactions	_	O	O	_	_	_	_	_
3	between	_	O	O	_	_	_	_	_
4	overlapping	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	sites	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	serum	_	O	O	_	_	_	_	_
10	response	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	ELK	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	proteins	_	O	O	_	_	_	_	_
17	mediate	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	basal	_	O	O	_	_	_	_	_
20	enhancement	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	phorbol	_	O	O	_	_	_	_	_
23	ester	_	O	O	_	_	_	_	_
24	responsiveness	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	primate	_	O	O	_	_	_	_	_
27	cytomegalovirus	_	O	O	_	_	_	_	_
28	major	_	O	O	_	_	_	_	_
29	immediate	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	early	_	O	O	_	_	_	_	_
32	promoters	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	monocyte	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	lymphocyte	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	types	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_


1	Cytomegalovirus	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	CMV	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	infection	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	nonpermissive	_	O	O	_	_	_	_	_
8	or	_	O	O	_	_	_	_	_
9	persistent	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	many	_	O	O	_	_	_	_	_
12	lymphoid	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	myeloid	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	types	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	can	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	activated	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	differentiated	_	O	O	_	_	_	_	_
23	macrophages	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	shown	_	O	O	_	_	_	_	_
4	elsewhere	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	major	_	O	O	_	_	_	_	_
9	immediate	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	early	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	MIE	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	lytic	_	O	O	_	_	_	_	_
18	cycle	_	O	O	_	_	_	_	_
19	infectious	_	O	O	_	_	_	_	_
20	progeny	_	O	O	_	_	_	_	_
21	virus	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	can	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	induced	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	otherwise	_	O	O	_	_	_	_	_
28	nonpermissive	_	O	O	_	_	_	_	_
29	monocyte	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	like	_	O	O	_	_	_	_	_
32	U	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	937	_	O	O	_	_	_	_	_
35	cell	_	O	O	_	_	_	_	_
36	cultures	_	O	O	_	_	_	_	_
37	infected	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	either	_	O	O	_	_	_	_	_
40	human	_	O	O	_	_	_	_	_
41	CMV	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	HCMV	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	or	_	O	O	_	_	_	_	_
46	simian	_	O	O	_	_	_	_	_
47	CMV	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	SCMV	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	by	_	O	O	_	_	_	_	_
52	treatment	_	O	O	_	_	_	_	_
53	with	_	O	O	_	_	_	_	_
54	the	_	O	O	_	_	_	_	_
55	phorbol	_	O	O	_	_	_	_	_
56	ester	_	O	O	_	_	_	_	_
57	12	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	O	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	tetradecanoylphorbol	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	13	_	O	O	_	_	_	_	_
64	-	_	O	O	_	_	_	_	_
65	acetate	_	O	O	_	_	_	_	_
66	(	_	O	O	_	_	_	_	_
67	TPA	_	O	O	_	_	_	_	_
68	)	_	O	O	_	_	_	_	_
69	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	multicopy	_	O	O	_	_	_	_	_
3	basal	_	O	O	_	_	_	_	_
4	enhancer	_	O	O	_	_	_	_	_
5	motifs	_	O	O	_	_	_	_	_
6	within	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	SCMV	_	O	O	_	_	_	_	_
9	MIE	_	O	O	_	_	_	_	_
10	enhancer	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	namely	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	11	_	O	O	_	_	_	_	_
15	copies	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	16	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	bp	_	O	O	_	_	_	_	_
21	cyclic	_	O	O	_	_	_	_	_
22	AMP	_	O	O	_	_	_	_	_
23	response	_	O	O	_	_	_	_	_
24	element	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	CRE	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	copies	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	novel	_	O	O	_	_	_	_	_
33	17	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	bp	_	O	O	_	_	_	_	_
36	serum	_	O	O	_	_	_	_	_
37	response	_	O	O	_	_	_	_	_
38	factor	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	SRF	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	binding	_	O	O	_	_	_	_	_
43	sites	_	O	O	_	_	_	_	_
44	referred	_	O	O	_	_	_	_	_
45	to	_	O	O	_	_	_	_	_
46	as	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	SNE	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	SRF	_	O	O	_	_	_	_	_
51	/	_	O	O	_	_	_	_	_
52	NFkappaB	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	like	_	O	O	_	_	_	_	_
55	element	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	as	_	O	O	_	_	_	_	_
59	well	_	O	O	_	_	_	_	_
60	as	_	O	O	_	_	_	_	_
61	four	_	O	O	_	_	_	_	_
62	classical	_	O	O	_	_	_	_	_
63	NFkappaB	_	O	O	_	_	_	_	_
64	sites	_	O	O	_	_	_	_	_
65	within	_	O	O	_	_	_	_	_
66	the	_	O	O	_	_	_	_	_
67	HCMV	_	O	O	_	_	_	_	_
68	version	_	O	O	_	_	_	_	_
69	,	_	O	O	_	_	_	_	_
70	contribute	_	O	O	_	_	_	_	_
71	to	_	O	O	_	_	_	_	_
72	TPA	_	O	O	_	_	_	_	_
73	responsiveness	_	O	O	_	_	_	_	_
74	in	_	O	O	_	_	_	_	_
75	transient	_	O	O	_	_	_	_	_
76	assays	_	O	O	_	_	_	_	_
77	in	_	O	O	_	_	_	_	_
78	monocyte	_	O	O	_	_	_	_	_
79	and	_	O	O	_	_	_	_	_
80	T	_	O	O	_	_	_	_	_
81	-	_	O	O	_	_	_	_	_
82	cell	_	O	O	_	_	_	_	_
83	types	_	O	O	_	_	_	_	_
84	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	SCMV	_	O	O	_	_	_	_	_
3	SNE	_	O	O	_	_	_	_	_
4	sites	_	O	O	_	_	_	_	_
5	contain	_	O	O	_	_	_	_	_
6	potential	_	O	O	_	_	_	_	_
7	overlapping	_	O	O	_	_	_	_	_
8	core	_	O	O	_	_	_	_	_
9	recognition	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	motifs	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	SRF	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	Rel	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	NFkappaB	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	ETS	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	YY	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	class	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	factors	_	O	O	_	_	_	_	_
27	but	_	O	O	_	_	_	_	_
28	fail	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	respond	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	either	_	O	O	_	_	_	_	_
33	serum	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	tumor	_	O	O	_	_	_	_	_
36	necrosis	_	O	O	_	_	_	_	_
37	factor	_	O	O	_	_	_	_	_
38	alpha	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	evaluate	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	mechanism	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	TPA	_	O	O	_	_	_	_	_
9	responsiveness	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	SNE	_	O	O	_	_	_	_	_
13	motifs	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	related	_	O	O	_	_	_	_	_
18	16	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	bp	_	O	O	_	_	_	_	_
21	SEE	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	SRF	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	ETS	_	O	O	_	_	_	_	_
26	element	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	motif	_	O	O	_	_	_	_	_
29	found	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	HCMV	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	chimpanzee	_	O	O	_	_	_	_	_
35	CMV	_	O	O	_	_	_	_	_
36	MIE	_	O	O	_	_	_	_	_
37	enhancers	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	we	_	O	O	_	_	_	_	_
40	have	_	O	O	_	_	_	_	_
41	examined	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	functional	_	O	O	_	_	_	_	_
44	responses	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	protein	_	O	O	_	_	_	_	_
47	binding	_	O	O	_	_	_	_	_
48	properties	_	O	O	_	_	_	_	_
49	of	_	O	O	_	_	_	_	_
50	multimerized	_	O	O	_	_	_	_	_
51	wild	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	type	_	O	O	_	_	_	_	_
54	and	_	O	O	_	_	_	_	_
55	mutant	_	O	O	_	_	_	_	_
56	elements	_	O	O	_	_	_	_	_
57	added	_	O	O	_	_	_	_	_
58	upstream	_	O	O	_	_	_	_	_
59	to	_	O	O	_	_	_	_	_
60	the	_	O	O	_	_	_	_	_
61	SCMV	_	O	O	_	_	_	_	_
62	MIE	_	O	O	_	_	_	_	_
63	or	_	O	O	_	_	_	_	_
64	simian	_	O	O	_	_	_	_	_
65	virus	_	O	O	_	_	_	_	_
66	40	_	O	O	_	_	_	_	_
67	minimal	_	O	O	_	_	_	_	_
68	promoter	_	O	O	_	_	_	_	_
69	regions	_	O	O	_	_	_	_	_
70	in	_	O	O	_	_	_	_	_
71	the	_	O	O	_	_	_	_	_
72	U	_	O	O	_	_	_	_	_
73	-	_	O	O	_	_	_	_	_
74	937	_	O	O	_	_	_	_	_
75	,	_	O	O	_	_	_	_	_
76	K	_	O	O	_	_	_	_	_
77	-	_	O	O	_	_	_	_	_
78	562	_	O	O	_	_	_	_	_
79	,	_	O	O	_	_	_	_	_
80	HL	_	O	O	_	_	_	_	_
81	-	_	O	O	_	_	_	_	_
82	60	_	O	O	_	_	_	_	_
83	,	_	O	O	_	_	_	_	_
84	THP	_	O	O	_	_	_	_	_
85	-	_	O	O	_	_	_	_	_
86	1	_	O	O	_	_	_	_	_
87	,	_	O	O	_	_	_	_	_
88	and	_	O	O	_	_	_	_	_
89	Jurkat	_	O	O	_	_	_	_	_
90	cell	_	O	O	_	_	_	_	_
91	lines	_	O	O	_	_	_	_	_
92	.	_	O	O	_	_	_	_	_

1	Unlike	_	O	O	_	_	_	_	_
2	classical	_	O	O	_	_	_	_	_
3	NFkappaB	_	O	O	_	_	_	_	_
4	sites	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	neither	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	SNE	_	O	O	_	_	_	_	_
9	nor	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	SEE	_	O	O	_	_	_	_	_
12	motif	_	O	O	_	_	_	_	_
13	responded	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	phosphatase	_	O	O	_	_	_	_	_
16	inhibition	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	okadaic	_	O	O	_	_	_	_	_
19	acid	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	TPA	_	O	O	_	_	_	_	_
5	responsiveness	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	both	_	O	O	_	_	_	_	_
8	CMV	_	O	O	_	_	_	_	_
9	elements	_	O	O	_	_	_	_	_
10	proved	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	involve	_	O	O	_	_	_	_	_
13	synergistic	_	O	O	_	_	_	_	_
14	interactions	_	O	O	_	_	_	_	_
15	between	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	core	_	O	O	_	_	_	_	_
18	SRF	_	O	O	_	_	_	_	_
19	binding	_	O	O	_	_	_	_	_
20	site	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	CCATATATGG	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	adjacent	_	O	O	_	_	_	_	_
27	inverted	_	O	O	_	_	_	_	_
28	ETS	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	motifs	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	TTCC	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	which	_	O	O	_	_	_	_	_
36	correlated	_	O	O	_	_	_	_	_
37	directly	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	formation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	bound	_	O	O	_	_	_	_	_
43	tripartite	_	O	O	_	_	_	_	_
44	complex	_	O	O	_	_	_	_	_
45	containing	_	O	O	_	_	_	_	_
46	both	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	cellular	_	O	O	_	_	_	_	_
49	SRF	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	ELK	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	1	_	O	O	_	_	_	_	_
54	proteins	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	complex	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	more	_	O	O	_	_	_	_	_
6	abundant	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	U	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	937	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	K	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	562	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	HeLa	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	extracts	_	O	O	_	_	_	_	_
20	than	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	Raji	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	HF	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	BALB	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	c	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	HL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	60	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	but	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	binding	_	O	O	_	_	_	_	_
42	activity	_	O	O	_	_	_	_	_
43	was	_	O	O	_	_	_	_	_
44	altered	_	O	O	_	_	_	_	_
45	only	_	O	O	_	_	_	_	_
46	twofold	_	O	O	_	_	_	_	_
47	after	_	O	O	_	_	_	_	_
48	TPA	_	O	O	_	_	_	_	_
49	treatment	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	40	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	fold	_	O	O	_	_	_	_	_
5	stimulation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	chloramphenicol	_	O	O	_	_	_	_	_
8	acetyltransferase	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	mediated	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	four	_	O	O	_	_	_	_	_
13	tandem	_	O	O	_	_	_	_	_
14	repeats	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	SNE	_	O	O	_	_	_	_	_
18	could	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	within	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	h	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	up	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	250	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	fold	_	O	O	_	_	_	_	_
31	within	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	h	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	after	_	O	O	_	_	_	_	_
36	addition	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	TPA	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	DNA	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	transfected	_	O	O	_	_	_	_	_
43	U	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	937	_	O	O	_	_	_	_	_
46	cells	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	indicating	_	O	O	_	_	_	_	_
49	that	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	stimulation	_	O	O	_	_	_	_	_
52	appeared	_	O	O	_	_	_	_	_
53	likely	_	O	O	_	_	_	_	_
54	to	_	O	O	_	_	_	_	_
55	be	_	O	O	_	_	_	_	_
56	a	_	O	O	_	_	_	_	_
57	true	_	O	O	_	_	_	_	_
58	protein	_	O	O	_	_	_	_	_
59	kinase	_	O	O	_	_	_	_	_
60	C	_	O	O	_	_	_	_	_
61	-	_	O	O	_	_	_	_	_
62	mediated	_	O	O	_	_	_	_	_
63	signal	_	O	O	_	_	_	_	_
64	transduction	_	O	O	_	_	_	_	_
65	event	_	O	O	_	_	_	_	_
66	rather	_	O	O	_	_	_	_	_
67	than	_	O	O	_	_	_	_	_
68	a	_	O	O	_	_	_	_	_
69	differentiation	_	O	O	_	_	_	_	_
70	response	_	O	O	_	_	_	_	_
71	.	_	O	O	_	_	_	_	_

1	Slight	_	O	O	_	_	_	_	_
2	differences	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	sequence	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	core	_	O	O	_	_	_	_	_
9	SRF	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	site	_	O	O	_	_	_	_	_
12	compared	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	classical	_	O	O	_	_	_	_	_
18	c	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	Fos	_	O	O	_	_	_	_	_
21	promoter	_	O	O	_	_	_	_	_
22	serum	_	O	O	_	_	_	_	_
23	response	_	O	O	_	_	_	_	_
24	element	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	together	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	differences	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	spacing	_	O	O	_	_	_	_	_
32	between	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	SRF	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	ETS	_	O	O	_	_	_	_	_
37	motifs	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	appear	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	account	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	inability	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	SCMV	_	O	O	_	_	_	_	_
48	SNEs	_	O	O	_	_	_	_	_
49	to	_	O	O	_	_	_	_	_
50	respond	_	O	O	_	_	_	_	_
51	to	_	O	O	_	_	_	_	_
52	serum	_	O	O	_	_	_	_	_
53	induction	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_


1	Northern	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	mouse	_	O	O	_	_	_	_	_
3	embryonic	_	O	O	_	_	_	_	_
4	tissue	_	O	O	_	_	_	_	_
5	Northern	_	O	O	_	_	_	_	_
6	blot	_	O	O	_	_	_	_	_
7	filter	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	Seegene	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	Rockville	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	Maryland	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	United	_	O	O	_	_	_	_	_
16	States	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	hybridized	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	Sox	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	probe	_	O	O	_	_	_	_	_
25	generated	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	RT	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	PCR	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	nucleotides	_	O	O	_	_	_	_	_
32	1353	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1927	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	labeled	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	alpha	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	32	_	O	O	_	_	_	_	_
43	P	_	O	O	_	_	_	_	_
44	]	_	O	O	_	_	_	_	_
45	dCTP	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	random	_	O	O	_	_	_	_	_
49	primer	_	O	O	_	_	_	_	_
50	labeling	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	RediprimeII	_	O	O	_	_	_	_	_
53	;	_	O	O	_	_	_	_	_
54	Amersham	_	O	O	_	_	_	_	_
55	Biosciences	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	Buckinghamshire	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	England	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	United	_	O	O	_	_	_	_	_
62	Kingdom	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	hybridization	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	performed	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	phosphate	_	O	O	_	_	_	_	_
7	buffered	_	O	O	_	_	_	_	_
8	7	_	O	O	_	_	_	_	_
9	%	_	O	O	_	_	_	_	_
10	SDS	_	O	O	_	_	_	_	_
11	hybridization	_	O	O	_	_	_	_	_
12	solution	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Blots	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	washed	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	0	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	x	_	O	O	_	_	_	_	_
9	SSC	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	%	_	O	O	_	_	_	_	_
13	SDS	_	O	O	_	_	_	_	_
14	at	_	O	O	_	_	_	_	_
15	60	_	O	O	_	_	_	_	_
16	degreesC	_	O	O	_	_	_	_	_
17	prior	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	exposure	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	X	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	ray	_	O	O	_	_	_	_	_
24	film	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	Kodak	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	Rochester	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	New	_	O	O	_	_	_	_	_
31	York	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	United	_	O	O	_	_	_	_	_
34	States	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	80	_	O	O	_	_	_	_	_
39	degreesC	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	6	_	O	O	_	_	_	_	_
42	d	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_



1	Decreased	_	O	O	_	_	_	_	_
2	concentration	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	dihydroxyvitamin	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	receptors	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	peripheral	_	O	O	_	_	_	_	_
14	mononuclear	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	X	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	linked	_	O	O	_	_	_	_	_
22	hypophosphatemic	_	O	O	_	_	_	_	_
23	rickets	_	O	O	_	_	_	_	_
24	:	_	O	O	_	_	_	_	_
25	effect	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	phosphate	_	O	O	_	_	_	_	_
28	supplementation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Abnormal	_	O	O	_	_	_	_	_
2	renal	_	O	O	_	_	_	_	_
3	tubular	_	O	O	_	_	_	_	_
4	phosphate	_	O	O	_	_	_	_	_
5	transport	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	considered	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	primary	_	O	O	_	_	_	_	_
12	defect	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	X	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	linked	_	O	O	_	_	_	_	_
17	hypophosphatemic	_	O	O	_	_	_	_	_
18	rickets	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	XLH	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	resistance	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	vitamin	_	O	O	_	_	_	_	_
7	D	_	O	O	_	_	_	_	_
8	treatment	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	XLH	_	O	O	_	_	_	_	_
11	cannot	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	explained	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	hypophosphatemia	_	O	O	_	_	_	_	_
16	alone	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Since	_	O	O	_	_	_	_	_
2	most	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	actions	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	vitamin	_	O	O	_	_	_	_	_
8	D	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	mediated	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	its	_	O	O	_	_	_	_	_
13	receptors	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	VDR	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	abnormalities	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	VDR	_	O	O	_	_	_	_	_
21	have	_	O	O	_	_	_	_	_
22	been	_	O	O	_	_	_	_	_
23	postulated	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	XLH	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	order	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	investigate	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	possibility	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	measured	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	concentration	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	VDR	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	PHA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	activated	_	O	O	_	_	_	_	_
18	peripheral	_	O	O	_	_	_	_	_
19	mononuclear	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	XLH	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Patients	_	O	O	_	_	_	_	_
2	without	_	O	O	_	_	_	_	_
3	phosphate	_	O	O	_	_	_	_	_
4	supplementation	_	O	O	_	_	_	_	_
5	showed	_	O	O	_	_	_	_	_
6	significantly	_	O	O	_	_	_	_	_
7	lower	_	O	O	_	_	_	_	_
8	concentration	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	21	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	7	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	fmol	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	mg	_	O	O	_	_	_	_	_
22	protein	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	mean	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	SEM	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	compared	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	normal	_	O	O	_	_	_	_	_
34	controls	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	60	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_
38	7	_	O	O	_	_	_	_	_
39	+	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	4	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_
44	0	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	there	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	no	_	O	O	_	_	_	_	_
8	significant	_	O	O	_	_	_	_	_
9	difference	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	phosphate	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	supplemented	_	O	O	_	_	_	_	_
15	patients	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	58	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	7	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	controls	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	positive	_	O	O	_	_	_	_	_
6	correlation	_	O	O	_	_	_	_	_
7	between	_	O	O	_	_	_	_	_
8	VDR	_	O	O	_	_	_	_	_
9	concentration	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	serum	_	O	O	_	_	_	_	_
12	phosphate	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	P	_	O	O	_	_	_	_	_
15	less	_	O	O	_	_	_	_	_
16	than	_	O	O	_	_	_	_	_
17	0	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	05	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	two	_	O	O	_	_	_	_	_
3	patients	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	VDR	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	increased	_	O	O	_	_	_	_	_
8	after	_	O	O	_	_	_	_	_
9	daily	_	O	O	_	_	_	_	_
10	phosphate	_	O	O	_	_	_	_	_
11	supplementation	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	started	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	decreased	_	O	O	_	_	_	_	_
7	concentration	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	VDR	_	O	O	_	_	_	_	_
10	secondary	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	persistent	_	O	O	_	_	_	_	_
13	hypophosphatemia	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	one	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	causes	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	vitamin	_	O	O	_	_	_	_	_
21	D	_	O	O	_	_	_	_	_
22	resistance	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	XLH	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Discussion	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	show	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	novel	_	O	O	_	_	_	_	_
13	factor	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	complicated	_	O	O	_	_	_	_	_
17	regulation	_	O	O	_	_	_	_	_
18	mechanism	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	globin	_	O	O	_	_	_	_	_
21	genes	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	null	_	O	O	_	_	_	_	_
6	mouse	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	there	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	transient	_	O	O	_	_	_	_	_
12	effect	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	embryonic	_	O	O	_	_	_	_	_
16	globin	_	O	O	_	_	_	_	_
17	genes	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	zeta	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	betaH	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	persistent	_	O	O	_	_	_	_	_
27	upregulation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	epsilony	_	O	O	_	_	_	_	_
31	globin	_	O	O	_	_	_	_	_
32	gene	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	directly	_	O	O	_	_	_	_	_
4	regulates	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	binds	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	proximal	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	epsilony	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	represses	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	epsilony	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	globin	_	O	O	_	_	_	_	_
20	gene	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	definitive	_	O	O	_	_	_	_	_
23	erythropoiesis	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	belongs	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	group	_	O	O	_	_	_	_	_
6	D	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	family	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	proteins	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	includes	_	O	O	_	_	_	_	_
15	Sox	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	12	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	13	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	23	_	O	O	_	_	_	_	_
24	[	_	O	O	_	_	_	_	_
25	34	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Group	_	O	O	_	_	_	_	_
2	D	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	contain	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	coiled	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	coiled	_	O	O	_	_	_	_	_
10	domain	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	mediates	_	O	O	_	_	_	_	_
13	homo	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	heterodimerization	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	35	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Functionally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	dimerization	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	5	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	has	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	shown	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	greatly	_	O	O	_	_	_	_	_
15	increase	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	efficiency	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	two	_	O	O	_	_	_	_	_
22	Sox	_	O	O	_	_	_	_	_
23	proteins	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	DNA	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	contains	_	O	O	_	_	_	_	_
28	adjacent	_	O	O	_	_	_	_	_
29	Sox	_	O	O	_	_	_	_	_
30	sites	_	O	O	_	_	_	_	_
31	[	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	binds	_	O	O	_	_	_	_	_
7	more	_	O	O	_	_	_	_	_
8	strongly	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	an	_	O	O	_	_	_	_	_
11	HMG	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	box	_	O	O	_	_	_	_	_
14	dimer	_	O	O	_	_	_	_	_
15	motif	_	O	O	_	_	_	_	_
16	than	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	single	_	O	O	_	_	_	_	_
20	HMG	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	box	_	O	O	_	_	_	_	_
23	motif	_	O	O	_	_	_	_	_
24	[	_	O	O	_	_	_	_	_
25	5	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	appears	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	target	_	O	O	_	_	_	_	_
7	genes	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	group	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	Sox	_	O	O	_	_	_	_	_
12	proteins	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	such	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	Sox	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	probably	_	O	O	_	_	_	_	_
20	harbor	_	O	O	_	_	_	_	_
21	pairs	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	HMG	_	O	O	_	_	_	_	_
24	binding	_	O	O	_	_	_	_	_
25	sites	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	configuration	_	O	O	_	_	_	_	_
29	compatible	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	binding	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	D	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	Sox	_	O	O	_	_	_	_	_
36	protein	_	O	O	_	_	_	_	_
37	dimers	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Indeed	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	present	_	O	O	_	_	_	_	_
6	study	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	defined	_	O	O	_	_	_	_	_
10	Sox	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	target	_	O	O	_	_	_	_	_
13	sequence	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	epsilony	_	O	O	_	_	_	_	_
17	promoter	_	O	O	_	_	_	_	_
18	contains	_	O	O	_	_	_	_	_
19	two	_	O	O	_	_	_	_	_
20	Sox	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	Sox	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	consensus	_	O	O	_	_	_	_	_
25	sites	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	Figure	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	A	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Functionally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	both	_	O	O	_	_	_	_	_
4	sites	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	essential	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	repression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	its	_	O	O	_	_	_	_	_
19	activity	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Figure	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	E	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	F	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	binds	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	this	_	O	O	_	_	_	_	_
10	sequence	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	either	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	homodimer	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	heterodimer	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	other	_	O	O	_	_	_	_	_
25	Sox	_	O	O	_	_	_	_	_
26	proteins	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	Sox	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	recognize	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	short	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	bp	_	O	O	_	_	_	_	_
10	core	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	sequence	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	allows	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	considerable	_	O	O	_	_	_	_	_
18	degeneracy	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	specificity	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	their	_	O	O	_	_	_	_	_
24	actions	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	thought	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	rely	_	O	O	_	_	_	_	_
29	upon	_	O	O	_	_	_	_	_
30	interactions	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	other	_	O	O	_	_	_	_	_
33	transcription	_	O	O	_	_	_	_	_
34	factors	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	36	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	our	_	O	O	_	_	_	_	_
3	EMSAs	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	had	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	run	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	electrophoresis	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	%	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	%	_	O	O	_	_	_	_	_
18	gel	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	least	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	8	_	O	O	_	_	_	_	_
25	h	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	detect	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	Sox	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	associated	_	O	O	_	_	_	_	_
33	band	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	suggesting	_	O	O	_	_	_	_	_
36	that	_	O	O	_	_	_	_	_
37	Sox	_	O	O	_	_	_	_	_
38	6	_	O	O	_	_	_	_	_
39	is	_	O	O	_	_	_	_	_
40	part	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	high	_	O	O	_	_	_	_	_
44	molecular	_	O	O	_	_	_	_	_
45	weight	_	O	O	_	_	_	_	_
46	complex	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	few	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	epsilony	_	O	O	_	_	_	_	_
5	globin	_	O	O	_	_	_	_	_
6	repressors	_	O	O	_	_	_	_	_
7	have	_	O	O	_	_	_	_	_
8	been	_	O	O	_	_	_	_	_
9	reported	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	bind	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	DNA	_	O	O	_	_	_	_	_
14	sequences	_	O	O	_	_	_	_	_
15	near	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	Sox	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	Sox	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	consensus	_	O	O	_	_	_	_	_
22	sites	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	including	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	DRED	_	O	O	_	_	_	_	_
27	complex	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	37	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	COUP	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	TF	_	O	O	_	_	_	_	_
35	[	_	O	O	_	_	_	_	_
36	38	_	O	O	_	_	_	_	_
37	]	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	might	_	O	O	_	_	_	_	_
4	interact	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	these	_	O	O	_	_	_	_	_
7	factors	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	form	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	large	_	O	O	_	_	_	_	_
12	repression	_	O	O	_	_	_	_	_
13	complex	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Identification	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	components	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	Sox	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	containing	_	O	O	_	_	_	_	_
11	complex	_	O	O	_	_	_	_	_
12	associated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	epsilony	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	will	_	O	O	_	_	_	_	_
18	shed	_	O	O	_	_	_	_	_
19	light	_	O	O	_	_	_	_	_
20	on	_	O	O	_	_	_	_	_
21	its	_	O	O	_	_	_	_	_
22	mechanism	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	repression	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	proteins	_	O	O	_	_	_	_	_
3	bind	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	bend	_	O	O	_	_	_	_	_
6	linear	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	partial	_	O	O	_	_	_	_	_
10	intercalation	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	minor	_	O	O	_	_	_	_	_
14	groove	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	can	_	O	O	_	_	_	_	_
18	also	_	O	O	_	_	_	_	_
19	bind	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	four	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	way	_	O	O	_	_	_	_	_
24	junctions	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	one	_	O	O	_	_	_	_	_
4	attractive	_	O	O	_	_	_	_	_
5	model	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	explain	_	O	O	_	_	_	_	_
8	how	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	control	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	they	_	O	O	_	_	_	_	_
18	function	_	O	O	_	_	_	_	_
19	as	_	O	O	_	_	_	_	_
20	architectural	_	O	O	_	_	_	_	_
21	factors	_	O	O	_	_	_	_	_
22	bound	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	DNA	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	influencing	_	O	O	_	_	_	_	_
27	local	_	O	O	_	_	_	_	_
28	chromatin	_	O	O	_	_	_	_	_
29	structure	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	bending	_	O	O	_	_	_	_	_
32	DNA	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	assembling	_	O	O	_	_	_	_	_
36	multiprotein	_	O	O	_	_	_	_	_
37	transcriptional	_	O	O	_	_	_	_	_
38	complexes	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	changing	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	local	_	O	O	_	_	_	_	_
5	chromatin	_	O	O	_	_	_	_	_
6	structure	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	could	_	O	O	_	_	_	_	_
11	either	_	O	O	_	_	_	_	_
12	interfere	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	other	_	O	O	_	_	_	_	_
17	activators	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	facilitate	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	other	_	O	O	_	_	_	_	_
26	repressors	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Another	_	O	O	_	_	_	_	_
2	example	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	repressor	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	interferes	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	activator	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	DRED	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	DRED	_	O	O	_	_	_	_	_
2	interferes	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	EKLF	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	activator	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	39	_	O	O	_	_	_	_	_
17	]	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	HMG	_	O	O	_	_	_	_	_
3	architectural	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	distantly	_	O	O	_	_	_	_	_
7	related	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	Sox	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	transcription	_	O	O	_	_	_	_	_
14	factors	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	HMG	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	I	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	HMG	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	Y	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	were	_	O	O	_	_	_	_	_
26	demonstrated	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	bind	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	human	_	O	O	_	_	_	_	_
32	adult	_	O	O	_	_	_	_	_
33	beta	_	O	O	_	_	_	_	_
34	globin	_	O	O	_	_	_	_	_
35	silencers	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	silencers	_	O	O	_	_	_	_	_
38	I	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	II	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	cause	_	O	O	_	_	_	_	_
44	bending	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	DNA	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	facilitating	_	O	O	_	_	_	_	_
50	the	_	O	O	_	_	_	_	_
51	binding	_	O	O	_	_	_	_	_
52	of	_	O	O	_	_	_	_	_
53	other	_	O	O	_	_	_	_	_
54	repressors	_	O	O	_	_	_	_	_
55	[	_	O	O	_	_	_	_	_
56	40	_	O	O	_	_	_	_	_
57	]	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	temporally	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	spatially	_	O	O	_	_	_	_	_
8	coincident	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	definitive	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	primitive	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	erythropoiesis	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	Figure	_	O	O	_	_	_	_	_
19	6	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	Sox	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	represses	_	O	O	_	_	_	_	_
26	epsilony	_	O	O	_	_	_	_	_
27	globin	_	O	O	_	_	_	_	_
28	expression	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	vivo	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	Figure	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	vitro	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	Figure	_	O	O	_	_	_	_	_
41	2	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	situ	_	O	O	_	_	_	_	_
5	hybridization	_	O	O	_	_	_	_	_
6	clearly	_	O	O	_	_	_	_	_
7	shows	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	persistent	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	globin	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	100	_	O	O	_	_	_	_	_
18	H	_	O	O	_	_	_	_	_
19	mutant	_	O	O	_	_	_	_	_
20	mice	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	due	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	defects	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	silencing	_	O	O	_	_	_	_	_
28	mechanism	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	definitive	_	O	O	_	_	_	_	_
31	erythropoiesis	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	takes	_	O	O	_	_	_	_	_
34	place	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	liver	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	Figure	_	O	O	_	_	_	_	_
40	5	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	data	_	O	O	_	_	_	_	_
6	demonstrate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	functions	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	definitive	_	O	O	_	_	_	_	_
13	erythropoiesis	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	silence	_	O	O	_	_	_	_	_
16	epsilony	_	O	O	_	_	_	_	_
17	globin	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	level	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	epsilony	_	O	O	_	_	_	_	_
6	globin	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	homozygous	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	null	_	O	O	_	_	_	_	_
12	mice	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	15	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	dpc	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	18	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	5	_	O	O	_	_	_	_	_
22	dpc	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	statistically	_	O	O	_	_	_	_	_
25	equivalent	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	level	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	betamaj	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	min	_	O	O	_	_	_	_	_
33	expression	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	livers	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	15	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	5	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	dpc	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	18	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_
46	5	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	dpc	_	O	O	_	_	_	_	_
49	homozygous	_	O	O	_	_	_	_	_
50	WT	_	O	O	_	_	_	_	_
51	mice	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	Figure	_	O	O	_	_	_	_	_
54	1	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	demonstrates	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	ectopic	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	quite	_	O	O	_	_	_	_	_
13	robust	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	homozygous	_	O	O	_	_	_	_	_
16	mutant	_	O	O	_	_	_	_	_
17	mice	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	other	_	O	O	_	_	_	_	_
7	embryonic	_	O	O	_	_	_	_	_
8	globin	_	O	O	_	_	_	_	_
9	genes	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	zeta	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	betah	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	also	_	O	O	_	_	_	_	_
18	higher	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	100	_	O	O	_	_	_	_	_
22	H	_	O	O	_	_	_	_	_
23	homozygotes	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	compared	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	WT	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Like	_	O	O	_	_	_	_	_
2	epsilony	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	levels	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	zeta	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	betah	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	dramatically	_	O	O	_	_	_	_	_
12	higher	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	mutant	_	O	O	_	_	_	_	_
15	mice	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	15	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	dpc	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	unlike	_	O	O	_	_	_	_	_
4	epsilony	_	O	O	_	_	_	_	_
5	globin	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	zeta	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	betah	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	decline	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	day	_	O	O	_	_	_	_	_
16	18	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	dpc	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Figure	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	suggesting	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	epsilony	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	regulated	_	O	O	_	_	_	_	_
30	differently	_	O	O	_	_	_	_	_
31	than	_	O	O	_	_	_	_	_
32	zeta	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	betah	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	possible	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	has	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	general	_	O	O	_	_	_	_	_
10	effect	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	embryonic	_	O	O	_	_	_	_	_
13	globin	_	O	O	_	_	_	_	_
14	genes	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	erythrocyte	_	O	O	_	_	_	_	_
18	maturation	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	addition	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	specific	_	O	O	_	_	_	_	_
25	role	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	silencing	_	O	O	_	_	_	_	_
28	epsilony	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	Although	_	O	O	_	_	_	_	_
2	most	_	O	O	_	_	_	_	_
3	p	_	O	O	_	_	_	_	_
4	100	_	O	O	_	_	_	_	_
5	H	_	O	O	_	_	_	_	_
6	mutant	_	O	O	_	_	_	_	_
7	mice	_	O	O	_	_	_	_	_
8	die	_	O	O	_	_	_	_	_
9	just	_	O	O	_	_	_	_	_
10	after	_	O	O	_	_	_	_	_
11	being	_	O	O	_	_	_	_	_
12	born	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	rare	_	O	O	_	_	_	_	_
16	few	_	O	O	_	_	_	_	_
17	survive	_	O	O	_	_	_	_	_
18	longer	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	None	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	been	_	O	O	_	_	_	_	_
4	observed	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	live	_	O	O	_	_	_	_	_
7	longer	_	O	O	_	_	_	_	_
8	than	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	wk	_	O	O	_	_	_	_	_
11	after	_	O	O	_	_	_	_	_
12	birth	_	O	O	_	_	_	_	_
13	[	_	O	O	_	_	_	_	_
14	14	_	O	O	_	_	_	_	_
15	]	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	examined	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	single	_	O	O	_	_	_	_	_
5	archived	_	O	O	_	_	_	_	_
6	sample	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	liver	_	O	O	_	_	_	_	_
9	RNA	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	mutant	_	O	O	_	_	_	_	_
13	mouse	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	postnatal	_	O	O	_	_	_	_	_
16	day	_	O	O	_	_	_	_	_
17	13	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	globin	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	detected	_	O	O	_	_	_	_	_
26	high	_	O	O	_	_	_	_	_
27	levels	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	epsilony	_	O	O	_	_	_	_	_
30	globin	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	this	_	O	O	_	_	_	_	_
33	RNA	_	O	O	_	_	_	_	_
34	sample	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	compared	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	undetectable	_	O	O	_	_	_	_	_
39	epsilony	_	O	O	_	_	_	_	_
40	RNA	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	WT	_	O	O	_	_	_	_	_
43	control	_	O	O	_	_	_	_	_
44	mice	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	point	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	development	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	levels	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	zeta	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	betah	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	RNA	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	undetectable	_	O	O	_	_	_	_	_
17	both	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	mutant	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	WT	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	however	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	adult	_	O	O	_	_	_	_	_
26	beta	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	like	_	O	O	_	_	_	_	_
29	globin	_	O	O	_	_	_	_	_
30	RNA	_	O	O	_	_	_	_	_
31	levels	_	O	O	_	_	_	_	_
32	were	_	O	O	_	_	_	_	_
33	moderately	_	O	O	_	_	_	_	_
34	elevated	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	mutant	_	O	O	_	_	_	_	_
38	RNA	_	O	O	_	_	_	_	_
39	compared	_	O	O	_	_	_	_	_
40	with	_	O	O	_	_	_	_	_
41	WT	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	unpublished	_	O	O	_	_	_	_	_
44	data	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	similar	_	O	O	_	_	_	_	_
48	to	_	O	O	_	_	_	_	_
49	what	_	O	O	_	_	_	_	_
50	we	_	O	O	_	_	_	_	_
51	observe	_	O	O	_	_	_	_	_
52	at	_	O	O	_	_	_	_	_
53	18	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_
55	5	_	O	O	_	_	_	_	_
56	dpc	_	O	O	_	_	_	_	_
57	(	_	O	O	_	_	_	_	_
58	Figure	_	O	O	_	_	_	_	_
59	1	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	continues	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	function	_	O	O	_	_	_	_	_
10	postnatally	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	silence	_	O	O	_	_	_	_	_
13	epsilony	_	O	O	_	_	_	_	_
14	globin	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	has	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	unique	_	O	O	_	_	_	_	_
20	function	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	regulation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	epsilony	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	globin	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	which	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	regulates	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	other	_	O	O	_	_	_	_	_
10	embryonic	_	O	O	_	_	_	_	_
11	globin	_	O	O	_	_	_	_	_
12	genes	_	O	O	_	_	_	_	_
13	remains	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	elucidated	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	other	_	O	O	_	_	_	_	_
5	effects	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	erythropoiesis	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	including	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	delay	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	enucleation	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	maturation	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	100	_	O	O	_	_	_	_	_
19	H	_	O	O	_	_	_	_	_
20	mutant	_	O	O	_	_	_	_	_
21	mice	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	may	_	O	O	_	_	_	_	_
3	be	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	result	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	indirect	_	O	O	_	_	_	_	_
8	effects	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	such	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	stress	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	proliferation	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	resulting	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	cardiac	_	O	O	_	_	_	_	_
20	defects	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	anemia	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Severe	_	O	O	_	_	_	_	_
2	anemia	_	O	O	_	_	_	_	_
3	can	_	O	O	_	_	_	_	_
4	lead	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	rapid	_	O	O	_	_	_	_	_
7	premature	_	O	O	_	_	_	_	_
8	release	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	red	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	prior	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	their	_	O	O	_	_	_	_	_
16	complete	_	O	O	_	_	_	_	_
17	maturation	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	hematocrit	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	18	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	dpc	_	O	O	_	_	_	_	_
11	mutant	_	O	O	_	_	_	_	_
12	mice	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	only	_	O	O	_	_	_	_	_
15	20	_	O	O	_	_	_	_	_
16	%	_	O	O	_	_	_	_	_
17	lower	_	O	O	_	_	_	_	_
18	than	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	WT	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	unpublished	_	O	O	_	_	_	_	_
24	data	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	this	_	O	O	_	_	_	_	_
29	mild	_	O	O	_	_	_	_	_
30	anemia	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	probably	_	O	O	_	_	_	_	_
33	not	_	O	O	_	_	_	_	_
34	sufficient	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	explain	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	extent	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	nucleated	_	O	O	_	_	_	_	_
41	red	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Alternatively	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	itself	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	play	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	red	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	terminal	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	it	_	O	O	_	_	_	_	_
18	has	_	O	O	_	_	_	_	_
19	been	_	O	O	_	_	_	_	_
20	shown	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	an	_	O	O	_	_	_	_	_
24	important	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	cardiac	_	O	O	_	_	_	_	_
28	[	_	O	O	_	_	_	_	_
29	15	_	O	O	_	_	_	_	_
30	]	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	neuronal	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	10	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	astrocytic	_	O	O	_	_	_	_	_
38	[	_	O	O	_	_	_	_	_
39	11	_	O	O	_	_	_	_	_
40	]	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	cartilage	_	O	O	_	_	_	_	_
44	differentiation	_	O	O	_	_	_	_	_
45	programs	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	32	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	41	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	44	_	O	O	_	_	_	_	_
52	]	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	restoration	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	normal	_	O	O	_	_	_	_	_
5	enucleation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	red	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	Sox	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	deficient	_	O	O	_	_	_	_	_
14	mouse	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	postnatal	_	O	O	_	_	_	_	_
17	day	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	5	_	O	O	_	_	_	_	_
21	may	_	O	O	_	_	_	_	_
22	result	_	O	O	_	_	_	_	_
23	from	_	O	O	_	_	_	_	_
24	functional	_	O	O	_	_	_	_	_
25	compensation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	other	_	O	O	_	_	_	_	_
28	Sox	_	O	O	_	_	_	_	_
29	proteins	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	expressed	_	O	O	_	_	_	_	_
32	at	_	O	O	_	_	_	_	_
33	later	_	O	O	_	_	_	_	_
34	developmental	_	O	O	_	_	_	_	_
35	stages	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	since	_	O	O	_	_	_	_	_
39	functional	_	O	O	_	_	_	_	_
40	redundancy	_	O	O	_	_	_	_	_
41	is	_	O	O	_	_	_	_	_
42	a	_	O	O	_	_	_	_	_
43	recurring	_	O	O	_	_	_	_	_
44	theme	_	O	O	_	_	_	_	_
45	with	_	O	O	_	_	_	_	_
46	Sox	_	O	O	_	_	_	_	_
47	proteins	_	O	O	_	_	_	_	_
48	[	_	O	O	_	_	_	_	_
49	13	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	45	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	46	_	O	O	_	_	_	_	_
54	]	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	erythropoiesis	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	already	_	O	O	_	_	_	_	_
6	shifted	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	fetal	_	O	O	_	_	_	_	_
9	liver	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	bone	_	O	O	_	_	_	_	_
12	marrow	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	postnatal	_	O	O	_	_	_	_	_
15	day	_	O	O	_	_	_	_	_
16	10	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	accompanying	_	O	O	_	_	_	_	_
3	change	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	microenvironment	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	red	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	production	_	O	O	_	_	_	_	_
11	may	_	O	O	_	_	_	_	_
12	permit	_	O	O	_	_	_	_	_
13	normal	_	O	O	_	_	_	_	_
14	enucleation	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Identification	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	downstream	_	O	O	_	_	_	_	_
6	target	_	O	O	_	_	_	_	_
7	genes	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	its	_	O	O	_	_	_	_	_
10	interacting	_	O	O	_	_	_	_	_
11	proteins	_	O	O	_	_	_	_	_
12	will	_	O	O	_	_	_	_	_
13	shed	_	O	O	_	_	_	_	_
14	light	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	role	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	Sox	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	red	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	terminal	_	O	O	_	_	_	_	_
25	differentiation	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	enucleation	_	O	O	_	_	_	_	_
29	process	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Recently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	vivo	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	vitro	_	O	O	_	_	_	_	_
8	analyses	_	O	O	_	_	_	_	_
9	suggest	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	reactivation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	epsilon	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	globin	_	O	O	_	_	_	_	_
17	would	_	O	O	_	_	_	_	_
18	be	_	O	O	_	_	_	_	_
19	therapeutically	_	O	O	_	_	_	_	_
20	beneficial	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	adults	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	sickle	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	disease	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	47	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	providing	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	rationale	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	detailed	_	O	O	_	_	_	_	_
36	investigations	_	O	O	_	_	_	_	_
37	into	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	molecular	_	O	O	_	_	_	_	_
40	basis	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	epsilon	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	globin	_	O	O	_	_	_	_	_
45	gene	_	O	O	_	_	_	_	_
46	silencing	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	identifies	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	novel	_	O	O	_	_	_	_	_
7	repressor	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	binds	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	epsilony	_	O	O	_	_	_	_	_
17	proximal	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	potentially	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	part	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	larger	_	O	O	_	_	_	_	_
26	repression	_	O	O	_	_	_	_	_
27	complex	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	murine	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	its	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	counterpart	_	O	O	_	_	_	_	_
9	are	_	O	O	_	_	_	_	_
10	94	_	O	O	_	_	_	_	_
11	%	_	O	O	_	_	_	_	_
12	identical	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	amino	_	O	O	_	_	_	_	_
16	acid	_	O	O	_	_	_	_	_
17	level	_	O	O	_	_	_	_	_
18	[	_	O	O	_	_	_	_	_
19	48	_	O	O	_	_	_	_	_
20	]	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	it	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	possible	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	Sox	_	O	O	_	_	_	_	_
28	6	_	O	O	_	_	_	_	_
29	may	_	O	O	_	_	_	_	_
30	also	_	O	O	_	_	_	_	_
31	be	_	O	O	_	_	_	_	_
32	important	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	human	_	O	O	_	_	_	_	_
35	epsilon	_	O	O	_	_	_	_	_
36	globin	_	O	O	_	_	_	_	_
37	silencing	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	significant	_	O	O	_	_	_	_	_
4	sequence	_	O	O	_	_	_	_	_
5	homology	_	O	O	_	_	_	_	_
6	between	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	mouse	_	O	O	_	_	_	_	_
11	epsilon	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	regions	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	contains	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	least	_	O	O	_	_	_	_	_
22	two	_	O	O	_	_	_	_	_
23	potential	_	O	O	_	_	_	_	_
24	Sox	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	binding	_	O	O	_	_	_	_	_
27	sites	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Indeed	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	existence	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	silencer	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	epsilon	_	O	O	_	_	_	_	_
12	globin	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	has	_	O	O	_	_	_	_	_
15	been	_	O	O	_	_	_	_	_
16	proposed	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	49	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	50	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	elucidation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	Sox	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	repression	_	O	O	_	_	_	_	_
9	mechanism	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	identification	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	other	_	O	O	_	_	_	_	_
14	components	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	Sox	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	containing	_	O	O	_	_	_	_	_
21	complex	_	O	O	_	_	_	_	_
22	may	_	O	O	_	_	_	_	_
23	further	_	O	O	_	_	_	_	_
24	our	_	O	O	_	_	_	_	_
25	understanding	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	epsilon	_	O	O	_	_	_	_	_
28	globin	_	O	O	_	_	_	_	_
29	regulation	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	potentially	_	O	O	_	_	_	_	_
32	reveal	_	O	O	_	_	_	_	_
33	additional	_	O	O	_	_	_	_	_
34	molecular	_	O	O	_	_	_	_	_
35	targets	_	O	O	_	_	_	_	_
36	for	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	treatment	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	sickle	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	anemia	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	beta	_	O	O	_	_	_	_	_
45	thalassemias	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_



1	Glucocorticoid	_	O	O	_	_	_	_	_
2	receptors	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	down	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	regulated	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	inflamed	_	O	O	_	_	_	_	_
9	colonic	_	O	O	_	_	_	_	_
10	mucosa	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	peripheral	_	O	O	_	_	_	_	_
15	blood	_	O	O	_	_	_	_	_
16	mononuclear	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	inflammatory	_	O	O	_	_	_	_	_
22	bowel	_	O	O	_	_	_	_	_
23	disease	_	O	O	_	_	_	_	_
24	[	_	O	O	_	_	_	_	_
25	see	_	O	O	_	_	_	_	_
26	comments	_	O	O	_	_	_	_	_
27	]	_	O	O	_	_	_	_	_

1	BACKGROUND	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Growing	_	O	O	_	_	_	_	_
4	evidence	_	O	O	_	_	_	_	_
5	indicates	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	immune	_	O	O	_	_	_	_	_
9	system	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	hypothalamic	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	pituitary	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	adrenal	_	O	O	_	_	_	_	_
17	system	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	linked	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	several	_	O	O	_	_	_	_	_
22	mechanisms	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	example	_	O	O	_	_	_	_	_
26	intracellular	_	O	O	_	_	_	_	_
27	glucocorticoid	_	O	O	_	_	_	_	_
28	receptors	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	hGR	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Glucocorticoids	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	standard	_	O	O	_	_	_	_	_
5	treatment	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	acute	_	O	O	_	_	_	_	_
8	attacks	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	inflammatory	_	O	O	_	_	_	_	_
11	bowel	_	O	O	_	_	_	_	_
12	disease	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	IBD	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	glucocorticoids	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	hGR	_	O	O	_	_	_	_	_
6	down	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	regulates	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	can	_	O	O	_	_	_	_	_
16	propagate	_	O	O	_	_	_	_	_
17	IBD	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	PATIENTS	_	O	O	_	_	_	_	_
2	AND	_	O	O	_	_	_	_	_
3	METHODS	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	IBD	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	either	_	O	O	_	_	_	_	_
9	treated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	60	_	O	O	_	_	_	_	_
14	mg	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	prednisolone	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	more	_	O	O	_	_	_	_	_
19	than	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	week	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	without	_	O	O	_	_	_	_	_
25	glucocorticoid	_	O	O	_	_	_	_	_
26	treatment	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	more	_	O	O	_	_	_	_	_
29	than	_	O	O	_	_	_	_	_
30	4	_	O	O	_	_	_	_	_
31	weeks	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	hGR	_	O	O	_	_	_	_	_
2	levels	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	determined	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	isolated	_	O	O	_	_	_	_	_
7	cytosol	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	peripheral	_	O	O	_	_	_	_	_
10	blood	_	O	O	_	_	_	_	_
11	mononuclear	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	PBMCs	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	mucosal	_	O	O	_	_	_	_	_
18	biopsies	_	O	O	_	_	_	_	_
19	using	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	radioassay	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	H	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	dexamethasone	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Interleukin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	levels	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	determined	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	enzyme	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	linked	_	O	O	_	_	_	_	_
13	immunosorbent	_	O	O	_	_	_	_	_
14	assay	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	ELISA	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	The	_	O	O	_	_	_	_	_
4	systemic	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	PBMC	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	hGR	_	O	O	_	_	_	_	_
9	levels	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	corticosteroid	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	treated	_	O	O	_	_	_	_	_
14	IBD	_	O	O	_	_	_	_	_
15	patients	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	significantly	_	O	O	_	_	_	_	_
18	lower	_	O	O	_	_	_	_	_
19	than	_	O	O	_	_	_	_	_
20	those	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	control	_	O	O	_	_	_	_	_
23	subjects	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	59	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	6	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	57	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	dpm	_	O	O	_	_	_	_	_
35	mg	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	cytosol	_	O	O	_	_	_	_	_
39	protein	_	O	O	_	_	_	_	_
40	vs	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	227	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_
3	0	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	90	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	8	_	O	O	_	_	_	_	_
10	dpm	_	O	O	_	_	_	_	_
11	mg	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	cytosol	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	P	_	O	O	_	_	_	_	_
18	=	_	O	O	_	_	_	_	_
19	0	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	007	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	IBD	_	O	O	_	_	_	_	_
25	patients	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	receiving	_	O	O	_	_	_	_	_
28	glucocorticoid	_	O	O	_	_	_	_	_
29	treatment	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	179	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	7	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	171	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	dpm	_	O	O	_	_	_	_	_
41	mg	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	cytosol	_	O	O	_	_	_	_	_
45	protein	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	P	_	O	O	_	_	_	_	_
48	=	_	O	O	_	_	_	_	_
49	0	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	002	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Systemic	_	O	O	_	_	_	_	_
2	hGR	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	untreated	_	O	O	_	_	_	_	_
6	IBD	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	did	_	O	O	_	_	_	_	_
9	not	_	O	O	_	_	_	_	_
10	differ	_	O	O	_	_	_	_	_
11	significantly	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	those	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	control	_	O	O	_	_	_	_	_
16	subjects	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	patients	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	connective	_	O	O	_	_	_	_	_
5	tissue	_	O	O	_	_	_	_	_
6	diseases	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	systemic	_	O	O	_	_	_	_	_
9	hGR	_	O	O	_	_	_	_	_
10	levels	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	also	_	O	O	_	_	_	_	_
13	found	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	decreased	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	absence	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	glucocorticoid	_	O	O	_	_	_	_	_
22	treatment	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Systemic	_	O	O	_	_	_	_	_
2	hGR	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	patients	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	Crohn	_	O	O	_	_	_	_	_
8	'	_	O	O	_	_	_	_	_
9	s	_	O	O	_	_	_	_	_
10	disease	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	treated	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	steroids	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	66	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	6	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	61	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	0	_	O	O	_	_	_	_	_
27	dpm	_	O	O	_	_	_	_	_
28	mg	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	cytosol	_	O	O	_	_	_	_	_
32	protein	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	were	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	different	_	O	O	_	_	_	_	_
37	from	_	O	O	_	_	_	_	_
38	those	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	patients	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	ulcerative	_	O	O	_	_	_	_	_
43	colitis	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	UC	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	56	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	+	_	O	O	_	_	_	_	_
52	/	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	51	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_
56	6	_	O	O	_	_	_	_	_
57	dpm	_	O	O	_	_	_	_	_
58	mg	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	1	_	O	O	_	_	_	_	_
61	cytosol	_	O	O	_	_	_	_	_
62	protein	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	findings	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	mucosal	_	O	O	_	_	_	_	_
8	hGR	_	O	O	_	_	_	_	_
9	levels	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	significantly	_	O	O	_	_	_	_	_
12	decreased	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	steroid	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	treated	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	18	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	0	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	15	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	5	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	steroid	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	treated	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	37	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	8	_	O	O	_	_	_	_	_
38	+	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	30	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_
43	5	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	patients	_	O	O	_	_	_	_	_
46	compared	_	O	O	_	_	_	_	_
47	with	_	O	O	_	_	_	_	_
48	control	_	O	O	_	_	_	_	_
49	subjects	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	125	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_
53	6	_	O	O	_	_	_	_	_
54	+	_	O	O	_	_	_	_	_
55	/	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	97	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_
59	1	_	O	O	_	_	_	_	_
60	;	_	O	O	_	_	_	_	_
61	P	_	O	O	_	_	_	_	_
62	=	_	O	O	_	_	_	_	_
63	0	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_
65	00009	_	O	O	_	_	_	_	_
66	and	_	O	O	_	_	_	_	_
67	P	_	O	O	_	_	_	_	_
68	=	_	O	O	_	_	_	_	_
69	0	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_
71	0008	_	O	O	_	_	_	_	_
72	respectively	_	O	O	_	_	_	_	_
73	)	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	levels	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	all	_	O	O	_	_	_	_	_
7	IBD	_	O	O	_	_	_	_	_
8	groups	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	without	_	O	O	_	_	_	_	_
12	steroids	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	significantly	_	O	O	_	_	_	_	_
15	different	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	those	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	control	_	O	O	_	_	_	_	_
20	subjects	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	CONCLUSION	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	IBD	_	O	O	_	_	_	_	_
5	there	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	no	_	O	O	_	_	_	_	_
8	difference	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	systemic	_	O	O	_	_	_	_	_
11	hGR	_	O	O	_	_	_	_	_
12	levels	_	O	O	_	_	_	_	_
13	between	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	steroid	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	treated	_	O	O	_	_	_	_	_
18	patients	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	control	_	O	O	_	_	_	_	_
21	subjects	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	spite	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	inflammatory	_	O	O	_	_	_	_	_
27	activity	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	6	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Mucosal	_	O	O	_	_	_	_	_
2	hGR	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	decreased	_	O	O	_	_	_	_	_
6	independently	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	treatment	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	probably	_	O	O	_	_	_	_	_
11	leading	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	decreased	_	O	O	_	_	_	_	_
15	protection	_	O	O	_	_	_	_	_
16	against	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	action	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	intestinal	_	O	O	_	_	_	_	_
24	mucosa	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	RB	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	novel	_	O	O	_	_	_	_	_
5	E	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	F	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	protein	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	MHC	_	O	O	_	_	_	_	_
14	class	_	O	O	_	_	_	_	_
15	II	_	O	O	_	_	_	_	_
16	deficient	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	lines	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	normal	_	O	O	_	_	_	_	_
23	IFN	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	gamma	_	O	O	_	_	_	_	_
26	induction	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	class	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	transactivator	_	O	O	_	_	_	_	_
32	CIITA	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	class	_	O	O	_	_	_	_	_
35	II	_	O	O	_	_	_	_	_
36	non	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	inducible	_	O	O	_	_	_	_	_
39	RB	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	defective	_	O	O	_	_	_	_	_
42	tumor	_	O	O	_	_	_	_	_
43	lines	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	major	_	O	O	_	_	_	_	_
3	histocompatibility	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	MHC	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	class	_	O	O	_	_	_	_	_
8	II	_	O	O	_	_	_	_	_
9	genes	_	O	O	_	_	_	_	_
10	encode	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	surface	_	O	O	_	_	_	_	_
13	proteins	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	bind	_	O	O	_	_	_	_	_
16	antigenic	_	O	O	_	_	_	_	_
17	peptide	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	presentation	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	class	_	O	O	_	_	_	_	_
3	II	_	O	O	_	_	_	_	_
4	proteins	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	constitutively	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	EBV	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	transformed	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	are	_	O	O	_	_	_	_	_
22	inducible	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	IFN	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	gamma	_	O	O	_	_	_	_	_
27	on	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	wide	_	O	O	_	_	_	_	_
30	variety	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	types	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Retinoblastoma	_	O	O	_	_	_	_	_
2	protein	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	RB	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	tumor	_	O	O	_	_	_	_	_
9	suppressor	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	functions	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	transcriptional	_	O	O	_	_	_	_	_
15	repressor	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	inactivating	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	transactivator	_	O	O	_	_	_	_	_
22	E	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	F	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	I	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	RB	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	defective	_	O	O	_	_	_	_	_
4	tumor	_	O	O	_	_	_	_	_
5	lines	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	non	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	inducible	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	MHC	_	O	O	_	_	_	_	_
12	class	_	O	O	_	_	_	_	_
13	II	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	IFN	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	gamma	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	very	_	O	O	_	_	_	_	_
21	weakly	_	O	O	_	_	_	_	_
22	inducible	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	but	_	O	O	_	_	_	_	_
25	transfection	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	different	_	O	O	_	_	_	_	_
29	lines	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	RB	_	O	O	_	_	_	_	_
32	expression	_	O	O	_	_	_	_	_
33	vectors	_	O	O	_	_	_	_	_
34	re	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	establishes	_	O	O	_	_	_	_	_
37	or	_	O	O	_	_	_	_	_
38	substantially	_	O	O	_	_	_	_	_
39	enhances	_	O	O	_	_	_	_	_
40	class	_	O	O	_	_	_	_	_
41	II	_	O	O	_	_	_	_	_
42	inducibility	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	examined	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	RB	_	O	O	_	_	_	_	_
7	status	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	series	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	mutants	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	defective	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	class	_	O	O	_	_	_	_	_
21	II	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	generated	_	O	O	_	_	_	_	_
25	either	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vitro	_	O	O	_	_	_	_	_
28	or	_	O	O	_	_	_	_	_
29	derived	_	O	O	_	_	_	_	_
30	from	_	O	O	_	_	_	_	_
31	Bare	_	O	O	_	_	_	_	_
32	Lymphocyte	_	O	O	_	_	_	_	_
33	Syndrome	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	BLS	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	patients	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	matrix	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	bound	_	O	O	_	_	_	_	_
5	RB	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	detectable	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	all	_	O	O	_	_	_	_	_
10	cases	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	indicating	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	loss	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	RB	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	responsible	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	decreased	_	O	O	_	_	_	_	_
22	class	_	O	O	_	_	_	_	_
23	II	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	these	_	O	O	_	_	_	_	_
27	lines	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	second	_	O	O	_	_	_	_	_
3	E	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	F	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	I	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	most	_	O	O	_	_	_	_	_
12	likely	_	O	O	_	_	_	_	_
13	DP	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	also	_	O	O	_	_	_	_	_
19	apparently	_	O	O	_	_	_	_	_
20	normal	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	both	_	O	O	_	_	_	_	_
23	class	_	O	O	_	_	_	_	_
24	II	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	positive	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	negative	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	lines	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	gamma	_	O	O	_	_	_	_	_
8	induction	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	CIITA	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	RB	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	defective	_	O	O	_	_	_	_	_
15	lines	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	CIITA	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	class	_	O	O	_	_	_	_	_
5	II	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	transactivator	_	O	O	_	_	_	_	_
8	known	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	defective	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	one	_	O	O	_	_	_	_	_
14	form	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	BLS	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	be	_	O	O	_	_	_	_	_
20	required	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	induction	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	MHC	_	O	O	_	_	_	_	_
26	class	_	O	O	_	_	_	_	_
27	II	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	IFN	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	gamma	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	CIITA	_	O	O	_	_	_	_	_
2	mRNA	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	normally	_	O	O	_	_	_	_	_
5	inducible	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	class	_	O	O	_	_	_	_	_
12	II	_	O	O	_	_	_	_	_
13	non	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	inducible	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	RB	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	defective	_	O	O	_	_	_	_	_
20	lines	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	one	_	O	O	_	_	_	_	_
25	line	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	re	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	RB	_	O	O	_	_	_	_	_
32	has	_	O	O	_	_	_	_	_
33	no	_	O	O	_	_	_	_	_
34	effect	_	O	O	_	_	_	_	_
35	on	_	O	O	_	_	_	_	_
36	CIITA	_	O	O	_	_	_	_	_
37	mRNA	_	O	O	_	_	_	_	_
38	induction	_	O	O	_	_	_	_	_
39	levels	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	block	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	MHC	_	O	O	_	_	_	_	_
7	class	_	O	O	_	_	_	_	_
8	II	_	O	O	_	_	_	_	_
9	inducibility	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	RB	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	defective	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	due	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	block	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	CIITA	_	O	O	_	_	_	_	_
23	inducibility	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	Retinoid	_	O	O	_	_	_	_	_
2	X	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	RXR	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	agonist	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	dominant	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	negative	_	O	O	_	_	_	_	_
15	RXR	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	retinoic	_	O	O	_	_	_	_	_
18	acid	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	alpha	_	O	O	_	_	_	_	_
21	403	_	O	O	_	_	_	_	_
22	heterodimers	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	developmentally	_	O	O	_	_	_	_	_
25	regulated	_	O	O	_	_	_	_	_
26	during	_	O	O	_	_	_	_	_
27	myeloid	_	O	O	_	_	_	_	_
28	differentiation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	multiple	_	O	O	_	_	_	_	_
3	biologic	_	O	O	_	_	_	_	_
4	activities	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	retinoic	_	O	O	_	_	_	_	_
7	acid	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	RA	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	mediated	_	O	O	_	_	_	_	_
13	through	_	O	O	_	_	_	_	_
14	RAR	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	retinoid	_	O	O	_	_	_	_	_
17	X	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	RXR	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	nuclear	_	O	O	_	_	_	_	_
23	receptors	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	interact	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	DNA	_	O	O	_	_	_	_	_
29	target	_	O	O	_	_	_	_	_
30	sequences	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	heterodimers	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	RXR	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	RAR	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	or	_	O	O	_	_	_	_	_
39	homodimers	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	RXR	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	RXR	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	RA	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	appears	_	O	O	_	_	_	_	_
5	critical	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	regulating	_	O	O	_	_	_	_	_
8	important	_	O	O	_	_	_	_	_
9	aspects	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	hematopoiesis	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	since	_	O	O	_	_	_	_	_
14	transducing	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	COOH	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	terminally	_	O	O	_	_	_	_	_
19	truncated	_	O	O	_	_	_	_	_
20	RARalpha	_	O	O	_	_	_	_	_
21	exhibiting	_	O	O	_	_	_	_	_
22	dominant	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	negative	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	RARalpha	_	O	O	_	_	_	_	_
28	403	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	into	_	O	O	_	_	_	_	_
31	normal	_	O	O	_	_	_	_	_
32	mouse	_	O	O	_	_	_	_	_
33	bone	_	O	O	_	_	_	_	_
34	marrow	_	O	O	_	_	_	_	_
35	generates	_	O	O	_	_	_	_	_
36	hematopoietic	_	O	O	_	_	_	_	_
37	growth	_	O	O	_	_	_	_	_
38	factor	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	dependent	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	lines	_	O	O	_	_	_	_	_
43	frozen	_	O	O	_	_	_	_	_
44	at	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	multipotent	_	O	O	_	_	_	_	_
47	progenitor	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	EML	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	or	_	O	O	_	_	_	_	_
52	committed	_	O	O	_	_	_	_	_
53	promyelocyte	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	MPRO	_	O	O	_	_	_	_	_
56	)	_	O	O	_	_	_	_	_
57	stages	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Nevertheless	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	relatively	_	O	O	_	_	_	_	_
4	high	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	pharmacological	_	O	O	_	_	_	_	_
7	concentrations	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	RA	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	&	_	O	O	_	_	_	_	_
15	mgr	_	O	O	_	_	_	_	_
16	;	_	O	O	_	_	_	_	_
17	M	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	overcome	_	O	O	_	_	_	_	_
20	these	_	O	O	_	_	_	_	_
21	differentiation	_	O	O	_	_	_	_	_
22	blocks	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	induce	_	O	O	_	_	_	_	_
25	terminal	_	O	O	_	_	_	_	_
26	granulocytic	_	O	O	_	_	_	_	_
27	differentiation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	MPRO	_	O	O	_	_	_	_	_
31	promyelocytes	_	O	O	_	_	_	_	_
32	while	_	O	O	_	_	_	_	_
33	potentiating	_	O	O	_	_	_	_	_
34	interleukin	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	3	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	induced	_	O	O	_	_	_	_	_
44	commitment	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	EML	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	to	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	granulocyte	_	O	O	_	_	_	_	_
51	/	_	O	O	_	_	_	_	_
52	monocyte	_	O	O	_	_	_	_	_
53	lineage	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	utilized	_	O	O	_	_	_	_	_
8	RXR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	RAR	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	specific	_	O	O	_	_	_	_	_
14	agonists	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	antagonists	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	determine	_	O	O	_	_	_	_	_
19	how	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	overcomes	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	dominant	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	negative	_	O	O	_	_	_	_	_
26	activity	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	truncated	_	O	O	_	_	_	_	_
30	RARalpha	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	these	_	O	O	_	_	_	_	_
33	different	_	O	O	_	_	_	_	_
34	myeloid	_	O	O	_	_	_	_	_
35	developmental	_	O	O	_	_	_	_	_
36	stages	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Unexpectedly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	observed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	RXR	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	specific	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	rather	_	O	O	_	_	_	_	_
12	than	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	RAR	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	agonist	_	O	O	_	_	_	_	_
19	induces	_	O	O	_	_	_	_	_
20	terminal	_	O	O	_	_	_	_	_
21	granulocytic	_	O	O	_	_	_	_	_
22	differentiation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	MPRO	_	O	O	_	_	_	_	_
25	promyelocytes	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	this	_	O	O	_	_	_	_	_
29	differentiation	_	O	O	_	_	_	_	_
30	is	_	O	O	_	_	_	_	_
31	associated	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	activation	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	DNA	_	O	O	_	_	_	_	_
36	response	_	O	O	_	_	_	_	_
37	elements	_	O	O	_	_	_	_	_
38	corresponding	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	RAR	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	RXR	_	O	O	_	_	_	_	_
43	heterodimers	_	O	O	_	_	_	_	_
44	rather	_	O	O	_	_	_	_	_
45	than	_	O	O	_	_	_	_	_
46	RXR	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	RXR	_	O	O	_	_	_	_	_
49	homodimers	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	RXR	_	O	O	_	_	_	_	_
3	agonist	_	O	O	_	_	_	_	_
4	activity	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	blocked	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	RAR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	specific	_	O	O	_	_	_	_	_
11	antagonists	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	suggesting	_	O	O	_	_	_	_	_
14	extensive	_	O	O	_	_	_	_	_
15	cross	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	talk	_	O	O	_	_	_	_	_
18	between	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	partners	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	RXR	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	RARalpha	_	O	O	_	_	_	_	_
26	403	_	O	O	_	_	_	_	_
27	heterodimer	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	more	_	O	O	_	_	_	_	_
7	immature	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	multipotent	_	O	O	_	_	_	_	_
10	EML	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	observed	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	this	_	O	O	_	_	_	_	_
16	RXR	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	specific	_	O	O	_	_	_	_	_
19	agonist	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	inactive	_	O	O	_	_	_	_	_
22	either	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	potentiating	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	mediated	_	O	O	_	_	_	_	_
30	commitment	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	EML	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	granulocyte	_	O	O	_	_	_	_	_
37	lineage	_	O	O	_	_	_	_	_
38	or	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	transactivating	_	O	O	_	_	_	_	_
41	RAR	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	RXR	_	O	O	_	_	_	_	_
44	response	_	O	O	_	_	_	_	_
45	elements	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	RA	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	triggered	_	O	O	_	_	_	_	_
4	GALdbd	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	RARalpha	_	O	O	_	_	_	_	_
7	hybrid	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	these	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	indicates	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	multipotent	_	O	O	_	_	_	_	_
16	EML	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	harbor	_	O	O	_	_	_	_	_
19	substantial	_	O	O	_	_	_	_	_
20	nuclear	_	O	O	_	_	_	_	_
21	hormone	_	O	O	_	_	_	_	_
22	receptor	_	O	O	_	_	_	_	_
23	coactivator	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	histone	_	O	O	_	_	_	_	_
5	deacetylase	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	HDAC	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	inhibitor	_	O	O	_	_	_	_	_
10	trichostatin	_	O	O	_	_	_	_	_
11	A	_	O	O	_	_	_	_	_
12	readily	_	O	O	_	_	_	_	_
13	activates	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	RXR	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	RAR	_	O	O	_	_	_	_	_
18	reporter	_	O	O	_	_	_	_	_
19	construct	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	multipotent	_	O	O	_	_	_	_	_
23	EML	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	but	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	committed	_	O	O	_	_	_	_	_
30	MPRO	_	O	O	_	_	_	_	_
31	promyelocytes	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	indicating	_	O	O	_	_	_	_	_
34	that	_	O	O	_	_	_	_	_
35	differences	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	HDAC	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	containing	_	O	O	_	_	_	_	_
40	repressor	_	O	O	_	_	_	_	_
41	complexes	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	these	_	O	O	_	_	_	_	_
44	two	_	O	O	_	_	_	_	_
45	closely	_	O	O	_	_	_	_	_
46	related	_	O	O	_	_	_	_	_
47	but	_	O	O	_	_	_	_	_
48	distinct	_	O	O	_	_	_	_	_
49	hematopoietic	_	O	O	_	_	_	_	_
50	lineages	_	O	O	_	_	_	_	_
51	might	_	O	O	_	_	_	_	_
52	account	_	O	O	_	_	_	_	_
53	for	_	O	O	_	_	_	_	_
54	the	_	O	O	_	_	_	_	_
55	differential	_	O	O	_	_	_	_	_
56	activation	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	the	_	O	O	_	_	_	_	_
59	RXR	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	RARalpha	_	O	O	_	_	_	_	_
62	403	_	O	O	_	_	_	_	_
63	heterodimers	_	O	O	_	_	_	_	_
64	that	_	O	O	_	_	_	_	_
65	we	_	O	O	_	_	_	_	_
66	observed	_	O	O	_	_	_	_	_
67	at	_	O	O	_	_	_	_	_
68	these	_	O	O	_	_	_	_	_
69	different	_	O	O	_	_	_	_	_
70	stages	_	O	O	_	_	_	_	_
71	of	_	O	O	_	_	_	_	_
72	myeloid	_	O	O	_	_	_	_	_
73	development	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_


1	Nuclear	_	O	O	_	_	_	_	_
2	factor	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	90	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	A	_	O	O	_	_	_	_	_
12	double	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	stranded	_	O	O	_	_	_	_	_
15	RNA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	substrate	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	double	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	stranded	_	O	O	_	_	_	_	_
26	RNA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	dependent	_	O	O	_	_	_	_	_
29	protein	_	O	O	_	_	_	_	_
30	kinase	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	PKR	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	NFAT	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factors	_	O	O	_	_	_	_	_
4	play	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	central	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	initiating	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	activation	_	O	O	_	_	_	_	_
14	through	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	induction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	immediate	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	early	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	specific	_	O	O	_	_	_	_	_
25	genes	_	O	O	_	_	_	_	_
26	including	_	O	O	_	_	_	_	_
27	interleukin	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	2	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	NFAT	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factors	_	O	O	_	_	_	_	_
4	bind	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	sequence	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	enhancer	_	O	O	_	_	_	_	_
14	known	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	antigen	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	response	_	O	O	_	_	_	_	_
20	element	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	ARRE	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Multiple	_	O	O	_	_	_	_	_
2	proteins	_	O	O	_	_	_	_	_
3	exhibiting	_	O	O	_	_	_	_	_
4	ARRE	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	have	_	O	O	_	_	_	_	_
10	been	_	O	O	_	_	_	_	_
11	isolated	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	including	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	heterodimer	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	stimulated	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	nuclear	_	O	O	_	_	_	_	_
22	extracts	_	O	O	_	_	_	_	_
23	consisting	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	Mr	_	O	O	_	_	_	_	_
26	=	_	O	O	_	_	_	_	_
27	90	_	O	O	_	_	_	_	_
28	000	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	NF	_	O	O	_	_	_	_	_
31	90	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	Mr	_	O	O	_	_	_	_	_
35	=	_	O	O	_	_	_	_	_
36	45	_	O	O	_	_	_	_	_
37	000	_	O	O	_	_	_	_	_
38	(	_	O	O	_	_	_	_	_
39	NF	_	O	O	_	_	_	_	_
40	45	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	subunits	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	subunits	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	heterodimer	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	cloned	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	NF	_	O	O	_	_	_	_	_
12	90	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	found	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	encode	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	containing	_	O	O	_	_	_	_	_
20	two	_	O	O	_	_	_	_	_
21	domains	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	are	_	O	O	_	_	_	_	_
24	predicted	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	form	_	O	O	_	_	_	_	_
27	motifs	_	O	O	_	_	_	_	_
28	capable	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	double	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	stranded	_	O	O	_	_	_	_	_
35	RNA	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	vitro	_	O	O	_	_	_	_	_
4	translated	_	O	O	_	_	_	_	_
5	polypeptides	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	have	_	O	O	_	_	_	_	_
9	demonstrated	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	NF	_	O	O	_	_	_	_	_
12	90	_	O	O	_	_	_	_	_
13	specifically	_	O	O	_	_	_	_	_
14	binds	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	double	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	stranded	_	O	O	_	_	_	_	_
19	RNA	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	90	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	phosphorylated	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	double	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	stranded	_	O	O	_	_	_	_	_
12	RNA	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	dependent	_	O	O	_	_	_	_	_
15	manner	_	O	O	_	_	_	_	_
16	likely	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	interferon	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	double	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	stranded	_	O	O	_	_	_	_	_
26	RNA	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	dependent	_	O	O	_	_	_	_	_
29	protein	_	O	O	_	_	_	_	_
30	kinase	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	PKR	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	90	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	found	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	only	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	also	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	nonimmune	_	O	O	_	_	_	_	_
21	HeLa	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	HeLa	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	protein	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	almost	_	O	O	_	_	_	_	_
9	exclusively	_	O	O	_	_	_	_	_
10	localized	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	ribosome	_	O	O	_	_	_	_	_
14	salt	_	O	O	_	_	_	_	_
15	wash	_	O	O	_	_	_	_	_
16	fraction	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lysates	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Western	_	O	O	_	_	_	_	_
2	blot	_	O	O	_	_	_	_	_
3	analysis	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	stimulated	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	20	_	O	O	_	_	_	_	_
10	min	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	indicated	_	O	O	_	_	_	_	_
14	concentrations	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	at	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	density	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	5	_	O	O	_	_	_	_	_
28	x	_	O	O	_	_	_	_	_
29	105	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	0	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	5	_	O	O	_	_	_	_	_
35	ml	_	O	O	_	_	_	_	_
36	culture	_	O	O	_	_	_	_	_
37	medium	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	10	_	O	O	_	_	_	_	_
40	%	_	O	O	_	_	_	_	_
41	FCS	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	examine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effect	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	serum	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	phosphorylation	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	normal	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	4	_	O	O	_	_	_	_	_
17	+	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	stimulated	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	20	_	O	O	_	_	_	_	_
24	min	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	30	_	O	O	_	_	_	_	_
27	%	_	O	O	_	_	_	_	_
28	active	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	serum	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	culture	_	O	O	_	_	_	_	_
33	medium	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	40	_	O	O	_	_	_	_	_
36	mug	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	ml	_	O	O	_	_	_	_	_
39	neutralizing	_	O	O	_	_	_	_	_
40	goat	_	O	O	_	_	_	_	_
41	anti	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	6	_	O	O	_	_	_	_	_
46	polyclonal	_	O	O	_	_	_	_	_
47	antibody	_	O	O	_	_	_	_	_
48	(	_	O	O	_	_	_	_	_
49	IgG	_	O	O	_	_	_	_	_
50	;	_	O	O	_	_	_	_	_
51	Techne	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	Princeton	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	NJ	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	USA	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	or	_	O	O	_	_	_	_	_
60	control	_	O	O	_	_	_	_	_
61	goat	_	O	O	_	_	_	_	_
62	IgG	_	O	O	_	_	_	_	_
63	(	_	O	O	_	_	_	_	_
64	Techne	_	O	O	_	_	_	_	_
65	)	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_

1	Whole	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	lysates	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	prepared	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	placing	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	100	_	O	O	_	_	_	_	_
11	mul	_	O	O	_	_	_	_	_
12	SDS	_	O	O	_	_	_	_	_
13	lysing	_	O	O	_	_	_	_	_
14	buffer	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	62	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	mM	_	O	O	_	_	_	_	_
20	Tris	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	HCl	_	O	O	_	_	_	_	_
23	[	_	O	O	_	_	_	_	_
24	pH	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	8	_	O	O	_	_	_	_	_
28	]	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	%	_	O	O	_	_	_	_	_
32	SDS	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	10	_	O	O	_	_	_	_	_
35	%	_	O	O	_	_	_	_	_
36	glycerol	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	50	_	O	O	_	_	_	_	_
39	mM	_	O	O	_	_	_	_	_
40	dithiothreitol	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	0	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	%	_	O	O	_	_	_	_	_
46	bromphenol	_	O	O	_	_	_	_	_
47	blue	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Then	_	O	O	_	_	_	_	_
2	20	_	O	O	_	_	_	_	_
3	mul	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	samples	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	fractionated	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	%	_	O	O	_	_	_	_	_
11	SDS	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	polyacrylamide	_	O	O	_	_	_	_	_
14	gels	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	transferred	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	nitrocellulose	_	O	O	_	_	_	_	_
20	membranes	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	Amersham	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	Buckinghamshire	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	UK	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	membrane	_	O	O	_	_	_	_	_
32	was	_	O	O	_	_	_	_	_
33	blocked	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	5	_	O	O	_	_	_	_	_
36	%	_	O	O	_	_	_	_	_
37	skim	_	O	O	_	_	_	_	_
38	milk	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	Tris	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	buffered	_	O	O	_	_	_	_	_
43	saline	_	O	O	_	_	_	_	_
44	with	_	O	O	_	_	_	_	_
45	0	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_
47	1	_	O	O	_	_	_	_	_
48	%	_	O	O	_	_	_	_	_
49	Tween	_	O	O	_	_	_	_	_
50	20	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Tyrosine	_	O	O	_	_	_	_	_
2	phosphorylation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	detected	_	O	O	_	_	_	_	_
11	using	_	O	O	_	_	_	_	_
12	commercial	_	O	O	_	_	_	_	_
13	available	_	O	O	_	_	_	_	_
14	kits	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	Cell	_	O	O	_	_	_	_	_
17	Signaling	_	O	O	_	_	_	_	_
18	Technology	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	Beverly	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	MA	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	USA	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	according	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	manufacturer	_	O	O	_	_	_	_	_
30	'	_	O	O	_	_	_	_	_
31	s	_	O	O	_	_	_	_	_
32	instructions	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Briefly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	membrane	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	incubated	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	antibodies	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	rabbit	_	O	O	_	_	_	_	_
12	IgG	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	STAT	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	antibody	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	anti	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	phosphorylated	_	O	O	_	_	_	_	_
23	tyrosine	_	O	O	_	_	_	_	_
24	701	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	STAT	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	antibody	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	anti	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	STAT	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	antibody	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	anti	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	phosphorylated	_	O	O	_	_	_	_	_
40	tyrosine	_	O	O	_	_	_	_	_
41	705	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	STAT	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	antibody	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	diluted	_	O	O	_	_	_	_	_
48	as	_	O	O	_	_	_	_	_
49	recommended	_	O	O	_	_	_	_	_
50	at	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	/	_	O	O	_	_	_	_	_
53	2000	_	O	O	_	_	_	_	_
54	with	_	O	O	_	_	_	_	_
55	Tris	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	buffered	_	O	O	_	_	_	_	_
58	saline	_	O	O	_	_	_	_	_
59	with	_	O	O	_	_	_	_	_
60	0	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_
62	1	_	O	O	_	_	_	_	_
63	%	_	O	O	_	_	_	_	_
64	Tween	_	O	O	_	_	_	_	_
65	20	_	O	O	_	_	_	_	_
66	with	_	O	O	_	_	_	_	_
67	5	_	O	O	_	_	_	_	_
68	%	_	O	O	_	_	_	_	_
69	BSA	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	Antibody	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	detected	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	horseradish	_	O	O	_	_	_	_	_
7	peroxidase	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	conjugated	_	O	O	_	_	_	_	_
10	anti	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	rabbit	_	O	O	_	_	_	_	_
13	IgG	_	O	O	_	_	_	_	_
14	antibody	_	O	O	_	_	_	_	_
15	diluted	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	4000	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	Tris	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	buffered	_	O	O	_	_	_	_	_
24	saline	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	0	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	%	_	O	O	_	_	_	_	_
30	Tween	_	O	O	_	_	_	_	_
31	20	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	5	_	O	O	_	_	_	_	_
34	%	_	O	O	_	_	_	_	_
35	BSA	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	was	_	O	O	_	_	_	_	_
39	revealed	_	O	O	_	_	_	_	_
40	using	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	chemiluminescence	_	O	O	_	_	_	_	_
43	system	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Protein	_	O	O	_	_	_	_	_
2	bands	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	quantified	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	densitometry	_	O	O	_	_	_	_	_
7	using	_	O	O	_	_	_	_	_
8	NIH	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	Image	_	O	O	_	_	_	_	_
11	analysis	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	compared	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	total	_	O	O	_	_	_	_	_
21	amount	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	protein	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	IFN	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	stimulated	_	O	O	_	_	_	_	_
6	Hela	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	used	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	positive	_	O	O	_	_	_	_	_
13	control	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	phosophorylation	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_



1	The	_	O	O	_	_	_	_	_
2	Persistent	_	O	O	_	_	_	_	_
3	Expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	epsilony	_	O	O	_	_	_	_	_
6	Globin	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Deficient	_	O	O	_	_	_	_	_
12	Mice	_	O	O	_	_	_	_	_
13	Is	_	O	O	_	_	_	_	_
14	Due	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	Defect	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	epsilony	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	Gene	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	Silencing	_	O	O	_	_	_	_	_
25	Mechanism	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	Definitive	_	O	O	_	_	_	_	_
28	Erythroid	_	O	O	_	_	_	_	_
29	Cells	_	O	O	_	_	_	_	_

1	Normally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	epsilony	_	O	O	_	_	_	_	_
5	globin	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	exclusively	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	primitive	_	O	O	_	_	_	_	_
12	erythrocytes	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	silenced	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	definitive	_	O	O	_	_	_	_	_
17	erythrocytes	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	persistent	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	due	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	residual	_	O	O	_	_	_	_	_
14	primitive	_	O	O	_	_	_	_	_
15	erythrocytes	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	due	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	ectopic	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	epsilony	_	O	O	_	_	_	_	_
24	globin	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	definitive	_	O	O	_	_	_	_	_
27	erythrocytes	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	we	_	O	O	_	_	_	_	_
30	examined	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	spatial	_	O	O	_	_	_	_	_
33	pattern	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	epsilony	_	O	O	_	_	_	_	_
36	globin	_	O	O	_	_	_	_	_
37	transcripts	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	mouse	_	O	O	_	_	_	_	_
40	embryos	_	O	O	_	_	_	_	_
41	by	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	situ	_	O	O	_	_	_	_	_
44	hybridization	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	Figure	_	O	O	_	_	_	_	_
47	5	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	expected	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	epsilony	_	O	O	_	_	_	_	_
5	globin	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	expressed	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	WT	_	O	O	_	_	_	_	_
12	14	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dpc	_	O	O	_	_	_	_	_
17	liver	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	site	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	definitive	_	O	O	_	_	_	_	_
23	erythropoiesis	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	fetus	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	abundant	_	O	O	_	_	_	_	_
5	ectopic	_	O	O	_	_	_	_	_
6	epsilony	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	seen	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	liver	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	14	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_
17	5	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	dpc	_	O	O	_	_	_	_	_
20	mutants	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	Figure	_	O	O	_	_	_	_	_
23	5	_	O	O	_	_	_	_	_
24	A	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	D	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	betamaj	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	min	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	equally	_	O	O	_	_	_	_	_
12	abundant	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	WT	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	100	_	O	O	_	_	_	_	_
19	H	_	O	O	_	_	_	_	_
20	mutant	_	O	O	_	_	_	_	_
21	mice	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	Figure	_	O	O	_	_	_	_	_
24	5	_	O	O	_	_	_	_	_
25	E	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	F	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	persistent	_	O	O	_	_	_	_	_
7	high	_	O	O	_	_	_	_	_
8	levels	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	epsilony	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	due	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	ectopic	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	definitive	_	O	O	_	_	_	_	_
19	erythroid	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	mature	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	fetal	_	O	O	_	_	_	_	_
26	liver	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	suggesting	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	there	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	intrinsic	_	O	O	_	_	_	_	_
34	defect	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	epsilony	_	O	O	_	_	_	_	_
38	silencing	_	O	O	_	_	_	_	_
39	mechanism	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	Sox	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	null	_	O	O	_	_	_	_	_
45	mice	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_



1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	c	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Rel	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	target	_	O	O	_	_	_	_	_
10	sequences	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	HTLV	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	I	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	transformed	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	type	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	leukemia	_	O	O	_	_	_	_	_
9	virus	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	HTLV	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	I	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	induces	_	O	O	_	_	_	_	_
16	abnormal	_	O	O	_	_	_	_	_
17	growth	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	subsequent	_	O	O	_	_	_	_	_
20	transformation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	which	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	associated	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	development	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	acute	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	cell	_	O	O	_	_	_	_	_
37	malignancy	_	O	O	_	_	_	_	_
38	termed	_	O	O	_	_	_	_	_
39	adult	_	O	O	_	_	_	_	_
40	T	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	leukemia	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	characteristic	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	HTLV	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	transformed	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	constitutive	_	O	O	_	_	_	_	_
14	nuclear	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	Rel	_	O	O	_	_	_	_	_
22	family	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	factors	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	which	_	O	O	_	_	_	_	_
28	appears	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	be	_	O	O	_	_	_	_	_
31	essential	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	growth	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	these	_	O	O	_	_	_	_	_
37	transformed	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	kappaB	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	Rel	_	O	O	_	_	_	_	_
7	factors	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	known	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	induce	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	growth	_	O	O	_	_	_	_	_
19	factor	_	O	O	_	_	_	_	_
20	interleukin	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	it	_	O	O	_	_	_	_	_
28	is	_	O	O	_	_	_	_	_
29	unclear	_	O	O	_	_	_	_	_
30	how	_	O	O	_	_	_	_	_
31	they	_	O	O	_	_	_	_	_
32	participate	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	independent	_	O	O	_	_	_	_	_
40	growth	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	HTLV	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	I	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	transformed	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	show	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	certain	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	kappaB	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	Rel	_	O	O	_	_	_	_	_
14	members	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	predominantly	_	O	O	_	_	_	_	_
17	c	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	Rel	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	interact	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	enhancer	_	O	O	_	_	_	_	_
24	sequences	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	STAT	_	O	O	_	_	_	_	_
27	5	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	key	_	O	O	_	_	_	_	_
31	transcription	_	O	O	_	_	_	_	_
32	factor	_	O	O	_	_	_	_	_
33	mediating	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	induced	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	proliferation	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Reporter	_	O	O	_	_	_	_	_
2	gene	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	reveal	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Rel	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	site	_	O	O	_	_	_	_	_
17	present	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	Fc	_	O	O	_	_	_	_	_
21	gammaR	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	gene	_	O	O	_	_	_	_	_
24	leads	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	potent	_	O	O	_	_	_	_	_
27	transactivation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	this	_	O	O	_	_	_	_	_
30	enhancer	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	c	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	Rel	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	Fc	_	O	O	_	_	_	_	_
9	gammaR	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	site	_	O	O	_	_	_	_	_
13	also	_	O	O	_	_	_	_	_
14	occurs	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	peripheral	_	O	O	_	_	_	_	_
18	blood	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	immortalized	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	HTLV	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	I	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vitro	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	is	_	O	O	_	_	_	_	_
30	correlated	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	enhanced	_	O	O	_	_	_	_	_
33	levels	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	proliferation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	these	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	raise	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	possibility	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappaB	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	Rel	_	O	O	_	_	_	_	_
12	may	_	O	O	_	_	_	_	_
13	participate	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	growth	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	HTLV	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	I	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	transformed	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	regulating	_	O	O	_	_	_	_	_
28	genes	_	O	O	_	_	_	_	_
29	driven	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	both	_	O	O	_	_	_	_	_
32	kappaB	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	certain	_	O	O	_	_	_	_	_
35	STAT	_	O	O	_	_	_	_	_
36	enhancers	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	7	_	O	O	_	_	_	_	_
4	can	_	O	O	_	_	_	_	_
5	induce	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	activation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	Jak	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	Jak	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	murine	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Janus	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	kinases	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	Jak	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	signal	_	O	O	_	_	_	_	_
15	transducer	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	activator	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	proteins	_	O	O	_	_	_	_	_
22	has	_	O	O	_	_	_	_	_
23	recently	_	O	O	_	_	_	_	_
24	been	_	O	O	_	_	_	_	_
25	linked	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	signal	_	O	O	_	_	_	_	_
29	transduction	_	O	O	_	_	_	_	_
30	mechanism	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	several	_	O	O	_	_	_	_	_
33	cytokines	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	7	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	induce	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	rapid	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	dose	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dependent	_	O	O	_	_	_	_	_
14	tyrosine	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	Jak	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	Jak	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	concomitantly	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	tyrosine	_	O	O	_	_	_	_	_
27	phosphorylation	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	DNA	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	activity	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	multiple	_	O	O	_	_	_	_	_
34	STAT	_	O	O	_	_	_	_	_
35	proteins	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	STAT	_	O	O	_	_	_	_	_
3	proteins	_	O	O	_	_	_	_	_
4	utilized	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	7	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	identical	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	those	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	could	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	identified	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	various	_	O	O	_	_	_	_	_
24	STAT	_	O	O	_	_	_	_	_
25	5	_	O	O	_	_	_	_	_
26	isoforms	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	induction	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	Jak	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	strongly	_	O	O	_	_	_	_	_
17	correlated	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	growth	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	promoting	_	O	O	_	_	_	_	_
23	effects	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	7	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	suggesting	_	O	O	_	_	_	_	_
30	that	_	O	O	_	_	_	_	_
31	this	_	O	O	_	_	_	_	_
32	signal	_	O	O	_	_	_	_	_
33	transduction	_	O	O	_	_	_	_	_
34	mechanism	_	O	O	_	_	_	_	_
35	may	_	O	O	_	_	_	_	_
36	play	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	key	_	O	O	_	_	_	_	_
39	role	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	7	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	induced	_	O	O	_	_	_	_	_
46	proliferation	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_


1	Discussion	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	first	_	O	O	_	_	_	_	_
6	described	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	product	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	proinflammatory	_	O	O	_	_	_	_	_
14	properties	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	22	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	RA	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	characterized	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	hyperplasia	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	synovial	_	O	O	_	_	_	_	_
8	lining	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	an	_	O	O	_	_	_	_	_
12	intense	_	O	O	_	_	_	_	_
13	infiltration	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	mononuclear	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	23	_	O	O	_	_	_	_	_
19	]	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Proinflammatory	_	O	O	_	_	_	_	_
2	cytokines	_	O	O	_	_	_	_	_
3	such	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	TNF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	abundant	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	rheumatoid	_	O	O	_	_	_	_	_
16	synovium	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	whereas	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	derived	_	O	O	_	_	_	_	_
24	cytokines	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	especially	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	4	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	interferon	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	gamma	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	have	_	O	O	_	_	_	_	_
36	often	_	O	O	_	_	_	_	_
37	proved	_	O	O	_	_	_	_	_
38	difficult	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	detect	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	RA	_	O	O	_	_	_	_	_
43	synovium	_	O	O	_	_	_	_	_
44	[	_	O	O	_	_	_	_	_
45	24	_	O	O	_	_	_	_	_
46	]	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	may	_	O	O	_	_	_	_	_
5	have	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	augmentation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	rheumatoid	_	O	O	_	_	_	_	_
13	synovial	_	O	O	_	_	_	_	_
14	inflammation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	lack	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	derived	_	O	O	_	_	_	_	_
23	cytokines	_	O	O	_	_	_	_	_
24	has	_	O	O	_	_	_	_	_
25	limited	_	O	O	_	_	_	_	_
26	its	_	O	O	_	_	_	_	_
27	importance	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	respect	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	17	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	appealing	_	O	O	_	_	_	_	_
10	because	_	O	O	_	_	_	_	_
11	it	_	O	O	_	_	_	_	_
12	has	_	O	O	_	_	_	_	_
13	been	_	O	O	_	_	_	_	_
14	described	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	derived	_	O	O	_	_	_	_	_
21	cytokine	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	proinflammatory	_	O	O	_	_	_	_	_
24	properties	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	our	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	tried	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	evaluate	_	O	O	_	_	_	_	_
9	how	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	17	_	O	O	_	_	_	_	_
13	production	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	regulated	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	PBMC	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	which	_	O	O	_	_	_	_	_
22	signaling	_	O	O	_	_	_	_	_
23	pathway	_	O	O	_	_	_	_	_
24	it	_	O	O	_	_	_	_	_
25	used	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Levels	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	higher	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	synovial	_	O	O	_	_	_	_	_
14	fluid	_	O	O	_	_	_	_	_
15	than	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	OA	_	O	O	_	_	_	_	_
18	synovial	_	O	O	_	_	_	_	_
19	fluid	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	15	_	O	O	_	_	_	_	_
22	]	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	there	_	O	O	_	_	_	_	_
4	are	_	O	O	_	_	_	_	_
5	few	_	O	O	_	_	_	_	_
6	data	_	O	O	_	_	_	_	_
7	available	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	agents	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	stimulate	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	although	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	highest	_	O	O	_	_	_	_	_
23	level	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	17	_	O	O	_	_	_	_	_
28	production	_	O	O	_	_	_	_	_
29	can	_	O	O	_	_	_	_	_
30	be	_	O	O	_	_	_	_	_
31	achieved	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	anti	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	anti	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	CD	_	O	O	_	_	_	_	_
41	28	_	O	O	_	_	_	_	_
42	stimulation	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	healthy	_	O	O	_	_	_	_	_
45	individuals	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	25	_	O	O	_	_	_	_	_
48	]	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	our	_	O	O	_	_	_	_	_
3	experiments	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	PHA	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	mitogens	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	well	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	anti	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	anti	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	28	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	signaling	_	O	O	_	_	_	_	_
23	through	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	increased	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	17	_	O	O	_	_	_	_	_
33	production	_	O	O	_	_	_	_	_
34	from	_	O	O	_	_	_	_	_
35	RA	_	O	O	_	_	_	_	_
36	PBMC	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	dose	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	dependent	_	O	O	_	_	_	_	_
42	manner	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	proliferation	_	O	O	_	_	_	_	_
8	assay	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	data	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	shown	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	that	_	O	O	_	_	_	_	_
16	this	_	O	O	_	_	_	_	_
17	upregulation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	17	_	O	O	_	_	_	_	_
22	might	_	O	O	_	_	_	_	_
23	be	_	O	O	_	_	_	_	_
24	due	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	increased	_	O	O	_	_	_	_	_
27	cellular	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	rather	_	O	O	_	_	_	_	_
30	than	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	cellular	_	O	O	_	_	_	_	_
33	proliferation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	produced	_	O	O	_	_	_	_	_
6	mainly	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	especially	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	Th	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	Th	_	O	O	_	_	_	_	_
21	0	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	Th	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	phenotype	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	26	_	O	O	_	_	_	_	_
31	]	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	can	_	O	O	_	_	_	_	_
5	also	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	produced	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	8	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	via	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	23	_	O	O	_	_	_	_	_
19	triggering	_	O	O	_	_	_	_	_
20	mechanism	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	Gram	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	negative	_	O	O	_	_	_	_	_
25	pulmonary	_	O	O	_	_	_	_	_
26	infection	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	14	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	17	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	significantly	_	O	O	_	_	_	_	_
10	augmented	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	recognizing	_	O	O	_	_	_	_	_
15	type	_	O	O	_	_	_	_	_
16	II	_	O	O	_	_	_	_	_
17	collagen	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	collagen	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	induced	_	O	O	_	_	_	_	_
23	arthritis	_	O	O	_	_	_	_	_
24	model	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	27	_	O	O	_	_	_	_	_
27	]	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	complex	_	O	O	_	_	_	_	_
3	interaction	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	inflamed	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	joints	_	O	O	_	_	_	_	_
10	might	_	O	O	_	_	_	_	_
11	produce	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	variety	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	proinflammatory	_	O	O	_	_	_	_	_
16	cytokines	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	chemokines	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	which	_	O	O	_	_	_	_	_
21	also	_	O	O	_	_	_	_	_
22	activate	_	O	O	_	_	_	_	_
23	other	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	joints	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	example	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	17	_	O	O	_	_	_	_	_
7	stimulates	_	O	O	_	_	_	_	_
8	rheumatoid	_	O	O	_	_	_	_	_
9	synoviocytes	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	secrete	_	O	O	_	_	_	_	_
12	several	_	O	O	_	_	_	_	_
13	cytokines	_	O	O	_	_	_	_	_
14	such	_	O	O	_	_	_	_	_
15	as	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	8	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	tumor	_	O	O	_	_	_	_	_
25	necrosis	_	O	O	_	_	_	_	_
26	factor	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	stimulated	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	well	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	prostaglandin	_	O	O	_	_	_	_	_
35	E	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	vitro	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	12	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	28	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	29	_	O	O	_	_	_	_	_
45	]	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	as	_	O	O	_	_	_	_	_
4	yet	_	O	O	_	_	_	_	_
5	few	_	O	O	_	_	_	_	_
6	data	_	O	O	_	_	_	_	_
7	available	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	agents	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	stimulate	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	although	_	O	O	_	_	_	_	_
21	some	_	O	O	_	_	_	_	_
22	cytokines	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	15	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	23	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	have	_	O	O	_	_	_	_	_
33	been	_	O	O	_	_	_	_	_
34	known	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	regulate	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	17	_	O	O	_	_	_	_	_
40	production	_	O	O	_	_	_	_	_
41	[	_	O	O	_	_	_	_	_
42	13	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	14	_	O	O	_	_	_	_	_
45	]	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	therefore	_	O	O	_	_	_	_	_
3	investigated	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	vitro	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	17	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	PBMC	_	O	O	_	_	_	_	_
15	responding	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	variety	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	cytokines	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	chemokines	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	mitogens	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	well	_	O	O	_	_	_	_	_
27	as	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	TCR	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	ligation	_	O	O	_	_	_	_	_
35	using	_	O	O	_	_	_	_	_
36	anti	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	CD	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	/	_	O	O	_	_	_	_	_
41	anti	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	28	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	15	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	MCP	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	well	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	TCR	_	O	O	_	_	_	_	_
16	ligation	_	O	O	_	_	_	_	_
17	significantly	_	O	O	_	_	_	_	_
18	increased	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	production	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	17	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	PBMC	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Adding	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	15	_	O	O	_	_	_	_	_
5	or	_	O	O	_	_	_	_	_
6	MCP	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	TCR	_	O	O	_	_	_	_	_
11	ligation	_	O	O	_	_	_	_	_
12	augmented	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	more	_	O	O	_	_	_	_	_
18	markedly	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	TNF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	known	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	have	_	O	O	_	_	_	_	_
17	proinflammatory	_	O	O	_	_	_	_	_
18	properties	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	increased	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	RA	_	O	O	_	_	_	_	_
25	joints	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	did	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	affect	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	17	_	O	O	_	_	_	_	_
33	production	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	consistent	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	recent	_	O	O	_	_	_	_	_
8	report	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	15	_	O	O	_	_	_	_	_
13	triggered	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	vitro	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	17	_	O	O	_	_	_	_	_
19	production	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	PBMC	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	TNF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	alpha	_	O	O	_	_	_	_	_
27	did	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	do	_	O	O	_	_	_	_	_
30	so	_	O	O	_	_	_	_	_
31	[	_	O	O	_	_	_	_	_
32	13	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	there	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	no	_	O	O	_	_	_	_	_
5	data	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	MCP	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	directly	_	O	O	_	_	_	_	_
11	induces	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	it	_	O	O	_	_	_	_	_
17	might	_	O	O	_	_	_	_	_
18	exert	_	O	O	_	_	_	_	_
19	effects	_	O	O	_	_	_	_	_
20	indirectly	_	O	O	_	_	_	_	_
21	on	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	through	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	activation	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	monocytes	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	macrophages	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	PBMC	_	O	O	_	_	_	_	_
33	cultures	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	reported	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	normal	_	O	O	_	_	_	_	_
5	individuals	_	O	O	_	_	_	_	_
6	[	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	]	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	activation	_	O	O	_	_	_	_	_
13	through	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	anti	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	28	_	O	O	_	_	_	_	_
23	also	_	O	O	_	_	_	_	_
24	increases	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	17	_	O	O	_	_	_	_	_
28	induction	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	RA	_	O	O	_	_	_	_	_
31	PBMC	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Although	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	signaling	_	O	O	_	_	_	_	_
4	pathway	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	induction	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	cytokines	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	chemokines	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	has	_	O	O	_	_	_	_	_
17	been	_	O	O	_	_	_	_	_
18	documented	_	O	O	_	_	_	_	_
19	widely	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	8	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	30	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	31	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	no	_	O	O	_	_	_	_	_
29	data	_	O	O	_	_	_	_	_
30	have	_	O	O	_	_	_	_	_
31	been	_	O	O	_	_	_	_	_
32	available	_	O	O	_	_	_	_	_
33	on	_	O	O	_	_	_	_	_
34	how	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	17	_	O	O	_	_	_	_	_
38	production	_	O	O	_	_	_	_	_
39	can	_	O	O	_	_	_	_	_
40	be	_	O	O	_	_	_	_	_
41	regulated	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	certain	_	O	O	_	_	_	_	_
44	signaling	_	O	O	_	_	_	_	_
45	pathways	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	using	_	O	O	_	_	_	_	_
3	signal	_	O	O	_	_	_	_	_
4	transduction	_	O	O	_	_	_	_	_
5	inhibitors	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	therefore	_	O	O	_	_	_	_	_
9	examined	_	O	O	_	_	_	_	_
10	which	_	O	O	_	_	_	_	_
11	signaling	_	O	O	_	_	_	_	_
12	pathway	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	mainly	_	O	O	_	_	_	_	_
15	involved	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	induction	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	17	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	RA	_	O	O	_	_	_	_	_
25	PBMC	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	identified	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	anti	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	17	_	O	O	_	_	_	_	_
13	production	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	RA	_	O	O	_	_	_	_	_
16	PBMC	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	significantly	_	O	O	_	_	_	_	_
19	hampered	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	PI	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	K	_	O	O	_	_	_	_	_
25	inhibitor	_	O	O	_	_	_	_	_
26	LY	_	O	O	_	_	_	_	_
27	294002	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	NF	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	kappaB	_	O	O	_	_	_	_	_
33	inhibitor	_	O	O	_	_	_	_	_
34	PDTC	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	comparable	_	O	O	_	_	_	_	_
37	levels	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	basal	_	O	O	_	_	_	_	_
40	production	_	O	O	_	_	_	_	_
41	without	_	O	O	_	_	_	_	_
42	stimulation	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	found	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	anti	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	17	_	O	O	_	_	_	_	_
14	production	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	downregulated	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	addition	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	SB	_	O	O	_	_	_	_	_
22	203580	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	38	_	O	O	_	_	_	_	_
27	MAPK	_	O	O	_	_	_	_	_
28	inhibitor	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	interesting	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	series	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	evidence	_	O	O	_	_	_	_	_
9	supports	_	O	O	_	_	_	_	_
10	crosstalk	_	O	O	_	_	_	_	_
11	between	_	O	O	_	_	_	_	_
12	NF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kappaB	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	38	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	myocytes	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IkappaB	_	O	O	_	_	_	_	_
5	kinase	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	p	_	O	O	_	_	_	_	_
12	38	_	O	O	_	_	_	_	_
13	[	_	O	O	_	_	_	_	_
14	32	_	O	O	_	_	_	_	_
15	]	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	activated	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	38	_	O	O	_	_	_	_	_
22	can	_	O	O	_	_	_	_	_
23	stimulate	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kappaB	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	mechanism	_	O	O	_	_	_	_	_
30	involving	_	O	O	_	_	_	_	_
31	histone	_	O	O	_	_	_	_	_
32	acetylase	_	O	O	_	_	_	_	_
33	p	_	O	O	_	_	_	_	_
34	300	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	CREB	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	binding	_	O	O	_	_	_	_	_
39	protein	_	O	O	_	_	_	_	_
40	[	_	O	O	_	_	_	_	_
41	33	_	O	O	_	_	_	_	_
42	]	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	revealed	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	MAPK	_	O	O	_	_	_	_	_
8	activation	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	affected	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	LY	_	O	O	_	_	_	_	_
14	294002	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	whereas	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	decreased	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	LY	_	O	O	_	_	_	_	_
26	294002	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	which	_	O	O	_	_	_	_	_
29	provided	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	evidence	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	p	_	O	O	_	_	_	_	_
35	38	_	O	O	_	_	_	_	_
36	MAPK	_	O	O	_	_	_	_	_
37	pathway	_	O	O	_	_	_	_	_
38	independent	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	PI	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	K	_	O	O	_	_	_	_	_
43	activation	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	direct	_	O	O	_	_	_	_	_
3	relationship	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappaB	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	17	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	needs	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	be	_	O	O	_	_	_	_	_
19	studied	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	future	_	O	O	_	_	_	_	_
22	experiments	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	search	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	downstream	_	O	O	_	_	_	_	_
6	pathway	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	PI	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	K	_	O	O	_	_	_	_	_
11	seemed	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	have	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	maximal	_	O	O	_	_	_	_	_
16	response	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	Akt	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	hour	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	gradual	_	O	O	_	_	_	_	_
26	loss	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	activity	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	hours	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	fact	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	Akt	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	phosphorylated	_	O	O	_	_	_	_	_
7	upon	_	O	O	_	_	_	_	_
8	anti	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	stimulation	_	O	O	_	_	_	_	_
13	suggests	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	possible	_	O	O	_	_	_	_	_
16	involvement	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	PI	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	K	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	induction	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	17	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	view	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	fact	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappaB	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	also	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	anti	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	28	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	15	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	mitogens	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	our	_	O	O	_	_	_	_	_
31	experiments	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	it	_	O	O	_	_	_	_	_
34	is	_	O	O	_	_	_	_	_
35	most	_	O	O	_	_	_	_	_
36	likely	_	O	O	_	_	_	_	_
37	that	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	NF	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	kappaB	_	O	O	_	_	_	_	_
42	pathway	_	O	O	_	_	_	_	_
43	is	_	O	O	_	_	_	_	_
44	also	_	O	O	_	_	_	_	_
45	actively	_	O	O	_	_	_	_	_
46	involved	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	induction	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	IL	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	17	_	O	O	_	_	_	_	_
54	in	_	O	O	_	_	_	_	_
55	RA	_	O	O	_	_	_	_	_
56	PBMC	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	AP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	signal	_	O	O	_	_	_	_	_
9	transduction	_	O	O	_	_	_	_	_
10	pathway	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	another	_	O	O	_	_	_	_	_
13	important	_	O	O	_	_	_	_	_
14	signaling	_	O	O	_	_	_	_	_
15	pathway	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	cytokines	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	chemokines	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	not	_	O	O	_	_	_	_	_
23	activated	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	our	_	O	O	_	_	_	_	_
26	experiments	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	data	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	shown	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	PI	_	O	O	_	_	_	_	_
3	3	_	O	O	_	_	_	_	_
4	K	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	its	_	O	O	_	_	_	_	_
7	downstream	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	Akt	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	association	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappaB	_	O	O	_	_	_	_	_
16	have	_	O	O	_	_	_	_	_
17	been	_	O	O	_	_	_	_	_
18	reported	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	deliver	_	O	O	_	_	_	_	_
21	activating	_	O	O	_	_	_	_	_
22	signals	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	many	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	types	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	data	_	O	O	_	_	_	_	_
30	on	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	signal	_	O	O	_	_	_	_	_
33	inducing	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	17	_	O	O	_	_	_	_	_
37	are	_	O	O	_	_	_	_	_
38	lacking	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	clearly	_	O	O	_	_	_	_	_
4	demonstrated	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	PI	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	K	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	Akt	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	resultant	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappaB	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	could	_	O	O	_	_	_	_	_
18	be	_	O	O	_	_	_	_	_
19	an	_	O	O	_	_	_	_	_
20	important	_	O	O	_	_	_	_	_
21	arbitrator	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	upregulation	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	17	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	RA	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	on	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	basis	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	our	_	O	O	_	_	_	_	_
37	experiments	_	O	O	_	_	_	_	_
38	showing	_	O	O	_	_	_	_	_
39	simultaneous	_	O	O	_	_	_	_	_
40	blocking	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	NF	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	kappaB	_	O	O	_	_	_	_	_
45	binding	_	O	O	_	_	_	_	_
46	activity	_	O	O	_	_	_	_	_
47	in	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	IL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	17	_	O	O	_	_	_	_	_
52	promoter	_	O	O	_	_	_	_	_
53	by	_	O	O	_	_	_	_	_
54	PDTC	_	O	O	_	_	_	_	_
55	and	_	O	O	_	_	_	_	_
56	LY	_	O	O	_	_	_	_	_
57	294002	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_

1	Considering	_	O	O	_	_	_	_	_
2	its	_	O	O	_	_	_	_	_
3	proinflammatory	_	O	O	_	_	_	_	_
4	activities	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	successful	_	O	O	_	_	_	_	_
7	induction	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	17	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	ameliorating	_	O	O	_	_	_	_	_
16	arthritis	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	animal	_	O	O	_	_	_	_	_
19	models	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	6	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	34	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	36	_	O	O	_	_	_	_	_
28	]	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	understanding	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	17	_	O	O	_	_	_	_	_
35	signaling	_	O	O	_	_	_	_	_
36	pathway	_	O	O	_	_	_	_	_
37	is	_	O	O	_	_	_	_	_
38	an	_	O	O	_	_	_	_	_
39	important	_	O	O	_	_	_	_	_
40	element	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	developing	_	O	O	_	_	_	_	_
43	new	_	O	O	_	_	_	_	_
44	targeted	_	O	O	_	_	_	_	_
45	therapies	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	RA	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_



1	Differential	_	O	O	_	_	_	_	_
2	nuclear	_	O	O	_	_	_	_	_
3	localization	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	50	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	52	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	RelB	_	O	O	_	_	_	_	_
13	proteins	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	accessory	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	immune	_	O	O	_	_	_	_	_
21	response	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	situ	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Rel	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kappa	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	50	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	52	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	65	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	c	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	Rel	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	RelB	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	constitute	_	O	O	_	_	_	_	_
27	a	_	O	O	_	_	_	_	_
28	family	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	factors	_	O	O	_	_	_	_	_
32	involved	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	positive	_	O	O	_	_	_	_	_
36	regulation	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	variety	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	genes	_	O	O	_	_	_	_	_
42	during	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	immune	_	O	O	_	_	_	_	_
45	response	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Recently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	shown	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	RelB	_	O	O	_	_	_	_	_
9	knockout	_	O	O	_	_	_	_	_
10	mice	_	O	O	_	_	_	_	_
11	have	_	O	O	_	_	_	_	_
12	no	_	O	O	_	_	_	_	_
13	dendritic	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	DC	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	overexpression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	50	_	O	O	_	_	_	_	_
6	has	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	described	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	follicular	_	O	O	_	_	_	_	_
11	dendritic	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	FDC	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	constitutive	_	O	O	_	_	_	_	_
3	NF	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	kappa	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	activity	_	O	O	_	_	_	_	_
8	has	_	O	O	_	_	_	_	_
9	been	_	O	O	_	_	_	_	_
10	reported	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	mature	_	O	O	_	_	_	_	_
13	macrophages	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	led	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	hypothesis	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	some	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	Rel	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	NF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kappa	_	O	O	_	_	_	_	_
15	B	_	O	O	_	_	_	_	_
16	proteins	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	key	_	O	O	_	_	_	_	_
19	nuclear	_	O	O	_	_	_	_	_
20	factors	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	functions	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	accessory	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	immune	_	O	O	_	_	_	_	_
29	response	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	investigated	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	situ	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	nuclear	_	O	O	_	_	_	_	_
9	localization	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	Rel	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	accessory	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	immune	_	O	O	_	_	_	_	_
24	system	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	immunohistochemistry	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	double	_	O	O	_	_	_	_	_
29	labeling	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	immunofluorescence	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	five	_	O	O	_	_	_	_	_
34	normal	_	O	O	_	_	_	_	_
35	human	_	O	O	_	_	_	_	_
36	tonsils	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	five	_	O	O	_	_	_	_	_
39	lymph	_	O	O	_	_	_	_	_
40	nodes	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	follicular	_	O	O	_	_	_	_	_
43	hyperplasia	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Nuclear	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	65	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	c	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	Rel	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	found	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	all	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	types	_	O	O	_	_	_	_	_
15	including	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	germinal	_	O	O	_	_	_	_	_
3	centers	_	O	O	_	_	_	_	_
4	GC	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	50	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	52	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	RelB	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	found	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	nuclei	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	FDC	_	O	O	_	_	_	_	_
21	only	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	detected	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	nuclei	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	68	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	cells	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	areas	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	p	_	O	O	_	_	_	_	_
7	50	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	52	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	RelB	_	O	O	_	_	_	_	_
14	were	_	O	O	_	_	_	_	_
15	found	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	nuclei	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	HLA	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	DR	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	antigen	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	presenting	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	APC	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	morphology	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	p	_	O	O	_	_	_	_	_
2	52	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	RelB	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	detected	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	nuclei	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	both	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	68	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	area	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	whereas	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	50	_	O	O	_	_	_	_	_
30	was	_	O	O	_	_	_	_	_
31	found	_	O	O	_	_	_	_	_
32	only	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	CD	_	O	O	_	_	_	_	_
35	68	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	CD	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	cells	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	nuclear	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	50	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	negative	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	38	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	20	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	markers	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	physiologically	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	high	_	O	O	_	_	_	_	_
9	levels	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	nuclear	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	50	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	52	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	RelB	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	restricted	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	accessory	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	immune	_	O	O	_	_	_	_	_
28	system	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	include	_	O	O	_	_	_	_	_
32	FDC	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	GC	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	DC	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	macrophages	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	T	_	O	O	_	_	_	_	_
43	cell	_	O	O	_	_	_	_	_
44	zone	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	that	_	O	O	_	_	_	_	_
47	specialized	_	O	O	_	_	_	_	_
48	scavenger	_	O	O	_	_	_	_	_
49	macrophages	_	O	O	_	_	_	_	_
50	from	_	O	O	_	_	_	_	_
51	GC	_	O	O	_	_	_	_	_
52	do	_	O	O	_	_	_	_	_
53	not	_	O	O	_	_	_	_	_
54	have	_	O	O	_	_	_	_	_
55	detectable	_	O	O	_	_	_	_	_
56	levels	_	O	O	_	_	_	_	_
57	of	_	O	O	_	_	_	_	_
58	p	_	O	O	_	_	_	_	_
59	52	_	O	O	_	_	_	_	_
60	and	_	O	O	_	_	_	_	_
61	RelB	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	whereas	_	O	O	_	_	_	_	_
64	macrophages	_	O	O	_	_	_	_	_
65	from	_	O	O	_	_	_	_	_
66	the	_	O	O	_	_	_	_	_
67	T	_	O	O	_	_	_	_	_
68	cell	_	O	O	_	_	_	_	_
69	area	_	O	O	_	_	_	_	_
70	,	_	O	O	_	_	_	_	_
71	known	_	O	O	_	_	_	_	_
72	to	_	O	O	_	_	_	_	_
73	present	_	O	O	_	_	_	_	_
74	the	_	O	O	_	_	_	_	_
75	antigen	_	O	O	_	_	_	_	_
76	to	_	O	O	_	_	_	_	_
77	T	_	O	O	_	_	_	_	_
78	cells	_	O	O	_	_	_	_	_
79	,	_	O	O	_	_	_	_	_
80	do	_	O	O	_	_	_	_	_
81	have	_	O	O	_	_	_	_	_
82	both	_	O	O	_	_	_	_	_
83	nuclear	_	O	O	_	_	_	_	_
84	p	_	O	O	_	_	_	_	_
85	52	_	O	O	_	_	_	_	_
86	and	_	O	O	_	_	_	_	_
87	RelB	_	O	O	_	_	_	_	_
88	,	_	O	O	_	_	_	_	_
89	and	_	O	O	_	_	_	_	_
90	that	_	O	O	_	_	_	_	_
91	in	_	O	O	_	_	_	_	_
92	the	_	O	O	_	_	_	_	_
93	T	_	O	O	_	_	_	_	_
94	cell	_	O	O	_	_	_	_	_
95	zone	_	O	O	_	_	_	_	_
96	,	_	O	O	_	_	_	_	_
97	p	_	O	O	_	_	_	_	_
98	52	_	O	O	_	_	_	_	_
99	and	_	O	O	_	_	_	_	_
100	RelB	_	O	O	_	_	_	_	_
101	are	_	O	O	_	_	_	_	_
102	located	_	O	O	_	_	_	_	_
103	in	_	O	O	_	_	_	_	_
104	nuclei	_	O	O	_	_	_	_	_
105	of	_	O	O	_	_	_	_	_
106	both	_	O	O	_	_	_	_	_
107	CD	_	O	O	_	_	_	_	_
108	1	_	O	O	_	_	_	_	_
109	a	_	O	O	_	_	_	_	_
110	+	_	O	O	_	_	_	_	_
111	,	_	O	O	_	_	_	_	_
112	CD	_	O	O	_	_	_	_	_
113	68	_	O	O	_	_	_	_	_
114	+	_	O	O	_	_	_	_	_
115	or	_	O	O	_	_	_	_	_
116	both	_	O	O	_	_	_	_	_
117	,	_	O	O	_	_	_	_	_
118	cells	_	O	O	_	_	_	_	_
119	APC	_	O	O	_	_	_	_	_
120	,	_	O	O	_	_	_	_	_
121	whereas	_	O	O	_	_	_	_	_
122	p	_	O	O	_	_	_	_	_
123	50	_	O	O	_	_	_	_	_
124	is	_	O	O	_	_	_	_	_
125	restricted	_	O	O	_	_	_	_	_
126	to	_	O	O	_	_	_	_	_
127	CD	_	O	O	_	_	_	_	_
128	1	_	O	O	_	_	_	_	_
129	a	_	O	O	_	_	_	_	_
130	-	_	O	O	_	_	_	_	_
131	and	_	O	O	_	_	_	_	_
132	CD	_	O	O	_	_	_	_	_
133	68	_	O	O	_	_	_	_	_
134	-	_	O	O	_	_	_	_	_
135	APC	_	O	O	_	_	_	_	_
136	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	different	_	O	O	_	_	_	_	_
3	patterns	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	50	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	52	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	RelB	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	localization	_	O	O	_	_	_	_	_
15	may	_	O	O	_	_	_	_	_
16	provide	_	O	O	_	_	_	_	_
17	insight	_	O	O	_	_	_	_	_
18	into	_	O	O	_	_	_	_	_
19	their	_	O	O	_	_	_	_	_
20	different	_	O	O	_	_	_	_	_
21	roles	_	O	O	_	_	_	_	_
22	during	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	immune	_	O	O	_	_	_	_	_
25	response	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	vivo	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Th	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	Th	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	type	_	O	O	_	_	_	_	_
9	cytokines	_	O	O	_	_	_	_	_
10	responding	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	HBsAg	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	HBxAg	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	chronic	_	O	O	_	_	_	_	_
17	hepatitis	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	cytokine	_	O	O	_	_	_	_	_
3	pattern	_	O	O	_	_	_	_	_
4	on	_	O	O	_	_	_	_	_
5	viral	_	O	O	_	_	_	_	_
6	antigen	_	O	O	_	_	_	_	_
7	recognition	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	believed	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	exert	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	profound	_	O	O	_	_	_	_	_
14	influence	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	resolution	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	viral	_	O	O	_	_	_	_	_
20	infections	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	viral	_	O	O	_	_	_	_	_
23	clearance	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	initiated	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	investigate	_	O	O	_	_	_	_	_
7	whether	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	cytokine	_	O	O	_	_	_	_	_
10	imbalance	_	O	O	_	_	_	_	_
11	oriented	_	O	O	_	_	_	_	_
12	toward	_	O	O	_	_	_	_	_
13	Th	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	type	_	O	O	_	_	_	_	_
16	response	_	O	O	_	_	_	_	_
17	plays	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	role	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	chronic	_	O	O	_	_	_	_	_
22	hepatitis	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Cytokine	_	O	O	_	_	_	_	_
2	profiles	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	peripheral	_	O	O	_	_	_	_	_
5	blood	_	O	O	_	_	_	_	_
6	mononuclear	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	associated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	chronic	_	O	O	_	_	_	_	_
11	hepatitis	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	analysed	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	RT	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	PCR	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Upon	_	O	O	_	_	_	_	_
2	HBsAg	_	O	O	_	_	_	_	_
3	stimulation	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	detected	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	41	_	O	O	_	_	_	_	_
27	%,	_	O	O	_	_	_	_	_
28	8	_	O	O	_	_	_	_	_
29	%,	_	O	O	_	_	_	_	_
30	41	_	O	O	_	_	_	_	_
31	%,	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	50	_	O	O	_	_	_	_	_
34	%	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	patients	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	respectively	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Among	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	cytokines	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IFN	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	gamma	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	associated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	high	_	O	O	_	_	_	_	_
15	levels	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	serum	_	O	O	_	_	_	_	_
18	AST	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	ALT	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	could	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	prove	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	Th	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	cytokines	_	O	O	_	_	_	_	_
12	had	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	protective	_	O	O	_	_	_	_	_
15	effect	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	hepatocytes	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Upon	_	O	O	_	_	_	_	_
2	HBxAg	_	O	O	_	_	_	_	_
3	stimulation	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	there	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	no	_	O	O	_	_	_	_	_
8	recognizable	_	O	O	_	_	_	_	_
9	association	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	cytokine	_	O	O	_	_	_	_	_
12	patterns	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	AST	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	ALT	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	production	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	Th	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	cytokine	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	IFN	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	HBsAg	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	reactive	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	associated	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	hepatocyte	_	O	O	_	_	_	_	_
24	damage	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	chronic	_	O	O	_	_	_	_	_
27	hepatitis	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	while	_	O	O	_	_	_	_	_
31	no	_	O	O	_	_	_	_	_
32	counteracting	_	O	O	_	_	_	_	_
33	effect	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	Th	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	cytokines	_	O	O	_	_	_	_	_
38	produced	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	those	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	was	_	O	O	_	_	_	_	_
43	observed	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_


1	Spi	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	novel	_	O	O	_	_	_	_	_
7	Ets	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	temporally	_	O	O	_	_	_	_	_
12	regulated	_	O	O	_	_	_	_	_
13	during	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	lymphocyte	_	O	O	_	_	_	_	_
16	development	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	novel	_	O	O	_	_	_	_	_
3	Ets	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	isolated	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	yeast	_	O	O	_	_	_	_	_
9	one	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	hybrid	_	O	O	_	_	_	_	_
12	screening	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	cDNA	_	O	O	_	_	_	_	_
16	library	_	O	O	_	_	_	_	_
17	made	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	lipopolysaccharide	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	stimulated	_	O	O	_	_	_	_	_
22	mouse	_	O	O	_	_	_	_	_
23	splenic	_	O	O	_	_	_	_	_
24	B	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	using	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	SP	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	kappa	_	O	O	_	_	_	_	_
32	promoter	_	O	O	_	_	_	_	_
33	kappaY	_	O	O	_	_	_	_	_
34	element	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	bait	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	novel	_	O	O	_	_	_	_	_
3	Ets	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	most	_	O	O	_	_	_	_	_
7	closely	_	O	O	_	_	_	_	_
8	related	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	PU	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	Spi	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	within	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	DNA	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	Ets	_	O	O	_	_	_	_	_
22	domain	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	therefore	_	O	O	_	_	_	_	_
26	named	_	O	O	_	_	_	_	_
27	Spi	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	C	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Spi	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	C	_	O	O	_	_	_	_	_
6	may	_	O	O	_	_	_	_	_
7	represent	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	novel	_	O	O	_	_	_	_	_
10	subgroup	_	O	O	_	_	_	_	_
11	within	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	Ets	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	family	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	as	_	O	O	_	_	_	_	_
18	it	_	O	O	_	_	_	_	_
19	differed	_	O	O	_	_	_	_	_
20	significantly	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	Spi	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	B	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	PU	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	within	_	O	O	_	_	_	_	_
30	helix	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	Ets	_	O	O	_	_	_	_	_
35	domain	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Spi	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	encoded	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	single	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	copy	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	mapped	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	chromosome	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	region	_	O	O	_	_	_	_	_
20	C	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Spi	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	interacted	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	similarly	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	PU	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	judged	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	methylation	_	O	O	_	_	_	_	_
16	interference	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	band	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	shift	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	site	_	O	O	_	_	_	_	_
23	selection	_	O	O	_	_	_	_	_
24	analysis	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	activated	_	O	O	_	_	_	_	_
28	transcription	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	kappaY	_	O	O	_	_	_	_	_
32	element	_	O	O	_	_	_	_	_
33	reporter	_	O	O	_	_	_	_	_
34	gene	_	O	O	_	_	_	_	_
35	upon	_	O	O	_	_	_	_	_
36	co	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	transfection	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	HeLa	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Spi	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	RNA	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	expressed	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	mature	_	O	O	_	_	_	_	_
9	B	_	O	O	_	_	_	_	_
10	lymphocytes	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	lower	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	macrophages	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	pre	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	plasma	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	lines	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	Spi	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	C	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	negative	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	suggesting	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	Spi	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	C	_	O	O	_	_	_	_	_
23	might	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	regulatory	_	O	O	_	_	_	_	_
27	molecule	_	O	O	_	_	_	_	_
28	during	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	specific	_	O	O	_	_	_	_	_
31	phase	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	B	_	O	O	_	_	_	_	_
34	lymphoid	_	O	O	_	_	_	_	_
35	development	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Cytokine	_	O	O	_	_	_	_	_
2	profile	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	PBMC	_	O	O	_	_	_	_	_
6	following	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	48	_	O	O	_	_	_	_	_
9	h	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	vitro	_	O	O	_	_	_	_	_
12	stimulation	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	TSST	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	GP	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	GP	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	LPS	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	+	_	O	O	_	_	_	_	_
28	TSST	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	band	_	O	O	_	_	_	_	_
8	shifts	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	seven	_	O	O	_	_	_	_	_
11	sites	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	TNFalpha	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	IFNgamma	_	O	O	_	_	_	_	_
25	promoters	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	it	_	O	O	_	_	_	_	_
28	could	_	O	O	_	_	_	_	_
29	be	_	O	O	_	_	_	_	_
30	assumed	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	GP	_	O	O	_	_	_	_	_
33	treatment	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	human	_	O	O	_	_	_	_	_
36	PBMC	_	O	O	_	_	_	_	_
37	would	_	O	O	_	_	_	_	_
38	lead	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	production	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	TNFalpha	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	8	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	6	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	IFNgamma	_	O	O	_	_	_	_	_
53	and	_	O	O	_	_	_	_	_
54	other	_	O	O	_	_	_	_	_
55	pro	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	inflammatory	_	O	O	_	_	_	_	_
58	mediators	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	Previous	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	reported	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	beta	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	--	_	O	O	_	_	_	_	_
9	>	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	D	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	glucans	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	only	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	limited	_	O	O	_	_	_	_	_
19	cytokine	_	O	O	_	_	_	_	_
20	secretion	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	blood	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	15	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	18	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Corroborating	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	extending	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	singular	_	O	O	_	_	_	_	_
6	findings	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	terms	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	examining	_	O	O	_	_	_	_	_
11	pro	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	eight	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	well	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	anti	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	three	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	inflammatory	_	O	O	_	_	_	_	_
25	cytokines	_	O	O	_	_	_	_	_
26	over	_	O	O	_	_	_	_	_
27	time	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	48	_	O	O	_	_	_	_	_
30	h	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	six	_	O	O	_	_	_	_	_
34	additional	_	O	O	_	_	_	_	_
35	transcription	_	O	O	_	_	_	_	_
36	factor	_	O	O	_	_	_	_	_
37	binding	_	O	O	_	_	_	_	_
38	sites	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	our	_	O	O	_	_	_	_	_
41	comprehensive	_	O	O	_	_	_	_	_
42	analysis	_	O	O	_	_	_	_	_
43	revealed	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	following	_	O	O	_	_	_	_	_
46	cytokine	_	O	O	_	_	_	_	_
47	profile	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	human	_	O	O	_	_	_	_	_
50	leukocytes	_	O	O	_	_	_	_	_
51	in	_	O	O	_	_	_	_	_
52	response	_	O	O	_	_	_	_	_
53	to	_	O	O	_	_	_	_	_
54	a	_	O	O	_	_	_	_	_
55	highly	_	O	O	_	_	_	_	_
56	purified	_	O	O	_	_	_	_	_
57	water	_	O	O	_	_	_	_	_
58	soluble	_	O	O	_	_	_	_	_
59	beta	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	1	_	O	O	_	_	_	_	_
62	--	_	O	O	_	_	_	_	_
63	>	_	O	O	_	_	_	_	_
64	3	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	D	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	glucan	_	O	O	_	_	_	_	_
69	and	_	O	O	_	_	_	_	_
70	in	_	O	O	_	_	_	_	_
71	comparison	_	O	O	_	_	_	_	_
72	to	_	O	O	_	_	_	_	_
73	two	_	O	O	_	_	_	_	_
74	pro	_	O	O	_	_	_	_	_
75	-	_	O	O	_	_	_	_	_
76	inflammatory	_	O	O	_	_	_	_	_
77	mediators	_	O	O	_	_	_	_	_
78	(	_	O	O	_	_	_	_	_
79	LPS	_	O	O	_	_	_	_	_
80	,	_	O	O	_	_	_	_	_
81	TSST	_	O	O	_	_	_	_	_
82	-	_	O	O	_	_	_	_	_
83	1	_	O	O	_	_	_	_	_
84	)	_	O	O	_	_	_	_	_
85	:	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	i	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	beta	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	detectable	_	O	O	_	_	_	_	_
10	following	_	O	O	_	_	_	_	_
11	PBMC	_	O	O	_	_	_	_	_
12	treatment	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	nor	_	O	O	_	_	_	_	_
16	100	_	O	O	_	_	_	_	_
17	mug	_	O	O	_	_	_	_	_
18	GP	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	insignificant	_	O	O	_	_	_	_	_
3	up	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	regulation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	beta	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	GP	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	LPS	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	observed	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	comparison	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	LPS	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	significant	_	O	O	_	_	_	_	_
11	reduction	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	18	_	O	O	_	_	_	_	_
19	h	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	24	_	O	O	_	_	_	_	_
22	h	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	latter	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	about	_	O	O	_	_	_	_	_
29	40	_	O	O	_	_	_	_	_
30	%	_	O	O	_	_	_	_	_
31	when	_	O	O	_	_	_	_	_
32	compared	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	TSST	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	or	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	theoretical	_	O	O	_	_	_	_	_
40	value	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	GP	_	O	O	_	_	_	_	_
43	/	_	O	O	_	_	_	_	_
44	TSST	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	calc	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	n	_	O	O	_	_	_	_	_
3	=	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	;	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	p	_	O	O	_	_	_	_	_
8	=	_	O	O	_	_	_	_	_
9	0	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_
11	01	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	whole	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	mediated	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	reduction	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	TSST	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	amount	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	beta	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	about	_	O	O	_	_	_	_	_
24	50	_	O	O	_	_	_	_	_
25	%	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	Fig	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	A	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_


1	(	_	O	O	_	_	_	_	_
2	ii	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	induced	_	O	O	_	_	_	_	_
3	only	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	small	_	O	O	_	_	_	_	_
6	amount	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	there	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	no	_	O	O	_	_	_	_	_
15	significant	_	O	O	_	_	_	_	_
16	alteration	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	LPS	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	production	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	GP	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	contrary	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	observed	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	decreased	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	production	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	GP	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	TSST	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	compared	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	TSST	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	or	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	TSST	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	calc	_	O	O	_	_	_	_	_
32	.,	_	O	O	_	_	_	_	_
33	especially	_	O	O	_	_	_	_	_
34	at	_	O	O	_	_	_	_	_
35	24	_	O	O	_	_	_	_	_
36	h	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	about	_	O	O	_	_	_	_	_
39	40	_	O	O	_	_	_	_	_
40	%	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	n	_	O	O	_	_	_	_	_
43	=	_	O	O	_	_	_	_	_
44	5	_	O	O	_	_	_	_	_
45	;	_	O	O	_	_	_	_	_
46	both	_	O	O	_	_	_	_	_
47	p	_	O	O	_	_	_	_	_
48	=	_	O	O	_	_	_	_	_
49	0	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	02	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	(	_	O	O	_	_	_	_	_
55	data	_	O	O	_	_	_	_	_
56	not	_	O	O	_	_	_	_	_
57	shown	_	O	O	_	_	_	_	_
58	in	_	O	O	_	_	_	_	_
59	detail	_	O	O	_	_	_	_	_
60	)	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_


1	(	_	O	O	_	_	_	_	_
2	iii	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	8	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	substantial	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	8	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	comparison	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	medium	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	especially	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	24	_	O	O	_	_	_	_	_
22	h	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	n	_	O	O	_	_	_	_	_
25	=	_	O	O	_	_	_	_	_
26	13	_	O	O	_	_	_	_	_
27	;	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	<	_	O	O	_	_	_	_	_
30	0	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_
32	01	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	combination	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	LPS	_	O	O	_	_	_	_	_
7	resulted	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	non	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	significant	_	O	O	_	_	_	_	_
13	increase	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	production	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	compared	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	LPS	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	GP	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	LPS	_	O	O	_	_	_	_	_
27	calc	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	alteration	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	8	_	O	O	_	_	_	_	_
10	production	_	O	O	_	_	_	_	_
11	following	_	O	O	_	_	_	_	_
12	GP	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	TSST	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	when	_	O	O	_	_	_	_	_
18	compared	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	TSST	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	GP	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	TSST	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	calc	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	not	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	detail	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_


1	(	_	O	O	_	_	_	_	_
2	iv	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_

1	Besides	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	8	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	RA	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	only	_	O	O	_	_	_	_	_
13	mediator	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	produced	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	significant	_	O	O	_	_	_	_	_
19	quantities	_	O	O	_	_	_	_	_
20	following	_	O	O	_	_	_	_	_
21	GP	_	O	O	_	_	_	_	_
22	treatment	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	especially	_	O	O	_	_	_	_	_
25	at	_	O	O	_	_	_	_	_
26	24	_	O	O	_	_	_	_	_
27	h	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	n	_	O	O	_	_	_	_	_
30	=	_	O	O	_	_	_	_	_
31	14	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	p	_	O	O	_	_	_	_	_
34	<	_	O	O	_	_	_	_	_
35	0	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	01	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	compared	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	LPS	_	O	O	_	_	_	_	_
5	stimulation	_	O	O	_	_	_	_	_
6	or	_	O	O	_	_	_	_	_
7	GP	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	calc	_	O	O	_	_	_	_	_
11	.,	_	O	O	_	_	_	_	_
12	GP	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	did	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	alter	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	kinetic	_	O	O	_	_	_	_	_
20	course	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	RA	_	O	O	_	_	_	_	_
27	production	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	following	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	TSST	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	we	_	O	O	_	_	_	_	_
10	found	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	synergistic	_	O	O	_	_	_	_	_
13	increase	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	production	_	O	O	_	_	_	_	_
20	from	_	O	O	_	_	_	_	_
21	18	_	O	O	_	_	_	_	_
22	h	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	48	_	O	O	_	_	_	_	_
25	h	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	when	_	O	O	_	_	_	_	_
28	compared	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	TSST	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	for	_	O	O	_	_	_	_	_
35	instance	_	O	O	_	_	_	_	_
36	at	_	O	O	_	_	_	_	_
37	24	_	O	O	_	_	_	_	_
38	h	_	O	O	_	_	_	_	_
39	:	_	O	O	_	_	_	_	_
40	n	_	O	O	_	_	_	_	_
41	=	_	O	O	_	_	_	_	_
42	6	_	O	O	_	_	_	_	_
43	;	_	O	O	_	_	_	_	_
44	p	_	O	O	_	_	_	_	_
45	=	_	O	O	_	_	_	_	_
46	0	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_
48	01	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	or	_	O	O	_	_	_	_	_
51	to	_	O	O	_	_	_	_	_
52	the	_	O	O	_	_	_	_	_
53	theoretical	_	O	O	_	_	_	_	_
54	value	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	GP	_	O	O	_	_	_	_	_
57	/	_	O	O	_	_	_	_	_
58	TSST	_	O	O	_	_	_	_	_
59	-	_	O	O	_	_	_	_	_
60	1	_	O	O	_	_	_	_	_
61	calc	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	from	_	O	O	_	_	_	_	_
3	18	_	O	O	_	_	_	_	_
4	h	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	36	_	O	O	_	_	_	_	_
7	h	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Over	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	time	_	O	O	_	_	_	_	_
4	course	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	48	_	O	O	_	_	_	_	_
7	h	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	GP	_	O	O	_	_	_	_	_
10	elevated	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	TSST	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	amount	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	RA	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	approximately	_	O	O	_	_	_	_	_
25	200	_	O	O	_	_	_	_	_
26	%	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	Fig	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	3	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_


1	Positive	_	O	O	_	_	_	_	_
2	correlation	_	O	O	_	_	_	_	_
3	between	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	8	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	productions	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	stimulation	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	24	_	O	O	_	_	_	_	_
7	h	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	we	_	O	O	_	_	_	_	_
11	observed	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	positive	_	O	O	_	_	_	_	_
14	correlation	_	O	O	_	_	_	_	_
15	between	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	found	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	correlation	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	dose	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	since	_	O	O	_	_	_	_	_
14	100	_	O	O	_	_	_	_	_
15	mug	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	GP	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	larger	_	O	O	_	_	_	_	_
20	amounts	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	8	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	than	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	mug	_	O	O	_	_	_	_	_
33	GP	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	n	_	O	O	_	_	_	_	_
36	=	_	O	O	_	_	_	_	_
37	5	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	p	_	O	O	_	_	_	_	_
40	<	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	=	_	O	O	_	_	_	_	_
43	0	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_
45	002	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	r	_	O	O	_	_	_	_	_
48	=	_	O	O	_	_	_	_	_
49	0	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	9	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	0	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_
55	98	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	respectively	_	O	O	_	_	_	_	_
58	)	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_


1	(	_	O	O	_	_	_	_	_
2	v	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	TNFalpha	_	O	O	_	_	_	_	_

1	With	_	O	O	_	_	_	_	_
2	respect	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	TNFalpha	_	O	O	_	_	_	_	_
5	production	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	100	_	O	O	_	_	_	_	_
8	mug	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	yielded	_	O	O	_	_	_	_	_
12	minor	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	statistically	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	distinguishable	_	O	O	_	_	_	_	_
17	amounts	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	when	_	O	O	_	_	_	_	_
20	compared	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	medium	_	O	O	_	_	_	_	_
23	control	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	+	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	did	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	change	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	TNFalpha	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	when	_	O	O	_	_	_	_	_
11	compared	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	LPS	_	O	O	_	_	_	_	_
14	supplementation	_	O	O	_	_	_	_	_
15	or	_	O	O	_	_	_	_	_
16	GP	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	LPS	_	O	O	_	_	_	_	_
19	calc	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	combined	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	GP	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	TSST	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	calc	_	O	O	_	_	_	_	_
14	.,	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	seemed	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	exert	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	synergistic	_	O	O	_	_	_	_	_
21	effect	_	O	O	_	_	_	_	_
22	on	_	O	O	_	_	_	_	_
23	TNFalpha	_	O	O	_	_	_	_	_
24	secretion	_	O	O	_	_	_	_	_
25	after	_	O	O	_	_	_	_	_
26	36	_	O	O	_	_	_	_	_
27	h	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	n	_	O	O	_	_	_	_	_
30	=	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	;	_	O	O	_	_	_	_	_
33	p	_	O	O	_	_	_	_	_
34	<	_	O	O	_	_	_	_	_
35	0	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	05	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	,	_	O	O	_	_	_	_	_
40	but	_	O	O	_	_	_	_	_
41	overall	_	O	O	_	_	_	_	_
42	an	_	O	O	_	_	_	_	_
43	enhancement	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	only	_	O	O	_	_	_	_	_
46	10	_	O	O	_	_	_	_	_
47	%	_	O	O	_	_	_	_	_
48	was	_	O	O	_	_	_	_	_
49	observed	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	p	_	O	O	_	_	_	_	_
52	>	_	O	O	_	_	_	_	_
53	0	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_
55	05	_	O	O	_	_	_	_	_
56	;	_	O	O	_	_	_	_	_
57	data	_	O	O	_	_	_	_	_
58	not	_	O	O	_	_	_	_	_
59	shown	_	O	O	_	_	_	_	_
60	in	_	O	O	_	_	_	_	_
61	detail	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_


1	(	_	O	O	_	_	_	_	_
2	vi	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	IFNgamma	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	IFNgamma	_	O	O	_	_	_	_	_
3	production	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	detectable	_	O	O	_	_	_	_	_
6	following	_	O	O	_	_	_	_	_
7	treatment	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	PBMC	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	100	_	O	O	_	_	_	_	_
12	mug	_	O	O	_	_	_	_	_
13	GP	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	minor	_	O	O	_	_	_	_	_
5	increase	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	IFNgamma	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	following	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	LPS	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	36	_	O	O	_	_	_	_	_
15	h	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	when	_	O	O	_	_	_	_	_
18	compared	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	LPS	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	GP	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	LPS	_	O	O	_	_	_	_	_
25	calc	_	O	O	_	_	_	_	_
26	.,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	slight	_	O	O	_	_	_	_	_
30	down	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	regulation	_	O	O	_	_	_	_	_
33	following	_	O	O	_	_	_	_	_
34	GP	_	O	O	_	_	_	_	_
35	+	_	O	O	_	_	_	_	_
36	TSST	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	1	_	O	O	_	_	_	_	_
39	at	_	O	O	_	_	_	_	_
40	24	_	O	O	_	_	_	_	_
41	h	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	36	_	O	O	_	_	_	_	_
44	h	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	when	_	O	O	_	_	_	_	_
47	compared	_	O	O	_	_	_	_	_
48	to	_	O	O	_	_	_	_	_
49	TSST	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	1	_	O	O	_	_	_	_	_
52	or	_	O	O	_	_	_	_	_
53	GP	_	O	O	_	_	_	_	_
54	/	_	O	O	_	_	_	_	_
55	TSST	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	1	_	O	O	_	_	_	_	_
58	calc	_	O	O	_	_	_	_	_
59	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	not	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_


1	(	_	O	O	_	_	_	_	_
2	vii	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	12	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	TGFbeta	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	production	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	12	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	4	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	TGFbeta	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	not	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	GP	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	no	_	O	O	_	_	_	_	_
5	significant	_	O	O	_	_	_	_	_
6	differences	_	O	O	_	_	_	_	_
7	between	_	O	O	_	_	_	_	_
8	medium	_	O	O	_	_	_	_	_
9	control	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	LPS	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	TSST	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	GP	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	GP	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	LPS	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	GP	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	calc	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	and	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	GP	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	TSST	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	calc	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	over	_	O	O	_	_	_	_	_
2	48	_	O	O	_	_	_	_	_
3	h	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	data	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	shown	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_



1	Altered	_	O	O	_	_	_	_	_
2	memory	_	O	O	_	_	_	_	_
3	T	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	differentiation	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	early	_	O	O	_	_	_	_	_
10	rheumatoid	_	O	O	_	_	_	_	_
11	arthritis	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	chronic	_	O	O	_	_	_	_	_
3	immune	_	O	O	_	_	_	_	_
4	response	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	rheumatoid	_	O	O	_	_	_	_	_
7	arthritis	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	RA	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	might	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	driven	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	activated	_	O	O	_	_	_	_	_
16	Th	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	without	_	O	O	_	_	_	_	_
20	sufficient	_	O	O	_	_	_	_	_
21	Th	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	differentiation	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	down	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	modulate	_	O	O	_	_	_	_	_
29	inflammation	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	test	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	disordered	_	O	O	_	_	_	_	_
5	memory	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	differentiation	_	O	O	_	_	_	_	_
9	contributes	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	typical	_	O	O	_	_	_	_	_
13	Th	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dominated	_	O	O	_	_	_	_	_
17	chronic	_	O	O	_	_	_	_	_
18	inflammation	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	RA	_	O	O	_	_	_	_	_
21	we	_	O	O	_	_	_	_	_
22	investigated	_	O	O	_	_	_	_	_
23	differentiation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	resting	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	memory	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	patients	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	early	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	6	_	O	O	_	_	_	_	_
38	wk	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	12	_	O	O	_	_	_	_	_
41	mo	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	untreated	_	O	O	_	_	_	_	_
44	RA	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	age	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	sex	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	matched	_	O	O	_	_	_	_	_
53	healthy	_	O	O	_	_	_	_	_
54	controls	_	O	O	_	_	_	_	_
55	in	_	O	O	_	_	_	_	_
56	vitro	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	No	_	O	O	_	_	_	_	_
2	difference	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	cytokine	_	O	O	_	_	_	_	_
5	secretion	_	O	O	_	_	_	_	_
6	profiles	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	freshly	_	O	O	_	_	_	_	_
9	isolated	_	O	O	_	_	_	_	_
10	memory	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	detected	_	O	O	_	_	_	_	_
15	between	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	controls	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	culture	_	O	O	_	_	_	_	_
4	system	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	then	_	O	O	_	_	_	_	_
7	employed	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	permitted	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	differentiation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Th	_	O	O	_	_	_	_	_
14	effectors	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	resting	_	O	O	_	_	_	_	_
17	memory	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	short	_	O	O	_	_	_	_	_
22	term	_	O	O	_	_	_	_	_
23	priming	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Marked	_	O	O	_	_	_	_	_
2	differences	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	found	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	response	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	priming	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Th	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	could	_	O	O	_	_	_	_	_
5	be	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	all	_	O	O	_	_	_	_	_
9	healthy	_	O	O	_	_	_	_	_
10	controls	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	priming	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	anti	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	28	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	absence	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	TCR	_	O	O	_	_	_	_	_
23	ligation	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	priming	_	O	O	_	_	_	_	_
5	under	_	O	O	_	_	_	_	_
6	those	_	O	O	_	_	_	_	_
7	conditions	_	O	O	_	_	_	_	_
8	resulted	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	Th	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	differentiation	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	only	_	O	O	_	_	_	_	_
15	9	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	24	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Exogenous	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	could	_	O	O	_	_	_	_	_
6	overcome	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	apparent	_	O	O	_	_	_	_	_
9	Th	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	differentiation	_	O	O	_	_	_	_	_
12	defect	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	seven	_	O	O	_	_	_	_	_
15	patients	_	O	O	_	_	_	_	_
16	but	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	without	_	O	O	_	_	_	_	_
19	effect	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	remaining	_	O	O	_	_	_	_	_
23	eight	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	all	_	O	O	_	_	_	_	_
3	patients	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	marked	_	O	O	_	_	_	_	_
6	decrease	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	producing	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	significant	_	O	O	_	_	_	_	_
17	increase	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	well	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	differentiated	_	O	O	_	_	_	_	_
22	Th	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	produced	_	O	O	_	_	_	_	_
27	IFN	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	gamma	_	O	O	_	_	_	_	_
30	but	_	O	O	_	_	_	_	_
31	not	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	were	_	O	O	_	_	_	_	_
36	evident	_	O	O	_	_	_	_	_
37	after	_	O	O	_	_	_	_	_
38	priming	_	O	O	_	_	_	_	_
39	with	_	O	O	_	_	_	_	_
40	anti	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	CD	_	O	O	_	_	_	_	_
43	3	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	anti	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	CD	_	O	O	_	_	_	_	_
48	28	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	memory	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	patients	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	early	_	O	O	_	_	_	_	_
15	untreated	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	manifest	_	O	O	_	_	_	_	_
18	an	_	O	O	_	_	_	_	_
19	intrinsic	_	O	O	_	_	_	_	_
20	abnormality	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	their	_	O	O	_	_	_	_	_
23	ability	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	differentiate	_	O	O	_	_	_	_	_
26	into	_	O	O	_	_	_	_	_
27	specific	_	O	O	_	_	_	_	_
28	cytokine	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	producing	_	O	O	_	_	_	_	_
31	effector	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	that	_	O	O	_	_	_	_	_
34	might	_	O	O	_	_	_	_	_
35	contribute	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	characteristic	_	O	O	_	_	_	_	_
39	Th	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	dominated	_	O	O	_	_	_	_	_
43	chronic	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	auto	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	immune	_	O	O	_	_	_	_	_
48	inflammation	_	O	O	_	_	_	_	_
49	in	_	O	O	_	_	_	_	_
50	RA	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	leukemia	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	type	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	Tax	_	O	O	_	_	_	_	_
10	associates	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	negatively	_	O	O	_	_	_	_	_
15	regulated	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kappa	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	100	_	O	O	_	_	_	_	_
25	gene	_	O	O	_	_	_	_	_
26	product	_	O	O	_	_	_	_	_
27	:	_	O	O	_	_	_	_	_
28	implications	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	viral	_	O	O	_	_	_	_	_
31	latency	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	leukemia	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	type	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	HTLV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	I	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	etiologic	_	O	O	_	_	_	_	_
17	agent	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	adult	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	leukemia	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	an	_	O	O	_	_	_	_	_
27	aggressive	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	often	_	O	O	_	_	_	_	_
30	fatal	_	O	O	_	_	_	_	_
31	malignancy	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	activated	_	O	O	_	_	_	_	_
34	human	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	4	_	O	O	_	_	_	_	_
37	T	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	HTLV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	encodes	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	essential	_	O	O	_	_	_	_	_
7	40	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kDa	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	termed	_	O	O	_	_	_	_	_
12	Tax	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	only	_	O	O	_	_	_	_	_
16	transactivates	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	long	_	O	O	_	_	_	_	_
19	terminal	_	O	O	_	_	_	_	_
20	repeat	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	this	_	O	O	_	_	_	_	_
23	retrovirus	_	O	O	_	_	_	_	_
24	but	_	O	O	_	_	_	_	_
25	also	_	O	O	_	_	_	_	_
26	induces	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	array	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	cellular	_	O	O	_	_	_	_	_
31	genes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Tax	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	mediated	_	O	O	_	_	_	_	_
4	transformation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	likely	_	O	O	_	_	_	_	_
9	involves	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	deregulated	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	various	_	O	O	_	_	_	_	_
15	cellular	_	O	O	_	_	_	_	_
16	genes	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	normally	_	O	O	_	_	_	_	_
19	regulate	_	O	O	_	_	_	_	_
20	lymphocyte	_	O	O	_	_	_	_	_
21	growth	_	O	O	_	_	_	_	_
22	produced	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	altered	_	O	O	_	_	_	_	_
25	activity	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	various	_	O	O	_	_	_	_	_
28	endogenous	_	O	O	_	_	_	_	_
29	host	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	factors	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	particular	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	Tax	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	capable	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	modulating	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	or	_	O	O	_	_	_	_	_
12	activity	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	various	_	O	O	_	_	_	_	_
15	host	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	factors	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	including	_	O	O	_	_	_	_	_
20	members	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	NF	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	kappa	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	Rel	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	CREB	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	ATF	_	O	O	_	_	_	_	_
33	families	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	well	_	O	O	_	_	_	_	_
37	as	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	cellular	_	O	O	_	_	_	_	_
40	factors	_	O	O	_	_	_	_	_
41	HEB	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	p	_	O	O	_	_	_	_	_
46	67	_	O	O	_	_	_	_	_
47	SRF	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	additional	_	O	O	_	_	_	_	_
3	distinguishing	_	O	O	_	_	_	_	_
4	characteristic	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	HTLV	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	I	_	O	O	_	_	_	_	_
9	infection	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	profound	_	O	O	_	_	_	_	_
13	state	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	viral	_	O	O	_	_	_	_	_
16	latency	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	present	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	circulating	_	O	O	_	_	_	_	_
22	primary	_	O	O	_	_	_	_	_
23	leukemic	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	demonstrate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	HTLV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	I	_	O	O	_	_	_	_	_
11	Tax	_	O	O	_	_	_	_	_
12	can	_	O	O	_	_	_	_	_
13	physically	_	O	O	_	_	_	_	_
14	associate	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	p	_	O	O	_	_	_	_	_
17	100	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	product	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	Rel	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	related	_	O	O	_	_	_	_	_
26	NF	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	gene	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	both	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	transfected	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	HTLV	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	I	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	infected	_	O	O	_	_	_	_	_
44	leukemic	_	O	O	_	_	_	_	_
45	T	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	cell	_	O	O	_	_	_	_	_
48	lines	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	physical	_	O	O	_	_	_	_	_
5	interaction	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Tax	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	p	_	O	O	_	_	_	_	_
10	100	_	O	O	_	_	_	_	_
11	leads	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	inhibition	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	Tax	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	HTLV	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	I	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	human	_	O	O	_	_	_	_	_
27	immunodeficiency	_	O	O	_	_	_	_	_
28	virus	_	O	O	_	_	_	_	_
29	type	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	long	_	O	O	_	_	_	_	_
32	terminal	_	O	O	_	_	_	_	_
33	repeats	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	reflecting	_	O	O	_	_	_	_	_
36	p	_	O	O	_	_	_	_	_
37	100	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	mediated	_	O	O	_	_	_	_	_
40	cytoplasmic	_	O	O	_	_	_	_	_
41	sequestration	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	normally	_	O	O	_	_	_	_	_
45	nuclearly	_	O	O	_	_	_	_	_
46	expressed	_	O	O	_	_	_	_	_
47	Tax	_	O	O	_	_	_	_	_
48	protein	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	mutant	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Tax	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	selectively	_	O	O	_	_	_	_	_
10	fails	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	activate	_	O	O	_	_	_	_	_
13	nuclear	_	O	O	_	_	_	_	_
14	NF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	kappa	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	does	_	O	O	_	_	_	_	_
20	not	_	O	O	_	_	_	_	_
21	associate	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	100	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	ABSTRACT	_	O	O	_	_	_	_	_
3	TRUNCATED	_	O	O	_	_	_	_	_
4	AT	_	O	O	_	_	_	_	_
5	250	_	O	O	_	_	_	_	_
6	WORDS	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_

1	Acetylsalicylic	_	O	O	_	_	_	_	_
2	acid	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	sodium	_	O	O	_	_	_	_	_
5	salicylate	_	O	O	_	_	_	_	_
6	inhibit	_	O	O	_	_	_	_	_
7	LPS	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	NF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	kappa	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	c	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	Rel	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	translocation	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	synthesis	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	tissue	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	TF	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	tumor	_	O	O	_	_	_	_	_
31	necrosis	_	O	O	_	_	_	_	_
32	factor	_	O	O	_	_	_	_	_
33	alfa	_	O	O	_	_	_	_	_
34	(	_	O	O	_	_	_	_	_
35	TNF	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	alpha	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	human	_	O	O	_	_	_	_	_
41	monocytes	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	investigated	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	effects	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	acetylsalicylic	_	O	O	_	_	_	_	_
8	acid	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	sodium	_	O	O	_	_	_	_	_
11	salicylate	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	LPS	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	synthesis	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	pro	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	coagulant	_	O	O	_	_	_	_	_
23	protein	_	O	O	_	_	_	_	_
24	tissue	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	TF	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	pro	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	inflammatory	_	O	O	_	_	_	_	_
34	protein	_	O	O	_	_	_	_	_
35	tumor	_	O	O	_	_	_	_	_
36	necrosis	_	O	O	_	_	_	_	_
37	factor	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	alpha	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	TNF	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	alpha	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	as	_	O	O	_	_	_	_	_
47	well	_	O	O	_	_	_	_	_
48	as	_	O	O	_	_	_	_	_
49	the	_	O	O	_	_	_	_	_
50	prostaglandin	_	O	O	_	_	_	_	_
51	PGE	_	O	O	_	_	_	_	_
52	2	_	O	O	_	_	_	_	_
53	in	_	O	O	_	_	_	_	_
54	human	_	O	O	_	_	_	_	_
55	monocytes	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	drugs	_	O	O	_	_	_	_	_
3	dose	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	dependently	_	O	O	_	_	_	_	_
6	inhibited	_	O	O	_	_	_	_	_
7	LPS	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	TF	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	TNF	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	alpha	_	O	O	_	_	_	_	_
15	synthesis	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	mRNA	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	level	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	reduced	_	O	O	_	_	_	_	_
26	PGE	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	production	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	evidenced	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	electro	_	O	O	_	_	_	_	_
5	mobility	_	O	O	_	_	_	_	_
6	shift	_	O	O	_	_	_	_	_
7	assay	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	EMSA	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	use	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	NF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	kappa	_	O	O	_	_	_	_	_
19	B	_	O	O	_	_	_	_	_
20	prototypic	_	O	O	_	_	_	_	_
21	probe	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	these	_	O	O	_	_	_	_	_
24	drugs	_	O	O	_	_	_	_	_
25	probably	_	O	O	_	_	_	_	_
26	exert	_	O	O	_	_	_	_	_
27	their	_	O	O	_	_	_	_	_
28	inhibitory	_	O	O	_	_	_	_	_
29	effects	_	O	O	_	_	_	_	_
30	by	_	O	O	_	_	_	_	_
31	interference	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	nuclear	_	O	O	_	_	_	_	_
35	translocation	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	NF	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	kappa	_	O	O	_	_	_	_	_
40	B	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	c	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	Rel	_	O	O	_	_	_	_	_
45	proteins	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	may	_	O	O	_	_	_	_	_
4	expand	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	understanding	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	anti	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	thrombotic	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	anti	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	inflammatory	_	O	O	_	_	_	_	_
16	effects	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	these	_	O	O	_	_	_	_	_
19	drugs	_	O	O	_	_	_	_	_
20	when	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	monocytes	_	O	O	_	_	_	_	_
24	occurs	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Charybdotoxin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	sensitive	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	Ca	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	membrane	_	O	O	_	_	_	_	_
13	potential	_	O	O	_	_	_	_	_
14	changes	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	not	_	O	O	_	_	_	_	_
17	involved	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	human	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	B	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	proliferation	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	involvement	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	ion	_	O	O	_	_	_	_	_
5	channels	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	lymphocyte	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	supported	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	many	_	O	O	_	_	_	_	_
16	reports	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	changes	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	ion	_	O	O	_	_	_	_	_
21	fluxes	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	membrane	_	O	O	_	_	_	_	_
24	potential	_	O	O	_	_	_	_	_
25	after	_	O	O	_	_	_	_	_
26	mitogen	_	O	O	_	_	_	_	_
27	binding	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	lymphocytes	_	O	O	_	_	_	_	_
6	demonstrate	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	early	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	transient	_	O	O	_	_	_	_	_
11	hyperpolarization	_	O	O	_	_	_	_	_
12	after	_	O	O	_	_	_	_	_
13	ligand	_	O	O	_	_	_	_	_
14	binding	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Inasmuch	_	O	O	_	_	_	_	_
2	as	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	change	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	membrane	_	O	O	_	_	_	_	_
7	potential	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	elevation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	free	_	O	O	_	_	_	_	_
14	cytosolic	_	O	O	_	_	_	_	_
15	calcium	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	hyperpolarization	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	presumably	_	O	O	_	_	_	_	_
21	through	_	O	O	_	_	_	_	_
22	opening	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	Ca	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	+	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	stimulated	_	O	O	_	_	_	_	_
31	K	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	channels	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	used	_	O	O	_	_	_	_	_
4	charybdotoxin	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	known	_	O	O	_	_	_	_	_
8	inhibitor	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Ca	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	dependent	_	O	O	_	_	_	_	_
17	K	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	channels	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	study	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	role	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	these	_	O	O	_	_	_	_	_
27	channels	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	lymphocyte	_	O	O	_	_	_	_	_
30	activation	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	mitogenesis	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	demonstrate	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	charybdotoxin	_	O	O	_	_	_	_	_
5	inhibits	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	ligand	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	transient	_	O	O	_	_	_	_	_
11	membrane	_	O	O	_	_	_	_	_
12	hyperpolarization	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	dose	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	dependent	_	O	O	_	_	_	_	_
23	fashion	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	without	_	O	O	_	_	_	_	_
26	affecting	_	O	O	_	_	_	_	_
27	changes	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	cytosolic	_	O	O	_	_	_	_	_
30	Ca	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	blockade	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	Ca	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	K	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	channel	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	associated	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	changes	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	cycle	_	O	O	_	_	_	_	_
25	gene	_	O	O	_	_	_	_	_
26	activation	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	production	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	2	_	O	O	_	_	_	_	_
36	R	_	O	O	_	_	_	_	_
37	expression	_	O	O	_	_	_	_	_
38	or	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	T	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	mitogenesis	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	imply	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	membrane	_	O	O	_	_	_	_	_
6	potential	_	O	O	_	_	_	_	_
7	changes	_	O	O	_	_	_	_	_
8	secondary	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	ligand	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dependent	_	O	O	_	_	_	_	_
14	opening	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	Ca	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	activated	_	O	O	_	_	_	_	_
23	K	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	channels	_	O	O	_	_	_	_	_
26	are	_	O	O	_	_	_	_	_
27	not	_	O	O	_	_	_	_	_
28	involved	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	B	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	T	_	O	O	_	_	_	_	_
33	lymphocyte	_	O	O	_	_	_	_	_
34	activation	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	mitogenesis	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Tumor	_	O	O	_	_	_	_	_
2	necrosis	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	alpha	_	O	O	_	_	_	_	_
5	decreases	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	interleukin	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	increases	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	sensitivity	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	monocytes	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	dexamethasone	_	O	O	_	_	_	_	_
20	:	_	O	O	_	_	_	_	_
21	potential	_	O	O	_	_	_	_	_
22	regulation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	glucocorticoid	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Resistance	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	glucocorticoid	_	O	O	_	_	_	_	_
4	therapy	_	O	O	_	_	_	_	_
5	has	_	O	O	_	_	_	_	_
6	been	_	O	O	_	_	_	_	_
7	observed	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	autoimmune	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	inflammatory	_	O	O	_	_	_	_	_
14	diseases	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	may	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	related	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	inflammatory	_	O	O	_	_	_	_	_
22	process	_	O	O	_	_	_	_	_
23	itself	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	aim	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	examine	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	ability	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	tumor	_	O	O	_	_	_	_	_
13	necrosis	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	alpha	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	TNFalpha	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	proinflammatory	_	O	O	_	_	_	_	_
21	cytokine	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	interleukin	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	an	_	O	O	_	_	_	_	_
32	anti	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	inflammatory	_	O	O	_	_	_	_	_
35	cytokine	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	differentially	_	O	O	_	_	_	_	_
39	regulate	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	sensitivity	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	human	_	O	O	_	_	_	_	_
44	monocytes	_	O	O	_	_	_	_	_
45	/	_	O	O	_	_	_	_	_
46	macrophages	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	glucocorticoids	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	accomplish	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	first	_	O	O	_	_	_	_	_
7	analyzed	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	pattern	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	TNFalpha	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	inhibition	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	dexamethasone	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	LPS	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	stimulated	_	O	O	_	_	_	_	_
23	whole	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	blood	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	cultures	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Second	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	studied	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	modulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	sensitivity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	these	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	dexamethasone	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	preincubation	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	TNFalpha	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	measurement	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	LPS	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	stimulated	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	6	_	O	O	_	_	_	_	_
32	secretion	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	evaluated	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	effect	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	dexamethasone	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	phorbolmyristate	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	acetate	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	stimulated	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	antagonist	_	O	O	_	_	_	_	_
21	secretion	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	human	_	O	O	_	_	_	_	_
25	monocytic	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	line	_	O	O	_	_	_	_	_
28	U	_	O	O	_	_	_	_	_
29	937	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	investigated	_	O	O	_	_	_	_	_
5	whether	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	modulation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	corticosensitivity	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	TNFalpha	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	10	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	pretreated	_	O	O	_	_	_	_	_
19	U	_	O	O	_	_	_	_	_
20	937	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	related	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	change	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	glucocorticoid	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	concentration	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	affinity	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Dexamethasone	_	O	O	_	_	_	_	_
2	had	_	O	O	_	_	_	_	_
3	different	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	LPS	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	induced	_	O	O	_	_	_	_	_
9	TNFalpha	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	secretion	_	O	O	_	_	_	_	_
15	;	_	O	O	_	_	_	_	_
16	whereas	_	O	O	_	_	_	_	_
17	it	_	O	O	_	_	_	_	_
18	suppressed	_	O	O	_	_	_	_	_
19	TNFalpha	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	dose	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	dependent	_	O	O	_	_	_	_	_
25	fashion	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	effect	_	O	O	_	_	_	_	_
29	on	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	secretion	_	O	O	_	_	_	_	_
34	was	_	O	O	_	_	_	_	_
35	biphasic	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	producing	_	O	O	_	_	_	_	_
38	stimulation	_	O	O	_	_	_	_	_
39	at	_	O	O	_	_	_	_	_
40	lower	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	inhibition	_	O	O	_	_	_	_	_
44	at	_	O	O	_	_	_	_	_
45	higher	_	O	O	_	_	_	_	_
46	doses	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	concentration	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	LPS	_	O	O	_	_	_	_	_
5	employed	_	O	O	_	_	_	_	_
6	influenced	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	effect	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	dexamethasone	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	secretion	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	P	_	O	O	_	_	_	_	_
18	<	_	O	O	_	_	_	_	_
19	0	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	001	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Pretreatment	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	TNFalpha	_	O	O	_	_	_	_	_
4	diminished	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	improved	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	ability	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	dexamethasone	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	suppress	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	secretion	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	whole	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	blood	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	cultures	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	P	_	O	O	_	_	_	_	_
31	<	_	O	O	_	_	_	_	_
32	0	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	01	_	O	O	_	_	_	_	_
35	for	_	O	O	_	_	_	_	_
36	both	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	enhance	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	receptor	_	O	O	_	_	_	_	_
45	antagonist	_	O	O	_	_	_	_	_
46	secretion	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	U	_	O	O	_	_	_	_	_
49	937	_	O	O	_	_	_	_	_
50	cells	_	O	O	_	_	_	_	_
51	(	_	O	O	_	_	_	_	_
52	P	_	O	O	_	_	_	_	_
53	<	_	O	O	_	_	_	_	_
54	0	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_
56	05	_	O	O	_	_	_	_	_
57	for	_	O	O	_	_	_	_	_
58	both	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	TNFalpha	_	O	O	_	_	_	_	_
2	decreased	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	P	_	O	O	_	_	_	_	_
5	<	_	O	O	_	_	_	_	_
6	0	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_
8	001	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	while	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	increased	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	P	_	O	O	_	_	_	_	_
18	<	_	O	O	_	_	_	_	_
19	0	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	001	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	concentration	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	dexamethasone	_	O	O	_	_	_	_	_
28	binding	_	O	O	_	_	_	_	_
29	sites	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	these	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	no	_	O	O	_	_	_	_	_
36	discernible	_	O	O	_	_	_	_	_
37	effect	_	O	O	_	_	_	_	_
38	on	_	O	O	_	_	_	_	_
39	their	_	O	O	_	_	_	_	_
40	binding	_	O	O	_	_	_	_	_
41	affinity	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	glucocorticoids	_	O	O	_	_	_	_	_
5	differentially	_	O	O	_	_	_	_	_
6	modulate	_	O	O	_	_	_	_	_
7	TNFalpha	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	10	_	O	O	_	_	_	_	_
12	secretion	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	monocytes	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	LPS	_	O	O	_	_	_	_	_
19	dose	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	dependent	_	O	O	_	_	_	_	_
22	fashion	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	sensitivity	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	these	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	glucocorticoids	_	O	O	_	_	_	_	_
32	is	_	O	O	_	_	_	_	_
33	altered	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	TNFalpha	_	O	O	_	_	_	_	_
36	or	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	10	_	O	O	_	_	_	_	_
40	pretreatment	_	O	O	_	_	_	_	_
41	;	_	O	O	_	_	_	_	_
42	TNFalpha	_	O	O	_	_	_	_	_
43	blocks	_	O	O	_	_	_	_	_
44	their	_	O	O	_	_	_	_	_
45	effects	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	whereas	_	O	O	_	_	_	_	_
48	IL	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	10	_	O	O	_	_	_	_	_
51	acts	_	O	O	_	_	_	_	_
52	synergistically	_	O	O	_	_	_	_	_
53	with	_	O	O	_	_	_	_	_
54	glucocorticoids	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	accompanied	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	opposite	_	O	O	_	_	_	_	_
6	glucocorticoid	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	changes	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	respectively	_	O	O	_	_	_	_	_
11	opposing	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	favoring	_	O	O	_	_	_	_	_
14	glucocorticoid	_	O	O	_	_	_	_	_
15	actions	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	study	_	O	O	_	_	_	_	_
3	suggests	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	pattern	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	pro	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	antiinflammatory	_	O	O	_	_	_	_	_
12	cytokine	_	O	O	_	_	_	_	_
13	secretion	_	O	O	_	_	_	_	_
14	may	_	O	O	_	_	_	_	_
15	alter	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	patients	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	glucocorticoid	_	O	O	_	_	_	_	_
22	therapy	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	FK	_	O	O	_	_	_	_	_
2	506	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	ciclosporin	_	O	O	_	_	_	_	_
5	:	_	O	O	_	_	_	_	_
6	molecular	_	O	O	_	_	_	_	_
7	probes	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	studying	_	O	O	_	_	_	_	_
10	intracellular	_	O	O	_	_	_	_	_
11	signal	_	O	O	_	_	_	_	_
12	transduction	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	immunosuppressants	_	O	O	_	_	_	_	_
3	ciclosporin	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	FK	_	O	O	_	_	_	_	_
6	506	_	O	O	_	_	_	_	_
7	block	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	Ca	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	dependent	_	O	O	_	_	_	_	_
16	signal	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	transduction	_	O	O	_	_	_	_	_
19	pathway	_	O	O	_	_	_	_	_
20	emanating	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	thereby	_	O	O	_	_	_	_	_
29	inhibiting	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	helper	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	these	_	O	O	_	_	_	_	_
3	drugs	_	O	O	_	_	_	_	_
4	as	_	O	O	_	_	_	_	_
5	probes	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	chemists	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	biologists	_	O	O	_	_	_	_	_
10	have	_	O	O	_	_	_	_	_
11	uncovered	_	O	O	_	_	_	_	_
12	several	_	O	O	_	_	_	_	_
13	intracellular	_	O	O	_	_	_	_	_
14	signalling	_	O	O	_	_	_	_	_
15	molecules	_	O	O	_	_	_	_	_
16	bridging	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	generation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	second	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	messenger	_	O	O	_	_	_	_	_
23	Ca	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	+	_	O	O	_	_	_	_	_
26	ions	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	transcriptional	_	O	O	_	_	_	_	_
30	activation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	among	_	O	O	_	_	_	_	_
37	which	_	O	O	_	_	_	_	_
38	are	_	O	O	_	_	_	_	_
39	calmodulin	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	calcineurin	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	nuclear	_	O	O	_	_	_	_	_
45	factor	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	activated	_	O	O	_	_	_	_	_
48	T	_	O	O	_	_	_	_	_
49	cells	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	NF	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	AT	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Hence	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Ca	_	O	O	_	_	_	_	_
4	2	_	O	O	_	_	_	_	_
5	+	_	O	O	_	_	_	_	_
6	binds	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	calmodulin	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	leading	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	calmodulin	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	calcineurin	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	activated	_	O	O	_	_	_	_	_
21	calcineurin	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	turn	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	may	_	O	O	_	_	_	_	_
27	dephosphorylate	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	cytoplasmic	_	O	O	_	_	_	_	_
30	subunit	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	NF	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	AT	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	resulting	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	its	_	O	O	_	_	_	_	_
39	translocation	_	O	O	_	_	_	_	_
40	from	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	cytoplasm	_	O	O	_	_	_	_	_
43	into	_	O	O	_	_	_	_	_
44	the	_	O	O	_	_	_	_	_
45	nucleus	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	form	_	O	O	_	_	_	_	_
48	a	_	O	O	_	_	_	_	_
49	competent	_	O	O	_	_	_	_	_
50	transcriptional	_	O	O	_	_	_	_	_
51	activator	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	described	_	O	O	_	_	_	_	_
3	by	_	O	O	_	_	_	_	_
4	Jun	_	O	O	_	_	_	_	_
5	Liu	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	these	_	O	O	_	_	_	_	_
8	drugs	_	O	O	_	_	_	_	_
9	manifest	_	O	O	_	_	_	_	_
10	their	_	O	O	_	_	_	_	_
11	effects	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	unprecedented	_	O	O	_	_	_	_	_
15	fashion	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	They	_	O	O	_	_	_	_	_
2	do	_	O	O	_	_	_	_	_
3	not	_	O	O	_	_	_	_	_
4	directly	_	O	O	_	_	_	_	_
5	intercept	_	O	O	_	_	_	_	_
6	intracellular	_	O	O	_	_	_	_	_
7	signalling	_	O	O	_	_	_	_	_
8	molecules	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	Instead	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	they	_	O	O	_	_	_	_	_
4	form	_	O	O	_	_	_	_	_
5	tight	_	O	O	_	_	_	_	_
6	complexes	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	two	_	O	O	_	_	_	_	_
9	different	_	O	O	_	_	_	_	_
10	classes	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	abundant	_	O	O	_	_	_	_	_
13	cytosolic	_	O	O	_	_	_	_	_
14	receptors	_	O	O	_	_	_	_	_
15	called	_	O	O	_	_	_	_	_
16	immunophilins	_	O	O	_	_	_	_	_
17	upon	_	O	O	_	_	_	_	_
18	entering	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	consequently	_	O	O	_	_	_	_	_
24	inhibit	_	O	O	_	_	_	_	_
25	their	_	O	O	_	_	_	_	_
26	peptidyl	_	O	O	_	_	_	_	_
27	prolyl	_	O	O	_	_	_	_	_
28	cis	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	trans	_	O	O	_	_	_	_	_
31	isomerase	_	O	O	_	_	_	_	_
32	activities	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	two	_	O	O	_	_	_	_	_
3	structurally	_	O	O	_	_	_	_	_
4	distinct	_	O	O	_	_	_	_	_
5	immunophilin	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	drug	_	O	O	_	_	_	_	_
8	complexes	_	O	O	_	_	_	_	_
9	bind	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	inhibit	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	phosphatase	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	calcineurin	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Disruption	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	SCL	_	O	O	_	_	_	_	_
6	locus	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	""""	_	O	O	_	_	_	_	_
9	illegitimate	_	O	O	_	_	_	_	_
10	""""	_	O	O	_	_	_	_	_
11	V	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	D	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	J	_	O	O	_	_	_	_	_
18	recombinase	_	O	O	_	_	_	_	_
19	activity	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	fusion	_	O	O	_	_	_	_	_
3	complementary	_	O	O	_	_	_	_	_
4	DNA	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	line	_	O	O	_	_	_	_	_
10	HSB	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	elucidates	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	provocative	_	O	O	_	_	_	_	_
16	mechanism	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	disruption	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	putative	_	O	O	_	_	_	_	_
23	hematopoietic	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	factor	_	O	O	_	_	_	_	_
26	SCL	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	fusion	_	O	O	_	_	_	_	_
3	cDNA	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	interstitial	_	O	O	_	_	_	_	_
8	deletion	_	O	O	_	_	_	_	_
9	between	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	previously	_	O	O	_	_	_	_	_
12	unknown	_	O	O	_	_	_	_	_
13	locus	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	SIL	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	SCL	_	O	O	_	_	_	_	_
18	interrupting	_	O	O	_	_	_	_	_
19	locus	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	5	_	O	O	_	_	_	_	_
25	'	_	O	O	_	_	_	_	_
26	untranslated	_	O	O	_	_	_	_	_
27	region	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	SCL	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Similar	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	;	_	O	O	_	_	_	_	_
5	14	_	O	O	_	_	_	_	_
6	translocations	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	this	_	O	O	_	_	_	_	_
9	deletion	_	O	O	_	_	_	_	_
10	disrupts	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	SCL	_	O	O	_	_	_	_	_
13	5	_	O	O	_	_	_	_	_
14	'	_	O	O	_	_	_	_	_
15	regulatory	_	O	O	_	_	_	_	_
16	region	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	event	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	probably	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	V	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	J	_	O	O	_	_	_	_	_
14	recombinase	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	although	_	O	O	_	_	_	_	_
18	neither	_	O	O	_	_	_	_	_
19	locus	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	immunoglobulin	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	receptor	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Two	_	O	O	_	_	_	_	_
2	other	_	O	O	_	_	_	_	_
3	T	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	lines	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	CEM	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	RPMI	_	O	O	_	_	_	_	_
10	8402	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	have	_	O	O	_	_	_	_	_
13	essentially	_	O	O	_	_	_	_	_
14	identical	_	O	O	_	_	_	_	_
15	deletions	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	lymphocytes	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	growth	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	affecting	_	O	O	_	_	_	_	_
9	genes	_	O	O	_	_	_	_	_
10	other	_	O	O	_	_	_	_	_
11	than	_	O	O	_	_	_	_	_
12	immune	_	O	O	_	_	_	_	_
13	receptors	_	O	O	_	_	_	_	_
14	risk	_	O	O	_	_	_	_	_
15	rearrangements	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	GP	_	O	O	_	_	_	_	_
2	modulated	_	O	O	_	_	_	_	_
3	TSST	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	DNA	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	new	_	O	O	_	_	_	_	_
13	NFATP	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	site	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	promoter	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	up	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	regulated	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	GP	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	GP	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	TSST	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	when	_	O	O	_	_	_	_	_
18	compared	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	GP	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	latter	_	O	O	_	_	_	_	_
26	case	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	both	_	O	O	_	_	_	_	_
30	GP	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	TSST	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	*	_	O	O	_	_	_	_	_
37	=	_	O	O	_	_	_	_	_
38	p	_	O	O	_	_	_	_	_
39	<	_	O	O	_	_	_	_	_
40	0	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_
42	05	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	PBMC	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	medium	_	O	O	_	_	_	_	_
7	control	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	TSST	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	GP	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	GP	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	TSST	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	GP	_	O	O	_	_	_	_	_
24	+	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	for	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	h	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	37	_	O	O	_	_	_	_	_
31	degreesC	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Schematic	_	O	O	_	_	_	_	_
2	representation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	elevated	_	O	O	_	_	_	_	_
6	NFAT	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	DNA	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	activity	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	site	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	promoter	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Bars	_	O	O	_	_	_	_	_
2	depicting	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	theoretical	_	O	O	_	_	_	_	_
5	values	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	GP	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	LPS	_	O	O	_	_	_	_	_
10	calc	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	and	_	O	O	_	_	_	_	_
2	GP	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	calc	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	are	_	O	O	_	_	_	_	_
2	added	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	Medium	_	O	O	_	_	_	_	_
2	control	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	set	_	O	O	_	_	_	_	_
6	equal	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	SEM	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	n	_	O	O	_	_	_	_	_
15	=	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	autoradiogram	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	representative	_	O	O	_	_	_	_	_
6	experiment	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	shown	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	lower	_	O	O	_	_	_	_	_
12	panel	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	lane	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	:	_	O	O	_	_	_	_	_
17	water	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	lane	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	:	_	O	O	_	_	_	_	_
22	medium	_	O	O	_	_	_	_	_
23	control	_	O	O	_	_	_	_	_
24	;	_	O	O	_	_	_	_	_
25	lane	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	:	_	O	O	_	_	_	_	_
28	GP	_	O	O	_	_	_	_	_
29	;	_	O	O	_	_	_	_	_
30	lane	_	O	O	_	_	_	_	_
31	4	_	O	O	_	_	_	_	_
32	:	_	O	O	_	_	_	_	_
33	LPS	_	O	O	_	_	_	_	_
34	;	_	O	O	_	_	_	_	_
35	lane	_	O	O	_	_	_	_	_
36	5	_	O	O	_	_	_	_	_
37	:	_	O	O	_	_	_	_	_
38	TSST	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	lane	_	O	O	_	_	_	_	_
43	6	_	O	O	_	_	_	_	_
44	:	_	O	O	_	_	_	_	_
45	GP	_	O	O	_	_	_	_	_
46	+	_	O	O	_	_	_	_	_
47	LPS	_	O	O	_	_	_	_	_
48	;	_	O	O	_	_	_	_	_
49	lane	_	O	O	_	_	_	_	_
50	7	_	O	O	_	_	_	_	_
51	:	_	O	O	_	_	_	_	_
52	GP	_	O	O	_	_	_	_	_
53	+	_	O	O	_	_	_	_	_
54	TSST	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	1	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	.	_	O	O	_	_	_	_	_



1	Disruption	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	GATA	_	O	O	_	_	_	_	_
5	motif	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	Duffy	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	abolishes	_	O	O	_	_	_	_	_
12	erythroid	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	Duffy	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	negative	_	O	O	_	_	_	_	_
19	individuals	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	mRNA	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	Duffy	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	group	_	O	O	_	_	_	_	_
8	antigen	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	erythrocyte	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	Plasmodium	_	O	O	_	_	_	_	_
16	vivax	_	O	O	_	_	_	_	_
17	malaria	_	O	O	_	_	_	_	_
18	parasite	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	has	_	O	O	_	_	_	_	_
21	recently	_	O	O	_	_	_	_	_
22	been	_	O	O	_	_	_	_	_
23	cloned	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	shown	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	encode	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	widely	_	O	O	_	_	_	_	_
30	expressed	_	O	O	_	_	_	_	_
31	chemokine	_	O	O	_	_	_	_	_
32	receptor	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	Duffy	_	O	O	_	_	_	_	_
8	antigen	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	chemokine	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	gene	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	DARC	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	composed	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	single	_	O	O	_	_	_	_	_
21	exon	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	most	_	O	O	_	_	_	_	_
25	Duffy	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	negative	_	O	O	_	_	_	_	_
28	blacks	_	O	O	_	_	_	_	_
29	carry	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	silent	_	O	O	_	_	_	_	_
32	FY	_	O	O	_	_	_	_	_
33	*	_	O	O	_	_	_	_	_
34	B	_	O	O	_	_	_	_	_
35	allele	_	O	O	_	_	_	_	_
36	with	_	O	O	_	_	_	_	_
37	a	_	O	O	_	_	_	_	_
38	single	_	O	O	_	_	_	_	_
39	T	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	C	_	O	O	_	_	_	_	_
42	substitution	_	O	O	_	_	_	_	_
43	at	_	O	O	_	_	_	_	_
44	nucleotide	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	46	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	mutation	_	O	O	_	_	_	_	_
3	impairs	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	promoter	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	erythroid	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	disrupting	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	GATA	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	erythroid	_	O	O	_	_	_	_	_
20	transcription	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	With	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	recent	_	O	O	_	_	_	_	_
4	characterization	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	FY	_	O	O	_	_	_	_	_
8	*	_	O	O	_	_	_	_	_
9	A	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	FY	_	O	O	_	_	_	_	_
12	*	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	alleles	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	these	_	O	O	_	_	_	_	_
17	findings	_	O	O	_	_	_	_	_
18	provide	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	molecular	_	O	O	_	_	_	_	_
21	basis	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	Duffy	_	O	O	_	_	_	_	_
25	blood	_	O	O	_	_	_	_	_
26	group	_	O	O	_	_	_	_	_
27	system	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	an	_	O	O	_	_	_	_	_
30	explanation	_	O	O	_	_	_	_	_
31	for	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	erythroid	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	specific	_	O	O	_	_	_	_	_
36	repression	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	DARC	_	O	O	_	_	_	_	_
40	gene	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	Duffy	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	negative	_	O	O	_	_	_	_	_
45	individuals	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_


1	Production	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	cytokines	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	chemokines	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	prepared	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	heparinized	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	Ficoll	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	Hypaque	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	SG	_	O	O	_	_	_	_	_
13	1077	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	density	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	gradient	_	O	O	_	_	_	_	_
18	centrifugation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Cell	_	O	O	_	_	_	_	_
2	cultures	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	performed	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	described	_	O	O	_	_	_	_	_
7	previously	_	O	O	_	_	_	_	_
8	[	_	O	O	_	_	_	_	_
9	18	_	O	O	_	_	_	_	_
10	]	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	brief	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	suspensions	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	adjusted	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	concentration	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	106	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	ml	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	RPMI	_	O	O	_	_	_	_	_
18	1640	_	O	O	_	_	_	_	_
19	medium	_	O	O	_	_	_	_	_
20	supplemented	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	%	_	O	O	_	_	_	_	_
24	fetal	_	O	O	_	_	_	_	_
25	calf	_	O	O	_	_	_	_	_
26	serum	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	100	_	O	O	_	_	_	_	_
29	U	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	ml	_	O	O	_	_	_	_	_
32	penicillin	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	100	_	O	O	_	_	_	_	_
35	mg	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	ml	_	O	O	_	_	_	_	_
38	streptomycin	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	mM	_	O	O	_	_	_	_	_
42	L	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	glutamine	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Cell	_	O	O	_	_	_	_	_
2	suspension	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	ml	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	dispensed	_	O	O	_	_	_	_	_
9	into	_	O	O	_	_	_	_	_
10	24	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	well	_	O	O	_	_	_	_	_
13	multi	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	well	_	O	O	_	_	_	_	_
16	plates	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	Nunc	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	Roskilde	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	Denmark	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	incubated	_	O	O	_	_	_	_	_
27	for	_	O	O	_	_	_	_	_
28	24	_	O	O	_	_	_	_	_
29	hours	_	O	O	_	_	_	_	_
30	at	_	O	O	_	_	_	_	_
31	37	_	O	O	_	_	_	_	_
32	degreesC	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	5	_	O	O	_	_	_	_	_
35	%	_	O	O	_	_	_	_	_
36	CO	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Subsequently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	various	_	O	O	_	_	_	_	_
4	concentrations	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	cyclosporin	_	O	O	_	_	_	_	_
7	A	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	500	_	O	O	_	_	_	_	_
12	ng	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ml	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	added	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	medium	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	incubated	_	O	O	_	_	_	_	_
25	for	_	O	O	_	_	_	_	_
26	24	_	O	O	_	_	_	_	_
27	hours	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	each	_	O	O	_	_	_	_	_
3	well	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	added	_	O	O	_	_	_	_	_
6	FK	_	O	O	_	_	_	_	_
7	506	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	rapamycin	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	curcumin	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	PDTC	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	LY	_	O	O	_	_	_	_	_
16	294002	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	SB	_	O	O	_	_	_	_	_
19	203580	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	PD	_	O	O	_	_	_	_	_
22	98059	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	dexamethasone	_	O	O	_	_	_	_	_
25	or	_	O	O	_	_	_	_	_
26	wortmannin	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	incubation	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	24	_	O	O	_	_	_	_	_
5	hours	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	unless	_	O	O	_	_	_	_	_
8	otherwise	_	O	O	_	_	_	_	_
9	stated	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	free	_	O	O	_	_	_	_	_
15	media	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	collected	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	stored	_	O	O	_	_	_	_	_
20	at	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	20	_	O	O	_	_	_	_	_
23	degreesC	_	O	O	_	_	_	_	_
24	until	_	O	O	_	_	_	_	_
25	assayed	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	cultures	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	set	_	O	O	_	_	_	_	_
5	up	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	triplicate	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	results	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	means	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	/	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	SEM	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_



1	Patients	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	samples	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	total	_	O	O	_	_	_	_	_
3	patient	_	O	O	_	_	_	_	_
4	population	_	O	O	_	_	_	_	_
5	consisted	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	32	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	25	_	O	O	_	_	_	_	_
13	women	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	seven	_	O	O	_	_	_	_	_
16	men	_	O	O	_	_	_	_	_
17	;	_	O	O	_	_	_	_	_
18	mean	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	standard	_	O	O	_	_	_	_	_
23	deviation	_	O	O	_	_	_	_	_
24	age	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	52	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	8	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	12	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	4	_	O	O	_	_	_	_	_
35	years	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	diagnosed	_	O	O	_	_	_	_	_
38	according	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	revised	_	O	O	_	_	_	_	_
42	1987	_	O	O	_	_	_	_	_
43	criteria	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	American	_	O	O	_	_	_	_	_
47	College	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	Rheumatology	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	formally	_	O	O	_	_	_	_	_
52	,	_	O	O	_	_	_	_	_
53	the	_	O	O	_	_	_	_	_
54	American	_	O	O	_	_	_	_	_
55	Rheumatism	_	O	O	_	_	_	_	_
56	Association	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	[	_	O	O	_	_	_	_	_
59	25	_	O	O	_	_	_	_	_
60	]	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	patients	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	receiving	_	O	O	_	_	_	_	_
5	prednisolone	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	<	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	=	_	O	O	_	_	_	_	_
10	7	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	mg	_	O	O	_	_	_	_	_
14	/	_	O	O	_	_	_	_	_
15	day	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	disease	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	modifying	_	O	O	_	_	_	_	_
21	antirheumatic	_	O	O	_	_	_	_	_
22	drugs	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Clinical	_	O	O	_	_	_	_	_
2	parameters	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	follows	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	mean	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	standard	_	O	O	_	_	_	_	_
16	deviation	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	:	_	O	O	_	_	_	_	_
19	erythrocyte	_	O	O	_	_	_	_	_
20	sedimentation	_	O	O	_	_	_	_	_
21	rate	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	55	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	9	_	O	O	_	_	_	_	_
26	+	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	35	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_
31	4	_	O	O	_	_	_	_	_
32	mm	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	hour	_	O	O	_	_	_	_	_
35	;	_	O	O	_	_	_	_	_
36	serum	_	O	O	_	_	_	_	_
37	C	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	reactive	_	O	O	_	_	_	_	_
40	protein	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	CRP	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	level	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	32	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_
48	0	_	O	O	_	_	_	_	_
49	+	_	O	O	_	_	_	_	_
50	/	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	32	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_
54	0	_	O	O	_	_	_	_	_
55	mg	_	O	O	_	_	_	_	_
56	/	_	O	O	_	_	_	_	_
57	l	_	O	O	_	_	_	_	_
58	;	_	O	O	_	_	_	_	_
59	and	_	O	O	_	_	_	_	_
60	IgM	_	O	O	_	_	_	_	_
61	class	_	O	O	_	_	_	_	_
62	rheumatoid	_	O	O	_	_	_	_	_
63	factor	_	O	O	_	_	_	_	_
64	titer	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	142	_	O	O	_	_	_	_	_
67	+	_	O	O	_	_	_	_	_
68	/	_	O	O	_	_	_	_	_
69	-	_	O	O	_	_	_	_	_
70	158	_	O	O	_	_	_	_	_
71	U	_	O	O	_	_	_	_	_
72	/	_	O	O	_	_	_	_	_
73	ml	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_

1	Patients	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	divided	_	O	O	_	_	_	_	_
4	into	_	O	O	_	_	_	_	_
5	two	_	O	O	_	_	_	_	_
6	groups	_	O	O	_	_	_	_	_
7	:	_	O	O	_	_	_	_	_
8	24	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	active	_	O	O	_	_	_	_	_
12	disease	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	who	_	O	O	_	_	_	_	_
15	had	_	O	O	_	_	_	_	_
16	multiple	_	O	O	_	_	_	_	_
17	tender	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	or	_	O	O	_	_	_	_	_
21	swollen	_	O	O	_	_	_	_	_
22	joints	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	elevated	_	O	O	_	_	_	_	_
25	serum	_	O	O	_	_	_	_	_
26	CRP	_	O	O	_	_	_	_	_
27	level	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	>	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	=	_	O	O	_	_	_	_	_
32	10	_	O	O	_	_	_	_	_
33	mg	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	l	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	;	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	eight	_	O	O	_	_	_	_	_
40	patients	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	inactive	_	O	O	_	_	_	_	_
43	disease	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	who	_	O	O	_	_	_	_	_
46	satisfied	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	American	_	O	O	_	_	_	_	_
49	College	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	Rheumatology	_	O	O	_	_	_	_	_
52	preliminary	_	O	O	_	_	_	_	_
53	criteria	_	O	O	_	_	_	_	_
54	for	_	O	O	_	_	_	_	_
55	clinical	_	O	O	_	_	_	_	_
56	remission	_	O	O	_	_	_	_	_
57	[	_	O	O	_	_	_	_	_
58	26	_	O	O	_	_	_	_	_
59	]	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	Sixteen	_	O	O	_	_	_	_	_
2	healthy	_	O	O	_	_	_	_	_
3	volunteers	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	11	_	O	O	_	_	_	_	_
6	women	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	five	_	O	O	_	_	_	_	_
9	men	_	O	O	_	_	_	_	_
10	;	_	O	O	_	_	_	_	_
11	age	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	45	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_
15	8	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	11	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	years	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	served	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	controls	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	ST	_	O	O	_	_	_	_	_
2	samples	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	obtained	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	three	_	O	O	_	_	_	_	_
7	RA	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	undergoing	_	O	O	_	_	_	_	_
10	total	_	O	O	_	_	_	_	_
11	knee	_	O	O	_	_	_	_	_
12	replacement	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	patients	_	O	O	_	_	_	_	_
3	gave	_	O	O	_	_	_	_	_
4	informed	_	O	O	_	_	_	_	_
5	consent	_	O	O	_	_	_	_	_
6	.	_	O	O	_	_	_	_	_



1	Inhibition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	transcription	_	O	O	_	_	_	_	_
4	factors	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	inhibit	_	O	O	_	_	_	_	_
3	translocation	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factors	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	promoter	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	PBMC	_	O	O	_	_	_	_	_
18	were	_	O	O	_	_	_	_	_
19	incubated	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	h	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	each	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	following	_	O	O	_	_	_	_	_
28	substances	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	concentrations	_	O	O	_	_	_	_	_
31	were	_	O	O	_	_	_	_	_
32	based	_	O	O	_	_	_	_	_
33	upon	_	O	O	_	_	_	_	_
34	50	_	O	O	_	_	_	_	_
35	%	_	O	O	_	_	_	_	_
36	inhibition	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	:	_	O	O	_	_	_	_	_
39	50	_	O	O	_	_	_	_	_
40	mug	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	ml	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	CAPE	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	caffeic	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	3	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	4	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	dihydroxycinnamic	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	acid	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	phenyl	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	ester	_	O	O	_	_	_	_	_
59	)	_	O	O	_	_	_	_	_
60	,	_	O	O	_	_	_	_	_
61	(	_	O	O	_	_	_	_	_
62	Biomol	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	Hamburg	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	Germany	_	O	O	_	_	_	_	_
67	)	_	O	O	_	_	_	_	_
68	;	_	O	O	_	_	_	_	_
69	400	_	O	O	_	_	_	_	_
70	ng	_	O	O	_	_	_	_	_
71	/	_	O	O	_	_	_	_	_
72	ml	_	O	O	_	_	_	_	_
73	cyclosporin	_	O	O	_	_	_	_	_
74	A	_	O	O	_	_	_	_	_
75	(	_	O	O	_	_	_	_	_
76	Calbiochem	_	O	O	_	_	_	_	_
77	-	_	O	O	_	_	_	_	_
78	Merck	_	O	O	_	_	_	_	_
79	Biosciences	_	O	O	_	_	_	_	_
80	,	_	O	O	_	_	_	_	_
81	Bad	_	O	O	_	_	_	_	_
82	Soden	_	O	O	_	_	_	_	_
83	,	_	O	O	_	_	_	_	_
84	Germany	_	O	O	_	_	_	_	_
85	)	_	O	O	_	_	_	_	_
86	;	_	O	O	_	_	_	_	_
87	10	_	O	O	_	_	_	_	_
88	mug	_	O	O	_	_	_	_	_
89	/	_	O	O	_	_	_	_	_
90	ml	_	O	O	_	_	_	_	_
91	cycloheximide	_	O	O	_	_	_	_	_
92	(	_	O	O	_	_	_	_	_
93	Santa	_	O	O	_	_	_	_	_
94	Cruz	_	O	O	_	_	_	_	_
95	Biotechnology	_	O	O	_	_	_	_	_
96	)	_	O	O	_	_	_	_	_
97	prior	_	O	O	_	_	_	_	_
98	to	_	O	O	_	_	_	_	_
99	incubation	_	O	O	_	_	_	_	_
100	with	_	O	O	_	_	_	_	_
101	GP	_	O	O	_	_	_	_	_
102	.	_	O	O	_	_	_	_	_

1	Band	_	O	O	_	_	_	_	_
2	shifts	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	determined	_	O	O	_	_	_	_	_
5	after	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	h	_	O	O	_	_	_	_	_
8	incubation	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	GP	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	described	_	O	O	_	_	_	_	_
13	before	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	including	_	O	O	_	_	_	_	_
16	mutated	_	O	O	_	_	_	_	_
17	oligos	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	NFIL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	TTA	_	O	O	_	_	_	_	_
24	CAA	_	O	O	_	_	_	_	_
25	CAG	_	O	O	_	_	_	_	_
26	TGG	_	O	O	_	_	_	_	_
27	ATT	_	O	O	_	_	_	_	_
28	GCG	_	O	O	_	_	_	_	_
29	ACA	_	O	O	_	_	_	_	_
30	CTT	_	O	O	_	_	_	_	_
31	AGT	_	O	O	_	_	_	_	_
32	GGG	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	NFATP	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	/	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	GGC	_	O	O	_	_	_	_	_
41	GCA	_	O	O	_	_	_	_	_
42	GAA	_	O	O	_	_	_	_	_
43	AAG	_	O	O	_	_	_	_	_
44	GTA	_	O	O	_	_	_	_	_
45	AAA	_	O	O	_	_	_	_	_
46	TAT	_	O	O	_	_	_	_	_
47	TTA	_	O	O	_	_	_	_	_
48	CTA	_	O	O	_	_	_	_	_
49	TCT	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	binding	_	O	O	_	_	_	_	_
52	sites	_	O	O	_	_	_	_	_
53	within	_	O	O	_	_	_	_	_
54	the	_	O	O	_	_	_	_	_
55	IL	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	1	_	O	O	_	_	_	_	_
58	RA	_	O	O	_	_	_	_	_
59	promoter	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	PBMC	_	O	O	_	_	_	_	_
2	RNA	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	isolated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	RNeasy	_	O	O	_	_	_	_	_
8	kit	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Qiagen	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	Germany	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	messenger	_	O	O	_	_	_	_	_
16	RNA	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	transcribed	_	O	O	_	_	_	_	_
19	into	_	O	O	_	_	_	_	_
20	cDNA	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	Reactin	_	O	O	_	_	_	_	_
23	Ready	_	O	O	_	_	_	_	_
24	First	_	O	O	_	_	_	_	_
25	Strand	_	O	O	_	_	_	_	_
26	kit	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	Biomol	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	analysed	_	O	O	_	_	_	_	_
32	for	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	RA	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	GAPDH	_	O	O	_	_	_	_	_
39	transcripts	_	O	O	_	_	_	_	_
40	by	_	O	O	_	_	_	_	_
41	PCR	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	HotStart	_	O	O	_	_	_	_	_
45	""""	_	O	O	_	_	_	_	_
46	sweet	_	O	O	_	_	_	_	_
47	""""	_	O	O	_	_	_	_	_
48	PCR	_	O	O	_	_	_	_	_
49	mastermix	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	Biomol	_	O	O	_	_	_	_	_
52	)	_	O	O	_	_	_	_	_
53	(	_	O	O	_	_	_	_	_
54	95	_	O	O	_	_	_	_	_
55	degreesC	_	O	O	_	_	_	_	_
56	,	_	O	O	_	_	_	_	_
57	30	_	O	O	_	_	_	_	_
58	sec	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	55	_	O	O	_	_	_	_	_
61	degreesC	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	30	_	O	O	_	_	_	_	_
64	sec	_	O	O	_	_	_	_	_
65	,	_	O	O	_	_	_	_	_
66	72	_	O	O	_	_	_	_	_
67	degreesC	_	O	O	_	_	_	_	_
68	,	_	O	O	_	_	_	_	_
69	30	_	O	O	_	_	_	_	_
70	sec	_	O	O	_	_	_	_	_
71	,	_	O	O	_	_	_	_	_
72	25	_	O	O	_	_	_	_	_
73	cycles	_	O	O	_	_	_	_	_
74	for	_	O	O	_	_	_	_	_
75	IL	_	O	O	_	_	_	_	_
76	-	_	O	O	_	_	_	_	_
77	1	_	O	O	_	_	_	_	_
78	RA	_	O	O	_	_	_	_	_
79	and	_	O	O	_	_	_	_	_
80	94	_	O	O	_	_	_	_	_
81	degreesC	_	O	O	_	_	_	_	_
82	for	_	O	O	_	_	_	_	_
83	30	_	O	O	_	_	_	_	_
84	sec	_	O	O	_	_	_	_	_
85	,	_	O	O	_	_	_	_	_
86	50	_	O	O	_	_	_	_	_
87	degreesC	_	O	O	_	_	_	_	_
88	for	_	O	O	_	_	_	_	_
89	30	_	O	O	_	_	_	_	_
90	sec	_	O	O	_	_	_	_	_
91	and	_	O	O	_	_	_	_	_
92	72	_	O	O	_	_	_	_	_
93	degreesC	_	O	O	_	_	_	_	_
94	for	_	O	O	_	_	_	_	_
95	45	_	O	O	_	_	_	_	_
96	sec	_	O	O	_	_	_	_	_
97	,	_	O	O	_	_	_	_	_
98	25	_	O	O	_	_	_	_	_
99	cycles	_	O	O	_	_	_	_	_
100	for	_	O	O	_	_	_	_	_
101	GAPDH	_	O	O	_	_	_	_	_
102	)	_	O	O	_	_	_	_	_
103	following	_	O	O	_	_	_	_	_
104	18	_	O	O	_	_	_	_	_
105	h	_	O	O	_	_	_	_	_
106	incubation	_	O	O	_	_	_	_	_
107	with	_	O	O	_	_	_	_	_
108	GP	_	O	O	_	_	_	_	_
109	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	protein	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	measured	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	supernatant	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	ELISA	_	O	O	_	_	_	_	_
13	after	_	O	O	_	_	_	_	_
14	24	_	O	O	_	_	_	_	_
15	h	_	O	O	_	_	_	_	_
16	incubation	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	GP	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_



1	Oligonucleotides	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Oligos	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	5	_	O	O	_	_	_	_	_
7	'	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	32	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	P	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Labeling	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	complementary	_	O	O	_	_	_	_	_
3	double	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	stranded	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	ds	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	oligonucleotides	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	oligos	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	TNFalpha	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	8	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	IFNgamma	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	promoters	_	O	O	_	_	_	_	_
27	were	_	O	O	_	_	_	_	_
28	synthesised	_	O	O	_	_	_	_	_
29	from	_	O	O	_	_	_	_	_
30	single	_	O	O	_	_	_	_	_
31	stranded	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	ss	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	oligos	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	illustrated	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	Table	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	(	_	O	O	_	_	_	_	_
44	TIB	_	O	O	_	_	_	_	_
45	Molbiol	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	Berlin	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	Germany	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	and	_	O	O	_	_	_	_	_
52	32	_	O	O	_	_	_	_	_
53	P	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	labeled	_	O	O	_	_	_	_	_
56	with	_	O	O	_	_	_	_	_
57	5	_	O	O	_	_	_	_	_
58	'	_	O	O	_	_	_	_	_
59	gamma	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	P	_	O	O	_	_	_	_	_
62	-	_	O	O	_	_	_	_	_
63	ATP	_	O	O	_	_	_	_	_
64	(	_	O	O	_	_	_	_	_
65	3	_	O	O	_	_	_	_	_
66	,	_	O	O	_	_	_	_	_
67	000	_	O	O	_	_	_	_	_
68	Ci	_	O	O	_	_	_	_	_
69	/	_	O	O	_	_	_	_	_
70	mmol	_	O	O	_	_	_	_	_
71	,	_	O	O	_	_	_	_	_
72	Amersham	_	O	O	_	_	_	_	_
73	,	_	O	O	_	_	_	_	_
74	Braunschweig	_	O	O	_	_	_	_	_
75	,	_	O	O	_	_	_	_	_
76	Germany	_	O	O	_	_	_	_	_
77	)	_	O	O	_	_	_	_	_
78	using	_	O	O	_	_	_	_	_
79	the	_	O	O	_	_	_	_	_
80	Ready	_	O	O	_	_	_	_	_
81	-	_	O	O	_	_	_	_	_
82	To	_	O	O	_	_	_	_	_
83	-	_	O	O	_	_	_	_	_
84	Go	_	O	O	_	_	_	_	_
85	-	_	O	O	_	_	_	_	_
86	Polynucleotide	_	O	O	_	_	_	_	_
87	-	_	O	O	_	_	_	_	_
88	Kinase	_	O	O	_	_	_	_	_
89	Kit	_	O	O	_	_	_	_	_
90	(	_	O	O	_	_	_	_	_
91	PNK	_	O	O	_	_	_	_	_
92	Kit	_	O	O	_	_	_	_	_
93	,	_	O	O	_	_	_	_	_
94	Pharmacia	_	O	O	_	_	_	_	_
95	LKB	_	O	O	_	_	_	_	_
96	,	_	O	O	_	_	_	_	_
97	Freiburg	_	O	O	_	_	_	_	_
98	,	_	O	O	_	_	_	_	_
99	Germany	_	O	O	_	_	_	_	_
100	)	_	O	O	_	_	_	_	_
101	according	_	O	O	_	_	_	_	_
102	to	_	O	O	_	_	_	_	_
103	the	_	O	O	_	_	_	_	_
104	manufacturer	_	O	O	_	_	_	_	_
105	'	_	O	O	_	_	_	_	_
106	s	_	O	O	_	_	_	_	_
107	instructions	_	O	O	_	_	_	_	_
108	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	test	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	specificity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	oligos	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	mutated	_	O	O	_	_	_	_	_
11	oligos	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	used	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	additional	_	O	O	_	_	_	_	_
17	control	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Mutations	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	P	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	site	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	IFNgamma	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	[	_	O	O	_	_	_	_	_
12	29	_	O	O	_	_	_	_	_
13	]	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	consensus	_	O	O	_	_	_	_	_
19	sequence	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	TNFalpha	_	O	O	_	_	_	_	_
23	promoter	_	O	O	_	_	_	_	_
24	[	_	O	O	_	_	_	_	_
25	55	_	O	O	_	_	_	_	_
26	]	_	O	O	_	_	_	_	_
27	have	_	O	O	_	_	_	_	_
28	been	_	O	O	_	_	_	_	_
29	reported	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	interfere	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	sequences	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	which	_	O	O	_	_	_	_	_
36	seem	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	be	_	O	O	_	_	_	_	_
39	crucial	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	binding	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	NFAT	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	NFkappaB	_	O	O	_	_	_	_	_
47	proteins	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	respectively	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	Afterwards	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	ds	_	O	O	_	_	_	_	_
5	oligos	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	purified	_	O	O	_	_	_	_	_
8	via	_	O	O	_	_	_	_	_
9	gel	_	O	O	_	_	_	_	_
10	filtration	_	O	O	_	_	_	_	_
11	using	_	O	O	_	_	_	_	_
12	Probe	_	O	O	_	_	_	_	_
13	Quant	_	O	O	_	_	_	_	_
14	G	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	50	_	O	O	_	_	_	_	_
17	Micro	_	O	O	_	_	_	_	_
18	Columns	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	Pharmacia	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	according	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	manufacturer	_	O	O	_	_	_	_	_
26	'	_	O	O	_	_	_	_	_
27	s	_	O	O	_	_	_	_	_
28	instructions	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_



1	Lymphocyte	_	O	O	_	_	_	_	_
2	glucocorticoid	_	O	O	_	_	_	_	_
3	receptor	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	predictor	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	sertraline	_	O	O	_	_	_	_	_
8	response	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	adolescent	_	O	O	_	_	_	_	_
11	major	_	O	O	_	_	_	_	_
12	depressive	_	O	O	_	_	_	_	_
13	disorder	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	MDD	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Major	_	O	O	_	_	_	_	_
2	depressive	_	O	O	_	_	_	_	_
3	disorder	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	MDD	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	adolescents	_	O	O	_	_	_	_	_
9	demonstrates	_	O	O	_	_	_	_	_
10	resistance	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	tricyclic	_	O	O	_	_	_	_	_
13	antidepressants	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	absence	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	hypercortisolemia	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	efficacy	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	serotonin	_	O	O	_	_	_	_	_
5	reuptake	_	O	O	_	_	_	_	_
6	inhibitors	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	SRIs	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	uncertain	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	response	_	O	O	_	_	_	_	_
15	predictors	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	unavailable	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Abnormal	_	O	O	_	_	_	_	_
2	fast	_	O	O	_	_	_	_	_
3	feedback	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	negative	_	O	O	_	_	_	_	_
6	feedback	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	hypothalamic	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	pituitary	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	adrenal	_	O	O	_	_	_	_	_
14	axis	_	O	O	_	_	_	_	_
15	implicates	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	dampened	_	O	O	_	_	_	_	_
18	limbic	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	hippocampal	_	O	O	_	_	_	_	_
21	glucocorticoid	_	O	O	_	_	_	_	_
22	type	_	O	O	_	_	_	_	_
23	II	_	O	O	_	_	_	_	_
24	receptor	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	GCII	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	hypothesized	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	lymphocyte	_	O	O	_	_	_	_	_
5	GCII	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	altered	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	adolescent	_	O	O	_	_	_	_	_
10	MDD	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	could	_	O	O	_	_	_	_	_
13	serve	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	marker	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	response	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	SRIs	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	an	_	O	O	_	_	_	_	_
3	open	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	label	_	O	O	_	_	_	_	_
6	study	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	adolescents	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	n	_	O	O	_	_	_	_	_
11	=	_	O	O	_	_	_	_	_
12	20	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	meeting	_	O	O	_	_	_	_	_
15	DSM	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	III	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	R	_	O	O	_	_	_	_	_
20	criteria	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	MDD	_	O	O	_	_	_	_	_
23	showed	_	O	O	_	_	_	_	_
24	baseline	_	O	O	_	_	_	_	_
25	lymphocyte	_	O	O	_	_	_	_	_
26	GCII	_	O	O	_	_	_	_	_
27	sites	_	O	O	_	_	_	_	_
28	per	_	O	O	_	_	_	_	_
29	cell	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	sites	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	cell	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	values	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	793	_	O	O	_	_	_	_	_
38	+	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	106	_	O	O	_	_	_	_	_
42	versus	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	563	_	O	O	_	_	_	_	_
46	+	_	O	O	_	_	_	_	_
47	/	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	499	_	O	O	_	_	_	_	_
50	(	_	O	O	_	_	_	_	_
51	+	_	O	O	_	_	_	_	_
52	/	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	SEM	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	for	_	O	O	_	_	_	_	_
57	matched	_	O	O	_	_	_	_	_
58	controls	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	n	_	O	O	_	_	_	_	_
61	=	_	O	O	_	_	_	_	_
62	18	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	(	_	O	O	_	_	_	_	_
65	t	_	O	O	_	_	_	_	_
66	=	_	O	O	_	_	_	_	_
67	3	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_
69	5	_	O	O	_	_	_	_	_
70	;	_	O	O	_	_	_	_	_
71	df	_	O	O	_	_	_	_	_
72	=	_	O	O	_	_	_	_	_
73	36	_	O	O	_	_	_	_	_
74	;	_	O	O	_	_	_	_	_
75	p	_	O	O	_	_	_	_	_
76	<	_	O	O	_	_	_	_	_
77	.	_	O	O	_	_	_	_	_
78	001	_	O	O	_	_	_	_	_
79	)	_	O	O	_	_	_	_	_
80	.	_	O	O	_	_	_	_	_

1	GCII	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	bimodally	_	O	O	_	_	_	_	_
4	distributed	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	SRI	_	O	O	_	_	_	_	_
8	responders	_	O	O	_	_	_	_	_
9	differing	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	nonresponders	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	t	_	O	O	_	_	_	_	_
14	=	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_
17	9	_	O	O	_	_	_	_	_
18	;	_	O	O	_	_	_	_	_
19	df	_	O	O	_	_	_	_	_
20	=	_	O	O	_	_	_	_	_
21	14	_	O	O	_	_	_	_	_
22	;	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	<	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	001	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	GCII	_	O	O	_	_	_	_	_
2	accurately	_	O	O	_	_	_	_	_
3	classified	_	O	O	_	_	_	_	_
4	90	_	O	O	_	_	_	_	_
5	percent	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	sertraline	_	O	O	_	_	_	_	_
8	responders	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	80	_	O	O	_	_	_	_	_
11	percent	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	nonresponders	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Only	_	O	O	_	_	_	_	_
2	SRI	_	O	O	_	_	_	_	_
3	responders	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	GCII	_	O	O	_	_	_	_	_
6	sites	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	upregulated	_	O	O	_	_	_	_	_
10	after	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	weeks	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	treatment	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	t	_	O	O	_	_	_	_	_
17	=	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	df	_	O	O	_	_	_	_	_
23	=	_	O	O	_	_	_	_	_
24	10	_	O	O	_	_	_	_	_
25	;	_	O	O	_	_	_	_	_
26	p	_	O	O	_	_	_	_	_
27	<	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	05	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Lineage	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	specific	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	STAT	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	interferon	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	neutrophils	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	interferon	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	its	_	O	O	_	_	_	_	_
13	heterodimeric	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	induces	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	tyrosine	_	O	O	_	_	_	_	_
20	kinases	_	O	O	_	_	_	_	_
21	JAK	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	JAK	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	followed	_	O	O	_	_	_	_	_
27	by	_	O	O	_	_	_	_	_
28	tyrosine	_	O	O	_	_	_	_	_
29	phosphorylation	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	STAT	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	alpha	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Selective	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	at	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	IFN	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	achieved	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	interaction	_	O	O	_	_	_	_	_
18	between	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	cytosolic	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	motif	_	O	O	_	_	_	_	_
23	including	_	O	O	_	_	_	_	_
24	Y	_	O	O	_	_	_	_	_
25	440	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	IFN	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	gamma	_	O	O	_	_	_	_	_
31	receptor	_	O	O	_	_	_	_	_
32	alpha	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	chain	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	SH	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	domain	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	STAT	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	alpha	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	demonstrate	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	addition	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	also	_	O	O	_	_	_	_	_
16	activated	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	IFN	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	gamma	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	neutrophils	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	found	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	human	_	O	O	_	_	_	_	_
11	eosinophils	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	monocytes	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	HL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	60	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	although	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	protein	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	expressed	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	these	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	cell	_	O	O	_	_	_	_	_
3	type	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	specific	_	O	O	_	_	_	_	_
6	activation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	IFN	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	also	_	O	O	_	_	_	_	_
16	observed	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	neutrophils	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	differentiated	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	vitro	_	O	O	_	_	_	_	_
24	from	_	O	O	_	_	_	_	_
25	human	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	34	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	hematopoietic	_	O	O	_	_	_	_	_
30	stem	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	single	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	can	_	O	O	_	_	_	_	_
10	activate	_	O	O	_	_	_	_	_
11	different	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	family	_	O	O	_	_	_	_	_
14	members	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	specific	_	O	O	_	_	_	_	_
20	manner	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	which	_	O	O	_	_	_	_	_
23	might	_	O	O	_	_	_	_	_
24	result	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	specific	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	transcription	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Transfection	_	O	O	_	_	_	_	_
2	Studies	_	O	O	_	_	_	_	_
3	Using	_	O	O	_	_	_	_	_
4	GM	_	O	O	_	_	_	_	_
5	979	_	O	O	_	_	_	_	_
6	Cells	_	O	O	_	_	_	_	_
7	Indicate	_	O	O	_	_	_	_	_
8	That	_	O	O	_	_	_	_	_
9	Sox	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	Directly	_	O	O	_	_	_	_	_
12	Represses	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	epsilony	_	O	O	_	_	_	_	_
15	Gene	_	O	O	_	_	_	_	_
16	Promoter	_	O	O	_	_	_	_	_
17	at	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	Transcriptional	_	O	O	_	_	_	_	_
20	Level	_	O	O	_	_	_	_	_

1	Real	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	time	_	O	O	_	_	_	_	_
4	PCR	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	Figure	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	measure	_	O	O	_	_	_	_	_
11	steady	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	state	_	O	O	_	_	_	_	_
14	levels	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	epsilony	_	O	O	_	_	_	_	_
17	mRNA	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	not	_	O	O	_	_	_	_	_
20	transcriptional	_	O	O	_	_	_	_	_
21	activity	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	epsilony	_	O	O	_	_	_	_	_
25	promoter	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	directly	_	O	O	_	_	_	_	_
7	acts	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	epsilony	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	transcriptional	_	O	O	_	_	_	_	_
16	level	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	we	_	O	O	_	_	_	_	_
19	used	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	vitro	_	O	O	_	_	_	_	_
23	transient	_	O	O	_	_	_	_	_
24	transfection	_	O	O	_	_	_	_	_
25	assay	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	GM	_	O	O	_	_	_	_	_
28	979	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	murine	_	O	O	_	_	_	_	_
33	erythroleukemic	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	line	_	O	O	_	_	_	_	_
36	that	_	O	O	_	_	_	_	_
37	expresses	_	O	O	_	_	_	_	_
38	both	_	O	O	_	_	_	_	_
39	epsilony	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	adult	_	O	O	_	_	_	_	_
42	beta	_	O	O	_	_	_	_	_
43	globins	_	O	O	_	_	_	_	_
44	[	_	O	O	_	_	_	_	_
45	30	_	O	O	_	_	_	_	_
46	]	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	generated	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	epsilony	_	O	O	_	_	_	_	_
5	promoter	_	O	O	_	_	_	_	_
6	reporter	_	O	O	_	_	_	_	_
7	construct	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	E	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	Luc	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	fusing	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	micro	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	LCR	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	muLCR	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	element	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_
26	5	_	O	O	_	_	_	_	_
27	kb	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	31	_	O	O	_	_	_	_	_
31	]	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	epsilony	_	O	O	_	_	_	_	_
35	proximal	_	O	O	_	_	_	_	_
36	promoter	_	O	O	_	_	_	_	_
37	(	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	2	_	O	O	_	_	_	_	_
41	kb	_	O	O	_	_	_	_	_
42	)	_	O	O	_	_	_	_	_
43	,	_	O	O	_	_	_	_	_
44	followed	_	O	O	_	_	_	_	_
45	by	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	luciferase	_	O	O	_	_	_	_	_
48	reporter	_	O	O	_	_	_	_	_
49	gene	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	as	_	O	O	_	_	_	_	_
52	shown	_	O	O	_	_	_	_	_
53	in	_	O	O	_	_	_	_	_
54	Figure	_	O	O	_	_	_	_	_
55	2	_	O	O	_	_	_	_	_
56	A	_	O	O	_	_	_	_	_
57	(	_	O	O	_	_	_	_	_
58	detailed	_	O	O	_	_	_	_	_
59	in	_	O	O	_	_	_	_	_
60	Materials	_	O	O	_	_	_	_	_
61	and	_	O	O	_	_	_	_	_
62	Methods	_	O	O	_	_	_	_	_
63	)	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_

1	Overexpression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	GM	_	O	O	_	_	_	_	_
7	979	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	transient	_	O	O	_	_	_	_	_
11	transfection	_	O	O	_	_	_	_	_
12	leads	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	dosage	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	dependent	_	O	O	_	_	_	_	_
18	repression	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	E	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	Luc	_	O	O	_	_	_	_	_
23	reporter	_	O	O	_	_	_	_	_
24	activity	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	Figure	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	B	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	overexpression	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	truncated	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	lacks	_	O	O	_	_	_	_	_
13	its	_	O	O	_	_	_	_	_
14	HMG	_	O	O	_	_	_	_	_
15	domain	_	O	O	_	_	_	_	_
16	[	_	O	O	_	_	_	_	_
17	32	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	similar	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	100	_	O	O	_	_	_	_	_
25	H	_	O	O	_	_	_	_	_
26	mouse	_	O	O	_	_	_	_	_
27	allele	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	fails	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	repress	_	O	O	_	_	_	_	_
32	E	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	Luc	_	O	O	_	_	_	_	_
35	activity	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	Figure	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	acts	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	repress	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	epsilony	_	O	O	_	_	_	_	_
12	promoter	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	transcriptional	_	O	O	_	_	_	_	_
16	level	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Sox	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	act	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	repressor	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	interact	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	widely	_	O	O	_	_	_	_	_
17	expressed	_	O	O	_	_	_	_	_
18	co	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	repressor	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	CtBP	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	fgf	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	promoter	_	O	O	_	_	_	_	_
31	[	_	O	O	_	_	_	_	_
32	5	_	O	O	_	_	_	_	_
33	]	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	CtBP	_	O	O	_	_	_	_	_
2	2	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	expressed	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	GM	_	O	O	_	_	_	_	_
7	979	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	unpublished	_	O	O	_	_	_	_	_
11	data	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	interaction	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	CtBP	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	required	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	Sox	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	repression	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	epsilony	_	O	O	_	_	_	_	_
18	promoter	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	we	_	O	O	_	_	_	_	_
21	introduced	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	point	_	O	O	_	_	_	_	_
24	mutation	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	L	_	O	O	_	_	_	_	_
27	386	_	O	O	_	_	_	_	_
28	H	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	Sox	_	O	O	_	_	_	_	_
33	6	_	O	O	_	_	_	_	_
34	protein	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	has	_	O	O	_	_	_	_	_
37	been	_	O	O	_	_	_	_	_
38	previously	_	O	O	_	_	_	_	_
39	reported	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	be	_	O	O	_	_	_	_	_
42	sufficient	_	O	O	_	_	_	_	_
43	to	_	O	O	_	_	_	_	_
44	abolish	_	O	O	_	_	_	_	_
45	Sox	_	O	O	_	_	_	_	_
46	6	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	CtBP	_	O	O	_	_	_	_	_
49	2	_	O	O	_	_	_	_	_
50	interaction	_	O	O	_	_	_	_	_
51	[	_	O	O	_	_	_	_	_
52	5	_	O	O	_	_	_	_	_
53	]	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	amino	_	O	O	_	_	_	_	_
3	acid	_	O	O	_	_	_	_	_
4	change	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	HMG	_	O	O	_	_	_	_	_
10	DNA	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	domain	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	mutant	_	O	O	_	_	_	_	_
5	version	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Sox	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	retains	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	ability	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	repress	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	epsilony	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	transfection	_	O	O	_	_	_	_	_
20	assay	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	Figure	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	B	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	indicating	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	Sox	_	O	O	_	_	_	_	_
30	6	_	O	O	_	_	_	_	_
31	represses	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	epsilony	_	O	O	_	_	_	_	_
34	promoter	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	CtBP	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	independent	_	O	O	_	_	_	_	_
41	manner	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Deletion	_	O	O	_	_	_	_	_
2	analysis	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	epsilony	_	O	O	_	_	_	_	_
6	promoter	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	shown	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	Figure	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	C	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	defined	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	region	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	63	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	37	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	within	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	epsilony	_	O	O	_	_	_	_	_
28	proximal	_	O	O	_	_	_	_	_
29	promoter	_	O	O	_	_	_	_	_
30	that	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	critical	_	O	O	_	_	_	_	_
33	for	_	O	O	_	_	_	_	_
34	Sox	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	repression	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Analysis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	short	_	O	O	_	_	_	_	_
5	region	_	O	O	_	_	_	_	_
6	reveals	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	Sox	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	consensus	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	sites	_	O	O	_	_	_	_	_
15	[	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	]	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	Figure	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_



1	Resistance	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	inhibition	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IFN	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	gamma	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	CD	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	+	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	28	_	O	O	_	_	_	_	_
4	costimulatory	_	O	O	_	_	_	_	_
5	pathway	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	crucial	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	effective	_	O	O	_	_	_	_	_
10	antigen	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	specific	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	can	_	O	O	_	_	_	_	_
24	directly	_	O	O	_	_	_	_	_
25	suppress	_	O	O	_	_	_	_	_
26	this	_	O	O	_	_	_	_	_
27	response	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	inhibiting	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	28	_	O	O	_	_	_	_	_
32	tyrosine	_	O	O	_	_	_	_	_
33	phosphorylation	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	binding	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	phosphatidylinositol	_	O	O	_	_	_	_	_
38	3	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	kinase	_	O	O	_	_	_	_	_
41	[	_	O	O	_	_	_	_	_
42	24	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	evaluate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	responsiveness	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	+	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	purified	_	O	O	_	_	_	_	_
18	PB	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	from	_	O	O	_	_	_	_	_
25	three	_	O	O	_	_	_	_	_
26	patients	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	active	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	three	_	O	O	_	_	_	_	_
33	healthy	_	O	O	_	_	_	_	_
34	controls	_	O	O	_	_	_	_	_
35	were	_	O	O	_	_	_	_	_
36	stimulated	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	immobilized	_	O	O	_	_	_	_	_
39	anti	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	CD	_	O	O	_	_	_	_	_
42	3	_	O	O	_	_	_	_	_
43	antibody	_	O	O	_	_	_	_	_
44	and	_	O	O	_	_	_	_	_
45	anti	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	CD	_	O	O	_	_	_	_	_
48	28	_	O	O	_	_	_	_	_
49	antibody	_	O	O	_	_	_	_	_
50	with	_	O	O	_	_	_	_	_
51	or	_	O	O	_	_	_	_	_
52	without	_	O	O	_	_	_	_	_
53	diluted	_	O	O	_	_	_	_	_
54	concentrations	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	10	_	O	O	_	_	_	_	_
59	for	_	O	O	_	_	_	_	_
60	36	_	O	O	_	_	_	_	_
61	hours	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	and	_	O	O	_	_	_	_	_
64	IFN	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	gamma	_	O	O	_	_	_	_	_
67	production	_	O	O	_	_	_	_	_
68	was	_	O	O	_	_	_	_	_
69	measured	_	O	O	_	_	_	_	_
70	by	_	O	O	_	_	_	_	_
71	ELISA	_	O	O	_	_	_	_	_
72	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Fig	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	1	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IFN	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	production	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	normal	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	4	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	mostly	_	O	O	_	_	_	_	_
17	inhibited	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	concentrations	_	O	O	_	_	_	_	_
20	as	_	O	O	_	_	_	_	_
21	low	_	O	O	_	_	_	_	_
22	as	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	ng	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	ml	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	RA	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	able	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	produce	_	O	O	_	_	_	_	_
13	significant	_	O	O	_	_	_	_	_
14	amounts	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	IFN	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	presence	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	ng	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	ml	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	maximal	_	O	O	_	_	_	_	_
34	but	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	complete	_	O	O	_	_	_	_	_
37	inhibition	_	O	O	_	_	_	_	_
38	by	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	10	_	O	O	_	_	_	_	_
42	was	_	O	O	_	_	_	_	_
43	obtained	_	O	O	_	_	_	_	_
44	at	_	O	O	_	_	_	_	_
45	10	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	100	_	O	O	_	_	_	_	_
48	ng	_	O	O	_	_	_	_	_
49	/	_	O	O	_	_	_	_	_
50	ml	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	thus	_	O	O	_	_	_	_	_
3	compared	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	production	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	after	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	28	_	O	O	_	_	_	_	_
23	costimulation	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	presence	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	ng	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	ml	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	10	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	RA	_	O	O	_	_	_	_	_
37	patients	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	active	_	O	O	_	_	_	_	_
40	disease	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	multiple	_	O	O	_	_	_	_	_
43	inflammatory	_	O	O	_	_	_	_	_
44	joints	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	CRP	_	O	O	_	_	_	_	_
47	level	_	O	O	_	_	_	_	_
48	>	_	O	O	_	_	_	_	_
49	/	_	O	O	_	_	_	_	_
50	=	_	O	O	_	_	_	_	_
51	10	_	O	O	_	_	_	_	_
52	mg	_	O	O	_	_	_	_	_
53	/	_	O	O	_	_	_	_	_
54	l	_	O	O	_	_	_	_	_
55	)	_	O	O	_	_	_	_	_
56	and	_	O	O	_	_	_	_	_
57	inactive	_	O	O	_	_	_	_	_
58	disease	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	in	_	O	O	_	_	_	_	_
61	remission	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	CRP	_	O	O	_	_	_	_	_
64	level	_	O	O	_	_	_	_	_
65	<	_	O	O	_	_	_	_	_
66	10	_	O	O	_	_	_	_	_
67	mg	_	O	O	_	_	_	_	_
68	/	_	O	O	_	_	_	_	_
69	l	_	O	O	_	_	_	_	_
70	)	_	O	O	_	_	_	_	_
71	[	_	O	O	_	_	_	_	_
72	26	_	O	O	_	_	_	_	_
73	]	_	O	O	_	_	_	_	_
74	and	_	O	O	_	_	_	_	_
75	in	_	O	O	_	_	_	_	_
76	healthy	_	O	O	_	_	_	_	_
77	controls	_	O	O	_	_	_	_	_
78	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	no	_	O	O	_	_	_	_	_
4	statistically	_	O	O	_	_	_	_	_
5	significant	_	O	O	_	_	_	_	_
6	differences	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	IFN	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	gamma	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	without	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	among	_	O	O	_	_	_	_	_
17	these	_	O	O	_	_	_	_	_
18	three	_	O	O	_	_	_	_	_
19	groups	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Fig	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	but	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	inhibitory	_	O	O	_	_	_	_	_
8	effect	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	on	_	O	O	_	_	_	_	_
14	IFN	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	gamma	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	significantly	_	O	O	_	_	_	_	_
20	limited	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	active	_	O	O	_	_	_	_	_
24	RA	_	O	O	_	_	_	_	_
25	group	_	O	O	_	_	_	_	_
26	as	_	O	O	_	_	_	_	_
27	compared	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	inactive	_	O	O	_	_	_	_	_
31	RA	_	O	O	_	_	_	_	_
32	group	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	healthy	_	O	O	_	_	_	_	_
35	controls	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	percentage	_	O	O	_	_	_	_	_
38	decrease	_	O	O	_	_	_	_	_
39	:	_	O	O	_	_	_	_	_
40	active	_	O	O	_	_	_	_	_
41	RA	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_
45	9	_	O	O	_	_	_	_	_
46	+	_	O	O	_	_	_	_	_
47	/	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	14	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	4	_	O	O	_	_	_	_	_
52	%;	_	O	O	_	_	_	_	_
53	inactive	_	O	O	_	_	_	_	_
54	RA	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	45	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_
58	6	_	O	O	_	_	_	_	_
59	+	_	O	O	_	_	_	_	_
60	/	_	O	O	_	_	_	_	_
61	-	_	O	O	_	_	_	_	_
62	14	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_
64	4	_	O	O	_	_	_	_	_
65	%;	_	O	O	_	_	_	_	_
66	controls	_	O	O	_	_	_	_	_
67	,	_	O	O	_	_	_	_	_
68	65	_	O	O	_	_	_	_	_
69	.	_	O	O	_	_	_	_	_
70	8	_	O	O	_	_	_	_	_
71	+	_	O	O	_	_	_	_	_
72	/	_	O	O	_	_	_	_	_
73	-	_	O	O	_	_	_	_	_
74	7	_	O	O	_	_	_	_	_
75	.	_	O	O	_	_	_	_	_
76	9	_	O	O	_	_	_	_	_
77	%	_	O	O	_	_	_	_	_
78	)	_	O	O	_	_	_	_	_
79	(	_	O	O	_	_	_	_	_
80	Fig	_	O	O	_	_	_	_	_
81	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	b	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	consequence	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	from	_	O	O	_	_	_	_	_
11	active	_	O	O	_	_	_	_	_
12	RA	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	produced	_	O	O	_	_	_	_	_
15	higher	_	O	O	_	_	_	_	_
16	levels	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IFN	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	gamma	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	presence	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	ng	_	O	O	_	_	_	_	_
27	/	_	O	O	_	_	_	_	_
28	ml	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	10	_	O	O	_	_	_	_	_
32	than	_	O	O	_	_	_	_	_
33	did	_	O	O	_	_	_	_	_
34	normal	_	O	O	_	_	_	_	_
35	CD	_	O	O	_	_	_	_	_
36	4	_	O	O	_	_	_	_	_
37	+	_	O	O	_	_	_	_	_
38	T	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	Fig	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	compared	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	production	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	CD	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	+	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	after	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	28	_	O	O	_	_	_	_	_
22	costimulation	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	presence	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	10	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	active	_	O	O	_	_	_	_	_
32	RA	_	O	O	_	_	_	_	_
33	patients	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	healthy	_	O	O	_	_	_	_	_
37	controls	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Similarly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	production	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	affected	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	ng	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	ml	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	patients	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	percentage	_	O	O	_	_	_	_	_
23	decrease	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	13	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	8	_	O	O	_	_	_	_	_
35	%	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	while	_	O	O	_	_	_	_	_
39	it	_	O	O	_	_	_	_	_
40	was	_	O	O	_	_	_	_	_
41	significantly	_	O	O	_	_	_	_	_
42	reduced	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	healthy	_	O	O	_	_	_	_	_
45	controls	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	61	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	+	_	O	O	_	_	_	_	_
51	/	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	13	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_
55	7	_	O	O	_	_	_	_	_
56	%;	_	O	O	_	_	_	_	_
57	P	_	O	O	_	_	_	_	_
58	<	_	O	O	_	_	_	_	_
59	0	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_
61	05	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_

1	Taken	_	O	O	_	_	_	_	_
2	together	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	+	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	become	_	O	O	_	_	_	_	_
15	less	_	O	O	_	_	_	_	_
16	susceptible	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	immunoregulatory	_	O	O	_	_	_	_	_
20	effect	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	10	_	O	O	_	_	_	_	_
25	during	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	active	_	O	O	_	_	_	_	_
28	phase	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_



1	A	_	O	O	_	_	_	_	_
2	chimeric	_	O	O	_	_	_	_	_
3	type	_	O	O	_	_	_	_	_
4	II	_	O	O	_	_	_	_	_
5	/	_	O	O	_	_	_	_	_
6	type	_	O	O	_	_	_	_	_
7	I	_	O	O	_	_	_	_	_
8	interleukin	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	receptor	_	O	O	_	_	_	_	_
12	can	_	O	O	_	_	_	_	_
13	mediate	_	O	O	_	_	_	_	_
14	interleukin	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	induction	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	gene	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	type	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	interleukin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	R	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	capable	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	transducing	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	signal	_	O	O	_	_	_	_	_
20	resulting	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	promoter	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	signal	_	O	O	_	_	_	_	_
3	transduction	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	dependent	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	cytoplasmic	_	O	O	_	_	_	_	_
9	domain	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	which	_	O	O	_	_	_	_	_
12	consists	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	213	_	O	O	_	_	_	_	_
15	amino	_	O	O	_	_	_	_	_
16	acids	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	type	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	II	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	R	_	O	O	_	_	_	_	_
16	has	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	small	_	O	O	_	_	_	_	_
19	cytoplasmic	_	O	O	_	_	_	_	_
20	tail	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	it	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	not	_	O	O	_	_	_	_	_
26	clear	_	O	O	_	_	_	_	_
27	whether	_	O	O	_	_	_	_	_
28	this	_	O	O	_	_	_	_	_
29	receptor	_	O	O	_	_	_	_	_
30	is	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	signal	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	transducing	_	O	O	_	_	_	_	_
35	or	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	regulatory	_	O	O	_	_	_	_	_
38	molecule	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	type	_	O	O	_	_	_	_	_
7	II	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	R	_	O	O	_	_	_	_	_
12	does	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	mediate	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	Jurkat	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	hybrid	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	composed	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	extracellular	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	transmembrane	_	O	O	_	_	_	_	_
12	regions	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	type	_	O	O	_	_	_	_	_
17	II	_	O	O	_	_	_	_	_
18	interleukin	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	fused	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	cytoplasmic	_	O	O	_	_	_	_	_
25	domain	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	human	_	O	O	_	_	_	_	_
29	type	_	O	O	_	_	_	_	_
30	I	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	R	_	O	O	_	_	_	_	_
35	was	_	O	O	_	_	_	_	_
36	capable	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	transducing	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	signal	_	O	O	_	_	_	_	_
41	across	_	O	O	_	_	_	_	_
42	the	_	O	O	_	_	_	_	_
43	membrane	_	O	O	_	_	_	_	_
44	resulting	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	pattern	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	gene	_	O	O	_	_	_	_	_
50	activation	_	O	O	_	_	_	_	_
51	identical	_	O	O	_	_	_	_	_
52	to	_	O	O	_	_	_	_	_
53	that	_	O	O	_	_	_	_	_
54	mediated	_	O	O	_	_	_	_	_
55	by	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	type	_	O	O	_	_	_	_	_
58	I	_	O	O	_	_	_	_	_
59	IL	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	1	_	O	O	_	_	_	_	_
62	R	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	extracellular	_	O	O	_	_	_	_	_
7	domain	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	type	_	O	O	_	_	_	_	_
11	II	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	R	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	capable	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	functionally	_	O	O	_	_	_	_	_
20	interacting	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	interleukin	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	transmitting	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	resulting	_	O	O	_	_	_	_	_
29	signal	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	heterologous	_	O	O	_	_	_	_	_
33	cytoplasmic	_	O	O	_	_	_	_	_
34	domain	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Constitutive	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	epithelial	_	O	O	_	_	_	_	_
6	signal	_	O	O	_	_	_	_	_
7	transducer	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	activator	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	pathway	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	asthma	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Cytokine	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	on	_	O	O	_	_	_	_	_
4	immunity	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	inflammation	_	O	O	_	_	_	_	_
7	often	_	O	O	_	_	_	_	_
8	depend	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	transcription	_	O	O	_	_	_	_	_
12	factors	_	O	O	_	_	_	_	_
13	termed	_	O	O	_	_	_	_	_
14	signal	_	O	O	_	_	_	_	_
15	transducers	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	activators	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	STATs	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	so	_	O	O	_	_	_	_	_
25	STAT	_	O	O	_	_	_	_	_
26	signaling	_	O	O	_	_	_	_	_
27	pathways	_	O	O	_	_	_	_	_
28	are	_	O	O	_	_	_	_	_
29	candidates	_	O	O	_	_	_	_	_
30	for	_	O	O	_	_	_	_	_
31	influencing	_	O	O	_	_	_	_	_
32	inflammatory	_	O	O	_	_	_	_	_
33	disease	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	reasoned	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	selective	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	responsiveness	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	first	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	member	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	Stat	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	Stat	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	dependent	_	O	O	_	_	_	_	_
22	immune	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	response	_	O	O	_	_	_	_	_
25	genes	_	O	O	_	_	_	_	_
26	such	_	O	O	_	_	_	_	_
27	as	_	O	O	_	_	_	_	_
28	intercellular	_	O	O	_	_	_	_	_
29	adhesion	_	O	O	_	_	_	_	_
30	molecule	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	ICAM	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	IFN	_	O	O	_	_	_	_	_
40	regulatory	_	O	O	_	_	_	_	_
41	factor	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	(	_	O	O	_	_	_	_	_
45	IRF	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	1	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	Stat	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	itself	_	O	O	_	_	_	_	_
54	in	_	O	O	_	_	_	_	_
55	airway	_	O	O	_	_	_	_	_
56	epithelial	_	O	O	_	_	_	_	_
57	cells	_	O	O	_	_	_	_	_
58	provides	_	O	O	_	_	_	_	_
59	a	_	O	O	_	_	_	_	_
60	basis	_	O	O	_	_	_	_	_
61	for	_	O	O	_	_	_	_	_
62	detecting	_	O	O	_	_	_	_	_
63	cytokine	_	O	O	_	_	_	_	_
64	signaling	_	O	O	_	_	_	_	_
65	abnormalities	_	O	O	_	_	_	_	_
66	in	_	O	O	_	_	_	_	_
67	inflammatory	_	O	O	_	_	_	_	_
68	airway	_	O	O	_	_	_	_	_
69	disease	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	basis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	localization	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	we	_	O	O	_	_	_	_	_
11	found	_	O	O	_	_	_	_	_
12	that	_	O	O	_	_	_	_	_
13	epithelial	_	O	O	_	_	_	_	_
14	Stat	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	other	_	O	O	_	_	_	_	_
20	control	_	O	O	_	_	_	_	_
21	transcription	_	O	O	_	_	_	_	_
22	factors	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	invariably	_	O	O	_	_	_	_	_
26	activated	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	asthmatic	_	O	O	_	_	_	_	_
29	compared	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	normal	_	O	O	_	_	_	_	_
32	control	_	O	O	_	_	_	_	_
33	or	_	O	O	_	_	_	_	_
34	chronic	_	O	O	_	_	_	_	_
35	bronchitis	_	O	O	_	_	_	_	_
36	subjects	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	epithelial	_	O	O	_	_	_	_	_
4	levels	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	Stat	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	correlated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	epithelial	_	O	O	_	_	_	_	_
16	ICAM	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	IRF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	Stat	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	turn	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	ICAM	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	levels	_	O	O	_	_	_	_	_
36	correlated	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	T	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	cell	_	O	O	_	_	_	_	_
41	accumulation	_	O	O	_	_	_	_	_
42	in	_	O	O	_	_	_	_	_
43	tissue	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	only	_	O	O	_	_	_	_	_
4	low	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IFN	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	or	_	O	O	_	_	_	_	_
11	IFN	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	gamma	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	producing	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	detected	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	airway	_	O	O	_	_	_	_	_
21	tissue	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	all	_	O	O	_	_	_	_	_
24	subjects	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	therefore	_	O	O	_	_	_	_	_
4	provide	_	O	O	_	_	_	_	_
5	initial	_	O	O	_	_	_	_	_
6	evidence	_	O	O	_	_	_	_	_
7	linking	_	O	O	_	_	_	_	_
8	abnormal	_	O	O	_	_	_	_	_
9	behavior	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	pathways	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	cytokine	_	O	O	_	_	_	_	_
15	signaling	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	development	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	inflammatory	_	O	O	_	_	_	_	_
22	disease	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	that	_	O	O	_	_	_	_	_
3	context	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	results	_	O	O	_	_	_	_	_
7	also	_	O	O	_	_	_	_	_
8	change	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	current	_	O	O	_	_	_	_	_
11	scheme	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	asthma	_	O	O	_	_	_	_	_
14	pathogenesis	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	one	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	must	_	O	O	_	_	_	_	_
19	include	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	localized	_	O	O	_	_	_	_	_
22	gain	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	transcriptional	_	O	O	_	_	_	_	_
25	signal	_	O	O	_	_	_	_	_
26	ordinarily	_	O	O	_	_	_	_	_
27	used	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	helper	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	type	_	O	O	_	_	_	_	_
35	cytokine	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	IFN	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	gamma	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	combination	_	O	O	_	_	_	_	_
43	with	_	O	O	_	_	_	_	_
44	allergy	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	driven	_	O	O	_	_	_	_	_
47	overproduction	_	O	O	_	_	_	_	_
48	of	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	helper	_	O	O	_	_	_	_	_
51	2	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	type	_	O	O	_	_	_	_	_
54	cytokines	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_


1	Conclusions	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	detected	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	more	_	O	O	_	_	_	_	_
6	pronounced	_	O	O	_	_	_	_	_
7	production	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	17	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	RA	_	O	O	_	_	_	_	_
14	PBMC	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	response	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	15	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	MCP	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	well	_	O	O	_	_	_	_	_
27	as	_	O	O	_	_	_	_	_
28	stimulation	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	anti	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	CD	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	/	_	O	O	_	_	_	_	_
35	anti	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	28	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	upregulation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	17	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	activated	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	could	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	result	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	via	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	PI	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	K	_	O	O	_	_	_	_	_
30	/	_	O	O	_	_	_	_	_
31	Akt	_	O	O	_	_	_	_	_
32	pathway	_	O	O	_	_	_	_	_
33	with	_	O	O	_	_	_	_	_
34	resultant	_	O	O	_	_	_	_	_
35	NF	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	kappaB	_	O	O	_	_	_	_	_
38	activation	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	provide	_	O	O	_	_	_	_	_
4	insights	_	O	O	_	_	_	_	_
5	into	_	O	O	_	_	_	_	_
6	cellular	_	O	O	_	_	_	_	_
7	mechanisms	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	regulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	17	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	highlight	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	role	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	which	_	O	O	_	_	_	_	_
28	has	_	O	O	_	_	_	_	_
29	hitherto	_	O	O	_	_	_	_	_
30	been	_	O	O	_	_	_	_	_
31	neglected	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	RA	_	O	O	_	_	_	_	_
34	pathogenesis	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Together	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	recent	_	O	O	_	_	_	_	_
4	data	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	successful	_	O	O	_	_	_	_	_
8	introduction	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	anti	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	17	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	our	_	O	O	_	_	_	_	_
19	results	_	O	O	_	_	_	_	_
20	have	_	O	O	_	_	_	_	_
21	added	_	O	O	_	_	_	_	_
22	information	_	O	O	_	_	_	_	_
23	for	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	future	_	O	O	_	_	_	_	_
26	molecular	_	O	O	_	_	_	_	_
27	targeting	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	new	_	O	O	_	_	_	_	_
30	therapeutic	_	O	O	_	_	_	_	_
31	applications	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	RA	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_



1	Genetic	_	O	O	_	_	_	_	_
2	evidence	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	an	_	O	O	_	_	_	_	_
5	additional	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	required	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	erythropoietin	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	signal	_	O	O	_	_	_	_	_
13	transduction	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Erythropoietin	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	EPO	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	its	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	EPOR	_	O	O	_	_	_	_	_
10	)	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	required	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	development	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	mature	_	O	O	_	_	_	_	_
18	erythrocytes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	binding	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	ligand	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	EPOR	_	O	O	_	_	_	_	_
8	activates	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	variety	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	signaling	_	O	O	_	_	_	_	_
13	pathways	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	ultimately	_	O	O	_	_	_	_	_
16	control	_	O	O	_	_	_	_	_
17	cellular	_	O	O	_	_	_	_	_
18	proliferation	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	survival	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	specific	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	erythroid	_	O	O	_	_	_	_	_
3	progenitors	_	O	O	_	_	_	_	_
4	appear	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	principal	_	O	O	_	_	_	_	_
9	EPO	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	responsive	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	type	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	vivo	_	O	O	_	_	_	_	_
16	due	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	restricted	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	EPOR	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	many	_	O	O	_	_	_	_	_
26	growth	_	O	O	_	_	_	_	_
27	factor	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	dependent	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	lines	_	O	O	_	_	_	_	_
32	expressing	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	EPOR	_	O	O	_	_	_	_	_
35	can	_	O	O	_	_	_	_	_
36	respond	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	EPO	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	activating	_	O	O	_	_	_	_	_
41	many	_	O	O	_	_	_	_	_
42	or	_	O	O	_	_	_	_	_
43	all	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	these	_	O	O	_	_	_	_	_
46	pathways	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	have	_	O	O	_	_	_	_	_
8	identified	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	cellular	_	O	O	_	_	_	_	_
11	context	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	interleukin	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	[	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	dependent	_	O	O	_	_	_	_	_
24	HT	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	line	_	O	O	_	_	_	_	_
28	)	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	EPO	_	O	O	_	_	_	_	_
33	stimulation	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	EPOR	_	O	O	_	_	_	_	_
37	fails	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	support	_	O	O	_	_	_	_	_
40	cellular	_	O	O	_	_	_	_	_
41	proliferation	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	STAT	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	5	_	O	O	_	_	_	_	_
46	induction	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	or	_	O	O	_	_	_	_	_
49	MAPK	_	O	O	_	_	_	_	_
50	activation	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	despite	_	O	O	_	_	_	_	_
53	efficient	_	O	O	_	_	_	_	_
54	phosphorylation	_	O	O	_	_	_	_	_
55	of	_	O	O	_	_	_	_	_
56	the	_	O	O	_	_	_	_	_
57	EPOR	_	O	O	_	_	_	_	_
58	and	_	O	O	_	_	_	_	_
59	JAK	_	O	O	_	_	_	_	_
60	2	_	O	O	_	_	_	_	_
61	and	_	O	O	_	_	_	_	_
62	inhibition	_	O	O	_	_	_	_	_
63	of	_	O	O	_	_	_	_	_
64	apoptosis	_	O	O	_	_	_	_	_
65	after	_	O	O	_	_	_	_	_
66	withdrawal	_	O	O	_	_	_	_	_
67	of	_	O	O	_	_	_	_	_
68	IL	_	O	O	_	_	_	_	_
69	-	_	O	O	_	_	_	_	_
70	2	_	O	O	_	_	_	_	_
71	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	when	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	fused	_	O	O	_	_	_	_	_
6	HT	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	expressing	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	EPOR	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	Ba	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	F	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	complementation	_	O	O	_	_	_	_	_
22	assay	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	resulting	_	O	O	_	_	_	_	_
26	hybridomas	_	O	O	_	_	_	_	_
27	proliferated	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	potently	_	O	O	_	_	_	_	_
30	activated	_	O	O	_	_	_	_	_
31	STAT	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	5	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	MAPK	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	response	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	EPO	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	an	_	O	O	_	_	_	_	_
6	unidentified	_	O	O	_	_	_	_	_
7	cellular	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	needed	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	mediate	_	O	O	_	_	_	_	_
13	signaling	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	EPOR	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Ba	_	O	O	_	_	_	_	_
4	/	_	O	O	_	_	_	_	_
5	F	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	apparently	_	O	O	_	_	_	_	_
9	express	_	O	O	_	_	_	_	_
10	this	_	O	O	_	_	_	_	_
11	factor	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	s	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	somatic	_	O	O	_	_	_	_	_
17	fusions	_	O	O	_	_	_	_	_
18	can	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	therefore	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	confer	_	O	O	_	_	_	_	_
23	EPO	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	responsiveness	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	HT	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	that	_	O	O	_	_	_	_	_
32	lack	_	O	O	_	_	_	_	_
33	this	_	O	O	_	_	_	_	_
34	factor	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Cutting	_	O	O	_	_	_	_	_
2	edge	_	O	O	_	_	_	_	_
3	:	_	O	O	_	_	_	_	_
4	TCR	_	O	O	_	_	_	_	_
5	stimulation	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	antibody	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	bacterial	_	O	O	_	_	_	_	_
10	superantigen	_	O	O	_	_	_	_	_
11	induces	_	O	O	_	_	_	_	_
12	Stat	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Recent	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	TCR	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	stimulation	_	O	O	_	_	_	_	_
10	induces	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	murine	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	show	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	CD	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	ligation	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	mAb	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	Staphylococcal	_	O	O	_	_	_	_	_
13	enterotoxin	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	SE	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	induce	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	rapid	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	gradually	_	O	O	_	_	_	_	_
22	accumulating	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	long	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	lasting	_	O	O	_	_	_	_	_
27	tyrosine	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	serine	_	O	O	_	_	_	_	_
31	phosphorylation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	Stat	_	O	O	_	_	_	_	_
34	3	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	but	_	O	O	_	_	_	_	_
37	not	_	O	O	_	_	_	_	_
38	Stat	_	O	O	_	_	_	_	_
39	5	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	allogen	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	specific	_	O	O	_	_	_	_	_
45	human	_	O	O	_	_	_	_	_
46	CD	_	O	O	_	_	_	_	_
47	4	_	O	O	_	_	_	_	_
48	+	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	cell	_	O	O	_	_	_	_	_
51	lines	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	induces	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	rapid	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	transient	_	O	O	_	_	_	_	_
12	tyrosine	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	serine	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	Stat	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Compared	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	ligation	_	O	O	_	_	_	_	_
10	induces	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	delayed	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	oligonucleotide	_	O	O	_	_	_	_	_
18	probes	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	ICAM	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	2	_	O	O	_	_	_	_	_
28	R	_	O	O	_	_	_	_	_
29	alpha	_	O	O	_	_	_	_	_
30	promoter	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Stat	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	almost	_	O	O	_	_	_	_	_
11	completely	_	O	O	_	_	_	_	_
12	inhibited	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	Src	_	O	O	_	_	_	_	_
16	kinase	_	O	O	_	_	_	_	_
17	inhibitor	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	PP	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	whereas	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	induced	_	O	O	_	_	_	_	_
29	Stat	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	is	_	O	O	_	_	_	_	_
33	unaffected	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	ligation	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	mAb	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	SE	_	O	O	_	_	_	_	_
14	triggers	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	rapid	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	PP	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	sensitive	_	O	O	_	_	_	_	_
22	tyrosine	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	serine	_	O	O	_	_	_	_	_
25	phosphorylation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	Stat	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	human	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	+	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	provide	_	O	O	_	_	_	_	_
5	evidence	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	TCR	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	induce	_	O	O	_	_	_	_	_
16	Stat	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	activation	_	O	O	_	_	_	_	_
19	via	_	O	O	_	_	_	_	_
20	distinct	_	O	O	_	_	_	_	_
21	signaling	_	O	O	_	_	_	_	_
22	pathways	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	kappa	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	inhibitor	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	tepoxalin	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	suppresses	_	O	O	_	_	_	_	_
11	surface	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	adhesion	_	O	O	_	_	_	_	_
17	molecules	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	62	_	O	O	_	_	_	_	_
20	E	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	11	_	O	O	_	_	_	_	_
24	b	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	18	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	106	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_


1	Tepoxalin	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	dual	_	O	O	_	_	_	_	_
5	enzyme	_	O	O	_	_	_	_	_
6	inhibitor	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	cyclooxygenase	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	lipoxygenase	_	O	O	_	_	_	_	_
13	has	_	O	O	_	_	_	_	_
14	been	_	O	O	_	_	_	_	_
15	shown	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	inhibit	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Its	_	O	O	_	_	_	_	_
2	immunosuppressive	_	O	O	_	_	_	_	_
3	property	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	distinct	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	cyclosporin	_	O	O	_	_	_	_	_
8	because	_	O	O	_	_	_	_	_
9	only	_	O	O	_	_	_	_	_
10	tepoxalin	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	not	_	O	O	_	_	_	_	_
14	cyclosporin	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	suppresses	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	activation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	tepoxalin	_	O	O	_	_	_	_	_
6	selectively	_	O	O	_	_	_	_	_
7	inhibits	_	O	O	_	_	_	_	_
8	intercellular	_	O	O	_	_	_	_	_
9	adhesion	_	O	O	_	_	_	_	_
10	molecule	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	ICAM	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	54	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	MAC	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	11	_	O	O	_	_	_	_	_
28	b	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	18	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	dependent	_	O	O	_	_	_	_	_
34	adhesion	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	polymorphonuclear	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	activated	_	O	O	_	_	_	_	_
43	human	_	O	O	_	_	_	_	_
44	umbilical	_	O	O	_	_	_	_	_
45	vein	_	O	O	_	_	_	_	_
46	endothelial	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	mechanism	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	inhibition	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	related	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	surface	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	several	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	adhesion	_	O	O	_	_	_	_	_
15	molecules	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Flow	_	O	O	_	_	_	_	_
2	cytometry	_	O	O	_	_	_	_	_
3	analyses	_	O	O	_	_	_	_	_
4	on	_	O	O	_	_	_	_	_
5	cultured	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	treated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	tepoxalin	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	antisense	_	O	O	_	_	_	_	_
14	oligonucleotides	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	P	_	O	O	_	_	_	_	_
18	65	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	p	_	O	O	_	_	_	_	_
21	50	_	O	O	_	_	_	_	_
22	subunit	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	NF	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	kappa	_	O	O	_	_	_	_	_
27	B	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	then	_	O	O	_	_	_	_	_
31	stimulated	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	PMA	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	revealed	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	reduced	_	O	O	_	_	_	_	_
38	expression	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	CD	_	O	O	_	_	_	_	_
41	11	_	O	O	_	_	_	_	_
42	b	_	O	O	_	_	_	_	_
43	/	_	O	O	_	_	_	_	_
44	CD	_	O	O	_	_	_	_	_
45	18	_	O	O	_	_	_	_	_
46	on	_	O	O	_	_	_	_	_
47	monocytic	_	O	O	_	_	_	_	_
48	HL	_	O	O	_	_	_	_	_
49	60	_	O	O	_	_	_	_	_
50	cells	_	O	O	_	_	_	_	_
51	,	_	O	O	_	_	_	_	_
52	and	_	O	O	_	_	_	_	_
53	endothelial	_	O	O	_	_	_	_	_
54	adhesion	_	O	O	_	_	_	_	_
55	molecule	_	O	O	_	_	_	_	_
56	-	_	O	O	_	_	_	_	_
57	1	_	O	O	_	_	_	_	_
58	(	_	O	O	_	_	_	_	_
59	CD	_	O	O	_	_	_	_	_
60	62	_	O	O	_	_	_	_	_
61	E	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	and	_	O	O	_	_	_	_	_
64	vascular	_	O	O	_	_	_	_	_
65	adhesion	_	O	O	_	_	_	_	_
66	molecule	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	1	_	O	O	_	_	_	_	_
69	(	_	O	O	_	_	_	_	_
70	CD	_	O	O	_	_	_	_	_
71	106	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	on	_	O	O	_	_	_	_	_
74	human	_	O	O	_	_	_	_	_
75	umbilical	_	O	O	_	_	_	_	_
76	vein	_	O	O	_	_	_	_	_
77	endothelial	_	O	O	_	_	_	_	_
78	cells	_	O	O	_	_	_	_	_
79	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	adhesion	_	O	O	_	_	_	_	_
5	molecules	_	O	O	_	_	_	_	_
6	such	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	lymphocyte	_	O	O	_	_	_	_	_
9	function	_	O	O	_	_	_	_	_
10	associated	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	antigen	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	11	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	18	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	CD	_	O	O	_	_	_	_	_
25	54	_	O	O	_	_	_	_	_
26	were	_	O	O	_	_	_	_	_
27	unaffected	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Tepoxalin	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	inhibited	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	secretion	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	kappa	_	O	O	_	_	_	_	_
11	B	_	O	O	_	_	_	_	_
12	regulated	_	O	O	_	_	_	_	_
13	chemokine	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	8	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	known	_	O	O	_	_	_	_	_
21	inducer	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	CD	_	O	O	_	_	_	_	_
24	11	_	O	O	_	_	_	_	_
25	b	_	O	O	_	_	_	_	_
26	/	_	O	O	_	_	_	_	_
27	CD	_	O	O	_	_	_	_	_
28	18	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	suppression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	11	_	O	O	_	_	_	_	_
7	b	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	18	_	O	O	_	_	_	_	_
11	expression	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	tepoxalin	_	O	O	_	_	_	_	_
14	may	_	O	O	_	_	_	_	_
15	involve	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	inhibiting	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	surface	_	O	O	_	_	_	_	_
14	expression	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	several	_	O	O	_	_	_	_	_
17	adhesion	_	O	O	_	_	_	_	_
18	molecules	_	O	O	_	_	_	_	_
19	can	_	O	O	_	_	_	_	_
20	be	_	O	O	_	_	_	_	_
21	modulated	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	tepoxalin	_	O	O	_	_	_	_	_
25	may	_	O	O	_	_	_	_	_
26	be	_	O	O	_	_	_	_	_
27	useful	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	treating	_	O	O	_	_	_	_	_
30	selected	_	O	O	_	_	_	_	_
31	adhesion	_	O	O	_	_	_	_	_
32	mediated	_	O	O	_	_	_	_	_
33	events	_	O	O	_	_	_	_	_
34	such	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	leukocyte	_	O	O	_	_	_	_	_
37	migration	_	O	O	_	_	_	_	_
38	or	_	O	O	_	_	_	_	_
39	atherosclerotic	_	O	O	_	_	_	_	_
40	plaque	_	O	O	_	_	_	_	_
41	formation	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	conserved	_	O	O	_	_	_	_	_
3	motif	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	promoters	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	several	_	O	O	_	_	_	_	_
9	cytokines	_	O	O	_	_	_	_	_
10	expressed	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	Th	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	type	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	recently	_	O	O	_	_	_	_	_
4	found	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	novel	_	O	O	_	_	_	_	_
7	conserved	_	O	O	_	_	_	_	_
8	motif	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	promoters	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	several	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	expressed	_	O	O	_	_	_	_	_
19	cytokines	_	O	O	_	_	_	_	_
20	[	_	O	O	_	_	_	_	_
21	human	_	O	O	_	_	_	_	_
22	interleukin	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	5	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	13	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	human	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	mouse	_	O	O	_	_	_	_	_
38	granulocyte	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	macrophage	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	colony	_	O	O	_	_	_	_	_
43	stimulating	_	O	O	_	_	_	_	_
44	factor	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	GM	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	CSF	_	O	O	_	_	_	_	_
49	)]	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	contains	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	core	_	O	O	_	_	_	_	_
5	sequence	_	O	O	_	_	_	_	_
6	CTTGG	_	O	O	_	_	_	_	_
7	...	_	O	O	_	_	_	_	_

1	CCAAG	_	O	O	_	_	_	_	_
2	which	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	present	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	part	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	larger	_	O	O	_	_	_	_	_
9	palindromic	_	O	O	_	_	_	_	_
10	sequences	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	each	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	suggest	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	they	_	O	O	_	_	_	_	_
5	may	_	O	O	_	_	_	_	_
6	interact	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	new	_	O	O	_	_	_	_	_
10	family	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	trans	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	acting	_	O	O	_	_	_	_	_
15	factors	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	transfection	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	GM	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	CSF	_	O	O	_	_	_	_	_
10	element	_	O	O	_	_	_	_	_
11	has	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	strong	_	O	O	_	_	_	_	_
14	positive	_	O	O	_	_	_	_	_
15	effect	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	reporter	_	O	O	_	_	_	_	_
22	gene	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	human	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	line	_	O	O	_	_	_	_	_
29	Jurkat	_	O	O	_	_	_	_	_
30	J	_	O	O	_	_	_	_	_
31	6	_	O	O	_	_	_	_	_
32	upon	_	O	O	_	_	_	_	_
33	stimulation	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	mobility	_	O	O	_	_	_	_	_
4	shift	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	this	_	O	O	_	_	_	_	_
8	sequence	_	O	O	_	_	_	_	_
9	can	_	O	O	_	_	_	_	_
10	give	_	O	O	_	_	_	_	_
11	either	_	O	O	_	_	_	_	_
12	six	_	O	O	_	_	_	_	_
13	different	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	bands	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	competed	_	O	O	_	_	_	_	_
19	out	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	different	_	O	O	_	_	_	_	_
22	parts	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	sequence	_	O	O	_	_	_	_	_
26	or	_	O	O	_	_	_	_	_
27	one	_	O	O	_	_	_	_	_
28	specific	_	O	O	_	_	_	_	_
29	band	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	competed	_	O	O	_	_	_	_	_
33	out	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	each	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	inverted	_	O	O	_	_	_	_	_
39	repeats	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	depending	_	O	O	_	_	_	_	_
42	on	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	reconstitution	_	O	O	_	_	_	_	_
45	conditions	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	different	_	O	O	_	_	_	_	_
3	genes	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	core	_	O	O	_	_	_	_	_
7	sequences	_	O	O	_	_	_	_	_
8	are	_	O	O	_	_	_	_	_
9	separated	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	integer	_	O	O	_	_	_	_	_
12	numbers	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	helical	_	O	O	_	_	_	_	_
15	turns	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Considering	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	strong	_	O	O	_	_	_	_	_
4	positive	_	O	O	_	_	_	_	_
5	regulatory	_	O	O	_	_	_	_	_
6	effect	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	this	_	O	O	_	_	_	_	_
9	element	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	its	_	O	O	_	_	_	_	_
12	presence	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	several	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	expressed	_	O	O	_	_	_	_	_
20	cytokine	_	O	O	_	_	_	_	_
21	genes	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	it	_	O	O	_	_	_	_	_
24	may	_	O	O	_	_	_	_	_
25	be	_	O	O	_	_	_	_	_
26	crucial	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	coordinated	_	O	O	_	_	_	_	_
30	expression	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	these	_	O	O	_	_	_	_	_
33	cytokines	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	T	_	O	O	_	_	_	_	_
36	helper	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_


1	Cloning	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	cDNA	_	O	O	_	_	_	_	_
4	from	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	NK	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	which	_	O	O	_	_	_	_	_
11	codes	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	high	_	O	O	_	_	_	_	_
17	proline	_	O	O	_	_	_	_	_
18	content	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	cDNA	_	O	O	_	_	_	_	_
3	clone	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	isolated	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	natural	_	O	O	_	_	_	_	_
15	killer	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	NK	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	minus	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	subtractive	_	O	O	_	_	_	_	_
23	library	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	clone	_	O	O	_	_	_	_	_
7	coded	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	2061	_	O	O	_	_	_	_	_
13	bp	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	length	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	encodes	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	deduced	_	O	O	_	_	_	_	_
5	327	_	O	O	_	_	_	_	_
6	aa	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	calculated	_	O	O	_	_	_	_	_
11	molecular	_	O	O	_	_	_	_	_
12	mass	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	35	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	kDa	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Searching	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	DNA	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	sequences	_	O	O	_	_	_	_	_
11	against	_	O	O	_	_	_	_	_
12	various	_	O	O	_	_	_	_	_
13	databases	_	O	O	_	_	_	_	_
14	revealed	_	O	O	_	_	_	_	_
15	no	_	O	O	_	_	_	_	_
16	high	_	O	O	_	_	_	_	_
17	homology	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	other	_	O	O	_	_	_	_	_
20	sequences	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	B	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	has	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	unusually	_	O	O	_	_	_	_	_
10	high	_	O	O	_	_	_	_	_
11	proline	_	O	O	_	_	_	_	_
12	content	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	13	_	O	O	_	_	_	_	_
15	%	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	contains	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	putative	_	O	O	_	_	_	_	_
21	nuclear	_	O	O	_	_	_	_	_
22	targeting	_	O	O	_	_	_	_	_
23	sequence	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	has	_	O	O	_	_	_	_	_
27	several	_	O	O	_	_	_	_	_
28	SPXX	_	O	O	_	_	_	_	_
29	motifs	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	are	_	O	O	_	_	_	_	_
32	frequently	_	O	O	_	_	_	_	_
33	found	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	gene	_	O	O	_	_	_	_	_
36	regulatory	_	O	O	_	_	_	_	_
37	proteins	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	One	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	stretches	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	prolines	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	closely	_	O	O	_	_	_	_	_
13	resembles	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	ligand	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	SH	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	domains	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Northern	_	O	O	_	_	_	_	_
2	hybridization	_	O	O	_	_	_	_	_
3	data	_	O	O	_	_	_	_	_
4	showed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	not	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	lymphoid	_	O	O	_	_	_	_	_
14	specific	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	is	_	O	O	_	_	_	_	_
18	expressed	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	hepatoma	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	line	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	also	_	O	O	_	_	_	_	_
26	weakly	_	O	O	_	_	_	_	_
27	transcribed	_	O	O	_	_	_	_	_
28	or	_	O	O	_	_	_	_	_
29	absent	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	a	_	O	O	_	_	_	_	_
32	variety	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	other	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	polyclonal	_	O	O	_	_	_	_	_
3	antiserum	_	O	O	_	_	_	_	_
4	raised	_	O	O	_	_	_	_	_
5	against	_	O	O	_	_	_	_	_
6	recombinant	_	O	O	_	_	_	_	_
7	B	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	recognizes	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	32	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	34	_	O	O	_	_	_	_	_
16	kDa	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	lymphocytes	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Does	_	O	O	_	_	_	_	_
2	activation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	TAL	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	gene	_	O	O	_	_	_	_	_
8	occur	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	majority	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	acute	_	O	O	_	_	_	_	_
19	lymphoblastic	_	O	O	_	_	_	_	_
20	leukemia	_	O	O	_	_	_	_	_
21	?	_	O	O	_	_	_	_	_
22	A	_	O	O	_	_	_	_	_
23	pediatric	_	O	O	_	_	_	_	_
24	oncology	_	O	O	_	_	_	_	_
25	group	_	O	O	_	_	_	_	_
26	study	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Almost	_	O	O	_	_	_	_	_
2	25	_	O	O	_	_	_	_	_
3	%	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	patients	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	acute	_	O	O	_	_	_	_	_
11	lymphoblastic	_	O	O	_	_	_	_	_
12	leukemia	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	ALL	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	have	_	O	O	_	_	_	_	_
19	tumor	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	specific	_	O	O	_	_	_	_	_
22	rearrangements	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	TAL	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	TAL	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	has	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	observed	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	normal	_	O	O	_	_	_	_	_
11	lymphocytes	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	TAL	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	products	_	O	O	_	_	_	_	_
17	are	_	O	O	_	_	_	_	_
18	readily	_	O	O	_	_	_	_	_
19	detected	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	leukemic	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	harbor	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	rearranged	_	O	O	_	_	_	_	_
27	TAL	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	allele	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Hence	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	has	_	O	O	_	_	_	_	_
5	been	_	O	O	_	_	_	_	_
6	proposed	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	ectopic	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	TAL	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	promotes	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	development	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	ALL	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	show	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	TAL	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	expressed	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	leukemic	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	most	_	O	O	_	_	_	_	_
18	patients	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	ALL	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	including	_	O	O	_	_	_	_	_
25	many	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	do	_	O	O	_	_	_	_	_
28	not	_	O	O	_	_	_	_	_
29	display	_	O	O	_	_	_	_	_
30	an	_	O	O	_	_	_	_	_
31	apparent	_	O	O	_	_	_	_	_
32	TAL	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	gene	_	O	O	_	_	_	_	_
35	alteration	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	polymorphic	_	O	O	_	_	_	_	_
3	dinucleotide	_	O	O	_	_	_	_	_
4	repeat	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	transcribed	_	O	O	_	_	_	_	_
8	sequences	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	TAL	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	used	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	determine	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	allele	_	O	O	_	_	_	_	_
18	specificity	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	TAL	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	transcription	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	primary	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	ALL	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Monoallelic	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	TAL	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	observed	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	leukemic	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	all	_	O	O	_	_	_	_	_
14	patients	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	8	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	bearing	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	TAL	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	rearrangement	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	leukemic	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	patients	_	O	O	_	_	_	_	_
7	without	_	O	O	_	_	_	_	_
8	detectable	_	O	O	_	_	_	_	_
9	TAL	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	rearrangements	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	TAL	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	transcription	_	O	O	_	_	_	_	_
16	occurred	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	either	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	monoallelic	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	7	_	O	O	_	_	_	_	_
25	patients	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	or	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	biallelic	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	4	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	7	_	O	O	_	_	_	_	_
34	patients	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	fashion	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	TAL	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	activation	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	these	_	O	O	_	_	_	_	_
8	patients	_	O	O	_	_	_	_	_
9	may	_	O	O	_	_	_	_	_
10	result	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	subtle	_	O	O	_	_	_	_	_
13	alterations	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	cis	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	acting	_	O	O	_	_	_	_	_
18	regulatory	_	O	O	_	_	_	_	_
19	sequences	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	affecting	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	single	_	O	O	_	_	_	_	_
26	TAL	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	allele	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	changes	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	trans	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	acting	_	O	O	_	_	_	_	_
36	factors	_	O	O	_	_	_	_	_
37	that	_	O	O	_	_	_	_	_
38	control	_	O	O	_	_	_	_	_
39	TAL	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	transcription	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	affecting	_	O	O	_	_	_	_	_
44	expression	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	both	_	O	O	_	_	_	_	_
47	TAL	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	alleles	_	O	O	_	_	_	_	_
50	)	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Overexpression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	DR	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	nm	_	O	O	_	_	_	_	_
6	23	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	encoded	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	member	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	nm	_	O	O	_	_	_	_	_
17	23	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	family	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	inhibits	_	O	O	_	_	_	_	_
22	granulocyte	_	O	O	_	_	_	_	_
23	differentiation	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	induces	_	O	O	_	_	_	_	_
26	apoptosis	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	32	_	O	O	_	_	_	_	_
29	Dc	_	O	O	_	_	_	_	_
30	13	_	O	O	_	_	_	_	_
31	myeloid	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Chronic	_	O	O	_	_	_	_	_
2	myelogenous	_	O	O	_	_	_	_	_
3	leukemia	_	O	O	_	_	_	_	_
4	evolves	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	two	_	O	O	_	_	_	_	_
7	clinically	_	O	O	_	_	_	_	_
8	distinct	_	O	O	_	_	_	_	_
9	stages	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	chronic	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	blast	_	O	O	_	_	_	_	_
16	crisis	_	O	O	_	_	_	_	_
17	phase	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	molecular	_	O	O	_	_	_	_	_
3	changes	_	O	O	_	_	_	_	_
4	associated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	chronic	_	O	O	_	_	_	_	_
7	phase	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	blast	_	O	O	_	_	_	_	_
10	crisis	_	O	O	_	_	_	_	_
11	transition	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	largely	_	O	O	_	_	_	_	_
14	unknown	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	identified	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	cDNA	_	O	O	_	_	_	_	_
6	clone	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	DR	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	nm	_	O	O	_	_	_	_	_
11	23	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	differentially	_	O	O	_	_	_	_	_
14	expressed	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	blast	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	crisis	_	O	O	_	_	_	_	_
20	cDNA	_	O	O	_	_	_	_	_
21	library	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	which	_	O	O	_	_	_	_	_
24	has	_	O	O	_	_	_	_	_
25	approximately	_	O	O	_	_	_	_	_
26	70	_	O	O	_	_	_	_	_
27	%	_	O	O	_	_	_	_	_
28	sequence	_	O	O	_	_	_	_	_
29	similarity	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	putative	_	O	O	_	_	_	_	_
33	metastatic	_	O	O	_	_	_	_	_
34	suppressor	_	O	O	_	_	_	_	_
35	genes	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	nm	_	O	O	_	_	_	_	_
38	23	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	H	_	O	O	_	_	_	_	_
41	1	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	nm	_	O	O	_	_	_	_	_
44	23	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	H	_	O	O	_	_	_	_	_
47	2	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	deduced	_	O	O	_	_	_	_	_
3	amino	_	O	O	_	_	_	_	_
4	acid	_	O	O	_	_	_	_	_
5	sequence	_	O	O	_	_	_	_	_
6	similarity	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	proteins	_	O	O	_	_	_	_	_
10	encoded	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	these	_	O	O	_	_	_	_	_
13	two	_	O	O	_	_	_	_	_
14	latter	_	O	O	_	_	_	_	_
15	genes	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	approximately	_	O	O	_	_	_	_	_
18	65	_	O	O	_	_	_	_	_
19	%	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	includes	_	O	O	_	_	_	_	_
22	domains	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	amino	_	O	O	_	_	_	_	_
25	acid	_	O	O	_	_	_	_	_
26	residues	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	leucine	_	O	O	_	_	_	_	_
30	zipper	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	like	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	RGD	_	O	O	_	_	_	_	_
36	domain	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	a	_	O	O	_	_	_	_	_
39	serine	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	a	_	O	O	_	_	_	_	_
42	histidine	_	O	O	_	_	_	_	_
43	residue	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	the	_	O	O	_	_	_	_	_
46	NH	_	O	O	_	_	_	_	_
47	2	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	and	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	COOH	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	terminal	_	O	O	_	_	_	_	_
55	portion	_	O	O	_	_	_	_	_
56	of	_	O	O	_	_	_	_	_
57	the	_	O	O	_	_	_	_	_
58	protein	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	respectively	_	O	O	_	_	_	_	_
61	)	_	O	O	_	_	_	_	_
62	postulated	_	O	O	_	_	_	_	_
63	to	_	O	O	_	_	_	_	_
64	be	_	O	O	_	_	_	_	_
65	important	_	O	O	_	_	_	_	_
66	for	_	O	O	_	_	_	_	_
67	nm	_	O	O	_	_	_	_	_
68	23	_	O	O	_	_	_	_	_
69	function	_	O	O	_	_	_	_	_
70	.	_	O	O	_	_	_	_	_

1	DR	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	nm	_	O	O	_	_	_	_	_
4	23	_	O	O	_	_	_	_	_
5	mRNA	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	preferentially	_	O	O	_	_	_	_	_
8	expressed	_	O	O	_	_	_	_	_
9	at	_	O	O	_	_	_	_	_
10	early	_	O	O	_	_	_	_	_
11	stages	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	myeloid	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	highly	_	O	O	_	_	_	_	_
17	purified	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	34	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Its	_	O	O	_	_	_	_	_
2	constitutive	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	myeloid	_	O	O	_	_	_	_	_
7	precursor	_	O	O	_	_	_	_	_
8	32	_	O	O	_	_	_	_	_
9	Dc	_	O	O	_	_	_	_	_
10	13	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	line	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	growth	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	factor	_	O	O	_	_	_	_	_
19	dependent	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	proliferation	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	differentiation	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	results	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	inhibition	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	granulocytic	_	O	O	_	_	_	_	_
31	differentiation	_	O	O	_	_	_	_	_
32	induced	_	O	O	_	_	_	_	_
33	by	_	O	O	_	_	_	_	_
34	granulocyte	_	O	O	_	_	_	_	_
35	colony	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	stimulating	_	O	O	_	_	_	_	_
38	factor	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	causes	_	O	O	_	_	_	_	_
41	apoptotic	_	O	O	_	_	_	_	_
42	cell	_	O	O	_	_	_	_	_
43	death	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	consistent	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	DR	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	nm	_	O	O	_	_	_	_	_
12	23	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	normal	_	O	O	_	_	_	_	_
15	hematopoiesis	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	raise	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	possibility	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	its	_	O	O	_	_	_	_	_
22	overexpression	_	O	O	_	_	_	_	_
23	contributes	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	differentiation	_	O	O	_	_	_	_	_
26	arrest	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	feature	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	blastic	_	O	O	_	_	_	_	_
32	transformation	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	chronic	_	O	O	_	_	_	_	_
35	myelogenous	_	O	O	_	_	_	_	_
36	leukemia	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Mutual	_	O	O	_	_	_	_	_
2	regulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	transcriptional	_	O	O	_	_	_	_	_
6	activator	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	its	_	O	O	_	_	_	_	_
13	inhibitor	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	kappa	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	alpha	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	NK	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	kappa	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	factor	_	O	O	_	_	_	_	_
8	complex	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	sequestered	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	cytoplasm	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	inhibitory	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	I	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	alpha	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	MAD	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Various	_	O	O	_	_	_	_	_
2	cellular	_	O	O	_	_	_	_	_
3	stimuli	_	O	O	_	_	_	_	_
4	relieve	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	inhibition	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	mechanisms	_	O	O	_	_	_	_	_
9	largely	_	O	O	_	_	_	_	_
10	unknown	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	leading	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	NF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	kappa	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	nuclear	_	O	O	_	_	_	_	_
19	localization	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	transactivation	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	its	_	O	O	_	_	_	_	_
24	target	_	O	O	_	_	_	_	_
25	genes	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	here	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	human	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	lymphocytes	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	monocytes	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	different	_	O	O	_	_	_	_	_
13	stimuli	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	including	_	O	O	_	_	_	_	_
16	tumor	_	O	O	_	_	_	_	_
17	necrosis	_	O	O	_	_	_	_	_
18	factor	_	O	O	_	_	_	_	_
19	alpha	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	phorbol	_	O	O	_	_	_	_	_
22	12	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	myristate	_	O	O	_	_	_	_	_
25	13	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	acetate	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	cause	_	O	O	_	_	_	_	_
30	rapid	_	O	O	_	_	_	_	_
31	degradation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	I	_	O	O	_	_	_	_	_
34	kappa	_	O	O	_	_	_	_	_
35	B	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	alpha	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	with	_	O	O	_	_	_	_	_
40	concomitant	_	O	O	_	_	_	_	_
41	activation	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	NF	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	kappa	_	O	O	_	_	_	_	_
46	B	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	followed	_	O	O	_	_	_	_	_
49	by	_	O	O	_	_	_	_	_
50	a	_	O	O	_	_	_	_	_
51	dramatic	_	O	O	_	_	_	_	_
52	increase	_	O	O	_	_	_	_	_
53	in	_	O	O	_	_	_	_	_
54	I	_	O	O	_	_	_	_	_
55	kappa	_	O	O	_	_	_	_	_
56	B	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	alpha	_	O	O	_	_	_	_	_
59	mRNA	_	O	O	_	_	_	_	_
60	and	_	O	O	_	_	_	_	_
61	protein	_	O	O	_	_	_	_	_
62	synthesis	_	O	O	_	_	_	_	_
63	.	_	O	O	_	_	_	_	_

1	Transfection	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	reveal	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	kappa	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	mRNA	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	encoded	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	potently	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	NF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	kappa	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	homodimers	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	65	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	c	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	Rel	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	propose	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	model	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappa	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	I	_	O	O	_	_	_	_	_
13	kappa	_	O	O	_	_	_	_	_
14	B	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	mutually	_	O	O	_	_	_	_	_
18	regulate	_	O	O	_	_	_	_	_
19	each	_	O	O	_	_	_	_	_
20	other	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	cycle	_	O	O	_	_	_	_	_
24	:	_	O	O	_	_	_	_	_
25	saturating	_	O	O	_	_	_	_	_
26	amounts	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	inhibitory	_	O	O	_	_	_	_	_
30	I	_	O	O	_	_	_	_	_
31	kappa	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	alpha	_	O	O	_	_	_	_	_
35	protein	_	O	O	_	_	_	_	_
36	are	_	O	O	_	_	_	_	_
37	destroyed	_	O	O	_	_	_	_	_
38	upon	_	O	O	_	_	_	_	_
39	stimulation	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	allowing	_	O	O	_	_	_	_	_
42	rapid	_	O	O	_	_	_	_	_
43	activation	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	NF	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	kappa	_	O	O	_	_	_	_	_
48	B	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Subsequently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	I	_	O	O	_	_	_	_	_
4	kappa	_	O	O	_	_	_	_	_
5	B	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	alpha	_	O	O	_	_	_	_	_
8	mRNA	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	quickly	_	O	O	_	_	_	_	_
14	induced	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	activated	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kappa	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	resurgence	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	I	_	O	O	_	_	_	_	_
5	kappa	_	O	O	_	_	_	_	_
6	B	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	alpha	_	O	O	_	_	_	_	_
9	protein	_	O	O	_	_	_	_	_
10	acts	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	restore	_	O	O	_	_	_	_	_
13	an	_	O	O	_	_	_	_	_
14	equilibrium	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	NF	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kappa	_	O	O	_	_	_	_	_
20	B	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	again	_	O	O	_	_	_	_	_
23	inhibited	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	induces	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	tyk	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	Jak	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	differential	_	O	O	_	_	_	_	_
17	assembly	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	STAT	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	complexes	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	human	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	monocytes	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	affects	_	O	O	_	_	_	_	_
5	monocytes	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	driving	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	progression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	immune	_	O	O	_	_	_	_	_
15	responsiveness	_	O	O	_	_	_	_	_
16	such	_	O	O	_	_	_	_	_
17	that	_	O	O	_	_	_	_	_
18	Th	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	lymphocyte	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	mediated	_	O	O	_	_	_	_	_
23	effects	_	O	O	_	_	_	_	_
24	predominate	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	show	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	monocytes	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	10	_	O	O	_	_	_	_	_
16	stimulates	_	O	O	_	_	_	_	_
17	tyrosine	_	O	O	_	_	_	_	_
18	phosphorylation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	signal	_	O	O	_	_	_	_	_
22	transducers	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	activators	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	transcription	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	STAT	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	alpha	_	O	O	_	_	_	_	_
31	and	_	O	O	_	_	_	_	_
32	STAT	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	a	_	O	O	_	_	_	_	_
37	differential	_	O	O	_	_	_	_	_
38	manner	_	O	O	_	_	_	_	_
39	such	_	O	O	_	_	_	_	_
40	that	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	relative	_	O	O	_	_	_	_	_
43	formation	_	O	O	_	_	_	_	_
44	of	_	O	O	_	_	_	_	_
45	homo	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	heterodimers	_	O	O	_	_	_	_	_
49	varies	_	O	O	_	_	_	_	_
50	between	_	O	O	_	_	_	_	_
51	the	_	O	O	_	_	_	_	_
52	two	_	O	O	_	_	_	_	_
53	cell	_	O	O	_	_	_	_	_
54	types	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	monocytes	_	O	O	_	_	_	_	_
4	express	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	novel	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	stimulated	_	O	O	_	_	_	_	_
12	STAT	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	M	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	r	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	70	_	O	O	_	_	_	_	_
22	kDa	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	is	_	O	O	_	_	_	_	_
25	recognized	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	STAT	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	Ab	_	O	O	_	_	_	_	_
33	but	_	O	O	_	_	_	_	_
34	is	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	observed	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	T	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	T	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	monocytes	_	O	O	_	_	_	_	_
11	results	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	ligand	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	tyrosine	_	O	O	_	_	_	_	_
18	phosphorylation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	tyk	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	Jak	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	but	_	O	O	_	_	_	_	_
27	not	_	O	O	_	_	_	_	_
28	Jak	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	or	_	O	O	_	_	_	_	_
31	Jak	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Selective	_	O	O	_	_	_	_	_
2	modulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	immune	_	O	O	_	_	_	_	_
5	responsiveness	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	such	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	monocytes	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	may	_	O	O	_	_	_	_	_
19	result	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	part	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	differential	_	O	O	_	_	_	_	_
25	activation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	STAT	_	O	O	_	_	_	_	_
28	protein	_	O	O	_	_	_	_	_
29	pairs	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	properties	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	heat	_	O	O	_	_	_	_	_
9	shock	_	O	O	_	_	_	_	_
10	factors	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	HSF	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	HSF	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	avian	_	O	O	_	_	_	_	_
23	erythroblast	_	O	O	_	_	_	_	_
24	cell	_	O	O	_	_	_	_	_
25	line	_	O	O	_	_	_	_	_
26	HD	_	O	O	_	_	_	_	_
27	6	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	Avian	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	express	_	O	O	_	_	_	_	_
4	three	_	O	O	_	_	_	_	_
5	heat	_	O	O	_	_	_	_	_
6	shock	_	O	O	_	_	_	_	_
7	transcription	_	O	O	_	_	_	_	_
8	factor	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	HSF	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	genes	_	O	O	_	_	_	_	_
13	corresponding	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	novel	_	O	O	_	_	_	_	_
17	factor	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	HSF	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	homologs	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	mouse	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	human	_	O	O	_	_	_	_	_
28	HSF	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	HSF	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Analysis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	biochemical	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	biological	_	O	O	_	_	_	_	_
8	properties	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	these	_	O	O	_	_	_	_	_
11	HSFs	_	O	O	_	_	_	_	_
12	reveals	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	HSF	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	has	_	O	O	_	_	_	_	_
17	properties	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	common	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	HSF	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	HSF	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	yet	_	O	O	_	_	_	_	_
29	has	_	O	O	_	_	_	_	_
30	features	_	O	O	_	_	_	_	_
31	which	_	O	O	_	_	_	_	_
32	are	_	O	O	_	_	_	_	_
33	distinct	_	O	O	_	_	_	_	_
34	from	_	O	O	_	_	_	_	_
35	both	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	HSF	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	constitutively	_	O	O	_	_	_	_	_
5	expressed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	erythroblast	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	line	_	O	O	_	_	_	_	_
11	HD	_	O	O	_	_	_	_	_
12	6	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	lymphoblast	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	line	_	O	O	_	_	_	_	_
18	MSB	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	embryo	_	O	O	_	_	_	_	_
22	fibroblasts	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	yet	_	O	O	_	_	_	_	_
26	its	_	O	O	_	_	_	_	_
27	DNA	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	activity	_	O	O	_	_	_	_	_
31	is	_	O	O	_	_	_	_	_
32	induced	_	O	O	_	_	_	_	_
33	only	_	O	O	_	_	_	_	_
34	upon	_	O	O	_	_	_	_	_
35	exposure	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	HD	_	O	O	_	_	_	_	_
38	6	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	to	_	O	O	_	_	_	_	_
41	heat	_	O	O	_	_	_	_	_
42	shock	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Acquisition	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	HSF	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	HD	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	accompanied	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	oligomerization	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	non	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	DNA	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	binding	_	O	O	_	_	_	_	_
24	dimer	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	DNA	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	trimer	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	whereas	_	O	O	_	_	_	_	_
33	the	_	O	O	_	_	_	_	_
34	effect	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	heat	_	O	O	_	_	_	_	_
37	shock	_	O	O	_	_	_	_	_
38	on	_	O	O	_	_	_	_	_
39	HSF	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	is	_	O	O	_	_	_	_	_
42	oligomerization	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	an	_	O	O	_	_	_	_	_
45	inert	_	O	O	_	_	_	_	_
46	monomer	_	O	O	_	_	_	_	_
47	to	_	O	O	_	_	_	_	_
48	a	_	O	O	_	_	_	_	_
49	DNA	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	binding	_	O	O	_	_	_	_	_
52	trimer	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	HSF	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	delayed	_	O	O	_	_	_	_	_
11	compared	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	HSF	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	occurs	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	HSF	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	heat	_	O	O	_	_	_	_	_
8	shock	_	O	O	_	_	_	_	_
9	leads	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	translocation	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	HSF	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	to	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	nucleus	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	HSF	_	O	O	_	_	_	_	_
2	exhibits	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	properties	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	transcriptional	_	O	O	_	_	_	_	_
8	activator	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	judged	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	stimulatory	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	transiently	_	O	O	_	_	_	_	_
18	overexpressed	_	O	O	_	_	_	_	_
19	HSF	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	measured	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	using	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	heat	_	O	O	_	_	_	_	_
26	shock	_	O	O	_	_	_	_	_
27	element	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	containing	_	O	O	_	_	_	_	_
30	reporter	_	O	O	_	_	_	_	_
31	construct	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	as	_	O	O	_	_	_	_	_
34	independently	_	O	O	_	_	_	_	_
35	assayed	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	activity	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	chimeric	_	O	O	_	_	_	_	_
42	GAL	_	O	O	_	_	_	_	_
43	4	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	HSF	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	protein	_	O	O	_	_	_	_	_
48	on	_	O	O	_	_	_	_	_
49	a	_	O	O	_	_	_	_	_
50	GAL	_	O	O	_	_	_	_	_
51	4	_	O	O	_	_	_	_	_
52	reporter	_	O	O	_	_	_	_	_
53	construct	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	reveal	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	HSF	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	negatively	_	O	O	_	_	_	_	_
9	regulated	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	avian	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	acquires	_	O	O	_	_	_	_	_
15	DNA	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	activity	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	certain	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	upon	_	O	O	_	_	_	_	_
23	heat	_	O	O	_	_	_	_	_
24	shock	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Two	_	O	O	_	_	_	_	_
2	glucocorticoid	_	O	O	_	_	_	_	_
3	binding	_	O	O	_	_	_	_	_
4	sites	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_


1	Glucocorticoids	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	known	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	have	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	lytic	_	O	O	_	_	_	_	_
8	effect	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	leukemic	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	via	_	O	O	_	_	_	_	_
13	interactions	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	glucocorticoid	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	GR	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Cortisol	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	various	_	O	O	_	_	_	_	_
4	synthetic	_	O	O	_	_	_	_	_
5	glucocorticoids	_	O	O	_	_	_	_	_
6	bind	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	GR	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	one	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	site	_	O	O	_	_	_	_	_
14	kinetics	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Cortivazol	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	CVZ	_	O	O	_	_	_	_	_
4	)	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	unique	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	high	_	O	O	_	_	_	_	_
10	potency	_	O	O	_	_	_	_	_
11	synthetic	_	O	O	_	_	_	_	_
12	glucocorticoid	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	has	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	phenylpyrazol	_	O	O	_	_	_	_	_
18	fused	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	ring	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	steroid	_	O	O	_	_	_	_	_
27	nucleus	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	displays	_	O	O	_	_	_	_	_
30	binding	_	O	O	_	_	_	_	_
31	consistent	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	two	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	more	_	O	O	_	_	_	_	_
36	sites	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	cytosol	_	O	O	_	_	_	_	_
40	from	_	O	O	_	_	_	_	_
41	CEM	_	O	O	_	_	_	_	_
42	C	_	O	O	_	_	_	_	_
43	7	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	a	_	O	O	_	_	_	_	_
47	human	_	O	O	_	_	_	_	_
48	acute	_	O	O	_	_	_	_	_
49	lymphoblastic	_	O	O	_	_	_	_	_
50	T	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	cell	_	O	O	_	_	_	_	_
53	line	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	has	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	lower	_	O	O	_	_	_	_	_
9	affinity	_	O	O	_	_	_	_	_
10	class	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	sites	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	similar	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	affinity	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	site	_	O	O	_	_	_	_	_
19	molarity	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	those	_	O	O	_	_	_	_	_
22	recognized	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	dexamethasone	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	higher	_	O	O	_	_	_	_	_
3	affinity	_	O	O	_	_	_	_	_
4	sites	_	O	O	_	_	_	_	_
5	bind	_	O	O	_	_	_	_	_
6	CVZ	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	20	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	50	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	fold	_	O	O	_	_	_	_	_
14	greater	_	O	O	_	_	_	_	_
15	affinity	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	consistent	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	CVZ	_	O	O	_	_	_	_	_
20	'	_	O	O	_	_	_	_	_
21	s	_	O	O	_	_	_	_	_
22	enhanced	_	O	O	_	_	_	_	_
23	biological	_	O	O	_	_	_	_	_
24	effects	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	mutant	_	O	O	_	_	_	_	_
3	leukemic	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	resistant	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	lytic	_	O	O	_	_	_	_	_
9	effects	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	dexamethasone	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	CVZ	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	lyses	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	recognizes	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	single	_	O	O	_	_	_	_	_
22	class	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	sites	_	O	O	_	_	_	_	_
25	similar	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	high	_	O	O	_	_	_	_	_
29	affinity	_	O	O	_	_	_	_	_
30	site	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	CEM	_	O	O	_	_	_	_	_
33	C	_	O	O	_	_	_	_	_
34	7	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	carried	_	O	O	_	_	_	_	_
4	out	_	O	O	_	_	_	_	_
5	experiments	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	define	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	nature	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	higher	_	O	O	_	_	_	_	_
13	affinity	_	O	O	_	_	_	_	_
14	CVZ	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	site	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	now	_	O	O	_	_	_	_	_
3	show	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	:	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	CVZ	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	more	_	O	O	_	_	_	_	_
11	than	_	O	O	_	_	_	_	_
12	one	_	O	O	_	_	_	_	_
13	binding	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	second	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	independent	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	cell	_	O	O	_	_	_	_	_
24	line	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	IM	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	9	_	O	O	_	_	_	_	_
29	;	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	antiglucocorticoid	_	O	O	_	_	_	_	_
34	RU	_	O	O	_	_	_	_	_
35	38486	_	O	O	_	_	_	_	_
36	is	_	O	O	_	_	_	_	_
37	able	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	block	_	O	O	_	_	_	_	_
40	both	_	O	O	_	_	_	_	_
41	CVZ	_	O	O	_	_	_	_	_
42	'	_	O	O	_	_	_	_	_
43	s	_	O	O	_	_	_	_	_
44	higher	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	lower	_	O	O	_	_	_	_	_
47	affinity	_	O	O	_	_	_	_	_
48	sites	_	O	O	_	_	_	_	_
49	;	_	O	O	_	_	_	_	_
50	3	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	all	_	O	O	_	_	_	_	_
53	of	_	O	O	_	_	_	_	_
54	CVZ	_	O	O	_	_	_	_	_
55	'	_	O	O	_	_	_	_	_
56	s	_	O	O	_	_	_	_	_
57	binding	_	O	O	_	_	_	_	_
58	sites	_	O	O	_	_	_	_	_
59	are	_	O	O	_	_	_	_	_
60	on	_	O	O	_	_	_	_	_
61	a	_	O	O	_	_	_	_	_
62	protein	_	O	O	_	_	_	_	_
63	immunologically	_	O	O	_	_	_	_	_
64	indistinguishable	_	O	O	_	_	_	_	_
65	from	_	O	O	_	_	_	_	_
66	the	_	O	O	_	_	_	_	_
67	human	_	O	O	_	_	_	_	_
68	GR	_	O	O	_	_	_	_	_
69	;	_	O	O	_	_	_	_	_
70	and	_	O	O	_	_	_	_	_
71	4	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	freshly	_	O	O	_	_	_	_	_
74	isolated	_	O	O	_	_	_	_	_
75	clones	_	O	O	_	_	_	_	_
76	of	_	O	O	_	_	_	_	_
77	CVZ	_	O	O	_	_	_	_	_
78	-	_	O	O	_	_	_	_	_
79	resistant	_	O	O	_	_	_	_	_
80	cells	_	O	O	_	_	_	_	_
81	have	_	O	O	_	_	_	_	_
82	lost	_	O	O	_	_	_	_	_
83	all	_	O	O	_	_	_	_	_
84	binding	_	O	O	_	_	_	_	_
85	sites	_	O	O	_	_	_	_	_
86	for	_	O	O	_	_	_	_	_
87	CVZ	_	O	O	_	_	_	_	_
88	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	CVZ	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	recognizing	_	O	O	_	_	_	_	_
8	two	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	binding	_	O	O	_	_	_	_	_
11	sites	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	human	_	O	O	_	_	_	_	_
15	GR	_	O	O	_	_	_	_	_
16	or	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	very	_	O	O	_	_	_	_	_
20	similar	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	it	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Clonality	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	isolated	_	O	O	_	_	_	_	_
4	eosinophils	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	hypereosinophilic	_	O	O	_	_	_	_	_
8	syndrome	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	idiopathic	_	O	O	_	_	_	_	_
3	hypereosinophilic	_	O	O	_	_	_	_	_
4	syndrome	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	IHES	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	rare	_	O	O	_	_	_	_	_
11	disorder	_	O	O	_	_	_	_	_
12	characterized	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	unexplained	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	persistent	_	O	O	_	_	_	_	_
17	eosinophilia	_	O	O	_	_	_	_	_
18	associated	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	multiple	_	O	O	_	_	_	_	_
21	organ	_	O	O	_	_	_	_	_
22	dysfunction	_	O	O	_	_	_	_	_
23	due	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	eosinophilic	_	O	O	_	_	_	_	_
26	tissue	_	O	O	_	_	_	_	_
27	infiltration	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	absence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	karyotypic	_	O	O	_	_	_	_	_
6	abnormalities	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	there	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	no	_	O	O	_	_	_	_	_
11	specific	_	O	O	_	_	_	_	_
12	test	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	detect	_	O	O	_	_	_	_	_
15	clonal	_	O	O	_	_	_	_	_
16	eosinophilia	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	IHES	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Analysis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	X	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	chromosome	_	O	O	_	_	_	_	_
6	inactivation	_	O	O	_	_	_	_	_
7	patterns	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	used	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	determine	_	O	O	_	_	_	_	_
13	whether	_	O	O	_	_	_	_	_
14	proliferative	_	O	O	_	_	_	_	_
15	disorders	_	O	O	_	_	_	_	_
16	are	_	O	O	_	_	_	_	_
17	clonal	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	origin	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Methylation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	HpaII	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	Hha	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	sites	_	O	O	_	_	_	_	_
8	near	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	polymorphic	_	O	O	_	_	_	_	_
11	trinucleotide	_	O	O	_	_	_	_	_
12	repeat	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	androgen	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	HUMARA	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	has	_	O	O	_	_	_	_	_
23	been	_	O	O	_	_	_	_	_
24	shown	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	correlate	_	O	O	_	_	_	_	_
27	with	_	O	O	_	_	_	_	_
28	X	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	inactivation	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	used	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	polymerase	_	O	O	_	_	_	_	_
10	chain	_	O	O	_	_	_	_	_
11	reaction	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	PCR	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	nested	_	O	O	_	_	_	_	_
17	primers	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	analyze	_	O	O	_	_	_	_	_
20	X	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	inactivation	_	O	O	_	_	_	_	_
23	patterns	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	HUMARA	_	O	O	_	_	_	_	_
27	loci	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	purified	_	O	O	_	_	_	_	_
30	eosinophils	_	O	O	_	_	_	_	_
31	from	_	O	O	_	_	_	_	_
32	female	_	O	O	_	_	_	_	_
33	patients	_	O	O	_	_	_	_	_
34	with	_	O	O	_	_	_	_	_
35	eosinophilia	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Peripheral	_	O	O	_	_	_	_	_
2	blood	_	O	O	_	_	_	_	_
3	eosinophils	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	isolated	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	their	_	O	O	_	_	_	_	_
8	autofluoresence	_	O	O	_	_	_	_	_
9	using	_	O	O	_	_	_	_	_
10	flow	_	O	O	_	_	_	_	_
11	cytometric	_	O	O	_	_	_	_	_
12	sorting	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Eosinophils	_	O	O	_	_	_	_	_
2	purified	_	O	O	_	_	_	_	_
3	from	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	female	_	O	O	_	_	_	_	_
6	patient	_	O	O	_	_	_	_	_
7	presenting	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	IHES	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	found	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	show	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	clonal	_	O	O	_	_	_	_	_
16	pattern	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	X	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	inactivation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Eosinophil	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	depleted	_	O	O	_	_	_	_	_
4	leukocytes	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	patient	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	polyclonal	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	HUMARA	_	O	O	_	_	_	_	_
12	analysis	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	thus	_	O	O	_	_	_	_	_
15	excluding	_	O	O	_	_	_	_	_
16	skewedness	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	random	_	O	O	_	_	_	_	_
19	X	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	inactivation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	corticosteroid	_	O	O	_	_	_	_	_
3	suppression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	her	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	eosinophilia	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	clonal	_	O	O	_	_	_	_	_
11	population	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	eosinophils	_	O	O	_	_	_	_	_
14	could	_	O	O	_	_	_	_	_
15	no	_	O	O	_	_	_	_	_
16	longer	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	detected	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	purified	_	O	O	_	_	_	_	_
21	eosinophils	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	eosinophils	_	O	O	_	_	_	_	_
5	purified	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	patient	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	Churg	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Strauss	_	O	O	_	_	_	_	_
13	syndrome	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	six	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	reactive	_	O	O	_	_	_	_	_
20	eosinophilias	_	O	O	_	_	_	_	_
21	attributed	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	allergy	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	parasitic	_	O	O	_	_	_	_	_
26	infection	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	or	_	O	O	_	_	_	_	_
29	drug	_	O	O	_	_	_	_	_
30	reaction	_	O	O	_	_	_	_	_
31	showed	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	polyclonal	_	O	O	_	_	_	_	_
34	pattern	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	X	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	inactivation	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	HUMARA	_	O	O	_	_	_	_	_
41	analysis	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	finding	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	clonal	_	O	O	_	_	_	_	_
5	eosinophilia	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	patient	_	O	O	_	_	_	_	_
9	presenting	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	IHES	_	O	O	_	_	_	_	_
12	indicates	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	such	_	O	O	_	_	_	_	_
15	patients	_	O	O	_	_	_	_	_
16	may	_	O	O	_	_	_	_	_
17	have	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	reality	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	low	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	grade	_	O	O	_	_	_	_	_
26	clonal	_	O	O	_	_	_	_	_
27	disorder	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	can	_	O	O	_	_	_	_	_
30	be	_	O	O	_	_	_	_	_
31	distinguished	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	reactive	_	O	O	_	_	_	_	_
34	eosinophilias	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	HUMARA	_	O	O	_	_	_	_	_
37	analysis	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	method	_	O	O	_	_	_	_	_
5	described	_	O	O	_	_	_	_	_
6	can	_	O	O	_	_	_	_	_
7	be	_	O	O	_	_	_	_	_
8	used	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	monitor	_	O	O	_	_	_	_	_
11	disease	_	O	O	_	_	_	_	_
12	progression	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	leukemia	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	type	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	Tax	_	O	O	_	_	_	_	_
10	protein	_	O	O	_	_	_	_	_
11	induces	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	STAT	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	genes	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Human	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	leukemia	_	O	O	_	_	_	_	_
6	virus	_	O	O	_	_	_	_	_
7	type	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	HTLV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	Tax	_	O	O	_	_	_	_	_
15	transforms	_	O	O	_	_	_	_	_
16	normal	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	presence	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	interleukin	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	vitro	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	STAT	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	family	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	transcription	_	O	O	_	_	_	_	_
7	factors	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	play	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	pivotal	_	O	O	_	_	_	_	_
12	role	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	cytokine	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	functions	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	various	_	O	O	_	_	_	_	_
21	type	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	involvement	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	STATs	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	transformation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	HTLV	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	HTLV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	transformed	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	lines	_	O	O	_	_	_	_	_
10	expressed	_	O	O	_	_	_	_	_
11	higher	_	O	O	_	_	_	_	_
12	amounts	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	STAT	_	O	O	_	_	_	_	_
21	5	_	O	O	_	_	_	_	_
22	RNA	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	proteins	_	O	O	_	_	_	_	_
25	than	_	O	O	_	_	_	_	_
26	virus	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	negative	_	O	O	_	_	_	_	_
29	T	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	human	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	line	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	Tax	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	HTLV	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	transformed	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	line	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	then	_	O	O	_	_	_	_	_
26	stimulated	_	O	O	_	_	_	_	_
27	its	_	O	O	_	_	_	_	_
28	proliferation	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	did	_	O	O	_	_	_	_	_
8	neither	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	line	_	O	O	_	_	_	_	_
13	lacking	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	STAT	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	STAT	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	mRNAs	_	O	O	_	_	_	_	_
13	were	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	cell	_	O	O	_	_	_	_	_
21	mitogen	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	normal	_	O	O	_	_	_	_	_
24	human	_	O	O	_	_	_	_	_
25	peripheral	_	O	O	_	_	_	_	_
26	blood	_	O	O	_	_	_	_	_
27	mononuclear	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	induction	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	Tax	_	O	O	_	_	_	_	_
15	enhances	_	O	O	_	_	_	_	_
16	cytokine	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	functions	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	virus	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	infected	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	hence	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	induction	_	O	O	_	_	_	_	_
31	may	_	O	O	_	_	_	_	_
32	play	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	role	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	dependent	_	O	O	_	_	_	_	_
41	transformation	_	O	O	_	_	_	_	_
42	steps	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	T	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	cells	_	O	O	_	_	_	_	_
47	by	_	O	O	_	_	_	_	_
48	HTLV	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	1	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_


1	Minimally	_	O	O	_	_	_	_	_
2	modified	_	O	O	_	_	_	_	_
3	low	_	O	O	_	_	_	_	_
4	density	_	O	O	_	_	_	_	_
5	lipoprotein	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	inflammatory	_	O	O	_	_	_	_	_
9	responses	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	endothelial	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	cyclic	_	O	O	_	_	_	_	_
17	adenosine	_	O	O	_	_	_	_	_
18	monophosphate	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	minimally	_	O	O	_	_	_	_	_
7	oxidized	_	O	O	_	_	_	_	_
8	LDL	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	MM	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	LDL	_	O	O	_	_	_	_	_
13	)	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	endothelial	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	increase	_	O	O	_	_	_	_	_
19	their	_	O	O	_	_	_	_	_
20	interaction	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	monocytes	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	not	_	O	O	_	_	_	_	_
25	neutrophils	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	inducing	_	O	O	_	_	_	_	_
28	monocyte	_	O	O	_	_	_	_	_
29	but	_	O	O	_	_	_	_	_
30	not	_	O	O	_	_	_	_	_
31	neutrophil	_	O	O	_	_	_	_	_
32	binding	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	synthesis	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	monocyte	_	O	O	_	_	_	_	_
37	chemotactic	_	O	O	_	_	_	_	_
38	protein	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	monocyte	_	O	O	_	_	_	_	_
43	colony	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	stimulating	_	O	O	_	_	_	_	_
46	factor	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	M	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	CSF	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	studies	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	have	_	O	O	_	_	_	_	_
7	examined	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	signaling	_	O	O	_	_	_	_	_
10	pathways	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	which	_	O	O	_	_	_	_	_
13	this	_	O	O	_	_	_	_	_
14	monocyte	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	specific	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	induced	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	monocyte	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	mRNA	_	O	O	_	_	_	_	_
8	levels	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	M	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	CSF	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	MM	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	LDL	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	inhibited	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	kinase	_	O	O	_	_	_	_	_
23	C	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	depleted	_	O	O	_	_	_	_	_
26	endothelial	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	number	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	studies	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	cAMP	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	second	_	O	O	_	_	_	_	_
12	messenger	_	O	O	_	_	_	_	_
13	for	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	effects	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	MM	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	LDL	_	O	O	_	_	_	_	_
20	cited	_	O	O	_	_	_	_	_
21	above	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Incubation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	endothelial	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	MM	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	LDL	_	O	O	_	_	_	_	_
9	caused	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	173	_	O	O	_	_	_	_	_
12	%	_	O	O	_	_	_	_	_
13	increase	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	intracellular	_	O	O	_	_	_	_	_
16	cAMP	_	O	O	_	_	_	_	_
17	levels	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Agents	_	O	O	_	_	_	_	_
2	which	_	O	O	_	_	_	_	_
3	increased	_	O	O	_	_	_	_	_
4	cAMP	_	O	O	_	_	_	_	_
5	levels	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	including	_	O	O	_	_	_	_	_
8	cholera	_	O	O	_	_	_	_	_
9	toxin	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	pertussis	_	O	O	_	_	_	_	_
12	toxin	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	dibutyryl	_	O	O	_	_	_	_	_
15	cAMP	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	isoproterenol	_	O	O	_	_	_	_	_
19	mimicked	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	actions	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	MM	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	LDL	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Agents	_	O	O	_	_	_	_	_
2	which	_	O	O	_	_	_	_	_
3	elevated	_	O	O	_	_	_	_	_
4	cAMP	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	also	_	O	O	_	_	_	_	_
7	shown	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	activate	_	O	O	_	_	_	_	_
10	NF	_	O	O	_	_	_	_	_
11	kappa	_	O	O	_	_	_	_	_
12	B	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	suggesting	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	role	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	this	_	O	O	_	_	_	_	_
19	transcription	_	O	O	_	_	_	_	_
20	factor	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	activation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	monocyte	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	endothelial	_	O	O	_	_	_	_	_
27	interactions	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	endothelial	_	O	O	_	_	_	_	_
3	leukocyte	_	O	O	_	_	_	_	_
4	adhesion	_	O	O	_	_	_	_	_
5	molecule	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	ELAM	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	mRNA	_	O	O	_	_	_	_	_
10	synthesis	_	O	O	_	_	_	_	_
11	can	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	regulated	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	NF	_	O	O	_	_	_	_	_
16	kappa	_	O	O	_	_	_	_	_
17	B	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	ELAM	_	O	O	_	_	_	_	_
20	was	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	expressed	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	ELAM	_	O	O	_	_	_	_	_
25	mRNA	_	O	O	_	_	_	_	_
26	was	_	O	O	_	_	_	_	_
27	only	_	O	O	_	_	_	_	_
28	slightly	_	O	O	_	_	_	_	_
29	elevated	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	response	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	MM	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	LDL	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	evidence	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	induction	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	neutrophil	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	LPS	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	actually	_	O	O	_	_	_	_	_
13	suppressed	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	agents	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	elevated	_	O	O	_	_	_	_	_
18	cAMP	_	O	O	_	_	_	_	_
19	levels	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Effects	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	interleukin	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	peripheral	_	O	O	_	_	_	_	_
9	blood	_	O	O	_	_	_	_	_
10	mononuclear	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	responses	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	Cryptococcus	_	O	O	_	_	_	_	_
15	neoformans	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	Candida	_	O	O	_	_	_	_	_
18	albicans	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	lipopolysaccharide	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	Deactivation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	mononuclear	_	O	O	_	_	_	_	_
4	phagocytes	_	O	O	_	_	_	_	_
5	is	_	O	O	_	_	_	_	_
6	critical	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	limit	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	inflammatory	_	O	O	_	_	_	_	_
11	response	_	O	O	_	_	_	_	_
12	but	_	O	O	_	_	_	_	_
13	can	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	detrimental	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	face	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	progressive	_	O	O	_	_	_	_	_
21	infection	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	compared	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	deactivating	_	O	O	_	_	_	_	_
8	cytokine	_	O	O	_	_	_	_	_
9	interleukin	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	peripheral	_	O	O	_	_	_	_	_
19	blood	_	O	O	_	_	_	_	_
20	mononuclear	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	PBMC	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	responses	_	O	O	_	_	_	_	_
26	to	_	O	O	_	_	_	_	_
27	lipopolysaccharide	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	LPS	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	Cryptococcus	_	O	O	_	_	_	_	_
33	neoformans	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	Candida	_	O	O	_	_	_	_	_
37	albicans	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	effected	_	O	O	_	_	_	_	_
5	dose	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependent	_	O	O	_	_	_	_	_
8	inhibition	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	tumor	_	O	O	_	_	_	_	_
11	necrosis	_	O	O	_	_	_	_	_
12	factor	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	TNF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	release	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	PBMC	_	O	O	_	_	_	_	_
22	stimulated	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	LPS	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	C	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	neoformans	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	inhibition	_	O	O	_	_	_	_	_
6	seen	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	0	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	U	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	ml	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	greater	_	O	O	_	_	_	_	_
16	than	_	O	O	_	_	_	_	_
17	90	_	O	O	_	_	_	_	_
18	%	_	O	O	_	_	_	_	_
19	inhibition	_	O	O	_	_	_	_	_
20	noted	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	10	_	O	O	_	_	_	_	_
23	U	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	ml	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	even	_	O	O	_	_	_	_	_
5	at	_	O	O	_	_	_	_	_
6	doses	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	high	_	O	O	_	_	_	_	_
9	as	_	O	O	_	_	_	_	_
10	100	_	O	O	_	_	_	_	_
11	U	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	ml	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	inhibited	_	O	O	_	_	_	_	_
19	TNF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	release	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	response	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	C	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	albicans	_	O	O	_	_	_	_	_
2	by	_	O	O	_	_	_	_	_
3	only	_	O	O	_	_	_	_	_
4	50	_	O	O	_	_	_	_	_
5	%.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	profoundly	_	O	O	_	_	_	_	_
5	inhibited	_	O	O	_	_	_	_	_
6	release	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	beta	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	PBMC	_	O	O	_	_	_	_	_
14	stimulated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	all	_	O	O	_	_	_	_	_
17	three	_	O	O	_	_	_	_	_
18	stimuli	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	TNF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	alpha	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	release	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	inhibited	_	O	O	_	_	_	_	_
9	even	_	O	O	_	_	_	_	_
10	if	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	added	_	O	O	_	_	_	_	_
16	up	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	8	_	O	O	_	_	_	_	_
19	h	_	O	O	_	_	_	_	_
20	after	_	O	O	_	_	_	_	_
21	cryptococcal	_	O	O	_	_	_	_	_
22	stimulation	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	inhibition	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	lesser	_	O	O	_	_	_	_	_
14	magnitude	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	occurred	_	O	O	_	_	_	_	_
17	only	_	O	O	_	_	_	_	_
18	when	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	10	_	O	O	_	_	_	_	_
22	was	_	O	O	_	_	_	_	_
23	added	_	O	O	_	_	_	_	_
24	within	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	h	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	cryptococcal	_	O	O	_	_	_	_	_
29	stimulation	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	inhibited	_	O	O	_	_	_	_	_
5	translocation	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	NF	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	kappaB	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	response	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	LPS	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	fungal	_	O	O	_	_	_	_	_
18	stimuli	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	three	_	O	O	_	_	_	_	_
3	stimuli	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	production	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	PBMC	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	although	_	O	O	_	_	_	_	_
13	over	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	fold	_	O	O	_	_	_	_	_
17	less	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	released	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	response	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	C	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	neoformans	_	O	O	_	_	_	_	_
2	compared	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	LPS	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	C	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	albicans	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	while	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	has	_	O	O	_	_	_	_	_
8	deactivating	_	O	O	_	_	_	_	_
9	effects	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	PBMC	_	O	O	_	_	_	_	_
12	responses	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	all	_	O	O	_	_	_	_	_
15	three	_	O	O	_	_	_	_	_
16	stimuli	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	disparate	_	O	O	_	_	_	_	_
19	stimulus	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	response	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	specific	_	O	O	_	_	_	_	_
25	patterns	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	deactivation	_	O	O	_	_	_	_	_
28	are	_	O	O	_	_	_	_	_
29	seen	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Inhibition	_	O	O	_	_	_	_	_
2	by	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	proinflammatory	_	O	O	_	_	_	_	_
8	cytokine	_	O	O	_	_	_	_	_
9	release	_	O	O	_	_	_	_	_
10	appears	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	occur	_	O	O	_	_	_	_	_
13	at	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	level	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	transcription	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	TNF	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	alpha	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	both	_	O	O	_	_	_	_	_
25	transcriptionally	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	posttranscriptionally	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Attenuation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	interferon	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	tyrosine	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	mononuclear	_	O	O	_	_	_	_	_
11	phagocytes	_	O	O	_	_	_	_	_
12	infected	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	Leishmania	_	O	O	_	_	_	_	_
15	donovani	_	O	O	_	_	_	_	_
16	:	_	O	O	_	_	_	_	_
17	selective	_	O	O	_	_	_	_	_
18	inhibition	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	signaling	_	O	O	_	_	_	_	_
21	through	_	O	O	_	_	_	_	_
22	Janus	_	O	O	_	_	_	_	_
23	kinases	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	Stat	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	transcription	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	response	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	interferon	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	impaired	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	mononuclear	_	O	O	_	_	_	_	_
15	phagocytes	_	O	O	_	_	_	_	_
16	infected	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	Leishmania	_	O	O	_	_	_	_	_
19	donovani	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	mechanisms	_	O	O	_	_	_	_	_
24	involved	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	not	_	O	O	_	_	_	_	_
27	fully	_	O	O	_	_	_	_	_
28	understood	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	changes	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	brought	_	O	O	_	_	_	_	_
7	about	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	gamma	_	O	O	_	_	_	_	_
10	interferon	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	thought	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	involve	_	O	O	_	_	_	_	_
15	transient	_	O	O	_	_	_	_	_
16	increases	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	activities	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	cellular	_	O	O	_	_	_	_	_
22	protein	_	O	O	_	_	_	_	_
23	tyrosine	_	O	O	_	_	_	_	_
24	kinases	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	including	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	Janus	_	O	O	_	_	_	_	_
29	kinases	_	O	O	_	_	_	_	_
30	Jak	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	Jak	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	leading	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	tyrosine	_	O	O	_	_	_	_	_
39	phosphorylation	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	the	_	O	O	_	_	_	_	_
42	transcription	_	O	O	_	_	_	_	_
43	factor	_	O	O	_	_	_	_	_
44	Stat	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	investigate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	mechanisms	_	O	O	_	_	_	_	_
5	accounting	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	impaired	_	O	O	_	_	_	_	_
9	responses	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	gamma	_	O	O	_	_	_	_	_
12	interferon	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	model	_	O	O	_	_	_	_	_
16	system	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	examining	_	O	O	_	_	_	_	_
19	overall	_	O	O	_	_	_	_	_
20	changes	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	protein	_	O	O	_	_	_	_	_
23	tyrosine	_	O	O	_	_	_	_	_
24	phosphorylation	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	activation	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	Jak	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	Jak	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	phosphorylation	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	Stat	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	was	_	O	O	_	_	_	_	_
39	developed	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	phorbol	_	O	O	_	_	_	_	_
42	12	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	myristate	_	O	O	_	_	_	_	_
45	13	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	acetate	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	differentiated	_	O	O	_	_	_	_	_
50	U	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	937	_	O	O	_	_	_	_	_
53	cells	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	Analysis	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	whole	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	lysates	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	antiphosphotyrosine	_	O	O	_	_	_	_	_
9	immunoblotting	_	O	O	_	_	_	_	_
10	showed	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	incubation	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	gamma	_	O	O	_	_	_	_	_
15	interferon	_	O	O	_	_	_	_	_
16	brought	_	O	O	_	_	_	_	_
17	about	_	O	O	_	_	_	_	_
18	specific	_	O	O	_	_	_	_	_
19	increases	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	phosphotyrosine	_	O	O	_	_	_	_	_
22	labeling	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	several	_	O	O	_	_	_	_	_
25	proteins	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Increased	_	O	O	_	_	_	_	_
2	labeling	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	proteins	_	O	O	_	_	_	_	_
6	occurred	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	similar	_	O	O	_	_	_	_	_
9	extents	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	control	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	had	_	O	O	_	_	_	_	_
18	been	_	O	O	_	_	_	_	_
19	infected	_	O	O	_	_	_	_	_
20	with	_	O	O	_	_	_	_	_
21	L	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	donovani	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	16	_	O	O	_	_	_	_	_
4	h	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	Jak	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	Jak	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	Stat	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	were	_	O	O	_	_	_	_	_
11	immunoprecipitated	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	control	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	interferon	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	treated	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	tyrosine	_	O	O	_	_	_	_	_
22	phosphorylation	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	these	_	O	O	_	_	_	_	_
25	proteins	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	detected	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	antiphosphotyrosine	_	O	O	_	_	_	_	_
30	immunoblotting	_	O	O	_	_	_	_	_
31	was	_	O	O	_	_	_	_	_
32	used	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	measured	_	O	O	_	_	_	_	_
35	their	_	O	O	_	_	_	_	_
36	activation	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Tyrosine	_	O	O	_	_	_	_	_
2	phosphorylation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Jak	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	Jak	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	Stat	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	increased	_	O	O	_	_	_	_	_
14	markedly	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	dose	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	dependent	_	O	O	_	_	_	_	_
21	manner	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	U	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	937	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	incubated	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	gamma	_	O	O	_	_	_	_	_
31	interferon	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	infected	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	L	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_

1	donovani	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	tyrosine	_	O	O	_	_	_	_	_
4	phosphorylation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	Jak	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	Jak	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	markedly	_	O	O	_	_	_	_	_
17	impaired	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	dependent	_	O	O	_	_	_	_	_
5	upon	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	duration	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	exposure	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	L	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	donovani	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	maximal	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	complete	_	O	O	_	_	_	_	_
7	at	_	O	O	_	_	_	_	_
8	16	_	O	O	_	_	_	_	_
9	h	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	Results	_	O	O	_	_	_	_	_
2	similar	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	those	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	U	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	937	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	were	_	O	O	_	_	_	_	_
12	also	_	O	O	_	_	_	_	_
13	obtained	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	human	_	O	O	_	_	_	_	_
16	peripheral	_	O	O	_	_	_	_	_
17	blood	_	O	O	_	_	_	_	_
18	monocytes	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	infection	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	mononuclear	_	O	O	_	_	_	_	_
9	phagocytes	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	L	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	donovani	_	O	O	_	_	_	_	_
2	leads	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	impaired	_	O	O	_	_	_	_	_
5	gamma	_	O	O	_	_	_	_	_
6	interferon	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	mediated	_	O	O	_	_	_	_	_
9	tyrosine	_	O	O	_	_	_	_	_
10	phosphorylation	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	selective	_	O	O	_	_	_	_	_
13	effects	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	Jak	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	Stat	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	pathway	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Unresponsiveness	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	gamma	_	O	O	_	_	_	_	_
4	interferon	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	activation	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	this	_	O	O	_	_	_	_	_
9	pathway	_	O	O	_	_	_	_	_
10	may	_	O	O	_	_	_	_	_
11	explain	_	O	O	_	_	_	_	_
12	impaired	_	O	O	_	_	_	_	_
13	transcriptional	_	O	O	_	_	_	_	_
14	responses	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	leishmania	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	infected	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Enzyme	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	linked	_	O	O	_	_	_	_	_
4	immunosorbent	_	O	O	_	_	_	_	_
5	assay	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	17	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	17	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	culture	_	O	O	_	_	_	_	_
6	supernatants	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	measured	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	sandwich	_	O	O	_	_	_	_	_
11	enzyme	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	linked	_	O	O	_	_	_	_	_
14	immunosorbent	_	O	O	_	_	_	_	_
15	assay	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	described	_	O	O	_	_	_	_	_
18	previously	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	20	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	brief	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	96	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	well	_	O	O	_	_	_	_	_
8	plate	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Nunc	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	coated	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	mug	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	ml	_	O	O	_	_	_	_	_
19	monoclonal	_	O	O	_	_	_	_	_
20	antibodies	_	O	O	_	_	_	_	_
21	against	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	17	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	R	_	O	O	_	_	_	_	_
27	&	_	O	O	_	_	_	_	_
28	D	_	O	O	_	_	_	_	_
29	Systems	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	at	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	degreesC	_	O	O	_	_	_	_	_
34	overnight	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	blocking	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	phosphate	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	buffered	_	O	O	_	_	_	_	_
7	saline	_	O	O	_	_	_	_	_
8	/	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	%	_	O	O	_	_	_	_	_
11	bovine	_	O	O	_	_	_	_	_
12	serum	_	O	O	_	_	_	_	_
13	albumin	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	BSA	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	/	_	O	O	_	_	_	_	_
18	0	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	05	_	O	O	_	_	_	_	_
21	%	_	O	O	_	_	_	_	_
22	Tween	_	O	O	_	_	_	_	_
23	20	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	hours	_	O	O	_	_	_	_	_
27	at	_	O	O	_	_	_	_	_
28	room	_	O	O	_	_	_	_	_
29	temperature	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	22	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	25	_	O	O	_	_	_	_	_
34	degreesC	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	test	_	O	O	_	_	_	_	_
38	samples	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	the	_	O	O	_	_	_	_	_
41	standard	_	O	O	_	_	_	_	_
42	recombinant	_	O	O	_	_	_	_	_
43	IL	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	17	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	R	_	O	O	_	_	_	_	_
48	&	_	O	O	_	_	_	_	_
49	D	_	O	O	_	_	_	_	_
50	Systems	_	O	O	_	_	_	_	_
51	)	_	O	O	_	_	_	_	_
52	were	_	O	O	_	_	_	_	_
53	added	_	O	O	_	_	_	_	_
54	to	_	O	O	_	_	_	_	_
55	the	_	O	O	_	_	_	_	_
56	96	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	well	_	O	O	_	_	_	_	_
59	plate	_	O	O	_	_	_	_	_
60	and	_	O	O	_	_	_	_	_
61	incubated	_	O	O	_	_	_	_	_
62	at	_	O	O	_	_	_	_	_
63	room	_	O	O	_	_	_	_	_
64	temperature	_	O	O	_	_	_	_	_
65	for	_	O	O	_	_	_	_	_
66	2	_	O	O	_	_	_	_	_
67	hours	_	O	O	_	_	_	_	_
68	.	_	O	O	_	_	_	_	_

1	Plates	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	washed	_	O	O	_	_	_	_	_
4	four	_	O	O	_	_	_	_	_
5	times	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	phosphate	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	buffered	_	O	O	_	_	_	_	_
10	saline	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	Tween	_	O	O	_	_	_	_	_
13	20	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	then	_	O	O	_	_	_	_	_
17	incubated	_	O	O	_	_	_	_	_
18	with	_	O	O	_	_	_	_	_
19	500	_	O	O	_	_	_	_	_
20	ng	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	ml	_	O	O	_	_	_	_	_
23	biotinylated	_	O	O	_	_	_	_	_
24	mouse	_	O	O	_	_	_	_	_
25	monoclonal	_	O	O	_	_	_	_	_
26	antibodies	_	O	O	_	_	_	_	_
27	against	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	17	_	O	O	_	_	_	_	_
31	(	_	O	O	_	_	_	_	_
32	R	_	O	O	_	_	_	_	_
33	&	_	O	O	_	_	_	_	_
34	D	_	O	O	_	_	_	_	_
35	Systems	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	for	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	hours	_	O	O	_	_	_	_	_
40	at	_	O	O	_	_	_	_	_
41	room	_	O	O	_	_	_	_	_
42	temperature	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	washing	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	streptavidin	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	alkaline	_	O	O	_	_	_	_	_
7	phosphate	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	horseradish	_	O	O	_	_	_	_	_
10	peroxidase	_	O	O	_	_	_	_	_
11	conjugate	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	Sigma	_	O	O	_	_	_	_	_
14	)	_	O	O	_	_	_	_	_
15	was	_	O	O	_	_	_	_	_
16	incubated	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	hours	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	then	_	O	O	_	_	_	_	_
22	washed	_	O	O	_	_	_	_	_
23	again	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	incubated	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	mg	_	O	O	_	_	_	_	_
29	/	_	O	O	_	_	_	_	_
30	ml	_	O	O	_	_	_	_	_
31	p	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	nitrophenyl	_	O	O	_	_	_	_	_
34	phosphate	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	Sigma	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	dissolved	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	diethanolamine	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	Sigma	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	to	_	O	O	_	_	_	_	_
45	develop	_	O	O	_	_	_	_	_
46	the	_	O	O	_	_	_	_	_
47	color	_	O	O	_	_	_	_	_
48	reaction	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	reaction	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	stopped	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	addition	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	M	_	O	O	_	_	_	_	_
11	NaOH	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	optical	_	O	O	_	_	_	_	_
15	density	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	each	_	O	O	_	_	_	_	_
18	well	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	read	_	O	O	_	_	_	_	_
21	at	_	O	O	_	_	_	_	_
22	405	_	O	O	_	_	_	_	_
23	nm	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	lower	_	O	O	_	_	_	_	_
3	limit	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	17	_	O	O	_	_	_	_	_
8	detection	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	pg	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	ml	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Recombinant	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	diluted	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	culture	_	O	O	_	_	_	_	_
9	medium	_	O	O	_	_	_	_	_
10	was	_	O	O	_	_	_	_	_
11	used	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	calibration	_	O	O	_	_	_	_	_
15	standard	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	ranging	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	2000	_	O	O	_	_	_	_	_
22	pg	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	ml	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	standard	_	O	O	_	_	_	_	_
3	curve	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	drawn	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	plotting	_	O	O	_	_	_	_	_
8	optical	_	O	O	_	_	_	_	_
9	density	_	O	O	_	_	_	_	_
10	against	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	log	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	concentration	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	recombinant	_	O	O	_	_	_	_	_
18	cytokines	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	used	_	O	O	_	_	_	_	_
22	for	_	O	O	_	_	_	_	_
23	determination	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	17	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	test	_	O	O	_	_	_	_	_
30	samples	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_



1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	tal	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	GATA	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	during	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	hematopoiesis	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Tal	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	rearrangements	_	O	O	_	_	_	_	_
5	are	_	O	O	_	_	_	_	_
6	associated	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	nearly	_	O	O	_	_	_	_	_
9	30	_	O	O	_	_	_	_	_
10	%	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	acute	_	O	O	_	_	_	_	_
15	lymphoblastic	_	O	O	_	_	_	_	_
16	leukemia	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Tal	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	encodes	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	putative	_	O	O	_	_	_	_	_
8	transcription	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	basic	_	O	O	_	_	_	_	_
13	helix	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	loop	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	helix	_	O	O	_	_	_	_	_
18	domain	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	is	_	O	O	_	_	_	_	_
21	known	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	be	_	O	O	_	_	_	_	_
24	predominantly	_	O	O	_	_	_	_	_
25	expressed	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	hematopoietic	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	pattern	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	tal	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	expression	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	purified	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	hematopoietic	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	situ	_	O	O	_	_	_	_	_
18	hybridization	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	reverse	_	O	O	_	_	_	_	_
21	transcriptase	_	O	O	_	_	_	_	_
22	polymerase	_	O	O	_	_	_	_	_
23	chain	_	O	O	_	_	_	_	_
24	reaction	_	O	O	_	_	_	_	_
25	analysis	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	methods	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	tal	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	expressed	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	megakaryocytes	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	erythroblasts	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	well	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	basophilic	_	O	O	_	_	_	_	_
21	granulocytes	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	our	_	O	O	_	_	_	_	_
5	results	_	O	O	_	_	_	_	_
6	indicate	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	tal	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	A	_	O	O	_	_	_	_	_
14	promoter	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	which	_	O	O	_	_	_	_	_
17	contains	_	O	O	_	_	_	_	_
18	two	_	O	O	_	_	_	_	_
19	consensus	_	O	O	_	_	_	_	_
20	GATA	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	sites	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	is	_	O	O	_	_	_	_	_
26	active	_	O	O	_	_	_	_	_
27	mainly	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	these	_	O	O	_	_	_	_	_
30	lineages	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	GATA	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	known	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	transactivate	_	O	O	_	_	_	_	_
11	several	_	O	O	_	_	_	_	_
12	genes	_	O	O	_	_	_	_	_
13	specific	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	megakaryocytic	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	mastocytic	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	basophilic	_	O	O	_	_	_	_	_
24	lineages	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	we	_	O	O	_	_	_	_	_
27	studied	_	O	O	_	_	_	_	_
28	GATA	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	expression	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	these	_	O	O	_	_	_	_	_
34	purified	_	O	O	_	_	_	_	_
35	hematopoietic	_	O	O	_	_	_	_	_
36	cells	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	found	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	GATA	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	tal	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	genes	_	O	O	_	_	_	_	_
12	are	_	O	O	_	_	_	_	_
13	coexpressed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	these	_	O	O	_	_	_	_	_
16	three	_	O	O	_	_	_	_	_
17	lineages	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Remarkably	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	both	_	O	O	_	_	_	_	_
7	genes	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	downmodulated	_	O	O	_	_	_	_	_
10	during	_	O	O	_	_	_	_	_
11	erythroid	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	megakaryocytic	_	O	O	_	_	_	_	_
14	terminal	_	O	O	_	_	_	_	_
15	maturation	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	immature	_	O	O	_	_	_	_	_
3	hematopoietic	_	O	O	_	_	_	_	_
4	cells	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	tal	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	GATA	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	genes	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	coexpressed	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	committed	_	O	O	_	_	_	_	_
18	progenitors	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	34	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	38	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	))	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	whereas	_	O	O	_	_	_	_	_
33	they	_	O	O	_	_	_	_	_
34	are	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	detectable	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	most	_	O	O	_	_	_	_	_
40	primitive	_	O	O	_	_	_	_	_
41	cells	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	34	_	O	O	_	_	_	_	_
45	(	_	O	O	_	_	_	_	_
46	2	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	/	_	O	O	_	_	_	_	_
50	CD	_	O	O	_	_	_	_	_
51	38	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	GATA	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	2	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	strongly	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	both	_	O	O	_	_	_	_	_
12	most	_	O	O	_	_	_	_	_
13	primitive	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	committed	_	O	O	_	_	_	_	_
16	progenitors	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	whereas	_	O	O	_	_	_	_	_
20	GATA	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	mostly	_	O	O	_	_	_	_	_
25	detected	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	most	_	O	O	_	_	_	_	_
28	primitive	_	O	O	_	_	_	_	_
29	ones	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Altogether	_	O	O	_	_	_	_	_
2	our	_	O	O	_	_	_	_	_
3	results	_	O	O	_	_	_	_	_
4	strongly	_	O	O	_	_	_	_	_
5	suggest	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	GATA	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	modulates	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	tal	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	during	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	differentiation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	erythroid	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	megakaryocytic	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	basosophilic	_	O	O	_	_	_	_	_
28	lineages	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	Expression	_	O	O	_	_	_	_	_
3	Pattern	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Sox	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	Suggests	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	Role	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	Definitive	_	O	O	_	_	_	_	_
12	Erythropoiesis	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	observation	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	deficient	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	ectopically	_	O	O	_	_	_	_	_
10	express	_	O	O	_	_	_	_	_
11	epsilony	_	O	O	_	_	_	_	_
12	globin	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	liver	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	where	_	O	O	_	_	_	_	_
17	definitive	_	O	O	_	_	_	_	_
18	erythroid	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	mature	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	suggests	_	O	O	_	_	_	_	_
23	that	_	O	O	_	_	_	_	_
24	Sox	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	is	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	important	_	O	O	_	_	_	_	_
29	regulator	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	definitive	_	O	O	_	_	_	_	_
32	erythropoiesis	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	temporal	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	spatial	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	pattern	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Sox	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	Northern	_	O	O	_	_	_	_	_
14	blot	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	situ	_	O	O	_	_	_	_	_
18	hybridization	_	O	O	_	_	_	_	_
19	assays	_	O	O	_	_	_	_	_
20	were	_	O	O	_	_	_	_	_
21	employed	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Figure	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	A	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	detectable	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	Northern	_	O	O	_	_	_	_	_
14	blot	_	O	O	_	_	_	_	_
15	beginning	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	dpc	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	coincident	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	temporal	_	O	O	_	_	_	_	_
26	onset	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	definitive	_	O	O	_	_	_	_	_
29	erythropoiesis	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	liver	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	situ	_	O	O	_	_	_	_	_
5	hybridization	_	O	O	_	_	_	_	_
6	shows	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	Sox	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	highly	_	O	O	_	_	_	_	_
12	transcribed	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	12	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	5	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	dpc	_	O	O	_	_	_	_	_
19	liver	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	but	_	O	O	_	_	_	_	_
22	not	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	yolk	_	O	O	_	_	_	_	_
25	sac	_	O	O	_	_	_	_	_
26	blood	_	O	O	_	_	_	_	_
27	islands	_	O	O	_	_	_	_	_
28	at	_	O	O	_	_	_	_	_
29	7	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_
31	5	_	O	O	_	_	_	_	_
32	dpc	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	Figure	_	O	O	_	_	_	_	_
35	6	_	O	O	_	_	_	_	_
36	B	_	O	O	_	_	_	_	_
37	)	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Sox	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	temporally	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	spatially	_	O	O	_	_	_	_	_
10	coincident	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	definitive	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	primitive	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	erythropoiesis	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	taken	_	O	O	_	_	_	_	_
5	together	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	observation	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	epsilony	_	O	O	_	_	_	_	_
11	globin	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	highly	_	O	O	_	_	_	_	_
14	expressed	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	liver	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	14	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_
22	5	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	dpc	_	O	O	_	_	_	_	_
25	p	_	O	O	_	_	_	_	_
26	100	_	O	O	_	_	_	_	_
27	H	_	O	O	_	_	_	_	_
28	mutant	_	O	O	_	_	_	_	_
29	mice	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	Figure	_	O	O	_	_	_	_	_
32	5	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	demonstrate	_	O	O	_	_	_	_	_
36	that	_	O	O	_	_	_	_	_
37	Sox	_	O	O	_	_	_	_	_
38	6	_	O	O	_	_	_	_	_
39	functions	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	definitive	_	O	O	_	_	_	_	_
42	erythropoiesis	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_



1	Induction	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	vascular	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	adhesion	_	O	O	_	_	_	_	_
6	molecule	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	low	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	density	_	O	O	_	_	_	_	_
13	lipoprotein	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_


1	Low	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	density	_	O	O	_	_	_	_	_
4	lipoprotein	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	LDL	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	well	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	established	_	O	O	_	_	_	_	_
13	risk	_	O	O	_	_	_	_	_
14	factor	_	O	O	_	_	_	_	_
15	for	_	O	O	_	_	_	_	_
16	atherosclerosis	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	endothelial	_	O	O	_	_	_	_	_
3	cells	_	O	O	_	_	_	_	_
4	are	_	O	O	_	_	_	_	_
5	incubated	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	this	_	O	O	_	_	_	_	_
8	lipoprotein	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	pathophysiologic	_	O	O	_	_	_	_	_
11	amounts	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	activated	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Among	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	documented	_	O	O	_	_	_	_	_
4	cellular	_	O	O	_	_	_	_	_
5	responses	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	LDL	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	increased	_	O	O	_	_	_	_	_
10	recruitment	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	monocytes	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	which	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	believed	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	play	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	major	_	O	O	_	_	_	_	_
21	role	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	promoting	_	O	O	_	_	_	_	_
24	intimal	_	O	O	_	_	_	_	_
25	plaque	_	O	O	_	_	_	_	_
26	formation	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	presented	_	O	O	_	_	_	_	_
4	here	_	O	O	_	_	_	_	_
5	link	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	atheogenic	_	O	O	_	_	_	_	_
8	lipoprotein	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	LDL	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	induction	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	an	_	O	O	_	_	_	_	_
17	adhesion	_	O	O	_	_	_	_	_
18	molecule	_	O	O	_	_	_	_	_
19	important	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	atherogenesis	_	O	O	_	_	_	_	_
22	Human	_	O	O	_	_	_	_	_
23	LDL	_	O	O	_	_	_	_	_
24	induces	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	vascular	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	adhesion	_	O	O	_	_	_	_	_
29	molecule	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	VCAM	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	1	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	transcriptionally	_	O	O	_	_	_	_	_
38	with	_	O	O	_	_	_	_	_
39	an	_	O	O	_	_	_	_	_
40	increase	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	mRNA	_	O	O	_	_	_	_	_
43	levels	_	O	O	_	_	_	_	_
44	through	_	O	O	_	_	_	_	_
45	activation	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	the	_	O	O	_	_	_	_	_
48	VCAM	_	O	O	_	_	_	_	_
49	promoter	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	effect	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	blocked	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	anti	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	VCAM	_	O	O	_	_	_	_	_
9	antibodies	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	After	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	day	_	O	O	_	_	_	_	_
6	incubation	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	LDL	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	believed	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	key	_	O	O	_	_	_	_	_
25	oxidative	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	stress	_	O	O	_	_	_	_	_
28	sensor	_	O	O	_	_	_	_	_
29	for	_	O	O	_	_	_	_	_
30	VCAM	_	O	O	_	_	_	_	_
31	regulation	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	remains	_	O	O	_	_	_	_	_
34	at	_	O	O	_	_	_	_	_
35	basal	_	O	O	_	_	_	_	_
36	level	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	activities	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	AP	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	GATA	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	other	_	O	O	_	_	_	_	_
17	hand	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	increased	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	LDL	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	component	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	LDL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	enhanced	_	O	O	_	_	_	_	_
9	endothelial	_	O	O	_	_	_	_	_
10	recruitment	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	monocytes	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	attributed	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	VCAM	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	which	_	O	O	_	_	_	_	_
22	appears	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	be	_	O	O	_	_	_	_	_
25	mediated	_	O	O	_	_	_	_	_
26	through	_	O	O	_	_	_	_	_
27	AP	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	GATA	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	identify	_	O	O	_	_	_	_	_
4	LDL	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	VCAM	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	inducer	_	O	O	_	_	_	_	_
10	possibly	_	O	O	_	_	_	_	_
11	distinct	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	cytokines	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	endotoxin	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	Cytokine	_	O	O	_	_	_	_	_
2	measurements	_	O	O	_	_	_	_	_

1	Supernatants	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	cultures	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	harvested	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	6	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	9	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	12	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	18	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	24	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	30	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	36	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	48	_	O	O	_	_	_	_	_
24	hours	_	O	O	_	_	_	_	_
25	after	_	O	O	_	_	_	_	_
26	stimulation	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	stored	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	80	_	O	O	_	_	_	_	_
32	degreesC	_	O	O	_	_	_	_	_
33	until	_	O	O	_	_	_	_	_
34	used	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	thawed	_	O	O	_	_	_	_	_
37	only	_	O	O	_	_	_	_	_
38	once	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	IFNgamma	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	TNFalpha	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	were	_	O	O	_	_	_	_	_
13	determined	_	O	O	_	_	_	_	_
14	using	_	O	O	_	_	_	_	_
15	an	_	O	O	_	_	_	_	_
16	ELISA	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	Bender	_	O	O	_	_	_	_	_
19	Systems	_	O	O	_	_	_	_	_
20	(	_	O	O	_	_	_	_	_
21	Vienna	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	Austria	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	RA	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	8	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	an	_	O	O	_	_	_	_	_
36	ELISA	_	O	O	_	_	_	_	_
37	from	_	O	O	_	_	_	_	_
38	R	_	O	O	_	_	_	_	_
39	&	_	O	O	_	_	_	_	_
40	D	_	O	O	_	_	_	_	_
41	Systems	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	Wiesbaden	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	Nordenstadt	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	Germany	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	and	_	O	O	_	_	_	_	_
51	TGFbeta	_	O	O	_	_	_	_	_
52	1	_	O	O	_	_	_	_	_
53	using	_	O	O	_	_	_	_	_
54	an	_	O	O	_	_	_	_	_
55	ELISA	_	O	O	_	_	_	_	_
56	as	_	O	O	_	_	_	_	_
57	previously	_	O	O	_	_	_	_	_
58	described	_	O	O	_	_	_	_	_
59	[	_	O	O	_	_	_	_	_
60	57	_	O	O	_	_	_	_	_
61	]	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	Quantification	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	2	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	an	_	O	O	_	_	_	_	_
8	indicator	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	bioactivity	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	done	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	previously	_	O	O	_	_	_	_	_
20	described	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	46	_	O	O	_	_	_	_	_
23	]	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Samples	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	diluted	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	same	_	O	O	_	_	_	_	_
7	buffer	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	that	_	O	O	_	_	_	_	_
10	used	_	O	O	_	_	_	_	_
11	for	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	standards	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	cytokines	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	quantified	_	O	O	_	_	_	_	_
5	using	_	O	O	_	_	_	_	_
6	an	_	O	O	_	_	_	_	_
7	ELISA	_	O	O	_	_	_	_	_
8	plate	_	O	O	_	_	_	_	_
9	reader	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Anthos	_	O	O	_	_	_	_	_
12	Labotec	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	Salzburg	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	Austria	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	Microplate	_	O	O	_	_	_	_	_
19	Reader	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	BioRad	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Cytokine	_	O	O	_	_	_	_	_
2	amounts	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	all	_	O	O	_	_	_	_	_
5	within	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	range	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	standard	_	O	O	_	_	_	_	_
11	curve	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	Only	_	O	O	_	_	_	_	_
2	stimulation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	PBMC	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	donors	_	O	O	_	_	_	_	_
8	showing	_	O	O	_	_	_	_	_
9	no	_	O	O	_	_	_	_	_
10	spontaneous	_	O	O	_	_	_	_	_
11	cytokine	_	O	O	_	_	_	_	_
12	release	_	O	O	_	_	_	_	_
13	was	_	O	O	_	_	_	_	_
14	included	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	statistics	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_



1	Differences	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	phosphorylation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	R	_	O	O	_	_	_	_	_
10	associated	_	O	O	_	_	_	_	_
11	JAK	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	proteins	_	O	O	_	_	_	_	_
15	between	_	O	O	_	_	_	_	_
16	HTLV	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	I	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	independent	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	2	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	dependent	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	lines	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	uncultured	_	O	O	_	_	_	_	_
38	leukemic	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	from	_	O	O	_	_	_	_	_
41	patients	_	O	O	_	_	_	_	_
42	with	_	O	O	_	_	_	_	_
43	adult	_	O	O	_	_	_	_	_
44	T	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	cell	_	O	O	_	_	_	_	_
47	lymphoma	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	leukemia	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	determine	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	status	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	2	_	O	O	_	_	_	_	_
10	R	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	associated	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	Jak	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	STAT	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	pathway	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	HTLV	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	I	_	O	O	_	_	_	_	_
24	infected	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	we	_	O	O	_	_	_	_	_
28	examined	_	O	O	_	_	_	_	_
29	tyrosine	_	O	O	_	_	_	_	_
30	phosphorylation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	Jak	_	O	O	_	_	_	_	_
33	3	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	STAT	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	STAT	_	O	O	_	_	_	_	_
40	5	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	several	_	O	O	_	_	_	_	_
43	HTLV	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	I	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	)	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	cell	_	O	O	_	_	_	_	_
52	lines	_	O	O	_	_	_	_	_
53	and	_	O	O	_	_	_	_	_
54	in	_	O	O	_	_	_	_	_
55	uncultured	_	O	O	_	_	_	_	_
56	leukemic	_	O	O	_	_	_	_	_
57	T	_	O	O	_	_	_	_	_
58	cells	_	O	O	_	_	_	_	_
59	isolated	_	O	O	_	_	_	_	_
60	from	_	O	O	_	_	_	_	_
61	patients	_	O	O	_	_	_	_	_
62	with	_	O	O	_	_	_	_	_
63	adult	_	O	O	_	_	_	_	_
64	T	_	O	O	_	_	_	_	_
65	-	_	O	O	_	_	_	_	_
66	cell	_	O	O	_	_	_	_	_
67	lymphoma	_	O	O	_	_	_	_	_
68	/	_	O	O	_	_	_	_	_
69	leukemia	_	O	O	_	_	_	_	_
70	(	_	O	O	_	_	_	_	_
71	ATLL	_	O	O	_	_	_	_	_
72	)	_	O	O	_	_	_	_	_
73	.	_	O	O	_	_	_	_	_

1	Constitutive	_	O	O	_	_	_	_	_
2	basal	_	O	O	_	_	_	_	_
3	phosphorylation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	Jak	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	usually	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	5	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	detected	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	all	_	O	O	_	_	_	_	_
20	four	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	independent	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	lines	_	O	O	_	_	_	_	_
28	tested	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	but	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	none	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	three	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	dependent	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	lines	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Similarly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	there	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	no	_	O	O	_	_	_	_	_
6	detectable	_	O	O	_	_	_	_	_
7	basal	_	O	O	_	_	_	_	_
8	phosphorylation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Jak	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	leukemic	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	from	_	O	O	_	_	_	_	_
20	ATLL	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	(	_	O	O	_	_	_	_	_
23	0	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	8	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	0	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	respectively	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	stimulation	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	resulted	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	Jak	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	both	_	O	O	_	_	_	_	_
18	leukemic	_	O	O	_	_	_	_	_
19	ATLL	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	dependent	_	O	O	_	_	_	_	_
27	lines	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	expression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	SHP	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	phosphatase	_	O	O	_	_	_	_	_
9	which	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	negative	_	O	O	_	_	_	_	_
13	regulator	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	cytokine	_	O	O	_	_	_	_	_
16	receptor	_	O	O	_	_	_	_	_
17	signaling	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	lost	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	most	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	independent	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	lines	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	/	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	)	_	O	O	_	_	_	_	_
34	but	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	leukemic	_	O	O	_	_	_	_	_
39	ATLL	_	O	O	_	_	_	_	_
40	cells	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	0	_	O	O	_	_	_	_	_
43	/	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	HTLV	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	+	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	lines	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	313	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	but	_	O	O	_	_	_	_	_
18	not	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	control	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	HTLV	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	I	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	lines	_	O	O	_	_	_	_	_
32	were	_	O	O	_	_	_	_	_
33	resistant	_	O	O	_	_	_	_	_
34	to	_	O	O	_	_	_	_	_
35	rapamycin	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	its	_	O	O	_	_	_	_	_
38	novel	_	O	O	_	_	_	_	_
39	analog	_	O	O	_	_	_	_	_
40	RAD	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	HTLV	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	I	_	O	O	_	_	_	_	_
10	infection	_	O	O	_	_	_	_	_
11	per	_	O	O	_	_	_	_	_
12	se	_	O	O	_	_	_	_	_
13	does	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	result	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	constitutive	_	O	O	_	_	_	_	_
19	phosphorylation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Jak	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	STAT	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	STAT	_	O	O	_	_	_	_	_
30	5	_	O	O	_	_	_	_	_
31	proteins	_	O	O	_	_	_	_	_
32	;	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	2	_	O	O	_	_	_	_	_
35	)	_	O	O	_	_	_	_	_
36	malignant	_	O	O	_	_	_	_	_
37	transformation	_	O	O	_	_	_	_	_
38	in	_	O	O	_	_	_	_	_
39	at	_	O	O	_	_	_	_	_
40	least	_	O	O	_	_	_	_	_
41	some	_	O	O	_	_	_	_	_
42	cases	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	ATLL	_	O	O	_	_	_	_	_
45	does	_	O	O	_	_	_	_	_
46	not	_	O	O	_	_	_	_	_
47	require	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	constitutive	_	O	O	_	_	_	_	_
50	,	_	O	O	_	_	_	_	_
51	but	_	O	O	_	_	_	_	_
52	may	_	O	O	_	_	_	_	_
53	require	_	O	O	_	_	_	_	_
54	IL	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	2	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	induced	_	O	O	_	_	_	_	_
59	,	_	O	O	_	_	_	_	_
60	activation	_	O	O	_	_	_	_	_
61	of	_	O	O	_	_	_	_	_
62	the	_	O	O	_	_	_	_	_
63	IL	_	O	O	_	_	_	_	_
64	-	_	O	O	_	_	_	_	_
65	2	_	O	O	_	_	_	_	_
66	R	_	O	O	_	_	_	_	_
67	Jak	_	O	O	_	_	_	_	_
68	/	_	O	O	_	_	_	_	_
69	STAT	_	O	O	_	_	_	_	_
70	pathway	_	O	O	_	_	_	_	_
71	;	_	O	O	_	_	_	_	_
72	and	_	O	O	_	_	_	_	_
73	(	_	O	O	_	_	_	_	_
74	3	_	O	O	_	_	_	_	_
75	)	_	O	O	_	_	_	_	_
76	there	_	O	O	_	_	_	_	_
77	are	_	O	O	_	_	_	_	_
78	major	_	O	O	_	_	_	_	_
79	differences	_	O	O	_	_	_	_	_
80	in	_	O	O	_	_	_	_	_
81	T	_	O	O	_	_	_	_	_
82	-	_	O	O	_	_	_	_	_
83	cell	_	O	O	_	_	_	_	_
84	immortalization	_	O	O	_	_	_	_	_
85	mechanism	_	O	O	_	_	_	_	_
86	(	_	O	O	_	_	_	_	_
87	s	_	O	O	_	_	_	_	_
88	)	_	O	O	_	_	_	_	_
89	which	_	O	O	_	_	_	_	_
90	appear	_	O	O	_	_	_	_	_
91	to	_	O	O	_	_	_	_	_
92	involve	_	O	O	_	_	_	_	_
93	SHP	_	O	O	_	_	_	_	_
94	-	_	O	O	_	_	_	_	_
95	1	_	O	O	_	_	_	_	_
96	and	_	O	O	_	_	_	_	_
97	target	_	O	O	_	_	_	_	_
98	molecules	_	O	O	_	_	_	_	_
99	for	_	O	O	_	_	_	_	_
100	rapamycin	_	O	O	_	_	_	_	_
101	and	_	O	O	_	_	_	_	_
102	RAD	_	O	O	_	_	_	_	_
103	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	56	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	59	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	kilodalton	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	identified	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	untransformed	_	O	O	_	_	_	_	_
11	steroid	_	O	O	_	_	_	_	_
12	receptor	_	O	O	_	_	_	_	_
13	complexes	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	unique	_	O	O	_	_	_	_	_
17	protein	_	O	O	_	_	_	_	_
18	that	_	O	O	_	_	_	_	_
19	exists	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	cytosol	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	a	_	O	O	_	_	_	_	_
24	complex	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	both	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	70	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	90	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	kilodalton	_	O	O	_	_	_	_	_
34	heat	_	O	O	_	_	_	_	_
35	shock	_	O	O	_	_	_	_	_
36	proteins	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	It	_	O	O	_	_	_	_	_
2	has	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	been	_	O	O	_	_	_	_	_
5	shown	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	9	_	O	O	_	_	_	_	_
8	S	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	untransformed	_	O	O	_	_	_	_	_
11	progestin	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	estrogen	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	androgen	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	glucocorticoid	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	complexes	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	rabbit	_	O	O	_	_	_	_	_
23	uterine	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	liver	_	O	O	_	_	_	_	_
26	cytosols	_	O	O	_	_	_	_	_
27	contain	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	59	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	kDa	_	O	O	_	_	_	_	_
32	protein	_	O	O	_	_	_	_	_
33	[	_	O	O	_	_	_	_	_
34	Tai	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	P	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_
38	K	_	O	O	_	_	_	_	_
39	.,	_	O	O	_	_	_	_	_
40	Maeda	_	O	O	_	_	_	_	_
41	,	_	O	O	_	_	_	_	_
42	Y	_	O	O	_	_	_	_	_
43	.,	_	O	O	_	_	_	_	_
44	Nakao	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	K	_	O	O	_	_	_	_	_
47	.,	_	O	O	_	_	_	_	_
48	Wakim	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	N	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_
52	G	_	O	O	_	_	_	_	_
53	.,	_	O	O	_	_	_	_	_
54	Duhring	_	O	O	_	_	_	_	_
55	,	_	O	O	_	_	_	_	_
56	J	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_
58	L	_	O	O	_	_	_	_	_
59	.,	_	O	O	_	_	_	_	_
60	&	_	O	O	_	_	_	_	_
61	Faber	_	O	O	_	_	_	_	_
62	,	_	O	O	_	_	_	_	_
63	L	_	O	O	_	_	_	_	_
64	.	_	O	O	_	_	_	_	_
65	E	_	O	O	_	_	_	_	_
66	.	_	O	O	_	_	_	_	_
67	(	_	O	O	_	_	_	_	_
68	1986	_	O	O	_	_	_	_	_
69	)	_	O	O	_	_	_	_	_
70	Biochemistry	_	O	O	_	_	_	_	_
71	25	_	O	O	_	_	_	_	_
72	,	_	O	O	_	_	_	_	_
73	5269	_	O	O	_	_	_	_	_
74	-	_	O	O	_	_	_	_	_
75	5275	_	O	O	_	_	_	_	_
76	]	_	O	O	_	_	_	_	_
77	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	work	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	monoclonal	_	O	O	_	_	_	_	_
9	antibody	_	O	O	_	_	_	_	_
10	KN	_	O	O	_	_	_	_	_
11	382	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	EC	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	raised	_	O	O	_	_	_	_	_
16	against	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	rabbit	_	O	O	_	_	_	_	_
19	59	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	kDa	_	O	O	_	_	_	_	_
22	protein	_	O	O	_	_	_	_	_
23	reacts	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	9	_	O	O	_	_	_	_	_
26	S	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	untransformed	_	O	O	_	_	_	_	_
29	glucocorticoid	_	O	O	_	_	_	_	_
30	receptor	_	O	O	_	_	_	_	_
31	complexes	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	cytosol	_	O	O	_	_	_	_	_
34	prepared	_	O	O	_	_	_	_	_
35	from	_	O	O	_	_	_	_	_
36	human	_	O	O	_	_	_	_	_
37	IM	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	9	_	O	O	_	_	_	_	_
40	lymphocytes	_	O	O	_	_	_	_	_
41	but	_	O	O	_	_	_	_	_
42	not	_	O	O	_	_	_	_	_
43	with	_	O	O	_	_	_	_	_
44	4	_	O	O	_	_	_	_	_
45	S	_	O	O	_	_	_	_	_
46	salt	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	transformed	_	O	O	_	_	_	_	_
49	receptors	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	human	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	recognized	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	EC	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	antibody	_	O	O	_	_	_	_	_
10	is	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	56	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	kDa	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	p	_	O	O	_	_	_	_	_
18	56	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	moderate	_	O	O	_	_	_	_	_
22	abundance	_	O	O	_	_	_	_	_
23	located	_	O	O	_	_	_	_	_
24	predominantly	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	cytoplasm	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	indirect	_	O	O	_	_	_	_	_
30	immunofluorescence	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	There	_	O	O	_	_	_	_	_
2	are	_	O	O	_	_	_	_	_
3	at	_	O	O	_	_	_	_	_
4	least	_	O	O	_	_	_	_	_
5	six	_	O	O	_	_	_	_	_
6	isomorphs	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	p	_	O	O	_	_	_	_	_
9	56	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	two	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	dimensional	_	O	O	_	_	_	_	_
14	gel	_	O	O	_	_	_	_	_
15	analysis	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	N	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	Terminal	_	O	O	_	_	_	_	_
4	sequencing	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	20	_	O	O	_	_	_	_	_
7	amino	_	O	O	_	_	_	_	_
8	acids	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	shows	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	56	_	O	O	_	_	_	_	_
14	is	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	unique	_	O	O	_	_	_	_	_
17	human	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	56	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	immunoadsorbed	_	O	O	_	_	_	_	_
6	from	_	O	O	_	_	_	_	_
7	IM	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	9	_	O	O	_	_	_	_	_
10	cell	_	O	O	_	_	_	_	_
11	cytosol	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	both	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	70	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	90	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	kDa	_	O	O	_	_	_	_	_
21	heat	_	O	O	_	_	_	_	_
22	shock	_	O	O	_	_	_	_	_
23	proteins	_	O	O	_	_	_	_	_
24	are	_	O	O	_	_	_	_	_
25	coadsorbed	_	O	O	_	_	_	_	_
26	in	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	immune	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	specific	_	O	O	_	_	_	_	_
31	manner	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Neither	_	O	O	_	_	_	_	_
2	heat	_	O	O	_	_	_	_	_
3	shock	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	reacts	_	O	O	_	_	_	_	_
6	directly	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	EC	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	antibody	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	56	_	O	O	_	_	_	_	_
6	exists	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	cytosol	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	higher	_	O	O	_	_	_	_	_
12	order	_	O	O	_	_	_	_	_
13	complex	_	O	O	_	_	_	_	_
14	containing	_	O	O	_	_	_	_	_
15	hsp	_	O	O	_	_	_	_	_
16	70	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	hsp	_	O	O	_	_	_	_	_
19	90	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	both	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	which	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	turn	_	O	O	_	_	_	_	_
26	have	_	O	O	_	_	_	_	_
27	been	_	O	O	_	_	_	_	_
28	found	_	O	O	_	_	_	_	_
29	to	_	O	O	_	_	_	_	_
30	be	_	O	O	_	_	_	_	_
31	associated	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	untransformed	_	O	O	_	_	_	_	_
34	steroid	_	O	O	_	_	_	_	_
35	receptors	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Mutation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Jak	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	patient	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	SCID	_	O	O	_	_	_	_	_
10	:	_	O	O	_	_	_	_	_
11	essential	_	O	O	_	_	_	_	_
12	role	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	Jak	_	O	O	_	_	_	_	_
15	3	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	lymphoid	_	O	O	_	_	_	_	_
18	development	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Males	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	X	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	linked	_	O	O	_	_	_	_	_
6	severe	_	O	O	_	_	_	_	_
7	combined	_	O	O	_	_	_	_	_
8	immunodeficiency	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	XSCID	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	have	_	O	O	_	_	_	_	_
13	defects	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	common	_	O	O	_	_	_	_	_
17	cytokine	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	gamma	_	O	O	_	_	_	_	_
20	chain	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	gamma	_	O	O	_	_	_	_	_
23	c	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	gene	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	encodes	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	shared	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	essential	_	O	O	_	_	_	_	_
32	component	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	receptors	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	interleukin	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	2	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	IL	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	2	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	IL	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	4	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	IL	_	O	O	_	_	_	_	_
51	-	_	O	O	_	_	_	_	_
52	7	_	O	O	_	_	_	_	_
53	,	_	O	O	_	_	_	_	_
54	IL	_	O	O	_	_	_	_	_
55	-	_	O	O	_	_	_	_	_
56	9	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	and	_	O	O	_	_	_	_	_
59	IL	_	O	O	_	_	_	_	_
60	-	_	O	O	_	_	_	_	_
61	15	_	O	O	_	_	_	_	_
62	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	Janus	_	O	O	_	_	_	_	_
3	family	_	O	O	_	_	_	_	_
4	tyrosine	_	O	O	_	_	_	_	_
5	kinase	_	O	O	_	_	_	_	_
6	Jak	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	only	_	O	O	_	_	_	_	_
11	signaling	_	O	O	_	_	_	_	_
12	molecule	_	O	O	_	_	_	_	_
13	known	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	be	_	O	O	_	_	_	_	_
16	associated	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	gamma	_	O	O	_	_	_	_	_
19	c	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	so	_	O	O	_	_	_	_	_
22	it	_	O	O	_	_	_	_	_
23	was	_	O	O	_	_	_	_	_
24	hypothesized	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	defects	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	Jak	_	O	O	_	_	_	_	_
29	3	_	O	O	_	_	_	_	_
30	might	_	O	O	_	_	_	_	_
31	cause	_	O	O	_	_	_	_	_
32	an	_	O	O	_	_	_	_	_
33	XSCID	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	like	_	O	O	_	_	_	_	_
36	phenotype	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	girl	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	immunological	_	O	O	_	_	_	_	_
5	features	_	O	O	_	_	_	_	_
6	indistinguishable	_	O	O	_	_	_	_	_
7	from	_	O	O	_	_	_	_	_
8	those	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	XSCID	_	O	O	_	_	_	_	_
11	was	_	O	O	_	_	_	_	_
12	therefore	_	O	O	_	_	_	_	_
13	selected	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	analysis	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	Epstein	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Barr	_	O	O	_	_	_	_	_
5	virus	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	EBV	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	transformed	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	line	_	O	O	_	_	_	_	_
13	derived	_	O	O	_	_	_	_	_
14	from	_	O	O	_	_	_	_	_
15	her	_	O	O	_	_	_	_	_
16	lymphocytes	_	O	O	_	_	_	_	_
17	had	_	O	O	_	_	_	_	_
18	normal	_	O	O	_	_	_	_	_
19	gamma	_	O	O	_	_	_	_	_
20	c	_	O	O	_	_	_	_	_
21	expression	_	O	O	_	_	_	_	_
22	but	_	O	O	_	_	_	_	_
23	lacked	_	O	O	_	_	_	_	_
24	Jak	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	protein	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	had	_	O	O	_	_	_	_	_
29	greatly	_	O	O	_	_	_	_	_
30	diminished	_	O	O	_	_	_	_	_
31	Jak	_	O	O	_	_	_	_	_
32	3	_	O	O	_	_	_	_	_
33	messenger	_	O	O	_	_	_	_	_
34	RNA	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Sequencing	_	O	O	_	_	_	_	_
2	revealed	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	different	_	O	O	_	_	_	_	_
5	mutation	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	each	_	O	O	_	_	_	_	_
8	allele	_	O	O	_	_	_	_	_
9	:	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	single	_	O	O	_	_	_	_	_
12	nucleotide	_	O	O	_	_	_	_	_
13	insertion	_	O	O	_	_	_	_	_
14	resulting	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	frame	_	O	O	_	_	_	_	_
18	shift	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	premature	_	O	O	_	_	_	_	_
21	termination	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	Jak	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	JH	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	domain	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	nonsense	_	O	O	_	_	_	_	_
32	mutation	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	Jak	_	O	O	_	_	_	_	_
36	3	_	O	O	_	_	_	_	_
37	JH	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	domain	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	lack	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Jak	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	correlated	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	impaired	_	O	O	_	_	_	_	_
10	B	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	signaling	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	as	_	O	O	_	_	_	_	_
15	demonstrated	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	inability	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	activate	_	O	O	_	_	_	_	_
25	Stat	_	O	O	_	_	_	_	_
26	6	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	EBV	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	transformed	_	O	O	_	_	_	_	_
32	cell	_	O	O	_	_	_	_	_
33	line	_	O	O	_	_	_	_	_
34	from	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	patient	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	functions	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	gamma	_	O	O	_	_	_	_	_
9	c	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	Jak	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	Jak	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	essential	_	O	O	_	_	_	_	_
21	for	_	O	O	_	_	_	_	_
22	lymphoid	_	O	O	_	_	_	_	_
23	development	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	signaling	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	functional	_	O	O	_	_	_	_	_
3	synergy	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	12	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	involves	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	38	_	O	O	_	_	_	_	_
15	mitogen	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	activated	_	O	O	_	_	_	_	_
18	protein	_	O	O	_	_	_	_	_
19	kinase	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	is	_	O	O	_	_	_	_	_
22	associated	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	augmentation	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	STAT	_	O	O	_	_	_	_	_
28	serine	_	O	O	_	_	_	_	_
29	phosphorylation	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	12	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	stimulate	_	O	O	_	_	_	_	_
10	mitogen	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	CD	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	activated	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	proliferate	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	produce	_	O	O	_	_	_	_	_
23	IFN	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	gamma	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	kill	_	O	O	_	_	_	_	_
29	tumor	_	O	O	_	_	_	_	_
30	cells	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	magnitude	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	functional	_	O	O	_	_	_	_	_
6	responses	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	greatly	_	O	O	_	_	_	_	_
9	augmented	_	O	O	_	_	_	_	_
10	when	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	combination	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	12	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	peripheral	_	O	O	_	_	_	_	_
3	blood	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	largely	_	O	O	_	_	_	_	_
8	unresponsive	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	these	_	O	O	_	_	_	_	_
11	cytokines	_	O	O	_	_	_	_	_
12	without	_	O	O	_	_	_	_	_
13	prior	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	small	_	O	O	_	_	_	_	_
18	subset	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	8	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	CD	_	O	O	_	_	_	_	_
27	8	_	O	O	_	_	_	_	_
28	+	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	18	_	O	O	_	_	_	_	_
31	bright	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	strongly	_	O	O	_	_	_	_	_
35	activated	_	O	O	_	_	_	_	_
36	by	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	combination	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	12	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	IL	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	2	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	report	_	O	O	_	_	_	_	_
4	we	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	functional	_	O	O	_	_	_	_	_
9	synergy	_	O	O	_	_	_	_	_
10	between	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	12	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	8	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	18	_	O	O	_	_	_	_	_
24	bright	_	O	O	_	_	_	_	_
25	T	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	correlates	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	activation	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	stress	_	O	O	_	_	_	_	_
34	kinases	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	p	_	O	O	_	_	_	_	_
37	38	_	O	O	_	_	_	_	_
38	mitogen	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	activated	_	O	O	_	_	_	_	_
41	protein	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	MAP	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	kinase	_	O	O	_	_	_	_	_
46	and	_	O	O	_	_	_	_	_
47	stress	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	activated	_	O	O	_	_	_	_	_
50	protein	_	O	O	_	_	_	_	_
51	kinase	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	SAPK	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	/	_	O	O	_	_	_	_	_
56	Jun	_	O	O	_	_	_	_	_
57	N	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	terminal	_	O	O	_	_	_	_	_
60	kinase	_	O	O	_	_	_	_	_
61	,	_	O	O	_	_	_	_	_
62	but	_	O	O	_	_	_	_	_
63	not	_	O	O	_	_	_	_	_
64	with	_	O	O	_	_	_	_	_
65	the	_	O	O	_	_	_	_	_
66	activation	_	O	O	_	_	_	_	_
67	of	_	O	O	_	_	_	_	_
68	the	_	O	O	_	_	_	_	_
69	extracellular	_	O	O	_	_	_	_	_
70	signal	_	O	O	_	_	_	_	_
71	-	_	O	O	_	_	_	_	_
72	regulated	_	O	O	_	_	_	_	_
73	kinases	_	O	O	_	_	_	_	_
74	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	functional	_	O	O	_	_	_	_	_
3	synergy	_	O	O	_	_	_	_	_
4	between	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	12	_	O	O	_	_	_	_	_
12	is	_	O	O	_	_	_	_	_
13	also	_	O	O	_	_	_	_	_
14	associated	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	prominent	_	O	O	_	_	_	_	_
18	increase	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	STAT	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	STAT	_	O	O	_	_	_	_	_
24	3	_	O	O	_	_	_	_	_
25	serine	_	O	O	_	_	_	_	_
26	phosphorylation	_	O	O	_	_	_	_	_
27	over	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	observed	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	12	_	O	O	_	_	_	_	_
34	or	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	2	_	O	O	_	_	_	_	_
38	alone	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	By	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	tyrosine	_	O	O	_	_	_	_	_
6	phosphorylation	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	augmented	_	O	O	_	_	_	_	_
10	over	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	seen	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	either	_	O	O	_	_	_	_	_
15	cytokine	_	O	O	_	_	_	_	_
16	alone	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	specific	_	O	O	_	_	_	_	_
3	inhibitor	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	p	_	O	O	_	_	_	_	_
6	38	_	O	O	_	_	_	_	_
7	MAP	_	O	O	_	_	_	_	_
8	kinase	_	O	O	_	_	_	_	_
9	completely	_	O	O	_	_	_	_	_
10	inhibits	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	serine	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	STAT	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	by	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	12	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	2	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	abrogates	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	functional	_	O	O	_	_	_	_	_
33	synergy	_	O	O	_	_	_	_	_
34	between	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	12	_	O	O	_	_	_	_	_
38	and	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	2	_	O	O	_	_	_	_	_
42	without	_	O	O	_	_	_	_	_
43	affecting	_	O	O	_	_	_	_	_
44	STAT	_	O	O	_	_	_	_	_
45	tyrosine	_	O	O	_	_	_	_	_
46	phosphorylation	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	suggests	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	p	_	O	O	_	_	_	_	_
5	38	_	O	O	_	_	_	_	_
6	MAP	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	may	_	O	O	_	_	_	_	_
9	play	_	O	O	_	_	_	_	_
10	an	_	O	O	_	_	_	_	_
11	important	_	O	O	_	_	_	_	_
12	role	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	regulating	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	serine	_	O	O	_	_	_	_	_
17	phosphorylation	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	response	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	combination	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	12	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	2	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	these	_	O	O	_	_	_	_	_
4	findings	_	O	O	_	_	_	_	_
5	indicate	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	optimal	_	O	O	_	_	_	_	_
9	activation	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	12	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	2	_	O	O	_	_	_	_	_
21	may	_	O	O	_	_	_	_	_
22	depend	_	O	O	_	_	_	_	_
23	on	_	O	O	_	_	_	_	_
24	an	_	O	O	_	_	_	_	_
25	interaction	_	O	O	_	_	_	_	_
26	between	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	p	_	O	O	_	_	_	_	_
29	38	_	O	O	_	_	_	_	_
30	MAP	_	O	O	_	_	_	_	_
31	kinase	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	Janus	_	O	O	_	_	_	_	_
34	kinase	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	STAT	_	O	O	_	_	_	_	_
37	signaling	_	O	O	_	_	_	_	_
38	pathways	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Oncogenicity	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	human	_	O	O	_	_	_	_	_
4	papillomavirus	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	or	_	O	O	_	_	_	_	_
7	adenovirus	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	transformed	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	correlates	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	resistance	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	lysis	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	natural	_	O	O	_	_	_	_	_
18	killer	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	reasons	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	dissimilar	_	O	O	_	_	_	_	_
6	oncogenicities	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	adenoviruses	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	human	_	O	O	_	_	_	_	_
12	papillomaviruses	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	HPV	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	humans	_	O	O	_	_	_	_	_
18	are	_	O	O	_	_	_	_	_
19	unknown	_	O	O	_	_	_	_	_
20	but	_	O	O	_	_	_	_	_
21	may	_	O	O	_	_	_	_	_
22	relate	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	differences	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	capacities	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	E	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	A	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	E	_	O	O	_	_	_	_	_
35	7	_	O	O	_	_	_	_	_
36	proteins	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	target	_	O	O	_	_	_	_	_
39	cells	_	O	O	_	_	_	_	_
40	for	_	O	O	_	_	_	_	_
41	rejection	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	host	_	O	O	_	_	_	_	_
45	natural	_	O	O	_	_	_	_	_
46	killer	_	O	O	_	_	_	_	_
47	(	_	O	O	_	_	_	_	_
48	NK	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	cell	_	O	O	_	_	_	_	_
51	response	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	one	_	O	O	_	_	_	_	_
3	test	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	hypothesis	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	compared	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	abilities	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	E	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	A	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	E	_	O	O	_	_	_	_	_
19	7	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	expressing	_	O	O	_	_	_	_	_
22	human	_	O	O	_	_	_	_	_
23	fibroblastic	_	O	O	_	_	_	_	_
24	or	_	O	O	_	_	_	_	_
25	keratinocyte	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	derived	_	O	O	_	_	_	_	_
28	human	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	be	_	O	O	_	_	_	_	_
32	selectively	_	O	O	_	_	_	_	_
33	killed	_	O	O	_	_	_	_	_
34	by	_	O	O	_	_	_	_	_
35	either	_	O	O	_	_	_	_	_
36	unstimulated	_	O	O	_	_	_	_	_
37	or	_	O	O	_	_	_	_	_
38	interferon	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	IFN	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	activated	_	O	O	_	_	_	_	_
44	NK	_	O	O	_	_	_	_	_
45	cells	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Cells	_	O	O	_	_	_	_	_
2	expressing	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	A	_	O	O	_	_	_	_	_
7	oncoprotein	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	selectively	_	O	O	_	_	_	_	_
10	killed	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	unstimulated	_	O	O	_	_	_	_	_
13	NK	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	while	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	same	_	O	O	_	_	_	_	_
19	parental	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	but	_	O	O	_	_	_	_	_
22	expressing	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	HPV	_	O	O	_	_	_	_	_
25	type	_	O	O	_	_	_	_	_
26	16	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	HPV	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	16	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	or	_	O	O	_	_	_	_	_
33	HPV	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	18	_	O	O	_	_	_	_	_
36	E	_	O	O	_	_	_	_	_
37	7	_	O	O	_	_	_	_	_
38	oncoprotein	_	O	O	_	_	_	_	_
39	were	_	O	O	_	_	_	_	_
40	resistant	_	O	O	_	_	_	_	_
41	to	_	O	O	_	_	_	_	_
42	NK	_	O	O	_	_	_	_	_
43	cell	_	O	O	_	_	_	_	_
44	lysis	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	ability	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IFN	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	activated	_	O	O	_	_	_	_	_
7	NK	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	selectively	_	O	O	_	_	_	_	_
11	kill	_	O	O	_	_	_	_	_
12	virally	_	O	O	_	_	_	_	_
13	transformed	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	depends	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	IFN	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	s	_	O	O	_	_	_	_	_
20	ability	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	induce	_	O	O	_	_	_	_	_
23	resistance	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	NK	_	O	O	_	_	_	_	_
26	cell	_	O	O	_	_	_	_	_
27	lysis	_	O	O	_	_	_	_	_
28	in	_	O	O	_	_	_	_	_
29	normal	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	i	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_
33	e	_	O	O	_	_	_	_	_
34	.,	_	O	O	_	_	_	_	_
35	non	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	viral	_	O	O	_	_	_	_	_
38	oncogene	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	expressing	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	but	_	O	O	_	_	_	_	_
43	not	_	O	O	_	_	_	_	_
44	virally	_	O	O	_	_	_	_	_
45	transformed	_	O	O	_	_	_	_	_
46	cells	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	E	_	O	O	_	_	_	_	_
2	1	_	O	O	_	_	_	_	_
3	A	_	O	O	_	_	_	_	_
4	blocked	_	O	O	_	_	_	_	_
5	IFN	_	O	O	_	_	_	_	_
6	'	_	O	O	_	_	_	_	_
7	s	_	O	O	_	_	_	_	_
8	induction	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	cytolytic	_	O	O	_	_	_	_	_
11	resistance	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	resulting	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	selective	_	O	O	_	_	_	_	_
17	lysis	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	adenovirus	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	transformed	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	IFN	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	activated	_	O	O	_	_	_	_	_
27	NK	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	extent	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IFN	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	NK	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	killing	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	E	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	A	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	expressing	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	proportional	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	level	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	E	_	O	O	_	_	_	_	_
24	1	_	O	O	_	_	_	_	_
25	A	_	O	O	_	_	_	_	_
26	expression	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	correlated	_	O	O	_	_	_	_	_
29	with	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	ability	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	E	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	A	_	O	O	_	_	_	_	_
36	to	_	O	O	_	_	_	_	_
37	block	_	O	O	_	_	_	_	_
38	IFN	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	stimulated	_	O	O	_	_	_	_	_
41	gene	_	O	O	_	_	_	_	_
42	expression	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	target	_	O	O	_	_	_	_	_
45	cells	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	7	_	O	O	_	_	_	_	_
6	blocked	_	O	O	_	_	_	_	_
7	neither	_	O	O	_	_	_	_	_
8	IFN	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	stimulated	_	O	O	_	_	_	_	_
11	gene	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	nor	_	O	O	_	_	_	_	_
14	IFN	_	O	O	_	_	_	_	_
15	'	_	O	O	_	_	_	_	_
16	s	_	O	O	_	_	_	_	_
17	induction	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	cytolytic	_	O	O	_	_	_	_	_
20	resistance	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	thereby	_	O	O	_	_	_	_	_
23	precluding	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	selective	_	O	O	_	_	_	_	_
26	lysis	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	HPV	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	transformed	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	IFN	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	activated	_	O	O	_	_	_	_	_
36	NK	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	E	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	A	_	O	O	_	_	_	_	_
7	expression	_	O	O	_	_	_	_	_
8	marks	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	destruction	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	host	_	O	O	_	_	_	_	_
15	NK	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	whereas	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	E	_	O	O	_	_	_	_	_
22	7	_	O	O	_	_	_	_	_
23	oncoprotein	_	O	O	_	_	_	_	_
24	lacks	_	O	O	_	_	_	_	_
25	this	_	O	O	_	_	_	_	_
26	activity	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_


1	Identification	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	essential	_	O	O	_	_	_	_	_
4	GATA	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	Ets	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	motifs	_	O	O	_	_	_	_	_
9	within	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	promoter	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	platelet	_	O	O	_	_	_	_	_
15	glycoprotein	_	O	O	_	_	_	_	_
16	Ib	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	gene	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	Platelet	_	O	O	_	_	_	_	_
2	glycoprotein	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	GP	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	Ib	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	IX	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	V	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	multisubunit	_	O	O	_	_	_	_	_
14	adhesion	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	that	_	O	O	_	_	_	_	_
17	supports	_	O	O	_	_	_	_	_
18	platelet	_	O	O	_	_	_	_	_
19	attachment	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	thrombogenic	_	O	O	_	_	_	_	_
22	surfaces	_	O	O	_	_	_	_	_
23	at	_	O	O	_	_	_	_	_
24	sites	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	vascular	_	O	O	_	_	_	_	_
27	injury	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	congenital	_	O	O	_	_	_	_	_
3	absence	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	receptor	_	O	O	_	_	_	_	_
7	results	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	bleeding	_	O	O	_	_	_	_	_
11	disorder	_	O	O	_	_	_	_	_
12	associated	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	""""	_	O	O	_	_	_	_	_
15	giant	_	O	O	_	_	_	_	_
16	""""	_	O	O	_	_	_	_	_
17	platelets	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	a	_	O	O	_	_	_	_	_
20	condition	_	O	O	_	_	_	_	_
21	linking	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	complex	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	platelet	_	O	O	_	_	_	_	_
29	morphogenesis	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	understand	_	O	O	_	_	_	_	_
3	better	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	GP	_	O	O	_	_	_	_	_
9	Ib	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	IX	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	V	_	O	O	_	_	_	_	_
14	complex	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	studies	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	undertaken	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	define	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	essential	_	O	O	_	_	_	_	_
23	genetic	_	O	O	_	_	_	_	_
24	elements	_	O	O	_	_	_	_	_
25	supporting	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	alpha	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	subunit	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	complex	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	GP	_	O	O	_	_	_	_	_
38	Ib	_	O	O	_	_	_	_	_
39	alpha	_	O	O	_	_	_	_	_
40	)	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	Ib	_	O	O	_	_	_	_	_
3	alpha	_	O	O	_	_	_	_	_
4	promoter	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	evaluated	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	transfection	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	human	_	O	O	_	_	_	_	_
12	erythroleukemia	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	reporter	_	O	O	_	_	_	_	_
16	plasmids	_	O	O	_	_	_	_	_
17	coding	_	O	O	_	_	_	_	_
18	for	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	enzyme	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	luciferase	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Studies	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	initiated	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	fragment	_	O	O	_	_	_	_	_
7	extending	_	O	O	_	_	_	_	_
8	2	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	738	_	O	O	_	_	_	_	_
11	nucleotides	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	'	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	transcription	_	O	O	_	_	_	_	_
17	start	_	O	O	_	_	_	_	_
18	site	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	lead	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	identification	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	253	_	O	O	_	_	_	_	_
26	nucleotides	_	O	O	_	_	_	_	_
27	retaining	_	O	O	_	_	_	_	_
28	full	_	O	O	_	_	_	_	_
29	promoter	_	O	O	_	_	_	_	_
30	activity	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	human	_	O	O	_	_	_	_	_
33	erythroleukemia	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	cells	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	nonhematopoietic	_	O	O	_	_	_	_	_
5	lineage	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	human	_	O	O	_	_	_	_	_
8	endothelial	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	HeLa	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	GP	_	O	O	_	_	_	_	_
15	Ib	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	promoter	_	O	O	_	_	_	_	_
18	activity	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	no	_	O	O	_	_	_	_	_
21	greater	_	O	O	_	_	_	_	_
22	than	_	O	O	_	_	_	_	_
23	background	_	O	O	_	_	_	_	_
24	levels	_	O	O	_	_	_	_	_
25	obtained	_	O	O	_	_	_	_	_
26	with	_	O	O	_	_	_	_	_
27	promoterless	_	O	O	_	_	_	_	_
28	constructs	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	Gel	_	O	O	_	_	_	_	_
2	shift	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	site	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	directed	_	O	O	_	_	_	_	_
8	mutagenesis	_	O	O	_	_	_	_	_
9	studies	_	O	O	_	_	_	_	_
10	defined	_	O	O	_	_	_	_	_
11	essential	_	O	O	_	_	_	_	_
12	GATA	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	Ets	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	motifs	_	O	O	_	_	_	_	_
17	93	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	150	_	O	O	_	_	_	_	_
20	nucleotides	_	O	O	_	_	_	_	_
21	upstream	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	transcription	_	O	O	_	_	_	_	_
25	start	_	O	O	_	_	_	_	_
26	site	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	finding	_	O	O	_	_	_	_	_
30	which	_	O	O	_	_	_	_	_
31	further	_	O	O	_	_	_	_	_
32	substantiates	_	O	O	_	_	_	_	_
33	these	_	O	O	_	_	_	_	_
34	elements	_	O	O	_	_	_	_	_
35	as	_	O	O	_	_	_	_	_
36	important	_	O	O	_	_	_	_	_
37	determinants	_	O	O	_	_	_	_	_
38	of	_	O	O	_	_	_	_	_
39	megakaryocytic	_	O	O	_	_	_	_	_
40	gene	_	O	O	_	_	_	_	_
41	expression	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	define	_	O	O	_	_	_	_	_
4	essential	_	O	O	_	_	_	_	_
5	cis	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	acting	_	O	O	_	_	_	_	_
8	elements	_	O	O	_	_	_	_	_
9	responsible	_	O	O	_	_	_	_	_
10	for	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	expression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	GP	_	O	O	_	_	_	_	_
15	Ib	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	provide	_	O	O	_	_	_	_	_
19	insights	_	O	O	_	_	_	_	_
20	into	_	O	O	_	_	_	_	_
21	molecular	_	O	O	_	_	_	_	_
22	events	_	O	O	_	_	_	_	_
23	coinciding	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	release	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	normal	_	O	O	_	_	_	_	_
29	platelets	_	O	O	_	_	_	_	_
30	into	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	bloodstream	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	ICSAT	_	O	O	_	_	_	_	_
2	overexpression	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	sufficient	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	cause	_	O	O	_	_	_	_	_
8	adult	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	leukemia	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	multiple	_	O	O	_	_	_	_	_
15	myeloma	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	ICSAT	_	O	O	_	_	_	_	_
2	(	_	O	O	_	_	_	_	_
3	Interferon	_	O	O	_	_	_	_	_
4	Consensus	_	O	O	_	_	_	_	_
5	Sequence	_	O	O	_	_	_	_	_
6	binding	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	Activated	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	lymphocyte	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	specific	_	O	O	_	_	_	_	_
18	member	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	interferon	_	O	O	_	_	_	_	_
22	regulatory	_	O	O	_	_	_	_	_
23	factor	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	IRF	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	family	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	factors	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	originally	_	O	O	_	_	_	_	_
33	identified	_	O	O	_	_	_	_	_
34	through	_	O	O	_	_	_	_	_
35	Southwestern	_	O	O	_	_	_	_	_
36	screening	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	ATL	_	O	O	_	_	_	_	_
40	(	_	O	O	_	_	_	_	_
41	Adult	_	O	O	_	_	_	_	_
42	T	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	cell	_	O	O	_	_	_	_	_
45	leukemia	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	16	_	O	O	_	_	_	_	_
49	T	_	O	O	_	_	_	_	_
50	expression	_	O	O	_	_	_	_	_
51	library	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	created	_	O	O	_	_	_	_	_
7	transgenic	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	overexpressing	_	O	O	_	_	_	_	_
10	ICSAT	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	spontaneous	_	O	O	_	_	_	_	_
3	tumorigenesis	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	observed	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	production	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	Concanavalin	_	O	O	_	_	_	_	_
14	A	_	O	O	_	_	_	_	_
15	stimulation	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	significantly	_	O	O	_	_	_	_	_
18	increased	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	transgenic	_	O	O	_	_	_	_	_
21	mice	_	O	O	_	_	_	_	_
22	overexpressing	_	O	O	_	_	_	_	_
23	ICSAT	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	ICSAT	_	O	O	_	_	_	_	_
2	overexpression	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	lymphocytes	_	O	O	_	_	_	_	_
5	seems	_	O	O	_	_	_	_	_
6	insufficient	_	O	O	_	_	_	_	_
7	for	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	leukemogenesis	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	ATL	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	multiple	_	O	O	_	_	_	_	_
14	myeloma	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	MM	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	however	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	it	_	O	O	_	_	_	_	_
22	may	_	O	O	_	_	_	_	_
23	regulate	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	activation	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	its	_	O	O	_	_	_	_	_
29	overexpression	_	O	O	_	_	_	_	_
30	may	_	O	O	_	_	_	_	_
31	lead	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	leukemogenesis	_	O	O	_	_	_	_	_
34	via	_	O	O	_	_	_	_	_
35	controlling	_	O	O	_	_	_	_	_
36	IL	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	production	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	Copyright	_	O	O	_	_	_	_	_
2	1999	_	O	O	_	_	_	_	_
3	Academic	_	O	O	_	_	_	_	_
4	Press	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_


1	Mutant	_	O	O	_	_	_	_	_
2	p	_	O	O	_	_	_	_	_
3	100	_	O	O	_	_	_	_	_
4	H	_	O	O	_	_	_	_	_
5	Mice	_	O	O	_	_	_	_	_
6	Have	_	O	O	_	_	_	_	_
7	Higher	_	O	O	_	_	_	_	_
8	Numbers	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Nucleated	_	O	O	_	_	_	_	_
11	Red	_	O	O	_	_	_	_	_
12	Cells	_	O	O	_	_	_	_	_

1	Among	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	Sox	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	effects	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	erythropoiesis	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	we	_	O	O	_	_	_	_	_
11	have	_	O	O	_	_	_	_	_
12	noticed	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	there	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	more	_	O	O	_	_	_	_	_
17	nucleated	_	O	O	_	_	_	_	_
18	red	_	O	O	_	_	_	_	_
19	blood	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	circulating	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	p	_	O	O	_	_	_	_	_
24	100	_	O	O	_	_	_	_	_
25	H	_	O	O	_	_	_	_	_
26	mutant	_	O	O	_	_	_	_	_
27	mice	_	O	O	_	_	_	_	_
28	than	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	WT	_	O	O	_	_	_	_	_
31	mice	_	O	O	_	_	_	_	_
32	at	_	O	O	_	_	_	_	_
33	14	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_
35	5	_	O	O	_	_	_	_	_
36	dpc	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	18	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	5	_	O	O	_	_	_	_	_
41	dpc	_	O	O	_	_	_	_	_
42	(	_	O	O	_	_	_	_	_
43	Figure	_	O	O	_	_	_	_	_
44	7	_	O	O	_	_	_	_	_
45	A	_	O	O	_	_	_	_	_
46	)	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	at	_	O	O	_	_	_	_	_
4	postnatal	_	O	O	_	_	_	_	_
5	day	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	we	_	O	O	_	_	_	_	_
11	do	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	see	_	O	O	_	_	_	_	_
14	circulating	_	O	O	_	_	_	_	_
15	nucleated	_	O	O	_	_	_	_	_
16	red	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	either	_	O	O	_	_	_	_	_
20	WT	_	O	O	_	_	_	_	_
21	or	_	O	O	_	_	_	_	_
22	mutant	_	O	O	_	_	_	_	_
23	mice	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	suggesting	_	O	O	_	_	_	_	_
26	that	_	O	O	_	_	_	_	_
27	this	_	O	O	_	_	_	_	_
28	may	_	O	O	_	_	_	_	_
29	be	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	transient	_	O	O	_	_	_	_	_
32	effect	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	mutant	_	O	O	_	_	_	_	_
6	liver	_	O	O	_	_	_	_	_
7	shows	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	significant	_	O	O	_	_	_	_	_
10	increase	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	hematopoietic	_	O	O	_	_	_	_	_
13	precursor	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	including	_	O	O	_	_	_	_	_
16	nucleated	_	O	O	_	_	_	_	_
17	erythrocytes	_	O	O	_	_	_	_	_
18	at	_	O	O	_	_	_	_	_
19	18	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	5	_	O	O	_	_	_	_	_
22	dpc	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	Figure	_	O	O	_	_	_	_	_
25	7	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	alteration	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	noted	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	early	_	O	O	_	_	_	_	_
7	as	_	O	O	_	_	_	_	_
8	14	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	dpc	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	observations	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	besides	_	O	O	_	_	_	_	_
6	silencing	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	epsilony	_	O	O	_	_	_	_	_
9	globin	_	O	O	_	_	_	_	_
10	gene	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	Sox	_	O	O	_	_	_	_	_
13	6	_	O	O	_	_	_	_	_
14	may	_	O	O	_	_	_	_	_
15	affect	_	O	O	_	_	_	_	_
16	red	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	maturation	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_



1	Alternative	_	O	O	_	_	_	_	_
2	polyadenylation	_	O	O	_	_	_	_	_
3	events	_	O	O	_	_	_	_	_
4	contribute	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	induction	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	ATc	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	effector	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	ATc	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	synthesized	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	three	_	O	O	_	_	_	_	_
11	prominent	_	O	O	_	_	_	_	_
12	isoforms	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	differ	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	length	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	their	_	O	O	_	_	_	_	_
8	C	_	O	O	_	_	_	_	_
9	terminal	_	O	O	_	_	_	_	_
10	peptides	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	mode	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	synthesis	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Due	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	switch	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	use	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	'	_	O	O	_	_	_	_	_
12	polyA	_	O	O	_	_	_	_	_
13	site	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	more	_	O	O	_	_	_	_	_
17	proximal	_	O	O	_	_	_	_	_
18	polyA	_	O	O	_	_	_	_	_
19	site	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	ATc	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	switches	_	O	O	_	_	_	_	_
26	from	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	synthesis	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	two	_	O	O	_	_	_	_	_
32	longer	_	O	O	_	_	_	_	_
33	isoforms	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	naive	_	O	O	_	_	_	_	_
36	T	_	O	O	_	_	_	_	_
37	cells	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	that	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	short	_	O	O	_	_	_	_	_
42	isoform	_	O	O	_	_	_	_	_
43	A	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	T	_	O	O	_	_	_	_	_
46	effector	_	O	O	_	_	_	_	_
47	cells	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	relative	_	O	O	_	_	_	_	_
3	low	_	O	O	_	_	_	_	_
4	binding	_	O	O	_	_	_	_	_
5	affinity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	cleavage	_	O	O	_	_	_	_	_
8	stimulation	_	O	O	_	_	_	_	_
9	factor	_	O	O	_	_	_	_	_
10	CstF	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	64	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	proximal	_	O	O	_	_	_	_	_
16	polyA	_	O	O	_	_	_	_	_
17	site	_	O	O	_	_	_	_	_
18	seems	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	contribute	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	its	_	O	O	_	_	_	_	_
23	neglect	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	naive	_	O	O	_	_	_	_	_
26	T	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	alternative	_	O	O	_	_	_	_	_
3	polyadenylation	_	O	O	_	_	_	_	_
4	events	_	O	O	_	_	_	_	_
5	ensure	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	rapid	_	O	O	_	_	_	_	_
8	accumulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	high	_	O	O	_	_	_	_	_
11	concentrations	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	ATc	_	O	O	_	_	_	_	_
16	necessary	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	exceed	_	O	O	_	_	_	_	_
19	critical	_	O	O	_	_	_	_	_
20	threshold	_	O	O	_	_	_	_	_
21	levels	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	NF	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	ATc	_	O	O	_	_	_	_	_
26	for	_	O	O	_	_	_	_	_
27	gene	_	O	O	_	_	_	_	_
28	induction	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	effector	_	O	O	_	_	_	_	_
31	T	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	Heterogeneity	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	antigen	_	O	O	_	_	_	_	_
4	molecules	_	O	O	_	_	_	_	_
5	recognized	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	anti	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	tax	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	monoclonal	_	O	O	_	_	_	_	_
12	antibody	_	O	O	_	_	_	_	_
13	Lt	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	lines	_	O	O	_	_	_	_	_
19	bearing	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	leukemia	_	O	O	_	_	_	_	_
24	virus	_	O	O	_	_	_	_	_
25	type	_	O	O	_	_	_	_	_
26	I	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	related	_	O	O	_	_	_	_	_
29	retroviruses	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	Using	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	monoclonal	_	O	O	_	_	_	_	_
4	antibody	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	Lt	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	directed	_	O	O	_	_	_	_	_
11	against	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cell	_	O	O	_	_	_	_	_
15	leukemia	_	O	O	_	_	_	_	_
16	virus	_	O	O	_	_	_	_	_
17	type	_	O	O	_	_	_	_	_
18	I	_	O	O	_	_	_	_	_
19	(	_	O	O	_	_	_	_	_
20	HTLV	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	I	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	trans	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	activator	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	tax	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	antigen	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	we	_	O	O	_	_	_	_	_
34	examined	_	O	O	_	_	_	_	_
35	the	_	O	O	_	_	_	_	_
36	expression	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	tax	_	O	O	_	_	_	_	_
39	1	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	related	_	O	O	_	_	_	_	_
42	antigens	_	O	O	_	_	_	_	_
43	in	_	O	O	_	_	_	_	_
44	a	_	O	O	_	_	_	_	_
45	variety	_	O	O	_	_	_	_	_
46	of	_	O	O	_	_	_	_	_
47	T	_	O	O	_	_	_	_	_
48	cell	_	O	O	_	_	_	_	_
49	lines	_	O	O	_	_	_	_	_
50	bearing	_	O	O	_	_	_	_	_
51	HTLV	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	I	_	O	O	_	_	_	_	_
54	and	_	O	O	_	_	_	_	_
55	related	_	O	O	_	_	_	_	_
56	retroviruses	_	O	O	_	_	_	_	_
57	,	_	O	O	_	_	_	_	_
58	simian	_	O	O	_	_	_	_	_
59	T	_	O	O	_	_	_	_	_
60	cell	_	O	O	_	_	_	_	_
61	leukemia	_	O	O	_	_	_	_	_
62	virus	_	O	O	_	_	_	_	_
63	type	_	O	O	_	_	_	_	_
64	I	_	O	O	_	_	_	_	_
65	(	_	O	O	_	_	_	_	_
66	STLV	_	O	O	_	_	_	_	_
67	-	_	O	O	_	_	_	_	_
68	I	_	O	O	_	_	_	_	_
69	)	_	O	O	_	_	_	_	_
70	and	_	O	O	_	_	_	_	_
71	HTLV	_	O	O	_	_	_	_	_
72	-	_	O	O	_	_	_	_	_
73	II	_	O	O	_	_	_	_	_
74	,	_	O	O	_	_	_	_	_
75	by	_	O	O	_	_	_	_	_
76	immunofluorescence	_	O	O	_	_	_	_	_
77	and	_	O	O	_	_	_	_	_
78	immunoblot	_	O	O	_	_	_	_	_
79	assays	_	O	O	_	_	_	_	_
80	.	_	O	O	_	_	_	_	_

1	Lt	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	reacted	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	all	_	O	O	_	_	_	_	_
7	HTLV	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	I	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	bearing	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	lines	_	O	O	_	_	_	_	_
14	tested	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	five	_	O	O	_	_	_	_	_
17	out	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	eight	_	O	O	_	_	_	_	_
20	simian	_	O	O	_	_	_	_	_
21	cell	_	O	O	_	_	_	_	_
22	lines	_	O	O	_	_	_	_	_
23	bearing	_	O	O	_	_	_	_	_
24	STLV	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	I	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	but	_	O	O	_	_	_	_	_
29	not	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	an	_	O	O	_	_	_	_	_
32	HTLV	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	II	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	bearing	_	O	O	_	_	_	_	_
37	cell	_	O	O	_	_	_	_	_
38	line	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Lt	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	detected	_	O	O	_	_	_	_	_
5	40	_	O	O	_	_	_	_	_
6	kd	_	O	O	_	_	_	_	_
7	tax	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	antigen	_	O	O	_	_	_	_	_
10	molecules	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	most	_	O	O	_	_	_	_	_
13	HTLV	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	bearing	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	lines	_	O	O	_	_	_	_	_
20	except	_	O	O	_	_	_	_	_
21	one	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	line	_	O	O	_	_	_	_	_
24	that	_	O	O	_	_	_	_	_
25	expressed	_	O	O	_	_	_	_	_
26	39	_	O	O	_	_	_	_	_
27	kd	_	O	O	_	_	_	_	_
28	tax	_	O	O	_	_	_	_	_
29	1	_	O	O	_	_	_	_	_
30	antigen	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	STLV	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	I	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	bearing	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cell	_	O	O	_	_	_	_	_
10	lines	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	tax	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	related	_	O	O	_	_	_	_	_
16	antigen	_	O	O	_	_	_	_	_
17	molecules	_	O	O	_	_	_	_	_
18	detected	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	Lt	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	were	_	O	O	_	_	_	_	_
24	heterogeneous	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	having	_	O	O	_	_	_	_	_
27	molecular	_	O	O	_	_	_	_	_
28	weights	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	range	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	36	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	41	_	O	O	_	_	_	_	_
36	kd	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_


1	Thyroid	_	O	O	_	_	_	_	_
2	hormone	_	O	O	_	_	_	_	_
3	receptors	_	O	O	_	_	_	_	_
4	form	_	O	O	_	_	_	_	_
5	distinct	_	O	O	_	_	_	_	_
6	nuclear	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dependent	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	independent	_	O	O	_	_	_	_	_
12	complexes	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	thyroid	_	O	O	_	_	_	_	_
16	hormone	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	element	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	nuclear	_	O	O	_	_	_	_	_
8	proteins	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	recombinant	_	O	O	_	_	_	_	_
11	thyroid	_	O	O	_	_	_	_	_
12	hormone	_	O	O	_	_	_	_	_
13	receptors	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	TRs	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	palindromic	_	O	O	_	_	_	_	_
20	thyroid	_	O	O	_	_	_	_	_
21	hormone	_	O	O	_	_	_	_	_
22	responsive	_	O	O	_	_	_	_	_
23	element	_	O	O	_	_	_	_	_
24	AGGTCATGACCT	_	O	O	_	_	_	_	_
25	(	_	O	O	_	_	_	_	_
26	TREp	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	using	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	gel	_	O	O	_	_	_	_	_
31	electrophoretic	_	O	O	_	_	_	_	_
32	mobility	_	O	O	_	_	_	_	_
33	shift	_	O	O	_	_	_	_	_
34	assay	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Four	_	O	O	_	_	_	_	_
2	specific	_	O	O	_	_	_	_	_
3	protein	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	DNA	_	O	O	_	_	_	_	_
6	complexes	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	detected	_	O	O	_	_	_	_	_
9	after	_	O	O	_	_	_	_	_
10	incubation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	nuclear	_	O	O	_	_	_	_	_
13	extracts	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	NE	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	from	_	O	O	_	_	_	_	_
18	T	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	responsive	_	O	O	_	_	_	_	_
22	pituitary	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	GH	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	TREp	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	containing	_	O	O	_	_	_	_	_
33	DNA	_	O	O	_	_	_	_	_
34	fragment	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	compared	_	O	O	_	_	_	_	_
4	with	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	TREp	_	O	O	_	_	_	_	_
7	binding	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	reticulocyte	_	O	O	_	_	_	_	_
10	lysate	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	synthesized	_	O	O	_	_	_	_	_
13	TRs	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	TR	_	O	O	_	_	_	_	_
2	alpha	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	TR	_	O	O	_	_	_	_	_
6	beta	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	each	_	O	O	_	_	_	_	_
9	formed	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	single	_	O	O	_	_	_	_	_
12	major	_	O	O	_	_	_	_	_
13	TR	_	O	O	_	_	_	_	_
14	:	_	O	O	_	_	_	_	_
15	TREp	_	O	O	_	_	_	_	_
16	complex	_	O	O	_	_	_	_	_
17	which	_	O	O	_	_	_	_	_
18	comigrated	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	least	_	O	O	_	_	_	_	_
22	retarded	_	O	O	_	_	_	_	_
23	complex	_	O	O	_	_	_	_	_
24	formed	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	GH	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	NE	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	while	_	O	O	_	_	_	_	_
31	TR	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	formed	_	O	O	_	_	_	_	_
35	multiple	_	O	O	_	_	_	_	_
36	complexes	_	O	O	_	_	_	_	_
37	suggesting	_	O	O	_	_	_	_	_
38	that	_	O	O	_	_	_	_	_
39	it	_	O	O	_	_	_	_	_
40	can	_	O	O	_	_	_	_	_
41	bind	_	O	O	_	_	_	_	_
42	to	_	O	O	_	_	_	_	_
43	TREp	_	O	O	_	_	_	_	_
44	as	_	O	O	_	_	_	_	_
45	an	_	O	O	_	_	_	_	_
46	oligomer	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	coincubation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	35	_	O	O	_	_	_	_	_
6	S	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	TR	_	O	O	_	_	_	_	_
9	alpha	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	GH	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	NE	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	unlabeled	_	O	O	_	_	_	_	_
18	TREp	_	O	O	_	_	_	_	_
19	resulted	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	only	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	35	_	O	O	_	_	_	_	_
25	S	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	TR	_	O	O	_	_	_	_	_
28	:	_	O	O	_	_	_	_	_
29	TREp	_	O	O	_	_	_	_	_
30	complex	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	but	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	two	_	O	O	_	_	_	_	_
35	additional	_	O	O	_	_	_	_	_
36	more	_	O	O	_	_	_	_	_
37	greatly	_	O	O	_	_	_	_	_
38	retarded	_	O	O	_	_	_	_	_
39	complexes	_	O	O	_	_	_	_	_
40	containing	_	O	O	_	_	_	_	_
41	35	_	O	O	_	_	_	_	_
42	S	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	TR	_	O	O	_	_	_	_	_
45	alpha	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	and	_	O	O	_	_	_	_	_
48	comigrating	_	O	O	_	_	_	_	_
49	with	_	O	O	_	_	_	_	_
50	those	_	O	O	_	_	_	_	_
51	formed	_	O	O	_	_	_	_	_
52	by	_	O	O	_	_	_	_	_
53	GH	_	O	O	_	_	_	_	_
54	3	_	O	O	_	_	_	_	_
55	extract	_	O	O	_	_	_	_	_
56	alone	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_

1	Incubation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	each	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	TRs	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	NE	_	O	O	_	_	_	_	_
9	from	_	O	O	_	_	_	_	_
10	COS	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	7	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	which	_	O	O	_	_	_	_	_
16	do	_	O	O	_	_	_	_	_
17	not	_	O	O	_	_	_	_	_
18	possess	_	O	O	_	_	_	_	_
19	sufficient	_	O	O	_	_	_	_	_
20	endogenous	_	O	O	_	_	_	_	_
21	TRs	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	mediate	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	responses	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	resulted	_	O	O	_	_	_	_	_
30	in	_	O	O	_	_	_	_	_
31	formation	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	new	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	more	_	O	O	_	_	_	_	_
37	greatly	_	O	O	_	_	_	_	_
38	shifted	_	O	O	_	_	_	_	_
39	complex	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	similar	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	heat	_	O	O	_	_	_	_	_
5	labile	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	which	_	O	O	_	_	_	_	_
8	altered	_	O	O	_	_	_	_	_
9	mobility	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	TR	_	O	O	_	_	_	_	_
13	:	_	O	O	_	_	_	_	_
14	TRE	_	O	O	_	_	_	_	_
15	complex	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	also	_	O	O	_	_	_	_	_
18	present	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	NE	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	unresponsive	_	O	O	_	_	_	_	_
26	JEG	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	At	_	O	O	_	_	_	_	_
2	high	_	O	O	_	_	_	_	_
3	concentration	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	NE	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	all	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	TR	_	O	O	_	_	_	_	_
11	bound	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	TREp	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	more	_	O	O	_	_	_	_	_
16	greatly	_	O	O	_	_	_	_	_
17	retarded	_	O	O	_	_	_	_	_
18	than	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	absence	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	NE	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Truncation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	TR	_	O	O	_	_	_	_	_
4	alpha	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	at	_	O	O	_	_	_	_	_
7	amino	_	O	O	_	_	_	_	_
8	acid	_	O	O	_	_	_	_	_
9	210	_	O	O	_	_	_	_	_
10	prevented	_	O	O	_	_	_	_	_
11	additional	_	O	O	_	_	_	_	_
12	complex	_	O	O	_	_	_	_	_
13	formation	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	presence	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	NE	_	O	O	_	_	_	_	_
19	without	_	O	O	_	_	_	_	_
20	affecting	_	O	O	_	_	_	_	_
21	DNA	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	suggesting	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	carboxyl	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	terminus	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	TRs	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	essential	_	O	O	_	_	_	_	_
35	for	_	O	O	_	_	_	_	_
36	interaction	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	nuclear	_	O	O	_	_	_	_	_
39	proteins	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	ABSTRACT	_	O	O	_	_	_	_	_
3	TRUNCATED	_	O	O	_	_	_	_	_
4	AT	_	O	O	_	_	_	_	_
5	250	_	O	O	_	_	_	_	_
6	WORDS	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_

1	Quantitation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	globin	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	RNA	_	O	O	_	_	_	_	_
2	was	_	O	O	_	_	_	_	_
3	first	_	O	O	_	_	_	_	_
4	reverse	_	O	O	_	_	_	_	_
5	transcribed	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	cDNA	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Primers	_	O	O	_	_	_	_	_
2	for	_	O	O	_	_	_	_	_
3	cDNA	_	O	O	_	_	_	_	_
4	PCR	_	O	O	_	_	_	_	_
5	amplification	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	globin	_	O	O	_	_	_	_	_
8	genes	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	obtained	_	O	O	_	_	_	_	_
11	from	_	O	O	_	_	_	_	_
12	Primerbank	_	O	O	_	_	_	_	_
13	[	_	O	O	_	_	_	_	_
14	51	_	O	O	_	_	_	_	_
15	]	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	primers	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	searched	_	O	O	_	_	_	_	_
5	against	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	NCBI	_	O	O	_	_	_	_	_
8	database	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	confirm	_	O	O	_	_	_	_	_
11	specificity	_	O	O	_	_	_	_	_
12	.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	epsilony	_	O	O	_	_	_	_	_
3	globin	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	MHB	_	O	O	_	_	_	_	_
6	1666	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	'	_	O	O	_	_	_	_	_
10	TGGCCTGTGGAGTAAGGTCAA	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	';	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	MHB	_	O	O	_	_	_	_	_
15	1667	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	5	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	GAAGCAGAGGACAAGTTCCCA	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	'.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	zeta	_	O	O	_	_	_	_	_
3	globin	_	O	O	_	_	_	_	_
4	:	_	O	O	_	_	_	_	_
5	MHB	_	O	O	_	_	_	_	_
6	1668	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	'	_	O	O	_	_	_	_	_
10	CTACCCCCAGACGAAGACCTA	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	';	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	MHB	_	O	O	_	_	_	_	_
15	1669	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	5	_	O	O	_	_	_	_	_
18	'	_	O	O	_	_	_	_	_
19	CTTAACCGCATCCCCTACGG	_	O	O	_	_	_	_	_
20	3	_	O	O	_	_	_	_	_
21	'.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	betaH	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	globin	_	O	O	_	_	_	_	_
5	:	_	O	O	_	_	_	_	_
6	MHB	_	O	O	_	_	_	_	_
7	1672	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	5	_	O	O	_	_	_	_	_
10	'	_	O	O	_	_	_	_	_
11	TGGACAACCTCAAGGAGACC	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	';	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	MHB	_	O	O	_	_	_	_	_
16	1673	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	5	_	O	O	_	_	_	_	_
19	'	_	O	O	_	_	_	_	_
20	ACCTCTGGGGTGAATTCCTT	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	'.	_	O	O	_	_	_	_	_

1	For	_	O	O	_	_	_	_	_
2	betamaj	_	O	O	_	_	_	_	_
3	/	_	O	O	_	_	_	_	_
4	min	_	O	O	_	_	_	_	_
5	globin	_	O	O	_	_	_	_	_
6	:	_	O	O	_	_	_	_	_
7	MHB	_	O	O	_	_	_	_	_
8	1674	_	O	O	_	_	_	_	_
9	:	_	O	O	_	_	_	_	_
10	5	_	O	O	_	_	_	_	_
11	'	_	O	O	_	_	_	_	_
12	ATGGCCTGAATCACTTGGAC	_	O	O	_	_	_	_	_
13	3	_	O	O	_	_	_	_	_
14	';	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	MHB	_	O	O	_	_	_	_	_
17	1675	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	5	_	O	O	_	_	_	_	_
20	'	_	O	O	_	_	_	_	_
21	ACGATCATATTGCCCAGGAG	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	'.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	SYBR	_	O	O	_	_	_	_	_
4	green	_	O	O	_	_	_	_	_
5	supermix	_	O	O	_	_	_	_	_
6	kit	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	ROX	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	Bio	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Rad	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	Hercules	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	California	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	United	_	O	O	_	_	_	_	_
19	States	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	PCR	_	O	O	_	_	_	_	_
23	amplification	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	run	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	an	_	O	O	_	_	_	_	_
28	ABI	_	O	O	_	_	_	_	_
29	7000	_	O	O	_	_	_	_	_
30	(	_	O	O	_	_	_	_	_
31	Applied	_	O	O	_	_	_	_	_
32	Biosystems	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	Foster	_	O	O	_	_	_	_	_
35	City	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	California	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	United	_	O	O	_	_	_	_	_
40	States	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	at	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	University	_	O	O	_	_	_	_	_
45	of	_	O	O	_	_	_	_	_
46	Arizona	_	O	O	_	_	_	_	_
47	core	_	O	O	_	_	_	_	_
48	facility	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	All	_	O	O	_	_	_	_	_
2	PCR	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	performed	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	mul	_	O	O	_	_	_	_	_
10	reaction	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	12	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_
14	5	_	O	O	_	_	_	_	_
15	mul	_	O	O	_	_	_	_	_
16	SYBR	_	O	O	_	_	_	_	_
17	green	_	O	O	_	_	_	_	_
18	supermix	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	GAPDH	_	O	O	_	_	_	_	_
2	mRNA	_	O	O	_	_	_	_	_
3	levels	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	used	_	O	O	_	_	_	_	_
6	as	_	O	O	_	_	_	_	_
7	control	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	input	_	O	O	_	_	_	_	_
10	RNA	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	Standard	_	O	O	_	_	_	_	_
2	curve	_	O	O	_	_	_	_	_
3	analyses	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	performed	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	test	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	efficiency	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	amplifications	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Triplicates	_	O	O	_	_	_	_	_
2	were	_	O	O	_	_	_	_	_
3	done	_	O	O	_	_	_	_	_
4	for	_	O	O	_	_	_	_	_
5	each	_	O	O	_	_	_	_	_
6	PCR	_	O	O	_	_	_	_	_
7	reaction	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Relative	_	O	O	_	_	_	_	_
2	quantitative	_	O	O	_	_	_	_	_
3	values	_	O	O	_	_	_	_	_
4	were	_	O	O	_	_	_	_	_
5	calculated	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	ABI	_	O	O	_	_	_	_	_
9	Prism	_	O	O	_	_	_	_	_
10	7000	_	O	O	_	_	_	_	_
11	SDS	_	O	O	_	_	_	_	_
12	Software	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	Applied	_	O	O	_	_	_	_	_
15	Biosystems	_	O	O	_	_	_	_	_
16	)	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	normalized	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	GAPDH	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	Microsoft	_	O	O	_	_	_	_	_
23	Excel	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Redmond	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	Washington	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	United	_	O	O	_	_	_	_	_
30	States	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_



1	Tumor	_	O	O	_	_	_	_	_
2	necrosis	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	signal	_	O	O	_	_	_	_	_
8	transduction	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	HIV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	infected	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	OBJECTIVE	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	To	_	O	O	_	_	_	_	_
4	examine	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	inter	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	relationship	_	O	O	_	_	_	_	_
9	between	_	O	O	_	_	_	_	_
10	HIV	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	infection	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	surface	_	O	O	_	_	_	_	_
18	receptors	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	tumor	_	O	O	_	_	_	_	_
21	necrosis	_	O	O	_	_	_	_	_
22	factor	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	TNF	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	an	_	O	O	_	_	_	_	_
30	immunoregulatory	_	O	O	_	_	_	_	_
31	cytokine	_	O	O	_	_	_	_	_
32	that	_	O	O	_	_	_	_	_
33	can	_	O	O	_	_	_	_	_
34	enhance	_	O	O	_	_	_	_	_
35	HIV	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	replication	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	DESIGN	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Infected	_	O	O	_	_	_	_	_
4	promyelocytic	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	promonocytic	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	were	_	O	O	_	_	_	_	_
9	examined	_	O	O	_	_	_	_	_
10	because	_	O	O	_	_	_	_	_
11	they	_	O	O	_	_	_	_	_
12	normally	_	O	O	_	_	_	_	_
13	express	_	O	O	_	_	_	_	_
14	both	_	O	O	_	_	_	_	_
15	types	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	TNF	_	O	O	_	_	_	_	_
18	receptors	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	METHODS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	TNF	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	surface	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	determined	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	specific	_	O	O	_	_	_	_	_
11	monoclonal	_	O	O	_	_	_	_	_
12	antibody	_	O	O	_	_	_	_	_
13	recognition	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	flow	_	O	O	_	_	_	_	_
16	cytometry	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	signal	_	O	O	_	_	_	_	_
20	transduction	_	O	O	_	_	_	_	_
21	was	_	O	O	_	_	_	_	_
22	detected	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	gel	_	O	O	_	_	_	_	_
25	shift	_	O	O	_	_	_	_	_
26	analysis	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	HIV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	quantitated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	reverse	_	O	O	_	_	_	_	_
11	transcriptase	_	O	O	_	_	_	_	_
12	assay	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	In	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	OM	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	promyelocytic	_	O	O	_	_	_	_	_
11	model	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	chronic	_	O	O	_	_	_	_	_
14	infection	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	TNF	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	induced	_	O	O	_	_	_	_	_
21	HIV	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	expression	_	O	O	_	_	_	_	_
25	also	_	O	O	_	_	_	_	_
26	resulted	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	substantial	_	O	O	_	_	_	_	_
30	increase	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	75	_	O	O	_	_	_	_	_
33	kd	_	O	O	_	_	_	_	_
34	TNF	_	O	O	_	_	_	_	_
35	receptor	_	O	O	_	_	_	_	_
36	(	_	O	O	_	_	_	_	_
37	TR	_	O	O	_	_	_	_	_
38	75	_	O	O	_	_	_	_	_
39	)	_	O	O	_	_	_	_	_
40	expression	_	O	O	_	_	_	_	_
41	although	_	O	O	_	_	_	_	_
42	55	_	O	O	_	_	_	_	_
43	kD	_	O	O	_	_	_	_	_
44	TNF	_	O	O	_	_	_	_	_
45	receptor	_	O	O	_	_	_	_	_
46	(	_	O	O	_	_	_	_	_
47	TR	_	O	O	_	_	_	_	_
48	55	_	O	O	_	_	_	_	_
49	)	_	O	O	_	_	_	_	_
50	levels	_	O	O	_	_	_	_	_
51	were	_	O	O	_	_	_	_	_
52	not	_	O	O	_	_	_	_	_
53	dramatically	_	O	O	_	_	_	_	_
54	altered	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	series	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	uninfected	_	O	O	_	_	_	_	_
5	parental	_	O	O	_	_	_	_	_
6	HL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	60	_	O	O	_	_	_	_	_
9	subclones	_	O	O	_	_	_	_	_
10	all	_	O	O	_	_	_	_	_
11	reduced	_	O	O	_	_	_	_	_
12	TR	_	O	O	_	_	_	_	_
13	75	_	O	O	_	_	_	_	_
14	surface	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	response	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	TNF	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	alpha	_	O	O	_	_	_	_	_
22	treatment	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Enhanced	_	O	O	_	_	_	_	_
2	TR	_	O	O	_	_	_	_	_
3	75	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	on	_	O	O	_	_	_	_	_
6	OM	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	.	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	cells	_	O	O	_	_	_	_	_
12	followed	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	same	_	O	O	_	_	_	_	_
15	TNF	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	alpha	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	dose	_	O	O	_	_	_	_	_
20	dependency	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	that	_	O	O	_	_	_	_	_
23	observed	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	HIV	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	production	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	increase	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	TR	_	O	O	_	_	_	_	_
5	75	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	also	_	O	O	_	_	_	_	_
9	evident	_	O	O	_	_	_	_	_
10	during	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	peak	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	acute	_	O	O	_	_	_	_	_
16	HIV	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	infection	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	HL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	60	_	O	O	_	_	_	_	_
24	promyelocytes	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Although	_	O	O	_	_	_	_	_
2	TR	_	O	O	_	_	_	_	_
3	55	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	unaltered	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	TNF	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	HIV	_	O	O	_	_	_	_	_
14	activation	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	this	_	O	O	_	_	_	_	_
17	receptor	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	still	_	O	O	_	_	_	_	_
20	involved	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	viral	_	O	O	_	_	_	_	_
24	activation	_	O	O	_	_	_	_	_
25	process	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Antibody	_	O	O	_	_	_	_	_
2	cross	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	linking	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	TR	_	O	O	_	_	_	_	_
7	55	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	absence	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	exogenous	_	O	O	_	_	_	_	_
14	TNF	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	alpha	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	maximal	_	O	O	_	_	_	_	_
20	HIV	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	expression	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	an	_	O	O	_	_	_	_	_
26	up	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	modulation	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	surface	_	O	O	_	_	_	_	_
31	TR	_	O	O	_	_	_	_	_
32	75	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	nuclear	_	O	O	_	_	_	_	_
36	NF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	kappa	_	O	O	_	_	_	_	_
39	B	_	O	O	_	_	_	_	_
40	activity	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	OM	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	10	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	cultures	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	Surprisingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	case	_	O	O	_	_	_	_	_
7	even	_	O	O	_	_	_	_	_
8	when	_	O	O	_	_	_	_	_
9	an	_	O	O	_	_	_	_	_
10	antagonistic	_	O	O	_	_	_	_	_
11	anti	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	TR	_	O	O	_	_	_	_	_
14	55	_	O	O	_	_	_	_	_
15	antibody	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	used	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Anti	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	TR	_	O	O	_	_	_	_	_
4	55	_	O	O	_	_	_	_	_
5	antibody	_	O	O	_	_	_	_	_
6	cross	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	linking	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	chronically	_	O	O	_	_	_	_	_
11	infected	_	O	O	_	_	_	_	_
12	U	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	promonocytic	_	O	O	_	_	_	_	_
15	cultures	_	O	O	_	_	_	_	_
16	could	_	O	O	_	_	_	_	_
17	only	_	O	O	_	_	_	_	_
18	partially	_	O	O	_	_	_	_	_
19	substitute	_	O	O	_	_	_	_	_
20	for	_	O	O	_	_	_	_	_
21	TNF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	alpha	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	induced	_	O	O	_	_	_	_	_
26	HIV	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	expression	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Our	_	O	O	_	_	_	_	_
4	results	_	O	O	_	_	_	_	_
5	demonstrated	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	HIV	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	infection	_	O	O	_	_	_	_	_
11	can	_	O	O	_	_	_	_	_
12	selectively	_	O	O	_	_	_	_	_
13	influence	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	surface	_	O	O	_	_	_	_	_
16	expression	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	TNF	_	O	O	_	_	_	_	_
19	receptors	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	potentially	_	O	O	_	_	_	_	_
22	influencing	_	O	O	_	_	_	_	_
23	its	_	O	O	_	_	_	_	_
24	own	_	O	O	_	_	_	_	_
25	expression	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	altering	_	O	O	_	_	_	_	_
28	normal	_	O	O	_	_	_	_	_
29	immunoregulatory	_	O	O	_	_	_	_	_
30	signal	_	O	O	_	_	_	_	_
31	transduction	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_


1	Protein	_	O	O	_	_	_	_	_
2	kinase	_	O	O	_	_	_	_	_
3	inhibitor	_	O	O	_	_	_	_	_
4	H	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	7	_	O	O	_	_	_	_	_
7	blocks	_	O	O	_	_	_	_	_
8	accumulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	unspliced	_	O	O	_	_	_	_	_
11	mRNA	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	T	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	cell	_	O	O	_	_	_	_	_
17	leukemia	_	O	O	_	_	_	_	_
18	virus	_	O	O	_	_	_	_	_
19	type	_	O	O	_	_	_	_	_
20	I	_	O	O	_	_	_	_	_
21	(	_	O	O	_	_	_	_	_
22	HTLV	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	I	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Rex	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	post	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	transcriptional	_	O	O	_	_	_	_	_
7	regulator	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	T	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	leukemia	_	O	O	_	_	_	_	_
14	virus	_	O	O	_	_	_	_	_
15	type	_	O	O	_	_	_	_	_
16	I	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	HTLV	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	I	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	known	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	induce	_	O	O	_	_	_	_	_
27	accumulation	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	unspliced	_	O	O	_	_	_	_	_
31	viral	_	O	O	_	_	_	_	_
32	gag	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	pol	_	O	O	_	_	_	_	_
35	mRNA	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Rex	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	phosphoprotein	_	O	O	_	_	_	_	_
5	found	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	nucleolus	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	whose	_	O	O	_	_	_	_	_
12	function	_	O	O	_	_	_	_	_
13	may	_	O	O	_	_	_	_	_
14	be	_	O	O	_	_	_	_	_
15	regulated	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	its	_	O	O	_	_	_	_	_
18	localization	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	phosphorylation	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	examined	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	role	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	on	_	O	O	_	_	_	_	_
9	Rex	_	O	O	_	_	_	_	_
10	function	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	using	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	protein	_	O	O	_	_	_	_	_
15	kinase	_	O	O	_	_	_	_	_
16	inhibitor	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	H	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	7	_	O	O	_	_	_	_	_
21	[	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	5	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	isoquinolinyl	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	sulfonyl	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	2	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	methylpiperazine	_	O	O	_	_	_	_	_
35	]	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	HTLV	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	I	_	O	O	_	_	_	_	_
7	infected	_	O	O	_	_	_	_	_
8	human	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	line	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	H	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	7	_	O	O	_	_	_	_	_
17	blocked	_	O	O	_	_	_	_	_
18	specifically	_	O	O	_	_	_	_	_
19	accumulation	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	unspliced	_	O	O	_	_	_	_	_
23	gag	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	pol	_	O	O	_	_	_	_	_
26	mRNA	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	resulting	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	decreased	_	O	O	_	_	_	_	_
32	Gag	_	O	O	_	_	_	_	_
33	protein	_	O	O	_	_	_	_	_
34	synthesis	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	corresponds	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	decreased	_	O	O	_	_	_	_	_
40	in	_	O	O	_	_	_	_	_
41	vivo	_	O	O	_	_	_	_	_
42	phosphorylation	_	O	O	_	_	_	_	_
43	of	_	O	O	_	_	_	_	_
44	Rex	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	other	_	O	O	_	_	_	_	_
5	viral	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	cellular	_	O	O	_	_	_	_	_
8	products	_	O	O	_	_	_	_	_
9	have	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	been	_	O	O	_	_	_	_	_
12	influenced	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	level	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	H	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	7	_	O	O	_	_	_	_	_
20	used	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	phosphorylation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	Rex	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	required	_	O	O	_	_	_	_	_
9	for	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	viral	_	O	O	_	_	_	_	_
12	RNA	_	O	O	_	_	_	_	_
13	partition	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	HTLV	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	I	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Modulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	normal	_	O	O	_	_	_	_	_
4	erythroid	_	O	O	_	_	_	_	_
5	differentiation	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	endogenous	_	O	O	_	_	_	_	_
9	thyroid	_	O	O	_	_	_	_	_
10	hormone	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	retinoic	_	O	O	_	_	_	_	_
13	acid	_	O	O	_	_	_	_	_
14	receptors	_	O	O	_	_	_	_	_
15	:	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	possible	_	O	O	_	_	_	_	_
18	target	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	v	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	erbA	_	O	O	_	_	_	_	_
23	oncogene	_	O	O	_	_	_	_	_
24	action	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	v	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	erbA	_	O	O	_	_	_	_	_
5	oncogene	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	mutated	_	O	O	_	_	_	_	_
9	version	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	thyroid	_	O	O	_	_	_	_	_
13	hormone	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	alpha	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	c	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	erbA	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	TR	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	alpha	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	inhibits	_	O	O	_	_	_	_	_
27	erythroid	_	O	O	_	_	_	_	_
28	differentiation	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	constitutively	_	O	O	_	_	_	_	_
31	represses	_	O	O	_	_	_	_	_
32	transcription	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	certain	_	O	O	_	_	_	_	_
35	erythrocyte	_	O	O	_	_	_	_	_
36	genes	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	suggesting	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	normal	_	O	O	_	_	_	_	_
41	function	_	O	O	_	_	_	_	_
42	of	_	O	O	_	_	_	_	_
43	the	_	O	O	_	_	_	_	_
44	proto	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	oncogene	_	O	O	_	_	_	_	_
47	c	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	erbA	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	erythropoiesis	_	O	O	_	_	_	_	_
52	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	endogenous	_	O	O	_	_	_	_	_
7	thyroid	_	O	O	_	_	_	_	_
8	hormone	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	(	_	O	O	_	_	_	_	_
12	c	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	erbA	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	TR	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	closely	_	O	O	_	_	_	_	_
23	related	_	O	O	_	_	_	_	_
24	retinoic	_	O	O	_	_	_	_	_
25	acid	_	O	O	_	_	_	_	_
26	receptor	_	O	O	_	_	_	_	_
27	alpha	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	RAR	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	alpha	_	O	O	_	_	_	_	_
32	)	_	O	O	_	_	_	_	_
33	play	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	role	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	regulation	_	O	O	_	_	_	_	_
39	of	_	O	O	_	_	_	_	_
40	normal	_	O	O	_	_	_	_	_
41	erythroid	_	O	O	_	_	_	_	_
42	differentiation	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Retinoic	_	O	O	_	_	_	_	_
2	acid	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	RA	_	O	O	_	_	_	_	_
5	)	_	O	O	_	_	_	_	_
6	distinctly	_	O	O	_	_	_	_	_
7	modulated	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	erythroid	_	O	O	_	_	_	_	_
10	differentiation	_	O	O	_	_	_	_	_
11	program	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	normal	_	O	O	_	_	_	_	_
14	erythroid	_	O	O	_	_	_	_	_
15	progenitors	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	erythroblasts	_	O	O	_	_	_	_	_
18	reversibly	_	O	O	_	_	_	_	_
19	transformed	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	conditional	_	O	O	_	_	_	_	_
23	tyrosine	_	O	O	_	_	_	_	_
24	kinase	_	O	O	_	_	_	_	_
25	oncogene	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	added	_	O	O	_	_	_	_	_
3	pulsewise	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	immature	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	differentiation	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	accelerated	_	O	O	_	_	_	_	_
11	while	_	O	O	_	_	_	_	_
12	more	_	O	O	_	_	_	_	_
13	mature	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	underwent	_	O	O	_	_	_	_	_
16	premature	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	death	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Thyroid	_	O	O	_	_	_	_	_
2	hormone	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	alone	_	O	O	_	_	_	_	_
8	caused	_	O	O	_	_	_	_	_
9	similar	_	O	O	_	_	_	_	_
10	but	_	O	O	_	_	_	_	_
11	weaker	_	O	O	_	_	_	_	_
12	effects	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	T	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	strongly	_	O	O	_	_	_	_	_
6	enhanced	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	action	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	suggesting	_	O	O	_	_	_	_	_
13	cooperative	_	O	O	_	_	_	_	_
14	action	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	two	_	O	O	_	_	_	_	_
18	receptors	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	modulating	_	O	O	_	_	_	_	_
21	erythroid	_	O	O	_	_	_	_	_
22	differentiation	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	RAR	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	alpha	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	negative	_	O	O	_	_	_	_	_
12	erythroblasts	_	O	O	_	_	_	_	_
13	conferred	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	induced	_	O	O	_	_	_	_	_
17	regulation	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	differentiation	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	otherwise	_	O	O	_	_	_	_	_
23	unresponsive	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	thus	_	O	O	_	_	_	_	_
27	showing	_	O	O	_	_	_	_	_
28	that	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	RAR	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	alpha	_	O	O	_	_	_	_	_
33	is	_	O	O	_	_	_	_	_
34	essential	_	O	O	_	_	_	_	_
35	for	_	O	O	_	_	_	_	_
36	the	_	O	O	_	_	_	_	_
37	RA	_	O	O	_	_	_	_	_
38	effect	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Likewise	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	enhanced	_	O	O	_	_	_	_	_
4	expression	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	exogenous	_	O	O	_	_	_	_	_
7	c	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	erbA	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	TR	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	alpha	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	erythroblasts	_	O	O	_	_	_	_	_
16	rendered	_	O	O	_	_	_	_	_
17	them	_	O	O	_	_	_	_	_
18	susceptible	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	modulation	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	differentiation	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	3	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	suggesting	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	similar	_	O	O	_	_	_	_	_
30	function	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	both	_	O	O	_	_	_	_	_
33	receptors	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	Identification	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	purification	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	human	_	O	O	_	_	_	_	_
6	Stat	_	O	O	_	_	_	_	_
7	proteins	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	response	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	interleukin	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	A	_	O	O	_	_	_	_	_
2	key	_	O	O	_	_	_	_	_
3	cytokine	_	O	O	_	_	_	_	_
4	induced	_	O	O	_	_	_	_	_
5	during	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	immune	_	O	O	_	_	_	_	_
8	response	_	O	O	_	_	_	_	_
9	is	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	T	_	O	O	_	_	_	_	_
3	cell	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	genes	_	O	O	_	_	_	_	_
8	encoding	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	2	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	various	_	O	O	_	_	_	_	_
15	chains	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	its	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	transcriptionally	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	turn	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	secreted	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	serves	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	stimulate	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	proliferation	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	differentiation	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Several	_	O	O	_	_	_	_	_
2	recent	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	have	_	O	O	_	_	_	_	_
5	implicated	_	O	O	_	_	_	_	_
6	Jak	_	O	O	_	_	_	_	_
7	kinases	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	signaling	_	O	O	_	_	_	_	_
11	pathway	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	this	_	O	O	_	_	_	_	_
3	lead	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	set	_	O	O	_	_	_	_	_
7	out	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	identify	_	O	O	_	_	_	_	_
10	transcription	_	O	O	_	_	_	_	_
11	factors	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	response	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	2	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Human	_	O	O	_	_	_	_	_
2	peripheral	_	O	O	_	_	_	_	_
3	blood	_	O	O	_	_	_	_	_
4	lymphocytes	_	O	O	_	_	_	_	_
5	were	_	O	O	_	_	_	_	_
6	observed	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	contain	_	O	O	_	_	_	_	_
9	several	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	inducible	_	O	O	_	_	_	_	_
15	DNA	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	activities	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Similar	_	O	O	_	_	_	_	_
2	activities	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	observed	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	transformed	_	O	O	_	_	_	_	_
9	human	_	O	O	_	_	_	_	_
10	lymphocyte	_	O	O	_	_	_	_	_
11	line	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	termed	_	O	O	_	_	_	_	_
14	YT	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	purified	_	O	O	_	_	_	_	_
4	these	_	O	O	_	_	_	_	_
5	activities	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	principal	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	inducible	_	O	O	_	_	_	_	_
16	component	_	O	O	_	_	_	_	_
17	bears	_	O	O	_	_	_	_	_
18	significant	_	O	O	_	_	_	_	_
19	relatedness	_	O	O	_	_	_	_	_
20	to	_	O	O	_	_	_	_	_
21	a	_	O	O	_	_	_	_	_
22	prolactin	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	induced	_	O	O	_	_	_	_	_
25	transcription	_	O	O	_	_	_	_	_
26	factor	_	O	O	_	_	_	_	_
27	first	_	O	O	_	_	_	_	_
28	identified	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	sheep	_	O	O	_	_	_	_	_
31	mammary	_	O	O	_	_	_	_	_
32	gland	_	O	O	_	_	_	_	_
33	tissue	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	hypothesize	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	activation	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	this	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	designated	_	O	O	_	_	_	_	_
10	hStat	_	O	O	_	_	_	_	_
11	5	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	helps	_	O	O	_	_	_	_	_
14	govern	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	biological	_	O	O	_	_	_	_	_
17	effects	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	during	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	immune	_	O	O	_	_	_	_	_
25	response	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_


1	Differential	_	O	O	_	_	_	_	_
2	inhibition	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Smad	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	Smad	_	O	O	_	_	_	_	_
8	7	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	bone	_	O	O	_	_	_	_	_
11	morphogenetic	_	O	O	_	_	_	_	_
12	protein	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	activin	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	growth	_	O	O	_	_	_	_	_
19	arrest	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	apoptosis	_	O	O	_	_	_	_	_
22	in	_	O	O	_	_	_	_	_
23	B	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_


1	Smad	_	O	O	_	_	_	_	_
2	6	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	Smad	_	O	O	_	_	_	_	_
5	7	_	O	O	_	_	_	_	_
6	prevent	_	O	O	_	_	_	_	_
7	ligand	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	induced	_	O	O	_	_	_	_	_
10	activation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	signal	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	transducing	_	O	O	_	_	_	_	_
15	Smad	_	O	O	_	_	_	_	_
16	proteins	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	transforming	_	O	O	_	_	_	_	_
20	growth	_	O	O	_	_	_	_	_
21	factor	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	beta	_	O	O	_	_	_	_	_
24	family	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	both	_	O	O	_	_	_	_	_
6	Smad	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	Smad	_	O	O	_	_	_	_	_
10	7	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	bone	_	O	O	_	_	_	_	_
14	morphogenetic	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	hBMP	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	2	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	inducible	_	O	O	_	_	_	_	_
25	antagonists	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	hBMP	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	2	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	induced	_	O	O	_	_	_	_	_
32	growth	_	O	O	_	_	_	_	_
33	arrest	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	apoptosis	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	mouse	_	O	O	_	_	_	_	_
38	B	_	O	O	_	_	_	_	_
39	cell	_	O	O	_	_	_	_	_
40	hybridoma	_	O	O	_	_	_	_	_
41	HS	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	72	_	O	O	_	_	_	_	_
44	cells	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	confirmed	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	ectopic	_	O	O	_	_	_	_	_
8	expressions	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Smad	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	Smad	_	O	O	_	_	_	_	_
14	7	_	O	O	_	_	_	_	_
15	inhibited	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	hBMP	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	2	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	Smad	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	Smad	_	O	O	_	_	_	_	_
26	5	_	O	O	_	_	_	_	_
27	phosphorylation	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	previously	_	O	O	_	_	_	_	_
3	reported	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Smad	_	O	O	_	_	_	_	_
6	7	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	an	_	O	O	_	_	_	_	_
9	activin	_	O	O	_	_	_	_	_
10	A	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	inducible	_	O	O	_	_	_	_	_
13	antagonist	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	activin	_	O	O	_	_	_	_	_
16	A	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	growth	_	O	O	_	_	_	_	_
20	arrest	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	apoptosis	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	HS	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	72	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	although	_	O	O	_	_	_	_	_
4	mRNA	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Smad	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	activin	_	O	O	_	_	_	_	_
13	A	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	HS	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	72	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	Smad	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	showed	_	O	O	_	_	_	_	_
23	no	_	O	O	_	_	_	_	_
24	antagonistic	_	O	O	_	_	_	_	_
25	effect	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	activin	_	O	O	_	_	_	_	_
28	A	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	induced	_	O	O	_	_	_	_	_
31	growth	_	O	O	_	_	_	_	_
32	arrest	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	apoptosis	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Moreover	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	found	_	O	O	_	_	_	_	_
5	that	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	ectopic	_	O	O	_	_	_	_	_
8	expression	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	Smad	_	O	O	_	_	_	_	_
11	7	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	not	_	O	O	_	_	_	_	_
15	Smad	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	inhibited	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	activin	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	induced	_	O	O	_	_	_	_	_
24	Smad	_	O	O	_	_	_	_	_
25	2	_	O	O	_	_	_	_	_
26	phosphorylation	_	O	O	_	_	_	_	_
27	in	_	O	O	_	_	_	_	_
28	HS	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	72	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	Smad	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	Smad	_	O	O	_	_	_	_	_
7	7	_	O	O	_	_	_	_	_
8	exhibit	_	O	O	_	_	_	_	_
9	differential	_	O	O	_	_	_	_	_
10	inhibitory	_	O	O	_	_	_	_	_
11	effects	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	bone	_	O	O	_	_	_	_	_
14	morphogenetic	_	O	O	_	_	_	_	_
15	protein	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	activin	_	O	O	_	_	_	_	_
21	A	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	mediated	_	O	O	_	_	_	_	_
24	signaling	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	B	_	O	O	_	_	_	_	_
27	lineage	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_


1	GP	_	O	O	_	_	_	_	_
2	modulated	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	induced	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	beta	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	ratio	_	O	O	_	_	_	_	_
19	towards	_	O	O	_	_	_	_	_
20	an	_	O	O	_	_	_	_	_
21	anti	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	inflammatory	_	O	O	_	_	_	_	_
24	phenotype	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	simplified	_	O	O	_	_	_	_	_
4	approach	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	might	_	O	O	_	_	_	_	_
16	represent	_	O	O	_	_	_	_	_
17	two	_	O	O	_	_	_	_	_
18	sides	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	coin	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	i	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	e	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	pro	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	or	_	O	O	_	_	_	_	_
4	anti	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	inflammatory	_	O	O	_	_	_	_	_
7	action	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Therefore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	we	_	O	O	_	_	_	_	_
4	applied	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	beta	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	RA	_	O	O	_	_	_	_	_
15	ratio	_	O	O	_	_	_	_	_
16	as	_	O	O	_	_	_	_	_
17	an	_	O	O	_	_	_	_	_
18	indicator	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	degree	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	inflammation	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	GP	_	O	O	_	_	_	_	_
6	+	_	O	O	_	_	_	_	_
7	LPS	_	O	O	_	_	_	_	_
8	treatments	_	O	O	_	_	_	_	_
9	resulted	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	generating	_	O	O	_	_	_	_	_
12	more	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	beta	_	O	O	_	_	_	_	_
17	than	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	1	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	at	_	O	O	_	_	_	_	_
23	early	_	O	O	_	_	_	_	_
24	time	_	O	O	_	_	_	_	_
25	points	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	i	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_
29	e	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	up	_	O	O	_	_	_	_	_
2	to	_	O	O	_	_	_	_	_
3	24	_	O	O	_	_	_	_	_
4	h	_	O	O	_	_	_	_	_
5	.	_	O	O	_	_	_	_	_

1	Comparing	_	O	O	_	_	_	_	_
2	LPS	_	O	O	_	_	_	_	_
3	vs	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	+	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	we	_	O	O	_	_	_	_	_
6	did	_	O	O	_	_	_	_	_
7	not	_	O	O	_	_	_	_	_
8	find	_	O	O	_	_	_	_	_
9	substantial	_	O	O	_	_	_	_	_
10	alterations	_	O	O	_	_	_	_	_
11	over	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	time	_	O	O	_	_	_	_	_
14	course	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	48	_	O	O	_	_	_	_	_
17	h	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	beta	_	O	O	_	_	_	_	_
24	/	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	RA	_	O	O	_	_	_	_	_
29	ratio	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	only	_	O	O	_	_	_	_	_
32	a	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	non	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	significant	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	2	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	5	_	O	O	_	_	_	_	_
41	fold	_	O	O	_	_	_	_	_
42	higher	_	O	O	_	_	_	_	_
43	ratio	_	O	O	_	_	_	_	_
44	at	_	O	O	_	_	_	_	_
45	6	_	O	O	_	_	_	_	_
46	h	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_

1	With	_	O	O	_	_	_	_	_
2	respect	_	O	O	_	_	_	_	_
3	to	_	O	O	_	_	_	_	_
4	TSST	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	or	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	theoretical	_	O	O	_	_	_	_	_
10	value	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	GP	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	TSST	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	calc	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	vs	_	O	O	_	_	_	_	_
2	.	_	O	O	_	_	_	_	_

1	GP	_	O	O	_	_	_	_	_
2	+	_	O	O	_	_	_	_	_
3	TSST	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	observed	_	O	O	_	_	_	_	_
9	a	_	O	O	_	_	_	_	_
10	pronounced	_	O	O	_	_	_	_	_
11	anti	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	inflammatory	_	O	O	_	_	_	_	_
14	action	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	GP	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	demonstrated	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	an	_	O	O	_	_	_	_	_
22	about	_	O	O	_	_	_	_	_
23	10	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	100	_	O	O	_	_	_	_	_
26	fold	_	O	O	_	_	_	_	_
27	reduced	_	O	O	_	_	_	_	_
28	ratio	_	O	O	_	_	_	_	_
29	at	_	O	O	_	_	_	_	_
30	18	_	O	O	_	_	_	_	_
31	h	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	24	_	O	O	_	_	_	_	_
34	h	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	incubation	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	i	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_
40	e	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	a	_	O	O	_	_	_	_	_
2	higher	_	O	O	_	_	_	_	_
3	production	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	1	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	than	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	1	_	O	O	_	_	_	_	_
14	beta	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	n	_	O	O	_	_	_	_	_
17	=	_	O	O	_	_	_	_	_
18	3	_	O	O	_	_	_	_	_
19	;	_	O	O	_	_	_	_	_
20	both	_	O	O	_	_	_	_	_
21	p	_	O	O	_	_	_	_	_
22	<	_	O	O	_	_	_	_	_
23	0	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	05	_	O	O	_	_	_	_	_
26	;	_	O	O	_	_	_	_	_
27	Fig	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	6	_	O	O	_	_	_	_	_
2	)	_	O	O	_	_	_	_	_
3	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	biological	_	O	O	_	_	_	_	_
3	relevance	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	result	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	suggested	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	decrease	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	dependent	_	O	O	_	_	_	_	_
18	release	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	from	_	O	O	_	_	_	_	_
24	murine	_	O	O	_	_	_	_	_
25	EL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	4	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	following	_	O	O	_	_	_	_	_
30	GP	_	O	O	_	_	_	_	_
31	+	_	O	O	_	_	_	_	_
32	TSST	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	when	_	O	O	_	_	_	_	_
36	compared	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	TSST	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	or	_	O	O	_	_	_	_	_
42	GP	_	O	O	_	_	_	_	_
43	/	_	O	O	_	_	_	_	_
44	TSST	_	O	O	_	_	_	_	_
45	-	_	O	O	_	_	_	_	_
46	1	_	O	O	_	_	_	_	_
47	calc	_	O	O	_	_	_	_	_
48	.	_	O	O	_	_	_	_	_

1	(	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	not	_	O	O	_	_	_	_	_
4	shown	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	detail	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	n	_	O	O	_	_	_	_	_
9	=	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	;	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	<	_	O	O	_	_	_	_	_
14	0	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_
16	07	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_



1	The	_	O	O	_	_	_	_	_
2	role	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	shared	_	O	O	_	_	_	_	_
5	receptor	_	O	O	_	_	_	_	_
6	motifs	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	common	_	O	O	_	_	_	_	_
9	Stat	_	O	O	_	_	_	_	_
10	proteins	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	generation	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	cytokine	_	O	O	_	_	_	_	_
16	pleiotropy	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	redundancy	_	O	O	_	_	_	_	_
19	by	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	IL	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	7	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	IL	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	13	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	15	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_


1	To	_	O	O	_	_	_	_	_
2	understand	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	molecular	_	O	O	_	_	_	_	_
5	bases	_	O	O	_	_	_	_	_
6	for	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	redundancy	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	pleiotropy	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	we	_	O	O	_	_	_	_	_
13	have	_	O	O	_	_	_	_	_
14	compared	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	Stat	_	O	O	_	_	_	_	_
17	proteins	_	O	O	_	_	_	_	_
18	activated	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	peripheral	_	O	O	_	_	_	_	_
21	blood	_	O	O	_	_	_	_	_
22	lymphocytes	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	PBLs	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	by	_	O	O	_	_	_	_	_
27	cytokines	_	O	O	_	_	_	_	_
28	with	_	O	O	_	_	_	_	_
29	shared	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	distinct	_	O	O	_	_	_	_	_
32	actions	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	2	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	rapidly	_	O	O	_	_	_	_	_
10	activated	_	O	O	_	_	_	_	_
11	Stat	_	O	O	_	_	_	_	_
12	5	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	fresh	_	O	O	_	_	_	_	_
15	PBL	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	Stat	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	Stat	_	O	O	_	_	_	_	_
22	5	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	preactivated	_	O	O	_	_	_	_	_
25	PBL	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	7	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	15	_	O	O	_	_	_	_	_
8	induced	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	same	_	O	O	_	_	_	_	_
11	complexes	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	feature	_	O	O	_	_	_	_	_
19	explained	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	existence	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	similar	_	O	O	_	_	_	_	_
25	tyrosine	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	phosphorylated	_	O	O	_	_	_	_	_
28	motifs	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	cytoplasmic	_	O	O	_	_	_	_	_
32	domains	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	2	_	O	O	_	_	_	_	_
37	R	_	O	O	_	_	_	_	_
38	beta	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	7	_	O	O	_	_	_	_	_
43	R	_	O	O	_	_	_	_	_
44	that	_	O	O	_	_	_	_	_
45	can	_	O	O	_	_	_	_	_
46	serve	_	O	O	_	_	_	_	_
47	as	_	O	O	_	_	_	_	_
48	docking	_	O	O	_	_	_	_	_
49	sites	_	O	O	_	_	_	_	_
50	for	_	O	O	_	_	_	_	_
51	Stat	_	O	O	_	_	_	_	_
52	proteins	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	13	_	O	O	_	_	_	_	_
4	Induced	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	same	_	O	O	_	_	_	_	_
7	complexes	_	O	O	_	_	_	_	_
8	as	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	4	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	finding	_	O	O	_	_	_	_	_
15	explained	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	our	_	O	O	_	_	_	_	_
18	studies	_	O	O	_	_	_	_	_
19	implicating	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	R	_	O	O	_	_	_	_	_
24	as	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	shared	_	O	O	_	_	_	_	_
27	component	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	receptors	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	studies	_	O	O	_	_	_	_	_
3	demonstrate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	single	_	O	O	_	_	_	_	_
7	cytokine	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	activate	_	O	O	_	_	_	_	_
10	different	_	O	O	_	_	_	_	_
11	combinations	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Stat	_	O	O	_	_	_	_	_
14	proteins	_	O	O	_	_	_	_	_
15	under	_	O	O	_	_	_	_	_
16	different	_	O	O	_	_	_	_	_
17	physiological	_	O	O	_	_	_	_	_
18	conditions	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	also	_	O	O	_	_	_	_	_
22	indicate	_	O	O	_	_	_	_	_
23	two	_	O	O	_	_	_	_	_
24	mechanisms	_	O	O	_	_	_	_	_
25	by	_	O	O	_	_	_	_	_
26	which	_	O	O	_	_	_	_	_
27	distinct	_	O	O	_	_	_	_	_
28	cytokines	_	O	O	_	_	_	_	_
29	can	_	O	O	_	_	_	_	_
30	activate	_	O	O	_	_	_	_	_
31	the	_	O	O	_	_	_	_	_
32	same	_	O	O	_	_	_	_	_
33	Stat	_	O	O	_	_	_	_	_
34	protein	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	and	_	O	O	_	_	_	_	_
3	role	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	PML	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	normal	_	O	O	_	_	_	_	_
9	adult	_	O	O	_	_	_	_	_
10	hematopoiesis	_	O	O	_	_	_	_	_
11	:	_	O	O	_	_	_	_	_
12	functional	_	O	O	_	_	_	_	_
13	interaction	_	O	O	_	_	_	_	_
14	between	_	O	O	_	_	_	_	_
15	PML	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	Rb	_	O	O	_	_	_	_	_
18	proteins	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	erythropoiesis	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	PML	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	investigated	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	purified	_	O	O	_	_	_	_	_
11	early	_	O	O	_	_	_	_	_
12	hematopoietic	_	O	O	_	_	_	_	_
13	progenitor	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	(	_	O	O	_	_	_	_	_
16	HPCs	_	O	O	_	_	_	_	_
17	)	_	O	O	_	_	_	_	_
18	induced	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	unilineage	_	O	O	_	_	_	_	_
21	erythroid	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	granulocytic	_	O	O	_	_	_	_	_
24	differentiation	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	PML	_	O	O	_	_	_	_	_
2	mRNA	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	protein	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	while	_	O	O	_	_	_	_	_
7	barely	_	O	O	_	_	_	_	_
8	detectable	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	quiescent	_	O	O	_	_	_	_	_
11	HPCs	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	are	_	O	O	_	_	_	_	_
14	consistently	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	by	_	O	O	_	_	_	_	_
17	growth	_	O	O	_	_	_	_	_
18	factor	_	O	O	_	_	_	_	_
19	stimulation	_	O	O	_	_	_	_	_
20	through	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	erythroid	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	granulocytic	_	O	O	_	_	_	_	_
25	lineage	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Thereafter	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	PML	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	downmodulated	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	late	_	O	O	_	_	_	_	_
8	granulocytic	_	O	O	_	_	_	_	_
9	maturation	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	whereas	_	O	O	_	_	_	_	_
12	it	_	O	O	_	_	_	_	_
13	is	_	O	O	_	_	_	_	_
14	sustainably	_	O	O	_	_	_	_	_
15	expressed	_	O	O	_	_	_	_	_
16	through	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	erythroid	_	O	O	_	_	_	_	_
19	pathway	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	functional	_	O	O	_	_	_	_	_
3	studies	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	PML	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	inhibited	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	addition	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	antisense	_	O	O	_	_	_	_	_
13	oligomers	_	O	O	_	_	_	_	_
14	targeting	_	O	O	_	_	_	_	_
15	PML	_	O	O	_	_	_	_	_
16	mRNA	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	alpha	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	PML	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Interestingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	early	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	day	_	O	O	_	_	_	_	_
7	0	_	O	O	_	_	_	_	_
8	HPCs	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	PML	_	O	O	_	_	_	_	_
14	reduced	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	number	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	both	_	O	O	_	_	_	_	_
19	erythroid	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	granulocytic	_	O	O	_	_	_	_	_
22	colonies	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	whereas	_	O	O	_	_	_	_	_
25	late	_	O	O	_	_	_	_	_
26	treatment	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	day	_	O	O	_	_	_	_	_
29	5	_	O	O	_	_	_	_	_
30	culture	_	O	O	_	_	_	_	_
31	)	_	O	O	_	_	_	_	_
32	reduced	_	O	O	_	_	_	_	_
33	erythroid	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	but	_	O	O	_	_	_	_	_
36	not	_	O	O	_	_	_	_	_
37	granulocytic	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	clonogenesis	_	O	O	_	_	_	_	_
40	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	PML	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	required	_	O	O	_	_	_	_	_
8	for	_	O	O	_	_	_	_	_
9	early	_	O	O	_	_	_	_	_
10	hematopoiesis	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	erythroid	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	but	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	granulocytic	_	O	O	_	_	_	_	_
17	maturation	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	pattern	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	PML	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	normal	_	O	O	_	_	_	_	_
8	hematopoiesis	_	O	O	_	_	_	_	_
9	mimics	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	retinoblastoma	_	O	O	_	_	_	_	_
13	pRb	_	O	O	_	_	_	_	_
14	105	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Combined	_	O	O	_	_	_	_	_
2	treatment	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	HPCs	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	alpha	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	PML	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	alpha	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	Rb	_	O	O	_	_	_	_	_
13	oligomers	_	O	O	_	_	_	_	_
14	inhibited	_	O	O	_	_	_	_	_
15	both	_	O	O	_	_	_	_	_
16	PML	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	Rb	_	O	O	_	_	_	_	_
19	protein	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	completely	_	O	O	_	_	_	_	_
23	blocked	_	O	O	_	_	_	_	_
24	erythroid	_	O	O	_	_	_	_	_
25	colony	_	O	O	_	_	_	_	_
26	development	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	PML	_	O	O	_	_	_	_	_
4	and	_	O	O	_	_	_	_	_
5	pRb	_	O	O	_	_	_	_	_
6	105	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	co	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	immunoprecipitated	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	cellular	_	O	O	_	_	_	_	_
13	lysates	_	O	O	_	_	_	_	_
14	derived	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	erythroid	_	O	O	_	_	_	_	_
17	precursors	_	O	O	_	_	_	_	_
18	indicating	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	this	_	O	O	_	_	_	_	_
21	functional	_	O	O	_	_	_	_	_
22	interaction	_	O	O	_	_	_	_	_
23	may	_	O	O	_	_	_	_	_
24	have	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	biochemical	_	O	O	_	_	_	_	_
27	basis	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	key	_	O	O	_	_	_	_	_
6	functional	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	PML	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	early	_	O	O	_	_	_	_	_
12	hematopoiesis	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	late	_	O	O	_	_	_	_	_
15	erythropoiesis	_	O	O	_	_	_	_	_
16	:	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	latter	_	O	O	_	_	_	_	_
19	phenomenon	_	O	O	_	_	_	_	_
20	may	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	related	_	O	O	_	_	_	_	_
23	to	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	molecular	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	functional	_	O	O	_	_	_	_	_
28	interaction	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	PML	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	pRb	_	O	O	_	_	_	_	_
33	105	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_


1	Regulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	human	_	O	O	_	_	_	_	_
5	interleukin	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	2	_	O	O	_	_	_	_	_
8	gene	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	the	_	O	O	_	_	_	_	_
11	alpha	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	beta	_	O	O	_	_	_	_	_
14	isoforms	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	glucocorticoid	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	immunosuppressive	_	O	O	_	_	_	_	_
3	effects	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	glucocorticoids	_	O	O	_	_	_	_	_
6	are	_	O	O	_	_	_	_	_
7	largely	_	O	O	_	_	_	_	_
8	due	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	transcriptional	_	O	O	_	_	_	_	_
11	inhibition	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	immunologically	_	O	O	_	_	_	_	_
14	relevant	_	O	O	_	_	_	_	_
15	genes	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	such	_	O	O	_	_	_	_	_
18	as	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	interleukin	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	2	_	O	O	_	_	_	_	_
27	)	_	O	O	_	_	_	_	_
28	gene	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	are	_	O	O	_	_	_	_	_
4	mediated	_	O	O	_	_	_	_	_
5	by	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	intracellular	_	O	O	_	_	_	_	_
8	glucocorticoid	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	GR	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	humans	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	alternative	_	O	O	_	_	_	_	_
5	splicing	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	GR	_	O	O	_	_	_	_	_
9	precursor	_	O	O	_	_	_	_	_
10	mRNA	_	O	O	_	_	_	_	_
11	gives	_	O	O	_	_	_	_	_
12	rise	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	two	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	isoforms	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	termed	_	O	O	_	_	_	_	_
19	GRalpha	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	GRbeta	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	previously	_	O	O	_	_	_	_	_
3	demonstrated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	GRbeta	_	O	O	_	_	_	_	_
6	could	_	O	O	_	_	_	_	_
7	antagonize	_	O	O	_	_	_	_	_
8	GRalpha	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	mediated	_	O	O	_	_	_	_	_
11	transactivation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	a	_	O	O	_	_	_	_	_
14	glucocorticoid	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	responsive	_	O	O	_	_	_	_	_
17	element	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	GRE	_	O	O	_	_	_	_	_
20	)	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	driven	_	O	O	_	_	_	_	_
23	reporter	_	O	O	_	_	_	_	_
24	gene	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	COS	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	7	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	present	_	O	O	_	_	_	_	_
3	study	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	designed	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	analyze	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	roles	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	two	_	O	O	_	_	_	_	_
13	GR	_	O	O	_	_	_	_	_
14	isoforms	_	O	O	_	_	_	_	_
15	on	_	O	O	_	_	_	_	_
16	glucocorticoid	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	mediated	_	O	O	_	_	_	_	_
19	transrepression	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	gene	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	recently	_	O	O	_	_	_	_	_
4	developed	_	O	O	_	_	_	_	_
5	transfection	_	O	O	_	_	_	_	_
6	technique	_	O	O	_	_	_	_	_
7	,	_	O	O	_	_	_	_	_
8	we	_	O	O	_	_	_	_	_
9	demonstrate	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	primary	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	lymphocytes	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	stimulation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	548	_	O	O	_	_	_	_	_
20	bp	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	promoter	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	luciferase	_	O	O	_	_	_	_	_
27	reporter	_	O	O	_	_	_	_	_
28	construct	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	phorbol	_	O	O	_	_	_	_	_
31	ester	_	O	O	_	_	_	_	_
32	and	_	O	O	_	_	_	_	_
33	calcium	_	O	O	_	_	_	_	_
34	ionophore	_	O	O	_	_	_	_	_
35	is	_	O	O	_	_	_	_	_
36	reversed	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	dexamethasone	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	a	_	O	O	_	_	_	_	_
41	similar	_	O	O	_	_	_	_	_
42	extent	_	O	O	_	_	_	_	_
43	as	_	O	O	_	_	_	_	_
44	in	_	O	O	_	_	_	_	_
45	Jurkat	_	O	O	_	_	_	_	_
46	T	_	O	O	_	_	_	_	_
47	lymphoma	_	O	O	_	_	_	_	_
48	cells	_	O	O	_	_	_	_	_
49	transfected	_	O	O	_	_	_	_	_
50	with	_	O	O	_	_	_	_	_
51	a	_	O	O	_	_	_	_	_
52	GRalpha	_	O	O	_	_	_	_	_
53	expression	_	O	O	_	_	_	_	_
54	vector	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Transfection	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	GRbeta	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	vector	_	O	O	_	_	_	_	_
7	alone	_	O	O	_	_	_	_	_
8	did	_	O	O	_	_	_	_	_
9	not	_	O	O	_	_	_	_	_
10	result	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	promoter	_	O	O	_	_	_	_	_
16	repression	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	response	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	glucocorticoids	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	GRbeta	_	O	O	_	_	_	_	_
4	did	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	antagonize	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	repressive	_	O	O	_	_	_	_	_
9	effects	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	GRalpha	_	O	O	_	_	_	_	_
12	on	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	2	_	O	O	_	_	_	_	_
16	promoter	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Surprisingly	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	overexpression	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	GRbeta	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	Jurkat	_	O	O	_	_	_	_	_
8	cells	_	O	O	_	_	_	_	_
9	did	_	O	O	_	_	_	_	_
10	not	_	O	O	_	_	_	_	_
11	cause	_	O	O	_	_	_	_	_
12	significant	_	O	O	_	_	_	_	_
13	inhibition	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	GRalpha	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	transactivation	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	a	_	O	O	_	_	_	_	_
21	GRE	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	dependent	_	O	O	_	_	_	_	_
24	luciferase	_	O	O	_	_	_	_	_
25	reporter	_	O	O	_	_	_	_	_
26	gene	_	O	O	_	_	_	_	_
27	either	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	conclude	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	transrepressive	_	O	O	_	_	_	_	_
6	effect	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	glucocorticoids	_	O	O	_	_	_	_	_
9	on	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	2	_	O	O	_	_	_	_	_
13	gene	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	exclusively	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	GRalpha	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	GRbeta	_	O	O	_	_	_	_	_
2	can	_	O	O	_	_	_	_	_
3	neither	_	O	O	_	_	_	_	_
4	antagonize	_	O	O	_	_	_	_	_
5	GRalpha	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	mediated	_	O	O	_	_	_	_	_
8	transactivation	_	O	O	_	_	_	_	_
9	nor	_	O	O	_	_	_	_	_
10	transrepression	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	Jurkat	_	O	O	_	_	_	_	_
13	cells	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	indicating	_	O	O	_	_	_	_	_
16	a	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	type	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	specific	_	O	O	_	_	_	_	_
21	pattern	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	GRbeta	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	mediated	_	O	O	_	_	_	_	_
26	antiglucocorticoid	_	O	O	_	_	_	_	_
27	activity	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_


1	beta	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	(	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	--	_	O	O	_	_	_	_	_
6	>	_	O	O	_	_	_	_	_
7	3	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	glucan	_	O	O	_	_	_	_	_
13	modulates	_	O	O	_	_	_	_	_
14	DNA	_	O	O	_	_	_	_	_
15	binding	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	nuclear	_	O	O	_	_	_	_	_
18	factors	_	O	O	_	_	_	_	_
19	kappaB	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	AT	_	O	O	_	_	_	_	_
22	and	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	leading	_	O	O	_	_	_	_	_
27	to	_	O	O	_	_	_	_	_
28	an	_	O	O	_	_	_	_	_
29	anti	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	inflammatory	_	O	O	_	_	_	_	_
32	shift	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	1	_	O	O	_	_	_	_	_
38	beta	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	1	_	O	O	_	_	_	_	_
43	receptor	_	O	O	_	_	_	_	_
44	antagonist	_	O	O	_	_	_	_	_
45	ratio	_	O	O	_	_	_	_	_

1	Background	_	O	O	_	_	_	_	_

1	beta	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	--	_	O	O	_	_	_	_	_
5	>	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	D	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	glucans	_	O	O	_	_	_	_	_
11	represent	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	pathogen	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	associated	_	O	O	_	_	_	_	_
16	molecular	_	O	O	_	_	_	_	_
17	pattern	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	are	_	O	O	_	_	_	_	_
20	able	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	modify	_	O	O	_	_	_	_	_
23	biological	_	O	O	_	_	_	_	_
24	responses	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Employing	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	comprehensive	_	O	O	_	_	_	_	_
4	methodological	_	O	O	_	_	_	_	_
5	approach	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	aim	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	our	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	vitro	_	O	O	_	_	_	_	_
13	study	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	elucidate	_	O	O	_	_	_	_	_
17	novel	_	O	O	_	_	_	_	_
18	molecular	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	cellular	_	O	O	_	_	_	_	_
21	mechanisms	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	human	_	O	O	_	_	_	_	_
24	peripheral	_	O	O	_	_	_	_	_
25	blood	_	O	O	_	_	_	_	_
26	immune	_	O	O	_	_	_	_	_
27	cells	_	O	O	_	_	_	_	_
28	mediated	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	a	_	O	O	_	_	_	_	_
31	fungal	_	O	O	_	_	_	_	_
32	beta	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	1	_	O	O	_	_	_	_	_
35	--	_	O	O	_	_	_	_	_
36	>	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	D	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	glucan	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	i	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_
45	e	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	glucan	_	O	O	_	_	_	_	_
2	phosphate	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	presence	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	lipopolysaccharide	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	LPS	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	or	_	O	O	_	_	_	_	_
13	toxic	_	O	O	_	_	_	_	_
14	shock	_	O	O	_	_	_	_	_
15	syndrome	_	O	O	_	_	_	_	_
16	toxin	_	O	O	_	_	_	_	_
17	1	_	O	O	_	_	_	_	_
18	(	_	O	O	_	_	_	_	_
19	TSST	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Results	_	O	O	_	_	_	_	_

1	Despite	_	O	O	_	_	_	_	_
2	an	_	O	O	_	_	_	_	_
3	activation	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	nuclear	_	O	O	_	_	_	_	_
6	factor	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	NF	_	O	O	_	_	_	_	_
9	)	_	O	O	_	_	_	_	_
10	kappaB	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	NFinterleukin	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	6	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	NFAT	_	O	O	_	_	_	_	_
20	similar	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	LPS	_	O	O	_	_	_	_	_
23	or	_	O	O	_	_	_	_	_
24	TSST	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	we	_	O	O	_	_	_	_	_
29	observed	_	O	O	_	_	_	_	_
30	no	_	O	O	_	_	_	_	_
31	significant	_	O	O	_	_	_	_	_
32	production	_	O	O	_	_	_	_	_
33	of	_	O	O	_	_	_	_	_
34	IL	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	1	_	O	O	_	_	_	_	_
37	beta	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	IL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	6	_	O	O	_	_	_	_	_
42	,	_	O	O	_	_	_	_	_
43	tumor	_	O	O	_	_	_	_	_
44	necrosis	_	O	O	_	_	_	_	_
45	factor	_	O	O	_	_	_	_	_
46	alpha	_	O	O	_	_	_	_	_
47	or	_	O	O	_	_	_	_	_
48	interferon	_	O	O	_	_	_	_	_
49	gamma	_	O	O	_	_	_	_	_
50	induced	_	O	O	_	_	_	_	_
51	by	_	O	O	_	_	_	_	_
52	glucan	_	O	O	_	_	_	_	_
53	phosphate	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_

1	Glucan	_	O	O	_	_	_	_	_
2	phosphate	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	treated	_	O	O	_	_	_	_	_
5	leukocytes	_	O	O	_	_	_	_	_
6	induced	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	substantial	_	O	O	_	_	_	_	_
9	amount	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	8	_	O	O	_	_	_	_	_
14	(	_	O	O	_	_	_	_	_
15	peak	_	O	O	_	_	_	_	_
16	at	_	O	O	_	_	_	_	_
17	18	_	O	O	_	_	_	_	_
18	h	_	O	O	_	_	_	_	_
19	:	_	O	O	_	_	_	_	_
20	5000	_	O	O	_	_	_	_	_
21	pg	_	O	O	_	_	_	_	_
22	/	_	O	O	_	_	_	_	_
23	ml	_	O	O	_	_	_	_	_
24	)	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	likely	_	O	O	_	_	_	_	_
27	due	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	of	_	O	O	_	_	_	_	_
31	NFkappaB	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	a	_	O	O	_	_	_	_	_
34	consensus	_	O	O	_	_	_	_	_
35	site	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	the	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	8	_	O	O	_	_	_	_	_
41	promoter	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	An	_	O	O	_	_	_	_	_
2	increase	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	receptor	_	O	O	_	_	_	_	_
8	antagonist	_	O	O	_	_	_	_	_
9	(	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	production	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	peak	_	O	O	_	_	_	_	_
15	at	_	O	O	_	_	_	_	_
16	24	_	O	O	_	_	_	_	_
17	h	_	O	O	_	_	_	_	_
18	:	_	O	O	_	_	_	_	_
19	12000	_	O	O	_	_	_	_	_
20	pg	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	ml	_	O	O	_	_	_	_	_
23	)	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	glucan	_	O	O	_	_	_	_	_
26	phosphate	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	treated	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	positively	_	O	O	_	_	_	_	_
31	correlated	_	O	O	_	_	_	_	_
32	with	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	8	_	O	O	_	_	_	_	_
36	levels	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Glucan	_	O	O	_	_	_	_	_
2	phosphate	_	O	O	_	_	_	_	_
3	induced	_	O	O	_	_	_	_	_
4	significant	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	known	_	O	O	_	_	_	_	_
9	NFIL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	6	_	O	O	_	_	_	_	_
12	site	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	new	_	O	O	_	_	_	_	_
16	NFAT	_	O	O	_	_	_	_	_
17	site	_	O	O	_	_	_	_	_
18	within	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	1	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	promoter	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	which	_	O	O	_	_	_	_	_
27	was	_	O	O	_	_	_	_	_
28	confirmed	_	O	O	_	_	_	_	_
29	by	_	O	O	_	_	_	_	_
30	inhibition	_	O	O	_	_	_	_	_
31	experiments	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	applied	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	combination	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	either	_	O	O	_	_	_	_	_
7	LPS	_	O	O	_	_	_	_	_
8	or	_	O	O	_	_	_	_	_
9	TSST	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	same	_	O	O	_	_	_	_	_
15	time	_	O	O	_	_	_	_	_
16	points	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	we	_	O	O	_	_	_	_	_
19	detected	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	glucan	_	O	O	_	_	_	_	_
22	phosphate	_	O	O	_	_	_	_	_
23	elevated	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	LPS	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	the	_	O	O	_	_	_	_	_
29	TSST	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	induced	_	O	O	_	_	_	_	_
34	DNA	_	O	O	_	_	_	_	_
35	binding	_	O	O	_	_	_	_	_
36	of	_	O	O	_	_	_	_	_
37	NFkappaB	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	NFIL	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	6	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	NFAT	_	O	O	_	_	_	_	_
44	,	_	O	O	_	_	_	_	_
45	leading	_	O	O	_	_	_	_	_
46	to	_	O	O	_	_	_	_	_
47	a	_	O	O	_	_	_	_	_
48	synergistic	_	O	O	_	_	_	_	_
49	increase	_	O	O	_	_	_	_	_
50	of	_	O	O	_	_	_	_	_
51	IL	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	1	_	O	O	_	_	_	_	_
54	RA	_	O	O	_	_	_	_	_
55	.	_	O	O	_	_	_	_	_

1	Further	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	glucan	_	O	O	_	_	_	_	_
4	phosphate	_	O	O	_	_	_	_	_
5	modulated	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	TSST	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	response	_	O	O	_	_	_	_	_
14	via	_	O	O	_	_	_	_	_
15	reduction	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	beta	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	consequence	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	glucan	_	O	O	_	_	_	_	_
6	phosphate	_	O	O	_	_	_	_	_
7	shifted	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	TSST	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	beta	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	IL	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	RA	_	O	O	_	_	_	_	_
23	ratio	_	O	O	_	_	_	_	_
24	towards	_	O	O	_	_	_	_	_
25	an	_	O	O	_	_	_	_	_
26	anti	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	inflammatory	_	O	O	_	_	_	_	_
29	phenotype	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Subsequently	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	glucan	_	O	O	_	_	_	_	_
4	phosphate	_	O	O	_	_	_	_	_
5	decreased	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	TSST	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	induced	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	dependent	_	O	O	_	_	_	_	_
18	production	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_


1	Conclusion	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	beta	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	--	_	O	O	_	_	_	_	_
7	>	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	glucans	_	O	O	_	_	_	_	_
13	may	_	O	O	_	_	_	_	_
14	induce	_	O	O	_	_	_	_	_
15	beneficial	_	O	O	_	_	_	_	_
16	effects	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	presence	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	pro	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	inflammatory	_	O	O	_	_	_	_	_
24	responses	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	downstream	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	receptor	_	O	O	_	_	_	_	_
29	binding	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	signaling	_	O	O	_	_	_	_	_
32	by	_	O	O	_	_	_	_	_
33	switching	_	O	O	_	_	_	_	_
34	a	_	O	O	_	_	_	_	_
35	pro	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	an	_	O	O	_	_	_	_	_
39	anti	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	inflammatory	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	RA	_	O	O	_	_	_	_	_
46	-	_	O	O	_	_	_	_	_
47	mediated	_	O	O	_	_	_	_	_
48	reaction	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Our	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	also	_	O	O	_	_	_	_	_
4	offer	_	O	O	_	_	_	_	_
5	new	_	O	O	_	_	_	_	_
6	insights	_	O	O	_	_	_	_	_
7	into	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	complex	_	O	O	_	_	_	_	_
10	regulation	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	1	_	O	O	_	_	_	_	_
16	RA	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	which	_	O	O	_	_	_	_	_
20	can	_	O	O	_	_	_	_	_
21	be	_	O	O	_	_	_	_	_
22	modulated	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	a	_	O	O	_	_	_	_	_
25	beta	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	--	_	O	O	_	_	_	_	_
29	>	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	D	_	O	O	_	_	_	_	_
33	-	_	O	O	_	_	_	_	_
34	glucan	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_



1	Bik	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	novel	_	O	O	_	_	_	_	_
5	death	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	inducing	_	O	O	_	_	_	_	_
8	protein	_	O	O	_	_	_	_	_
9	shares	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	distinct	_	O	O	_	_	_	_	_
12	sequence	_	O	O	_	_	_	_	_
13	motif	_	O	O	_	_	_	_	_
14	with	_	O	O	_	_	_	_	_
15	Bcl	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	2	_	O	O	_	_	_	_	_
18	family	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	interacts	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	viral	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	cellular	_	O	O	_	_	_	_	_
26	survival	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	promoting	_	O	O	_	_	_	_	_
29	proteins	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	survival	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	promoting	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	Bcl	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	2	_	O	O	_	_	_	_	_
11	family	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	proteins	_	O	O	_	_	_	_	_
14	appears	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	be	_	O	O	_	_	_	_	_
17	modulated	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	interactions	_	O	O	_	_	_	_	_
20	between	_	O	O	_	_	_	_	_
21	various	_	O	O	_	_	_	_	_
22	cellular	_	O	O	_	_	_	_	_
23	proteins	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	identified	_	O	O	_	_	_	_	_
4	a	_	O	O	_	_	_	_	_
5	novel	_	O	O	_	_	_	_	_
6	cellular	_	O	O	_	_	_	_	_
7	protein	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	Bik	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	interacts	_	O	O	_	_	_	_	_
13	with	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	cellular	_	O	O	_	_	_	_	_
16	survival	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	promoting	_	O	O	_	_	_	_	_
19	proteins	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	Bcl	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	2	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	Bcl	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	xL	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	as	_	O	O	_	_	_	_	_
30	well	_	O	O	_	_	_	_	_
31	as	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	viral	_	O	O	_	_	_	_	_
34	survival	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	promoting	_	O	O	_	_	_	_	_
37	proteins	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	Epstein	_	O	O	_	_	_	_	_
40	Barr	_	O	O	_	_	_	_	_
41	virus	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	BHRF	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	adenovirus	_	O	O	_	_	_	_	_
47	E	_	O	O	_	_	_	_	_
48	1	_	O	O	_	_	_	_	_
49	B	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	19	_	O	O	_	_	_	_	_
52	kDa	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	transient	_	O	O	_	_	_	_	_
3	transfection	_	O	O	_	_	_	_	_
4	assays	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	Bik	_	O	O	_	_	_	_	_
7	promotes	_	O	O	_	_	_	_	_
8	cell	_	O	O	_	_	_	_	_
9	death	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	manner	_	O	O	_	_	_	_	_
13	similar	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	death	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	promoting	_	O	O	_	_	_	_	_
19	members	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	Bcl	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	2	_	O	O	_	_	_	_	_
25	family	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	Bax	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	Bak	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	death	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	promoting	_	O	O	_	_	_	_	_
5	activity	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	Bik	_	O	O	_	_	_	_	_
8	can	_	O	O	_	_	_	_	_
9	be	_	O	O	_	_	_	_	_
10	suppressed	_	O	O	_	_	_	_	_
11	by	_	O	O	_	_	_	_	_
12	coexpression	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	Bcl	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	2	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	Bcl	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	XL	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	EBV	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	BHRF	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	E	_	O	O	_	_	_	_	_
28	1	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	19	_	O	O	_	_	_	_	_
32	kDa	_	O	O	_	_	_	_	_
33	proteins	_	O	O	_	_	_	_	_
34	suggesting	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	Bik	_	O	O	_	_	_	_	_
37	may	_	O	O	_	_	_	_	_
38	be	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	common	_	O	O	_	_	_	_	_
41	target	_	O	O	_	_	_	_	_
42	for	_	O	O	_	_	_	_	_
43	both	_	O	O	_	_	_	_	_
44	cellular	_	O	O	_	_	_	_	_
45	and	_	O	O	_	_	_	_	_
46	viral	_	O	O	_	_	_	_	_
47	anti	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	apoptotic	_	O	O	_	_	_	_	_
50	proteins	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	While	_	O	O	_	_	_	_	_
2	Bik	_	O	O	_	_	_	_	_
3	does	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	show	_	O	O	_	_	_	_	_
6	overt	_	O	O	_	_	_	_	_
7	homology	_	O	O	_	_	_	_	_
8	to	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	BH	_	O	O	_	_	_	_	_
11	1	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	BH	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	conserved	_	O	O	_	_	_	_	_
16	domains	_	O	O	_	_	_	_	_
17	characteristic	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	Bcl	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	2	_	O	O	_	_	_	_	_
23	family	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	it	_	O	O	_	_	_	_	_
26	does	_	O	O	_	_	_	_	_
27	share	_	O	O	_	_	_	_	_
28	a	_	O	O	_	_	_	_	_
29	9	_	O	O	_	_	_	_	_
30	amino	_	O	O	_	_	_	_	_
31	acid	_	O	O	_	_	_	_	_
32	domain	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	BH	_	O	O	_	_	_	_	_
35	3	_	O	O	_	_	_	_	_
36	)	_	O	O	_	_	_	_	_
37	with	_	O	O	_	_	_	_	_
38	Bax	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	Bak	_	O	O	_	_	_	_	_
41	which	_	O	O	_	_	_	_	_
42	may	_	O	O	_	_	_	_	_
43	be	_	O	O	_	_	_	_	_
44	a	_	O	O	_	_	_	_	_
45	critical	_	O	O	_	_	_	_	_
46	determinant	_	O	O	_	_	_	_	_
47	for	_	O	O	_	_	_	_	_
48	the	_	O	O	_	_	_	_	_
49	death	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	promoting	_	O	O	_	_	_	_	_
52	activity	_	O	O	_	_	_	_	_
53	of	_	O	O	_	_	_	_	_
54	these	_	O	O	_	_	_	_	_
55	proteins	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_


1	Effects	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	1	_	O	O	_	_	_	_	_
4	alpha	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	25	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	dihydroxyvitamin	_	O	O	_	_	_	_	_
9	D	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	on	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	human	_	O	O	_	_	_	_	_
14	chronic	_	O	O	_	_	_	_	_
15	myelogenous	_	O	O	_	_	_	_	_
16	leukemia	_	O	O	_	_	_	_	_
17	cell	_	O	O	_	_	_	_	_
18	line	_	O	O	_	_	_	_	_
19	RWLeu	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	effects	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	1	_	O	O	_	_	_	_	_
5	alpha	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	25	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	dihydroxyvitamin	_	O	O	_	_	_	_	_
10	D	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	(	_	O	O	_	_	_	_	_
13	VD	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	on	_	O	O	_	_	_	_	_
17	proliferation	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	differentiation	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	macromolecular	_	O	O	_	_	_	_	_
23	synthesis	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	new	_	O	O	_	_	_	_	_
27	Philadelphia	_	O	O	_	_	_	_	_
28	chromosome	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	positive	_	O	O	_	_	_	_	_
31	chronic	_	O	O	_	_	_	_	_
32	myelogenous	_	O	O	_	_	_	_	_
33	leukemia	_	O	O	_	_	_	_	_
34	cell	_	O	O	_	_	_	_	_
35	line	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	RWLeu	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	4	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	were	_	O	O	_	_	_	_	_
42	investigated	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	[	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	H	_	O	O	_	_	_	_	_
6	]	_	O	O	_	_	_	_	_
7	VD	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	saturable	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	approximately	_	O	O	_	_	_	_	_
14	2000	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	3000	_	O	O	_	_	_	_	_
17	sites	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	cell	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	half	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	maximal	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	occurring	_	O	O	_	_	_	_	_
27	at	_	O	O	_	_	_	_	_
28	0	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_
30	21	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	0	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_
34	33	_	O	O	_	_	_	_	_
35	nM	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Treatment	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	RWLeu	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	with	_	O	O	_	_	_	_	_
8	VD	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	24	_	O	O	_	_	_	_	_
12	R	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	hydroxylase	_	O	O	_	_	_	_	_
15	activity	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	marker	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	vitamin	_	O	O	_	_	_	_	_
21	D	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	responsiveness	_	O	O	_	_	_	_	_
24	in	_	O	O	_	_	_	_	_
25	many	_	O	O	_	_	_	_	_
26	tissues	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Exposure	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	RWLeu	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	VD	_	O	O	_	_	_	_	_
9	3	_	O	O	_	_	_	_	_
10	also	_	O	O	_	_	_	_	_
11	inhibited	_	O	O	_	_	_	_	_
12	proliferation	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	DNA	_	O	O	_	_	_	_	_
15	synthesis	_	O	O	_	_	_	_	_
16	with	_	O	O	_	_	_	_	_
17	a	_	O	O	_	_	_	_	_
18	50	_	O	O	_	_	_	_	_
19	%	_	O	O	_	_	_	_	_
20	effective	_	O	O	_	_	_	_	_
21	dose	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	3	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_
25	5	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	10	_	O	O	_	_	_	_	_
28	nM	_	O	O	_	_	_	_	_
29	within	_	O	O	_	_	_	_	_
30	72	_	O	O	_	_	_	_	_
31	h	_	O	O	_	_	_	_	_
32	;	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	addition	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	protein	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	RNA	_	O	O	_	_	_	_	_
39	synthesis	_	O	O	_	_	_	_	_
40	were	_	O	O	_	_	_	_	_
41	inhibited	_	O	O	_	_	_	_	_
42	by	_	O	O	_	_	_	_	_
43	VD	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	treatment	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Exposure	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	RWLeu	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	4	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	5	_	O	O	_	_	_	_	_
9	nM	_	O	O	_	_	_	_	_
10	VD	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	72	_	O	O	_	_	_	_	_
14	h	_	O	O	_	_	_	_	_
15	caused	_	O	O	_	_	_	_	_
16	50	_	O	O	_	_	_	_	_
17	%	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	differentiate	_	O	O	_	_	_	_	_
23	into	_	O	O	_	_	_	_	_
24	macrophage	_	O	O	_	_	_	_	_
25	/	_	O	O	_	_	_	_	_
26	monocyte	_	O	O	_	_	_	_	_
27	type	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	as	_	O	O	_	_	_	_	_
30	judged	_	O	O	_	_	_	_	_
31	by	_	O	O	_	_	_	_	_
32	nitroblue	_	O	O	_	_	_	_	_
33	tetrazolium	_	O	O	_	_	_	_	_
34	staining	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	adherence	_	O	O	_	_	_	_	_
37	to	_	O	O	_	_	_	_	_
38	plastic	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	Progressive	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	cell	_	O	O	_	_	_	_	_
5	surface	_	O	O	_	_	_	_	_
6	maturation	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	specific	_	O	O	_	_	_	_	_
9	antigens	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	monocyte	_	O	O	_	_	_	_	_
13	/	_	O	O	_	_	_	_	_
14	macrophage	_	O	O	_	_	_	_	_
15	lineage	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	induced	_	O	O	_	_	_	_	_
18	by	_	O	O	_	_	_	_	_
19	treatment	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	RWLeu	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	VD	_	O	O	_	_	_	_	_
27	3	_	O	O	_	_	_	_	_
28	for	_	O	O	_	_	_	_	_
29	24	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	72	_	O	O	_	_	_	_	_
32	h	_	O	O	_	_	_	_	_
33	at	_	O	O	_	_	_	_	_
34	doses	_	O	O	_	_	_	_	_
35	that	_	O	O	_	_	_	_	_
36	inhibited	_	O	O	_	_	_	_	_
37	cellular	_	O	O	_	_	_	_	_
38	proliferation	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	c	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	myc	_	O	O	_	_	_	_	_
4	RNA	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	which	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	constitutively	_	O	O	_	_	_	_	_
9	expressed	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	RWLeu	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	increased	_	O	O	_	_	_	_	_
17	after	_	O	O	_	_	_	_	_
18	0	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_
20	5	_	O	O	_	_	_	_	_
21	h	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	treatment	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	50	_	O	O	_	_	_	_	_
26	nM	_	O	O	_	_	_	_	_
27	VD	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	and	_	O	O	_	_	_	_	_
30	then	_	O	O	_	_	_	_	_
31	rapidly	_	O	O	_	_	_	_	_
32	decreased	_	O	O	_	_	_	_	_
33	to	_	O	O	_	_	_	_	_
34	barely	_	O	O	_	_	_	_	_
35	detectable	_	O	O	_	_	_	_	_
36	levels	_	O	O	_	_	_	_	_
37	after	_	O	O	_	_	_	_	_
38	4	_	O	O	_	_	_	_	_
39	h	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	treatment	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	Finally	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	vitro	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	kinase	_	O	O	_	_	_	_	_
8	activity	_	O	O	_	_	_	_	_
9	associated	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	p	_	O	O	_	_	_	_	_
13	210	_	O	O	_	_	_	_	_
14	bcr	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	abl	_	O	O	_	_	_	_	_
17	oncogene	_	O	O	_	_	_	_	_
18	product	_	O	O	_	_	_	_	_
19	was	_	O	O	_	_	_	_	_
20	decreased	_	O	O	_	_	_	_	_
21	approximately	_	O	O	_	_	_	_	_
22	50	_	O	O	_	_	_	_	_
23	%	_	O	O	_	_	_	_	_
24	by	_	O	O	_	_	_	_	_
25	VD	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	treatment	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	presence	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	a	_	O	O	_	_	_	_	_
7	functional	_	O	O	_	_	_	_	_
8	receptor	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	effector	_	O	O	_	_	_	_	_
11	system	_	O	O	_	_	_	_	_
12	for	_	O	O	_	_	_	_	_
13	VD	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	multiple	_	O	O	_	_	_	_	_
17	biological	_	O	O	_	_	_	_	_
18	responses	_	O	O	_	_	_	_	_
19	to	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	hormone	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	these	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	provide	_	O	O	_	_	_	_	_
26	a	_	O	O	_	_	_	_	_
27	unique	_	O	O	_	_	_	_	_
28	model	_	O	O	_	_	_	_	_
29	system	_	O	O	_	_	_	_	_
30	with	_	O	O	_	_	_	_	_
31	which	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	probe	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	specific	_	O	O	_	_	_	_	_
36	effects	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	VD	_	O	O	_	_	_	_	_
39	3	_	O	O	_	_	_	_	_
40	on	_	O	O	_	_	_	_	_
41	cell	_	O	O	_	_	_	_	_
42	growth	_	O	O	_	_	_	_	_
43	and	_	O	O	_	_	_	_	_
44	differentiation	_	O	O	_	_	_	_	_
45	in	_	O	O	_	_	_	_	_
46	chronic	_	O	O	_	_	_	_	_
47	myelogenous	_	O	O	_	_	_	_	_
48	leukemia	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_


1	Regulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	17	_	O	O	_	_	_	_	_
6	production	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	RA	_	O	O	_	_	_	_	_
9	PBMC	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	inflammatory	_	O	O	_	_	_	_	_
12	cytokines	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	chemokines	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	RA	_	O	O	_	_	_	_	_
3	PBMC	_	O	O	_	_	_	_	_
4	include	_	O	O	_	_	_	_	_
5	several	_	O	O	_	_	_	_	_
6	cell	_	O	O	_	_	_	_	_
7	types	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	addition	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	cells	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	some	_	O	O	_	_	_	_	_
15	inflammatory	_	O	O	_	_	_	_	_
16	cytokines	_	O	O	_	_	_	_	_
17	released	_	O	O	_	_	_	_	_
18	from	_	O	O	_	_	_	_	_
19	macrophages	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	other	_	O	O	_	_	_	_	_
22	lymphocytes	_	O	O	_	_	_	_	_
23	might	_	O	O	_	_	_	_	_
24	have	_	O	O	_	_	_	_	_
25	affected	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	production	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	IL	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	17	_	O	O	_	_	_	_	_
32	from	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	evaluate	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	effects	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	inflammatory	_	O	O	_	_	_	_	_
7	cytokines	_	O	O	_	_	_	_	_
8	released	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	activated	_	O	O	_	_	_	_	_
11	PBMC	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	we	_	O	O	_	_	_	_	_
14	tested	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	effects	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	several	_	O	O	_	_	_	_	_
19	cytokines	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	chemokines	_	O	O	_	_	_	_	_
22	on	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	17	_	O	O	_	_	_	_	_
26	production	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	detected	_	O	O	_	_	_	_	_
3	an	_	O	O	_	_	_	_	_
4	increase	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	17	_	O	O	_	_	_	_	_
9	level	_	O	O	_	_	_	_	_
10	after	_	O	O	_	_	_	_	_
11	stimulation	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	15	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	ng	_	O	O	_	_	_	_	_
19	/	_	O	O	_	_	_	_	_
20	ml	_	O	O	_	_	_	_	_
21	)	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	whereas	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	beta	_	O	O	_	_	_	_	_
29	(	_	O	O	_	_	_	_	_
30	10	_	O	O	_	_	_	_	_
31	ng	_	O	O	_	_	_	_	_
32	/	_	O	O	_	_	_	_	_
33	ml	_	O	O	_	_	_	_	_
34	)	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	TNF	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	alpha	_	O	O	_	_	_	_	_
39	(	_	O	O	_	_	_	_	_
40	10	_	O	O	_	_	_	_	_
41	ng	_	O	O	_	_	_	_	_
42	/	_	O	O	_	_	_	_	_
43	ml	_	O	O	_	_	_	_	_
44	)	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	IL	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	18	_	O	O	_	_	_	_	_
49	(	_	O	O	_	_	_	_	_
50	10	_	O	O	_	_	_	_	_
51	ng	_	O	O	_	_	_	_	_
52	/	_	O	O	_	_	_	_	_
53	ml	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	or	_	O	O	_	_	_	_	_
56	TGF	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	beta	_	O	O	_	_	_	_	_
59	(	_	O	O	_	_	_	_	_
60	10	_	O	O	_	_	_	_	_
61	ng	_	O	O	_	_	_	_	_
62	/	_	O	O	_	_	_	_	_
63	ml	_	O	O	_	_	_	_	_
64	)	_	O	O	_	_	_	_	_
65	the	_	O	O	_	_	_	_	_
66	levels	_	O	O	_	_	_	_	_
67	in	_	O	O	_	_	_	_	_
68	IL	_	O	O	_	_	_	_	_
69	-	_	O	O	_	_	_	_	_
70	17	_	O	O	_	_	_	_	_
71	were	_	O	O	_	_	_	_	_
72	unchanged	_	O	O	_	_	_	_	_
73	(	_	O	O	_	_	_	_	_
74	Fig	_	O	O	_	_	_	_	_
75	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	When	_	O	O	_	_	_	_	_
2	treated	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	MCP	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	1	_	O	O	_	_	_	_	_
7	(	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	ng	_	O	O	_	_	_	_	_
10	/	_	O	O	_	_	_	_	_
11	ml	_	O	O	_	_	_	_	_
12	)	_	O	O	_	_	_	_	_
13	or	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	6	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	10	_	O	O	_	_	_	_	_
19	ng	_	O	O	_	_	_	_	_
20	/	_	O	O	_	_	_	_	_
21	ml	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	significant	_	O	O	_	_	_	_	_
25	upregulations	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	17	_	O	O	_	_	_	_	_
30	proteins	_	O	O	_	_	_	_	_
31	were	_	O	O	_	_	_	_	_
32	observed	_	O	O	_	_	_	_	_
33	(	_	O	O	_	_	_	_	_
34	62	_	O	O	_	_	_	_	_
35	+	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	42	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	50	_	O	O	_	_	_	_	_
41	+	_	O	O	_	_	_	_	_
42	/	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	10	_	O	O	_	_	_	_	_
45	versus	_	O	O	_	_	_	_	_
46	31	_	O	O	_	_	_	_	_
47	+	_	O	O	_	_	_	_	_
48	/	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	11	_	O	O	_	_	_	_	_
51	pg	_	O	O	_	_	_	_	_
52	/	_	O	O	_	_	_	_	_
53	ml	_	O	O	_	_	_	_	_
54	,	_	O	O	_	_	_	_	_
55	respectively	_	O	O	_	_	_	_	_
56	;	_	O	O	_	_	_	_	_
57	P	_	O	O	_	_	_	_	_
58	<	_	O	O	_	_	_	_	_
59	0	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_
61	05	_	O	O	_	_	_	_	_
62	)	_	O	O	_	_	_	_	_
63	,	_	O	O	_	_	_	_	_
64	whereas	_	O	O	_	_	_	_	_
65	none	_	O	O	_	_	_	_	_
66	was	_	O	O	_	_	_	_	_
67	observed	_	O	O	_	_	_	_	_
68	with	_	O	O	_	_	_	_	_
69	IL	_	O	O	_	_	_	_	_
70	-	_	O	O	_	_	_	_	_
71	8	_	O	O	_	_	_	_	_
72	(	_	O	O	_	_	_	_	_
73	10	_	O	O	_	_	_	_	_
74	ng	_	O	O	_	_	_	_	_
75	/	_	O	O	_	_	_	_	_
76	ml	_	O	O	_	_	_	_	_
77	)	_	O	O	_	_	_	_	_
78	,	_	O	O	_	_	_	_	_
79	MIP	_	O	O	_	_	_	_	_
80	-	_	O	O	_	_	_	_	_
81	1	_	O	O	_	_	_	_	_
82	alpha	_	O	O	_	_	_	_	_
83	(	_	O	O	_	_	_	_	_
84	10	_	O	O	_	_	_	_	_
85	ng	_	O	O	_	_	_	_	_
86	/	_	O	O	_	_	_	_	_
87	ml	_	O	O	_	_	_	_	_
88	)	_	O	O	_	_	_	_	_
89	or	_	O	O	_	_	_	_	_
90	MIP	_	O	O	_	_	_	_	_
91	-	_	O	O	_	_	_	_	_
92	1	_	O	O	_	_	_	_	_
93	beta	_	O	O	_	_	_	_	_
94	(	_	O	O	_	_	_	_	_
95	10	_	O	O	_	_	_	_	_
96	ng	_	O	O	_	_	_	_	_
97	/	_	O	O	_	_	_	_	_
98	ml	_	O	O	_	_	_	_	_
99	)	_	O	O	_	_	_	_	_
100	(	_	O	O	_	_	_	_	_
101	Fig	_	O	O	_	_	_	_	_
102	.	_	O	O	_	_	_	_	_

1	2	_	O	O	_	_	_	_	_
2	b	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_



1	The	_	O	O	_	_	_	_	_
2	DNA	_	O	O	_	_	_	_	_
3	and	_	O	O	_	_	_	_	_
4	steroid	_	O	O	_	_	_	_	_
5	binding	_	O	O	_	_	_	_	_
6	domains	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	glucocorticoid	_	O	O	_	_	_	_	_
10	receptor	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	altered	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	mononuclear	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	treated	_	O	O	_	_	_	_	_
19	CLL	_	O	O	_	_	_	_	_
20	patients	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	aim	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	study	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	investigate	_	O	O	_	_	_	_	_
9	whether	_	O	O	_	_	_	_	_
10	mutations	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	glucocorticoid	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	could	_	O	O	_	_	_	_	_
16	account	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	increasing	_	O	O	_	_	_	_	_
20	unresponsiveness	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	patients	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	chronic	_	O	O	_	_	_	_	_
25	lymphatic	_	O	O	_	_	_	_	_
26	leukemia	_	O	O	_	_	_	_	_
27	(	_	O	O	_	_	_	_	_
28	CLL	_	O	O	_	_	_	_	_
29	)	_	O	O	_	_	_	_	_
30	to	_	O	O	_	_	_	_	_
31	combination	_	O	O	_	_	_	_	_
32	chemotherapy	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	tested	_	O	O	_	_	_	_	_
5	immunocytochemically	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	steroid	_	O	O	_	_	_	_	_
9	binding	_	O	O	_	_	_	_	_
10	assays	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	by	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	mutation	_	O	O	_	_	_	_	_
16	screening	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	denaturing	_	O	O	_	_	_	_	_
19	gradient	_	O	O	_	_	_	_	_
20	gel	_	O	O	_	_	_	_	_
21	electrophoresis	_	O	O	_	_	_	_	_
22	)	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	receptor	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	cDNA	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	concentration	_	O	O	_	_	_	_	_
4	,	_	O	O	_	_	_	_	_
5	as	_	O	O	_	_	_	_	_
6	measured	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	staining	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	steroid	_	O	O	_	_	_	_	_
11	binding	_	O	O	_	_	_	_	_
12	test	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	varied	_	O	O	_	_	_	_	_
15	considerably	_	O	O	_	_	_	_	_
16	but	_	O	O	_	_	_	_	_
17	showed	_	O	O	_	_	_	_	_
18	no	_	O	O	_	_	_	_	_
19	clear	_	O	O	_	_	_	_	_
20	correlation	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	clinical	_	O	O	_	_	_	_	_
23	response	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	Using	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	highly	_	O	O	_	_	_	_	_
4	sensitive	_	O	O	_	_	_	_	_
5	mutation	_	O	O	_	_	_	_	_
6	screening	_	O	O	_	_	_	_	_
7	assay	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	DNA	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	steroid	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	binding	_	O	O	_	_	_	_	_
17	region	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	none	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	treated	_	O	O	_	_	_	_	_
23	patients	_	O	O	_	_	_	_	_
24	revealed	_	O	O	_	_	_	_	_
25	any	_	O	O	_	_	_	_	_
26	mutation	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	suggesting	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	glucocorticoid	_	O	O	_	_	_	_	_
32	receptor	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	CLL	_	O	O	_	_	_	_	_
36	patients	_	O	O	_	_	_	_	_
37	tested	_	O	O	_	_	_	_	_
38	is	_	O	O	_	_	_	_	_
39	not	_	O	O	_	_	_	_	_
40	altered	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	these	_	O	O	_	_	_	_	_
43	domains	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	one	_	O	O	_	_	_	_	_
3	individual	_	O	O	_	_	_	_	_
4	who	_	O	O	_	_	_	_	_
5	had	_	O	O	_	_	_	_	_
6	not	_	O	O	_	_	_	_	_
7	been	_	O	O	_	_	_	_	_
8	treated	_	O	O	_	_	_	_	_
9	before	_	O	O	_	_	_	_	_
10	analysis	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	silent	_	O	O	_	_	_	_	_
13	mutation	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	found	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	one	_	O	O	_	_	_	_	_
18	receptor	_	O	O	_	_	_	_	_
19	allele	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	mechanisms	_	O	O	_	_	_	_	_
6	other	_	O	O	_	_	_	_	_
7	than	_	O	O	_	_	_	_	_
8	altered	_	O	O	_	_	_	_	_
9	ligand	_	O	O	_	_	_	_	_
10	or	_	O	O	_	_	_	_	_
11	DNA	_	O	O	_	_	_	_	_
12	binding	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	receptor	_	O	O	_	_	_	_	_
16	may	_	O	O	_	_	_	_	_
17	be	_	O	O	_	_	_	_	_
18	responsible	_	O	O	_	_	_	_	_
19	for	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	lack	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	response	_	O	O	_	_	_	_	_
24	to	_	O	O	_	_	_	_	_
25	chemotherapy	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	conclusion	_	O	O	_	_	_	_	_
3	is	_	O	O	_	_	_	_	_
4	discussed	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	relation	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	mechanism	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	corticoid	_	O	O	_	_	_	_	_
12	resistance	_	O	O	_	_	_	_	_
13	in	_	O	O	_	_	_	_	_
14	mouse	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	human	_	O	O	_	_	_	_	_
17	lymphoma	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	culture	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	orchestrate	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	Th	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	type	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	mediated	_	O	O	_	_	_	_	_
15	immune	_	O	O	_	_	_	_	_
16	response	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	RA	_	O	O	_	_	_	_	_
19	[	_	O	O	_	_	_	_	_
20	22	_	O	O	_	_	_	_	_
21	]	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	Activated	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	stimulate	_	O	O	_	_	_	_	_
8	macrophages	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	synovial	_	O	O	_	_	_	_	_
11	fibroblasts	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	osteoclasts	_	O	O	_	_	_	_	_
18	through	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	of	_	O	O	_	_	_	_	_
22	cell	_	O	O	_	_	_	_	_
23	surface	_	O	O	_	_	_	_	_
24	molecules	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	Th	_	O	O	_	_	_	_	_
27	1	_	O	O	_	_	_	_	_
28	cytokines	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	thereby	_	O	O	_	_	_	_	_
31	contributing	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	both	_	O	O	_	_	_	_	_
34	the	_	O	O	_	_	_	_	_
35	chronic	_	O	O	_	_	_	_	_
36	inflammation	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	the	_	O	O	_	_	_	_	_
39	joint	_	O	O	_	_	_	_	_
40	destruction	_	O	O	_	_	_	_	_
41	.	_	O	O	_	_	_	_	_

1	CD	_	O	O	_	_	_	_	_
2	4	_	O	O	_	_	_	_	_
3	+	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	require	_	O	O	_	_	_	_	_
7	two	_	O	O	_	_	_	_	_
8	signals	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	activated	_	O	O	_	_	_	_	_
12	;	_	O	O	_	_	_	_	_
13	antigen	_	O	O	_	_	_	_	_
14	receptor	_	O	O	_	_	_	_	_
15	occupancy	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	28	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	mediated	_	O	O	_	_	_	_	_
21	costimulation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	ST	_	O	O	_	_	_	_	_
4	lesion	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	CD	_	O	O	_	_	_	_	_
8	28	_	O	O	_	_	_	_	_
9	ligands	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	both	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	80	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	86	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	together	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	MHC	_	O	O	_	_	_	_	_
21	class	_	O	O	_	_	_	_	_
22	II	_	O	O	_	_	_	_	_
23	antigens	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	are	_	O	O	_	_	_	_	_
26	substantially	_	O	O	_	_	_	_	_
27	expressed	_	O	O	_	_	_	_	_
28	by	_	O	O	_	_	_	_	_
29	antigen	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	presenting	_	O	O	_	_	_	_	_
32	cells	_	O	O	_	_	_	_	_
33	such	_	O	O	_	_	_	_	_
34	as	_	O	O	_	_	_	_	_
35	macrophages	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	dendritic	_	O	O	_	_	_	_	_
38	cells	_	O	O	_	_	_	_	_
39	[	_	O	O	_	_	_	_	_
40	18	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	20	_	O	O	_	_	_	_	_
43	]	_	O	O	_	_	_	_	_
44	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	significance	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	CD	_	O	O	_	_	_	_	_
5	28	_	O	O	_	_	_	_	_
6	engagement	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	T	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	cell	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	mediated	_	O	O	_	_	_	_	_
14	disease	_	O	O	_	_	_	_	_
15	process	_	O	O	_	_	_	_	_
16	has	_	O	O	_	_	_	_	_
17	recently	_	O	O	_	_	_	_	_
18	been	_	O	O	_	_	_	_	_
19	proven	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	the	_	O	O	_	_	_	_	_
22	clinical	_	O	O	_	_	_	_	_
23	efficacy	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	its	_	O	O	_	_	_	_	_
26	blocker	_	O	O	_	_	_	_	_
27	cytotoxic	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	cell	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	associated	_	O	O	_	_	_	_	_
33	antigen	_	O	O	_	_	_	_	_
34	4	_	O	O	_	_	_	_	_
35	(	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	152	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	IgG	_	O	O	_	_	_	_	_
41	in	_	O	O	_	_	_	_	_
42	RA	_	O	O	_	_	_	_	_
43	patients	_	O	O	_	_	_	_	_
44	[	_	O	O	_	_	_	_	_
45	23	_	O	O	_	_	_	_	_
46	]	_	O	O	_	_	_	_	_
47	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	plays	_	O	O	_	_	_	_	_
5	a	_	O	O	_	_	_	_	_
6	predominant	_	O	O	_	_	_	_	_
7	role	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	limiting	_	O	O	_	_	_	_	_
10	immune	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	inflammatory	_	O	O	_	_	_	_	_
13	responses	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	regulating	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	function	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	both	_	O	O	_	_	_	_	_
20	macrophages	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	Th	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	[	_	O	O	_	_	_	_	_
26	1	_	O	O	_	_	_	_	_
27	]	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	inhibits	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	tyrosine	_	O	O	_	_	_	_	_
7	phosphorylation	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	28	_	O	O	_	_	_	_	_
12	molecule	_	O	O	_	_	_	_	_
13	and	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	subsequent	_	O	O	_	_	_	_	_
16	phosphatidylinositol	_	O	O	_	_	_	_	_
17	3	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	kinase	_	O	O	_	_	_	_	_
20	binding	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	thereby	_	O	O	_	_	_	_	_
27	directly	_	O	O	_	_	_	_	_
28	acts	_	O	O	_	_	_	_	_
29	on	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	[	_	O	O	_	_	_	_	_
33	24	_	O	O	_	_	_	_	_
34	]	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	present	_	O	O	_	_	_	_	_
4	study	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	we	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	that	_	O	O	_	_	_	_	_
9	PB	_	O	O	_	_	_	_	_
10	CD	_	O	O	_	_	_	_	_
11	4	_	O	O	_	_	_	_	_
12	+	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	cells	_	O	O	_	_	_	_	_
15	from	_	O	O	_	_	_	_	_
16	patients	_	O	O	_	_	_	_	_
17	with	_	O	O	_	_	_	_	_
18	active	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	presence	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	10	_	O	O	_	_	_	_	_
28	,	_	O	O	_	_	_	_	_
29	are	_	O	O	_	_	_	_	_
30	able	_	O	O	_	_	_	_	_
31	to	_	O	O	_	_	_	_	_
32	produce	_	O	O	_	_	_	_	_
33	higher	_	O	O	_	_	_	_	_
34	levels	_	O	O	_	_	_	_	_
35	of	_	O	O	_	_	_	_	_
36	IFN	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	gamma	_	O	O	_	_	_	_	_
39	after	_	O	O	_	_	_	_	_
40	CD	_	O	O	_	_	_	_	_
41	3	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	CD	_	O	O	_	_	_	_	_
44	28	_	O	O	_	_	_	_	_
45	costimulation	_	O	O	_	_	_	_	_
46	than	_	O	O	_	_	_	_	_
47	normal	_	O	O	_	_	_	_	_
48	CD	_	O	O	_	_	_	_	_
49	4	_	O	O	_	_	_	_	_
50	+	_	O	O	_	_	_	_	_
51	T	_	O	O	_	_	_	_	_
52	cells	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	Despite	_	O	O	_	_	_	_	_
2	high	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	level	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	R	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	constitutive	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	induced	_	O	O	_	_	_	_	_
22	tyrosine	_	O	O	_	_	_	_	_
23	phosphorylation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	STAT	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	is	_	O	O	_	_	_	_	_
28	suppressed	_	O	O	_	_	_	_	_
29	in	_	O	O	_	_	_	_	_
30	RA	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	4	_	O	O	_	_	_	_	_
33	+	_	O	O	_	_	_	_	_
34	T	_	O	O	_	_	_	_	_
35	cells	_	O	O	_	_	_	_	_
36	,	_	O	O	_	_	_	_	_
37	in	_	O	O	_	_	_	_	_
38	contrast	_	O	O	_	_	_	_	_
39	to	_	O	O	_	_	_	_	_
40	normal	_	O	O	_	_	_	_	_
41	CD	_	O	O	_	_	_	_	_
42	4	_	O	O	_	_	_	_	_
43	+	_	O	O	_	_	_	_	_
44	T	_	O	O	_	_	_	_	_
45	cells	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	where	_	O	O	_	_	_	_	_
48	STAT	_	O	O	_	_	_	_	_
49	3	_	O	O	_	_	_	_	_
50	phosphorylation	_	O	O	_	_	_	_	_
51	is	_	O	O	_	_	_	_	_
52	dose	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	dependently	_	O	O	_	_	_	_	_
55	inducible	_	O	O	_	_	_	_	_
56	by	_	O	O	_	_	_	_	_
57	IL	_	O	O	_	_	_	_	_
58	-	_	O	O	_	_	_	_	_
59	10	_	O	O	_	_	_	_	_
60	.	_	O	O	_	_	_	_	_

1	Serum	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	from	_	O	O	_	_	_	_	_
6	RA	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	induces	_	O	O	_	_	_	_	_
9	STAT	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	not	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	1	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	normal	_	O	O	_	_	_	_	_
18	CD	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	+	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	cells	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	exogenous	_	O	O	_	_	_	_	_
26	IL	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	6	_	O	O	_	_	_	_	_
29	induces	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	resistance	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	IL	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	10	_	O	O	_	_	_	_	_
36	inhibition	_	O	O	_	_	_	_	_
37	of	_	O	O	_	_	_	_	_
38	IFN	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	gamma	_	O	O	_	_	_	_	_
41	production	_	O	O	_	_	_	_	_
42	.	_	O	O	_	_	_	_	_

1	RA	_	O	O	_	_	_	_	_
2	CD	_	O	O	_	_	_	_	_
3	4	_	O	O	_	_	_	_	_
4	+	_	O	O	_	_	_	_	_
5	T	_	O	O	_	_	_	_	_
6	cells	_	O	O	_	_	_	_	_
7	contain	_	O	O	_	_	_	_	_
8	higher	_	O	O	_	_	_	_	_
9	levels	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	SOCS	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	but	_	O	O	_	_	_	_	_
14	contain	_	O	O	_	_	_	_	_
15	lower	_	O	O	_	_	_	_	_
16	levels	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	SOCS	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	transcripts	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	comparison	_	O	O	_	_	_	_	_
23	with	_	O	O	_	_	_	_	_
24	normal	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	4	_	O	O	_	_	_	_	_
27	+	_	O	O	_	_	_	_	_
28	T	_	O	O	_	_	_	_	_
29	cells	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	findings	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	CD	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	+	_	O	O	_	_	_	_	_
8	T	_	O	O	_	_	_	_	_
9	cells	_	O	O	_	_	_	_	_
10	become	_	O	O	_	_	_	_	_
11	resistant	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	inhibitory	_	O	O	_	_	_	_	_
15	effect	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	before	_	O	O	_	_	_	_	_
21	migration	_	O	O	_	_	_	_	_
22	into	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	inflamed	_	O	O	_	_	_	_	_
25	ST	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	suggest	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	this	_	O	O	_	_	_	_	_
31	resistance	_	O	O	_	_	_	_	_
32	may	_	O	O	_	_	_	_	_
33	be	_	O	O	_	_	_	_	_
34	attributable	_	O	O	_	_	_	_	_
35	to	_	O	O	_	_	_	_	_
36	impaired	_	O	O	_	_	_	_	_
37	IL	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	10	_	O	O	_	_	_	_	_
40	-	_	O	O	_	_	_	_	_
41	dependent	_	O	O	_	_	_	_	_
42	STAT	_	O	O	_	_	_	_	_
43	3	_	O	O	_	_	_	_	_
44	activation	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	in	_	O	O	_	_	_	_	_
47	association	_	O	O	_	_	_	_	_
48	with	_	O	O	_	_	_	_	_
49	sustained	_	O	O	_	_	_	_	_
50	STAT	_	O	O	_	_	_	_	_
51	3	_	O	O	_	_	_	_	_
52	phosphorylation	_	O	O	_	_	_	_	_
53	and	_	O	O	_	_	_	_	_
54	SOCS	_	O	O	_	_	_	_	_
55	1	_	O	O	_	_	_	_	_
56	induction	_	O	O	_	_	_	_	_
57	.	_	O	O	_	_	_	_	_


1	IL	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	mediated	_	O	O	_	_	_	_	_
6	inhibition	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	CD	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	+	_	O	O	_	_	_	_	_
11	T	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	cell	_	O	O	_	_	_	_	_
14	cytokine	_	O	O	_	_	_	_	_
15	production	_	O	O	_	_	_	_	_
16	is	_	O	O	_	_	_	_	_
17	principally	_	O	O	_	_	_	_	_
18	dependent	_	O	O	_	_	_	_	_
19	on	_	O	O	_	_	_	_	_
20	its	_	O	O	_	_	_	_	_
21	inhibition	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	macrophage	_	O	O	_	_	_	_	_
24	antigen	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	presenting	_	O	O	_	_	_	_	_
27	cell	_	O	O	_	_	_	_	_
28	function	_	O	O	_	_	_	_	_
29	[	_	O	O	_	_	_	_	_
30	1	_	O	O	_	_	_	_	_
31	]	_	O	O	_	_	_	_	_
32	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	this	_	O	O	_	_	_	_	_
4	indirect	_	O	O	_	_	_	_	_
5	inhibitory	_	O	O	_	_	_	_	_
6	effect	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	thought	_	O	O	_	_	_	_	_
9	to	_	O	O	_	_	_	_	_
10	be	_	O	O	_	_	_	_	_
11	restricted	_	O	O	_	_	_	_	_
12	at	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	site	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	activation	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	RA	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	because	_	O	O	_	_	_	_	_
24	macrophages	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	ST	_	O	O	_	_	_	_	_
28	express	_	O	O	_	_	_	_	_
29	high	_	O	O	_	_	_	_	_
30	levels	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	cytokines	_	O	O	_	_	_	_	_
33	,	_	O	O	_	_	_	_	_
34	CD	_	O	O	_	_	_	_	_
35	80	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	CD	_	O	O	_	_	_	_	_
38	86	_	O	O	_	_	_	_	_
39	molecules	_	O	O	_	_	_	_	_
40	,	_	O	O	_	_	_	_	_
41	and	_	O	O	_	_	_	_	_
42	MHC	_	O	O	_	_	_	_	_
43	class	_	O	O	_	_	_	_	_
44	II	_	O	O	_	_	_	_	_
45	antigens	_	O	O	_	_	_	_	_
46	[	_	O	O	_	_	_	_	_
47	10	_	O	O	_	_	_	_	_
48	,	_	O	O	_	_	_	_	_
49	18	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	20	_	O	O	_	_	_	_	_
52	]	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	More	_	O	O	_	_	_	_	_
2	recently	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	has	_	O	O	_	_	_	_	_
8	been	_	O	O	_	_	_	_	_
9	shown	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	induce	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	antigen	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	specific	_	O	O	_	_	_	_	_
16	T	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	cell	_	O	O	_	_	_	_	_
19	unresponsiveness	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	inhibiting	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	28	_	O	O	_	_	_	_	_
24	tyrosine	_	O	O	_	_	_	_	_
25	phosphorylation	_	O	O	_	_	_	_	_
26	[	_	O	O	_	_	_	_	_
27	33	_	O	O	_	_	_	_	_
28	]	_	O	O	_	_	_	_	_
29	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	direct	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	also	_	O	O	_	_	_	_	_
5	may	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	limited	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	active	_	O	O	_	_	_	_	_
10	RA	_	O	O	_	_	_	_	_
11	patients	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	because	_	O	O	_	_	_	_	_
14	their	_	O	O	_	_	_	_	_
15	PB	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	showed	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	defective	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	10	_	O	O	_	_	_	_	_
27	inhibition	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	CD	_	O	O	_	_	_	_	_
30	28	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	costimulated	_	O	O	_	_	_	_	_
33	production	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	both	_	O	O	_	_	_	_	_
36	IFN	_	O	O	_	_	_	_	_
37	-	_	O	O	_	_	_	_	_
38	gamma	_	O	O	_	_	_	_	_
39	and	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	2	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_



1	Effects	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	on	_	O	O	_	_	_	_	_
11	LPS	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	induced	_	O	O	_	_	_	_	_
14	transcription	_	O	O	_	_	_	_	_
15	factors	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	AP	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	1	_	O	O	_	_	_	_	_
20	,	_	O	O	_	_	_	_	_
21	NF	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	IL	_	O	O	_	_	_	_	_
24	6	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	NF	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	kappa	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	which	_	O	O	_	_	_	_	_
32	are	_	O	O	_	_	_	_	_
33	involved	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	IL	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	6	_	O	O	_	_	_	_	_
38	regulation	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_


1	Interleukin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	10	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	,	_	O	O	_	_	_	_	_
10	like	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	is	_	O	O	_	_	_	_	_
16	known	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	inhibit	_	O	O	_	_	_	_	_
19	cytokine	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	activated	_	O	O	_	_	_	_	_
23	human	_	O	O	_	_	_	_	_
24	monocytes	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	showed	_	O	O	_	_	_	_	_
3	that	_	O	O	_	_	_	_	_
4	both	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	10	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	4	_	O	O	_	_	_	_	_
12	inhibit	_	O	O	_	_	_	_	_
13	LPS	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	induced	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	6	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	and	_	O	O	_	_	_	_	_
21	protein	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	inhibiting	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	transcription	_	O	O	_	_	_	_	_
27	rate	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	gene	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	strong	_	O	O	_	_	_	_	_
3	inhibition	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	6	_	O	O	_	_	_	_	_
9	transcription	_	O	O	_	_	_	_	_
10	rate	_	O	O	_	_	_	_	_
11	prompted	_	O	O	_	_	_	_	_
12	us	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	study	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	effect	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	IL	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	4	_	O	O	_	_	_	_	_
25	on	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	expression	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	transcription	_	O	O	_	_	_	_	_
30	factors	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	questioned	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	or	_	O	O	_	_	_	_	_
5	not	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	4	_	O	O	_	_	_	_	_
13	affected	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	transcription	_	O	O	_	_	_	_	_
18	factors	_	O	O	_	_	_	_	_
19	that	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	known	_	O	O	_	_	_	_	_
22	to	_	O	O	_	_	_	_	_
23	be	_	O	O	_	_	_	_	_
24	involved	_	O	O	_	_	_	_	_
25	in	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	control	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	the	_	O	O	_	_	_	_	_
30	IL	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	transcription	_	O	O	_	_	_	_	_
34	rate	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	namely	_	O	O	_	_	_	_	_
37	activator	_	O	O	_	_	_	_	_
38	protein	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	1	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	AP	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	1	_	O	O	_	_	_	_	_
45	)	_	O	O	_	_	_	_	_
46	,	_	O	O	_	_	_	_	_
47	nuclear	_	O	O	_	_	_	_	_
48	factor	_	O	O	_	_	_	_	_
49	IL	_	O	O	_	_	_	_	_
50	-	_	O	O	_	_	_	_	_
51	6	_	O	O	_	_	_	_	_
52	(	_	O	O	_	_	_	_	_
53	NF	_	O	O	_	_	_	_	_
54	-	_	O	O	_	_	_	_	_
55	IL	_	O	O	_	_	_	_	_
56	6	_	O	O	_	_	_	_	_
57	)	_	O	O	_	_	_	_	_
58	,	_	O	O	_	_	_	_	_
59	and	_	O	O	_	_	_	_	_
60	nuclear	_	O	O	_	_	_	_	_
61	factor	_	O	O	_	_	_	_	_
62	kappa	_	O	O	_	_	_	_	_
63	B	_	O	O	_	_	_	_	_
64	(	_	O	O	_	_	_	_	_
65	NF	_	O	O	_	_	_	_	_
66	-	_	O	O	_	_	_	_	_
67	kappaB	_	O	O	_	_	_	_	_
68	)	_	O	O	_	_	_	_	_
69	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	electrophoretic	_	O	O	_	_	_	_	_
3	mobility	_	O	O	_	_	_	_	_
4	shift	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	EMSAs	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	we	_	O	O	_	_	_	_	_
10	showed	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	10	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	IL	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	inhibited	_	O	O	_	_	_	_	_
20	LPS	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	induced	_	O	O	_	_	_	_	_
23	AP	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	1	_	O	O	_	_	_	_	_
26	binding	_	O	O	_	_	_	_	_
27	activity	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	inhibiting	_	O	O	_	_	_	_	_
3	effect	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	IL	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	4	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	slightly	_	O	O	_	_	_	_	_
10	more	_	O	O	_	_	_	_	_
11	pronounced	_	O	O	_	_	_	_	_
12	than	_	O	O	_	_	_	_	_
13	that	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	10	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Downregulation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	LPS	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	AP	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	1	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	accompanied	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	thus	_	O	O	_	_	_	_	_
14	possibly	_	O	O	_	_	_	_	_
15	explained	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	by	_	O	O	_	_	_	_	_
18	a	_	O	O	_	_	_	_	_
19	reduced	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	at	_	O	O	_	_	_	_	_
22	mRNA	_	O	O	_	_	_	_	_
23	level	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	two	_	O	O	_	_	_	_	_
27	major	_	O	O	_	_	_	_	_
28	components	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	the	_	O	O	_	_	_	_	_
31	AP	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	complex	_	O	O	_	_	_	_	_
35	,	_	O	O	_	_	_	_	_
36	namely	_	O	O	_	_	_	_	_
37	c	_	O	O	_	_	_	_	_
38	-	_	O	O	_	_	_	_	_
39	fos	_	O	O	_	_	_	_	_
40	and	_	O	O	_	_	_	_	_
41	c	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	jun	_	O	O	_	_	_	_	_
44	as	_	O	O	_	_	_	_	_
45	determined	_	O	O	_	_	_	_	_
46	by	_	O	O	_	_	_	_	_
47	Northern	_	O	O	_	_	_	_	_
48	experiments	_	O	O	_	_	_	_	_
49	.	_	O	O	_	_	_	_	_

1	Binding	_	O	O	_	_	_	_	_
2	activity	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	also	_	O	O	_	_	_	_	_
10	strongly	_	O	O	_	_	_	_	_
11	inhibited	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	4	_	O	O	_	_	_	_	_
16	whereas	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	showed	_	O	O	_	_	_	_	_
21	no	_	O	O	_	_	_	_	_
22	effect	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	NF	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	mRNA	_	O	O	_	_	_	_	_
6	levels	_	O	O	_	_	_	_	_
7	were	_	O	O	_	_	_	_	_
8	not	_	O	O	_	_	_	_	_
9	affected	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	or	_	O	O	_	_	_	_	_
15	IL	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	,	_	O	O	_	_	_	_	_
19	suggesting	_	O	O	_	_	_	_	_
20	that	_	O	O	_	_	_	_	_
21	IL	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	4	_	O	O	_	_	_	_	_
24	affects	_	O	O	_	_	_	_	_
25	binding	_	O	O	_	_	_	_	_
26	activity	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	preexisting	_	O	O	_	_	_	_	_
29	NF	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	IL	_	O	O	_	_	_	_	_
32	6	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	Neither	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	10	_	O	O	_	_	_	_	_
5	nor	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	4	_	O	O	_	_	_	_	_
9	inhibited	_	O	O	_	_	_	_	_
10	LPS	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	NF	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	kappa	_	O	O	_	_	_	_	_
16	B	_	O	O	_	_	_	_	_
17	binding	_	O	O	_	_	_	_	_
18	activity	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	agreement	_	O	O	_	_	_	_	_
3	with	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	finding	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	Northern	_	O	O	_	_	_	_	_
8	experiments	_	O	O	_	_	_	_	_
9	where	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	65	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	p	_	O	O	_	_	_	_	_
14	105	_	O	O	_	_	_	_	_
15	mRNA	_	O	O	_	_	_	_	_
16	levels	_	O	O	_	_	_	_	_
17	were	_	O	O	_	_	_	_	_
18	determined	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	demonstrated	_	O	O	_	_	_	_	_
21	that	_	O	O	_	_	_	_	_
22	expression	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	these	_	O	O	_	_	_	_	_
25	components	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	kappa	_	O	O	_	_	_	_	_
31	B	_	O	O	_	_	_	_	_
32	transcription	_	O	O	_	_	_	_	_
33	factor	_	O	O	_	_	_	_	_
34	were	_	O	O	_	_	_	_	_
35	not	_	O	O	_	_	_	_	_
36	affected	_	O	O	_	_	_	_	_
37	by	_	O	O	_	_	_	_	_
38	IL	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	10	_	O	O	_	_	_	_	_
41	or	_	O	O	_	_	_	_	_
42	IL	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	4	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	neither	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	nor	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	4	_	O	O	_	_	_	_	_
11	showed	_	O	O	_	_	_	_	_
12	any	_	O	O	_	_	_	_	_
13	effect	_	O	O	_	_	_	_	_
14	on	_	O	O	_	_	_	_	_
15	I	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	kappa	_	O	O	_	_	_	_	_
18	B	_	O	O	_	_	_	_	_
19	mRNA	_	O	O	_	_	_	_	_
20	expression	_	O	O	_	_	_	_	_
21	as	_	O	O	_	_	_	_	_
22	determined	_	O	O	_	_	_	_	_
23	by	_	O	O	_	_	_	_	_
24	Northern	_	O	O	_	_	_	_	_
25	experiments	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Thus	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	IL	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	10	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	IL	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	4	_	O	O	_	_	_	_	_
10	similarly	_	O	O	_	_	_	_	_
11	affect	_	O	O	_	_	_	_	_
12	IL	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	expression	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	However	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	for	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	4	_	O	O	_	_	_	_	_
7	this	_	O	O	_	_	_	_	_
8	was	_	O	O	_	_	_	_	_
9	accompanied	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	a	_	O	O	_	_	_	_	_
12	reduction	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	AP	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	NF	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	IL	_	O	O	_	_	_	_	_
21	6	_	O	O	_	_	_	_	_
22	binding	_	O	O	_	_	_	_	_
23	activity	_	O	O	_	_	_	_	_
24	whereas	_	O	O	_	_	_	_	_
25	IL	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	10	_	O	O	_	_	_	_	_
28	only	_	O	O	_	_	_	_	_
29	inhibited	_	O	O	_	_	_	_	_
30	AP	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	1	_	O	O	_	_	_	_	_
33	binding	_	O	O	_	_	_	_	_
34	activity	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_


1	[	_	O	O	_	_	_	_	_
2	Glucocorticoid	_	O	O	_	_	_	_	_
3	receptors	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	peripheral	_	O	O	_	_	_	_	_
6	blood	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	bronchial	_	O	O	_	_	_	_	_
12	asthma	_	O	O	_	_	_	_	_
13	]	_	O	O	_	_	_	_	_

1	Quantitation	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	glucocorticoid	_	O	O	_	_	_	_	_
4	receptors	_	O	O	_	_	_	_	_
5	(	_	O	O	_	_	_	_	_
6	GCR	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	study	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	their	_	O	O	_	_	_	_	_
13	affinity	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	glucocorticosteroids	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	GCS	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	were	_	O	O	_	_	_	_	_
20	made	_	O	O	_	_	_	_	_
21	in	_	O	O	_	_	_	_	_
22	peripheral	_	O	O	_	_	_	_	_
23	blood	_	O	O	_	_	_	_	_
24	lymphocytes	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	bronchial	_	O	O	_	_	_	_	_
27	asthma	_	O	O	_	_	_	_	_
28	(	_	O	O	_	_	_	_	_
29	BA	_	O	O	_	_	_	_	_
30	)	_	O	O	_	_	_	_	_
31	patients	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	consideration	_	O	O	_	_	_	_	_
34	of	_	O	O	_	_	_	_	_
35	GCR	_	O	O	_	_	_	_	_
36	treatment	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	serum	_	O	O	_	_	_	_	_
39	levels	_	O	O	_	_	_	_	_
40	of	_	O	O	_	_	_	_	_
41	endogenous	_	O	O	_	_	_	_	_
42	cortisol	_	O	O	_	_	_	_	_
43	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	stated	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	GCR	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	healthy	_	O	O	_	_	_	_	_
8	controls	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	GCS	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	untreated	_	O	O	_	_	_	_	_
13	patients	_	O	O	_	_	_	_	_
14	outnumbered	_	O	O	_	_	_	_	_
15	those	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	cortisol	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	dependent	_	O	O	_	_	_	_	_
20	BA	_	O	O	_	_	_	_	_
21	patients	_	O	O	_	_	_	_	_
22	on	_	O	O	_	_	_	_	_
23	hormone	_	O	O	_	_	_	_	_
24	therapy	_	O	O	_	_	_	_	_
25	.	_	O	O	_	_	_	_	_

1	Following	_	O	O	_	_	_	_	_
2	discontinuation	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	glucocorticoid	_	O	O	_	_	_	_	_
5	drugs	_	O	O	_	_	_	_	_
6	GCR	_	O	O	_	_	_	_	_
7	count	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	cortisol	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	dependent	_	O	O	_	_	_	_	_
12	BA	_	O	O	_	_	_	_	_
13	tends	_	O	O	_	_	_	_	_
14	to	_	O	O	_	_	_	_	_
15	rise	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_

1	Endogenous	_	O	O	_	_	_	_	_
2	cortisol	_	O	O	_	_	_	_	_
3	has	_	O	O	_	_	_	_	_
4	no	_	O	O	_	_	_	_	_
5	effect	_	O	O	_	_	_	_	_
6	on	_	O	O	_	_	_	_	_
7	GCR	_	O	O	_	_	_	_	_
8	level	_	O	O	_	_	_	_	_
9	estimated	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	3	_	O	O	_	_	_	_	_
12	H	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	triamcinolone	_	O	O	_	_	_	_	_
15	acetonide	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	Increased	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	17	_	O	O	_	_	_	_	_
5	production	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	PBMC	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	patients	_	O	O	_	_	_	_	_
10	with	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	by	_	O	O	_	_	_	_	_
13	anti	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	CD	_	O	O	_	_	_	_	_
16	3	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	/	_	O	O	_	_	_	_	_
19	or	_	O	O	_	_	_	_	_
20	anti	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	CD	_	O	O	_	_	_	_	_
23	28	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	PHA	_	O	O	_	_	_	_	_

1	Because	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	17	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	already	_	O	O	_	_	_	_	_
7	known	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	earlier	_	O	O	_	_	_	_	_
10	reports	_	O	O	_	_	_	_	_
11	to	_	O	O	_	_	_	_	_
12	be	_	O	O	_	_	_	_	_
13	produced	_	O	O	_	_	_	_	_
14	mainly	_	O	O	_	_	_	_	_
15	by	_	O	O	_	_	_	_	_
16	activated	_	O	O	_	_	_	_	_
17	T	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	we	_	O	O	_	_	_	_	_
21	investigated	_	O	O	_	_	_	_	_
22	the	_	O	O	_	_	_	_	_
23	effect	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	different	_	O	O	_	_	_	_	_
26	concentrations	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	3	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	1	_	O	O	_	_	_	_	_
34	,	_	O	O	_	_	_	_	_
35	5	_	O	O	_	_	_	_	_
36	and	_	O	O	_	_	_	_	_
37	10	_	O	O	_	_	_	_	_
38	mug	_	O	O	_	_	_	_	_
39	/	_	O	O	_	_	_	_	_
40	ml	_	O	O	_	_	_	_	_
41	)	_	O	O	_	_	_	_	_
42	as	_	O	O	_	_	_	_	_
43	a	_	O	O	_	_	_	_	_
44	T	_	O	O	_	_	_	_	_
45	cell	_	O	O	_	_	_	_	_
46	activation	_	O	O	_	_	_	_	_
47	,	_	O	O	_	_	_	_	_
48	which	_	O	O	_	_	_	_	_
49	showed	_	O	O	_	_	_	_	_
50	a	_	O	O	_	_	_	_	_
51	dose	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	dependent	_	O	O	_	_	_	_	_
54	increase	_	O	O	_	_	_	_	_
55	in	_	O	O	_	_	_	_	_
56	IL	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	17	_	O	O	_	_	_	_	_
59	levels	_	O	O	_	_	_	_	_
60	(	_	O	O	_	_	_	_	_
61	data	_	O	O	_	_	_	_	_
62	not	_	O	O	_	_	_	_	_
63	shown	_	O	O	_	_	_	_	_
64	)	_	O	O	_	_	_	_	_
65	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	basis	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	this	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	we	_	O	O	_	_	_	_	_
8	chose	_	O	O	_	_	_	_	_
9	10	_	O	O	_	_	_	_	_
10	mug	_	O	O	_	_	_	_	_
11	/	_	O	O	_	_	_	_	_
12	ml	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	stimulation	_	O	O	_	_	_	_	_
16	concentration	_	O	O	_	_	_	_	_
17	for	_	O	O	_	_	_	_	_
18	anti	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	3	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	As	_	O	O	_	_	_	_	_
2	shown	_	O	O	_	_	_	_	_
3	in	_	O	O	_	_	_	_	_
4	Table	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	anti	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	CD	_	O	O	_	_	_	_	_
10	3	_	O	O	_	_	_	_	_
11	significantly	_	O	O	_	_	_	_	_
12	upregulated	_	O	O	_	_	_	_	_
13	IL	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	17	_	O	O	_	_	_	_	_
16	production	_	O	O	_	_	_	_	_
17	up	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	3	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	7	_	O	O	_	_	_	_	_
22	-	_	O	O	_	_	_	_	_
23	fold	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	combination	_	O	O	_	_	_	_	_
28	of	_	O	O	_	_	_	_	_
29	anti	_	O	O	_	_	_	_	_
30	-	_	O	O	_	_	_	_	_
31	CD	_	O	O	_	_	_	_	_
32	28	_	O	O	_	_	_	_	_
33	and	_	O	O	_	_	_	_	_
34	anti	_	O	O	_	_	_	_	_
35	-	_	O	O	_	_	_	_	_
36	CD	_	O	O	_	_	_	_	_
37	3	_	O	O	_	_	_	_	_
38	produced	_	O	O	_	_	_	_	_
39	more	_	O	O	_	_	_	_	_
40	IL	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	17	_	O	O	_	_	_	_	_
43	(	_	O	O	_	_	_	_	_
44	approximately	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_
47	3	_	O	O	_	_	_	_	_
48	-	_	O	O	_	_	_	_	_
49	1	_	O	O	_	_	_	_	_
50	.	_	O	O	_	_	_	_	_
51	5	_	O	O	_	_	_	_	_
52	-	_	O	O	_	_	_	_	_
53	fold	_	O	O	_	_	_	_	_
54	)	_	O	O	_	_	_	_	_
55	than	_	O	O	_	_	_	_	_
56	anti	_	O	O	_	_	_	_	_
57	-	_	O	O	_	_	_	_	_
58	CD	_	O	O	_	_	_	_	_
59	3	_	O	O	_	_	_	_	_
60	alone	_	O	O	_	_	_	_	_
61	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	when	_	O	O	_	_	_	_	_
4	incubated	_	O	O	_	_	_	_	_
5	with	_	O	O	_	_	_	_	_
6	T	_	O	O	_	_	_	_	_
7	cell	_	O	O	_	_	_	_	_
8	mitogens	_	O	O	_	_	_	_	_
9	such	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	PHA	_	O	O	_	_	_	_	_
12	,	_	O	O	_	_	_	_	_
13	increased	_	O	O	_	_	_	_	_
14	IL	_	O	O	_	_	_	_	_
15	-	_	O	O	_	_	_	_	_
16	17	_	O	O	_	_	_	_	_
17	production	_	O	O	_	_	_	_	_
18	was	_	O	O	_	_	_	_	_
19	more	_	O	O	_	_	_	_	_
20	pronounced	_	O	O	_	_	_	_	_
21	than	_	O	O	_	_	_	_	_
22	with	_	O	O	_	_	_	_	_
23	anti	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	CD	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	anti	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	CD	_	O	O	_	_	_	_	_
31	28	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	588	_	O	O	_	_	_	_	_
34	+	_	O	O	_	_	_	_	_
35	/	_	O	O	_	_	_	_	_
36	-	_	O	O	_	_	_	_	_
37	85	_	O	O	_	_	_	_	_
38	versus	_	O	O	_	_	_	_	_
39	211	_	O	O	_	_	_	_	_
40	+	_	O	O	_	_	_	_	_
41	/	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	1	_	O	O	_	_	_	_	_
44	pg	_	O	O	_	_	_	_	_
45	/	_	O	O	_	_	_	_	_
46	ml	_	O	O	_	_	_	_	_
47	;	_	O	O	_	_	_	_	_
48	P	_	O	O	_	_	_	_	_
49	<	_	O	O	_	_	_	_	_
50	0	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_
52	05	_	O	O	_	_	_	_	_
53	)	_	O	O	_	_	_	_	_
54	.	_	O	O	_	_	_	_	_



1	The	_	O	O	_	_	_	_	_
2	murine	_	O	O	_	_	_	_	_
3	BCL	_	O	O	_	_	_	_	_
4	6	_	O	O	_	_	_	_	_
5	gene	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	induced	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	activated	_	O	O	_	_	_	_	_
10	lymphocytes	_	O	O	_	_	_	_	_
11	as	_	O	O	_	_	_	_	_
12	an	_	O	O	_	_	_	_	_
13	immediate	_	O	O	_	_	_	_	_
14	early	_	O	O	_	_	_	_	_
15	gene	_	O	O	_	_	_	_	_
16	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	chromosomal	_	O	O	_	_	_	_	_
3	translocation	_	O	O	_	_	_	_	_
4	involving	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	q	_	O	O	_	_	_	_	_
7	27	_	O	O	_	_	_	_	_
8	is	_	O	O	_	_	_	_	_
9	often	_	O	O	_	_	_	_	_
10	detected	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	human	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	cell	_	O	O	_	_	_	_	_
16	lymphomas	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	especially	_	O	O	_	_	_	_	_
19	diffuse	_	O	O	_	_	_	_	_
20	lymphomas	_	O	O	_	_	_	_	_
21	with	_	O	O	_	_	_	_	_
22	a	_	O	O	_	_	_	_	_
23	large	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	cell	_	O	O	_	_	_	_	_
26	component	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	BCL	_	O	O	_	_	_	_	_
3	6	_	O	O	_	_	_	_	_
4	gene	_	O	O	_	_	_	_	_
5	has	_	O	O	_	_	_	_	_
6	been	_	O	O	_	_	_	_	_
7	isolated	_	O	O	_	_	_	_	_
8	from	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	chromosomal	_	O	O	_	_	_	_	_
11	breakpoint	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	these	_	O	O	_	_	_	_	_
14	lymphomas	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	Here	_	O	O	_	_	_	_	_
2	we	_	O	O	_	_	_	_	_
3	cloned	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	murine	_	O	O	_	_	_	_	_
6	BCL	_	O	O	_	_	_	_	_
7	6	_	O	O	_	_	_	_	_
8	(	_	O	O	_	_	_	_	_
9	mBCL	_	O	O	_	_	_	_	_
10	6	_	O	O	_	_	_	_	_
11	)	_	O	O	_	_	_	_	_
12	cDNA	_	O	O	_	_	_	_	_
13	from	_	O	O	_	_	_	_	_
14	the	_	O	O	_	_	_	_	_
15	muscle	_	O	O	_	_	_	_	_
16	cDNA	_	O	O	_	_	_	_	_
17	library	_	O	O	_	_	_	_	_
18	using	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	human	_	O	O	_	_	_	_	_
21	BCL	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	hBCL	_	O	O	_	_	_	_	_
25	6	_	O	O	_	_	_	_	_
26	)	_	O	O	_	_	_	_	_
27	cDNA	_	O	O	_	_	_	_	_
28	as	_	O	O	_	_	_	_	_
29	a	_	O	O	_	_	_	_	_
30	probe	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	predicted	_	O	O	_	_	_	_	_
3	amino	_	O	O	_	_	_	_	_
4	acid	_	O	O	_	_	_	_	_
5	sequence	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	95	_	O	O	_	_	_	_	_
8	%	_	O	O	_	_	_	_	_
9	identical	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	that	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	hBCL	_	O	O	_	_	_	_	_
14	6	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_

1	It	_	O	O	_	_	_	_	_
2	contains	_	O	O	_	_	_	_	_
3	six	_	O	O	_	_	_	_	_
4	repeats	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	Kruppel	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	like	_	O	O	_	_	_	_	_
10	zinc	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	finger	_	O	O	_	_	_	_	_
13	motif	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	are	_	O	O	_	_	_	_	_
16	completely	_	O	O	_	_	_	_	_
17	identical	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	those	_	O	O	_	_	_	_	_
20	of	_	O	O	_	_	_	_	_
21	hBCL	_	O	O	_	_	_	_	_
22	6	_	O	O	_	_	_	_	_
23	,	_	O	O	_	_	_	_	_
24	indicating	_	O	O	_	_	_	_	_
25	that	_	O	O	_	_	_	_	_
26	the	_	O	O	_	_	_	_	_
27	BCL	_	O	O	_	_	_	_	_
28	6	_	O	O	_	_	_	_	_
29	gene	_	O	O	_	_	_	_	_
30	is	_	O	O	_	_	_	_	_
31	well	_	O	O	_	_	_	_	_
32	conserved	_	O	O	_	_	_	_	_
33	between	_	O	O	_	_	_	_	_
34	humans	_	O	O	_	_	_	_	_
35	and	_	O	O	_	_	_	_	_
36	mice	_	O	O	_	_	_	_	_
37	.	_	O	O	_	_	_	_	_

1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	mBCL	_	O	O	_	_	_	_	_
5	6	_	O	O	_	_	_	_	_
6	gene	_	O	O	_	_	_	_	_
7	was	_	O	O	_	_	_	_	_
8	ubiquitously	_	O	O	_	_	_	_	_
9	detected	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	adult	_	O	O	_	_	_	_	_
12	mouse	_	O	O	_	_	_	_	_
13	tissues	_	O	O	_	_	_	_	_
14	including	_	O	O	_	_	_	_	_
15	lymphatic	_	O	O	_	_	_	_	_
16	organs	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_

1	Furthermore	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	it	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	induced	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	with	_	O	O	_	_	_	_	_
10	phorbol	_	O	O	_	_	_	_	_
11	ester	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	Ca	_	O	O	_	_	_	_	_
14	2	_	O	O	_	_	_	_	_
15	+	_	O	O	_	_	_	_	_
16	ionophore	_	O	O	_	_	_	_	_
17	within	_	O	O	_	_	_	_	_
18	30	_	O	O	_	_	_	_	_
19	min	_	O	O	_	_	_	_	_
20	after	_	O	O	_	_	_	_	_
21	stimulation	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	was	_	O	O	_	_	_	_	_
4	not	_	O	O	_	_	_	_	_
5	inhibited	_	O	O	_	_	_	_	_
6	by	_	O	O	_	_	_	_	_
7	treatment	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	cells	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	protein	_	O	O	_	_	_	_	_
14	synthesis	_	O	O	_	_	_	_	_
15	inhibitor	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	cycloheximide	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	BCL	_	O	O	_	_	_	_	_
6	6	_	O	O	_	_	_	_	_
7	plays	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	role	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	activated	_	O	O	_	_	_	_	_
12	lymphocytes	_	O	O	_	_	_	_	_
13	as	_	O	O	_	_	_	_	_
14	an	_	O	O	_	_	_	_	_
15	immediate	_	O	O	_	_	_	_	_
16	early	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


1	Multiple	_	O	O	_	_	_	_	_
2	NF	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	ATc	_	O	O	_	_	_	_	_
5	isoforms	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	individual	_	O	O	_	_	_	_	_
8	transcriptional	_	O	O	_	_	_	_	_
9	properties	_	O	O	_	_	_	_	_
10	are	_	O	O	_	_	_	_	_
11	synthesized	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	T	_	O	O	_	_	_	_	_
14	lymphocytes	_	O	O	_	_	_	_	_
15	.	_	O	O	_	_	_	_	_


1	The	_	O	O	_	_	_	_	_
2	transcription	_	O	O	_	_	_	_	_
3	factor	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	ATc	_	O	O	_	_	_	_	_
7	that	_	O	O	_	_	_	_	_
8	controls	_	O	O	_	_	_	_	_
9	gene	_	O	O	_	_	_	_	_
10	expression	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	T	_	O	O	_	_	_	_	_
13	lymphocytes	_	O	O	_	_	_	_	_
14	and	_	O	O	_	_	_	_	_
15	embryonic	_	O	O	_	_	_	_	_
16	cardiac	_	O	O	_	_	_	_	_
17	cells	_	O	O	_	_	_	_	_
18	is	_	O	O	_	_	_	_	_
19	expressed	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	three	_	O	O	_	_	_	_	_
22	prominent	_	O	O	_	_	_	_	_
23	isoforms	_	O	O	_	_	_	_	_
24	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	is	_	O	O	_	_	_	_	_
3	due	_	O	O	_	_	_	_	_
4	to	_	O	O	_	_	_	_	_
5	alternative	_	O	O	_	_	_	_	_
6	splice	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	polyadenylation	_	O	O	_	_	_	_	_
9	events	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	lead	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	predominant	_	O	O	_	_	_	_	_
15	synthesis	_	O	O	_	_	_	_	_
16	of	_	O	O	_	_	_	_	_
17	two	_	O	O	_	_	_	_	_
18	long	_	O	O	_	_	_	_	_
19	isoforms	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	naive	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	a	_	O	O	_	_	_	_	_
26	shorter	_	O	O	_	_	_	_	_
27	NF	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	ATc	_	O	O	_	_	_	_	_
30	isoform	_	O	O	_	_	_	_	_
31	in	_	O	O	_	_	_	_	_
32	effector	_	O	O	_	_	_	_	_
33	T	_	O	O	_	_	_	_	_
34	cells	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	Whereas	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	previously	_	O	O	_	_	_	_	_
4	described	_	O	O	_	_	_	_	_
5	isoform	_	O	O	_	_	_	_	_
6	NF	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	ATc	_	O	O	_	_	_	_	_
9	/	_	O	O	_	_	_	_	_
10	A	_	O	O	_	_	_	_	_
11	contains	_	O	O	_	_	_	_	_
12	a	_	O	O	_	_	_	_	_
13	relatively	_	O	O	_	_	_	_	_
14	short	_	O	O	_	_	_	_	_
15	C	_	O	O	_	_	_	_	_
16	terminus	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	longer	_	O	O	_	_	_	_	_
20	isoforms	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	B	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	C	_	O	O	_	_	_	_	_
25	,	_	O	O	_	_	_	_	_
26	span	_	O	O	_	_	_	_	_
27	extra	_	O	O	_	_	_	_	_
28	C	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	terminal	_	O	O	_	_	_	_	_
31	peptides	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	128	_	O	O	_	_	_	_	_
34	and	_	O	O	_	_	_	_	_
35	246	_	O	O	_	_	_	_	_
36	aa	_	O	O	_	_	_	_	_
37	,	_	O	O	_	_	_	_	_
38	respectively	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	show	_	O	O	_	_	_	_	_
3	here	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	in	_	O	O	_	_	_	_	_
6	addition	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	strong	_	O	O	_	_	_	_	_
10	N	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	terminal	_	O	O	_	_	_	_	_
13	trans	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	activation	_	O	O	_	_	_	_	_
16	domain	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	TAD	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	A	_	O	O	_	_	_	_	_
21	,	_	O	O	_	_	_	_	_
22	which	_	O	O	_	_	_	_	_
23	is	_	O	O	_	_	_	_	_
24	common	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	all	_	O	O	_	_	_	_	_
27	three	_	O	O	_	_	_	_	_
28	NF	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	ATc	_	O	O	_	_	_	_	_
31	isoforms	_	O	O	_	_	_	_	_
32	,	_	O	O	_	_	_	_	_
33	NF	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	ATc	_	O	O	_	_	_	_	_
36	/	_	O	O	_	_	_	_	_
37	C	_	O	O	_	_	_	_	_
38	contains	_	O	O	_	_	_	_	_
39	a	_	O	O	_	_	_	_	_
40	second	_	O	O	_	_	_	_	_
41	trans	_	O	O	_	_	_	_	_
42	-	_	O	O	_	_	_	_	_
43	activation	_	O	O	_	_	_	_	_
44	domain	_	O	O	_	_	_	_	_
45	,	_	O	O	_	_	_	_	_
46	TAD	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	B	_	O	O	_	_	_	_	_
49	,	_	O	O	_	_	_	_	_
50	in	_	O	O	_	_	_	_	_
51	its	_	O	O	_	_	_	_	_
52	C	_	O	O	_	_	_	_	_
53	-	_	O	O	_	_	_	_	_
54	terminal	_	O	O	_	_	_	_	_
55	peptide	_	O	O	_	_	_	_	_
56	.	_	O	O	_	_	_	_	_

1	Various	_	O	O	_	_	_	_	_
2	stimuli	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	T	_	O	O	_	_	_	_	_
5	cells	_	O	O	_	_	_	_	_
6	that	_	O	O	_	_	_	_	_
7	induce	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	TAD	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	A	_	O	O	_	_	_	_	_
14	also	_	O	O	_	_	_	_	_
15	enhance	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	activity	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	TAD	_	O	O	_	_	_	_	_
20	-	_	O	O	_	_	_	_	_
21	B	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	but	_	O	O	_	_	_	_	_
24	,	_	O	O	_	_	_	_	_
25	unlike	_	O	O	_	_	_	_	_
26	TAD	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	A	_	O	O	_	_	_	_	_
29	,	_	O	O	_	_	_	_	_
30	TAD	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	B	_	O	O	_	_	_	_	_
33	remains	_	O	O	_	_	_	_	_
34	unphosphorylated	_	O	O	_	_	_	_	_
35	by	_	O	O	_	_	_	_	_
36	protein	_	O	O	_	_	_	_	_
37	from	_	O	O	_	_	_	_	_
38	12	_	O	O	_	_	_	_	_
39	-	_	O	O	_	_	_	_	_
40	O	_	O	O	_	_	_	_	_
41	-	_	O	O	_	_	_	_	_
42	tetradecanoyl	_	O	O	_	_	_	_	_
43	12	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	phorbol	_	O	O	_	_	_	_	_
46	13	_	O	O	_	_	_	_	_
47	-	_	O	O	_	_	_	_	_
48	acetate	_	O	O	_	_	_	_	_
49	-	_	O	O	_	_	_	_	_
50	stimulated	_	O	O	_	_	_	_	_
51	T	_	O	O	_	_	_	_	_
52	cells	_	O	O	_	_	_	_	_
53	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	shorter	_	O	O	_	_	_	_	_
3	C	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	terminal	_	O	O	_	_	_	_	_
6	peptide	_	O	O	_	_	_	_	_
7	of	_	O	O	_	_	_	_	_
8	isoform	_	O	O	_	_	_	_	_
9	NF	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	ATc	_	O	O	_	_	_	_	_
12	/	_	O	O	_	_	_	_	_
13	B	_	O	O	_	_	_	_	_
14	exerts	_	O	O	_	_	_	_	_
15	a	_	O	O	_	_	_	_	_
16	suppressive	_	O	O	_	_	_	_	_
17	transcriptional	_	O	O	_	_	_	_	_
18	effect	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	properties	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	NF	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	ATc	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	C	_	O	O	_	_	_	_	_
12	might	_	O	O	_	_	_	_	_
13	be	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	importance	_	O	O	_	_	_	_	_
16	for	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	regulation	_	O	O	_	_	_	_	_
19	in	_	O	O	_	_	_	_	_
20	naive	_	O	O	_	_	_	_	_
21	T	_	O	O	_	_	_	_	_
22	lymphocytes	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	which	_	O	O	_	_	_	_	_
25	NF	_	O	O	_	_	_	_	_
26	-	_	O	O	_	_	_	_	_
27	ATc	_	O	O	_	_	_	_	_
28	/	_	O	O	_	_	_	_	_
29	B	_	O	O	_	_	_	_	_
30	and	_	O	O	_	_	_	_	_
31	-	_	O	O	_	_	_	_	_
32	C	_	O	O	_	_	_	_	_
33	are	_	O	O	_	_	_	_	_
34	predominantly	_	O	O	_	_	_	_	_
35	synthesized	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_


1	Flutamide	_	O	O	_	_	_	_	_
2	in	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	treatment	_	O	O	_	_	_	_	_
5	of	_	O	O	_	_	_	_	_
6	hirsutism	_	O	O	_	_	_	_	_
7	:	_	O	O	_	_	_	_	_
8	long	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	term	_	O	O	_	_	_	_	_
11	clinical	_	O	O	_	_	_	_	_
12	effects	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	endocrine	_	O	O	_	_	_	_	_
15	changes	_	O	O	_	_	_	_	_
16	,	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	androgen	_	O	O	_	_	_	_	_
19	receptor	_	O	O	_	_	_	_	_
20	behavior	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_


1	OBJECTIVE	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	To	_	O	O	_	_	_	_	_
4	investigate	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	long	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	term	_	O	O	_	_	_	_	_
9	effects	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	treatment	_	O	O	_	_	_	_	_
12	with	_	O	O	_	_	_	_	_
13	low	_	O	O	_	_	_	_	_
14	doses	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	flutamide	_	O	O	_	_	_	_	_
17	on	_	O	O	_	_	_	_	_
18	clinical	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	hormonal	_	O	O	_	_	_	_	_
21	parameters	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	as	_	O	O	_	_	_	_	_
24	well	_	O	O	_	_	_	_	_
25	as	_	O	O	_	_	_	_	_
26	on	_	O	O	_	_	_	_	_
27	the	_	O	O	_	_	_	_	_
28	androgen	_	O	O	_	_	_	_	_
29	receptor	_	O	O	_	_	_	_	_
30	status	_	O	O	_	_	_	_	_
31	,	_	O	O	_	_	_	_	_
32	in	_	O	O	_	_	_	_	_
33	hirsute	_	O	O	_	_	_	_	_
34	women	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	DESIGN	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Eighteen	_	O	O	_	_	_	_	_
4	hirsute	_	O	O	_	_	_	_	_
5	patients	_	O	O	_	_	_	_	_
6	with	_	O	O	_	_	_	_	_
7	regular	_	O	O	_	_	_	_	_
8	menses	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	studied	_	O	O	_	_	_	_	_
11	basally	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	during	_	O	O	_	_	_	_	_
14	treatment	_	O	O	_	_	_	_	_
15	with	_	O	O	_	_	_	_	_
16	125	_	O	O	_	_	_	_	_
17	mg	_	O	O	_	_	_	_	_
18	flutamide	_	O	O	_	_	_	_	_
19	,	_	O	O	_	_	_	_	_
20	three	_	O	O	_	_	_	_	_
21	times	_	O	O	_	_	_	_	_
22	per	_	O	O	_	_	_	_	_
23	day	_	O	O	_	_	_	_	_
24	for	_	O	O	_	_	_	_	_
25	12	_	O	O	_	_	_	_	_
26	months	_	O	O	_	_	_	_	_
27	.	_	O	O	_	_	_	_	_

1	Barrier	_	O	O	_	_	_	_	_
2	or	_	O	O	_	_	_	_	_
3	intrauterine	_	O	O	_	_	_	_	_
4	contraception	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	used	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	study	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	sexually	_	O	O	_	_	_	_	_
12	active	_	O	O	_	_	_	_	_
13	women	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Safety	_	O	O	_	_	_	_	_
2	parameters	_	O	O	_	_	_	_	_
3	were	_	O	O	_	_	_	_	_
4	assessed	_	O	O	_	_	_	_	_
5	throughout	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	study	_	O	O	_	_	_	_	_
8	.	_	O	O	_	_	_	_	_

1	Hirsutism	_	O	O	_	_	_	_	_
2	,	_	O	O	_	_	_	_	_
3	graded	_	O	O	_	_	_	_	_
4	by	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	modified	_	O	O	_	_	_	_	_
7	Ferriman	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	Gallwey	_	O	O	_	_	_	_	_
10	score	_	O	O	_	_	_	_	_
11	,	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	hormonal	_	O	O	_	_	_	_	_
14	parameters	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	evaluated	_	O	O	_	_	_	_	_
17	basally	_	O	O	_	_	_	_	_
18	and	_	O	O	_	_	_	_	_
19	at	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	month	_	O	O	_	_	_	_	_
23	intervals	_	O	O	_	_	_	_	_
24	during	_	O	O	_	_	_	_	_
25	treatment	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Gonadotropin	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	releasing	_	O	O	_	_	_	_	_
4	hormone	_	O	O	_	_	_	_	_
5	and	_	O	O	_	_	_	_	_
6	ACTH	_	O	O	_	_	_	_	_
7	stimulation	_	O	O	_	_	_	_	_
8	tests	_	O	O	_	_	_	_	_
9	were	_	O	O	_	_	_	_	_
10	performed	_	O	O	_	_	_	_	_
11	before	_	O	O	_	_	_	_	_
12	and	_	O	O	_	_	_	_	_
13	after	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	to	_	O	O	_	_	_	_	_
16	4	_	O	O	_	_	_	_	_
17	months	_	O	O	_	_	_	_	_
18	of	_	O	O	_	_	_	_	_
19	therapy	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	addition	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	concentration	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	androgen	_	O	O	_	_	_	_	_
8	receptors	_	O	O	_	_	_	_	_
9	in	_	O	O	_	_	_	_	_
10	mononuclear	_	O	O	_	_	_	_	_
11	leukocytes	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	measured	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	both	_	O	O	_	_	_	_	_
17	the	_	O	O	_	_	_	_	_
18	follicular	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	luteal	_	O	O	_	_	_	_	_
21	phases	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	menstrual	_	O	O	_	_	_	_	_
25	cycle	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	basally	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	after	_	O	O	_	_	_	_	_
30	4	_	O	O	_	_	_	_	_
31	months	_	O	O	_	_	_	_	_
32	of	_	O	O	_	_	_	_	_
33	flutamide	_	O	O	_	_	_	_	_
34	treatment	_	O	O	_	_	_	_	_
35	.	_	O	O	_	_	_	_	_

1	RESULTS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Flutamide	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	well	_	O	O	_	_	_	_	_
6	tolerated	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	all	_	O	O	_	_	_	_	_
9	women	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	with	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	noticeable	_	O	O	_	_	_	_	_
14	exception	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	one	_	O	O	_	_	_	_	_
17	patient	_	O	O	_	_	_	_	_
18	who	_	O	O	_	_	_	_	_
19	presented	_	O	O	_	_	_	_	_
20	increased	_	O	O	_	_	_	_	_
21	serum	_	O	O	_	_	_	_	_
22	transaminase	_	O	O	_	_	_	_	_
23	after	_	O	O	_	_	_	_	_
24	8	_	O	O	_	_	_	_	_
25	months	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	therapy	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	Hirsutism	_	O	O	_	_	_	_	_
2	markedly	_	O	O	_	_	_	_	_
3	improved	_	O	O	_	_	_	_	_
4	in	_	O	O	_	_	_	_	_
5	all	_	O	O	_	_	_	_	_
6	women	_	O	O	_	_	_	_	_
7	during	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	treatment	_	O	O	_	_	_	_	_
10	(	_	O	O	_	_	_	_	_
11	Ferriman	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	Gallwey	_	O	O	_	_	_	_	_
14	score	_	O	O	_	_	_	_	_
15	after	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	year	_	O	O	_	_	_	_	_
18	:	_	O	O	_	_	_	_	_
19	4	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_
21	1	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	/	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	0	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_
27	5	_	O	O	_	_	_	_	_
28	versus	_	O	O	_	_	_	_	_
29	14	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_
31	1	_	O	O	_	_	_	_	_
32	+	_	O	O	_	_	_	_	_
33	/	_	O	O	_	_	_	_	_
34	-	_	O	O	_	_	_	_	_
35	0	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_
37	9	_	O	O	_	_	_	_	_
38	)	_	O	O	_	_	_	_	_
39	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	reduction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	serum	_	O	O	_	_	_	_	_
5	androgens	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	found	_	O	O	_	_	_	_	_
8	,	_	O	O	_	_	_	_	_
9	whereas	_	O	O	_	_	_	_	_
10	no	_	O	O	_	_	_	_	_
11	change	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	observed	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	either	_	O	O	_	_	_	_	_
16	basal	_	O	O	_	_	_	_	_
17	or	_	O	O	_	_	_	_	_
18	GnRH	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	stimulated	_	O	O	_	_	_	_	_
21	gonadotropins	_	O	O	_	_	_	_	_
22	or	_	O	O	_	_	_	_	_
23	in	_	O	O	_	_	_	_	_
24	the	_	O	O	_	_	_	_	_
25	cortisol	_	O	O	_	_	_	_	_
26	and	_	O	O	_	_	_	_	_
27	17	_	O	O	_	_	_	_	_
28	alpha	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	hydroxyprogesterone	_	O	O	_	_	_	_	_
31	response	_	O	O	_	_	_	_	_
32	to	_	O	O	_	_	_	_	_
33	ACTH	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	Cycles	_	O	O	_	_	_	_	_
2	remained	_	O	O	_	_	_	_	_
3	ovulatory	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	Before	_	O	O	_	_	_	_	_
2	treatment	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	number	_	O	O	_	_	_	_	_
6	of	_	O	O	_	_	_	_	_
7	androgen	_	O	O	_	_	_	_	_
8	receptors	_	O	O	_	_	_	_	_
9	was	_	O	O	_	_	_	_	_
10	higher	_	O	O	_	_	_	_	_
11	in	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	luteal	_	O	O	_	_	_	_	_
14	than	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	the	_	O	O	_	_	_	_	_
17	follicular	_	O	O	_	_	_	_	_
18	phase	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	rhythmic	_	O	O	_	_	_	_	_
3	differentiation	_	O	O	_	_	_	_	_
4	disappeared	_	O	O	_	_	_	_	_
5	after	_	O	O	_	_	_	_	_
6	the	_	O	O	_	_	_	_	_
7	patients	_	O	O	_	_	_	_	_
8	had	_	O	O	_	_	_	_	_
9	been	_	O	O	_	_	_	_	_
10	given	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	antiandrogen	_	O	O	_	_	_	_	_
13	drug	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	CONCLUSIONS	_	O	O	_	_	_	_	_
2	:	_	O	O	_	_	_	_	_
3	Flutamide	_	O	O	_	_	_	_	_
4	is	_	O	O	_	_	_	_	_
5	effective	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	treatment	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	hirsutism	_	O	O	_	_	_	_	_
11	but	_	O	O	_	_	_	_	_
12	requires	_	O	O	_	_	_	_	_
13	constant	_	O	O	_	_	_	_	_
14	surveillance	_	O	O	_	_	_	_	_
15	of	_	O	O	_	_	_	_	_
16	liver	_	O	O	_	_	_	_	_
17	function	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_

1	Androgen	_	O	O	_	_	_	_	_
2	receptor	_	O	O	_	_	_	_	_
3	blockade	_	O	O	_	_	_	_	_
4	might	_	O	O	_	_	_	_	_
5	be	_	O	O	_	_	_	_	_
6	potentiated	_	O	O	_	_	_	_	_
7	by	_	O	O	_	_	_	_	_
8	a	_	O	O	_	_	_	_	_
9	reduction	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	serum	_	O	O	_	_	_	_	_
12	androgens	_	O	O	_	_	_	_	_
13	.	_	O	O	_	_	_	_	_

1	Flutamide	_	O	O	_	_	_	_	_
2	affects	_	O	O	_	_	_	_	_
3	androgen	_	O	O	_	_	_	_	_
4	receptor	_	O	O	_	_	_	_	_
5	behavior	_	O	O	_	_	_	_	_
6	during	_	O	O	_	_	_	_	_
7	the	_	O	O	_	_	_	_	_
8	menstrual	_	O	O	_	_	_	_	_
9	cycle	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	meaning	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	this	_	O	O	_	_	_	_	_
5	finding	_	O	O	_	_	_	_	_
6	remains	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	be	_	O	O	_	_	_	_	_
9	elucidated	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_


1	Defective	_	O	O	_	_	_	_	_
2	IL	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	10	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	mediated	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	phosphorylation	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	RA	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	T	_	O	O	_	_	_	_	_
16	cells	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	interaction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	IL	_	O	O	_	_	_	_	_
5	-	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	R	_	O	O	_	_	_	_	_
8	with	_	O	O	_	_	_	_	_
9	IL	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	10	_	O	O	_	_	_	_	_
12	induces	_	O	O	_	_	_	_	_
13	tyrosine	_	O	O	_	_	_	_	_
14	phosphorylation	_	O	O	_	_	_	_	_
15	and	_	O	O	_	_	_	_	_
16	activation	_	O	O	_	_	_	_	_
17	of	_	O	O	_	_	_	_	_
18	the	_	O	O	_	_	_	_	_
19	latent	_	O	O	_	_	_	_	_
20	transcription	_	O	O	_	_	_	_	_
21	factors	_	O	O	_	_	_	_	_
22	STAT	_	O	O	_	_	_	_	_
23	1	_	O	O	_	_	_	_	_
24	and	_	O	O	_	_	_	_	_
25	STAT	_	O	O	_	_	_	_	_
26	3	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	3	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	Macrophage	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	specific	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	deficient	_	O	O	_	_	_	_	_
8	mice	_	O	O	_	_	_	_	_
9	demonstrated	_	O	O	_	_	_	_	_
10	that	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	3	_	O	O	_	_	_	_	_
13	plays	_	O	O	_	_	_	_	_
14	a	_	O	O	_	_	_	_	_
15	dominant	_	O	O	_	_	_	_	_
16	role	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	IL	_	O	O	_	_	_	_	_
19	-	_	O	O	_	_	_	_	_
20	10	_	O	O	_	_	_	_	_
21	-	_	O	O	_	_	_	_	_
22	mediated	_	O	O	_	_	_	_	_
23	anti	_	O	O	_	_	_	_	_
24	-	_	O	O	_	_	_	_	_
25	inflammatory	_	O	O	_	_	_	_	_
26	responses	_	O	O	_	_	_	_	_
27	[	_	O	O	_	_	_	_	_
28	5	_	O	O	_	_	_	_	_
29	]	_	O	O	_	_	_	_	_
30	,	_	O	O	_	_	_	_	_
31	which	_	O	O	_	_	_	_	_
32	has	_	O	O	_	_	_	_	_
33	recently	_	O	O	_	_	_	_	_
34	been	_	O	O	_	_	_	_	_
35	confirmed	_	O	O	_	_	_	_	_
36	in	_	O	O	_	_	_	_	_
37	human	_	O	O	_	_	_	_	_
38	macrophages	_	O	O	_	_	_	_	_
39	by	_	O	O	_	_	_	_	_
40	studies	_	O	O	_	_	_	_	_
41	of	_	O	O	_	_	_	_	_
42	dominant	_	O	O	_	_	_	_	_
43	-	_	O	O	_	_	_	_	_
44	negative	_	O	O	_	_	_	_	_
45	STAT	_	O	O	_	_	_	_	_
46	3	_	O	O	_	_	_	_	_
47	overexpression	_	O	O	_	_	_	_	_
48	[	_	O	O	_	_	_	_	_
49	30	_	O	O	_	_	_	_	_
50	]	_	O	O	_	_	_	_	_
51	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	induction	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	1	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	3	_	O	O	_	_	_	_	_
9	phosphorylation	_	O	O	_	_	_	_	_
10	by	_	O	O	_	_	_	_	_
11	IL	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	PB	_	O	O	_	_	_	_	_
16	CD	_	O	O	_	_	_	_	_
17	4	_	O	O	_	_	_	_	_
18	+	_	O	O	_	_	_	_	_
19	T	_	O	O	_	_	_	_	_
20	cells	_	O	O	_	_	_	_	_
21	from	_	O	O	_	_	_	_	_
22	active	_	O	O	_	_	_	_	_
23	RA	_	O	O	_	_	_	_	_
24	patients	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	from	_	O	O	_	_	_	_	_
27	healthy	_	O	O	_	_	_	_	_
28	controls	_	O	O	_	_	_	_	_
29	was	_	O	O	_	_	_	_	_
30	examined	_	O	O	_	_	_	_	_
31	using	_	O	O	_	_	_	_	_
32	western	_	O	O	_	_	_	_	_
33	blotting	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	STAT	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	phosphorylation	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	dose	_	O	O	_	_	_	_	_
6	-	_	O	O	_	_	_	_	_
7	dependently	_	O	O	_	_	_	_	_
8	induced	_	O	O	_	_	_	_	_
9	after	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	activation	_	O	O	_	_	_	_	_
14	for	_	O	O	_	_	_	_	_
15	20	_	O	O	_	_	_	_	_
16	min	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	normal	_	O	O	_	_	_	_	_
19	CD	_	O	O	_	_	_	_	_
20	4	_	O	O	_	_	_	_	_
21	+	_	O	O	_	_	_	_	_
22	T	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	(	_	O	O	_	_	_	_	_
25	Fig	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	4	_	O	O	_	_	_	_	_
5	b	_	O	O	_	_	_	_	_
6	)	_	O	O	_	_	_	_	_
7	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	contrast	_	O	O	_	_	_	_	_
3	,	_	O	O	_	_	_	_	_
4	STAT	_	O	O	_	_	_	_	_
5	3	_	O	O	_	_	_	_	_
6	was	_	O	O	_	_	_	_	_
7	phosphorylated	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	freshly	_	O	O	_	_	_	_	_
10	isolated	_	O	O	_	_	_	_	_
11	PB	_	O	O	_	_	_	_	_
12	CD	_	O	O	_	_	_	_	_
13	4	_	O	O	_	_	_	_	_
14	+	_	O	O	_	_	_	_	_
15	cells	_	O	O	_	_	_	_	_
16	from	_	O	O	_	_	_	_	_
17	RA	_	O	O	_	_	_	_	_
18	patients	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	this	_	O	O	_	_	_	_	_
21	STAT	_	O	O	_	_	_	_	_
22	3	_	O	O	_	_	_	_	_
23	phosphorylation	_	O	O	_	_	_	_	_
24	was	_	O	O	_	_	_	_	_
25	detectable	_	O	O	_	_	_	_	_
26	for	_	O	O	_	_	_	_	_
27	up	_	O	O	_	_	_	_	_
28	to	_	O	O	_	_	_	_	_
29	6	_	O	O	_	_	_	_	_
30	hours	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	STAT	_	O	O	_	_	_	_	_
2	3	_	O	O	_	_	_	_	_
3	phosphorylation	_	O	O	_	_	_	_	_
4	was	_	O	O	_	_	_	_	_
5	augmented	_	O	O	_	_	_	_	_
6	only	_	O	O	_	_	_	_	_
7	when	_	O	O	_	_	_	_	_
8	activated	_	O	O	_	_	_	_	_
9	by	_	O	O	_	_	_	_	_
10	as	_	O	O	_	_	_	_	_
11	much	_	O	O	_	_	_	_	_
12	as	_	O	O	_	_	_	_	_
13	10	_	O	O	_	_	_	_	_
14	ng	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	ml	_	O	O	_	_	_	_	_
17	IL	_	O	O	_	_	_	_	_
18	-	_	O	O	_	_	_	_	_
19	10	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	Both	_	O	O	_	_	_	_	_
2	sustained	_	O	O	_	_	_	_	_
3	STAT	_	O	O	_	_	_	_	_
4	3	_	O	O	_	_	_	_	_
5	phosphorylation	_	O	O	_	_	_	_	_
6	and	_	O	O	_	_	_	_	_
7	defective	_	O	O	_	_	_	_	_
8	IL	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	10	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	induced	_	O	O	_	_	_	_	_
13	STAT	_	O	O	_	_	_	_	_
14	3	_	O	O	_	_	_	_	_
15	phosphorylation	_	O	O	_	_	_	_	_
16	were	_	O	O	_	_	_	_	_
17	found	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	ST	_	O	O	_	_	_	_	_
21	CD	_	O	O	_	_	_	_	_
22	4	_	O	O	_	_	_	_	_
23	+	_	O	O	_	_	_	_	_
24	T	_	O	O	_	_	_	_	_
25	cells	_	O	O	_	_	_	_	_
26	(	_	O	O	_	_	_	_	_
27	Fig	_	O	O	_	_	_	_	_
28	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	c	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	On	_	O	O	_	_	_	_	_
2	the	_	O	O	_	_	_	_	_
3	other	_	O	O	_	_	_	_	_
4	hand	_	O	O	_	_	_	_	_
5	,	_	O	O	_	_	_	_	_
6	IL	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	10	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	induced	_	O	O	_	_	_	_	_
11	STAT	_	O	O	_	_	_	_	_
12	1	_	O	O	_	_	_	_	_
13	phosphorylation	_	O	O	_	_	_	_	_
14	was	_	O	O	_	_	_	_	_
15	not	_	O	O	_	_	_	_	_
16	detected	_	O	O	_	_	_	_	_
17	in	_	O	O	_	_	_	_	_
18	either	_	O	O	_	_	_	_	_
19	RA	_	O	O	_	_	_	_	_
20	CD	_	O	O	_	_	_	_	_
21	4	_	O	O	_	_	_	_	_
22	+	_	O	O	_	_	_	_	_
23	T	_	O	O	_	_	_	_	_
24	cells	_	O	O	_	_	_	_	_
25	or	_	O	O	_	_	_	_	_
26	normal	_	O	O	_	_	_	_	_
27	CD	_	O	O	_	_	_	_	_
28	4	_	O	O	_	_	_	_	_
29	+	_	O	O	_	_	_	_	_
30	T	_	O	O	_	_	_	_	_
31	cells	_	O	O	_	_	_	_	_
32	(	_	O	O	_	_	_	_	_
33	Fig	_	O	O	_	_	_	_	_
34	.	_	O	O	_	_	_	_	_

1	4	_	O	O	_	_	_	_	_
2	a	_	O	O	_	_	_	_	_
3	)	_	O	O	_	_	_	_	_
4	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	indicate	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	STAT	_	O	O	_	_	_	_	_
6	3	_	O	O	_	_	_	_	_
7	is	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	major	_	O	O	_	_	_	_	_
10	IL	_	O	O	_	_	_	_	_
11	-	_	O	O	_	_	_	_	_
12	10	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	activated	_	O	O	_	_	_	_	_
15	STAT	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	CD	_	O	O	_	_	_	_	_
18	4	_	O	O	_	_	_	_	_
19	+	_	O	O	_	_	_	_	_
20	T	_	O	O	_	_	_	_	_
21	cells	_	O	O	_	_	_	_	_
22	,	_	O	O	_	_	_	_	_
23	and	_	O	O	_	_	_	_	_
24	IL	_	O	O	_	_	_	_	_
25	-	_	O	O	_	_	_	_	_
26	10	_	O	O	_	_	_	_	_
27	-	_	O	O	_	_	_	_	_
28	induced	_	O	O	_	_	_	_	_
29	STAT	_	O	O	_	_	_	_	_
30	3	_	O	O	_	_	_	_	_
31	activation	_	O	O	_	_	_	_	_
32	may	_	O	O	_	_	_	_	_
33	be	_	O	O	_	_	_	_	_
34	diminished	_	O	O	_	_	_	_	_
35	in	_	O	O	_	_	_	_	_
36	active	_	O	O	_	_	_	_	_
37	RA	_	O	O	_	_	_	_	_
38	,	_	O	O	_	_	_	_	_
39	in	_	O	O	_	_	_	_	_
40	association	_	O	O	_	_	_	_	_
41	with	_	O	O	_	_	_	_	_
42	sustained	_	O	O	_	_	_	_	_
43	STAT	_	O	O	_	_	_	_	_
44	3	_	O	O	_	_	_	_	_
45	phosphorylation	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_



1	The	_	O	O	_	_	_	_	_
2	Epstein	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Barr	_	O	O	_	_	_	_	_
5	virus	_	O	O	_	_	_	_	_
6	latency	_	O	O	_	_	_	_	_
7	BamHI	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	Q	_	O	O	_	_	_	_	_
10	promoter	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	positively	_	O	O	_	_	_	_	_
13	regulated	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	STATs	_	O	O	_	_	_	_	_
16	and	_	O	O	_	_	_	_	_
17	Zta	_	O	O	_	_	_	_	_
18	interference	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	JAK	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	STAT	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	leads	_	O	O	_	_	_	_	_
25	to	_	O	O	_	_	_	_	_
26	loss	_	O	O	_	_	_	_	_
27	of	_	O	O	_	_	_	_	_
28	BamHI	_	O	O	_	_	_	_	_
29	-	_	O	O	_	_	_	_	_
30	Q	_	O	O	_	_	_	_	_
31	promoter	_	O	O	_	_	_	_	_
32	activity	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_


1	In	_	O	O	_	_	_	_	_
2	Epstein	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	Barr	_	O	O	_	_	_	_	_
5	virus	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	EBV	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	associated	_	O	O	_	_	_	_	_
11	tumors	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	nonimmunocompromised	_	O	O	_	_	_	_	_
14	patients	_	O	O	_	_	_	_	_
15	,	_	O	O	_	_	_	_	_
16	EBV	_	O	O	_	_	_	_	_
17	gene	_	O	O	_	_	_	_	_
18	expression	_	O	O	_	_	_	_	_
19	is	_	O	O	_	_	_	_	_
20	highly	_	O	O	_	_	_	_	_
21	restricted	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	EBV	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	encoded	_	O	O	_	_	_	_	_
4	nuclear	_	O	O	_	_	_	_	_
5	antigen	_	O	O	_	_	_	_	_
6	(	_	O	O	_	_	_	_	_
7	EBNA	_	O	O	_	_	_	_	_
8	)	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	1	_	O	O	_	_	_	_	_
11	is	_	O	O	_	_	_	_	_
12	expressed	_	O	O	_	_	_	_	_
13	,	_	O	O	_	_	_	_	_
14	whereas	_	O	O	_	_	_	_	_
15	the	_	O	O	_	_	_	_	_
16	immunogenic	_	O	O	_	_	_	_	_
17	and	_	O	O	_	_	_	_	_
18	proliferative	_	O	O	_	_	_	_	_
19	EBNAs	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	not	_	O	O	_	_	_	_	_
22	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	pattern	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	EBNA	_	O	O	_	_	_	_	_
5	expression	_	O	O	_	_	_	_	_
6	is	_	O	O	_	_	_	_	_
7	generated	_	O	O	_	_	_	_	_
8	by	_	O	O	_	_	_	_	_
9	usage	_	O	O	_	_	_	_	_
10	of	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	BamHI	_	O	O	_	_	_	_	_
13	-	_	O	O	_	_	_	_	_
14	Q	_	O	O	_	_	_	_	_
15	promoter	_	O	O	_	_	_	_	_
16	(	_	O	O	_	_	_	_	_
17	Qp	_	O	O	_	_	_	_	_
18	)	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	have	_	O	O	_	_	_	_	_
3	determined	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	JAK	_	O	O	_	_	_	_	_
7	/	_	O	O	_	_	_	_	_
8	STAT	_	O	O	_	_	_	_	_
9	pathway	_	O	O	_	_	_	_	_
10	positively	_	O	O	_	_	_	_	_
11	regulates	_	O	O	_	_	_	_	_
12	Qp	_	O	O	_	_	_	_	_
13	activity	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	In	_	O	O	_	_	_	_	_
2	transient	_	O	O	_	_	_	_	_
3	-	_	O	O	_	_	_	_	_
4	transfection	_	O	O	_	_	_	_	_
5	assays	_	O	O	_	_	_	_	_
6	,	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	Qp	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	CAT	_	O	O	_	_	_	_	_
11	reporter	_	O	O	_	_	_	_	_
12	was	_	O	O	_	_	_	_	_
13	activated	_	O	O	_	_	_	_	_
14	by	_	O	O	_	_	_	_	_
15	cotransfected	_	O	O	_	_	_	_	_
16	JAK	_	O	O	_	_	_	_	_
17	-	_	O	O	_	_	_	_	_
18	1	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	treatment	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	cells	_	O	O	_	_	_	_	_
24	with	_	O	O	_	_	_	_	_
25	the	_	O	O	_	_	_	_	_
26	cytokine	_	O	O	_	_	_	_	_
27	IL	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	6	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	ability	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	Qp	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	bind	_	O	O	_	_	_	_	_
7	signal	_	O	O	_	_	_	_	_
8	transducer	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	activator	_	O	O	_	_	_	_	_
11	of	_	O	O	_	_	_	_	_
12	transcription	_	O	O	_	_	_	_	_
13	(	_	O	O	_	_	_	_	_
14	STAT	_	O	O	_	_	_	_	_
15	)	_	O	O	_	_	_	_	_
16	proteins	_	O	O	_	_	_	_	_
17	was	_	O	O	_	_	_	_	_
18	directly	_	O	O	_	_	_	_	_
19	demonstrated	_	O	O	_	_	_	_	_
20	by	_	O	O	_	_	_	_	_
21	electrophoretic	_	O	O	_	_	_	_	_
22	mobility	_	O	O	_	_	_	_	_
23	-	_	O	O	_	_	_	_	_
24	shift	_	O	O	_	_	_	_	_
25	assay	_	O	O	_	_	_	_	_
26	,	_	O	O	_	_	_	_	_
27	and	_	O	O	_	_	_	_	_
28	mutation	_	O	O	_	_	_	_	_
29	of	_	O	O	_	_	_	_	_
30	potential	_	O	O	_	_	_	_	_
31	STAT	_	O	O	_	_	_	_	_
32	-	_	O	O	_	_	_	_	_
33	binding	_	O	O	_	_	_	_	_
34	sites	_	O	O	_	_	_	_	_
35	reduced	_	O	O	_	_	_	_	_
36	Qp	_	O	O	_	_	_	_	_
37	responsiveness	_	O	O	_	_	_	_	_
38	to	_	O	O	_	_	_	_	_
39	Janus	_	O	O	_	_	_	_	_
40	kinase	_	O	O	_	_	_	_	_
41	(	_	O	O	_	_	_	_	_
42	JAK	_	O	O	_	_	_	_	_
43	)	_	O	O	_	_	_	_	_
44	-	_	O	O	_	_	_	_	_
45	1	_	O	O	_	_	_	_	_
46	.	_	O	O	_	_	_	_	_

1	Consistent	_	O	O	_	_	_	_	_
2	with	_	O	O	_	_	_	_	_
3	a	_	O	O	_	_	_	_	_
4	role	_	O	O	_	_	_	_	_
5	for	_	O	O	_	_	_	_	_
6	STATs	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	Qp	_	O	O	_	_	_	_	_
9	function	_	O	O	_	_	_	_	_
10	,	_	O	O	_	_	_	_	_
11	Qp	_	O	O	_	_	_	_	_
12	using	_	O	O	_	_	_	_	_
13	Burkitt	_	O	O	_	_	_	_	_
14	'	_	O	O	_	_	_	_	_
15	s	_	O	O	_	_	_	_	_
16	lymphoma	_	O	O	_	_	_	_	_
17	Rael	_	O	O	_	_	_	_	_
18	cells	_	O	O	_	_	_	_	_
19	and	_	O	O	_	_	_	_	_
20	cultured	_	O	O	_	_	_	_	_
21	nasopharyngeal	_	O	O	_	_	_	_	_
22	carcinoma	_	O	O	_	_	_	_	_
23	(	_	O	O	_	_	_	_	_
24	NPC	_	O	O	_	_	_	_	_
25	)	_	O	O	_	_	_	_	_
26	cells	_	O	O	_	_	_	_	_
27	contained	_	O	O	_	_	_	_	_
28	nuclear	_	O	O	_	_	_	_	_
29	STAT	_	O	O	_	_	_	_	_
30	protein	_	O	O	_	_	_	_	_
31	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	investigated	_	O	O	_	_	_	_	_
3	whether	_	O	O	_	_	_	_	_
4	the	_	O	O	_	_	_	_	_
5	inability	_	O	O	_	_	_	_	_
6	to	_	O	O	_	_	_	_	_
7	maintain	_	O	O	_	_	_	_	_
8	EBV	_	O	O	_	_	_	_	_
9	-	_	O	O	_	_	_	_	_
10	positive	_	O	O	_	_	_	_	_
11	NPC	_	O	O	_	_	_	_	_
12	cell	_	O	O	_	_	_	_	_
13	lines	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	culture	_	O	O	_	_	_	_	_
16	was	_	O	O	_	_	_	_	_
17	related	_	O	O	_	_	_	_	_
18	to	_	O	O	_	_	_	_	_
19	Qp	_	O	O	_	_	_	_	_
20	activity	_	O	O	_	_	_	_	_
21	.	_	O	O	_	_	_	_	_

1	Passaging	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	the	_	O	O	_	_	_	_	_
4	NPC	_	O	O	_	_	_	_	_
5	cell	_	O	O	_	_	_	_	_
6	line	_	O	O	_	_	_	_	_
7	HK	_	O	O	_	_	_	_	_
8	666	_	O	O	_	_	_	_	_
9	led	_	O	O	_	_	_	_	_
10	to	_	O	O	_	_	_	_	_
11	activation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	expression	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	BZLF	_	O	O	_	_	_	_	_
16	1	_	O	O	_	_	_	_	_
17	,	_	O	O	_	_	_	_	_
18	which	_	O	O	_	_	_	_	_
19	encodes	_	O	O	_	_	_	_	_
20	Zta	_	O	O	_	_	_	_	_
21	and	_	O	O	_	_	_	_	_
22	loss	_	O	O	_	_	_	_	_
23	of	_	O	O	_	_	_	_	_
24	Qp	_	O	O	_	_	_	_	_
25	function	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	Transient	_	O	O	_	_	_	_	_
2	expression	_	O	O	_	_	_	_	_
3	assays	_	O	O	_	_	_	_	_
4	linked	_	O	O	_	_	_	_	_
5	Zta	_	O	O	_	_	_	_	_
6	expression	_	O	O	_	_	_	_	_
7	to	_	O	O	_	_	_	_	_
8	the	_	O	O	_	_	_	_	_
9	down	_	O	O	_	_	_	_	_
10	-	_	O	O	_	_	_	_	_
11	regulation	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	Qp	_	O	O	_	_	_	_	_
14	.	_	O	O	_	_	_	_	_

1	Cotransfection	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	Zta	_	O	O	_	_	_	_	_
4	reduced	_	O	O	_	_	_	_	_
5	Qp	_	O	O	_	_	_	_	_
6	activity	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	reporter	_	O	O	_	_	_	_	_
9	assays	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	This	_	O	O	_	_	_	_	_
2	negative	_	O	O	_	_	_	_	_
3	regulation	_	O	O	_	_	_	_	_
4	required	_	O	O	_	_	_	_	_
5	Zta	_	O	O	_	_	_	_	_
6	DNA	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	binding	_	O	O	_	_	_	_	_
9	activity	_	O	O	_	_	_	_	_
10	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	provide	_	O	O	_	_	_	_	_
3	evidence	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	Zta	_	O	O	_	_	_	_	_
6	up	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	regulation	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	p	_	O	O	_	_	_	_	_
11	53	_	O	O	_	_	_	_	_
12	leads	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	p	_	O	O	_	_	_	_	_
15	53	_	O	O	_	_	_	_	_
16	-	_	O	O	_	_	_	_	_
17	mediated	_	O	O	_	_	_	_	_
18	interference	_	O	O	_	_	_	_	_
19	with	_	O	O	_	_	_	_	_
20	JAK	_	O	O	_	_	_	_	_
21	/	_	O	O	_	_	_	_	_
22	STAT	_	O	O	_	_	_	_	_
23	activation	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	Qp	_	O	O	_	_	_	_	_
26	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	data	_	O	O	_	_	_	_	_
3	imply	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	JAK	_	O	O	_	_	_	_	_
6	/	_	O	O	_	_	_	_	_
7	STAT	_	O	O	_	_	_	_	_
8	signaling	_	O	O	_	_	_	_	_
9	has	_	O	O	_	_	_	_	_
10	a	_	O	O	_	_	_	_	_
11	role	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	EBV	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	associated	_	O	O	_	_	_	_	_
16	malignancies	_	O	O	_	_	_	_	_
17	.	_	O	O	_	_	_	_	_


1	Expression	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	erythroid	_	O	O	_	_	_	_	_
4	-	_	O	O	_	_	_	_	_
5	specific	_	O	O	_	_	_	_	_
6	genes	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	acute	_	O	O	_	_	_	_	_
9	megakaryoblastic	_	O	O	_	_	_	_	_
10	leukaemia	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	transient	_	O	O	_	_	_	_	_
13	myeloproliferative	_	O	O	_	_	_	_	_
14	disorder	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	Down	_	O	O	_	_	_	_	_
17	'	_	O	O	_	_	_	_	_
18	s	_	O	O	_	_	_	_	_
19	syndrome	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	Acute	_	O	O	_	_	_	_	_
2	megakaryoblastic	_	O	O	_	_	_	_	_
3	leukaemia	_	O	O	_	_	_	_	_
4	(	_	O	O	_	_	_	_	_
5	M	_	O	O	_	_	_	_	_
6	7	_	O	O	_	_	_	_	_
7	)	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	transient	_	O	O	_	_	_	_	_
10	myeloproliferative	_	O	O	_	_	_	_	_
11	disorder	_	O	O	_	_	_	_	_
12	in	_	O	O	_	_	_	_	_
13	Down	_	O	O	_	_	_	_	_
14	'	_	O	O	_	_	_	_	_
15	s	_	O	O	_	_	_	_	_
16	syndrome	_	O	O	_	_	_	_	_
17	(	_	O	O	_	_	_	_	_
18	TMD	_	O	O	_	_	_	_	_
19	)	_	O	O	_	_	_	_	_
20	are	_	O	O	_	_	_	_	_
21	characterized	_	O	O	_	_	_	_	_
22	by	_	O	O	_	_	_	_	_
23	rapid	_	O	O	_	_	_	_	_
24	growth	_	O	O	_	_	_	_	_
25	of	_	O	O	_	_	_	_	_
26	abnormal	_	O	O	_	_	_	_	_
27	blast	_	O	O	_	_	_	_	_
28	cells	_	O	O	_	_	_	_	_
29	which	_	O	O	_	_	_	_	_
30	express	_	O	O	_	_	_	_	_
31	megakaryocytic	_	O	O	_	_	_	_	_
32	markers	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	To	_	O	O	_	_	_	_	_
2	clarify	_	O	O	_	_	_	_	_
3	properties	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	the	_	O	O	_	_	_	_	_
6	blast	_	O	O	_	_	_	_	_
7	cells	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	M	_	O	O	_	_	_	_	_
10	7	_	O	O	_	_	_	_	_
11	and	_	O	O	_	_	_	_	_
12	TMD	_	O	O	_	_	_	_	_
13	cases	_	O	O	_	_	_	_	_
14	,	_	O	O	_	_	_	_	_
15	we	_	O	O	_	_	_	_	_
16	examined	_	O	O	_	_	_	_	_
17	erythroid	_	O	O	_	_	_	_	_
18	markers	_	O	O	_	_	_	_	_
19	expression	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	blasts	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	six	_	O	O	_	_	_	_	_
24	cases	_	O	O	_	_	_	_	_
25	with	_	O	O	_	_	_	_	_
26	M	_	O	O	_	_	_	_	_
27	7	_	O	O	_	_	_	_	_
28	and	_	O	O	_	_	_	_	_
29	seven	_	O	O	_	_	_	_	_
30	cases	_	O	O	_	_	_	_	_
31	with	_	O	O	_	_	_	_	_
32	TMD	_	O	O	_	_	_	_	_
33	in	_	O	O	_	_	_	_	_
34	this	_	O	O	_	_	_	_	_
35	study	_	O	O	_	_	_	_	_
36	.	_	O	O	_	_	_	_	_

1	Erythroid	_	O	O	_	_	_	_	_
2	-	_	O	O	_	_	_	_	_
3	specific	_	O	O	_	_	_	_	_
4	mRNAs	_	O	O	_	_	_	_	_
5	encoding	_	O	O	_	_	_	_	_
6	gamma	_	O	O	_	_	_	_	_
7	-	_	O	O	_	_	_	_	_
8	globin	_	O	O	_	_	_	_	_
9	and	_	O	O	_	_	_	_	_
10	erythroid	_	O	O	_	_	_	_	_
11	delta	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	aminolevulinate	_	O	O	_	_	_	_	_
14	synthase	_	O	O	_	_	_	_	_
15	were	_	O	O	_	_	_	_	_
16	found	_	O	O	_	_	_	_	_
17	to	_	O	O	_	_	_	_	_
18	be	_	O	O	_	_	_	_	_
19	expressed	_	O	O	_	_	_	_	_
20	in	_	O	O	_	_	_	_	_
21	blasts	_	O	O	_	_	_	_	_
22	from	_	O	O	_	_	_	_	_
23	most	_	O	O	_	_	_	_	_
24	of	_	O	O	_	_	_	_	_
25	these	_	O	O	_	_	_	_	_
26	cases	_	O	O	_	_	_	_	_
27	,	_	O	O	_	_	_	_	_
28	indicating	_	O	O	_	_	_	_	_
29	that	_	O	O	_	_	_	_	_
30	majorities	_	O	O	_	_	_	_	_
31	of	_	O	O	_	_	_	_	_
32	the	_	O	O	_	_	_	_	_
33	blasts	_	O	O	_	_	_	_	_
34	in	_	O	O	_	_	_	_	_
35	M	_	O	O	_	_	_	_	_
36	7	_	O	O	_	_	_	_	_
37	and	_	O	O	_	_	_	_	_
38	TMD	_	O	O	_	_	_	_	_
39	cases	_	O	O	_	_	_	_	_
40	have	_	O	O	_	_	_	_	_
41	erythroid	_	O	O	_	_	_	_	_
42	and	_	O	O	_	_	_	_	_
43	megakaryocytic	_	O	O	_	_	_	_	_
44	phenotypes	_	O	O	_	_	_	_	_
45	.	_	O	O	_	_	_	_	_

1	We	_	O	O	_	_	_	_	_
2	also	_	O	O	_	_	_	_	_
3	found	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	mRNAs	_	O	O	_	_	_	_	_
6	encoding	_	O	O	_	_	_	_	_
7	GATA	_	O	O	_	_	_	_	_
8	-	_	O	O	_	_	_	_	_
9	1	_	O	O	_	_	_	_	_
10	and	_	O	O	_	_	_	_	_
11	GATA	_	O	O	_	_	_	_	_
12	-	_	O	O	_	_	_	_	_
13	2	_	O	O	_	_	_	_	_
14	are	_	O	O	_	_	_	_	_
15	expressed	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	all	_	O	O	_	_	_	_	_
18	these	_	O	O	_	_	_	_	_
19	cases	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_

1	These	_	O	O	_	_	_	_	_
2	results	_	O	O	_	_	_	_	_
3	suggest	_	O	O	_	_	_	_	_
4	that	_	O	O	_	_	_	_	_
5	M	_	O	O	_	_	_	_	_
6	7	_	O	O	_	_	_	_	_
7	blasts	_	O	O	_	_	_	_	_
8	and	_	O	O	_	_	_	_	_
9	TMD	_	O	O	_	_	_	_	_
10	blasts	_	O	O	_	_	_	_	_
11	correspond	_	O	O	_	_	_	_	_
12	to	_	O	O	_	_	_	_	_
13	the	_	O	O	_	_	_	_	_
14	erythroid	_	O	O	_	_	_	_	_
15	/	_	O	O	_	_	_	_	_
16	megakaryocytic	_	O	O	_	_	_	_	_
17	bipotential	_	O	O	_	_	_	_	_
18	progenitor	_	O	O	_	_	_	_	_
19	cells	_	O	O	_	_	_	_	_
20	.	_	O	O	_	_	_	_	_


1	[	_	O	O	_	_	_	_	_
2	The	_	O	O	_	_	_	_	_
3	role	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	glucocorticoid	_	O	O	_	_	_	_	_
6	receptors	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	HLA	_	O	O	_	_	_	_	_
9	antigens	_	O	O	_	_	_	_	_
10	in	_	O	O	_	_	_	_	_
11	the	_	O	O	_	_	_	_	_
12	pathogenesis	_	O	O	_	_	_	_	_
13	of	_	O	O	_	_	_	_	_
14	Cushing	_	O	O	_	_	_	_	_
15	'	_	O	O	_	_	_	_	_
16	s	_	O	O	_	_	_	_	_
17	syndrome	_	O	O	_	_	_	_	_
18	]	_	O	O	_	_	_	_	_

1	Lymphocytic	_	O	O	_	_	_	_	_
2	levels	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	glucocorticoid	_	O	O	_	_	_	_	_
5	receptors	_	O	O	_	_	_	_	_
6	were	_	O	O	_	_	_	_	_
7	evaluated	_	O	O	_	_	_	_	_
8	in	_	O	O	_	_	_	_	_
9	114	_	O	O	_	_	_	_	_
10	patients	_	O	O	_	_	_	_	_
11	suffering	_	O	O	_	_	_	_	_
12	from	_	O	O	_	_	_	_	_
13	Icenko	_	O	O	_	_	_	_	_
14	-	_	O	O	_	_	_	_	_
15	Cushing	_	O	O	_	_	_	_	_
16	'	_	O	O	_	_	_	_	_
17	s	_	O	O	_	_	_	_	_
18	syndrome	_	O	O	_	_	_	_	_
19	.	_	O	O	_	_	_	_	_

1	Incidence	_	O	O	_	_	_	_	_
2	of	_	O	O	_	_	_	_	_
3	HLA	_	O	O	_	_	_	_	_
4	antigens	_	O	O	_	_	_	_	_
5	was	_	O	O	_	_	_	_	_
6	determined	_	O	O	_	_	_	_	_
7	in	_	O	O	_	_	_	_	_
8	94	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	them	_	O	O	_	_	_	_	_
11	.	_	O	O	_	_	_	_	_

1	A	_	O	O	_	_	_	_	_
2	significant	_	O	O	_	_	_	_	_
3	rise	_	O	O	_	_	_	_	_
4	of	_	O	O	_	_	_	_	_
5	A	_	O	O	_	_	_	_	_
6	10	_	O	O	_	_	_	_	_
7	and	_	O	O	_	_	_	_	_
8	B	_	O	O	_	_	_	_	_
9	27	_	O	O	_	_	_	_	_
10	antigen	_	O	O	_	_	_	_	_
11	incidence	_	O	O	_	_	_	_	_
12	compared	_	O	O	_	_	_	_	_
13	to	_	O	O	_	_	_	_	_
14	that	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	normal	_	O	O	_	_	_	_	_
17	subjects	_	O	O	_	_	_	_	_
18	allows	_	O	O	_	_	_	_	_
19	these	_	O	O	_	_	_	_	_
20	antigens	_	O	O	_	_	_	_	_
21	to	_	O	O	_	_	_	_	_
22	be	_	O	O	_	_	_	_	_
23	considered	_	O	O	_	_	_	_	_
24	genetic	_	O	O	_	_	_	_	_
25	markers	_	O	O	_	_	_	_	_
26	of	_	O	O	_	_	_	_	_
27	Icenko	_	O	O	_	_	_	_	_
28	-	_	O	O	_	_	_	_	_
29	Cushing	_	O	O	_	_	_	_	_
30	'	_	O	O	_	_	_	_	_
31	s	_	O	O	_	_	_	_	_
32	syndrome	_	O	O	_	_	_	_	_
33	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	levels	_	O	O	_	_	_	_	_
3	of	_	O	O	_	_	_	_	_
4	glucocorticoid	_	O	O	_	_	_	_	_
5	receptors	_	O	O	_	_	_	_	_
6	in	_	O	O	_	_	_	_	_
7	lymphocytes	_	O	O	_	_	_	_	_
8	of	_	O	O	_	_	_	_	_
9	the	_	O	O	_	_	_	_	_
10	patients	_	O	O	_	_	_	_	_
11	are	_	O	O	_	_	_	_	_
12	lower	_	O	O	_	_	_	_	_
13	than	_	O	O	_	_	_	_	_
14	in	_	O	O	_	_	_	_	_
15	normal	_	O	O	_	_	_	_	_
16	subjects	_	O	O	_	_	_	_	_
17	both	_	O	O	_	_	_	_	_
18	in	_	O	O	_	_	_	_	_
19	the	_	O	O	_	_	_	_	_
20	active	_	O	O	_	_	_	_	_
21	stage	_	O	O	_	_	_	_	_
22	of	_	O	O	_	_	_	_	_
23	the	_	O	O	_	_	_	_	_
24	disease	_	O	O	_	_	_	_	_
25	and	_	O	O	_	_	_	_	_
26	following	_	O	O	_	_	_	_	_
27	bilateral	_	O	O	_	_	_	_	_
28	total	_	O	O	_	_	_	_	_
29	adrenalectomy	_	O	O	_	_	_	_	_
30	.	_	O	O	_	_	_	_	_

1	The	_	O	O	_	_	_	_	_
2	patients	_	O	O	_	_	_	_	_
3	carrying	_	O	O	_	_	_	_	_
4	B	_	O	O	_	_	_	_	_
5	27	_	O	O	_	_	_	_	_
6	antigen	_	O	O	_	_	_	_	_
7	had	_	O	O	_	_	_	_	_
8	lymphocytic	_	O	O	_	_	_	_	_
9	receptor	_	O	O	_	_	_	_	_
10	concentrations	_	O	O	_	_	_	_	_
11	under	_	O	O	_	_	_	_	_
12	the	_	O	O	_	_	_	_	_
13	levels	_	O	O	_	_	_	_	_
14	of	_	O	O	_	_	_	_	_
15	such	_	O	O	_	_	_	_	_
16	in	_	O	O	_	_	_	_	_
17	patients	_	O	O	_	_	_	_	_
18	free	_	O	O	_	_	_	_	_
19	of	_	O	O	_	_	_	_	_
20	the	_	O	O	_	_	_	_	_
21	antigen	_	O	O	_	_	_	_	_
22	carriage	_	O	O	_	_	_	_	_
23	.	_	O	O	_	_	_	_	_

1	Antigen	_	O	O	_	_	_	_	_
2	B	_	O	O	_	_	_	_	_
3	27	_	O	O	_	_	_	_	_
4	seems	_	O	O	_	_	_	_	_
5	to	_	O	O	_	_	_	_	_
6	be	_	O	O	_	_	_	_	_
7	a	_	O	O	_	_	_	_	_
8	cause	_	O	O	_	_	_	_	_
9	of	_	O	O	_	_	_	_	_
10	lower	_	O	O	_	_	_	_	_
11	levels	_	O	O	_	_	_	_	_
12	of	_	O	O	_	_	_	_	_
13	glucocorticoid	_	O	O	_	_	_	_	_
14	receptors	_	O	O	_	_	_	_	_
15	in	_	O	O	_	_	_	_	_
16	blood	_	O	O	_	_	_	_	_
17	lymphocytes	_	O	O	_	_	_	_	_
18	.	_	O	O	_	_	_	_	_


